PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Crane, J				Crane, Johanna			Scrambling for Africa? Universities and global health	LANCET			English	Editorial Material									Univ Washington, Bothell, WA 98011 USA	University of Washington; University of Washington Bothell	Crane, J (corresponding author), Univ Washington, Bothell, WA 98011 USA.	johcrane@uw.edu						BROWN D, 2008, WASHINGTON POST 0919, pA1; *CONS U GLOB HLTH, MEMB BROCH; *CONS U GLOB HLTH, 2008, IN M REP; Holm J. D., 2010, CHRONICLE HIGHE 0613; Janes CR, 2009, ANNU REV ANTHROPOL, V38, P167, DOI 10.1146/annurev-anthro-091908-164314; Koplan JP, 2009, LANCET, V373, P1993, DOI 10.1016/S0140-6736(09)60332-9; Macfarlane SB, 2008, J PUBLIC HEALTH POL, V29, P383, DOI 10.1057/jphp.2008.25; Merson M.H., 2009, DRAMATIC EXPANSION U; QUIGQUIGLEY F, 2009, WALKING TOGETHER WAL; Volmink J, 2005, BMJ-BRIT MED J, V331, P705, DOI 10.1136/bmj.331.7519.705; *WHO REG OFF AFR D, 2007, INT WORKSH PRIM HLTH	11	56	56	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 23	2011	377	9775					1388	1390		10.1016/S0140-6736(10)61920-4	http://dx.doi.org/10.1016/S0140-6736(10)61920-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755UF	21074254				2022-12-28	WOS:000289963000008
J	Mullan, F; Frehywot, S; Omaswa, F; Buch, E; Chen, C; Greysen, SR; Wassermann, T; Abubakr, DEE; Awases, M; Boelen, C; Diomande, MJMI; Dovlo, D; Ferro, J; Haileamlak, A; Iputo, J; Jacobs, M; Koumare, AK; Mipando, M; Monekosso, GL; Olapade-Olaopa, EO; Rugarabamu, P; Sewankambo, NK; Ross, H; Ayas, H; Chale, SB; Cyprien, S; Cohen, J; Haile-Mariam, T; Hamburger, E; Jolley, L; Kolars, JC; Kombe, G; Neusy, AJ				Mullan, Fitzhugh; Frehywot, Seble; Omaswa, Francis; Buch, Eric; Chen, Candice; Greysen, S. Ryan; Wassermann, Travis; Abubakr, Diaa ElDin ElGaili; Awases, Magda; Boelen, Charles; Diomande, Mohenou Jean-Marie Isidore; Dovlo, Delanyo; Ferro, Josefo; Haileamlak, Abraham; Iputo, Jehu; Jacobs, Marian; Koumare, Abdel Karim; Mipando, Mwapatsa; Monekosso, Gottleib Lobe; Olapade-Olaopa, Emiola Oluwabunmi; Rugarabamu, Paschalis; Sewankambo, Nelson K.; Ross, Heather; Ayas, Huda; Chale, Selam Bedada; Cyprien, Soeurette; Cohen, Jordan; Haile-Mariam, Tenagne; Hamburger, Ellen; Jolley, Laura; Kolars, Joseph C.; Kombe, Gilbert; Neusy, Andre-Jacques			Medical schools in sub-Saharan Africa	LANCET			English	Article								Small numbers of graduates from few medical schools, and emigration of graduates to other countries, contribute to low physician presence in sub-Saharan Africa. The Sub-Saharan African Medical School Study examined the challenges, innovations, and emerging trends in medical education in the region. We identified 168 medical schools; of the 146 surveyed, 105 (72%) responded. Findings from the study showed that countries are prioritising medical education scale-up as part of health-system strengthening, and we identified many innovations in premedical preparation, team-based education, and creative use of scarce research support. The study also drew attention to ubiquitous faculty shortages in basic and clinical sciences, weak physical infrastructure, and little use of external accreditation. Patterns recorded include the growth of private medical schools, community-based education, and international partnerships, and the benefit of research for faculty development. Ten recommendations provide guidance for efforts to strengthen medical education in sub-Saharan Africa.	[Mullan, Fitzhugh; Frehywot, Seble; Chen, Candice; Wassermann, Travis; Ross, Heather; Ayas, Huda; Chale, Selam Bedada; Cyprien, Soeurette; Cohen, Jordan; Haile-Mariam, Tenagne; Hamburger, Ellen; Jolley, Laura] George Washington Univ, Washington, DC 20037 USA; [Buch, Eric] Univ Pretoria, ZA-0002 Pretoria, South Africa; [Greysen, S. Ryan] Yale Univ, New Haven, CT USA; [Abubakr, Diaa ElDin ElGaili] Univ Gezira, Wad Madani, Sudan; [Diomande, Mohenou Jean-Marie Isidore] Univ Cocody, Abidjan, Cote Ivoire; [Dovlo, Delanyo] WHO, CH-1211 Geneva, Switzerland; [Ferro, Josefo] Catholic Univ Mozambique, Beira, Mozambique; [Haileamlak, Abraham] Jimma Univ, Jimma, Ethiopia; [Iputo, Jehu] Walter Sisulu Univ, Mthatha, South Africa; [Jacobs, Marian] Univ Cape Town, ZA-7925 Cape Town, South Africa; [Koumare, Abdel Karim] Univ Mali, Bamako, Mali; [Mipando, Mwapatsa] Univ Malawi, Blantyre, Malawi; [Monekosso, Gottleib Lobe] Global Hlth Dialogue Fdn, Yaounde, Cameroon; [Olapade-Olaopa, Emiola Oluwabunmi] Univ Ibadan, Ibadan, Nigeria; [Rugarabamu, Paschalis] Hubert Kairuki Mem Univ, Dar Es Salaam, Tanzania; [Sewankambo, Nelson K.] Makerere Univ, Kampala, Uganda; [Boelen, Charles] Hlth Syst & Personnel, Sciez Sur Leman, France; [Omaswa, Francis] African Ctr Global Hlth & Social Transformat, Kampala, Uganda; [Awases, Magda] WHO, Harare, Zimbabwe; [Kolars, Joseph C.] Univ Michigan, Sch Med, Ann Arbor, MI USA; [Kombe, Gilbert] Abt Associates Inc, Bethesda, MD USA; [Neusy, Andre-Jacques] NYU, Sch Med, New York, NY USA	George Washington University; University of Pretoria; Yale University; World Health Organization; Jimma University; Walter Sisulu University; University of Cape Town; University of Bamako; University of Malawi; University of Ibadan; Makerere University; World Health Organization; University of Michigan System; University of Michigan; ABT Associates; New York University	Mullan, F (corresponding author), George Washington Univ, 2121 K St NW,Suite 210, Washington, DC 20037 USA.	fmullan@gwu.edu		Kolars, Joseph/0000-0002-2603-188X; Sewankambo, Nelson/0000-0001-9362-053X; Mipando, Mwapatsa/0000-0001-7236-0708	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This work was supported by the Bill & Melinda Gates Foundation.	[Anonymous], 2010, WORLD HLTH STAT 2010; [Anonymous], 2004, HUM RES HLTH OV CRIS; BOWERS JZ, 1962, J MED EDUC, V37, P220; Mullan F, 2007, LANCET, V370, P2158, DOI 10.1016/S0140-6736(07)60785-5; Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, 2009, WORLD POP PROSP 2008; WHO, 2006, WORK TOG HLTH WORLD; [WHO Global Health Workforce Alliance], 2008, SCAL SAV LIV TASK FO; World Health Organisation, 2008, TASK SHIFT GLOB REC; World Health Organization, 2009, REP WHO PEPFAR PLANN; Zuvekas A, 1998, IMPACT COMMUNITY HLT	10	217	221	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2011	377	9771					1113	1121		10.1016/S0140-6736(10)61961-7	http://dx.doi.org/10.1016/S0140-6736(10)61961-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	743QY	21074256	Green Submitted			2022-12-28	WOS:000289035000033
J	Canfield, DE; Stewart, FJ; Thamdrup, B; De Brabandere, L; Dalsgaard, T; Delong, EF; Revsbech, NP; Ulloa, O				Canfield, Don E.; Stewart, Frank J.; Thamdrup, Bo; De Brabandere, Loreto; Dalsgaard, Tage; Delong, Edward F.; Revsbech, Niels Peter; Ulloa, Osvaldo			A Cryptic Sulfur Cycle in Oxygen-Minimum-Zone Waters off the Chilean Coast	SCIENCE			English	Article							NITRATE REDUCTION; SULFATE-REDUCTION; MOLECULAR ANALYSIS; HYDROGEN-SULFIDE; PROKARYOTES; PHYLOGENY; DIVERSITY; OXIDATION; SEDIMENTS; SYMBIONT	Nitrogen cycling is normally thought to dominate the biogeochemistry and microbial ecology of oxygen-minimum zones in marine environments. Through a combination of molecular techniques and process rate measurements, we showed that both sulfate reduction and sulfide oxidation contribute to energy flux and elemental cycling in oxygen-free waters off the coast of northern Chile. These processes may have been overlooked because in nature, the sulfide produced by sulfate reduction immediately oxidizes back to sulfate. This cryptic sulfur cycle is linked to anammox and other nitrogen cycling processes, suggesting that it may influence biogeochemical cycling in the global ocean.	[Canfield, Don E.; Thamdrup, Bo; De Brabandere, Loreto] Univ So Denmark, Inst Biol, DK-5230 Odense M, Denmark; [Canfield, Don E.; Thamdrup, Bo; De Brabandere, Loreto] Univ So Denmark, Nord Ctr Earth Evolut, DK-5230 Odense M, Denmark; [Stewart, Frank J.; Delong, Edward F.] MIT, Dept Biol Engn, Cambridge, MA 02138 USA; [Stewart, Frank J.; Delong, Edward F.] MIT, Dept Civil & Environm Engn, Cambridge, MA 02138 USA; [Dalsgaard, Tage] Aarhus Univ, Natl Environm Res Inst, DK-8600 Silkeborg, Denmark; [Revsbech, Niels Peter] Aarhus Univ, Dept Biol Sci, Microbiol Sect, DK-8000 Aarhus C, Denmark; [Ulloa, Osvaldo] Univ Concepcion, Dept Oceanog, Concepcion, Chile; [Ulloa, Osvaldo] Univ Concepcion, Ctr Invest Oceanog Pacifico Sur Oriental, Concepcion, Chile	University of Southern Denmark; University of Southern Denmark; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Aarhus University; Aarhus University; Universidad de Concepcion; Universidad de Concepcion	Canfield, DE (corresponding author), Univ So Denmark, Inst Biol, Campusvej 55, DK-5230 Odense M, Denmark.	dec@biology.sdu.dk	Dalsgaard, Tage/J-6258-2014; Ulloa, Osvaldo/E-1821-2011; Revsbech, Niels P/I-8040-2013; Thamdrup, Bo/F-3889-2016; Canfield, Don/C-1735-2012; De Brabandere, Loreto C/A-8134-2014	Dalsgaard, Tage/0000-0003-2604-6499; Ulloa, Osvaldo/0000-0002-9501-5576; Thamdrup, Bo/0000-0002-1221-7077; Canfield, Don/0000-0001-7602-8366; Revsbech, Niels Peter/0000-0002-2193-262X	Agouron Institute; Danish National Research Foundation; Gordon and Betty Moore Foundation; Chilean Fondap Program	Agouron Institute(Pfizer); Danish National Research Foundation(Danmarks Grundforskningsfond); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Chilean Fondap Program(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDAP)	We thank the captain and crew of the Agor Vidal Gormaz from the Chilean Navy for their kind support, and the Agouron Institute, the Danish National Research Foundation, the Gordon and Betty Moore Foundation, and the Chilean Fondap Program for financial support. Additional thanks to G. Alarcon, G. Friederich, and J. Jennings for operational and experimental support. The genome sequence data are accessible on NCBI's Sequence Read Archive via accession number SRA025088.	ALBERT DB, 1995, DEEP-SEA RES PT I, V42, P1239, DOI 10.1016/0967-0637(95)00042-5; Bruchert V, 2003, GEOCHIM COSMOCHIM AC, V67, P4505, DOI 10.1016/S0016-7037(03)00275-8; Bulow SE, 2010, DEEP-SEA RES PT I, V57, P384, DOI 10.1016/j.dsr.2009.10.014; CALVERT SE, 1971, DEEP-SEA RES, V18, P505, DOI 10.1016/0011-7471(71)90074-X; CLINE JD, 1972, LIMNOL OCEANOGR, V17, P885, DOI 10.4319/lo.1972.17.6.0885; DALSGAARD T, 1994, APPL ENVIRON MICROB, V60, P291, DOI 10.1128/AEM.60.1.291-297.1994; DUGDALE RC, 1977, DEEP-SEA RES, V24, P601, DOI 10.1016/0146-6291(77)90530-6; Escribano R, 2004, DEEP-SEA RES PT II, V51, P2389, DOI 10.1016/j.dsr2.2004.08.011; Finster KW, 2010, ANTON LEEUW INT J G, V97, P221, DOI 10.1007/s10482-009-9403-y; FROELICH PN, 1979, GEOCHIM COSMOCHIM AC, V43, P1075, DOI 10.1016/0016-7037(79)90095-4; Galloway JN, 2004, BIOGEOCHEMISTRY, V70, P153, DOI 10.1007/s10533-004-0370-0; Grimm F, 2008, MICROBIAL SULFUR METABOLISM, P101, DOI 10.1007/978-3-540-72682-1_9; Jensen MM, 2009, MAR CHEM, V113, P102, DOI 10.1016/j.marchem.2009.01.002; Kuwahara H, 2007, CURR BIOL, V17, P881, DOI 10.1016/j.cub.2007.04.039; Lam P, 2009, P NATL ACAD SCI USA, V106, P4752, DOI 10.1073/pnas.0812444106; Lavik G, 2009, NATURE, V457, P581, DOI 10.1038/nature07588; Lavin P, 2010, ENV MICROBIOL REP, V2, P728, DOI 10.1111/j.1758-2229.2010.00167.x; MCCREADY RGL, 1983, ARCH MICROBIOL, V135, P182, DOI 10.1007/BF00414476; Meyer B, 2007, APPL ENVIRON MICROB, V73, P7664, DOI 10.1128/AEM.01272-07; Meyer B, 2007, MICROBIOL-SGM, V153, P3478, DOI 10.1099/mic.0.2007/008250-0; Meyer B, 2007, MICROBIOL-SGM, V153, P2026, DOI 10.1099/mic.0.2006/003152-0; Morrison JM, 1999, DEEP-SEA RES PT II, V46, P1903, DOI 10.1016/S0967-0645(99)00048-X; Newton ILG, 2007, SCIENCE, V315, P998, DOI 10.1126/science.1138438; OLSON DB, 1993, DEEP-SEA RES PT II, V40, P673, DOI 10.1016/0967-0645(93)90051-N; Redfield A. C, 1963, SEA, P26, DOI DOI 10.1016/J.ORGGEOCHEM.2014.06.002; Revsbech NP, 2009, LIMNOL OCEANOGR-METH, V7, P371, DOI 10.4319/lom.2009.7.371; Stevens H, 2008, ENVIRON MICROBIOL, V10, P1244, DOI 10.1111/j.1462-2920.2007.01539.x; Thamdrup B, 2006, LIMNOL OCEANOGR, V51, P2145, DOI 10.4319/lo.2006.51.5.2145; Walsh DA, 2009, SCIENCE, V326, P578, DOI 10.1126/science.1175309; WYRTKI K, 1962, DEEP-SEA RES, V9, P11, DOI 10.1016/0011-7471(62)90243-7	30	411	423	12	366	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2010	330	6009					1375	1378		10.1126/science.1196889	http://dx.doi.org/10.1126/science.1196889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	689BK	21071631	Green Published			2022-12-28	WOS:000284902100041
J	Dehaene, S; Pegado, F; Braga, LW; Ventura, P; Nunes, G; Jobert, A; Dehaene-Lambertz, G; Kolinsky, R; Morais, J; Cohen, L				Dehaene, Stanislas; Pegado, Felipe; Braga, Lucia W.; Ventura, Paulo; Nunes Filho, Gilberto; Jobert, Antoinette; Dehaene-Lambertz, Ghislaine; Kolinsky, Regine; Morais, Jose; Cohen, Laurent			How Learning to Read Changes the Cortical Networks for Vision and Language	SCIENCE			English	Article							CHILDREN LEARN; VISUAL-CORTEX; SPEECH SOUNDS; BRAIN; RECOGNITION; LITERACY; REORGANIZATION; ACTIVATION; REGIONS; WRITE	Does literacy improve brain function? Does it also entail losses? Using functional magnetic resonance imaging, we measured brain responses to spoken and written language, visual faces, houses, tools, and checkers in adults of variable literacy (10 were illiterate, 22 became literate as adults, and 31 were literate in childhood). As literacy enhanced the left fusiform activation evoked by writing, it induced a small competition with faces at this location, but also broadly enhanced visual responses in fusiform and occipital cortex, extending to area V1. Literacy also enhanced phonological activation to speech in the planum temporale and afforded a top-down activation of orthography from spoken inputs. Most changes occurred even when literacy was acquired in adulthood, emphasizing that both childhood and adult education can profoundly refine cortical organization.	[Dehaene, Stanislas; Pegado, Felipe; Jobert, Antoinette; Dehaene-Lambertz, Ghislaine] INSERM, Cognit Neuroimaging Unit, F-91191 Gif Sur Yvette, France; [Dehaene, Stanislas; Pegado, Felipe; Jobert, Antoinette; Dehaene-Lambertz, Ghislaine] CEA, Direct Sci Vivant, I2BM, Neurospin Ctr, F-91191 Gif Sur Yvette, France; [Dehaene, Stanislas; Pegado, Felipe; Jobert, Antoinette; Dehaene-Lambertz, Ghislaine] Univ Paris 11, F-91405 Orsay, France; [Dehaene, Stanislas] Coll France, F-75005 Paris, France; [Braga, Lucia W.; Nunes Filho, Gilberto] Int Ctr Neurosci & Rehabil, SARAH Network, BR-71535005 Brasilia, DF, Brazil; [Ventura, Paulo] Univ Lisbon, Fac Psychol, P-1600214 Lisbon, Portugal; [Kolinsky, Regine; Morais, Jose] Univ Libre Bruxelles, Fac Psychol, B-1050 Brussels, Belgium; [Kolinsky, Regine] Fonds Rech Sci FNRS, B-1000 Brussels, Belgium; [Cohen, Laurent] Univ Paris 06, Fac Med Pitie Salpetriere, F-75013 Paris, France; [Cohen, Laurent] Grp Hosp Pitie Salpetriere, AP HP, Dept ofNeurol, F-75651 Paris, France; [Cohen, Laurent] INSERM, Inst Cerveau & Moelle Epiniere, Ctr Rech, UMRS 975, Paris, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; College de France; Universidade de Lisboa; Universite Libre de Bruxelles; Fonds de la Recherche Scientifique - FNRS; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Dehaene, S (corresponding author), INSERM, Cognit Neuroimaging Unit, F-91191 Gif Sur Yvette, France.	stanislas.dehaene@gmail.com	Braga, Lucia/AAQ-1030-2020; Ventura, Paulo/D-8585-2013; Nunes Filho, Gilberto/J-1535-2012; Dehaene, Ghislaine/O-3633-2017	Dehaene, Ghislaine/0000-0003-2221-9081; Ventura, Paulo/0000-0002-4059-4419; Ventura, Paulo/0000-0003-0150-6268; Pegado, Felipe/0000-0001-9203-8687; cohen, laurent/0000-0002-5010-9085	Institut National de la Sante et de la Recherche Medicale (INSERM); Commissariat a l'Energie Atomique (CEA); College de France; Agence Nationale de la Recherche; Fundacao para a Ciencia e a Tecnologia; European Community [PTDC/PSI/66077/2006]; SARAH Network of Rehabilitation Hospitals; Belgian French community [2.4586.07, 06/11-342]	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Commissariat a l'Energie Atomique (CEA)(French Atomic Energy Commission); College de France; Agence Nationale de la Recherche(French National Research Agency (ANR)); Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); European Community(European Commission); SARAH Network of Rehabilitation Hospitals; Belgian French community	This work was supported by Institut National de la Sante et de la Recherche Medicale (INSERM), Commissariat a l'Energie Atomique (CEA), College de France, Agence Nationale de la Recherche (project CORELEX), Fundacao para a Ciencia e a Tecnologia, the European Community FEDER funding (Project PTDC/PSI/66077/2006, "Cognitive consequences of literacy"), SARAH Network of Rehabilitation Hospitals, and by two grants from the Belgian French community (Fonds de la Recherche Fondamentale Collective 2.4586.07 and Action de Recherche Concertee 06/11-342). We gratefully acknowledge A. Amadon, M.-H. Baju, L. Labruna, D. Le Bihan, L. Hertz-Pannier, P. Pinel, and the NeuroSpin infrastructure groups at NeuroSpin; C. Carvalho, L. Querido, S. Fernandes, and T. Fernandes at the Faculty of Psychology, University of Lisbon; and D. Y. Suguieda, R. S. Vera, A. G. Tauil, E. Amemiya, L. G. N. Nunes, S. B. de Oliveira, and C. L. M. Gillis at SARAH Brasilia.	Baker CI, 2007, P NATL ACAD SCI USA, V104, P9087, DOI 10.1073/pnas.0703300104; Blau V, 2010, BRAIN, V133, P868, DOI 10.1093/brain/awp308; Bolger DJ, 2005, HUM BRAIN MAPP, V25, P92, DOI 10.1002/hbm.20124; Booth JR, 2003, HUM BRAIN MAPP, V19, P155, DOI 10.1002/hbm.10111; Brem S, 2010, P NATL ACAD SCI USA, V107, P7939, DOI 10.1073/pnas.0904402107; Carreiras M, 2009, NATURE, V461, P983, DOI 10.1038/nature08461; Castro-Caldas A, 1999, EUR J NEUROL, V6, P23, DOI 10.1046/j.1468-1331.1999.610023.x; Castro-Caldas A, 1998, BRAIN, V121, P1053, DOI 10.1093/brain/121.6.1053; Cheung H, 2004, LANG COGNITIVE PROC, V19, P1, DOI 10.1080/01690960344000071; Cohen L, 2004, NEUROIMAGE, V23, P1256, DOI 10.1016/j.neuroimage.2004.07.052; Cohen L, 2004, NEUROIMAGE, V22, P466, DOI 10.1016/j.neuroimage.2003.12.049; Cohen L, 2008, NEUROIMAGE, V40, P353, DOI 10.1016/j.neuroimage.2007.11.036; Dehaene S, 2009, READING BRAIN; Dehaene S, 2007, NEURON, V56, P384, DOI 10.1016/j.neuron.2007.10.004; Desroches AS, 2010, BRAIN RES, V1356, P73, DOI 10.1016/j.brainres.2010.07.097; Downing PE, 2006, CEREB CORTEX, V16, P1453, DOI 10.1093/cercor/bhj086; Eger E, 2005, NEUROIMAGE, V26, P1128, DOI 10.1016/j.neuroimage.2005.03.010; Gaillard R, 2006, NEURON, V50, P191, DOI 10.1016/j.neuron.2006.03.031; Gauthier I, 2003, NAT NEUROSCI, V6, P428, DOI 10.1038/nn1029; Golarai G, 2007, NAT NEUROSCI, V10, P512, DOI 10.1038/nn1865; Harel A, 2010, CEREB CORTEX, V20, P2304, DOI 10.1093/cercor/bhp316; Henrich J, 2010, BEHAV BRAIN SCI, V33, P111, DOI 10.1017/S0140525X10000725; Jacquemot C, 2003, J NEUROSCI, V23, P9541; Kherif F, 2011, CEREB CORTEX, V21, P103, DOI 10.1093/cercor/bhq063; Li G, 2006, HUM BRAIN MAPP, V27, P144, DOI 10.1002/hbm.20173; Li W, 2004, NAT NEUROSCI, V7, P651, DOI 10.1038/nn1255; Longcamp M, 2003, NEUROIMAGE, V19, P1492, DOI 10.1016/S1053-8119(03)00088-0; Maurer U, 2006, NEUROIMAGE, V33, P749, DOI 10.1016/j.neuroimage.2006.06.025; MORAIS J, 1986, COGNITION, V24, P45, DOI 10.1016/0010-0277(86)90004-1; Nazir TA, 2004, BRAIN LANG, V88, P294, DOI 10.1016/S0093-934X(03)00168-8; Perre L, 2009, BRAIN RES, V1275, P73, DOI 10.1016/j.brainres.2009.04.018; Petersson KM, 2007, EUR J NEUROSCI, V26, P791, DOI 10.1111/j.1460-9568.2007.05701.x; Petersson KM, 1999, NEUROIMAGE, V10, P45, DOI 10.1006/nimg.1999.0446; Petersson KM, 2000, J COGNITIVE NEUROSCI, V12, P364, DOI 10.1162/089892900562147; Polley DB, 2006, J NEUROSCI, V26, P4970, DOI 10.1523/JNEUROSCI.3771-05.2006; Rayner K, 1998, PSYCHOL BULL, V124, P372, DOI 10.1037/0033-2909.124.3.372; Rossion B, 2004, P NATL ACAD SCI USA, V101, P14521, DOI 10.1073/pnas.0405613101; Shaywitz BA, 2002, BIOL PSYCHIAT, V52, P101, DOI 10.1016/S0006-3223(02)01365-3; Sigman M, 2005, NEURON, V46, P823, DOI 10.1016/j.neuron.2005.05.014; Turkeltaub PE, 2003, NAT NEUROSCI, V6, P767, DOI 10.1038/nn1065; van Atteveldt N, 2004, NEURON, V43, P271, DOI 10.1016/j.neuron.2004.06.025; Ventura P, 2007, COGNITION, V105, P547, DOI 10.1016/j.cognition.2006.12.005; Yoncheva YN, 2010, CEREB CORTEX, V20, P622, DOI 10.1093/cercor/bhp129; Ziegler JC, 2008, J EXP PSYCHOL LEARN, V34, P643, DOI 10.1037/0278-7393.34.3.643	44	748	773	11	284	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2010	330	6009					1359	1364		10.1126/science.1194140	http://dx.doi.org/10.1126/science.1194140			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	689BK	21071632	Green Published			2022-12-28	WOS:000284902100037
J	Samb, B; Desai, N; Nishtar, S; Mendis, S; Bekedam, H; Wright, A; Hsu, J; Martiniuk, A; Celletti, F; Patel, K; Adshead, F; McKee, M; Evans, T; Alwan, A; Etienne, C				Samb, Badara; Desai, Nina; Nishtar, Sania; Mendis, Shanti; Bekedam, Henk; Wright, Anna; Hsu, Justine; Martiniuk, Alexandra; Celletti, Francesca; Patel, Kiran; Adshead, Fiona; McKee, Martin; Evans, Tim; Alwan, Ala; Etienne, Carissa			Chronic Diseases: Chronic Diseases and Development 4 Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries	LANCET			English	Article							SUB-SAHARAN AFRICA; SELF-MANAGEMENT; DIABETES CARE; INITIATIVES; HIV/AIDS; ACCESS; SURVIVAL; DELIVERY; THERAPY; BURDEN	National health systems need strengthening if they are to meet the growing challenge of chronic diseases in low-income and middle-income countries. By application of an accepted health-systems framework to the evidence, we report that the factors that limit countries' capacity to implement proven strategies for chronic diseases relate to the way in which health systems are designed and function. Substantial constraints are apparent across each of the six key health-systems components of health financing, governance, health workforce, health information, medical products and technologies, and health-service delivery. These constraints have become more evident as development partners have accelerated efforts to respond to HIV, tuberculosis, malaria, and vaccine-preventable diseases. A new global agenda for health-systems strengthening is arising from the urgent need to scale up and sustain these priority interventions. Most chronic diseases are neglected in this dialogue about health systems, despite the fact that non-communicable diseases (most of which are chronic) will account for 69% of all global deaths by 2030 with 80% of these deaths in low-income and middle-income countries. At the same time, advocates for action against chronic diseases are not paying enough attention to health systems as part of an effective response. Efforts to scale up interventions for management of common chronic diseases in these countries tend to focus on one disease and its causes, and are often fragmented and vertical. Evidence is emerging that chronic disease interventions could contribute to strengthening the capacity of health systems to deliver a comprehensive range of services-provided that such investments are planned to include these broad objectives. Because effective chronic disease programmes are highly dependent on well-functioning national health systems, chronic diseases should be a litmus test for health-systems strengthening.	[Samb, Badara] WHO, Hlth Syst & Serv, CH-1201 Geneva, Switzerland; [Desai, Nina] George Inst Global Hlth, London, England; [Nishtar, Sania] Heartfile, Islamabad, Pakistan; [Bekedam, Henk] WHO, Manila, Philippines; [Hsu, Justine; McKee, Martin] London Sch Hyg & Trop Med, London WC1, England; [Martiniuk, Alexandra] George Inst Global Hlth, Sydney, NSW, Australia; [Patel, Kiran] W Midlands Strateg Hlth Author, Natl Hlth Serv, Birmingham, W Midlands, England; [Adshead, Fiona] UK Dept Hlth, London, England	World Health Organization; WHO Western Pacific Regional Office; World Health Organization; University of London; London School of Hygiene & Tropical Medicine; George Institute for Global Health; University of Sydney; NHS Blood & Transplant (NHSBT)	Samb, B (corresponding author), WHO, Hlth Syst & Serv, 20 Ave Appia, CH-1201 Geneva, Switzerland.	sambb@who.int	McKee, Marc D/E-2187-2011; Martiniuk, Alexandra/K-2600-2019; Mendis, Shanthi/GLT-0465-2022; McKee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Martiniuk, Alexandra/0000-0003-1368-8206; McKee, Martin/0000-0002-0121-9683; mendis, shanthi/0000-0002-8959-5738				AbouZahr C, 2010, LANCET, V375, P619, DOI 10.1016/S0140-6736(09)60004-0; Adeyi O, 2007, DIR DEV, P1, DOI 10.1596/978-0-8213-7044-5; Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6; [Anonymous], 2005, PREV CHRON DIS VIT I; Asaria P, 2007, LANCET, V370, P2044, DOI 10.1016/S0140-6736(07)61698-5; BACKMAN G, 2007, SURV QUAL ANT MED CI; Backman G, 2008, LANCET, V372, P2047, DOI 10.1016/S0140-6736(08)61781-X; Balabanova D, 2009, HEALTH POLICY PLANN, V24, P46, DOI 10.1093/heapol/czn041; Beaglehole R, 2008, LANCET, V372, P940, DOI 10.1016/S0140-6736(08)61404-X; Beran D, 2005, DIABETES CARE, V28, P2136, DOI 10.2337/diacare.28.9.2136; Beran D, 2006, LANCET, V368, P1689, DOI 10.1016/S0140-6736(06)69704-3; Bhowmik D, 2008, Indian J Public Health, V52, P224; Biesma RG, 2009, HEALTH POLICY PLANN, V24, P239, DOI 10.1093/heapol/czp025; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; Cisse B, 2007, HEALTH POLICY, V80, P51, DOI 10.1016/j.healthpol.2006.02.011; Commission on the Social Determinants of Health, 2008, CLOS GAP GEN HLTH EQ; Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9; Doyle C, 2008, SOC SCI MED, V66, P1928, DOI 10.1016/j.socscimed.2007.12.029; Drager Sigrid, 2006, Hum Resour Health, V4, P23, DOI 10.1186/1478-4491-4-23; Emoti C E, 2008, Niger Postgrad Med J, V15, P10; Epping-Jordan JE, 2004, QUAL SAF HEALTH CARE, V13, P299, DOI 10.1136/qshc.2004.010744; Evans T, 2003, B WORLD HEALTH ORGAN, V81, P856; G8 Health Expert Group, 2008, TOYAK FRAM ACT GLOB; GENEAU R, 2010, LANCET          1111, DOI DOI 10.1016/S0140-6736(10)61414-6; *GLOB ALL VACC IMM, HLTH SYST STRENGTH; *GLOB FUND, INV OUR FUT GLOB FUN; Goudge J, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-75; Harries AD, 2008, PLOS MED, V5, P859, DOI 10.1371/journal.pmed.0050124; Harries AD, 2009, JAIDS-J ACQ IMM DEF, V52, pS14, DOI 10.1097/QAI.0b013e3181bbc99e; Harries AD, 2009, T ROY SOC TROP MED H, V103, P537, DOI 10.1016/j.trstmh.2008.12.008; *HLTH METR NET, 2008, FRAM STAND COUNTR IN; Hopkinson B, 2004, INT J HEALTH PLAN M, V19, P43, DOI 10.1002/hpm.745; *I MED, 2009, US COMM GLOB HLTH RE; International Finance Corporation, 2008, BUS HLTH AFR PARTN P; Joshi R, 2008, J AM COLL CARDIOL, V52, P1817, DOI 10.1016/j.jacc.2008.08.049; KOBER K, 2006, EXPERT PATIENTS AIDS; Liu Wei-wei, 2005, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V23, P263; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Lu CL, 2010, LANCET, V375, P1375, DOI 10.1016/S0140-6736(10)60233-4; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Miranda JJ, 2008, TROP MED INT HEALTH, V13, P1225, DOI 10.1111/j.1365-3156.2008.02116.x; Nishtar S, 2010, CHOKED PIPES REFORMI; Nolte E, 2008, CARING PEOPLE CHRONI; NOTE V, 2010, ACCESSED OCT, V10; NUGENT R, 2010, PROMOTING CARDIOVASC; Onyango J F, 2006, East Afr Med J, V83, P85; Organization WH, 2009, GLOB HLTH RISKS MORT; Preker Alexander S, 2005, SPENDING WISELY BUYI; Price JE, 2009, AIDS CARE, V21, P608, DOI 10.1080/09540120802310957; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Reddy KS, 2005, LANCET, V366, P1744, DOI [10.1016/s0140-6736(05)67343-6, 10.1016/S0140-6736(05)67343-6]; *ROCK FDN, RES DEV INT HLTH POL; Sama M, 2008, GOVERNING HLTH SYSTE, V1st; Samb B, 2007, NEW ENGL J MED, V357, P2510, DOI 10.1056/NEJMsb071889; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Schmittdiel JA, 2006, ANN FAM MED, V4, P117, DOI 10.1370/afm.520; SECKEINELGIN H, 2002, GLOBAL CIVIL SOC, P422; Seckinelgin H, 2005, GLOBAL GOV, V11, P351, DOI 10.1163/19426720-01103006; Sepulveda J, 2006, LANCET, V368, P2017, DOI 10.1016/S0140-6736(06)69569-X; Setel PW, 2007, LANCET, V370, P1569, DOI 10.1016/S0140-6736(07)61307-5; Smith SR, 2003, PATIENT EDUC COUNS, V50, P187; Souteyrand YP, 2008, AIDS, V22, pS161, DOI 10.1097/01.aids.0000327637.59672.02; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; Stuckler D, 2008, LANCET, V372, P1563, DOI 10.1016/S0140-6736(08)61656-6; Suhrcke M, 2007, HLTH VITAL INVESTMEN; Sun Q, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-42; *SWEET RES, OV PARTN CHRON DIS; Thorogood M, 2007, SCAND J PUBLIC HEALT, V35, P52, DOI 10.1080/14034950701355411; Valsecchi MG, 2008, LANCET ONCOL, V9, P159, DOI 10.1016/S1470-2045(08)70028-7; Wagner AK, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-161; WHO, 2009, PACK ESS NCD INT PRI; WHO, TASK SHIFT GLOB REC; *WHO, GLOB WORKF ALL; *WHO, 2005, MONTR CHALL MAK HLTH; WHO, 2007, EV BUS STRENGTH HLTH; *WHO, HLTH METR NETW; *WORLD EC FOR, GLOB RISKS 2009; World Health Organization, 2010, WHO MOD LIST ESS MED; World Health Organization, 2008, TALL CHART HLTH SYST; World Health Organization (WHO), 2006, WORLD HLTH REP 2006; *WORLD HLTH ASS, A618 WORLD HLTH ASS; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; Yeole BB, 2001, EUR J CANCER, V37, P1402, DOI 10.1016/S0959-8049(01)00108-3; PARIS DECLARATION AI; ACCRA AGEND ACTION; 2009, LANCET, V374, P10; BAMAKO CALL TO ACTIO	90	260	267	2	48	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2010	376	9754					1785	1797		10.1016/S0140-6736(10)61353-0	http://dx.doi.org/10.1016/S0140-6736(10)61353-0			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690EI	21074253				2022-12-28	WOS:000284984900034
J	Peitgen, HO				Peitgen, Heinz-Otto			RETROSPECTIVE Benoit B. Mandelbrot (1924-2010)	SCIENCE			English	Biographical-Item									Univ Bremen, Dept Math & Biomed Sci, D-28359 Bremen, Germany; [Peitgen, Heinz-Otto] Florida Atlantic Univ, Fraunhofer MEVIS, D-28359 Bremen, Germany	University of Bremen	Peitgen, HO (corresponding author), Univ Bremen, Dept Math & Biomed Sci, D-28359 Bremen, Germany.	peitgen@mevis.de	Peitgen, Heinz-Otto/ABG-2100-2021						0	2	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					926	926		10.1126/science.1199471	http://dx.doi.org/10.1126/science.1199471			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071658				2022-12-28	WOS:000284118000030
J	Reid, WV; Chen, D; Goldfarb, L; Hackmann, H; Lee, YT; Mokhele, K; Ostrom, E; Raivio, K; Rockstrom, J; Schellnhuber, HJ; Whyte, A				Reid, W. V.; Chen, D.; Goldfarb, L.; Hackmann, H.; Lee, Y. T.; Mokhele, K.; Ostrom, E.; Raivio, K.; Rockstrom, J.; Schellnhuber, H. J.; Whyte, A.			Earth System Science for Global Sustainability: Grand Challenges	SCIENCE			English	Editorial Material							FRAMEWORK		[Reid, W. V.] David & Lucile Packard Fdn, Los Altos, CA 94022 USA; [Chen, D.; Goldfarb, L.; Lee, Y. T.; Raivio, K.] Int Council Sci ICSU, F-75116 Paris, France; [Hackmann, H.] Int Social Sci Council, F-75732 Paris, France; [Mokhele, K.] Natl Res Fdn S Africa, ZA-0001 Pretoria, South Africa; [Ostrom, E.] Indiana Univ, Bloomington, IN 47408 USA; [Rockstrom, J.] Stockholm Environm Inst, SE-10691 Stockholm, Sweden; [Schellnhuber, H. J.] Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany; [Whyte, A.] Int Dev Res Ctr, Ottawa, ON K1G 3H9, Canada	National Research Foundation - South Africa; Indiana University System; Indiana University Bloomington; Stockholm Environment Institute; Potsdam Institut fur Klimafolgenforschung	Reid, WV (corresponding author), David & Lucile Packard Fdn, Los Altos, CA 94022 USA.	wreid@packard.org	currie, morgan/G-1449-2011; Schellnhuber, Hans Joachim/O-3873-2019; Lee, Yuan-Tseh/F-7914-2012; Chen, Deliang/A-5107-2013; Schellnhuber, Hans Joachim/B-2607-2012	Schellnhuber, Hans Joachim/0000-0001-7453-4935; Chen, Deliang/0000-0003-0288-5618; Schellnhuber, Hans Joachim/0000-0001-7453-4935; Rockstrom, Johan/0000-0001-8988-2983				CLARK WC, 2004, EARTH SYSTEM ANAL SU, P1; Kates RW, 2001, SCIENCE, V292, P641, DOI 10.1126/science.1059386; Ostrom E, 2009, SCIENCE, V325, P419, DOI 10.1126/science.1172133; Reid WV, 2009, SCIENCE, V325, P245, DOI 10.1126/science.1178591; Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a; Schellnhuber H. J., 2002, GLOBAL CHANGE NEWSLE, V49, P20; Turner BL, 2003, P NATL ACAD SCI USA, V100, P8074, DOI 10.1073/pnas.1231335100; Walker B, 2009, SCIENCE, V325, P1345, DOI 10.1126/science.1175325	8	347	380	10	267	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					916	917		10.1126/science.1196263	http://dx.doi.org/10.1126/science.1196263			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678XY	21071651				2022-12-28	WOS:000284118000023
J	Davies, P				Davies, Peter			Primary Care Darzi centres: an expensive luxury the UK can no longer afford?	BRITISH MEDICAL JOURNAL			English	Editorial Material												petergdavies@ntlworld.com						*DEP HLTH, 2007, OUR NHS OUR FUT NHS; GAINSBURY S, 2010, HLTH SERVICE J  0519; *HC HLTH COMM, 1 HOUS COMM HLTH COM; IACOBUCCI G, 2010, PULSE           0428; PRAITIES N, 2010, PULSE           1011	5	6	6	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 8	2010	341								c6287	10.1136/bmj.c6287	http://dx.doi.org/10.1136/bmj.c6287			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KD	21059729				2022-12-28	WOS:000284310100002
J	Negre, C; Zahn, R; Thomas, AL; Masque, P; Henderson, GM; Martinez-Mendez, G; Hall, IR; Mas, JL				Negre, Cesar; Zahn, Rainer; Thomas, Alexander L.; Masque, Pere; Henderson, Gideon M.; Martinez-Mendez, Gema; Hall, Ian R.; Mas, Jose L.			Reversed flow of Atlantic deep water during the Last Glacial Maximum	NATURE			English	Article							MERIDIONAL OVERTURNING CIRCULATION; OCEAN THERMOHALINE CIRCULATION; PLASMA-MASS SPECTROMETRY; PA-231/TH-230 RATIO; MARINE-SEDIMENTS; SOUTH ATLANTIC; PARTICLE-FLUX; SORTABLE SILT; INDIAN-OCEAN; PROXY	The meridional overturning circulation (MOC) of the Atlantic Ocean is considered to be one of the most important components of the climate system. This is because its warm surface currents, such as the Gulf Stream, redistribute huge amounts of energy from tropical to high latitudes and influence regional weather and climate patterns, whereas its lower limb ventilates the deep ocean and affects the storage of carbon in the abyss, away from the atmosphere. Despite its significance for future climate, the operation of the MOC under contrasting climates of the past remains controversial. Nutrient-based proxies(1,2) and recent model simulations(3) indicate that during the Last Glacial Maximum the convective activity in the North Atlantic Ocean was much weaker than at present. In contrast, rate-sensitive radiogenic Pa-231/Th-230 isotope ratios from the North Atlantic have been interpreted to indicate only minor changes in MOC strength(4-6). Here we show that the basin-scale abyssal circulation of the Atlantic Ocean was probably reversed during the Last Glacial Maximum and was dominated by northward water flow from the Southern Ocean. These conclusions are based on new high-resolution data from the South Atlantic Ocean that establish the basin-scale north to south gradient in Pa-231/Th-230, and thus the direction of the deep ocean circulation. Our findings are consistent with nutrient-based proxies and argue that further analysis of Pa-231/Th-230 outside the North Atlantic basin will enhance our understanding of past ocean circulation, provided that spatial gradients are carefully considered. This broader perspective suggests that the modern pattern of the Atlantic MOC-with a prominent southerly flow of deep waters originating in the North Atlantic-arose only during the Holocene epoch.	[Negre, Cesar; Zahn, Rainer; Masque, Pere; Martinez-Mendez, Gema] Univ Autonoma Barcelona, ICTA, Bellaterra 08193, Spain; [Zahn, Rainer] Lluis Co 23, ICREA, Barcelona 08010, Spain; [Zahn, Rainer; Masque, Pere] Univ Autonoma Barcelona, Dept Fis, Bellaterra 08193, Spain; [Thomas, Alexander L.; Henderson, Gideon M.] Univ Oxford, Dept Earth Sci, Oxford OX1 3AN, England; [Hall, Ian R.] Cardiff Univ, Sch Earth & Ocean Sci, Cardiff CF10 3YE, S Glam, Wales; [Mas, Jose L.] Univ Seville, Escuela Univ Politecn, Dipartimento Fis Aplicada 1, E-41012 Seville, Spain	Autonomous University of Barcelona; ICREA; Autonomous University of Barcelona; University of Oxford; Cardiff University; University of Sevilla	Negre, C (corresponding author), Univ Autonoma Barcelona, ICTA, Bellaterra 08193, Spain.	cesar@negre.us	Méndez, Gema Martínez/AAB-2245-2020; Thomas, Alex/D-1028-2012; Masque, Pere/B-7379-2008; Mas, Jose Luis/AAB-2158-2019; Masque, Pere/AAC-9349-2022; Hall, Ian R/C-2755-2009	Méndez, Gema Martínez/0000-0001-7950-6837; Thomas, Alex/0000-0002-0734-9593; Masque, Pere/0000-0002-1789-320X; Mas, Jose Luis/0000-0002-7512-2788; Hall, Ian R/0000-0001-6960-1419; Henderson, Gideon/0000-0002-6279-7137	Ministerio de Ciencia e Innovacion, Spain [AP-2004-4278, REN2002-01958]; Comer Abrupt Climate Change Foundation; Generalitat de Catalunya;  [CGL2007-61579/CLI]; Natural Environment Research Council [NE/F017316/1, NE/D012546/1, NE/F007558/1] Funding Source: researchfish; NERC [NE/D012546/1, NE/F017316/1, NE/F007558/1] Funding Source: UKRI; ICREA Funding Source: Custom	Ministerio de Ciencia e Innovacion, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comer Abrupt Climate Change Foundation; Generalitat de Catalunya(Generalitat de Catalunya); ; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); ICREA(ICREA)	MD02-2594 and MD02-2588 sediment cores were provided by the International Marine Past Global Changes Study (IMAGES) and the Institute Polaire Francais Paul Emile Victor (IPEV). TN057-21 and PS2489-2 samples were supplied by S. Barker and A. Martinez-Garcia. Financial support is acknowledged from the Ministerio de Ciencia e Innovacion, Spain, through scholarship AP-2004-4278 to C.N., REN2002-01958 to G.M.-M., and grant CGL2007-61579/CLI and funds from the Comer Abrupt Climate Change Foundation to R.Z. P.M. acknowledges an ICREA Academia award by the Generalitat de Catalunya.	Adkins JF, 2002, SCIENCE, V298, P1769, DOI 10.1126/science.1076252; Bianchi GG, 1999, SEDIMENTOLOGY, V46, P1001; BOYLE EA, 1987, NATURE, V330, P35, DOI 10.1038/330035a0; Bradtmiller LI, 2007, PALEOCEANOGRAPHY, V22, DOI 10.1029/2007PA001443; Chase Z, 2002, EARTH PLANET SC LETT, V204, P215, DOI 10.1016/S0012-821X(02)00984-6; Curry WB, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001021; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; Fairbanks RG, 2005, QUATERNARY SCI REV, V24, P1781, DOI 10.1016/j.quascirev.2005.04.007; Francois R, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000939; Gherardi JM, 2009, PALEOCEANOGRAPHY, V24, DOI 10.1029/2008PA001696; Gherardi JM, 2005, EARTH PLANET SC LETT, V240, P710, DOI 10.1016/j.epsl.2005.09.061; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Hall IR, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026239; Henderson GM, 2003, REV MINERAL GEOCHEM, V52, P493, DOI 10.2113/0520493; HONJO S, 1993, DEEP-SEA RES PT II, V40, P587, DOI 10.1016/0967-0645(93)90034-K; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; Huhn O, 2008, DEEP-SEA RES PT I, V55, P1252, DOI 10.1016/j.dsr.2008.05.016; Keigwin LD, 2008, PALEOCEANOGRAPHY, V23, DOI 10.1029/2007PA001500; Koroleff F., 1983, METHODS SEAWATER ANA, P174; Lippold J, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL038068; Liu Z, 2009, SCIENCE, V325, P310, DOI 10.1126/science.1171041; Liu ZY, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021929; Lynch-Stieglitz J, 2007, SCIENCE, V316, P66, DOI 10.1126/science.1137127; Marchal O, 2000, PALEOCEANOGRAPHY, V15, P625, DOI 10.1029/2000PA000496; Marchitto TM, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2006GC001323; Martinez-Mendez G, 2008, EARTH PLANET SC LETT, V267, P309, DOI 10.1016/j.epsl.2007.11.050; MARTINEZMENDEZ G, PALEOCEANOG IN PRESS, DOI DOI 10.1029/2009PA001879; MCCAVE IN, 1995, PALEOCEANOGRAPHY, V10, P593, DOI 10.1029/94PA03039; McManus JF, 2004, NATURE, V428, P834, DOI 10.1038/nature02494; MORTLOCK RA, 1989, DEEP-SEA RES, V36, P1415, DOI 10.1016/0198-0149(89)90092-7; Negre C, 2009, ANAL CHEM, V81, P1914, DOI 10.1021/ac802341y; Piotrowski AM, 2005, SCIENCE, V307, P1933, DOI 10.1126/science.1104883; Regelous M, 2004, ANAL CHEM, V76, P3584, DOI 10.1021/ac030374l; Roberts NL, 2010, SCIENCE, V327, P75, DOI 10.1126/science.1178068; Shackleton N.J., 1974, Colloques int Cent natn Res Scient, VNo. 219,1974, P203; Siddall M, 2005, EARTH PLANET SC LETT, V237, P135, DOI 10.1016/j.epsl.2005.05.031; Siddall M, 2007, PALEOCEANOGRAPHY, V22, DOI 10.1029/2006PA001358; Southon J, 2002, RADIOCARBON, V44, P167, DOI 10.1017/S0033822200064778; Taylor S.R., 1985, CONTINENTAL CRUST IT; Thomas AL, 2006, EARTH PLANET SC LETT, V241, P493, DOI 10.1016/j.epsl.2005.11.031; Thomas AL, 2007, PALEOCEANOGRAPHY, V22, DOI 10.1029/2007PA001415; Walter HJ, 1997, EARTH PLANET SC LETT, V149, P85, DOI 10.1016/S0012-821X(97)00068-X; Yu EF, 1996, NATURE, V379, P689, DOI 10.1038/379689a0; Zahn R, 2002, EARTH PLANET SC LETT, V200, P191, DOI 10.1016/S0012-821X(02)00613-1	44	70	72	1	84	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					84	+		10.1038/nature09508	http://dx.doi.org/10.1038/nature09508			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048764	Green Accepted			2022-12-28	WOS:000283786900040
J	Mindell, JA				Mindell, Joseph A.			The Tao of Chloride Transporter Structure	SCIENCE			English	Editorial Material							CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; CHANNEL; SELECTIVITY; ANTIPORTER		NINDS, Membrane Transport Biophys Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Mindell, JA (corresponding author), NINDS, Membrane Transport Biophys Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.	mindellj@ninds.nih.gov	Mindell, Joseph/P-4461-2017	Mindell, Joseph/0000-0002-6952-8247	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Accardi A., COMMUNICATION; Bell SP, 2006, BIOCHEMISTRY-US, V45, P6773, DOI 10.1021/bi0523815; Bennetts B, 2005, J BIOL CHEM, V280, P32452, DOI 10.1074/jbc.M502890200; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Elvington SM, 2009, EMBO J, V28, P3090, DOI 10.1038/emboj.2009.259; Feng LA, 2010, SCIENCE, V330, P635, DOI 10.1126/science.1195230; Forrest LR, 2009, PHYSIOLOGY, V24, P377, DOI 10.1152/physiol.00030.2009; Jayaram H, 2008, P NATL ACAD SCI USA, V105, P11194, DOI 10.1073/pnas.0804503105; Jentsch TJ, 2008, CRIT REV BIOCHEM MOL, V43, P3, DOI [10.1080/10409230701829110, 10.1080/10409230701829110 ]; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Matsuda JJ, 2010, J BIOL CHEM, V285, P2569, DOI 10.1074/jbc.M109.018002; Meyer S, 2006, STRUCTURE, V14, P299, DOI 10.1016/j.str.2005.10.008; Meyer S, 2007, NAT STRUCT MOL BIOL, V14, P60, DOI 10.1038/nsmb1188; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Reyes N, 2009, NATURE, V462, P880, DOI 10.1038/nature08616; Waley A, 1994, WAY ITS POWER LAO TZ, P262	18	2	3	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					601	602		10.1126/science.1198306	http://dx.doi.org/10.1126/science.1198306			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030639				2022-12-28	WOS:000283580600027
J	Mulder, AM; Yoshioka, C; Beck, AH; Bunner, AE; Milligan, RA; Potter, CS; Carragher, B; Williamson, JR				Mulder, Anke M.; Yoshioka, Craig; Beck, Andrea H.; Bunner, Anne E.; Milligan, Ronald A.; Potter, Clinton S.; Carragher, Bridget; Williamson, James R.			Visualizing Ribosome Biogenesis: Parallel Assembly Pathways for the 30S Subunit	SCIENCE			English	Article							ESCHERICHIA-COLI; RNA; PROTEINS; RECONSTITUTION; LANDSCAPE; COMPLEXES; DYNAMICS	Ribosomes are self-assembling macromolecular machines that translate DNA into proteins, and an understanding of ribosome biogenesis is central to cellular physiology. Previous studies on the Escherichia coli 30S subunit suggest that ribosome assembly occurs via multiple parallel pathways rather than through a single rate-limiting step, but little mechanistic information is known about this process. Discovery single-particle profiling (DSP), an application of time-resolved electron microscopy, was used to obtain more than 1 million snapshots of assembling 30S subunits, identify and visualize the structures of 14 assembly intermediates, and monitor the population flux of these intermediates over time. DSP results were integrated with mass spectrometry data to construct the first ribosome-assembly mechanism that incorporates binding dependencies, rate constants, and structural characterization of populated intermediates.	[Beck, Andrea H.; Bunner, Anne E.; Williamson, James R.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Beck, Andrea H.; Bunner, Anne E.; Williamson, James R.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; [Beck, Andrea H.; Bunner, Anne E.; Williamson, James R.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Mulder, Anke M.; Yoshioka, Craig; Milligan, Ronald A.; Potter, Clinton S.; Carragher, Bridget] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Williamson, JR (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	jrwill@scripps.edu	Williamson, James R/B-2891-2009; Williamson, James/AAL-2104-2021; Yoshioka, Craig/ABH-3720-2020	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X; Carragher, Bridget/0000-0002-0624-5020; Bunner, Anne/0000-0002-0305-1300	NIH [RR175173, R37-GM-53757, GM-52468]; NSF; NIH through the National Center for Research Resources [RR175173, RR023093]; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR023093, P41RR017573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053757, R37GM052468, R01GM052468] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NIH through the National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the NIH (grants RR175173, R37-GM-53757, and GM-52468) and the NSF (graduate research fellowship to A. M. M.). The EM data collection and analysis were conducted at the National Resource for Automated Molecular Microscopy, which is supported by the NIH through the National Center for Research Resources P41 program (grants RR175173 and RR023093). We thank N. R. Voss and members of the Automated Molecular Imaging and Williamson laboratories for critical discussion of experiments. MAP, structure factors, and layer-line data have been deposited at EMDB with accession code EMD-1783.	Adilakshmi T, 2008, NATURE, V455, P1268, DOI 10.1038/nature07298; Bunner AE, 2010, J MOL BIOL, V398, P1, DOI 10.1016/j.jmb.2010.02.036; Bunner AE, 2010, P NATL ACAD SCI USA, V107, P5417, DOI 10.1073/pnas.0912007107; Fischer N, 2010, NATURE, V466, P329, DOI 10.1038/nature09206; Frank J, 2006, 3 DIMENSIONAL ELECT; Kaczanowska M, 2007, MICROBIOL MOL BIOL R, V71, P477, DOI 10.1128/MMBR.00013-07; MANDIYAN V, 1991, P NATL ACAD SCI USA, V88, P8174, DOI 10.1073/pnas.88.18.8174; MIZUSHIMA S, 1970, NATURE, V226, P1214, DOI 10.1038/2261214a0; NIERHAUS KH, 1974, P NATL ACAD SCI USA, V71, P4713, DOI 10.1073/pnas.71.12.4713; NOMURA M, 1973, SCIENCE, V179, P864, DOI 10.1126/science.179.4076.864; PAULING L, 1968, P NATL ACAD SCI USA, V60, P59, DOI 10.1073/pnas.60.1.59; POWERS T, 1993, J MOL BIOL, V232, P362, DOI 10.1006/jmbi.1993.1396; Ruiz Teresa, 2006, V319, P403; SERDYUK IN, 1983, J MOL BIOL, V169, P409, DOI 10.1016/S0022-2836(83)80058-8; Sharma MR, 2005, MOL CELL, V18, P319, DOI 10.1016/j.molcel.2005.03.028; Talkington MWT, 2005, NATURE, V438, P628, DOI 10.1038/nature04261; Zhang W, 2008, STRUCTURE, V16, P1770, DOI 10.1016/j.str.2008.10.011	17	144	148	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					673	677		10.1126/science.1193220	http://dx.doi.org/10.1126/science.1193220			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030658	Green Accepted			2022-12-28	WOS:000283580600049
J	Warren, CA; Guerrant, RL				Warren, Cirle A.; Guerrant, Richard L.			Pathogenic C difficile is here (and everywhere) to stay	LANCET			English	Editorial Material							INFECTION; EPIDEMIC; STRAIN		[Guerrant, Richard L.] Univ Virginia, Div Infect Dis, Ctr Global Hlth, Charlottesville, VA 22908 USA; [Warren, Cirle A.] Univ Virginia, Div Infect Dis, Ctr Int Hlth, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Guerrant, RL (corresponding author), Univ Virginia, Div Infect Dis, Ctr Global Hlth, Charlottesville, VA 22908 USA.	guerrant@virginia.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI075526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK067629] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI075526] Funding Source: Medline; NIDDK NIH HHS [P30 DK067629] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akerlund T, 2008, J CLIN MICROBIOL, V46, P1530, DOI 10.1128/JCM.01964-07; ARCHBALDPANNONE L, 2009, UVA J MED, V6, P45; Bakker D, 2010, J CLIN MICROBIOL, V48, P3744, DOI 10.1128/JCM.01171-10; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4; BORRIELLO SP, 1990, ANN MED, V22, P61, DOI 10.3109/07853899009147244; Cloud J, 2009, CLIN GASTROENTEROL H, V7, P868, DOI 10.1016/j.cgh.2009.05.018; Jhung MA, 2008, EMERG INFECT DIS, V14, P1039, DOI 10.3201/eid1407.071641; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; Mullany P, 2010, METHODS MOL BIOL, V646, P1, DOI 10.1007/978-1-60327-365-7; Muto CA, 2005, INFECT CONT HOSP EP, V26, P273, DOI 10.1086/502539; Pawlowski SW, 2009, J HOSP INFECT, V73, P185, DOI 10.1016/j.jhin.2009.05.013; Rabatsky-Ehr T., 2008, Morbidity and Mortality Weekly Report, V57, P340; Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164; Wilson V, 2010, CLIN INFECT DIS, V50, pE77, DOI 10.1086/653012	15	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 1	2011	377	9759					8	9		10.1016/S0140-6736(10)61885-5	http://dx.doi.org/10.1016/S0140-6736(10)61885-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	709MQ	21084110				2022-12-28	WOS:000286445200007
J	Coll, NS; Vercammen, D; Smidler, A; Clover, C; Van Breusegem, F; Dangl, JL; Epple, P				Coll, Nuria S.; Vercammen, Dominique; Smidler, Andrea; Clover, Charles; Van Breusegem, Frank; Dangl, Jeffery L.; Epple, Petra			Arabidopsis Type I Metacaspases Control Cell Death	SCIENCE			English	Article							DISEASE RESISTANCE; SIGNALING COMPONENTS; THALIANA; PROTEASE; LESION-SIMULATING-DISEASE1; ACCLIMATION; SPECIFICITY; BACTERIAL; PATHOGEN; FAMILIES	Metacaspases are distant relatives of animal caspases found in protozoa, fungi, and plants. Limited experimental data exist defining their function(s), despite their discovery by homology modeling a decade ago. We demonstrated that two type I metacaspases, AtMC1 and AtMC2, antagonistically control programmed cell death in Arabidopsis. AtMC1 is a positive regulator of cell death and requires conserved caspase-like putative catalytic residues for its function. AtMC2 negatively regulates cell death. This function is independent of the putative catalytic residues. Manipulation of the Arabidopsis type I metacaspase regulatory module can nearly eliminate the hypersensitive cell death response (HR) activated by plant intracellular immune receptors. This does not lead to enhanced pathogen proliferation, decoupling HR from restriction of pathogen growth.	[Coll, Nuria S.; Smidler, Andrea; Clover, Charles; Dangl, Jeffery L.; Epple, Petra] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; [Vercammen, Dominique; Van Breusegem, Frank] Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; [Vercammen, Dominique; Van Breusegem, Frank] Univ Ghent, Dept Plant Biotechnol & Genet, B-9052 Ghent, Belgium; [Dangl, Jeffery L.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Dangl, Jeffery L.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Dangl, Jeffery L.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dangl, JL (corresponding author), Univ N Carolina, Dept Biol, 108 Coker Hall,CB 3280, Chapel Hill, NC 27599 USA.	dangl@email.unc.edu; pepple@email.unc.edu	Van Breusegem, Frank/AAJ-2647-2020; Coll, Nuria S./Y-6326-2019; Van Breusegem, Frank/Y-2999-2019; Coll, Núria Sánchez/L-4961-2015	Van Breusegem, Frank/0000-0002-3147-0860; Coll, Nuria S./0000-0002-8889-0399; Coll, Núria Sánchez/0000-0002-8889-0399; Smidler, Andrea/0000-0002-3281-1161	NIH [RO1 GM057171]; Swiss National Science Foundation [PBEZA-115173]; Ghent University [12051403]; Fonds voor Wetenschappelijk Onderzoek-Vlaanderen; Direct For Biological Sciences [0639964] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057171] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Ghent University(Ghent University); Fonds voor Wetenschappelijk Onderzoek-Vlaanderen(FWO); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. McDowell (Virginia Tech, Blacksburg, VA) and M. Nishimura (UNC) for critical reading of the manuscript. This work was funded by NIH RO1 GM057171 to J. L. D.; a Swiss National Science Foundation Fellowship (PBEZA-115173) to N.S.C.; and the Research Fund, Ghent University (grant 12051403), and Fonds voor Wetenschappelijk Onderzoek-Vlaanderen to F. V. B. and D. V., respectively. We thank D. Baltrus for statistical analysis, T. Perdue of the UNC Biology Microscope Facility for patient and expert assistance, E. Washington and T. Eitas for pMDC7 vectors, B. van de Cotte for technical assistance, and K. Overmyer for early contributions to this work.	Aravind L, 2002, PROTEINS, V46, P355, DOI 10.1002/prot.10060; Aviv DH, 2002, PLANT J, V29, P381, DOI 10.1046/j.0960-7412.2001.01225.x; Belenghi B, 2007, J BIOL CHEM, V282, P1352, DOI 10.1074/jbc.M608931200; Bozhkov PV, 2005, P NATL ACAD SCI USA, V102, P14463, DOI 10.1073/pnas.0506948102; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; Chichkova NV, 2010, EMBO J, V29, P1149, DOI 10.1038/emboj.2010.1; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859; Hatsugai N, 2009, GENE DEV, V23, P2496, DOI 10.1101/gad.1825209; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Kaminaka H, 2006, EMBO J, V25, P4400, DOI 10.1038/sj.emboj.7601312; Lam E, 2000, PLANT MOL BIOL, V44, pVII; Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358; LeBlanc PM, 2008, CELL HOST MICROBE, V3, P146, DOI 10.1016/j.chom.2008.02.004; Mateo A, 2004, PLANT PHYSIOL, V136, P2818, DOI 10.1104/pp.104.043646; Muhlenbock P, 2008, PLANT CELL, V20, P2339, DOI 10.1105/tpc.108.059618; Muhlenbock P, 2007, PLANT CELL, V19, P3819, DOI 10.1105/tpc.106.048843; Rojo E, 2004, CURR BIOL, V14, P1897, DOI 10.1016/j.cub.2004.09.056; Rusterucci C, 2001, PLANT CELL, V13, P2211, DOI 10.1105/tpc.13.10.2211; Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656; Sundstrom JF, 2009, NAT CELL BIOL, V11, P1347, DOI 10.1038/ncb1979; Szallies A, 2002, FEBS LETT, V517, P144, DOI 10.1016/S0014-5793(02)02608-X; Torres MA, 2005, NAT GENET, V37, P1130, DOI 10.1038/ng1639; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; van der Biezen EA, 2002, PLANT J, V29, P439, DOI 10.1046/j.0960-7412.2001.01229.x; Vercammen D, 2004, J BIOL CHEM, V279, P45329, DOI 10.1074/jbc.M406329200; Vercammen D, 2007, J CELL BIOL, V179, P375, DOI 10.1083/jcb.200705193; Watanabe N, 2005, J BIOL CHEM, V280, P14691, DOI 10.1074/jbc.M413527200	31	290	318	5	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2010	330	6009					1393	1397		10.1126/science.1194980	http://dx.doi.org/10.1126/science.1194980			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	689BK	21097903				2022-12-28	WOS:000284902100046
J	Fang, M; Shen, ZR; Huang, S; Zhao, LP; Chen, S; Mak, TW; Wang, XD				Fang, Min; Shen, Zhirong; Huang, Song; Zhao, Liping; Chen, She; Mak, Tak W.; Wang, Xiaodong			The ER UDPase ENTPD5 Promotes Protein N-Glycosylation, the Warburg Effect, and Proliferation in the PTEN Pathway	CELL			English	Article							SECRETORY PATHWAY; ENDOPLASMIC-RETICULUM; TUMOR-SUPPRESSOR; QUALITY-CONTROL; CELL-SURVIVAL; AKT; KINASE; CANCER; METABOLISM; GROWTH	PI3K and PTEN lipid phosphatase control the level of cellular phosphatidylinositol (3,4,5)-trisphosphate, an activator of AKT kinases that promotes cell growth and survival. Mutations activating AKT are commonly observed in human cancers. We report here that ENTPD5, an endoplasmic reticulum (ER) enzyme, is upregulated in cell lines and primary human tumor samples with active AKT. ENTPD5 hydrolyzes UDP to UMP to promote protein N-glycosylation and folding in ER. Knockdown of ENTPD5 in PTEN null cells causes ER stress and loss of growth factor receptors. ENTPD5, together with cytidine monophosphate kinase-1 and adenylate kinase-1, constitute an ATP hydrolysis cycle that converts ATP to AMP, resulting in a compensatory increase in aerobic glycolysis known as the Warburg effect. The growth of PTEN null cells is inhibited both in vitro and in mouse xenograft tumor models. ENTPD5 is therefore an integral part of the PI3K/PTEN regulatory loop and a potential target for anti-cancer therapy.	[Fang, Min; Shen, Zhirong; Huang, Song; Zhao, Liping; Wang, Xiaodong] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; [Fang, Min; Shen, Zhirong; Huang, Song; Zhao, Liping; Wang, Xiaodong] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Chen, She; Wang, Xiaodong] Natl Inst Biol Sci, Beijing 102206, Peoples R China; [Mak, Tak W.] Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada	Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Institute of Biological Sciences, Beijing; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Wang, XD (corresponding author), Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	xiaodong.wang@utsouthwestern.edu		Wang, Xiaodong/0000-0001-9885-356X; Shen, Zhirong/0000-0003-4552-1670	National Cancer Institute (NCI) [PO1 CA 95471]; Chinese Ministry of Science and Technology; NATIONAL CANCER INSTITUTE [P01CA095471] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to express our gratitude to Drs. Fenghe Du and Liping Liu for excellent technical assistance. We are grateful for Dr. Aijun Liu from the 301 Hospital in Beijing for providing the human prostate tumor samples and Dr. Benjamin Tu from University of Texas Southwestern for help with the phosphofructose sugar measurement. We thank Mr. Gregory Kunkel and Dr. Lai Wang for critical reading of the manuscript. This work is also supported by a grant from the National Cancer Institute (NCI) (PO1 CA 95471) and the National High Technology Projects 863 from Chinese Ministry of Science and Technology.	Bermudo R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-315; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GEVERS W, 1966, BIOCHEM J, V98, P720, DOI 10.1042/bj0980720; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lau KS, 2007, CELL, V129, P123, DOI 10.1016/j.cell.2007.01.049; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Read R, 2009, VET PATHOL, V46, P491, DOI 10.1354/vp.08-VP-0201-R-AM; Robson Simon C, 2006, Purinergic Signal, V2, P409, DOI 10.1007/s11302-006-9003-5; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Warburg O, 1925, KLIN WOCHENSCHR, V4, P534, DOI DOI 10.1007/BF01726151; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	27	148	157	3	64	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2010	143	5					711	724		10.1016/j.cell.2010.10.010	http://dx.doi.org/10.1016/j.cell.2010.10.010			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	684VX	21074248	Bronze			2022-12-28	WOS:000284583500014
J	Someya, S; Yu, W; Hallows, WC; Xu, JZ; Vann, JM; Leeuwenburgh, C; Tanokura, M; Denu, JM; Prolla, TA				Someya, Shinichi; Yu, Wei; Hallows, William C.; Xu, Jinze; Vann, James M.; Leeuwenburgh, Christiaan; Tanokura, Masaru; Denu, John M.; Prolla, Tomas A.			Sirt3 Mediates Reduction of Oxidative Damage and Prevention of Age-Related Hearing Loss under Caloric Restriction	CELL			English	Article							GLUTATHIONE REDOX STATE; DIETARY RESTRICTION; CELL-DEATH; RAT-LIVER; LIFE-SPAN; MICE; DISEASE; STRESS; MITOCHONDRIA; DEACETYLASE	Caloric restriction (CR) extends the life span and health span of a variety of species and slows the progression of age-related hearing loss (AHL), a common age-related disorder associated with oxidative stress. Here, we report that CR reduces oxidative DNA damage in multiple tissues and prevents AHL in wild-type mice but fails to modify these phenotypes in mice lacking the mitochondrial deacetylase Sirt3, a member of the sirtuin family. In response to CR, Sirt3 directly deacetylates and activates mitochondrial isocitrate dehydrogenase 2 (Idh2), leading to increased NADPH levels and an increased ratio of reduced-to-oxidized glutathione in mitochondria. In cultured cells, overexpression of Sirt3 and/or Idh2 increases NADPH levels and protects from oxidative stress-induced cell death. Therefore, our findings identify Sirt3 as an essential player in enhancing the mitochondrial glutathione antioxidant defense system during CR and suggest that Sirt3-dependent mitochondrial adaptations may be a central mechanism of aging retardation in mammals.	[Yu, Wei; Hallows, William C.; Denu, John M.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; [Someya, Shinichi; Vann, James M.; Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; [Someya, Shinichi; Vann, James M.; Prolla, Tomas A.] Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; [Someya, Shinichi; Tanokura, Masaru] Univ Tokyo, Dept Appl Biol Chem, Tokyo 1138657, Japan; [Xu, Jinze; Leeuwenburgh, Christiaan] Univ Florida, Dept Aging & Geriatr, Gainesville, FL 32611 USA; [Xu, Jinze; Leeuwenburgh, Christiaan] Univ Florida, Inst Aging, Gainesville, FL 32611 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Tokyo; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Denu, JM (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.	jmdenu@wisc.edu; taprolla@wisc.edu	YU, WEI/G-4128-2013; Xu, Jinze/G-7868-2011; YU, WEI/C-3822-2012	YU, WEI/0000-0001-9898-4607; Leeuwenburgh, Christiaan/0000-0003-0826-4257; Tanokura, Masaru/0000-0001-5072-2480	NIH [AG021905, GM065386]; Ministry of Education, Culture, Sports, Science, and Technologies of Japan; Marine Bio Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740, R01AG021905] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education, Culture, Sports, Science, and Technologies of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Marine Bio Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank S. Kinoshita for histological processing. This research was supported by NIH grants AG021905 (T.A.P.) and GM065386 (J.M.D.), the National Projects on Protein Structural and Functional Analyses from the Ministry of Education, Culture, Sports, Science, and Technologies of Japan, and Marine Bio Foundation.	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Donmez G, 2010, AGING CELL, V9, P285, DOI 10.1111/j.1474-9726.2010.00548.x; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Halliwell B.G.J.M.C., 2007, FREE RADICALS BIOL M; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hofer T, 2006, BIOL CHEM, V387, P103, DOI 10.1515/BC.2006.014; HUNTER KP, 1987, HEARING RES, V30, P207, DOI 10.1016/0378-5955(87)90137-7; Jiang H, 2007, NEUROBIOL AGING, V28, P1605, DOI 10.1016/j.neurobiolaging.2006.06.025; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Johnson KR, 2010, HEARING RES, V268, P85, DOI 10.1016/j.heares.2010.05.002; Keithley EM, 2004, HEARING RES, V188, P21, DOI 10.1016/S0378-5955(03)00365-4; KORNBERG A, 1955, METHOD ENZYMOL, V1, P705, DOI 10.1016/0076-6879(55)01122-1; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; KUBO K, 1992, BIOCHEMISTRY-US, V31, P3703, DOI 10.1021/bi00129a020; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu XZ, 2007, J PATHOL, V211, P188, DOI 10.1002/path.2102; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McFadden SL, 1999, NEUROBIOL AGING, V20, P1, DOI 10.1016/S0197-4580(99)00018-4; McNeill DR, 2007, MOL CANCER RES, V5, P61, DOI 10.1158/1541-7786.MCR-06-0329; Meira LB, 2009, P NATL ACAD SCI USA, V106, P888, DOI 10.1073/pnas.0807030106; Noben-Trauth K, 2003, NAT GENET, V35, P21, DOI 10.1038/ng1226; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; Paeratakul S, 2002, INT J OBESITY, V26, P1205, DOI 10.1038/sj.ijo.0802026; Poirier P, 2006, ARTERIOSCL THROM VAS, V26, P968, DOI 10.1161/01.ATV.0000216787.85457.f3; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378; Rebrin I, 2003, FREE RADICAL BIO MED, V35, P626, DOI 10.1016/S0891-5849(03)00388-5; Rebrin I, 2008, ADV DRUG DELIVER REV, V60, P1545, DOI 10.1016/j.addr.2008.06.001; Rebrin I, 2007, BRAIN RES, V1127, P10, DOI 10.1016/j.brainres.2006.10.040; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schlicker C, 2008, J MOL BIOL, V382, P790, DOI 10.1016/j.jmb.2008.07.048; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Smith BC, 2009, ANAL BIOCHEM, V394, P101, DOI 10.1016/j.ab.2009.07.019; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Someya S, 2007, NEUROBIOL AGING, V28, P1613, DOI 10.1016/j.neurobiolaging.2006.06.024; Someya S, 2010, MECH AGEING DEV, V131, P480, DOI 10.1016/j.mad.2010.04.006; Someya S, 2009, P NATL ACAD SCI USA, V106, P19432, DOI 10.1073/pnas.0908786106; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; STEEL KP, 1996, HEARING RES, V28, P227; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; SWEET RJ, 1988, AUDIOLOGY, V27, P305; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Weindruch R., 1988, RETARDATION AGING DI; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9; Zhu HY, 1999, BRAIN RES, V842, P224, DOI 10.1016/S0006-8993(99)01827-2	63	842	886	7	141	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2010	143	5					802	812		10.1016/j.cell.2010.10.002	http://dx.doi.org/10.1016/j.cell.2010.10.002			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	684VX	21094524	Green Accepted, Bronze			2022-12-28	WOS:000284583500021
J	Lambert, LC; Fauci, AS				Lambert, Linda C.; Fauci, Anthony S.			CURRENT CONCEPTS Influenza Vaccines for the Future	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; RESEARCH-AND-DEVELOPMENT; PANDEMIC INFLUENZA; MF59-ADJUVANTED INFLUENZA; ANTIBODY-RESPONSE; UNITED-STATES; DNA VACCINES; A VIRUSES; IMMUNOGENICITY; SAFETY		[Lambert, Linda C.] NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA; [Fauci, Anthony S.] NIAID, Off Director, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lambert, LC (corresponding author), NIAID, Div Microbiol & Infect Dis, NIH, 6610 Rockledge Dr, Bethesda, MD 20892 USA.	lclambert@mail.nih.gov						[Anonymous], 2010, MMWR MORB MORTAL WKL, V59, P1057; Ansaldi F, 2010, VACCINE, V28, P4123, DOI 10.1016/j.vaccine.2010.04.030; Atmar RL, 2006, CLIN INFECT DIS, V43, P1135, DOI 10.1086/508174; Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129; Chen ZY, 2010, J VIROL, V84, P44, DOI 10.1128/JVI.02106-09; *CLINICALTRIALS GO, SAF IMM REPL COMP AD; *CLINICALTRIALS GO, 2009, COMP SAF IMM 1 0 MUG; *CLINICALTRIALS GO, 2008, SAF STUD REC M2E INF; ClinicalTrials.gov, SAF IMM STUD AD VECT; Couch RB, 2007, VACCINE, V25, P7656, DOI 10.1016/j.vaccine.2007.08.042; Couch RB, 2009, VACCINE, V27, P5344, DOI 10.1016/j.vaccine.2009.06.084; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; Cryz SJ, 1996, VACCINE, V14, P1381, DOI 10.1016/S0264-410X(96)00040-0; *DEP HLTH HUM SERV, 2010, PUBL HLTH EM MED COU; DiNapoli JM, 2010, J VIROL, V84, P1489, DOI 10.1128/JVI.01946-09; Drape RJ, 2006, VACCINE, V24, P4475, DOI 10.1016/j.vaccine.2005.08.012; Du LY, 2010, MICROBES INFECT, V12, P280, DOI 10.1016/j.micinf.2010.01.001; Ferko B, 2004, J VIROL, V78, P13037, DOI 10.1128/JVI.78.23.13037-13045.2004; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Food and Drug Administration, 2007, GUID IND CLIN DAT NE; Girard MP, 2005, VACCINE, V23, P5708, DOI 10.1016/j.vaccine.2005.07.046; Health Canada, 2009, HLTH CAN APPR PAND H; HEATON P, 2009, 47 ANN M INF DIS SOC; Hoelscher MA, 2006, LANCET, V367, P475, DOI 10.1016/S0140-6736(06)68076-8; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Johansen K, 2009, EUROSURVEILLANCE, V14, P12; Jones S, 2009, VACCINE, V27, P2506, DOI 10.1016/j.vaccine.2009.02.061; Kaiser J, 2006, SCIENCE, V312, P380, DOI 10.1126/science.312.5772.380; Kang SM, 2009, CURR TOP MICROBIOL, V333, P269, DOI 10.1007/978-3-540-92165-3_14; KATZ JM, 1990, J VIROL, V64, P1808, DOI 10.1128/JVI.64.4.1808-1811.1990; Kayamuro H, 2009, BIOMATERIALS, V30, P5869, DOI 10.1016/j.biomaterials.2009.07.009; KILBOURN.ED, 1971, J INFECT DIS, V124, P449, DOI 10.1093/infdis/124.5.449; Kim JH, 2009, CURR TOP MICROBIOL, V333, P197, DOI 10.1007/978-3-540-92165-3_10; Kreijtz JHCM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007790; Laddy DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002517; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Matthews JT, 2006, BRIDGE, V36, P17; Nichol KL, 2006, J INFECT DIS, V194, pS111, DOI 10.1086/507544; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Prabakaran M, 2010, J VIROL, V84, P3201, DOI 10.1128/JVI.02175-09; Price GE, 2009, VACCINE, V27, P6512, DOI 10.1016/j.vaccine.2009.08.053; SCHILD GC, 1983, NATURE, V303, P706, DOI 10.1038/303706a0; Schotsaert M, 2009, EXPERT REV VACCINES, V8, P499, DOI [10.1586/erv.09.6, 10.1586/ERV.09.6]; Schwartz JA, 2010, J VIROL, V84, P4611, DOI 10.1128/JVI.02637-09; Smith LR, 2010, VACCINE, V28, P2565, DOI 10.1016/j.vaccine.2010.01.029; Smith W, 1933, LANCET, V2, P66, DOI 10.1016/S0140-6736(00)78541-2; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Stephenson I, 2006, J VIROL, V80, P4962, DOI 10.1128/JVI.80.10.4962-4970.2006; Subbarao K, 2006, IMMUNITY, V24, P5, DOI 10.1016/j.immuni.2005.12.005; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Talon J, 2000, P NATL ACAD SCI USA, V97, P4309, DOI 10.1073/pnas.070525997; Tang DCC, 2009, EXPERT REV VACCINES, V8, P469, DOI [10.1586/erv.09.1, 10.1586/ERV.09.1]; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Treanor JJ, 2006, J INFECT DIS, V193, P1223, DOI 10.1086/503050; Treanor JJ, 2007, JAMA-J AM MED ASSOC, V297, P1577, DOI 10.1001/jama.297.14.1577; Van Kampen KR, 2005, VACCINE, V23, P1029, DOI 10.1016/j.vaccine.2004.07.043; Vogel FR, 2009, EXPERT REV VACCINES, V8, P483, DOI [10.1586/erv.09.5, 10.1586/ERV.09.5]; Wacheck V, 2010, J INFECT DIS, V201, P354, DOI 10.1086/649428; Wack A, 2008, VACCINE, V26, P552, DOI 10.1016/j.vaccine.2007.11.054; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; Wichmann O, 2010, EUROSURVEILLANCE, V15, P2; World Health Organization (WHO), 2009, INFL LIK ILLN US MEX; 2010, FED REG, V75, P15639	64	235	266	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2036	2044		10.1056/NEJMra1002842	http://dx.doi.org/10.1056/NEJMra1002842			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083388				2022-12-28	WOS:000284310000008
J	Dhruva, SS; Redberg, RF				Dhruva, Sanket S.; Redberg, Rita F.			Accelerated Approval and Possible Withdrawal of Midodrine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Redberg, Rita F.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Redberg, RF (corresponding author), Univ Calif San Francisco, Sch Med, Dept Med, 505 Parnassus Ave,Ste M-1180, San Francisco, CA 94143 USA.	redberg@medicine.ucsf.edu						Fleming TR, 2005, HEALTH AFFAIR, V24, P67, DOI 10.1377/hlthaff.24.1.67; *GEN, 2010, GEN PROV UPD AV ADV; HARRIS G, 2010, NY TIMES        0903; NAINGGOLAN L, FDA DOES U TURN MIDO; POLLACK A, 2010, NY TIMES        0917; Temple R, 1999, JAMA-J AM MED ASSOC, V282, P790, DOI 10.1001/jama.282.8.790; U.S. Government Accounting Office, 2009, NEW DRUG APPR FDA NE; *US FDA, 2010, FDA PROP WITHDR LOW; *US FDA, 2010, MID UPD SEPT 10	9	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2172	2173		10.1001/jama.2010.1695	http://dx.doi.org/10.1001/jama.2010.1695			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081731				2022-12-28	WOS:000284269800029
J	Maxson, E; Jain, S; Kendall, M; Mostashari, F; Blumenthal, D				Maxson, Emily; Jain, Sachin; Kendall, Mat; Mostashari, Farzad; Blumenthal, David			The Regional Extension Center Program: Helping Physicians Meaningfully Use Health Information Technology	ANNALS OF INTERNAL MEDICINE			English	Article							RECORDS; EFFICIENCY; ADOPTION; IMPACT	Many physicians face financial and organizational barriers that inhibit their adoption of electronic health record (EHR) systems. The 2009 Health Information Technology for Economic and Clinical Health Act included provisions to facilitate the transition from paper to electronic records, including Medicare and Medicaid incentive payments to support the adoption and meaningful use of EHR systems. It also created the Health Information Technology Regional Extension Center (REC) program to ease the barriers faced by primary care physicians and rural and critical-access hospitals seeking to implement EHRs. The 60 RECs will administer individualized assistance to primary care practices and rural and critical-access hospitals as they implement new EHR systems or upgrade existing ones. In aggregate, the RECs aim to help 100 000 primary care physicians, physician assistants, and nurse practitioners to effectively implement EHR systems and qualify for incentive payments for meaningful use. This article describes the rationale for the REC program and describes how the 60 RECs promote the meaningful use of EHR systems.	[Maxson, Emily; Jain, Sachin; Kendall, Mat; Mostashari, Farzad; Blumenthal, David] US Dept HHS, Off Natl Coordinator Hlth Informat Technol, Washington, DC 20201 USA		Jain, S (corresponding author), 200 Independence Ave, Washington, DC 20201 USA.		Tao, Youyou/D-2367-2014					Blumenthal D, 2010, NEW ENGL J MED, V363, P501, DOI 10.1056/NEJMp1006114; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Fernandopulle R, 2010, HEALTH AFFAIR, V29, P622, DOI 10.1377/hlthaff.2010.0065; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Mostashari F, 2009, HEALTH AFFAIR, V28, P345, DOI 10.1377/hlthaff.28.2.345; Poissant L, 2005, J AM MED INFORM ASSN, V12, P505, DOI 10.1197/jamia.M1700; Shekelle Paul G, 2006, Evid Rep Technol Assess (Full Rep), P1; Simon SR, 2007, J AM MED INFORM ASSN, V14, P110, DOI 10.1197/jamia.M2187; Torda P, 2010, HEALTH AFFAIR, V29, P668, DOI 10.1377/hlthaff.2010.0188; van der Sijs H, 2010, INT J MED INFORM, V79, P361, DOI 10.1016/j.ijmedinf.2010.01.008; Wang SJ, 2003, AM J MED, V114, P397, DOI 10.1016/S0002-9343(03)00057-3; FED REG, V75, P1843	12	45	45	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					666	670		10.7326/0003-4819-153-10-201011160-00011	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680ES	21079224				2022-12-28	WOS:000284215800021
J	Feachem, RGA; Phillips, AA; Hwang, J; Cotter, C; Wielgosz, B; Greenwood, BM; Sabot, O; Rodriguez, MH; Abeyasinghe, RR; Ghebreyesus, TA; Snow, RW				Feachem, Richard G. A.; Phillips, Allison A.; Hwang, Jimee; Cotter, Chris; Wielgosz, Benjamin; Greenwood, Brian M.; Sabot, Oliver; Henry Rodriguez, Mario; Abeyasinghe, Rabindra R.; Ghebreyesus, Tedros Adhanom; Snow, Robert W.			Malaria Elimination 1 Shrinking the malaria map: progress and prospects	LANCET			English	Article							PRIVATE HEALTH-INSURANCE; GLOBAL PUBLIC-GOODS; PLASMODIUM-FALCIPARUM; VIVAX MALARIA; TRANSMISSION; ERADICATION; COMBINATION; RESISTANCE; MORTALITY; THERAPY	In the past 150 years, roughly half of the countries in the world eliminated malaria. Nowadays, there are 99 endemic countries-67 are controlling malaria and 32 are pursuing an elimination strategy. This four-part Series presents evidence about the technical, operational, and financial dimensions of malaria elimination. The first paper in this Series reviews definitions of elimination and the state that precedes it: controlled low-endemic malaria. Feasibility assessments are described as a crucial step for a country transitioning from controlled low-endemic malaria to elimination. Characteristics of the 32 malaria-eliminating countries are presented, and contrasted with countries that pursued elimination in the past. Challenges and risks of elimination are presented, including Plasmodium vivax, resistance in the parasite and mosquito populations, and potential resurgence if investment and vigilance decrease. The benefits of elimination are outlined, specifically elimination as a regional and global public good. Priorities for the next decade are described.	[Feachem, Richard G. A.] Univ Calif San Francisco, UCSF Global Hlth Sci, Global Hlth Grp, San Francisco, CA 94105 USA; [Hwang, Jimee] Ctr Dis Control & Prevent, Atlanta, GA USA; [Wielgosz, Benjamin] Int Food Policy Res Inst, Washington, DC 20036 USA; [Greenwood, Brian M.] London Sch Hyg & Trop Med, London WC1, England; [Sabot, Oliver] Clinton Hlth Access Initiat, Boston, MA USA; [Henry Rodriguez, Mario] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Abeyasinghe, Rabindra R.] Minist Hlth, Colombo, Sri Lanka; [Ghebreyesus, Tedros Adhanom] Minist Hlth, Addis Ababa, Ethiopia; [Snow, Robert W.] Kenya Govt Med Res Ctr, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; [Snow, Robert W.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Ctr Vaccinol & Trop Med CCVTM, Oxford, England	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; CGIAR; International Food Policy Research Institute (IFPRI); University of London; London School of Hygiene & Tropical Medicine; Instituto Nacional de Salud Publica; Kenya Medical Research Institute; University of Oxford	Feachem, RGA (corresponding author), Univ Calif San Francisco, UCSF Global Hlth Sci, Global Hlth Grp, 50 Beale St,Suite 1200, San Francisco, CA 94105 USA.	feachemr@globalhealth.ucsf.edu	Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088	Bill & Melinda Gates Foundation; ExxonMobil; Wellcome Trust [078925]; Kenyan Medical Research Institute (KEMRI); Consultative Group on International Agricultural Research; United States Agency for International Development; German Federal Ministry for Economic Cooperation and Development; World Bank Group; Novartis; Pfizer	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); ExxonMobil(Exxon Mobil Corporation); Wellcome Trust(Wellcome TrustEuropean Commission); Kenyan Medical Research Institute (KEMRI); Consultative Group on International Agricultural Research; United States Agency for International Development(United States Agency for International Development (USAID)); German Federal Ministry for Economic Cooperation and Development; World Bank Group; Novartis(Novartis); Pfizer(Pfizer)	The work of the Global Health Group on malaria elimination is supported by grants from the Bill & Melinda Gates Foundation and ExxonMobil. RWS is a Wellcome Trust Principal Research Fellow (#078925) and acknowledges the support of the Kenyan Medical Research Institute (KEMRI). BW is supported by the Consultative Group on International Agricultural Research, the Bill & Melinda Gates Foundation, United States Agency for International Development, the German Federal Ministry for Economic Cooperation and Development, and the World Bank Group. The authors acknowledge the members of the Malaria Elimination Group for reinvigorating the science and practice of malaria elimination. We are grateful to the five anonymous reviewers of this paper for their extremely helpful comments. We also thank Hyun-Ju Woo for invaluable assistance in the preparation of the manuscript.; RGAF, CC, and AAP, work at the Global Health Group of the University of California, San Francisco, CA, USA. The Global Health Group exists in part to support countries that are embarked on an evidence-based pathway towards elimination. RRA, TAG, and MHR play leading roles in the malaria elimination programmes of Sri Lanka, Ethiopia, and Mexico, respectively. OS leads the malaria programme at the Clinton Health Access Initiative which actively supports malaria elimination in southern Africa. RGAF, AAP, BMG, OS, MHR, RRA, and RWS serve as members of the Malaria Elimination Group. RWS has received funding from Novartis for chairing meetings of national control programmes in Africa and has received a research grant from Pfizer. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of their employing organisations nor of the sources of funding.	*ALL PART PARL GRO, 2007, FIN MECH MAL; *ALL PART PARL GRO, 2010, CONTR MAL 2005 15 PR; ANDREWS JM, 1959, 6 INT C TROP MED MAL, P652; *ANGLOGOLD ASH, NAT MOD MAL CONTR GH; Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; [Anonymous], 2008, MAL RAP DIAGN TEST P; [Anonymous], 2006, IRIN NEWS; [Anonymous], GLOB MAL ACT PLAN MA; [Anonymous], DAILY NEWS; [Anonymous], 2007, BUS HLTH AFR PARTN P; Atkinson JA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-298; Atkinson JA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-119; Atkinson JAM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-93; Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011; Baird JK, 2003, TRENDS PARASITOL, V19, P115, DOI 10.1016/S1471-4922(03)00005-9; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; CHAIN KL, 1985, SINGAPORES DENGUE HA; Cohen JM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-213; Coleman M, 2010, T ROY SOC TROP MED H, V104, P143, DOI 10.1016/j.trstmh.2009.07.010; Cook J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-169; D'Ortenzio E, 2010, T ROY SOC TROP MED H, V104, P251, DOI 10.1016/j.trstmh.2009.10.008; Delacollette C, 2006, WHO GMP INFORMAL CON; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Dowdle W R, 1998, Bull World Health Organ, V76 Suppl 2, P22; DUANE J, 1998, EMERG INFECT DIS, V4, P442; Feachem RGA, 2002, NATURE, V417, P695, DOI 10.1038/417695a; Feachem RGA, 2009, SHRINKING MALARIA MA; Feachem R, 2008, LANCET, V371, P1633, DOI 10.1016/S0140-6736(08)60424-9; Feachem RGA, 2010, LANCET, V376, P1517, DOI 10.1016/S0140-6736(10)61500-0; FONTAINE RE, 1961, AM J TROP MED HYG, V10, P795, DOI 10.4269/ajtmh.1961.10.795; GALAPPATHTHY GNL, 2010, 2 AS PAC MAL EL NETW; *GLOB FUND FIGHT A, 2010, GLOB FUND 2010 INN I; *GLOB FUND FIGHT A, GRANT PORTF; *GLOB HLTH GROUP, EL 8 E8 REG IN; GOH K T, 1983, SMJ Singapore Medical Journal, V24, P255; Greenwood B, 2009, PARASITE IMMUNOL, V31, P582, DOI 10.1111/j.1365-3024.2009.01140.x; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Hsiang MS, 2010, LANCET, V375, P1586, DOI 10.1016/S0140-6736(10)60350-9; Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5; Kaneko A, 2010, ACTA TROP, V114, P177, DOI 10.1016/j.actatropica.2010.01.012; KAUL I, 2002, PROVIDING GLOBAL PUB, P1; Keating J, 2010, LANCET INFECT DIS, V10, P291, DOI 10.1016/S1473-3099(10)70075-X; *KINGD MOR MIN HLT, 2007, MAL EL STRAT MOR PLA; Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882, DOI 10.4269/ajtmh.2009.80.882; Laxminarayan R, 2009, HEALTH AFFAIR, V28, P949, DOI 10.1377/hlthaff.28.4.949; Lee Y, 2009, ANN ACAD MED SINGAP, V38, P840; LEPERS JP, 1988, LANCET, V1, P586; Lines J., 2007, PROSPECTS ERADICATIO; Lines J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a869; *MAR OIL CORP, MAL CONTR PROJ; Matthys B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-217; Maude RJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-31; Mendis K, 2009, TROP MED INT HEALTH, V14, P802, DOI 10.1111/j.1365-3156.2009.02287.x; Mills A, 2002, B WORLD HEALTH ORGAN, V80, P325; Molyneux DH, 2004, TRENDS PARASITOL, V20, P347, DOI 10.1016/j.pt.2004.06.004; Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; Najera J., 1999, WHOCDSRBM9910; NAJERA JA, 1989, B WORLD HEALTH ORGAN, V67, P229; Newman RD, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2714; Noedl H, 2009, NEW ENGL J MED, V361, P540, DOI 10.1056/NEJMc0900231; Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33; Otten M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-14; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; Phimpraphi W, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-99; *PRES MAL IN, 2009, MAL OP PLAN FY10 MAD; *PRES MAL IN, PMI COUNTR PROF; Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Reid H, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-150; Robert V, 2003, AM J TROP MED HYG, V68, P169, DOI 10.4269/ajtmh.2003.68.169; *ROLL BACK MAL PAR, 2010, PROGR IMP SER MAL FU; Sabot O, 2010, LANCET, V376, P1604, DOI 10.1016/S0140-6736(10)61355-4; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; *SAMERG MAL RES LE, 2009, SAMERG M OBJ M UNPUB, V2; Sandler T, 2006, REV INT ORGAN, V1, P5, DOI 10.1007/s11558-006-6604-2; Sattabongkot J, 2004, TRENDS PARASITOL, V20, P192, DOI 10.1016/j.pt.2004.02.001; Scheffler RM, 2008, B WORLD HEALTH ORGAN, V86, P516, DOI 10.2471/BLT.07.046474; SEHGAL BS, 1985, MOBIUS J CONT ED PRO, V5, P4; Sekhri N, 2005, B WORLD HEALTH ORGAN, V83, P127; Sekhri N, 2006, INT J HEALTH PLAN M, V21, P357, DOI 10.1002/hpm.857; Smith RD, 2007, GLOBALIZATION HEALTH, V3, DOI 10.1186/1744-8603-3-9; Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Snow RW, 2001, TRENDS PARASITOL, V17, P593, DOI 10.1016/S1471-4922(01)02031-1; Snow RW, 2002, ADV PARASIT, V52, P235, DOI 10.1016/S0065-308X(02)52013-3; *SO AFR DEV COMM, 2007, SADC MAL STRAT PLAN; Tang LH, 2000, CHINESE MED J-PEKING, V113, P89; TANTULAR I, 2002, TROP MED INT HEALTH, V4, P245; Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3; Tatem AJ, 2010, P NATL ACAD SCI USA, V107, P12222, DOI 10.1073/pnas.1002971107; Teklehaimanot HD, 2009, AM J TROP MED HYG, V80, P133, DOI 10.4269/ajtmh.2009.80.133; *UN, 2008, SECR GEN ANN ROLL BA; *USAID, 2009, MEAS IMP HLTH SYST S; von Seidlein L, 2003, T ROY SOC TROP MED H, V97, P217, DOI 10.1016/S0035-9203(03)90125-8; von Seidlein L, 2003, TRENDS PARASITOL, V19, P452, DOI 10.1016/j.pt.2003.08.003; Wells TNC, 2010, TRENDS PARASITOL, V26, P145, DOI 10.1016/j.pt.2009.12.005; Wernsdorfer W.H., 1980, P1; Wernsdorfer WH, 2009, SHRINKING MALARIA MA, P95; *WHO, 2008, GLOB MAL CONTR EL M; *WHO, 16 WHO EXP COMM MAL; *WHO, WORLD MAL REP 2009; *WHO REG OFF EUR, 2006, TASHK DECL MOV MAL C; WHO: Regional Office for the Eastern Mediterranean, 2007, GUID EL RES FOC MAL; WIJESUNDERA MD, 1988, PARASITOL TODAY, V4, P147, DOI 10.1016/0169-4758(88)90193-7; WILFORD JN, 2010, NY TIMES; Wipasa J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000770; *WORLD BANK, HNP STATS HLTH FIN; World Bank, 2010, GROSS NAT INC PER CA; World Health Organization, WORLD HLTH STAT 2009; World Health Organization, 2007, MAL EL FIELD MAN LOW; World Health Organization, 1969, REEX GLOB STRAT MAL; World Health Organization, 2000, WORLD HLTH REP 2000; *ZANZ MAL CONTR PR, 2009, MAL EL FEAS ASS	115	286	299	0	67	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1566	1578		10.1016/S0140-6736(10)61270-6	http://dx.doi.org/10.1016/S0140-6736(10)61270-6			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	21035842	Green Published			2022-12-28	WOS:000284248700034
J	Dalva, MB				Dalva, Matthew B.			Ephecting Excitatory Synapse Development	CELL			English	Editorial Material							EPHEXIN1	Alterations in synapse number and morphology are associated with devastating psychiatric and neurologic disorders. In this issue of Cell, Margolis et al. (2010) show that the RhoA-guanine exchange factor (GEF) Ephexin5 limits the numbers of excitatory synapses that neurons receive, thus identifying a new mechanism controlling synaptogenesis.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania	Dalva, MB (corresponding author), Univ Penn, Sch Med, Dept Neurosci, 421 Curie Blvd, Philadelphia, PA 19104 USA.	dalva@mail.med.upenn.edu		Dalva, Matthew/0000-0002-7737-8787	NIDA NIH HHS [R01 DA022727] Funding Source: Medline; NIMH NIH HHS [R01 MH086425] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH086425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA022727] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Dalva MB, 2007, NAT REV NEUROSCI, V8, P206, DOI 10.1038/nrn2075; Dan B, 2009, EPILEPSIA, V50, P2331, DOI 10.1111/j.1528-1167.2009.02311.x; Flavell SW, 2006, SCIENCE, V311, P1008, DOI 10.1126/science.1122511; Kayser MS, 2008, NEURON, V59, P56, DOI 10.1016/j.neuron.2008.05.007; Margolis SS, 2010, CELL, V143, P442, DOI 10.1016/j.cell.2010.09.038; Ogita H, 2003, CIRC RES, V93, P23, DOI 10.1161/01.RES.0000079310.81429.C8; Patel MR, 2009, SCIENCE, V323, P1500, DOI 10.1126/science.1169025; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Shi L, 2010, NEURON, V65, P204, DOI 10.1016/j.neuron.2010.01.012	10	2	2	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 29	2010	143	3					341	342		10.1016/j.cell.2010.10.017	http://dx.doi.org/10.1016/j.cell.2010.10.017			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029857	Bronze, Green Accepted			2022-12-28	WOS:000283603900008
J	Wassarman, PM; Litscher, ES				Wassarman, Paul M.; Litscher, Eveline S.			Egg's ZP3 Structure Speaks Volumes	CELL			English	Editorial Material							DOMAIN	Binding of mammalian sperm to eggs depends in part on ZP3, a glycoprotein in the egg's extracellular coat, the zona pellucida. In this issue, Han et al. (2010) describe the structure of an avian ZP3 homolog, providing insights into ZP3 processing and polymerization and the roles of the ZP3 polypeptide and its carbohydrate in sperm binding.	[Wassarman, Paul M.; Litscher, Eveline S.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Wassarman, PM (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, 1468 Madison Ave, New York, NY 10029 USA.	paul.wassarman@mssm.edu						Clark GF, 2006, J BIOL CHEM, V281, P13853, DOI 10.1074/jbc.R600001200; FLORMAN HM, 2006, PHYSL REPROD, P55; Gahlay G, 2010, SCIENCE, V329, P216, DOI 10.1126/science.1188178; Han L, 2010, CELL, V143, P404, DOI 10.1016/j.cell.2010.09.041; Jovine L, 2005, ANNU REV BIOCHEM, V74, P83, DOI 10.1146/annurev.biochem.74.082803.133039; Monne M, 2008, NATURE, V456, P653, DOI 10.1038/nature07599; Turner LM, 2008, INT J DEV BIOL, V52, P769, DOI 10.1387/ijdb.082577lt; Varki A., 2009, ESSENTIALS GLYCOBIOL, P784; Wassarman PM, 2008, INT J DEV BIOL, V52, P665, DOI 10.1387/ijdb.072524pw; Wassarman PM, 2008, J BIOL CHEM, V283, P24285, DOI 10.1074/jbc.R800027200	10	7	8	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					337	338		10.1016/j.cell.2010.10.013	http://dx.doi.org/10.1016/j.cell.2010.10.013			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029855	Bronze			2022-12-28	WOS:000283603900006
J	Xiang, Y; Yuan, QA; Vogt, N; Looger, LL; Jan, LY; Jan, YN				Xiang, Yang; Yuan, Quan; Vogt, Nina; Looger, Loren L.; Jan, Lily Yeh; Jan, Yuh Nung			Light-avoidance-mediating photoreceptors tile the Drosophila larval body wall	NATURE			English	Article							DEG/ENAC PROTEIN PICKPOCKET1; PROGRAMMED CELL-DEATH; SENSORY NEURONS; C-ELEGANS; GENE; EXPRESSION; CHANNELS; TRANSDUCTION; NOCICEPTION; VERTEBRATES	Photoreceptors for visual perception, phototaxis or light avoidance are typically clustered in eyes or related structures such as the Bolwig organ of Drosophila larvae. Unexpectedly, we found that the class IV dendritic arborization neurons of Drosophila melanogaster larvae respond to ultraviolet, violet and blue light, and are major mediators of light avoidance, particularly at high intensities. These class IV dendritic arborization neurons, which are present in every body segment, have dendrites tiling the larval body wall nearly completely without redundancy. Dendritic illumination activates class IV dendritic arborization neurons. These novel photoreceptors use phototransduction machinery distinct from other photoreceptors in Drosophila and enable larvae to sense light exposure over their entire bodies and move out of danger.	[Xiang, Yang; Yuan, Quan; Jan, Lily Yeh; Jan, Yuh Nung] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94158 USA; [Xiang, Yang; Yuan, Quan; Jan, Lily Yeh; Jan, Yuh Nung] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem, San Francisco, CA 94158 USA; [Xiang, Yang; Yuan, Quan; Jan, Lily Yeh; Jan, Yuh Nung] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biophys, San Francisco, CA 94158 USA; [Vogt, Nina] NYU, Ctr Dev Genet, New York, NY 10003 USA; [Looger, Loren L.] Howard Hughes Med Inst, Ashburn, VA 20147 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; New York University; Howard Hughes Medical Institute	Jan, YN (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Physiol, San Francisco, CA 94158 USA.	yuhnung.jan@ucsf.edu	Yuan, Quan/E-7688-2013	Jan, Lily/0000-0003-3938-8498; Vogt, Nina/0000-0002-2658-9138; Jan, Yuh Nung/0000-0003-1367-6299	Human Frontier Science Program; Deutsche Forschungsgemeinschaft; NIH [2R37NS040929]; Howard Hughes Medical Institute, Janelia Farm Campus; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH084234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS040929] Funding Source: NIH RePORTER	Human Frontier Science Program(Human Frontier Science Program); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute, Janelia Farm Campus(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank P. Garrity, C. Desplan, J. Blau, C. Montell, J. Hall, H. Amrein, L. Tian, S. Younger and S. Zhu for fly stocks and reagents; T. Jin for technical support; C. Han for generating whole larval images; H. H. Lee for collaboration to identify the 19-12-GAL4 and 21-7-GAL4 lines; R. Yang, H. H. Lee, B. Ye, J. Parrish, P. Soba, B. Schroeder and J. Bagley for discussions and advice; B. Ye, R. Yang, W. Ge and J. Berg for critical reading of the manuscript; and Jan laboratory members for discussions. Y.X. was a recipient of a Long-term Fellowship from the Human Frontier Science Program, N.V. is supported by Deutsche Forschungsgemeinschaft. This work is supported by a NIH grant (2R37NS040929) to Y.N.J. Y.X. and Q.Y. are associates, L.Y.J. and Y.N.J. are investigators of the Howard Hughes Medical Institute. L. L. L. is supported by the Howard Hughes Medical Institute, Janelia Farm Campus.	Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Ainsley JA, 2003, CURR BIOL, V13, P1557, DOI 10.1016/S0960-9822(03)00596-7; Ainsley JA, 2008, DEV BIOL, V322, P46, DOI 10.1016/j.ydbio.2008.07.003; AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; Bai JW, 2009, NAT PROTOC, V4, P1502, DOI 10.1038/nprot.2009.147; Dolezelova E, 2007, GENETICS, V177, P329, DOI 10.1534/genetics.107.076513; Edwards SL, 2008, PLOS BIOL, V6, P1715, DOI 10.1371/journal.pbio.0060198; Fu YB, 2005, CURR OPIN NEUROBIOL, V15, P415, DOI 10.1016/j.conb.2005.06.011; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Grueber WB, 2003, CURR BIOL, V13, P618, DOI 10.1016/S0960-9822(03)00207-0; Grueber WB, 2002, DEVELOPMENT, V129, P2867; Grueber WB, 2007, DEVELOPMENT, V134, P55, DOI 10.1242/dev.02666; Halford S, 2009, CURR BIOL, V19, P1396, DOI 10.1016/j.cub.2009.06.066; Hamada FN, 2008, NATURE, V454, P217, DOI 10.1038/nature07001; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Hwang RY, 2007, CURR BIOL, V17, P2105, DOI 10.1016/j.cub.2007.11.029; Kang K, 2010, NATURE, V464, P597, DOI 10.1038/nature08848; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Kwon Y, 2008, NAT NEUROSCI, V11, P871, DOI 10.1038/nn.2170; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Liu J, 2010, NAT NEUROSCI, V13, P715, DOI 10.1038/nn.2540; Mazzoni EO, 2005, NEURON, V45, P293, DOI 10.1016/j.neuron.2004.12.038; Millott N., 1968, Symposia of the Zoological Society of London, VNo. 23, P1; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; MONTELL C, 1985, SCIENCE, V230, P1040, DOI 10.1126/science.3933112; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Phillips JB, 2001, J EXP BIOL, V204, P2543; POLLOCK JA, 1988, NATURE, V333, P779, DOI 10.1038/333779a0; Rosenzweig M, 2005, GENE DEV, V19, P419, DOI 10.1101/gad.1278205; SAITO M, 1991, J NEUROSCI, V11, P2135; SawinMcCormack EP, 1995, J NEUROGENET, V10, P119, DOI 10.3109/01677069509083459; Schroll C, 2006, CURR BIOL, V16, P1741, DOI 10.1016/j.cub.2006.07.023; Sprecher SG, 2008, NATURE, V454, P533, DOI 10.1038/nature07062; STEVEN DM, 1963, BIOL REV, V38, P204, DOI 10.1111/j.1469-185X.1963.tb00783.x; Thorne N, 2008, J COMP NEUROL, V506, P548, DOI 10.1002/cne.21547; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Ueda A, 2008, J NEUROGENET, V22, P103, DOI 10.1080/01677060701807954; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Ward A, 2008, NAT NEUROSCI, V11, P916, DOI 10.1038/nn.2155; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILLSON RC, 1981, SCIENCE, V211, P700, DOI 10.1126/science.211.4483.700; Xu KY, 2004, CURR BIOL, V14, P1025, DOI 10.1016/j.cub.2004.05.055; Yau KW, 2009, CELL, V139, P246, DOI 10.1016/j.cell.2009.09.029; Zhang F, 2007, NAT REV NEUROSCI, V8, P577, DOI 10.1038/nrn2192; Zhong LX, 2010, CURR BIOL, V20, P429, DOI 10.1016/j.cub.2009.12.057; [No title captured]	49	295	299	3	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	2010	468	7326					921	U312		10.1038/nature09576	http://dx.doi.org/10.1038/nature09576			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	695BC	21068723	Green Accepted			2022-12-28	WOS:000285344600038
J	Cecchini, M; Sassi, F; Lauer, JA; Lee, YY; Guajardo-Barron, V; Chisholm, D				Cecchini, Michele; Sassi, Franco; Lauer, Jeremy A.; Lee, Yong Y.; Guajardo-Barron, Veronica; Chisholm, Daniel			Chronic Diseases: Chronic Diseases and Development 3 Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness	LANCET			English	Article							MIDDLE-INCOME COUNTRIES; CARDIOVASCULAR-DISEASE; PREVENTION; INTERVENTIONS; TRANSITION; BURDEN; REDUCE; RISK	The obesity epidemic is spreading to low-income and middle-income countries as a result of new dietary habits and sedentary ways of life, fuelling chronic diseases and premature mortality. In this report we present an assessment of public health strategies designed to tackle behavioural risk factors for chronic diseases that are closely linked with obesity, including aspects of diet and physical inactivity, in Brazil, China, India, Mexico, Russia, and South Africa. England was included for comparative purposes. Several population-based prevention policies can be expected to generate substantial health gains while entirely or largely paying for themselves through future reductions of health-care expenditures. These strategies include health information and communication strategies that improve population awareness about the benefits of healthy eating and physical activity; fiscal measures that increase the price of unhealthy food content or reduce the cost of healthy foods rich in fibre; and regulatory measures that improve nutritional information or restrict the marketing of unhealthy foods to children. A package of measures for the prevention of chronic diseases would deliver substantial health gains, with a very favourable cost-effectiveness profile.	[Sassi, Franco] Org Econ Cooperat & Dev, Hlth Div, Directorate Employment Labour & Social Affairs, F-75775 Paris 16, France; [Lauer, Jeremy A.; Chisholm, Daniel] WHO, Hlth Syst Financing, CH-1211 Geneva, Switzerland; [Lee, Yong Y.] Univ Queensland, Sch Populat Hlth, Ctr Burden Dis & Cost Effectiveness, Brisbane, Qld, Australia; [Guajardo-Barron, Veronica] Minist Hlth, Econ Anal Unit, Mexico City, DF, Mexico	Organisation for Economic Co-operation & Development (OECD); World Health Organization; University of Queensland	Sassi, F (corresponding author), Org Econ Cooperat & Dev, Hlth Div, Directorate Employment Labour & Social Affairs, 2 Rue Andre Pascal, F-75775 Paris 16, France.	franco.sassi@oecd.org	Lee, Yong Yi/C-1373-2015	Lee, Yong Yi/0000-0003-2359-6823; Sassi, Franco/0000-0001-9773-2117				Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Adam T, 2006, SOC SCI MED, V63, P1700, DOI 10.1016/j.socscimed.2006.04.023; Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; Anderson P, 2009, LANCET, V373, P2234, DOI 10.1016/S0140-6736(09)60744-3; Asaria P, 2007, LANCET, V370, P2044, DOI 10.1016/S0140-6736(07)61698-5; Baillie K, 2008, OBES REV, V9, P146, DOI 10.1111/j.1467-789X.2007.00457.x; Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824; Food and Agriculture Organization of the United Nations, 2006, DOUBL BURD MALN CAS; Gaziano TA, 2007, LANCET, V370, P1939, DOI 10.1016/S0140-6736(07)61697-3; Gonzalez-Pier E, 2006, LANCET, V368, P1608, DOI 10.1016/S0140-6736(06)69567-6; *GOV IND PRESS INF, 2008, PIL PHAS NAT PROGR P; Jha P., 2000, TOBACCO CONTROL DEV; Johns Benjamin, 2006, Cost Eff Resour Alloc, V4, P8, DOI 10.1186/1478-7547-4-8; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; LU Y, 2010, NBER WORKING PAPER S; Monteiro CA, 2007, AM J PUBLIC HEALTH, V97, P1808, DOI 10.2105/AJPH.2006.099630; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; OLAIZFERNANDEZ G, 2006, ENC NAC SAL NUTR 200; Prentice AM, 2006, INT J EPIDEMIOL, V35, P93, DOI 10.1093/ije/dyi272; Puoane T, 2002, OBES RES, V10, P1038, DOI 10.1038/oby.2002.141; Sassi F, 2010, OBESITY EC PREVENTIO; Sassi F., 2009, 48 OECD; *STAT RES CTR PREV, 2008, STRAT PREV CONTR NON; Wang Y, 2009, OBES REV, V10, P456, DOI 10.1111/j.1467-789X.2009.00568.x; *WHO, 2010, WHO INF; *WHO REG OFF EUR, 2010, NUTR POL DAT; WILLETT WC, 2006, DIS CONTROL PRIORITI, P869; World Health Organization, 2008, 2008 2013 ACT PLAN G; World Health Organization, 2009, INT DIET PHYS ACT WH; World Health Organization, 2004, GLOB STRAT DIET PHYS; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292	32	529	556	6	175	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2010	376	9754					1775	1784		10.1016/S0140-6736(10)61514-0	http://dx.doi.org/10.1016/S0140-6736(10)61514-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690EI	21074255				2022-12-28	WOS:000284984900033
J	Ronald, PC; Beutler, B				Ronald, Pamela C.; Beutler, Bruce			Plant and Animal Sensors of Conserved Microbial Signatures	SCIENCE			English	Review							DISEASE RESISTANCE; SIGNALING PATHWAYS; IMMUNE-RESPONSE; INNATE IMMUNITY; TOLL; BACTERIAL; GENE; RECOGNITION; RECEPTORS; FLAGELLIN	The last common ancestor of plants and animals may have lived 1 billion years ago. Plants and animals have occasionally exchanged genes but, for the most part, have countered selective pressures independently. Microbes (bacteria, eukaryotes, and viruses) were omnipresent threats, influencing the direction of multicellular evolution. Receptors that detect molecular signatures of infectious organisms mediate awareness of nonself and are integral to host defense in plants and animals alike. The discoveries leading to elucidation of these receptors and their ligands followed a similar logical and methodological pathway in both plant and animal research.	[Ronald, Pamela C.] Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; [Ronald, Pamela C.] Joint Bioenergy Inst, Emeryville, CA 94710 USA; [Ronald, Pamela C.] Kyung Hee Univ, Crop Biotech Inst, Yongin 446701, South Korea; [Ronald, Pamela C.] Kyung Hee Univ, Dept Plant Mol Syst Biotechnol, Yongin 446701, South Korea; [Beutler, Bruce] Scripps Res Inst, Dept Genet, La Jolla, CA 92037 USA	University of California System; University of California Davis; United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Kyung Hee University; Kyung Hee University; Scripps Research Institute	Ronald, PC (corresponding author), Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.	pcronald@ucdavis.edu	Ronald, Pamela/AAK-7664-2020					Ausubel FM, 2005, NAT IMMUNOL, V6, P973, DOI 10.1038/ni1253; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Boller T, 2009, SCIENCE, V324, P742, DOI 10.1126/science.1171647; Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Cirl C, 2010, INT J MED MICROBIOL, V300, P396, DOI 10.1016/j.ijmm.2010.04.001; Cooper MD, 2006, CELL, V124, P815, DOI 10.1016/j.cell.2006.02.001; Dardick C, 2006, PLOS PATHOG, V2, P14, DOI 10.1371/journal.ppat.0020002; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Fu DL, 2009, SCIENCE, V323, P1357, DOI 10.1126/science.1166289; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; Lee SW, 2009, SCIENCE, V326, P850, DOI 10.1126/science.1173438; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; O'Neill LAJ, 2008, IMMUNITY, V29, P12, DOI 10.1016/j.immuni.2008.06.004; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Robatzek S, 2006, GENE DEV, V20, P537, DOI 10.1101/gad.366506; Smirnova I, 2000, GENOME BIOL, V1; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; Taguchi T, 1996, GENOMICS, V32, P486, DOI 10.1006/geno.1996.0150; Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485	27	174	183	6	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2010	330	6007					1061	1064		10.1126/science.1189468	http://dx.doi.org/10.1126/science.1189468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097929	Green Published			2022-12-28	WOS:000284374700031
J	Yu, JM; Broecker, WS; Elderfield, H; Jin, ZD; McManus, J; Zhang, F				Yu, Jimin; Broecker, Wally S.; Elderfield, Harry; Jin, Zhangdong; McManus, Jerry; Zhang, Fei			Loss of Carbon from the Deep Sea Since the Last Glacial Maximum	SCIENCE			English	Article							BENTHIC FORAMINIFERAL B/CA; SOUTHERN-OCEAN; ATMOSPHERIC CO2; ATLANTIC-OCEAN; NORTH-ATLANTIC; PACIFIC-OCEAN; CIRCULATION; WATER; ION; PH	Deep-ocean carbonate ion concentrations ([CO(3)(2-)]) and carbon isotopic ratios (delta(13)C) place important constraints on past redistributions of carbon in the ocean-land-atmosphere system and hence provide clues to the causes of atmospheric CO(2) concentration changes. However, existing deep-sea [CO(3)(2-)] reconstructions conflict with one another, complicating paleoceanographic interpretations. Here, we present deep-sea [CO(3)(2-)] for five cores from the three major oceans quantified using benthic foraminiferal boron/calcium ratios since the last glacial period. Combined benthic delta(13)C and [CO(3)(2-)] results indicate that deep-sea-released CO(2) during the early deglacial period (17.5 to 14.5 thousand years ago) was preferentially stored in the atmosphere, whereas during the late deglacial period (14 to 10 thousand years ago), besides contributing to the contemporary atmospheric CO(2) rise, a substantial portion of CO(2) released from oceans was absorbed by the terrestrial biosphere.	[Yu, Jimin; Broecker, Wally S.; McManus, Jerry] Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; [Elderfield, Harry] Univ Cambridge, Dept Earth Sci, Godwin Lab Palaeoclimate Res, Cambridge CB2 3EQ, England; [Jin, Zhangdong; Zhang, Fei] Chinese Acad Sci, Inst Earth Environm, State Key Lab Loess & Quaternary Geol, Xian 710075, Peoples R China	Columbia University; University of Cambridge; Chinese Academy of Sciences; Institute of Earth Environment, CAS	Yu, JM (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, 61 Route 9W,POB 1000, Palisades, NY 10964 USA.	jiminyu@ldeo.columbia.edu	张, 飞/T-3895-2019; Zhang, Fei/I-8831-2014; Yu, Jimin/I-7770-2012; Jin, Zhangdong/I-8642-2014	张, 飞/0000-0002-9038-7047; Zhang, Fei/0000-0002-9038-7047; Yu, Jimin/0000-0002-3896-1777; 	Lamont-Doherty Postdoctoral Fellowship; NSF; National Oceanic and Atmospheric Administration; Comer Education Foundation; National Natural Science Foundation of China; U.K. Natural Environment Research Council	Lamont-Doherty Postdoctoral Fellowship; NSF(National Science Foundation (NSF)); National Oceanic and Atmospheric Administration(National Oceanic Atmospheric Admin (NOAA) - USA); Comer Education Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); U.K. Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank N. McCave and D. McCorckle for providing core materials used in this study; P. deMenocal, P. Tomascak, B. Honisch, X. Wang, and B. Yan for assistance with laboratory work; and three anonymous reviewers for their constructive comments. This research is funded by Lamont-Doherty Postdoctoral Fellowship (J.Y.), NSF, National Oceanic and Atmospheric Administration, Comer Education Foundation, National Natural Science Foundation of China, and U.K. Natural Environment Research Council. This is LDEO contribution 7412.	Allen JRM, 1999, NATURE, V400, P740, DOI 10.1038/23432; Anderson DM, 2002, NATURE, V416, P70, DOI 10.1038/416070a; Anderson RF, 2009, SCIENCE, V323, P1443, DOI 10.1126/science.1167441; BIRD MI, 1994, NATURE, V371, P566, DOI 10.1038/371566a0; Broecker WS, 1987, GLOBAL BIOGEOCHEM CY, V1, P15, DOI 10.1029/GB001i001p00015; Broecker WS, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000231; BROECKER WS, 1982, PROG OCEANOGR, V11, P151, DOI 10.1016/0079-6611(82)90007-6; Broecker WS, 2001, SCIENCE, V294, P2152, DOI 10.1126/science.1064171; Curry WB, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001021; Elsig J, 2009, NATURE, V461, P507, DOI 10.1038/nature08393; Farrell JW, 1989, PALEOCEANOGRAPHY, V4, P447, DOI 10.1029/PA004i004p00447; Fleitmann D, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040050; Herguera JC, 1992, PALEOCEANOGRAPHY, V7, P273, DOI 10.1029/92PA00869; Hodell DA, 2001, EARTH PLANET SC LETT, V192, P109, DOI 10.1016/S0012-821X(01)00430-7; HOWARD WR, 1994, PALEOCEANOGRAPHY, V9, P453, DOI 10.1029/93PA03524; Kaplan JO, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013366; Keigwin LD, 1998, PALEOCEANOGRAPHY, V13, P323, DOI 10.1029/98PA00874; Luthi D, 2008, NATURE, V453, P379, DOI 10.1038/nature06949; Marchitto TM, 2005, EARTH PLANET SC LETT, V231, P317, DOI 10.1016/j.epsl.2004.12.024; Marchitto TM, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2000PA000598; Matsumoto K, 2002, QUATERNARY SCI REV, V21, P1693, DOI 10.1016/S0277-3791(01)00142-1; McManus JF, 2004, NATURE, V428, P834, DOI 10.1038/nature02494; Monnin E, 2001, SCIENCE, V291, P112, DOI 10.1126/science.291.5501.112; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; Schmitz W.J., 1996, WORLD OCEAN CIRCULAT, VII, DOI 10.1575/1912/356; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Smith HJ, 1999, NATURE, V400, P248, DOI 10.1038/22291; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Yu JM, 2008, EARTH PLANET SC LETT, V271, P209, DOI 10.1016/j.epsl.2008.04.010; Yu JM, 2007, EARTH PLANET SC LETT, V258, P73, DOI 10.1016/j.epsl.2007.03.025; Yu JM, 2010, EARTH PLANET SC LETT, V293, P114, DOI 10.1016/j.epsl.2010.02.029	31	122	124	4	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1084	1087		10.1126/science.1193221	http://dx.doi.org/10.1126/science.1193221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097932				2022-12-28	WOS:000284374700038
J	Horvat, LD; Cuerden, MS; Kim, SJ; Koval, JJ; Young, A; Garg, AX				Horvat, Lucy D.; Cuerden, Meaghan S.; Kim, S. Joseph; Koval, John J.; Young, Ann; Garg, Amit X.			Informing the Debate: Rates of Kidney Transplantation in Nations With Presumed Consent	ANNALS OF INTERNAL MEDICINE			English	Article							ORGAN DONATION; LIVING-DONOR; RENAL-TRANSPLANTATION; IMPACT; LEGISLATION; SINGAPORE; LAW; SHORTAGE; CRISIS	Background: The kidney is the most common transplanted organ, accounting for almost all living donor transplantations and most deceased donor organ transplantations. The organ shortage has caused policymakers in many nations to debate the merits of adopting presumed consent legislation as a way to increase donor organ donation from deceased donors. Objective: To compare characteristics and kidney transplantation rates for countries with presumed consent for deceased organ donation with countries with explicit consent. Design: A longitudinal study of international kidney transplantation from 1997 to 2007. Setting: 44 nations performing kidney transplantation. Patients: Recipients of deceased and living kidney donor transplants. Measurements: Rates of transplantation of kidneys from deceased and living donors. Results: National characteristics, such as population size, proportion of the population self-identified as Catholic, per capita gross domestic product, health expenditures, and physician density, varied widely for the 22 nations with presumed consent and the 22 nations with explicit consent. Deceased donor kidney transplantation rates were higher in nations with presumed consent (median, 22.6 transplantations per million population [pmp]; interquartile range [IQR], 9.3 to 33.8) versus nations with explicit consent (median, 13.9 transplantations pmp; IQR, 3.6 to 23.1). Living donor kidney transplantation rates were lower in nations with presumed consent (median, 2.4 transplantations pmp; IQR, 1.7 to 4.3) versus nations with explicit consent (median, 5.9 transplantations pmp; IQR, 2.3 to 12.2). The findings were consistent when nations were classified according to per capita gross domestic product, health expenditures, and physician density. Limitation: As with any observational study, associations may not be causal. Conclusion: Nations with presumed consent have higher rates of deceased donor kidney transplantation than nations with explicit consent. Any nation deciding to adopt presumed consent should carefully consider and reduce any negative effect on rates of living donation.	Univ Western Ontario, London, ON, Canada; Univ Waterloo, Waterloo, ON N2L 3G1, Canada; Univ Toronto, Toronto, ON, Canada	Western University (University of Western Ontario); University of Waterloo; University of Toronto	Garg, AX (corresponding author), London Hlth Sci Ctr, London Kidney Clin Res Unit, Room ELL-101,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	amit.garg@lhsc.on.ca	Garg, Amit X/G-3295-2011		Canadian Institutes of Health Research; University of Western Ontario; Lawson Health Research Institute; National Sciences and Engineering Research Council of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); University of Western Ontario; Lawson Health Research Institute; National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	By research funds from the Canadian Institutes of Health Research. Ms. Horvat was supported by a Schulich Graduate Scholarship from the University of Western Ontario and a research award from the Lawson Health Research Institute. Ms. Cuerden was supported by a National Sciences and Engineering Research Council of Canada Doctoral Scholarship. Drs. Kim and Garg were supported by Clinician Scientist Awards from the Canadian Institutes of Health Research. Dr. Young was supported by a Canadian Institutes of Health Research Doctoral Award.	Abadie A, 2006, J HEALTH ECON, V25, P599, DOI 10.1016/j.jhealeco.2006.01.003; Al Sayyari AA, 2008, AM J KIDNEY DIS, V51, P1033, DOI 10.1053/j.ajkd.2008.01.016; [Anonymous], INT DAT BAS IDB; Aubrey P, 2008, TRANSPL P, V40, P1008, DOI 10.1016/j.transproceed.2008.03.059; BENAMMAR MS, 2009, ORGANS TISSUES  0721, P27953; *BUND NIER, ORG SCHENKT LEB, P27953; Central Intelligence Agency, WORLD FACTB FIELD LI; Csillag C, 1998, LANCET, V352, P1367, DOI 10.1016/S0140-6736(05)60767-2; Csillag C, 1997, LANCET, V349, P482, DOI 10.1016/S0140-6736(05)61201-9; *CTR NAC TRANSPL, MARC NORM, P27953; *CTR NAC TRAP, EL NORM, P27953; de Klerk M, 2007, Ned Tijdschr Geneeskd, V151, P130; de Klerk M, 2008, FRONT BIOSCI, V13, P3373; *DEP HLTH CHILDR, BOD ORG DON, P27953; *DIAR REP EL, 2007, DIAR REP 1, V124, P27953; Einollahi Behzad, 2008, Iran J Kidney Dis, V2, P55; *ENC NAT, GUAT REL, P27953; English V, 2003, J MED ETHICS, V29, P147, DOI 10.1136/jme.29.3.147; English V, 2007, BRIT MED J, V334, P1088, DOI 10.1136/bmj.39199.475301.AD; *ESDS NESST CAT, BRIT SOC ATT SURV 20, P27953; Essman Christian C, 2005, Prog Transplant, V15, P124; Feeley TH, 2008, PROG TRANSPLANT, V18, P103, DOI 10.7182/prtr.18.2.76081615346x5284; *GES OST, TRANSPL TRANSF GES H, P27953; Ghods Ahad J, 2005, Exp Clin Transplant, V3, P351; Ghods AJ, 2007, SAUDI J KIDNEY DIS T, V18, P648; Ghods AJ, 2004, TRANSPL P, V36, P11, DOI 10.1016/j.transproceed.2003.11.015; GILL J, 2008, CST ANN M MONT TREMB, P27953; Gimbel Ronald W, 2003, Prog Transplant, V13, P17; GNANT MFX, 1991, TRANSPL P, V23, P2685; *GRUP PUNT CAN, VER CIFR INGR PAIS A, P27953; Hanto RL, 2008, TRANSPLANTATION, V86, P1744, DOI 10.1097/TP.0b013e3181909035; HEALY K, 2005, THEORY RES COMP SOCI, P31; Horvat LD, 2009, KIDNEY INT, V75, P1088, DOI 10.1038/ki.2009.20; *HRVATSK DON MREZ, ZAK TRANSPL EUR, P27953; Huh KH, 2008, TRANSPLANTATION, V86, P430, DOI 10.1097/TP.0b013e3181804a34; *JAP ORG TRANSPL N, ORG TRANSPL LAWS, P27953; Kandus A, 2006, NEPHROL DIAL TRANSPL, V21, P36, DOI 10.1093/ndt/gfi277; Kirste Gunter, 2006, Ann Transplant, V11, P52; Kwek TK, 2009, ANN ACAD MED SINGAP, V38, P346; Low HC, 2006, TRANSPLANTATION, V82, P1234, DOI 10.1097/01.tp.0000236720.66204.16; *MIN ZDRAV CESK RE, PRIL, P27953; Mizraji R, 2007, TRANSPL P, V39, P333, DOI 10.1016/j.transproceed.2007.01.017; *NAC TRANSPL BIUR, LAW DON TRANSPL HUM, P27953; *NAT ORG PROC SERV, FACTS ORG DON IR, P27953; NETO GB, 2007, LATIN AM CARIBBEAN L, P27953; O'Connor KJ, 2005, SEMIN DIALYSIS, V18, P460, DOI 10.1111/j.1525-139X.2005.00089.x; *ORG NAC TRANSPL V, TRANSPL ORG VEN, P27953; Persson MO, 1998, TRANSPLANT INT, V11, P419, DOI 10.1111/j.1432-2277.1998.tb00830.x; Rithalia A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3162; ROELS L, 1991, TRANSPLANT P, V23, P903; Rosental R, 1997, TRANSPLANT P, V29, P3218, DOI 10.1016/S0041-1345(97)00877-4; Said R, 1999, Saudi J Kidney Dis Transpl, V10, P64; Santiago-Delpin EA, 1997, TRANSPL P, V29, P3203, DOI 10.1016/S0041-1345(97)00870-1; Saudi Center for Organ Transplantation, ANN REP ORG TRANSPL; Sickand M, 2009, AM J TRANSPLANT, V9, P2825, DOI 10.1111/j.1600-6143.2009.02829.x; *SLOV TRANSPL, REM TRANSPL HUM BOD, P27953; Smith CR, 2000, TRANSPLANTATION, V69, P311, DOI 10.1097/00007890-200001270-00020; SOH P, 1992, TRANSPLANT P, V24, P1337; *SVER RIKSD, 1995, OM TRANSPL MM, P27953; *SWISSTR, ORG DON TRANSPL, P27953; *SZERVK IR ORSZ VE, JOGSZ, P27953; *TRANSPL SOC LATIN, LAT AM TRANSPL REP 2, P27953; *UN NETW ORG SHAR, MIN PROC STAND ORG P, P27953; United Nations Statistics Division, NAT ACC MAIN AGGR DA; *US REN DAT SYST, 2008 ANN DAT REP ATL; Van Gelder F, 2008, ACTA CHIR BELG, V108, P27, DOI 10.1080/00015458.2008.11680170; Vanrenterghem Y, 1988, Clin Transpl, P91; WHO, GLOB HLTH ATL; *WHO, WHOSIS WHO STAT INF; World Health Organization, WHO GUID PRINC HUM C; World Health Organization, WHO MORT DAT; Wright Linda, 2007, BMJ, V334, P1089, DOI 10.1136/bmj.39199.492894.AD	72	42	42	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					641	649		10.7326/0003-4819-153-10-201011160-00006	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079219				2022-12-28	WOS:000284215800016
J	Siegler, EL				Siegler, Eugenia L.			The Evolving Medical Record	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							COPY	Form dictates content, and the manner of recordkeeping imposed on us probably influences how we think about patients. At The New York Hospital, physicians began to maintain permanent patient case records in the early 1800s. Originally proposed and valued as teaching cases for medical students, these freeform patient records varied in quality and often reflected not just the medical care of the time but also the personalities of the physicians composing them. At the end of the 19th century, the change from retrospective to real-time recording of cases and the imposition of a fixed chart structure through the use of forms dramatically reduced the narrative dimension of the hospital course. Gradually, physicians found ways to circumvent these restrictions. Changes in record format, designed to manage increasing volumes of data, and physicians' responses to those changes parallel some of the contemporary threats to documentation posed by the electronic health record.	Weill Cornell Med Coll, Div Geriatr & Gerontol, New York, NY 10065 USA	Cornell University	Siegler, EL (corresponding author), Weill Cornell Med Coll, Div Geriatr & Gerontol, 525 E 68th St,Box 39, New York, NY 10065 USA.	els2006@med.cornell.edu		Siegler, Eugenia/0000-0001-9449-5873				BALDY JM, 1918, MOD HOSP, V10, P397; BEAN WB, 1963, ARCH INTERN MED, V112, P813, DOI 10.1001/archinte.1963.03860060051001; Berg M, 1997, SOCIOL QUART, V38, P513, DOI 10.1111/j.1533-8525.1997.tb00490.x; BURNUM JF, 1989, ANN INTERN MED, V110, P482, DOI 10.7326/0003-4819-110-6-482; Craig B L, 1990, Archivaria, P21; FEINSTEI.AR, 1973, ANN INTERN MED, V78, P751, DOI 10.7326/0003-4819-78-5-751; Hartzband P, 2008, NEW ENGL J MED, V358, P1656, DOI 10.1056/NEJMp0802221; Hirschtick RE, 2006, JAMA-J AM MED ASSOC, V295, P2335, DOI 10.1001/jama.295.20.2335; HOWELL JD, 1995, TECHNOLOGY HOSP, P27953; JEFFE ER, 2004, NEW YORK J AM HIST, V65, P54; KAHN AP, 1970, MED REC NEWS     JUN, P42; KAHN AP, 1970, MED REC NEWS     AUG, P16; Kirkland Larry R, 2007, J Med Biogr, V15 Suppl 1, P50; Landry JB, 1859, GAZETTE HEBDOMADAIRE, V6, p[472, 486]; Landry O., 1859, GAZETTE HEBDOMADAIRE, V6, P486; Lincoln H.B., 1937, MOD HOSP, V48, P56; MacEachern MT, 1922, CAN MED ASSOC J, V7, P520; Oxentenko AS, 2010, ARCH INTERN MED, V170, P377, DOI 10.1001/archinternmed.2009.534; REISER SJ, 1991, ANN INTERN MED, V114, P980, DOI 10.7326/0003-4819-114-11-980; REISER SJ, 1984, TRANSFORMATION TRADI, P303; RISSE GB, 1999, MENDING BODIES SAVIN, P236; Siegler EL, 2009, AM J MED, V122, P495, DOI 10.1016/j.amjmed.2009.02.010; *SOC HOSP NEW YORK, 1811, ACC NEW YORK HOSP, P27953; Thielke Stephen, 2007, Int J Med Inform, V76 Suppl 1, pS122, DOI 10.1016/j.ijmedinf.2006.06.004; Warner J.H., 1986, THERAPEUTIC PERSPECT; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; Wrenn JO, 2010, J AM MED INFORM ASSN, V17, P49, DOI 10.1197/jamia.M3390	27	44	45	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					671	677		10.7326/0003-4819-153-10-201011160-00012	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079225				2022-12-28	WOS:000284215800022
J	Neely, GG; Hess, A; Costigan, M; Keene, AC; Goulas, S; Langeslag, M; Griffin, RS; Belfer, I; Dai, F; Smith, SB; Diatchenko, L; Gupta, V; Xia, CP; Amann, S; Kreitz, S; Heindl-Erdmann, C; Wolz, S; Ly, CV; Arora, S; Sarangi, R; Dan, D; Novatchkova, M; Rosenzweig, M; Gibson, DG; Truong, D; Schramek, D; Zoranovic, T; Cronin, SJF; Angjeli, B; Brune, K; Dietzl, G; Maixner, W; Meixner, A; Thomas, W; Pospisilik, JA; Alenius, M; Kress, M; Subramaniam, S; Garrity, PA; Bellen, HJ; Woolf, CJ; Penninger, JM				Neely, G. Gregory; Hess, Andreas; Costigan, Michael; Keene, Alex C.; Goulas, Spyros; Langeslag, Michiel; Griffin, Robert S.; Belfer, Inna; Dai, Feng; Smith, Shad B.; Diatchenko, Luda; Gupta, Vaijayanti; Xia, Cui-Ping; Amann, Sabina; Kreitz, Silke; Heindl-Erdmann, Cornelia; Wolz, Susanne; Ly, Cindy V.; Arora, Suchir; Sarangi, Rinku; Dan, Debasis; Novatchkova, Maria; Rosenzweig, Mark; Gibson, Dustin G.; Truong, Darwin; Schramek, Daniel; Zoranovic, Tamara; Cronin, Shane J. F.; Angjeli, Belinda; Brune, Kay; Dietzl, Georg; Maixner, William; Meixner, Arabella; Thomas, Winston; Pospisilik, J. Andrew; Alenius, Mattias; Kress, Michaela; Subramaniam, Sai; Garrity, Paul A.; Bellen, Hugo J.; Woolf, Clifford J.; Penninger, Josef M.			A Genome-wide Drosophila Screen for Heat Nociception Identifies alpha 2 delta 3 as an Evolutionarily Conserved Pain Gene	CELL			English	Article							BLOOD OXYGENATION; NEUROPATHIC PAIN; BARREL CORTEX; MECHANISMS; SYNESTHESIA; MORPHOGENESIS; TRANSDUCTION; STIMULATION; PERCEPTION; MANAGEMENT	Worldwide, acute, and chronic pain affects 20% of the adult population and represents an enormous financial and emotional burden. Using genome-wide neuronal-specific RNAi knockdown in Drosophila, we report a global screen for an innate behavior and identify hundreds of genes implicated in heat nociception, including the alpha 2 delta family calcium channel subunit straightjacket (stj). Mice mutant for the stj ortholog CACNA2D3 (alpha 2 delta 3) also exhibit impaired behavioral heat pain sensitivity. In addition, in humans, alpha 2 delta 3 SNP variants associate with reduced sensitivity to acute noxious heat and chronic back pain. Functional imaging in alpha 2 delta 3 mutant mice revealed impaired transmission of thermal pain-evoked signals from the thalamus to higher-order pain centers. Intriguingly, in alpha 2 delta 3 mutant mice, thermal pain and tactile stimulation triggered strong cross-activation, or synesthesia, of brain regions involved in vision, olfaction, and hearing.	[Costigan, Michael; Woolf, Clifford J.] Harvard Univ, Sch Med, Childrens Hosp Boston, Program Neurobiol, Boston, MA 02115 USA; [Costigan, Michael; Woolf, Clifford J.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Neely, G. Gregory; Goulas, Spyros; Xia, Cui-Ping; Amann, Sabina; Novatchkova, Maria; Truong, Darwin; Schramek, Daniel; Zoranovic, Tamara; Cronin, Shane J. F.; Angjeli, Belinda; Meixner, Arabella; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; [Neely, G. Gregory] Garvan Inst Med Res, Neurosci Program, Sydney, NSW 2010, Australia; [Hess, Andreas; Kreitz, Silke; Heindl-Erdmann, Cornelia; Wolz, Susanne; Brune, Kay] Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany; [Keene, Alex C.] NYU, Dept Biol, New York, NY 10003 USA; [Langeslag, Michiel; Kress, Michaela] Innsbruck Med Univ, Dept Physiol, Div Physiol & Med Phys, A-6020 Innsbruck, Austria; [Griffin, Robert S.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02129 USA; [Belfer, Inna; Dai, Feng] Univ Pittsburgh, Dept Anesthesiol, Mol Epidemiol Pain Program, Pittsburgh, PA USA; [Smith, Shad B.; Diatchenko, Luda; Gibson, Dustin G.; Maixner, William] Univ N Carolina, Ctr Neurosensory Disorders, Chapel Hill, NC 27599 USA; [Gupta, Vaijayanti; Arora, Suchir; Sarangi, Rinku; Dan, Debasis; Subramaniam, Sai] Strand Life Sci Pvt Ltd, Bangalore, Karnataka, India; [Bellen, Hugo J.] Baylor Coll Med, Dept Neurosci, Dept Mol & Human Genet, HHMI, Houston, TX 77030 USA; [Rosenzweig, Mark; Garrity, Paul A.] Brandeis Univ, Dept Biol, Natl Ctr Behav Genom, Waltham, MA 02458 USA; [Dietzl, Georg] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Thomas, Winston] Deltagen Inc, San Mateo, CA 94403 USA; [Pospisilik, J. Andrew] Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; [Alenius, Mattias] Linkoping Univ, Dept Clin & Expt Med, SE-58185 Linkoping, Sweden	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Garvan Institute of Medical Research; University of Erlangen Nuremberg; New York University; Medical University of Innsbruck; Harvard University; Massachusetts General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Howard Hughes Medical Institute; Brandeis University; Howard Hughes Medical Institute; Stanford University; Max Planck Society; Linkoping University	Woolf, CJ (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Program Neurobiol, Boston, MA 02115 USA.	clifford.woolf@childrens.harvard.edu; josef.penninger@imba.oeaw.ac.at	Schramek, Daniel/J-5792-2014; Penninger, Josef M/I-6860-2013; Heindl-Erdmann, Cornelia/F-4809-2018; Pryjda, Tamara/O-5714-2019; neely, graham/A-6511-2011; Schramek, Daniel/AAL-1470-2020; Woolf, Clifford/A-9784-2010; Smith, Shad/AAO-8760-2020; Neely, Greg/AAB-4642-2020	Penninger, Josef M/0000-0002-8194-3777; Schramek, Daniel/0000-0001-9977-2104; Neely, Greg/0000-0002-1957-9732; zoranovic, tamara/0000-0002-5369-6385; Bellen, Hugo/0000-0001-5992-5989; Goulas, Spyros/0000-0002-7445-8917; Kress, Michaela/0000-0002-8921-7470; Gibson, Dustin/0000-0002-9073-3376; Garrity, Paul/0000-0002-8274-6564; Langeslag, Michiel/0000-0003-4883-7339	National Institute of Health NRSA [1 F32GM086207-01]; NIH [NS039518, NS038253, NS044232]; Mary Curie IIF; EuroThymaide; DFG [661/TP4]; BMBF [01EM0514, 01GQ0731, 0314102]; Doerenkamp Foundation for Innovations in Animal and Consumer Protection; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM086207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044232, R01NS039518, R01NS058870, R37NS039518, P01NS072040, R01NS038253] Funding Source: NIH RePORTER	National Institute of Health NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Curie IIF; EuroThymaide(European Commission); DFG(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); Doerenkamp Foundation for Innovations in Animal and Consumer Protection; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank all members of our laboratories and the VDRC for helpful discussions and excellent technical support. We thank Ricardo de Matos Simoes for support with statistical analysis. We thank B.J. Dickson for elav/UAS Dicer 2 stocks. alpha 2 delta 3 mutant mice were generated by Deltagen (San Mateo, CA). J.M.P. is supported by grants from IMBA, the Austrian Ministry of Sciences, the Austrian Academy of Sciences, GEN-AU (AustroMouse), ApoSys, and an EU ERC Advanced Grant. A.C.K. is supported by National Institute of Health NRSA 1 F32GM086207-01. C.J.W. is supported by NIH NS039518 and NS038253. G.G.N. was supported by a Mary Curie IIF Fellowship and EuroThymaide. A.H. is supported by DFG 661/TP4 and BMBF (01EM0514, 01GQ0731, 0314102) and K.B. by the Doerenkamp Foundation for Innovations in Animal and Consumer Protection. P.A.G. is supported by NIH NS044232.	Aleman A, 2001, NEUROREPORT, V12, P2827, DOI 10.1097/00001756-200109170-00015; Arthurs OJ, 2002, TRENDS NEUROSCI, V25, P27, DOI 10.1016/S0166-2236(00)01995-0; Atlas SJ, 2001, SPINE, V26, P1179, DOI 10.1097/00007632-200105150-00017; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Beauchamp MS, 2008, J NEUROSCI, V28, P13696, DOI 10.1523/JNEUROSCI.3872-08.2008; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Costigan M, 2009, ANNU REV NEUROSCI, V32, P1, DOI 10.1146/annurev.neuro.051508.135531; Cox JJ, 2006, NATURE, V444, P894, DOI 10.1038/nature05413; Crawley JN, 2008, NEURON, V57, P809, DOI 10.1016/j.neuron.2008.03.001; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Dickman DK, 2008, J NEUROSCI, V28, P31, DOI 10.1523/JNEUROSCI.4498-07.2008; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Dudycha GJ, 1935, J ABNORM SOC PSYCH, V30, P57, DOI 10.1037/h0060678; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Field MJ, 2006, P NATL ACAD SCI USA, V103, P17537, DOI 10.1073/pnas.0409066103; Hess A, 2000, J NEUROSCI, V20, P3328, DOI 10.1523/JNEUROSCI.20-09-03328.2000; Hubbard EM, 2005, NEURON, V48, P509, DOI 10.1016/j.neuron.2005.10.012; Hucho T, 2007, NEURON, V55, P365, DOI 10.1016/j.neuron.2007.07.008; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; Knabl J, 2008, NATURE, V451, P330, DOI 10.1038/nature06493; Koester SE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-212; Kurshan PT, 2009, NAT NEUROSCI, V12, P1415, DOI 10.1038/nn.2417; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lumpkin EA, 2007, NATURE, V445, P858, DOI 10.1038/nature05662; Ly CV, 2008, J CELL BIOL, V181, P157, DOI 10.1083/jcb.200712152; Manev H, 2004, EUR J PHARMACOL, V491, P207, DOI 10.1016/j.ejphar.2004.03.030; MELZACK R., 1999, PAIN S, V6, pS121, DOI [10.1016/s0304-3959(99)00145-1, DOI 10.1016/S0304-3959(99)00145-1]; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Petersen CCH, 2007, NEURON, V56, P339, DOI 10.1016/j.neuron.2007.09.017; PITCHER GM, 1995, NEUROSCIENCE, V65, P273, DOI 10.1016/0306-4522(94)00477-M; Premkumar LS, 2010, AAPS J, V12, P361, DOI 10.1208/s12248-010-9196-y; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Shmuel A, 2002, NEURON, V36, P1195, DOI 10.1016/S0896-6273(02)01061-9; Silva AC, 2004, NMR BIOMED, V17, P532, DOI 10.1002/nbm.945; Sokabe T, 2008, J NEUROSCI, V28, P9929, DOI 10.1523/JNEUROSCI.2757-08.2008; Stuurman N, 1999, EXP CELL RES, V248, P350, DOI 10.1006/excr.1999.4396; Tegeder I, 2006, NAT MED, V12, P1269, DOI 10.1038/nm1490; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Tracey WD, 2003, CELL, V113, P261, DOI 10.1016/S0092-8674(03)00272-1; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Venken KJT, 2009, NAT METHODS, V6, P431, DOI [10.1038/NMETH.1331, 10.1038/nmeth.1331]; Xu SY, 2006, GENES BRAIN BEHAV, V5, P602, DOI 10.1111/j.1601-183X.2006.00213.x	44	194	200	2	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					628	638		10.1016/j.cell.2010.09.047	http://dx.doi.org/10.1016/j.cell.2010.09.047			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074052	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000284149100019
J	Preker, P; Jensen, TH				Preker, Pascal; Jensen, Torben Heick			Translation by Remote Control	CELL			English	Editorial Material							RNA-POLYMERASE-II; RPB7; COMPLEX		[Preker, Pascal; Jensen, Torben Heick] Aarhus Univ, Dept Mol Biol, Ctr mRNP Biogenesis & Metab, DK-8000 Aarhus, Denmark	Aarhus University	Preker, P (corresponding author), Aarhus Univ, Dept Mol Biol, Ctr mRNP Biogenesis & Metab, CF Mollers Alle 3,Bldg 1130, DK-8000 Aarhus, Denmark.	pap@mb.au.dk; thj@mb.au.dk	Jensen, Torben H/G-2954-2017	Jensen, Torben Heick/0000-0001-5127-1239				Brueckner F, 2009, ACTA CRYSTALLOGR D, V65, P112, DOI 10.1107/S0907444908039875; Choder M, 2004, TRENDS BIOCHEM SCI, V29, P674, DOI 10.1016/j.tibs.2004.10.007; Goler-Baron V, 2008, GENE DEV, V22, P2022, DOI 10.1101/gad.473608; Harel-Sharvit L, 2010, CELL, V143, P552, DOI 10.1016/j.cell.2010.10.033; Jasiak AJ, 2008, J BIOL CHEM, V283, P26423, DOI 10.1074/jbc.M803237200; Parker R, 2007, MOL CELL, V25, P635, DOI 10.1016/j.molcel.2007.02.011; Sampath V, 2005, IUBMB LIFE, V57, P93, DOI 10.1080/15216540500078905; Schmidt EE, 2007, BIOESSAYS, V29, P262, DOI 10.1002/bies.20546; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Ujvari A, 2006, NAT STRUCT MOL BIOL, V13, P49, DOI 10.1038/nsmb1026	10	3	3	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 12	2010	143	4					501	502		10.1016/j.cell.2010.10.039	http://dx.doi.org/10.1016/j.cell.2010.10.039			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074041	Bronze			2022-12-28	WOS:000284149100007
J	Sligar, SG				Sligar, Stephen G.			Glimpsing the Critical Intermediate in Cytochrome P450 Oxidations	SCIENCE			English	Editorial Material							ELECTRON-PARAMAGNETIC-RESONANCE; COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; MOSSBAUER; IRON		Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Sligar, SG (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.	s-sligar@illinois.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031756, R01GM033775] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM031756, R01 GM033775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; GROVES JT, 1976, J AM CHEM SOC, V98, P859, DOI 10.1021/ja00419a049; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; Rittle J, 2010, SCIENCE, V330, P933, DOI 10.1126/science.1193478; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SCHULZ CE, 1984, BIOCHEMISTRY-US, V23, P4743, DOI 10.1021/bi00315a033; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; Sligar SG, 1999, ESSAYS BIOCHEM, V34, P71, DOI 10.1042/bse0340071	10	42	42	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					924	925		10.1126/science.1197881	http://dx.doi.org/10.1126/science.1197881			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071657	Green Accepted			2022-12-28	WOS:000284118000029
J	Kirshner, R				Kirshner, Robert			John Huchra (1948-2010) OBITUARY	NATURE			English	Biographical-Item									[Kirshner, Robert] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Kirshner, Robert] CALTECH, Pasadena, CA 91125 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; California Institute of Technology	Kirshner, R (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	kirshner@cfa.harvard.edu							0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					174	174		10.1038/468174a	http://dx.doi.org/10.1038/468174a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068817	Bronze			2022-12-28	WOS:000284051000026
J	Wykes, T				Wykes, Til			Cognitive remediation therapy needs funding	NATURE			English	Editorial Material							SCHIZOPHRENIA; METAANALYSIS		Kings Coll London, Inst Psychiat, London, England	University of London; King's College London	Wykes, T (corresponding author), Kings Coll London, Inst Psychiat, London, England.	til.wykes@kcl.ac.uk	Wykes, Til/AAE-9718-2022; Wykes, Til/B-3812-2011; Wykes, Til/AFE-8438-2022	Wykes, Til/0000-0002-5881-8003; Wykes, Til/0000-0002-5881-8003; Wykes, Til/0000-0002-5881-8003				Carter CS, 2008, BIOL PSYCHIAT, V64, P4, DOI 10.1016/j.biopsych.2008.03.020; Dickinson D, 2010, AM J PSYCHIAT, V167, P170, DOI 10.1176/appi.ajp.2009.09020264; Eack SM, 2010, ARCH GEN PSYCHIAT, V67, P674, DOI 10.1001/archgenpsychiatry.2010.63; Elie D, 2010, J PSYCHOPHARMACOL, V24, P1037, DOI 10.1177/0269881108100777; HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409; Kaneda Y, 2009, PSYCHIAT RES, V169, P178, DOI 10.1016/j.psychres.2008.08.003; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; Wykes T, 1998, SCHIZOPHR RES, V34, P77, DOI 10.1016/S0920-9964(98)00076-0	9	15	16	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					165	166		10.1038/468165a	http://dx.doi.org/10.1038/468165a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678DG	21068807				2022-12-28	WOS:000284051000016
J	Roe, M				Roe, Michael			Personal View Child patients: WNB not DNA	BRITISH MEDICAL JOURNAL			English	Editorial Material									Southampton Univ Hosp NHS Trust, Southampton, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Roe, M (corresponding author), Southampton Univ Hosp NHS Trust, Southampton, Hants, England.	michael.roe@suht.swest.nhs.uk							0	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2010	341								c6332	10.1136/bmj.c6332	http://dx.doi.org/10.1136/bmj.c6332			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KO	21068113				2022-12-28	WOS:000284312700002
J	Trinidad, AC				Trinidad, Antolin C.			Suitable for Framing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												atrinidad@mfa.gwu.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					1992	1992		10.1001/jama.2010.1556	http://dx.doi.org/10.1001/jama.2010.1556			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063002				2022-12-28	WOS:000284000600001
J	Feachem, RGA; Phillips, AA; Targett, GA; Snow, RW				Feachem, Richard G. A.; Phillips, Allison A.; Targett, Geoffrey A.; Snow, Robert W.			Call to action: priorities for malaria elimination	LANCET			English	Editorial Material									[Feachem, Richard G. A.; Phillips, Allison A.] UCSF Global Hlth Sci, Global Hlth Grp, San Francisco, CA 94105 USA; [Targett, Geoffrey A.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England; [Snow, Robert W.] Kenya Govt Med Res Ctr, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; [Snow, Robert W.] Univ Oxford, Ctr Vaccinol & Trop Med, Ctr Trop Med, Oxford, England	University of California System; University of California San Francisco; University of London; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute; University of Oxford	Feachem, RGA (corresponding author), UCSF Global Hlth Sci, Global Hlth Grp, San Francisco, CA 94105 USA.	FeachemR@globalhealth.ucsf.edu	Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088	Wellcome Trust [079080] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], GLOB MAL ACT PLAN MA; Cohen JM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-213; Cook J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-169; Feachem RGA, 2009, SHRINKING MALARIA MA; Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6; *GLOB FUND FIGHT A, 2010, PRIOR ROUND 10 INF N; *GLOB FUND FIGHT A, GRANT PORTF; Greenwood BM, 2008, TRENDS PARASITOL, V24, P449, DOI 10.1016/j.pt.2008.07.002; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X; Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X; SABOT C, 2010, LANCET, DOI DOI 10.1016/S0140-6736(10)61355-4; TARGETT GA, 2009, SHRINKING MALARIA MA; Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3; Zanzibar Malaria Control Program, 2009, MAL EL ZANZ FEAS ASS	15	84	84	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1517	1521		10.1016/S0140-6736(10)61500-0	http://dx.doi.org/10.1016/S0140-6736(10)61500-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21035844	Green Accepted			2022-12-28	WOS:000284248700005
J	Srivastava, R				Srivastava, Ranjana			The Power Proxy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Monash Med Ctr, Melbourne, Vic, Australia	Monash University	Srivastava, R (corresponding author), Monash Med Ctr, Melbourne, Vic, Australia.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1786	1789		10.1056/NEJMp1003221	http://dx.doi.org/10.1056/NEJMp1003221			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674YK	21047221				2022-12-28	WOS:000283787800003
J	Flaherty, KT				Flaherty, Keith T.			Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma	ANNALS OF INTERNAL MEDICINE			English	Review							METASTATIC MALIGNANT-MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; PHASE-III; IMATINIB MESYLATE; TUMOR PROGRESSION; B-RAF; DACARBAZINE; INHIBITION; MUTATIONS; KINASE	Patients with metastatic melanoma have a poor prognosis and limited treatment options. In about one half of analyzed patients with metastatic melanoma, a mutated signal transduction molecule has been identified: v-raf murine sarcoma viral oncogene homolog B1 (BRAF). This molecule is part of an intracellular signaling cascade and may play a role in many different types of cancer. This article provides an overview of the current treatment options for metastatic melanoma and describes the pathophysiology underlying the development of therapies based on inhibition of BRAF. It summarizes findings of phase 1 and phase 2 studies of BRAF inhibitor therapy primarily in patients with metastatic melanoma, who have shown objective response rates of 70% to 80%. However, initial responses have not been sustained, with a median time to relapse of approximately 9 months. Clinicians should be aware of phase 3 trials of these agents and trials combining these therapies with other novel therapies because, at a minimum, BRAF inhibitors seem to be valuable as palliative therapy for metastatic melanoma.	Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Flaherty, KT (corresponding author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.	kflaherty@partners.org			Plexxikon [PLX4032]	Plexxikon	The phase 1 and phase 2 trials of PLX4032 were supported by Plexxikon.	Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Atkins MB, 2008, J CLIN ONCOL, V26, P5748, DOI 10.1200/JCO.2008.17.5448; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; Chapman PB, 1999, J CLIN ONCOL, V17, P2745, DOI 10.1200/JCO.1999.17.9.2745; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kefford R., 2010, J CLIN ONCOL S, V28; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Kirkwood JM, 2004, CLIN CANCER RES, V10, P1670, DOI 10.1158/1078-0432.CCR-1103-3; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; SZNOL M, 2010, J CLIN ONCOL S, V28; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443	23	28	30	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					587	591		10.7326/0003-4819-153-9-201011020-00008	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	21041578				2022-12-28	WOS:000283667000005
J	Margolis, SS; Salogiannis, J; Lipton, DM; Mandel-Brehm, C; Wills, ZP; Mardinly, AR; Hu, LD; Greer, PL; Bikoff, JB; Ho, HYH; Soskis, MJ; Sahin, M; Greenberg, ME				Margolis, Seth S.; Salogiannis, John; Lipton, David M.; Mandel-Brehm, Caleigh; Wills, Zachary P.; Mardinly, Alan R.; Hu, Linda; Greer, Paul L.; Bikoff, Jay B.; Ho, Hsin-Yi Henry; Soskis, Michael J.; Sahin, Mustafa; Greenberg, Michael E.			EphB-Mediated Degradation of the RhoA GEF Ephexin5 Relieves a Developmental Brake on Excitatory Synapse Formation	CELL			English	Article							DENDRITIC SPINE MORPHOGENESIS; GROWTH CONE; TYROSINE PHOSPHORYLATION; ANGELMAN SYNDROME; EXCHANGE FACTORS; STRUCTURAL BASIS; IN-VIVO; RECEPTORS; SYNAPTOGENESIS; ACTIVATION	The mechanisms that promote excitatory synapse formation and maturation have been extensively studied. However, the molecular events that limit excitatory synapse development so that synapses form at the right time and place and in the correct numbers are less well understood. We have identified a RhoA guanine nucleotide exchange factor, Ephexin5, which negatively regulates excitatory synapse development until EphrinB binding to the EphB receptor tyrosine kinase triggers Ephexin5 phosphorylation, ubiquitination, and degradation. The degradation of Ephexin5 promotes EphB-dependent excitatory synapse development and is mediated by Ube3A, a ubiquitin ligase that is mutated in the human cognitive disorder Angelman syndrome and duplicated in some forms of Autism Spectrum Disorders (ASDs). These findings suggest that aberrant EphB/Ephexin5 signaling during the development of synapses may contribute to the abnormal cognitive function that occurs in Angelman syndrome and, possibly, ASDs.	[Margolis, Seth S.; Salogiannis, John; Lipton, David M.; Mandel-Brehm, Caleigh; Wills, Zachary P.; Mardinly, Alan R.; Hu, Linda; Greer, Paul L.; Bikoff, Jay B.; Ho, Hsin-Yi Henry; Soskis, Michael J.; Greenberg, Michael E.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Sahin, Mustafa] Harvard Univ, Sch Med, Childrens Hosp Boston, FM Kirby Neurobiol Ctr,Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Greenberg, ME (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	michael_greenberg@hms.harvard.edu	SAHIN, MUSTAFA/I-8653-2019; Bikoff, Jay/N-8107-2018; Salogiannis, John/AAX-3128-2021	SAHIN, MUSTAFA/0000-0001-7044-2953; Salogiannis, John/0000-0002-1988-7284; mandel-brehm, caleigh/0000-0001-7764-6529; Wills, Zachary/0000-0001-9822-6742; Mardinly, Alan/0000-0001-9891-6719	National Institute of Neurological Disorders and Stroke [RO1 5R01NS045500]; NRSA [5T32AG00222-15]; Edward R. and Anne G. Lefler postdoctoral fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000222] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Edward R. and Anne G. Lefler postdoctoral fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank M. Thompson, Y. Zhou, and H. Ye for assistance in generating mice; E. Griffith, J. Zieg, S. Cohen, I. Spiegel, M. Andzelm, and the Greenberg lab for critical discussions. This work was supported by National Institute of Neurological Disorders and Stroke grant RO1 5R01NS045500 (M.E.G); NRSA Training grant 5T32AG00222-15 (S.S.M.); and Edward R. and Anne G. Lefler postdoctoral fellowship (S.S.M.).	Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Dalva MB, 2007, NAT REV NEUROSCI, V8, P206, DOI 10.1038/nrn2075; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Fasen K, 2008, TRAFFIC, V9, P251, DOI 10.1111/j.1600-0854.2007.00679.x; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fu WY, 2007, NAT NEUROSCI, V10, P67, DOI 10.1038/nn1811; Greer PL, 2010, CELL, V140, P704, DOI 10.1016/j.cell.2010.01.026; Grunwald IC, 2004, NAT NEUROSCI, V7, P33, DOI 10.1038/nn1164; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Henkemeyer M, 2003, J CELL BIOL, V163, P1313, DOI 10.1083/jcb.200306033; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jontes JD, 2000, NAT NEUROSCI, V3, P231, DOI 10.1038/72936; Kayser MS, 2008, NEURON, V59, P56, DOI 10.1016/j.neuron.2008.05.007; Kayser MS, 2006, J NEUROSCI, V26, P12152, DOI 10.1523/JNEUROSCI.3072-06.2006; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Klein R, 2009, NAT NEUROSCI, V12, P15, DOI 10.1038/nn.2231; Lai KO, 2009, CURR OPIN NEUROBIOL, V19, P275, DOI 10.1016/j.conb.2009.04.009; Lim BK, 2008, NAT NEUROSCI, V11, P160, DOI 10.1038/nn2033; Micheva KD, 2007, NEURON, V55, P25, DOI 10.1016/j.neuron.2007.06.014; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Ogita H, 2003, CIRC RES, V93, P23, DOI 10.1161/01.RES.0000079310.81429.C8; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sahin M, 2005, NEURON, V46, P191, DOI 10.1016/j.neuron.2005.01.030; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Sharfe N, 2003, J IMMUNOL, V170, P6024, DOI 10.4049/jimmunol.170.12.6024; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Yashiro K, 2009, NAT NEUROSCI, V12, P777, DOI 10.1038/nn.2327; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	33	172	181	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					442	455		10.1016/j.cell.2010.09.038	http://dx.doi.org/10.1016/j.cell.2010.09.038			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029865	Green Accepted, Bronze			2022-12-28	WOS:000283603900017
J	Jan, CH; Friedman, RC; Ruby, JG; Bartel, DP				Jan, Calvin H.; Friedman, Robin C.; Ruby, J. Graham; Bartel, David P.			Formation, regulation and evolution of Caenorhabditis elegans 3 ' UTRs	NATURE			English	Article							3' UNTRANSLATED REGIONS; GENE-EXPRESSION; MESSENGER-RNAS; POLYADENYLATION; COMPLEX; SEQUENCES; TARGETS; SWITCH	Post-transcriptional gene regulation frequently occurs through elements in mRNA 3' untranslated regions (UTRs)(1,2). Although crucial roles for 3'UTR-mediated gene regulation have been found in Caenorhabditis elegans(3-5), most C. elegans genes have lacked annotated 3'UTRs(6,7). Here we describe a high-throughput method for reliable identification of polyadenylated RNA termini, and we apply this method, called poly(A)-position profiling by sequencing (3P-Seq), to determine C. elegans 3'UTRs. Compared to standard methods also recently applied to C. elegans UTRs(8), 3P-Seq identified 8,580 additional UTRs while excluding thousands of shorter UTR isoforms that do not seem to be authentic. Analysis of this expanded and corrected data set suggested that the high A/U content of C. elegans 3'UTRs facilitated genome compaction, because the elements specifying cleavage and polyadenylation, which are A/U rich, can more readily emerge in A/U-rich regions. Indeed, 30% of the protein-coding genes have mRNAs with alternative, partially overlapping end regions that generate another 10,480 cleavage and polyadenylation sites that had gone largely unnoticed and represent potential evolutionary intermediates of progressive UTR shortening. Moreover, a third of the convergently transcribed genes use palindromic arrangements of bidirectional elements to specify UTRs with convergent overlap, which also contributes to genome compaction by eliminating regions between genes. Although nematode 3'UTRs have median length only one-sixth that of mammalian 3'UTRs, they have twice the density of conserved microRNA sites, in part because additional types of seed-complementary sites are preferentially conserved. These findings reveal the influence of cleavage and polyadenylation on the evolution of genome architecture and provide resources for studying post-transcriptional gene regulation.	[Jan, Calvin H.; Friedman, Robin C.; Ruby, J. Graham; Bartel, David P.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Jan, Calvin H.; Friedman, Robin C.; Ruby, J. Graham; Bartel, David P.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Jan, Calvin H.; Friedman, Robin C.; Ruby, J. Graham; Bartel, David P.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Friedman, Robin C.] MIT, Computat & Syst Biol Program, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Bartel, DP (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dbartel@wi.mit.edu		Friedman, Robin/0000-0003-2097-8332	NIH [GM067031]; National Science Foundation; Krell Institute/Department of Energy; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067031] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Krell Institute/Department of Energy(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank C. Burge and members of the Bartel lab for discussions and the WIBR Genome Technology Core for sequencing. This work was supported by NIH grant GM067031 (D.P.B.), a National Science Foundation predoctoral fellowship (C.H.J.) and a Krell Institute/Department of Energy Computational Sciences Graduate Fellowship (R.C.F.).	Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; Batista PJ, 2008, MOL CELL, V31, P67, DOI 10.1016/j.molcel.2008.06.002; Blumenthal Thomas, 2005, WormBook, P1, DOI 10.1895/wormbook.1.5.1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chiang HR, 2010, GENE DEV, V24, P992, DOI 10.1101/gad.1884710; Clark AM, 2010, NUCLEIC ACIDS RES, V38, P3780, DOI 10.1093/nar/gkq083; Evans D, 2001, GENE DEV, V15, P2562, DOI 10.1101/gad.920501; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hillier LW, 2009, GENOME RES, V19, P657, DOI 10.1101/gr.088112.108; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993; Mandel CR, 2008, CELL MOL LIFE SCI, V65, P1099, DOI 10.1007/s00018-007-7474-3; Mangone M, 2008, NUCLEIC ACIDS RES, V36, pD57, DOI 10.1093/nar/gkm946; Mangone M, 2010, SCIENCE, V329, P432, DOI 10.1126/science.1191244; Martin KC, 2009, CELL, V136, P719, DOI 10.1016/j.cell.2009.01.044; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Merritt C, 2008, CURR BIOL, V18, P1476, DOI 10.1016/j.cub.2008.08.013; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Nam DK, 2002, P NATL ACAD SCI USA, V99, P6152, DOI 10.1073/pnas.092140899; Nunes NM, 2010, EMBO J, V29, P1523, DOI 10.1038/emboj.2010.42; Prescott EM, 2002, P NATL ACAD SCI USA, V99, P8796, DOI 10.1073/pnas.132270899; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rogers A, 2008, NUCLEIC ACIDS RES, V36, pD612, DOI 10.1093/nar/gkm975; Ruby JG, 2007, NATURE, V448, P83, DOI 10.1038/nature05983; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; Zisoulis DG, 2010, NAT STRUCT MOL BIOL, V17, P173, DOI 10.1038/nsmb.1745	36	314	330	1	43	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 6	2011	469	7328					97	U114		10.1038/nature09616	http://dx.doi.org/10.1038/nature09616			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	702UO	21085120	Green Accepted, Green Submitted			2022-12-28	WOS:000285921600039
J	Barnett, BP; Hwang, YS; Taylor, MS; Kirchner, H; Pfluger, PT; Bernard, V; Lin, YY; Bowers, EM; Mukherjee, C; Song, WJ; Longo, PA; Leahy, DJ; Hussain, MA; Tschop, MH; Boeke, JD; Cole, PA				Barnett, Brad P.; Hwang, Yousang; Taylor, Martin S.; Kirchner, Henriette; Pfluger, Paul T.; Bernard, Vincent; Lin, Yu-yi; Bowers, Erin M.; Mukherjee, Chandrani; Song, Woo-Jin; Longo, Patti A.; Leahy, Daniel J.; Hussain, Mehboob A.; Tschoep, Matthias H.; Boeke, Jef D.; Cole, Philip A.			Glucose and Weight Control in Mice with a Designed Ghrelin O-Acyltransferase Inhibitor	SCIENCE			English	Article							DES-ACYL GHRELIN; INSULIN-SECRETION; OBESITY; GOAT; HORMONE; ADIPOSITY; PHENOTYPE; RELEASE; PEPTIDE; HUMANS	Ghrelin is a gastric peptide hormone that stimulates weight gain in vertebrates. The biological activities of ghrelin require octanoylation of the peptide on Ser(3), an unusual posttranslational modification that is catalyzed by the enzyme ghrelin O-acyltransferase (GOAT). Here, we describe the design, synthesis, and characterization of GO-CoA-Tat, a peptide-based bisubstrate analog that antagonizes GOAT. GO-CoA-Tat potently inhibits GOAT in vitro, in cultured cells, and in mice. Intraperitoneal administration of GO-CoA-Tat improves glucose tolerance and reduces weight gain in wild-type mice but not in ghrelin-deficient mice, supporting the concept that its beneficial metabolic effects are due specifically to GOAT inhibition. In addition to serving as a research tool for mapping ghrelin actions, GO-CoA-Tat may help pave the way for clinical targeting of GOAT in metabolic diseases.	[Barnett, Brad P.; Hwang, Yousang; Taylor, Martin S.; Bowers, Erin M.; Mukherjee, Chandrani; Cole, Philip A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Barnett, Brad P.; Taylor, Martin S.; Bernard, Vincent; Lin, Yu-yi; Boeke, Jef D.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Barnett, Brad P.; Taylor, Martin S.; Bernard, Vincent; Lin, Yu-yi; Boeke, Jef D.] Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; [Kirchner, Henriette; Pfluger, Paul T.; Tschoep, Matthias H.] Univ Cincinnati, Dept Internal Med, Metab Dis Inst, Obes Res Ctr, Cincinnati, OH 45237 USA; [Song, Woo-Jin; Hussain, Mehboob A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Metab, Baltimore, MD 21205 USA; [Song, Woo-Jin; Hussain, Mehboob A.] Johns Hopkins Univ, Sch Med, Dept Med, Div Metab, Baltimore, MD 21205 USA; [Song, Woo-Jin; Hussain, Mehboob A.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Div Metab, Baltimore, MD 21205 USA; [Longo, Patti A.; Leahy, Daniel J.] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; [Lin, Yu-yi] Natl Taiwan Univ, Inst Biochem & Mol Biol, Coll Med, Taipei 100, Taiwan; [Kirchner, Henriette; Tschoep, Matthias H.] German Inst Human Nutr, Dept Pharmacol, D-14558 Nuthetal, Germany	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Ohio; University of Cincinnati; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Taiwan University; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	pcole@jhmi.edu	Tschoep, Matthias H/I-5443-2014; Barnett, Bradley/AAN-1628-2020; Barnett, Brad/AAY-2578-2020; song, woojin/G-3357-2013; Kirchner, Henriette/D-6699-2011; Pfluger, Paul T/A-3770-2019	Barnett, Bradley/0000-0002-8301-404X; Pfluger, Paul T/0000-0002-8118-7588; Tschoep, Matthias/0000-0002-4744-371X; Bernard, Vincent/0000-0003-1555-608X; Taylor, Martin/0000-0003-1560-9276; song, woojin/0000-0003-3197-6682; Boeke, Jef/0000-0001-5322-4946; Taylor, Martin/0000-0001-5824-142X	NIH; Pfeiffer Foundation; Kaufman Foundation; Keck Foundation; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081472, P60DK079637, P30DK079637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062437] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfeiffer Foundation; Kaufman Foundation; Keck Foundation(W.M. Keck Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M. Shamblott, S. Bhat, A. Chambers, C. Schrum, J. Hembree, N. Forbes, M. Li, J. McClellan, M. Miller, K. O'Donnell-Mendell, J. Jabbari, W. Gibson, J. Liu, and D. Gladowski for advice and assistance; G. Ronnett, J. Liu, and R. Alani for critical reading of the manuscript; and the NIH Common Fund, Pfeiffer Foundation, Kaufman Foundation, and Keck Foundation for financial support. The authors (P. A. C., J. D. B., Y.H., and B. P. B.) and Johns Hopkins University have filed a patent on the GOAT inhibitors described here. The inhibitors have been licensed to the biotechnology company Acylin Therapeutics, Inc. P. A. C., J. D. B., and M. H. T. are on the Scientific Advisory Board and have equity in Acylin Therapeutics. M. H. T. also has equity in and is a member of the Scientific Advisory Boards of Marcadia Biotech, Inc., and Ambrx, Inc.	Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Broglio F, 2004, J CLIN ENDOCR METAB, V89, P3062, DOI 10.1210/jc.2003-031964; Dezaki K, 2008, PHARMACOL THERAPEUT, V118, P239, DOI 10.1016/j.pharmthera.2008.02.008; Dezaki K, 2007, DIABETES, V56, P2319, DOI 10.2337/db07-0345; Gauna C, 2005, J CLIN ENDOCR METAB, V90, P1055, DOI 10.1210/jc.2004-1069; Granata R, 2010, J MOL ENDOCRINOL, V45, P107, DOI 10.1677/JME-10-0019; Gualillo O, 2008, TRENDS PHARMACOL SCI, V29, P398, DOI 10.1016/j.tips.2008.06.003; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Lu SC, 2009, MOL PHARMACOL, V75, P901, DOI 10.1124/mol.108.052852; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; Sun Y, 2006, CELL METAB, V3, P379, DOI 10.1016/j.cmet.2006.04.004; Tong J, 2010, DIABETES, V59, P2145, DOI 10.2337/db10-0504; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540; Yada T, 2008, CURR DIABETES REV, V4, P18, DOI 10.2174/157339908783502352; Yang J, 2008, P NATL ACAD SCI USA, V105, P10750, DOI 10.1073/pnas.0805353105; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhang WZ, 2008, ENDOCRINOLOGY, V149, P4710, DOI 10.1210/en.2008-0263; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107; Zigman JM, 2005, J CLIN INVEST, V115, P3564, DOI 10.1172/JCI26002	28	198	207	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	2010	330	6011					1689	1692		10.1126/science.1196154	http://dx.doi.org/10.1126/science.1196154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	695RO	21097901	Green Accepted			2022-12-28	WOS:000285390500070
J	Reiter, NJ; Osterman, A; Torres-Larios, A; Swinger, KK; Pan, T; Mondragon, A				Reiter, Nicholas J.; Osterman, Amy; Torres-Larios, Alfredo; Swinger, Kerren K.; Pan, Tao; Mondragon, Alfonso			Structure of a bacterial ribonuclease P holoenzyme in complex with tRNA	NATURE			English	Article							PRECURSOR TRANSFER-RNA; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 2-METAL-ION MECHANISM; THERMOTOGA-MARITIMA; PROTEIN-COMPONENT; CONSERVED CORE; BINDING-SITE; ACTIVE-SITE; SUBSTRATE	Ribonuclease (RNase) P is the universal ribozyme responsible for 5'-end tRNA processing. We report the crystal structure of the Thermotoga maritima RNase P holoenzyme in complex with tRNA(Phe). The 154 kDa complex consists of a large catalytic RNA (P RNA), a small protein cofactor and a mature tRNA. The structure shows that RNA-RNA recognition occurs through shape complementarity, specific intermolecular contacts and base-pairing interactions. Soaks with a pre-tRNA 5' leader sequence with and without metal help to identify the 5' substrate path and potential catalytic metal ions. The protein binds on top of a universally conserved structural module in P RNA and interacts with the leader, but not with the mature tRNA. The active site is composed of phosphate backbone moieties, a universally conserved uridine nucleobase, and at least two catalytically important metal ions. The active site structure and conserved RNase P-tRNA contacts suggest a universal mechanism of catalysis by RNase P.	[Reiter, Nicholas J.; Osterman, Amy; Torres-Larios, Alfredo; Swinger, Kerren K.; Mondragon, Alfonso] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA; [Pan, Tao] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Northwestern University; University of Chicago	Mondragon, A (corresponding author), Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu		Torres-Larios, Alfredo/0000-0002-0702-350X	NIH; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM087055, R01GM058443] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank E. Sontheimer and O. Uhlenbeck for comments and suggestions, N. Pace for the gift of the T. maritima RNase P protein plasmid, Obiter Research, A. Davis and M. E. Duban for advice and preparation of iridium hexammine, and A. Samelson for discussions and assistance. In addition, we are grateful for data collection assistance from S. Anderson, Z. Wawrzak, and staff at LS-CAT. Research was supported by the NIH. N.J.R. is an NRSA postdoctoral fellow.	Biswas R, 2000, J MOL BIOL, V296, P19, DOI 10.1006/jmbi.1999.3443; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; Buck AH, 2005, NAT STRUCT MOL BIOL, V12, P958, DOI 10.1038/nsmb1004; Buck AH, 2005, EMBO J, V24, P3360, DOI 10.1038/sj.emboj.7600805; BURKARD U, 1988, NUCLEIC ACIDS RES, V16, P11617, DOI 10.1093/nar/16.24.11617; Chen JL, 1997, RNA, V3, P557; Chen Y, 1997, BIOCHEMISTRY-US, V36, P2425; Christian EL, 2000, RNA, V6, P511, DOI 10.1017/S1355838200000042; Christian EL, 2006, RNA, V12, P1463, DOI 10.1261/rna.158606; Crary SM, 2002, RNA, V8, P933, DOI 10.1017/S1355838202025025; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L, PYMOL MOL GRAPHICS S; Ferre-D'Amare AR, 1998, J MOL BIOL, V279, P621, DOI 10.1006/jmbi.1998.1789; Gaur RK, 1996, RNA, V2, P674; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Hartmann RK, 2009, PROG MOL BIOL TRANSL, V85, P319, DOI 10.1016/S0079-6603(08)00808-8; Hsieh J, 2010, J MOL BIOL, V400, P38, DOI 10.1016/j.jmb.2010.04.050; Kazantsev AV, 2006, NAT REV MICROBIOL, V4, P729, DOI 10.1038/nrmicro1491; Kazantsev AV, 2009, RNA, V15, P266, DOI 10.1261/rna.1331809; Kazantsev AV, 2005, P NATL ACAD SCI USA, V102, P13392, DOI 10.1073/pnas.0506662102; Kazantsev AV, 2003, P NATL ACAD SCI USA, V100, P7497, DOI 10.1073/pnas.0932597100; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; Kirsebom LA, 2010, PROTEIN REV, V10, P113, DOI 10.1007/978-1-4419-1142-1_7; Koutmou KS, 2010, J MOL BIOL, V396, P195, DOI 10.1016/j.jmb.2009.11.039; Krasilnikov AS, 2004, SCIENCE, V306, P104, DOI 10.1126/science.1101489; Krasilnikov AS, 2003, NATURE, V421, P760, DOI 10.1038/nature01386; Krivenko AA, 2002, ACTA CRYSTALLOGR D, V58, P1234, DOI 10.1107/S0907444902007965; Krummel DAP, 2000, J MOL BIOL, V295, P1113, DOI 10.1006/jmbi.1999.3424; Kurz JC, 1998, BIOCHEMISTRY-US, V37, P2393, DOI 10.1021/bi972530m; LAGRANDEUR TE, 1994, EMBO J, V13, P3945, DOI 10.1002/j.1460-2075.1994.tb06710.x; Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370; LIU F, 2010, PROTEIN REV, V10; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Mondragon A, 2010, PROTEIN REV, V10, P63, DOI 10.1007/978-1-4419-1142-1_4; Niranjanakumari S, 1998, P NATL ACAD SCI USA, V95, P15212, DOI 10.1073/pnas.95.26.15212; Pan T, 1995, P NATL ACAD SCI USA, V92, P12510, DOI 10.1073/pnas.92.26.12510; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; Stahley MR, 2005, SCIENCE, V309, P1587, DOI 10.1126/science.1114994; Stams T, 1998, SCIENCE, V280, P752, DOI 10.1126/science.280.5364.752; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Sun L, 2006, EMBO J, V25, P3998, DOI 10.1038/sj.emboj.7601290; Toor N, 2008, SCIENCE, V320, P77, DOI 10.1126/science.1153803; Torres-Larios A, 2005, NATURE, V437, P584, DOI 10.1038/nature04074; Torres-Larios A, 2006, CURR OPIN STRUC BIOL, V16, P327, DOI 10.1016/j.sbi.2006.04.002; Tsai HY, 2003, J MOL BIOL, V325, P661, DOI 10.1016/S0022-2836(02)01267-6; Walker SC, 2006, CRIT REV BIOCHEM MOL, V41, P77, DOI 10.1080/10409230600602634; Warnecke JM, 1996, P NATL ACAD SCI USA, V93, P8924, DOI 10.1073/pnas.93.17.8924	50	204	205	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	2010	468	7325					784	789		10.1038/nature09516	http://dx.doi.org/10.1038/nature09516			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691PQ	21076397	Green Accepted			2022-12-28	WOS:000285093700037
J	Ai, M; Min, S; Grosjean, Y; Leblanc, C; Bell, R; Benton, R; Suh, GSB				Ai, Minrong; Min, Soohong; Grosjean, Yael; Leblanc, Charlotte; Bell, Rati; Benton, Richard; Suh, Greg S. B.			Acid sensing by the Drosophila olfactory system	NATURE			English	Article							CARBON-DIOXIDE; CHEMOSENSORY RECEPTORS; TARGETED EXPRESSION; AVOIDANCE; NEURONS; TRANSMISSION; BEHAVIOR; REVEALS; MINOS; MAP	The odour of acids has a distinct quality that is perceived as sharp, pungent and often irritating(1). How acidity is sensed and translated into an appropriate behavioural response is poorly understood. Here we describe a functionally segregated population of olfactory sensory neurons in the fruitfly, Drosophila melanogaster, that are highly selective for acidity. These olfactory sensory neurons express IR64a, a member of the recently identified ionotropic receptor (IR) family of putative olfactory receptors(2). In vivo calcium imaging showed that IR64a+ neurons projecting to the DC4 glomerulus in the antennal lobe are specifically activated by acids. Flies in which the function of IR64a+ neurons or the IR64a gene is disrupted had defects in acid-evoked physiological and behavioural responses, but their responses to non-acidic odorants remained unaffected. Furthermore, artificial stimulation of IR64a+ neurons elicited avoidance responses. Taken together, these results identify cellular and molecular substrates for acid detection in the Drosophila olfactory system and support a labelled-line mode of acidity coding at the periphery.	[Ai, Minrong; Min, Soohong; Leblanc, Charlotte; Suh, Greg S. B.] NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Mol Neurobiol Program, New York, NY 10016 USA; [Grosjean, Yael; Bell, Rati; Benton, Richard] Univ Lausanne, Fac Biol & Med, Ctr Integrat Genom, CH-1015 Lausanne, Switzerland	New York University; University of Lausanne	Suh, GSB (corresponding author), NYU, Sch Med, Dept Cell Biol, Skirball Inst Biomol Med,Mol Neurobiol Program, New York, NY 10016 USA.	greg.suh@med.nyu.edu	Suh, Seong Bae/K-2434-2016; Grosjean, Yael/E-2634-2017; Min, Soohong/AEK-2200-2022; Min, Soohong/I-1607-2018	Grosjean, Yael/0000-0003-0689-8344; Suh, Greg/0000-0003-4381-658X; Min, Soohong/0000-0003-0683-2935	National Research Service Award; Boehringer Ingelheim Foundation; Centre National de la Recherche Scientifique; European Research Council; Swiss National Science Foundation; Alfred P. Sloan Foundation; Whitehall Foundation; Whitehead President Award; NIH [1RO1GM089746]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC010936] Funding Source: NIH RePORTER	National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boehringer Ingelheim Foundation(Boehringer Ingelheim); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); European Research Council(European Research Council (ERC)European Commission); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); Whitehall Foundation; Whitehead President Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank M. Dus for helpful discussions and technical support for making anti-IR64a antibody; M. Kim for technical assistance; J. Treisman, N. Ringstad, C. Desplan, M. Warman, G. Fishell, M. Chesler, A. Wong, L. Vosshall and D. Anderson for discussions and comments on the manuscript; and R. Lehmann for sharing her two-photon microscope. This work was initiated in D. Anderson's laboratory at California Institute of Technology. G.S.B.S. thanks H.-R. Song for support. Financial support was provided by a National Research Service Award fellowship (M.A.), the Boehringer Ingelheim Foundation (R. Bell), the Centre National de la Recherche Scientifique (Y.G.), a European Research Council Starting Independent Researcher Grant (R. Benton), the Swiss National Science Foundation (R. Benton), the Alfred P. Sloan Foundation (G.S.), the Whitehall Foundation (G.S.), a Whitehead President Award (G.S.) and NIH grant 1RO1GM089746 (G.S).	Asahina Kenta, 2009, J Biol, V8, P9, DOI 10.1186/jbiol108; Benton R, 2009, CELL, V136, P149, DOI 10.1016/j.cell.2008.12.001; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; DRAVNIEKS A, 1982, SCIENCE, V218, P799, DOI 10.1126/science.7134974; Faucher C, 2006, J EXP BIOL, V209, P2739, DOI 10.1242/jeb.02297; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Jones WD, 2007, NATURE, V445, P86, DOI 10.1038/nature05466; Joseph RM, 2009, P NATL ACAD SCI USA, V106, P11352, DOI 10.1073/pnas.0901419106; KELLOGG FE, 1970, J INSECT PHYSIOL, V16, P99, DOI 10.1016/0022-1910(70)90117-4; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; Kwon JY, 2007, P NATL ACAD SCI USA, V104, P3574, DOI 10.1073/pnas.0700079104; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Metaxakis A, 2005, GENETICS, V171, P571, DOI 10.1534/genetics.105.041848; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Ng M, 2002, NEURON, V36, P463, DOI 10.1016/S0896-6273(02)00975-3; Sambongi Y, 2000, NEUROREPORT, V11, P2229, DOI 10.1097/00001756-200007140-00033; SHANBHAG SR, 1995, CELL TISSUE RES, V282, P237, DOI 10.1007/BF00319115; Suh GSB, 2004, NATURE, V431, P854, DOI 10.1038/nature02980; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Thom C, 2004, J CHEM ECOL, V30, P1285, DOI 10.1023/B:JOEC.0000030298.77377.7d; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Yorozu S, 2009, NATURE, V458, P201, DOI 10.1038/nature07843; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029	25	223	234	13	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2010	468	7324					691	U112		10.1038/nature09537	http://dx.doi.org/10.1038/nature09537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688GB	21085119	Green Submitted, Green Accepted			2022-12-28	WOS:000284836700040
J	Alabugin, IV; Gold, B; Shatruk, M; Kovnir, K				Alabugin, Igor V.; Gold, Brian; Shatruk, Michael; Kovnir, Kirill			Comment on "Single-Crystal X-ray Structure of 1,3-Dimethylcyclobutadiene by Confinement in a Crystalline Matrix"	SCIENCE			English	Editorial Material							CYCLOBUTADIENE; STATES	Legrand et al. (Reports, 16 July 2010, p. 299) reported the experimental observation of square-planar and rectangular-bent geometries of 1,3-dimethylcyclobutadiene (Me(2)CBD) confined within a crystalline matrix. However, we found no evidence for the Me(2)CBD formation. We argue that the experimental x-ray density data are better attributed to the bicyclic beta-lactone intermediate where carbon dioxide is covalently bound to cyclobutadiene.	[Alabugin, Igor V.; Gold, Brian; Shatruk, Michael; Kovnir, Kirill] Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University	Alabugin, IV (corresponding author), Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA.	alabugin@chem.fsu.edu	Alabugin, Igor/C-3659-2015; Shatruk, Michael/AFH-5616-2022; Kovnir, Kirill/A-8618-2010	Alabugin, Igor/0000-0001-9289-3819; Kovnir, Kirill/0000-0003-1152-1912; Shatruk, Michael/0000-0002-2883-4694				ARNOLD B, 1990, KINETICS SPECTROSCOP, pCH1; BALKOVA A, 1994, J CHEM PHYS, V101, P8972, DOI 10.1063/1.468025; BALLY T, 1980, TETRAHEDRON, V36, P343, DOI 10.1016/0040-4020(80)87003-7; BORDEN WT, 1978, J AM CHEM SOC, V100, P388, DOI 10.1021/ja00470a006; CHAPMAN OL, 1973, J AM CHEM SOC, V95, P614, DOI 10.1021/ja00783a066; COREY EJ, 1964, J AM CHEM SOC, V86, P950, DOI 10.1021/ja01059a059; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; Legrand YM, 2010, SCIENCE, V329, P299, DOI 10.1126/science.1188002; LIN CY, 1972, J CHEM SOC CHEM COMM, P1111, DOI 10.1039/c39720001111; MAIER G, 1974, ANGEW CHEM INT EDIT, V13, P425, DOI 10.1002/anie.197404251; Menke JL, 2010, J PHYS CHEM A, V114, P6431, DOI [10.1021/jp101963p, 10.1021/jp101063p]; PONG RGS, 1977, J AM CHEM SOC, V99, P4153, DOI 10.1021/ja00454a043; ROSENBLUM M, 1968, J AM CHEM SOC, V90, P1060, DOI 10.1021/ja01006a040; Rowland RS, 1996, J PHYS CHEM-US, V100, P7384, DOI 10.1021/jp953141+; Toda F, 2000, EUR J ORG CHEM, V2000, P1377, DOI 10.1002/(SICI)1099-0690(200004)2000:8<1377::AID-EJOC1377>3.0.CO;2-I; WATTS L, 1965, J AM CHEM SOC, V87, P3253, DOI 10.1021/ja01092a049; WHITMAN DW, 1980, J AM CHEM SOC, V102, P4272, DOI 10.1021/ja00532a055	17	22	23	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007								10.1126/science.1196188	http://dx.doi.org/10.1126/science.1196188			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097920				2022-12-28	WOS:000284374700021
J	Heinberg, R; Fridley, D				Heinberg, Richard; Fridley, David			The end of cheap coal	NATURE			English	Editorial Material							MODEL		[Heinberg, Richard; Fridley, David] Post Carbon Inst, Santa Rosa, CA 95404 USA		Heinberg, R (corresponding author), Post Carbon Inst, Santa Rosa, CA 95404 USA.	richardheinberg@postcarbon.org						Campbell C., 1998, SCI AM           MAR; *EN INF ADM, 1997, ANN EN OUTL 1998; Hook M, 2010, FUEL, V89, P3546, DOI 10.1016/j.fuel.2010.06.013; Legislative Assembly of Alberta, 2009, CARBON CAPTURE STORA; Luppens J., 2008, 20081202 USGS; Mohr SH, 2009, FUEL, V88, P2059, DOI 10.1016/j.fuel.2009.01.032; Patzek TW, 2010, ENERGY, V35, P3109, DOI 10.1016/j.energy.2010.02.009; Rutledge D, 2007, HUBBERTS PEAK COAL Q; Tao ZP, 2007, ENERG POLICY, V35, P3145, DOI 10.1016/j.enpol.2006.11.011; *USGS, 2003, 9355 USGS US BUR MIN; World Energy Council, 2010, 2010 SURV EN RES; Zittel W., 2007, 107 EN WATCH GROUP; 2009, 2050 CHINA ENERGY CO	13	72	72	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2010	468	7322					367	369		10.1038/468367a	http://dx.doi.org/10.1038/468367a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	681KP	21085152	Bronze			2022-12-28	WOS:000284313100015
J	Sigmundsson, F; Hreinsdottir, S; Hooper, A; Arnadottir, T; Pedersen, R; Roberts, MJ; Oskarsson, N; Auriac, A; Decriem, J; Einarsson, P; Geirsson, H; Hensch, M; Ofeigsson, BG; Sturkell, E; Sveinbjornsson, H; Feigl, KL				Sigmundsson, Freysteinn; Hreinsdottir, Sigrun; Hooper, Andrew; Arnadottir, Thora; Pedersen, Rikke; Roberts, Matthew J.; Oskarsson, Niels; Auriac, Amandine; Decriem, Judicael; Einarsson, Pall; Geirsson, Halldor; Hensch, Martin; Ofeigsson, Benedikt G.; Sturkell, Erik; Sveinbjornsson, Hjorleifur; Feigl, Kurt L.			Intrusion triggering of the 2010 Eyjafjallajokull explosive eruption	NATURE			English	Article							ICELAND; VOLCANO; DEFORMATION; RADAR; SEISMICITY; CALIFORNIA; EARTHQUAKE; EPISODE; UNREST; KATLA	Gradual inflation of magma chambers often precedes eruptions at highly active volcanoes. During such eruptions, rapid deflation occurs as magma flows out and pressure is reduced(1-3). Less is known about the deformation style at moderately active volcanoes, such as Eyjafjallajokull, Iceland, where an explosive summit eruption of trachyandesite beginning on 14 April 2010 caused exceptional disruption to air traffic, closing airspace over much of Europe for days. This eruption was preceded by an effusive flank eruption of basalt from 20 March to 12 April 2010. The 2010 eruptions are the culmination of 18 years of intermittent volcanic unrest(4-9). Here we show that deformation associated with the eruptions was unusual because it did not relate to pressure changes within a single magma chamber. Deformation was rapid before the first eruption (>5 mm per day after 4 March), but negligible during it. Lack of distinct co-eruptive deflation indicates that the net volume of magma drained from shallow depth during this eruption was small; rather, magma flowed from considerable depth. Before the eruption, a similar to 0.05 km(3) magmatic intrusion grew over a period of three months, in a temporally and spatially complex manner, as revealed by GPS (Global Positioning System) geodetic measurements and interferometric analysis of satellite radar images. The second eruption occurred within the ice-capped caldera of the volcano, with explosivity amplified by magma-ice interaction. Gradual contraction of a source, distinct from the pre-eruptive inflation sources, is evident from geodetic data. Eyjafjallajokull's behaviour can be attributed to its off-rift setting with a 'cold' subsurface structure and limited magma at shallow depth, as may be typical for moderately active volcanoes. Clear signs of volcanic unrest signals over years to weeks may indicate reawakening of such volcanoes, whereas immediate short-term eruption precursors may be subtle and difficult to detect.	[Sigmundsson, Freysteinn; Hreinsdottir, Sigrun; Arnadottir, Thora; Pedersen, Rikke; Oskarsson, Niels; Auriac, Amandine; Decriem, Judicael; Einarsson, Pall; Hensch, Martin; Ofeigsson, Benedikt G.] Univ Iceland, Inst Earth Sci, Nord Volcanol Ctr, IS-101 Reykjavik, Iceland; [Hooper, Andrew] Delft Univ Technol, Delft Inst Earth Observat & Space Syst, NL-2629 HS Delft, Netherlands; [Roberts, Matthew J.; Geirsson, Halldor; Sveinbjornsson, Hjorleifur] Iceland Meteorol Off, IS-150 Reykjavik, Iceland; [Sturkell, Erik] Univ Gothenburg, Dept Earth Sci, SE-40530 Gothenburg, Sweden; [Feigl, Kurt L.] Univ Wisconsin, Dept Geosci, Madison, WI 53706 USA	University of Iceland; Delft University of Technology; University of Gothenburg; University of Wisconsin System; University of Wisconsin Madison	Sigmundsson, F (corresponding author), Univ Iceland, Inst Earth Sci, Nord Volcanol Ctr, Sturlugata 7, IS-101 Reykjavik, Iceland.	fs@hi.is	Hooper, Andrew/A-9614-2008; Arnadottir, Thora/C-7183-2013; Sigmundsson, Freysteinn/F-7160-2015; Pedersen, Rikke/C-8584-2013; Feigl, Kurt/E-8106-2012	Arnadottir, Thora/0000-0002-8275-8813; Sigmundsson, Freysteinn/0000-0001-9052-4665; Hensch, Martin/0000-0001-6515-4826; Hooper, Andrew/0000-0003-4244-6652; Geirsson, Halldor/0000-0003-2056-1588; Einarsson, Pall/0000-0002-6893-9626; Feigl, Kurt/0000-0002-2059-6708	University of Iceland; US National Science Foundation [EAR 1042103]; Icelandic government	University of Iceland; US National Science Foundation(National Science Foundation (NSF)); Icelandic government	We acknowledge the efforts of Th. Jonsson, J. Holmjarn, S. Steinthorsson, H. Olafsson, Th. Ingvarsson and B. Brandsdottir in making field operations run smoothly, as well as consultation and discussions with the staff of our institutes. We thank P. Segall and C. Wicks for comments on the manuscript, and NASA/GSFC for use of the MODIS image. Financial support for this work was received from the Icelandic Research Fund, the research fund at the University of Iceland, and the US National Science Foundation (grant EAR 1042103). Funds were received for hazard mitigation from the Icelandic government. We thank the Geodesy Laboratory at the University of Arizona for computing facilities and UNAVCO for technical support. GMT public domain software was used for some figures. TerraSAR-X data were provided by the German Space Agency under project number GEO0609.	Altamimi Z, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2007JB004949; Amelung F, 2000, NATURE, V407, P993, DOI 10.1038/35039604; Arnadottir T, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB003907; Bodvarsson R., 1996, SEISMOL RES LETT, V67, P35, DOI [10.1785/gssrl.67.5.35, DOI 10.1785/GSSRL.67.5.35]; Dzurisin D., 2007, VOLCANO DEFORMATION; Eichelberger JC, 2006, LITHOS, V87, P135, DOI 10.1016/j.lithos.2005.05.006; EINEDER M, 2009, TXGSDD3302 DLR; Feigl KL, 2009, GEOPHYS J INT, V176, P491, DOI 10.1111/j.1365-246X.2008.03881.x; Fialko Y, 2001, GEOPHYS J INT, V146, P181, DOI 10.1046/j.1365-246X.2001.00452.x; GUDMUNDSSON MT, EOS S, V91; HERRING T, 2003, GPS SOLUT, V7, P194, DOI DOI 10.1007/S10291-003-0068-0; Herring T.A., 2006, GLOBK REFERENCE MANU; HJALTADOTTIR S, EOS S, V91; Hjaltadottir S., 2009, 6200913 IC MET OFF; Hooper A, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004763; Hooper A., 2009, VOLUME PROJECT VOLCA, P13; Hooper A., 2010, ESA, V677; Hooper A, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034654; Hreinsdottir S, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL038391; Hreinsdottir S, 2009, GEOLOGY, V37, P683, DOI 10.1130/G30194A.1; JAKOBSDOTTIR SS, 2002, JOKULL, V51, P87; Jakobsdottir SS, 2008, JOKULL, V58, P75; Jakobsson S.P., 1979, ICELAND ACTA NAT ISL, V26, P1, DOI DOI 10.1002/2016JB013044; Jonsson S, 2002, B SEISMOL SOC AM, V92, P1377, DOI 10.1785/0120000922; Kampes B., 2004, ESA; King R. W., 2006, GAMIT REFERENCE MANU; Larsen G, 1999, HOLOCENE, V9, P463, DOI 10.1191/095968399669624108; LOUGHLIN SC, 1996, THESIS U DURHAM; MARSH B, 2004, EOS, V47, P497; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; OSKARSSON N, 1982, J PETROL, V23, P28, DOI 10.1093/petrology/23.1.28; Pedersen R, 2006, B VOLCANOL, V68, P377, DOI 10.1007/s00445-005-0020-y; Pedersen R, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020368; SIGMARSSON O, EOS S, V91; Sigmundsson F, 2006, S-P BKS GEOPHYS SCI; Sturkell E, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000917; Sturkell E, 2010, DEV QUATER SCI, V13, P5; Taisne B, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB006228; VOGFJORD KS, 2009, VOLUME PROJECT VOLCA, P237; Yun S, 2006, J VOLCANOL GEOTH RES, V150, P232, DOI 10.1016/j.jvolgeores.2005.07.009	40	302	304	2	157	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					426	U253		10.1038/nature09558	http://dx.doi.org/10.1038/nature09558			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085177				2022-12-28	WOS:000284313100040
J	Baigent, C; Blackwell, L; Emberson, J; Holland, LE; Reith, C; Bhala, N; Peto, R; Barnes, EH; Keech, A; Simes, J; Collins, R				Baigent, C.; Blackwell, L.; Emberson, J.; Holland, L. E.; Reith, C.; Bhala, N.; Peto, R.; Barnes, E. H.; Keech, A.; Simes, J.; Collins, R.		Cholesterol Treatment Trialists	Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials	LANCET			English	Article							CORONARY-HEART-DISEASE; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; CARDIAC OUTCOMES; ATORVASTATIN; EVENTS; MEN; PRAVASTATIN	Background Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals We aimed to assess the safety and efficacy of more intensive lowering of LDL cholesterol with statin therapy Methods We undertook meta analyses of individual participant data from randomised trials involving at least 1000 participants and at least 2 years' treatment duration of more versus less intensive statin regimens (five trials 39 612 individuals, median follow up 5 1 years) and of statin versus control (21 trials 129 526 individuals, median follow up 4 8 years) For each type of trial we calculated not only the average risk reduction, but also the average risk reduction per 1 0 mmol/L LDL cholesterol reduction at 1 year after randomisation Findings In the trials of more versus less intensive statin therapy the weighted mean further reduction in LDL cholesterol at 1 year was 0 51 mmol/L Compared with less intensive regimens more intensive regimens produced a highly significant 15% (95% CI 11-18, p<0 0001) further reduction in major vascular events consisting of separately significant reductions in coronary death or non fatal myocardial infarction of 13% (95% CI 7-19, p<0 0001) in coronary revasculansation of 19% (95% CI 15-24, p<0 0001) and in ischaemic stroke of 16% (95% CI 5-26 p=0 005) Per 1 0 mmol/L reduction in LDL cholesterol these further reductions in risk were similar to the proportional reductions in the trials of statin versus control When both types of trial were combined similar proportional reductions in major vascular events per 1 0 mmol/L LDL cholesterol reduction were found in all types of patient studied (rate ratio [RR] 0 78 95% CI 0 76-0 80 p<0 0001) including those with LDL cholesterol lower than 2 mmol/L on the less intensive or control regimen Across all 26 trials, all cause mortality was reduced by 10% per 1 0 mmol/L LDL reduction (RR 0 90, 95% CI 0 87-0 93, p<0 0001), largely reflecting significant reductions in deaths due to coronary heart disease (RR 0 80, 99% CI 0 74-0 87 p<0 0001) and other cardiac causes (RR 0 89 99% CI 0 81-0 98 p=0 002) with no significant effect on deaths due to stroke (RR 0 96 95% CI 0 84-1 09, p=0 5) or other vascular causes (RR 0 98, 99% CI 0 81-1 18, p=0 8) No significant effects were observed on deaths due to cancer or other non vascular causes (RR 0 97 95% CI 0 92-1 03, p=0 3) or on cancer incidence (RR 1 00, 95% CI 0 96-1 04, p=0 9), even at low LDL cholesterol concentrations Interpretation Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revasculansation and of ischaemic stroke, with each 1 0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth There was no evidence of any threshold within the cholesterol range studied suggesting that reduction of LDL cholesterol by 2-3 mmol/L would reduce risk by about 40-50%	[Baigent, C.] Clin Trial Serv Unit, Oxford OX3 7LF, England; [Emberson, J.; Barnes, E. H.; Keech, A.; Simes, J.] Univ Sydney, Natl Hlth & Med Res Council NHMRC Clin Trial Ctr, Sydney, NSW 2006, Australia	University of Oxford; University of Sydney	Baigent, C (corresponding author), Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.		Collins, Rory/ABA-8487-2020; Simes, Robert John/P-1497-2014; Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779; Yusuf, Salim/0000-0003-4776-5601; MacMahon, Stephen/0000-0003-2064-7699; Buck, Georgina/0000-0001-5909-4265; Marschner, Ian/0000-0002-6225-1572; Bhala, Neeraj/0000-0003-2502-1177; Kearney, Patricia/0000-0001-9599-3540; Jardine, Alan/0000-0001-5815-9370; Emberson, Jonathan/0000-0001-7792-9422	UK Medical Research Council British Heart Foundation at the CTSU; European Community; Australian National Health and Medical Research Council at the CTC; National Heart Foundation; MRC [MC_U137686853, G0701732, MC_U137686849] Funding Source: UKRI; Medical Research Council [G0701732, MC_U137686849, MC_U137686853] Funding Source: researchfish	UK Medical Research Council British Heart Foundation at the CTSU(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Community(European Commission); Australian National Health and Medical Research Council at the CTC(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation(National Heart Foundation of Australia); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This collaboration is coordinated Jointly by the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford UK and the National Health and Medical Research Council Clinical Trials Centre (CTC) at the University of Sydney Australia This work is supported at the CTSU by the UK Medical Research Council British Heart Foundation and previously the European Community Biomed Programme and at the CTC by the Australian National Health and Medical Research Council and National Heart Foundation	ALI AAA, 2007, J AM COLL CARDIOL, V50, P409; *ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; Amarenco P, 2006, NEW ENGL J MED, V355, P549; [Anonymous], 1995, Am J Cardiol, V75, P1130; [Anonymous], ELECT MED COMPENDIUM; ARA R, 2001, HEALTH TECHNOL ASSES, V13, P75; Armitage J, 2007, LANCET, V370, P1781, DOI 10.1016/S0140-6736(07)60716-8; Athyros VG, 2002, CURR MED RES OPIN, V18, P220, DOI 10.1185/030079902125000787; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Ben-Yehuda O, 2008, J AM COLL CARDIOL, V52, P1150, DOI 10.1016/j.jacc.2008.08.001; Campeau L, 1997, NEW ENGL J MED, V336, P153; Cannon CP, 2006, J AM COLL CARDIOL, V48, P438, DOI 10.1016/j.jacc.2006.04.070; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Davidson MH, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(96)00742-4; Davidson MH, 2007, J AM COLL CARDIOL, V49, P1753, DOI 10.1016/j.jacc.2007.01.067; de Lemos JA, 2004, JAMA-J AM MED ASSOC, V292, P1307, DOI 10.1001/jama.292.11.1307; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; GISSI Prevenzione Investigators, 2000, ITAL HEART J, V1, P810; Goldstein LB, 2007, NEUROLOGY, V68, P719, DOI 10.1212/01.wnl.0000258538.06950.a1; Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001; Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140-6736(03)13638-0; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201; Knopp RH, 2006, DIABETES CARE, V29, P1478, DOI 10.2337/dc05-2415; Koren MJ, 2004, J AM COLL CARDIOL, V44, P1772, DOI 10.1016/j.jacc.2004.07.053; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4; Nakamura H, 2006, LANCET, V368, P1155, DOI 10.1016/S0140-6736(06)69472-5; *NICE, 2008, 67 NICE; Pedersen TR, 1996, DRUG SAFETY, V14, P11, DOI 10.2165/00002018-199614010-00003; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2010, LANCET, V376, P333, DOI 10.1016/S0140-6736(10)60713-1; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SEARCH COLL GROUP, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)60310.8; Serruys PWJC, 2002, JAMA-J AM MED ASSOC, V287, P3215, DOI 10.1001/jama.287.24.3215; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Tavazzi L, 2008, LANCET, V372, P1231, DOI 10.1016/S0140-6736(08)61240-4; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545	48	4014	4185	5	387	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1670	1681		10.1016/S0140-6736(10)61350-5	http://dx.doi.org/10.1016/S0140-6736(10)61350-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21067804	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000284451000032
J	Gray, MW; Lukes, J; Archibald, JM; Keeling, PJ; Doolittle, WF				Gray, Michael W.; Lukes, Julius; Archibald, John M.; Keeling, Patrick J.; Doolittle, W. Ford			Irremediable Complexity?	SCIENCE			English	Editorial Material							EVOLUTION; INTRONS		[Gray, Michael W.; Archibald, John M.; Doolittle, W. Ford] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 1X5, Canada; [Lukes, Julius] Univ S Bohemia, Inst Parasitol, Ceske Budejovice 37005, Czech Republic; [Keeling, Patrick J.] Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada	Dalhousie University; University of South Bohemia Ceske Budejovice; University of British Columbia	Gray, MW (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 1X5, Canada.	ford@dal.ca	Lukes, Julius/H-6760-2012	Lukes, Julius/0000-0002-0578-6618; Gray, Michael/0000-0001-7125-2625; Keeling, Patrick/0000-0002-7644-0745; Doolittle, W. Ford/0000-0002-4675-8832				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; COVELLO PS, 1993, TRENDS GENET, V9, P265, DOI 10.1016/0168-9525(93)90011-6; Fox GE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003483; Lukes J, 2005, CURR GENET, V48, P277, DOI 10.1007/s00294-005-0027-0; Lynch M, 2007, ORIGINS GENOME ARCHI; Lynch M, 2007, P NATL ACAD SCI USA, V104, P8597, DOI 10.1073/pnas.0702207104; Martin W, 2006, NATURE, V440, P41, DOI 10.1038/nature04531; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Paukstelis PJ, 2008, P NATL ACAD SCI USA, V105, P6010, DOI 10.1073/pnas.0801722105; Sancar A, 2008, NAT STRUCT MOL BIOL, V15, P23, DOI 10.1038/nsmb0108-23; Speijer D, 2006, IUBMB LIFE, V58, P91, DOI 10.1080/15216540600551355; Stoltzfus A, 1999, J MOL EVOL, V49, P169, DOI 10.1007/PL00006540; Szathmary E, 1995, MAJOR TRANSITIONS EV	13	168	168	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					920	921		10.1126/science.1198594	http://dx.doi.org/10.1126/science.1198594			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071654				2022-12-28	WOS:000284118000026
J	Rogowski, K; van Dijk, J; Magiera, MM; Bosc, C; Deloulme, JC; Bosson, A; Peris, L; Gold, ND; Lacroix, B; Grau, MB; Bec, N; Larroque, C; Desagher, S; Holzer, M; Andrieux, A; Moutin, MJ; Janke, C				Rogowski, Krzysztof; van Dijk, Juliette; Magiera, Maria M.; Bosc, Christophe; Deloulme, Jean-Christophe; Bosson, Anouk; Peris, Leticia; Gold, Nicholas D.; Lacroix, Benjamin; Grau, Montserrat Bosch; Bec, Nicole; Larroque, Christian; Desagher, Solange; Holzer, Max; Andrieux, Annie; Moutin, Marie-Jo; Janke, Carsten			A Family of Protein-Deglutamylating Enzymes Associated with Neurodegeneration	CELL			English	Article							PURKINJE-CELL-DEGENERATION; LIGHT-CHAIN KINASE; BETA-TUBULIN; POSTTRANSLATIONAL MODIFICATION; ALPHA-TUBULIN; POLYGLUTAMYLATION; MOUSE; GLUTAMYLATION; EXPRESSION; TISSUES	Polyglutamylation is a posttranslational modification that generates glutamate side chains on tubulins and other proteins. Although this modification has been shown to be reversible, little is known about the enzymes catalyzing deglutamylation. Here we describe the enzymatic mechanism of protein deglutamylation by members of the cytosolic carboxypeptidase (CCP) family. Three enzymes (CCP1, CCP4, and CCP6) catalyze the shortening of polyglutamate chains and a fourth (CCP5) specifically removes the branching point glutamates. In addition, CCP1, CCP4, and CCP6 also remove gene-encoded glutamates from the carboxyl termini of proteins. Accordingly, we show that these enzymes convert detyrosinated tubulin into Delta 2-tubulin and also modify other substrates, including myosin light chain kinase 1. We further analyze Purkinje cell degeneration (pcd) mice that lack functional CCP1 and show that microtubule hyperglutamylation is directly linked to neurodegeneration. Taken together, our results reveal that controlling the length of the polyglutamate side chains on tubulin is critical for neuronal survival.	[Rogowski, Krzysztof; van Dijk, Juliette; Magiera, Maria M.; Gold, Nicholas D.; Lacroix, Benjamin; Grau, Montserrat Bosch; Janke, Carsten] Univ Montpellier 2 & 1, CNRS, UMR 5237, CRBM, F-34293 Montpellier, France; [Bosc, Christophe; Deloulme, Jean-Christophe; Bosson, Anouk; Peris, Leticia; Andrieux, Annie; Moutin, Marie-Jo] Univ Grenoble 1, CEA IRTSV GPC, Grenoble Inst Neurosci, INSERM U836, F-38042 Grenoble, France; [Bec, Nicole; Larroque, Christian] INSERM, Inst Rech Cancerol Montpellier, CRLC Val Aurelle, F-34298 Montpellier, France; [Desagher, Solange] Univ Montpellier 2, IGMM, CNRS, UMR 5535, F-34293 Montpellier, France; [Holzer, Max] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Leipzig University	Rogowski, K (corresponding author), Univ Montpellier 2 & 1, CNRS, UMR 5237, CRBM, F-34293 Montpellier, France.	krzysztof.rogowski@crbm.cnrs.fr; carsten.janke@curie.fr	Magiera, Maria M./Y-8754-2019; Holzer, Max/A-1729-2008; Moutin, Marie-Jo/P-7518-2017; peris, leticia/P-9249-2017; Bosc, Christophe/Q-8877-2019; Janke, Carsten/A-7279-2011; ANDRIEUX, ANNIE/B-2134-2017; Bosc, Christophe/P-3401-2017; Lacroix, Benjamin/AAL-8428-2020; Deloulme, Jean Christophe/P-6858-2017	Magiera, Maria M./0000-0003-4847-3053; Holzer, Max/0000-0003-1754-9932; Moutin, Marie-Jo/0000-0003-2681-9818; peris, leticia/0000-0002-0668-1252; Bosc, Christophe/0000-0002-3195-6692; Janke, Carsten/0000-0001-7053-2000; ANDRIEUX, ANNIE/0000-0002-4022-6405; Bosc, Christophe/0000-0002-3195-6692; Lacroix, Benjamin/0000-0003-2533-9150; Deloulme, Jean Christophe/0000-0002-2234-5865; Rogowski, Krzysztof/0000-0002-0206-3289; Bosch Grau, Montserrat/0000-0002-8990-9485; bec, nicole/0000-0001-7608-2434	CNRS; Universities Montpellier; Institut Curie; Association pour la Recherche sur le Cancer (ARC) [3140, 4892, 7927]; French National Research Agency (ANR) [05-JCJC-0035, 08-JCJC-0007]; Fondation pour la Recherche Medicale (FRM) [DEQ20081213977]; HFSP [RGP 23/2008]; EMBO [R07Job, ASTF 157-2007, ALTF 546-2006]; Alzheimer Forschung Initiative [06825]; La Ligue contre le Cancer	CNRS(Centre National de la Recherche Scientifique (CNRS)); Universities Montpellier; Institut Curie; Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); French National Research Agency (ANR)(French National Research Agency (ANR)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); HFSP(Human Frontier Science Program); EMBO(European Molecular Biology Organization (EMBO)); Alzheimer Forschung Initiative; La Ligue contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the CNRS, the Universities Montpellier 2 and 1, the Institut Curie, the Association pour la Recherche sur le Cancer (ARC) award 3140 to C.J. and awards 4892 and 7927 to A.A., the French National Research Agency (ANR) awards 05-JCJC-0035 and 08-JCJC-0007 to C.J. and "Tyr-Tips" to A.A., the Fondation pour la Recherche Medicale (FRM) research grant DEQ20081213977, the HFSP program grant RGP 23/2008, and the EMBO Young Investigator Program grant to C.J., the La Ligue contre le cancer research grant R07Job to A.A., and the Alzheimer Forschung Initiative project 06825 to M.H. B.L. was supported by a fellowship from the La Ligue contre le Cancer and the EMBO short-term fellowship ASTF 157-2007. K.R. received two postdoctoral fellowships from the La Ligue contre le Cancer and the EMBO long-term fellowship ALTF 546-2006.	AUDEBERT S, 1993, MOL BIOL CELL, V4, P615, DOI 10.1091/mbc.4.6.615; Berezniuk I, 2010, FASEB J, V24, P1813, DOI 10.1096/fj.09-147942; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; BRE MH, 1994, CELL MOTIL CYTOSKEL, V27, P337, DOI 10.1002/cm.970270406; Chakrabarti L, 2008, VISION RES, V48, P1999, DOI 10.1016/j.visres.2008.05.026; Chakrabarti L, 2010, NEURON, V66, P835, DOI 10.1016/j.neuron.2010.05.024; de la Vega MR, 2007, FASEB J, V21, P851, DOI 10.1096/fj.06-7330com; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; ERSFELD K, 1993, J CELL BIOL, V120, P725, DOI 10.1083/jcb.120.3.725; Fernandez-Gonzalez A, 2002, SCIENCE, V295, P1904, DOI 10.1126/science.1068912; Gao Y, 2001, IUBMB LIFE, V51, P337; Herring BP, 2006, AM J PHYSIOL-CELL PH, V291, pC817, DOI 10.1152/ajpcell.00198.2006; Ikegami K, 2010, P NATL ACAD SCI USA, V107, P10490, DOI 10.1073/pnas.1002128107; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Kalinina E, 2007, FASEB J, V21, P836, DOI 10.1096/fj.06-7329com; Kimura Y, 2010, J BIOL CHEM, V285, P22934, DOI 10.1074/jbc.C110.128280; Kubo T, 2010, CURR BIOL, V20, P441, DOI 10.1016/j.cub.2009.12.058; Lacroix B, 2010, J CELL BIOL, V189, P945, DOI 10.1083/jcb.201001024; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; Pathak N, 2007, MOL BIOL CELL, V18, P4353, DOI 10.1091/mbc.E07-06-0537; PATURLELAFANECHERE L, 1994, J CELL SCI, V107, P1529; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; Redeker V, 2004, BIOCHEMISTRY-US, V43, P12265, DOI 10.1021/bi049070z; Regnard C, 2000, J BIOL CHEM, V275, P15969, DOI 10.1074/jbc.M000045200; Regnard C, 1999, J CELL SCI, V112, P4281; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; Rusconi F, 1997, BIOCHEMISTRY-US, V36, P11021, DOI 10.1021/bi970752e; Smith AF, 1998, AM J PHYSIOL-CELL PH, V274, pC1188, DOI 10.1152/ajpcell.1998.274.5.C1188; Suryavanshi S, 2010, CURR BIOL, V20, P435, DOI 10.1016/j.cub.2009.12.062; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; Van Dijk J, 2008, J BIOL CHEM, V283, P3915, DOI 10.1074/jbc.M705813200; van Dijk J, 2007, MOL CELL, V26, P437, DOI 10.1016/j.molcel.2007.04.012; Wang TY, 2007, BRAIN RES, V1140, P26, DOI 10.1016/j.brainres.2006.07.065; Wang TY, 2006, MOL CELL NEUROSCI, V33, P200, DOI 10.1016/j.mcn.2006.07.009; Wloga D, 2010, EUKARYOT CELL, V9, P184, DOI 10.1128/EC.00176-09; WOLFF A, 1992, EUR J CELL BIOL, V59, P425	36	208	219	2	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					564	578		10.1016/j.cell.2010.10.014	http://dx.doi.org/10.1016/j.cell.2010.10.014			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074048	Green Submitted, Bronze			2022-12-28	WOS:000284149100014
J	Maertens, GN; Hare, S; Cherepanov, P				Maertens, Goedele N.; Hare, Stephen; Cherepanov, Peter			The mechanism of retroviral integration from X-ray structures of its key intermediates	NATURE			English	Article							VIRUS INTEGRASE; DNA INTEGRATION; AMINO-ACID; SITES; TRANSPOSITION; INTASOME; COMPLEX; HIV-1	To establish productive infection, a retrovirus must insert a DNA replica of its genome into host cell chromosomal DNA(1,2). This process is operated by the intasome, a nucleoprotein complex composed of an integrase tetramer (IN) assembled on the viral DNA ends(3,4). The intasome engages chromosomal DNA within a target capture complex to carry out strand transfer, irreversibly joining the viral and cellular DNA molecules. Although several intasome/transpososome structures from the DDE(D) recombinase superfamily have been reported(4-6), the mechanics of target DNA capture and strand transfer by these enzymes remained unclear. Here we report crystal structures of the intasome from prototype foamy virus in complex with target DNA, elucidating the pre-integration target DNA capture and post-catalytic strand transfer intermediates of the retroviral integration process. The cleft between IN dimers within the intasome accommodates chromosomal DNA in a severely bent conformation, allowing widely spaced IN active sites to access the scissile phosphodiester bonds. Our results resolve the structural basis for retroviral DNA integration and provide a framework for the design of INs with altered target sequences.	[Maertens, Goedele N.; Hare, Stephen; Cherepanov, Peter] Univ London Imperial Coll Sci Technol & Med, Div Infect Dis, London W2 1PG, England	Imperial College London	Cherepanov, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Infect Dis, St Marys Campus,Norfolk Pl, London W2 1PG, England.	p.cherepanov@imperial.ac.uk	Maertens, Goedele/D-8628-2015; Cherepanov, Peter P/F-6859-2010	Maertens, Goedele/0000-0002-1963-8026; Cherepanov, Peter P/0000-0002-0634-538X; Hare, Stephen/0000-0003-2951-1595	UK Medical Research Council; MRC [G0900116] Funding Source: UKRI; Medical Research Council [G0900116] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank A. Engelman and F. Dyda for critical reading of the manuscript, J. Sanchez-Weatherby for assistance with X-ray data collection at the I02 beamline of the Diamond Light Source and J. Moore for help with crystallization screening and the X-ray generator. This work was funded by the UK Medical Research Council.	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berry C, 2006, PLOS COMPUT BIOL, V2, P1450, DOI 10.1371/journal.pcbi.0020157; CHEREPANOV PP, 1995, GENE, V158, P9, DOI 10.1016/0378-1119(95)00193-A; Craigie R, 2002, MOBILE DNA, P613; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Hare S, 2010, NATURE, V464, P232, DOI 10.1038/nature08784; Harper AL, 2003, J VIROL, V77, P3838, DOI 10.1128/JVI.77.6.3838-3845.2003; Holman AG, 2005, P NATL ACAD SCI USA, V102, P6103, DOI 10.1073/pnas.0501646102; Johnson RC, 2008, RSC BIOMOL SCI, P176; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Konsavage WM, 2005, J VIROL, V79, P4691, DOI 10.1128/JVI.79.8.4691-4699.2005; Krishnan L, 2010, P NATL ACAD SCI USA, V107, P15910, DOI 10.1073/pnas.1002346107; Lewinski MK, 2005, ADV GENET, V55, P147, DOI 10.1016/S0065-2660(05)55005-3; Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005; Lim KI, 2010, P NATL ACAD SCI USA, V107, P12475, DOI 10.1073/pnas.1001402107; Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353; Luscombe NM, 2001, NUCLEIC ACIDS RES, V29, P2860, DOI 10.1093/nar/29.13.2860; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; Richardson JM, 2009, CELL, V138, P1096, DOI 10.1016/j.cell.2009.07.012; Trobridge GD, 2006, P NATL ACAD SCI USA, V103, P1498, DOI 10.1073/pnas.0510046103; Valkov E, 2009, NUCLEIC ACIDS RES, V37, P243, DOI 10.1093/nar/gkn938; Wu XL, 2005, J VIROL, V79, P5211, DOI 10.1128/JVI.79.8.5211-5214.2005	26	240	242	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					326	U217		10.1038/nature09517	http://dx.doi.org/10.1038/nature09517			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068843	Green Accepted, Green Submitted			2022-12-28	WOS:000284051000055
J	Mitrovich, QM; Tuch, BB; De La Vega, FM; Guthrie, C; Johnson, AD				Mitrovich, Quinn M.; Tuch, Brian B.; De La Vega, Francisco M.; Guthrie, Christine; Johnson, Alexander D.			Evolution of Yeast Noncoding RNAs Reveals an Alternative Mechanism for Widespread Intron Loss	SCIENCE			English	Article							SMALL NUCLEOLAR RNAS; CANDIDA-ALBICANS; SNORNAS; GENOME	The evolutionary forces responsible for intron loss are unresolved. Whereas research has focused on protein-coding genes, here we analyze noncoding small nucleolar RNA ( snoRNA) genes in which introns, rather than exons, are typically the functional elements. Within the yeast lineage exemplified by the human pathogen Candida albicans, we find-through deep RNA sequencing and genome-wide annotation of splice junctions-extreme compaction and loss of associated exons, but retention of snoRNAs within introns. In the Saccharomyces yeast lineage, however, we find it is the introns that have been lost through widespread degeneration of splicing signals. This intron loss, perhaps facilitated by innovations in snoRNA processing, is distinct from that observed in protein-coding genes with respect to both mechanism and evolutionary timing.	[Mitrovich, Quinn M.; Guthrie, Christine; Johnson, Alexander D.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Mitrovich, Quinn M.; Tuch, Brian B.; Johnson, Alexander D.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; [Tuch, Brian B.; De La Vega, Francisco M.] Life Technol, Res & Dev, Genet Syst Div, Foster City, CA 94404 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Thermo Fisher Scientific	Guthrie, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	christineguthrie@gmail.com; ajohnson@cgl.ucsf.edu	De La Vega, Francisco/H-3832-2011		NIH [GM021119, GM37049]; Life Technologies Corp.; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049, R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Life Technologies Corp.; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank C. Barbacioru, O. Homann, S. Kuersten, S. Ledoux, I. Listerman, T. Lowe, C. Maeder, K. Pande, A. Price, S. Roy, J. Steitz, and members of the Guthrie and Johnson laboratories for helpful discussions and support; and M. Barker and C. Monighetti for providing sequence reads. This work was supported by NIH grants GM021119 (C. G.) and GM37049 (A. D. J.) and by Life Technologies Corp. C. G. is an American Cancer Society Research Professor of Molecular Genetics. Sequence data are available at the Gene Expression Omnibus (accession number GSE21291).	Braun BR, 2005, PLOS GENET, V1, P36, DOI 10.1371/journal.pgen.0010001; Brown JWS, 2008, TRENDS PLANT SCI, V13, P335, DOI 10.1016/j.tplants.2008.04.010; Carmel L, 2007, GENOME RES, V17, P1034, DOI 10.1101/gr.6438607; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; Li WL, 2009, SCIENCE, V326, P1260, DOI 10.1126/science.1179302; Liu N, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-515; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Lynch M, 2002, P NATL ACAD SCI USA, V99, P6118, DOI 10.1073/pnas.092595699; Marck C, 2006, NUCLEIC ACIDS RES, V34, P1816, DOI 10.1093/nar/gkl085; Mitrovich QM, 2007, GENOME RES, V17, P492, DOI 10.1101/gr.6111907; Penny D, 2009, J MOL EVOL, V69, P527, DOI 10.1007/s00239-009-9279-5; Piekna-Przybylska D, 2007, RNA, V13, P305, DOI 10.1261/rna.373107; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roy SW, 2006, NAT REV GENET, V7, P211, DOI 10.1038/nrg1807; Roy SW, 2005, P NATL ACAD SCI USA, V102, P5773, DOI 10.1073/pnas.0500383102; Stajich JE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r223; Tuch BB, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001070; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2	21	29	420	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					838	841		10.1126/science.1194554	http://dx.doi.org/10.1126/science.1194554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051641	Green Accepted			2022-12-28	WOS:000283855700048
J	Robertson, BE; Ellis, RS; Dunlop, JS; McLure, RJ; Stark, DP				Robertson, Brant E.; Ellis, Richard S.; Dunlop, James S.; McLure, Ross J.; Stark, Daniel P.			Early star-forming galaxies and the reionization of the Universe	NATURE			English	Review							STELLAR MASS DENSITY; LY-ALPHA EMITTERS; ULTRA DEEP FIELD; SIMILAR-TO 7; ULTRAVIOLET LUMINOSITY DENSITY; LYMAN-CONTINUUM EMISSION; RADIATIVE-TRANSFER; INTERGALACTIC MEDIUM; COSMIC REIONIZATION; IONIZING-RADIATION	Star-forming galaxies trace cosmic history. Recent observational progress with the NASA Hubble Space Telescope has led to the discovery and study of the earliest known galaxies, which correspond to a period when the Universe was only similar to 800 million years old. Intense ultraviolet radiation from these early galaxies probably induced a major event in cosmic history: the reionization of intergalactic hydrogen.	[Robertson, Brant E.; Ellis, Richard S.] CALTECH, Dept Astron, Pasadena, CA 91125 USA; [Dunlop, James S.; McLure, Ross J.] Univ Edinburgh, Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland; [Stark, Daniel P.] Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England	California Institute of Technology; University of Edinburgh; University of Cambridge	Robertson, BE (corresponding author), CALTECH, Dept Astron, MC 249-17, Pasadena, CA 91125 USA.	brant@astro.caltech.edu	Robertson, Brant/AAA-6124-2022	Robertson, Brant/0000-0002-4271-0364	Hubble Fellowship; Royal Society; European Research Council; STFC; Darwin College; STFC [ST/G001979/1, ST/H001913/1] Funding Source: UKRI; Science and Technology Facilities Council [ST/G001979/1, ST/H001913/1] Funding Source: researchfish	Hubble Fellowship; Royal Society(Royal Society of London); European Research Council(European Research Council (ERC)European Commission); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Darwin College; STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	We thank A. Klypin for the use of his cosmological simulation, and A. Loeb, A. Shapley and L. Hernquist for comments. B.E.R. acknowledges support from a Hubble Fellowship. R.S.E. acknowledges the hospitality of Leiden Observatory. J.S.D. acknowledges the support of the Royal Society through a Wolfson Research Merit award, and also the support of the European Research Council through the award of an Advanced Grant. R.J.M. acknowledges the support of the Royal Society through a University Research Fellowship. D. P. S. acknowledges financial support from an STFC postdoctoral research fellowship and a Schlumberger Research Fellowship at Darwin College.	Alvarez MA, 2009, ASTROPHYS J LETT, V703, pL167, DOI 10.1088/0004-637X/703/2/L167; Anders P, 2003, ASTRON ASTROPHYS, V401, P1063, DOI 10.1051/0004-6361:20030151; Aubert D, 2008, MON NOT R ASTRON SOC, V387, P295, DOI 10.1111/j.1365-2966.2008.13223.x; Becker GD, 2007, ASTROPHYS J, V662, P72, DOI 10.1086/517866; Bolton JS, 2007, MON NOT R ASTRON SOC, V382, P325, DOI 10.1111/j.1365-2966.2007.12372.x; Bouwens RJ, 2007, ASTROPHYS J, V670, P928, DOI 10.1086/521811; Bouwens RJ, 2010, ASTROPHYS J LETT, V708, pL69, DOI 10.1088/2041-8205/708/2/L69; Bouwens RJ, 2009, ASTROPHYS J, V705, P936, DOI 10.1088/0004-637X/705/1/936; Bromm V, 2009, NATURE, V459, P49, DOI 10.1038/nature07990; BROWN RL, 1970, ASTROPHYS J, V160, P939, DOI 10.1086/150483; Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; BUNKER A, MON NOT R A IN PRESS; Bunker AJ, 1998, ASTRON J, V116, P2086, DOI 10.1086/300623; Chabrier G, 2003, PUBL ASTRON SOC PAC, V115, P763, DOI 10.1086/376392; Choudhury TR, 2009, MON NOT R ASTRON SOC, V394, P960, DOI 10.1111/j.1365-2966.2008.14383.x; Choudhury TR, 2005, MON NOT R ASTRON SOC, V361, P577, DOI 10.1111/j.1365-2966.2005.09196.x; Cole S, 2001, MON NOT R ASTRON SOC, V326, P255, DOI 10.1046/j.1365-8711.2001.04591.x; Dijkstra M, 2006, ASTROPHYS J, V649, P14, DOI 10.1086/506243; Eyles LP, 2007, MON NOT R ASTRON SOC, V374, P910, DOI 10.1111/j.1365-2966.2006.11197.x; Fan XH, 2002, ASTRON J, V123, P1247, DOI 10.1086/339030; Fan XH, 2006, ANNU REV ASTRON ASTR, V44, P415, DOI 10.1146/annurev.astro.44.051905.092514; Finkelstein SL, 2010, ASTROPHYS J, V719, P1250, DOI 10.1088/0004-637X/719/2/1250; Finlator K, 2009, MON NOT R ASTRON SOC, V393, P1090, DOI 10.1111/j.1365-2966.2008.14190.x; Furlanetto SR, 2005, ASTROPHYS J, V634, P1, DOI 10.1086/429080; Furlanetto SR, 2006, PHYS REP, V433, P181, DOI 10.1016/j.physrep.2006.08.002; Gardner JP, 2006, SPACE SCI REV, V123, P485, DOI 10.1007/s11214-006-8315-7; *GMTO CORP, 2006, GIANT MAG TEL SCI RE; Gnedin NY, 2008, ASTROPHYS J, V672, P765, DOI 10.1086/524007; Gnedin NY, 2006, ASTROPHYS J, V648, P1, DOI 10.1086/505790; Gonzalez V, 2010, ASTROPHYS J, V713, P115, DOI 10.1088/0004-637X/713/1/115; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; Iwata I, 2009, ASTROPHYS J, V692, P1287, DOI 10.1088/0004-637X/692/2/1287; Iye M, 2006, NATURE, V443, P186, DOI 10.1038/nature05104; Karzas W.J., 1961, APJS, V6, P167, DOI [10.1086/190063, DOI 10.1086/190063]; Kashikawa N, 2006, ASTROPHYS J, V648, P7, DOI 10.1086/504966; Kawai N, 2006, NATURE, V440, P184, DOI 10.1038/nature04498; Kneib JP, 2004, ASTROPHYS J, V607, P697, DOI 10.1086/386281; Komatsu E, 2009, ASTROPHYS J SUPPL S, V180, P330, DOI 10.1088/0067-0049/180/2/330; Labbe I, 2010, ASTROPHYS J LETT, V708, pL26, DOI 10.1088/2041-8205/708/1/L26; Labbe I, 2006, ASTROPHYS J, V649, pL67, DOI 10.1086/508512; LEHNERT MD, NATURE IN PRESS; Loeb A, 1999, ASTROPHYS J, V524, P527, DOI 10.1086/307844; LOEB A, 2010, DID 1 STARS GALAXIES; Madau P, 1999, ASTROPHYS J, V514, P648, DOI 10.1086/306975; Malhotra S, 2004, ASTROPHYS J, V617, pL5, DOI 10.1086/427182; McQuinn M, 2007, MON NOT R ASTRON SOC, V381, P75, DOI 10.1111/j.1365-2966.2007.12085.x; McQuinn M, 2007, MON NOT R ASTRON SOC, V377, P1043, DOI 10.1111/j.1365-2966.2007.11489.x; Mesinger A, 2007, ASTROPHYS J, V669, P663, DOI 10.1086/521806; Meurer GR, 1999, ASTROPHYS J, V521, P64, DOI 10.1086/307523; Miralda-Escude J, 1998, ASTROPHYS J, V501, P15, DOI 10.1086/305799; Miralda-Escude J, 2000, ASTROPHYS J, V530, P1, DOI 10.1086/308330; Oesch PA, 2010, ASTROPHYS J LETT, V709, pL16, DOI 10.1088/2041-8205/709/1/L16; Oesch PA, 2010, ASTROPHYS J LETT, V709, pL21, DOI 10.1088/2041-8205/709/1/L21; OSTERBROCK DE, 2006, ASTROPHYS J ASTROPHY, P67; Ota K, 2010, ASTROPHYS J, V722, P803, DOI 10.1088/0004-637X/722/1/803; OUCHI M, ASTROPHYS J IN PRESS; Ouchi M, 2008, ASTROPHYS J SUPPL S, V176, P301, DOI 10.1086/527673; Ouchi M, 2009, ASTROPHYS J, V706, P1136, DOI 10.1088/0004-637X/706/2/1136; Pawlik AH, 2009, MON NOT R ASTRON SOC, V394, P1812, DOI 10.1111/j.1365-2966.2009.14486.x; Razoumov AO, 2010, ASTROPHYS J, V710, P1239, DOI 10.1088/0004-637X/710/2/1239; Reddy NA, 2009, ASTROPHYS J, V692, P778, DOI 10.1088/0004-637X/692/1/778; Richard J, 2008, ASTROPHYS J, V685, P705, DOI 10.1086/591312; Robertson BE, 2010, ASTROPHYS J, V713, P1266, DOI 10.1088/0004-637X/713/2/1266; SALPETER EE, 1955, ASTROPHYS J, V121, P161, DOI 10.1086/145971; Santos MR, 2004, MON NOT R ASTRON SOC, V349, P1137, DOI 10.1111/j.1365-2966.2004.07594.x; Schaerer D, 2003, ASTRON ASTROPHYS, V397, P527, DOI 10.1051/0004-6361:20021525; Schaerer D, 2010, ASTRON ASTROPHYS, V515, DOI 10.1051/0004-6361/200913946; Schaerer D, 2009, ASTRON ASTROPHYS, V502, P423, DOI 10.1051/0004-6361/200911781; Schiminovich D, 2005, ASTROPHYS J, V619, pL47, DOI 10.1086/427077; Shapley AE, 2006, ASTROPHYS J, V651, P688, DOI 10.1086/507511; Springel V, 2005, NATURE, V435, P629, DOI 10.1038/nature03597; Stark DP, 2007, ASTROPHYS J, V659, P84, DOI 10.1086/511325; Stark DP, 2009, ASTROPHYS J, V697, P1493, DOI 10.1088/0004-637X/697/2/1493; STARK DP, MON NOT R A IN PRESS; Steidel CC, 2001, ASTROPHYS J, V546, P665, DOI 10.1086/318323; Steidel CC, 1995, ASTRON J, V110, P2519, DOI 10.1086/117709; Sutherland RS, 1998, MON NOT R ASTRON SOC, V300, P321, DOI 10.1046/j.1365-8711.1998.01687.x; Thomas RM, 2009, MON NOT R ASTRON SOC, V393, P32, DOI 10.1111/j.1365-2966.2008.14206.x; *TMT SCI ADV COMM, 2007, 30 MET TEL DET SCI C; Trac H, 2008, ASTROPHYS J LETT, V689, pL81, DOI 10.1086/595678; Walter F, 2008, ASTROPHYS SPACE SCI, V313, P313, DOI 10.1007/s10509-007-9634-1; Wilkins SM, 2010, MON NOT R ASTRON SOC, V403, P938, DOI 10.1111/j.1365-2966.2009.16175.x; Wyithe JSB, 2003, ASTROPHYS J, V586, P693, DOI 10.1086/367721; Yan HJ, 2010, RES ASTRON ASTROPHYS, V10, P867, DOI 10.1088/1674-4527/10/9/003	90	251	251	0	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					49	55		10.1038/nature09527	http://dx.doi.org/10.1038/nature09527			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048759	Green Submitted			2022-12-28	WOS:000283786900033
J	Gill, TM; Allore, HG; Gahbauer, EA; Murphy, TE				Gill, Thomas M.; Allore, Heather G.; Gahbauer, Evelyne A.; Murphy, Terrence E.			Change in Disability After Hospitalization or Restricted Activity in Older Persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL PERFORMANCE; CONTROLLED-TRIAL; LIFE EXPECTANCY; ELDERLY-PEOPLE; GAIT SPEED; ADULTS; RISK; CARE; REHABILITATION; FORECASTS	Context Disability among older persons is a complex and highly dynamic process, with high rates of recovery and frequent transitions between states of disability. The role of intervening illnesses and injuries (ie, events) on these transitions is uncertain. Objectives To evaluate the relationship between intervening events and transitions among states of no disability, mild disability, severe disability, and death and to determine the association of physical frailty with these transitions. Design, Setting, and Participants Prospective cohort study conducted in greater New Haven, Connecticut, from March 1998 to December 2008 of 754 community-living persons aged 70 years or older who were nondisabled at baseline in 4 essential activities of daily living: bathing, dressing, walking, and transferring. Telephone interviews were completed monthly for more than 10 years to assess disability and ascertain exposure to intervening events, which included illnesses and injuries leading to either hospitalization or restricted activity. Physical frailty (defined as gait speed > 10 seconds on the rapid gait test) was assessed every 18 months through 108 months. Main Outcome Measure Transitions between no disability, mild disability, and severe disability and 3 transitions from each of these states to death, evaluated each month. Results Hospitalization was strongly associated with 8 of the 9 possible transitions, with increased multivariable hazard ratios (HRs) as high as 168 (95% confidence interval [CI], 118-239) for the transition from no disability to severe disability and decreased HRs as low as 0.41 (95% CI, 0.30-0.54) for the transition from mild disability to no disability. Restricted activity also increased the likelihood of transitioning from no disability to both mild and severe disability (HR, 2.59; 95% CI, 2.23-3.02; and HR, 8.03; 95% CI, 5.28-12.21), respectively, and from mild disability to severe disability (HR, 1.45; 95% CI, 1.14-1.84), but was not associated with recovery from mild or severe disability. For all 9 transitions, the presence of physical frailty accentuated the associations of the intervening events. For example, the absolute risk of transitioning from no disability to mild disability within 1 month after hospitalization for frail individuals was 34.9% (95% CI, 34.5%-35.3%) vs 4.9% (95% CI, 4.7%-5.1%) for non-frail individuals. Among the possible reasons for hospitalization, fall-related injury conferred the highest likelihood of developing new or worsening disability. Conclusions Among older persons, particularly those who were physically frail, intervening illnesses and injuries greatly increased the likelihood of developing new or worsening disability. Only the most potent events, ie, those leading to hospitalization, reduced the likelihood of recovery from disability. JAMA. 2010; 304(17): 1919-1928	[Gill, Thomas M.] Yale Univ, Sch Med, Dept Internal Med, Adler Geriatr Ctr, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Adler Geriatr Ctr, 20 York St, New Haven, CT 06504 USA.	thomas.gill@yale.edu	Gill, Thomas M./H-7043-2019; Murphy, Terrence E/A-9394-2009	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	National Institute on Aging [R37AG17560, R01AG022993, K24AG021507]; NATIONAL INSTITUTE ON AGING [R37AG017560, R01AG022993, K24AG021507, P30AG021342] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The work for this report was funded by grants from the National Institute on Aging (R37AG17560, R01AG022993). The study was conducted at the Yale Claude D. Pepper Older Americans Independence Center (P30AG21342). Dr Gill is the recipient of a Midcareer Investigator Award in Patient-Oriented Research (K24AG021507) from the National Institute on Aging.	Allison P. D., 1995, SURVIVAL ANAL USING; Baker CJ, 2010, ANN INTERN MED, V152, P36, DOI 10.7326/0003-4819-152-1-201001050-00008; Barry LC, 2008, ARCH GEN PSYCHIAT, V65, P172, DOI 10.1001/archgenpsychiatry.2007.17; BENICHOU J, 1990, BIOMETRICS, V46, P813, DOI 10.2307/2532098; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beswick AD, 2008, LANCET, V371, P725, DOI 10.1016/S0140-6736(08)60342-6; Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Ferrucci Luigi, 1997, JAMA (Journal of the American Medical Association), V277, P728, DOI 10.1001/jama.277.9.728; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Gill TM, 2008, J AM GERIATR SOC, V56, P436, DOI 10.1111/j.1532-5415.2007.01603.x; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Gill TM, 2001, J AM GERIATR SOC, V49, P1039, DOI 10.1046/j.1532-5415.2001.49206.x; Goodwin James S, 2002, Lancet, V359, P1358, DOI 10.1016/S0140-6736(02)08318-6; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; Hardy SE, 2005, AM J EPIDEMIOL, V161, P575, DOI 10.1093/aje/kwi083; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Lin HQ, 2008, BIOMETRICS, V64, P1032, DOI 10.1111/j.1541-0420.2008.01011.x; Manton KG, 2006, P NATL ACAD SCI USA, V103, P18374, DOI 10.1073/pnas.0608483103; MANTON KG, 1993, J GERONTOL, V48, P11, DOI 10.1093/geronj/48.Special_Issue.11; Olshansky SJ, 2009, MILBANK Q, V87, P842, DOI 10.1111/j.1468-0009.2009.00581.x; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88, DOI 10.1093/gerona/56.2.M88; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1396, DOI 10.1001/jama.288.11.1396; Tinetti ME, 2008, NEW ENGL J MED, V359, P252, DOI 10.1056/NEJMoa0801748; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; US Census Bureau, AM FACTFINDER; van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881	40	336	341	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1919	1928		10.1001/jama.2010.1568	http://dx.doi.org/10.1001/jama.2010.1568			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045098	Green Accepted, Bronze			2022-12-28	WOS:000283725900022
J	Feldmann, H; Geisbert, TW				Feldmann, Heinz; Geisbert, Thomas W.			Ebola haemorrhagic fever	LANCET			English	Article							PROTECTS NONHUMAN-PRIMATES; VIRUS-INFECTION; GUINEA-PIGS; POSTEXPOSURE PROTECTION; DENDRITIC CELLS; MARBURG-VIRUS; PERSISTENT INFECTION; IN-VITRO; VACCINE; CONGO	Ebola viruses are the causative agents of a severe form of viral haemorrhagic fever in man, designated Ebola haemorrhagic fever, and are endemic in regions of central Africa. The exception is the species Reston Ebola virus, which has not been associated with human disease and is found in the Philippines. Ebola virus constitutes an important local public health threat in Africa, with a worldwide effect through imported infections and through the fear of misuse for biological terrorism. Ebola virus is thought to also have a detrimental effect on the great ape population in Africa. Case-fatality rates of the African species in man are as high as 90%, with no prophylaxis or treatment available. Ebola virus infections are characterised by immune suppression and a systemic inflammatory response that causes impairment of the vascular, coagulation, and immune systems, leading to multiorgan failure and shock, and thus, in some ways, resembling septic shock.	[Feldmann, Heinz] NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA; [Feldmann, Heinz] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada; [Geisbert, Thomas W.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX USA; [Geisbert, Thomas W.] Galveston Natl Lab, Galveston, TX USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Manitoba; University of Texas System; University of Texas Medical Branch Galveston	Feldmann, H (corresponding author), NIAID, Virol Lab, Div Intramural Res, NIH,Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59840 USA.	feldmannh@niaid.nih.gov	Rezaeian, Mohsen/C-6513-2008	Rezaeian, Mohsen/0000-0003-3070-0166	Canadian Institutes of Health Research (CIHR); Division of Intramural Research (DIR); National Institutes of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); Public Health Agency of Canada (PHAC); Defense Threat Reduction Agency; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001163, ZIAAI001089] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Division of Intramural Research (DIR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Public Health Agency of Canada (PHAC); Defense Threat Reduction Agency(United States Department of DefenseDefense Threat Reduction Agency); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank many colleagues in the field for helpful discussions; and the Canadian Institutes of Health Research (CIHR), the intramural (Division of Intramural Research (DIR)), and extramural divisions of the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Public Health Agency of Canada (PHAC), and the Defense Threat Reduction Agency for financial support of our work over the past decade.	[Anonymous], INFECT CONTROL VIRAL; Arata A., 1978, EBOLA VIRUS HAEMORRH, P191; Baize S, 2000, APOPTOSIS, V5, P5, DOI 10.1023/A:1009657006550; Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422; Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x; Barrette RW, 2009, SCIENCE, V325, P204, DOI 10.1126/science.1172705; BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basler CF, 2004, EBOLA AND MARBURG VIRUSES: MOLECULAR AND CELLULAR BIOLOGY, P305; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; Bausch DG, 2006, NEW ENGL J MED, V355, P909, DOI 10.1056/NEJMoa051465; Bosio CM, 2003, J INFECT DIS, V188, P1630, DOI 10.1086/379199; BRANDT CD, 1969, AM J EPIDEMIOL, V90, P484, DOI 10.1093/oxfordjournals.aje.a121094; Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386; Bray M, 2001, J COMP PATHOL, V125, P243, DOI 10.1053/jcpa.2001.0503; Bray M, 2002, ANTIVIR RES, V54, P1, DOI 10.1016/S0166-3542(02)00005-0; Breman JG, 1999, J INFECT DIS, V179, pS139, DOI 10.1086/514278; Breman JG, 1976, EBOLA VIRUS HAEMORRH, P103; Bukreyev A, 2006, J VIROL, V80, P2267, DOI 10.1128/JVI.80.5.2267-2279.2006; Bukreyev A, 2007, J VIROL, V81, P6379, DOI 10.1128/JVI.00105-07; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Centers for Disease Control and Prevention, BIOT AG DIS; Chepurnov AA, 1999, IMMUNOL LETT, V68, P257, DOI 10.1016/S0165-2478(99)00058-9; Cohen J, 2007, SCIENCE, V318, P1048, DOI 10.1126/science.318.5853.1048; Connolly BM, 1999, J INFECT DIS, V179, pS203, DOI 10.1086/514305; COX NJ, 1983, J INFECT DIS, V147, P272, DOI 10.1093/infdis/147.2.272; DALGARD DW, 1992, LAB ANIM SCI, V42, P152; Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247; Dowell SF, 1999, J INFECT DIS, V179, pS87, DOI 10.1086/514284; Ebihara H, 2006, PLOS PATHOG, V2, P705, DOI 10.1371/journal.ppat.0020073; ELLIOTT LH, 1982, J CLIN MICROBIOL, V16, P704, DOI 10.1128/JCM.16.4.704-708.1982; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154; Feldmann H., 2004, VIRUS TAXONOMY 8 REP, P645; Feldmann H, 2007, J INFECT DIS, V196, pS129, DOI 10.1086/520550; Feldmann H, 2007, PLOS PATHOG, V3, P54, DOI 10.1371/journal.ppat.0030002; Feldmann Heinz, 2005, Curr Opin Investig Drugs, V6, P823; FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887; FISHERHOCH SP, 1992, J INFECT DIS, V166, P753, DOI 10.1093/infdis/166.4.753; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Geisbert TW, 2008, J VIROL, V82, P5664, DOI 10.1128/JVI.00456-08; Geisbert TW, 2006, J INFECT DIS, V193, P1650, DOI 10.1086/504267; Geisbert TW, 2010, REV MED VIROL, V20, P344, DOI 10.1002/rmv.661; Geisbert TW, 2010, LANCET, V375, P1896, DOI 10.1016/S0140-6736(10)60357-1; Geisbert TW, 2009, J VIROL, V83, P7296, DOI 10.1128/JVI.00561-09; Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082; Geisbert TW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000225; Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021; Geisbert TW, 2003, J INFECT DIS, V188, P1618, DOI 10.1086/379724; Geisbert TW, 2003, LANCET, V362, P1953, DOI 10.1016/S0140-6736(03)15012-X; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; Geisbert TW, 2003, AM J PATHOL, V163, P2371, DOI 10.1016/S0002-9440(10)63592-4; Geisbert TW, 2002, EMERG INFECT DIS, V8, P503; GeorgesCourbot MC, 1997, EMERG INFECT DIS, V3, P59, DOI 10.3201/eid0301.970107; Grolla A, 2005, Bull Soc Pathol Exot, V98, P205; Groseth A, 2007, TRENDS MICROBIOL, V15, P408, DOI 10.1016/j.tim.2007.08.001; Gupta M, 2004, J VIROL, V78, P958, DOI 10.1128/JVI.78.2.958-967.2004; Halfmann P, 2008, P NATL ACAD SCI USA, V105, P1129, DOI 10.1073/pnas.0708057105; Halfmann P, 2009, J VIROL, V83, P3810, DOI 10.1128/JVI.00074-09; Harcourt BH, 1998, VIROLOGY, V252, P179, DOI 10.1006/viro.1998.9446; Harcourt BH, 1999, J VIROL, V73, P3491, DOI 10.1128/JVI.73.4.3491-3496.1999; Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3; Hensley LE, 2007, J INFECT DIS, V196, pS390, DOI 10.1086/520598; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; Ignatyev G, 2000, J BIOTECHNOL, V83, P67, DOI 10.1016/S0168-1656(00)00300-X; International Society for Infectious Diseases, 2009, EB VIR NEEDL INJ GER; International Society for Infectious Diseases, 2008, MARB HEM FEV US AM E; International Society for Infectious Diseases, 2009, MARB HEM FEV NETH EX; International Society for Infectious Diseases, 2004, EB LAB ACC DEATH RUS; Isaacson M, 1978, EBOLA VIRUS HAEMORRH, P15; Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; Jahrling PB, 1996, ARCH VIROL, P115; Jahrling PB, 1996, ARCH VIROL, P135; Jahrling PB, 2007, J INFECT DIS, V196, pS400, DOI 10.1086/520587; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Khan AS, 1999, J INFECT DIS, V179, pS76, DOI 10.1086/514306; KILEY MP, 1982, INTERVIROLOGY, V18, P24, DOI 10.1159/000149300; Ksiazek TG, 1999, J INFECT DIS, V179, pS192, DOI 10.1086/514313; LEGUENNO B, 1995, LANCET, V345, P1271, DOI 10.1016/S0140-6736(95)90925-7; Leirs H, 1999, J INFECT DIS, V179, pS155, DOI 10.1086/514299; Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a; Leroy EM, 2009, VECTOR-BORNE ZOONOT, V9, P723, DOI 10.1089/vbz.2008.0167; Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B; Lloyd ES, 1999, J INFECT DIS, V179, pS274, DOI 10.1086/514312; Mahanty S, 2003, J IMMUNOL, V170, P2797, DOI 10.4049/jimmunol.170.6.2797; Maruyama T, 1999, J VIROL, V73, P6024, DOI 10.1128/JVI.73.7.6024-6030.1999; MIKHAILOV VV, 1994, VOP VIRUSOL+, V39, P82; Miranda ME, 1999, J INFECT DIS, V179, pS115, DOI 10.1086/514314; Monath TP, 1999, J INFECT DIS, V179, pS127, DOI 10.1086/514281; Morvan JM, 1999, MICROBES INFECT, V1, P1193, DOI 10.1016/S1286-4579(99)00242-7; Muhlberger E, 1999, J VIROL, V73, P2333; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Murphy FA, 1978, EBOLA VIRUS HAEMORRH; Noda T, 2002, J VIROL, V76, P4855, DOI 10.1128/JVI.76.10.4855-4865.2002; Oswald WB, 2007, PLOS PATHOG, V3, P62, DOI 10.1371/journal.ppat.0030009; Parren PWHI, 2002, J VIROL, V76, P6408, DOI 10.1128/JVI.76.12.6408-6412.2002; Pattyn S, 1978, EBOLA VIRUS HAEMORRH; Peters CJ, 1999, J INFECT DIS, V179, pIX; Pourrut X, 2007, J INFECT DIS, V196, pS176, DOI 10.1086/520541; Qiu XG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005547; Reid SP, 2006, J VIROL, V80, P5156, DOI 10.1128/JVI.02349-05; Reiter P, 1999, J INFECT DIS, V179, pS148, DOI 10.1086/514304; Risi GF, 2010, EMERG INFECT DIS, V16, P373, DOI 10.3201/eid1603.091485; Rodriguez LL, 1999, J INFECT DIS, V179, pS170, DOI 10.1086/514291; Rowe AK, 1999, J INFECT DIS, V179, pS28, DOI 10.1086/514318; Ryabchikova E, 1996, ARCH VIROL, V141, P909, DOI 10.1007/BF01718165; Ryabchikova EI, 1999, J INFECT DIS, V179, pS199, DOI 10.1086/514293; Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; Sanchez A, 2006, FIELDS VIROLOGY, P1409; Schnittler HJ, 1998, CLIN INFECT DIS, V27, P404, DOI 10.1086/517704; SIEGERT R, 1967, DEUT MED WOCHENSCHR, V92, P2341, DOI 10.1055/s-0028-1106144; Smith PW, 2006, BIOSECUR BIOTERROR, V4, P351, DOI 10.1089/bsp.2006.4.351; Stroher U, 2001, J VIROL, V75, P11025, DOI 10.1128/JVI.75.22.11025-11033.2001; Strong JE, 2006, MANUAL OF MOLECULAR AND CLINICAL LABORATORY IMMUNOLOGY, 7TH EDITION, P774; Strong JE, 2008, P NATL ACAD SCI USA, V105, P17982, DOI 10.1073/pnas.0809698105; Sullivan NJ, 2009, NAT REV MICROBIOL, V7, P393, DOI 10.1038/nrmicro2129; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; Sullivan NJ, 2003, NATURE, V424, P681, DOI 10.1038/nature01876; Swanepoel R, 1996, EMERG INFECT DIS, V2, P321, DOI 10.3201/eid0204.960407; Swenson DL, 2008, CLIN VACCINE IMMUNOL, V15, P460, DOI 10.1128/CVI.00431-07; Towner JS, 2007, J INFECT DIS, V196, pS205, DOI 10.1086/520601; Towner JS, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000536; Towner JS, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000212; Towner JS, 2004, J VIROL, V78, P4330, DOI 10.1128/JVI.78.8.4330-4341.2004; Tuffs A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1223; Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283; Volchkov VE, 2000, VIROLOGY, V277, P147, DOI 10.1006/viro.2000.0572; VOLCHKOV VE, 1992, FEBS LETT, V305, P181, DOI 10.1016/0014-5793(92)80662-Z; Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052; Warfield KL, 2007, J INFECT DIS, V196, pS276, DOI 10.1086/520605; Warfield Kelly L., 2006, PLoS Pathogens, V2, P5; Wilson JA, 2000, SCIENCE, V287, P1664, DOI 10.1126/science.287.5458.1664; Yaddanapudi K, 2006, FASEB J, V20, P2519, DOI 10.1096/fj.06-6151com; Yang LJ, 2008, VIROLOGY, V377, P255, DOI 10.1016/j.virol.2008.04.029; Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654; Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319; Zaki SR, 1999, CURR TOP MICROBIOL, V235, P97	139	846	923	5	783	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	2011	377	9768					849	862		10.1016/S0140-6736(10)60667-8	http://dx.doi.org/10.1016/S0140-6736(10)60667-8			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738GO	21084112	Green Accepted, Green Submitted			2022-12-28	WOS:000288628500033
J	Zannad, F; McMurray, JJV; Krum, H; van Veldhuisen, DJ; Swedberg, K; Shi, H; Vincent, J; Pocock, SJ; Pitt, B				Zannad, Faiez; McMurray, John J. V.; Krum, Henry; van Veldhuisen, Dirk J.; Swedberg, Karl; Shi, Harry; Vincent, John; Pocock, Stuart J.; Pitt, Bertram		EMPHASIS-HF Study Grp	Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; TASK-FORCE; ALDOSTERONE; SPIRONOLACTONE; ASSOCIATION; SURVIVAL; COLLABORATION; CANDESARTAN; ACTIVATION	Background: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms. Methods: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. Results: The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 months. The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001). A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P=0.008); 10.8% and 13.5%, respectively, died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Hospitalizations for heart failure and for any cause were also reduced with eplerenone. A serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P<0.001). Conclusions: Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.) N Engl J Med 2011;364:11-21.	[Zannad, Faiez] Nancy Univ, Ctr Invest Clin 9501, INSERM, Nancy, France; [Zannad, Faiez] Nancy Univ, Ctr Hosp Univ, U961, Nancy, France; [Zannad, Faiez] Nancy Univ, Dept Cardiol, Nancy, France; [McMurray, John J. V.] Univ Glasgow, British Heart Fdn Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Krum, Henry] Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [van Veldhuisen, Dirk J.] Univ Groningen, Univ Med Ctr Groningen, Ctr Thorax, Dept Cardiol, NL-9713 AV Groningen, Netherlands; [Swedberg, Karl] Univ Gothenburg, Sahlgrenska Acad, Dept Emergency & Cardiovasc Med, Gothenburg, Sweden; [Shi, Harry; Vincent, John] Pfizer, New York, NY USA; [Pocock, Stuart J.] London Sch Hyg & Trop Med, Dept Med Stat, London, England; [Pitt, Bertram] Univ Michigan, Sch Med, Ann Arbor, MI USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; CHU de Nancy; Universite de Lorraine; Universite de Lorraine; University of Glasgow; Monash University; University of Groningen; University of Gothenburg; Pfizer; University of London; London School of Hygiene & Tropical Medicine; University of Michigan System; University of Michigan	Zannad, F (corresponding author), Clin Invest Ctr, INSERM, Inst Lorrain Coeur & Vaisseaux, F-54500 Nancy, France.	f.zannad@chu-nancy.fr	Senni, Michele/J-9380-2018; sinagra, gianfranco gs/P-7643-2014; mcmurray, John/B-2467-2013; Swedberg, Karl/B-2475-2008; Trochu, Jean-Noel/D-6378-2015; van Veldhuisen, Dirk Jan/E-8967-2014; Zannad, Faiez/K-4649-2019; De Keulenaer, Gilles/D-9321-2017; Prozesky, Hans Walter/ABE-6956-2020; Ručka, David/O-6785-2017; Bazylevych, Andriy/G-2834-2019; Motovska, Zuzana/J-1122-2016; Maas, A.H.E.M./H-8070-2014; Hradec, Jaromir/S-2388-2016; Kluiver, E.P./L-4438-2015; Monte, Ines/G-8642-2013; Mareev, Vyacheslav Yurievich/Q-1375-2017	Senni, Michele/0000-0001-5502-7882; mcmurray, John/0000-0002-6317-3975; De Keulenaer, Gilles/0000-0002-4238-4183; Prozesky, Hans Walter/0000-0001-9715-3449; Ručka, David/0000-0002-3564-9788; Bazylevych, Andriy/0000-0001-5053-2548; Motovska, Zuzana/0000-0002-5319-473X; Maas, A.H.E.M./0000-0001-5782-9926; Hradec, Jaromir/0000-0001-7597-8239; jourdain, patrick/0000-0002-5202-6902; GALINIER, Michel/0000-0003-1735-3390; Monte, Ines/0000-0001-7059-7525; Leischik, Roman/0000-0002-3731-1051; Boman, Kurt/0000-0002-0350-2132; Mareev, Vyacheslav Yurievich/0000-0002-7285-2048; Colucci, Wilson/0000-0002-0576-9420; Hittinger, Luc/0000-0003-1933-5815	Pfizer; board of Boston Scientific; Novartis; Takeda; AstraZeneca; Boehringer Ingelheim; GE Healthcare; Relypsa; Servier; Boston Scientific; Bayer; Johnson Johnson; Resmed; BG Medicine; Roche Diagnostics; Eugene Braunwald Endowment for the Advancement of Cardiovascular Discovery; Amgen; Nile Therapeutics; Merck; Forest Laboratories	Pfizer(Pfizer); board of Boston Scientific; Novartis(Novartis); Takeda(Takeda Pharmaceutical Company Ltd); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GE Healthcare(General ElectricGE Healthcare); Relypsa; Servier(Servier); Boston Scientific(Boston Scientific); Bayer(Bayer AG); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Resmed; BG Medicine; Roche Diagnostics; Eugene Braunwald Endowment for the Advancement of Cardiovascular Discovery; Amgen(Amgen); Nile Therapeutics; Merck(Merck & Company); Forest Laboratories	Supported by Pfizer.; Dr. Zannad reports receiving fees for serving on the board of Boston Scientific, consulting fees from Novartis, Takeda, AstraZeneca, Boehringer Ingelheim, GE Healthcare, Relypsa, Servier, Boston Scientific, Bayer, Johnson & Johnson, and Resmed, and speaker's fees from Pfizer and AstraZeneca and that his institution receives grant support from BG Medicine and Roche Diagnostics on his behalf. Dr. McMurray reports receiving grant support from the Eugene Braunwald Endowment for the Advancement of Cardiovascular Discovery and Care. Dr. Krum reports receiving travel reimbursements from Pfizer. Mr. Shi and Dr. Vincent report being employees of Pfizer and receiving stock options and travel reimbursements from Pfizer. Dr. Pocock reports receiving consulting fees from Servier, Amgen, AstraZeneca, and Novartis and that his institution receives grants from Servier and AstraZeneca on his behalf. Dr. Pitt reports receiving fees for serving on the board of Novartis, consulting fees from Takeda, AstraZeneca, Boehringer Ingelheim, GE Healthcare, Relypsa, BG Medicine, Nile Therapeutics, Merck, Forest Laboratories, and Novartis, grant support from Forest Laboratories and Novartis, and stock options from Relypsa, BG Medicine, Nile Therapeutics, and Aurasenc and that his institution receives grant support from Forest Laboratories on his behalf and he and his institution receive grant support from Bayer. No other potential conflict of interest relevant to this article was reported.	Ahmed A, 2007, EUR HEART J, V28, P1334, DOI 10.1093/eurheartj/ehm091; Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Boccanelli A, 2009, EUR J HEART FAIL, V11, P68, DOI 10.1093/eurjhf/hfn015; Cohn JN, 2003, CIRCULATION, V108, P1306, DOI 10.1161/01.CIR.0000091234.45664.62; Delcayre C, 2002, J MOL CELL CARDIOL, V34, P1577, DOI 10.1006/jmcc.2002.2088; Dickstein K, 2008, EUR HEART J, V10, P933; Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005; Dickstein K, 2009, EUR J HEART FAIL, V11, P110, DOI 10.1093/eurjhf/hfn030; FULLERTON MJ, 1994, CARDIOVASC RES, V28, P1863, DOI 10.1093/cvr/28.12.1863; Funder JW, 2009, HYPERTENSION, V53, P286, DOI 10.1161/HYPERTENSIONAHA.108.119966; Fung JWH, 2003, AM J CARDIOL, V92, P406, DOI 10.1016/S0002-9149(03)00658-1; Hayashi M, 2003, CIRCULATION, V107, P2559, DOI 10.1161/01.CIR.0000068340.96506.0F; Hunt SA, 2009, J AM COLL CARDIOL, V54, P2464, DOI 10.1016/j.jacc.2009.11.006; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Iraqi W, 2009, CIRCULATION, V119, P2471, DOI 10.1161/CIRCULATIONAHA.108.809194; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pocock SJ, 2005, JAMA-J AM MED ASSOC, V294, P2228, DOI 10.1001/jama.294.17.2228; Rocha R, 2002, AM J PHYSIOL-HEART C, V283, pH1802, DOI 10.1152/ajpheart.01096.2001; Silvestre JS, 1999, CIRCULATION, V99, P2694, DOI 10.1161/01.CIR.99.20.2694; Struthers AD, 2004, EUR J HEART FAIL, V6, P539, DOI 10.1016/j.ejheart.2004.04.013; Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1; Tsutamoto T, 2001, J AM COLL CARDIOL, V37, p165A; van Veldhuisen DJ, 2009, EUR J HEART FAIL, V11, P1143, DOI 10.1093/eurjhf/hfp149; Weber KT, 1999, NEW ENGL J MED, V341, P753, DOI 10.1056/NEJM199909023411009; Zannad F, 2000, CIRCULATION, V102, P2700, DOI 10.1161/01.CIR.102.22.2700; Zannad F, 2010, EUR J HEART FAIL, V12, P617, DOI 10.1093/eurjhf/hfq049	29	1877	1941	0	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 6	2011	364	1					11	21		10.1056/NEJMoa1009492	http://dx.doi.org/10.1056/NEJMoa1009492			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702UY	21073363	Green Accepted, Bronze			2022-12-28	WOS:000285922600006
J	Smith, MD; Asche, F; Guttormsen, AG; Wiener, JB				Smith, Martin D.; Asche, Frank; Guttormsen, Atle G.; Wiener, Jonathan B.			Genetically Modified Salmon and Full Impact Assessment	SCIENCE			English	Editorial Material									[Smith, Martin D.; Wiener, Jonathan B.] Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA; [Smith, Martin D.] Duke Univ, Dept Econ, Durham, NC 27708 USA; [Asche, Frank] Univ Stavanger, Dept Ind Econ, N-4036 Stavanger, Norway; [Guttormsen, Atle G.] Norwegian Univ Life Sci, Dept Econ & Resource Management, N-1432 As, Norway; [Wiener, Jonathan B.] Duke Univ, Sch Law, Durham, NC 27708 USA; [Wiener, Jonathan B.] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27708 USA; [Wiener, Jonathan B.] Resources Future Inc, Washington, DC 20036 USA	Duke University; Duke University; Universitetet i Stavanger; Norwegian University of Life Sciences; Duke University; Duke University; Resources for the Future	Smith, MD (corresponding author), Duke Univ, Nicholas Sch Environm, Durham, NC 27708 USA.	marsmith@duke.edu	Asche, Frank/AAG-9920-2020; Smith, Martin D/D-9168-2016; Guttormsen, Atle/GZG-2356-2022	Asche, Frank/0000-0002-1540-9728; Smith, Martin D/0000-0002-4714-463X; 				*AQUABOUNTY TECHN, 2010, ENV ASS AQUADVANTAG; Asche F, 2008, MAR RESOUR ECON, V23, P527, DOI 10.1086/mre.23.4.42629678; CHALFANT JA, 1988, J POLIT ECON, V96, P391, DOI 10.1086/261543; *CVM, 2009, 187 CVM FDA; Food and Nutrition Board, 2007, SEAF CHOIC BAL BEN R; Guttormsen A. G., 2002, Marine Resource Economics, V17, P91; Hibbeln JR, 2007, LANCET, V369, P578, DOI 10.1016/S0140-6736(07)60277-3; McLaren L, 2007, EPIDEMIOL REV, V29, P29, DOI 10.1093/epirev/mxm001; Mozaffarian D, 2006, JAMA-J AM MED ASSOC, V296, P1885, DOI 10.1001/jama.296.15.1885; Muir WM, 2004, EMBO REP, V5, P654, DOI 10.1038/sj.embor.7400197; Naylor RL, 2000, NATURE, V405, P1017, DOI 10.1038/35016500; Naylor RL, 2009, P NATL ACAD SCI USA, V106, P18040, DOI 10.1073/pnas.0910577106; Pollack A, 2010, NY TIMES        0627, pA1; Searchinger T, 2008, SCIENCE, V319, P1238, DOI 10.1126/science.1151861; Smith MD, 2010, SCIENCE, V327, P784, DOI 10.1126/science.1185345; Tacon AGJ, 2008, AQUACULTURE, V285, P146, DOI 10.1016/j.aquaculture.2008.08.015; Tveteras S., 2002, Marine Resource Economics, V17, P121; *VMAC, 2010, VMAC BRIEF PACK AQUA; Wilen JE, 2006, B MAR SCI, V78, P529	19	53	54	4	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2010	330	6007					1052	1053		10.1126/science.1197769	http://dx.doi.org/10.1126/science.1197769			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097923				2022-12-28	WOS:000284374700025
J	Dondorp, AM; Fanello, CI; Hendriksen, ICE; Gomes, E; Seni, A; Chhaganlal, KD; Bojang, K; Olaosebikan, R; Anunobi, N; Maitland, K; Kivaya, E; Agbenyega, T; Nguah, SB; Evans, J; Gesase, S; Kahabuka, C; Mtove, G; Nadjm, B; Deen, J; Amumpaire, JM; Nansumba, M; Karema, C; Umulisa, N; Uwimana, A; Mokuolu, OA; Adedoyin, OT; Johnson, WBR; Tshefu, AK; Onyamboko, MA; Sakulthaew, T; Ngum, WP; Silamut, K; Stepniewska, K; Woodrow, CJ; Bethell, D; Wills, B; Oneko, M; Peto, TE; von Seidlein, L; Day, NPJ; White, NJ				Dondorp, Arjen M.; Fanello, Caterina I.; Hendriksen, Ilse C. E.; Gomes, Ermelinda; Seni, Amir; Chhaganlal, Kajal D.; Bojang, Kalifa; Olaosebikan, Rasaq; Anunobi, Nkechinyere; Maitland, Kathryn; Kivaya, Esther; Agbenyega, Tsiri; Nguah, Samuel Blay; Evans, Jennifer; Gesase, Samwel; Kahabuka, Catherine; Mtove, George; Nadjm, Behzad; Deen, Jacqueline; Amumpaire, Juliet Mwanga; Nansumba, Margaret; Karema, Corine; Umulisa, Noella; Uwimana, Aline; Mokuolu, Olugbenga A.; Adedoyin, Olanrewaju T.; Johnson, Wahab B. R.; Tshefu, Antoinette K.; Onyamboko, Marie A.; Sakulthaew, Tharisara; Ngum, Wirichada Pan; Silamut, Kamolrat; Stepniewska, Kasia; Woodrow, Charles J.; Bethell, Delia; Wills, Bridget; Oneko, Martina; Peto, Tim E.; von Seidlein, Lorenz; Day, Nicholas P. J.; White, Nicholas J.		AQUAMAT Grp	Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial	LANCET			English	Article							INTRAMUSCULAR ARTESUNATE; INTRAVENOUS QUININE; ARTEMETHER; DIHYDROARTEMISININ; PHARMACOKINETICS; MORTALITY	Background Severe malaria is a major cause of childhood death and often the main reason for paediatric hospital admission in sub Saharan Africa Quinine is still the established treatment of choice, although evidence from Asia suggests that artesunate is associated with a lower mortality We compared parenteral treatment with either artesunate or quinine in African children with severe malaria Methods This open label randomised trial was undertaken in 11 centres in nine African countries Children (<15 years) with severe falciparum malaria were randomly assigned to parenteral artesunate or parenteral quinine Randomisation was in blocks of 20, with study numbers corresponding to treatment allocations kept inside opaque sealed paper envelopes The trial was open label at each site, and none of the investigators or trialists apart from for the trial statistician had access to the summaries of treatment allocations The primary outcome measure was in hospital mortality analysed by intention to treat This trial is registered, number ISRCTN50258054 Findings 5425 children were enrolled 2712 were assigned to artesunate and 2713 to quinine All patients were analysed for the primary outcome 230 (8 5%) patients assigned to artesunate treatment died compared with 297 (10 9%) assigned to quinine treatment (odds ratio [OR] stratified for study site 0 75 95% CI 0 63-0 90, relative reduction 22 5% 95% CI 8 1-36 9, p=0 0022) Incidence of neurological sequelae did not differ significantly between groups, but the development of coma (65/1832 [3 5%] with artesunate vs 91/1768 [5 1%] with quinine OR 0 69 95% CI 0 49-0 95, p=0 0231) convulsions (224/2712 [8 3%] vs 273/2713 [10 1%] OR 0 80, 0 66-0 97 p=0 0199) and deterioration of the coma score (166/2712 [6 1%] vs 208/2713 [7 7%], OR 0 78, 0 64-0 97, p=0 0245) were all significantly less frequent in artesunate recipients than in quinine recipients Post treatment hypoglycaemia was also less frequent in patients assigned to artesunate than in those assigned to quinine (48/2712 [1 8%] vs 75/2713 [2 8%] OR 0 63 0 43-0 91 p=0 0134) Artesunate was well tolerated with no serious drug related adverse effects Interpretation Artesunate substantially reduces mortality in African children with severe malaria These data together with a meta analysis of all trials comparing artesunate and quinine, strongly suggest that parenteral artesunate should replace quinine as the treatment of choice for severe falciparum malaria worldwide	[Dondorp, Arjen M.; Fanello, Caterina I.; Hendriksen, Ilse C. E.; Sakulthaew, Tharisara; Ngum, Wirichada Pan; Silamut, Kamolrat; Stepniewska, Kasia; Woodrow, Charles J.; Day, Nicholas P. J.; White, Nicholas J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, 420-6 Rajvithi Rd, Bangkok 10400, Thailand; [Gomes, Ermelinda; Seni, Amir; Chhaganlal, Kajal D.] Hosp Cent Beira, Beira, Mozambique; [Bojang, Kalifa; Olaosebikan, Rasaq; Anunobi, Nkechinyere] MRC Labs, Banjul, Gambia; [Agbenyega, Tsiri; Nguah, Samuel Blay; Evans, Jennifer] Komfo Anokye Hosp, Kumasi, Ghana; [Maitland, Kathryn; Kivaya, Esther] Kilifi Dist Gen Hosp, Kilifi, Kenya; [Gesase, Samwel; Kahabuka, Catherine] Magunga Distnct Hosp, NIMR Korogwe Res Lab, Tanga, Tanzania; [Nadjm, Behzad; Deen, Jacqueline] Teule Designated Dist Hosp, Muheza, Tanzania; [Mtove, George] NIMR Amani Ctr, Tanga, Tanzania; [Karema, Corine; Umulisa, Noella; Uwimana, Aline] Minist Hlth, Malaria Control Program, Kigali, Rwanda; [Mokuolu, Olugbenga A.; Adedoyin, Olanrewaju T.; Johnson, Wahab B. R.] Univ Ilorin, Teaching Hosp, Ilorin, Nigeria; [Amumpaire, Juliet Mwanga; Nansumba, Margaret] Mbarara Univ Sci & Technol, Mbarara, Uganda; [Amumpaire, Juliet Mwanga; Nansumba, Margaret] Epictr Res Base, Mbarara, Uganda; [Nansumba, Margaret; Tshefu, Antoinette K.] Kingasani Res Ctr, Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO; [Bethell, Delia; Peto, Tim E.] Univ Oxford, Nuffield Dept Clin Med, Oxford, England; [von Seidlein, Lorenz] Menzies Sch Hlth Res, Casuarina, NT, Australia; [Wills, Bridget] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam; [Oneko, Martina] KEMRI CDC Kisumu, Kisumu, Kenya	Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; MRC Laboratory Molecular Biology; Kwame Nkrumah University Science & Technology; University of Ilorin; Mbarara University of Science & Technology; University of Oxford; Charles Darwin University; Menzies School of Health Research; University of Oxford	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit MORU, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		Mokuolu, Olugbenga/G-4334-2016; Akor, Francis/L-3836-2019; Amos, Ben/AFL-6820-2022; Fanello, Caterina/AAT-9679-2021; Nguah, Samuel/AAQ-9725-2020; Amos, Ben/AAG-6934-2022; White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019	Mokuolu, Olugbenga/0000-0001-8273-5876; Akor, Francis/0000-0002-5181-8609; Amos, Ben/0000-0002-8569-1650; Fanello, Caterina/0000-0003-1932-9562; Amos, Ben/0000-0002-8569-1650; White, Nick/0000-0002-1897-1978; peto, tim/0000-0003-3477-8307; pan-ngum, wirichada/0000-0002-9839-5359; Nadjm, Behzad/0000-0002-7704-3629; Stepniewska, Kasia/0000-0002-1713-6209; Mtove, George/0000-0001-5173-0829; Woodrow, Charles/0000-0002-5134-7165; Maitland, Kathryn/0000-0002-0007-0645; Chirasatienpon, Tharisara/0000-0003-4320-054X; Wills, Bridget/0000-0001-9086-8804; Okebe, Joseph/0000-0001-5466-1611; Bojang, Kalifa/0000-0001-7506-0938	National Institute for Health Research Oxford Biomedical Research Centre; Wellcome Trust [076908, 082541]; Wellcome Trust of Great Britain; National Institute for Health Research [NF-SI-0508-10279, CL-2008-20-001] Funding Source: researchfish	National Institute for Health Research Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission); Wellcome Trust of Great Britain(Wellcome Trust); National Institute for Health Research(National Institute for Health Research (NIHR))	TEP is funded by the National Institute for Health Research Oxford Biomedical Research Centre This trial was supported by grants 076908 and 082541 from the Wellcome Trust and was coordinated as part of the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme funded by the Wellcome Trust of Great Britain We thank all the patients and their families the directors and staff of the trial hospitals and the Bangkok coordinating centre and the many doctors research nurses and research assistants for their help and support the ministries of health and institutional authorities for their support Loice Magaria and Ghiorghis Belai for their assistance and support Novartis for providing artemether lumefantrine for several of the study sites Marja Schilstra for help with database construction Epicentre (Philippe Guerin and Elizabeth Ashley) for assistance in setting up the study in Uganda and Richard Peto for advice	[Anonymous], 1990, Trans R Soc Trop Med Hyg, V84 Suppl 2, P1; Anstey NM, 2006, MED J AUSTRALIA, V184, P3, DOI 10.5694/j.1326-5377.2006.tb00084.x; Bartoloni A, 2010, AM J TROP MED HYG, V83, P274, DOI 10.4269/ajtmh.2010.10-0128; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Chotivanich K, 2002, J INFECT DIS, V185, P1538, DOI 10.1086/340213; Dondorp AM, 2008, J INFECT DIS, V197, P79, DOI 10.1086/523762; Eltahir HG, 2010, T ROY SOC TROP MED H, V104, P684, DOI 10.1016/j.trstmh.2010.05.009; Faiz MA, 2005, LANCET, V366, P717; Gomes MF, 2009, LANCET, V373, P557, DOI 10.1016/S0140-6736(08)61734-1; Gravenor MB, 1998, P NATL ACAD SCI USA, V95, P7620, DOI 10.1073/pnas.95.13.7620; Gwer S, 2007, AM J TROP MED HYG, V77, P6, DOI 10.4269/ajtmh.2007.77.6; HIEN TT, 1992, T ROY SOC TROP MED H, V86, P582, DOI 10.1016/0035-9203(92)90137-2; Hien TT, 2004, ANTIMICROB AGENTS CH, V48, P4234, DOI 10.1128/AAC.48.11.4234-4239.2004; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7; Ilett KF, 2002, BRIT J CLIN PHARMACO, V53, P23, DOI 10.1046/j.0306-5251.2001.01519.x; JELINEK T, 2005, EUROSURVEILLANCE, V10, P2841; Lalloo DG, 2007, J INFECTION, V54, P111, DOI 10.1016/j.jinf.2006.12.003; Lee SJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-149; Lubell Y, 2009, TROP MED INT HEALTH, V14, P332, DOI 10.1111/j.1365-3156.2009.02227.x; Mithwani S, 2004, BRIT J CLIN PHARMACO, V57, P146, DOI 10.1046/j.1365-2125.2003.01986.x; MURPHY S, 1995, AM J TROP MED HYG, V53, P303, DOI 10.4269/ajtmh.1995.53.303; Murphy SA, 1997, T ROY SOC TROP MED H, V91, P331, DOI 10.1016/S0035-9203(97)90097-3; Nealon C, 2002, ANTIMICROB AGENTS CH, V46, P3933, DOI 10.1128/AAC.46.12.3933-3939.2002; Newton PN, 2003, CLIN INFECT DIS, V37, P7, DOI 10.1086/375059; Phu NH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-97; Phuong CXT, 1997, T ROY SOC TROP MED H, V91, P335, DOI 10.1016/S0035-9203(97)90099-7; Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050; Silamut K, 2003, ANTIMICROB AGENTS CH, V47, P3795, DOI 10.1128/AAC.47.12.3795-3798.2003; Stepniewska K, 2001, T ROY SOC TROP MED H, V95, P637, DOI 10.1016/S0035-9203(01)90104-X; Stepniewska K, 2010, J INFECT DIS, V201, P570, DOI 10.1086/650301; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; UDOMSANGPETDI R, 1996, PLASRRIODIUMFALCIPAR, V173, P691; White NJ, 2007, BMJ-BRIT MED J, V334, P490, DOI 10.1136/bmj.39143.014005.1F; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; WIN K, 1992, B WORLD HEALTH ORGAN, V70, P777; World Health Organization, 2010, TREATM MAL; YEN LM, 1994, LANCET, V344, P786, DOI 10.1016/S0140-6736(94)92342-6	40	619	635	0	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1647	1657		10.1016/S0140-6736(10)61924-1	http://dx.doi.org/10.1016/S0140-6736(10)61924-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21062666	Green Accepted, Green Published			2022-12-28	WOS:000284451000030
J	Hanna, JH; Saha, K; Jaenisch, R				Hanna, Jacob H.; Saha, Krishanu; Jaenisch, Rudolf			Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues	CELL			English	Review							EMBRYONIC STEM-CELLS; GENE-EXPRESSION; DNA METHYLATION; HOMOLOGOUS RECOMBINATION; GROUND-STATE; T-CELLS; B-CELLS; FIBROBLASTS; GENERATION; DERIVATION	Direct reprogramming of somatic cells to induced pluripotent stem cells by ectopic expression of defined transcription factors has raised fundamental questions regarding the epigenetic stability of the differentiated cell state. In addition, evidence has accumulated that distinct states of pluripotency can interconvert through the modulation of both cell-intrinsic and exogenous factors. To fully realize the potential of in vitro reprogrammed cells, we need to understand the molecular and epigenetic determinants that convert one cell type into another. Here we review recent advances in this rapidly moving field and emphasize unresolved and controversial questions.	[Hanna, Jacob H.; Saha, Krishanu; Jaenisch, Rudolf] MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Jaenisch, Rudolf] MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Hanna, JH (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	hanna@wi.mit.edu; jaenisch@wi.mit.edu	liang, yan/H-3894-2011; Hanna, Jacob/K-1339-2012; Saha, Krishanu/J-3980-2014	Hanna, Jacob/0000-0003-2042-9974; Saha, Krishanu/0000-0003-2837-0858	Genzyme Fellowship; Helen Hay Whitney Foundation; Branco-Weiss fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD045022] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA087869, R01CA084198] Funding Source: NIH RePORTER	Genzyme Fellowship(Sanofi-AventisGenzyme Corporation); Helen Hay Whitney Foundation; Branco-Weiss fellowship; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Hillel and Liliana Bachrach, Susan Whitehead, and Landon Clay for their generous gifts supporting research conducted in our laboratory. We thank R. Young and members of the Jaenisch lab for discussions. J.H.H. is supported by a Genzyme Fellowship and a Helen Hay Whitney Foundation Fellowship; K.S. by a Society in Science: Branco-Weiss fellowship. R.J. is a cofounder of Fate Therapeutics and an adviser to Stemgent. We apologize to authors whose work has not been covered or directly cited due to space limitations.	Bao SQ, 2009, NATURE, V461, P1292, DOI 10.1038/nature08534; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Bloom JD, 2005, CURR OPIN STRUC BIOL, V15, P447, DOI 10.1016/j.sbi.2005.06.004; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Boland MJ, 2009, NATURE, V461, P91, DOI 10.1038/nature08310; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Buecker C, 2010, CELL STEM CELL, V6, P535, DOI 10.1016/j.stem.2010.05.003; Buehr M, 2008, CELL, V135, P1287, DOI 10.1016/j.cell.2008.12.007; Carvajal-Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chin MH, 2009, CELL STEM CELL, V5, P111, DOI 10.1016/j.stem.2009.06.008; Chou YF, 2008, CELL, V135, P449, DOI 10.1016/j.cell.2008.08.035; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; Conrad S, 2008, NATURE, V456, P344, DOI 10.1038/nature07404; Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677; Eminli S, 2009, NAT GENET, V41, P968, DOI 10.1038/ng.428; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Guenther MG, 2010, CELL STEM CELL, V7, P249, DOI 10.1016/j.stem.2010.06.015; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; GURDON JB, 1962, DEV BIOL, V5, P68, DOI 10.1016/0012-1606(62)90004-0; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Hanna J, 2008, CELL, V133, P250, DOI 10.1016/j.cell.2008.03.028; Hanna J, 2007, SCIENCE, V318, P1920, DOI 10.1126/science.1152092; Hanna J, 2010, P NATL ACAD SCI USA, V107, P9222, DOI 10.1073/pnas.1004584107; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Hanna J, 2009, CELL STEM CELL, V4, P513, DOI 10.1016/j.stem.2009.04.015; Hasegawa K, 2010, STEM CELLS, V28, P1338, DOI 10.1002/stem.466; Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027; Hockemeyer D, 2009, NAT BIOTECHNOL, V27, P851, DOI 10.1038/nbt.1562; HOGAN BLM, 1976, NATURE, V263, P136, DOI 10.1038/263136a0; Huang S, 2009, BIOESSAYS, V31, P546, DOI 10.1002/bies.200800189; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Ichida JK, 2009, CELL STEM CELL, V5, P491, DOI 10.1016/j.stem.2009.09.012; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Kang L, 2009, CELL STEM CELL, V5, P135, DOI 10.1016/j.stem.2009.07.001; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Ko K, 2010, NATURE, V465, pE1, DOI 10.1038/nature09089; Krizhanovsky V, 2009, NATURE, V460, P1085, DOI 10.1038/4601085a; Lengner CJ, 2010, CELL, V141, P872, DOI 10.1016/j.cell.2010.04.010; Liu L, 2010, J BIOL CHEM, V285, P19483, DOI 10.1074/jbc.M110.131995; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Loh YH, 2010, CELL STEM CELL, V7, P15, DOI 10.1016/j.stem.2010.06.004; Lu R, 2009, NATURE, V462, P358, DOI 10.1038/nature08575; Maherali N, 2009, CURR BIOL, V19, P1718, DOI 10.1016/j.cub.2009.08.025; Marson A, 2008, CELL STEM CELL, V3, P132, DOI 10.1016/j.stem.2008.06.019; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Newman AM, 2010, CELL STEM CELL, V7, P258, DOI 10.1016/j.stem.2010.06.016; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nichols J, 2009, CELL STEM CELL, V4, P487, DOI 10.1016/j.stem.2009.05.015; Ohta H, 2009, BIOL REPROD, V81, P1147, DOI 10.1095/biolreprod.109.079368; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Osafune K, 2008, NAT BIOTECHNOL, V26, P313, DOI 10.1038/nbt1383; Pereira CF, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000170; Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050; Saha K, 2009, CELL STEM CELL, V5, P584, DOI 10.1016/j.stem.2009.11.009; Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Seki T, 2010, CELL STEM CELL, V7, P11, DOI 10.1016/j.stem.2010.06.003; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Silva SS, 2008, P NATL ACAD SCI USA, V105, P4820, DOI 10.1073/pnas.0712136105; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith ZD, 2010, NAT BIOTECHNOL, V28, P521, DOI 10.1038/nbt.1632; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Staerk J, 2010, CELL STEM CELL, V7, P20, DOI 10.1016/j.stem.2010.06.002; Surani MA, 1999, SEMIN CELL DEV BIOL, V10, P273, DOI 10.1006/scdb.1998.0285; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takahashi N, 2009, HUM MOL GENET, V18, P1879, DOI 10.1093/hmg/ddp108; Tang FC, 2010, CELL STEM CELL, V6, P468, DOI 10.1016/j.stem.2010.03.015; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Urbach A, 2010, CELL STEM CELL, V6, P407, DOI 10.1016/j.stem.2010.04.005; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhao XY, 2009, NATURE, V461, P86, DOI 10.1038/nature08267; Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314; Zou JZ, 2009, CELL STEM CELL, V5, P97, DOI 10.1016/j.stem.2009.05.023; Zwaka TP, 2003, NAT BIOTECHNOL, V21, P319, DOI 10.1038/nbt788	99	504	537	5	140	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					508	525		10.1016/j.cell.2010.10.008	http://dx.doi.org/10.1016/j.cell.2010.10.008			18	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074044	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000284149100010
J	Rittle, J; Green, MT				Rittle, Jonathan; Green, Michael T.			Cytochrome P450 Compound I: Capture, Characterization, and C-H Bond Activation Kinetics	SCIENCE			English	Article							BIOINORGANIC CHEMISTRY; LAURIC ACID; CHLOROPEROXIDASE; P450CAM; HYDROXYLATION; INTERMEDIATE; SPECTROSCOPY; RESONANCE; FUNCTIONALIZATION; OXIDATIONS	Cytochrome P450 enzymes are responsible for the phase I metabolism of approximately 75% of known pharmaceuticals. P450s perform this and other important biological functions through the controlled activation of C-H bonds. Here, we report the spectroscopic and kinetic characterization of the long-sought principal intermediate involved in this process, P450 compound I (P450-I), which we prepared in approximately 75% yield by reacting ferric CYP119 with m-chloroperbenzoic acid. The Mossbauer spectrum of CYP119-I is similar to that of chloroperoxidase compound I, although its electron paramagnetic resonance spectrum reflects an increase in vertical bar J vertical bar/D, the ratio of the exchange coupling to the zero-field splitting. CYP119-I hydroxylates the unactivated C-H bonds of lauric acid [D(C-H) similar to 100 kilocalories per mole], with an apparent second-order rate constant of k(app) = 1.1 x 10(7) per molar per second at 4 degrees C. Direct measurements put a lower limit of k >= 210 per second on the rate constant for bound substrate oxidation, whereas analyses involving kinetic isotope effects predict a value in excess of 1400 per second.	[Rittle, Jonathan; Green, Michael T.] Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Green, MT (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	mtg10@psu.edu			NSF	NSF(National Science Foundation (NSF))	This work was supported by NSF. We thank T. Grove and J. C. Calixto Moreno for assistance with GC-MS and C. Krest for help with preliminary EPR experiments. The CYP119 plasmid was graciously provided by P. R. Ortiz de Montellano.	Behan RK, 2007, J AM CHEM SOC, V129, P5855, DOI 10.1021/ja064590y; Chandrasena REP, 2004, J AM CHEM SOC, V126, P115, DOI 10.1021/ja038237t; Davies HML, 2008, NATURE, V451, P417, DOI 10.1038/nature06485; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Davydov R, 2005, J AM CHEM SOC, V127, P1403, DOI 10.1021/ja045351i; de Montellano PRO, 2010, CHEM REV, V110, P932, DOI 10.1021/cr9002193; Denisov IG, 2001, J BIOL CHEM, V276, P11648, DOI 10.1074/jbc.M010219200; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Denisov IG, 2001, J INORG BIOCHEM, V87, P215, DOI 10.1016/S0162-0134(01)00328-2; EGAWA T, 1992, FEBS LETT, V305, P206, DOI 10.1016/0014-5793(92)80668-7; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; Godula K, 2006, SCIENCE, V312, P67, DOI 10.1126/science.1114731; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Green MT, 2001, J AM CHEM SOC, V123, P9218, DOI 10.1021/ja010105h; Groves JT, 2003, P NATL ACAD SCI USA, V100, P3569, DOI 10.1073/pnas.0830019100; GROVES JT, 1978, BIOCHEM BIOPH RES CO, V81, P154, DOI 10.1016/0006-291X(78)91643-1; Hoffman BM, 2003, P NATL ACAD SCI USA, V100, P3575, DOI 10.1073/pnas.0636464100; Karlin KD, 2010, NATURE, V463, P168, DOI 10.1038/463168a; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; Kim SH, 2005, DALTON T, P3464, DOI 10.1039/b506764m; Kim SH, 2006, J AM CHEM SOC, V128, P5598, DOI 10.1021/ja060776l; Klinman Judith P., 2009, P132, DOI 10.1039/9781847559975-00132; Koo LS, 2002, J AM CHEM SOC, V124, P5684, DOI 10.1021/ja017174g; Lim YR, 2010, J MICROBIOL BIOTECHN, V20, P574, DOI 10.4014/jmb.0909.09007; Makris TM, 2006, J INORG BIOCHEM, V100, P507, DOI 10.1016/j.jinorgbio.2006.01.025; McLean MA, 1998, BIOCHEM BIOPH RES CO, V252, P166, DOI 10.1006/bbrc.1998.9584; Newcomb M, 2003, J AM CHEM SOC, V125, P6064, DOI 10.1021/ja0343858; Ortiz de Montellano P. R., 2005, CYTOCHROME P450 STRU; Que L, 2001, SCIENCE, V292, P651; Rabe KS, 2008, CHEMBIOCHEM, V9, P420, DOI 10.1002/cbic.200700450; Rittle J, 2010, INORG CHEM, V49, P3610, DOI 10.1021/ic902062d; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Sligar SG, 2005, BIOCHEM BIOPH RES CO, V338, P346, DOI 10.1016/j.bbrc.2005.08.094; Spolitak T, 2005, J BIOL CHEM, V280, P20300, DOI 10.1074/jbc.M501761200; Stone KL, 2006, P NATL ACAD SCI USA, V103, P12307, DOI 10.1073/pnas.0603159103; Stone KL, 2005, P NATL ACAD SCI USA, V102, P16563, DOI 10.1073/pnas.0507069102; van Rantwijk F, 2000, CURR OPIN BIOTECH, V11, P554, DOI 10.1016/S0958-1669(00)00143-9; Wang Q, 2009, J AM CHEM SOC, V131, P10629, DOI 10.1021/ja9031105; Wright RL, 1996, FEBS LETT, V384, P235, DOI 10.1016/0014-5793(96)00322-5; ZAKS A, 1995, J AM CHEM SOC, V117, P10419, DOI 10.1021/ja00147a001; Zhang R, 2006, ORG LETT, V8, P2731, DOI 10.1021/ol060762k	43	923	923	13	490	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2010	330	6006					933	937		10.1126/science.1193478	http://dx.doi.org/10.1126/science.1193478			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071661				2022-12-28	WOS:000284118000033
J	Thomas, MC; Cooper, ME				Thomas, Merlin C.; Cooper, Mark E.			Into the light? Diabetic nephropathy and vitamin D	LANCET			English	Editorial Material							CHRONIC KIDNEY-DISEASE; PARICALCITOL; HEMODIALYSIS; TRIAL		[Thomas, Merlin C.; Cooper, Mark E.] Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia; [Thomas, Merlin C.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Baker Heart and Diabetes Institute; Monash University	Cooper, ME (corresponding author), Baker IDI Heart & Diabet Inst, Melbourne, Vic 8008, Australia.	mark.cooper@bakeridi.edu.au	Cooper, Mark/AAC-5326-2020	Thomas, Merlin/0000-0003-0694-8743				Agarwal R, 2005, KIDNEY INT, V68, P2823, DOI 10.1111/j.1523-1755.2005.00755.x; Alborzi P, 2008, HYPERTENSION, V52, P249, DOI 10.1161/HYPERTENSIONAHA.108.113159; de Zeeuw D, 2010, LANCET, V376, P1543, DOI 10.1016/S0140-6736(10)61032-X; Dusso A, 2010, J STEROID BIOCHEM, V121, P193, DOI 10.1016/j.jsbmb.2010.03.064; Fishbane S, 2009, AM J KIDNEY DIS, V54, P647, DOI 10.1053/j.ajkd.2009.04.036; Freundlich M, 2008, KIDNEY INT, V74, P1394, DOI 10.1038/ki.2008.408; Tanaka H, 2009, BONE, V45, P949, DOI 10.1016/j.bone.2009.07.016; Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536; Tentori F, 2006, KIDNEY INT, V70, P1858, DOI 10.1038/sj.ki.5001868; Thrailkill KM, 2009, DIABETES CARE, V32, P1266, DOI 10.2337/dc09-0112; Witham MD, 2010, DIABETOLOGIA, V53, P2112, DOI 10.1007/s00125-010-1838-1; Zhang Z, 2008, KIDNEY INT, V73, P163, DOI 10.1038/sj.ki.5002572	13	14	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1521	1522		10.1016/S0140-6736(10)61304-9	http://dx.doi.org/10.1016/S0140-6736(10)61304-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21055802				2022-12-28	WOS:000284248700006
J	Toms, DJ				Toms, David J.			Quantum gravitational contributions to quantum electrodynamics	NATURE			English	Article							ONE-LOOP DIVERGENCES; FIELD-THEORY; GAUGE-THEORIES; RENORMALIZATION; NONRENORMALIZABILITY; INVARIANCE; SCALE	Quantum electrodynamics describes the interactions of electrons and photons. Electric charge (the gauge coupling constant) is energy dependent, and there is a previous claim that charge is affected by gravity (described by general relativity) with the implication that the charge is reduced at high energies. However, that claim has been very controversial and the matter has not been settled. Here I report an analysis (free from the earlier controversies) demonstrating that quantum gravity corrections to quantum electrodynamics have a quadratic energy dependence that result in the electric charge vanishing at high energies, a result known as asymptotic freedom.	Newcastle Univ, Sch Math & Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK	Toms, DJ (corresponding author), Newcastle Univ, Sch Math & Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	d.j.toms@newcastle.ac.uk	Toms, David J/F-7599-2011	Toms, David/0000-0003-3588-1058				Arkani-Hamed N, 1998, PHYS LETT B, V429, P263, DOI 10.1016/S0370-2693(98)00466-3; Arkani-Hamed N, 2007, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2007/06/060; BARVINSKY AO, 1985, PHYS REP, V119, P1, DOI 10.1016/0370-1573(85)90148-6; BUNCH TS, 1979, PHYS REV D, V20, P2499, DOI 10.1103/PhysRevD.20.2499; BURGESS CP, 2004, LIVING REV RELATIVIT; CALLAN CG, 1970, PHYS REV D, V2, P1541, DOI 10.1103/PhysRevD.2.1541; Daum JE, 2010, J HIGH ENERGY PHYS, DOI 10.1007/JHEP01(2010)084; DESER S, 1974, PHYS REV D, V10, P411, DOI 10.1103/PhysRevD.10.411; DESER S, 1974, PHYS REV D, V10, P401, DOI 10.1103/PhysRevD.10.401; DESER S, 1974, PHYS REV LETT, V32, P245, DOI 10.1103/PhysRevLett.32.245; DESER S, 1974, PHYS REV D, V10, P3337, DOI 10.1103/PhysRevD.10.3337; DeWitt B., 1987, Quantum field theory and quantum statistics. Essays in honour of the sixtieth birthday of E.S. Fradkin, P191; DONOGHUE JF, 1994, PHYS REV LETT, V72, P2996, DOI 10.1103/PhysRevLett.72.2996; DONOGHUE JF, 1994, PHYS REV D, V50, P3874, DOI 10.1103/PhysRevD.50.3874; Ebert D, 2009, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2009/02/028; FRADKIN ES, 1984, NUCL PHYS B, V234, P509, DOI 10.1016/0550-3213(84)90075-0; Gilkey PB., 1975, J DIFFER GEOM, V10, P601, DOI [DOI 10.4310/JDG/1214433164, 10.4310/jdg/1214433164]; Gogoladze I, 2007, PHYS LETT B, V645, P451, DOI 10.1016/j.physletb.2006.11.063; GROSS DJ, 1973, PHYS REV LETT, V30, P1343, DOI 10.1103/PhysRevLett.30.1343; Huang QG, 2007, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2007/03/053; Mackay PT, 2010, PHYS LETT B, V684, P251, DOI 10.1016/j.physletb.2009.12.032; Parker LE, 2009, CAM M MATH, P1, DOI 10.1017/CBO9780511813924; Peeters K, 2007, COMPUT PHYS COMMUN, V176, P550, DOI 10.1016/j.cpc.2007.01.003; Pietrykowski AR, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.061801; POLITZER HD, 1973, PHYS REV LETT, V30, P1346, DOI 10.1103/PhysRevLett.30.1346; Robinson SP, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.231601; Rodigast A, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.081301; SCHWINGER J, 1951, PHYS REV, V82, P664, DOI 10.1103/PhysRev.82.664; Shaposhnikov M, 2010, PHYS LETT B, V683, P196, DOI 10.1016/j.physletb.2009.12.022; Spergel DN, 2007, ASTROPHYS J SUPPL S, V170, P377, DOI 10.1086/513700; SYMANZIK K, 1970, COMMUN MATH PHYS, V18, P227, DOI 10.1007/BF01649434; TANG Y, GRAVITATIONAL CONTRI; THOOFT G, 1974, ANN I H POINCARE A, V20, P69; THOOFT G, 1972, NUCL PHYS B, VB-44, P189, DOI 10.1016/0550-3213(72)90279-9; Toms DJ, 2007, PHYS REV D, V76, DOI 10.1103/PhysRevD.76.045015; Toms DJ, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.131301; TOMS DJ, 1982, PHYS REV D, V26, P2713, DOI 10.1103/PhysRevD.26.2713; TOMS DJ, 1983, PHYS REV D, V27, P1803, DOI 10.1103/PhysRevD.27.1803; VILKOVISKY GA, 1984, NUCL PHYS B, V234, P125, DOI 10.1016/0550-3213(84)90228-1; Zanusso O, 2010, PHYS LETT B, V689, P90, DOI 10.1016/j.physletb.2010.04.043	43	64	64	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					56	59		10.1038/nature09506	http://dx.doi.org/10.1038/nature09506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048760	Green Submitted			2022-12-28	WOS:000283786900034
J	Younes, A; Bartlett, NL; Leonard, JP; Kennedy, DA; Lynch, CM; Sievers, EL; Forero-Torres, A				Younes, Anas; Bartlett, Nancy L.; Leonard, John P.; Kennedy, Dana A.; Lynch, Carmel M.; Sievers, Eric L.; Forero-Torres, Andres			Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; ANTIBODY-DRUG CONJUGATE; HODGKINS LYMPHOMA; ANTITUMOR-ACTIVITY; RESPONSE CRITERIA; CHEMOKINE TARC; PHASE-II; DISEASE; GEMCITABINE; TRANSPLANTATION	Background: Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal activity. To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35). Methods: In this phase 1, open-label, multicenter dose-escalation study, we administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma. Patients had received a median of three previous chemotherapy regimens (range, one to seven), and 73% had undergone autologous stem-cell transplantation. Results: The maximum tolerated dose was 1.8 mg per kilogram, administered every 3 weeks. Objective responses, including 11 complete remissions, were observed in 17 patients. Of 12 patients who received the 1.8-mg-per-kilogram dose, 6 (50%) had an objective response. The median duration of response was at least 9.7 months. Tumor regression was observed in 36 of 42 patients who could be evaluated (86%). The most common adverse events were fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral neuropathy. Conclusions: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study. Treatment was associated primarily with grade 1 or 2 (mild-to-moderate) toxic effects. (Funded by Seattle Genetics; ClinicalTrials.gov number, NCT00430846.) N Engl J Med 2010;363:1812-21.	[Younes, Anas] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Bartlett, Nancy L.] Washington Univ, St Louis, MO 63130 USA; [Leonard, John P.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Kennedy, Dana A.; Lynch, Carmel M.; Sievers, Eric L.] Seattle Genet, Bothell, WA USA; [Forero-Torres, Andres] Univ Alabama, Birmingham, AL USA	University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL); Cornell University; Seattle Genetics; University of Alabama System; University of Alabama Birmingham	Younes, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ayounes@mdanderson.org	Leonard, John/M-4379-2014	Leonard, John/0000-0002-5083-1115; Sievers, Eric/0000-0002-0794-9441; Bartlett, Nancy/0000-0001-8470-394X	Seattle Genetics	Seattle Genetics	Supported by Seattle Genetics.	Ansell SM, 2007, J CLIN ONCOL, V25, P2764, DOI 10.1200/JCO.2006.07.8972; Aurer I, 2005, ONKOLOGIE, V28, P567, DOI 10.1159/000088621; Bartlett NL, 2007, ANN ONCOL, V18, P1071, DOI 10.1093/annonc/mdm090; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Diehl V, 2003, NEW ENGL J MED, V348, P2386, DOI 10.1056/NEJMoa022473; DIEHL V, 2005, NEW ENGL J MED, V353, P744; Doronina SO, 2003, NAT BIOTECHNOL, V21, P778, DOI 10.1038/nbt832; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FALINI B, 1995, BLOOD, V85, P1; Forero-Torres A, 2009, BRIT J HAEMATOL, V146, P171, DOI 10.1111/j.1365-2141.2009.07740.x; Hamblett KJ, 2004, CLIN CANCER RES, V10, P7063, DOI 10.1158/1078-0432.CCR-04-0789; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Lee JJ, 2006, J CLIN ONCOL, V24, P1633, DOI 10.1200/JCO.2005.04.0543; Little R, 1998, J CLIN ONCOL, V16, P584, DOI 10.1200/JCO.1998.16.2.584; Majhail NS, 2006, BIOL BLOOD MARROW TR, V12, P1065, DOI 10.1016/j.bbmt.2006.06.006; Martinez C, 2010, J CLIN ONCOL S, V28, p7s; Matsumoto K, 2004, J IMMUNOL, V172, P2186, DOI 10.4049/jimmunol.172.4.2186; McDonagh CF, 2006, PROTEIN ENG DES SEL, V19, P299, DOI 10.1093/protein/gzl013; Niens M, 2008, BRIT J HAEMATOL, V140, P527, DOI 10.1111/j.1365-2141.2007.06964.x; Oflazoglu E, 2008, BRIT J HAEMATOL, V142, P69, DOI 10.1111/j.1365-2141.2008.07146.x; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Oki Y, 2008, CANCER-AM CANCER SOC, V112, P831, DOI 10.1002/cncr.23237; Re D, 2005, BLOOD, V105, P4553, DOI 10.1182/blood-2004-12-4750; Rule S, 1998, HEMATOL ONCOL, V16, P101, DOI 10.1002/(SICI)1099-1069(199809)16:3<101::AID-HON629>3.3.CO;2-R; Stein H., 2008, WHO CLASSIFICATION T, P326; Sun MMC, 2005, BIOCONJUGATE CHEM, V16, P1282, DOI 10.1021/bc050201y; Sureda A, 2005, ANN ONCOL, V16, P625, DOI 10.1093/annonc/mdi119; Swain Sandra M, 2008, Clin Adv Hematol Oncol, V6, P455; TIAN ZG, 1995, CANCER RES, V55, P5335; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; Venkatesh H, 2004, CLIN LYMPHOMA, V5, P110, DOI 10.3816/CLM.2004.n.017; Weihrauch MR, 2005, CANCER RES, V65, P5516, DOI 10.1158/0008-5472.CAN-05-0100; Younes Anas, 2009, Hematology Am Soc Hematol Educ Program, P507, DOI 10.1182/asheducation-2009.1.507; Zinzani PL, 2000, HAEMATOLOGICA, V85, P926	35	939	981	0	124	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1812	1821		10.1056/NEJMoa1002965	http://dx.doi.org/10.1056/NEJMoa1002965			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047225	Green Published			2022-12-28	WOS:000283787800006
J	Rahimi, K; Malhotra, A; Banning, AP; Jenkinson, C				Rahimi, Kazem; Malhotra, Aneil; Banning, Adrian P.; Jenkinson, Crispin			Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIALS; ACUTE CORONARY SYNDROMES; CLINICAL-TRIALS; HEART-FAILURE; HEALTH-STATUS; CLOPIDOGREL; PRASUGREL; DISEASE	Objectives To systematically assess the type of outcomes selected and the prevalence of patient reported outcomes in contemporary cardiovascular trials and to quantify any misuse or underuse of patient reported outcomes using a specially developed tool that would allow estimation of the relevance of such outcomes to clinical decision making. Design Systematic review. Data sources Medline and Embase. Study selection Randomised controlled trials of the treatment for or prevention of cardiovascular disease published in 10 leading general medical and cardiology journals from January 2005 to December 2008. Results Primary outcomes were patient important (death, morbidity, or patient reported outcomes) in only 93 of 413 trials (23%, SE 2%), whereas another 92 (22%, SE 2%) combined these outcomes with other less important ones into a composite. Sixty five trials (16%; SE 2%) used at least one instrument to measure patient reported outcomes, mostly in trials where such information would have been important or crucial for clinical decision making (52 trials). Patient reported outcomes were judged to be of little incremental value to a large number of, mostly explanatory, cardiovascular trials (152 trials). However, many trials in which patient reported outcomes would have been important or crucial for clinical decision making did not report such outcomes (122 of 174 trials, 70%). These included several trials that primarily aimed to improve symptoms or functional status, trials that tested interventions with a considerable potential for causing harm (mainly bleeding) that were not meaningfully measured, and trials with composite outcomes that were dominated by outcomes of questionable importance to patients. Conclusions Despite a continued rise in the reporting of patient reported outcomes with no evidence for their misuse in more recent cardiovascular trials, they seem to be still underused once their relevance to clinical decision making has been taken into account. This was largely explained by inappropriate use of composite outcomes and inadequate measurement of harms.	[Rahimi, Kazem; Malhotra, Aneil; Banning, Adrian P.] John Radcliffe Hosp, Oxford Heart Ctr, Dept Cardiol, Oxford OX3 9DU, England; [Jenkinson, Crispin] Univ Oxford, Hlth Serv Res Unit, Dept Publ Hlth, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Rahimi, K (corresponding author), John Radcliffe Hosp, Oxford Heart Ctr, Dept Cardiol, Oxford OX3 9DU, England.	kazem.rahimi@orh.nhs.uk	banning, adrian p/AAF-7229-2021; Rahimi, Kazem/Q-1279-2015; Rahimi, Kazem/AAA-4250-2022	Rahimi, Kazem/0000-0002-4807-4610; Banning, Adrian/0000-0002-2842-7861				Acquadro C, 2003, VALUE HEALTH, V6, P522, DOI 10.1046/j.1524-4733.2003.65309.x; [Anonymous], 1995, LANCET, V346, P1; Campbell DJ, 2005, CIRCULATION, V111, P315, DOI 10.1161/01.CIR.0000153269.07762.3B; Clarke M, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-39; Contopoulos-Ioannidis DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3006; DeMets DL, 2002, CIRCULATION, V106, P746, DOI 10.1161/01.CIR.0000023219.51483.66; Fayers PM, 2007, QUALITY LIFE ASSESSM; Feeny D., 2005, ASSESSING QUALITY LI, P405; Ferreira-Gonzalez I, 2007, BRIT MED J, V334, P786, DOI 10.1136/bmj.39136.682083.AE; Gandhi GY, 2008, JAMA-J AM MED ASSOC, V299, P2543, DOI 10.1001/jama.299.21.2543; GANZ PA, 1992, J NATL CANCER I, V84, P994, DOI 10.1093/jnci/84.13.994; GOTAY CC, 1992, J NATL CANCER I, V84, P575, DOI 10.1093/jnci/84.8.575; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Jourdain P, 2007, J AM COLL CARDIOL, V49, P1733, DOI 10.1016/j.jacc.2006.10.081; KAASA S, 1992, ONCOLOGY, V49, P288; LESPERANCE F, 2007, PSYCHOTHER, V297, P367; McDermott MM, 1998, J VASC SURG, V28, P1072, DOI 10.1016/S0741-5214(98)70034-5; Normand SLT, 2005, J CARD FAIL, V11, P396, DOI 10.1016/j.cardfail.2005.04.002; Panzini L, 2006, TUMORI J, V92, P373, DOI 10.1177/030089160609200501; POCOCK SJ, 1991, CONTROL CLIN TRIALS, V12, pS257, DOI 10.1016/S0197-2456(05)80029-7; Rao SV, 2006, J AM COLL CARDIOL, V47, P809, DOI 10.1016/j.jacc.2005.09.060; Sanders C, 1998, BRIT MED J, V317, P1191, DOI 10.1136/bmj.317.7167.1191; Schomig A, 2005, JAMA-J AM MED ASSOC, V293, P2865, DOI 10.1001/jama.293.23.2865; Spertus JA, 2008, CIRCULATION, V118, P2103, DOI 10.1161/CIRCULATIONAHA.107.747568; Tawakol A, 2005, J AM COLL CARDIOL, V45, P1580, DOI 10.1016/j.jacc.2005.02.038; Unger EF, 2009, NEW ENGL J MED, V361, P942, DOI 10.1056/NEJMp0907122; VANZANTEN SJO, 1991, CONTROLLED CLIN TRIA, V12, P234; von Beckerath N, 2005, CIRCULATION, V112, pU676; WENGER NK, 1984, AM J CARDIOL, V54, P908, DOI 10.1016/S0002-9149(84)80232-5; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	32	41	41	2	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	2010	341								c5707	10.1136/bmj.c5707	http://dx.doi.org/10.1136/bmj.c5707			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CD	21041324	Green Published, hybrid			2022-12-28	WOS:000284045500003
J	Bourc'his, D; Voinnet, O				Bourc'his, Deborah; Voinnet, Olivier			A Small-RNA Perspective on Gametogenesis, Fertilization, and Early Zygotic Development	SCIENCE			English	Review							SMALL SILENCING RNAS; TRANSPOSABLE ELEMENTS; EPIGENETIC CONTROL; DNA ELIMINATION; ARABIDOPSIS; DROSOPHILA; GENE; RETROTRANSPOSITION; DEMETHYLATION; TRANSCRIPTS	Transient populations of cis- and trans-acting small RNAs have recently emerged as key regulators of extensive epigenetic changes taking place during periconception, which encompasses gametogenesis, fertilization, and early zygotic development. These small RNAs are not only important to maintain genome integrity in the gametes and zygote, but they also actively contribute to assessing the compatibility of parental genomes at fertilization and to promoting long-term memory of the zygotic epigenetic landscape by affecting chromatin. Striking parallels exist in the biogenesis and modus operandi of these molecules among diverse taxa, unraveling universal themes of small-RNA-mediated epigenetic reprogramming during sexual reproduction.	[Bourc'his, Deborah] Inst Curie, CNRS, UMR 3215, INSERM,U934, F-75248 Paris 05, France; [Voinnet, Olivier] Univ Strasbourg, CNRS, UPR2357, Inst Biol Mol Plantes, F-67081 Strasbourg, France; [Voinnet, Olivier] Swiss Fed Inst Technol ETH Z, CH-8092 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bourc'his, D (corresponding author), Inst Curie, CNRS, UMR 3215, INSERM,U934, F-75248 Paris 05, France.	Deborah.Bourchis@curie.fr; olivier.voinnet@ibmp-ulp.u-strasbg.fr		Voinnet, Olivier/0000-0001-6982-9544; Bourc'his, Deborah/0000-0001-9499-7291	European Young Investigator award; Fondation Schlumberger pour l'Enseignement et la Recherche; European Research Council [210890]; Bettencourt Foundation	European Young Investigator award; Fondation Schlumberger pour l'Enseignement et la Recherche; European Research Council(European Research Council (ERC)European Commission); Bettencourt Foundation	We are indebted to J. Brennecke, S. Duharcourt, and A. Pelisson for valuable discussions and advice. D. B. is supported by a European Young Investigator award and the Fondation Schlumberger pour l'Enseignement et la Recherche. O.V. is supported by a European Research Council starting grant (210890) "Frontiers of RNAi" and an award from the Bettencourt Foundation.	Aravin AA, 2007, SCIENCE, V316, P744, DOI 10.1126/science.1142612; BABINET C, 1990, DEVELOPMENT, P81; Bell TA, 2006, GENETICS, V172, P411, DOI 10.1534/genetics.105.047118; Bohne A, 2008, CHROMOSOME RES, V16, P203, DOI 10.1007/s10577-007-1202-6; Brennecke J, 2008, SCIENCE, V322, P1387, DOI 10.1126/science.1165171; Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043; Brower-Toland B, 2007, GENE DEV, V21, P2300, DOI 10.1101/gad.1564307; Chambeyron S, 2008, P NATL ACAD SCI USA, V105, P14964, DOI 10.1073/pnas.0805943105; Choi YH, 2002, CELL, V110, P33, DOI 10.1016/S0092-8674(02)00807-3; Dramard X, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000304; Duharcourt S, 2009, TRENDS GENET, V25, P344, DOI 10.1016/j.tig.2009.05.007; Dunoyer P, 2010, EMBO J, V29, P1699, DOI 10.1038/emboj.2010.65; Dunoyer P, 2010, SCIENCE, V328, P912, DOI 10.1126/science.1185880; Gehring M, 2009, SCIENCE, V324, P1447, DOI 10.1126/science.1171609; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Grandjean V, 2009, DEVELOPMENT, V136, P3647, DOI 10.1242/dev.041061; Hsieh TF, 2009, SCIENCE, V324, P1451, DOI [10.1126/science.1172417, 10.1126/science.112417]; Josefsson C, 2006, CURR BIOL, V16, P1322, DOI 10.1016/j.cub.2006.05.045; Jullien PE, 2008, PLOS BIOL, V6, P1693, DOI 10.1371/journal.pbio.0060194; Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909; Klattenhoff C, 2009, CELL, V138, P1137, DOI 10.1016/j.cell.2009.07.014; Lepere G, 2008, GENE DEV, V22, P1501, DOI 10.1101/gad.473008; Li CJ, 2009, CELL, V137, P509, DOI 10.1016/j.cell.2009.04.027; Malone CD, 2009, CELL, V137, P522, DOI 10.1016/j.cell.2009.03.040; Martienssen RA, 2010, NEW PHYTOL, V186, P46, DOI 10.1111/j.1469-8137.2010.03193.x; Mirouze M, 2009, NATURE, V461, P427, DOI 10.1038/nature08328; Mochizuki K, 2005, GENE DEV, V19, P77, DOI 10.1101/gad.1265105; Molnar A, 2010, SCIENCE, V328, P872, DOI 10.1126/science.1187959; Mosher RA, 2009, NATURE, V460, P283, DOI 10.1038/nature08084; Nishida KM, 2007, RNA, V13, P1911, DOI 10.1261/rna.744307; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038; Tarutani Y, 2010, NATURE, V466, P983, DOI 10.1038/nature09308; Taverna SD, 2002, CELL, V110, P701, DOI 10.1016/S0092-8674(02)00941-8; Teixeira FK, 2010, HEREDITY, V105, P14, DOI 10.1038/hdy.2010.52; Teixeira FK, 2009, SCIENCE, V323, P1600, DOI 10.1126/science.1165313; Tsukahara S, 2009, NATURE, V461, P423, DOI 10.1038/nature08351; Vagin VV, 2006, SCIENCE, V313, P320, DOI 10.1126/science.1129333; Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908; Wu L, 2010, MOL CELL, V38, P465, DOI 10.1016/j.molcel.2010.03.008; Yan W, 2008, BIOL REPROD, V78, P896, DOI 10.1095/biolreprod.107.067033; Zamudio N, 2010, HEREDITY, V105, P92, DOI 10.1038/hdy.2010.53; Zheng XW, 2008, NATURE, V455, P1259, DOI 10.1038/nature07305	44	119	123	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					617	622		10.1126/science.1194776	http://dx.doi.org/10.1126/science.1194776			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030645				2022-12-28	WOS:000283580600033
J	Brookes, D; Etkina, E				Brookes, David; Etkina, Eugenia			Physical Phenomena in Real Time	SCIENCE			English	Editorial Material									[Brookes, David; Etkina, Eugenia] Rutgers State Univ, Grad Sch Educ, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Etkina, E (corresponding author), Rutgers State Univ, Grad Sch Educ, New Brunswick, NJ 08901 USA.	eugenia.etkina@gse.rutgers.edu			U.S. Department of Education; NSF	U.S. Department of Education(US Department of Education); NSF(National Science Foundation (NSF))	We thank A. Van Heuvelen, S. Murthy, M. Lawrence, M. Gentile, L. Largo, Y. Sakano, A. Warren, D. Maiullo, and many others who provided ideas and technical assistance for our project. This work would be impossible without the funds from the U.S. Department of Education and the NSF.	Chin P., 2004, RECONSIDERING SCI LE, P118; Etkina E., 2007, RES BASED REFORM U P; Etkina E, 2006, PHYS REV SPEC TOP-PH, V2, DOI 10.1103/PhysRevSTPER.2.020103	3	7	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					605	606		10.1126/science.1186992	http://dx.doi.org/10.1126/science.1186992			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030642				2022-12-28	WOS:000283580600030
J	Quere, Y				Quere, Yves			Georges Charpak (1924-2010)	SCIENCE			English	Editorial Material									Acad Sci Delegat Enseignement & Format, F-75006 Paris, France		Quere, Y (corresponding author), Acad Sci Delegat Enseignement & Format, 23 Quai Conti, F-75006 Paris, France.	yves.quere@academie-sciences.fr							0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					604	604		10.1126/science.1198962	http://dx.doi.org/10.1126/science.1198962			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030641				2022-12-28	WOS:000283580600029
J	Cerf, M; Thiruvengadam, N; Mormann, F; Kraskov, A; Quiroga, RQ; Koch, C; Fried, I				Cerf, Moran; Thiruvengadam, Nikhil; Mormann, Florian; Kraskov, Alexander; Quiroga, Rodrigo Quian; Koch, Christof; Fried, Itzhak			On-line, voluntary control of human temporal lobe neurons	NATURE			English	Article							SINGLE NEURONS; HUMAN HIPPOCAMPUS; REPRESENTATION; ATTENTION; COMPUTER; EXPLICIT	Daily life continually confronts us with an exuberance of external, sensory stimuli competing with a rich stream of internal deliberations, plans and ruminations. The brain must select one or more of these for further processing. How this competition is resolved across multiple sensory and cognitive regions is not known; nor is it clear how internal thoughts and attention regulate this competition(1-4). Recording from single neurons in patients implanted with intracranial electrodes for clinical reasons(5-9), here we demonstrate that humans can regulate the activity of their neurons in the medial temporal lobe (MTL) to alter the outcome of the contest between external images and their internal representation. Subjects looked at a hybrid superposition of two images representing familiar individuals, landmarks, objects or animals and had to enhance one image at the expense of the other, competing one. Simultaneously, the spiking activity of their MTL neurons in different subregions and hemispheres was decoded in real time to control the content of the hybrid. Subjects reliably regulated, often on the first trial, the firing rate of their neurons, increasing the rate of some while simultaneously decreasing the rate of others. They did so by focusing onto one image, which gradually became clearer on the computer screen in front of their eyes, and thereby overriding sensory input. On the basis of the firing of these MTL neurons, the dynamics of the competition between visual images in the subject's mind was visualized on an external display.	[Cerf, Moran; Thiruvengadam, Nikhil; Mormann, Florian; Kraskov, Alexander; Quiroga, Rodrigo Quian; Koch, Christof] CALTECH, Pasadena, CA 91125 USA; [Cerf, Moran; Fried, Itzhak] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA; [Cerf, Moran] NYU, Stern Sch Business, New York, NY 10012 USA; [Thiruvengadam, Nikhil] Carnegie Mellon Univ, Sch Comp Sci, Pittsburgh, PA 15213 USA; [Mormann, Florian] Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany; [Quiroga, Rodrigo Quian] Univ Leicester, Dept Engn, Leicester LE1 7RH, Leics, England; [Koch, Christof] Korea Univ, Dept Brain & Cognit Engn, Seoul 136713, South Korea; [Fried, Itzhak] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; [Fried, Itzhak] Tel Aviv Med Ctr & Sch Med, Funct Neurosurg Unit, IL-64239 Tel Aviv, Israel; [Fried, Itzhak] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	California Institute of Technology; University of California System; University of California Los Angeles; New York University; Carnegie Mellon University; University of Bonn; University of Leicester; Korea University; University of California System; University of California Los Angeles; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Cerf, M (corresponding author), CALTECH, Pasadena, CA 91125 USA.	moran@klab.caltech.edu; koch@klab.caltech.edu; ifried@mednet.ucla.edu	Kraskov, Alexander/J-7964-2012; Mormann, Florian/K-1582-2014	Kraskov, Alexander/0000-0002-3576-4719; Mormann, Florian/0000-0003-1305-8028; Koch, Christof/0000-0001-6482-8067	National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Mental Health (NIMH); G. Harold & Leila Y. Mathers Charitable Foundation; Ministry of Education, Science and Technology [R31-2008-000-10008-0]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033221] Funding Source: NIH RePORTER; MRC [G0701038] Funding Source: UKRI; Medical Research Council [G0701038] Funding Source: researchfish	National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); G. Harold & Leila Y. Mathers Charitable Foundation; Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the patients for their participation in these studies. We thank K. Laird, A. Postolova, N. Parikshak and V. Isiaka for help with the recordings; E. Behnke and T. Fields for technical support; G. Mulliken and U. Rutishauser for comments on the manuscript; and M. Moon for help with data visualization. This work was supported by grants from the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), the G. Harold & Leila Y. Mathers Charitable Foundation, and the WCU programme through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (R31-2008-000-10008-0).	BLAKE DAR, 2005, BINOCULAR RIVALRY; Chalupa L.M., 2004, VISUAL NEUROSCIENCES; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Foldiak P, 2009, CURR BIOL, V19, pR904, DOI 10.1016/j.cub.2009.08.020; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; Gelbard-Sagiv H, 2008, SCIENCE, V322, P96, DOI 10.1126/science.1164685; Guenther FH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008218; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Kennedy PR, 2000, IEEE T REHABIL ENG, V8, P198, DOI 10.1109/86.847815; Kim SP, 2008, J NEURAL ENG, V5, P455, DOI 10.1088/1741-2560/5/4/010; Kreiman G, 2000, NATURE, V408, P357, DOI 10.1038/35042575; Moritz CT, 2008, NATURE, V456, P639, DOI 10.1038/nature07418; Musallam S, 2004, SCIENCE, V305, P258, DOI 10.1126/science.1097938; Quiroga RQ, 2007, J NEUROPHYSIOL, V98, P1997, DOI 10.1152/jn.00125.2007; Quiroga RQ, 2009, CURR BIOL, V19, P1308, DOI 10.1016/j.cub.2009.06.060; Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687; Reddy L, 2009, P NATL ACAD SCI USA, V106, P21447, DOI 10.1073/pnas.0907330106; Reynolds JH, 2004, ANNU REV NEUROSCI, V27, P611, DOI 10.1146/annurev.neuro.26.041002.131039; Serences JT, 2004, CEREB CORTEX, V14, P1346, DOI 10.1093/cercor/bhh095; Thorpe SJ, 2009, PERCEPTION, V38, P802; Velliste M, 2008, NATURE, V453, P1098, DOI 10.1038/nature06996; Waydo S, 2006, J NEUROSCI, V26, P10232, DOI 10.1523/JNEUROSCI.2101-06.2006; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582	23	110	110	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2010	467	7319					1104	U115		10.1038/nature09510	http://dx.doi.org/10.1038/nature09510			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981100	Green Accepted			2022-12-28	WOS:000283548600047
J	Weis, S; Riviere, R; Deleglise, S; Gavartin, E; Arcizet, O; Schliesser, A; Kippenberg, TJ				Weis, Stefan; Riviere, Remi; Deleglise, Samuel; Gavartin, Emanuel; Arcizet, Olivier; Schliesser, Albert; Kippenberg, Tobias J.			Optomechanically Induced Transparency	SCIENCE			English	Article							ELECTROMAGNETICALLY INDUCED TRANSPARENCY; CAVITY OPTOMECHANICS; RADIATION-PRESSURE; LIGHT; OSCILLATORS; MICROMIRROR; REDUCTION; STORAGE; FIELD	Electromagnetically induced transparency is a quantum interference effect observed in atoms and molecules, in which the optical response of an atomic medium is controlled by an electromagnetic field. We demonstrated a form of induced transparency enabled by radiation-pressure coupling of an optical and a mechanical mode. A control optical beam tuned to a sideband transition of a micro-optomechanical system leads to destructive interference for the excitation of an intracavity probe field, inducing a tunable transparency window for the probe beam. Optomechanically induced transparency may be used for slowing and on-chip storage of light pulses via microfabricated optomechanical arrays.	[Weis, Stefan; Deleglise, Samuel; Gavartin, Emanuel; Schliesser, Albert; Kippenberg, Tobias J.] Ecole Polytech Fed Lausanne, Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland; [Weis, Stefan; Riviere, Remi; Deleglise, Samuel; Schliesser, Albert; Kippenberg, Tobias J.] Max Planck Inst Quantum Opt, D-85748 Garching, Germany; [Arcizet, Olivier] Inst Neel, F-38042 Grenoble, France	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Kippenberg, TJ (corresponding author), Ecole Polytech Fed Lausanne, Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland.	tobias.kippenberg@epfl.ch	Schliesser, Albert/C-5619-2014; Deléglise, Samuel X/B-1599-2015; Kippenberg, T. J./B-3133-2013	Schliesser, Albert/0000-0003-4317-5030; Deléglise, Samuel X/0000-0002-8680-5170; Kippenberg, T. J./0000-0002-3408-886X	Max Planck Society, European Research Council; European Union; Swiss National Science Foundation, National Centre of Competence and Research of Quantum Photonics; Defense Advanced Research Projects Agency; Marie Curie Individual Fellowship	Max Planck Society, European Research Council(Max Planck SocietyEuropean Research Council (ERC)); European Union(European Commission); Swiss National Science Foundation, National Centre of Competence and Research of Quantum Photonics(Swiss National Science Foundation (SNSF)); Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Marie Curie Individual Fellowship(European Commission)	T.J.K. acknowledges financial support by the Max Planck Society, European Research Council Starting Grant (SiMP), the European Union's MINOS, a Marie Curie Excellence Grant, the Swiss National Science Foundation, National Centre of Competence and Research of Quantum Photonics, and the Defense Advanced Research Projects Agency. S. D. is funded by a Marie Curie Individual Fellowship.	Agarwal GS, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.041803; Anetsberger G, 2009, NAT PHYS, V5, P909, DOI 10.1038/NPHYS1425; Arcizet O, 2006, NATURE, V444, P71, DOI 10.1038/nature05244; BOLLER KJ, 1991, PHYS REV LETT, V66, P2593, DOI 10.1103/PhysRevLett.66.2593; Brunner D, 2009, SCIENCE, V325, P70, DOI 10.1126/science.1173684; Cai M, 2000, PHYS REV LETT, V85, P74, DOI 10.1103/PhysRevLett.85.74; Dobrindt JM, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.263602; Eichenfield M, 2009, NATURE, V462, P78, DOI 10.1038/nature08524; Eichenfield M, 2009, NATURE, V459, P550, DOI 10.1038/nature08061; FABRE C, 1994, PHYS REV A, V49, P1337, DOI 10.1103/PhysRevA.49.1337; Fleischhauer M, 2005, REV MOD PHYS, V77, P633, DOI 10.1103/RevModPhys.77.633; Gigan S, 2006, NATURE, V444, P67, DOI 10.1038/nature05273; Groblacher S, 2009, NATURE, V460, P724, DOI 10.1038/nature08171; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; KASAPI A, 1995, PHYS REV LETT, V74, P2447, DOI 10.1103/PhysRevLett.74.2447; Kippenberg TJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.033901; Lin Q, 2010, NAT PHOTONICS, V4, P236, DOI [10.1038/nphoton.2010.5, 10.1038/NPHOTON.2010.5]; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Lukin MD, 2001, NATURE, V413, P273, DOI 10.1038/35095000; Marquardt F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.093902; Mucke M, 2010, NATURE, V465, P755, DOI 10.1038/nature09093; Phillips DF, 2001, PHYS REV LETT, V86, P783, DOI 10.1103/PhysRevLett.86.783; Regal CA, 2008, NAT PHYS, V4, P555, DOI 10.1038/nphys974; Schliesser A, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.243905; Schliesser A, 2009, NAT PHYS, V5, P509, DOI 10.1038/NPHYS1304; Schliesser A., 2009, THESIS LUDWIG MAXIMI; Schliesser A, 2010, ADV ATOM MOL OPT PHY, V58, P207, DOI 10.1016/S1049-250X(10)05810-6; Thompson JD, 2008, NATURE, V452, P72, DOI 10.1038/nature06715; Zhang J, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.013808	29	1156	1168	17	301	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2010	330	6010					1520	1523		10.1126/science.1195596	http://dx.doi.org/10.1126/science.1195596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	692LE	21071628	Green Submitted			2022-12-28	WOS:000285153500059
J	Denoeud, F; Henriet, S; Mungpakdee, S; Aury, JM; Da Silva, C; Brinkmann, H; Mikhaleva, J; Olsen, LC; Jubin, C; Canestro, C; Bouquet, JM; Danks, G; Poulain, J; Campsteijn, C; Adamski, M; Cross, I; Yadetie, F; Muffato, M; Louis, A; Butcher, S; Tsagkogeorga, G; Konrad, A; Singh, S; Jensen, MF; Cong, EH; Eikeseth-Otteraa, H; Noel, B; Anthouard, V; Porcel, BM; Kachouri-Lafond, R; Nishino, A; Ugolini, M; Chourrout, P; Nishida, H; Aasland, R; Huzurbazar, S; Westhof, E; Delsuc, F; Lehrach, H; Reinhardt, R; Weissenbach, J; Roy, SW; Artiguenave, F; Postlethwait, JH; Manak, JR; Thompson, EM; Jaillon, O; Du Pasquier, L; Boudinot, P; Liberles, DA; Volff, JN; Philippe, H; Lenhard, B; Roest Crollius, H; Wincker, P; Chourrout, D				Denoeud, France; Henriet, Simon; Mungpakdee, Sutada; Aury, Jean-Marc; Da Silva, Corinne; Brinkmann, Henner; Mikhaleva, Jana; Olsen, Lisbeth Charlotte; Jubin, Claire; Canestro, Cristian; Bouquet, Jean-Marie; Danks, Gemma; Poulain, Julie; Campsteijn, Coen; Adamski, Marcin; Cross, Ismael; Yadetie, Fekadu; Muffato, Matthieu; Louis, Alexandra; Butcher, Stephen; Tsagkogeorga, Georgia; Konrad, Anke; Singh, Sarabdeep; Jensen, Marit Flo; Cong, Evelyne Huynh; Eikeseth-Otteraa, Helen; Noel, Benjamin; Anthouard, Veronique; Porcel, Betina M.; Kachouri-Lafond, Rym; Nishino, Atsuo; Ugolini, Matteo; Chourrout, Pascal; Nishida, Hiroki; Aasland, Rein; Huzurbazar, Snehalata; Westhof, Eric; Delsuc, Frederic; Lehrach, Hans; Reinhardt, Richard; Weissenbach, Jean; Roy, Scott W.; Artiguenave, Francois; Postlethwait, John H.; Manak, J. Robert; Thompson, Eric M.; Jaillon, Olivier; Du Pasquier, Louis; Boudinot, Pierre; Liberles, David A.; Volff, Jean-Nicolas; Philippe, Herve; Lenhard, Boris; Roest Crollius, Hugues; Wincker, Patrick; Chourrout, Daniel			Plasticity of Animal Genome Architecture Unmasked by Rapid Evolution of a Pelagic Tunicate	SCIENCE			English	Article							ORIGINS; INTRON; GENES	Genomes of animals as different as sponges and humans show conservation of global architecture. Here we show that multiple genomic features including transposon diversity, developmental gene repertoire, physical gene order, and intron-exon organization are shattered in the tunicate Oikopleura, belonging to the sister group of vertebrates and retaining chordate morphology. Ancestral architecture of animal genomes can be deeply modified and may therefore be largely nonadaptive. This rapidly evolving animal lineage thus offers unique perspectives on the level of genome plasticity. It also illuminates issues as fundamental as the mechanisms of intron gain.	[Denoeud, France; Aury, Jean-Marc; Da Silva, Corinne; Jubin, Claire; Poulain, Julie; Noel, Benjamin; Anthouard, Veronique; Porcel, Betina M.; Weissenbach, Jean; Artiguenave, Francois; Jaillon, Olivier; Wincker, Patrick] CEA, Inst Genom, Evry, France; [Denoeud, France; Aury, Jean-Marc; Da Silva, Corinne; Jubin, Claire; Poulain, Julie; Noel, Benjamin; Anthouard, Veronique; Porcel, Betina M.; Weissenbach, Jean; Artiguenave, Francois; Jaillon, Olivier; Wincker, Patrick] CNRS, UMR 8030, Evry, France; [Denoeud, France; Aury, Jean-Marc; Da Silva, Corinne; Jubin, Claire; Poulain, Julie; Noel, Benjamin; Anthouard, Veronique; Porcel, Betina M.; Weissenbach, Jean; Artiguenave, Francois; Jaillon, Olivier; Wincker, Patrick] Univ Evry, Evry, France; [Henriet, Simon; Mungpakdee, Sutada; Mikhaleva, Jana; Olsen, Lisbeth Charlotte; Bouquet, Jean-Marie; Danks, Gemma; Campsteijn, Coen; Adamski, Marcin; Yadetie, Fekadu; Jensen, Marit Flo; Cong, Evelyne Huynh; Eikeseth-Otteraa, Helen; Ugolini, Matteo; Thompson, Eric M.; Lenhard, Boris; Chourrout, Daniel] Univ Bergen, Sars Int Ctr Marine Mol Biol, Bergen, Norway; [Brinkmann, Henner; Philippe, Herve] Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; [Canestro, Cristian; Postlethwait, John H.] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA; [Danks, Gemma; Lenhard, Boris] Univ Bergen, Bergen Ctr Computat Sci, Bergen, Norway; [Cross, Ismael] Univ Cadiz, Genet Lab, Cadiz, Spain; [Muffato, Matthieu; Louis, Alexandra; Roest Crollius, Hugues] Ecole Normale Super, CNRS, IBENS, Dyogen Lab,UMR8197, Paris, France; [Butcher, Stephen; Manak, J. Robert] Univ Iowa, Dept Biol, Iowa City, IA 52242 USA; [Tsagkogeorga, Georgia; Delsuc, Frederic] Univ Montpellier 2, CNRS, Inst Sci Evolut, Lab Paleontol Phylogenie & Paleobiol,UMR 5554, Montpellier, France; [Singh, Sarabdeep; Huzurbazar, Snehalata] Univ Wyoming, Dept Stat, Laramie, WY 82071 USA; [Kachouri-Lafond, Rym; Westhof, Eric] Univ Strasbourg, CNRS, Inst Biol Cellulaire & Mol, Strasbourg, France; [Nishino, Atsuo; Nishida, Hiroki] Osaka Univ, Dept Biol Sci, Osaka, Japan; [Chourrout, Pascal] Ctr Hosp Albi, Albi, France; [Aasland, Rein] Univ Bergen, Dept Mol Biol, Bergen, Norway; [Lehrach, Hans; Reinhardt, Richard] Max Planck Inst Mol Genet, Berlin, Germany; [Roy, Scott W.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; [Thompson, Eric M.; Lenhard, Boris] Univ Bergen, Dept Biol, Bergen, Norway; [Du Pasquier, Louis] Univ Basel, Inst Zool & Evolutionary Biol, Basel, Switzerland; [Boudinot, Pierre] INRA Virol & Immunol Mol, Jouy En Josas, France; [Konrad, Anke; Liberles, David A.] Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; [Volff, Jean-Nicolas] Univ Lyon 1, Ecole Normale Super Lyon, Ecole Normale Super, Inst Genom Fonct Lyon,UMR 5242,CNRS,INRA, F-69365 Lyon, France; [Canestro, Cristian] Univ Barcelona, Dept Genet, E-08007 Barcelona, Spain	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Bergen; Universite de Montreal; University of Oregon; University of Bergen; Universidad de Cadiz; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); University of Iowa; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; University of Wyoming; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Osaka University; University of Bergen; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of Bergen; University of Basel; INRAE; University of Wyoming; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); University of Barcelona	Wincker, P (corresponding author), CEA, Inst Genom, Evry, France.	pwincker@genoscope.cns.fr; Daniel.Chourrout@sars.uib.no	Singh, Sarabdeep/D-7881-2017; Yadetie, Fekadu/HDL-8798-2022; Delsuc, Frederic/B-4381-2009; Aury, Jean-Marc/N-1621-2019; Nishino, Atsuo/F-5393-2013; Nishida, Hiroki/B-1851-2008; Cross, Ismael/K-1674-2014; Cañestro, Cristian/L-9661-2014; Konrad, Anke/X-9107-2019; Nishino, Atsuo/AAH-1387-2019; boudinot, pierre/L-4246-2016; Konrad, Anke/AAP-4688-2020; Jaillon, Olivier/GRY-6287-2022	Delsuc, Frederic/0000-0002-6501-6287; Aury, Jean-Marc/0000-0003-1718-3010; Nishino, Atsuo/0000-0003-2818-4377; Nishida, Hiroki/0000-0002-7249-1668; Cross, Ismael/0000-0002-2291-5629; Cañestro, Cristian/0000-0003-4623-8105; Konrad, Anke/0000-0003-3994-460X; Nishino, Atsuo/0000-0003-2818-4377; Poulain, Julie/0000-0002-8744-3116; Mikhaleva, Yana/0000-0002-5872-0495; Reinhardt, Richard/0000-0001-9376-2132; Danks, Gemma/0000-0001-7004-0065; Noel, Benjamin/0000-0002-5830-3253; ROEST CROLLIUS, Hugues/0000-0002-8209-173X; Manak, John/0000-0002-6562-7694; Huzurbazar, Snehalata/0000-0001-9637-5445; Yadetie, Fekadu/0000-0002-2484-9047; Olsen, Lisbeth Charlotte/0000-0002-7469-0169; Lenhard, Boris/0000-0002-1114-1509; Henriet, Simon/0000-0001-8792-6639; DA SILVA, Corinne/0000-0002-7618-7831; boudinot, pierre/0000-0002-7490-9677; Muffato, Matthieu/0000-0002-7860-3560; Porcel, Betina/0000-0003-0169-5302; Denoeud, France/0000-0001-8819-7634; Jaillon, Olivier/0000-0002-7237-9596; Louis, Alexandra/0000-0001-7032-5650	Sars Centre; Norwegian Research Council; Genoscope; NSF [IOS-0719577, DBI-0743374]; NATIONAL LIBRARY OF MEDICINE [Z01LM000073, ZIALM000073] Funding Source: NIH RePORTER	Sars Centre; Norwegian Research Council(Research Council of NorwayEuropean Commission); Genoscope; NSF(National Science Foundation (NSF)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	The Sars Centre budget, the Functional Genomics (FUGE) Programme of the Norwegian Research Council, Genoscope, and NSF grants IOS-0719577 and DBI-0743374 supported the research. This is publication ISEM-2010-123 of the Institut des Sciences de l'Evolution de Montpellier. GENBANK/European Molecular Biology Laboratory sequence accession numbers are CABV01000001-CABV01005917, CABW01000001-CABW01006678, FN653015-FN654274, FN654275-FN658470, FP700189-FP710243, FP710258-FP791398, and FP791400-FP884219. The sequence data for Capitella teleta, Daphnia pulex, Helobdella robusta and Lottia gigantea were produced by the U.S. Department of Energy Joint Genome Institute (www.jgi.doe.gov/) in collaboration with the community of users. We thank I. Ahel, B. Haubold, and one anonymous reviewer for generous advice. This article is dedicated to Hans Prydz and Kare Rommetveit for their pioneer roles in the Sars Centre establishment.	Bouquet JM, 2009, J PLANKTON RES, V31, P359, DOI 10.1093/plankt/fbn132; Cousineau B, 1998, CELL, V94, P451, DOI 10.1016/S0092-8674(00)81586-X; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Edvardsen RB, 2005, CURR BIOL, V15, pR12, DOI 10.1016/j.cub.2004.12.010; Eickbush TH, 2002, CURR OPIN GENET DEV, V12, P669, DOI 10.1016/S0959-437X(02)00359-3; Hughes T, 2007, J MOL EVOL, V65, P574, DOI 10.1007/s00239-007-9041-9; Katju V, 2003, GENETICS, V165, P1793; Li WL, 2009, SCIENCE, V326, P1260, DOI 10.1126/science.1179302; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Lynch M, 2006, MOL BIOL EVOL, V23, P450, DOI 10.1093/molbev/msj050; Lynch M, 2007, P NATL ACAD SCI USA, V104, P8597, DOI 10.1073/pnas.0702207104; Marz M, 2008, J MOL EVOL, V67, P594, DOI 10.1007/s00239-008-9149-6; Mourier T, 2003, SCIENCE, V300, P1393, DOI 10.1126/science.1080559; Nguyen HD, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-69; Putnam NH, 2008, NATURE, V453, P1064, DOI 10.1038/nature06967; Putnam NH, 2007, SCIENCE, V317, P86, DOI 10.1126/science.1139158; Roy SW, 2009, TRENDS GENET, V25, P67, DOI 10.1016/j.tig.2008.11.004; Roy SW, 2006, NAT REV GENET, V7, P211, DOI 10.1038/nrg1807; Satou Y, 2003, DEV GENES EVOL, V213, P211, DOI 10.1007/s00427-003-0330-z; Srivastava M, 2008, NATURE, V454, P955, DOI 10.1038/nature07191; Srivastava M, 2010, NATURE, V466, P720, DOI 10.1038/nature09201; Thompson EM, 2001, DEV BIOL, V238, P260, DOI 10.1006/dbio.2001.0414; Volff JN, 2004, MOL BIOL EVOL, V21, P2022, DOI 10.1093/molbev/msh207; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007; Zorio DAR, 1999, NATURE, V402, P835, DOI 10.1038/45597	25	198	202	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2010	330	6009					1381	1385		10.1126/science.1194167	http://dx.doi.org/10.1126/science.1194167			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	689BK	21097902	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000284902100043
J	Hiemstra, TF; Walsh, M; Mahr, A; Savage, CO; de Groot, K; Harper, L; Hauser, T; Neumann, I; Tesar, V; Wissing, KM; Pagnoux, C; Schmitt, W; Jayne, DRW				Hiemstra, Thomas F.; Walsh, Michael; Mahr, Alfred; Savage, Caroline O.; de Groot, Kirsten; Harper, Lorraine; Hauser, Thomas; Neumann, Irmgard; Tesar, Vladimir; Wissing, Karl-Martin; Pagnoux, Christian; Schmitt, Wilhelm; Jayne, David R. W.		European Vasculitis Study Grp	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMIC NECROTIZING VASCULITIS; LUPUS NEPHRITIS; WEGENERS-GRANULOMATOSIS; RENAL INVOLVEMENT; ACUTE REJECTION; VESSEL VASCULITIS; CLINICAL-TRIAL; LONG-TERM; CYCLOPHOSPHAMIDE; INDUCTION	Context Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are limited by partial efficacy and toxicity. Objective To compare the effects of mycophenolate mofetil with azathioprine on the prevention of relapses in patients with AAV. Design, Setting, and Participants Open-label randomized controlled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Vasculitides (IMPROVE), to test the hypothesis that mycophenolate mofetil is more effective than azathioprine for preventing relapses in AAV. The trial was conducted at 42 centers in 11 European countries between April 2002 and January 2009 (42-month study). Eligible patients had newly diagnosed AAV (Wegener granulomatosis or microscopic polyangiitis) and were aged 18 to 75 years at diagnosis. Interventions Patients were randomly assigned to azathioprine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after induction of remission with cyclophosphamide and prednisolone. Main Outcome Measures The primary end point was relapse-free survival, which was assessed using a Cox proportional hazards model. The secondary end points were Vasculitis Damage Index, estimated glomerular filtration rate, and proteinuria. Results A total of 156 patients were assigned to azathioprine (n=80) or mycophenolate mofetil (n=76) and were followed up for a median of 39 months (interquartile range, 0.66-53.6 months). All patients were retained in the analysis by intention to treat. Relapses were more common in the mycophenolate mofetil group (42/76 patients) compared with the azathioprine group (30/80 patients), with an unadjusted hazard ratio (HR) for mycophenolate mofetil of 1.69 (95% confidence interval [CI], 1.06-2.70; P=.03). Severe adverse events did not differ significantly between groups. There were 22 severe adverse events in 13 patients (16%) in the azathioprine group and there were 8 severe adverse events in 8 patients (7.5%) in the mycophenolate mofetil group (HR, 0.53 [95% CI, 0.23-1.18]; P=.12). The secondary outcomes of Vasculitis Damage Index, estimated glomerular filtration rate, and proteinuria did not differ significantly between groups. Conclusions Among patients with AAV, mycophenolate mofetil was less effective than azathioprine for maintaining disease remission. Both treatments had similar adverse event rates.	[Hiemstra, Thomas F.; Jayne, David R. W.] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Lupus & Vasculitis Clin, Cambridge CB2 0QQ, England; [Hiemstra, Thomas F.; Jayne, David R. W.] Univ Cambridge, Cambridge, England; [Walsh, Michael] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Mahr, Alfred; Pagnoux, Christian] Univ Paris 05, Hop Cochin, Dept Internal Med, Paris, France; [Savage, Caroline O.; Harper, Lorraine] Univ Birmingham, Sch Immun & Infect, Birmingham, W Midlands, England; [de Groot, Kirsten] Klinikum Offenbach, Dept Med 3, Offenbach, Germany; [de Groot, Kirsten] KfH Nierenzentrum Offenbach, Offenbach, Germany; [Hauser, Thomas] Immunol Zentrum Zurich, Zurich, Switzerland; [Neumann, Irmgard] Wilhelminenspital Stadt Wien, Dept Internal Med 6, Vienna, Austria; [Tesar, Vladimir] Charles Univ Prague, Dept Nephrol, Sch Med 1, Prague, Czech Republic; [Wissing, Karl-Martin] Free Univ Brussels, Hop Erasme, Dept Nephrol, B-1070 Brussels, Belgium; [Schmitt, Wilhelm] Weinheim Kidney Ctr, Mannheim, Germany; [Schmitt, Wilhelm] Mannheim Univ Hosp, Mannheim, Germany	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Birmingham; Sana Klinikum Offenbach; Wilhelminenspital; Charles University Prague; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ruprecht Karls University Heidelberg	Hiemstra, TF (corresponding author), Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Lupus & Vasculitis Clin, POB 118,Hills Rd, Cambridge CB2 0QQ, England.	tfh24@cam.ac.uk	Tesar, Vladimir/O-2312-2017; Wissing, Karl Martin/A-5264-2012; Lundberg, Sigrid/AGM-4891-2022; Walsh, Michael/ABE-1278-2021; Hrušková, Zdenka/O-2079-2017; Pagnoux, Christian/C-4612-2015	Tesar, Vladimir/0000-0001-6982-0689; Wissing, Karl Martin/0000-0002-6094-3233; Lundberg, Sigrid/0000-0003-1224-5200; Walsh, Michael/0000-0001-8292-2014; Hrušková, Zdenka/0000-0002-2658-365X; Cacoub, Patrice/0000-0002-6727-4992; Bruchfeld, Annette/0000-0002-9752-9941; Jayne, David/0000-0002-1712-0637; Mahr, Alfred/0000-0002-1564-9115; Fakhouri, Fadi/0000-0001-5390-8002; Bergner, Raoul/0000-0002-7965-1273	Novartis; Hoffman-La Roche; Amgen; Viforpharma; Cambridge Biomedical Research Centre; Programme Hospitalier de Recherche Clinique Regionale; French Ministry of Health; Canadian Institute for Health Research; Alberta Heritage Foundation for Medical Research; Krescent Postdoctoral Training Award	Novartis(Novartis); Hoffman-La Roche; Amgen(Amgen); Viforpharma; Cambridge Biomedical Research Centre(General Electric); Programme Hospitalier de Recherche Clinique Regionale; French Ministry of Health; Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research(Alberta Heritage Foundation for Medical ResearchGeneral Electric); Krescent Postdoctoral Training Award	Dr Hiemstra reported receiving honoraria from Amgen. Dr Savage reported that after the completion of the trial, including data analysis and initial manuscript preparation, she became an employee of GlaxoSmithKline. Dr Harper reported receiving grant support from Novartis. Dr Hauser reported receiving grant support from Hoffman-La Roche. Dr Tesar reported receiving consulting fees from Novartis, Hoffman-La Roche, and Amgen. Dr Wissing reported receiving research grant support from Hoffman-La Roche. Dr Schmitt reported receiving research grant support from Hoffman-La Roche. Dr Jayne reported receiving research grant support from Aspreva (now Viforpharma) and consulting fees and research grant support from Hoffman-La Roche. None of the other authors reported financial disclosures.; This trial received funding from the Cambridge Biomedical Research Centre, the Programme Hospitalier de Recherche Clinique Regionale 2001, and the French Ministry of Health. Hoffman-La Roche Ltd provided reimbursement for the study drugs to investigators in Germany, France, and Switzerland; for patients recruited in Belgium, France, and Switzerland; and for trial insurance in Germany. Dr Hiemstra is supported by the Cambridge Biomedical Research Centre. Dr Walsh is supported by a Randomized Controlled Trial Mentoring Award from the Canadian Institute for Health Research, a Clinical Scholar award from the Alberta Heritage Foundation for Medical Research, and a Krescent Postdoctoral Training Award.	Appel GB, 2009, J AM SOC NEPHROL, V20, P1103, DOI 10.1681/ASN.2008101028; Booth AD, 2003, AM J KIDNEY DIS, V41, P776, DOI 10.1016/S0272-6386(03)00025-8; Chan TM, 2005, J AM SOC NEPHROL, V16, P1076, DOI 10.1681/ASN.2004080686; de Groot K, 2009, ANN INTERN MED, V150, P670, DOI 10.7326/0003-4819-150-10-200905190-00004; Ekberg H, 2009, AM J TRANSPLANT, V9, P1876, DOI 10.1111/j.1600-6143.2009.02726.x; Exley AR, 1997, ARTHRITIS RHEUM, V40, P371, DOI 10.1002/art.1780400222; FAUCI AS, 1979, NEW ENGL J MED, V301, P235, DOI 10.1056/NEJM197908023010503; GRINYO J, 1995, LANCET, V345, P1321; Hu WH, 2008, NEPHROL DIAL TRANSPL, V23, P1307, DOI 10.1093/ndt/gfm780; Iatrou C, 2009, CLIN NEPHROL, V72, P31; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Joy MS, 2005, NEPHROL DIAL TRANSPL, V20, P2725, DOI 10.1093/ndt/gfi117; Kazderova M, 2008, ARCH MED RES, V39, P115, DOI 10.1016/j.arcmed.2007.07.006; Keown P, 1996, TRANSPLANTATION, V61, P1029; Koukoulaki M, 2006, NEPHRON CLIN PRACT, V102, pC100, DOI 10.1159/000089667; Langford CA, 2004, ARTHRIT RHEUM-ARTHR, V51, P278, DOI 10.1002/art.20240; LUQMANI RA, 1994, Q J MED, V87, P671; Meier-Kriesche HU, 2003, AM J TRANSPLANT, V3, P68, DOI 10.1034/j.1600-6143.2003.30112.x; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P310, DOI 10.1136/ard.2008.088096; Neumann I, 2008, NEPHROL DIAL TRANSPL, V23, P3514, DOI 10.1093/ndt/gfn360; Nowack R, 1999, J AM SOC NEPHROL, V10, P1965; Pagnoux C, 2008, NEW ENGL J MED, V359, P2790, DOI 10.1056/NEJMoa0802311; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Popa ER, 1999, J ALLERGY CLIN IMMUN, V103, P885, DOI 10.1016/S0091-6749(99)70434-3; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; Rabe-Hesketh S., 2008, MULTILEVEL LONGITUDI; Silva F, 2010, CLIN J AM SOC NEPHRO, V5, P445, DOI 10.2215/CJN.06010809; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; Stassen PM, 2007, ANN RHEUM DIS, V66, P798, DOI 10.1136/ard.2006.060301; Walsh M, 2007, CLIN J AM SOC NEPHRO, V2, P968, DOI 10.2215/CJN.01200307	31	357	385	2	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2010	304	21					2381	2388		10.1001/jama.2010.1658	http://dx.doi.org/10.1001/jama.2010.1658			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687FH	21060104				2022-12-28	WOS:000284763900019
J	Chien, EYT; Liu, W; Zhao, QA; Katritch, V; Han, GW; Hanson, MA; Shi, L; Newman, AH; Javitch, JA; Cherezov, V; Stevens, RC				Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Katritch, Vsevolod; Han, Gye Won; Hanson, Michael A.; Shi, Lei; Newman, Amy Hauck; Javitch, Jonathan A.; Cherezov, Vadim; Stevens, Raymond C.			Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTORS; DRUG-SEEKING BEHAVIOR; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; BINDING-SITE; INDUCED REINSTATEMENT; COCAINE-SEEKING; IONIC LOCK; D-3; IDENTIFICATION	Dopamine modulates movement, cognition, and emotion through activation of dopamine G protein-coupled receptors in the brain. The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small molecule D2R/D3R-specific antagonist eticlopride reveals important features of the ligand binding pocket and extracellular loops. On the intracellular side of the receptor, a locked conformation of the ionic lock and two distinctly different conformations of intracellular loop 2 are observed. Docking of R-22, a D3R-selective antagonist, reveals an extracellular extension of the eticlopride binding site that comprises a second binding pocket for the aryl amide of R-22, which differs between the highly homologous D2R and D3R. This difference provides direction to the design of D3R-selective agents for treating drug abuse and other neuropsychiatric indications.	[Chien, Ellen Y. T.; Liu, Wei; Zhao, Qiang; Han, Gye Won; Cherezov, Vadim; Stevens, Raymond C.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Katritch, Vsevolod] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA; [Katritch, Vsevolod] Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; [Hanson, Michael A.] Receptos, San Diego, CA 92121 USA; [Shi, Lei] Cornell Univ, Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; [Shi, Lei] Cornell Univ, Weill Cornell Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY 10021 USA; [Newman, Amy Hauck] Natl Inst Drug Abuse, Med Chem Sect, Intramural Res Program, Baltimore, MD 21224 USA; [Javitch, Jonathan A.] Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; [Javitch, Jonathan A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; [Javitch, Jonathan A.] Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Columbia University; Columbia University; Columbia University	Stevens, RC (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stevens@scripps.edu	Han, Gye Won/GLQ-8724-2022; Stevens, Raymond/K-7272-2015; Cherezov, Vadim/L-9812-2013; soler, martha maricel m gomez/L-6025-2014; Katritch, Vsevolod/Q-8357-2016; Shi, Lei/AAV-1321-2020; Han, Gye Won/GLT-1531-2022; Liu, Wei/F-1820-2011; Katritch, Vsevolod/Y-2721-2019; Han, Gye Won/GLQ-8673-2022	Han, Gye Won/0000-0003-4107-835X; Stevens, Raymond/0000-0002-4522-8725; Cherezov, Vadim/0000-0002-5265-3914; soler, martha maricel m gomez/0000-0002-4412-8108; Katritch, Vsevolod/0000-0003-3883-4505; Shi, Lei/0000-0002-4137-096X; Javitch, Jonathan/0000-0001-7395-2967	Protein Structure Initiative (PSI) [U54 GM074961, U54 GM094618]; NIH Roadmap [P50 GM073197]; NIH [R21 RR025336, GM075915]; Pfizer; National Institute on Drug Abuse [DA022413, MH54137, DA023694]; National Science Foundation [IIS0308078]; Science Foundation Ireland [02-IN1-B266]; National Cancer Institute [Y1-CO-1020]; National Institute of General Medical Sciences [Y1-GM-1104]; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR025336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089857, R01GM075915, P50GM073197, U54GM074961, U54GM094618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R00DA023694, ZIADA000424, K05DA022413] Funding Source: NIH RePORTER	Protein Structure Initiative (PSI); NIH Roadmap(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Science Foundation(National Science Foundation (NSF)); Science Foundation Ireland(Science Foundation IrelandEuropean Commission); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported in part by Protein Structure Initiative (PSI) grant U54 GM074961 and PSI: Biology grant U54 GM094618 for structure production, NIH Roadmap grant P50 GM073197 for technology development, NIH grant R21 RR025336 (V. C.), and Pfizer. Additional support was provided by the National Institute on Drug Abuse Intramural Research Program (A.H.N.), grants DA022413 and MH54137 (J.A.J.), and grant DA023694 (L. S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Science or the NIH. We thank J. Velasquez for help with molecular biology, T. Trinh and K. Allin for help with baculovirus expression, D. Gray for assistance with eticlopride synthesis, M. Griffor for large-scale production of the receptor, X. Qiu for suggestions, and A. Walker for assistance with manuscript preparation. We acknowledge Y. Zheng, The Ohio State University and M. Caffrey, Trinity College (Dublin, Ireland), for the generous loan of the in meso robot (built with support from NIH grant GM075915), the National Science Foundation (grant IIS0308078), and Science Foundation Ireland (grant 02-IN1-B266); and J. Smith, R. Fischetti, and N. Sanishvili at the GM/CA-CAT beamline at the Advanced Photon Source, for assistance in development and use of the minibeam and beamtime. The GM/CA-CAT beamline (23-ID) is supported by the National Cancer Institute (grant Y1-CO-1020) and the National Institute of General Medical Sciences (grant Y1-GM-1104). Atomic coordinates and structure factors have been deposited in the Protein Data Bank with identification code 3PBL. A. H. N. is an inventor on a patent application from the National Institutes of Health that covers the use of R-22 and analogs as D3 receptor selective agents. R. C. S. is on the Board of Directors of Receptos, which does structure-directed drug discovery on GPCRs.	Alberts GL, 1998, MOL PHARMACOL, V54, P379, DOI 10.1124/mol.54.2.379; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; Boeckler F, 2006, PHARMACOL THERAPEUT, V112, P281, DOI 10.1016/j.pharmthera.2006.04.007; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Civelli Olivier, 1995, P155; DEPAULIS T, 1985, EUR J MED CHEM, V20, P273; Dror RO, 2009, P NATL ACAD SCI USA, V106, P4689, DOI 10.1073/pnas.0811065106; Duman Ronald S., 1995, P303; Gilbert JG, 2005, SYNAPSE, V57, P17, DOI 10.1002/syn.20152; Griffon N, 1996, J NEURAL TRANSM, V103, P1163, DOI 10.1007/BF01271201; Guo W, 2008, EMBO J, V27, P2293, DOI 10.1038/emboj.2008.153; Hanson MA, 2008, STRUCTURE, V16, P897, DOI 10.1016/j.str.2008.05.001; Heidbreder CA, 2010, ANN NY ACAD SCI, V1187, P4, DOI 10.1111/j.1749-6632.2009.05149.x; Holmes A, 2004, NEUROPHARMACOLOGY, V47, P1117, DOI 10.1016/j.neuropharm.2004.07.034; Jaakola VP, 2008, SCIENCE, V322, P1211, DOI 10.1126/science.1164772; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kuzhikandathil EV, 2004, MOL CELL NEUROSCI, V26, P144, DOI 10.1016/j.mcn.2004.01.014; Levant B, 1997, PHARMACOL REV, V49, P231; Newman AH, 2009, J MED CHEM, V52, P2559, DOI 10.1021/jm900095y; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; Rosenbaum DM, 2007, SCIENCE, V318, P1266, DOI 10.1126/science.1150609; Roth CB, 2008, J MOL BIOL, V376, P1305, DOI 10.1016/j.jmb.2007.12.028; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Shi L, 2001, BIOCHEMISTRY-US, V40, P12339, DOI 10.1021/bi011204a; Silvano E, 2010, MOL PHARMACOL, V78, P925, DOI 10.1124/mol.110.065755; Simpson MM, 1999, MOL PHARMACOL, V56, P1116, DOI 10.1124/mol.56.6.1116; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SOKOLOFF P, 1992, EUR J PHARM-MOLEC PH, V225, P331, DOI 10.1016/0922-4106(92)90107-7; Spiller K, 2008, PSYCHOPHARMACOLOGY, V196, P533, DOI 10.1007/s00213-007-0986-6; STRADER CD, 1991, J BIOL CHEM, V266, P5; Vogel R, 2008, J MOL BIOL, V380, P648, DOI 10.1016/j.jmb.2008.05.022; Vorel SR, 2002, J NEUROSCI, V22, P9595; Warne T, 2008, NATURE, V454, P486, DOI 10.1038/nature07101; Xi ZX, 2006, NEUROPSYCHOPHARMACOL, V31, P1393, DOI 10.1038/sj.npp.1300912	39	919	934	2	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2010	330	6007					1091	1095		10.1126/science.1197410	http://dx.doi.org/10.1126/science.1197410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097933	Green Accepted			2022-12-28	WOS:000284374700040
J	Daffis, S; Szretter, KJ; Schriewer, J; Li, JQ; Youn, S; Errett, J; Lin, TY; Schneller, S; Zust, R; Dong, HP; Thiel, V; Sen, GC; Fensterl, V; Klimstra, WB; Pierson, TC; Buller, RM; Gale, M; Shi, PY; Diamond, MS				Daffis, Stephane; Szretter, Kristy J.; Schriewer, Jill; Li, Jianqing; Youn, Soonjeon; Errett, John; Lin, Tsai-Yu; Schneller, Stewart; Zust, Roland; Dong, Hongping; Thiel, Volker; Sen, Ganes C.; Fensterl, Volker; Klimstra, William B.; Pierson, Theodore C.; Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.			2 '-O methylation of the viral mRNA cap evades host restriction by IFIT family members	NATURE			English	Article							NILE-VIRUS-INFECTION; PROTEINS; GENES; METHYLTRANSFERASE; TRANSLATION; IDENTIFICATION; INITIATION; INDUCTION; PROTECTS; ALPHA	Cellular messenger RNA (mRNA) of higher eukaryotes and many viral RNAs are methylated at the N-7 and 2'-O positions of the 5' guanosine cap by specific nuclear and cytoplasmic methyltransferases (MTases), respectively. Whereas N-7 methylation is essential for RNA translation and stability(1), the function of 2'-O methylation has remained uncertain since its discovery 35 years ago(2-4). Here we show that a West Nile virus (WNV) mutant (E218A) that lacks 2'-O MTase activity was attenuated in wild-type primary cells and mice but was pathogenic in the absence of type I interferon (IFN) signalling. 2'-O methylation of viral RNA did not affect IFN induction in WNV-infected fibroblasts but instead modulated the antiviral effects of IFN-induced proteins with tetratricopeptide repeats (IFIT), which are interferon-stimulated genes (ISGs) implicated in regulation of protein translation. Poxvirus and coronavirus mutants that lacked 2'-O MTase activity similarly showed enhanced sensitivity to the antiviral actions of IFN and, specifically, IFIT proteins. Our results demonstrate that the 2'-O methylation of the 5' cap of viral RNA functions to subvert innate host antiviral responses through escape of IFIT-mediated suppression, and suggest an evolutionary explanation for 2'-O methylation of cellular mRNA: to distinguish self from non-self RNA. Differential methylation of cytoplasmic RNA probably serves as an example for pattern recognition and restriction of propagation of foreign viral RNA in host cells.	[Daffis, Stephane; Szretter, Kristy J.; Youn, Soonjeon; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Li, Jianqing; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.] Midw Reg Ctr Biodef & Emerging Infect Dis Res, St Louis, MO 63104 USA; [Schriewer, Jill; Buller, R. Mark] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; [Errett, John; Gale, Michael, Jr.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; [Lin, Tsai-Yu; Pierson, Theodore C.] NIH, Viral Pathogenesis Sect, Viral Dis Lab, Bethesda, MD 20892 USA; [Schneller, Stewart] Auburn Univ, Dept Chem & Biochem, Auburn, AL 36849 USA; [Zust, Roland; Thiel, Volker] Kantonal Hosp St Gallen, Inst Immunobiol, CH-9007 St Gallen, Switzerland; [Thiel, Volker] Univ Zurich, Vetsuisse Fac, CH-8006 Zurich, Switzerland; [Dong, Hongping; Shi, Pei-Yong] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12208 USA; [Sen, Ganes C.; Fensterl, Volker] Cleveland Clin, Lerner Res Inst, Cleveland, OH 44195 USA; [Klimstra, William B.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15261 USA; [Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.] Pacific NW Reg Ctr Biodef & Emerging Infect Dis R, St Louis, MO 63104 USA; [Buller, R. Mark; Gale, Michael, Jr.; Shi, Pei-Yong; Diamond, Michael S.] NE Reg Ctr Biodef & Emerging Infect Dis Res, St Louis, MO 63104 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Saint Louis University; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; Auburn University System; Auburn University; Kantonsspital St. Gallen; University of Zurich; State University of New York (SUNY) System; Wadsworth Center; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	diamond@borcim.wustl.edu	Lin, Tsai-Yu/B-8873-2016; Diamond, Michael/AAH-1733-2019; Thiel, Volker/AAI-2391-2019	Lin, Tsai-Yu/0000-0002-8076-1584; Diamond, Michael/0000-0002-8791-3165; Szretter, Kristy/0000-0003-0391-2307; Gale, Michael/0000-0002-6332-7436; Thiel, Volker/0000-0002-5783-0887	National Institutes of Health [U54 AI081680, U19 AI083019, R01 AI074973, R01 AI56540, U54 AI057160, U54 AI057158, R01 CA068782]; Swiss National Science Foundation [3100A0-118425/1]; Novartis Foundation; NATIONAL CANCER INSTITUTE [R01CA068782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000957, U54AI057160, U54AI081680, U19AI056540, R01AI074973, U19AI083019, U54AI057158] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health grants U54 AI081680, U19 AI083019 and R01 AI074973 (to M.G. and M.S.D.), R01 AI56540 (to S.S.), U54 AI057160 (to R.M.B.) and U54 AI057158 (to P.Y.S.), R01 CA068782 (to G.C.S.) the Swiss National Science Foundation, 3100A0-118425/1, and the Novartis Foundation (to V.T. and R.Z.). We thank H. Virgin and B. Moss for reading the manuscript.	Coley SE, 2005, J VIROL, V79, P3097, DOI 10.1128/JVI.79.5.3097-3106.2005; Daffis S, 2008, J VIROL, V82, P10349, DOI 10.1128/JVI.00935-08; Daffis S, 2008, J VIROL, V82, P8465, DOI 10.1128/JVI.00918-08; Daffis S, 2007, PLOS PATHOG, V3, P1005, DOI 10.1371/journal.ppat.0030106; Daffis S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000607; Decroly E, 2008, J VIROL, V82, P8071, DOI 10.1128/JVI.00407-08; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Dong HP, 2008, ANTIVIR RES, V80, P1, DOI 10.1016/j.antiviral.2008.05.003; Fechter P, 2005, J GEN VIROL, V86, P1239, DOI 10.1099/vir.0.80755-0; Fensterl V, 2008, J VIROL, V82, P11045, DOI 10.1128/JVI.01593-08; Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9; Hui DJ, 2005, J BIOL CHEM, V280, P3433, DOI 10.1074/jbc.M406700200; Hui DJ, 2003, J BIOL CHEM, V278, P39477, DOI 10.1074/jbc.M305038200; LANGBERG SR, 1981, J BIOL CHEM, V256, P54; Latner DR, 2002, VIROLOGY, V301, P64, DOI 10.1006/viro.2002.1538; MUTHUKRISHNAN S, 1978, J BIOL CHEM, V253, P1710; Samuel MA, 2005, J VIROL, V79, P13350, DOI 10.1128/JVI.79.21.13350-13361.2005; Sarkar SN, 2004, PHARMACOL THERAPEUT, V103, P245, DOI 10.1016/j.pharmthera.2004.07.007; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Terenzi F, 2006, J BIOL CHEM, V281, P34064, DOI 10.1074/jbc.M605771200; Wacher C, 2007, J VIROL, V81, P860, DOI 10.1128/JVI.01167-06; WEI CM, 1975, CELL, V4, P379, DOI 10.1016/0092-8674(75)90158-0; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; Zhang YG, 2007, J VIROL, V81, P11246, DOI 10.1128/JVI.01282-07; Zhou YS, 2007, J VIROL, V81, P3891, DOI 10.1128/JVI.02704-06	25	560	585	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					452	456		10.1038/nature09489	http://dx.doi.org/10.1038/nature09489			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085181	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000284313100046
J	Fornoni, A				Fornoni, Alessia			Proteinuria, the Podocyte, and Insulin Resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GLOMERULAR PODOCYTE		[Fornoni, Alessia] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA; [Fornoni, Alessia] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA	University of Miami; University of Miami	Fornoni, A (corresponding author), Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA.		Fornoni, Alessia/F-8350-2013	fornoni, Alessia/0000-0002-1313-7773				Coward RJM, 2005, DIABETES, V54, P3095, DOI 10.2337/diabetes.54.11.3095; Engel H, 1996, J NUCL MED, V37, P441; MOGENSEN CE, 1980, DIABETOLOGIA, V18, P453; Musso C, 2006, CLIN J AM SOC NEPHRO, V1, P616, DOI 10.2215/CJN.01271005; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Welsh GI, 2010, CELL METAB, V12, P329, DOI 10.1016/j.cmet.2010.08.015	6	34	45	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2068	2069		10.1056/NEJMcibr1008395	http://dx.doi.org/10.1056/NEJMcibr1008395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083394				2022-12-28	WOS:000284310000015
J	Law, RHP; Lukoyanova, N; Voskoboinik, I; Caradoc-Davies, TT; Baran, K; Dunstone, MA; D'Angelo, ME; Orlova, EV; Coulibaly, F; Verschoor, S; Browne, KA; Ciccone, A; Kuiper, MJ; Bird, PI; Trapani, JA; Saibil, HR; Whisstock, JC				Law, Ruby H. P.; Lukoyanova, Natalya; Voskoboinik, Ilia; Caradoc-Davies, Tom T.; Baran, Katherine; Dunstone, Michelle A.; D'Angelo, Michael E.; Orlova, Elena V.; Coulibaly, Fasseli; Verschoor, Sandra; Browne, Kylie A.; Ciccone, Annette; Kuiper, Michael J.; Bird, Phillip I.; Trapani, Joseph A.; Saibil, Helen R.; Whisstock, James C.			The structural basis for membrane binding and pore formation by lymphocyte perforin	NATURE			English	Article							CHOLESTEROL-DEPENDENT CYTOLYSIN; GRANZYME-B; CRYSTAL-STRUCTURE; HUMAN-COMPLEMENT; 9TH COMPONENT; CELL-DEATH; T-CELLS; DOMAIN; CYTOTOXICITY; IDENTIFICATION	Natural killer cells and cytotoxic T lymphocytes accomplish the critically important function of killing virus-infected and neoplastic cells. They do this by releasing the pore-forming protein perforin and granzyme proteases from cytoplasmic granules into the cleft formed between the abutting killer and target cell membranes. Perforin, a 67-kilodalton multidomain protein, oligomerizes to form pores that deliver the pro-apoptopic granzymes into the cytosol of the target cell(1-6). The importance of perforin is highlighted by the fatal consequences of congenital perforin deficiency, with more than 50 different perforin mutations linked to familial haemophagocytic lymphohistiocytosis (type 2 FHL)(7). Here we elucidate the mechanism of perforin pore formation by determining the X-ray crystal structure of monomeric murine perforin, together with a cryo-electron microscopy reconstruction of the entire perforin pore. Perforin is a thin 'key-shaped' molecule, comprising an amino-terminal membrane attack complex perforin-like (MACPF)/cholesterol dependent cytolysin (CDC) domain(8,9) followed by an epidermal growth factor (EGF) domain that, together with the extreme carboxy-terminal sequence, forms a central shelf-like structure. A C-terminal C2 domain mediates initial, Ca2+-dependent membrane binding. Most unexpectedly, however, electron microscopy reveals that the orientation of the perforin MACPF domain in the pore is inside-out relative to the subunit arrangement in CDCs10,11. These data reveal remarkable flexibility in the mechanism of action of the conserved MACPF/CDC fold and provide new insights into how related immune defence molecules such as complement proteins assemble into pores.	[Voskoboinik, Ilia; Baran, Katherine; Verschoor, Sandra; Browne, Kylie A.; Ciccone, Annette; Trapani, Joseph A.] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia; [Law, Ruby H. P.; Dunstone, Michelle A.; D'Angelo, Michael E.; Coulibaly, Fasseli; Bird, Phillip I.; Whisstock, James C.] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia; [Law, Ruby H. P.; Whisstock, James C.] Monash Univ, ARC Ctr Excellence Struct & Funct Microbial Genom, Melbourne, Vic 3800, Australia; [Lukoyanova, Natalya; Orlova, Elena V.; Saibil, Helen R.] Univ London Birkbeck Coll, Inst Struct & Mol Biol, London WC1E 7HX, England; [Voskoboinik, Ilia] Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia; [Caradoc-Davies, Tom T.] Australian Synchrotron, Melbourne, Vic 3168, Australia; [Dunstone, Michelle A.] Monash Univ, Dept Microbiol, Melbourne, Vic 3800, Australia; [Kuiper, Michael J.] Victorian Partnership Adv Comp, Dept Life Sci, Carlton, Vic 3053, Australia; [Trapani, Joseph A.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia	Peter Maccallum Cancer Center; Monash University; Monash University; University of London; Birkbeck University London; University of Melbourne; Monash University; University of Melbourne	Trapani, JA (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Program, St Andrews Pl, Melbourne, Vic 3002, Australia.	joe.trapani@petermac.org; h.saibil@mail.cryst.bbk.ac.uk; james.whisstock@monash.edu	Orlova, Elena/CAF-8290-2022; Dunstone, Michelle/I-2895-2014	Lukoyanova, Natalya/0000-0002-2051-0812; Trapani, Joseph/0000-0003-0983-1532; Coulibaly, Fasseli/0000-0003-3380-2117; Voskoboinik, Ilia/0000-0002-6410-009X; law, ruby/0000-0001-5432-5781; Whisstock, James/0000-0003-4200-5611; Orlova, Elena/0000-0003-3371-415X; Bird, Phillip/0000-0002-6695-606X; D'Angelo, Michael/0000-0001-9342-0132; Dunstone, Michelle/0000-0002-6026-648X	NHMRC; ARC; UK BBSRC; Wellcome Trust; BBSRC [BB/D008573/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D008573/1] Funding Source: researchfish	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); ARC(Australian Research Council); UK BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	J.C.W. is an Australian Research Council Federation Fellow and Honorary National Health and Medical Research Council of Australia Principal Research Fellow. I.V., F.C. and M.A.D. are NHMRC Career Development Fellows. K.B. is an NHMRC C.J. Martin overseas training fellow. J.A.T. acknowledges the support of an NHMRC Senior Principal Research Fellowship during the course of the work. The authors thank the NHMRC, the ARC, the UK BBSRC and the Wellcome Trust for grant support. We thank the Australian synchrotron beamline scientists for technical support and access to the MX-2 Microfocus Beamline; we thank D. Clare and L. Wang for electron microscopy support, and D. Houldershaw, R. Westlake and K. Mahmood for computing support. We thank D. Steer and the Monash University Proteomics Unit for technical support.	Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baran K, 2009, IMMUNITY, V30, P684, DOI 10.1016/j.immuni.2009.03.016; Bird CH, 2005, MOL CELL BIOL, V25, P7854, DOI 10.1128/MCB.25.17.7854-7867.2005; BRICKNER A, 1985, BIOCHEMISTRY-US, V24, P4603, DOI 10.1021/bi00338a019; Bricogne G, 2009, BUSTER VERSION 2 8 0; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Cowtan K, 2006, ACTA CRYSTALLOGR D, V62, P1002, DOI 10.1107/S0907444906022116; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Czajkowsky DM, 2004, EMBO J, V23, P3206, DOI 10.1038/sj.emboj.7600350; Dang TX, 2005, J STRUCT BIOL, V150, P100, DOI 10.1016/j.jsb.2005.02.003; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL., 2020, PYMOL MOL GRAPHICS S; DOURMASHKIN RR, 1980, CLIN EXP IMMUNOL, V42, P554; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Grobler JA, 1997, NAT STRUCT BIOL, V4, P261, DOI 10.1038/nsb0497-261; Hadders MA, 2007, SCIENCE, V317, P1552, DOI 10.1126/science.1147103; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAWASAKI A, 1990, INT IMMUNOL, V2, P677, DOI 10.1093/intimm/2.7.677; Konagurthu AS, 2006, PROTEINS, V64, P559, DOI 10.1002/prot.20921; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Moreno RU, 2009, BLOOD, V113, P338, DOI 10.1182/blood-2008-08-172924; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; Ramachandran R, 2005, P NATL ACAD SCI USA, V102, P7139, DOI 10.1073/pnas.0500556102; Rosado CJ, 2007, SCIENCE, V317, P1548, DOI 10.1126/science.1144706; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Sheldrick GM, 2010, ACTA CRYSTALLOGR D, V66, P479, DOI 10.1107/S0907444909038360; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Shin OH, 2010, NAT STRUCT MOL BIOL, V17, P280, DOI 10.1038/nsmb.1758; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; Slade DJ, 2008, J MOL BIOL, V379, P331, DOI 10.1016/j.jmb.2008.03.061; Strong M, 2006, P NATL ACAD SCI USA, V103, P8060, DOI 10.1073/pnas.0602606103; Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989; Sutton VR, 2008, METHODS, V44, P241, DOI 10.1016/j.ymeth.2007.11.011; Thiery J, 2010, BLOOD, V115, P1582, DOI 10.1182/blood-2009-10-246116; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033; TSCHOPP J, 1986, NATURE, V322, P831, DOI 10.1038/322831a0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; Voskoboinik I, 2005, J BIOL CHEM, V280, P8426, DOI 10.1074/jbc.M413303200; Voskoboinik I, 2006, NAT REV IMMUNOL, V6, P940, DOI 10.1038/nri1983; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; White HE, 2004, J MOL BIOL, V336, P453, DOI 10.1016/j.jmb.2003.12.015; YOUNG JDE, 1986, P NATL ACAD SCI USA, V83, P150, DOI 10.1073/pnas.83.1.150; YOUNG JDE, 1986, SCIENCE, V233, P184, DOI 10.1126/science.2425429	57	281	291	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					447	U277		10.1038/nature09518	http://dx.doi.org/10.1038/nature09518			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21037563				2022-12-28	WOS:000284313100045
J	Kamerow, D				Kamerow, Douglas			Yankee Doodling Screening for early detection of lung cancer	BRITISH MEDICAL JOURNAL			English	Editorial Material									RTI Int, Res Triangle Pk, NC USA	Research Triangle Institute	Kamerow, D (corresponding author), RTI Int, Res Triangle Pk, NC USA.	dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				2010, BRIT MED J, V341, pC6480, DOI DOI 10.1136/BMJ.C6480	1	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2010	341								c6544	10.1136/bmj.c6544	http://dx.doi.org/10.1136/bmj.c6544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684WO	21084372				2022-12-28	WOS:000284586200015
J	Santos, RD				Santos, Raul D.			Review: Fibrates reduce risk for cardiovascular outcomes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Sao Paulo, Lipid Clin Heart Inst InCor, Sao Paulo, Brazil	Universidade de Sao Paulo	Santos, RD (corresponding author), Univ Sao Paulo, Lipid Clin Heart Inst InCor, Sao Paulo, Brazil.		Santos, Raul/A-1170-2010	Santos, Raul/0000-0002-9860-6582				Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Chapman MJ, 2003, ATHEROSCLEROSIS, V171, P1, DOI 10.1016/S0021-9150(03)00156-4; Deedwania P, 2006, LANCET, V368, P919, DOI 10.1016/S0140-6736(06)69292-1; Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619; Sacks FM, 2010, NEW ENGL J MED, V363, P692, DOI 10.1056/NEJMc1006407	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-11	10.1059/0003-4819-153-10-201011160-02011	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079206				2022-12-28	WOS:000284215800010
J	Armitage, J; Bowman, L; Wallendszus, K; Bulbulia, R; Rahimi, K; Haynes, R; Parish, S; Peto, R; Collins, R; Meade, T; Sleight, P; Collins, R; Armitage, J; Bowman, L; Parish, S; Peto, R; Barton, J; Bray, C; Wincott, E; Dayanandan, R; Clarke, R; Graham, I; Simpson, D; Warlow, C; Wilken, D; Tobert, J; Mushner, T; Doll, R; Wilhelmsen, L; Fox, K; Hill, C; Sandercock, P; Webster, J; Henderson, J; Nixon, A; Lackie, S; Thompson, J; Brown, M; Blackwood, S; Morgan, M; Rhoden, W; Saeed, B; Houghton, M; Nicholson, A; Simpson, C; Hoburn, B; Cooper, I; Gallivan, A; Pickerell, E; Hancock, J; Watkinson, J; Ryder, B; Jones, S; Burbridge, W; Kitchen, M; Leary, HO; Verow, C; Meynell, L; Rollinson, L; Bain, S; Jones, A; Jewkes, C; Russon, C; Bateson, M; Gill, P; Nicol, J; Bayly, G; Stansbie, D; Andrews, G; Halestrap, M; Meredith, J; Best, R; Appleyard, D; Briggs, R; Wareing, H; Holmes, K; Holt, J; Kenyon, M; White, C; Khalifa, M; Newton, D; Wass, A; Watkinson, R; Creamer, J; Anderson, S; Bethell, A; Butler, C; Castro, K; Washington, M; Weston, M; Cleaver, K; Machin, J; Wray, R; Sinclair, J; Van Aalst, A; Been, M; Mattu, R; Bates, D; Burke, A; Gill, L; Walton, E; Cowley, M; Robson, H; Graham, A; Rose, G; Kerr, M; Mallinson, J; Peascod, B; Donnelly, R; Kalk, J; Scott, A; Gibson, T; Hannah, J; Henshaw, L; Margetts, M; Pearson, N; Frost, S; Murray, S; Marshall, A; Went, J; Inman, A; Simmonds, J; Teasdale, A; Kemp, T; Roberts, G; Kooner, J; Cahill, S; Lloyd, M; Molloy, O; Wigley, J; Galvin, M; Wilder, C; Lindley, R; Shaw, S; Swainson, C; Hillis, L; Johnston, J; Johnstone, A; Miller, D; Kennedy, M; Mushahwar, S; Savage, M; Appleyard, D; Ayer, G; Schofield, J; Greenhalgh, S; Parks, J; Speak, S; Coulson, C; Papouchado, M; Carpenter, R; Wisby, J; Cobbe, S; Campbell, C; Hunter, J; Young, H; Gallacher, M; Lindsay, D; Halliday, A; Godfrey, S; Donahoo, LO; Chambers, J; Wierzbicki, A; Jones, A; Parkin, D; Nwafor, K; Oldroyd, K; Vallance, B; Cunningham, N; Moreland, G; Oldroyd, C; Young, H; Crawford, M; Hillson, R; Knott, K; Mahabir, N; Crouch, A; MacDonald, Y; Bellamy, C; Green, J; Brown, L; Heron, J; Jones, N; Roberts, M; Hainsworth, D; Williams, J; Barnes, P; Fitchet, A; Longworth, C; Davidson, J; Irvine, N; Oliver, R; Pond, C; Nuttall, M; Mostyn, RL; Brown, M; Barrowcliffe, J; Blackburn, S; Furnell, W; Webster, S; Wheatley, L; Hudson, I; Pohl, J; Nicholson, S; Mallya, S; Nash, M; Spruce, J; Bonner, A; Leather, J; Searle, A; Davies, E; Egdell, R; Price, B; Bennett, AT; Horton, S; Cunnington, A; Giles, P; Sidaway, J; Tomlinson, L; Walton, E; Hawkins, L; Long, J; Murphy, J; Brennan, G; Boon, M; Cassidy, S; Rodger, C; Hunter, J; McNeilly, A; Moreland, G; Radcliffe, A; Farrer, M; Bluett, J; Cowell, L; Farrell, A; Gilroy, S; Warren, S; MacConnell, T; Burtchaell, S; Williams, L; Rylance, P; Hodgson, A; Hill, KK; Robinson, L; Smallwood, A; Lomas, S; Ball, J; Benbow, S; Hardy, K; Gerrard, M; Langley, C; Beattie, M; Fagan, C; Green, B; Pringle, T; Hanna, H; Mackintosh, A; Watson, E; Swan, J; Appleyard, D; McSorland, D; Thompson, G; Neill, CO; Curless, R; Doig, C; McKenna, P; Martin, J; Murdy, J; Scott, A; Martin, S; Birkhead, J; Donnell, JO; Fox, C; Dixon, S; Hassall, A; Tanqueray, E; Vass, D; Cosford, I; Elderkin, M; McKenzie, P; Gray, T; Appleyard, D; Holmshaw, N; McKinnon, A; Bennett, AT; Ali, I; Stephens, N; Banfield, A; Chester, L; Wiseman, J; Harrisingh, N; Patel, R; Thaker, P; Armitage, J; Watkins, H; Beebe, S; Fitzgerald, J; Godden, J; Lawson, A; Lochhead, H; Taylor, A; Turner, S; Rowlands, D; Cooper, A; Graham, J; Hennessy, S; Rashid, T; Smith, C; Nyman, C; Adams, J; Hardwick, A; Buck, P; Pattinson, C; Trigg, J; McLeod, A; Gardner, S; Haimes, L; Orr, S; Johns, S; Capps, N; Cook, A; Donaldson, D; Keighley, C; Stiles, C; Asbridge, S; Buller, N; Townend, J; Hooks, J; Jewkes, C; Jones, H; Watson, R; Salt, P; Francis, M; MacLeod, D; Allcoat, P; Stuart, R; Reynolds, T; Maiden, J; Reynolds, J; Murray, D; MacFadyen, R; Potts, L; Smith, A; King, L; Muthusamy, R; Jones, M; Lawan, M; Nixon, J; Wasnidge, L; Weston, C; Hutchesson, A; Evans, J; Morris, K; Oultram, M; Armitage, M; Skule, R; Cope, C; Page, M; Fleming, S; Andain, K; Parrett, M; Soper, R; MacLeod, K; Gordon, K; Green, E; Havill, S; Stewart, V; Allen, S; Henson, S; Rimmer, C; Davies, J; Javed, M; Norris, A; Williams, M; Khan, S; Dobie, G; Fitton, J; Gilbert, S; Davenport, C; Williamson, M; Vincent, R; Joyce, E; Reckless, J; Bishop, A; Brice, L; Carpenter, R; Field, P; Shute, C; Pope, S; Stacey, D; Findlay, I; Campbell, C; Hunter, J; Gallacher, M; Labib, M; Hodgson, A; Sidaway, J; Beddoe, L; Reed, J; Barron, J; Odemuyiwa, O; Bradford, B; McDonnell, M; West, L; Beck, P; Gilbey, S; Clarkson, A; Drury, K; Hall, S; Quartey, D; Whittam, B; Lund, D; Stott, L; Griffiths, H; Appleyard, D; Fitzgerald, J; Kudarenko, A; Watkins, J; Golledge, S; Pottle, J; Little, S; Paine, B; Shears, C; Baxter, M; Wilkinson, P; Chambers, R; Hamper, C; Hollister, E; Ramsay, H; Barber, J; Hopkins, T; Hughes, L; Whittaker, JE; Verow, C; Burke, RL; Lloyd, C; Dhawan, J; John, J; Bramley, D; Catchpole, A; Colecchia, A; Gray, C; LeQuelenec, M; Remington, D; Wiseman, J; Gray, C; Anderson, P; Woolass, R; Thomas, P; Weston, C; Guy, F; Lynch, J; Thomas, R; Coates, S; Gait, M; Waller, D; Elkins, K; Franklin, M; Moore, L; Signy, M; Chilton, R; Joyce, E; Wrapson, C; Wiltshire, C; Lewis, P; Curtis, J; Toole, JO; Scanlon, S; Carey, C; Dobson, L; Gould, M; Mansfield, H; Ranson, G; Rodaway, M; Germon, J; Cockcroft, J; McDowell, I; Field, R; Whiting, J; Dennison, C; Roberts, D; Cooper, M; Davies, C; Fitton, J; Hutt, L; Radford, L; Ward, L; Williamson, M; McAlpine, H; Dougall, H; Robertson, L; Scott, L; Young, H; Humphrey, P; Saminaden, S; Watling, D; Davies, J; Owen, L; Clements, M; Walker, E; Atkins, E; Lindley, R; Shaw, T; Swainson, C; Webb, D; MacCallum, H; Markie, D; Melville, V; Adamson, L; Johnston, A; Polukord, E; Rudden, M; Hogan, J; Lie, F; Badger, V; Duffy, S; Mitchell, C; MacQueen, E; Baxter, R; Campbell, S; McDonald, L; Wood, H; Munro, A; Pycock, C; Cadwell, J; Doughty, A; Harvey, M; Price, S; Aldersley, M; Lock, S; Pendrey, P; Barton, J; Bray, C; Dayanandan, R; Wmcott, E; Achiri, P; Anderson, C; Benham, J; Bojowsky, H; Boller, I; Booker, V; Brewer, A; Brindley, G; Cobb, L; Collett, A; Corbett, M; Crowther, J; Pour, SD; Edmunds, K; Fortun, A; Grimsey, T; Harwood, C; Hope, C; Jones, R; Jones, S; Kidney, K; King, M; Knight, S; Lang, H; Madgwick, Z; Marsden, C; Matthews, C; Matthewson, M; Miller, J; Moss, B; Mostefai, Y; Murphy, K; Naughten, A; Pickworth, S; Radley, A; Southren, S; Sutherland, S; Tong, R; Turakani, M; Umbrath, M; Armitage, J; Baigent, C; Bowman, L; Bulbulia, R; Chen, Z; Clarke, R; Collins, R; Dunachie, S; Dasgupta, T; Haynes, R; Landray, M; Mafham, M; Majoni, W; Murray, C; Naessens, K; Porter, T; Rahimi, K; Reith, C; Clarke, MT; Turnbull, C; Walter, K; Harding, P; Lay, M; Wallendszus, K; Berry, C; Bettesworth, H; Booth, J; Bowes, M; Bu, Y; Charles, A; Cody, A; Cox, J; Emberson, J; Goodwin, N; Hurt, C; Link, E; McCabe, P; Munday, A; Murawska, A; Offer, A; Palmer, A; Parish, S; Peto, R; Prajapati, N; Tochlin, S; Young, A; Young, A; Clark, S; Kourelhas, K; Radley, M; Ambrose, V; Bradley, M; Bush, E; Chavagnon, T; Chukwurah, B; Crowley, S; Dunseath, J; Emmens, K; Fletcher, L; Gordon, J; Gordon, A; Hickman, C; Hill, J; Ji, M; Lee, A; Luker, N; Norris, S; Priestley, H; Sullivan, J; Taylor, J; Wintour, J; Yeung, M; Youngman, L; Beebe, S; Fitzgerald, J; Godden, J; Haimes, L; Lawson, A; Lochhead, H; McDonnell, M; Nash, M; Taylor, A; Bennett, AT; Walton, E				Armitage, Jane; Bowman, Louise; Wallendszus, Karl; Bulbulia, Richard; Rahimi, Kazem; Haynes, Richard; Parish, Sarah; Peto, Richard; Collins, Rory; Meade, T.; Sleight, P.; Collins, R.; Armitage, J.; Bowman, L.; Parish, S.; Peto, R.; Barton, J.; Bray, C.; Wincott, E.; Dayanandan, R.; Clarke, R.; Graham, I.; Simpson, D.; Warlow, C.; Wilken, D.; Tobert, J.; Mushner, T.; Doll, R.; Wilhelmsen, L.; Fox, K.; Hill, C.; Sandercock, P.; Webster, J.; Henderson, J.; Nixon, A.; Lackie, S.; Thompson, J.; Brown, M.; Blackwood, S.; Morgan, M.; Rhoden, W.; Saeed, B.; Houghton, M.; Nicholson, A.; Simpson, C.; Hoburn, B.; Cooper, I.; Gallivan, A.; Pickerell, E.; Hancock, J.; Watkinson, J.; Ryder, B.; Jones, S.; Burbridge, W.; Kitchen, M.; Leary, H. O.; Verow, C.; Meynell, L.; Rollinson, L.; Bain, S.; Jones, A.; Jewkes, C.; Russon, C.; Bateson, M.; Gill, P.; Nicol, J.; Bayly, G.; Stansbie, D.; Andrews, G.; Halestrap, M.; Meredith, J.; Best, R.; Appleyard, D.; Briggs, R.; Wareing, H.; Holmes, K.; Holt, J.; Kenyon, M.; White, C.; Khalifa, M.; Newton, D.; Wass, A.; Watkinson, R.; Creamer, J.; Anderson, S.; Bethell, A.; Butler, C.; Castro, K.; Washington, M.; Weston, M.; Cleaver, K.; Machin, J.; Wray, R.; Sinclair, J.; Van Aalst, A.; Been, M.; Mattu, R.; Bates, D.; Burke, A.; Gill, L.; Walton, E.; Cowley, M.; Robson, H.; Graham, A.; Rose, G.; Kerr, M.; Mallinson, J.; Peascod, B.; Donnelly, R.; Kalk, J.; Scott, A.; Gibson, T.; Hannah, J.; Henshaw, L.; Margetts, M.; Pearson, N.; Frost, S.; Murray, S.; Marshall, A.; Went, J.; Inman, A.; Simmonds, J.; Teasdale, A.; Kemp, T.; Roberts, G.; Kooner, J.; Cahill, S.; Lloyd, M.; Molloy, O.; Wigley, J.; Galvin, M.; Wilder, C.; Lindley, R.; Shaw, S.; Swainson, C.; Hillis, L.; Johnston, J.; Johnstone, A.; Miller, D.; Kennedy, M.; Mushahwar, S.; Savage, M.; Appleyard, D.; Ayer, G.; Schofield, J.; Greenhalgh, S.; Parks, J.; Speak, S.; Coulson, C.; Papouchado, M.; Carpenter, R.; Wisby, J.; Cobbe, S.; Campbell, C.; Hunter, J.; Young, H.; Gallacher, M.; Lindsay, D.; Halliday, A.; Godfrey, S.; Donahoo, L. O.; Chambers, J.; Wierzbicki, A.; Jones, A.; Parkin, D.; Nwafor, K.; Oldroyd, K.; Vallance, B.; Cunningham, N.; Moreland, G.; Oldroyd, C.; Young, H.; Crawford, M.; Hillson, R.; Knott, K.; Mahabir, N.; Crouch, A.; MacDonald, Y.; Bellamy, C.; Green, J.; Brown, L.; Heron, J.; Jones, N.; Roberts, M.; Hainsworth, D.; Williams, J.; Barnes, P.; Fitchet, A.; Longworth, C.; Davidson, J.; Irvine, N.; Oliver, R.; Pond, C.; Nuttall, M.; Mostyn, R. Lloyd; Brown, M.; Barrowcliffe, J.; Blackburn, S.; Furnell, W.; Webster, S.; Wheatley, L.; Hudson, I.; Pohl, J.; Nicholson, S.; Mallya, S.; Nash, M.; Spruce, J.; Bonner, A.; Leather, J.; Searle, A.; Davies, E.; Egdell, R.; Price, B.; Bennett, A. Taylor; Horton, S.; Cunnington, A.; Giles, P.; Sidaway, J.; Tomlinson, L.; Walton, E.; Hawkins, L.; Long, J.; Murphy, J.; Brennan, G.; Boon, M.; Cassidy, S.; Rodger, C.; Hunter, J.; McNeilly, A.; Moreland, G.; Radcliffe, A.; Farrer, M.; Bluett, J.; Cowell, L.; Farrell, A.; Gilroy, S.; Warren, S.; MacConnell, T.; Burtchaell, S.; Williams, L.; Rylance, P.; Hodgson, A.; Hill, K. Kertland; Robinson, L.; Smallwood, A.; Lomas, S.; Ball, J.; Benbow, S.; Hardy, K.; Gerrard, M.; Langley, C.; Beattie, M.; Fagan, C.; Green, B.; Pringle, T.; Hanna, H.; Mackintosh, A.; Watson, E.; Swan, J.; Appleyard, D.; McSorland, D.; Thompson, G.; Neill, C. O.; Curless, R.; Doig, C.; McKenna, P.; Martin, J.; Murdy, J.; Scott, A.; Martin, S.; Birkhead, J.; Donnell, J. O.; Fox, C.; Dixon, S.; Hassall, A.; Tanqueray, E.; Vass, D.; Cosford, I.; Elderkin, M.; McKenzie, P.; Gray, T.; Appleyard, D.; Holmshaw, N.; McKinnon, A.; Bennett, A. Taylor; Ali, I.; Stephens, N.; Banfield, A.; Chester, L.; Wiseman, J.; Harrisingh, N.; Patel, R.; Thaker, P.; Armitage, J.; Watkins, H.; Beebe, S.; Fitzgerald, J.; Godden, J.; Lawson, A.; Lochhead, H.; Taylor, A.; Turner, S.; Rowlands, D.; Cooper, A.; Graham, J.; Hennessy, S.; Rashid, T.; Smith, C.; Nyman, C.; Adams, J.; Hardwick, A.; Buck, P.; Pattinson, C.; Trigg, J.; McLeod, A.; Gardner, S.; Haimes, L.; Orr, S.; Johns, S.; Capps, N.; Cook, A.; Donaldson, D.; Keighley, C.; Stiles, C.; Asbridge, S.; Buller, N.; Townend, J.; Hooks, J.; Jewkes, C.; Jones, H.; Watson, R.; Salt, P.; Francis, M.; MacLeod, D.; Allcoat, P.; Stuart, R.; Reynolds, T.; Maiden, J.; Reynolds, J.; Murray, D.; MacFadyen, R.; Potts, L.; Smith, A.; King, L.; Muthusamy, R.; Jones, M.; Lawan, M.; Nixon, J.; Wasnidge, L.; Weston, C.; Hutchesson, A.; Evans, J.; Morris, K.; Oultram, M.; Armitage, M.; Skule, R.; Cope, C.; Page, M.; Fleming, S.; Andain, K.; Parrett, M.; Soper, R.; MacLeod, K.; Gordon, K.; Green, E.; Havill, S.; Stewart, V.; Allen, S.; Henson, S.; Rimmer, C.; Davies, J.; Javed, M.; Norris, A.; Williams, M.; Khan, S.; Dobie, G.; Fitton, J.; Gilbert, S.; Davenport, C.; Williamson, M.; Vincent, R.; Joyce, E.; Reckless, J.; Bishop, A.; Brice, L.; Carpenter, R.; Field, P.; Shute, C.; Pope, S.; Stacey, D.; Findlay, I.; Campbell, C.; Hunter, J.; Gallacher, M.; Labib, M.; Hodgson, A.; Sidaway, J.; Beddoe, L.; Reed, J.; Barron, J.; Odemuyiwa, O.; Bradford, B.; McDonnell, M.; West, L.; Beck, P.; Gilbey, S.; Clarkson, A.; Drury, K.; Hall, S.; Quartey, D.; Whittam, B.; Lund, D.; Stott, L.; Griffiths, H.; Appleyard, D.; Fitzgerald, J.; Kudarenko, A.; Watkins, J.; Golledge, S.; Pottle, J.; Little, S.; Paine, B.; Shears, C.; Baxter, M.; Wilkinson, P.; Chambers, R.; Hamper, C.; Hollister, E.; Ramsay, H.; Barber, J.; Hopkins, T.; Hughes, L.; Whittaker, J. Elson; Verow, C.; Burke, R. Lambley; Lloyd, C.; Dhawan, J.; John, J.; Bramley, D.; Catchpole, A.; Colecchia, A.; Gray, C.; LeQuelenec, M.; Remington, D.; Wiseman, J.; Gray, C.; Anderson, P.; Woolass, R.; Thomas, P.; Weston, C.; Guy, F.; Lynch, J.; Thomas, R.; Coates, S.; Gait, M.; Waller, D.; Elkins, K.; Franklin, M.; Moore, L.; Signy, M.; Chilton, R.; Joyce, E.; Wrapson, C.; Wiltshire, C.; Lewis, P.; Curtis, J.; Toole, J. O.; Scanlon, S.; Carey, C.; Dobson, L.; Gould, M.; Mansfield, H.; Ranson, G.; Rodaway, M.; Germon, J.; Cockcroft, J.; McDowell, I.; Field, R.; Whiting, J.; Dennison, C.; Roberts, D.; Cooper, M.; Davies, C.; Fitton, J.; Hutt, L.; Radford, L.; Ward, L.; Williamson, M.; McAlpine, H.; Dougall, H.; Robertson, L.; Scott, L.; Young, H.; Humphrey, P.; Saminaden, S.; Watling, D.; Davies, J.; Owen, L.; Clements, M.; Walker, E.; Atkins, E.; Lindley, R.; Shaw, T.; Swainson, C.; Webb, D.; MacCallum, H.; Markie, D.; Melville, V.; Adamson, L.; Johnston, A.; Polukord, E.; Rudden, M.; Hogan, J.; Lie, F.; Badger, V.; Duffy, S.; Mitchell, C.; MacQueen, E.; Baxter, R.; Campbell, S.; McDonald, L.; Wood, H.; Munro, A.; Pycock, C.; Cadwell, J.; Doughty, A.; Harvey, M.; Price, S.; Aldersley, M.; Lock, S.; Pendrey, P.; Barton, J.; Bray, C.; Dayanandan, R.; Wmcott, E.; Achiri, P.; Anderson, C.; Benham, J.; Bojowsky, H.; Boller, I.; Booker, V.; Brewer, A.; Brindley, G.; Cobb, L.; Collett, A.; Corbett, M.; Crowther, J.; Pour, S. Danesh; Edmunds, K.; Fortun, A.; Grimsey, T.; Harwood, C.; Hope, C.; Jones, R.; Jones, S.; Kidney, K.; King, M.; Knight, S.; Lang, H.; Madgwick, Z.; Marsden, C.; Matthews, C.; Matthewson, M.; Miller, J.; Moss, B.; Mostefai, Y.; Murphy, K.; Naughten, A.; Pickworth, S.; Radley, A.; Southren, S.; Sutherland, S.; Tong, R.; Turakani, M.; Umbrath, M.; Armitage, J.; Baigent, C.; Bowman, L.; Bulbulia, R.; Chen, Z.; Clarke, R.; Collins, R.; Dunachie, S.; Dasgupta, T.; Haynes, R.; Landray, M.; Mafham, M.; Majoni, W.; Murray, C.; Naessens, K.; Porter, T.; Rahimi, K.; Reith, C.; Clarke, M. Taylor; Turnbull, C.; Walter, K.; Harding, P.; Lay, M.; Wallendszus, K.; Berry, C.; Bettesworth, H.; Booth, J.; Bowes, M.; Bu, Y.; Charles, A.; Cody, A.; Cox, J.; Emberson, J.; Goodwin, N.; Hurt, C.; Link, E.; McCabe, P.; Munday, A.; Murawska, A.; Offer, A.; Palmer, A.; Parish, S.; Peto, R.; Prajapati, N.; Tochlin, S.; Young, A.; Young, A.; Clark, S.; Kourelhas, K.; Radley, M.; Ambrose, V.; Bradley, M.; Bush, E.; Chavagnon, T.; Chukwurah, B.; Crowley, S.; Dunseath, J.; Emmens, K.; Fletcher, L.; Gordon, J.; Gordon, A.; Hickman, C.; Hill, J.; Ji, M.; Lee, A.; Luker, N.; Norris, S.; Priestley, H.; Sullivan, J.; Taylor, J.; Wintour, J.; Yeung, M.; Youngman, L.; Beebe, S.; Fitzgerald, J.; Godden, J.; Haimes, L.; Lawson, A.; Lochhead, H.; McDonnell, M.; Nash, M.; Taylor, A.; Bennett, A. Taylor; Walton, E.		Study Effectiveness Additional Red	Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial	LANCET			English	Article							CORONARY-HEART-DISEASE; TASK-FORCE; PREVENTION; ATORVASTATIN; GUIDELINES; MORTALITY; STATINS	Background Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safely produces extra benefits is uncertain We aimed to establish efficacy and safety of more intensive statin treatment in patients at high cardiovascular risk Methods We undertook a double-blind randomised trial in 12064 men and women aged 18-80 years with a history of myocardial infarction Participants were either currently on or had clear indication for statin therapy, and had a total cholesterol concentration of at least 3 5 mmol/L if already on a stain or 4 5 mmol/L. if not Randomisation to either 80 mg or 20 mg simvastatin daily was done centrally using a minimisation algorithm Participants were assessed at 2 4 8, and 12 months after randomisation and then every 6 months until final follow up The primary endpoint was major vascular events, defined as coronary death, myocardial infarction, stroke or arterial revascularisation Analysis was by intention to treat This study is registered number ISRCTN74348595 Findings 6031 participants were allocated 80 mg simvastatin daily, and 6033 allocated 20 mg simvastatin daily During a mean follow up of 6 7 (SD 1 5) years allocation to 80 mg simvastatin produced an average 0 35 (SE 0 01) mmol/L greater reduction in LDL cholesterol compared with allocation to 20 mg Major vascular events occurred m 1477 (24 5%) participants allocated 80 mg simvastatin versus 1553 (25 7%) of those allocated 20 mg, corresponding to a 6% proportional reduction (risk ratio 0 94 95% CI 0 88-1 01, p=0 10) There were no apparent differences in numbers of haemorrhagic strokes (24 [0 4%] vs 25 [0 4%]) or deaths attributed to vascular (565 [9 4%] vs 572 [9 5%]) or non vascular (399 [6 6%] vs 398 [6 6%]) causes Compared with two (0 03%) cases of myopathy in patients taking 20 mg simvastatin daily there were 53 (0 9%) cases in the 80 mg group Interpretation The 6% (SE 3 5%) reduction in major vascular events with a further 0 35 mmol/L reduction in LDL cholesterol in our trial is consistent with previous trials Myopathy was increased with 80 mg simvastatin daily, but intensive lowering of LDL cholesterol can be achieved safely with other regimens	[Armitage, Jane] SEARCH Study Clin Trial Serv Unit, Oxford OX3 7LF, England	University of Oxford	Armitage, J (corresponding author), SEARCH Study Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.		Tobert, Jonathan/AAD-2155-2020; Taylor, Naomi/H-4016-2014; Colecchia, Antonio/AAK-7356-2020; Aldersley, Mark/AGG-5271-2022; McCabe, Patrick/M-3718-2013; Colecchia, Antonio/R-5446-2019; Rahimi, Kazem/AAA-4250-2022; Wierzbicki, Anthony/AAP-1735-2020; Rahimi, Kazem/Q-1279-2015; Halliday, Alison/AAA-2230-2022; Lindley, Richard/B-8148-2013	Tobert, Jonathan/0000-0001-7105-299X; McCabe, Patrick/0000-0003-2538-4920; Colecchia, Antonio/0000-0002-8384-801X; Wierzbicki, Anthony/0000-0003-2756-372X; Rahimi, Kazem/0000-0002-4807-4610; Halliday, Alison/0000-0001-9828-3579; Lindley, Richard/0000-0002-0104-5679; Townend, Jonathan/0000-0002-5881-5806; Dunachie, Susanna/0000-0001-5665-6293; Haynes, Richard/0000-0002-1179-0023; Hurt, Chris/0000-0003-1206-8355; Rose, Giuseppina/0000-0002-4264-4184; Landray, Martin/0000-0001-6646-827X; Cox, Jafna/0000-0001-7908-5323; Wallendszus, Karl/0000-0003-0971-3026; Martin, Seth/0000-0002-7021-7622; Emberson, Jonathan/0000-0001-7792-9422; Tomlinson, Laurie/0000-0001-8848-9493; Offer, Alison/0000-0002-3367-3207	Merck; UK Medical Research Council; British Heart Foundation; MRC [MC_U137686853, MC_EX_G0801669] Funding Source: UKRI; Medical Research Council [MC_U137686853, MC_EX_G0801669] Funding Source: researchfish	Merck(Merck & Company); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the participants in the study and the doctors nurses and administrative staff in hospitals and general practices throughout the UK who assisted with its conduct The study was supported by a grant from Merck (manufacturers of the simvastatin and suppliers of the vitamins) and the Clinical Trial Service Unit also receives core support from the UK Medical Research Council and the British Heart Foundation	[Anonymous], 2007, AM HEART J, V154, P815, DOI 10.1016/j.ahj.2007.06.034; [Anonymous], ELECT MED COMPENDIUM; Armitage J, 2007, LANCET, V370, P1781, DOI 10.1016/S0140-6736(07)60716-8; Armitage JM, 2010, JAMA-J AM MED ASSOC, V303, P2486, DOI 10.1001/jama.2010.840; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bainbridge KE, 2008, ANN INTERN MED, V149, P1, DOI 10.7326/0003-4819-149-1-200807010-00231; Cannon CP, 2006, J AM COLL CARDIOL, V48, P438, DOI 10.1016/j.jacc.2006.04.070; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Chang NC, 2007, OTOLARYNG HEAD NECK, V137, P603, DOI 10.1016/j.otohns.2007.04.022; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; *CHOL TREATM TRIAL, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61350.5; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; Davidson MH, 1997, AM J CARDIOL, V79, P38, DOI 10.1016/S0002-9149(96)00742-4; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; de Lemos JA, 2004, JAMA-J AM MED ASSOC, V292, P1307, DOI 10.1001/jama.292.11.1307; GREENLAND S, 1990, STAT MED, V9, P247, DOI 10.1002/sim.4780090307; Grundy Scott M, 2004, J Am Coll Cardiol, V44, P720, DOI 10.1016/j.jacc.2004.07.001; Kakarlapudi V, 2003, OTOL NEUROTOL, V24, P382, DOI 10.1097/00129492-200305000-00006; LANG JM, 1991, STAT MED, V10, P1585, DOI 10.1002/sim.4780101010; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; *NICE, 2008, 67 NICE; Pedersen TR, 1996, DRUG SAFETY, V14, P11, DOI 10.2165/00002018-199614010-00003; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Peto R, 2008, NEW ENGL J MED, V359, P1357, DOI 10.1056/NEJMsa0806603; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988; Wood D, 1998, EUR HEART J, V19, P1434; [No title captured]	35	402	419	0	120	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1658	1669		10.1016/S0140-6736(10)60310-8	http://dx.doi.org/10.1016/S0140-6736(10)60310-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21067805	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000284451000031
J	Shanks, GD				Shanks, G. Dennis			For severe malaria, artesunate is the answer	LANCET			English	Editorial Material							QUININE; TRIAL		[Shanks, G. Dennis] Army Malaria Inst, Enoggera, Qld 4051, Australia; [Shanks, G. Dennis] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia	University of Queensland	Shanks, GD (corresponding author), Army Malaria Inst, Enoggera, Qld 4051, Australia.		Shanks, George Dennis/F-4056-2014	Shanks, George Dennis/0000-0001-5763-8660				Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; DONDORP AM, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61924.1; Faiz MA, 2005, LANCET, V366, P717; *GLOB FUND FIGHT A, AFF MED FAC MAL AMFM; Newton PN, 2006, LANCET INFECT DIS, V6, P602, DOI 10.1016/S1473-3099(06)70581-3; Shanks GD, 2009, CLIN INFECT DIS, V49, P850, DOI 10.1086/605432; Smithuis F, 2010, LANCET INFECT DIS, V10, P673, DOI 10.1016/S1473-3099(10)70187-0; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201	8	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 13	2010	376	9753					1621	1622		10.1016/S0140-6736(10)61928-9	http://dx.doi.org/10.1016/S0140-6736(10)61928-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21062665				2022-12-28	WOS:000284451000005
J	van Os, J; Kenis, G; Rutten, BPF				van Os, Jim; Kenis, Gunter; Rutten, Bart P. F.			The environment and schizophrenia	NATURE			English	Article							DAILY-LIFE STRESS; PSYCHOTIC SYMPTOMS; CHILDHOOD TRAUMA; CANNABIS USE; NONPSYCHOTIC DISORDERS; FAMILIAL LIABILITY; BIRTH-COHORT; BRAIN-INJURY; RISK-FACTORS; URBANICITY	Psychotic syndromes can be understood as disorders of adaptation to social context. Although heritability is often emphasized, onset is associated with environmental factors such as early life adversity, growing up in an urban environment, minority group position and cannabis use, suggesting that exposure may have an impact on the developing 'social' brain during sensitive periods. Therefore heritability, as an index of genetic influence, may be of limited explanatory power unless viewed in the context of interaction with social effects. Longitudinal research is needed to uncover gene-environment interplay that determines how expression of vulnerability in the general population may give rise to more severe psychopathology.	[van Os, Jim; Kenis, Gunter; Rutten, Bart P. F.] Maastricht Univ, Med Ctr, SEARCH, European Grad Sch Neurosci, NL-6200 MD Maastricht, Netherlands; [van Os, Jim] Kings Coll London, Dept Psychosis Studies, Inst Psychiat, London SE5 8AF, England	Maastricht University; University of London; King's College London	van Os, J (corresponding author), Maastricht Univ, Med Ctr, SEARCH, European Grad Sch Neurosci, NL-6200 MD Maastricht, Netherlands.	j.vanos@sp.unimaas.nl	van Os, Jim/V-8884-2019; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/C-2113-2014; van Os, Jim/I-9496-2012	van Os, Jim/0000-0002-7245-1586; van Os, Jim/0000-0002-7245-1586; Rutten, Bart/0000-0002-9834-6346	Dutch Health Research Council [10-000-1002]; European Community [HEALTH-F2-2009-241909]	Dutch Health Research Council; European Community(European Commission)	The authors thank P. R. Hof, C. Morgan and M. Wichers for comments on earlier versions of this paper. Supported by the Geestkracht program of the Dutch Health Research Council (ZON-MW, grant number 10-000-1002), and the European Community's Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI).	Argyropoulos SV, 2008, ACTA PSYCHIAT SCAND, V118, P214, DOI 10.1111/j.1600-0447.2008.01205.x; Arnsten AFT, 2009, NAT REV NEUROSCI, V10, P410, DOI 10.1038/nrn2648; ARSENEAULT L, AM J PSYCHI IN PRESS; Barkus E, 2010, ANNU REV CLIN PSYCHO, V6, P365, DOI 10.1146/annurev.clinpsy.121208.131220; Bendall S, 2008, SCHIZOPHRENIA BULL, V34, P568, DOI 10.1093/schbul/sbm121; Bourque F, 2011, PSYCHOL MED, V41, P897, DOI 10.1017/S0033291710001406; Boydell J, 2001, BMJ-BRIT MED J, V323, P1336, DOI 10.1136/bmj.323.7325.1336; Bresnahan M, 2007, INT J EPIDEMIOL, V36, P751, DOI 10.1093/ije/dym041; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Cantor-Graae E, 2005, AM J PSYCHIAT, V162, P12, DOI 10.1176/appi.ajp.162.1.12; Carboni E, 2010, NEUROSCIENCE, V168, P156, DOI 10.1016/j.neuroscience.2010.03.046; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; Chen LS, 2009, SCHIZOPHR RES, V111, P159, DOI 10.1016/j.schres.2009.03.030; Colvert E, 2008, J ABNORM CHILD PSYCH, V36, P1057, DOI 10.1007/s10802-008-9232-x; D'Souza DC, 2005, BIOL PSYCHIAT, V57, P594, DOI 10.1016/j.biopsych.2004.12.006; Darroch J, 1997, AM J EPIDEMIOL, V145, P661; DAVID A, 1995, SCHIZOPHR RES, V14, P247, DOI 10.1016/0920-9964(94)00068-J; Di Forti M, 2009, BRIT J PSYCHIAT, V195, P488, DOI 10.1192/bjp.bp.109.064220; Dominguez MDG, 2011, SCHIZOPHRENIA BULL, V37, P84, DOI 10.1093/schbul/sbp022; Dominguez MDG, 2010, AM J PSYCHIAT, V167, P1075, DOI 10.1176/appi.ajp.2010.09060883; Dreher JC, 2009, P NATL ACAD SCI USA, V106, P617, DOI 10.1073/pnas.0805517106; Elklit A, 2011, SCHIZOPHRENIA BULL, V37, P1305, DOI 10.1093/schbul/sbq048; Ferdinand RF, 2005, ADDICTION, V100, P612, DOI 10.1111/j.1360-0443.2005.01070.x; Fergusson DM, 2003, PSYCHOL MED, V33, P15, DOI 10.1017/S0033291702006402; Fett AKJ, 2011, NEUROSCI BIOBEHAV R, V35, P573, DOI 10.1016/j.neubiorev.2010.07.001; Fisher HL, 2011, SCHIZOPHRENIA BULL, V37, P546, DOI 10.1093/schbul/sbp103; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Galdos M, 2011, SCHIZOPHRENIA BULL, V37, P1179, DOI 10.1093/schbul/sbq029; Gardener H, 2009, BRIT J PSYCHIAT, V195, P7, DOI 10.1192/bjp.bp.108.051672; Glaser JP, 2006, J PSYCHOSOM RES, V61, P229, DOI 10.1016/j.jpsychores.2006.04.014; Goodwin RD, 2003, PSYCHOL MED, V33, P1089, DOI 10.1017/S0033291703007888; Grace AA, 2007, TRENDS NEUROSCI, V30, P220, DOI 10.1016/j.tins.2007.03.003; Guo SW, 2000, HUM HERED, V50, P286, DOI 10.1159/000022931; Habets P, 2011, BIOL PSYCHIAT, V69, P487, DOI 10.1016/j.biopsych.2010.08.010; Hanssen M, 2003, SOC PSYCH PSYCH EPID, V38, P149, DOI 10.1007/s00127-003-0622-7; Homer BD, 2008, PSYCHOL BULL, V134, P301, DOI 10.1037/0033-2909.134.2.301; Howes OD, 2009, SCHIZOPHRENIA BULL, V35, P549, DOI 10.1093/schbul/sbp006; Hutchinson G, 1996, BRIT J PSYCHIAT, V169, P776, DOI 10.1192/bjp.169.6.776; Jager G, 2010, J AM ACAD CHILD PSY, V49, P561, DOI 10.1016/j.jaac.2010.02.001; Janssen I, 2004, ACTA PSYCHIAT SCAND, V109, P38, DOI 10.1046/j.0001-690X.2003.00217.x; Kahn RS, 2011, ARCH GEN PSYCHIAT, V68, P138, DOI 10.1001/archgenpsychiatry.2010.132; Kaschube M, 2002, J NEUROSCI, V22, P7206; Keen DV, 2010, BRIT J PSYCHIAT, V196, P274, DOI 10.1192/bjp.bp.109.065490; Keller MC, 2010, BEHAV GENET, V40, P377, DOI 10.1007/s10519-009-9320-x; Kelly BD, 2010, SCHIZOPHR RES, V116, P75, DOI 10.1016/j.schres.2009.10.015; KENDLER KS, 1994, AM J PSYCHIAT, V151, P1605; Krabbendam L, 2005, SCHIZOPHRENIA BULL, V31, P795, DOI 10.1093/schbul/sbi060; Lieberman JA, 1997, NEUROPSYCHOPHARMACOL, V17, P205, DOI 10.1016/S0893-133X(97)00045-6; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; March D, 2008, EPIDEMIOL REV, V30, P84, DOI 10.1093/epirev/mxn006; Maric N, 2004, SOC PSYCH PSYCH EPID, V39, P600, DOI 10.1007/s00127-004-0803-z; Mason OJ, 2009, J NERV MENT DIS, V197, P783, DOI 10.1097/NMD.0b013e3181b9760b; McGrath J, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-13; McMillan KA, 2009, CAN J PSYCHIAT, V54, P477, DOI 10.1177/070674370905400709; Minozzi S, 2010, DRUG ALCOHOL REV, V29, P304, DOI 10.1111/j.1465-3362.2009.00132.x; Morgan C, 2007, SCHIZOPHRENIA BULL, V33, P3, DOI 10.1093/schbul/sbl053; Morgan C, 2010, SCHIZOPHRENIA BULL, V36, P655, DOI 10.1093/schbul/sbq051; Morrison PD, 2009, PSYCHOL MED, V39, P1607, DOI 10.1017/S0033291709005522; Mortensen PB, 2010, PSYCHOL MED, V40, P201, DOI 10.1017/S0033291709990419; Mueller SC, 2010, NEUROPSYCHOLOGIA, V48, P3037, DOI 10.1016/j.neuropsychologia.2010.06.013; Myin-Germeys I, 2005, PSYCHOL MED, V35, P733, DOI 10.1017/S0033291704004179; Myin-Germeys I, 2009, PSYCHOL MED, V39, P1533, DOI 10.1017/S0033291708004947; Nestor L, 2008, NEUROIMAGE, V40, P1328, DOI 10.1016/j.neuroimage.2007.12.059; Nestor L, 2010, NEUROIMAGE, V49, P1133, DOI 10.1016/j.neuroimage.2009.07.022; Pedersen CB, 2001, ARCH GEN PSYCHIAT, V58, P1039, DOI 10.1001/archpsyc.58.11.1039; Perala J, 2007, ARCH GEN PSYCHIAT, V64, P19, DOI 10.1001/archpsyc.64.1.19; PETERSON CC, 1995, J CHILD PSYCHOL PSYC, V36, P459, DOI 10.1111/j.1469-7610.1995.tb01303.x; Polanczyk G, 2010, ARCH GEN PSYCHIAT, V67, P328, DOI 10.1001/archgenpsychiatry.2010.14; Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004; Read J, 2005, ACTA PSYCHIAT SCAND, V112, P330, DOI 10.1111/j.1600-0447.2005.00634.x; RODGERS B, 1990, J CHILD PSYCHOL PSYC, V31, P393, DOI 10.1111/j.1469-7610.1990.tb01577.x; Rutten BPF, 2009, SCHIZOPHRENIA BULL, V35, P1045, DOI 10.1093/schbul/sbp104; Schmidt-Kastner R, 2006, SCHIZOPHR RES, V84, P253, DOI 10.1016/j.schres.2006.02.022; Schreier A, 2009, ARCH GEN PSYCHIAT, V66, P527, DOI 10.1001/archgenpsychiatry.2009.23; Selten JP, 2005, BRIT J PSYCHIAT, V187, P101, DOI 10.1192/bjp.187.2.101; Shergill SS, 2005, AM J PSYCHIAT, V162, P2384, DOI 10.1176/appi.ajp.162.12.2384; Sheu YS, 2010, NEUROIMAGE, V53, P412, DOI 10.1016/j.neuroimage.2010.06.043; Stefanis N, 2006, SCHIZOPHR RES, V85, P266, DOI 10.1016/j.schres.2006.03.036; Taylor SE, 2006, BIOL PSYCHIAT, V60, P296, DOI 10.1016/j.biopsych.2005.09.027; Thomas D, 2010, NAT REV GENET, V11, P259, DOI 10.1038/nrg2764; Toulopoulou T, 2007, ARCH GEN PSYCHIAT, V64, P1348, DOI 10.1001/archpsyc.64.12.1348; van Os J, 2003, AM J PSYCHIAT, V160, P477, DOI 10.1176/appi.ajp.160.3.477; Van Os J, 2000, BRIT J PSYCHIAT, V176, P243, DOI 10.1192/bjp.176.3.243; van Os J, 2004, AM J PSYCHIAT, V161, P2312, DOI 10.1176/appi.ajp.161.12.2312; van Os J, 2009, PSYCHOL MED, V39, P179, DOI 10.1017/S0033291708003814; van Os J, 2008, SCHIZOPHRENIA BULL, V34, P1066, DOI 10.1093/schbul/sbn117; van Os J, 2009, LANCET, V374, P635, DOI [10.1016/S0140-6736(09)60995-8, 10.1016/S0140-6736(15)01121-6]; VANWINKEL R, ARCH GEN PS IN PRESS; Veling W, 2008, PSYCHOL MED, V38, P1251, DOI 10.1017/S0033291708003474; Veling W, 2008, AM J PSYCHIAT, V165, P66, DOI 10.1176/appi.ajp.2007.07030423; Weiser M, 2004, ACTA PSYCHIAT SCAND, V110, P471, DOI 10.1111/j.1600-0447.2004.00385.x; Weiser M, 2008, BIOL PSYCHIAT, V63, P602, DOI 10.1016/j.biopsych.2007.05.029; Weiser M, 2007, BRIT J PSYCHIAT, V191, P320, DOI 10.1192/bjp.bp.106.031328; Wichers M, 2009, PSYCHOL MED, V39, P1077, DOI 10.1017/S0033291708004388; Wichers M, 2008, NEUROPSYCHOPHARMACOL, V33, P3030, DOI 10.1038/sj.npp.1301520; Yucel M, 2008, ARCH GEN PSYCHIAT, V65, P694, DOI 10.1001/archpsyc.65.6.694; Zammit S, 2010, ARCH GEN PSYCHIAT, V67, P914, DOI 10.1001/archgenpsychiatry.2010.101; [No title captured], DOI DOI 10.1093/SCHBUL/SBQ011	99	991	1000	8	336	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					203	212		10.1038/nature09563	http://dx.doi.org/10.1038/nature09563			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068828				2022-12-28	WOS:000284051000036
J	Himmelfarb, J; Ikizler, TA				Himmelfarb, Jonathan; Ikizler, T. Alp			MEDICAL PROGRESS Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; CENTER NOCTURNAL HEMODIALYSIS; CARDIOVASCULAR EVENTS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; MORTALITY RISK; BLOOD-PRESSURE; TREATMENT TIME; UNITED-STATES		[Himmelfarb, Jonathan] Univ Washington, Kidney Res Inst, Dept Med, Div Nephrol, Seattle, WA 98104 USA; [Ikizler, T. Alp] Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN USA	University of Washington; University of Washington Seattle; Vanderbilt University	Himmelfarb, J (corresponding author), Univ Washington, Kidney Res Inst, Dept Med, Div Nephrol, Box 359606,325 9th Ave, Seattle, WA 98104 USA.	himmej@u.washington.edu		Ikizler, Talat/0000-0002-5717-4218	KAI Pharmaceuticals; Fresenius Medical Care North America; Kidney Research Institute at the University of Washington; Amgen; Abbott Renal Care; Novo Nordisk; Renal Advantage; Eli Lilly; Medical Nutrition USA	KAI Pharmaceuticals; Fresenius Medical Care North America; Kidney Research Institute at the University of Washington; Amgen(Amgen); Abbott Renal Care; Novo Nordisk(Novo Nordisk); Renal Advantage; Eli Lilly(Eli Lilly); Medical Nutrition USA	Dr. Himmelfarb reports serving on the Shire Pharmaceuticals scientific advisory board on Outcomes Studies in Hemodialysis Patients and the CytoPherx (formerly Nephrion) medical advisory board and receiving consulting fees from KAI Pharmaceuticals, as well as receipt by his former institution, the Maine Medical Center Research Institute, of research support from Fresenius Medical Services of North America (now Fresenius Medical Care North America). All payments for board membership and consulting were donated to the Kidney Research Institute at the University of Washington. Dr. Ikizler reports serving on the boards of the American Board of Internal Medicine and Satellite Healthcare, receiving consulting fees from Amgen, Abbott Renal Care, Novo Nordisk, Renal Advantage, Eli Lilly, and Fresenius Medical Care North America, royalties from Wolter Kluwer, as well as receipt by his institution, the Vanderbilt University Medical Center, of research support from Medical Nutrition USA and Fresenius Medical Care North America. Dr. Ikizler reports having been the medical director of the Vanderbilt Dialysis Unit, which is owned by Vanderbilt University Medical Center and managed by Fresenius Medical Care North America, until June 2010. No other potential conflict of interest relevant to this article was reported.	Agarwal R, 2002, SEMIN DIALYSIS, V15, P299, DOI 10.1046/j.1525-139X.2002.00074.x; Annuk M, 2001, J AM SOC NEPHROL, V12, P2747, DOI 10.1681/ASN.V12122747; [Anonymous], 2009, USRDS 2009 ANN DAT R; Arnold RM, 2009, NEW ENGL J MED, V361, P1597, DOI 10.1056/NEJMe0907698; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059; Bugeja A, 2009, CLIN J AM SOC NEPHRO, V4, P778, DOI 10.2215/CJN.05221008; Charra B, 1996, AM J NEPHROL, V16, P35, DOI 10.1159/000168968; COLLINS AJ, 1994, AM J KIDNEY DIS, V23, P272, DOI 10.1016/S0272-6386(12)80984-X; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; *CTR MED MED SERV, DIAL FAC COMP DEC; *CTR MED STAT OP S, 2008, ENDST REN DIS ESRD P; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Daugirdas JT, 2008, SEMIN DIALYSIS, V21, P415, DOI 10.1111/j.1525-139X.2008.00482.x; DEFRONZO RA, 1981, J CLIN INVEST, V67, P563, DOI 10.1172/JCI110067; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Fellstrom BC, 2010, NEW ENGL J MED, V362, P1450; Fissell WH, 2009, SEMIN DIALYSIS, V22, P665, DOI 10.1111/j.1525-139X.2009.00662.x; *FIST 1 BREAKTHR I, NAT AV FIST RAT REAC; Foley RN, 2009, J AM SOC NEPHROL, V20, P1432, DOI 10.1681/ASN.2009030282; Goodkin DA, 2004, AM J KIDNEY DIS, V44, pS16, DOI 10.1053/j.akjd.2004.08.006; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Gura V, 2009, CLIN J AM SOC NEPHRO, V4, P1441, DOI 10.2215/CJN.02790409; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Herzog CA, 2008, SEMIN DIALYSIS, V21, P300, DOI 10.1111/j.1525-139X.2008.00455.x; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; HIMMELFARB J, 2008, HEMODIALYSIS; Himmelfarb J, 2007, J AM SOC NEPHROL, V18, P2021, DOI 10.1681/ASN.2007020152; Himmelfarb J, 2007, ANNU REV MED, V58, P387, DOI 10.1146/annurev.med.58.061705.151442; HORNBERGER JC, 1992, J AM SOC NEPHROL, V3, P1227; Ikizler TA, 1999, KIDNEY INT, V55, P1945, DOI 10.1046/j.1523-1755.1999.00410.x; Jamison RL, 2008, JAMA-J AM MED ASSOC, V300, P170; Jamison RL, 2007, JAMA-J AM MED ASSOC, V298, P1163, DOI 10.1001/jama.298.10.1163; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Kliger AS, 2007, CLIN J AM SOC NEPHRO, V2, P390, DOI 10.2215/CJN.03110906; Knauf F, 2009, J AM SOC NEPHROL, V20, P2093, DOI 10.1681/ASN.2009070715; Koda Y, 1997, KIDNEY INT, V52, P1096, DOI 10.1038/ki.1997.434; Lacson E, 2007, AM J KIDNEY DIS, V50, P379, DOI 10.1053/j.ajkd.2007.06.006; Li L, 2008, KIDNEY INT, V74, P1247, DOI 10.1038/ki.2008.318; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Locatelli F, 2005, NEPHROL DIAL TRANSPL, V20, P22, DOI 10.1093/ndt/gfh555; Locatelli F, 1996, KIDNEY INT, V50, P1293, DOI 10.1038/ki.1996.441; Locatelli Francesco, 2002, Kidney Int Suppl, P115; Lopot F, 2004, J Vasc Access, V5, P25; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 2003, AM J KIDNEY DIS, V41, P1286, DOI 10.1016/S0272-6386(03)00361-5; Maduell F, 2008, AM J KIDNEY DIS, V52, P85, DOI 10.1053/j.ajkd.2008.03.014; Maggiore Q, 2002, AM J KIDNEY DIS, V40, P280, DOI 10.1053/ajkd.2002.34506; Marshall MR, 2006, KIDNEY INT, V69, P1229, DOI 10.1038/sj.ki.5000188; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Middleton RJ, 2001, J AM SOC NEPHROL, V12, P1079, DOI 10.1681/ASN.V1251079; Moss AH, 2001, AM J KIDNEY DIS, V37, P1081; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Nissenson Allen R, 2005, Hemodial Int, V9, P210, DOI 10.1111/j.1492-7535.2005.01135.x; Oliver MJ, 2001, J AM SOC NEPHROL, V12, P151, DOI 10.1681/ASN.V121151; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Passauer J, 2000, J AM SOC NEPHROL, V11, P1726, DOI 10.1681/ASN.V1191726; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Port FK, 2004, AM J KIDNEY DIS, V43, P1014, DOI 10.1053/j.ajkd.2004.02.014; Port FK, 2001, AM J KIDNEY DIS, V37, P276, DOI 10.1053/ajkd.2001.21290; Powell JR, 2009, CLIN J AM SOC NEPHRO, V4, P1097, DOI 10.2215/CJN.06651208; QUINTON W, 1960, T AM SOC ART INT ORG, V6, P104; Raggi P, 2007, KIDNEY INT, V71, P802, DOI 10.1038/sj.ki.5002164; Rastogi A, 2009, CLIN J AM SOC NEPHRO, V4, pS132, DOI 10.2215/CJN.02860409; RETTIG RA, 1976, LAW CONTEMP PROBL, V40, P196, DOI 10.2307/1191314; Saran R, 2006, KIDNEY INT, V69, P1222, DOI 10.1038/sj.ki.5000186; Schreiner GE, 2000, AM J KIDNEY DIS, V35, pS37, DOI 10.1016/S0272-6386(00)70229-0; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P88; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Spalding EM, 2008, KIDNEY INT, V74, P348, DOI 10.1038/ki.2008.185; Spiegel DM, 2009, CLIN J AM SOC NEPHRO, V4, P1009, DOI 10.2215/CJN.00270109; Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466; Suri RS, 2007, KIDNEY INT, V71, P349, DOI 10.1038/sj.ki.5002032; Suri RS, 2006, CLIN J AM SOC NEPHRO, V1, P33, DOI 10.2215/CJN.00340705; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; Troidle L, 2007, ADV CHRONIC KIDNEY D, V14, P244, DOI 10.1053/j.ackd.2007.03.002; Unger EF, 2010, NEW ENGL J MED, V362, P189, DOI 10.1056/NEJMp0912328; VALLANCE P, 1992, LANCET, V339, P572; Vanholder R, 2008, J AM SOC NEPHROL, V19, P863, DOI 10.1681/ASN.2007121377; Wanner C, 2005, NEW ENGL J MED, V353, P1640; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Ward RA, 2004, SEMIN DIALYSIS, V17, P489, DOI 10.1111/j.0894-0959.2004.17617.x; Ward RA, 2009, BLOOD PURIFICAT, V27, P6, DOI 10.1159/000167001; Williams ME, 2006, KIDNEY INT, V70, P1503, DOI 10.1038/sj.ki.5001789; Yilmaz MI, 2009, CLIN J AM SOC NEPHRO, V4, P1716, DOI 10.2215/CJN.02760409; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x; Zoccali C, 2002, J AM SOC NEPHROL, V13, P134, DOI 10.1681/ASN.V131134	95	214	226	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1833	1845		10.1056/NEJMra0902710	http://dx.doi.org/10.1056/NEJMra0902710			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047227				2022-12-28	WOS:000283787800008
J	Gaffney, AM; Wildhirt, SM; Griffin, MJ; Annich, GM; Radomski, MW				Gaffney, Alan M.; Wildhirt, Stephen M.; Griffin, Michael J.; Annich, Gail M.; Radomski, Marek W.			Extracorporeal life support	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RESPIRATORY-DISTRESS-SYNDROME; MEMBRANE-OXYGENATION; CARDIAC-ARREST; FAILURE; ECMO; EXPERIENCE; SURVIVAL; CHILDREN; TRIAL		[Gaffney, Alan M.; Radomski, Marek W.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland; [Wildhirt, Stephen M.] Univ Tubingen, Dept Thorac Cardiac & Vasc Surg, Tubingen, Germany; [Gaffney, Alan M.; Griffin, Michael J.] Mater Misericordiae Univ Hosp, Dublin, Ireland; [Annich, Gail M.] Univ Michigan Hlth Syst, CS Mott Childrens Hosp, Ann Arbor, MI 48109 USA	Trinity College Dublin; Eberhard Karls University of Tubingen; Mater Misericordiae University Hospital; University College Dublin; University of Michigan System; University of Michigan	Radomski, MW (corresponding author), Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland.	marek.radomski@tcd.ie	Radomski, Marek W/C-5195-2014		Science Foundation Ireland; Health Research Board and Health Service Executive, Ireland	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board and Health Service Executive, Ireland	The work was supported by grants from Science Foundation Ireland (MWR) and the Health Research Board and Health Service Executive, Ireland (AMG).	[Anonymous], 2009, ELSO GUID CARD EXTR; BARTLETT RH, 1985, PEDIATRICS, V76, P479; BARTLETT RH, 1976, T AM SOC ART INT ORG, V22, P80; Bennett CC, 2001, LANCET, V357, P1094, DOI 10.1016/S0140-6736(00)04310-5; BIFANO E M, 1992, Pediatric Research, V31, p196A; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Combes A, 2008, CRIT CARE MED, V36, P1404, DOI 10.1097/CCM.0b013e31816f7cf7; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; DELNIDO PJ, 1992, CIRCULATION, V86, P300; *ELSO, 2010, EXTR LIF SUPP ORG EL; Field D, 1996, LANCET, V348, P75; Green TP, 1996, CRIT CARE MED, V24, P323, DOI 10.1097/00003246-199602000-00023; Hemmila MR, 2004, ANN SURG, V240, P595, DOI 10.1097/01.sla.0000141159.90676.2d; HILL JD, 1972, NEW ENGL J MED, V286, P629, DOI 10.1056/NEJM197203232861204; Linden V, 2000, INTENS CARE MED, V26, P1630, DOI 10.1007/s001340000697; Mahle WT, 2005, J THORAC CARDIOV SUR, V129, P1084, DOI 10.1016/j.jtcvs.2004.08.012; Marasco SF, 2007, PERFUSION-UK, V22, P23, DOI 10.1177/0267659106074789; MORTON A, 1994, CRIT CARE MED, V22, P1659; Mugford M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001340.pub2; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Oliver WC, 2009, SEMIN CARDIOTHORAC V, V13, P154, DOI 10.1177/1089253209347384; OROURKE PP, 1989, PEDIATRICS, V84, P957; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Petrou S, 2006, PEDIATRICS, V117, P1640, DOI 10.1542/peds.2005-1150; Rich PB, 1998, J CRIT CARE, V13, P26, DOI 10.1016/S0883-9441(98)90026-0; Roberts TE, 1998, BMJ-BRIT MED J, V317, P911; STOLAR CJH, 1991, J PEDIATR SURG, V26, P563, DOI 10.1016/0022-3468(91)90708-2; Tajik M, 2008, EUR J CARDIO-THORAC, V33, P409, DOI 10.1016/j.ejcts.2007.12.018; Thiagarajan RR, 2009, ANN THORAC SURG, V87, P778, DOI 10.1016/j.athoracsur.2008.12.079; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	30	49	52	2	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2010	341								c5317	10.1136/bmj.c5317	http://dx.doi.org/10.1136/bmj.c5317			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CU	21045023				2022-12-28	WOS:000284048200005
J	Riddihough, G; Zahn, LM				Riddihough, Guy; Zahn, Laura M.			What Is Epigenetics? INTRODUCTION	SCIENCE			English	Editorial Material																			0	51	55	5	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					611	611		10.1126/science.330.6004.611	http://dx.doi.org/10.1126/science.330.6004.611			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030643				2022-12-28	WOS:000283580600031
J	Yudkin, JS; Richter, B; Gale, EAM				Yudkin, John S.; Richter, Bernd; Gale, Edwin A. M.			Intensified glucose control in type 2 diabetes-whose agenda?	LANCET			English	Editorial Material							SURVIVAL; TIME		[Yudkin, John S.] UCL, London WC1E 6BT, England; [Richter, Bernd] Univ Dusseldorf, Cochrane Metab & Endocrine Disorders Review Grp, Dusseldorf, Germany; [Gale, Edwin A. M.] Univ Bristol, Bristol, Avon, England	University of London; University College London; Heinrich Heine University Dusseldorf; University of Bristol	Yudkin, JS (corresponding author), UCL, Mortimer St, London WC1E 6BT, England.	j.yudkin@ucl.ac.uk	Yudkin, John S/C-1988-2008	Richter, Bernd/0000-0002-7117-3983				*AM DIAB ASS, 2010, AM DIABETES ASS  SPR, P14; Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI 10.2337/dc10-S011; Currie CJ, 2010, LANCET, V375, P481, DOI 10.1016/S0140-6736(09)61969-3; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gerstein HC, 1996, LANCET, V347, P949, DOI 10.1016/S0140-6736(96)91420-8; Hauber A, 2006, DIABETOLOGIA, V49, P247, DOI 10.1007/s00125-005-0108-0; Holman RR, 2009, NEW ENGL J MED, V361, P1736, DOI 10.1056/NEJMoa0905479; Huang ES, 2007, DIABETES CARE, V30, P2478, DOI 10.2337/dc07-0499; Kahn R, 2010, LANCET, V375, P1365, DOI 10.1016/S0140-6736(09)62162-0; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Montori VM, 2009, ANN INTERN MED, V150, P803, DOI 10.7326/0003-4819-150-11-200906020-00008; Rothman DJ, 2009, JAMA-J AM MED ASSOC, V301, P1367, DOI 10.1001/jama.2009.407; Royal College of Physicians, 2009, INN HLTH PAT PHYS PH; Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turnbull FM, 2009, DIABETOLOGIA, V52, P2288, DOI 10.1007/s00125-009-1470-0; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Yudkin JS, 2010, DIABETOLOGIA, V53, P2079, DOI 10.1007/s00125-010-1864-z	18	27	27	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2011	377	9773					1220	1222		10.1016/S0140-6736(10)61112-9	http://dx.doi.org/10.1016/S0140-6736(10)61112-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	751DI	21093903				2022-12-28	WOS:000289597300008
J	Ko, M; Huang, Y; Jankowska, AM; Pape, UJ; Tahiliani, M; Bandukwala, HS; An, J; Lamperti, ED; Koh, KP; Ganetzky, R; Liu, XS; Aravind, L; Agarwal, S; Maciejewski, JP; Rao, A				Ko, Myunggon; Huang, Yun; Jankowska, Anna M.; Pape, Utz J.; Tahiliani, Mamta; Bandukwala, Hozefa S.; An, Jungeun; Lamperti, Edward D.; Koh, Kian Peng; Ganetzky, Rebecca; Liu, X. Shirley; Aravind, L.; Agarwal, Suneet; Maciejewski, Jaroslaw P.; Rao, Anjana			Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2	NATURE			English	Article							DNA METHYLATION; MUTATIONS; MALIGNANCIES; THERAPY; COMMON; HYPOMETHYLATION; MYELOFIBROSIS; EPIGENETICS; CONVERSION; NEOPLASMS	TET2 is a close relative of TET1, an enzyme that converts 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA(1,2). The gene encoding TET2 resides at chromosome 4q24, in a region showing recurrent microdeletions and copy-neutral loss of heterozygosity (CN-LOH) in patients with diverse myeloid malignancies(3). Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemias (AML) and secondary AML (sAML)(4-12). We show here that TET2 mutations associated with myeloid malignancies compromise catalytic activity. Bone marrow samples from patients with TET2 mutations displayed uniformly low levels of 5hmC in genomic DNA compared to bone marrow samples from healthy controls. Moreover, small hairpin RNA (shRNA)-mediated depletion of Tet2 in mouse haematopoietic precursors skewed their differentiation towards monocyte/macrophage lineages in culture. There was no significant difference in DNA methylation between bone marrow samples from patients with high 5hmC versus healthy controls, but samples from patients with low 5hmC showed hypomethylation relative to controls at the majority of differentially methylated CpG sites. Our results demonstrate that Tet2 is important for normal myelopoiesis, and suggest that disruption of TET2 enzymatic activity favours myeloid tumorigenesis. Measurement of 5hmC levels in myeloid malignancies may prove valuable as a diagnostic and prognostic tool, to tailor therapies and assess responses to anticancer drugs.	[Ko, Myunggon; Huang, Yun; Pape, Utz J.; Tahiliani, Mamta; Bandukwala, Hozefa S.; An, Jungeun; Lamperti, Edward D.; Koh, Kian Peng; Rao, Anjana] Harvard Univ, Sch Med, Dept Pathol, Immune Dis Inst, Boston, MA 02115 USA; [Ko, Myunggon; Huang, Yun; Pape, Utz J.; Tahiliani, Mamta; Bandukwala, Hozefa S.; An, Jungeun; Lamperti, Edward D.; Koh, Kian Peng; Rao, Anjana] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA; [Jankowska, Anna M.; Ganetzky, Rebecca; Maciejewski, Jaroslaw P.] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH 44195 USA; [Jankowska, Anna M.; Ganetzky, Rebecca; Maciejewski, Jaroslaw P.] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44195 USA; [Pape, Utz J.; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Pape, Utz J.; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; [Agarwal, Suneet] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; [Agarwal, Suneet] Harvard Stem Cell Inst, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Rao, A (corresponding author), La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA.	maciejj@ccf.org; arao@idi.harvard.edu	Koh, Kian Peng/S-6279-2016	Koh, Kian Peng/0000-0003-2523-5175; Huang, Yun/0000-0001-5950-9168; Ko, Myunggon/0000-0002-6007-2570; Aravind, L/0000-0003-0771-253X; Ganetzky, Rebecca/0000-0001-6238-8109	NIH [R01 AI44432, RC1 DA028422, K24 HL077522, R01 HL098522, R01 HG4069]; Aplastic Anemia MDS Foundation; Bob Duggan Memorial Research Fund; Harvard Catalyst; Harvard Clinical and Translational Science Center (NIH) [1 UL1 RR 025758-02]; GlaxoSmithKline-Immune Disease Institute (GSK-IDI) Alliance; Leukemia and Lymphoma Society of America; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD065812] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA042471] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL089150, K24HL077522] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [RC1DA028422] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aplastic Anemia MDS Foundation; Bob Duggan Memorial Research Fund; Harvard Catalyst; Harvard Clinical and Translational Science Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline-Immune Disease Institute (GSK-IDI) Alliance; Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by NIH grants R01 AI44432 and RC1 DA028422 (to A.R.), NIH grants K24 HL077522 and R01 HL098522, an Established Investigator award from the Aplastic Anemia & MDS Foundation, and an award from the Bob Duggan Memorial Research Fund (to J.P.M), NIH grant R01 HG4069 (to X.S.L.) and a pilot grant from Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH Grant #1 UL1 RR 025758-02, to S.A.). Y.H. was supported by postdoctoral fellowships from the GlaxoSmithKline-Immune Disease Institute (GSK-IDI) Alliance and the Leukemia and Lymphoma Society of America. H.S.B. is supported by a postdoctoral fellowship from the GSK-IDI Alliance.	Abdel-Wahab O, 2009, BLOOD, V114, P144, DOI 10.1182/blood-2009-03-210039; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; HAYATSU H, 1979, BIOCHEMISTRY-US, V18, P632, DOI 10.1021/bi00571a013; Huang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008888; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Iyer LM, 2009, CELL CYCLE, V8, P1698, DOI 10.4161/cc.8.11.8580; Jankowska AM, 2009, BLOOD, V113, P6403, DOI 10.1182/blood-2009-02-205690; Jiang Y, 2009, BLOOD, V113, P1315, DOI 10.1182/blood-2008-06-163246; Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; Levine RL, 2009, NEW ENGL J MED, V360, P2355, DOI 10.1056/NEJMe0902257; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Mullighan CG, 2009, NAT GENET, V41, P766, DOI 10.1038/ng0709-766; Smith LT, 2007, TRENDS GENET, V23, P449, DOI 10.1016/j.tig.2007.07.005; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tefferi A, 2009, LEUKEMIA, V23, P1343, DOI 10.1038/leu.2009.59; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Tefferi A, 2009, LEUKEMIA, V23, P900, DOI 10.1038/leu.2009.37; Tefferi A, 2008, LEUKEMIA LYMPHOMA, V49, P2231, DOI 10.1080/10428190802578866; Viguie F, 2005, LEUKEMIA, V19, P1411, DOI 10.1038/sj.leu.2403818; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413	26	983	1032	1	177	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	2010	468	7325					839	843		10.1038/nature09586	http://dx.doi.org/10.1038/nature09586			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691PQ	21057493	Green Accepted			2022-12-28	WOS:000285093700049
J	Hoorn, C; Wesselingh, FP; ter Steege, H; Bermudez, MA; Mora, A; Sevink, J; Sanmartin, I; Sanchez-Meseguer, A; Anderson, CL; Figueiredo, JP; Jaramillo, C; Riff, D; Negri, FR; Hooghiemstra, H; Lundberg, J; Stadler, T; Sarkinen, T; Antonelli, A				Hoorn, C.; Wesselingh, F. P.; ter Steege, H.; Bermudez, M. A.; Mora, A.; Sevink, J.; Sanmartin, I.; Sanchez-Meseguer, A.; Anderson, C. L.; Figueiredo, J. P.; Jaramillo, C.; Riff, D.; Negri, F. R.; Hooghiemstra, H.; Lundberg, J.; Stadler, T.; Saerkinen, T.; Antonelli, A.			Amazonia Through Time: Andean Uplift, Climate Change, Landscape Evolution, and Biodiversity	SCIENCE			English	Review							AMERICAN BIOTIC INTERCHANGE; LATE MIOCENE ONSET; SEA FAN EVIDENCE; RAPID DIVERSIFICATION; MARINE INCURSIONS; WESTERN AMAZONIA; SOUTH-AMERICA; PLANT; SPECIATION; DIVERSITY	The Amazonian rainforest is arguably the most species-rich terrestrial ecosystem in the world, yet the timing of the origin and evolutionary causes of this diversity are a matter of debate. We review the geologic and phylogenetic evidence from Amazonia and compare it with uplift records from the Andes. This uplift and its effect on regional climate fundamentally changed the Amazonian landscape by reconfiguring drainage patterns and creating a vast influx of sediments into the basin. On this "Andean" substrate, a region-wide edaphic mosaic developed that became extremely rich in species, particularly in Western Amazonia. We show that Andean uplift was crucial for the evolution of Amazonian landscapes and ecosystems, and that current biodiversity patterns are rooted deep in the pre-Quaternary.	[Hoorn, C.; Sevink, J.; Hooghiemstra, H.] Univ Amsterdam, IBED, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands; [Wesselingh, F. P.] Nederlands Ctr Biodiversiteit Nat, NL-2300 RA Leiden, Netherlands; [ter Steege, H.] Univ Utrecht, Fac Sci, Dept Biol, Inst Environm Biol, NL-3584 CH Utrecht, Netherlands; [Bermudez, M. A.] Cent Univ Venezuela, Fac Ingn, Escuela Geol Minas & Geofis, Labs Termocronol & Geomatemat, Caracas, Venezuela; [Mora, A.] Inst Colombiano Petroleo, ECOPETROL, Piedecuesta, Santander, Colombia; [Sanmartin, I.; Sanchez-Meseguer, A.; Anderson, C. L.] CSIC, Real Jardin Bot, E-28014 Madrid, Spain; [Figueiredo, J. P.] Petroleo Brasileiro SA Petrobras, BR-20031170 Rio De Janeiro, Brazil; [Jaramillo, C.] Smithsonian Trop Res Inst, Balboa, Panama; [Riff, D.] Univ Fed Uberlandia, Inst Biol, BR-38400902 Uberlandia, MG, Brazil; [Negri, F. R.] Univ Fed Acre, Lab Paleontol, BR-69980000 Acre, AC, Brazil; [Lundberg, J.] Acad Nat Sci Philadelphia, Dept Ichthyol, Philadelphia, PA 19103 USA; [Stadler, T.] ETH, Inst Integrat Biol, CH-8092 Zurich, Switzerland; [Saerkinen, T.] Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; [Antonelli, A.] Univ Zurich, Inst Systemat Bot, CH-8008 Zurich, Switzerland	University of Amsterdam; Utrecht University; University of Central Venezuela; Ecopetrol; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Real Jardin Botanico de Madrid; Petrobras; Smithsonian Institution; Smithsonian Tropical Research Institute; Universidade Federal de Uberlandia; Universidade Federal do Acre (UFAC); Drexel University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Oxford; University of Zurich	Hoorn, C (corresponding author), Univ Amsterdam, IBED, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands.	carina.hoorn@milne.cc; alexandre.antonelli@vgregion.se	Antonelli, Alexandre/ABE-6321-2020; Wesselingh, Frank/C-1367-2018; Riff, Douglas/B-5183-2012; Antonelli, Alexandre/A-5353-2011; Sanmartin, Isabel/G-3131-2015; Steege, Hans ter/B-5866-2011; Stadler, Tanja/J-4742-2013; Figueiredo, Jorge/AAR-8243-2020; Hoorn, Carina/A-9372-2015	Antonelli, Alexandre/0000-0003-1842-9297; Wesselingh, Frank/0000-0003-3655-0701; Riff, Douglas/0000-0003-0805-2828; Antonelli, Alexandre/0000-0003-1842-9297; Sanmartin, Isabel/0000-0001-6104-9658; Steege, Hans ter/0000-0002-8738-2659; Stadler, Tanja/0000-0001-6431-535X; Figueiredo, Jorge/0000-0002-6989-7456; Hoorn, Carina/0000-0001-5402-6191; jaramillo, carlos/0000-0002-2616-5079; Bermudez, Mauricio A/0000-0003-0584-4790; Sanchez Meseguer, Andrea/0000-0003-0743-404X	Osk. Huttunen Foundation; Ella and Georg Ehrnrooth Fund; Helsingin Sanomain Saatio; Academy of Sciences of Finland	Osk. Huttunen Foundation; Ella and Georg Ehrnrooth Fund; Helsingin Sanomain Saatio; Academy of Sciences of Finland(Academy of Finland)	We thank all colleagues who shared their data; M. F. Tognelli for mammal richness data; and B. P. Kohn, M. Bernet, P. van der Beek, R. T. Pennington, S. B. Kroonenberg, B. Bookhagen, C. Uba, and three anonymous reviewers for constructive comments on the manuscript. Supported by the Osk. Huttunen Foundation, the Ella and Georg Ehrnrooth Fund, and the Helsingin Sanomain Saatio (T.S.) and by the Academy of Sciences of Finland (F.P.W.).	Aalto R, 2006, J GEOL, V114, P85, DOI 10.1086/498101; Albert JS, 2006, J S AM EARTH SCI, V21, P14, DOI 10.1016/j.jsames.2005.07.010; Antonelli A, 2009, P NATL ACAD SCI USA, V106, P9749, DOI 10.1073/pnas.0811421106; Bermudez MA, 2010, TECTONICS, V29, DOI 10.1029/2009TC002635; Brumfield RT, 2007, EVOLUTION, V61, P346, DOI 10.1111/j.1558-5646.2007.00039.x; BUSH MB, 1994, J BIOGEOGR, V21, P5, DOI 10.2307/2845600; Campbell KE, 2004, PALEOGENE MAMMALIAN; COATES AG, 1992, GEOL SOC AM BULL, V104, P814, DOI 10.1130/0016-7606(1992)104<0814:COTIOP>2.3.CO;2; Cody S, 2010, ECOGRAPHY, V33, P326, DOI 10.1111/j.1600-0587.2010.06327.x; Costa JBS, 2001, J S AM EARTH SCI, V14, P335, DOI 10.1016/S0895-9811(01)00025-6; da Silva-Caminha SAF, 2010, PALAEONTOGR ABT B, V284, P13, DOI 10.1127/palb/284/2010/13; de Aguiar MAM, 2009, NATURE, V460, P384, DOI 10.1038/nature08168; De Carvalho Marcelo R., 2004, Bulletin of the American Museum of Natural History, V284, P1, DOI 10.1206/0003-0090(2004)284<0001:FSOTGR>2.0.CO;2; Erkens RHJ, 2007, MOL PHYLOGENET EVOL, V44, P399, DOI 10.1016/j.ympev.2007.02.017; Figueiredo J, 2010, GEOLOGY, V38, pE213, DOI 10.1130/G31057Y.1; Figueiredo J, 2009, GEOLOGY, V37, P619, DOI 10.1130/G25567A.1; Finarelli JA, 2010, P ROY SOC B-BIOL SCI, V277, P2721, DOI 10.1098/rspb.2010.0348; Fine PVA, 2005, EVOLUTION, V59, P1464; GENTRY AH, 1982, ANN MO BOT GARD, V69, P557, DOI 10.2307/2399084; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Hayes FE, 2004, J BIOGEOGR, V31, P1809, DOI 10.1111/j.1365-2699.2004.01139.x; HOORN C, 1993, PALAEOGEOGR PALAEOCL, V105, P267, DOI 10.1016/0031-0182(93)90087-Y; Hoorn C, 2010, AMAZONIA: LANDSCAPE AND SPECIES EVOLUTION: A LOOK INTO THE PAST, P123; Horton BK, 2001, BASIN RES, V13, P43, DOI 10.1046/j.1365-2117.2001.00137.x; Hovikoski J, 2007, GEOL SOC AM BULL, V119, P1506, DOI 10.1130/0016-7606(2007)119[1506:TNOMAE]2.0.CO;2; Hughes C, 2006, P NATL ACAD SCI USA, V103, P10334, DOI 10.1073/pnas.0601928103; Insel N, 2009, CLIM DYN; ISACKS BL, 1988, J GEOPHYS RES-SOLID, V93, P3211, DOI 10.1029/JB093iB04p03211; Jaramillo C, 2006, SCIENCE, V311, P1893, DOI 10.1126/science.1121380; Kaandorp RJG, 2005, PALAEOGEOGR PALAEOCL, V221, P1, DOI 10.1016/j.palaeo.2004.12.024; Kohn MJ, 2008, GEOLOGY, V36, P783, DOI 10.1130/G24928A.1; Latrubesse EM, 2010, EARTH-SCI REV, V99, P99, DOI 10.1016/j.earscirev.2010.02.005; Lovejoy NR, 2006, J S AM EARTH SCI, V21, P5, DOI 10.1016/j.jsames.2005.07.009; Lundberg John G., 1998, P13; MacFadden BJ, 2006, TRENDS ECOL EVOL, V21, P157, DOI 10.1016/j.tree.2005.12.003; Malabarba MC, 2010, J VERTEBR PALEONTOL, V30, P341, DOI 10.1080/02724631003618348; Mapes Russell W., 2009, THESIS U N CAROLINA; Marshall L.G., 1990, Palaeovertebrata (Montpellier), V19, P169; Mcclain ME, 2008, BIOSCIENCE, V58, P325, DOI 10.1641/B580408; Mora A, 2010, AMAZONIA: LANDSCAPE AND SPECIES EVOLUTION: A LOOK INTO THE PAST, P38; NEGRI, 2004, THESIS PONTIFICIA U; NELSON BW, 1990, NATURE, V345, P714, DOI 10.1038/345714a0; Noonan BP, 2006, AM NAT, V168, P730, DOI 10.1086/509052; Pennington RT, 2004, PHILOS T R SOC B, V359, P1611, DOI 10.1098/rstb.2004.1532; Pons D, 2007, B GEOSCI, V82, P343, DOI 10.3140/bull.geosci.2007.04.343; Potter PE, 2009, EARTH-SCI REV, V96, P279, DOI 10.1016/j.earscirev.2009.07.003; Poulsen CJ, 2010, SCIENCE, V328, P490, DOI 10.1126/science.1185078; Quesada C. A., 2009, BIOGEOSCIENCES DISCU, V6, P3923, DOI DOI 10.5194/bgd-6-3923-2009; Renema W, 2008, SCIENCE, V321, P654, DOI 10.1126/science.1155674; Renner S, 2004, INT J PLANT SCI, V165, pS23, DOI 10.1086/383334; Richardson JE, 2001, SCIENCE, V293, P2242, DOI 10.1126/science.1061421; Riff D, 2010, AMAZONIA: LANDSCAPE AND SPECIES EVOLUTION: A LOOK INTO THE PAST, P259; Roddaz M, 2010, AMAZONIA: LANDSCAPE AND SPECIES EVOLUTION: A LOOK INTO THE PAST, P61; Rull V, 2008, MOL ECOL, V17, P2722, DOI 10.1111/j.1365-294X.2008.03789.x; Sanmartin I, 2004, SYST BIOL, V53, P216, DOI 10.1080/10635150490423430; SANTOS JC, 2009, PLOS BIOL, V460; Smith BT, 2010, ECOGRAPHY, V33, P333, DOI 10.1111/j.1600-0587.2009.06335.x; Strecker MR, 2009, GEOLOGY, V37, P643, DOI 10.1130/G25545A.1; ter Steege H, 2010, AMAZONIA: LANDSCAPE AND SPECIES EVOLUTION: A LOOK INTO THE PAST, P349; Tognelli MF, 2004, ECOGRAPHY, V27, P427, DOI 10.1111/j.0906-7590.2004.03732.x; Toivonen T, 2007, J BIOGEOGR, V34, P1374, DOI 10.1111/j.1365-2699.2007.01741.x; Uba CE, 2007, GEOLOGY, V35, P979, DOI 10.1130/G224025A.1; VIZCAINO SF, 1995, ANTARCT SCI, V7, P407, DOI 10.1017/S0954102095000563; Vonhof HB, 2003, GEOL SOC AM BULL, V115, P983, DOI 10.1130/B25058.1; Wanderley JR, 2010, AMAZONIA: LANDSCAPE AND SPECIES EVOLUTION: A LOOK INTO THE PAST, P29; Weir JT, 2009, P NATL ACAD SCI USA, V106, P21737, DOI 10.1073/pnas.0903811106; Wesselingh F.P., 2006, Scripta Geologica (Leiden), V133, P439; Zachos JC, 2008, NATURE, V451, P279, DOI 10.1038/nature06588	68	1430	1485	28	661	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2010	330	6006					927	931		10.1126/science.1194585	http://dx.doi.org/10.1126/science.1194585			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071659	Green Accepted, Green Submitted			2022-12-28	WOS:000284118000031
J	Bijl, PK; Houben, AJP; Schouten, S; Bohaty, SM; Sluijs, A; Reichart, GJ; Damste, JSS; Brinkhuis, H				Bijl, Peter K.; Houben, Alexander J. P.; Schouten, Stefan; Bohaty, Steven M.; Sluijs, Appy; Reichart, Gert-Jan; Damste, Jaap S. Sinninghe; Brinkhuis, Henk			Transient Middle Eocene Atmospheric CO2 and Temperature Variations	SCIENCE			English	Article							OLIGOCENE CLIMATE TRANSITION; CARBON-DIOXIDE; PALEOGENE; PACIFIC; GREENHOUSE; TRENDS; OCEAN; TOOL	The long-term warmth of the Eocene (similar to 56 to 34 million years ago) is commonly associated with elevated partial pressure of atmospheric carbon dioxide (pCO(2)). However, a direct relationship between the two has not been established for short-term climate perturbations. We reconstructed changes in both pCO(2) and temperature over an episode of transient global warming called the Middle Eocene Climatic Optimum (MECO; similar to 40 million years ago). Organic molecular paleothermometry indicates a warming of southwest Pacific sea surface temperatures (SSTs) by 3 to 6 degrees C. Reconstructions of pCO(2) indicate a concomitant increase by a factor of 2 to 3. The marked consistency between SST and pCO(2) trends during the MECO suggests that elevated pCO(2) played a major role in global warming during the MECO.	[Bijl, Peter K.; Houben, Alexander J. P.; Sluijs, Appy; Brinkhuis, Henk] Univ Utrecht, Palaeobot & Palynol Lab, Fac Sci, Inst Environm Biol, NL-3584 CD Utrecht, Netherlands; [Schouten, Stefan; Damste, Jaap S. Sinninghe] NIOZ Royal Netherlands Inst Sea Res, Dept Marine Organ Biogeochem, NL-1790 AB Den Burg, Texel, Netherlands; [Bohaty, Steven M.] Univ Southampton, Natl Oceanog Ctr, Sch Ocean & Earth Sci, Southampton SO14 3ZH, Hants, England; [Reichart, Gert-Jan; Damste, Jaap S. Sinninghe] Univ Utrecht, Fac Geosci, Dept Earth Sci, NL-3584 CD Utrecht, Netherlands	Utrecht University; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); NERC National Oceanography Centre; University of Southampton; Utrecht University	Bijl, PK (corresponding author), Univ Utrecht, Palaeobot & Palynol Lab, Fac Sci, Inst Environm Biol, Budapestlaan 4, NL-3584 CD Utrecht, Netherlands.	p.k.bijl@uu.nl; a.j.p.houben@uu.nl	Damste, Jaap S Sinninghe/F-6128-2011; Reichart, Gert-Jan/N-6308-2018; Sluijs, Appy/B-3726-2009; Brinkhuis, Henk/B-4223-2009	Damste, Jaap S Sinninghe/0000-0002-8683-1854; Reichart, Gert-Jan/0000-0002-7256-2243; Sluijs, Appy/0000-0003-2382-0215; Houben, Alexander/0000-0002-9497-1048; Bijl, Peter/0000-0002-1710-4012; Brinkhuis, Henk/0000-0003-0253-6610	NSF; Utrecht University; LPP foundation; Statoil; Netherlands Organization for Scientific Research [863.07.001]; European Community [259627]; NERC [NE/G003270/1] Funding Source: UKRI; Natural Environment Research Council [NE/G003270/1] Funding Source: researchfish	NSF(National Science Foundation (NSF)); Utrecht University; LPP foundation; Statoil; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); European Community(European Commission); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This research used samples and data provided by the Ocean Drilling Program (ODP) sponsored by NSF and participating countries under the management of Joint Oceanographic Institutions Inc. We thank Utrecht University and the LPP foundation (P. K. B.), Statoil (A. J. P. H.), and the Netherlands Organization for Scientific Research (Vici grant to S. S.; Veni grant 863.07.001 to A. S.) for financial support. A. S. acknowledges the European Research Council under the European Community's Seventh Framework Program for ERC Starting Grant 259627. Groundwork for this research was provided at the Urbino Summer School of Paleoclimatology. We thank N. Welters, J. van Tongeren, J. Ossebaar, E. Hopmans, M. Kienhuis, G. Nobbe, E. van Bentum, E. Speelman, and E. van Soelen for technical support and M. Pagani, C. Stickley, J. Zachos, and two anonymous reviewers for invaluable discussions and comments.	Aitchison JC, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004706; Bijl PK, 2009, NATURE, V461, P776, DOI 10.1038/nature08399; Bohaty SM, 2003, GEOLOGY, V31, P1017, DOI 10.1130/G19800.1; Bohaty SM, 2009, PALEOCEANOGRAPHY, V24, DOI 10.1029/2008PA001676; BRASSELL SC, 1986, NATURE, V320, P129, DOI 10.1038/320129a0; BRINKHUIS H, 2003, P OCEAN DRILLING PRO, V0189; Burgess CE, 2008, GEOLOGY, V36, P651, DOI 10.1130/G24762A.1; Dupont-Nivet G, 2008, GEOLOGY, V36, P987, DOI 10.1130/G25063A.1; Exon N. F., 2003, P OCEAN DRILLING PRO, V189; Exon N.F., 2004, GEOPHYS MONOGR SER, V151, P367, DOI [10.1029/GM151, DOI 10.1029/GM151]; Hollis CJ, 2009, GEOLOGY, V37, P99, DOI 10.1130/G25200A.1; Huber M, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2004PA001014; Kent DV, 2008, P NATL ACAD SCI USA, V105, P16065, DOI 10.1073/pnas.0805382105; Liu ZH, 2009, SCIENCE, V323, P1187, DOI 10.1126/science.1166368; Pagani M, 2005, SCIENCE, V309, P600, DOI 10.1126/science.1110063; Pagani M, 2002, PHILOS T ROY SOC A, V360, P609, DOI 10.1098/rsta.2001.0959; Pagani M, 2010, NAT GEOSCI, V3, P27, DOI 10.1038/NGEO724; Pearson PN, 2009, NATURE, V461, P1110, DOI 10.1038/nature08447; Pearson PN, 2001, NATURE, V413, P481, DOI 10.1038/35097000; Rohl U, 2004, GEOPH MONOG SERIES, V151, P127; Rost B, 2002, LIMNOL OCEANOGR, V47, P120, DOI 10.4319/lo.2002.47.1.0120; Schouten S, 2002, EARTH PLANET SC LETT, V204, P265, DOI 10.1016/S0012-821X(02)00979-2; Sluijs A, 2005, EARTH-SCI REV, V68, P281, DOI 10.1016/j.earscirev.2004.06.001; STICKLEY CE, 2003, P OCEAN DRILLING PRO, V189, P1; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; Zachos JC, 2008, NATURE, V451, P279, DOI 10.1038/nature06588	26	137	142	1	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					819	821		10.1126/science.1193654	http://dx.doi.org/10.1126/science.1193654			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051636	Green Published			2022-12-28	WOS:000283855700042
J	Pearson, PN				Pearson, Paul N.			Increased Atmospheric CO2 During the Middle Eocene	SCIENCE			English	Editorial Material									Cardiff Univ, Sch Earth & Ocean Sci, Cardiff CF10 3YE, S Glam, Wales	Cardiff University	Pearson, PN (corresponding author), Cardiff Univ, Sch Earth & Ocean Sci, Cardiff CF10 3YE, S Glam, Wales.	pearsonp@cardiff.ac.uk	Pearson, Paul N/B-2276-2009	Pearson, Paul N/0000-0003-4628-9818				Bijl PK, 2010, SCIENCE, V330, P819, DOI 10.1126/science.1193654; Bohaty SM, 2003, GEOLOGY, V31, P1017, DOI 10.1130/G19800.1; Bohaty SM, 2009, PALEOCEANOGRAPHY, V24, DOI 10.1029/2008PA001676; Pagani M, 2002, PHILOS T ROY SOC A, V360, P609, DOI 10.1098/rsta.2001.0959; Pearson PN, 2009, NATURE, V461, P1110, DOI 10.1038/nature08447; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	6	12	13	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2010	330	6005					763	764		10.1126/science.1197894	http://dx.doi.org/10.1126/science.1197894			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051620				2022-12-28	WOS:000283855700024
J	Burden, AD; Boon, MH; Leman, J; Wilson, H; Richmond, R; Ormerod, AD				Burden, A. D.; Boon, M. Hilton; Leman, J.; Wilson, H.; Richmond, R.; Ormerod, A. D.		Guideline Dev Grp	Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material							MYOCARDIAL-INFARCTION; EPIDEMIOLOGY; DISEASES; RISK		[Boon, M. Hilton] Scottish Intercollegiate Guidelines Network, Glasgow, Lanark, Scotland; [Burden, A. D.] Univ Glasgow, Western Infirm, Alan Lyell Ctr Dermatol, Glasgow G11 6NT, Lanark, Scotland; [Leman, J.] Western Infirm & Associated Hosp, Glasgow G11 6NT, Lanark, Scotland; [Wilson, H.] Stobhill Hosp, Glasgow G21 3UW, Lanark, Scotland; [Richmond, R.] Borders Gen Hosp, Melrose TD6 9BS, Roxburghshire, Scotland; [Ormerod, A. D.] Univ Aberdeen, Dept Appl Med, Aberdeen AB9 1FX, Scotland; [Ormerod, A. D.] Aberdeen Royal Infirm, Aberdeen AB25 2ZN, Scotland	University of Glasgow; University of Aberdeen; University of Aberdeen	Boon, MH (corresponding author), Scottish Intercollegiate Guidelines Network, Glasgow, Lanark, Scotland.	michele.hiltonboon@nhs.net	Ozakinci, Gozde/B-7897-2012; Boon, Michele Hilton/AAB-8745-2021	Ozakinci, Gozde/0000-0001-5869-3274; Boon, Michele Hilton/0000-0002-2240-7923	Janssen-Cilag; Merck; Serono; Schering-Plough; Abbott; Pfizer; Wyeth	Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Serono; Schering-Plough(Merck & CompanySchering Plough Corporation); Abbott(Abbott Laboratories); Pfizer(Pfizer); Wyeth(Wyeth)	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no funding from any organisation for the submitted work; ADB has been paid for consultancy and delivering lectures for Abbott, Pfizer, MSD, Janssen-Cilag, Leo, and Basilea and does consultancy for Merck and Novartis; MHB is employed by SIGN; JL was paid to attend one Abbott Advisory Board meeting and to deliver postgraduate education by Leo, has received meeting expenses from Pfizer, and has undertaken trials funded by Janssen-Cilag, Merck, Serono, Schering-Plough, Abbott, and Pfizer; HW has been paid to provide expert testimony to the Psoriatic Arthritis Advisory Panel and to develop and deliver a Wyeth educational presentation, and has received expenses from Abbott to attend one conference; HW's institution will receive payment for participating in a study of the validity of the PEST questionnaire; RR received travel costs and a conference registration fee from Wyeth; ADO was paid to attend one Abbott advisory board meeting, one Schering-Plough advisory board meeting, and to deliver lectures for Wyeth and Abbott, and received expenses to attend one conference from Wyeth and one conference from Janssen-Cilag; ADO's institution has received grants to conduct clinical trials of biologics for Abbott, Wyeth, Schering-Plough, and Janssen-Cilag; no other relationships or activities that could appear to have influenced the submitted work.	Gelfand JM, 2006, JAMA-J AM MED ASSOC, V296, P1735, DOI 10.1001/jama.296.14.1735; Ibrahim GH, 2009, CLIN EXP RHEUMATOL, V27, P469; Kaye JA, 2008, BRIT J DERMATOL, V159, P895, DOI 10.1111/j.1365-2133.2008.08707.x; Kimball AB, 2005, AM J CLIN DERMATOL, V6, P383, DOI 10.2165/00128071-200506060-00005; Neimann AL, 2006, J AM ACAD DERMATOL, V55, P829, DOI 10.1016/j.jaad.2006.08.040; Rapp SR, 1999, J AM ACAD DERMATOL, V41, P401, DOI 10.1016/S0190-9622(99)70112-X; Reich K, 2009, BRIT J DERMATOL, V160, P1040, DOI 10.1111/j.1365-2133.2008.09023.x; SIGN, 2010, 121 SIGN	8	32	34	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 29	2010	341								c5623	10.1136/bmj.c5623	http://dx.doi.org/10.1136/bmj.c5623			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674ZN	21036815	Green Submitted			2022-12-28	WOS:000283792500001
J	Halfmann, R; Lindquist, S				Halfmann, Randal; Lindquist, Susan			Epigenetics in the Extreme: Prions and the Inheritance of Environmentally Acquired Traits	SCIENCE			English	Editorial Material							YEAST; EVOLUTION; FORM	Prions are an unusual form of epigenetics: Their stable inheritance and complex phenotypes come about through protein folding rather than nucleic acid-associated changes. With intimate ties to protein homeostasis and a remarkable sensitivity to stress, prions are a robust mechanism that links environmental extremes with the acquisition and inheritance of new traits.	[Halfmann, Randal; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Halfmann, Randal; Lindquist, Susan] MIT, Dept Biol, Cambridge, MA 02139 USA; [Lindquist, Susan] Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute	Lindquist, S (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lindquist_admin@wi.mit.edu		Halfmann, Randal/0000-0002-6592-1471	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		Aguzzi A, 2009, PHYSIOL REV, V89, P1105, DOI 10.1152/physrev.00006.2009; Alberti S, 2009, CELL, V137, P146, DOI 10.1016/j.cell.2009.02.044; Brown JCS, 2009, GENE DEV, V23, P2320, DOI 10.1101/gad.1839109; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Derdowski A, 2010, SCIENCE, V330, P680, DOI 10.1126/science.1197785; Du ZQ, 2008, NAT GENET, V40, P460, DOI 10.1038/ng.112; Eigen M, 1996, BIOPHYS CHEM, V63, pA1, DOI 10.1016/S0301-4622(96)02250-8; Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; Halfmann R, 2010, TRENDS CELL BIOL, V20, P125, DOI 10.1016/j.tcb.2009.12.003; Hogan DJ, 2008, PLOS BIOL, V6, P2297, DOI 10.1371/journal.pbio.0060255; Jablonka E, 2009, Q REV BIOL, V84, P131, DOI 10.1086/598822; Koonin EV, 2009, BIOL DIRECT, V4, DOI 10.1186/1745-6150-4-42; Lancaster AK, 2010, GENETICS, V184, P393, DOI 10.1534/genetics.109.110213; Masel J, 2009, TRENDS GENET, V25, P395, DOI 10.1016/j.tig.2009.07.005; Namy O, 2008, NAT CELL BIOL, V10, P1069, DOI 10.1038/ncb1766; Patel BK, 2009, NAT CELL BIOL, V11, P344, DOI 10.1038/ncb1843; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Rando OJ, 2007, CELL, V128, P655, DOI 10.1016/j.cell.2007.01.023; Rogoza T, 2010, P NATL ACAD SCI USA, V107, P10573, DOI 10.1073/pnas.1005949107; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Saupe SJ, 2007, PRION, V1, P110, DOI 10.4161/pri.1.2.4666; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Shkundina IS, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1519, DOI 10.1134/S0006297907130081; Si K, 2010, CELL, V140, P421, DOI 10.1016/j.cell.2010.01.008; True HL, 2004, NATURE, V431, P184, DOI 10.1038/nature02885; Tyedmers J, 2008, PLOS BIOL, V6, P2605, DOI 10.1371/journal.pbio.0060294; Uversky VN, 2009, FRONT BIOSCI-LANDMRK, V14, P5188, DOI 10.2741/3594; Weissman DB, 2009, THEOR POPUL BIOL, V75, P286, DOI 10.1016/j.tpb.2009.02.006; West-Eberhard Mary Jane, 2003, pi	31	163	166	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					629	632		10.1126/science.1191081	http://dx.doi.org/10.1126/science.1191081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030648				2022-12-28	WOS:000283580600036
J	Lastoskie, C				Lastoskie, Christian			Caging Carbon Dioxide	SCIENCE			English	Editorial Material							METAL-ORGANIC FRAMEWORKS; CO2 CAPTURE; ADSORPTION		Univ Michigan, Dept Civil & Environm Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lastoskie, C (corresponding author), Univ Michigan, Dept Civil & Environm Engn, Ann Arbor, MI 48109 USA.	cmlasto@umich.edu						Aaron D, 2005, SEP SCI TECHNOL, V40, P321, DOI 10.1081/SS-200042244; Campana C, 2009, J CHEM THEORY COMPUT, V5, P2866, DOI 10.1021/ct9003405; Chen DL, 2010, J PHYS CHEM A, V114, P10225, DOI 10.1021/jp103944q; Cole DR, 2010, PHILOS MAG, V90, P2339, DOI 10.1080/14786430903559458; Dubbeldam D, 2007, ANGEW CHEM INT EDIT, V46, P4496, DOI 10.1002/anie.200700218; Greathouse JA, 2008, J PHYS CHEM C, V112, P5795, DOI 10.1021/jp076853w; Kanoh H, 2009, J COLLOID INTERF SCI, V334, P1, DOI 10.1016/j.jcis.2009.03.020; Keskin S, 2010, CHEMSUSCHEM, V3, P879, DOI 10.1002/cssc.201000114; Klara J, 2007, DOENETL20071281; Krishna R, 2010, J MEMBRANE SCI, V360, P323, DOI 10.1016/j.memsci.2010.05.032; Millward AR, 2005, J AM CHEM SOC, V127, P17998, DOI 10.1021/ja0570032; Mindrup EM, 2010, CHEMSUSCHEM, V3, P931, DOI 10.1002/cssc.201000060; Morris W, 2010, J AM CHEM SOC, V132, P11006, DOI 10.1021/ja104035j; Tenney CM, 2006, ENVIRON PROG, V25, P343, DOI 10.1002/ep.10168; Torrisi A, 2010, CRYST GROWTH DES, V10, P2839, DOI 10.1021/cg100646e; Vaidhyanathan R, 2010, SCIENCE, V330, P650, DOI 10.1126/science.1194237; Xiang ZH, 2010, ENERG ENVIRON SCI, V3, P1469, DOI 10.1039/c0ee00049c; Yazaydin AO, 2009, CHEM MATER, V21, P1425, DOI 10.1021/cm900049x	18	73	74	7	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					595	596		10.1126/science.1198066	http://dx.doi.org/10.1126/science.1198066			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030635				2022-12-28	WOS:000283580600023
J	Law, MJ; Lower, KM; Voon, HPJ; Hughes, JR; Garrick, D; Viprakasit, V; Mitson, M; De Gobbi, M; Marra, M; Morris, A; Abbott, A; Wilder, SP; Taylor, S; Santos, GM; Cross, J; Ayyub, H; Jones, S; Ragoussis, J; Rhodes, D; Dunham, I; Higgs, DR; Gibbons, RJ				Law, Martin J.; Lower, Karen M.; Voon, Hsiao P. J.; Hughes, Jim R.; Garrick, David; Viprakasit, Vip; Mitson, Matthew; De Gobbi, Marco; Marra, Marco; Morris, Andrew; Abbott, Aaron; Wilder, Steven P.; Taylor, Stephen; Santos, Guilherme M.; Cross, Joe; Ayyub, Helena; Jones, Steven; Ragoussis, Jiannis; Rhodes, Daniela; Dunham, Ian; Higgs, Douglas R.; Gibbons, Richard J.			ATR-X Syndrome Protein Targets Tandem Repeats and Influences Allele-Specific Expression in a Size-Dependent Manner	CELL			English	Article							LINKED MENTAL-RETARDATION; CHROMATIN IMMUNOPRECIPITATION; HISTONE CHAPERONE; MUTATIONS; LOCALIZATION; DAXX; HETEROCHROMATIN; QUADRUPLEXES; BINDING; GENES	ATRX is an X-linked gene of the SWI/SNF family, mutations in which cause syndromal mental retardation and downregulation of a-globin expression. Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression. This reveals the characteristics of the affected genes, explains the variable phenotypes seen with identical ATRX mutations, and illustrates a new mechanism underlying variable penetrance. Many of the TRs are G rich and predicted to form non-B DNA structures (including G-quadruplex) in vivo. We show that ATRX binds G-quadruplex structures in vitro, suggesting a mechanism by which ATRX may play a role in various nuclear processes and how this is perturbed when ATRX is mutated.	[Law, Martin J.; Lower, Karen M.; Voon, Hsiao P. J.; Hughes, Jim R.; Garrick, David; Mitson, Matthew; De Gobbi, Marco; Cross, Joe; Ayyub, Helena; Higgs, Douglas R.; Gibbons, Richard J.] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England; [Taylor, Stephen] John Radcliffe Hosp, Weatherall Inst Mol Med, Computat Biol Res Grp, Oxford OX3 9DS, England; [Viprakasit, Vip] Mahidol Univ, Siriaj Hosp, Fac Med, Dept Paediat, Bangkok 10700, Thailand; [Morris, Andrew; Abbott, Aaron; Ragoussis, Jiannis] Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Wilder, Steven P.; Dunham, Ian] European Bioinformat Inst, Cambridge CB10 1SD, England; [Santos, Guilherme M.; Rhodes, Daniela] MRC, Struct Studies Div, Mol Biol Lab, Cambridge CB2 0QH, England; [Marra, Marco; Jones, Steven] Univ British Columbia, BCCA Genome Sci Ctr, Vancouver, BC V6T 1Z4, Canada	University of Oxford; University of Oxford; Mahidol University; University of Oxford; Wellcome Centre for Human Genetics; European Molecular Biology Laboratory (EMBL); MRC Laboratory Molecular Biology; University of British Columbia	Gibbons, RJ (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Mol Haematol Unit, Oxford OX3 9DS, England.	richard.gibbons@imm.ox.ac.uk	Ragoussis, Ioannis/AAD-9790-2022; Marra, Marco A/B-5987-2008; GARRICK, David/O-5734-2019; De Gobbi, Marco/E-8136-2013; Jones, Steven J/C-3621-2009; Garrick, David/F-1728-2017; Voon, Hsiao/G-9264-2014; Gibbons, Richard/E-6937-2011	Marra, Marco A/0000-0001-7146-7175; GARRICK, David/0000-0001-7422-7986; Jones, Steven J/0000-0003-3394-2208; Garrick, David/0000-0001-7422-7986; Voon, Hsiao/0000-0002-7179-6611; Dunham, Ian/0000-0003-2525-5598; De Gobbi, Marco/0000-0003-4261-7642; Cross, Joe Wilson/0000-0003-4814-7098; Wilder, Steven/0000-0001-8049-2559; Santos, Guilherme/0000-0003-1489-2161; Higgs, Douglas/0000-0003-3579-8705; Ragoussis, Ioannis/0000-0002-8515-0934; Gibbons, Richard/0000-0002-7680-9311; Lower, Karen/0000-0003-2196-5234	Medical Research Council; National Institute of Health Biomedical Research Centre; Thailand Research Fund (TRF); BIOTEC, Thailand; Oxford University; Medical Research Council [MC_U137961147, G1000801j, MC_U105184333, G1000801b] Funding Source: researchfish; MRC [MC_U137961147, MC_U105184333] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute of Health Biomedical Research Centre; Thailand Research Fund (TRF)(Thailand Research Fund (TRF)); BIOTEC, Thailand; Oxford University; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the members of the families studied for their participation; S. Butler and J. Sloane-Stanley for tissue culture; C. Wippo, J. Huddleston, and L. Marcelline for genotyping; P. Vathesatogkit and R. Totong for SNP validation; A. Goriely for assistance with pyrosequencing; C. Bachrati for gel-shift probes; and W. Wood for critical reading of the manuscript. In addition to others, the work was supported by the Medical Research Council and the National Institute of Health Biomedical Research Centre Programme. V.V. is supported by Thailand Research Fund (TRF) and BIOTEC, Thailand. K.M.L. was supported by an Oxford Nuffield Medical Fellowship, Oxford University.	Argentaro A, 2007, P NATL ACAD SCI USA, V104, P11939, DOI 10.1073/pnas.0704057104; Bachrati CZ, 2006, METHOD ENZYMOL, V409, P86, DOI 10.1016/S0076-6879(05)09005-1; Bacolla A, 2009, MOL CARCINOGEN, V48, P273, DOI 10.1002/mc.20507; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; De Gobbi M, 2007, BLOOD, V110, P4503, DOI 10.1182/blood-2007-06-097964; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Drane P, 2010, GENE DEV, V24, P1253, DOI 10.1101/gad.566910; FIBACH E, 1991, INT J CELL CLONING, V9, P57, DOI 10.1002/stem.5530090108; Flaus A, 2006, NUCLEIC ACIDS RES, V34, P2887, DOI 10.1093/nar/gkl295; Gibbons RJ, 2008, HUM MUTAT, V29, P796, DOI 10.1002/humu.20734; GIBBONS RJ, 1991, J MED GENET, V28, P729, DOI 10.1136/jmg.28.11.729; GIBBONS RJ, 1992, AM J HUM GENET, V51, P1136; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; GIRALDO R, 1994, P NATL ACAD SCI USA, V91, P7658, DOI 10.1073/pnas.91.16.7658; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Higgs DR, 1998, SEMIN HEMATOL, V35, P93; Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kernohan KD, 2010, DEV CELL, V18, P191, DOI 10.1016/j.devcel.2009.12.017; Kourmouli N, 2005, BIOCHEM BIOPH RES CO, V337, P901, DOI 10.1016/j.bbrc.2005.09.132; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; Lipps HJ, 2009, TRENDS CELL BIOL, V19, P414, DOI 10.1016/j.tcb.2009.05.002; McDowell TL, 1999, P NATL ACAD SCI USA, V96, P13983, DOI 10.1073/pnas.96.24.13983; Paramasivan S, 2007, METHODS, V43, P324, DOI 10.1016/j.ymeth.2007.02.009; Rhead B, 2010, NUCLEIC ACIDS RES, V38, pD613, DOI 10.1093/nar/gkp939; Ribeyre C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000475; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Schneiderman JI, 2009, P NATL ACAD SCI USA, V106, P14472, DOI 10.1073/pnas.0905816106; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WILKIE AOM, 1990, AM J HUM GENET, V46, P1127; Wong LH, 2010, GENOME RES, V20, P351, DOI 10.1101/gr.101477.109; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100	37	287	298	4	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					367	378		10.1016/j.cell.2010.09.023	http://dx.doi.org/10.1016/j.cell.2010.09.023			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029860	Bronze			2022-12-28	WOS:000283603900011
J	Mollner, AK; Valluvadasan, S; Feng, L; Sprague, MK; Okumura, M; Milligan, DB; Bloss, WJ; Sander, SP; Martien, PT; Harley, RA; McCoy, AB; Carter, WPL				Mollner, Andrew K.; Valluvadasan, Sivakumaran; Feng, Lin; Sprague, Matthew K.; Okumura, Mitchio; Milligan, Daniel B.; Bloss, William J.; Sander, Stanley P.; Martien, Philip T.; Harley, Robert A.; McCoy, Anne B.; Carter, William P. L.			Rate of Gas Phase Association of Hydroxyl Radical and Nitrogen Dioxide	SCIENCE			English	Article							PRESSURE-DEPENDENCE; CIS-CIS; TEMPERATURE; KINETICS; OH; SPECTROSCOPY; UNCERTAINTY; REACTIVITY; ABSORPTION; OH+NO2	The reaction of OH and NO2 to form gaseous nitric acid (HONO2) is among the most influential in atmospheric chemistry. Despite its importance, the rate coefficient remains poorly determined under tropospheric conditions because of difficulties in making laboratory rate measurements in air at 760 torr and uncertainties about a secondary channel producing peroxynitrous acid (HOONO). We combined two sensitive laser spectroscopy techniques to measure the overall rate of both channels and the partitioning between them at 25 degrees C and 760 torr. The result is a significantly more precise value of the rate constant for the HONO2 formation channel, 9.2 (+/- 0.4) x 10(-12) cm(3) molecule(-1) s(-1) (1 SD) at 760 torr of air, which lies toward the lower end of the previously established range. We demonstrate the impact of the revised value on photochemical model predictions of ozone concentrations in the Los Angeles airshed.	[Mollner, Andrew K.; Feng, Lin; Sprague, Matthew K.; Okumura, Mitchio] CALTECH, Div Chem & Chem Engn, Arthur Amos Noyes Lab Chem Phys, Pasadena, CA 91125 USA; [Valluvadasan, Sivakumaran; Milligan, Daniel B.; Bloss, William J.; Sander, Stanley P.] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; [Martien, Philip T.; Harley, Robert A.] Univ Calif Berkeley, Dept Civil & Environm Engn, Berkeley, CA 94720 USA; [McCoy, Anne B.] Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; [Carter, William P. L.] Univ Calif Riverside, Ctr Environm Res & Technol, Coll Engn, Riverside, CA 92521 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Berkeley; University System of Ohio; Ohio State University; University of California System; University of California Riverside	Okumura, M (corresponding author), CALTECH, Div Chem & Chem Engn, Arthur Amos Noyes Lab Chem Phys, Pasadena, CA 91125 USA.	mo@caltech.edu; stanley.p.sander@jpl.nasa.gov; harley@ce.berkeley.edu; mccoy@chemistry.ohio-state.edu; wpcarter@ucr.edu	Bloss, William J/N-1305-2014; Carter, William/AAC-4469-2019; Okumura, Mitchio/I-3326-2013; Harley, Robert/C-9177-2016	Bloss, William J/0000-0002-3017-4461; Carter, William/0000-0003-1682-8219; Okumura, Mitchio/0000-0001-6874-1137; Harley, Robert/0000-0002-0559-1917; Sprague, Matthew/0000-0002-3526-7077	National Aeronautics and Space Administration (NASA) [NAG5-11657, NNG06GD88G, NNX09AE21G]; California Air Resources Board [03-333, 07-730]; National Science Foundation [CHE-0515627/0848242]; Department of Defense	National Aeronautics and Space Administration (NASA)(National Aeronautics & Space Administration (NASA)); California Air Resources Board; National Science Foundation(National Science Foundation (NSF)); Department of Defense(United States Department of Defense)	This work was supported by National Aeronautics and Space Administration (NASA) grants NAG5-11657, NNG06GD88G, and NNX09AE21G; California Air Resources Board contracts 03-333 and 07-730; National Science Foundation grant CHE-0515627/0848242 (A. B. M.); a NASA Earth Systems Science Fellowship (A. K. M.); and a Department of Defense National Defense Science and Engineering Graduate Fellowship (M. K. S.). Research at JPL was supported by the NASA Upper Atmosphere Research and Tropospheric Chemistry Programs. This work was carried out in part at JPL, California Institute of Technology, under contract with NASA.	ANASTASI C, 1976, J CHEM SOC FARAD T 2, V72, P1459, DOI 10.1039/f29767201459; Bean BD, 2003, J PHYS CHEM A, V107, P6974, DOI 10.1021/jp034407c; Carter W. P., 2009, DEV SAPRC 07 CHEM ME; CARTER WPL, 1982, INT J CHEM KINET, V14, P1071, DOI 10.1002/kin.550141003; D'Ottone L, 2005, FARADAY DISCUSS, V130, P111, DOI 10.1039/b417458p; D'Ottone L, 2001, J PHYS CHEM A, V105, P10538, DOI 10.1021/jp012250n; Donahue NM, 1997, J GEOPHYS RES-ATMOS, V102, P6159, DOI 10.1029/96JD02329; Fry JL, 2004, J CHEM PHYS, V121, P1432, DOI 10.1063/1.1760714; Golden DM, 2003, J PHYS CHEM A, V107, P11057, DOI 10.1021/jp0353183; Hippler H, 2002, PHYS CHEM CHEM PHYS, V4, P2959, DOI 10.1039/b201932a; Hippler H, 2006, J PHYS CHEM A, V110, P6781, DOI 10.1021/jp0562734; Jerrett M, 2009, NEW ENGL J MED, V360, P1085, DOI 10.1056/NEJMoa0803894; JOHNSON RD, 2010, NIST STANDARD REFERE, V101; Konen IM, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1854094; Martien PT, 2006, ENVIRON SCI TECHNOL, V40, P2663, DOI 10.1021/es0510257; Martien PT, 2003, ENVIRON SCI TECHNOL, V37, P1598, DOI 10.1021/es026174t; McCoy AB, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1859273; Nizkorodov SA, 2004, J PHYS CHEM A, V108, P4864, DOI 10.1021/jp049461n; Nizkorodov SA, 2002, J PHYS CHEM A, V106, P855, DOI [10.1021/jp013598l, 10.1021/jp0135981]; ROBERTSHAW JS, 1982, J PHYS CHEM-US, V86, P785, DOI 10.1021/j100394a038; *S COAST AIR QUAL, 2003, 2003 AIR QUAL MAN PL; Sander S P, 2000, JPL PUBLICATION; Sander S. P., 2006, JPL PUBLICATION; Troe J, 2001, INT J CHEM KINET, V33, P878, DOI 10.1002/kin.10019; Wang LH, 2000, ATMOS ENVIRON, V34, P4337, DOI 10.1016/S1352-2310(00)00205-3; Zhang JY, 2006, J PHYS CHEM A, V110, P6898, DOI 10.1021/jp0556512; Zhang XB, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2162532	27	92	94	3	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					646	649		10.1126/science.1193030	http://dx.doi.org/10.1126/science.1193030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030650				2022-12-28	WOS:000283580600040
J	Tian, D; Sun, S; Lee, JT				Tian, Di; Sun, Sha; Lee, Jeannie T.			The Long Noncoding RNA, Jpx, Is a Molecular Switch for X Chromosome Inactivation	CELL			English	Article							IMPRINTED XIST EXPRESSION; EMBRYONIC STEM-CELLS; EARLY MOUSE EMBRYOS; DOSAGE COMPENSATION; TSIX TRANSCRIPTION; ANTISENSE TRANSCRIPTION; CHROMATIN-STRUCTURE; GENE; METHYLATION; REPEAT	Once protein-coding, the X-inactivation center (Xic) is now dominated by large noncoding RNAs (ncRNA). X chromosome inactivation (XCI) equalizes gene expression between mammalian males and females by inactivating one X in female cells. XCI requires Xist, an ncRNA that coats the X and recruits Polycomb proteins. How Xist is controlled remains unclear but likely involves negative and positive regulators. For the active X, the antisense Tsix RNA is an established Xist repressor. For the inactive X, here, we identify Xic-encoded Jpx as an Xist activator. Jpx is developmentally regulated and accumulates during XCI. Deleting Jpx blocks XCI and is female lethal. Posttranscriptional Jpx knockdown recapitulates the knockout, and supplying Jpx in trans rescues lethality. Thus, Jpx is trans-acting and functions as ncRNA. Furthermore, Delta Jpx is rescued by truncating Tsix, indicating an antagonistic relationship between the ncRNAs. We conclude that Xist is controlled by two RNA-based switches: Tsix for Xa and Jpx for Xi.	[Tian, Di; Sun, Sha; Lee, Jeannie T.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; [Tian, Di; Sun, Sha; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02115 USA; [Tian, Di; Sun, Sha; Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Tian, Di; Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Lee, JT (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.	lee@molbio.mgh.harvard.edu			NIH [K08-HD053824, RO1-GM58839];  [T32-CA009216]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD053824] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058839] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Y. Jeon for providing Xist riboprobes, and A. Chess, D. Lessing, B. Payer, and S. Pinter for critical reading of the manuscript and all members of the laboratory for their helpful input throughout this project. This work was funded by NIH grants K08-HD053824 to D.T., RO1-GM58839 to J.T.L., and a Pathology training grant T32-CA009216. J.T.L. is also an Investigator of the Howard Hughes Medical Institute.	Ahn Janice Y, 2010, BMC Dev Biol, V10, P90, DOI 10.1186/1471-213X-10-90; ARIEL M, 1995, NAT GENET, V9, P312, DOI 10.1038/ng0395-312; Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CATTANACH BM, 1967, GENETICS, V57, P331; Chow JC, 2003, GENOMICS, V82, P309, DOI 10.1016/S0888-7543(03)00170-8; Chureau C, 2002, GENOME RES, V12, P894, DOI 10.1101/gr.152902; Clemson CM, 2006, P NATL ACAD SCI USA, V103, P7688, DOI 10.1073/pnas.0601069103; Davidow LS, 2007, CHROMOSOME RES, V15, P137, DOI 10.1007/s10577-007-1121-6; Donohoe ME, 2009, NATURE, V460, P128, DOI 10.1038/nature08098; Duret L, 2006, SCIENCE, V312, P1653, DOI 10.1126/science.1126316; Hoki Y, 2009, DEVELOPMENT, V136, P139, DOI 10.1242/dev.026427; Hore TA, 2007, CHROMOSOME RES, V15, P147, DOI 10.1007/s10577-007-1119-0; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; Johnston CM, 2002, GENOMICS, V80, P236, DOI 10.1006/geno.2002.6819; Jonkers I, 2009, CELL, V139, P999, DOI 10.1016/j.cell.2009.10.034; Koerner MV, 2009, DEVELOPMENT, V136, P1771, DOI 10.1242/dev.030403; Lee JT, 2009, GENE DEV, V23, P1831, DOI 10.1101/gad.1811209; Lee JT, 2000, CELL, V103, P17, DOI 10.1016/S0092-8674(00)00101-X; Lee JT, 2005, SCIENCE, V309, P768, DOI 10.1126/science.1113673; Lee JT, 1999, P NATL ACAD SCI USA, V96, P3836, DOI 10.1073/pnas.96.7.3836; Lee JT, 1999, CELL, V99, P47, DOI 10.1016/S0092-8674(00)80061-6; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Luikenhuis S, 2001, MOL CELL BIOL, V21, P8512, DOI 10.1128/MCB.21.24.8512-8520.2001; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; Monkhorst K, 2008, CELL, V132, P410, DOI 10.1016/j.cell.2007.12.036; Morey C, 2004, EMBO J, V23, P594, DOI 10.1038/sj.emboj.7600071; Namekawa SH, 2010, MOL CELL BIOL, V30, P3187, DOI 10.1128/MCB.00227-10; Navarro P, 2005, GENE DEV, V19, P1474, DOI 10.1101/gad.341105; Navarro P, 2008, SCIENCE, V321, P1693, DOI 10.1126/science.1160952; Nicodemi M, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.108104; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Ogawa Y, 2003, MOL CELL, V11, P731, DOI 10.1016/S1097-2765(03)00063-7; Ogawa Y, 2008, SCIENCE, V320, P1336, DOI 10.1126/science.1157676; Ohhata T, 2006, CYTOGENET GENOME RES, V113, P345, DOI 10.1159/000090851; Ohhata T, 2008, DEVELOPMENT, V135, P227, DOI 10.1242/dev.008490; Payer B, 2008, ANNU REV GENET, V42, P733, DOI 10.1146/annurev.genet.42.110807.091711; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Sado T, 2005, DEV CELL, V9, P159, DOI 10.1016/j.devcel.2005.05.015; Sado T, 2001, DEVELOPMENT, V128, P1275; Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187; Shevchenko AI, 2007, CHROMOSOME RES, V15, P127, DOI 10.1007/s10577-006-1115-9; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Simmler MC, 1996, HUM MOL GENET, V5, P1713, DOI 10.1093/hmg/5.11.1713; Starmer J, 2009, DEVELOPMENT, V136, P1, DOI 10.1242/dev.025908; Stavropoulos N, 2001, P NATL ACAD SCI USA, V98, P10232, DOI 10.1073/pnas.171243598; Sun BK, 2006, MOL CELL, V21, P617, DOI 10.1016/j.molcel.2006.01.028; Tsai CL, 2008, DEV BIOL, V319, P416, DOI 10.1016/j.ydbio.2008.04.010; Vigneau S, 2006, P NATL ACAD SCI USA, V103, P7390, DOI 10.1073/pnas.0602381103; Wan LB, 2008, ADV GENET, V61, P207, DOI 10.1016/S0065-2660(07)00007-7; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Wutz A, 2007, CURR OPIN GENET DEV, V17, P387, DOI 10.1016/j.gde.2007.08.001; Xu N, 2006, SCIENCE, V311, P1149, DOI 10.1126/science.1122984; Yang Y, 2003, NAT BIOTECHNOL, V21, P447, DOI 10.1038/nbt803; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045; ZUCCOTTI M, 1995, NAT GENET, V9, P316, DOI 10.1038/ng0395-316	63	364	400	2	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					390	403		10.1016/j.cell.2010.09.049	http://dx.doi.org/10.1016/j.cell.2010.09.049			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029862	Bronze, Green Accepted			2022-12-28	WOS:000283603900013
J	Whitehouse, I; Owen-Hughes, T				Whitehouse, Iestyn; Owen-Hughes, Tom			ATRX: Put Me on Repeat	CELL			English	Editorial Material							HISTONE CHAPERONE; H3.3; DAXX; MUTATIONS; REGIONS	Mutations in the chromatin-remodeling protein ATRX cause alpha thalassaemia and mental retardation, but the severity of the disorder is independent of the specific mutation. In this issue of Cell, Law et al. (2010) demonstrate that ATRX alters gene expression by binding to G-rich tandem repeats, and the degree of transcriptional silencing caused by ATRX mutations correlates with the number of repeats.	[Owen-Hughes, Tom] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland; [Whitehouse, Iestyn] Sloan Kettering Inst, Program Mol Biol, New York, NY 10065 USA	University of Dundee; Memorial Sloan Kettering Cancer Center	Owen-Hughes, T (corresponding author), Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland.	t.a.owenhughes@dundee.ac.uk		Owen-Hughes, Tom/0000-0002-0618-8185; Whitehouse, Iestyn/0000-0003-0385-3116	Wellcome Trust [064414] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Argentaro A, 2007, P NATL ACAD SCI USA, V104, P11939, DOI 10.1073/pnas.0704057104; Berube NG, 2000, HUM MOL GENET, V9, P539, DOI 10.1093/hmg/9.4.539; Drane P, 2010, GENE DEV, V24, P1253, DOI 10.1101/gad.566910; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409; Law MJ, 2010, CELL, V143, P367, DOI 10.1016/j.cell.2010.09.023; Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107; Wong LH, 2010, GENOME RES, V20, P351, DOI 10.1101/gr.101477.109; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100	10	11	11	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					335	336		10.1016/j.cell.2010.10.021	http://dx.doi.org/10.1016/j.cell.2010.10.021			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029854	Bronze			2022-12-28	WOS:000283603900005
J	Baker, M				Baker, M.			Genomics Seeing more SNPs	NATURE			English	Editorial Material																			0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2010	467	7319					1138	1138		10.1038/4671138a	http://dx.doi.org/10.1038/4671138a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981105	Bronze			2022-12-28	WOS:000283548600059
J	Webb, DJ				Webb, David J.			Value-based medicine pricing: NICE work?	LANCET			English	Editorial Material									Univ Edinburgh, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Webb, DJ (corresponding author), Univ Edinburgh, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland.	cpu@ed.ac.uk						*2020HEALTH ORG, 2009, IMPR PAT OUTC CAN VA; BOSELEY S, 2010, NICE LOSE POWERS DEC; Collier J, 2007, BRIT MED J, V334, P435, DOI 10.1136/bmj.39136.464421.BE; *DEP BUS INN SKILL, 2009, PHARM PRIC REG SCHEM; Hutton J, 2007, INT J TECHNOL ASSESS, V23, P425, DOI 10.1017/S0266462307070651; Martin S., 2007, LINK HEALTHCARE SPEN; Taylor D, 2009, HEALTH ECON POLICY L, V4, P515, DOI 10.1017/S1744133109990247; Webb DJ, 2007, LANCET, V369, P1415, DOI 10.1016/S0140-6736(07)60648-5; 2007, PHARM PRICE REGULATI	9	13	14	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 7	2011	377	9777					1552	1553		10.1016/S0140-6736(10)62137-X	http://dx.doi.org/10.1016/S0140-6736(10)62137-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	763IJ	21093902				2022-12-28	WOS:000290549700008
J	Heymann, DL; Fine, PE; Griffiths, UK; Hall, AJ; Mounier-Jack, S				Heymann, David L.; Fine, Paul E.; Griffiths, Ulla K.; Hall, Andrew J.; Mounier-Jack, Sandra			Measles eradication: past is prologue	LANCET			English	Editorial Material							POLIO; HEALTH		[Heymann, David L.; Fine, Paul E.; Griffiths, Ulla K.; Hall, Andrew J.; Mounier-Jack, Sandra] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Heymann, David L.] Chatham House Ctr Global Hlth Secur, London, England	University of London; London School of Hygiene & Tropical Medicine	Heymann, DL (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	david.heymann@hpa.org.uk						Closser S, 2010, CHASING POLIO PAKIST; de Quadros CA, 2008, EXPERT REV VACCINES, V7, P355, DOI 10.1586/14760584.7.3.355; *FORT WORLD HLTH A, 1988, GLOB ER POL YEAR 200; Heymann DL, 2006, BIOLOGICALS, V34, P75, DOI 10.1016/j.biologicals.2006.03.005; Heymann DL, 2004, NEW ENGL J MED, V351, P1275, DOI 10.1056/NEJMp048204; Meissner HC, 2004, PEDIATRICS, V114, P1065, DOI 10.1542/peds.2004-0440; MORLEY D, 1969, BMJ-BRIT MED J, V1, P363, DOI 10.1136/bmj.1.5640.363; MORLEY D, 1969, BRIT MED J, V1, P291; Moss WJ, 2009, CURR TOP MICROBIOL, V330, P173; Renne E, 2006, SOC SCI MED, V63, P1857, DOI 10.1016/j.socscimed.2006.04.025; Unger Jean-Pierre, 2006, Int J Integr Care, V6, pe14; Unger JP, 2003, INT J HEALTH PLAN M, V18, pS27, DOI 10.1002/hpm.723; *WHO, 2010, EXP ASS MEASL ER FEA; *WHO, 2010, WHO EP BRIEF, V8; World Health Organization, 2010, WHO UNICEF EST NAT I	15	22	22	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 20	2010	376	9754					1719	1720		10.1016/S0140-6736(10)61934-4	http://dx.doi.org/10.1016/S0140-6736(10)61934-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690EI	21093636				2022-12-28	WOS:000284984900008
J	Li, Y; Baledent, V; Yu, G; Barisic, N; Hradil, K; Mole, RA; Sidis, Y; Steffens, P; Zhao, X; Bourges, P; Greven, M				Li, Yuan; Baledent, V.; Yu, G.; Barisic, N.; Hradil, K.; Mole, R. A.; Sidis, Y.; Steffens, P.; Zhao, X.; Bourges, P.; Greven, M.			Hidden magnetic excitation in the pseudogap phase of a high-T-c superconductor	NATURE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTOR; SPIN EXCITATIONS; HGBA2CUO4+DELTA; STATES; MODEL	The elucidation of the pseudogap phenomenon of the high-transition-temperature (high-T-c) copper oxides-a set of anomalous physical properties below the characteristic temperature T* and above T-c-has been a major challenge in condensed matter physics for the past two decades(1). Following initial indications of broken time-reversal symmetry in photoemission experiments(2), recent polarized neutron diffraction work demonstrated the universal existence of an unusual magnetic order below T* (refs 3, 4). These findings have the profound implication that the pseudogap regime constitutes a genuine new phase of matter rather than a mere crossover phenomenon. They are furthermore consistent with a particular type of order involving circulating orbital currents, and with the notion that the phase diagram is controlled by a quantum critical point(5). Here we report inelastic neutron scattering results for HgBa2CuO4+delta that reveal a fundamental collective magnetic mode associated with the unusual order, and which further support this picture. The mode's intensity rises below the same temperature T* and its dispersion is weak, as expected for an Ising-like order parameter(6). Its energy of 52-56 meV renders it a new candidate for the hitherto unexplained ubiquitous electron-boson coupling features observed in spectroscopic studies(7-10).	[Yu, G.; Greven, M.] Univ Minnesota, Sch Phys & Astron, Minneapolis, MN 55455 USA; [Li, Yuan] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Baledent, V.; Sidis, Y.; Bourges, P.] CEA Saclay, CEA, CNRS, Lab Leon Brillouin, F-91191 Gif Sur Yvette, France; [Barisic, N.; Zhao, X.] Stanford Univ, TH Geballe Lab Adv Mat, Stanford, CA 94305 USA; [Barisic, N.] Univ Stuttgart, Inst Phys 1, D-70550 Stuttgart, Germany; [Hradil, K.] Univ Gottingen, Inst Phys Chem, D-37077 Gottingen, Germany; [Mole, R. A.] Forsch Neutronenquelle Heinz Maier Leibnitz, D-85747 Garching, Germany; [Steffens, P.] Inst Laue Langevin, F-38042 Grenoble 9, France; [Zhao, X.] Jilin Univ, Coll Chem, State Key Lab Inorgan Synth & Preparat Chem, Changchun 130012, Peoples R China	University of Minnesota System; University of Minnesota Twin Cities; Stanford University; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Stanford University; University of Stuttgart; University of Gottingen; Institut Laue-Langevin (ILL); Jilin University	Greven, M (corresponding author), Univ Minnesota, Sch Phys & Astron, Minneapolis, MN 55455 USA.	greven@physics.umn.edu	Barisic, Neven/E-4246-2015; Hradil, Klaudia/M-7069-2014; Balédent, Victor/S-8894-2018; Yu, Guichuan/K-4025-2014	Hradil, Klaudia/0000-0002-6989-2495; Balédent, Victor/0000-0002-9437-434X; 	US Department of Energy; US National Science Foundation; National Natural Science Foundation, China; Alexander von Humboldt Foundation	US Department of Energy(United States Department of Energy (DOE)); US National Science Foundation(National Science Foundation (NSF)); National Natural Science Foundation, China(National Natural Science Foundation of China (NSFC)); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation)	We thank T. H. Geballe, S. A. Kivelson, E. M. Motoyama and C. M. Varma for discussions. This work was supported by the US Department of Energy and the US National Science Foundation, and by the National Natural Science Foundation, China. Y.L. acknowledges support from the Alexander von Humboldt Foundation during the final stage of completing the manuscript.	Barisic N, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.054518; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Eisaki H, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.064512; Grbic MS, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.094511; Hayden SM, 2004, NATURE, V429, P531, DOI 10.1038/nature02576; Hinkov V, 2007, NAT PHYS, V3, P780, DOI 10.1038/nphys720; Kaminski A, 2002, NATURE, V416, P610, DOI 10.1038/416610a; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Lee J, 2006, NATURE, V442, P546, DOI 10.1038/nature04973; Li Y, 2008, NATURE, V455, P372, DOI 10.1038/nature07251; Norman MR, 2005, ADV PHYS, V54, P715, DOI [10.1080/00018730500459906, 10.1080/00018730500489906]; Norman MR, 2003, REP PROG PHYS, V66, P1547, DOI 10.1088/0034-4885/66/10/R01; Pailhes S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.167001; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; Simon ME, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.247003; Tahir-Kheli J, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.014514; Tranquada JM, 2004, NATURE, V429, P534, DOI 10.1038/nature02574; van Heumen E, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.184512; Varma CM, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.155113; Varma CM, 1997, PHYS REV B, V55, P14554, DOI 10.1103/PhysRevB.55.14554; Vignolle B, 2007, NAT PHYS, V3, P163, DOI 10.1038/nphys546; Weber C, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.017005; Yang J, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.027003; Yu G, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.064518; Zhao XD, 2006, ADV MATER, V18, P3243, DOI 10.1002/adma.200600931	29	96	96	2	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					283	285		10.1038/nature09477	http://dx.doi.org/10.1038/nature09477			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068838	Green Submitted			2022-12-28	WOS:000284051000046
J	Meyer-Lindenberg, A				Meyer-Lindenberg, Andreas			From maps to mechanisms through neuroimaging of schizophrenia	NATURE			English	Article							VAL(108/158) MET GENOTYPE; O-METHYLTRANSFERASE COMT; GENOME-WIDE ASSOCIATION; PREFRONTAL CORTEX; FUNCTIONAL CONNECTIVITY; GENE-EXPRESSION; GRAY-MATTER; REWARD PREDICTION; CORTICAL FUNCTION; DOPAMINE FUNCTION	Functional and structural brain imaging has identified neural and neurotransmitter systems involved in schizophrenia and their link to cognitive and behavioural disturbances such as psychosis. Mapping such abnormalities in patients, however, cannot fully capture the strong neurodevelopmental component of schizophrenia that pre-dates manifest illness. A recent strategy to address this issue has been to focus on mechanisms of disease risk. Imaging genetics techniques have made it possible to define neural systems that mediate heritable risk linked to candidate and genome-wide-supported common variants, and mechanisms for environmental risk and gene-environment interactions are emerging. Characterizing the neural risk architecture of schizophrenia provides a translational research strategy for future treatments.	Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, D-68159 Mannheim, Germany	Central Institute of Mental Health; Ruprecht Karls University Heidelberg	Meyer-Lindenberg, A (corresponding author), Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, J5, D-68159 Mannheim, Germany.	a.meyer-lindenberg@zi-mannheim.de	Meyer-Lindenberg, Andreas/H-1076-2011	Meyer-Lindenberg, Andreas/0000-0001-5619-1123	Deutsche Forschungsgemeinschaft [SFB 636]; BMBF; EU; NARSAD	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); EU(European Commission); NARSAD(NARSAD)	I acknowledge grant support by Deutsche Forschungsgemeinschaft (SFB 636), BMBF (NGFN-MooDs, Bernstein-Programme), EU (NEWMEDS, OPTIMIZE, EU-GEI) and NARSAD (Distinguished Investigator Award) during the preparation of this manuscript.	Achim AM, 2005, BRIT J PSYCHIAT, V187, P500, DOI 10.1192/bjp.187.6.500; Aleman A, 2005, PROG NEUROBIOL, V77, P283, DOI 10.1016/j.pneurobio.2005.11.005; [Anonymous], 2010, NATURE, V463, P9, DOI 10.1038/463009a; Apud JA, 2007, NEUROPSYCHOPHARMACOL, V32, P1011, DOI 10.1038/sj.npp.1301227; Barros CS, 2009, P NATL ACAD SCI USA, V106, P4507, DOI 10.1073/pnas.0900355106; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Ben-Shachar S, 2009, J MED GENET, V46, P382, DOI 10.1136/jmg.2008.064378; Bertolino A, 2004, AM J PSYCHIAT, V161, P1798, DOI 10.1176/appi.ajp.161.10.1798; Bertolino A, 1997, CEREB CORTEX, V7, P740, DOI 10.1093/cercor/7.8.740; Boos HBM, 2007, ARCH GEN PSYCHIAT, V64, P297, DOI 10.1001/archpsyc.64.3.297; BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181; Brunet-Gouet E, 2006, PSYCHIAT RES-NEUROIM, V148, P75, DOI 10.1016/j.pscychresns.2006.05.001; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Byne W, 2009, ACTA NEUROPATHOL, V117, P347, DOI 10.1007/s00401-008-0404-0; Callicott JH, 2000, CEREB CORTEX, V10, P1078, DOI 10.1093/cercor/10.11.1078; Callicott JH, 2005, P NATL ACAD SCI USA, V102, P8627, DOI 10.1073/pnas.0500515102; Cannon TD, 2005, ARCH GEN PSYCHIAT, V62, P1205, DOI 10.1001/archpsyc.62.11.1205; Caspi A, 2005, BIOL PSYCHIAT, V57, P1117, DOI 10.1016/j.biopsych.2005.01.026; Chen JS, 2004, AM J HUM GENET, V75, P807, DOI 10.1086/425589; Cho RY, 2006, P NATL ACAD SCI USA, V103, P19878, DOI 10.1073/pnas.0609440103; Crossley NA, 2009, HUM BRAIN MAPP, V30, P4129, DOI 10.1002/hbm.20834; DAVIS KL, 1991, AM J PSYCHIAT, V148, P1474; Di Giorgio A, 2008, EUR J NEUROSCI, V28, P2129, DOI 10.1111/j.1460-9568.2008.06482.x; Dierks T, 1999, NEURON, V22, P615, DOI 10.1016/S0896-6273(00)80715-1; Durstewitz D, 2008, BIOL PSYCHIAT, V64, P739, DOI 10.1016/j.biopsych.2008.05.015; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Ellison-Wright I, 2008, AM J PSYCHIAT, V165, P1015, DOI 10.1176/appi.ajp.2008.07101562; Erk S, 2010, ARCH GEN PSYCHIAT, V67, P803, DOI 10.1001/archgenpsychiatry.2010.94; Esslinger C, 2009, SCIENCE, V324, P605, DOI 10.1126/science.1167768; Fan JB, 2005, BIOL PSYCHIAT, V57, P139, DOI 10.1016/j.biopsych.2004.10.018; Ferreira MAR, 2008, NAT GENET, V40, P1056, DOI 10.1038/ng.209; Friston KJ, 1996, CEREB CORTEX, V6, P156, DOI 10.1093/cercor/6.2.156; Fusar-Poli P, 2011, MOL PSYCHIATR, V16, P67, DOI 10.1038/mp.2009.108; Fusar-Poli P, 2007, NEUROSCI BIOBEHAV R, V31, P465, DOI 10.1016/j.neubiorev.2006.11.006; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Goldman AL, 2008, BIOL PSYCHIAT, V63, P475, DOI 10.1016/j.biopsych.2007.06.006; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Gruber O, 2008, J PSYCHIATR RES, V43, P1, DOI 10.1016/j.jpsychires.2008.01.009; Gur RE, 2007, ARCH GEN PSYCHIAT, V64, P1356, DOI 10.1001/archpsyc.64.12.1356; Gurden H, 1999, NEUROSCIENCE, V94, P1019, DOI 10.1016/S0306-4522(99)00395-4; Hall J, 2006, NAT NEUROSCI, V9, P1477, DOI 10.1038/nn1795; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Hashimoto T, 2003, J NEUROSCI, V23, P6315; Homayoun H, 2007, J NEUROSCI, V27, P11496, DOI 10.1523/JNEUROSCI.2213-07.2007; Honea R, 2009, NEUROIMAGE, V45, P44, DOI 10.1016/j.neuroimage.2008.10.064; Hong LE, 2008, ARCH GEN PSYCHIAT, V65, P1008, DOI 10.1001/archpsyc.65.9.1008; Howes OD, 2009, ARCH GEN PSYCHIAT, V66, P13, DOI 10.1001/archgenpsychiatry.2008.514; Hubl D, 2004, ARCH GEN PSYCHIAT, V61, P658, DOI 10.1001/archpsyc.61.7.658; Insel TR, 2006, MOL PSYCHIATR, V11, P11, DOI 10.1038/sj.mp.4001777; Ishizuka K, 2006, BIOL PSYCHIAT, V59, P1189, DOI 10.1016/j.biopsych.2006.03.065; Ito HT, 2007, FRONT NEURAL CIRCUIT, V1, DOI [10.3389/neuro.04/001.2007, 10.3389/neuro.04.001.2007]; JASKIW GE, 1990, BRAIN RES, V534, P321, DOI 10.1016/0006-8993(90)90149-6; Juckel G, 2006, NEUROIMAGE, V29, P409, DOI 10.1016/j.neuroimage.2005.07.051; Kapur S, 2003, AM J PSYCHIAT, V160, P13, DOI 10.1176/appi.ajp.160.1.13; Karayiorgou M, 2010, NAT REV NEUROSCI, V11, P402, DOI 10.1038/nrn2841; Kempf L, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000252; Laruelle M, 1998, Q J NUCL MED, V42, P211; Lencz T, 2010, NEUROPSYCHOPHARMACOL, V35, P2284, DOI 10.1038/npp.2010.102; Lewis DA, 2009, J CLIN INVEST, V119, P706, DOI 10.1172/JCI37335; Lieberman JA, 1997, NEUROPSYCHOPHARMACOL, V17, P205, DOI 10.1016/S0893-133X(97)00045-6; Lisman J, 2008, SCHIZOPHRENIA BULL, V34, P974, DOI 10.1093/schbul/sbn060; Liu JY, 2009, HUM BRAIN MAPP, V30, P241, DOI 10.1002/hbm.20508; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mata I, 2010, NEUROIMAGE, V53, P1016, DOI 10.1016/j.neuroimage.2009.11.010; Mata I, 2009, BIOL PSYCHIAT, V65, P535, DOI 10.1016/j.biopsych.2008.10.020; McIntosh AM, 2008, MOL PSYCHIATR, V13, P1054, DOI 10.1038/sj.mp.4002103; Meechan DW, 2007, GENE EXPRESSION, V13, P299; Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392; Meyer-Lindenberg A, 2002, NAT NEUROSCI, V5, P267, DOI 10.1038/nn804; Meyer-Lindenberg A, 2005, NAT NEUROSCI, V8, P594, DOI 10.1038/nn1438; Meyer-Lindenberg A, 2001, AM J PSYCHIAT, V158, P1809, DOI 10.1176/appi.ajp.158.11.1809; Meyer-Lindenberg AS, 2005, ARCH GEN PSYCHIAT, V62, P379, DOI 10.1001/archpsyc.62.4.379; Mier D, 2010, MOL PSYCHIATR, V15, P918, DOI 10.1038/mp.2009.36; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Munafo MR, 2008, BIOL PSYCHIAT, V63, P852, DOI 10.1016/j.biopsych.2007.08.016; Murray GK, 2008, MOL PSYCHIATR, V13, P267, DOI 10.1038/sj.mp.4002058; Nicodemus KK, 2007, HUM GENET, V120, P889, DOI 10.1007/s00439-006-0257-3; Nicodemus KK, 2010, HUM GENET, V127, P441, DOI 10.1007/s00439-009-0782-y; O'Donovan MC, 2008, NAT GENET, V40, P1053, DOI 10.1038/ng.201; Prata DP, 2008, MOL PSYCHIATR, V13, P915, DOI 10.1038/mp.2008.76; Pruessner JC, 2004, J NEUROSCI, V24, P2825, DOI 10.1523/JNEUROSCI.3422-03.2004; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Rasetti R, 2009, AM J PSYCHIAT, V166, P216, DOI 10.1176/appi.ajp.2008.08020261; SEEMAN P, 1975, SCIENCE, V188, P1217, DOI 10.1126/science.1145194; Selemon LD, 1999, BIOL PSYCHIAT, V45, P17, DOI 10.1016/S0006-3223(98)00281-9; Selten JP, 2005, BRIT J PSYCHIAT, V187, P101, DOI 10.1192/bjp.187.2.101; Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192; Sigurdsson T, 2010, NATURE, V464, P763, DOI 10.1038/nature08855; Simon JJ, 2010, SCHIZOPHR RES, V118, P154, DOI 10.1016/j.schres.2009.11.007; Sirota A, 2008, NEURON, V60, P683, DOI 10.1016/j.neuron.2008.09.014; Sohal VS, 2009, NATURE, V459, P698, DOI 10.1038/nature07991; Soliman A, 2008, NEUROPSYCHOPHARMACOL, V33, P2033, DOI 10.1038/sj.npp.1301597; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stokes PRA, 2010, NEUROIMAGE, V52, P1521, DOI 10.1016/j.neuroimage.2010.04.274; Tan HY, 2006, AM J PSYCHIAT, V163, P1969, DOI 10.1176/appi.ajp.163.11.1969; Tost H, 2010, NAT NEUROSCI, V13, P920, DOI 10.1038/nn.2572; Uhlhaas PJ, 2009, P NATL ACAD SCI USA, V106, P9866, DOI 10.1073/pnas.0900390106; von Stein A, 2000, P NATL ACAD SCI USA, V97, P14748, DOI 10.1073/pnas.97.26.14748; Walter H, 2011, MOL PSYCHIATR, V16, P462, DOI 10.1038/mp.2010.18; Walter H, 2009, SOC COGN AFFECT NEUR, V4, P166, DOI 10.1093/scan/nsn047; Walters JTR, 2010, ARCH GEN PSYCHIAT, V67, P692, DOI 10.1001/archgenpsychiatry.2010.81; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; Wessa M, 2010, MOL PSYCHIATR, V15, P1126, DOI 10.1038/mp.2009.103; Whitfield-Gabrieli S, 2009, P NATL ACAD SCI USA, V106, P1279, DOI 10.1073/pnas.0809141106; Wolf RC, 2009, PROG NEURO-PSYCHOPH, V33, P1464, DOI 10.1016/j.pnpbp.2009.07.032; Zink CF, 2008, NEURON, V58, P273, DOI 10.1016/j.neuron.2008.01.025	112	219	222	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					194	202		10.1038/nature09569	http://dx.doi.org/10.1038/nature09569			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068827				2022-12-28	WOS:000284051000035
J	Das, P; Horton, R				Das, Pam; Horton, Richard			Malaria elimination: worthy, challenging, and just possible	LANCET			English	Editorial Material									[Das, Pam; Horton, Richard] The Lancet, London NW1 7BY, England		Das, P (corresponding author), The Lancet, London NW1 7BY, England.							Amina K, 2010, ASIAN PAC J TROP MED, V3, P412, DOI 10.1016/S1995-7645(10)60101-0; Feachem RGA, 2010, LANCET, V376, P1517, DOI 10.1016/S0140-6736(10)61500-0; Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6; Feachem RGA, 2009, LANCET, V373, P1409, DOI 10.1016/S0140-6736(09)60801-1; GREENWOOD B, 2009, T R SOC TROP MED HYG, V1035, P52; Henderson D. A., 2009, SMALLPOX DEATH DIS; Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X; Roll Back Malaria, 2010, SAV LIV MAL CONTR CO; Sabot O, 2010, LANCET, V376, P1604, DOI 10.1016/S0140-6736(10)61355-4; Snow RW, 2010, LANCET, V376, P1409, DOI 10.1016/S0140-6736(10)61340-2; Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3; 2009, LANCET, V374, P1794; 2010, LANCET, V375, P1407	13	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1515	1517		10.1016/S0140-6736(10)61551-6	http://dx.doi.org/10.1016/S0140-6736(10)61551-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21035845				2022-12-28	WOS:000284248700004
J	Negrello, M; Hopwood, R; De Zotti, G; Cooray, A; Verma, A; Bock, J; Frayer, DT; Gurwell, MA; Omont, A; Neri, R; Dannerbauer, H; Leeuw, LL; Barton, E; Cooke, J; Kim, S; da Cunha, E; Rodighiero, G; Cox, P; Bonfield, DG; Jarvis, MJ; Serjeant, S; Ivison, RJ; Dye, S; Aretxaga, I; Hughes, DH; Ibar, E; Bertoldi, F; Valtchanov, I; Eales, S; Dunne, L; Driver, SP; Auld, R; Buttiglione, S; Cava, A; Grady, CA; Clements, DL; Dariush, A; Fritz, J; Hill, D; Hornbeck, JB; Kelvin, L; Lagache, G; Lopez-Caniego, M; Gonzalez-Nuevo, J; Maddox, S; Pascale, E; Pohlen, M; Rigby, EE; Robotham, A; Simpson, C; Smith, DJB; Temi, P; Thompson, MA; Woodgate, BE; York, DG; Aguirre, JE; Beelen, A; Blain, A; Baker, AJ; Birkinshaw, M; Blundell, R; Bradford, CM; Burgarella, D; Danese, L; Dunlop, JS; Fleuren, S; Glenn, J; Harris, AI; Kamenetzky, J; Lupu, RE; Maddalena, RJ; Madore, BF; Maloney, PR; Matsuhara, H; Michaowski, MJ; Murphy, EJ; Naylor, BJ; Nguyen, H; Popescu, C; Rawlings, S; Rigopoulou, D; Scott, D; Scott, KS; Seibert, M; Smail, I; Tuffs, RJ; Vieira, JD; van der Werf, PP; Zmuidzinas, J				Negrello, Mattia; Hopwood, R.; De Zotti, G.; Cooray, A.; Verma, A.; Bock, J.; Frayer, D. T.; Gurwell, M. A.; Omont, A.; Neri, R.; Dannerbauer, H.; Leeuw, L. L.; Barton, E.; Cooke, J.; Kim, S.; da Cunha, E.; Rodighiero, G.; Cox, P.; Bonfield, D. G.; Jarvis, M. J.; Serjeant, S.; Ivison, R. J.; Dye, S.; Aretxaga, I.; Hughes, D. H.; Ibar, E.; Bertoldi, F.; Valtchanov, I.; Eales, S.; Dunne, L.; Driver, S. P.; Auld, R.; Buttiglione, S.; Cava, A.; Grady, C. A.; Clements, D. L.; Dariush, A.; Fritz, J.; Hill, D.; Hornbeck, J. B.; Kelvin, L.; Lagache, G.; Lopez-Caniego, M.; Gonzalez-Nuevo, J.; Maddox, S.; Pascale, E.; Pohlen, M.; Rigby, E. E.; Robotham, A.; Simpson, C.; Smith, D. J. B.; Temi, P.; Thompson, M. A.; Woodgate, B. E.; York, D. G.; Aguirre, J. E.; Beelen, A.; Blain, A.; Baker, A. J.; Birkinshaw, M.; Blundell, R.; Bradford, C. M.; Burgarella, D.; Danese, L.; Dunlop, J. S.; Fleuren, S.; Glenn, J.; Harris, A. I.; Kamenetzky, J.; Lupu, R. E.; Maddalena, R. J.; Madore, B. F.; Maloney, P. R.; Matsuhara, H.; Michaowski, M. J.; Murphy, E. J.; Naylor, B. J.; Nguyen, H.; Popescu, C.; Rawlings, S.; Rigopoulou, D.; Scott, D.; Scott, K. S.; Seibert, M.; Smail, I.; Tuffs, R. J.; Vieira, J. D.; van der Werf, P. P.; Zmuidzinas, J.			The Detection of a Population of Submillimeter-Bright, Strongly Lensed Galaxies	SCIENCE			English	Article							EXTRAGALACTIC SOURCES; REDSHIFT DEADLOCK; STAR-FORMATION; PREDICTIONS; TELESCOPE; EMISSION; CATALOG; COUNTS; QUASAR; FIELD	Gravitational lensing is a powerful astrophysical and cosmological probe and is particularly valuable at submillimeter wavelengths for the study of the statistical and individual properties of dusty star-forming galaxies. However, the identification of gravitational lenses is often time-intensive, involving the sifting of large volumes of imaging or spectroscopic data to find few candidates. We used early data from the Herschel Astrophysical Terahertz Large Area Survey to demonstrate that wide-area submillimeter surveys can simply and easily detect strong gravitational lensing events, with close to 100% efficiency.	[Negrello, Mattia; Hopwood, R.; Serjeant, S.] Open Univ, Dept Phys & Astron, Milton Keynes MK7 6AA, Bucks, England; [De Zotti, G.; Buttiglione, S.] Osserv Astron Padova, Ist Nazl Astrofis, I-35122 Padua, Italy; [De Zotti, G.; Gonzalez-Nuevo, J.; Danese, L.] Scuola Int Super Studi Avanzati, I-34136 Trieste, Italy; [Cooray, A.; Barton, E.; Cooke, J.; Kim, S.] Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; [Verma, A.; Rawlings, S.; Rigopoulou, D.] Univ Oxford, Oxford OX1 3RH, England; [Bock, J.; Bradford, C. M.; Naylor, B. J.; Nguyen, H.; Zmuidzinas, J.] Jet Prop Lab, Pasadena, CA 91009 USA; [Bock, J.; Cooke, J.; Blain, A.; Bradford, C. M.; Vieira, J. D.; Zmuidzinas, J.] CALTECH, Pasadena, CA 91125 USA; [Frayer, D. T.; Maddalena, R. J.] Natl Radio Astron Observ, Green Bank, WV 24944 USA; [Gurwell, M. A.; Blundell, R.] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Omont, A.] Univ Paris 06, Inst Astrophys Paris, F-75014 Paris, France; [Omont, A.] CNRS, F-75014 Paris, France; [Neri, R.; Cox, P.] Inst Radio Astron Millimetr, F-38406 St Martin Dheres, France; [Dannerbauer, H.] Univ Paris Diderot, Lab Astrophys Instrumentat & Modelisat Paris Sard, Direct Sci Matiere,CEA,CNRS,Serv Astrophys, Inst Rech Lois Fondamentales Universe,CEA Saclay, F-91191 Gif Sur Yvette, France; [Leeuw, L. L.] Univ Johannesburg, Dept Phys, ZA-2006 Auckland Pk, South Africa; [Leeuw, L. L.] SETI Inst, Mountain View, CA 94043 USA; [da Cunha, E.] Univ Crete, Dept Phys, Iraklion 71003, Greece; [Rodighiero, G.] Univ Padua, Dipartimento Astron, I-35122 Padua, Italy; [Bonfield, D. G.; Jarvis, M. J.; Thompson, M. A.] Univ Hertfordshire, Sci & Technol Res Inst, Ctr Astrophys Res, Hatfield AL10 9AB, Herts, England; [Ivison, R. J.; Ibar, E.; Dunlop, J. S.] Royal Observ, UK Astron Technol Ctr, Edinburgh EH9 3HJ, Midlothian, Scotland; [Ivison, R. J.; Michaowski, M. J.; van der Werf, P. P.] Univ Edinburgh, Royal Observ, Inst Astron, Scottish Univ Phys Alliance, Edinburgh EH9 3HJ, Midlothian, Scotland; [Dye, S.; Eales, S.; Auld, R.; Dariush, A.; Pascale, E.; Pohlen, M.] Cardiff Univ, Sch Phys & Astron, Cardiff CF24 3AA, S Glam, Wales; [Aretxaga, I.; Hughes, D. H.] Inst Nacl Astrofis Opt & Electr, Puebla 72000, Mexico; [Bertoldi, F.] Univ Bonn, Argelander Inst Astron, D-53121 Bonn, Germany; [Valtchanov, I.] European Space Agcy, European Space Astron Ctr, Herschel Sci Ctr, Madrid 28691, Spain; [Dunne, L.; Maddox, S.; Rigby, E. E.; Smith, D. J. B.] Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; [Driver, S. P.; Hill, D.; Kelvin, L.; Robotham, A.] Univ St Andrews, Sch Phys & Astron, Scottish Univ Phys Alliance, St Andrews KY16 9SS, Fife, Scotland; [Cava, A.] Inst Astrofis Canarias, E-38200 San Cristobal la Laguna, Spain; [Cava, A.] Univ La Laguna, Dept Astrofis, E-38205 Tenerife, Spain; [Grady, C. A.] Eureka Sci, Oakland, CA 94602 USA; [Grady, C. A.; Woodgate, B. E.] NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; [Clements, D. L.] Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, Astrophys Grp, London SW7 2AZ, England; [Fritz, J.] Univ Ghent, Sterrenkundig Observ, B-9000 Ghent, Belgium; [Hornbeck, J. B.] Univ Louisville, Dept Phys & Astron, Louisville, KY 40292 USA; [Lagache, G.] Inst Astrophys Spatiale, F-91405 Orsay, France; [Lagache, G.; Beelen, A.] Univ Paris 11, F-91400 Orsay, France; [Lagache, G.; Beelen, A.] CNRS, UMR 8617, F-91400 Orsay, France; [Lopez-Caniego, M.] Univ Cantabria, CSIC, Inst Fis Cantabria, E-39005 Santander, Spain; [Simpson, C.] Liverpool John Moores Univ, Astrophys Res Inst, Birkenhead CH41 1LD, Merseyside, England; [Temi, P.] NASA, Astrophys Branch, Ames Res Ctr, Moffett Field, CA 94035 USA; [York, D. G.] Univ Chicago, Dept Astrophys, Chicago, IL 60637 USA; [York, D. G.] Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; [Aguirre, J. E.; Lupu, R. E.; Scott, K. S.] Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; [Baker, A. J.] Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; [Birkinshaw, M.] Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; [Burgarella, D.] CNRS, UMR6110, Lab Astrophys Marseille, F-13388 Marseille, France; [Burgarella, D.] Aix Marseille Univ, F-13388 Marseille, France; [Fleuren, S.] Univ London, Sch Math Sci, London E1 4NS, England; [Glenn, J.; Kamenetzky, J.; Maloney, P. R.] Univ Colorado, Ctr Astrophys & Space Astron, Boulder, CO 80303 USA; [Harris, A. I.] Univ Maryland, Dept Astron, College Pk, MD 20742 USA; [Madore, B. F.; Seibert, M.] Observ Camegie Inst, Pasadena, CA 91101 USA; [Matsuhara, H.] Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Chuo Ku, Sagamihara, Kanagawa 2525210, Japan; [Murphy, E. J.] CALTECH, Ctr Infrared Proc & Anal, Pasadena, CA 91125 USA; [Popescu, C.] Univ Cent Lancashire, Jeremiah Horrocks Inst, Preston PR1 2HE, Lancs, England; [Rigopoulou, D.] Rutherford Appleton Lab, Space Sci & Technol Dept, Didcot OX11 0QX, Oxon, England; [Scott, D.] Univ British Columbia, Vancouver, BC V6T 1Z1, Canada; [Smail, I.] Univ Durham, Inst Computat Cosmol, Durham DH1 3LE, England; [Tuffs, R. J.] Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; [van der Werf, P. P.] Leiden Univ, Leiden Observ, NL-2300 RA Leiden, Netherlands	Open University - UK; Istituto Nazionale Astrofisica (INAF); University of Padua; International School for Advanced Studies (SISSA); University of California System; University of California Irvine; University of Oxford; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology; National Radio Astronomy Observatory (NRAO); Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; CEA; Centre National de la Recherche Scientifique (CNRS); Universite Paris Saclay; University of Johannesburg; University of Crete; University of Padua; University of Hertfordshire; University of Edinburgh; University of Edinburgh; Cardiff University; Instituto Nacional de Astrofisica, Optica y Electronica; University of Bonn; European Space Agency; University of Nottingham; University of St Andrews; Instituto de Astrofisica de Canarias; Universidad de la Laguna; Eureka Scientific; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Imperial College London; Ghent University; University of Louisville; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Saclay; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Fisica de Cantabria (IFCA); Liverpool John Moores University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Chicago; University of Chicago; University of Pennsylvania; Rutgers State University New Brunswick; University of Bristol; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of London; University of Colorado System; University of Colorado Boulder; University System of Maryland; University of Maryland College Park; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); California Institute of Technology; University of Central Lancashire; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; University of British Columbia; Durham University; Max Planck Society; Leiden University; Leiden University - Excl LUMC	Negrello, M (corresponding author), Open Univ, Dept Phys & Astron, Walton Hall, Milton Keynes MK7 6AA, Bucks, England.	m.negrello@open.ac.uk	da Cunha, Elisabete/AAY-2027-2021; Smail, Ian/AAL-9018-2020; Smail, Ian/M-5161-2013; Ivison, R. J./G-4450-2011; Lupu, Roxana/P-9060-2014; Woodgate, Bruce E/D-2970-2012; Murphy, Eric/AAE-8450-2021; López-Caniego, Marcos/M-4695-2013; Ibar, Edo/AAI-5516-2020; Driver, Simon P/H-9115-2014; Baker, Andrew/HHM-6373-2022; Cava, Antonio/C-5274-2017; Robotham, Aaron/H-5733-2014; Fritz, Jacopo/HIK-2511-2022; Gonzalez-Nuevo, Joaquin/I-3562-2014; Serjeant, Stephen/AAN-1908-2021; Pascale, Enzo/A-3665-2012; Rodighiero, Giulia/U-7935-2017	da Cunha, Elisabete/0000-0001-9759-4797; Smail, Ian/0000-0003-3037-257X; Smail, Ian/0000-0003-3037-257X; Ivison, R. J./0000-0001-5118-1313; Lupu, Roxana/0000-0003-3444-5908; Driver, Simon P/0000-0001-9491-7327; Cava, Antonio/0000-0002-4821-1275; Robotham, Aaron/0000-0003-0429-3579; Gonzalez-Nuevo, Joaquin/0000-0003-1354-6822; Serjeant, Stephen/0000-0002-0517-7943; Pascale, Enzo/0000-0002-3242-8154; Lopez-Caniego, Marcos/0000-0003-1016-9283; Baker, Andrew/0000-0002-7892-396X; Kim, Sam/0000-0001-8332-0023; Seibert, Mark/0000-0002-1143-5515; Birkinshaw, Mark/0000-0002-1858-277X; Aretxaga, Itziar/0000-0002-6590-3994; Maddox, Stephen/0000-0001-5549-195X; Gurwell, Mark/0000-0003-0685-3621; Fritz, Jacopo/0000-0002-7042-1965; Smith, Daniel/0000-0001-9708-253X; Rodighiero, Giulia/0000-0002-9415-2296; Scott, Douglas/0000-0002-6878-9840; Dye, Simon/0000-0002-1318-8343; Harris, Andrew/0000-0001-6159-9174	NASA through a contract from JPL; Science and Technology Facilities Council [PP/D002400/1, ST/G002533/1, SF/F005288/1]; Agenzia Spaziale Italiana (ASI) [I/016/07/0 COFIS]; ASI/Istituto Nazionale di Astrofisica [I/072/09/0]; Consejo Nacional de Ciencia y Tecnolog a (CONACyT) [39953-F, 39548-F]; W.M. Keck Foundation; Smithsonian Institution; Academia Sinica; Institut National des Sciences de l'Univers (INSU)/CNRS (France); Max Planck Society (MPG) (Germany); Instituto Geogrifico Nacional (IGN) (Spain); NSF [AST-0807990, AST-0239270, AST-0503946, AST-0708653]; CSO NSF [AST-0838261]; NASA SARA [NAGS-11911, NAGS-12788]; Research Corporation Award [RI0928]; JPL; California Institute of Technology; STFC [ST/G001871/1, ST/F002963/1, ST/H004254/1, ST/H002391/1, ST/G001979/1, ST/F00298X/1, ST/F007566/1, ST/G001987/1, ST/G002533/1, PP/D002400/1, PP/E001149/1, ST/G002622/1, PP/D000963/1, ST/H001530/1, ST/G002630/1, PP/E001637/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D000963/1, ST/G001979/1, PP/E001637/1, ST/F002963/1, ST/H004254/1, ST/F00298X/1, ST/G001871/1, ST/H002391/1, PP/E001181/1, ST/G001987/1, ST/G002630/1, PP/E001149/1, ST/G002622/1] Funding Source: researchfish; UK Space Agency [ST/G003874/1] Funding Source: researchfish	NASA through a contract from JPL; Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Agenzia Spaziale Italiana (ASI)(Agenzia Spaziale Italiana (ASI)); ASI/Istituto Nazionale di Astrofisica(Istituto Nazionale Astrofisica (INAF)Agenzia Spaziale Italiana (ASI)); Consejo Nacional de Ciencia y Tecnolog a (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); W.M. Keck Foundation(W.M. Keck Foundation); Smithsonian Institution(Smithsonian Institution); Academia Sinica(Academia Sinica - Taiwan); Institut National des Sciences de l'Univers (INSU)/CNRS (France)(Centre National de la Recherche Scientifique (CNRS)); Max Planck Society (MPG) (Germany)(Max Planck Society); Instituto Geogrifico Nacional (IGN) (Spain); NSF(National Science Foundation (NSF)); CSO NSF; NASA SARA; Research Corporation Award(Research Corporation for Science Advancement); JPL; California Institute of Technology; STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); UK Space Agency	Herschel is an ESA space observatory with science instruments provided by European-led principal investigator consortia and with important participation from NASA. U. S. participants in H-ATLAS acknowledge support from NASA through a contract from JPL. This work was supported by the Science and Technology Facilities Council (grants PP/D002400/1 and ST/G002533/1) and studentship SF/F005288/1. We thank Agenzia Spaziale Italiana (ASI) for funding through contract No. I/016/07/0 COFIS and ASI/Istituto Nazionale di Astrofisica agreement I/072/09/0 for the Planck Low-Frequency Instrument (LFI) Activity of Phase E2. Research supported in part by Consejo Nacional de Ciencia y Tecnolog a (CONACyT) grants 39953-F and 39548-F. The W. M. Keck Observatory is operated as a scientific partnership among the California Institute of Technology, the University of California, and NASA. The Observatory was made possible by the generous financial support of the W.M. Keck Foundation. The Submillimeter Array is a joint project between the Smithsonian Astrophysical Observatory and the Academia Sinica Institute of Astronomy and Astrophysics and is funded by the Smithsonian Institution and the Academia Sinica. IRAM is supported by Institut National des Sciences de l'Univers (INSU)/CNRS (France), Max Planck Society (MPG) (Germany), and Instituto Geogrifico Nacional (IGN) (Spain). Z-spec was supported by NSF grant AST-0807990 to J. A. and by the CSO NSF Cooperative Agreement AST-0838261. Support was provided to J. K. by an NSF Graduate Research Fellowship. Z-spec was constructed under NASA SARA grants NAGS-11911 and NAGS-12788 and an NSF Career grant (AST-0239270) and a Research Corporation Award (RI0928) to J. G., in collaboration with JPL, California Institute of Technology, under a contract with NASA. Construction of and observations with the Zpectrometer have been supported by NSF grants AST-0503946 and AST-0708653. NRAO is a facility of the NSF operated under cooperative agreement by Associated Universities. The optical spectroscopic redshift of ID130 was derived from observations obtained with the Apache Point Observatory 3.5-m telescope, which is owned and operated by the Astrophysical Research Consortium. The optical spectroscopic redshifts of ID9 and ID11 were obtained with the William Herschel Telescope, which is operated on the island of La Palma by the Isaac Newton Group in the Spanish Observatorio del Roque de los Muchachos of the Instituto de Astrofisica de Canarias. For the use of Keck, SMA, and CSO, the authors wish to recognize and acknowledge the very important cultural role and reverence that the summit of Mauna Kea has always had within the indigenous Hawaiian community. We are most fortunate to have the opportunity to conduct observations from this mountain.	Aretxaga I, 2003, MON NOT R ASTRON SOC, V342, P759, DOI 10.1046/j.1365-8711.2003.06560.x; Auger MW, 2009, ASTROPHYS J, V705, P1099, DOI 10.1088/0004-637X/705/2/1099; Baes M, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014644; Blain AW, 1999, ASTROPHYS J, V512, pL87, DOI 10.1086/311879; Blain AW, 1996, MON NOT R ASTRON SOC, V283, P1340, DOI 10.1093/mnras/283.4.1340; Bradford CM, 2009, ASTROPHYS J, V705, P112, DOI 10.1088/0004-637X/705/1/112; Browne IWA, 2001, ASTR SOC P, V237, P15; Chapman SC, 2005, ASTROPHYS J, V622, P772, DOI 10.1086/428082; Clements DL, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014581; Coppin K, 2006, MON NOT R ASTRON SOC, V372, P1621, DOI 10.1111/j.1365-2966.2006.10961.x; da Cunha E, 2008, MON NOT R ASTRON SOC, V388, P1595, DOI 10.1111/j.1365-2966.2008.13535.x; DACUNHA E, ASTROPHYS J IN PRESS; Daddi E, 2009, ASTROPHYS J LETT, V695, pL176, DOI 10.1088/0004-637X/695/2/L176; De Zotti G, 2005, ASTRON ASTROPHYS, V431, P893, DOI 10.1051/0004-6361:20042108; Devlin MJ, 2009, NATURE, V458, P737, DOI 10.1038/nature07918; DRIVER S, ASTROPHYS J IN PRESS; Eales S, 2010, PUBL ASTRON SOC PAC, V122, P499, DOI 10.1086/653086; FABER SM, 1976, ASTROPHYS J, V204, P668, DOI 10.1086/154215; Faure C, 2008, ASTROPHYS J SUPPL S, V176, P19, DOI 10.1086/526426; FRAYER D, ASTROPHYS J IN PRESS; Gonzalez-Nuevo J, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014637; Griffin MJ, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014519; GUDEHUS DH, 1991, ASTROPHYS J, V382, P1, DOI 10.1086/170687; Harris AI, 2007, ASTR SOC P, V375, P82; Huang JS, 1998, ASTROPHYS J, V496, P31, DOI 10.1086/305373; Hughes DH, 2002, MON NOT R ASTRON SOC, V335, P871, DOI 10.1046/j.1365-8711.2002.05670.x; IBAR E, ASTROPHYS J IN PRESS; Koopmans LVE, 2006, ASTROPHYS J, V649, P599, DOI 10.1086/505696; LUPU R, 2010, UNPUB; Maddox SJ, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014663; Marshall PJ, 2007, ASTROPHYS J, V671, P1196, DOI 10.1086/523091; Naylor BJ, 2003, PROC SPIE, V4855, P239, DOI 10.1117/12.459419; Negrello M, 2007, MON NOT R ASTRON SOC, V377, P1557, DOI 10.1111/j.1365-2966.2007.11708.x; Oguri M, 2006, ASTRON J, V132, P999, DOI 10.1086/506019; Perrotta F, 2003, MON NOT R ASTRON SOC, V338, P623, DOI 10.1046/j.1365-8711.2003.06072.x; Perrotta F, 2002, MON NOT R ASTRON SOC, V329, P445, DOI 10.1046/j.1365-8711.2002.05009.x; Pilbratt GL, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014759; Poglitsch A, 2010, ASTRON ASTROPHYS, V518, DOI 10.1051/0004-6361/201014535; ROWANROBINSON M, 1991, NATURE, V351, P719, DOI 10.1038/351719a0; Serjeant S, 2005, MON NOT R ASTRON SOC, V356, P192, DOI 10.1111/j.1365-2966.2004.08440.x; Smail I, 2002, MON NOT R ASTRON SOC, V331, P495, DOI 10.1046/j.1365-8711.2002.05203.x; Smail I, 1997, ASTROPHYS J, V490, pL5, DOI 10.1086/311017; SMITH DJB, MNRAS IN PRESS; Stark DP, 2008, NATURE, V455, P775, DOI 10.1038/nature07294; Swinbank AM, 2010, NATURE, V464, P733, DOI 10.1038/nature08880; Vieira JD, 2010, ASTROPHYS J, V719, P763, DOI 10.1088/0004-637X/719/1/763; Weiss A, 2009, ASTROPHYS J, V707, P1201, DOI 10.1088/0004-637X/707/2/1201; Weiss A, 2009, ASTROPHYS J LETT, V705, pL45, DOI 10.1088/0004-637X/705/1/L45; Willott CJ, 2003, MON NOT R ASTRON SOC, V339, P173, DOI 10.1046/j.1365-8711.2003.06172.x	49	307	307	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					800	804		10.1126/science.1193420	http://dx.doi.org/10.1126/science.1193420			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051633	Green Accepted, Green Submitted			2022-12-28	WOS:000283855700037
J	Davies, P				Davies, Peter			Medicine and the Media Attitudes to healthcare-then and now	BRITISH MEDICAL JOURNAL			English	Editorial Material												petergdavies@ntlworld.com							0	0	0	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 3	2010	341								c6205	10.1136/bmj.c6205	http://dx.doi.org/10.1136/bmj.c6205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678DE	21047892				2022-12-28	WOS:000284050400003
J	Stephenson, L; Stephenson, T				Stephenson, Lucy; Stephenson, Terence			Selecting tomorrow's doctors-not a level playing field	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Stephenson, Lucy; Stephenson, Terence] Royal Coll Paediat & Child Hlth, London, England		Stephenson, L (corresponding author), Royal Coll Paediat & Child Hlth, London, England.	t.stephenson@ich.ucl.ac.uk		Stephenson, Terence/0000-0001-8871-7847				2010, BMJ-BRIT MED J, V341, pC6130, DOI DOI 10.1136/BMJ.C6130	1	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 3	2010	341								c6108	10.1136/bmj.c6108	http://dx.doi.org/10.1136/bmj.c6108			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678DE	21045052				2022-12-28	WOS:000284050400012
J	Gakidou, E; Lopez, AD				Gakidou, Emmanuela; Lopez, Alan D.			What do children die from in India today?	LANCET			English	Editorial Material									[Gakidou, Emmanuela] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA; [Lopez, Alan D.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld 4006, Australia	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Queensland	Gakidou, E (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.	gakidou@u.washington.edu	Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lopez, Alan D/0000-0001-5818-6512				[Anonymous], 1996, GLOBAL BURDEN DIS CO; Bassani DG, 2010, LANCET, V376, P1853, DOI 10.1016/S0140-6736(10)61461-4; Birnbaum J, 2009, LANCET, V374, P1730, DOI 10.1016/S0140-6736(09)61426-4; Byass Peter, 2009, Popul Health Metr, V7, P6, DOI 10.1186/1478-7954-7-6; Chan M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000223; Murray CJL, 2007, PLOS MED, V4, P1739, DOI 10.1371/journal.pmed.0040327; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Setel PW, 2005, B WORLD HEALTH ORGAN, V83, P611; World Health Organization, 2007, VERB AUT STAND ASC A	9	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2010	376	9755					1810	1811		10.1016/S0140-6736(10)62054-5	http://dx.doi.org/10.1016/S0140-6736(10)62054-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696KG	21075445				2022-12-28	WOS:000285439700010
J	Sachedina, N; Donaldson, LJ				Sachedina, Nabihah; Donaldson, Liam J.			Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study	LANCET			English	Article							VIRUS-INFECTION; UNITED-STATES; CHILDREN; DEATHS	Background Young people (aged 0-18 years) have been disproportionately affected by pandemic influenza A H1N1 infection. We aimed to analyse paediatric mortality to inform clinical and public health policies for future influenza seasons and pandemics. Methods All paediatric deaths related to pandemic influenza A H1N1 infection from June 26,2009, to March 22,2010 in England were identified through daily reporting systems and cross-checking of records and were validated by confirmation of influenza infection by laboratory results or death certificates. Clinicians responsible for each individual child provided detailed information about past medical history, presentation, and clinical course of the acute illness. Case estimates of influenza A H1N1 were obtained from the Health Protection Agency. The primary outcome measures were population mortality rates and case-fatality rates. Findings 70 paediatric deaths related to pandemic influenza A H1N1 were reported. Childhood mortality rate was 6 per million population. The rate was highest for children aged less than 1 year. Mortality rates were higher for Bangladeshi children (47 deaths per million population [95% CI 17-103]) and Pakistani children (36 deaths per million population [18-64]) than for white British children (4 deaths per million [3-6]). 15 (21%) children who died were previously healthy; 45 (64%) had severe pre-existing disorders. The highest age-standardised mortality rate for a preexisting disorder was for chronic neurological disease (1536 per million population). 19 (27%) deaths occurred before inpatient admission. Children in this subgroup were significantly more likely to have been healthy or had only mild pre-existing disorders than those who died after admission (p=0-0109). Overall, 45 (64%) children had received oseltamivir: seven within 48 h of symptom onset. Interpretation Vaccination priority should be for children at increased risk of severe illness or death from influenza. This group might include those with specified pre-existing disorders and those in some ethnic minority groups. Early pre-hospital supportive and therapeutic care is also important.	[Donaldson, Liam J.] Natl Patient Safety Agcy, London W1T 5HD, England; [Sachedina, Nabihah; Donaldson, Liam J.] Dept Hlth, London SE1 6TE, England		Donaldson, LJ (corresponding author), Natl Patient Safety Agcy, 4-8 Maple St, London W1T 5HD, England.	liam.donaldson@npsa.nhs.uk			Department of Health	Department of Health	We thank the many clinicians in England who supplied the clinical information about their patients; Matthew Mak, Emma Stanton, Paul Rutter, and Tara Fajeyisan for their work in the validation of all deaths; Oliver Mytton for assistance with data analysis; and lain Yardley for assistance in editing the manuscript. This work was done as part of the public health response to pandemic influenza in England. The costs of the study were small and met from the Chief Medical Officer's budget within the Department of Health without the need for additional funding.	Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; Butland BK, 2006, THORAX, V61, P383, DOI 10.1136/thx.2005.043646; Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612; Castrodale L., 2009, Morbidity and Mortality Weekly Report, V58, P1341; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P941; Cunha BA, 2009, CLIN INFECT DIS, V49, P1454, DOI 10.1086/644496; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Johnson BF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007671; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Lister P, 2009, LANCET, V374, P605, DOI [10.1016/S0140-6736(09)61512-9, 10.1016/S0140-6736(09)61513-0]; Maines TR, 2009, SCIENCE, V325, P484, DOI 10.1126/science.1177238; Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Office for National Statistics, MID2007 POP EST ETHN; Office for National Statistics, 20029 ONS; Office for National Statistics, MID2008 POP EST ENGL; Pitman RJ, 2007, J INFECTION, V54, P530, DOI 10.1016/j.jinf.2006.09.017; Saklad M., 1941, ANESTHESIOLOGY, V2, P281, DOI DOI 10.1097/00000542-194105000-00004; Shun-Shin M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3172; To KKW, 2010, J MED VIROL, V82, P1, DOI 10.1002/jmv.21664; Turner SJ, 2008, J BIOL, V8, P69; van 't Klooster TM, 2010, EUROSURV, V15; WHO, WHO GUID PHARM MAN P; Wright Peter F, 2009, N Engl J Med, V361, pe112, DOI 10.1056/NEJMopv0910749	24	105	107	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2010	376	9755					1846	1852		10.1016/S0140-6736(10)61195-6	http://dx.doi.org/10.1016/S0140-6736(10)61195-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KG	21030071	Green Accepted			2022-12-28	WOS:000285439700033
J	Perry, JJ; Stiell, IG; Sivilotti, MLA; Bullard, MJ; Lee, JS; Eisenhauer, M; Symington, C; Mortensen, M; Sutherland, J; Lesiuk, H; Wells, GA				Perry, Jeffrey J.; Stiell, Ian G.; Sivilotti, Marco L. A.; Bullard, Michael J.; Lee, Jacques S.; Eisenhauer, Mary; Symington, Cheryl; Mortensen, Melodie; Sutherland, Jane; Lesiuk, Howard; Wells, George A.			High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTRACRANIAL ANEURYSMS; CIGARETTE-SMOKING; PREDICTION RULES; MEDICAL PROGRESS; DECISION RULES; MANAGEMENT; DIAGNOSIS; HYPERTENSION; RADIOGRAPHY; USERS	Objective To identify high risk clinical characteristics for subarachnoid haemorrhage in neurologically intact patients with headache. Design Multicentre prospective cohort study over five years. Setting Six university affiliated tertiary care teaching hospitals in Canada. Data collected from November 2000 until November 2005. Participants Neurologically intact adults with a non-traumatic headache peaking within an hour. Main outcome measures Subarachnoid haemorrhage, as defined by any of subarachnoid haemorrhage on computed tomography of the head, xanthochromia in the cerebrospinal fluid, or red blood cells in the final sample of cerebrospinal fluid with positive results on angiography. Physicians completed data collection forms before investigations. Results In the 1999 patients enrolled there were 130 cases of subarachnoid haemorrhage. Mean (range) age was 43.4 (16-93), 1207 (60.4%) were women, and 1546 (78.5%) reported that it was the worst headache of their life. Thirteen of the variables collected on history and three on examination were reliable and associated with subarachnoid haemorrhage. We used recursive partitioning with different combinations of these variables to create three clinical decisions rules. All had 100% (95% confidence interval 97.1% to 100.0%) sensitivity with specificities from 28.4% to 38.8%. Use of any one of these rules would have lowered rates of investigation (computed tomography, lumbar puncture, or both) from the current 82.9% to between 63.7% and 73.5%. Conclusion Clinical characteristics can be predictive for subarachnoid haemorrhage. Practical and sensitive clinical decision rules can be used in patients with a headache peaking within an hour. Further study of these proposed decision rules, including prospective validation, could allow clinicians to be more selective and accurate when investigating patients with headache.	[Perry, Jeffrey J.; Stiell, Ian G.; Symington, Cheryl; Mortensen, Melodie] Univ Ottawa, Dept Emergency Med, Ottawa, ON K1Y 4E9, Canada; [Sutherland, Jane] Univ Ottawa, Clin Epidemiol Program, Ottawa Hosp Res Inst, Ottawa, ON K1Y 4E9, Canada; [Sivilotti, Marco L. A.] Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; [Bullard, Michael J.] Univ Alberta, Div Emergency Med, Edmonton, AB, Canada; [Lee, Jacques S.] Univ Toronto, Div Emergency Med, Toronto, ON, Canada; [Eisenhauer, Mary] Univ Western Ontario, Div Emergency Med, London, ON, Canada; [Lesiuk, Howard] Ottawa Hosp Res Inst, Div Neurosurg, Ottawa, ON K1Y 4E9, Canada; [Wells, George A.] Ottawa Hosp Res Inst, Dept Epidemiol & Community Med, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Queens University - Canada; University of Alberta; University of Toronto; Western University (University of Western Ontario); University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Perry, JJ (corresponding author), Univ Ottawa, Dept Emergency Med, Ottawa, ON K1Y 4E9, Canada.	jperry@ohri.ca	Sivilotti, Marco L.A./AAR-8892-2020; Wells, George A/M-4549-2017; Lee, Jacques/CAF-4380-2022	Sivilotti, Marco L.A./0000-0001-6641-1118; Wells, George A/0000-0002-2289-9139; Lee, Jacques/0000-0002-9143-6285; Perry, Jeffrey/0000-0003-2134-9597; Stiell, Ian/0000-0002-2583-6408	Ontario Ministry of Health and Long Term Care through the Physician's Services Incorporated Foundation [01-39]; Canadian Institutes for Health Research [67107]; Ontario Ministry of Health; Canadian Institutes for Health Research	Ontario Ministry of Health and Long Term Care through the Physician's Services Incorporated Foundation; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by Ontario Ministry of Health and Long Term Care, physicians of Ontario through the Physician's Services Incorporated Foundation (grant No 01-39), the Canadian Institutes for Health Research (grant No 67107). JJP was funded as a career scientist by the Ontario Ministry of Health and is now funded by a Canadian Institutes for Health Research New Investigator Award. IGS is a University Health Research Chair, University of Ottawa.	ADAMS HP, 1980, JAMA-J AM MED ASSOC, V244, P794, DOI 10.1001/jama.244.8.794; ADAMSON J, 1994, STROKE, V25, P963, DOI 10.1161/01.STR.25.5.963; BASSI P, 1991, ACTA NEUROL SCAND, V84, P277, DOI 10.1111/j.1600-0404.1991.tb04954.x; Berrington de Gonzalez A, 2004, LANCET, V363, P345, DOI 10.1016/S0140-6736(04)15433-0; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760; Butler WE, 1996, NEUROSURGERY, V38, P506; CHAPMAN AB, 1992, NEW ENGL J MED, V327, P916, DOI 10.1056/NEJM199209243271303; Edlow JA, 2000, NEW ENGL J MED, V342, P29, DOI 10.1056/NEJM200001063420106; Edlow JA, 2008, ANN EMERG MED, V52, P407, DOI 10.1016/j.annemergmed.2008.07.001; Evans RW, 2000, NEUROLOGY, V55, P909, DOI 10.1212/WNL.55.7.909; Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8; Hillman J, 1996, J NEUROSURG, V85, P33, DOI 10.3171/jns.1996.85.1.0033; JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639; Kowalski RG, 2004, JAMA-J AM MED ASSOC, V291, P866, DOI 10.1001/jama.291.7.866; Landtblom AM, 2002, CEPHALALGIA, V22, P354, DOI 10.1046/j.1468-2982.2002.00368.x; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LEICHT MJ, 1980, ANN EMERG MED, V9, P404, DOI 10.1016/S0196-0644(80)80152-1; LONGSTRETH WT, 1994, ANN INTERN MED, V121, P168, DOI 10.7326/0003-4819-121-3-199408010-00002; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Morgenstern LB, 2001, HEADACHE, V41, P537, DOI 10.1046/j.1526-4610.2001.041006537.x; NeilDwyer G, 1997, J ROY COLL PHYS LOND, V31, P49; Perry JJ, 2006, STROKE, V37, P2467, DOI 10.1161/01.STR.0000240689.15109.47; Perry Jeffrey J, 2002, CJEM, V4, P333; Perry JJ, 2005, ACAD EMERG MED, V12, P33, DOI 10.1197/j.aem.2004.11.007; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; RamirezLassepas M, 1997, ARCH NEUROL-CHICAGO, V54, P1506, DOI 10.1001/archneur.1997.00550240058013; ROOST KT, 1972, NEUROLOGY, V22, P973, DOI 10.1212/WNL.22.9.973; SAKAS DE, 1995, BRIT MED J, V310, P1186, DOI 10.1136/bmj.310.6988.1186; Sames TA, 1996, ACAD EMERG MED, V3, P16, DOI 10.1111/j.1553-2712.1996.tb03296.x; Schievink WI, 1996, J NEUROSURG, V84, P781, DOI 10.3171/jns.1996.84.5.0781; SCHIEVINK WI, 1994, LANCET, V343, P452, DOI 10.1016/S0140-6736(94)92693-X; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; SCHIEVINK WI, 1994, STROKE, V25, P889, DOI 10.1161/01.STR.25.4.889; SCHIEVINK WI, 1988, SURG NEUROL, V29, P367, DOI 10.1016/0090-3019(88)90045-6; SCHIEVINK WI, 1989, SURG NEUROL, V32, P266, DOI 10.1016/0090-3019(89)90228-0; SCHULL M, 2004, ACAD EMERG MED, V11, P487; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; Stiell IG, 2001, JAMA-J AM MED ASSOC, V286, P1841, DOI 10.1001/jama.286.15.1841; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; TAYLOR CL, 1995, J NEUROSURG, V83, P812, DOI 10.3171/jns.1995.83.5.0812; TOFTDAHL DB, 1995, NEUROSURGERY, V37, P235, DOI 10.1227/00006123-199508000-00007; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P908, DOI 10.1227/00006123-198512000-00007; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; Vermeulen MJ, 2007, STROKE, V38, P1216, DOI 10.1161/01.STR.0000259661.05525.9a; VESSEY MP, 1989, BMJ-BRIT MED J, V299, P1487, DOI 10.1136/bmj.299.6714.1487; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEIR B, 1994, CEPHALALGIA, V14, P79, DOI 10.1046/j.1468-2982.1994.1402079.x; WIEBERS DO, 1992, NEW ENGL J MED, V327, P953, DOI 10.1056/NEJM199209243271310	55	92	92	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 28	2010	341								c5204	10.1136/bmj.c5204	http://dx.doi.org/10.1136/bmj.c5204			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674ZH	21030443	hybrid, Green Published			2022-12-28	WOS:000283791700001
J	Freeman, JV; Zhu, RP; Owens, DK; Garber, AM; Hutton, DW; Go, AS; Wang, PJ; Turakhia, MP				Freeman, James V.; Zhu, Ruo P.; Owens, Douglas K.; Garber, Alan M.; Hutton, David W.; Go, Alan S.; Wang, Paul J.; Turakhia, Mintu P.			Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL CLASSIFICATION SCHEMES; RISK-FACTOR; HEMORRHAGIC COMPLICATIONS; MYOCARDIAL-INFARCTION; ORAL ANTICOAGULATION; NATIONAL REGISTRY; ASPIRIN; POPULATION; THERAPY; MANAGEMENT	Background: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation (AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin inhibitor with similar or reduced rates of ischemic stroke and intracranial hemorrhage in patients with AF compared with those of warfarin. Objective: To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF. Design: Markov decision model. Data Sources: The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial and other published studies of anticoagulation. The cost of dabigatran was estimated on the basis of pricing in the United Kingdom. Target Population: Patients aged 65 years or older with nonvalvular AF and risk factors for stroke (CHADS(2) score >= 1 or equivalent) and no contraindications to anticoagulation. Time Horizon: Lifetime. Perspective: Societal. Intervention: Warfarin anticoagulation (target international normalized ratio, 2.0 to 3.0); dabigatran, 110 mg twice daily (low dose); and dabigatran, 150 mg twice daily (high dose). Outcome Measures: Quality-adjusted life-years (QALYs), costs (in 2008 U. S. dollars), and incremental cost-effectiveness ratios. Results of Base-Case Analysis: The quality-adjusted life expectancy was 10.28 QALYs with warfarin, 10.70 QALYs with low-dose dabigatran, and 10.84 QALYs with high-dose dabigatran. Total costs were $143 193 for warfarin, $164 576 for low-dose dabigatran, and $168 398 for high-dose dabigatran. The incremental cost-effectiveness ratios compared with warfarin were $51 229 per QALY for low-dose dabigatran and $45 372 per QALY for high-dose dabigatran. Results of Sensitivity Analysis: The model was sensitive to the cost of dabigatran but was relatively insensitive to other model inputs. The incremental cost-effectiveness ratio increased to $50 000 per QALY at a cost of $13.70 per day for high-dose dabigatran but remained less than $85 000 per QALY over the full range of model inputs evaluated. The cost-effectiveness of high-dose dabigatran improved with increasing risk for stroke and intracranial hemorrhage. Limitation: Event rates were largely derived from a single randomized clinical trial and extrapolated to a 35-year time frame from clinical trials with approximately 2-year follow-up. Conclusion: In patients aged 65 years or older with nonvalvular AF at increased risk for stroke (CHADS(2) score >= 1 or equivalent), dabigatran may be a cost-effective alternative to warfarin depending on pricing in the United States.	[Turakhia, Mintu P.] Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Kaiser Permanente No Calif, Oakland, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Michigan System; University of Michigan; Kaiser Permanente; University of California System; University of California San Francisco	Turakhia, MP (corresponding author), Stanford Univ, Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave,111C, Palo Alto, CA 94304 USA.	mintu@stanford.edu	Go, Alan S./AAE-7745-2019	Turakhia, Minang/0000-0001-8025-0904	American Heart Association [0875162N]; Veterans Affairs Health Services Research & Development Service [CDA09027-1]; American Heart Association National Scientist Development [09SDG2250647]	American Heart Association(American Heart Association); Veterans Affairs Health Services Research & Development Service(US Department of Veterans Affairs); American Heart Association National Scientist Development(American Heart Association)	Primary Funding Source: American Heart Association and Veterans Affairs Health Services Research & Development Service.; Grant Support: By an American Heart Association Pharmaceutical Round Table Outcomes Research Postdoctoral Fellowship (0875162N; Dr. Freeman), a Veterans Affairs Health Services Research & Development Career Development Award (CDA09027-1; Dr. Turakhia), and an American Heart Association National Scientist Development Grant (09SDG2250647; Dr. Turakhia).	Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690; Albers GW, 2003, LANCET, V362, P1691; American Medical Association, CPT COD REL VAL SEAR; [Anonymous], 2009, IND ROCH DIAGN; [Anonymous], 2010, PRIC ORD COMP; [Anonymous], 2010, DAB APPR HIST LETT R; [Anonymous], 2009, PRESCR COST AN ENGL; Arias Elizabeth, 2007, Natl Vital Stat Rep, V56, P1; Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Blackshear JL, 1996, LANCET, V348, P633; Centers for Medicare & Medicaid Services, 2008, 2009 PHYS FEE SCHED; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Copland M, 2001, ARCH INTERN MED, V161, P2125, DOI 10.1001/archinte.161.17.2125; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Dries DL, 1998, J AM COLL CARDIOL, V32, P695, DOI 10.1016/S0735-1097(98)00297-6; Eckman MH, 2009, ANN INTERN MED, V150, P73, DOI 10.7326/0003-4819-150-2-200901200-00005; Epstein RS, 2010, J AM COLL CARDIOL, V55, P2804, DOI 10.1016/j.jacc.2010.03.009; Eriksson BI, 2007, LANCET, V370, P949, DOI 10.1016/S0140-6736(07)61445-7; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034; Fang MC, 2007, AM J MED, V120, P700, DOI 10.1016/j.amjmed.2006.07.034; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gage BF, 2000, AM J MED, V109, P481, DOI 10.1016/S0002-9343(00)00545-3; Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Gross DJ, 2007, TRENDS MANUFACTURER; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Hart RG, 1999, HEART, V82, P539, DOI 10.1136/hrt.82.5.539; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Holloway RG, 1996, NEUROLOGY, V46, P854; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Kauf TL, 2006, AM HEART J, V151, P206, DOI 10.1016/j.ahj.2005.02.028; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Leey JA, 2009, AM J GERIATR PHARMAC, V7, P197, DOI 10.1016/j.amjopharm.2009.07.002; Leibson CL, 1996, NEUROLOGY, V46, P861; Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Mark DB, 2008, AM HEART J, V156, P698, DOI 10.1016/j.ahj.2008.05.032; Matchar DB, 2000, AHRQ PUBL; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; National Institute for Health and Clinical Excellence, 2008, NICE TECHN APPR GUID; O'Brien CL, 2005, JAMA-J AM MED ASSOC, V293, P699, DOI 10.1001/jama.293.6.699; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; PETERSEN P, 1989, LANCET, V1, P175; Red Book, 2009, RED BOOK; Schulman S, 2009, NEW ENGL J MED, V361, P2342, DOI 10.1056/NEJMoa0906598; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stangier J, 2009, CLIN APPL THROMB-HEM, V15, p9S, DOI 10.1177/1076029609343004; Sullivan PW, 2006, MED DECIS MAKING, V26, P401, DOI 10.1177/0272989X06290496; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Tsevat J, 2001, AM HEART J, V141, P727, DOI 10.1067/mhj.2001.114805; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Waterman AD, 2004, AM J HEALTH-SYST PH, V61, P1258, DOI 10.1093/ajhp/61.12.1258; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Wyse DG, 2001, J INTERV CARD ELECTR, V5, P267, DOI 10.1023/A:1011460631369; Yuan Z, 1998, AM J PUBLIC HEALTH, V88, P395, DOI 10.2105/AJPH.88.3.395	75	324	330	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2011	154	1					1	U129		10.7326/0003-4819-154-1-201101040-00289	http://dx.doi.org/10.7326/0003-4819-154-1-201101040-00289			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701OT	21041570				2022-12-28	WOS:000285830900001
J	Sinaiko, AD; Rosenthal, MB				Sinaiko, Anna D.; Rosenthal, Meredith B.			Patients' Role in Accountable Care Organizations.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sinaiko, Anna D.; Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Sinaiko, AD (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.			Rosenthal, Meredith/0000-0003-3410-0184				Beshears J, 2008, J PUBLIC ECON, V92, P1787, DOI 10.1016/j.jpubeco.2008.04.010; Christianson JB, 2002, HEALTH AFFAIR, V21, P76, DOI 10.1377/hlthaff.21.1.76; Fisher ES, 2007, HEALTH AFFAIR, V26, pW44, DOI 10.1377/hlthaff.26.1.w44; KLING JR, 2008, MISPERCEPTION CHOOSI; Sinaiko AD, 2010, AM J MANAG CARE, V16, P123	5	21	21	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2010	363	27					2583	2585		10.1056/NEJMp1011927	http://dx.doi.org/10.1056/NEJMp1011927			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	700SD	21067375				2022-12-28	WOS:000285763700003
J	Morishita, H; Miwa, JM; Heintz, N; Hensch, TK				Morishita, Hirofumi; Miwa, Julie M.; Heintz, Nathaniel; Hensch, Takao K.			Lynx1, a Cholinergic Brake, Limits Plasticity in Adult Visual Cortex	SCIENCE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; OCULAR-DOMINANCE PLASTICITY; LATERAL GENICULATE-NUCLEUS; MUSCARINIC RECEPTORS; PROTOTOXIN LYNX1; GABA RELEASE; MODULATION; INHIBITION; NEUROMODULATORS; INTERNEURONS	Experience-dependent brain plasticity typically declines after an early critical period during which circuits are established. Loss of plasticity with closure of the critical period limits improvement of function in adulthood, but the mechanisms that change the brain's plasticity remain poorly understood. Here, we identified an increase in expression of Lynx1 protein in mice that prevented plasticity in the primary visual cortex late in life. Removal of this molecular brake enhanced nicotinic acetylcholine receptor signaling. Lynx1 expression thus maintains stability of mature cortical networks in the presence of cholinergic innervation. The results suggest that modulating the balance between excitatory and inhibitory circuits reactivates visual plasticity and may present a therapeutic target.	[Morishita, Hirofumi; Hensch, Takao K.] Harvard Univ, Sch Med, Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Miwa, Julie M.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Miwa, Julie M.; Heintz, Nathaniel] Rockefeller Univ, Howard Hughes Med Inst, Mol Biol Lab, New York, NY 10065 USA; [Hensch, Takao K.] Harvard Univ, Dept Mol Cellular Biol, Ctr Brain Sci, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; California Institute of Technology; Howard Hughes Medical Institute; Rockefeller University; Harvard University	Hensch, TK (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.	takao.hensch@childrens.harvard.edu	Morishita, Hirofumi/J-9619-2015; Hensch, Takao/L-4182-2019	Morishita, Hirofumi/0000-0002-1045-1337; Miwa, Julie/0000-0002-4418-3756	James S. McDonnell Foundation "Recovery from Amblyopia" network; NIH [1 DP1 OD 003699-01]; Ellison Medical Foundation; Howard Hughes Medical Institute; California Tobacco-Related Disease Research Program; Japanese Society for Promotion of Science;  [DA-17279]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017279] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003699] Funding Source: NIH RePORTER	James S. McDonnell Foundation "Recovery from Amblyopia" network; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); Howard Hughes Medical Institute(Howard Hughes Medical Institute); California Tobacco-Related Disease Research Program(University of California System); Japanese Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); ; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank M. Fagiolini, H. A. Lester, and A. Takesian for their helpful comments on the manuscript and M. Marcotrigiano for animal maintenance. This study was supported by the James S. McDonnell Foundation "Recovery from Amblyopia" network (T. K. H.), NIH Director's Pioneer Award (1 DP1 OD 003699-01 to T. K. H.), the Ellison Medical Foundation (T. K. H.), Howard Hughes Medical Institute (N.H.), DA-17279 and California Tobacco-Related Disease Research Program (J.M.M.), and the Japanese Society for Promotion of Science (H.M.)	Alkondon M, 2000, J NEUROSCI, V20, P66, DOI 10.1523/JNEUROSCI.20-01-00066.2000; Aracri P, 2010, CEREB CORTEX, V20, P1539, DOI 10.1093/cercor/bhp214; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; Chen Y, 2008, NAT NEUROSCI, V11, P974, DOI 10.1038/nn.2147; Davis JA, 2006, PSYCHOPHARMACOLOGY, V184, P345, DOI 10.1007/s00213-005-0047-y; Disney AA, 2007, NEURON, V56, P701, DOI 10.1016/j.neuron.2007.09.034; Dye MWG, 2009, NEUROPSYCHOLOGIA, V47, P1780, DOI 10.1016/j.neuropsychologia.2009.02.002; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; Goard M, 2009, NAT NEUROSCI, V12, P1444, DOI 10.1038/nn.2402; GU Q, 1993, EUR J NEUROSCI, V5, P475, DOI 10.1111/j.1460-9568.1993.tb00514.x; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Herrero JL, 2008, NATURE, V454, P1110, DOI 10.1038/nature07141; Hess RF, 2009, EUR J NEUROSCI, V29, P1064, DOI 10.1111/j.1460-9568.2009.06650.x; Ibanez-Tallon I, 2002, NEURON, V33, P893, DOI 10.1016/S0896-6273(02)00632-3; Kang JI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005995; Kruglikov I, 2008, NEURON, V58, P911, DOI 10.1016/j.neuron.2008.04.024; Kuo MC, 2009, NEUROSCIENCE, V163, P430, DOI 10.1016/j.neuroscience.2009.06.026; Lempert P, 2005, OPHTHAL PHYSL OPT, V25, P592, DOI 10.1111/j.1475-1313.2005.00329.x; Levi DM, 2009, PHILOS T R SOC B, V364, P399, DOI 10.1098/rstb.2008.0203; Lucas-Meunier E, 2009, CEREB CORTEX, V19, P2411, DOI 10.1093/cercor/bhn258; Mann EO, 2008, CURR OPIN NEUROL, V21, P155, DOI 10.1097/WCO.0b013e3282f52f5f; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Mitchell JF, 2007, NEURON, V55, P131, DOI 10.1016/j.neuron.2007.06.018; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; Miwa JM, 2006, NEURON, V51, P587, DOI 10.1016/j.neuron.2006.07.025; Morishita H, 2008, CURR OPIN NEUROBIOL, V18, P101, DOI 10.1016/j.conb.2008.05.009; PARKINSON D, 1988, EXP BRAIN RES, V73, P553, DOI 10.1007/BF00406614; Pfeffer CK, 2009, J NEUROSCI, V29, P3419, DOI 10.1523/JNEUROSCI.1377-08.2009; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Plessy C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003012; PRUSKY GT, 1987, BRAIN RES, V412, P131, DOI 10.1016/0006-8993(87)91447-8; Sarter M, 2005, BRAIN RES REV, V48, P98, DOI 10.1016/j.brainresrev.2004.08.006; Satta R, 2008, P NATL ACAD SCI USA, V105, P16356, DOI 10.1073/pnas.0808699105; Silver MA, 2008, NEURON, V60, P904, DOI 10.1016/j.neuron.2008.09.038; Syken J, 2006, SCIENCE, V313, P1795, DOI 10.1126/science.1128232; Wandell BA, 2009, NAT REV NEUROSCI, V10, P873, DOI 10.1038/nrn2741	36	275	285	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2010	330	6008					1238	1240		10.1126/science.1195320	http://dx.doi.org/10.1126/science.1195320			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	685FE	21071629	Green Accepted			2022-12-28	WOS:000284613700040
J	Di Lazzaro, V; Pilato, F; Batocchi, AP; Restuccia, D; Cammarota, G; Profice, P				Di Lazzaro, Vincenzo; Pilato, Fabio; Batocchi, Anna Paola; Restuccia, Domenico; Cammarota, Giovanni; Profice, Paolo			Tired legs-a gut diagnosis	LANCET			English	Editorial Material									[Di Lazzaro, Vincenzo; Pilato, Fabio; Batocchi, Anna Paola; Restuccia, Domenico; Profice, Paolo] Univ Cattolica, Dept Neurosci, I-00168 Rome, Italy; [Cammarota, Giovanni] Univ Cattolica, Dept Internal Med, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Di Lazzaro, V (corresponding author), Univ Cattolica, Dept Neurosci, Largo A Gemelli 8, I-00168 Rome, Italy.	vdilazzaro@rm.unicatt.it	Pilato, Fabio/AAE-9229-2022; Cammarota, Giovanni/AAD-1732-2022; Di Lazzaro, Vincenzo/L-3731-2018; Pilato, Fabio/AAB-9059-2019; Pilato, Fabio/B-6397-2013	Pilato, Fabio/0000-0002-7248-3916; Cammarota, Giovanni/0000-0002-3626-6148; Di Lazzaro, Vincenzo/0000-0002-9113-5925; Pilato, Fabio/0000-0002-7248-3916; restuccia, domenico/0000-0002-7273-7162; Profice, Paolo/0000-0001-9923-9246				DILAZZARO V, 1992, ELECTROEN CLIN NEURO, V84, P433, DOI 10.1016/0168-5597(92)90030-F; Hadjivassiliou M, 1998, LANCET, V352, P1582, DOI 10.1016/S0140-6736(98)05342-2; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; Siebert E, 2009, NAT REV NEUROL, V5, P392, DOI 10.1038/nrneurol.2009.90; Wong S H, 2008, Pract Neurol, V8, P90, DOI 10.1136/jnnp.2008.144121	5	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2010	376	9754					1798	1798		10.1016/S0140-6736(10)61163-4	http://dx.doi.org/10.1016/S0140-6736(10)61163-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	690EI	21093652				2022-12-28	WOS:000284984900035
J	Frieden, TR; Koplan, JP				Frieden, Thomas R.; Koplan, Jeffrey P.			Stronger national public health institutes for global health	LANCET			English	Editorial Material							EPIDEMIC INTELLIGENCE SERVICE; FOR-DISEASE-CONTROL		[Frieden, Thomas R.] Ctr Dis Control & Prevent, Off Director, Atlanta, GA 30329 USA; [Koplan, Jeffrey P.] Emory Univ, Emory Global Hlth Inst, Atlanta, GA 30322 USA	Centers for Disease Control & Prevention - USA; Emory University	Frieden, TR (corresponding author), Ctr Dis Control & Prevent, Off Director, Atlanta, GA 30329 USA.			Frieden, Thomas/0000-0002-4759-2256				Binder S, 2008, J PUBLIC HEALTH POL, V29, P3, DOI 10.1057/palgrave.jphp.3200167; *CDCP, 2010, FIELD EP LAB TRAIN P; Etheridge E.W, 1992, SENTINEL HLTH HIST C, P36; Frieden TR, 2009, GLOB PUBLIC HEALTH, V4, P323, DOI 10.1080/17441690903089430; International Association of National Public Health Networks, 2007, FRAM CREAT DEV NAT P, V1; LANGMUIR AD, 1980, PUBLIC HEALTH REP, V95, P470; Thacker SB, 2001, AM J EPIDEMIOL, V154, P985, DOI 10.1093/aje/154.11.985	7	30	31	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 20	2010	376	9754					1721	1722		10.1016/S0140-6736(10)62007-7	http://dx.doi.org/10.1016/S0140-6736(10)62007-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690EI	21093637	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000284984900009
J	Millum, J; Menikoff, J				Millum, Joseph; Menikoff, Jerry			Streamlining Ethical Review	ANNALS OF INTERNAL MEDICINE			English	Review								The review system for human subjects research in the United States has been widely criticized in recent years for requirements that delay research without improving human subject protections. Any major reformulation of regulations may take some time to implement. However, current regulations often allow for streamlined ethics review that does not jeopardize-and may improve-protections for research participants. The authors discuss under-utilized options, including research that need not be classified as human subjects research, categories of studies that can be exempt from ethical review, studies that need only undergo expedited review by 1 institutional review board (IRB) member, and simplifying reviews of multicenter research by using the IRB of 1 institution. The authors speculate on multiple reasons for the underuse of these mechanisms and exhort IRBs and researchers to take advantage of these important opportunities to improve the review process.	[Millum, Joseph] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA; NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; Off Human Res Protect, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Millum, J (corresponding author), NIH, Ctr Clin, Dept Bioeth, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	millumj@cc.nih.gov			Intramural NIH HHS [Z99 CL999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Burman W, 2009, CLIN INFECT DIS, V49, P328, DOI 10.1086/605454; Byrne MM, 2006, ACAD MED, V81, P708, DOI 10.1097/00001888-200608000-00006; Department of Agriculture Department of Energy National Aeronautics and Space Administration Department of Commerce Consumer Product Safety Commission International Development Cooperation Agency Agency for International Development Department of Housing and Urban Development Department of Justice Department of Defense Department of Education Department of Veterans Affairs Environmental Protection Agency Department of Health and Human Services National Science Foundation and Department of Transportation, 1991, FED REGISTER, V56, P28003; Fost N, 2007, JAMA-J AM MED ASSOC, V298, P2196, DOI 10.1001/jama.298.18.2196; Gunsalus CK, 2007, QUAL INQ, V13, P617, DOI 10.1177/1077800407300785; Larson E, 2004, J NURS SCHOLARSHIP, V36, P260, DOI 10.1111/j.1547-5069.2004.04047.x; Levine RJ, 2001, ANN INTERN MED, V134, P161, DOI 10.7326/0003-4819-134-2-200101160-00018; Menikoff J, 2007, NORTHWEST U LAW REV, V101, P791; *OFF HUM RES PROT, 2009, REQ INF COMM IRB ACC, P27953; Office for human research protections, 2008, GUID RES INV COD PRI; SATEL S, 2009, NY TIMES        0808, pA19; Wagner RM, 2003, MUSCLE NERVE, V28, P27, DOI 10.1002/mus.10398; 1998, FED REG, V63, P60353	13	24	24	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					655	657		10.7326/0003-4819-153-10-201011160-00008	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680ES	21079221	Green Accepted, Green Submitted			2022-12-28	WOS:000284215800018
J	Beaglehole, R; Horton, R				Beaglehole, Robert; Horton, Richard			Chronic diseases: global action must match global evidence	LANCET			English	Editorial Material							LOW-INCOME; PREVENTION; COSTS		[Beaglehole, Robert] Devonport, Auckland 0624, New Zealand; [Horton, Richard] The Lancet, London, England		Beaglehole, R (corresponding author), Devonport, Auckland 0624, New Zealand.							Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Alleyne G, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-15; ALWAN A, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61853.3; [Anonymous], 2005, PREV CHRON DIS VIT I; Asaria P, 2007, LANCET, V370, P2044, DOI 10.1016/S0140-6736(07)61698-5; Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; CECCHINI M, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61514.0; Epping-Jordan JE, 2005, LANCET, V366, P1667, DOI 10.1016/S0140-6736(05)67342-4; Gaziano TA, 2007, LANCET, V370, P1939, DOI 10.1016/S0140-6736(07)61697-3; GENEAU R, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61414.6; Horton R, 2005, LANCET, V366, P1514, DOI 10.1016/S0140-6736(05)67454-5; Horton R, 2007, LANCET, V370, P1881, DOI 10.1016/S0140-6736(07)61701-2; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; LOCK K, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61352.9; Reddy KS, 2005, LANCET, V366, P1744, DOI [10.1016/s0140-6736(05)67343-6, 10.1016/S0140-6736(05)67343-6]; SAMB B, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61353.0; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11	18	60	61	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1619	1621		10.1016/S0140-6736(10)61929-0	http://dx.doi.org/10.1016/S0140-6736(10)61929-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	683DD	21074261				2022-12-28	WOS:000284451000004
J	Garrick-Bethell, I; Nimmo, F; Wieczorek, MA				Garrick-Bethell, Ian; Nimmo, Francis; Wieczorek, Mark A.			Structure and Formation of the Lunar Farside Highlands	SCIENCE			English	Article							ICE SHELL; EUROPA; MOON; ASYMMETRY; CONSTRAINTS; TOPOGRAPHY; ORIGIN; MANTLE; CREEP; SHAPE	The formation of the lunar farside highlands has long been an open problem in lunar science. We show that much of the topography and crustal thickness in this terrain can be described by a degree-2 harmonic. No other portion of the Moon exhibits comparable degree-2 structure. The quantified structure of the farside highlands unites them with the nearside and suggests a relation between lunar crustal structure, nearside volcanism, and heat-producing elements. The farside topography cannot be explained by a frozen-in tidal bulge. However, the farside crustal thickness and the topography it produces may have been caused by spatial variations in tidal heating when the ancient crust was decoupled from the mantle by a liquid magma ocean, similar to Europa's present ice shell.	[Garrick-Bethell, Ian] Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; [Garrick-Bethell, Ian; Nimmo, Francis] Univ Calif Santa Cruz, Dept Earth & Planetary Sci, Santa Cruz, CA 95064 USA; [Wieczorek, Mark A.] Inst Phys Globe Paris Sorbonne Paris Cite, Paris, France	Brown University; University of California System; University of California Santa Cruz; UDICE-French Research Universities; Universite Paris Cite	Garrick-Bethell, I (corresponding author), Univ Calif Santa Cruz, Dept Earth & Planetary Sci, 1156 High St, Santa Cruz, CA 95064 USA.	igarrick@ucsc.edu	Wieczorek, Mark A/G-6427-2010; Garrick-Bethell, Ian/E-7051-2013	Wieczorek, Mark A/0000-0001-7007-4222; Garrick-Bethell, Ian/0000-0002-6327-5867				Garrick-Bethell I, 2009, ICARUS, V204, P399, DOI 10.1016/j.icarus.2009.05.032; HESS PC, 1978, P LUNAR PLANET SCI C, V9, P705; Jeffreys H, 1976, EARTH; Jolliff BL, 2000, J GEOPHYS RES-PLANET, V105, P4197, DOI 10.1029/1999JE001103; KAULA WM, 1974, P LUNAR PLANET SCI C, V5, P3049; Loper DE, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2000JE001441; Namiki N, 2009, SCIENCE, V323, P900, DOI 10.1126/science.1168029; Nemchin A, 2009, NAT GEOSCI, V2, P133, DOI 10.1038/NGEO417; Nimmo F, 2007, ICARUS, V191, P183, DOI 10.1016/j.icarus.2007.04.021; Nimmo F, 2010, ICARUS, V208, P896, DOI 10.1016/j.icarus.2010.02.020; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; Parmentier EM, 2002, EARTH PLANET SC LETT, V201, P473, DOI 10.1016/S0012-821X(02)00726-4; PARMENTIER EM, 2010, 41 LUN PLAN SCI C LP; Rybacki E, 2000, J GEOPHYS RES-SOL EA, V105, P26017, DOI 10.1029/2000JB900223; Shearer CK, 2006, REV MINERAL GEOCHEM, V60, P365, DOI 10.2138/rmg.2006.60.4; Smith DE, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2010GL043751; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Solomon S. C., 1977, P LUNAR PLANET SCI C, P583; Tobie G, 2005, ICARUS, V177, P534, DOI 10.1016/j.icarus.2005.04.006; Van Orman JA, 2000, METEORIT PLANET SCI, V35, P783, DOI 10.1111/j.1945-5100.2000.tb01462.x; WASSON JT, 1980, ICARUS, V44, P752, DOI 10.1016/0019-1035(80)90142-6; Wieczorek MA, 1999, ICARUS, V139, P246, DOI 10.1006/icar.1999.6102; Wilhelms D.E., 1987, USGS PROFESSIONAL PA; Wood J. A., 1973, Moon, V8, P73, DOI 10.1007/BF00562751; Zhong SJ, 2000, J GEOPHYS RES-PLANET, V105, P4153, DOI 10.1029/1999JE001075; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839	27	32	32	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					949	951		10.1126/science.1193424	http://dx.doi.org/10.1126/science.1193424			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071665				2022-12-28	WOS:000284118000038
J	Resnic, FS; Gross, TP; Marinac-Dabic, D; Loyo-Berrios, N; Donnelly, S; Normand, SLT; Matheny, ME				Resnic, Frederic S.; Gross, Thomas P.; Marinac-Dabic, Danica; Loyo-Berrios, Nilsa; Donnelly, Sharon; Normand, Sharon-Lise T.; Matheny, Michael E.			Automated Surveillance to Detect Postprocedure Safety Signals of Approved Cardiovascular Devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERVENTIONAL CARDIOLOGY; RANDOMIZED-TRIAL; MEDICAL DEVICE; STENTS; CATHETERIZATION; COMPLICATIONS; METAANALYSIS; REGISTRY; HOLES; RISK	Context Ensuring the safety of medical devices challenges current surveillance approaches, which rely heavily on voluntary reporting of adverse events. Automated surveillance of clinical registries may provide early warnings in the postmarket evaluation of medical device safety. Objective To determine whether automated safety surveillance of clinical registries using a computerized tool can provide early warnings regarding the safety of new cardiovascular devices. Design, Setting, and Patients Prospective propensity-matched cohort analysis of 7 newly introduced cardiovascular devices, using clinical data captured in the Massachusetts implementation of the National Cardiovascular Data Repository CathPCI Registry for all adult patients undergoing percutaneous coronary intervention from April 2003 through September 2007 in Massachusetts. Main Outcome Measure Presence of any safety alert, triggered if the cumulative observed risk for a given device exceeded the upper 95% confidence interval (CI) of comparator control device. Predefined sensitivity analyses assessed robustness of alerts when triggered. Results We evaluated 74 427 consecutive interventional coronary procedures. Three of 21 safety analyses triggered sustained alerts in 2 implantable devices. Patients receiving Taxus Express2 drug-eluting stents experienced a 1.28-fold increased risk of post-procedural myocardial infarction (2.87% vs 2.25%; absolute risk increase, 0.62% [95% CI, 0.25%-0.99%]) and a 1.21-fold increased risk of major adverse cardiac events (4.24% vs 3.50%; absolute increase, 0.74% [95% CI, 0.29%-1.19%]) compared with those receiving alternative drug-eluting stents. Patients receiving Angio-Seal STS vascular closure devices experienced a 1.51-fold increased risk of major vascular complications (1.09% vs 0.72%; absolute increased risk, 0.37% [95% CI, 0.03%-0.71%]) compared with those receiving alternative vascular closure devices. Sensitivity analyses confirmed increased risk following use of the Taxus Express2 stent but not the Angio-Seal STS device. Conclusion Automated prospective surveillance of clinical registries is feasible and can identify low-frequency safety signals for new cardiovascular devices. JAMA. 2010;304(18):2019-2027 www.jama.com	[Resnic, Frederic S.; Donnelly, Sharon] Brigham & Womens Hosp, Boston, MA 02115 USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Gross, Thomas P.; Marinac-Dabic, Danica; Loyo-Berrios, Nilsa] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Matheny, Michael E.] Tennessee Valley Healthcare Syst, Vet Adm Med Ctr, Nashville, TN USA; [Matheny, Michael E.] Vanderbilt Univ, Med Ctr, Nashville, TN USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Food & Drug Administration (FDA); Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Resnic, FS (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	fresnic@partners.org	Matheny, Michael E/B-3541-2008	Matheny, Michael E/0000-0003-3217-4147; Normand, Sharon-Lise/0000-0001-7027-4769; Marinac-Dabic, Danica/0000-0002-1824-0104	Boston Scientific Inc; Abbott Vascular Inc; Cordis Corp; St Jude Medical; Medicines Company; National Library of Medicine [NIH R01-LM008142]; US Food and Drug Administration [HHSF 223200830058C]; Veterans Administration Health Services Research and Development Service [CDP 09-387]; Division of Healthcare Quality and Statistics, Massachusetts Department of Public Health; NATIONAL LIBRARY OF MEDICINE [R01LM008142] Funding Source: NIH RePORTER	Boston Scientific Inc(Boston Scientific); Abbott Vascular Inc(Abbott Laboratories); Cordis Corp; St Jude Medical(St. Jude Medical); Medicines Company; National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); US Food and Drug Administration; Veterans Administration Health Services Research and Development Service; Division of Healthcare Quality and Statistics, Massachusetts Department of Public Health; NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Dr Resnic and Dr Matheny reported filing a patent application, currently under review at the US Patent Office, for several key analytic components of the DELTA surveillance system; the intellectual property rights of Drs Resnic and Matheny (current and former employees of Brigham and Women's Hospital) related to the development of DELTA are assigned to the institution, and Partners Healthcare, the parent organization of Brigham and Women's Hospital, retains partial rights for DELTA use and licensing. Neither Dr Resnic nor Dr Matheny have previously received or anticipate any financial compensation, stock options, income, or ownership in DELTA, Coping Systems, or any other related commercial entity. Dr Resnic reported receiving modest consulting income from Boston Scientific Inc, Abbott Vascular Inc, Cordis Corp, and St Jude Medical and receiving research grants from The Medicines Company. No other authors reported dislosures.; This study was funded, in part, by grants from the National Library of Medicine (NIH R01-LM008142) and the US Food and Drug Administration (HHSF 223200830058C) as well as from the Veterans Administration Health Services Research and Development Service (CDP 09-387).; The National Institutes of Health, the Veterans Administration Health Services Research and Development Service, and the US Food and Drug Administration had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. However, the preliminary proposed study protocol was provided to the Veterans Administration Health Services Research and Development Service and the US Food and Drug Administration as part of the original grant and contract application process.; We acknowledge the significant system development and technical contributions of Richard Cope, BS, and Susan Robbins, BS, of Coping Systems Inc, Andover, Massachusetts. Coping Systems was a subcontractor to Brigham and Women's Hospital, and neither Mr Cope nor Ms Robbins received extra compensation for their contributions; Mr Cope is part owner of Coping Systems and is also named on the patent application filed by Dr Resnic and Dr Matheny. We also acknowledge the support of the Division of Healthcare Quality and Statistics, Massachusetts Department of Public Health.	Aggarwal A, 2009, HEART RHYTHM, V6, P1565, DOI 10.1016/j.hrthm.2009.08.006; Austin PC, 2009, MED DECIS MAKING, V29, P661, DOI 10.1177/0272989X09341755; Austin PC, 2009, BIOMETRICAL J, V51, P171, DOI 10.1002/bimj.200810488; Brindis R G, 2001, J Am Coll Cardiol, V37, P2240, DOI 10.1016/S0735-1097(01)01372-9; Garber AM, 2010, NEW ENGL J MED, V362, P1161, DOI 10.1056/NEJMp1000447; Gross T P, 1996, Stud Health Technol Inform, V28, P17; Hammill S, 2006, HEART RHYTHM, V3, P470, DOI 10.1016/j.hrthm.2006.01.019; Holman WL, 2009, J AM COLL SURGEONS, V208, P755, DOI 10.1016/j.jamcollsurg.2008.11.016; Koreny M, 2004, JAMA-J AM MED ASSOC, V291, P350, DOI 10.1001/jama.291.3.350; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; *MA DAT AN CTR, 2009, PERC COR INT COMM MA; Maisel WH, 2007, NEW ENGL J MED, V356, P981, DOI 10.1056/NEJMp068305; Matheny ME, 2006, J AM MED INFORM ASSN, V13, P180, DOI 10.1197/jamia.M1908; Matheny ME, 2008, AM HEART J, V155, P114, DOI 10.1016/j.ahj.2007.08.022; Matheny Michael E, 2007, AMIA Annu Symp Proc, P518; Matheny ME, 2009, MED DECIS MAKING, V29, P247, DOI 10.1177/0272989X08327110; Mauri L, 2008, CIRCULATION, V118, P1817, DOI 10.1161/CIRCULATIONAHA.108.781377; Mauri L, 2008, NEW ENGL J MED, V359, P1330, DOI 10.1056/NEJMoa0801485; *NAT CARD DAT REG, 2010, DESCR NCDR CATHPCI R; Nikolsky E, 2004, J AM COLL CARDIOL, V44, P1200, DOI 10.1016/j.jacc.2004.06.048; O'Shea JC, 2004, AM HEART J, V147, P977, DOI 10.1016/j.ahj.2004.03.001; Peterson ED, 2004, AM HEART J, V147, P985, DOI 10.1016/j.ahj.2004.03.002; Platt R, 2009, NEW ENGL J MED, V361, P645, DOI 10.1056/NEJMp0905338; Popma JJ, 2009, CIRC-CARDIOVASC INTE, V2, P133, DOI 10.1161/CIRCINTERVENTIONS.108.832048; Rao SV, 2008, AM HEART J, V156, P201, DOI 10.1016/j.ahj.2008.01.036; Resnic FS, 2004, MED DECIS MAKING, V24, P399, DOI 10.1177/0272989X04267012; Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167; Samore MH, 2004, JAMA-J AM MED ASSOC, V291, P325, DOI 10.1001/jama.291.3.325; Shah JS, 2006, JAMA-J AM MED ASSOC, V296, P655, DOI 10.1001/jama.296.6.655; Stone GW, 2007, JAMA-J AM MED ASSOC, V298, P2497, DOI 10.1001/jama.298.21.2497; Stone GW, 2005, JAMA-J AM MED ASSOC, V294, P1215, DOI 10.1001/jama.294.10.1215; Tavris Dale R, 2005, J Invasive Cardiol, V17, P644; Warren BS, 1999, CATHETER CARDIO INTE, V48, P162, DOI 10.1002/(SICI)1522-726X(199910)48:2<162::AID-CCD8>3.0.CO;2-2	33	50	50	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2019	2027		10.1001/jama.2010.1633	http://dx.doi.org/10.1001/jama.2010.1633			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063011	Bronze, Green Accepted			2022-12-28	WOS:000284000600020
J	Sitzwohl, C; Langheinrich, A; Schober, A; Krafft, P; Sessler, DI; Herkner, H; Gonano, C; Weinstabl, C; Kettner, SC				Sitzwohl, Christian; Langheinrich, Angelika; Schober, Andreas; Krafft, Peter; Sessler, Daniel I.; Herkner, Harald; Gonano, Christopher; Weinstabl, Christian; Kettner, Stephan C.			Endobronchial intubation detected by insertion depth of endotracheal tube, bilateral auscultation, or observation of chest movements: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACOUSTIC REFLECTOMETRY; INCIDENT REPORTS; BREATH SOUNDS; ANESTHESIA; PLACEMENT; ADULTS; CLAIMS	Objective To determine which bedside method of detecting inadvertent endobronchial intubation in adults has the highest sensitivity and specificity. Design Prospective randomised blinded study. Setting Department of anaesthesia in tertiary academic hospital. Participants 160 consecutive patients (American Society of Anesthesiologists category I or II) aged 19-75 scheduled for elective gynaecological or urological surgery. Interventions Patients were randomly assigned to eight study groups. In four groups, an endotracheal tube was fibreoptically positioned 2.5-4.0 cm above the carina, whereas in the other four groups the tube was positioned in the right mainstem bronchus. The four groups differed in the bedside test used to verify the position of the endotracheal tube. To determine whether the tube was properly positioned in the trachea, in each patient first year residents and experienced anaesthetists were randomly assigned to independently perform bilateral auscultation of the chest (auscultation); observation and palpation of symmetrical chest movements (observation); estimation of the position of the tube by the insertion depth (tube depth); or a combination of all three (all three). Main outcome measures Correct and incorrect judgments of endotracheal tube position. Results 160 patients underwent 320 observations by experienced and inexperienced anaesthetists. First year residents missed endobronchial intubation by auscultation in 55% of cases and performed significantly worse than experienced anaesthetists with this bedside test (odds ratio 10.0, 95% confidence interval 1.4 to 434). With a sensitivity of 88% (95% confidence interval 75% to 100%) and 100%, respectively, tube depth and the three tests combined were significantly more sensitive for detecting endobronchial intubation than auscultation (65%, 49% to 81%) or observation(43%, 25% to 60%) (P<0.001). The four tested methods had the same specificity for ruling out endobronchial intubation (that is, confirming correct tracheal intubation). The average correct tube insertion depth was 21 cm in women and 23 cm in men. By inserting the tube to these distances, however, the distal tip of the tube was less than 2.5 cm away from the carina (the recommended safety distance, to prevent inadvertent endobronchial intubation with changes in the position of the head in intubated patients) in 20% (24/118) of women and 18% (7/42) of men. Therefore optimal tube insertion depth was considered to be 20 cm in women and 22 cm in men. Conclusion Less experienced clinicians should rely more on tube insertion depth than on auscultation to detect inadvertent endobronchial intubation. But even experienced physicians will benefit from inserting tubes to 20-21 cm in women and 22-23 cm in men, especially when high ambient noise precludes accurate auscultation (such as in emergency situations or helicopter transport). The highest sensitivity and specificity for ruling out endobronchial intubation, however, is achieved by combining tube depth, auscultation of the lungs, and observation of symmetrical chest movements.	[Sitzwohl, Christian; Langheinrich, Angelika; Schober, Andreas; Krafft, Peter; Gonano, Christopher; Weinstabl, Christian; Kettner, Stephan C.] Med Univ Vienna, Gen Hosp, Dept Anaesthesiol Gen Intens Care & Pain Control, A-1090 Vienna, Austria; [Sessler, Daniel I.] Cleveland Clin, Dept Outcomes Res, Cleveland, OH USA; [Herkner, Harald] Med Univ Vienna, Gen Hosp, Dept Emergency Med, A-1090 Vienna, Austria	Medical University of Vienna; Cleveland Clinic Foundation; Medical University of Vienna	Sitzwohl, C (corresponding author), Med Univ Vienna, Gen Hosp, Dept Anaesthesiol Gen Intens Care & Pain Control, A-1090 Vienna, Austria.	christian.sitzwohl@meduniwien.ac.at	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077; Schober, Andreas/0000-0003-1410-6108; Herkner, Harald/0000-0003-1329-6149				BRUNEL W, 1989, CHEST, V96, P1043, DOI 10.1378/chest.96.5.1043; CAPLAN RA, 1990, ANESTHESIOLOGY, V72, P828, DOI 10.1097/00000542-199005000-00010; Chun Rosaleen, 2004, Prehosp Disaster Med, V19, P366; Donald MJ, 2006, EMERG MED J, V23, P728, DOI 10.1136/emj.2006.037184; *EM CARD CAR COMM, 1992, JAMA-J AM MED ASSOC, V268, P2171; Evron S, 2007, J CLIN ANESTH, V19, P15, DOI 10.1016/j.jclinane.2006.06.005; Grmec S, 2002, INTENS CARE MED, V28, P701, DOI 10.1007/s00134-002-1290-x; KLEPPER ID, 1993, ANAESTH INTENS CARE, V21, P575, DOI 10.1177/0310057X9302100514; Knapp S, 1999, ANESTH ANALG, V88, P766, DOI 10.1097/00000539-199904000-00016; LARSEN R, 1999, LARSEN ANASTHESIE, P463; MORRAY JP, 1993, ANESTHESIOLOGY, V78, P461, DOI 10.1097/00000542-199303000-00009; Nolan J, 2005, RESUSCITATION, V67, pS3, DOI 10.1016/j.resuscitation.2005.10.002; O'Connor CJ, 2005, ANESTH ANALG, V101, P735, DOI 10.1213/01.ane.0000167068.71601.e4; OWEN RL, 1987, ANESTHESIOLOGY, V67, P255, DOI 10.1097/00000542-198708000-00019; Raphael DT, 2003, J CLIN ANESTH, V15, P41, DOI 10.1016/S0952-8180(02)00480-4; Raphael DT, 2002, ANESTHESIOLOGY, V97, P1371, DOI 10.1097/00000542-200212000-00007; ROBERTS JR, 1995, ACAD EMERG MED, V2, P20, DOI 10.1111/j.1553-2712.1995.tb03073.x; SCHWARTZ DE, 1994, CRIT CARE MED, V22, P1127, DOI 10.1097/00003246-199407000-00013; Sintavanuruk Krairerk, 2008, Journal of the Medical Association of Thailand, V91, P1854; Stone D.J., 2000, ANESTHESIA, V5th ed., P1431; Timmermann A, 2006, RESUSCITATION, V70, P179, DOI 10.1016/j.resuscitation.2006.01.010	21	64	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 9	2010	341								c5943	10.1136/bmj.c5943	http://dx.doi.org/10.1136/bmj.c5943			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KI	21062875	Green Published, hybrid			2022-12-28	WOS:000284311400011
J	Bredenoord, AL; Braude, P				Bredenoord, Annelien L.; Braude, Peter			Ethics of mitochondrial gene replacement: from bench to bedside	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DNA DISORDERS; DIAGNOSIS; RISKS		[Bredenoord, Annelien L.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; [Braude, Peter] Kings Coll London, Dept Womens Hlth, London WC2R 2LS, England; [Braude, Peter] Guys Hosp, Ctr Preimplantat Genet Diag, London SE1 9RT, England	Utrecht University; Utrecht University Medical Center; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Bredenoord, AL (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Stratenum 6-131,PO Box 85500, NL-3508 GA Utrecht, Netherlands.	A.L.Bredenoord@umcutrecht.nl			MRC [G0701172, G0801061] Funding Source: UKRI; Medical Research Council [G0701172, G0801061] Funding Source: Medline; Wellcome Trust [086034] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 2008, NATURE, V452, P913, DOI 10.1038/452913a; BARRITT JA, 2001, REPROD BIOMED ONLINE, V3, P47; Bredenoord AL, 2008, HUM REPROD UPDATE, V14, P669, DOI 10.1093/humupd/dmn035; Bredenoord AL, 2008, HUM REPROD, V23, P2392, DOI 10.1093/humrep/den290; Bredenoord A, 2009, EUR J HUM GENET, V17, P1550, DOI 10.1038/ejhg.2009.88; Bredenoord AL, 2010, HUM REPROD, V25, P1354, DOI 10.1093/humrep/deq077; Craven L, 2010, NATURE, V465, P82, DOI 10.1038/nature08958; Dresser Rebecca, 2004, IRB, V26, P1, DOI 10.2307/3563945; Dresser R, 2009, J LAW MED ETHICS, V37, P38, DOI 10.1111/j.1748-720X.2009.00349.x; Hawes SM, 2002, HUM REPROD, V17, P850, DOI 10.1093/humrep/17.4.850; Kimmelman J, 2008, NAT REV GENET, V9, P239, DOI 10.1038/nrg2317; Kimmelman Jonathan., 2010, GENE TRANSFER ETHICS; Malek J, 2007, J MED PHILOS, V32, P339, DOI 10.1080/03605310701515369; *MRC, 2004, ASS REPR SAF SOUND F; Parens E, 2001, SCIENCE, V292, P397, DOI 10.1126/science.292.5516.397; Pennings G, 2007, HUM REPROD, V22, P2585, DOI 10.1093/humrep/dem237; Pennings G, 2003, HUM REPROD UPDATE, V9, P397, DOI 10.1093/humupd/dmg031; Poulton J, 2010, NEUROMUSCULAR DISORD, V20, P559, DOI 10.1016/j.nmd.2010.05.008; Poulton J, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b94; Sugarman J, 1999, SCIENCE, V285, P2071, DOI 10.1126/science.285.5436.2071; Tachibana M, 2009, NATURE, V461, P367, DOI 10.1038/nature08368; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; THE PRESIDENT'S COUNCIL ON BIOETHICS, 2004, REPR RESP REG NEW BI; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245	24	25	25	0	51	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	2010	341								c6021	10.1136/bmj.c6021	http://dx.doi.org/10.1136/bmj.c6021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KD	21059727				2022-12-28	WOS:000284310100003
J	Sabot, O; Cohen, JM; Hsiang, MS; Kahn, JG; Basu, S; Tang, LH; Zheng, B; Gao, Q; Zou, LD; Tatarsky, A; Aboobakar, S; Usas, J; Barrett, S; Cohen, JL; Jamison, DT; Feachem, RGA				Sabot, Oliver; Cohen, Justin M.; Hsiang, Michelle S.; Kahn, James G.; Basu, Suprotik; Tang, Linhua; Zheng, Bin; Gao, Qi; Zou, Linda; Tatarsky, Allison; Aboobakar, Shahina; Usas, Jennifer; Barrett, Scott; Cohen, Jessica L.; Jamison, Dean T.; Feachem, Richard G. A.			Malaria Elimination 4 Costs and financial feasibility of malaria elimination	LANCET			English	Article							HEALTH-CARE; IMMUNIZATION SERVICES; ECONOMIC-EVALUATION; ERADICATION; POLIOMYELITIS; THERAPY; IMPACT; SOUTH; RISK	The marginal costs and benefits of converting malaria programmes from a control to an elimination goal are central to strategic decisions, but empirical evidence is scarce. We present a conceptual framework to assess the economics of elimination and analyse a central component of that framework potential short-term to medium-term financial savings. After a review that showed a dearth of existing evidence, the net present value of elimination in five sites was calculated and compared with effective control. The probability that elimination would be cost-saving over SO years ranged from 0% to 42%, with only one site achieving cost-savings in the base case. These findings show that financial savings should not be a primary rationale for elimination, but that elimination might still be a worthy investment if total benefits are sufficient to outweigh marginal costs. Robust research into these elimination benefits is urgently needed.	[Sabot, Oliver; Cohen, Justin M.; Zou, Linda; Tatarsky, Allison; Usas, Jennifer] Clinton Hlth Access Initiat, Boston, MA 02127 USA; [Cohen, Jessica L.] Harvard Univ, Harvard Sch Publ Hlth, Boston, MA 02115 USA; [Hsiang, Michelle S.; Feachem, Richard G. A.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA; [Kahn, James G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Basu, Suprotik] Off UN Special Envoy Malaria, New York, NY USA; [Aboobakar, Shahina] Mauritius Minist Hlth & Qual Life, Port Louis, Mauritius; [Barrett, Scott] Columbia Univ, Earth Inst, New York, NY USA; [Tang, Linhua; Zheng, Bin] Natl Inst Parasit Dis, Shanghai, Peoples R China; [Gao, Qi] Jiangsu Inst Parasit Dis, Wuxi City, Peoples R China; [Jamison, Dean T.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Columbia University; Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention; University of Washington; University of Washington Seattle	Sabot, O (corresponding author), Clinton Hlth Access Initiat, 383 Dorchester Ave,Suite 400, Boston, MA 02127 USA.	osabot@clintonhealthaccess.org	Zou, Linda/ABG-2276-2021	Zou, Linda/0000-0001-5222-6173; Cohen, Justin/0000-0003-4481-6784	Bill & Melinda Gates Foundation; ExxonMobil; NIH/NCRR UCSF-CTSI [UL1 RR024131]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); ExxonMobil(Exxon Mobil Corporation); NIH/NCRR UCSF-CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank the many other individuals who contributed to this work, particularly Simon Kunene, Abdullah Ali, and the members of the Swaziland and Zanzibar National Malaria Control Programmes for their inspiring analysis and pursuit of malaria elimination; Cohn Boyle, Chris Cotter, Clara Kim, Angela Ni, Yuan Sun, Mitsuru Toda, Shanqing Wang, and Huayun Zhou for their invaluable contributions. The work of the Global Health Group of the University of California, San Francisco, on malaria elimination is supported by grants from the Bill & Melinda Gates Foundation and ExxonMobil. The Clinton Health Access Initiative acknowledges support from the Global Health Group for their work on malaria elimination in southern Africa. We are also grateful for the financial support from the Bill & Melinda Gates Foundation to the Clinton Health Access Initiative and the Institute of Health Metrics and Evaluation, University of Washington. JGK was supported in part by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. Lastly, we are grateful to members of the Malaria Elimination Group for their guidance on the material in this paper.	Akumu AO, 2007, B WORLD HEALTH ORGAN, V85, P511, DOI 10.2471/BLT.06.034686; [Anonymous], 1969, TXB MALARIA ERADICAT; ASHRAF QH, 2008, NBER WORK PAP SER; Barrett S, 2004, B WORLD HEALTH ORGAN, V82, P683; Barrett S, 2007, ENVIRON DEV ECON, V12, P627, DOI 10.1017/S1355770X07003816; Bart KJ, 1996, B WORLD HEALTH ORGAN, V74, P35; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; BLEAKLEY H, 2008, MALARIA ERADICATION; Bleichrodt H, 2004, J HEALTH ECON, V23, P157, DOI 10.1016/j.jhealeco.2003.08.002; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Brug J, 2009, INT J BEHAV MED, V16, P3, DOI 10.1007/s12529-008-9000-x; Castro-Leal F, 2000, B WORLD HEALTH ORGAN, V78, P66; Celasun O, 2008, ECON POLICY, P546; Cleary SM, 2010, HEALTH POLICY PLANN, V25, P99, DOI 10.1093/heapol/czp068; Cohen JM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-213; COHN EJ, 1973, AM J PUBLIC HEALTH, V63, P1086, DOI 10.2105/AJPH.63.12.1086; CUTLER D, 2007, NBER WORK PAP SER; DEZULUETA J, 1972, T ROY SOC TROP MED H, V66, P679, DOI 10.1016/0035-9203(72)90082-X; DRAKE B, 1994, PUBLIC BUDGETING FIN, V14, P54; Edejer T, 2003, WHO GUIDE COST EFFEC; Feachem RGA, 2009, SHRINKING MALARIA MA; Feachem R, 2008, LANCET, V371, P1633, DOI 10.1016/S0140-6736(08)60424-9; Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6; Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301; GRIFFITH ME, 1961, B NATL SOC INDIA MAL, V9, P385; Humphreys M, 1996, ISIS, V87, P1, DOI 10.1086/357400; *INT MON FUND, 2009, INT MON FUND WORLD E; Jackson S, 2002, B WORLD HEALTH ORGAN, V80, P653; Jamison D. T., 2009, Oxford textbook of public health, Volume 2: the methods of public health, P767; Jehu-Appiah C, 2008, VALUE HEALTH, V11, P1081, DOI 10.1111/j.1524-4733.2008.00392.x; Johnstone KM, 2000, AUDITING-J PRACT TH, V19, P1, DOI 10.2308/aud.2000.19.1.1; KAHN JG, 2009, SHRINKING MALARIA MA; KASER MC, 1968, EC EFFECTS MALARIA E, P145; Khan MM, 2003, VACCINE, V21, P702, DOI 10.1016/S0264-410X(02)00584-4; KIM A, 1997, COST BENEFIT ANAL DR; LANE C, 2009, SMOOTH PREDICTABLE A; LAZZARI S, 2004, BLACK LUNG EXCISE TA; Lines J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a869; Litsios Socrates, 1993, World Health Forum, V14, P43; Lomborg B., 2009, GLOBAL CRISES GLOBAL; Lu CL, 2010, LANCET, V375, P1375, DOI 10.1016/S0140-6736(10)60233-4; Lucas AM, 2010, AM ECON J-APPL ECON, V2, P46, DOI 10.1257/app.2.2.46; Maartens F, 2007, J TRAVEL MED, V14, P96, DOI 10.1111/j.1708-8305.2006.00086.x; MALAM MS, 2009, MAL ER FG DISTR 63 M; Mills A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S11; *MIN HLTH, 2009, CHIN ANN MAL REP 200; Ministry of Health. National Institute of Parasitic Diseases. China Centers for Disease Control and Prevention, 2010, CONTR EL REV NAT MAL; Moonen B., 2009, SHRINKING MALARIA MA; Moonen B, 2010, LANCET, V376, P1592, DOI 10.1016/S0140-6736(10)61269-X; Najera JA., 1998, MALARIA EPIDEMICS DE; Najera JA, 1999, MALARIA CONTROL ACHI; National Bureau of Statistics of China, 2008, CHIN STAT YB 2008; Ong KS, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-34; Ottersen T, 2008, HEALTH POLICY, V85, P218, DOI 10.1016/j.healthpol.2007.07.012; Robberstad B, 2004, B WORLD HEALTH ORGAN, V82, P523; Sachs JD, 2005, NEW ENGL J MED, V352, P115, DOI 10.1056/NEJMp048319; Smith RD, 2006, SOC SCI MED, V63, P3113, DOI 10.1016/j.socscimed.2006.08.004; Soeung SC, 2006, HEALTH POLICY PLANN, V21, P302, DOI 10.1093/heapol/czl012; Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3; Thompson KM, 2007, LANCET, V369, P1363, DOI 10.1016/S0140-6736(07)60532-7; *UN SECR POP DEP E, WORLD POP PROSP 2008; *UNICEF, 2009, IMM SUMM; *WHO, 1957, TECHN REP SER WHO, V123; World Health Organization, 2007, MAL EL FIELD MAN LOW; World Health Organization (WHO), 2009, WORLD HLTH STAT; Yekutiel P, 1980, ERADICATION INFECT D, P34; Yip K., 2000, Parassitologia (Rome), V42, P117; *ZMCP, 2009, MAL EL FEAS ASS	68	79	80	0	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1604	1615		10.1016/S0140-6736(10)61355-4	http://dx.doi.org/10.1016/S0140-6736(10)61355-4			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21035839	Green Published			2022-12-28	WOS:000284248700037
J	Alwan, A; MacLean, DR; Riley, LM; d'Espaignet, ET; Mathers, CD; Stevens, GA; Bettcher, D				Alwan, Ala; MacLean, David R.; Riley, Leanne M.; d'Espaignet, Edouard Tursan; Mathers, Colin Douglas; Stevens, Gretchen Anna; Bettcher, Douglas			Chronic Diseases: Chronic Diseases and Development 5 Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries	LANCET			English	Article							PREVENTION	The burden of chronic, non-communicable diseases in low-income and middle-income countries is increasing. We outline a framework for monitoring of such diseases and review the mortality burden and the capacity of countries to respond to them. We show data from WHO data sources and published work for prevalence of tobacco use, overweight, and cause-specific mortality in 23 low-income and middle-income countries with a high burden of non-communicable disease. Data for national capacity for chronic disease prevention and control were generated from a global assessment that was done in WHO member states in 2009-10. Although reliable data for cause-specific mortality are scarce, non-communicable diseases were estimated to be responsible for 23.4 million (or 64% of the total) deaths in the 23 countries that we analysed, with 47% occurring in people who were younger than 70 years. Tobacco use and overweight are common in most of the countries and populations we examined, but coverage of cost-effective interventions to reduce these risk factors is low. Capacity for prevention and control of non-communicable diseases, including monitoring and surveillance operations nationally, is inadequate. A surveillance framework, including a minimum set of indicators covering exposures and outcomes, is essential for policy development and assessment and for monitoring of trends in disease. Technical, human, and fiscal resource constraints are major impediments to the establishment of effective prevention and control programmes. Despite increasing awareness and commitment to address chronic disease, concrete actions by global partners to plan and implement cost-effective interventions are inadequate.	[Alwan, Ala; Riley, Leanne M.] WHO, Dept Chron Dis & Hlth Promot, CH-1211 Geneva, Switzerland; [d'Espaignet, Edouard Tursan; Bettcher, Douglas] WHO, Tobacco Free Initiat, CH-1211 Geneva, Switzerland; [Mathers, Colin Douglas; Stevens, Gretchen Anna] WHO, Dept Hlth Stat & Informat, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization; World Health Organization	Alwan, A (corresponding author), WHO, Dept Chron Dis & Hlth Promot, 20 Ave Appia, CH-1211 Geneva, Switzerland.	alwana@who.int	Harding, Richard/G-9729-2012; d'Espaignet, Edouard Tursan/V-3857-2019	Mathers, Colin/0000-0002-0617-6731				Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Alleyne G, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-15; [Anonymous], GLOB EC PROSP 2010; [Anonymous], CAUS DEATH IND 2001; [Anonymous], 2004, WHA5717 WHO; [Anonymous], WHO SURV MON; [Anonymous], 3 MIN HLTH; [Anonymous], WHO MORT DAT 2008; [Anonymous], 2010, WORLD HLTH STAT 2010; [Anonymous], INT STAT CLASS DIS; [Anonymous], WHO GLOB INFOBASE; [Anonymous], DISC PAP NONC DIS PO; [Anonymous], GLOB RISKS 2010 GLOB; [Anonymous], WHA561 WHO; [Anonymous], INT FUT EXPL ALT GLO; [Anonymous], WHOMNC012; [Anonymous], 2005, PREV CHRON DIS VIT I; [Anonymous], B WHO; [Anonymous], WHAA5314 WHO; [Anonymous], 2 WHO GLOB INFOBASE; Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gaziano TA, 2007, LANCET, V370, P1939, DOI 10.1016/S0140-6736(07)61697-3; Geneau R, 2010, LANCET, V376, P1689, DOI 10.1016/S0140-6736(10)61414-6; Horton R, 2007, LANCET, V370, P1881, DOI 10.1016/S0140-6736(07)61701-2; Jha P, 2006, PLOS MED, V3, P191, DOI 10.1371/journal.pmed.0030018; Mahapatra P, 2007, LANCET, V370, P1653, DOI 10.1016/S0140-6736(07)61308-7; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mathers CD, 2009, BRIT MED BULL, V92, P7, DOI 10.1093/bmb/ldp028; Ngo Anh D, 2010, BMC Res Notes, V3, P78, DOI 10.1186/1756-0500-3-78; Porapakkham Y, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-14; Strong K, 2008, EUR J CANCER PREV, V17, P162, DOI 10.1097/CEJ.0b013e3282b6fcc9; World Bank, 2009, GLOBAL ECONOMIC PROSPECTS: COMMODITIES AT THE CROSSROADS, P1, DOI 10.1596/978-0-8213-7799-4; World Health Organization, 2008, The global burden of disease: 2004 update; World Health Organization, 2008, ACT PLAN GLOB STRAT; World Health Organization, 2009, WHO REP GLOB TOB EP; World Health Organization, 2007, VERB AUT STAND ASC A; World Health Organization (WHO), WHO STEPS SURV MAN W	39	374	395	0	41	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2010	376	9755					1861	1868		10.1016/S0140-6736(10)61853-3	http://dx.doi.org/10.1016/S0140-6736(10)61853-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KG	21074258				2022-12-28	WOS:000285439700035
J	Chi, BH; Stringer, JSA				Chi, Benjamin H.; Stringer, Jeffrey S. A.			Mobile phones to improve HIV treatment adherence	LANCET			English	Editorial Material							THERAPY		[Chi, Benjamin H.; Stringer, Jeffrey S. A.] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Chi, Benjamin H.; Stringer, Jeffrey S. A.] Univ Alabama, Sch Med, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham	Chi, BH (corresponding author), Ctr Infect Dis Res Zambia, Lusaka, Zambia.	bchi@cidrz.org	Stringer, Jeffrey S. A./AAU-2342-2021	Stringer, Jeffrey/0000-0002-9590-7216				Boyd M, 2009, LANCET, V374, P185, DOI 10.1016/S0140-6736(09)61313-1; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; *KEN NAT AIDS CONT, UNGASS 2010 UN GEN A; Lester R, 2008, LANCET INFECT DIS, V8, P738, DOI 10.1016/S1473-3099(08)70265-2; Lester RT, 2010, LANCET, V376, P1838, DOI 10.1016/S0140-6736(10)61997-6; Nachega JB, 2010, CURR OPIN HIV AIDS, V5, P70, DOI 10.1097/COH.0b013e328333ad61; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; United Nations Foundation, 2009, MHEALTH DEV OPP MOB; *US PRES EM PLAN A, KEN FY 2009 APPR FUN; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; World Health Organization, 2006, PROGR GLOB ACC HIV A	11	25	26	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV-DEC	2010	376	9755					1807	1808		10.1016/S0140-6736(10)62046-6	http://dx.doi.org/10.1016/S0140-6736(10)62046-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696KG	21071073				2022-12-28	WOS:000285439700008
J	Martin, LB; Coon, CAC				Martin, Lynn B.; Coon, Courtney A. C.			Infection Protection and Natural Selection	SCIENCE			English	Editorial Material							EVOLUTIONARY ECOLOGY; TRADE-OFFS; IMMUNOLOGY; IMMUNITY; MEDICINE		[Martin, Lynn B.; Coon, Courtney A. C.] Univ S Florida, Dept Integrat Biol, Tampa, FL 33620 USA	State University System of Florida; University of South Florida	Martin, LB (corresponding author), Univ S Florida, Dept Integrat Biol, Tampa, FL 33620 USA.	lmartin@cas.usf.edu	Martin, Lynn/C-2037-2009; Coon, Courtney/E-7302-2011	Martin, Lynn/0000-0002-5887-4937; 				Adelman JS, 2009, INTEGR COMP BIOL, V49, P202, DOI 10.1093/icb/icp028; Finch CE, 2010, P NATL ACAD SCI USA, V107, P1718, DOI 10.1073/pnas.0909606106; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; Friberg IM, 2010, TRENDS PARASITOL, V26, P540, DOI 10.1016/j.pt.2010.06.010; GRAHAM A, FUNCT ECOL, DOI DOI 10.1111/J.1365-2435.2010.01777.X; Graham AL, 2010, SCIENCE, V330, P662, DOI 10.1126/science.1194878; Lochmiller RL, 2000, OIKOS, V88, P87, DOI 10.1034/j.1600-0706.2000.880110.x; McDade TW, 2008, AM J PHYS ANTHROPOL, V136, P478, DOI 10.1002/ajpa.20831; Nesse RM, 2010, P NATL ACAD SCI USA, V107, P1800, DOI 10.1073/pnas.0906224106; Schmid-Hempel P, 2003, P ROY SOC B-BIOL SCI, V270, P357, DOI 10.1098/rspb.2002.2265; Segerstrom SC, 2007, CURR DIR PSYCHOL SCI, V16, P326, DOI 10.1111/j.1467-8721.2007.00522.x; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; Stearns SC, 2010, P NATL ACAD SCI USA, V107, P1691, DOI 10.1073/pnas.0914475107; Trotter JH, 2011, FUNCT ECOL, V25, P40, DOI 10.1111/j.1365-2435.2010.01780.x; 2011, FUNCTIONAL ECOLOGY; 2009, PHILOS T R SOC LON B, V364, P3	16	5	6	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					602	603		10.1126/science.1198303	http://dx.doi.org/10.1126/science.1198303			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030640				2022-12-28	WOS:000283580600028
J	Schofield, PN; Eppig, J; Huala, E; de Angelis, MH; Harvey, M; Davidson, D; Weaver, T; Brown, S; Smedley, D; Rosenthal, N; Schughart, K; Aidinis, V; Tocchini-Valentini, G; Hancock, JM				Schofield, Paul N.; Eppig, Janan; Huala, Eva; de Angelis, Martin Hrabe; Harvey, Mark; Davidson, Duncan; Weaver, Tom; Brown, Steve; Smedley, Damian; Rosenthal, Nadia; Schughart, Klaus; Aidinis, Vassilis; Tocchini-Valentini, Glauco; Hancock, John M.			Sustaining the Data and Bioresource Commons	SCIENCE			English	Editorial Material									[Schofield, Paul N.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England; [Eppig, Janan] Jackson Lab, Bar Harbor, ME 04609 USA; [Huala, Eva] Carnegie Inst Sci, Stanford, CA 94305 USA; [de Angelis, Martin Hrabe] Helmholtz Zentrum Munchen, Inst Expt Genet, D-85764 Munich, Germany; [Harvey, Mark] Univ Essex, Dept Sociol, Colchester CO4 3SQ, Essex, England; [Davidson, Duncan] Western Gen Hosp, Human Genet Unit, MRC, Edinburgh EH4 2XU, Midlothian, Scotland; [Weaver, Tom] MRC Mary Lyon Ctr, Didcot OX11 0RD, Oxon, England; [Brown, Steve; Hancock, John M.] MRC Harwell, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England; [Smedley, Damian] European Bioinformat Inst, Cambridge CB10 1SD, England; [Rosenthal, Nadia] European Mol Biol Lab, I-00015 Monterotondo, Rome, Italy; [Schughart, Klaus] Helmholtz Ctr Infect Res, Dept Infect Genet, D-38124 Braunschweig, Germany; [Schughart, Klaus] Univ Vet Med, D-38124 Braunschweig, Germany; [Aidinis, Vassilis] Biomed Sci Res Ctr Alexander Fleming, GR-16672 Athens, Greece; [Tocchini-Valentini, Glauco] CNR, Ist Biol Cellulare, I-00015 Rome, Italy	University of Cambridge; Jackson Laboratory; Carnegie Institution for Science; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Essex; University of Edinburgh; MRC Harwell; European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Helmholtz-Center for Infection Research; Alexander Fleming Biomedical Sciences Research Center; Consiglio Nazionale delle Ricerche (CNR)	Schofield, PN (corresponding author), Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 3EG, England.	ps@mole.bio.cam.ac.uk	de Angelis, Martin Hrabe/F-5531-2012; Huala, Eva L/B-1377-2009; Schofield, Paul/AAA-9414-2020; Hancock, John/A-2442-2009; Aidinis, Vassilis/AAF-5380-2021; Rosenthal, Nadia/O-7009-2015; Smedley, Damian/AAL-8172-2021	de Angelis, Martin Hrabe/0000-0002-7898-2353; Schofield, Paul/0000-0002-5111-7263; Hancock, John/0000-0003-2991-2217; Huala, Eva/0000-0003-4631-7241; Schughart, Klaus/0000-0002-6824-7523; Harvey, Mark/0000-0001-5486-7257; Aidinis, Vassilis/0000-0001-9531-7729; Rosenthal, Nadia/0000-0002-7599-7365	MRC [MC_U142684171, MC_UP_1502/1, MC_U127527203] Funding Source: UKRI; Medical Research Council [MC_UP_1502/1, MC_U142684171, MC_U127527203] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott A, 2009, NATURE, V462, P258, DOI 10.1038/462258b; [Anonymous], Research Portfolio Online Reporting Tools (RePORT); Chandras C, 2009, DATABASE-OXFORD, DOI 10.1093/database/bap017; Collins FS, 2007, CELL, V128, P9, DOI 10.1016/j.cell.2006.12.018; Collins FS, 2010, SCIENCE, V327, P36, DOI 10.1126/science.1185055; *DIR GEN RES, 2010, LEG FRAM EUR RES INF; Field D, 2009, SCIENCE, V326, P234, DOI 10.1126/science.1180598; Mattaj IW, 2010, NATURE, V465, P1005, DOI 10.1038/4651005a; McMeekin A, 2007, PUBLIC PRIVATE EC KN; Schofield PN, 2009, NATURE, V461, P171, DOI 10.1038/461171a; Toronto Int Data Release Workshop, 2009, NATURE, V461, P168, DOI 10.1038/461168a; Wilkinson P, 2010, NUCLEIC ACIDS RES, V38, pD570, DOI 10.1093/nar/gkp799; Williams RW, 2009, FRONT NEUROSCI-SWITZ, V3, P154, DOI 10.3389/neuro.01.016.2009	13	30	35	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					592	593		10.1126/science.1191506	http://dx.doi.org/10.1126/science.1191506			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030633				2022-12-28	WOS:000283580600021
J	Baker, M				Baker, M.			Genomics The tough new variants	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2010	467	7319					1136	1136		10.1038/4671136a	http://dx.doi.org/10.1038/4671136a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981104	Bronze			2022-12-28	WOS:000283548600058
J	Campbell, PJ; Yachida, S; Mudie, LJ; Stephens, PJ; Pleasance, ED; Stebbings, LA; Morsberger, LA; Latimer, C; McLaren, S; Lin, ML; McBride, DJ; Varela, I; Nik-Zainal, SA; Leroy, C; Jia, MM; Menzies, A; Butler, AP; Teague, JW; Griffin, CA; Burton, J; Swerdlow, H; Quail, MA; Stratton, MR; Iacobuzio-Donahue, C; Futreal, PA				Campbell, Peter J.; Yachida, Shinichi; Mudie, Laura J.; Stephens, Philip J.; Pleasance, Erin D.; Stebbings, Lucy A.; Morsberger, Laura A.; Latimer, Calli; McLaren, Stuart; Lin, Meng-Lay; McBride, David J.; Varela, Ignacio; Nik-Zainal, Serena A.; Leroy, Catherine; Jia, Mingming; Menzies, Andrew; Butler, Adam P.; Teague, Jon W.; Griffin, Constance A.; Burton, John; Swerdlow, Harold; Quail, Michael A.; Stratton, Michael R.; Iacobuzio-Donahue, Christine; Futreal, P. Andrew			The patterns and dynamics of genomic instability in metastatic pancreatic cancer	NATURE			English	Article							COPY NUMBER ANALYSIS; HUMAN BREAST-CANCER; GENETIC-HETEROGENEITY; EVOLUTION; TUMORS; REARRANGEMENTS; RESOLUTION; MUTATIONS; LEUKEMIA; CELLS	Pancreatic cancer is an aggressive malignancy with a five-year mortality of 97-98%, usually due to widespread metastatic disease. Previous studies indicate that this disease has a complex genomic landscape, with frequent copy number changes and point mutations(1-5), but genomic rearrangements have not been characterized in detail. Despite the clinical importance of metastasis, there remain fundamental questions about the clonal structures of metastatic tumours(6,7), including phylogenetic relationships among metastases, the scale of ongoing parallel evolution in metastatic and primary sites(7), and how the tumour disseminates. Here we harness advances in DNA sequencing(8-12) to annotate genomic rearrangements in 13 patients with pancreatic cancer and explore clonal relationships among metastases. We find that pancreatic cancer acquires rearrangements indicative of telomere dysfunction and abnormal cell-cycle control, namely dysregulated G1-to-S-phase transition with intact G2-M checkpoint. These initiate amplification of cancer genes and occur predominantly in early cancer development rather than the later stages of the disease. Genomic instability frequently persists after cancer dissemination, resulting in ongoing, parallel and even convergent evolution among different metastases. We find evidence that there is genetic heterogeneity among metastasis-initiating cells, that seeding metastasis may require driver mutations beyond those required for primary tumours, and that phylogenetic trees across metastases show organ-specific branches. These data attest to the richness of genetic variation in cancer, brought about by the tandem forces of genomic instability and evolutionary selection.	[Campbell, Peter J.; Mudie, Laura J.; Stephens, Philip J.; Pleasance, Erin D.; Stebbings, Lucy A.; Latimer, Calli; McLaren, Stuart; Lin, Meng-Lay; McBride, David J.; Varela, Ignacio; Nik-Zainal, Serena A.; Leroy, Catherine; Jia, Mingming; Menzies, Andrew; Butler, Adam P.; Teague, Jon W.; Burton, John; Swerdlow, Harold; Quail, Michael A.; Stratton, Michael R.; Futreal, P. Andrew] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton CB10 1SA, England; [Campbell, Peter J.] Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; [Yachida, Shinichi; Morsberger, Laura A.; Griffin, Constance A.; Iacobuzio-Donahue, Christine] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA; [Yachida, Shinichi; Morsberger, Laura A.; Griffin, Constance A.; Iacobuzio-Donahue, Christine] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21287 USA; [Stratton, Michael R.] Inst Canc Res, Sutton SM2 5NG, Surrey, England	Wellcome Trust Sanger Institute; University of Cambridge; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of London; Institute of Cancer Research - UK	Futreal, PA (corresponding author), Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton CB10 1SA, England.	ciacobu@jhmi.edu; paf@sanger.ac.uk	Quail, michael/ABE-6131-2020; Nik-Zainal, Serena/ABD-4437-2020; Varela, Ignacio/AAA-7680-2021; Iacobuzio-Donahue, Christine/ABF-1295-2020; Varela, Ignacio/G-1699-2016	Varela, Ignacio/0000-0002-0969-506X; Iacobuzio-Donahue, Christine/0000-0002-4672-3023; Varela, Ignacio/0000-0002-0969-506X; Nik-Zainal, Serena/0000-0001-5054-1727; Swerdlow, Harold/0000-0002-9510-160X	Wellcome Trust [077012/Z/05/Z, WT088340MA]; Uehara memorial foundation; Skip Viragh Foundation; Michael Rolphe Foundation; National Institutes of Health [CA106610, CA140599]; The International Human Frontier Science Program Organization; NATIONAL CANCER INSTITUTE [R01CA140599, K08CA106610] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome TrustEuropean Commission); Uehara memorial foundation(Uehara Memorial Foundation); Skip Viragh Foundation; Michael Rolphe Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The International Human Frontier Science Program Organization(Human Frontier Science Program); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Wellcome Trust (grant reference 077012/Z/05/Z). P.J.C. is funded through a Wellcome Trust Senior Clinical Research Fellowship (grant reference WT088340MA). S.Y. has support from the Uehara memorial foundation. We would also like to acknowledge the financial support of the Skip Viragh Foundation and the Michael Rolphe Foundation for the autopsy programme, and funding from the National Institutes of Health (grants CA106610 and CA140599). I.V. is supported by a fellowship from The International Human Frontier Science Program Organization. We would like to thank U. McDermott for discussions and a critical reading of the manuscript.	Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bignell GR, 2007, GENOME RES, V17, P1296, DOI 10.1101/gr.6522707; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; Campbell PJ, 2008, P NATL ACAD SCI USA, V105, P13081, DOI 10.1073/pnas.0801523105; Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Flohr T, 2008, LEUKEMIA, V22, P771, DOI 10.1038/leu.2008.5; Fu BJ, 2008, CANCER BIOL THER, V7, P1593, DOI 10.4161/cbt.7.10.6565; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Hashimoto Y, 2008, J GASTROINTEST SURG, V12, P17, DOI 10.1007/s11605-007-0383-9; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kimmelman AC, 2008, P NATL ACAD SCI USA, V105, P19372, DOI 10.1073/pnas.0809966105; Klein CA, 2002, LANCET, V360, P683, DOI 10.1016/S0140-6736(02)09838-0; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; MCLINTOCK B, 1941, GENETICS, V26, P234; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pleasance ED, 2010, NATURE, V463, P184, DOI 10.1038/nature08629; Quail MA, 2008, NAT METHODS, V5, P1005, DOI 10.1038/nmeth.1270; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645	30	971	1004	3	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2010	467	7319					1109	1113		10.1038/nature09460	http://dx.doi.org/10.1038/nature09460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981101	Green Accepted			2022-12-28	WOS:000283548600048
J	Kassirer, JP				Kassirer, Jerome P.			Does instant access to compiled information undermine clinical cognition?	LANCET			English	Editorial Material							DELIBERATE PRACTICE; EXPERT PERFORMANCE; ACQUISITION; TECHNOLOGY; LOAD		[Kassirer, Jerome P.] Stanford Univ, Stanford, CA 94305 USA; [Kassirer, Jerome P.] Tufts Univ, Sch Med, Boston, MA 02111 USA	Stanford University; Tufts University	Kassirer, JP (corresponding author), 136 Harrison Ave, Boston, MA 02111 USA.	jpkassirer@aol.com						CARR N, 2008, ATLANTIC BOSTON  JUL; Custers EJFM, 1996, ACAD MED, V71, pS55, DOI 10.1097/00001888-199610000-00044; DOMASIO A, 1994, DESCARTES ERROR EMOT; ELLIS D, 2010, RESPONSE DOES GOOGLE; ERICSSON KA, 1994, AM PSYCHOL, V49, P725, DOI 10.1037/0003-066X.49.8.725; Ericsson KA, 2004, ACAD MED, V79, pS70, DOI 10.1097/00001888-200410001-00022; Gorry GA, 2009, KNOWL MAN RES PRACT, V7, P178, DOI 10.1057/kmrp.2009.7; Greenfield PM, 2009, SCIENCE, V323, P69, DOI 10.1126/science.1167190; Joseph J, 2001, THORAX, V56, P867, DOI 10.1136/thorax.56.11.867; Norman GR, 2000, ACAD MED, V75, pS127, DOI 10.1097/00001888-200010001-00041; Patel V, 2004, CAMBRIDGE HDB THINKI; Rikers RMJP, 2005, APPL COGNITIVE PSYCH, V19, P145, DOI 10.1002/acp.1108; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; van Gog T, 2005, ETR&D-EDUC TECH RES, V53, P73, DOI 10.1007/BF02504799; van Merrienboer JJG, 2005, EDUC PSYCHOL REV, V17, P147, DOI 10.1007/s10648-005-3951-0; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002	16	6	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1510	1511		10.1016/S0140-6736(10)60895-1	http://dx.doi.org/10.1016/S0140-6736(10)60895-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	21036275				2022-12-28	WOS:000284248500034
J	Gwatkin, DR; Ergo, A				Gwatkin, Davidson R.; Ergo, Alex			Universal health coverage: friend or foe of health equity?	LANCET			English	Editorial Material							CHILD HEALTH; TRENDS		[Gwatkin, Davidson R.] Results Dev Inst, Washington, DC 20009 USA; [Ergo, Alex] Broad Branch Associates, Washington, DC USA		Gwatkin, DR (corresponding author), Results Dev Inst, Washington, DC 20009 USA.	dgwatkin@resultsfordevelopment.org						Barros A. J. D., 2005, Reaching the poor with health, nutrition, and population services: what works, what doesn't and why, P281; Boerma JT, 2008, LANCET, V371, P1259, DOI 10.1016/S0140-6736(08)60560-7; Frenk J, 2006, LANCET, V368, P1524, DOI 10.1016/S0140-6736(06)69564-0; Garrett L, 2009, LANCET, V374, P1294, DOI 10.1016/S0140-6736(09)61503-8; *UN, 1958, ACH UN ACC REPR HLTH; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; WHO, 2010, WOR HEALT REP, P1; World Health Organization, 2010, SPEC PROGR RES TRAIN; World Health Organization, WORLD HLTH REP 2008; World Health Organization, 2010, UN ACC SCAL PRIOR HI; 2009, COMM HEADS GOV M CHO	11	116	117	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN-JUL	2011	377	9784					2160	2161		10.1016/S0140-6736(10)62058-2	http://dx.doi.org/10.1016/S0140-6736(10)62058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	786XI	21084113				2022-12-28	WOS:000292340800008
J	Dolovich, MB; Dhand, R				Dolovich, Myrna B.; Dhand, Rajiv			Aerosol drug delivery: developments in device design and clinical use	LANCET			English	Review							METERED-DOSE INHALER; DRY-POWDER INHALERS; PULMONARY ARTERIAL-HYPERTENSION; RESPIRATORY-DISTRESS-SYNDROME; VIBRATING-MESH NEBULIZER; SOFT MIST(TM) INHALER; BECLOMETHASONE DIPROPIONATE; CYSTIC-FIBROSIS; PARTICLE-SIZE; IN-VITRO	Aerosolised drugs are prescribed for use in a range of inhaler devices and systems. Delivering drugs by inhalation requires a formulation that can be successfully aerosolised and a delivery system that produces a useful aerosol of the drug; the particles or droplets need to be of sufficient size and mass to be carried to the distal lung or deposited on proximal airways to give rise to a therapeutic effect. Patients and caregivers must use and maintain these aerosol drug delivery devices correctly. In recent years, several technical innovations have led to aerosol drug delivery devices with efficient drug delivery and with novel features that take into account factors such as dose tracking, portability, materials of manufacture, breath actuation, the interface with the patient, combination therapies, and systemic delivery. These changes have improved performance in all four categories of devices: metered dose inhalers, spacers and holding chambers, dry powder inhalers, and nebulisers. Additionally, several therapies usually given by injection are now prescribed as aerosols for use in a range of drug delivery devices. In this Review, we discuss recent developments in the design and clinical use of aerosol devices over the past 10-15 years with an emphasis on the treatment of respiratory disorders.	[Dolovich, Myrna B.] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada; [Dolovich, Myrna B.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Dhand, Rajiv] Univ Missouri, Dept Internal Med, Div Pulm Crit Care & Environm Med, Columbia, MO USA	McMaster University; McMaster University; University of Missouri System; University of Missouri Columbia	Dolovich, MB (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E,Room JT2135, Hamilton, ON L8N 4A6, Canada.	mdolovic@mcmaster.ca		Dhand, Rajiv/0000-0002-3621-2422	Pfizer; GlaxoSmithKline; AstraZeneca; Cogentus Pharmaceuticals; Novartis Imaging; Boehringer Ingelheim; Bayer; Novartis; Sepracor and Trudell Medical International	Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Cogentus Pharmaceuticals; Novartis Imaging; Boehringer Ingelheim(Boehringer Ingelheim); Bayer(Bayer AG); Novartis(Novartis); Sepracor and Trudell Medical International	Within the past 5 years, MBD has received research grants from Pfizer, GlaxoSmithKline, and AstraZeneca, and has received consultancy fees from Cogentus Pharmaceuticals, Novartis Imaging, AstraZeneca, and Boehringer Ingelheim. MBD has consulted for Medicines in Need but did not receive any fees. Within the past 5 years, RD has received speaker fees from GlaxoSmithKline, Boehringer-Ingelheim, Pfizer, and Bayer, consultancy fees from Novartis and Bayer, and research support from Sepracor and Trudell Medical International. RD was a principal site. investigator for a clinical trial sponsored by Novartis.	Agertoft L, 1999, J AEROSOL MED, V12, P161, DOI 10.1089/jam.1999.12.161; Ahrens Richard C, 2005, Respir Care, V50, P1323; Akapo S, 2008, ANN PHARMACOTHER, V42, P1416, DOI 10.1345/aph.1L273; Alton E, 2007, GENE THER, V14, P1555, DOI 10.1038/sj.gt.3303033; [Anonymous], MONTREAL PROTOCOL SU; Bennett JV, 2002, B WORLD HEALTH ORGAN, V80, P806; Berlinski A, 1998, CHEST, V114, P847, DOI 10.1378/chest.114.3.847; Berry J, 2003, DRUG DEV IND PHARM, V29, P865, DOI 10.1081/DDC-120024182; Bhashyam AR, 2008, J AEROSOL MED PULM D, V21, P181, DOI 10.1089/jamp.2007.0662; Birchall J, 2007, EXPERT OPIN DRUG DEL, V4, P575, DOI 10.1517/17425247.4.6.575; Borgstrom L, 1999, ALLERGY, V54, P88, DOI 10.1111/j.1398-9995.1999.tb04394.x; Brand P, 2003, EUR RESPIR J, V22, P263, DOI 10.1183/09031936.03.00096802; Brand P, 2009, EUR RESPIR J, V34, P354, DOI 10.1183/09031936.00118408; Brashier B, 2007, RESP MED, V101, P2464, DOI 10.1016/j.rmed.2007.07.006; Broeders MEAC, 2003, EUR J CLIN PHARMACOL, V59, P449, DOI 10.1007/s00228-003-0614-2; BROWN PH, 1993, THORAX, V48, P967, DOI 10.1136/thx.48.10.967; Bunnag C, 2007, ASIAN PAC J ALLERGY, V25, P99; Burger JL, 2008, J AEROSOL MED PULM D, V21, P25, DOI 10.1089/jamp.2007.0658; Corcoran TE, 2002, J AEROSOL MED, V15, P271, DOI 10.1089/089426802760292618; Daley-Yates PT, 2009, CLIN THER, V31, P370, DOI 10.1016/j.clinthera.2009.02.007; Dames P, 2007, NAT NANOTECHNOL, V2, P495, DOI 10.1038/nnano.2007.217; de Castro JF, 2005, VACCINE, V23, P1079, DOI 10.1016/j.vaccine.2004.08.018; DeCanio SJ, 2007, J ENVIRON MANAGE, V85, P1, DOI 10.1016/j.jenvman.2006.07.005; Denyer J, 2004, Expert Opin Drug Deliv, V1, P165, DOI 10.1517/17425247.1.1.165; Dhand R, 2008, CLIN CHEST MED, V29, P277, DOI 10.1016/j.ccm.2008.02.003; Dhand Rajiv, 2002, Respir Care, V47, P1406; Dilraj A, 2007, VACCINE, V25, P4170, DOI 10.1016/j.vaccine.2007.03.003; DOLOVICH M, 1993, AEROSOL SCI TECH, V18, P230, DOI 10.1080/02786829308959600; Dolovich M, 1999, Can Respir J, V6, P290; DOLOVICH M, 1981, CHEST, V80, P834; Dolovich M, 2009, MIDDLETONS ALLERGY P, P679; DOLOVICH M, 1997, J AEROSOL MED, V10, P238; Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335; Dolovich Myrna B, 2004, Can Respir J, V11, P489; Dompeling E, 2001, ARCH DIS CHILD, V84, P178, DOI 10.1136/adc.84.2.178; Drblik S, 2003, ARCH DIS CHILD, V88, P319, DOI 10.1136/adc.88.4.319; Edwards DA, 2002, ANNU REV BIOMED ENG, V4, P93, DOI 10.1146/annurev.bioeng.4.100101.132311; Elhissi AMA, 2006, J PHARM PHARMACOL, V58, P887, DOI 10.1211/jpp.58.7.0002; Erzinger S, 2007, J AEROSOL MED, V20, pS78, DOI 10.1089/jam.2007.0572; Esposito-Festen J, 2005, PEDIAT ALLERG IMM-UK, V16, P348, DOI 10.1111/j.1399-3038.2005.00285.x; *EUR MED AG, EMEA 2006; Fairfax AJ, 2000, RESP MED, V94, pS31, DOI 10.1016/S0954-6111(00)90122-7; Finlay W.H., 2001, MECH INHALED PHARM A, P17; Fok TF, 1999, ARCH DIS CHILD-FETAL, V80, pF203, DOI 10.1136/fn.80.3.F203; Fok TF, 1996, PEDIATR PULM, V21, P301, DOI 10.1002/(SICI)1099-0496(199605)21:5<301::AID-PPUL5>3.0.CO;2-P; Ganderton D, 2002, RESP MED, V96, pS3, DOI 10.1016/S0954-6111(02)80018-X; Geller DE, 2003, CHEST, V123, P28, DOI 10.1378/chest.123.1.28; Ghazanfari T, 2007, INT J PHARM, V339, P103, DOI 10.1016/j.ijpharm.2007.02.035; Ghofrani HA, 2003, J AM COLL CARDIOL, V42, P158, DOI 10.1016/S0735-1097(03)00555-2; Goode ML, 2001, AM J RESP CRIT CARE, V163, P109, DOI 10.1164/ajrccm.163.1.2003025; Gross G, 2003, J ASTHMA, V40, P487, DOI 10.1081/JAS-120018777; Gustafsson P, 2005, INT J CLIN PRACT, V59, P13, DOI 10.1111/j.1368-504X.2005.00722.x; Hawksworth RJ, 2002, ANN ALLERG ASTHMA IM, V88, P473, DOI 10.1016/S1081-1206(10)62385-X; Hayden JT, 2004, ARCH DIS CHILD, V89, P72; Hendeles L, 2007, NEW ENGL J MED, V356, P1344, DOI 10.1056/NEJMra050380; Hess DR, 2007, J AEROSOL MED, V20, pS85, DOI 10.1089/jam.2007.0574; Hess DR, 1999, CHEST, V115, P184, DOI 10.1378/chest.115.1.184; Heyder Joachim, 2004, Proc Am Thorac Soc, V1, P315, DOI 10.1513/pats.200409-046TA; Hochrainer D, 2005, J AEROSOL MED, V18, P273, DOI 10.1089/jam.2005.18.273; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Huang J, 2007, HUM VACCINES, V3, P90, DOI 10.4161/hv.3.3.4011; Iacono AT, 2006, NEW ENGL J MED, V354, P141, DOI 10.1056/NEJMoa043204; Janssens HM, 2006, PAEDIATR RESPIR REV, V7, pS83, DOI 10.1016/j.prrv.2006.04.167; Janssens W, 2008, EUR RESPIR J, V31, P78, DOI 10.1183/09031936.00024807; Johnson JC, 2008, RESP CARE, V53, P1703; Julius SM, 2002, CHEST, V121, P871, DOI 10.1378/chest.121.3.871; Kamin W, 2006, J CYST FIBROS, V5, P205, DOI 10.1016/j.jcf.2006.03.007; Kelly HW, 2003, ANN PHARMACOTHER, V37, P23; Kishida M, 2002, J ASTHMA, V39, P337, DOI 10.1081/JAS-120002291; Koping-Hoggard M, 2005, J GENE MED, V7, P1215, DOI 10.1002/jgm.762; Langley SJ, 2005, CLIN THER, V27, P1004, DOI 10.1016/j.clintera.2005.07.006; Laube BL, 2000, CHEST, V118, P1069, DOI 10.1378/chest.118.4.1069; Lauricella S, 2007, J AEROSOL MED, V20, P202; Lavorini F, 2008, RESP MED, V102, P593, DOI 10.1016/j.rmed.2007.11.003; Leach Chet L, 2005, Respir Care, V50, P1201; Lenney J, 2000, RESP MED, V94, P496, DOI 10.1053/rmed.1999.0767; Lentz YK, 2006, J AEROSOL MED, V19, P372, DOI 10.1089/jam.2006.19.372; MacNeish CF, 1997, CHEST, V111, P204, DOI 10.1378/chest.111.1.204; Magnussen H, 2000, RESP MED, V94, P549, DOI 10.1053/rmed.1999.0772; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; McCarthy MW, 2004, ANN PHARMACOTHER, V38, P2086, DOI 10.1345/aph.1E191; McLaughlin VV, 2006, AM J RESP CRIT CARE, V174, P1257, DOI 10.1164/rccm.200603-358OC; Nair A, 2009, BRIT J CLIN PHARMACO, V67, P191, DOI 10.1111/j.1365-2125.2008.03350.x; Nair P, 2009, POL ARCH MED WEWN, V119, P731, DOI 10.20452/pamw.825; Nathan RA, 2006, CLIN THER, V28, P73, DOI 10.1016/j.clinthera.2006.01.008; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; Newman S., 2005, J APPL THER RES, V5, P29; Newman Stephen P, 2005, Respir Care, V50, P1177; O'Callaghan C, 2007, J AEROSOL MED, V20, P434, DOI 10.1089/jam.2007.0614; O'Connell Oisin, 2006, N Z Med J, V119, pU2282; Omer SB, 2010, LANCET, V375, P706, DOI 10.1016/S0140-6736(09)62028-6; Parameswaran KN, 1999, AM J RESP CRIT CARE, V160, P354, DOI 10.1164/ajrccm.160.1.9812035; Parameswaran Krishnan, 2003, Can Respir J, V10, P27; Peters SG, 2007, CHEST, V131, P286, DOI 10.1378/chest.06-2125; Pitcairn G, 2005, J AEROSOL MED, V18, P264, DOI 10.1089/jam.2005.18.264; Piva Jefferson P, 2002, Pediatr Crit Care Med, V3, P6, DOI 10.1097/00130478-200201000-00002; Plank C, 2008, TRENDS BIOTECHNOL, V26, P59, DOI 10.1016/j.tibtech.2007.11.001; Price D, 2003, RESP MED, V97, P12, DOI 10.1053/rmed.2002.1426; Rau JL, 2006, RESP CARE, V51, P503; Rau Joseph L, 2004, Respir Care, V49, P174; Reichel W, 2001, INT J CLIN PRACT, V55, P100; Restrepo Ruben D, 2008, Int J Chron Obstruct Pulmon Dis, V3, P371; Retsch-Bogart GZ, 2008, PEDIATR PULM, V43, P47, DOI 10.1002/ppul.20736; Rowe BH, 2003, COCHRANE DB SYST REV, V4; Rubin BK, 2004, CHEST, V126, P1134, DOI 10.1378/chest.126.4.1134; SALZMAN GA, 1988, J ALLERGY CLIN IMMUN, V81, P424, DOI 10.1016/0091-6749(88)90911-6; Self TH, 2007, J ASTHMA, V44, P593, DOI 10.1080/02770900701554334; Selting K, 2008, J AEROSOL MED PULM D, V21, P255, DOI 10.1089/jamp.2008.0684; Shapiro GS, 2000, J ASTHMA, V37, P667, DOI 10.3109/02770900009087305; Shoyele SA, 2006, INT J PHARMACEUT, V314, P1, DOI 10.1016/j.ijpharm.2006.02.014; Smaldone GC, 2006, J AEROSOL MED, V19, P36, DOI 10.1089/jam.2006.19.36; Smaldone GC, 2007, J AEROSOL MED, V20, pS66, DOI 10.1089/jam.2007.0579; Smith DJ, 2003, VACCINE, V21, P2805, DOI 10.1016/S0264-410X(03)00224-X; SMITH DW, 1991, NEW ENGL J MED, V325, P24, DOI 10.1056/NEJM199107043250105; SMITH EC, 1995, EUR RESPIR J, V8, P1214, DOI 10.1183/09031936.95.08071214; Smyth HDC, 2003, ADV DRUG DELIVER REV, V55, P807, DOI 10.1016/S0169-409X(03)00079-6; Son YJ, 2008, DRUG DEV IND PHARM, V34, P948, DOI 10.1080/03639040802235902 ; Ten Have WHO, 2008, J ASTHMA, V45, P67, DOI 10.1080/02770900701815834; Tobyn M, 2004, INT J PHARM, V277, P31, DOI 10.1016/j.ijpharm.2003.09.040; Usmani OS, 2003, J APPL PHYSIOL, V95, P2106, DOI 10.1152/japplphysiol.00525.2003; Voswinckel R, 2009, PULM PHARMACOL THER, V22, P50, DOI 10.1016/j.pupt.2008.11.009; Waldrep JC, 2007, J AEROSOL MED, V20, P310, DOI 10.1089/jam.2007.0538; Walmrath D, 1996, AM J RESP CRIT CARE, V153, P991, DOI 10.1164/ajrccm.153.3.8630585; Wasserman RL, 2006, ALLERGY ASTHMA PROC, V27, P486, DOI 10.2500/aap.2006.27.2921; WAYNE CJ, 2005, VACCINE, V23, P2477; Williams RO, 2001, DRUG DEV IND PHARM, V27, P401, DOI 10.1081/DDC-100104315; Worth H, 2001, RESPIRATION, V68, P517, DOI 10.1159/000050561; Zhang GF, 2007, J AEROSOL MED, V20, P408, DOI 10.1089/jam.2007.0622; Zou YY, 2007, CLIN CANCER RES, V13, P4900, DOI 10.1158/1078-0432.CCR-07-0395	129	317	333	3	121	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 19	2011	377	9770					1032	1045		10.1016/S0140-6736(10)60926-9	http://dx.doi.org/10.1016/S0140-6736(10)60926-9			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	740FA	21036392				2022-12-28	WOS:000288775800032
J	Baird, JK				Baird, J. Kevin			Eliminating malaria-all of them	LANCET			English	Editorial Material							PLASMODIUM-VIVAX		[Baird, J. Kevin] Eijkman Oxford Clin Res Unit, Jakarta 10430, Indonesia; [Baird, J. Kevin] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England	Eijkman Institute; University of Oxford	Baird, JK (corresponding author), Eijkman Oxford Clin Res Unit, Jakarta 10430, Indonesia.	kbaird@eocru.org						Baird JK, 2003, TRENDS PARASITOL, V19, P115, DOI 10.1016/S1471-4922(03)00005-9; BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; Branch O, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-27; COGGESHALL LT, 1952, AM J TROP MED HYG, V1, P124, DOI 10.4269/ajtmh.1952.1.124; Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243; Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08; Greenwood B, 2004, AM J TROP MED HYG, V70, P1; Wells TN, 2010, DISCOV MED, V9, P389	8	40	40	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 4	2010	376	9756					1883	1885		10.1016/S0140-6736(10)61494-8	http://dx.doi.org/10.1016/S0140-6736(10)61494-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696KH	21035840				2022-12-28	WOS:000285439800009
J	Kowey, PR; Reiffel, JA; Ellenbogen, KA; Naccarelli, GV; Pratt, CM				Kowey, Peter R.; Reiffel, James A.; Ellenbogen, Kenneth A.; Naccarelli, Gerald V.; Pratt, Craig M.			Efficacy and Safety of Prescription Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYUNSATURATED FATTY-ACIDS; ARTERY-BYPASS SURGERY; HEART-FAILURE; DOUBLE-BLIND	Context Atrial fibrillation (AF) is common, yet there remains an unmet medical need for additional treatment options. Current pharmacological treatments have limited efficacy and significant adverse events. Limited data from small trials suggest omega-3 polyunsaturated fatty acids may provide a safe, effective treatment option for AF patients. Objective To evaluate the safety and efficacy of prescription omega-3 fatty acids (prescription omega-3) for the prevention of recurrent symptomatic AF. Design, Setting, and Participants Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter trial involving 663 US outpatient participants with confirmed symptomatic paroxysmal (n=542) or persistent (n=121) AF, with no substantial structural heart disease, and in normal sinus rhythm at baseline were recruited from November 2006 to July 2009 (final follow-up was January 2010). Interventions Prescription omega-3 (8 g/d) or placebo for the first 7 days; prescription omega-3 (4 g/d) or placebo thereafter through week 24. Main Outcome Measures The primary end point was symptomatic recurrence of AF (first recurrence) in participants with paroxysmal AF. Secondary analyses included first recurrence in the persistent stratum and both strata combined. Participants were followed up for 6 months. Results At 24 weeks, in the paroxysmal AF stratum, 129 of 269 participants (48%) in the placebo group and 135 of 258 participants (52%) in the prescription group had a recurrent symptomatic AF or flutter event. In the persistent AF stratum, 18 participants (33%) in the placebo group and 32 (50%) in the prescription group had documented symptomatic AF or flutter events. There was no difference between treatment groups for recurrence of symptomatic AF in the paroxysmal stratum (hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.90-1.46; P=.26), in the persistent stratum (HR, 1.64; 95% CI, 0.92-2.92; P=.09), and both strata combined (HR, 1.22; 95% CI, 0.98-1.52; P=.08). Other, secondary end points were supportive of the primary result. A total of 5% of those receiving placebo and 4% of those receiving prescription omega-3 discontinued due to adverse events. Eicosapentaenoic and docosahexaenoic acid blood levels were significantly higher in the prescription group than in the placebo group at weeks 4 and 24. Conclusion Among participants with paroxysmal AF, 24-week treatment with prescription omega-3 compared with placebo did not reduce recurrent AF over 6 months.	[Kowey, Peter R.] Lankenau Inst Med Res, Div Cardiovasc Dis, Wynnewood, PA USA; [Kowey, Peter R.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; [Reiffel, James A.] Columbia Univ, Med Ctr, Div Cardiol, New York, NY USA; [Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA; [Naccarelli, Gerald V.] Penn State Univ, Coll Med, Div Cardiol, Hershey, PA USA; [Pratt, Craig M.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA; [Pratt, Craig M.] Weill Cornell Med Coll, Dept Med, New York, NY USA	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University; Columbia University; Virginia Commonwealth University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; Cornell University	Kowey, PR (corresponding author), 558 Lankenau Med Off Bldg E,100 Lancaster Ave, Wynnewood, PA 19096 USA.	KoweyP@mlhs.org	Ellenbogen, Kenneth/AAJ-3992-2021		GlaxoSmithKline; Boston Scientific Corp; Biosense Webster; Medtronic Inc; St Jude Medical; Sanofi Aventis; Boehringer Ingelheim; Reliant Pharmaceuticals (acquired by GlaxoSmithKline)	GlaxoSmithKline(GlaxoSmithKline); Boston Scientific Corp(Boston Scientific); Biosense Webster; Medtronic Inc(Medtronic); St Jude Medical(St. Jude Medical); Sanofi Aventis(Sanofi-Aventis); Boehringer Ingelheim(Boehringer Ingelheim); Reliant Pharmaceuticals (acquired by GlaxoSmithKline)	Dr Kowey reports serving as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Blue Ash Pharmaceuticals, Gilead, HUYA Biosciences, sanofi-aventis, Solvay, AstraZeneca, Johnson & Johnson, Merck, Astellas, Pfizer, Sequel, Medtronic, Boston Scientific, St Jude Medical, GlaxoSmithKline, Boehringer Ingelheim, and Otsuka; serving on the speakers bureau of sanofi-aventis; holding stock in Cardionet; and receiving honoraria from GlaxoSmithKline. Dr Reiffel reports receiving a research grant from GlaxoSmithKline; receiving honoraria from sanofi-aventis, Gilead, GlaxoSmithKline, and sanofi-aventis; expects receiving honoraria from and Boehringer Ingelheim; and serving as a consultant for or on the advisory boards of Gilead and GlaxoSmithKline. Dr Ellenbogen reports receiving research grants from Boston Scientific Corp, Biosense Webster, Medtronic Inc, St Jude Medical, and Sanofi Aventis; serving on the speakers bureau of Boston Scientific, St Jude Medical, Biotronik, and Medtronic Inc; expects receiving honoraria from Boehringer Ingelheim; receiving honoraria from Boston Scientific Corp, St Jude Medical, Biosense Webster, and sanofi-aventis; serving as a consultant to or on the advisory boards of Boston Scientific Corp, Biosense Webster, Medtronic Inc, sanofi-aventis, St Jude Medical, Cardionet, Modest, Atritech, EBR, Biotronik, Sorin Biomedical, and GlaxoSmithKline. Dr Naccarelli reports receiving research support from GlaxoSmithKline, Boston Scientific Corp, sanofi-aventis, Boehringer Ingelheim, and GlaxoSmithKline; serving as a consultant for or on the advisory boards of Astellas, GlaxoSmithKline, Medtronic, Boston Scientific Corp, Pfizer, Xention, sanofi-aventis, Gilead, Novartis, Portola, AstraZeneca, Bristol-Myers Squibb, Merck, Biosense-Webster, Ortho-McNeil-Janssen, Blue Ash Pharmaceuticals, St Jude's Medical, and Daiichi-Sankyo. Dr Pratt reports serving as a consultant for or on the advisory boards of Merck, Modest; sanofi-aventis, and GlaxoSmithKline.; The sponsor, Reliant Pharmaceuticals (acquired by GlaxoSmithKline in 2007), designed this clinical trial in collaboration with Drs Kowey, Reiffel, Ellenbogen, Naccarelli, and Pratt. The sponsor conducted the statistical analysis, reviewed the manuscript, and provided minor comments. Editorial support, in the form of development, assembling tables and figures, collating author comments, copyediting, fact checking, and referencing, was performed by Cactus Communications Inc, coordinated by Donald Samulack, PhD, United States, and Elvira D'souza, India, and funded by GlaxoSmithKline. Independent Statistical Analysis: Todd MacKenzie, PhD, associate professor of biostatistics, Dartmouth Medical School, received the analytic data and the raw data, conducted an independent analysis of the data, and verified the results of the efficacy end points, vital statistics, and adverse events. Dr MacKenzie also processed the data to obtain another version of the primary end point, defined as time to recurrence of atrial fibrillation or flutter, and also recommended inclusion of an analysis in which participants were not censored at the time of use of antiarrhythmic agents. Dr MacKenzie verified that the results presented herein were provided by him. This independent statistical analysis was funded by GlaxoSmithKline.	Anter E, 2009, CIRCULATION, V119, P2516, DOI 10.1161/CIRCULATIONAHA.108.821306; Bays HE, 2007, AM J CARDIOL, V99, p35C, DOI 10.1016/j.amjcard.2006.11.020; Berry JD, 2010, AM J CARDIOL, V105, P844, DOI 10.1016/j.amjcard.2009.11.039; Biscione Francesco, 2005, Ital Heart J Suppl, V6, P53; Calo L, 2005, J AM COLL CARDIOL, V45, p245A; Friberg J, 2003, EPIDEMIOLOGY, V14, P666, DOI 10.1097/01.ede.0000091649.26364.c0; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Heidarsdottir R, 2010, EUROPACE, V12, P356, DOI 10.1093/europace/eup429; Heidt MC, 2009, THORAC CARDIOV SURG, V57, P276, DOI 10.1055/s-0029-1185301; KUMAR S, 2010, HEART RHYTHM, V7, pS108; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; MAVRAKIS HE, 2007, HEART RHYTHM, V4, pS184; MUHAMMAD KI, 2009, AM COLL CARD M MARCH; Ninio DM, 2005, J CARDIOVASC ELECTR, V16, P1189, DOI 10.1111/j.1540-8167.2005.50007.x; Nodari S, 2006, EUR HEART J, V27, P887; Nodari S, 2010, J AM COLL CARDIOL, V55; Podrid P J, 1999, Curr Cardiol Rep, V1, P289, DOI 10.1007/s11886-999-0052-6; Pratt CM, 2009, AM HEART J, V158, P163, DOI 10.1016/j.ahj.2009.05.024; Reiffel JA, 2006, AM J CARDIOL, V98, p50I, DOI 10.1016/j.amjcard.2005.12.027; SANDESARA C, 2010, HEART RHYTHM SOC M M; Saravanan P, 2010, CIRC-ARRHYTHMIA ELEC, V3, P46, DOI 10.1161/CIRCEP.109.899633; Sarrazin JF, 2007, J AM COLL CARDIOL, V50, P1505, DOI 10.1016/j.jacc.2007.05.046; Singh Steven N., 2004, Curr Treat Options Cardiovasc Med, V6, P357, DOI 10.1007/s11936-004-0019-2; Tavazzi L, 2008, LANCET, V372, P1223, DOI 10.1016/S0140-6736(08)61239-8; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Xiao YF, 2005, J MEMBRANE BIOL, V206, P141, DOI 10.1007/S00232-005-0786-Z	26	146	155	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2010	304	21					2363	2372		10.1001/jama.2010.1735	http://dx.doi.org/10.1001/jama.2010.1735			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	687FH	21078810	Bronze			2022-12-28	WOS:000284763900017
J	Sun, ZZ; Yan, Z; Yao, J; Beitler, E; Zhu, Y; Tour, JM				Sun, Zhengzong; Yan, Zheng; Yao, Jun; Beitler, Elvira; Zhu, Yu; Tour, James M.			Growth of graphene from solid carbon sources	NATURE			English	Article							CHEMICAL-VAPOR-DEPOSITION; EPITAXIAL GRAPHENE; DOPED GRAPHENE; LARGE-AREA; FILMS; TRANSISTORS; SCATTERING; GRAPHITE; BANDGAP; GAS	Monolayer graphene was first obtained(1) as a transferable material in 2004 and has stimulated intense activity among physicists, chemists and material scientists(1-4). Much research has been focused on developing routes for obtaining large sheets of monolayer or bilayer graphene. This has been recently achieved by chemical vapour deposition (CVD) of CH4 or C2H2 gases on copper or nickel substrates(5-7). But CVD is limited to the use of gaseous raw materials, making it difficult to apply the technology to a wider variety of potential feedstocks. Here we demonstrate that large area, high-quality graphene with controllable thickness can be grown from different solid carbon sources-such as polymer films or small molecules-deposited on a metal catalyst substrate at temperatures as low as 800 degrees C. Both pristine graphene and doped graphene were grown with this one-step process using the same experimental set-up.	[Sun, Zhengzong; Yan, Zheng; Beitler, Elvira; Zhu, Yu; Tour, James M.] Rice Univ, Dept Chem, Houston, TX 77005 USA; [Yao, Jun] Rice Univ, Dept Bioengn, Appl Phys Program, Houston, TX 77005 USA; [Tour, James M.] Rice Univ, Dept Mech Engn & Mat Sci, Richard E Smalley Inst Nanoscale Sci & Technol, Houston, TX 77005 USA	Rice University; Rice University; Rice University	Tour, JM (corresponding author), Rice Univ, Dept Chem, 6100 Main St, Houston, TX 77005 USA.	tour@rice.edu	Li, jiayu/H-3827-2014; Sun, Zhengzong/C-5292-2014; Zhu, Yu/C-4420-2013; yang, zheng/HGC-7753-2022	Li, jiayu/0000-0003-2639-213X; Sun, Zhengzong/0000-0002-3710-4001; Yan, Zheng/0000-0001-5968-0934; Tour, James/0000-0002-8479-9328	AFOSR [FA9550-09-1-0581]; ONR MURI [00006766]	AFOSR(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); ONR MURI(MURIOffice of Naval Research)	This work was funded by the AFOSR (FA9550-09-1-0581) and the ONR MURI graphene programme (00006766).	Balog R, 2010, NAT MATER, V9, P315, DOI [10.1038/nmat2710, 10.1038/NMAT2710]; Berger C, 2006, SCIENCE, V312, P1191, DOI 10.1126/science.1125925; Chen JH, 2008, NAT PHYS, V4, P377, DOI 10.1038/nphys935; Ci L, 2010, NAT MATER, V9, P430, DOI [10.1038/nmat2711, 10.1038/NMAT2711]; Ci L, 2008, NANO RES, V1, P116, DOI 10.1007/s12274-008-8020-9; Das A, 2008, NAT NANOTECHNOL, V3, P210, DOI 10.1038/nnano.2008.67; Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Hernandez Y, 2008, NAT NANOTECHNOL, V3, P563, DOI 10.1038/nnano.2008.215; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Li XL, 2008, SCIENCE, V319, P1229, DOI 10.1126/science.1150878; Li XL, 2009, J AM CHEM SOC, V131, P15939, DOI 10.1021/ja907098f; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Lin YM, 2010, SCIENCE, V327, P662, DOI 10.1126/science.1184289; Lin YT, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3282797; Lin YM, 2009, NANO LETT, V9, P422, DOI 10.1021/nl803316h; Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Panchokarla LS, 2009, ADV MATER, V21, P4726, DOI 10.1002/adma.200901285; Rao CNR, 2010, J PHYS CHEM LETT, V1, P572, DOI 10.1021/jz9004174; Reina A, 2009, NANO LETT, V9, P30, DOI 10.1021/nl801827v; Ruoff R, 2008, NAT NANOTECHNOL, V3, P10, DOI 10.1038/nnano.2007.432; Schedin F, 2007, NAT MATER, V6, P652, DOI 10.1038/nmat1967; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034; Stankovich S, 2006, NATURE, V442, P282, DOI 10.1038/nature04969; Stoller MD, 2008, NANO LETT, V8, P3498, DOI 10.1021/nl802558y; Wang XR, 2009, SCIENCE, V324, P768, DOI 10.1126/science.1170335; Wei DC, 2009, NANO LETT, V9, P1752, DOI 10.1021/nl803279t; Zhang YB, 2009, NATURE, V459, P820, DOI 10.1038/nature08105; Zheng M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3318263	31	1121	1184	20	1445	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2010	468	7323					549	552		10.1038/nature09579	http://dx.doi.org/10.1038/nature09579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	684WA	21068724				2022-12-28	WOS:000284584200039
J	Teschke, R; Schulze, J				Teschke, Rolf; Schulze, Johannes			Risk of Kava Hepatotoxicity and the FDA Consumer Advisory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Teschke, Rolf] Goethe Univ Frankfurt, Teaching Hosp, Dept Internal Med 2, Div Gastroenterol & Hepatol,Klinikum Hanau, D-63450 Hanau, Germany; [Schulze, Johannes] Goethe Univ Frankfurt, Fac Med, Off Dean, D-63450 Hanau, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Teschke, R (corresponding author), Goethe Univ Frankfurt, Teaching Hosp, Dept Internal Med 2, Div Gastroenterol & Hepatol,Klinikum Hanau, Leimenstr 20, D-63450 Hanau, Germany.	rolf.teschke@gmx.de						*AUSTR GOV DEP HLT, 2005, KAV FACT SHEET; Lasme P, 2008, J AGR FOOD CHEM, V56, P4976, DOI 10.1021/jf800439g; Sarris J, 2009, PSYCHOPHARMACOLOGY, V205, P399, DOI 10.1007/s00213-009-1549-9; Schmidt M., 2007, HERBALGRAM, V73, P45; Teschke R, 2010, LIVER INT, V30, P1270, DOI 10.1111/j.1478-3231.2010.02308.x; Teschke R, 2010, ANN HEPATOL, V9, P251, DOI 10.1016/S1665-2681(19)31634-5; U.S. Food and Drug Administration, CONS ADV KAV CONT DI; *WHO, 2007, ASS RISK HEP KAV PRO; Zhou P, 2010, FASEB J, V24, P4722, DOI 10.1096/fj.10-163311	9	32	33	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2174	2175		10.1001/jama.2010.1689	http://dx.doi.org/10.1001/jama.2010.1689			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081732				2022-12-28	WOS:000284269800030
J	Hsu, CY				Hsu, Chi-yuan			Review: Erythropoiesis-stimulating agents targeted to higher hemoglobin levels increase risk for adverse outcomes in CKD	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CHRONIC KIDNEY-DISEASE; EPOETIN; ANEMIA; ALPHA		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Hsu, CY (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Hsu CY, 2002, J AM SOC NEPHROL, V13, P504, DOI 10.1681/ASN.V132504; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485	4	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-3	10.1059/0003-4819-153-10-201011160-02003	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079210				2022-12-28	WOS:000284215800002
J	Carvalho, P; Stanley, AM; Rapoport, TA				Carvalho, Pedro; Stanley, Ann Marie; Rapoport, Tom A.			Retrotranslocation of a Misfolded Luminal ER Protein by the Ubiquitin-Ligase Hrd1p	CELL			English	Article							RETICULUM-ASSOCIATED DEGRADATION; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; AAA-ATPASE; QUALITY-CONTROL; SACCHAROMYCES-CEREVISIAE; RETRO-TRANSLOCATION; COMPLEX; GLYCOPROTEINS; DISLOCATION	Misfolded, luminal endoplasmic reticulum (ER) proteins are retrotranslocated into the cytosol and degraded by the ubiquitin/proteasome system. This ERAD-L pathway requires a protein complex consisting of the ubiquitin ligase Hrd1p, which spans the ER membrane multiple times, and the membrane proteins Hrd3p, Usa1p, and Der1p. Here, we show that Hrd1p is the central membrane component in ERAD-L; its overexpression bypasses the need for the other components of the Hrd1p complex. Hrd1p function requires its oligomerization, which in wildtype cells is facilitated by Usa1p. Site-specific photo-crosslinking indicates that, at early stages of retro-translocation, Hrd1p interacts with a substrate segment close to the degradation signal. This interaction follows the delivery of substrate through other ERAD components, requires the presence of transmembrane segments of Hrd1p, and depends on both the ubiquitin ligase activity of Hrd1p and the function of the Cdc48p ATPase complex. Our results suggest a model for how Hrd1p promotes polypeptide movement through the ER membrane.	[Carvalho, Pedro; Stanley, Ann Marie; Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Carvalho, Pedro; Stanley, Ann Marie; Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Carvalho, P (corresponding author), CRG, Dept Cell & Dev Biol, Dr Aiguader 88, Barcelona 08003, Spain.	pedro.carvalho@crg.es; tom_rapoport@hms.harvard.edu	Carvalho, Pedro/HHN-1424-2022	Carvalho, Pedro/0000-0002-9691-5277	Jane Coffin Child Memorial fund; Ruth L. Kirschstein National Research Service Award; NIH [GM052586]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052586] Funding Source: NIH RePORTER	Jane Coffin Child Memorial fund; Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank R. Hampton, D. Ng, D. Pellman, P. Schultz, J. Weissman, and Y. Ye for reagents. We thank D. Pellman, Y. Ye, A. Stein, and D. Finley for critical reading of the manuscript. P.C. was supported by the Jane Coffin Child Memorial fund and is currently a special fellow of the Leukemia and Lymphoma Society, and A.M.S. is supported by a Ruth L. Kirschstein National Research Service Award postdoctoral fellowship. T.A.R. is supported by NIH grant GM052586 and is a Howard Hughes Medical Institute Investigator.	Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bernardi KM, 2010, MOL BIOL CELL, V21, P140, DOI 10.1091/mbc.E09-07-0586; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Carroll SM, 2010, J BIOL CHEM, V285, P5146, DOI 10.1074/jbc.M109.067876; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Chen S, 2007, J MOL BIOL, V371, P112, DOI 10.1016/j.jmb.2007.05.017; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; Clerc S, 2009, J CELL BIOL, V184, P159, DOI 10.1083/jcb.200809198; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gauss R, 2006, EMBO J, V25, P1827, DOI 10.1038/sj.emboj.7601088; Gauss R, 2006, NAT CELL BIOL, V8, P849, DOI 10.1038/ncb1445; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hassink GC, 2006, J BIOL CHEM, V281, P30063, DOI 10.1074/jbc.M602248200; Hirsch C, 2009, NATURE, V458, P453, DOI 10.1038/nature07962; Horn SC, 2009, MOL CELL, V36, P782, DOI 10.1016/j.molcel.2009.10.015; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Plemper RK, 1999, J CELL SCI, V112, P4123; Ploegh HL, 2007, NATURE, V448, P435, DOI 10.1038/nature06004; Quan EM, 2008, MOL CELL, V32, P870, DOI 10.1016/j.molcel.2008.11.017; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Ramadan K, 2007, NATURE, V450, P1258, DOI 10.1038/nature06388; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Schafer A, 2009, EMBO J, V28, P2874, DOI 10.1038/emboj.2009.231; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Willer M, 2008, J BIOL CHEM, V283, P33883, DOI 10.1074/jbc.M803054200; Xie W, 2010, SEMIN CELL DEV BIOL, V21, P533, DOI 10.1016/j.semcdb.2010.02.007; Xie W, 2009, MOL BIOL CELL, V20, P3317, DOI 10.1091/mbc.E09-03-0231; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Ye YH, 2006, J STRUCT BIOL, V156, P29, DOI 10.1016/j.jsb.2006.01.005; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	47	217	225	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 12	2010	143	4					579	591		10.1016/j.cell.2010.10.028	http://dx.doi.org/10.1016/j.cell.2010.10.028			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074049	Green Accepted, Bronze			2022-12-28	WOS:000284149100015
J	Tsukagoshi, H; Busch, W; Benfey, PN				Tsukagoshi, Hironaka; Busch, Wolfgang; Benfey, Philip N.			Transcriptional Regulation of ROS Controls Transition from Proliferation to Differentiation in the Root	CELL			English	Article							REACTIVE OXYGEN; ARABIDOPSIS ROOT; HYDROGEN-PEROXIDE; CELL-DIVISION; THIOREDOXIN; SUPEROXIDE; EXPRESSION; OXIDASE; INTERPLAY; PATHWAY	The balance between cellular proliferation and differentiation is a key aspect of development in multicellular organisms. Using high-resolution expression data from the Arabidopsis root, we identified a transcription factor, UPBEAT1 (UPB1), that regulates this balance. Genomewide expression profiling coupled with ChIP-chip analysis revealed that UPB1 directly regulates the expression of a set of peroxidases that modulate the balance of reactive oxygen species (ROS) between the zones of cell proliferation and the zone of cell elongation where differentiation begins. Disruption of UPB1 activity alters this ROS balance, leading to a delay in the onset of differentiation. Modulation of either ROS balance or peroxidase activity through chemical reagents affects the onset of differentiation in a manner consistent with the postulated UPB1 function. This pathway functions independently of auxin and cytokinin plant hormonal signaling. Comparison to ROS-regulated growth control in animals suggests that a similar mechanism is used in plants and animals.	[Tsukagoshi, Hironaka; Busch, Wolfgang; Benfey, Philip N.] Duke Univ, Dept Biol, Durham, NC 27708 USA; [Tsukagoshi, Hironaka; Busch, Wolfgang; Benfey, Philip N.] Duke Univ, Inst Genome Sci, Durham, NC 27708 USA; [Tsukagoshi, Hironaka; Busch, Wolfgang; Benfey, Philip N.] Duke Univ, Policy Ctr Syst Biol, Durham, NC 27708 USA	Duke University; Duke University; Duke University	Benfey, PN (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.	philip.benfey@duke.edu	Busch, Wolfgang/B-8593-2008; Tsukagoshi, Hironaka/D-5832-2018	Busch, Wolfgang/0000-0003-2042-7290; Tsukagoshi, Hironaka/0000-0003-0058-4926	NSF; JSPS	NSF(National Science Foundation (NSF)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by a grant from the NSF Arabidopsis 2010 program. H.T. was supported by a JSPS Postdoctoral Fellowship for Research Abroad. We thank H. Cui for advice on ChIP-chip; R. Mittler for the apx1 mutant; M.A. Torres for AtrbohC, D, and F mutants; K.D. Birnbaum, Y. Helariutta, Y. Tada, X. Dong, and B. Scheres for comments on the manuscript; and members of the Benfey laboratory for discussions and advice. P.N.B. is a founder and CEO of GrassRoots Biotechnology.	Aida M, 2004, CELL, V119, P109, DOI 10.1016/j.cell.2004.09.018; Asada K, 2006, PLANT PHYSIOL, V141, P391, DOI 10.1104/pp.106.082040; Barcelo AR, 1997, INT REV CYTOL, V176, P87, DOI 10.1016/S0074-7696(08)61609-5; Bashandy T, 2010, PLANT CELL, V22, P376, DOI 10.1105/tpc.109.071225; Beemster GTS, 1998, PLANT PHYSIOL, V116, P1515, DOI 10.1104/pp.116.4.1515; Bestwick CS, 1997, PLANT CELL, V9, P209, DOI 10.1105/tpc.9.2.209; BIELSKI BHJ, 1980, J PHYS CHEM-US, V84, P830, DOI 10.1021/j100445a006; Brady SM, 2007, PLANT PHYSIOL, V143, P172, DOI 10.1104/pp.106.087262; BROUWER KS, 1986, PLANT PHYSIOL, V82, P236, DOI 10.1104/pp.82.1.236; Burch PM, 2005, ANTIOXID REDOX SIGN, V7, P741, DOI 10.1089/ars.2005.7.741; Busch W, 2010, DEV CELL, V18, P849, DOI 10.1016/j.devcel.2010.03.012; Caliskan M, 1998, PLANT J, V15, P165, DOI 10.1046/j.1365-313X.1998.00191.x; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Davletova S, 2005, PLANT PHYSIOL, V139, P847, DOI 10.1104/pp.105.068254; Dello Ioio R, 2008, SCIENCE, V322, P1380, DOI 10.1126/science.1164147; Dello Ioio R, 2007, CURR BIOL, V17, P678, DOI 10.1016/j.cub.2007.02.047; Dunand C, 2007, NEW PHYTOL, V174, P332, DOI 10.1111/j.1469-8137.2007.01995.x; ELSTNER EF, 1976, ANAL BIOCHEM, V70, P616, DOI 10.1016/0003-2697(76)90488-7; FEDERICO R, 1986, PLANTA, V167, P300, DOI 10.1007/BF00391430; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Kurata T, 2005, DEVELOPMENT, V132, P5387, DOI 10.1242/dev.02139; Leibfried A, 2005, NATURE, V438, P1172, DOI 10.1038/nature04270; Levesque MP, 2006, PLOS BIOL, V4, P739, DOI 10.1371/journal.pbio.0040143; Maeda H, 2004, ANGEW CHEM INT EDIT, V43, P2389, DOI 10.1002/anie.200452381; Maeda H, 2008, ANN NY ACAD SCI, V1130, P149, DOI 10.1196/annals.1430.012; Menon SG, 2007, ONCOGENE, V26, P1101, DOI 10.1038/sj.onc.1209895; Meyer Y, 2005, PHOTOSYNTH RES, V86, P419, DOI 10.1007/s11120-005-5220-y; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Owusu-Ansah E., 2008, NATURE PROTOCOLS, DOI [10.1038/nprot.2008.23, DOI 10.1038/NPROT.2008.23]; Owusu-Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313; Passardi F, 2006, PLANTA, V223, P965, DOI 10.1007/s00425-005-0153-4; Pitzschke A, 2006, ANTIOXID REDOX SIGN, V8, P1757, DOI 10.1089/ars.2006.8.1757; Reichheld JP, 2007, PLANT CELL, V19, P1851, DOI 10.1105/tpc.107.050849; Sarsour EH, 2008, AGING CELL, V7, P405, DOI 10.1111/j.1474-9726.2008.00384.x; Tognolli M, 2002, GENE, V288, P129, DOI 10.1016/S0378-1119(02)00465-1; Toledo-Ortiz G, 2003, PLANT CELL, V15, P1749, DOI 10.1105/tpc.013839; Ubeda-Tomas S, 2009, CURR BIOL, V19, P1194, DOI 10.1016/j.cub.2009.06.023; Vernoux T, 2000, PLANT CELL, V12, P97, DOI 10.1105/tpc.12.1.97; Willemsen V, 2008, DEV CELL, V15, P913, DOI 10.1016/j.devcel.2008.09.019	41	647	681	7	183	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					606	616		10.1016/j.cell.2010.10.020	http://dx.doi.org/10.1016/j.cell.2010.10.020			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074051	Bronze			2022-12-28	WOS:000284149100017
J	Insel, TR				Insel, Thomas R.			Rethinking schizophrenia	NATURE			English	Article							CHILDHOOD-ONSET SCHIZOPHRENIA; ULTRA-HIGH RISK; FOLLOW-UP; OBSTETRIC COMPLICATIONS; ADULT SCHIZOPHRENIA; PSYCHOTIC DISORDERS; PRENATAL EXPOSURE; BRAIN-DEVELOPMENT; DEFICITS; GENES	How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently disabling mental disorder that affects about one per cent of the world's population. After a century of studying schizophrenia, the cause of the disorder remains unknown. Treatments, especially pharmacological treatments, have been in wide use for nearly half a century, yet there is little evidence that these treatments have substantially improved outcomes for most people with schizophrenia. These current unsatisfactory outcomes may change as we approach schizophrenia as a neurodevelopmental disorder with psychosis as a late, potentially preventable stage of the illness. This 'rethinking' of schizophrenia as a neurodevelopmental disorder, which is profoundly different from the way we have seen this illness for the past century, yields new hope for prevention and cure over the next two decades.	NIMH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Insel, TR (corresponding author), NIMH, Bethesda, MD 20892 USA.	tinsel@mail.nih.gov						Alaraisanen A, 2009, SOC PSYCH PSYCH EPID, V44, P1107, DOI 10.1007/s00127-009-0033-5; Amminger GP, 2010, ARCH GEN PSYCHIAT, V67, P146, DOI 10.1001/archgenpsychiatry.2009.192; [Anonymous], 1988, NATURE, V336, P95, DOI 10.1038/336095a0; Arieti S, 1974, INTERPRETATION SCHIZ, V2nd; Bassett AS, 2010, AM J PSYCHIAT, V167, P899, DOI 10.1176/appi.ajp.2009.09071016; Bassett AS, 2003, AM J PSYCHIAT, V160, P1580, DOI 10.1176/appi.ajp.160.9.1580; Bell MD, 2008, SCHIZOPHR RES, V105, P18, DOI 10.1016/j.schres.2008.06.026; Berger G, 2007, EARLY INTERV PSYCHIA, V1, P114, DOI 10.1111/j.1751-7893.2007.00021.x; Bleuler E., 1950, DEMENTIA PRAECOX GRO; Brandon NJ, 2009, J NEUROSCI, V29, P12768, DOI 10.1523/JNEUROSCI.3355-09.2009; Brown AS, 2010, AM J PSYCHIAT, V167, P261, DOI 10.1176/appi.ajp.2009.09030361; Buchanan RW, 2005, SCHIZOPHRENIA BULL, V31, P5, DOI 10.1093/schbul/sbi020; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Cannon TD, 2000, SCHIZOPHRENIA BULL, V26, P379, DOI 10.1093/oxfordjournals.schbul.a033460; Cannon TD, 2008, ARCH GEN PSYCHIAT, V65, P28, DOI 10.1001/archgenpsychiatry.2007.3; Cardno AG, 1999, ARCH GEN PSYCHIAT, V56, P162, DOI 10.1001/archpsyc.56.2.162; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Carter CS, 2009, SCHIZOPHRENIA BULL, V35, P153, DOI 10.1093/schbul/sbn157; Chow EWC, 2006, SCHIZOPHR RES, V87, P270, DOI 10.1016/j.schres.2006.04.007; Cohen JD, 1999, J ABNORM PSYCHOL, V108, P120, DOI 10.1037/0021-843X.108.1.120; Colantuoni C, 2008, BRAIN STRUCT FUNCT, V213, P255, DOI 10.1007/s00429-008-0181-5; Colton Craig W, 2006, Prev Chronic Dis, V3, pA42; Cornblatt B, 1999, DEV PSYCHOPATHOL, V11, P487, DOI 10.1017/S0954579499002175; Cornblatt BA, 2007, J CLIN PSYCHIAT, V68, P546, DOI 10.4088/JCP.v68n0410; Coyle JT, 2006, CELL MOL NEUROBIOL, V26, P365, DOI 10.1007/s10571-006-9062-8; Ellman LM, 2010, SCHIZOPHR RES, V121, P46, DOI 10.1016/j.schres.2010.05.014; Erlenmeyer-Kimling L, 2000, AM J PSYCHIAT, V157, P1416, DOI 10.1176/appi.ajp.157.9.1416; Ettinger U, 2012, SCHIZOPHRENIA BULL, V38, P192, DOI 10.1093/schbul/sbq060; Fair DA, 2008, P NATL ACAD SCI USA, V105, P4028, DOI 10.1073/pnas.0800376105; Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107; FEINBERG I, 1983, J PSYCHIAT RES, V17, P319, DOI 10.1016/0022-3956(82)90038-3; Folsom DP, 2005, AM J PSYCHIAT, V162, P370, DOI 10.1176/appi.ajp.162.2.370; Gogtay N, 2004, ARCH GEN PSYCHIAT, V61, P17, DOI 10.1001/archpsyc.61.1.17; Gregory SG, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-62; Guilmatre A, 2009, ARCH GEN PSYCHIAT, V66, P947, DOI 10.1001/archgenpsychiatry.2009.80; Hahn CG, 2006, NAT MED, V12, P824, DOI 10.1038/nm1418; Harrison G, 2001, BRIT J PSYCHIAT, V178, P506, DOI 10.1192/bjp.178.6.506; Harvey PD, 2010, BIOL PSYCHIAT, V67, p84S; Hashimoto T, 2009, BIOL PSYCHIAT, V65, P1015, DOI 10.1016/j.biopsych.2009.01.004; HEGARTY JD, 1994, AM J PSYCHIAT, V151, P1409; Henry LP, 2010, J CLIN PSYCHIAT, V71, P716, DOI 10.4088/JCP.08m04846yel; Huffaker SJ, 2009, NAT MED, V15, P509, DOI 10.1038/nm.1962; HUTTENLOCHER PR, 1984, AM J MENT DEF, V88, P488; Hyman SE, 2003, SCIENCE, V299, P350, DOI 10.1126/science.1077141; Jaaro-Peled H, 2009, TRENDS NEUROSCI, V32, P485, DOI 10.1016/j.tins.2009.05.007; Karayiorgou M, 2010, NAT REV NEUROSCI, V11, P402, DOI 10.1038/nrn2841; Keefe RSE, 2007, AM J PSYCHIAT, V164, P1061, DOI 10.1176/appi.ajp.164.7.1061; Keefe RSE, 2011, SCHIZOPHRENIA BULL, V37, P1057, DOI 10.1093/schbul/sbq010; Kelly D, 2009, THEATER HEUTE, pA2; KETY SS, 1987, J PSYCHIAT RES, V21, P423, DOI 10.1016/0022-3956(87)90089-6; Kirkpatrick B, 2001, ARCH GEN PSYCHIAT, V58, P165, DOI 10.1001/archpsyc.58.2.165; Kirkpatrick B, 2006, SCHIZOPHRENIA BULL, V32, P214, DOI 10.1093/schbul/sbj053; Kraepelin E., 1919, CUTTING SHEPHERD; Kremen WS, 2010, SCHIZOPHR RES, V118, P1, DOI 10.1016/j.schres.2010.01.009; Lambe EK, 2000, J NEUROSCI, V20, P8780; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Lewis DA, 2008, NEUROPSYCHOPHARMACOL, V33, P141, DOI 10.1038/sj.npp.1301563; Li W, 2007, P NATL ACAD SCI USA, V104, P18280, DOI 10.1073/pnas.0706900104; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Marwaha S, 2007, BRIT J PSYCHIAT, V191, P30, DOI 10.1192/bjp.bp.105.020982; McClellan J, 2010, CELL, V141, P210, DOI 10.1016/j.cell.2010.03.032; McEvoy JP, 2005, SCHIZOPHR RES, V80, P19, DOI 10.1016/j.schres.2005.07.014; McGorry PD, 2008, ARCH GEN PSYCHIAT, V65, P25, DOI 10.1001/archgenpsychiatry.2007.9; McGuffin P, 1999, NEW ENGL J MED, V341, P370; Morrison AP, 2004, BRIT J PSYCHIAT, V185, P291, DOI 10.1192/bjp.185.4.291; Mukai J, 2008, NAT NEUROSCI, V11, P1302, DOI 10.1038/nn.2204; MURRAY RM, 1991, CIBA F SYMP, V156, P155; Nakata K, 2009, P NATL ACAD SCI USA, V106, P15873, DOI 10.1073/pnas.0903413106; Need AC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000373; Nicodemus KK, 2008, MOL PSYCHIATR, V13, P873, DOI 10.1038/sj.mp.4002153; Niwa M, 2010, NEURON, V65, P480, DOI 10.1016/j.neuron.2010.01.019; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; RAKIC P, 1986, SCIENCE, V232, P232, DOI 10.1126/science.3952506; Rapoport JL, 1999, ARCH GEN PSYCHIAT, V56, P649, DOI 10.1001/archpsyc.56.7.649; Reichenberg A, 2010, AM J PSYCHIAT, V167, P160, DOI 10.1176/appi.ajp.2009.09040574; Riecher-Rossler A, 2009, BIOL PSYCHIAT, V66, P1023, DOI 10.1016/j.biopsych.2009.07.020; Robinson DG, 2004, AM J PSYCHIAT, V161, P473, DOI 10.1176/appi.ajp.161.3.473; ROSENBERG DR, 1995, J COMP NEUROL, V358, P383, DOI 10.1002/cne.903580306; Rujescu D, 2009, HUM MOL GENET, V18, P988, DOI 10.1093/hmg/ddn351; Seidman LJ, 2010, ARCH GEN PSYCHIAT, V67, P578, DOI 10.1001/archgenpsychiatry.2010.66; Smieskova R, 2010, NEUROSCI BIOBEHAV R, V34, P1207, DOI 10.1016/j.neubiorev.2010.01.016; Sorensen HJ, 2010, SCHIZOPHR RES, V118, P41, DOI 10.1016/j.schres.2010.01.029; St Clair D, 2005, JAMA-J AM MED ASSOC, V294, P557, DOI 10.1001/jama.294.5.557; Stark KL, 2008, NAT GENET, V40, P751, DOI 10.1038/ng.138; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Straub RE, 2002, AM J HUM GENET, V71, P337, DOI 10.1086/341750; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; Swartz MS, 2007, AM J PSYCHIAT, V164, P428, DOI 10.1176/appi.ajp.164.3.428; Takahashi H, 2009, SCHIZOPHR RES, V112, P149, DOI 10.1016/j.schres.2009.03.037; Tan W, 2007, J BIOL CHEM, V282, P24343, DOI 10.1074/jbc.M702953200; Thompson BL, 2010, NEURON, V65, P437, DOI 10.1016/j.neuron.2010.02.010; Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; Woodberry KA, 2008, AM J PSYCHIAT, V165, P579, DOI 10.1176/appi.ajp.2008.07081242; Woods SW, 2009, SCHIZOPHRENIA BULL, V35, P894, DOI 10.1093/schbul/sbp027; Woods SW, 2003, BIOL PSYCHIAT, V54, P453, DOI 10.1016/S0006-3223(03)00321-4; Yakovlev P.I., 1967, REGIONAL DEV BRAIN E; Yung AR, 2008, SCHIZOPHR RES, V105, P10, DOI 10.1016/j.schres.2008.07.012	99	1109	1151	5	256	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					187	193		10.1038/nature09552	http://dx.doi.org/10.1038/nature09552			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068826	Bronze, Green Published			2022-12-28	WOS:000284051000034
J	Joesch, M; Schnell, B; Raghu, SV; Reiff, DF; Borst, A				Joesch, Maximilian; Schnell, Bettina; Raghu, Shamprasad Varija; Reiff, Dierk F.; Borst, Alexander			ON and OFF pathways in Drosophila motion vision	NATURE			English	Article							OPTIC LOBE; VISUAL INTERNEURONS; RESPONSE PROPERTIES; WILD-TYPE; MELANOGASTER; EXPRESSION; MEDULLA; CHANNEL; NEURONS; SYSTEM	Motion vision is a major function of all visual systems, yet the underlying neural mechanisms and circuits are still elusive. In the lamina, the first optic neuropile of Drosophila melanogaster, photoreceptor signals split into five parallel pathways, L1-L5(1). Here we examine how these pathways contribute to visual motion detection by combining genetic block and reconstitution of neural activity in different lamina cell types with whole-cell recordings from downstream motion-sensitive neurons(2,3). We find reduced responses to moving gratings if L1 or L2 is blocked; however, reconstitution of photoreceptor input to only L1 or L2 results in wild-type responses. Thus, the first experiment indicates the necessity of both pathways, whereas the second indicates sufficiency of each single pathway. This contradiction can be explained by electrical coupling between L1 and L2, allowing for activation of both pathways even when only one of them receives photoreceptor input. A fundamental difference between the L1 pathway and the L2 pathway is uncovered when blocking L1 or L2 output while presenting moving edges of positive (ON) or negative (OFF) contrast polarity: blocking L1 eliminates the response to moving ON edges, whereas blocking L2 eliminates the response to moving OFF edges. Thus, similar to the segregation of photoreceptor signals in ON and OFF bipolar cell pathways in the vertebrate retina(4), photoreceptor signals segregate into ON-L1 and OFF-L2 channels in the lamina of Drosophila.	[Joesch, Maximilian; Schnell, Bettina; Raghu, Shamprasad Varija; Reiff, Dierk F.; Borst, Alexander] MPI Neurobiol, Dept Syst & Computat Neurobiol, D-82152 Martinsried, Germany		Borst, A (corresponding author), MPI Neurobiol, Dept Syst & Computat Neurobiol, Klopferspitz 18, D-82152 Martinsried, Germany.	borst@neuro.mpg.de	Raghu, Shamprasad Varija/AAV-3044-2020	Schnell, Bettina/0000-0001-7700-2600; Joesch, Maximilian/0000-0002-3937-1330				BARLOW HB, 1964, J PHYSIOL-LONDON, V173, P377, DOI 10.1113/jphysiol.1964.sp007463; BAUSENWEIN B, 1992, CELL TISSUE RES, V270, P25, DOI 10.1007/BF00381876; BAUSENWEIN B, 1992, CELL TISSUE RES, V267, P17, DOI 10.1007/BF00318687; Blagburn JM, 1999, J COMP NEUROL, V404, P449; Borst A, 2010, ANNU REV NEUROSCI, V33, P49, DOI 10.1146/annurev-neuro-060909-153155; BRAND AH, 1993, DEVELOPMENT, V118, P401; DUBNER R, 1971, BRAIN RES, V35, P528, DOI 10.1016/0006-8993(71)90494-X; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; Gao SY, 2008, NEURON, V60, P328, DOI 10.1016/j.neuron.2008.08.010; Gengs CX, 2002, J BIOL CHEM, V277, P42113, DOI 10.1074/jbc.M207133200; Haag J, 2005, J COMP PHYSIOL A, V191, P445, DOI 10.1007/s00359-005-0605-0; HARDIE RC, 1989, NATURE, V339, P704, DOI 10.1038/339704a0; HASSENSTEIN B, 1956, Z NATURFORSCH PT B, V11, P513; Joesch M, 2008, CURR BIOL, V18, P368, DOI 10.1016/j.cub.2008.02.022; Johns DC, 1999, J NEUROSCI, V19, P1691; Katsov AY, 2008, NEURON, V59, P322, DOI 10.1016/j.neuron.2008.05.022; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; LAUGHLIN SB, 1989, J EXP BIOL, V144, P113; Luan HJ, 2006, NEURON, V52, P425, DOI 10.1016/j.neuron.2006.08.028; MEINERTZHAGEN IA, 1991, J COMP NEUROL, V305, P232, DOI 10.1002/cne.903050206; Phelan P, 1998, TRENDS GENET, V14, P348, DOI 10.1016/S0168-9525(98)01547-9; Reichardt W, 1961, SENS COMMUN, P303; Reiff DF, 2010, NAT NEUROSCI, V13, P973, DOI 10.1038/nn.2595; Rister J, 2007, NEURON, V56, P155, DOI 10.1016/j.neuron.2007.09.014; Sanes JR, 2010, NEURON, V66, P15, DOI 10.1016/j.neuron.2010.01.018; Schnell B, 2010, J NEUROPHYSIOL, V103, P1646, DOI 10.1152/jn.00950.2009; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; Takemura SY, 2008, J COMP NEUROL, V509, P493, DOI 10.1002/cne.21757; Wassle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497; Zhu Y, 2009, CURR BIOL, V19, P613, DOI 10.1016/j.cub.2009.02.053	30	215	216	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					300	U186		10.1038/nature09545	http://dx.doi.org/10.1038/nature09545			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068841				2022-12-28	WOS:000284051000050
J	Yi, CQ; Jia, GF; Hou, GH; Dai, Q; Zhang, W; Zheng, GQ; Jian, X; Yang, CG; Cui, QA; He, CA				Yi, Chengqi; Jia, Guifang; Hou, Guanhua; Dai, Qing; Zhang, Wen; Zheng, Guanqun; Jian, Xing; Yang, Cai-Guang; Cui, Qiang; He, Chuan			Iron-catalysed oxidation intermediates captured in a DNA repair dioxygenase	NATURE			English	Article							BASE-EXCISION-REPAIR; CRYSTAL-STRUCTURES; ALKB PROTEIN; FTO GENE; DEMETHYLATION; 3-METHYLTHYMINE; RECOGNITION; BACTERIAL; LESIONS; DAMAGE	Mononuclear iron-containing oxygenases conduct a diverse variety of oxidationfunctions in biology(1,2), includingthe oxidative demethylation of methylated nucleic acids and histones(3,4). Escherichia coli AlkB is the first such enzyme that was discovered to repair methylated nucleic acids(5,6), which are otherwise cytotoxic and/or mutagenic. AlkB human homologues are known to play pivotal roles in various processes(7-11). Here we present structural characterization of oxidation intermediates for these demethylases. Using a chemical cross-linking strategy(12,13), complexes of AlkB-double stranded DNA (dsDNA) containing 1,N-6-etheno adenine (epsilon A), N-3-methyl thymine (3-meT) and N-3-methyl cytosine (3-meC) are stabilized and crystallized, respectively. Exposing these crystals, grown under anaerobic conditions containing iron(II) and alpha-ketoglutarate (alpha KG), to dioxygen initiates oxidation in crystallo. Glycol (from epsilon A) and hemiaminal (from 3-meT) intermediates are captured; a zwitterionic intermediate (from 3-meC) is also proposed, based on crystallographic observations and computational analysis. The observation of these unprecedented intermediates provides direct support for the oxidative demethylation mechanism for these demethylases. This study also depicts a general mechanistic view of how a methyl group is oxidatively removed from different biological substrates.	[Yi, Chengqi; Jia, Guifang; Zhang, Wen; Zheng, Guanqun; Jian, Xing; Yang, Cai-Guang; He, Chuan] Univ Chicago, Dept Chem, Chicago, IL 60637 USA; [Yi, Chengqi; Jia, Guifang; Zhang, Wen; Zheng, Guanqun; Jian, Xing; Yang, Cai-Guang; He, Chuan] Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA; [Hou, Guanhua; Cui, Qiang] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; [Hou, Guanhua; Cui, Qiang] Univ Wisconsin, Inst Theoret Chem, Madison, WI 53706 USA; [Dai, Qing] Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; [Yang, Cai-Guang] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China	University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Chicago; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	He, CA (corresponding author), Univ Chicago, Dept Chem, 929 E 57th St, Chicago, IL 60637 USA.	chuanhe@uchicago.edu	Jian, Xing/N-3753-2018; Dai, Qing/ABD-8444-2021	Jian, Xing/0000-0002-0043-8729; Yi, Chengqi/0000-0003-2540-9729	National Institutes of Health [GM071440, GM084028]; Advanced Photon Source at Argonne National Laboratory; United States Department of Energy; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084028, R01GM071440] Funding Source: NIH RePORTER; Division Of Chemistry [0840494] Funding Source: National Science Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Advanced Photon Source at Argonne National Laboratory; United States Department of Energy(United States Department of Energy (DOE)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Division Of Chemistry(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	This study was supported by the National Institutes of Health (GM071440 to C.H.; GM084028 to Q.C.), beamlines 23ID-B (General Medicine and Cancer Institutes Collaborative Access Team (GM/CA-CAT)), 19BM-D (Structual Biology Center (SBC-CAT)), 14BM-C (BioCARS) and 21ID-D (Life Sciences Collaborative Access Team (LS-CAT)) at the Advanced Photon Source at Argonne National Laboratory, the National Institutes of Health and the United States Department of Energy. Computational resources from the National Center for Supercomputing Applications at the University of Illinois and the Center of High Throughput Computing at UW-Madison are appreciated. We also thank X. Yang, Z. Ren and E. Duguid for crystallographic discussions.	Aas PA, 2003, NATURE, V421, P859, DOI 10.1038/nature01363; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Burzlaff NI, 1999, NATURE, V401, P721, DOI 10.1038/44400; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Delaney JC, 2005, NAT STRUCT MOL BIOL, V12, P855, DOI 10.1038/nsmb996; Delaney JC, 2004, P NATL ACAD SCI USA, V101, P14051, DOI 10.1073/pnas.0403489101; DeLano W.L, PYMOL MOL GRAPHICS S; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; Falnes PO, 2004, NUCLEIC ACIDS RES, V32, P6260, DOI 10.1093/nar/gkh964; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Fromme JC, 2004, CURR OPIN STRUC BIOL, V14, P43, DOI 10.1016/j.sbi.2004.01.003; Gerken T, 2007, SCIENCE, V318, P1469, DOI 10.1126/science.1151710; Han ZF, 2010, NATURE, V464, P1205, DOI 10.1038/nature08921; Hitomi K, 2007, DNA REPAIR, V6, P410, DOI 10.1016/j.dnarep.2006.10.004; Holland PJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008680; Jia GF, 2008, FEBS LETT, V582, P3313, DOI 10.1016/j.febslet.2008.08.019; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Koivisto P, 2004, J BIOL CHEM, V279, P40470, DOI 10.1074/jbc.M407960200; Kovaleva EG, 2008, NAT CHEM BIOL, V4, P186, DOI 10.1038/nchembio.71; Kovaleva EG, 2007, SCIENCE, V316, P453, DOI 10.1126/science.1134697; Mishina Y, 2003, J AM CHEM SOC, V125, P8730, DOI 10.1021/ja034636c; Mishina Y, 2005, J AM CHEM SOC, V127, P14594, DOI 10.1021/ja055957m; Mishina Y, 2004, J AM CHEM SOC, V126, P16930, DOI 10.1021/ja045066z; Qi Y, 2009, NATURE, V462, P762, DOI 10.1038/nature08561; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Ringvoll J, 2006, EMBO J, V25, P2189, DOI 10.1038/sj.emboj.7601109; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Searls T, 1999, TETRAHEDRON, V55, P11985, DOI 10.1016/S0040-4020(99)00703-6; Sundheim O, 2006, EMBO J, V25, P3389, DOI 10.1038/sj.emboj.7601219; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Westbye MP, 2008, J BIOL CHEM, V283, P25046, DOI 10.1074/jbc.M803776200; Yang CG, 2008, NATURE, V452, P961, DOI 10.1038/nature06889; YI C, 2009, ACCOUNTS CHEM RES, V42, P530; Yu B, 2006, NATURE, V439, P879, DOI 10.1038/nature04561; Yu B, 2009, P NATL ACAD SCI USA, V106, P14315, DOI 10.1073/pnas.0812938106	38	110	112	1	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					330	U223		10.1038/nature09497	http://dx.doi.org/10.1038/nature09497			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068844	Green Accepted			2022-12-28	WOS:000284051000056
J	Griner, PF				Griner, Paul F.			Payment Reform and the Mission of Academic Medical Centers.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA	University of Rochester	Griner, PF (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA.							*AM HOSP ASS COMM, 2010, BUNDL PAYM AHA SYNTH; Gittell JH, 2010, ORGAN SCI, V21, P490, DOI 10.1287/orsc.1090.0446; GRINER PF, 1971, ANN INTERN MED, V75, P157, DOI 10.7326/0003-4819-75-2-157; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; Pham Hoangmai H., 2010, EPISODE BASED PAYMEN	5	10	10	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1784	1786		10.1056/NEJMp1005413	http://dx.doi.org/10.1056/NEJMp1005413			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674YK	21047220				2022-12-28	WOS:000283787800002
J	Ouslander, JG				Ouslander, Joseph G.			A Murmur of Music	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												joseph.ouslander@fau.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1875	1875		10.1001/jama.2010.1141	http://dx.doi.org/10.1001/jama.2010.1141			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674GT	21045087				2022-12-28	WOS:000283725900001
J	Lenzer, J; Brownlee, S				Lenzer, Jeanne; Brownlee, Shannon			Post-marketing Surveillance Why the FDA can't protect the public	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EPILEPSY; SUDDEN		[Brownlee, Shannon] Dartmouth Inst Hlth Policy & Clin Practice, Washington, DC USA			jeanne.lenzer@gmail.com						Annegers JF, 2000, EPILEPSIA, V41, P549, DOI 10.1111/j.1528-1157.2000.tb00208.x; BUNKER M, 2010, COMMUNICATION   0503; DASHEIFF RM, 1991, J CLIN NEUROPHYSIOL, V8, P216, DOI 10.1097/00004691-199104000-00010; Dhruva SS, 2009, JAMA-J AM MED ASSOC, V302, P2679, DOI 10.1001/jama.2009.1899; DRAZEN JM, 2007, FORUM DRUG DISCOVERY; *FDA, 2010, MAN US FAC DEV EXP; *FDA CTR DEV RAD H, 1997, 10 M FDAS CTR DEV RA; Levinson Daniel, 2009, ADVERSE EVENT REPORT; MAISEL WH, 2008, COMMUNICATION   0514; MALISOW C, 2005, EXPOSED NERVE; Nikolas H, 2007, EPILEPSY BEHAV, V10, P363, DOI 10.1016/j.yebeh.2007.01.005; STINE N, 2005, COMMUNICATION   0511; *US FDA, 1997, PREM APPR VAG NERV S; US Food Drug Adm, 1999, MAN RISKS MED PROD U	14	19	19	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2010	341								c4753	10.1136/bmj.c4753	http://dx.doi.org/10.1136/bmj.c4753			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678CU	21045048				2022-12-28	WOS:000284048200030
J	Rauzi, M; Lenne, PF; Lecuit, T				Rauzi, Matteo; Lenne, Pierre-Francois; Lecuit, Thomas			Planar polarized actomyosin contractile flows control epithelial junction remodelling	NATURE			English	Article							ADHERENS JUNCTIONS; APICAL CONSTRICTION; CELL-SHAPE; TISSUE MORPHOGENESIS; ALPHA-CATENIN; E-CADHERIN; DROSOPHILA; NETWORK; FORCES; INTERCALATION	Force generation by Myosin-II motors on actin filaments drives cell and tissue morphogenesis(1-15). In epithelia, contractile forces are resisted at apical junctions by adhesive forces dependent on E-cadherin(16), which also transmits tension(6,17-19). During Drosophila embryonic germband extension, tissue elongation is driven by cell intercalation(20), which requires an irreversible and planar polarized remodelling of epithelial cell junctions(4,5). We investigate how cell deformations emerge from the interplay between force generation and cortical force transmission during this remodelling in Drosophila melanogaster. The shrinkage of dorsal-ventral-oriented ('vertical') junctions during this process is known to require planar polarized junctional contractility by Myosin II (refs 4,5,7,12). Here we show that this shrinkage is not produced by junctional Myosin II itself, but by the polarized flow of medial actomyosin pulses towards 'vertical' junctions. This anisotropic flow is oriented by the planar polarized distribution of E-cadherin complexes, in that medial Myosin II flows towards 'vertical' junctions, which have relatively less E-cadherin than transverse junctions. Our evidence suggests that the medial flow pattern reflects equilibrium properties of force transmission and coupling to E-cadherin by a-Catenin. Thus, epithelial morphogenesis is not properly reflected by Myosin II steady state distribution but by polarized contractile actomyosin flows that emerge from interactions between E-cadherin and actomyosin networks.	[Rauzi, Matteo; Lenne, Pierre-Francois; Lecuit, Thomas] Univ Aix Marseille 2, CNRS, IBDML, UMR6216, F-13288 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Lecuit, T (corresponding author), Univ Aix Marseille 2, CNRS, IBDML, UMR6216, Campus Luminy,Case 907, F-13288 Marseille 09, France.	lenne@ibdml.univ-mrs.fr; lecuit@ibdml.univ-mrs.fr		Rauzi, Matteo/0000-0002-6313-0668; Lenne, Pierre-Francois/0000-0003-1066-7506	HFSP; CNRS; Fondation pour la Recherche Medicale; ANR-Blanc; Region PACA; ANR-PCV; Amplitude Systems	HFSP(Human Frontier Science Program); CNRS(Centre National de la Recherche Scientifique (CNRS)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); ANR-Blanc(French National Research Agency (ANR)); Region PACA(Region Provence-Alpes-Cote d'Azur); ANR-PCV(French National Research Agency (ANR)); Amplitude Systems	We thank R. Levayer, M. Mavrakis and J.-M. Philippe for making and sharing respectively the utrophin-GFP, GAP43-Venus and GAP43-Cherry transgenic lines. We are grateful to our colleagues for their gifts of reagents: B. Bement, R. Karess, H. Oda, A. Martin and E. Wieschaus. We thank E. Munro and all members of the Lecuit and Lenne groups for discussions, and comments on the manuscript. This work was supported by a Programme Grant from HFSP to T. L, P.-F.L and E. Munro, by the CNRS, the Fondation pour la Recherche Medicale (to T. L), the ANR-Blanc 2005 (to T. L. and P.-F.L), Region PACA and ANR-PCV 2008 (to P.-F.L and T. L.). M. R. was supported by a PhD fellowship by the Region PACA and Amplitude Systems.	Bendix PM, 2008, BIOPHYS J, V94, P3126, DOI 10.1529/biophysj.107.117960; Bertet C, 2004, NATURE, V429, P667, DOI 10.1038/nature02590; Bertet C, 2009, DEVELOPMENT, V136, P4199, DOI 10.1242/dev.040402; Blankenship JT, 2006, DEV CELL, V11, P459, DOI 10.1016/j.devcel.2006.09.007; Burkel BM, 2007, CELL MOTIL CYTOSKEL, V64, P822, DOI 10.1002/cm.20226; Cavey M, 2008, NATURE, V453, P751, DOI 10.1038/nature06953; Cavey Matthieu, 2008, V420, P219, DOI 10.1007/978-1-59745-583-1_13; Dawes-Hoang RE, 2005, DEVELOPMENT, V132, P4165, DOI 10.1242/dev.01938; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Fernandez-Gonzalez R, 2009, DEV CELL, V17, P736, DOI 10.1016/j.devcel.2009.09.003; Gorfinkiel N, 2007, J CELL SCI, V120, P3289, DOI 10.1242/jcs.010850; Hildebrand JD, 2005, J CELL SCI, V118, P5191, DOI 10.1242/jcs.02626; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; Hutson MS, 2003, SCIENCE, V300, P145, DOI 10.1126/science.1079552; IRVINE KD, 1994, DEVELOPMENT, V120, P827; Kobielak A, 2004, NAT CELL BIOL, V6, P21, DOI 10.1038/ncb1075; Koenderink GH, 2009, P NATL ACAD SCI USA, V106, P15192, DOI 10.1073/pnas.0903974106; Krieg M, 2008, NAT CELL BIOL, V10, P429, DOI 10.1038/ncb1705; Landsberg KP, 2009, CURR BIOL, V19, P1950, DOI 10.1016/j.cub.2009.10.021; Lecuit T, 2007, NAT REV MOL CELL BIO, V8, P633, DOI 10.1038/nrm2222; Martin AC, 2010, J CELL BIOL, V188, P735, DOI 10.1083/jcb.200910099; Martin AC, 2009, NATURE, V457, P495, DOI 10.1038/nature07522; Mavrakis M, 2009, DEV CELL, V16, P93, DOI 10.1016/j.devcel.2008.11.003; Monier B, 2010, NAT CELL BIOL, V12, P60, DOI 10.1038/ncb2005; Montell DJ, 2008, SCIENCE, V322, P1502, DOI 10.1126/science.1164073; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Nishimura T, 2008, DEVELOPMENT, V135, P1493, DOI 10.1242/dev.019646; Nishimura T, 2009, CURR TOP DEV BIOL, V89, P33, DOI 10.1016/S0070-2153(09)89002-9; Oda H, 2001, J CELL SCI, V114, P493; Pilot F, 2006, NATURE, V442, P580, DOI 10.1038/nature04935; Rauzi M, 2008, NAT CELL BIOL, V10, P1401, DOI 10.1038/ncb1798; Royou A, 2004, MOL BIOL CELL, V15, P838, DOI 10.1091/mbc.E03-06-0440; Sawyer JK, 2009, J CELL BIOL, V186, P57, DOI 10.1083/jcb.200904001; Skoglund P, 2008, DEVELOPMENT, V135, P2435, DOI 10.1242/dev.014704; Yonemura S, 2010, NAT CELL BIOL, V12, P533, DOI 10.1038/ncb2055; Zallen JA, 2004, DEV CELL, V6, P343, DOI 10.1016/S1534-5807(04)00060-7	36	422	429	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 23	2010	468	7327					1110	U515		10.1038/nature09566	http://dx.doi.org/10.1038/nature09566			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	697XT	21068726				2022-12-28	WOS:000285553800060
J	Colgan, R; Zaner, CI				Colgan, Richard; Zaner, Caitlin Iafolla			A Modern Family	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rcolgan@som.umaryland.edu							0	0	0	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2010	304	20					2221	2222		10.1001/jama.2010.1709	http://dx.doi.org/10.1001/jama.2010.1709			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KI	21098763				2022-12-28	WOS:000284548400005
J	Mishra, NK; Ahmed, N; Andersen, G; Egido, JA; Lindsberg, PJ; Ringleb, PA; Wahlgren, NG; Lees, KR				Mishra, Nishant K.; Ahmed, Niaz; Andersen, Grethe; Egido, Jose A.; Lindsberg, Perttu J.; Ringleb, Peter A.; Wahlgren, Nils G.; Lees, Kennedy R.		VISTA Collaborator; SITS Collaborator	Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE ISCHEMIC-STROKE; AGED 80 YEARS; TISSUE-PLASMINOGEN ACTIVATOR; UPDATED POOLED ANALYSIS; IN-HOSPITAL MORTALITY; INTRAVENOUS THROMBOLYSIS; SAFE IMPLEMENTATION; RT-PA; ALTEPLASE; OUTCOMES	Objective To assess effect of age on response to alteplase in acute ischaemic stroke. Design Adjusted controlled comparison of outcomes between non-randomised patients who did or did not undergo thrombolysis. Analysis used Cochran-Mantel-Haenszel test and proportional odds logistic regression analysis. Setting Collaboration between International Stroke Thrombolysis Registry (SITS-ISTR) and Virtual International Stroke Trials Archive (VISTA). Participants 23 334 patients from SITS-ISTR (December 2002 to November 2009) who underwent thrombolysis and 6166 from VISTA neuroprotection trials (1998-2007) who did not undergo thrombolysis (as controls). Of the 29 500 patients (3472 aged >80 ("elderly," mean 84.6), data on 272 patients were missing for baseline National Institutes of Health stroke severity score, leaving 29 228 patients for analysis adjusted for age and baseline severity. Main outcome measures Functional outcomes at 90 days measured by score on modified Rankin scale. Results Median severity at baseline was the same for patients who underwent thrombolysis and controls (median baseline stroke scale score: 12 for each group, P = 0.14; n = 29 228). The distribution of scores on the modified Rankin scale was better among all thrombolysis patients than controls (odds ratio 1.6, 95% confidence interval 1.5 to 1.7; Cochran-Mantel-Haenszel P<0.001). The association occurred independently among patients aged <= 80 (1.6, 1.5 to 1.7; P<0.001; n = 25 789) and in those aged >80 (1.4, 1.3 to 1.6; P<0.001; n = 3439). Odds ratios were consistent across all 10 year age ranges above 30, and benefit was significant from age 41 to 90; dichotomised outcomes (score on modified Rankin scale 0-1 v 2-6; 0-2 v 3-6; and 6 (death) v rest) were consistent with the results of the ordinal analysis. Conclusions Outcome in patients with acute ischaemic stroke is significantly better in those who undergo thrombolysis compared with those who do not. Increasing age is associated with poorer outcome but the association between thrombolysis treatment and improved outcome is maintained in very elderly people. Age alone should not be a barrier to treatment.	[Mishra, Nishant K.; Lees, Kennedy R.] Univ Glasgow, Western Infirm & Fac Med,Gardiner Inst, Univ Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Scotland; [Ahmed, Niaz; Wahlgren, Nils G.] Karolinska Inst, Karolinska Univ Hosp, Dept Neurol, Stockholm 17176, Sweden; [Andersen, Grethe] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark; [Egido, Jose A.] Hosp San Carlos, Dept Neurol, San Carlos, Spain; [Lindsberg, Perttu J.] Helsinki Univ Cent Hosp, Dept Neurol, Helsinki, Finland; [Lindsberg, Perttu J.] Univ Helsinki, Prgm Mol Neurol, Helsinki, Finland; [Ringleb, Peter A.] Univ Hosp Heidelberg, Dept Neurol, Heidelberg, Germany	University of Glasgow; Karolinska Institutet; Karolinska University Hospital; Aarhus University; Hospital Clinico San Carlos; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Ruprecht Karls University Heidelberg	Lees, KR (corresponding author), Univ Glasgow, Western Infirm & Fac Med,Gardiner Inst, Univ Dept Med & Therapeut, Acute Stroke Unit, Glasgow G11 6NT, Scotland.	k.r.lees@clinmed.gla.ac.uk	Egido, Jose A/E-3837-2015; Lindsberg, Perttu J/F-1271-2010; Toni, Danilo/K-3151-2016; Mishra, Nishant/GVT-6508-2022; Ahmed, Niaz/AAV-4361-2020; Mishra, Nishant K./D-4409-2015; Ahmed, Niaz/G-6717-2013; Davis, Stephen M/L-5260-2013	Egido, Jose A/0000-0003-1698-9127; Toni, Danilo/0000-0003-2735-8427; Mishra, Nishant K./0000-0002-9327-3707; Ahmed, Niaz/0000-0001-7970-0146; Davis, Stephen M/0000-0003-0962-2300; Lindsberg, Perttu/0000-0001-7690-811X; Gregson, Barbara/0000-0003-4868-9137; Andersen, Grethe/0000-0001-6807-2500; Ringleb, Peter/0000-0002-5473-8671	European Stroke Organisation; Boehringer Ingelheim; Ferrer; European Union Public Health Executive Authority (PHEA); Stockholm County Council; Karolinska Institute; University of Glasgow; European Stroke Organisation for Young Neurologists; Finnish Academy; Sigrid Juselius foundation; Helsinki University Hospital; Scottish Overseas Research Studentship	European Stroke Organisation; Boehringer Ingelheim(Boehringer Ingelheim); Ferrer; European Union Public Health Executive Authority (PHEA)(European Commission); Stockholm County Council(Stockholm County Council); Karolinska Institute(Karolinska Institutet); University of Glasgow; European Stroke Organisation for Young Neurologists; Finnish Academy(Academy of Finland); Sigrid Juselius foundation(Sigrid Juselius Foundation); Helsinki University Hospital; Scottish Overseas Research Studentship	VISTA has received financial support from the European Stroke Organisation in the form of an unrestricted grant and contributions towards data extraction and capacity building from the Universities of Glasgow, California San Diego, Nottingham, Edmonton, Calgary, Texas, and Massachusetts; from commercial groups including Brainsgate, Novartis, Boehringer Ingelheim, and the Vertical Group; and from grant agencies and charities including the UK Stroke Association. SITS-ISTR is funded by an unrestricted grant from Boehringer Ingelheim, Ferrer, and a grant from European Union Public Health Executive Authority (PHEA). Financial support was also provided through the regional agreement on medical training and research (ALF) between Stockholm County Council and the Karolinska Institute. NKM is supported by a Scottish Overseas Research Studentship, a University of Glasgow scholarship, and an educational grant from the European Stroke Organisation for Young Neurologists. PJL is supported by the Finnish Academy and Sigrid Juselius foundation and Helsinki University Hospital research funds (EVO).	AHMED A, 2010, CEREBROVASC DIS, V29, P1; Ahmed N, 2010, LANCET NEUROL, V9, P866, DOI 10.1016/S1474-4422(10)70165-4; Ali M, 2007, STROKE, V38, P1905, DOI 10.1161/STROKEAHA.106.473579; Ali M, 2009, STROKE, V40, P35, DOI 10.1161/STROKEAHA.108.518035; Bateman BT, 2006, STROKE, V37, P440, DOI 10.1161/01.STR.0000199851.24668.f1; Bath P, 2009, STROKE, V40, P888, DOI 10.1161/STROKEAHA.108.519207; Bath PMW, 2007, STROKE, V38, P1911, DOI 10.1161/STROKEAHA.106.474080; Bluhmki E, 2000, NERVENARZT, V71, P797, DOI 10.1007/s001150050666; BONITA R, 1994, STROKE, V25, P552, DOI 10.1161/01.STR.25.3.552; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Brown DL, 2009, NEUROLOGY, V72, P1292, DOI 10.1212/WNL.0b013e3181a11417; Chacon Marcus R, 2008, Curr Cardiol Rep, V10, P37, DOI 10.1007/s11886-008-0008-2; *COMM PROPR MED PR, 2002, CPMP334602EN EMEA; *COMM PROPR MED PR, 2001, CPMPEWP56098 EUR AG; Derex L, 2009, NAT REV NEUROL, V5, P506, DOI 10.1038/nrneurol.2009.127; Di Carlo A, 2003, CEREBROVASC DIS, V16, P141, DOI 10.1159/000070594; Dunnell Karen, 2008, Popul Trends, P6; Engelter ST, 2005, NEUROLOGY, V65, P1795, DOI 10.1212/01.wnl.0000183702.04080.27; Engelter ST, 2006, AGE AGEING, V35, P572, DOI 10.1093/ageing/afl104; *EUR UN, EUR AR LIV LONG; Fedorov V, 2009, PHARM STAT, V8, P50, DOI 10.1002/pst.331; Foerch C, 2009, STROKE, V40, pE111; Fonarow GC, 2010, CIRCULATION, V121, P879, DOI 10.1161/CIRCULATIONAHA.109.892497; Ford GA, 2010, STROKE, V41, P2568, DOI 10.1161/STROKEAHA.110.581884; GAMEROFF MJ, SUGI 30 P; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2004, LANCET, V363, P768; Hacke Werner, 2008, N Engl J Med, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; Heuschmann PU, 2004, JAMA-J AM MED ASSOC, V292, P1831, DOI 10.1001/jama.292.15.1831; Koenig IR, 2008, STROKE, V39, P1821, DOI 10.1161/STROKEAHA.107.505867; Lees KR, 2008, QJM-INT J MED, V101, P863, DOI 10.1093/qjmed/hcn102; Lees KR, 2006, STROKE, V37, P2970, DOI 10.1161/01.STR.0000249410.91473.44; Lees Kennedy R, 2010, Lancet, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Lees KR, 2010, STROKE, V41, pE247; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; MAJJ J, 2002, CMAJ, V166, P1652; Mann J, 2002, CAN MED ASSOC J, V166, P1651; Marini C, 2004, NEUROLOGY, V62, P77, DOI 10.1212/01.WNL.0000101461.61501.65; Mateen FJ, 2010, STROKE, V41, P1833, DOI 10.1161/STROKEAHA.110.586438; Mishra NK, 2010, STROKE, V41, pE25, DOI 10.1161/STROKEAHA.109.566869; MISHRA NK, STROKE          1028; National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581, DOI [10.1056/NEJM199512143332401, DOI 10.1056/NEJM199512143332401]; Poppe AY, 2008, DRUG AGING, V25, P95, DOI 10.2165/00002512-200825020-00002; Quinn TJ, 2008, SCOT MED J, V53, P44, DOI 10.1258/rsmsmj.53.1.44; Ringleb A, 2007, J NEUROL NEUROSUR PS, V78, P690, DOI 10.1136/jnnp.2006.105890; SANDERCOCK P, 2009, THROMBOLYSIS PATIENT; Sandercock P, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-37; Saver JL, 2007, STROKE, V38, P3055, DOI 10.1161/STROKEAHA.107.488536; Saver JL, 2007, STROKE, V38, P414, DOI 10.1161/01.STR.0000254580.39297.3c; Saver JL, 2009, NEUROLOGY, V72, P1310, DOI 10.1212/01.wnl.0000341308.73506.b7; Savitz SI, 2007, STROKE, V38, P3205, DOI 10.1161/STROKEAHA.107.489351; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; Senn S, 2009, STAT MED, V28, P3189, DOI 10.1002/sim.3603; Sylaja PN, 2006, J NEUROL NEUROSUR PS, V77, P826, DOI 10.1136/jnnp.2005.086595; Toni D, 2008, CEREBROVASC DIS, V25, P129, DOI 10.1159/000112323; Toni D, 2009, INT J STROKE, V4, P21, DOI 10.1111/j.1747-4949.2009.00242.x; Uyttenboogaart M, 2007, AGE AGEING, V36, P577, DOI 10.1093/ageing/afm022; Vatankhah B, 2005, J THROMB THROMBOLYS, V20, P5, DOI 10.1007/s11239-005-2477-0; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Wahlgren N, 2009, CEREBROVASC DIS, V27, P168, DOI 10.1159/000200456; Wahlgren N, 2008, STROKE, V39, P3316, DOI 10.1161/STROKEAHA.107.510768; Weimar C, 2004, STROKE, V35, P158, DOI 10.1161/01.STR.0000106761.94985.8B	66	165	166	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2010	341								c6046	10.1136/bmj.c6046	http://dx.doi.org/10.1136/bmj.c6046			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688DV	21098614	Green Published, hybrid, Green Accepted			2022-12-28	WOS:000284830900032
J	Nowack, B				Nowack, Bernd			Nanosilver Revisited Downstream	SCIENCE			English	Editorial Material							SILVER NANOPARTICLES; NANO-SILVER; EXPOSURE; SULFIDE; SLUDGE; RISK		Empa, Swiss Fed Labs Mat Sci & Technol, CH-9014 St Gallen, Switzerland	Swiss Federal Institutes of Technology Domain; Swiss Federal Laboratories for Materials Science & Technology (EMPA)	Nowack, B (corresponding author), Empa, Swiss Fed Labs Mat Sci & Technol, CH-9014 St Gallen, Switzerland.	nowack@empa.ch	Nowack, Bernd/B-6425-2008	Nowack, Bernd/0000-0002-5676-112X				Benn TM, 2008, ENVIRON SCI TECHNOL, V42, P4133, DOI 10.1021/es7032718; Blaser SA, 2008, SCI TOTAL ENVIRON, V390, P396, DOI 10.1016/j.scitotenv.2007.10.010; Choi O, 2009, WATER RES, V43, P1879, DOI 10.1016/j.watres.2009.01.029; Faunce T, 2010, NANOMEDICINE-UK, V5, P617, DOI [10.2217/nnm.10.33, 10.2217/NNM.10.33]; Geranio L, 2009, ENVIRON SCI TECHNOL, V43, P8113, DOI 10.1021/es9018332; Gottschalk F, 2009, ENVIRON SCI TECHNOL, V43, P9216, DOI 10.1021/es9015553; Impellitteri CA, 2009, J ENVIRON QUAL, V38, P1528, DOI 10.2134/jeq2008.0390; Kim B, 2010, ENVIRON SCI TECHNOL, V44, P7509, DOI 10.1021/es101565j; Liu JY, 2010, ENVIRON SCI TECHNOL, V44, P2169, DOI 10.1021/es9035557; Tiede K, 2010, J ANAL ATOM SPECTROM, V25, P1149, DOI 10.1039/b926029c; Wijnhoven SWP, 2009, NANOTOXICOLOGY, V3, P109, DOI 10.1080/17435390902725914	11	110	113	0	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1054	1055		10.1126/science.1198074	http://dx.doi.org/10.1126/science.1198074			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097924				2022-12-28	WOS:000284374700026
J	Zhang, YT; Baicker, K; Newhouse, JP				Zhang, Yuting; Baicker, Katherine; Newhouse, Joseph P.			Geographic Variation in the Quality of Prescribing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Zhang, Yuting] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA; [Baicker, Katherine; Newhouse, Joseph P.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Newhouse, Joseph P.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Newhouse, Joseph P.] Harvard Univ, Kennedy Sch Govt, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University	Zhang, YT (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022	Zhang, Yuting/0000-0002-6460-6779	NATIONAL INSTITUTE OF MENTAL HEALTH [RC1MH088510] Funding Source: NIH RePORTER; NIMH NIH HHS [RC1 MH088510, RC1 MH088510-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*NAT COMM QUAL ASS, 2009, STAT HLTH CAR QUAL; National Committee for Quality Assurance, 2010, HEALTHC EFF DAT INF; Song YJ, 2010, NEW ENGL J MED, V363, P198; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872	5	93	93	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					1985	1988		10.1056/NEJMp1010220	http://dx.doi.org/10.1056/NEJMp1010220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KC	21047217	Green Accepted			2022-12-28	WOS:000284310000002
J	Baerlocher, MO; Detsky, AS				Baerlocher, Mark Otto; Detsky, Allan S.			Discussing Radiation Risks Associated With CT Scans With Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMPUTED-TOMOGRAPHY; EXPOSURE		[Baerlocher, Mark Otto; Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Baerlocher, Mark Otto] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Univ Hlth Network, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Baerlocher, MO (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Room 429, Toronto, ON M5G 1X5, Canada.	mark.baerlocher@utoronto.ca						Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Couchman GR, 2004, ACAD RADIOL, V11, P735, DOI 10.1016/j.acra.2004.03.050; EVAN KG, 2006, CONSENT GUIDE CANADI; Larson DB, 2007, AM J ROENTGENOL, V189, P271, DOI 10.2214/AJR.07.2248; Lee CI, 2004, RADIOLOGY, V231, P393, DOI 10.1148/radiol.2312030767; National Research Council (US) Committee on the Biological Effects of Ionizing Radiation, 2006, HLTH RISKS EXP LOW L; Prokop M, 2005, EUR RADIOL, V15, pE35, DOI 10.1007/s10406-005-0164-z; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Terry PB, 2007, CHEST, V131, P563, DOI 10.1378/chest.06-1955	9	48	48	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2170	2171		10.1001/jama.2010.1591	http://dx.doi.org/10.1001/jama.2010.1591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081730				2022-12-28	WOS:000284269800028
J	Guiducci, S; Porta, F; Saccardi, R; Guidi, S; Ibba-Manneschi, L; Manetti, M; Mazzanti, B; Dal Pozzo, S; Milia, AF; Bellando-Randone, S; Miniati, I; Fiori, G; Fontana, R; Amanzi, L; Braschi, F; Bosi, A; Matucci-Cerinic, M				Guiducci, Serena; Porta, Francesco; Saccardi, Riccardo; Guidi, Stefano; Ibba-Manneschi, Lidia; Manetti, Mirko; Mazzanti, Benedetta; Dal Pozzo, Simone; Milia, Anna Franca; Bellando-Randone, Silvia; Miniati, Irene; Fiori, Ginevra; Fontana, Rossana; Amanzi, Laura; Braschi, Francesca; Bosi, Alberto; Matucci-Cerinic, Marco			Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis A Case Report	ANNALS OF INTERNAL MEDICINE			English	Article							ENDOTHELIAL-CELLS; TRANSPLANTATION; ANGIOGENESIS	Background: Mesenchymal stem cells can differentiate into endothelial cells and participate in angiogenesis in adults. In experimental models of acute myocardial infarction, mesenchymal stem cells led to the recovery of cardiac function through the formation of a new vascular network. Objective: To describe treatment with intravenous infusions of expanded autologous mesenchymal stem cells in 1 patient with critical limb ischemia due to systemic sclerosis. Design: Case report. Setting: The rheumatology unit at the University of Florence, Florence, Italy. Patient: A woman, aged 34 years, with systemic sclerosis who developed acute gangrene of the upper and lower limbs. Intervention: 3 intravenous pulses of expanded autologous mesenchymal stem cells. Measurements: Angiography, skin histopathology, and immunohistochemistry. Results: Areas of necrotic skin were reduced after the first mesenchymal stem-cell infusion. After the third infusion, angiography showed revascularization of the patient's extremities. Skin section analysis revealed cell clusters with tubelike structures, and angiogenic factors were strongly expressed. Limitation: Causality cannot be established by a single case. Conclusion: In patients with systemic sclerosis who have severe peripheral ischemia, intravenous infusion of expanded autologous mesenchymal stem cells may foster the recovery of the vascular network, restore blood flow, and reduce skin necrosis.	[Guiducci, Serena] Univ Florence, Div Rheumatol, Azienda Osped Univ Careggi, Dept Biomed,Denothe Ctr, I-50139 Florence, Italy	University of Florence; Azienda Ospedaliero Universitaria Careggi	Guiducci, S (corresponding author), Univ Florence, Div Rheumatol, Azienda Osped Univ Careggi, Dept Biomed,Denothe Ctr, Viale Pieraccini 18, I-50139 Florence, Italy.	s.guiducci@hotmail.com	Manetti, Mirko/AEH-9944-2022; Guiducci, Serena/AAB-9949-2019; CERINIC, marco MATUCCI/AAO-2769-2020	Manetti, Mirko/0000-0003-3956-8480; Guiducci, Serena/0000-0003-2722-6475; BOSI, ALBERTO/0000-0002-5486-4838; Saccardi, Riccardo/0000-0002-5763-5467; porta, francesco/0000-0001-7899-6651	Fondazione Cassa di Risparmio di Pistoia e Pescia	Fondazione Cassa di Risparmio di Pistoia e Pescia	By Fondazione Cassa di Risparmio di Pistoia e Pescia (partial funding).	Dash NR, 2009, REJUV RES, V12, P359, DOI 10.1089/rej.2009.0872; Guiducci S, 2007, AUTOIMMUN REV, V6, P520, DOI 10.1016/j.autrev.2006.12.006; Ishigatsubo Y, 2010, MOD RHEUMATOL, V20, P263, DOI 10.1007/s10165-010-0274-x; Iwase T, 2005, CARDIOVASC RES, V66, P543, DOI 10.1016/j.cardiores.2005.02.006; Liu KM, 2008, MICROVASC RES, V75, P59, DOI 10.1016/j.mvr.2007.06.003; Martens Timothy P, 2006, Nat Clin Pract Cardiovasc Med, V3 Suppl 1, pS18, DOI 10.1038/ncpcardio0404; Mazzanti B, 2008, J NEUROIMMUNOL, V199, P142, DOI 10.1016/j.jneuroim.2008.05.006; Nagaya N, 2004, AM J PHYSIOL-HEART C, V287, pH2670, DOI 10.1152/ajpheart.01071.2003; Nevskaya T, 2009, RHEUMATOLOGY, V48, P61, DOI 10.1093/rheumatology/ken407; Oswald J, 2004, STEM CELLS, V22, P377, DOI 10.1634/stemcells.22-3-377; Passweg J, 2007, SEMIN HEMATOL, V44, P278, DOI 10.1053/j.seminhematol.2007.08.001; Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582-4934.2009.00857.x; Togel F, 2007, AM J PHYSIOL-RENAL, V292, pF1626, DOI 10.1152/ajprenal.00339.2006; Urbani S, 2006, CYTOTHERAPY, V8, P243, DOI 10.1080/14653240600735834; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226	15	79	86	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					650	654		10.7326/0003-4819-153-10-201011160-00007	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079220				2022-12-28	WOS:000284215800017
J	Walsh, M				Walsh, Michael			Early and late initiation of dialysis did not differ for reduction of all-cause mortality in stage 5 chronic kidney disease	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									McMaster Univ, Hamilton, ON, Canada	McMaster University	Walsh, M (corresponding author), McMaster Univ, Hamilton, ON, Canada.		Walsh, Michael/ABE-1278-2021	Walsh, Michael/0000-0001-8292-2014				Hemodialysis Adequacy 2006 Work Group, 2006, AM J KIDNEY DIS S, V48, pS2, DOI 10.1053/j.ajkd.2006.03.051; Kelly J, 2005, NEPHROLOGY, V10, pS46, DOI 10.1111/j.1440-1797.2005.00486_1.x; *PER DIAL AD WORK, 2006, AM J KIDNEY DIS S, V48, pS98	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-2	10.1059/0003-4819-153-10-201011160-02002	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079209				2022-12-28	WOS:000284215800001
J	Nanayakkara, PWB; Meijboom, M; Kramer, MHH; Wevers, RA; Jakobs, C				Nanayakkara, Prabath W. B.; Meijboom, Martina; Kramer, Mark H. H.; Wevers, Ron A.; Jakobs, Cornelis			What have we here? A man or a fish?	LANCET			English	Editorial Material							TRIMETHYLAMINURIA; GENE		[Nanayakkara, Prabath W. B.; Meijboom, Martina; Kramer, Mark H. H.] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, NL-1007 MB Amsterdam, Netherlands; [Wevers, Ron A.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Lab Metab Endocnne & Genet Dis, NL-6525 ED Nijmegen, Netherlands; [Jakobs, Cornelis] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, Metab Unit, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Radboud University Nijmegen; Vrije Universiteit Amsterdam	Nanayakkara, PWB (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, POB 7057, NL-1007 MB Amsterdam, Netherlands.		Wevers, Ron A./H-8116-2014; Kramer, Mark/GWQ-3502-2022	Wevers, Ron A./0000-0003-2278-9746; 				ALWAIZ M, 1987, CLIN PHARMACOL THER, V42, P588, DOI 10.1038/clpt.1987.201; Mitchell SC, 2001, DRUG METAB DISPOS, V29, P517; RODD WA, 1979, J PEDIAT, V94, P936; Treacy EP, 1998, HUM MOL GENET, V7, P839, DOI 10.1093/hmg/7.5.839; Zschocke J, 1999, LANCET, V354, P834	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 13	2010	376	9753					1710	1710		10.1016/S0140-6736(10)61151-8	http://dx.doi.org/10.1016/S0140-6736(10)61151-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21075259				2022-12-28	WOS:000284451000036
J	Rustagi, D; Engel, S; Kosfeld, M				Rustagi, Devesh; Engel, Stefanie; Kosfeld, Michael			Conditional Cooperation and Costly Monitoring Explain Success in Forest Commons Management	SCIENCE			English	Article							PUBLIC-GOODS EXPERIMENTS; CONFORMIST TRANSMISSION; ALTRUISTIC PUNISHMENT; LOCAL ENFORCEMENT; COLLECTIVE ACTION; EVOLUTION; GOVERNANCE; PEOPLE; INSTITUTIONS; SANCTIONS	Recent evidence suggests that prosocial behaviors like conditional cooperation and costly norm enforcement can stabilize large-scale cooperation for commons management. However, field evidence on the extent to which variation in these behaviors among actual commons users accounts for natural commons outcomes is altogether missing. Here, we combine experimental measures of conditional cooperation and survey measures on costly monitoring among 49 forest user groups in Ethiopia with measures of natural forest commons outcomes to show that (i) groups vary in conditional cooperator share, (ii) groups with larger conditional cooperator share are more successful in forest commons management, and (iii) costly monitoring is a key instrument with which conditional cooperators enforce cooperation. Our findings are consistent with models of gene-culture coevolution on human cooperation and provide external validity to laboratory experiments on social dilemmas.	[Rustagi, Devesh; Engel, Stefanie] ETH, Inst Environm Decis, CH-8092 Zurich, Switzerland; [Kosfeld, Michael] Goethe Univ Frankfurt, Fac Econ & Business Adm, D-60323 Frankfurt, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Goethe University Frankfurt	Rustagi, D (corresponding author), ETH, Inst Environm Decis, Univ Str 22, CH-8092 Zurich, Switzerland.	devesh.rustagi@env.ethz.ch; kosfeld@econ.uni-frankfurt.de	Engel, Stefanie/A-7397-2009; Engel, Stefanie/B-6533-2009		North-South Centre at ETH Zurich; German Federal Ministry of Education and Research (BMBF) [BioTEAM 01LM0201]; German Federal Ministry of Economic Cooperation and Development (BMZ) via the Centre for Development Research, Bonn; German Organization for Technical Cooperation (GTZ); Oromia State Forest Enterprises Supervising Agency	North-South Centre at ETH Zurich; German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Federal Ministry of Economic Cooperation and Development (BMZ) via the Centre for Development Research, Bonn; German Organization for Technical Cooperation (GTZ); Oromia State Forest Enterprises Supervising Agency	We especially thank the communities that participated in our research and our research assistants. This study was financially supported by the North-South Centre at ETH Zurich, the German Federal Ministry of Education and Research (BMBF) (BioTEAM 01LM0201), and the German Federal Ministry of Economic Cooperation and Development (BMZ) via the Centre for Development Research, Bonn. We also acknowledge in-kind support from the German Organization for Technical Cooperation (GTZ) and the Oromia State Forest Enterprises Supervising Agency.	Agrawal A, 2006, WORLD DEV, V34, P149, DOI 10.1016/j.worlddev.2005.07.013; Agrawal A, 2001, WORLD DEV, V29, P1649, DOI 10.1016/S0305-750X(01)00063-8; AMENTE G, 2005, THESIS A LUDWIGS U F; [Anonymous], 1965, LOGIC COLLECTIVE ACT; [Anonymous], 1996, HALTING DEGRADATION; Bowles S, 2008, SCIENCE, V320, P1605, DOI 10.1126/science.1152110; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; Cardenas J.C., 2000, ENVIRON DEV SUSTAIN, V2, P305, DOI DOI 10.1023/A:1011422313042; Cardenas JC, 2003, J DEV ECON, V70, P263, DOI 10.1016/S0304-3878(02)00098-6; Chhatre A, 2008, P NATL ACAD SCI USA, V105, P13286, DOI 10.1073/pnas.0803399105; Falk A, 2005, ECONOMETRICA, V73, P2017, DOI 10.1111/j.1468-0262.2005.00644.x; Falk A, 2002, DRAMA COMMONS, P157; Falk A, 2009, SCIENCE, V326, P535, DOI 10.1126/science.1168244; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Fischbacher U, 2001, ECON LETT, V71, P397, DOI 10.1016/S0165-1765(01)00394-9; Fischbacher U, 2010, AM ECON REV, V100, P541, DOI 10.1257/aer.100.1.541; Gachter S, 2008, SCIENCE, V322, P1510, DOI 10.1126/science.1164744; Gibson CC, 2005, WORLD DEV, V33, P273, DOI 10.1016/j.worlddev.2004.07.013; Gunnthorsdottir A, 2007, J ECON BEHAV ORGAN, V62, P304, DOI 10.1016/j.jebo.2005.03.008; Gurerk O, 2006, SCIENCE, V312, P108, DOI 10.1126/science.1123633; Gurven M, 2008, AM ANTHROPOL, V110, P179, DOI 10.1111/j.1548-1433.2008.00024.x; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Henrich J, 1998, EVOL HUM BEHAV, V19, P215, DOI 10.1016/S1090-5138(98)00018-X; Henrich J, 2005, BEHAV BRAIN SCI, V28, P795, DOI 10.1017/S0140525X05000142; Henrich J, 2001, EVOL HUM BEHAV, V22, P165, DOI 10.1016/S1090-5138(00)00071-4; Henrich J, 2001, J THEOR BIOL, V208, P79, DOI 10.1006/jtbi.2000.2202; Henrich J, 2006, SCIENCE, V312, P1767, DOI 10.1126/science.1127333; Henrich J, 2010, BEHAV BRAIN SCI, V33, P61, DOI 10.1017/S0140525X0999152X; Henrich J, 2010, SCIENCE, V327, P1480, DOI 10.1126/science.1182238; Herrmann B, 2009, EXP ECON, V12, P87, DOI 10.1007/s10683-008-9197-1; Keser C, 2000, SCAND J ECON, V102, P23, DOI 10.1111/1467-9442.00182; Kocher MG, 2008, ECON LETT, V101, P175, DOI 10.1016/j.econlet.2008.07.015; Kurzban R, 2005, P NATL ACAD SCI USA, V102, P1803, DOI 10.1073/pnas.0408759102; Levitt SD, 2008, SCIENCE, V319, P909, DOI 10.1126/science.1153640; Ones U, 2007, J ECON BEHAV ORGAN, V62, P495, DOI 10.1016/j.jebo.2005.04.018; Ostrom E, 1999, SCIENCE, V284, P278, DOI 10.1126/science.284.5412.278; OSTROM E, 1992, AM POLIT SCI REV, V86, P404, DOI 10.2307/1964229; Ostrom E., 1990, GOVERNING COMMONS EV; Ostrom E, 2007, P NATL ACAD SCI USA, V104, P15181, DOI 10.1073/pnas.0702288104; Price ME, 2002, EVOL HUM BEHAV, V23, P203, DOI 10.1016/S1090-5138(01)00093-9; Rand DG, 2009, SCIENCE, V325, P1272, DOI 10.1126/science.1177418; Trainer J., 1996, FOREST INVENTORY IND; YAMAGISHI T, 1986, J PERS SOC PSYCHOL, V51, P110, DOI 10.1037/0022-3514.51.1.110	44	291	298	6	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					961	965		10.1126/science.1193649	http://dx.doi.org/10.1126/science.1193649			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678XY	21071668				2022-12-28	WOS:000284118000042
J	Chao, HT; Chen, HM; Samaco, RC; Xue, MS; Chahrour, M; Yoo, J; Neul, JL; Gong, SC; Lu, HC; Heintz, N; Ekker, M; Rubenstein, JLR; Noebels, JL; Rosenmund, C; Zoghbi, HY				Chao, Hsiao-Tuan; Chen, Hongmei; Samaco, Rodney C.; Xue, Mingshan; Chahrour, Maria; Yoo, Jong; Neul, Jeffrey L.; Gong, Shiaoching; Lu, Hui-Chen; Heintz, Nathaniel; Ekker, Marc; Rubenstein, John L. R.; Noebels, Jeffrey L.; Rosenmund, Christian; Zoghbi, Huda Y.			Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes	NATURE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; CPG-BINDING PROTEIN-2; MOUSE MODEL; NEURONAL MECP2; YOUNG GIRLS; 67 KDA; MICE; GENE; SCHIZOPHRENIA; MUTATION	Mutations in the X-linked MECP2 gene, which encodes the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2), cause Rett syndrome and several neurodevelopmental disorders including cognitive disorders, autism, juvenile-onset schizophrenia and encephalopathy with early lethality. Rett syndrome is characterized by apparently normal early development followed by regression, motor abnormalities, seizures and features of autism, especially stereotyped behaviours. The mechanisms mediating these features are poorly understood. Here we show that mice lacking Mecp2 from GABA (c-aminobutyric acid)-releasing neurons recapitulate numerous Rett syndrome and autistic features, including repetitive behaviours. Loss of MeCP2 from a subset of forebrain GABAergic neurons also recapitulates many features of Rett syndrome. MeCP2-deficient GABAergic neurons show reduced inhibitory quantal size, consistent with a presynaptic reduction in glutamic acid decarboxylase 1 (Gad1) and glutamic acid decarboxylase 2 (Gad2) levels, and GABA immunoreactivity. These data demonstrate that MeCP2 is critical for normal function of GABA-releasing neurons and that subtle dysfunction of GABAergic neurons contributes to numerous neuropsychiatric phenotypes.	[Chao, Hsiao-Tuan; Xue, Mingshan; Noebels, Jeffrey L.; Rosenmund, Christian; Zoghbi, Huda Y.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Chao, Hsiao-Tuan; Chen, Hongmei; Samaco, Rodney C.; Chahrour, Maria; Noebels, Jeffrey L.; Rosenmund, Christian; Zoghbi, Huda Y.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Yoo, Jong; Noebels, Jeffrey L.; Zoghbi, Huda Y.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Neul, Jeffrey L.; Lu, Hui-Chen; Zoghbi, Huda Y.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Neul, Jeffrey L.; Lu, Hui-Chen; Zoghbi, Huda Y.] Baylor Coll Med, Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; [Gong, Shiaoching; Heintz, Nathaniel] Rockefeller Univ, New York, NY 10021 USA; [Gong, Shiaoching; Heintz, Nathaniel] Howard Hughes Med Inst, New York, NY 10021 USA; [Ekker, Marc] Univ Ottawa, Dept Biol, Ctr Adv Res Environm Genom, Ottawa, ON K1N 6N5, Canada; [Rubenstein, John L. R.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94158 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Rockefeller University; Howard Hughes Medical Institute; University of Ottawa; University of California System; University of California San Francisco	Rosenmund, C (corresponding author), Charite, Neurosci Res Ctr, D-10117 Berlin, Germany.	christian.rosenmund@charite.de; hzoghbi@bcm.edu	Rosenmund, Christian/AAC-3596-2020; Neul, Jeffrey/AAF-5324-2020	Rosenmund, Christian/0000-0002-3905-2444; Chahrour, Maria/0000-0002-3174-1480; Zoghbi, Huda/0000-0002-0700-3349; Xue, Mingshan/0000-0003-1463-8884; Neul, Jeffrey/0000-0002-5628-5872; Noebels, Jeffrey/0000-0002-2887-0839; Samaco, Rodney/0000-0001-5636-5314	Howard Hughes Medical Institute; National Institute of Neurological Disorders and Stroke (NINDS) [HD053862, 29709]; Simons Foundation; Rett Syndrome Research Trust; Intellectual and Developmental Disability Research Centers [HD024064]; International Rett Syndrome Foundation; Autism Speaks; National Institute of Mental Health [F31MH078678]; Baylor Research Advocates for Student Scientists; McNair Fellowships; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064, R01HD062553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH078678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS052240, R01NS048884, T32NS043124, R01NS057819] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Simons Foundation; Rett Syndrome Research Trust; Intellectual and Developmental Disability Research Centers; International Rett Syndrome Foundation; Autism Speaks; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Baylor Research Advocates for Student Scientists; McNair Fellowships; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank G. Schuster for pronuclear injections; C. Spencer and R. Paylor for advice on behavioural assays; M. Albright for advice on slice electrophysiology; R. Atkinson, Y. Sun, J. Tang and S. Vaishnav for technical advice; V. Brandt for editorial advice. This work was supported by the Howard Hughes Medical Institute, the National Institute of Neurological Disorders and Stroke (NINDS) HD053862, the Simons Foundation, the Rett Syndrome Research Trust (H.Y.Z.); the Intellectual and Developmental Disability Research Centers HD024064 (H.Y.Z., C.R. and J. L. Noebels); NINDS 29709 (J. L. Noebels); the International Rett Syndrome Foundation (C.R.); Autism Speaks (R.C.S.); the National Institute of Mental Health F31MH078678, Baylor Research Advocates for Student Scientists and McNair Fellowships (H.-T.C.).	Adachi M, 2009, J NEUROSCI, V29, P4218, DOI 10.1523/JNEUROSCI.4225-08.2009; Addington AM, 2005, MOL PSYCHIATR, V10, P581, DOI 10.1038/sj.mp.4001599; AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ballas N, 2009, NAT NEUROSCI, V12, P311, DOI 10.1038/nn.2275; Carney RM, 2003, PEDIATR NEUROL, V28, P205, DOI 10.1016/S0887-8994(02)00624-0; Chadman KK, 2008, AUTISM RES, V1, P147, DOI 10.1002/aur.22; Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cohen D, 2002, AM J PSYCHIAT, V159, P148, DOI 10.1176/appi.ajp.159.1.148-a; Cui YJ, 2008, CELL, V135, P549, DOI 10.1016/j.cell.2008.09.060; Dani VS, 2009, J NEUROSCI, V29, P11263, DOI 10.1523/JNEUROSCI.1019-09.2009; Dani VS, 2005, P NATL ACAD SCI USA, V102, P12560, DOI 10.1073/pnas.0506071102; Deidrick Kathleen M, 2005, J Child Neurol, V20, P708, DOI 10.1177/08830738050200090201; Fatemi SH, 2005, SCHIZOPHR RES, V72, P109, DOI 10.1016/j.schres.2004.02.017; Fatemi SH, 2002, BIOL PSYCHIAT, V52, P805, DOI 10.1016/S0006-3223(02)01430-0; Fernandez F, 2007, NAT NEUROSCI, V10, P411, DOI 10.1038/nn1860; Fyffe SL, 2008, NEURON, V59, P947, DOI 10.1016/j.neuron.2008.07.030; Gemelli T, 2006, BIOL PSYCHIAT, V59, P468, DOI 10.1016/j.biopsych.2005.07.025; Gong SC, 2007, J NEUROSCI, V27, P9817, DOI 10.1523/JNEUROSCI.2707-07.2007; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; HAGBERG B, 1983, ANN NEUROL, V14, P471, DOI 10.1002/ana.410140412; Hagberg B, 2002, MENT RETARD DEV D R, V8, P61, DOI 10.1002/mrdd.10020; Jedele Kerry Baldwin, 2007, Semin Pediatr Neurol, V14, P108, DOI 10.1016/j.spen.2007.07.002; Klauck SM, 2002, AM J HUM GENET, V70, P1034, DOI 10.1086/339553; Kohwi M, 2007, J NEUROSCI, V27, P6878, DOI 10.1523/JNEUROSCI.0254-07.2007; Lam C W, 2000, J Med Genet, V37, pE41, DOI 10.1136/jmg.37.12.e41; Lundorf MD, 2005, AM J MED GENET B, V135B, P94, DOI 10.1002/ajmg.b.30137; Maezawa I, 2009, J NEUROSCI, V29, P5051, DOI 10.1523/JNEUROSCI.0324-09.2009; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Medrihan L, 2008, J NEUROPHYSIOL, V99, P112, DOI 10.1152/jn.00826.2007; Monory K, 2006, NEURON, V51, P455, DOI 10.1016/j.neuron.2006.07.006; Neul JL, 2008, NEUROLOGY, V70, P1313, DOI 10.1212/01.wnl.0000291011.54508.aa; Samaco RC, 2008, HUM MOL GENET, V17, P1718, DOI 10.1093/hmg/ddn062; Samaco RC, 2009, P NATL ACAD SCI USA, V106, P21966, DOI 10.1073/pnas.0912257106; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Skene PJ, 2010, MOL CELL, V37, P457, DOI 10.1016/j.molcel.2010.01.030; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Swerdlow NR, 2001, PSYCHOPHARMACOLOGY, V156, P194, DOI 10.1007/s002130100799; Tabuchi K, 2007, SCIENCE, V318, P71, DOI 10.1126/science.1146221; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Weese-Mayer DE, 2008, PEDIATR PULM, V43, P1045, DOI 10.1002/ppul.20866; Weese-Mayer DE, 2006, PEDIATR RES, V60, P443, DOI 10.1203/01.pdr.0000238302.84552.d0; Wojcik SM, 2006, NEURON, V50, P575, DOI 10.1016/j.neuron.2006.04.016; Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104; Zhang L, 2008, HIPPOCAMPUS, V18, P294, DOI 10.1002/hipo.20389	50	806	823	2	141	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					263	269		10.1038/nature09582	http://dx.doi.org/10.1038/nature09582			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068835	Green Submitted, Green Accepted			2022-12-28	WOS:000284051000043
J	Nallamothu, BK; Krumholz, HM				Nallamothu, Brahmajee K.; Krumholz, Harlan M.			Putting Ad Hoc PCI on Pause	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PERCUTANEOUS CORONARY INTERVENTIONS; CARDIAC-CATHETERIZATION; AMERICAN-COLLEGE; MEDICAL THERAPY; ARTERY-DISEASE; CARDIOLOGISTS		[Nallamothu, Brahmajee K.] Vet Affairs Ann Arbor Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; [Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Div Cardiovasc Med, Ann Arbor, MI USA; [Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, CHOP, Ann Arbor, MI USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University; Yale University	Nallamothu, BK (corresponding author), 1500 E Med Ctr Dr,SPC 5869, Ann Arbor, MI 48109 USA.	bnallamo@umich.edu	, Harlan/AAI-2875-2020					Blankenship JC, 2004, CATHETER CARDIO INTE, V63, P444, DOI 10.1002/ccd.20229; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Hannan EL, 2010, CIRCULATION, V121, P267, DOI 10.1161/CIRCULATIONAHA.109.887539; Hannan EL, 2009, JACC-CARDIOVASC INTE, V2, P350, DOI 10.1016/j.jcin.2009.01.006; Krone RJ, 2006, CATHETER CARDIO INTE, V68, P696, DOI 10.1002/ccd.20910; Morgan MW, 2000, J GEN INTERN MED, V15, P685, DOI 10.1046/j.1525-1497.2000.91139.x; MYLER RK, 1986, CATHETER CARDIO DIAG, V12, P213, DOI 10.1002/ccd.1810120402; Peterson ED, 2008, NEW ENGL J MED, V359, P751, DOI 10.1056/NEJMe0804662; Rothberg MB, 2010, ANN INTERN MED, V153, P307, DOI 10.7326/0003-4819-153-5-201009070-00005; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626	10	32	34	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2059	2060		10.1001/jama.2010.1509	http://dx.doi.org/10.1001/jama.2010.1509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063016				2022-12-28	WOS:000284000600026
J	Gregg, C				Gregg, Christopher			Parental Control over the Brain	SCIENCE			English	Editorial Material									Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Gregg, C (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	cgregg@MCB.harvard.edu						Alboni S, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-9; Alter MD, 2009, BIOL PSYCHIAT, V66, P1061, DOI 10.1016/j.biopsych.2009.05.026; Cassidy SB, 2009, EUR J HUM GENET, V17, P3, DOI 10.1038/ejhg.2008.165; Curley JP, 2010, DEV PSYCHOBIOL, V52, P312, DOI 10.1002/dev.20430; GREGG C, 2010, SCIENCE, V329, P5992; Hoppenbrouwers IA, 2008, ARCH NEUROL-CHICAGO, V65, P345, DOI 10.1001/archneurol.2007.63; Kaati G, 2007, EUR J HUM GENET, V15, P784, DOI 10.1038/sj.ejhg.5201832; Keverne E B, 2001, Prog Brain Res, V133, P279; Nguyen DK, 2006, BRAIN RES, V1126, P46, DOI 10.1016/j.brainres.2006.08.053; Van Buggenhout G, 2009, EUR J HUM GENET, V17, P1367, DOI 10.1038/ejhg.2009.67	10	6	6	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					770	771		10.1126/science.1199054	http://dx.doi.org/10.1126/science.1199054			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051625				2022-12-28	WOS:000283855700029
J	Shahinian, VB; Kuo, YF; Gilbert, SM				Shahinian, Vahakn B.; Kuo, Yong-Fang; Gilbert, Scott M.			Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIATION-THERAPY; HORMONAL-THERAPY; SUPPRESSION; MANAGEMENT; CARCINOMA; RADIOTHERAPY; ORCHIECTOMY; TRIAL	Background: The Medicare Modernization Act led to moderate reductions in reimbursement for androgen-deprivation therapy (ADT) for prostate cancer, starting in 2004 and followed by substantial changes in 2005. We hypothesized that these reductions would lead to decreases in the use of ADT for indications that were not evidence based. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) Medicare database, we identified 54,925 men who received a diagnosis of incident prostate cancer from 2003 through 2005. We divided these men into groups according to the strength of the indication for ADT use. The use of ADT was deemed to be inappropriate as primary therapy for men with localized cancers of a low-to-moderate grade (for whom a survival benefit of such therapy was improbable), appropriate as adjuvant therapy with radiation therapy for men with locally advanced cancers (for whom a survival benefit was established), and discretionary for men receiving either primary or adjuvant therapy for localized but high-grade tumors. The proportion of men receiving ADT was calculated according to the year of diagnosis for each group. We used modified Poisson regression models to calculate the effect of the year of diagnosis on the use of ADT. Results: The rate of inappropriate use of ADT declined substantially during the study period, from 38.7% in 2003 to 30.6% in 2004 to 25.7% in 2005 (odds ratio for ADT use in 2005 vs. 2003, 0.72; 95% confidence interval [CI], 0.65 to 0.79). There was no decrease in the appropriate use of adjuvant ADT (odds ratio, 1.01; 95% CI, 0.86 to 1.19). In cases involving discretionary use, there was a significant decline in use in 2005 but not in 2004. Conclusions: Changes in the Medicare reimbursement policy in 2004 and 2005 were associated with reductions in ADT use, particularly among men for whom the benefits of such therapy were unclear. (Funded by the American Cancer Society.) N Engl J Med 2010;363:1822-32.	[Shahinian, Vahakn B.] Univ Michigan, Simpson Mem Inst 208, Dept Internal Med, Ann Arbor, MI 48109 USA; [Kuo, Yong-Fang] Univ Texas Med Branch, Dept Internal Med, Galveston, TX USA; [Kuo, Yong-Fang] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX USA; [Kuo, Yong-Fang] Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX USA; [Gilbert, Scott M.] Univ Florida, Coll Med, Dept Urol, Gainesville, FL USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; State University System of Florida; University of Florida	Shahinian, VB (corresponding author), Univ Michigan, Simpson Mem Inst 208, Dept Internal Med, 102 Observ Rd, Ann Arbor, MI 48109 USA.	vahakn@umich.edu			American Cancer Society [118244-RSGI-10-076-01-CPHPS]	American Cancer Society(American Cancer Society)	Supported by a Research Scholar Grant (118244-RSGI-10-076-01-CPHPS, to Dr. Shahinian) from the American Cancer Society.	[Anonymous], 2001, GAO011118; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Chang SL, 2009, J UROLOGY, V182, P255, DOI 10.1016/j.juro.2009.02.141; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Chodak GW, 2002, UROLOGY, V60, P201, DOI 10.1016/S0090-4295(02)01677-1; Christianson JB, 2006, J GEN INTERN MED, V21, pS9, DOI 10.1111/j.1525-1497.2006.00356.x; Conrad DA, 2004, MED CARE RES REV, V61, p37S, DOI 10.1177/1077558704266770; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; D'Amico AV, 2004, JAMA-J AM MED ASSOC, V292, P821, DOI 10.1001/jama.292.7.821; Granfors T, 1998, J UROLOGY, V159, P2030, DOI 10.1016/S0022-5347(01)63235-X; Hillman AL, 1998, AM J PUBLIC HEALTH, V88, P1699, DOI 10.2105/AJPH.88.11.1699; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Loblaw DA, 2004, J CLIN ONCOL, V22, P2927, DOI 10.1200/jco.2004.04.579; LOBLAW DA, 2004, J CLIN ONCOL, V22, P4435; Lu-Yao G, 2006, J UROLOGY, V176, P526, DOI 10.1016/j.juro.2006.03.098; *MED PAYM ADV COMM, 2007, REP C EFF MED PAYM C; National Comprehensive Cancer Network, 2004, J Natl Compr Canc Netw, V2, P224; Painter M Ray, 2005, Rev Urol, V7 Suppl 5, pS44; Pilepich MV, 1997, J CLIN ONCOL, V15, P1013, DOI 10.1200/JCO.1997.15.3.1013; Scardino Peter, 2005, J Natl Compr Canc Netw, V3 Suppl 1, pS29; Scherr D, 2003, UROLOGY, V61, P14, DOI 10.1016/S0090-4295(02)02395-6; Shahinian VB, 2007, J CLIN ONCOL, V25, P5359, DOI 10.1200/JCO.2006.09.9580; Shahinian VB, 2005, CANCER-AM CANCER SOC, V103, P1615, DOI 10.1002/cncr.20955; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056/NEJMoa041943; Shen J, 2004, MED CARE, V42, P297, DOI 10.1097/01.mlr.0000114918.50088.1c; Weight CJ, 2008, CANCER-AM CANCER SOC, V112, P2195, DOI 10.1002/cncr.23421; Welch HG, 1996, ANN INTERN MED, V124, P577, DOI 10.7326/0003-4819-124-6-199603150-00007; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	31	140	144	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1822	1832		10.1056/NEJMsa0910784	http://dx.doi.org/10.1056/NEJMsa0910784			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047226				2022-12-28	WOS:000283787800007
J	Bartke, T; Vermeulen, M; Xhemalce, B; Robson, SC; Mann, M; Kouzarides, T				Bartke, Till; Vermeulen, Michiel; Xhemalce, Blerta; Robson, Samuel C.; Mann, Matthias; Kouzarides, Tony			Nucleosome-Interacting Proteins Regulated by DNA and Histone Methylation	CELL			English	Article							CHROMATIN MODIFICATIONS; HETEROCHROMATIN; TRANSCRIPTION; BINDING; H3; ACETYLATION; RECOGNITION; COMPLEX; KDM2A; HP1	Modifications on histones or on DNA recruit proteins that regulate chromatin function. Here, we use nucleosomes methylated on DNA and on histone H3 in an affinity assay, in conjunction with a SILAC-based proteomic analysis, to identify "crosstalk'' between these two distinct classes of modification. Our analysis reveals proteins whose binding to nucleosomes is regulated by methylation of CpGs, H3K4, H3K9, and H3K27 or a combination thereof. We identify the origin recognition complex (ORC), including LRWD1 as a subunit, to be a methylation-sensitive nucleosome interactor that is recruited cooperatively by DNA and histone methylation. Other interactors, such as the lysine demethylase Fbxl11/KDM2A, recognize nucleosomes methylated on histones, but their recruitment is disrupted by DNA methylation. These data establish SILAC nucleosome affinity purifications (SNAP) as a tool for studying the dynamics between different chromatin modifications and provide a modification binding "profile'' for proteins regulated by DNA and histone methylation.	[Bartke, Till; Xhemalce, Blerta; Robson, Samuel C.; Kouzarides, Tony] Gurdon Inst, Cambridge CB2 1QN, England; [Bartke, Till; Xhemalce, Blerta; Robson, Samuel C.; Kouzarides, Tony] Dept Pathol, Cambridge CB2 1QN, England; [Vermeulen, Michiel; Mann, Matthias] Max Planck Inst Biochem, Dept Prote & Signal Transduct, D-82152 Martinsried, Germany	Max Planck Society	Kouzarides, T (corresponding author), Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	t.kouzarides@gurdon.cam.ac.uk	Vermeulen, Michiel/C-8883-2013; Mann, Matthias/A-3454-2013	Vermeulen, Michiel/0000-0003-0836-6894; Mann, Matthias/0000-0003-1292-4799; Xhemalce, Blerta/0000-0002-0517-9607; Kouzarides, Tony/0000-0002-8918-4162	EMBO; HFSP; Dutch Cancer Society; European Union; Cancer Research UK	EMBO(European Molecular Biology Organization (EMBO)); HFSP(Human Frontier Science Program); Dutch Cancer Society(KWF Kankerbestrijding); European Union(European Commission); Cancer Research UK(Cancer Research UK)	We would like to thank Kevin Ford, Timothy Richmond, Bruce Stillman, Jonathan Widom, and Yi Zhang for providing materials; Helder Ferreira and Tom Owen-Hughes for advice on native chemical ligations; and Peter Tessarz and Emmanuelle Vire for experimental help. This work was supported by postdoctoral fellowships to T.B. from EMBO and HFSP and by a fellowship to M.V. from the Dutch Cancer Society. The M.M. laboratory is supported by the Max-Planck Society for the Advancement of Science and HEROIC, a grant from the European Union under the 6<SUP>th</SUP> Research Framework Programme. The T.K. lab is funded by grants from Cancer Research UK and the European Union (Epitron, HEROIC, and SMARTER). T. K. is a director of Abcam Ltd.	Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Blackledge NP, 2010, MOL CELL, V38, P179, DOI 10.1016/j.molcel.2010.04.009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hashimoto H, 2009, EPIGENETICS-US, V4, P8, DOI 10.4161/epi.4.1.7370; Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07; Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Le Guezennec X, 2006, MOL CELL BIOL, V26, P843, DOI 10.1128/MCB.26.3.843-851.2006; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027; Nguyen DP, 2009, J AM CHEM SOC, V131, P14194, DOI 10.1021/ja906603s; Vicent GP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000567; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Prasanth SG, 2004, EMBO J, V23, P2651, DOI 10.1038/sj.emboj.7600255; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Sasai N, 2009, INT J DEV BIOL, V53, P323, DOI 10.1387/ijdb.082652ns; Shogren-Knaak MA, 2003, J BIOL CHEM, V278, P15744, DOI 10.1074/jbc.M301445200; Simon MD, 2007, CELL, V128, P1003, DOI 10.1016/j.cell.2006.12.041; Tanaka Y, 2010, EMBO J, V29, P1510, DOI 10.1038/emboj.2010.56; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Tolbert TJ, 2002, ANGEW CHEM INT EDIT, V41, P2171, DOI 10.1002/1521-3773(20020617)41:12<2171::AID-ANIE2171>3.0.CO;2-Q; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; van der Laan MJ, 2003, J STAT PLAN INFER, V117, P275, DOI 10.1016/S0378-3758(02)00388-9; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Xhemalce B, 2010, GENE DEV, V24, P647, DOI 10.1101/gad.1881710; Zhao Q, 2007, J BIOL CHEM, V282, P647, DOI 10.1074/jbc.M604029200	34	422	436	0	69	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					470	484		10.1016/j.cell.2010.10.012	http://dx.doi.org/10.1016/j.cell.2010.10.012			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029866	Bronze, Green Accepted			2022-12-28	WOS:000283603900019
J	Zipursky, SL; Sanes, JR				Zipursky, S. Lawrence; Sanes, Joshua R.			Chemoaffinity Revisited: Dscams, Protocadherins, and Neural Circuit Assembly	CELL			English	Review							MOUSE OLFACTORY SYSTEM; GAMMA-PROTOCADHERINS; AXON GUIDANCE; DROSOPHILA DSCAM; SENSORY NEURONS; SELF-AVOIDANCE; MOLECULAR MECHANISMS; STRUCTURAL BASIS; NERVOUS-SYSTEM; CELL-ADHESION	The chemoaffinity hypothesis for neural circuit assembly posits that axons and their targets bear matching molecular labels that endow neurons with unique identities and specify synapses between appropriate partners. Here, we focus on two intriguing candidates for fulfilling this role, Drosophila Dscams and vertebrate clustered protocadherins (Pcdhs). In each, a complex genomic locus encodes large numbers of neuronal transmembrane proteins with homophilic binding specificity, individual members of which are expressed combinatorially. Although these properties suggest that Dscams and Pcdhs could act as specificity molecules, they may do so in ways that challenge traditional views of how neural circuits assemble.	[Zipursky, S. Lawrence] Univ Calif Los Angeles, David Geffen Sch Med, Howard Hughes Med Inst, Dept Biol Chem, Los Angeles, CA 90095 USA; [Sanes, Joshua R.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA; [Sanes, Joshua R.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Harvard University; Harvard University	Zipursky, SL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Howard Hughes Med Inst, Dept Biol Chem, Los Angeles, CA 90095 USA.	lzipursky@mednet.ucla.edu; sanesj@mcb.harvard.edu		Zipursky, Stephen/0000-0001-5630-7181	NIH	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Renate Hellmiss for drawing the figures, Dr. Michael Sawaya for the structures shown in Figure 3D, and Daisuke Hattori, Julie Lefebvre, Kelsey Martin, Woj Wojtowicz, and members of our labs for comments on the manuscript. Work on protocadherins and Dscams in J.R.S.' lab and on Dscam1 in S.L.Z.'s lab is supported by the NIH. S.L.Z. is an investigator of the Howard Hughes Medical Institute.	BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Chen WH, 2004, ARCH MATH, V82, P371, DOI 10.1007/s00013-003-4887-6; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Dreyer WJ, 1998, P NATL ACAD SCI USA, V95, P9072, DOI 10.1073/pnas.95.16.9072; Esumi S, 2005, NAT GENET, V37, P171, DOI 10.1038/ng1500; Fuerst PG, 2008, NATURE, V451, P470, DOI 10.1038/nature06514; Fuerst PG, 2009, NEURON, V64, P484, DOI 10.1016/j.neuron.2009.09.027; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; Han MH, 2010, MOL CELL PROTEOMICS, V9, P71, DOI 10.1074/mcp.M900343-MCP200; Hasegawa S, 2008, MOL CELL NEUROSCI, V38, P66, DOI 10.1016/j.mcn.2008.01.016; Hattori D, 2008, ANNU REV CELL DEV BI, V24, P597, DOI 10.1146/annurev.cellbio.24.110707.175250; Hattori D, 2007, NATURE, V449, P223, DOI 10.1038/nature06099; Hattori D, 2009, NATURE, V461, P644, DOI 10.1038/nature08431; Hughes ME, 2007, NEURON, V54, P417, DOI 10.1016/j.neuron.2007.04.013; Hummel T, 2003, NEURON, V37, P221, DOI 10.1016/S0896-6273(02)01183-2; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Junghans D, 2008, EUR J NEUROSCI, V27, P559, DOI 10.1111/j.1460-9568.2008.06052.x; Kaneko R, 2006, J BIOL CHEM, V281, P30551, DOI 10.1074/jbc.M605677200; Katori S, 2009, J NEUROSCI, V29, P9137, DOI 10.1523/JNEUROSCI.5478-08.2009; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; KRAMER AP, 1985, J NEUROSCI, V5, P768; KRAMER AP, 1983, J NEUROSCI, V3, P2474; Langley J N, 1895, J Physiol, V18, P280; Lefebvre JL, 2008, DEVELOPMENT, V135, P4141, DOI 10.1242/dev.027912; Matthews BJ, 2007, CELL, V129, P593, DOI 10.1016/j.cell.2007.04.013; McLaughlin T, 2005, ANNU REV NEUROSCI, V28, P327, DOI 10.1146/annurev.neuro.28.061604.135714; Meijers R, 2007, NATURE, V449, P487, DOI 10.1038/nature06147; Millard SS, 2010, NEURON, V67, P761, DOI 10.1016/j.neuron.2010.08.030; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 2006, ANNU REV CELL DEV BI, V22, P713, DOI 10.1146/annurev.cellbio.21.012804.093915; Morishita H, 2007, CURR OPIN CELL BIOL, V19, P584, DOI 10.1016/j.ceb.2007.09.006; Morishita H, 2006, J BIOL CHEM, V281, P33650, DOI 10.1074/jbc.M603298200; Murata Y, 2004, J BIOL CHEM, V279, P49508, DOI 10.1074/jbc.M408771200; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Phillips GR, 2003, J NEUROSCI, V23, P5096; Prasad T, 2008, DEVELOPMENT, V135, P4153, DOI 10.1242/dev.026807; Sakano H, 2010, NEURON, V67, P530, DOI 10.1016/j.neuron.2010.07.003; Sanes JR, 2010, NEURON, V66, P15, DOI 10.1016/j.neuron.2010.01.018; Sanes JR, 2009, ANNU REV CELL DEV BI, V25, P161, DOI 10.1146/annurev.cellbio.24.110707.175402; Sawaya MR, 2008, CELL, V134, P1007, DOI 10.1016/j.cell.2008.07.042; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schreiner D, 2010, P NATL ACAD SCI USA, V107, P14893, DOI 10.1073/pnas.1004526107; Shapiro L, 2007, ANNU REV NEUROSCI, V30, P451, DOI 10.1146/annurev.neuro.29.051605.113034; Soba P, 2007, NEURON, V54, P403, DOI 10.1016/j.neuron.2007.03.029; Sperry RW, 1943, J COMP NEUROL, V79, P33, DOI 10.1002/cne.900790104; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Sperry RW, 1944, J NEUROPHYSIOL, V7, P57, DOI 10.1152/jn.1944.7.1.57; Su H, 2010, DEV BIOL, V339, P38, DOI 10.1016/j.ydbio.2009.12.010; Sudhof TC, 2008, NATURE, V455, P903, DOI 10.1038/nature07456; Takeichi M, 2007, NAT REV NEUROSCI, V8, P11, DOI 10.1038/nrn2043; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Wang J, 2004, NEURON, V43, P663, DOI 10.1016/j.neuron.2004.06.033; Wang J, 2002, NEURON, V33, P559, DOI 10.1016/S0896-6273(02)00570-6; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; Weiner JA, 2005, P NATL ACAD SCI USA, V102, P8, DOI 10.1073/pnas.0407931101; Wojtowicz WM, 2004, CELL, V118, P619, DOI 10.1016/j.cell.2004.08.021; Wojtowicz WM, 2007, CELL, V130, P1134, DOI 10.1016/j.cell.2007.08.026; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yamagata M, 2008, NATURE, V451, P465, DOI 10.1038/nature06469; Zhan XL, 2004, NEURON, V43, P673, DOI 10.1016/j.neuron.2004.07.020; Zhu HT, 2006, NAT NEUROSCI, V9, P349, DOI 10.1038/nn1652; Zou C, 2007, NEUROSCIENCE, V144, P579, DOI 10.1016/j.neuroscience.2006.10.011	64	216	218	1	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 29	2010	143	3					343	353		10.1016/j.cell.2010.10.009	http://dx.doi.org/10.1016/j.cell.2010.10.009			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029858	Bronze			2022-12-28	WOS:000283603900009
J	Yachida, S; Jones, S; Bozic, I; Antal, T; Leary, R; Fu, BJ; Kamiyama, M; Hruban, RH; Eshleman, JR; Nowak, MA; Velculescu, VE; Kinzler, KW; Vogelstein, B; Iacobuzio-Donahue, CA				Yachida, Shinichi; Jones, Sian; Bozic, Ivana; Antal, Tibor; Leary, Rebecca; Fu, Baojin; Kamiyama, Mihoko; Hruban, Ralph H.; Eshleman, James R.; Nowak, Martin A.; Velculescu, Victor E.; Kinzler, Kenneth W.; Vogelstein, Bert; Iacobuzio-Donahue, Christine A.			Distant metastasis occurs late during the genetic evolution of pancreatic cancer	NATURE			English	Article							CARCINOMA; GENOME; TUMORS; MODEL	Metastasis, the dissemination and growth of neoplastic cells in an organ distinct from that in which they originated(1,2), is the most common cause of death in cancer patients. This is particularly true for pancreatic cancers, where most patients are diagnosed with metastatic disease and few show a sustained response to chemotherapy or radiation therapy(3). Whether the dismal prognosis of patients with pancreatic cancer compared to patients with other types of cancer is a result of late diagnosis or early dissemination of disease to distant organs is not known. Here we rely on data generated by sequencing the genomes of seven pancreatic cancer metastases to evaluate the clonal relationships among primary and metastatic cancers. We find that clonal populations that give rise to distant metastases are represented within the primary carcinoma, but these clones are genetically evolved from the original parental, non-metastatic clone. Thus, genetic heterogeneity of metastases reflects that within the primary carcinoma. A quantitative analysis of the timing of the genetic evolution of pancreatic cancer was performed, indicating at least a decade between the occurrence of the initiating mutation and the birth of the parental, non-metastatic founder cell. At least five more years are required for the acquisition of metastatic ability and patients die an average of two years thereafter. These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease.	[Yachida, Shinichi; Fu, Baojin; Kamiyama, Mihoko; Hruban, Ralph H.; Eshleman, James R.; Iacobuzio-Donahue, Christine A.] Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21231 USA; [Jones, Sian; Leary, Rebecca; Velculescu, Victor E.; Kinzler, Kenneth W.; Vogelstein, Bert] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA; [Jones, Sian; Leary, Rebecca; Velculescu, Victor E.; Kinzler, Kenneth W.; Vogelstein, Bert] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; [Bozic, Ivana; Antal, Tibor; Nowak, Martin A.] Harvard Univ, Dept Organism & Evolutionary Biol, Dept Math, Program Evolutionary Dynam, Cambridge, MA 02138 USA; [Antal, Tibor] Univ Edinburgh, Sch Math, Edinburgh EH9 3JZ, Midlothian, Scotland; [Hruban, Ralph H.; Iacobuzio-Donahue, Christine A.] Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21231 USA; [Iacobuzio-Donahue, Christine A.] Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Surg, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Harvard University; University of Edinburgh; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Iacobuzio-Donahue, CA (corresponding author), Johns Hopkins Med Inst, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21231 USA.	ciacobu@jhmi.edu	Velculescu, Victor/ABF-4846-2020; Antal, Tibor/A-4512-2008; Bozic, Ivana/C-5003-2008; Gotoh, Osamu/B-4704-2012; Iacobuzio-Donahue, Christine/ABF-1295-2020; Nowak, Martin A/A-6977-2008; Jones, Sian/A-5050-2012	Velculescu, Victor/0000-0003-1195-438X; Bozic, Ivana/0000-0003-2761-825X; Iacobuzio-Donahue, Christine/0000-0002-4672-3023; 	National Institutes of Health [CA106610, CA62924, CA43460, CA57345, CA121113, GM078986]; Bill and Melinda Gates Foundation [37874]; Uehara Memorial Foundation; AACR-Barletta Foundation; John Templeton Foundation; Sol Goldman Pancreatic Cancer Research Center; Michael Rolfe Pancreatic Cancer Foundation; George Rubis Endowment for Pancreatic Cancer Research; Joseph C. Monastra Foundation for Pancreatic Cancer Research; Alfredo Scatena Memorial Fund; Virginia and the D. K. Ludwig Fund for Cancer Research; The Joint Programin Mathematical Biology and J. Epstein; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA043460, R01CA121113, R01CA057345, K08CA106610, R37CA057345, R37CA043460, R01CA140599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078986] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Uehara Memorial Foundation(Uehara Memorial Foundation); AACR-Barletta Foundation; John Templeton Foundation; Sol Goldman Pancreatic Cancer Research Center; Michael Rolfe Pancreatic Cancer Foundation; George Rubis Endowment for Pancreatic Cancer Research; Joseph C. Monastra Foundation for Pancreatic Cancer Research; Alfredo Scatena Memorial Fund; Virginia and the D. K. Ludwig Fund for Cancer Research; The Joint Programin Mathematical Biology and J. Epstein; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants CA106610 (C.A.I.-D.), CA62924 (C.A.I.-D., M.A.N.), CA43460 (B. V.), CA57345 (K. W. K. and V. E. V.), CA121113 (V. E. V. and K. W. K.), GM078986 (M.A.N.), the Bill and Melinda Gates Foundation Grand Challenges Grant 37874, the Uehara Memorial Foundation (S.Y.), the AACR-Barletta Foundation (C.A.I.-D.), the John Templeton Foundation, Pilot Funding from the Sol Goldman Pancreatic Cancer Research Center, the Michael Rolfe Pancreatic Cancer Foundation, the George Rubis Endowment for Pancreatic Cancer Research, the Joseph C. Monastra Foundation for Pancreatic Cancer Research, the Alfredo Scatena Memorial Fund, the Virginia and the D. K. Ludwig Fund for Cancer Research, The Joint Programin Mathematical Biology and J. Epstein. We would like to acknowledge T. C. Cornish, C. Henderson,	AMIKURA K, 1995, INT J PANCREATOL, V17, P139; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Fu BJ, 2007, CANCER BIOL THER, V6, P1546, DOI 10.4161/cbt.6.10.4708; Hisa T, 2008, WORLD J GASTROENTERO, V14, P1958, DOI 10.3748/wjg.14.1958; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Naumov GN, 2006, JNCI-J NATL CANCER I, V98, P316, DOI 10.1093/jnci/djj068; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Peiffer DA, 2006, GENOME RES, V16, P1136, DOI 10.1101/gr.5402306; Rew DA, 2000, EUR J SURG ONCOL, V26, P405, DOI 10.1053/ejso.1999.0907; SASAKI K, 1988, CANCER, V62, P989, DOI 10.1002/1097-0142(19880901)62:5<989::AID-CNCR2820620525>3.0.CO;2-U; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Steel GG, 1977, GROWTH KINETICS TUMO; Terada T, 1998, ARCH PATHOL LAB MED, V122, P42; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413	21	1765	1850	5	255	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2010	467	7319					1114	U126		10.1038/nature09515	http://dx.doi.org/10.1038/nature09515			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981102	Green Accepted			2022-12-28	WOS:000283548600049
J	Bauer, MP; Notermans, DW; van Benthem, BHB; Brazier, JS; Wilcox, MH; Rupnik, M; Monnet, DL; van Dissel, JT; Kuijper, EJ				Bauer, Martijn P.; Notermans, Daan W.; van Benthem, Birgit H. B.; Brazier, Jon S.; Wilcox, Mark H.; Rupnik, Maja; Monnet, Dominique L.; van Dissel, Jaap T.; Kuijper, Ed J.		ECDIS Study Grp	Clostridium difficile infection in Europe: a hospital-based survey	LANCET			English	Article							NORTH-AMERICA; RISK-FACTORS; DISEASE; TOXIN; PCR; NETHERLANDS; COLITIS; STRAIN; EPIDEMIOLOGY; STRATEGIES	Background Little is known about the extent of Clostridium difficile infection in Europe. Our aim was to obtain a more complete overview of C difficile infection in Europe and build capacity for diagnosis and surveillance. Methods We set up a network of 106 laboratories in 34 European countries. In November, 2008, one to six hospitals per country, relative to population size, tested stool samples of patients with suspected C difficile infection or diarrhoea that developed 3 or more days after hospital admission. A case was defined when, subsequently, toxins were identified in stool samples. Detailed clinical data and stool isolates were collected for the first ten cases per hospital. After 3 months, clinical data were followed up. Findings The incidence of C difficile infection varied across hospitals (weighted mean 4.1 per 10 000 patient-days per hospital, range 0.0-36.3). Detailed information was obtained for 509 patients. For 389 of these patients, isolates were available for characterisation. 65 different PCR ribotypes were identified, of which 014/020 (61 patients [16%]), 001 (37 [9%]), and 078 (31 [8%]) were the most prevalent. The prevalence of PCR-ribotype 027 was 5%. Most patients had a previously identified risk profile of old age, comorbidity, and recent antibiotic use. At follow up, 101 (22%) of 455 patients had died, and C difficile infection played a part in 40 (40%) of deaths. After adjustment for potential confounders, an age of 65 years or older (adjusted odds ratio 3.26,95% CI 1.08-9.78; p=0.026), and infection by PCR-ribotypes 018 (6.19, 1.28-29.81; p=0.023) and 056 (13.01; 1.14-148.26; p=0.039) were significantly associated with complicated disease outcome. Interpretation PCR ribotypes other than 027 are prevalent in European hospitals. The data emphasise the importance of multicountry surveillance to detect and control C difficile infection in Europe.	[Bauer, Martijn P.; van Dissel, Jaap T.; Kuijper, Ed J.] Leiden Univ, Med Ctr, Ctr Infect Dis, NL-2300 RC Leiden, Netherlands; [Bauer, Martijn P.; Notermans, Daan W.; van Benthem, Birgit H. B.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control Netherlands, NL-3720 BA Bilthoven, Netherlands; [Brazier, Jon S.] Microbiol Cardiff Univ Hosp Wales, Natl Publ Hlth Serv Wales, Anaerobe Reference Lab, Cardiff, S Glam, Wales; [Wilcox, Mark H.] Leeds Gen Infirm, Old Med Sch, Dept Microbiol, Leeds, W Yorkshire, England; [Wilcox, Mark H.] Univ Leeds, Leeds, W Yorkshire, England; [Rupnik, Maja] Ctr Microbiol, Inst Publ Hlth Maribor, Maribor, Slovenia; [Monnet, Dominique L.] European Ctr Dis Prevent & Control, Sci Advice Unit, Stockholm, Sweden	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands National Institute for Public Health & the Environment; Leeds General Infirmary; University of Leeds; University of Leeds; European Centre for Disease Prevention & Control	Bauer, MP (corresponding author), Leiden Univ, Med Ctr, Ctr Infect Dis, Albinusdreef 2, NL-2300 RC Leiden, Netherlands.	m.p.bauer@lumc.nl	Novakova, Elena/X-7553-2018; Kuijper, ed/AAB-7853-2022; fitzpatrick, fidelma/P-5483-2018; Mossong, Joël/D-4998-2009; Pituch, Hanna/N-5919-2018; Bouza, Emilio/D-8661-2014; Akalin, Halis/AAU-8952-2020; Coia, John/AAP-5379-2020; Afset, Jan Egil/G-9579-2013	Novakova, Elena/0000-0001-5939-3820; Kuijper, ed/0000-0001-5726-2405; fitzpatrick, fidelma/0000-0002-3204-5962; Mossong, Joël/0000-0003-0717-9835; Pituch, Hanna/0000-0002-2348-4402; Bouza, Emilio/0000-0001-6967-9267; Coia, John/0000-0002-4966-8453; GARCIA-GARCIA, M.-INMACULADA/0000-0002-5804-2444; Afset, Jan Egil/0000-0003-2489-4179; Harmanus, Celine/0000-0002-5328-3273; Allerberger, Franz/0000-0002-0045-8164	European Centre for Disease Prevention and Control [ECD.894]	European Centre for Disease Prevention and Control	Funding European Centre for Disease Prevention and Control.; We would like to acknowledge Celine Harmanus and Ingrid Sanders for PCR-ribotyping isolates at Leiden University Medical Centre, Jeroen Alblas for support in the development of the web-based questionnaire, Jan Vandenbroucke for advice on multivariate analysis, and the laboratory technicians of all participating laboratories. The study was financed by the European Centre for Disease Prevention and Control through a specific service contract (ECD.894).	Alvarez-Perez S, 2009, VET MICROBIOL, V137, P302, DOI 10.1016/j.vetmic.2009.01.015; Barbut F, 2007, CLIN MICROBIOL INFEC, V13, P1048, DOI 10.1111/j.1469-0691.2007.01824.x; Barbut F, 2003, CLIN MICROBIOL INFEC, V9, P989, DOI 10.1046/j.1469-0691.2003.00683.x; Bauer MP, 2009, CLIN MICROBIOL INFEC, V15, P1067, DOI 10.1111/j.1469-0691.2009.03099.x; Bidet P, 2000, J CLIN MICROBIOL, V38, P2484, DOI 10.1128/JCM.38.7.2484-2487.2000; Debast SB, 2009, ENVIRON MICROBIOL, V11, P505, DOI 10.1111/j.1462-2920.2008.01790.x; Goorhuis A, 2007, CLIN INFECT DIS, V45, P695, DOI 10.1086/520984; Goorhuis A, 2008, CLIN INFECT DIS, V47, P1162, DOI 10.1086/592257; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Henrich TJ, 2009, EMERG INFECT DIS, V15, P415, DOI 10.3201/eid1503.080312; Jhung MA, 2008, EMERG INFECT DIS, V14, P1039, DOI 10.3201/eid1407.071641; Kato H, 1998, J CLIN MICROBIOL, V36, P2178, DOI 10.1128/JCM.36.8.2178-2182.1998; Kelly CP, 2008, NEW ENGL J MED, V359; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kuijper EJ, 2006, CLIN MICROBIOL INFEC, V12, P2, DOI 10.1111/j.1469-0691.2006.01580.x; Kuijper E J, 2008, Euro Surveill, V13; Kuijper EJ, 2006, EMERG INFECT DIS, V12, P827; Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639; Lyytikainen O, 2009, EMERG INFECT DIS, V15, P761, DOI 10.3201/eid1505.081154; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McDonald LC, 2007, INFECT CONT HOSP EP, V28, P140, DOI 10.1086/511798; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; McFarland LV, 2002, AM J GASTROENTEROL, V97, P1769, DOI 10.1111/j.1572-0241.2002.05839.x; Moshkowitz M, 2007, COLORECTAL DIS, V9, P173, DOI 10.1111/j.1463-1318.2006.01013.x; Paltansing S, 2007, CLIN MICROBIOL INFEC, V13, P1058, DOI 10.1111/j.1469-0691.2007.01793.x; Pepin J, 2006, CLIN INFECT DIS, V42, P758, DOI 10.1086/501126; Pepin J, 2005, CLIN INFECT DIS, V40, P1591, DOI 10.1086/430315; Rupnik M, 1998, J CLIN MICROBIOL, V36, P2240, DOI 10.1128/JCM.36.8.2240-2247.1998; Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164; Sailhamer EA, 2009, ARCH SURG-CHICAGO, V144, P433, DOI 10.1001/archsurg.2009.51; Smith A., 2005, EUROSURVEILLANCE, V10, P2735; Soes L, 2009, EUROSURVEILLANCE, V14, P11; Soler P, 2008, INFECT CONT HOSP EP, V29, P887, DOI 10.1086/590392; Songer JG, 2009, EMERG INFECT DIS, V15, P819, DOI 10.3201/eid1505.081071; Stubbs S, 2000, FEMS MICROBIOL LETT, V186, P307, DOI 10.1016/S0378-1097(00)00162-2; Stubbs SLJ, 1999, J CLIN MICROBIOL, V37, P461, DOI 10.1128/JCM.37.2.461-463.1999; Sundram F, 2009, J HOSP INFECT, V72, P111, DOI 10.1016/j.jhin.2009.02.020; Vonberg RP, 2007, EMERG INFECT DIS, V13, P179, DOI 10.3201/eid1301.060611; Warny M, 2005, LANCET, V366, P1079, DOI 10.1016/S0140-6736(05)67420-X	39	808	848	1	95	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 1	2011	377	9759					63	73		10.1016/S0140-6736(10)61266-4	http://dx.doi.org/10.1016/S0140-6736(10)61266-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709MQ	21084111				2022-12-28	WOS:000286445200032
J	Nicodeme, E; Jeffrey, KL; Schaefer, U; Beinke, S; Dewell, S; Chung, CW; Chandwani, R; Marazzi, I; Wilson, P; Coste, H; White, J; Kirilovsky, J; Rice, CM; Lora, JM; Prinjha, RK; Lee, K; Tarakhovsky, A				Nicodeme, Edwige; Jeffrey, Kate L.; Schaefer, Uwe; Beinke, Soren; Dewell, Scott; Chung, Chun-wa; Chandwani, Rohit; Marazzi, Ivan; Wilson, Paul; Coste, Herve; White, Julia; Kirilovsky, Jorge; Rice, Charles M.; Lora, Jose M.; Prinjha, Rab K.; Lee, Kevin; Tarakhovsky, Alexander			Suppression of inflammation by a synthetic histone mimic	NATURE			English	Article							BROMODOMAIN PROTEIN BRD4; TRANSCRIPTIONAL ELONGATION; GENE-EXPRESSION; BINDING MODULES; P-TEFB; CHROMATIN; COMPLEXES; MACHINES	Interaction of pathogens with cells of the immune system results in activation of inflammatory gene expression. This response, although vital for immune defence, is frequently deleterious to the host due to the exaggerated production of inflammatory proteins. The scope of inflammatory responses reflects the activation state of signalling proteins upstream of inflammatory genes as well as signal-induced assembly of nuclear chromatin complexes that support mRNA expression(1-4). Recognition of post-translationally modified histones by nuclear proteins that initiate mRNA transcription and support mRNA elongation is a critical step in the regulation of gene expression(5-10). Here we present a novel pharmacological approach that targets inflammatory gene expression by interfering with the recognition of acetylated histones by the bromodomain and extra terminal domain (BET) family of proteins. We describe a synthetic compound (I-BET) that by 'mimicking' acetylated histones disrupts chromatin complexes responsible for the expression of key inflammatory genes in activated macrophages, and confers protection against lipopolysaccharide-induced endotoxic shock and bacteria-induced sepsis. Our findings suggest that synthetic compounds specifically targeting proteins that recognize post-translationally modified histones can serve as a new generation of immunomodulatory drugs.	[Jeffrey, Kate L.; Schaefer, Uwe; Chandwani, Rohit; Marazzi, Ivan; Tarakhovsky, Alexander] Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10065 USA; [Nicodeme, Edwige; Coste, Herve; Kirilovsky, Jorge] Ctr Res GSK, F-91140 Villebon Sur Yvette, France; [Beinke, Soren; Lora, Jose M.; Prinjha, Rab K.; Lee, Kevin] GlaxoSmithKline, Med Res Ctr, Epinova DPU, Immunoinflammat Ctr Excellence Drug Discovery, Stevenage SG1 2NY, Herts, England; [Dewell, Scott] Rockefeller Univ, Genom Resource Ctr, New York, NY 10065 USA; [Chung, Chun-wa; Wilson, Paul; White, Julia] GlaxoSmithKline R&D, Med Res Ctr, Stevenage SG1 2NY, Herts, England; [Rice, Charles M.] Rockefeller Univ, Lab Virol & Infect Dis, New York, NY 10065 USA	Rockefeller University; GlaxoSmithKline; GlaxoSmithKline; Rockefeller University; GlaxoSmithKline; Rockefeller University	Tarakhovsky, A (corresponding author), Rockefeller Univ, Lab Lymphocyte Signaling, 1230 York Ave, New York, NY 10065 USA.	Kevin.2.Lee@gsk.com; tarakho@rockefeller.edu		Chandwani, Rohit/0000-0003-4781-6069; Jeffrey, Kate/0000-0001-5746-0153; marazzi, ivan/0000-0003-3376-0922	NIHKL2 Career Development Award; American Italian Cancer Foundation; National Health and Medical Research Council of Australia	NIHKL2 Career Development Award; American Italian Cancer Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We would like to acknowledge R. Grimley and C. Patel for supplying FRET data and R. Woodward, C. Delves, E. Jones and P. Holmes for protein production. J. Witherington, N. Smithers, S. Baddeley, J. Seal and L. Cutler provided compound selectivity and pharmacokinetics data. G. Krysa, O. Mirguet and R. Gosmini contributed to the discovery, development and characterization of the compound. We thank R. Anthony and S. McCleary for assistance with animal models, R. Gejman for bioinformatics analysis of gene expression kinetics and A. Santana and T. Chapman for technical assistance. We would like to thank C. Nathan, R. Medzhitov, S. Rudensky and S. Smale for helpful discussions and S. Sampath for his contribution to the concept of 'histone mimicry'. R. C. is supported by an NIHKL2 Career Development Award and I. M. is supported by the American Italian Cancer Foundation. K. L. J. is supported by the National Health and Medical Research Council of Australia and is currently a Rockefeller University Women in Science Fellow.	Denis GV, 2006, J PROTEOME RES, V5, P502, DOI 10.1021/pr050430u; Gavrilin MA, 2009, J IMMUNOL, V182, P7982, DOI 10.4049/jimmunol.0803073; Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; Hargreaves DC, 2009, CELL, V138, P129, DOI 10.1016/j.cell.2009.05.047; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Huang HD, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-57; Jang MK, 2005, MOL CELL, V19, P523, DOI 10.1016/j.molcel.2005.06.027; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018; Liu Y, 2008, BIOCHEMISTRY-US, V47, P6403, DOI 10.1021/bi8001659; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Natoli G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000224; Nishiyama A, 2006, MOL BIOL CELL, V17, P814, DOI 10.1091/mbc.E05-08-0729; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; RITTIRSCH D, 2008, NAT PROTOC, V4, P31, DOI DOI 10.1038/NPROT.2008.214; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Smale ST, 2010, CELL, V140, P833, DOI 10.1016/j.cell.2010.01.037; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Vollmuth F, 2009, J BIOL CHEM, V284, P36547, DOI 10.1074/jbc.M109.033712; Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029	27	1128	1264	5	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	2010	468	7327					1119	1123		10.1038/nature09589	http://dx.doi.org/10.1038/nature09589			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	697XT	21068722	Green Accepted			2022-12-28	WOS:000285553800062
J	Setiawan, J; Klement, RJ; Henning, T; Rix, HW; Rochau, B; Rodmann, J; Schulze-Hartung, T				Setiawan, Johny; Klement, Rainer J.; Henning, Thomas; Rix, Hans-Walter; Rochau, Boyke; Rodmann, Jens; Schulze-Hartung, Tim			A Giant Planet Around a Metal-Poor Star of Extragalactic Origin	SCIENCE			English	Article							HORIZONTAL-BRANCH STARS; RED-GIANT; RADIAL-VELOCITY; MILKY-WAY; SOLAR NEIGHBORHOOD; GLOBULAR-CLUSTERS; STELLAR HALO; HOST STARS; K-GIANTS; COMPANION	Stars in their late stage of evolution, such as horizontal branch stars, are still largely unexplored for planets. We detected a planetary companion around HIP 13044, a very metal-poor star on the red horizontal branch, on the basis of radial velocity observations with a high-resolution spectrograph at the 2.2-meter Max-Planck Gesellschaft-European Southern Observatory telescope. The star's periodic radial velocity variation of P = 16.2 days caused by the planet can be distinguished from the periods of the stellar activity indicators. The minimum mass of the planet is 1.25 times the mass of Jupiter and its orbital semimajor axis is 0.116 astronomical units. Because HIP 13044 belongs to a group of stars that have been accreted from a disrupted satellite galaxy of the Milky Way, the planet most likely has an extragalactic origin.	[Setiawan, Johny; Klement, Rainer J.; Henning, Thomas; Rix, Hans-Walter; Rochau, Boyke; Schulze-Hartung, Tim] Max Planck Inst Astron, D-69117 Heidelberg, Germany; [Rodmann, Jens] European Space Agcy, Space Environm & Effects Sect, European Space Res & Technol Ctr, NL-2201 AZ Noordwijk, Netherlands	Max Planck Society; European Space Agency	Setiawan, J (corresponding author), Max Planck Inst Astron, Konigstuhl 17, D-69117 Heidelberg, Germany.	setiawan@mpia.de	Klement, Rainer J/H-3484-2019; Henning, Thomas K/O-4372-2018	Klement, Rainer J/0000-0003-1401-4270; Henning, Thomas K/0000-0002-1493-300X				Beer ME, 2004, MON NOT R ASTRON SOC, V355, P1244, DOI 10.1111/j.1365-2966.2004.08404.x; BEERS TC, 1990, ASTRON J, V100, P849, DOI 10.1086/115568; BUONANNO R, 1994, ASTRON ASTROPHYS, V290, P69; Carlberg JK, 2009, ASTROPHYS J, V700, P832, DOI 10.1088/0004-637X/700/1/832; Carney BW, 2008, ASTRON J, V135, P892, DOI 10.1088/0004-6256/135/3/892; Carney BW, 2008, ASTRON J, V135, P196, DOI 10.1088/0004-6256/135/1/196; CARNEY BW, 1986, ASTRON J, V92, P60, DOI 10.1086/114134; Carney BW, 2003, ASTRON J, V125, P293, DOI 10.1086/345386; Chiba M, 2000, ASTRON J, V119, P2843, DOI 10.1086/301409; Dollinger MP, 2007, ASTRON ASTROPHYS, V472, P649, DOI 10.1051/0004-6361:20066987; Ford EB, 2000, ASTROPHYS J, V528, P336, DOI 10.1086/308167; Geier S, 2009, ASTROPHYS J LETT, V702, pL96, DOI 10.1088/0004-637X/702/1/L96; Gray DF, 2008, ASTRON J, V135, P2033, DOI 10.1088/0004-6256/135/6/2033; Gregory P., 2005, BAYESIAN LOGICAL DAT; Harris WE, 1996, ASTRON J, V112, P1487, DOI 10.1086/118116; HATZES AP, 1993, ASTROPHYS J, V413, P339, DOI 10.1086/173002; Hatzes AP, 1996, PUBL ASTRON SOC PAC, V108, P839, DOI 10.1086/133805; Helmi A, 1999, NATURE, V402, P53, DOI 10.1038/46980; Heyl J, 2007, MON NOT R ASTRON SOC, V382, P915, DOI 10.1111/j.1365-2966.2007.12441.x; Ida S, 2005, PROG THEOR PHYS SUPP, P68, DOI 10.1143/PTPS.158.68; Johnson JA, 2010, PUBL ASTRON SOC PAC, V122, P701, DOI 10.1086/653809; KAUFER A, 2008, SPIE C SER, V4008, P459; Kepley AA, 2007, ASTRON J, V134, P1579, DOI 10.1086/521429; Klement R, 2009, ASTROPHYS J, V698, P865, DOI 10.1088/0004-637X/698/1/865; Lee JW, 2009, ASTRON J, V137, P3181, DOI 10.1088/0004-6256/137/2/3181; Levrard B, 2009, ASTROPHYS J LETT, V692, pL9, DOI 10.1088/0004-637X/692/1/L9; LIVIO M, 1983, ASTRON ASTROPHYS, V125, pL12; MATHIS JS, 1992, ASTRON ASTROPHYS, V259, pL39; Maxted PFL, 2001, MON NOT R ASTRON SOC, V326, P1391, DOI 10.1111/j.1365-2966.2001.04714.x; PERRYMAN MAC, 1997, ESA SPEC PUBL SER, V1200; Pollacco DL, 2006, PUBL ASTRON SOC PAC, V118, P1407, DOI 10.1086/508556; Roederer IU, 2010, ASTROPHYS J, V711, P573, DOI 10.1088/0004-637X/711/2/573; Setiawan J, 2004, ASTRON ASTROPHYS, V421, P241, DOI [10.1051/0004-6361:20041042-1, 10.1051/0004-6361:20041042]; Shkolnik E, 2008, ASTROPHYS J, V676, P628, DOI 10.1086/527351; Sigurdsson S, 2003, SCIENCE, V301, P193, DOI 10.1126/science.1086326; Silvotti R, 2007, NATURE, V449, P189, DOI 10.1038/nature06143; Soker N, 1998, ASTRON J, V116, P1308, DOI 10.1086/300503; Stello D, 2009, ASTROPHYS J, V700, P949, DOI 10.1088/0004-637X/700/2/949; Valenti JA, 2005, ASTROPHYS J SUPPL S, V159, P141, DOI 10.1086/430500; WALKER GAH, 1992, ASTROPHYS J, V396, pL91, DOI 10.1086/186524; Xiong DR, 1998, ASTROPHYS J, V500, P449, DOI 10.1086/305695; Zechmeister M, 2009, ASTRON ASTROPHYS, V496, P577, DOI 10.1051/0004-6361:200811296	45	39	39	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 17	2010	330	6011					1642	1644		10.1126/science.1193342	http://dx.doi.org/10.1126/science.1193342			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	695RO	21097905	Green Submitted			2022-12-28	WOS:000285390500057
J	Guzman, JN; Sanchez-Padilla, J; Wokosin, D; Kondapalli, J; Ilijic, E; Schumacker, PT; Surmeier, DJ				Guzman, Jaime N.; Sanchez-Padilla, Javier; Wokosin, David; Kondapalli, Jyothisri; Ilijic, Ema; Schumacker, Paul T.; Surmeier, D. James			Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1	NATURE			English	Article							CALCIUM-CHANNEL BLOCKERS; MITOCHONDRIA; DISEASE; CELLS; MUTATIONS	Parkinson's disease is a pervasive, ageing-related neurodegenerative disease the cardinal motor symptoms of which reflect the loss of a small group of neurons, the dopaminergic neurons in the substantia nigra pars compacta(1) (SNc). Mitochondrial oxidant stress is widely viewed as being responsible for this loss(2), but why these particular neurons should be stressed is a mystery. Here we show, using transgenic mice that expressed a redox-sensitive variant of green fluorescent protein targeted to the mitochondrial matrix, that the engagement of plasma membrane L-type calcium channels during normal autonomous pacemaking created an oxidant stress that was specific to vulnerable SNc dopaminergic neurons. The oxidant stress engaged defences that induced transient, mild mitochondrial depolarization or uncoupling. The mild uncoupling was not affected by deletion of cyclophilin D, which is a component of the permeability transition pore, but was attenuated by genipin and purine nucleotides, which are antagonists of cloned uncoupling proteins. Knocking out DJ-1 (also known as PARK7 in humans and Park7 in mice), which is a gene associated with an early-onset form of Parkinson's disease, downregulated the expression of two uncoupling proteins (UCP4 (SLC25A27) and UCP5 (SLC25A14)), compromised calcium-induced uncoupling and increased oxidation of matrix proteins specifically in SNc dopaminergic neurons. Because drugs approved for human use can antagonize calcium entry through L-type channels, these results point to a novel neuroprotective strategy for both idiopathic and familial forms of Parkinson's disease.	[Guzman, Jaime N.; Sanchez-Padilla, Javier; Wokosin, David; Ilijic, Ema; Surmeier, D. James] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; [Kondapalli, Jyothisri; Schumacker, Paul T.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Surmeier, DJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA.	j-surmeier@northwestern.edu	Tuluc, Petronel/C-2527-2011	Schumacker, Paul T/0000-0001-9591-2034	Picower Foundation; Hartman Foundation; Falk Trust; Parkinson's Disease Foundation; NIH [NS047085, NS 054850, K12GM088020, HL35440, RR025355]; DOD [W81XWH-07-1-0170]; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR025355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM088020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS054850, P50NS047085] Funding Source: NIH RePORTER	Picower Foundation; Hartman Foundation; Falk Trust(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Parkinson's Disease Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We acknowledge the technical help of P. Hockberger, N. Schwarz, S. Ulrich, Y. Chen, C. S. Chan, D. Dryanovskiand K. Saporito. We acknowledge S. Chan for supplying quantitative PCR primer sets. We acknowledge the gifts of DJ-1 knockout mice from T. and V. Dawson, Ucp2 knockout mice from D. Kong and B. Lowell, and cyclophilin D knockout mice from S. J. Korsmeyer. This work was supported by the Picower Foundation, the Hartman Foundation, the Falk Trust, the Parkinson's Disease Foundation, NIH grants NS047085 (D.J.S.), NS 054850 (D.J.S.), K12GM088020 (J.S.-P.), HL35440 (P.T.S.) and RR025355 (P.T.S.), and DOD contract W81XWH-07-1-0170 (D.J.S.).	ALBIN RL, 1995, TRENDS NEUROSCI, V18, P63; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Becker C, 2008, NEUROLOGY, V70, P1438, DOI 10.1212/01.wnl.0000303818.38960.44; Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Bender A, 2008, J NEUROL, V255, P1231, DOI 10.1007/s00415-008-0892-9; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bookout Angie L, 2006, Curr Protoc Mol Biol, VChapter 15, DOI 10.1002/0471142727.mb1508s73; Brand MD, 2004, BIOCHEM SOC SYMP, V71, P203; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chan CS, 2007, NATURE, V447, P1081, DOI 10.1038/nature05865; Cookson MR, 2010, MOVEMENT DISORD, V25, pS44, DOI 10.1002/mds.22713; Dooley CT, 2004, J BIOL CHEM, V279, P22284, DOI 10.1074/jbc.M312847200; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Eisenberg MJ, 2004, AM J MED, V116, P35, DOI 10.1016/j.amjmed.2003.08.027; Fath T, 2009, NAT PROTOC, V4, P78, DOI 10.1038/nprot.2008.199; Guzman JN, 2009, J NEUROSCI, V29, P11011, DOI 10.1523/JNEUROSCI.2519-09.2009; Kahle PJ, 2009, FREE RADICAL BIO MED, V47, P1354, DOI 10.1016/j.freeradbiomed.2009.08.003; Khaliq ZM, 2010, J NEUROSCI, V30, P7401, DOI 10.1523/JNEUROSCI.0143-10.2010; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024; Matlib MA, 1998, J BIOL CHEM, V273, P10223, DOI 10.1074/jbc.273.17.10223; Nicholls D., 2002, BIOENERGETICS, V3; Nicholls DG, 2008, ANN NY ACAD SCI, V1147, P53, DOI 10.1196/annals.1427.002; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Puopolo M, 2007, J NEUROSCI, V27, P645, DOI 10.1523/JNEUROSCI.4341-06.2007; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Ritz B, 2010, ANN NEUROL, V67, P600, DOI 10.1002/ana.21937; Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; Tian XY, 2010, MOL CELL NEUROSCI, V44, P94, DOI 10.1016/j.mcn.2010.01.012; Zhang CY, 2006, CELL METAB, V3, P417, DOI 10.1016/j.cmet.2006.04.010	33	575	588	4	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2010	468	7324					696	U119		10.1038/nature09536	http://dx.doi.org/10.1038/nature09536			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688GB	21068725	Green Accepted			2022-12-28	WOS:000284836700041
J	Gerrett, D; Lamont, T; Paton, C; Barnes, TRE; Shah, A				Gerrett, David; Lamont, Tara; Paton, Carol; Barnes, Thomas R. E.; Shah, Amar			Safety Alerts Prescribing and monitoring lithium therapy: summary of a safety report from the National Patient Safety Agency	BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACOKINETICS		[Gerrett, David; Lamont, Tara] Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England; [Paton, Carol; Barnes, Thomas R. E.] Royal Coll Psychiatrists, Prescribing Observ Mental Hlth, London E1 8AA, England; [Paton, Carol] Oxleas NHS Fdn Trust, Dartford DA2 7WG, England; [Barnes, Thomas R. E.] Univ London Imperial Coll Sci Technol & Med, Ctr Mental Hlth, London W6 8RP, England; [Shah, Amar] Barnet Enfield & Haringey Mental Hlth Trust, N London Forensic Serv, London, England	Imperial College London	Gerrett, D (corresponding author), Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England.	david.gerrett@npsa.nhs.uk						*HLTH SOC CAR INF, 2009, PRESCR COST AN DAT; Johnston AM, 1999, BRIT J PSYCHIAT, V175, P336, DOI 10.1192/bjp.175.4.336; *NAT I HLTH CLIN E, 2006, CLIN GUID NAT I HLTH, V38; National Patient Safety Agency, 2009, SAF LITH THER PAT SA; *PRESCR OBS MENT H, 2009, CRTUO69 PRESCR OBS M; Sproule BA, 2000, DRUG AGING, V16, P165, DOI 10.2165/00002512-200016030-00002; THAU K, 1993, LITHIUM, V4, P149; WARD ME, 1994, J CLIN PHARMACOL, V34, P280, DOI 10.1002/j.1552-4604.1994.tb01994.x	8	13	13	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 19	2010	341								c6258	10.1136/bmj.c6258	http://dx.doi.org/10.1136/bmj.c6258			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684WU	21097572				2022-12-28	WOS:000284586800006
J	Grantab, R; Shenoy, VB; Ruoff, RS				Grantab, Rassin; Shenoy, Vivek B.; Ruoff, Rodney S.			Anomalous Strength Characteristics of Tilt Grain Boundaries in Graphene	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; CARBON NANOTUBES; GRAPHITE; DEFECTS; STM	Graphene in its pristine form is one of the strongest materials tested, but defects influence its strength. Using atomistic calculations, we find that, counter to standard reasoning, graphene sheets with large-angle tilt boundaries that have a high density of defects are as strong as the pristine material and, unexpectedly, are much stronger than those with low-angle boundaries having fewer defects. We show that this trend is not explained by continuum fracture models but can be understood by considering the critical bonds in the strained seven-membered carbon rings that lead to failure; the large-angle boundaries are stronger because they are able to better accommodate these strained rings. Our results provide guidelines for designing growth methods to obtain sheets with strengths close to that of pristine graphene.	[Grantab, Rassin; Shenoy, Vivek B.] Brown Univ, Sch Engn, Providence, RI 02906 USA; [Ruoff, Rodney S.] Univ Texas Austin, Texas Mat Inst, Austin, TX 78712 USA; [Ruoff, Rodney S.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA	Brown University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Shenoy, VB (corresponding author), Brown Univ, Sch Engn, Providence, RI 02906 USA.	vivek_shenoy@brown.edu; r.ruoff@mail.utexas.edu	Shenoy, Vivek/ABD-5075-2021; Ruoff, Rodney/ABE-6532-2020; Ruoff, Rodney S/B-7605-2009	Ruoff, Rodney/0000-0002-6599-6764; Ruoff, Rodney S/0000-0002-6599-6764	NSF [CMMI-0825771, CMMI-0855853]; Nanoelectronics Research Initiative through Brown University's Materials Research Science and Engineering Center; TeraGrid Advanced Support Program [TG-DMR090098]; Center for Computation and Visualization at Brown University	NSF(National Science Foundation (NSF)); Nanoelectronics Research Initiative through Brown University's Materials Research Science and Engineering Center; TeraGrid Advanced Support Program; Center for Computation and Visualization at Brown University	R.G. and V.B.S. gratefully acknowledge research support from NSF and the Nanoelectronics Research Initiative through Brown University's Materials Research Science and Engineering Center program and from NSF through grants CMMI-0825771 and CMMI-0855853. The computational support for this work was provided by grant TG-DMR090098 from the TeraGrid Advanced Support Program and the Center for Computation and Visualization at Brown University.	ALBRECHT TR, 1988, APPL PHYS LETT, V52, P362, DOI 10.1063/1.99465; Bertram Broberg K., 1999, CRACKS FRACTURE; Cervenka J, 2009, NAT PHYS, V5, P840, DOI 10.1038/NPHYS1399; Cervenka J, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.195429; Gan Y, 2003, SURF SCI, V539, P120, DOI 10.1016/S0039-6028(03)00786-6; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877; Hashimoto A, 2004, NATURE, V430, P870, DOI 10.1038/nature02817; Huang JY, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.035503; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Levendorf MP, 2009, NANO LETT, V9, P4479, DOI 10.1021/nl902790r; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Li ZL, 2005, J APPL PHYS, V97, DOI 10.1063/1.1870102; Lu Q, 2005, NANOTECHNOLOGY, V16, P555, DOI 10.1088/0957-4484/16/4/037; Malola S, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.165447; Osing J, 1998, SURF SCI, V417, P145, DOI 10.1016/S0039-6028(98)00678-5; Pei QX, 2010, CARBON, V48, P898, DOI 10.1016/j.carbon.2009.11.014; Pong WT, 2007, SURF SCI, V601, P498, DOI 10.1016/j.susc.2006.10.012; Simonis P, 2002, SURF SCI, V511, P319, DOI 10.1016/S0039-6028(02)01511-X; Wong HS, 2009, ACS NANO, V3, P3455, DOI 10.1021/nn9011785; Xiao JR, 2010, MAT SCI ENG A-STRUCT, V527, P715, DOI 10.1016/j.msea.2009.10.052; Xiao JR, 2009, COMPOS STRUCT, V88, P602, DOI 10.1016/j.compstruct.2008.06.008; Yazyev OV, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.195420; Yu QK, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2982585; Zhang SL, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.115403; Zhang X, 2006, J MECH PHYS SOLIDS, V54, P2304, DOI 10.1016/j.jmps.2006.06.007	27	679	710	16	436	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					946	948		10.1126/science.1196893	http://dx.doi.org/10.1126/science.1196893			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071664	Green Submitted			2022-12-28	WOS:000284118000037
J	Kim, JS; Holtzman, DM				Kim, Jungsu; Holtzman, David M.			Prion-Like Behavior of Amyloid-beta	SCIENCE			English	Editorial Material							ALZHEIMERS-DISEASE; INDUCTION; PROTEIN		[Kim, Jungsu; Holtzman, David M.] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Hope Ctr Neurol Disorders,Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kim, JS (corresponding author), Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Hope Ctr Neurol Disorders,Dept Neurol, St Louis, MO 63110 USA.	holtzman@neuro.wustl.edu	Kim, Jungsu/F-2457-2012	Kim, Jungsu/0000-0002-6931-8581				Eisele YS, 2010, SCIENCE, V330, P980, DOI 10.1126/science.1194516; Eisele YS, 2009, P NATL ACAD SCI USA, V106, P12926, DOI 10.1073/pnas.0903200106; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Kane MD, 2000, J NEUROSCI, V20, P3606, DOI 10.1523/JNEUROSCI.20-10-03606.2000; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748	10	21	23	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					918	919		10.1126/science.1198314	http://dx.doi.org/10.1126/science.1198314			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071652				2022-12-28	WOS:000284118000024
J	Levene, LS; Baker, R; Bankart, MJG; Khunti, K				Levene, Louis S.; Baker, Richard; Bankart, M. John G.; Khunti, Kamlesh			Association of Features of Primary Health Care With Coronary Heart Disease Mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES FRAMEWORK; SOCIAL INEQUALITIES; CANCER-MORTALITY; RISK-FACTORS; US COUNTIES; ALL-CAUSE; QUALITY; DEPRIVATION; ENGLAND; INDICATORS	Context The goal of US health care reform is to extend access. In England, with a universal access health system, coronary heart disease (CHD) mortality rates have decreased by more than two-fifths in the last decade, but variations in rates between local populations persist. Objective To identify which features of populations and primary health care explain variations in CHD mortality rates between the 152 primary care trust populations in England. Design, Setting, and Participants A cross-sectional study in England of all 152 primary care trusts (total registered population, 54.3 million in 2008) using a hierarchical regression model with age-standardized CHD mortality rate as the dependent variable, and population characteristics (index of multiple deprivation, smoking, ethnicity, and registers of individuals with diabetes) and service characteristics (level of provision of primary care services, levels of detected hypertension, pay for performance data) as candidate explanatory variables. Main Outcome Measures Age-standardized CHD mortality rates in 2006, 2007, and 2008. Results The mean age-standardized CHD mortality rates per 100 000 European Standard Population were 97.9 (95% confidence interval [CI], 94.9-100.9) in 2006, 93.5 (95% CI, 90.4-96.5) in 2007, and 88.4 (95% CI, 85.7-91.1) in 2008. In all 3 years, 4 population characteristics were significantly positively associated with CHD mortality (index of multiple deprivation, smoking, white ethnicity, and registers of individuals with diabetes), and 1 service characteristic (levels of detected hypertension) was significantly negatively associated with CHD mortality (adjusted r(2) = 0.66 in 2006, adjusted r(2) = 0.68 in 2007, and adjusted r(2) = 0.67 in 2008). Other service characteristics did not contribute significantly to the model. Conclusion In England, variations in CHD mortality are predominantly explained by population characteristics; however, greater detection of hypertension is associated with lower CHD mortality. JAMA. 2010;304(18):2028-2034 www.jama.com	[Levene, Louis S.; Baker, Richard; Bankart, M. John G.; Khunti, Kamlesh] Univ Leicester, Dept Hlth Sci, Leicester LE1 6TP, Leics, England; [Levene, Louis S.; Baker, Richard; Bankart, M. John G.; Khunti, Kamlesh] Natl Inst Hlth Res Collaborat Leadership Appl Hlt, Rutland, England	University of Leicester	Levene, LS (corresponding author), Univ Leicester, Dept Hlth Sci, 22-28 Princess Rd W, Leicester LE1 6TP, Leics, England.	lsl7@le.ac.uk	/ABC-9527-2021	Khunti, Kamlesh/0000-0003-2343-7099	NIHR	NIHR(National Institute for Health Research (NIHR))	The study formed part of the program of the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Research and Care (CLARHC) in Leicestershire, Northamptonshire, and Rutland. The CLARHC is funded by the NIHR.	[Anonymous], QUAL OUTC FRAM; Ashworth M, 2007, BRIT J GEN PRACT, V57, P441; Ashworth Mark, 2006, BMC Fam Pract, V7, P68, DOI 10.1186/1471-2296-7-68; Ashworth M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2030; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; Cohen J., 1983, APPL MULTIPLE REGRES; *COMM LOC GOV, ENGL IND DEPR 2007 S; Doran T, 2008, LANCET, V372, P728, DOI 10.1016/S0140-6736(08)61123-X; Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650; Gostin LO, 2010, JAMA-J AM MED ASSOC, V303, P1188, DOI 10.1001/jama/2010.375; Gulliford MC, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-12; Huxley R, 2006, INT J EPIDEMIOL, V35, P1025, DOI 10.1093/ije/dyl058; Lomax, 2007, STAT CONCEPTS 2 COUR; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; *NHS EMPL QUAL OUT, QUAL OUTC FRAM GUID; NHS Employers, QUAL OUTC FRAM GUID; *NHS INC CTR, NEIGH STAT MOD BAS E; *NHS INF CTR, NHS STAFF NUMB; *NHS NAT STAT, HLTH SURV ENGL 2006; *NHS NAT STAT, HLTH SURV ENGL 2008; Noble M, 2006, ENVIRON PLANN A, V38, P169, DOI 10.1068/a37168; *OFF NAT STAT, NAT STAT ONL POP EST; *OFF NAT STAT E RE, PCO POP 2008 RES INT; Saxena S, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-96; *SECR STAT, 2000, NAT SERV FRAM COR HE; Shi L, 2005, PUBLIC HEALTH, V119, P699, DOI 10.1016/j.puhe.2004.12.007; Shi LY, 2005, AM J PUBLIC HEALTH, V95, P674, DOI 10.2105/AJPH.2003.031716; Strong M, 2006, J PUBLIC HEALTH, V28, P39, DOI 10.1093/pubmed/fdi065; Unal B, 2004, CIRCULATION, V109, P1101, DOI 10.1161/01.CIR.0000118498.35499.B2; World Health Organization, INT STAT CLASS DIS R, V10th; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	31	23	23	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2028	2034		10.1001/jama.2010.1636	http://dx.doi.org/10.1001/jama.2010.1636			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	677OB	21063012	Bronze			2022-12-28	WOS:000284000600021
J	Keshavjee, S; Farmer, PE				Keshavjee, Salmaan; Farmer, Paul E.			GLOBAL HEALTH Picking Up the Pace - Scale-Up of MDR Tuberculosis Treatment Programs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Keshavjee, Salmaan] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Program Infect Dis & Social Change, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA; Partners Hlth, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Keshavjee, S (corresponding author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Program Infect Dis & Social Change, Boston, MA 02115 USA.			Keshavjee, Salmaan/0000-0002-6967-3305				FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Keshavjee S., 2009, ADDRESSING THREAT DR, P141; Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665; WHO, PAND H1N1 2009 UPD 1; World Health Organization, 2010, WHOHTMTB20103	5	45	47	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1781	1784		10.1056/NEJMp1010023	http://dx.doi.org/10.1056/NEJMp1010023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674YK	21047219				2022-12-28	WOS:000283787800001
J	Evans, JW; Thiel, PA				Evans, James W.; Thiel, Patricia A.			A Little Chemistry Helps the Big Get Bigger	SCIENCE			English	Editorial Material							SURFACE SELF-DIFFUSION; METAL-SURFACES; GROWTH		[Evans, James W.] Iowa State Univ, US Dept Energy, Ames Lab, Dept Phys & Astron, Ames, IA 50011 USA; [Thiel, Patricia A.] Iowa State Univ, US Dept Energy, Ames Lab, Dept Chem, Ames, IA 50011 USA	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory	Evans, JW (corresponding author), Iowa State Univ, US Dept Energy, Ames Lab, Dept Phys & Astron, Ames, IA 50011 USA.	evans@ameslab.gov; thiel@ameslab.gov		Thiel, Patricia/0000-0003-4195-0216				BRAY AJ, 1994, ADV PHYS, V43, P357, DOI 10.1080/00018739400101505; Feibelman PJ, 2000, PHYS REV LETT, V85, P606, DOI 10.1103/PhysRevLett.85.606; HARRIS PJF, 1995, INT MATER REV, V40, P97, DOI 10.1179/imr.1995.40.3.97; Kellogg GL, 1997, PHYS REV B, V55, P7206, DOI 10.1103/PhysRevB.55.7206; Kodambaka S, 2006, SURF SCI REP, V60, P55, DOI 10.1016/j.surfrep.2005.10.002; Ling WL, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166101; Morgenstern K, 2005, PHYS STATUS SOLIDI B, V242, P773, DOI 10.1002/pssb.200440002; PERDEREAU J, 1967, SURF SCI, V7, P175, DOI 10.1016/0039-6028(67)90124-0; Ratke L., 2002, GROWTH COARSENING, P127; Shen MM, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3078033; THEIS W, 1995, PHYS REV LETT, V75, P3328, DOI 10.1103/PhysRevLett.75.3328; Thiel PA, 2009, J PHYS CHEM C, V113, P5047, DOI 10.1021/jp8063849; Zheng HM, 2009, SCIENCE, V324, P1309, DOI 10.1126/science.1172104	13	15	17	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					599	600		10.1126/science.1191665	http://dx.doi.org/10.1126/science.1191665			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030638				2022-12-28	WOS:000283580600026
J	Graham, AL; Hayward, AD; Watt, KA; Pilkington, JG; Pemberton, JM; Nussey, DH				Graham, Andrea L.; Hayward, Adam D.; Watt, Kathryn A.; Pilkington, Jill G.; Pemberton, Josephine M.; Nussey, Daniel H.			Fitness Correlates of Heritable Variation in Antibody Responsiveness in a Wild Mammal	SCIENCE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; FEMALE SOAY SHEEP; AUTOIMMUNE-DISEASE; SUSCEPTIBILITY; AUTOANTIBODIES; POPULATION; TOLERANCE; PREVALENCE; MODEL; AGE	A functional immune system is important for survival in natural environments, where individuals are frequently exposed to parasites. Yet strong immune responses may have fitness costs if they deplete limited energetic resources or cause autoimmune disease. We have found associations between fitness and heritable self-reactive antibody responsiveness in a wild population of Soay sheep. The occurrence of self-reactive antibodies correlated with overall antibody responsiveness and was associated with reduced reproduction in adults of both sexes. However, in females, the presence of self-reactive antibodies was positively associated with adult survival during harsh winters. Our results highlight the complex effects of natural selection on immune responsiveness and suggest that fitness trade-offs may maintain immunoheterogeneity, including genetic variation in autoimmune susceptibility.	[Graham, Andrea L.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; [Graham, Andrea L.; Hayward, Adam D.; Watt, Kathryn A.; Pilkington, Jill G.; Pemberton, Josephine M.; Nussey, Daniel H.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland; [Graham, Andrea L.; Watt, Kathryn A.] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland; [Graham, Andrea L.; Nussey, Daniel H.] Univ Edinburgh, Sch Biol Sci, Ctr Immun Infect & Evolut, Edinburgh EH9 3JT, Midlothian, Scotland	Princeton University; University of Edinburgh; University of Edinburgh; University of Edinburgh	Graham, AL (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	algraham@princeton.edu	Graham, Andrea L./P-7296-2019; Hayward, Adam/B-7659-2016; Pemberton, Josephine M/F-3100-2010; Nussey, Daniel H/F-4155-2010; Graham, Andrea L./A-8808-2010; Graham, Andrea/GON-8450-2022	Graham, Andrea L./0000-0002-6580-2755; Hayward, Adam/0000-0001-6953-7509; Graham, Andrea L./0000-0002-6580-2755; 	Biotechnology and Biological Sciences Research Council; Natural Environment Research Council; Wellcome Trust; Science and Technology Directorate, U.S. Department of Homeland Security; Fogarty International Center; Biotechnology and Biological Sciences Research Council [BB/H021868/1] Funding Source: researchfish; Natural Environment Research Council [NE/E01237X/1, NE/G004854/1] Funding Source: researchfish; BBSRC [BB/H021868/1] Funding Source: UKRI; NERC [NE/E01237X/1, NE/G004854/1] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Wellcome Trust(Wellcome TrustEuropean Commission); Science and Technology Directorate, U.S. Department of Homeland Security(United States Department of Homeland Security (DHS)); Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was funded by the Biotechnology and Biological Sciences and Natural Environment Research Councils; the Wellcome Trust; and the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, U.S. Department of Homeland Security, and the Fogarty International Center. Thanks to the National Trust for Scotland and Scottish National Heritage for permission to work on St. Kilda; the Ministry of Defense, QinetiQ, Amey, and Eurest Support Services staff on St. Kilda and Benbecula for logistical support; T. Clutton-Brock, M. Crawley, B. Grenfell, and many field volunteers for the data set and samples; F. Howison, N. Sanderson, K. Fairlie-Clarke, J. Matthews, and A. Nisbet for laboratory assistance; and A. Read, B. Grenfell, T. Little, D. Gray, R. Mellanby, S. Caserta, B. Craig, T. Coulson, J. Slate, R. Maizels, W. Craigens, and members of the Wild Evolution Group for discussions.	Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Attanasio R, 2001, CLIN EXP IMMUNOL, V123, P361, DOI 10.1046/j.1365-2249.2001.01454.x; Clatworthy MR, 2007, P NATL ACAD SCI USA, V104, P7169, DOI 10.1073/pnas.0608889104; Clutton-Brock T.H., 2004, SOAY SHEEP DYNAMICS; Clutton-Brock TH, 1988, REPROD SUCCESS STUDI; CluttonBrock TH, 1996, J ANIM ECOL, V65, P675, DOI 10.2307/5667; Coulson T, 2001, SCIENCE, V292, P1528, DOI 10.1126/science.292.5521.1528; COVELLI V, 1989, J IMMUNOL, V142, P1224; Devalapalli AP, 2006, SCAND J IMMUNOL, V64, P125, DOI 10.1111/j.1365-3083.2006.01785.x; Dighiero G, 1999, IMMUNOL TODAY, V20, P423, DOI 10.1016/S0167-5699(99)01509-1; Falconer DS, 1996, INTRO QUANTITATIVE G; Frank S. A., 2002, IMMUNOLOGY EVOLUTION, P33; Graham AL, 2005, ANNU REV ECOL EVOL S, V36, P373, DOI 10.1146/annurev.ecolsys.36.102003.152622; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; Grindstaff JL, 2003, P ROY SOC B-BIOL SCI, V270, P2309, DOI 10.1098/rspb.2003.2485; Kruuk LEB, 2004, PHILOS T R SOC B, V359, P873, DOI 10.1098/rstb.2003.1437; Kumar KR, 2006, SCIENCE, V312, P1665, DOI 10.1126/science.1125893; Lazzaro BP, 2009, PHILOS T R SOC B, V364, P15, DOI 10.1098/rstb.2008.0141; Lee YH, 2009, LUPUS, V18, P727, DOI 10.1177/0961203309104020; Liang KP, 2007, J RHEUMATOL, V34, P1203; Limaye N, 2008, GENES IMMUN, V9, P61, DOI 10.1038/sj.gene.6364446; Lipsky PE, 2001, NAT IMMUNOL, V2, P764, DOI 10.1038/ni0901-764; Lleo A, 2010, AUTOIMMUN REV, V9, pA259, DOI 10.1016/j.autrev.2009.12.002; Marrow P, 1996, PHILOS T R SOC B, V351, P17, DOI 10.1098/rstb.1996.0002; Nilsson BO, 2006, J AUTOIMMUN, V27, P281, DOI 10.1016/j.jaut.2006.10.002; Njemini R, 2002, CLIN EXP IMMUNOL, V127, P99, DOI 10.1046/j.1365-2249.2002.01713.x; Rioux JD, 2009, P NATL ACAD SCI USA, V106, P18680, DOI 10.1073/pnas.0909307106; Rolff J, 2003, SCIENCE, V301, P472, DOI 10.1126/science.1080623; Smee NM, 2007, JAVMA-J AM VET MED A, V230, P1180, DOI 10.2460/javma.230.8.1180; Tavecchia G, 2005, J ANIM ECOL, V74, P201, DOI 10.1111/j.1365-2656.2005.00916.x; Trowsdale J, 2006, NAT IMMUNOL, V7, P241, DOI 10.1038/ni1317; Viney ME, 2005, TRENDS ECOL EVOL, V20, P665, DOI 10.1016/j.tree.2005.10.003; Wood JD, 1998, DIGEST DIS SCI, V43, P1443, DOI 10.1023/A:1018842210330	33	153	154	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					662	665		10.1126/science.1194878	http://dx.doi.org/10.1126/science.1194878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030656				2022-12-28	WOS:000283580600046
J	Sallusto, F; Lanzavecchia, A				Sallusto, Federica; Lanzavecchia, Antonio			Monocytes Join the Dendritic Cell Family	CELL			English	Editorial Material							INFECTION; RESPONSES	Dendritic cells are professional antigen-presenting cells that mediate immunity and tolerance. Cheong et al. (2010) uncover a new route for dendritic cell production in vivo. They show that in response to infection by gram-negative bacteria, monocytes are recruited to the lymph node where they rapidly differentiate into dendritic cells that present antigens to T cells.	[Sallusto, Federica; Lanzavecchia, Antonio] Inst Biomed Res, CH-6500 Bellinzona, Switzerland	Universita della Svizzera Italiana	Sallusto, F (corresponding author), Inst Biomed Res, CH-6500 Bellinzona, Switzerland.	federica.sallusto@irb.unisi.ch; lanzavecchia@irb.unisi.ch						Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Liu K, 2010, IMMUNOL REV, V234, P45, DOI 10.1111/j.0105-2896.2009.00879.x; Naik SH, 2006, NAT IMMUNOL, V7, P663, DOI 10.1038/ni1340; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schmid MA, 2010, IMMUNOL REV, V234, P32, DOI 10.1111/j.0105-2896.2009.00877.x; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7	10	19	19	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 29	2010	143	3					339	340		10.1016/j.cell.2010.10.022	http://dx.doi.org/10.1016/j.cell.2010.10.022			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029856	Bronze			2022-12-28	WOS:000283603900007
J	Tang, ASL; Wells, GA; Talajic, M; Arnold, MO; Sheldon, R; Connolly, S; Hohnloser, SH; Nichol, G; Birnie, DH; Sapp, JL; Yee, R; Healey, JS; Rouleau, JL				Tang, Anthony S. L.; Wells, George A.; Talajic, Mario; Arnold, Malcolm O.; Sheldon, Robert; Connolly, Stuart; Hohnloser, Stefan H.; Nichol, Graham; Birnie, David H.; Sapp, John L.; Yee, Raymond; Healey, Jeffrey S.; Rouleau, Jean L.		Resynchronization Defibrillation A	Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; INTRAVENTRICULAR-CONDUCTION DELAY; TRIAL; MULTICENTER; IMPROVEMENT; MANAGEMENT; DIAGNOSIS; MIRACLE	Background: Cardiac-resynchronization therapy (CRT) benefits patients with left ventricular systolic dysfunction and a wide QRS complex. Most of these patients are candidates for an implantable cardioverter-defibrillator (ICD). We evaluated whether adding CRT to an ICD and optimal medical therapy might reduce mortality and morbidity among such patients. Methods: We randomly assigned patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and an intrinsic QRS duration of 120 msec or more or a paced QRS duration of 200 msec or more to receive either an ICD alone or an ICD plus CRT. The primary outcome was death from any cause or hospitalization for heart failure. Results: We followed 1798 patients for a mean of 40 months. The primary outcome occurred in 297 of 894 patients (33.2%) in the ICD-CRT group and 364 of 904 patients (40.3%) in the ICD group (hazard ratio in the ICD-CRT group, 0.75; 95% confidence interval [CI], 0.64 to 0.87; P<0.001). In the ICD-CRT group, 186 patients died, as compared with 236 in the ICD group (hazard ratio, 0.75; 95% CI, 0.62 to 0.91; P=0.003), and 174 patients were hospitalized for heart failure, as compared with 236 in the ICD group (hazard ratio, 0.68; 95% CI, 0.56 to 0.83; P<0.001). However, at 30 days after device implantation, adverse events had occurred in 124 patients in the ICD-CRT group, as compared with 58 in the ICD group (P<0.001). Conclusions: Among patients with NYHA class II or III heart failure, a wide QRS complex, and left ventricular systolic dysfunction, the addition of CRT to an ICD reduced rates of death and hospitalization for heart failure. This improvement was accompanied by more adverse events. (Funded by the Canadian Institutes of Health Research and Medtronic of Canada; ClinicalTrials.gov number, NCT00251251.) N Engl J Med 2010;363:2385-95.	[Tang, Anthony S. L.] Univ British Columbia, Isl Med Program, Vancouver, BC V5Z 1M9, Canada; [Tang, Anthony S. L.; Wells, George A.; Birnie, David H.] Univ Ottawa, Inst Heart, Ottawa, ON, Canada; [Talajic, Mario; Rouleau, Jean L.] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Talajic, Mario; Rouleau, Jean L.] Univ Montreal, Montreal, PQ, Canada; [Arnold, Malcolm O.; Yee, Raymond] London Hlth Sci Ctr, London, ON, Canada; [Sheldon, Robert] Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB, Canada; [Connolly, Stuart; Healey, Jeffrey S.] Hamilton Hlth Sci Ctr, Hamilton, ON, Canada; [Sapp, John L.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany; [Nichol, Graham] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	University of British Columbia; University of Ottawa; University of Ottawa Heart Institute; Universite de Montreal; Universite de Montreal; London Health Sciences Centre; Libin Cardiovascular Institute Of Alberta; University of Calgary; McMaster University; Queen Elizabeth II Health Sciences Centre; Goethe University Frankfurt; Harborview Medical Center; University of Washington; University of Washington Seattle	Tang, ASL (corresponding author), 335-1900 Richmond Ave, Victoria, BC V8R 4R2, Canada.	atang@westerncardiology.ca	Nery, Pablo/D-1754-2011; Nichol, Graham/Z-4996-2019; Wells, George A/M-4549-2017; Yee, Raymond/H-1323-2011; Gula, Lorne/G-3298-2011; Tang, Anthony S/E-6203-2014; Heidbuchel, Hein/C-2331-2019; Willems, Rik/AAM-2392-2020; Sanders, Prashanthan/D-7641-2013	Wells, George A/0000-0002-2289-9139; Heidbuchel, Hein/0000-0001-9301-8127; Willems, Rik/0000-0002-5469-9609; Talajic, Mario/0000-0001-8469-4748; Howlett, Jonathan/0000-0002-0535-9771; Sanders, Prashanthan/0000-0003-3803-8429; Essebag, Vidal/0000-0003-0107-5197; Nuyens, Dieter/0000-0001-9390-3273; Kimber, Shane/0000-0002-5065-4390	Canadian Institutes of Health Research; Medtronic of Canada	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Medtronic of Canada	Supported by the Canadian Institutes of Health Research and Medtronic of Canada.	Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; Arnold JMO, 2006, CAN J CARDIOL, V22, P23, DOI 10.1016/S0828-282X(06)70237-9; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Chan KL, 2003, CAN J CARDIOL, V19, P387; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Curtis AB, 2009, CIRCULATION, V120, P921, DOI 10.1161/CIRCULATIONAHA.109.890335; Duray GZ, 2009, EUROPACE, V11, P297, DOI 10.1093/europace/eun322; Epstein AE, 2008, CIRCULATION, V117, pE350, DOI 10.1161/CIRCUALTIONAHA.108.189742; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064; Leon AR, 2005, J AM COLL CARDIOL, V46, P2348, DOI 10.1016/j.jacc.2005.08.031; Linde C, 2008, J AM COLL CARDIOL, V52, P1834, DOI 10.1016/j.jacc.2008.08.027; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Nelson GS, 2000, CIRCULATION, V102, P3053; Nelson GS, 2001, CIRCULATION, V103, P476; Sutton MGS, 2006, CIRCULATION, V113, P266, DOI 10.1161/CIRCULATIONAHA.104.520817; Tang AS, 2009, CURR OPIN CARDIOL, V24, P1, DOI 10.1097/HCO.0b013e32831bc63b; Ukkonen H, 2003, CIRCULATION, V107, P28, DOI 10.1161/01.CIR.0000047068.02226.95; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Ypenburg C, 2008, EUR HEART J, V29, P757, DOI 10.1093/eurheartj/ehn063	27	1180	1242	0	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2010	363	25					2385	2395		10.1056/NEJMoa1009540	http://dx.doi.org/10.1056/NEJMoa1009540			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694ZK	21073365				2022-12-28	WOS:000285340200004
J	Giorgi, C; Ito, K; Lin, HK; Santangelo, C; Wieckowski, MR; Lebiedzinska, M; Bononi, A; Bonora, M; Duszynski, J; Bernardi, R; Rizzuto, R; Tacchetti, C; Pinton, P; Pandolfi, PP				Giorgi, Carlotta; Ito, Keisuke; Lin, Hui-Kuan; Santangelo, Clara; Wieckowski, Mariusz R.; Lebiedzinska, Magdalena; Bononi, Angela; Bonora, Massimo; Duszynski, Jerzy; Bernardi, Rosa; Rizzuto, Rosario; Tacchetti, Carlo; Pinton, Paolo; Pandolfi, Pier Paolo			PML Regulates Apoptosis at Endoplasmic Reticulum by Modulating Calcium Release	SCIENCE			English	Article							CA2+ RELEASE; MITOCHONDRIA; BCL-2; CELLS	The promyelocytic leukemia (PML) tumor suppressor is a pleiotropic modulator of apoptosis. However, the molecular basis for such a diverse proapoptotic role is currently unknown. We show that extranuclear Pml was specifically enriched at the endoplasmic reticulum (ER) and at the mitochondria-associated membranes, signaling domains involved in ER-to-mitochondria calcium ion (Ca2+) transport and in induction of apoptosis. We found Pml in complexes of large molecular size with the inositol 1,4,5-trisphosphate receptor (IP3R), protein kinase Akt, and protein phosphatase 2a (PP2a). Pml was essential for Akt- and PP2a-dependent modulation of IP3R phosphorylation and in turn for IP3R-mediated Ca2+ release from ER. Our findings provide a mechanistic explanation for the pleiotropic role of Pml in apoptosis and identify a pharmacological target for the modulation of Ca2+ signals.	[Giorgi, Carlotta; Bononi, Angela; Bonora, Massimo; Pinton, Paolo] Univ Ferrara, Emilia Romagna Lab BioPharmaNet, Dept Expt & Diagnost Med, Sect Gen Pathol,ICSI, I-44100 Ferrara, Italy; [Giorgi, Carlotta; Bononi, Angela; Bonora, Massimo; Pinton, Paolo] Univ Ferrara, Lab Technol Adv Therapies, I-44100 Ferrara, Italy; [Giorgi, Carlotta] Univ Vita Salute San Raffaele, Ctr Excellence Cell Dev, Milan, Italy; [Giorgi, Carlotta] IIT Network, Res Unit Mol Neurosci, Milan, Italy; [Giorgi, Carlotta; Ito, Keisuke; Bernardi, Rosa; Pinton, Paolo; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Dept Med, Beth Israel Deaconess Canc Ctr,Canc Genet Program, Boston, MA 02215 USA; [Giorgi, Carlotta; Ito, Keisuke; Bernardi, Rosa; Pinton, Paolo; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr,Dept Pathol, Beth Israel Deaconess Canc Ctr,Canc Genet Program, Boston, MA 02215 USA; [Giorgi, Carlotta; Ito, Keisuke; Lin, Hui-Kuan; Bernardi, Rosa; Pinton, Paolo; Pandolfi, Pier Paolo] Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10065 USA; [Santangelo, Clara; Tacchetti, Carlo] Univ Genoa, Ctr Cell Oncol, IFOM FIRC Inst Mol Oncol Fdn, Genoa, Italy; [Santangelo, Clara; Tacchetti, Carlo] Univ Genoa, Dept Expt Med, Ultrastruct MicroSCoBiO Res Ctr, Genoa, Italy; [Wieckowski, Mariusz R.; Lebiedzinska, Magdalena; Duszynski, Jerzy] M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; [Bernardi, Rosa] San Raffaele Res Inst, Dept Mol Oncol, Milan, Italy; [Rizzuto, Rosario] Univ Padua, Dept Biomed Sci, Padua, Italy; [Tacchetti, Carlo] Ist Sci San Raffaele, Expt Imaging Ctr, I-20132 Milan, Italy	University of Ferrara; University of Ferrara; Vita-Salute San Raffaele University; Istituto Italiano di Tecnologia - IIT; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Memorial Sloan Kettering Cancer Center; IFOM - FIRC Institute of Molecular Oncology; University of Genoa; University of Genoa; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; University of Padua; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Pinton, P (corresponding author), Univ Ferrara, Emilia Romagna Lab BioPharmaNet, Dept Expt & Diagnost Med, Sect Gen Pathol,ICSI, I-44100 Ferrara, Italy.	pnp@unife.it; ppandolf@bidmc.harvard.edu	Lebiedzińska-Arciszewska, Magdalena/AAC-5956-2021; Lebiedzińska-Arciszewska, Magdalena/AAA-3279-2022; Pinton, Paolo/J-8025-2012; Giorgi, Carlotta/K-4649-2016; bernardi, rosa/B-1650-2013; Bonora, Massimo/AAC-3609-2022	Lebiedzińska-Arciszewska, Magdalena/0000-0002-2725-5551; Pinton, Paolo/0000-0001-7108-6508; bernardi, rosa/0000-0002-3607-6336; Bonora, Massimo/0000-0002-5752-3318; TACCHETTI, CARLO/0000-0003-4602-000X; Rizzuto, Rosario/0000-0001-7044-5097; Wieckowski, Mariusz/0000-0003-0789-4521; Giorgi, Carlotta/0000-0002-2494-7405; Duszynski, Jerzy/0000-0003-2937-6725; Pandolfi, Pier Paolo/0000-0002-5352-5295	National Cancer Institute; NIH; AIRC; FISM; Telethon; Ministry of Health; PRIN; FP7 "MyoAGE"; Cariparo Foundation; Ministry of Science and Higher Education in Poland; Polish Mitochondrial Network; NATIONAL CANCER INSTITUTE [R01CA102142, K99CA139009, R01CA071692, R01CA142874] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AIRC(Fondazione AIRC per la ricerca sul cancro); FISM(Fondazione Italiana Sclerosi Multipla (FISM)); Telethon(Fondazione Telethon); Ministry of Health; PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); FP7 "MyoAGE"; Cariparo Foundation(Fondazione Cariparo); Ministry of Science and Higher Education in Poland(Ministry of Science and Higher Education, Poland); Polish Mitochondrial Network; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grants from the National Cancer Institute (to P. P. P.); by K99 NIH (to I. K.); by AIRC, FISM, Telethon, Ministry of Health, and PRIN (to P. P.); by FP7 "MyoAGE", NIH, Cariparo Foundation, and AIRC (to R. R.); and by grants from the Ministry of Science and Higher Education in Poland and the Polish Mitochondrial Network (to M. L., J.D., and M. R. W.). We thank S. Missiroli, F. Poletti, and C. Agnoletto for carrying out some experiments, and J. Meldolesi and members of the Pandolfi and Pinton lab for stimulating discussions.	Bernardi R, 2008, ONCOGENE, V27, P6299, DOI 10.1038/onc.2008.305; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Giorgi C, 2008, CURR MOL MED, V8, P119; Giorgi C, 2009, INT J BIOCHEM CELL B, V41, P1817, DOI 10.1016/j.biocel.2009.04.010; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hayashi T, 2009, TRENDS CELL BIOL, V19, P81, DOI 10.1016/j.tcb.2008.12.002; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Marchi S, 2008, BIOCHEM BIOPH RES CO, V375, P501, DOI 10.1016/j.bbrc.2008.07.153; Mendes CCP, 2005, J BIOL CHEM, V280, P40892, DOI 10.1074/jbc.M506623200; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2007, METHOD CELL BIOL, V80, P297, DOI 10.1016/S0091-679X(06)80015-4; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Szado T, 2008, P NATL ACAD SCI USA, V105, P2427, DOI 10.1073/pnas.0711324105; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	21	305	316	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2010	330	6008					1247	1251		10.1126/science.1189157	http://dx.doi.org/10.1126/science.1189157			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	685FE	21030605	Green Accepted			2022-12-28	WOS:000284613700043
J	Scheschkewitz, D				Scheschkewitz, David			Comment on "Single-Crystal X-ray Structure of 1,3-Dimethylcyclobutadiene by Confinement in a Crystalline Matrix"	SCIENCE			English	Editorial Material								Legrand et al. (Reports, 16 July 2010, p. 299) reported on the photolytic reaction of an a-pyrone confined in a crystalline matrix. Their structural analysis invoked four products: activated precursor, isomeric Dewar beta-lactone, and square and rectangular isomers of 1,3-dimethylcyclobutadiene. The reported x-ray data, however, suggest that all observed structures correspond to only one distinct species, the Dewar beta-lactone.	Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England	Imperial College London	Scheschkewitz, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England.	d.scheschkewitz@imperial.ac.uk	Scheschkewitz, David/A-5050-2008	Scheschkewitz, David/0000-0001-5600-8034				Abersfelder K, 2010, SCIENCE, V327, P564, DOI 10.1126/science.1181771; Braunschweig H, 2008, ANGEW CHEM INT EDIT, V47, P1951, DOI 10.1002/anie.200704771; Demel O, 2008, J PHYS CHEM A, V112, P11895, DOI 10.1021/jp800577q; HEGMANN J, 1987, TETRAHEDRON LETT, V28, P6429, DOI 10.1016/S0040-4039(00)96879-5; Kaeobamrung J, 2009, ORG LETT, V11, P677, DOI 10.1021/ol802739d; Legrand YM, 2010, SCIENCE, V329, P299, DOI 10.1126/science.1188002; MAIER G, 1981, CHEM BER-RECL, V114, P3916, DOI 10.1002/cber.19811141214; Otto M, 2002, ANGEW CHEM INT EDIT, V41, P2275, DOI 10.1002/1521-3773(20020703)41:13<2275::AID-ANIE2275>3.0.CO;2-1; Scheschkewitz D, 1999, ANGEW CHEM INT EDIT, V38, P2936, DOI 10.1002/(SICI)1521-3773(19991004)38:19<2936::AID-ANIE2936>3.0.CO;2-9; Scheschkewitz D, 2000, ANGEW CHEM INT EDIT, V39, P1272, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1272::AID-ANIE1272>3.0.CO;2-Z; Tokhadze KG, 1996, J CHEM SOC FARADAY T, V92, P3473, DOI 10.1039/ft9969203473	11	20	20	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007								10.1126/science.1195752	http://dx.doi.org/10.1126/science.1195752			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097921	Bronze			2022-12-28	WOS:000284374700020
J	Chan, PS; Krumholz, HM; Spertus, JA; Jones, PG; Cram, P; Berg, RA; Peberdy, MA; Nadkarni, V; Mancini, ME; Nallamothu, BK				Chan, Paul S.; Krumholz, Harlan M.; Spertus, John A.; Jones, Philip G.; Cram, Peter; Berg, Robert A.; Peberdy, Mary Ann; Nadkarni, Vinay; Mancini, Mary E.; Nallamothu, Brahmajee K.		Amer Heart Assoc	Automated External Defibrillators and Survival After In-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUSTRALIAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE-PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; PROPENSITY SCORES; CHEST COMPRESSIONS; STROKE-FOUNDATION; SOUTHERN-AFRICA; TIME; STATEMENT	Context Automated external defibrillators (AEDs) improve survival from out-of-hospital cardiac arrests, but data on their effectiveness in hospitalized patients are limited. Objective To evaluate the association between AED use and survival for in-hospital cardiac arrest. Design, Setting, and Patients Cohort study of 11 695 hospitalized patients with cardiac arrests between January 1, 2000, and August 26, 2008, at 204 US hospitals following the introduction of AEDs on general hospital wards. Main Outcome Measure Survival to hospital discharge by AED use, using multivariable hierarchical regression analyses to adjust for patient factors and hospital site. Results Of 11 695 patients, 9616 (82.2%) had nonshockable rhythms (asystole and pulseless electrical activity) and 2079 (17.8%) had shockable rhythms (ventricular fibrillation and pulseless ventricular tachycardia). AEDs were used in 4515 patients (38.6%). Overall, 2117 patients (18.1%) survived to hospital discharge. Within the entire study population, AED use was associated with a lower rate of survival after in-hospital cardiac arrest compared with no AED use (16.3% vs 19.3%; adjusted rate ratio [RR], 0.85; 95% confidence interval [CI], 0.78-0.92; P<.001). Among cardiac arrests due to nonshockable rhythms, AED use was associated with lower survival (10.4% vs 15.4%; adjusted RR, 0.74; 95% CI, 0.65-0.83; P<.001). In contrast, for cardiac arrests due to shockable rhythms, AED use was not associated with survival (38.4% vs 39.8%; adjusted RR, 1.00; 95% CI, 0.88-1.13; P=.99). These patterns were consistently observed in both monitored and nonmonitored hospital units where AEDs were used, after matching patients to the individual units in each hospital where the cardiac arrest occurred, and with a propensity score analysis. Conclusion Among hospitalized patients with cardiac arrest, use of AEDs was not associated with improved survival. JAMA. 2010;304(19):2129-2136 www.jama.com	[Chan, Paul S.; Spertus, John A.; Jones, Philip G.] St Lukes Mid Amer Heart Inst, Kansas City, MO 64111 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA; [Krumholz, Harlan M.] Ctr Outcomes Res & Evaluat, New Haven, CT USA; [Cram, Peter] Univ Iowa, Iowa City, IA USA; [Berg, Robert A.; Nadkarni, Vinay] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Peberdy, Mary Ann] Virginia Commonwealth Univ, Richmond, VA USA; [Mancini, Mary E.] Univ Texas Arlington, Coll Nursing, Arlington, TX USA; [Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, Vet Affairs Ann Arbor Hlth Serv Res & Dev Ctr Exc, Div Cardiovasc Med, Ann Arbor, MI USA; [Nallamothu, Brahmajee K.] Univ Michigan, Sch Med, CHOP, Ann Arbor, MI USA	Saint Luke's Mid America Heart Institute; Yale University; Yale University; Yale University; Yale University; University of Iowa; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Virginia Commonwealth University; University of Texas System; University of Texas Arlington; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan	Chan, PS (corresponding author), St Lukes Mid Amer Heart Inst, 4401 Wornall Rd,5th Floor, Kansas City, MO 64111 USA.	pchan@cc-pc.com	, Harlan/AAI-2875-2020; Spertus, John/ABD-3075-2021; Cram, Peter/K-4472-2014	Cram, Peter/0000-0002-1910-346X	American Heart Association; National Heart, Lung, and Blood Institute [K23HL 102224]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL102224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG033035] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The American Heart Association provided funding for the collection and management of data in the NRCPR and reviewed and approved the final manuscript. Dr Chan is supported by a Career Development Grant Award (K23HL 102224) from the National Heart, Lung, and Blood Institute.	Bardy GH, 2008, NEW ENGL J MED, V358, P1793, DOI 10.1056/NEJMoa0801651; Berg MD, 2005, RESUSCITATION, V64, P287, DOI 10.1016/j.resuscitation.2004.07.017; Berg RA, 2003, ANN EMERG MED, V42, P458, DOI 10.1067/S0196-0644(03)00525-0; Bobrow BJ, 2008, JAMA-J AM MED ASSOC, V299, P1158, DOI 10.1001/jama.299.10.1158; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Chan PS, 2009, ARCH INTERN MED, V169, P1265, DOI 10.1001/archinternmed.2009.196; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; D'Agostino RB, 2007, CIRCULATION, V115, P2340, DOI 10.1161/CIRCULATIONAHA.105.594952; *ECC COMM, 2005, CIRCULATION S, V112, P35; Forcina MS, 2009, CRIT CARE MED, V37, P1229, DOI 10.1097/CCM.0b013e3181960ff3; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; Kaye W, 2005, RESUSCITATION, V65, P285, DOI 10.1016/j.resuscitation.2004.12.020; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; R Development Core Team, R PROJ STAT COMP; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Sanders AB, 2002, ANN EMERG MED, V40, P553, DOI 10.1067/mem.2002.129507; Saxon LA, 2008, NEW ENGL J MED, V358, P77, DOI 10.1056/NEJMe0707823; US Food and Drug Administration, EN LEV EXT BIPH DEF; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; van Alem AP, 2003, ANN EMERG MED, V42, P449, DOI 10.1067/S0196-0644(03)00383-4; Walker G.A., 2002, COMMON STAT METHODS, V2nd, P173; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; Zafari AM, 2004, J AM COLL CARDIOL, V44, P846, DOI 10.1016/j.jacc.2004.04.054; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; US EXTERNAL DEFIBRIL	34	68	71	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2129	2136		10.1001/jama.2010.1576	http://dx.doi.org/10.1001/jama.2010.1576			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21078809	Green Accepted, Bronze			2022-12-28	WOS:000284269800023
J	Lock, K; Smith, RD; Dangour, AD; Brown, MK; Pigatto, G; Hawkes, C; Fisberg, RM; Chalabi, Z				Lock, Karen; Smith, Richard D.; Dangour, Alan D.; Brown, Marcus Keogh; Pigatto, Gessuir; Hawkes, Corinna; Fisberg, Regina Mara; Chalabi, Zaid			Chronic Diseases: Chronic Diseases and Development 2 Health, agricultural, and economic effects of adoption of healthy diet recommendations	LANCET			English	Article							CORONARY-HEART-DISEASE; GLOBAL BURDEN; CONSUMPTION; RISK; TIME; FAT	Transition to diets that are high in saturated fat and sugar has caused a global public health concern as the pattern of food consumption is a mayor modifiable risk factor for chronic non-communicable diseases Although agri food systems are intimately associated with this transition, agriculture and health sectors are largely disconnected in their priorities policy, and analysis with neither side considering the complex inter relation between agri trade patterns of food consumption health, and development We show the importance of connection of these perspectives through estimation of the effect of adopting a healthy diet on population health, agricultural production trade the economy and livelihoods, with a computable general equilibrium approach On the basis of case studies from the UK and Brazil we suggest that benefits of a healthy diet policy will vary substantially between different populations, not only because of population dietary intake but also because of agricultural production trade and other economic factors	[Smith, Richard D.] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1H 9SH, England; [Lock, Karen; Smith, Richard D.; Dangour, Alan D.; Brown, Marcus Keogh; Chalabi, Zaid] Leverhulme Ctr Integrat Res Agr & Hlth, London, England; [Pigatto, Gessuir] Univ Estadual Paulista, Tupa, Brazil; [Hawkes, Corinna; Fisberg, Regina Mara] Univ Sao Paulo, Fac Publ Hlth, Sao Paulo, Brazil	University of London; London School of Hygiene & Tropical Medicine; Universidade Estadual Paulista; Universidade de Sao Paulo	Smith, RD (corresponding author), London Sch Hyg & Trop Med, Dept Global Hlth & Dev, 15-17 Tavistock Pl, London WC1H 9SH, England.		Fisberg, Regina Mara/Q-6494-2019; Fisberg, Regina M/C-4069-2012; Pigatto, Gessuir GP/F-9053-2012	Fisberg, Regina Mara/0000-0002-4490-9035; Fisberg, Regina M/0000-0002-4490-9035; Pigatto, Gessuir GP/0000-0002-5240-2381; Smith, Richard/0000-0003-3837-6559; Dangour, Alan/0000-0001-6908-1273; Keogh-Brown, Marcus/0000-0002-7556-0016				*ABEF, 2008, REL AN 2008 2009; *ABIPECS, 2008, REL AB 2008; Allender S., 2008, CORONARY HEART DIS S; [Anonymous], 2008, WORLD HLTH STAT 2008; Bates B, 2010, NATL DIET NUTR SURVE; Beutels P, 2008, HEALTH ECON, V17, P1317, DOI 10.1002/hec.1339; Castro Michelle Alessandra de, 2009, Rev. Saúde Pública, V43, P991, DOI 10.1590/S0034-89102009005000084; *CENTR INT AG, 2009, WORLD FACTB GDP COMP; Curioni C, 2009, REV PANAM SALUD PUBL, V25, P9, DOI 10.1590/S1020-49892009000100002; Daar AS, 2007, NATURE, V450, P494, DOI 10.1038/450494a; DEJESUS C, 2007, CADEIA CARNE FRANGO, P191; DENKE MA, 1991, AM J CLIN NUTR, V54, P1036, DOI 10.1093/ajcn/54.6.1036; Ezzati M, 2004, COMP QUANTIFICATION; *FAO, 2008, LIV LONG SHAD ENV IS; FAO, 2008, STAT FOOD INS WORLD; *FAO STAT DIV, 2009, SUMM WORLD FOOD AGR; Fisberg RM, 2006, J AM DIET ASSOC, V106, P2067, DOI 10.1016/j.jada.2006.09.010; Friel S, 2009, LANCET, V374, P2016, DOI 10.1016/S0140-6736(09)61753-0; GENEAU R, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61414-6; Hawkes C, 2010, TRADE FOOD DIET HLTH; Hawkes C, 2007, FOOD NUTR BULL, V28, pS312, DOI 10.1177/15648265070282S210; Hawkes C, 2006, B WORLD HEALTH ORGAN, V84, P984, DOI 10.2471/BLT.05.025650; *HLTH SAF EX, EST DAYS FULL DAY EQ; *HLTH SAF EX, EST INC RAT SELF REP; *HM GOV, 2008, FOOD MATT STRAT 21 C; Horridge M, 2008, EXERCISES CONTRIBUTI; Hu FB, 2001, J AM COLL NUTR, V20, P5, DOI 10.1080/07315724.2001.10719008; *IBGE, 2001, EST PESQ INF DEM SOC; *ILO, 2010, EC ACT POP 1950 2010; Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124; Keogh-Brown MR, 2010, EUR J HEALTH ECON, V11, P543, DOI 10.1007/s10198-009-0210-1; Lin HH, 2008, LANCET, V372, P1473, DOI 10.1016/S0140-6736(08)61345-8; Lock K, 2005, B WORLD HEALTH ORGAN, V83, P100; Lock K, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2403; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Moura EC, 2009, REV PANAM SALUD PUBL, V26, P17, DOI 10.1590/S1020-49892009000700003; Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252; *NAT, BRAZ LAB STATS; *OFF NAT STAT, 2010, LAB MARK STAT STAT B; *OFF NAT STAT, LAB FORC SURV 2005; Organization WH, 2009, GLOB HLTH RISKS MORT; Pattanayak SK, 2009, BE J ECON ANAL POLI, V9, DOI 10.2202/1935-1682.2096; Popkin BM, 1998, PUBLIC HEALTH NUTR, V1, P5, DOI 10.1079/PHN19980004; Popkin BM, 2004, NUTR REV, V62, pS140, DOI 10.1111/j.1753-4887.2004.tb00084.x; SCARF H, 1967, SIAM J APPL MATH, V15, P1328, DOI 10.1137/0115116; SCARF HE, 1967, 10 EC STUDIES TRADIT; Skeaff CM, 2009, ANN NUTR METAB, V55, P173, DOI 10.1159/000229002; Smith RD, 2006, APPL HEALTH ECON HEA, V5, P55, DOI 10.2165/00148365-200605010-00007; Smith RD, 2010, J PUBLIC HEALTH-UK, V32, P2, DOI 10.1093/pubmed/fdp122; Smith RD, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4571; Speedy AW, 2003, J NUTR, V133, p4048S, DOI 10.1093/jn/133.11.4048S; Srinivasan CS, 2006, FOOD POLICY, V31, P53, DOI 10.1016/j.foodpol.2005.08.002; Stamler J, 2010, AM J CLIN NUTR, V91, P497, DOI 10.3945/ajcn.2010.29216; TARINO PWS, 2010, AM J CLIN NUTR, V91, P502; *UN FAO, FAOSTAT FOOD CONS DA; *WCRF, 2007, FOOD NUTR PHYS ACT P, pCH10; *WHO FAO, 2003, TECHN REP SER WHO FA, V916; *WHO FAO, 2008, COD AL AN FOOD PROD; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; YACH D, 2004, GLOB STRAT DIET PHYS; Ye CY, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-62	61	78	79	2	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1699	1709		10.1016/S0140-6736(10)61352-9	http://dx.doi.org/10.1016/S0140-6736(10)61352-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	683DD	21074259				2022-12-28	WOS:000284451000035
J	Arrenberg, AB; Stainier, DYR; Baier, H; Huisken, J				Arrenberg, Aristides B.; Stainier, Didier Y. R.; Baier, Herwig; Huisken, Jan			Optogenetic Control of Cardiac Function	SCIENCE			English	Article							CONDUCTION SYSTEM; ZEBRAFISH; CHANNELRHODOPSIN-2; DISSECTION; BEHAVIOR	The cardiac pacemaker controls the rhythmicity of heart contractions and can be substituted by a battery-operated device as a last resort. We created a genetically encoded, optically controlled pacemaker by expressing halorhodopsin and channelrhodopsin in zebrafish cardiomyocytes. Using patterned illumination in a selective plane illumination microscope, we located the pacemaker and simulated tachycardia, bradycardia, atrioventricular blocks, and cardiac arrest. The pacemaker converges to the sinoatrial region during development and comprises fewer than a dozen cells by the time the heart loops. Perturbation of the activity of these cells was entirely reversible, demonstrating the resilience of the endogenous pacemaker. Our studies combine optogenetics and light-sheet microscopy to reveal the emergence of organ function during development.	[Stainier, Didier Y. R.; Huisken, Jan] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; [Stainier, Didier Y. R.; Huisken, Jan] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Arrenberg, Aristides B.; Baier, Herwig] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 95158 USA; [Arrenberg, Aristides B.] Univ Freiburg, Inst Biol 1, D-79104 Freiburg, Germany; [Huisken, Jan] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Freiburg; Max Planck Society	Stainier, DYR (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.	didier.stainier@ucsf.edu	Huisken, Jan/B-2472-2009	Huisken, Jan/0000-0001-7250-3756; Stainier, Didier/0000-0002-0382-0026; Arrenberg, Aristides/0000-0001-8262-7381	NIH [HL54737, R01 NS053358]; Packard Foundation; Sandler Opportunity Award; Byers Award for Basic Science; NIH Nanomedicine Development Center; Human Frontier Science Program (HFSP); Boehringer Ingelheim Fonds (B.I.F.); Krevans fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053358] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Packard Foundation(The David & Lucile Packard Foundation); Sandler Opportunity Award; Byers Award for Basic Science; NIH Nanomedicine Development Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier Science Program (HFSP)(Human Frontier Science Program); Boehringer Ingelheim Fonds (B.I.F.)(Boehringer Ingelheim); Krevans fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank T. Mikawa, R. Shaw, and A. Mussigbrodt for feedback and comments on the manuscript. Supported by NIH grant HL54737 (D.Y.R.S.), the Packard Foundation (D.Y.R.S.), NIH grant R01 NS053358 (H.B.), a Sandler Opportunity Award, the Byers Award for Basic Science (H.B.), and the NIH Nanomedicine Development Center "Optical Control of Biological Functions" (H.B.). J.H. was supported by a Human Frontier Science Program (HFSP) cross-disciplinary fellowship. A.B.A. was supported by a Boehringer Ingelheim Fonds (B.I.F.) and a Krevans fellowship. The optogenetic idea, transgenic lines, and original observation originated in H.B.'s lab; follow-up experiments were carried out in D.Y.R.S.'s lab as an equal collaboration between A.B.A. and J.H. All authors worked on the manuscript, which was drafted by A.B.A. and J.H.	Arrenberg AB, 2009, P NATL ACAD SCI USA, V106, P17968, DOI 10.1073/pnas.0906252106; Ayling OGS, 2009, NAT METHODS, V6, P219, DOI [10.1038/NMETH.1303, 10.1038/nmeth.1303]; Baier H, 2009, CURR OPIN NEUROBIOL, V19, P553, DOI 10.1016/j.conb.2009.08.001; Beis D, 2005, DEVELOPMENT, V132, P4193, DOI 10.1242/dev.01970; Chi NC, 2008, PLOS BIOL, V6, P1006, DOI 10.1371/journal.pbio.0060109; Douglass AD, 2008, CURR BIOL, V18, P1133, DOI 10.1016/j.cub.2008.06.077; Hahn C, 2009, NAT REV MOL CELL BIO, V10, P53, DOI 10.1038/nrm2596; Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282; Huisken J, 2004, SCIENCE, V305, P1007, DOI 10.1126/science.1100035; Huisken J, 2007, OPT LETT, V32, P2608, DOI 10.1364/OL.32.002608; Jenkins MW, 2010, NAT PHOTONICS, V4, P623, DOI 10.1038/NPHOTON.2010.166; Jongbloed MRM, 2008, THESCIENTIFICWORLDJO, V8, P239, DOI 10.1100/tsw.2008.40; KAMINO K, 1981, NATURE, V290, P595, DOI 10.1038/290595a0; Luo L, 2008, NEURON, V57, P634, DOI 10.1016/j.neuron.2008.01.002; Mikawa T, 2007, SEMIN CELL DEV BIOL, V18, P90, DOI 10.1016/j.semcdb.2006.12.008; Milan DJ, 2006, DEVELOPMENT, V133, P1125, DOI 10.1242/dev.02279; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Nygren A, 1998, CIRC RES, V82, P63; Scanziani M, 2009, NATURE, V461, P930, DOI 10.1038/nature08540; SCHERF D., 1927, ZEIT SCHR GES EXP MED, V57, P188, DOI 10.1007/BF02610224; Scherz PJ, 2008, DEVELOPMENT, V135, P1179, DOI 10.1242/dev.010694; Scott EK, 2007, NAT METHODS, V4, P323, DOI 10.1038/NMETH1033; Sedmera D, 2003, AM J PHYSIOL-HEART C, V284, pH1152, DOI 10.1152/ajpheart.00870.2002; Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875; Szobota S, 2007, NEURON, V54, P535, DOI 10.1016/j.neuron.2007.05.010; WILDERS R, 2007, C P IEEE ENG MED BIO, P152; Wyart C, 2009, NATURE, V461, P407, DOI 10.1038/nature08323; Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744	28	316	327	7	206	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2010	330	6006					971	974		10.1126/science.1195929	http://dx.doi.org/10.1126/science.1195929			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071670				2022-12-28	WOS:000284118000045
J	Beggs, S; Salter, MW				Beggs, Simon; Salter, Michael W.			A Straightjacket for Pain?	CELL			English	Editorial Material							CALCIUM-CHANNELS		[Beggs, Simon; Salter, Michael W.] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Salter, MW (corresponding author), Hosp Sick Children, Program Neurosci & Mental Hlth, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mike.salter@utoronto.ca	Beggs, Simon/AAI-4438-2021	Beggs, Simon/0000-0002-1582-8391				Bauer CS, 2010, CURR OPIN NEUROBIOL, V20, P563, DOI 10.1016/j.conb.2010.05.007; Davies A, 2010, P NATL ACAD SCI USA, V107, P1654, DOI 10.1073/pnas.0908735107; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Dolphin AC, 2009, CURR OPIN NEUROBIOL, V19, P237, DOI 10.1016/j.conb.2009.06.006; Field MJ, 2006, P NATL ACAD SCI USA, V103, P17537, DOI 10.1073/pnas.0409066103; Kurshan PT, 2009, NAT NEUROSCI, V12, P1415, DOI 10.1038/nn.2417; Neely GG, 2010, CELL, V143, P628, DOI 10.1016/j.cell.2010.09.047	7	1	1	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					505	507		10.1016/j.cell.2010.10.038	http://dx.doi.org/10.1016/j.cell.2010.10.038			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074043	Bronze			2022-12-28	WOS:000284149100009
J	Han, DW; Tapia, N; Joo, JY; Greber, B; Arauzo-Bravo, MJ; Bernemann, C; Ko, K; Wu, GM; Stehling, M; Do, JT; Scholer, HR				Han, Dong Wook; Tapia, Natalia; Joo, Jin Young; Greber, Boris; Arauzo-Bravo, Marcos J.; Bernemann, Christof; Ko, Kinarm; Wu, Guangming; Stehling, Martin; Do, Jeong Tae; Schoeler, Hans R.			Epiblast Stem Cell Subpopulations Represent Mouse Embryos of Distinct Pregastrulation Stages	CELL			English	Article							CLONAL ANALYSIS; GROUND-STATE; PLURIPOTENCY; EXPRESSION; NANOG; LINES; CYCLE; MICE	Embryonic stem cells (ESCs) comprise at least two populations of cells with divergent states of pluripotency. Here, we show that epiblast stem cells (EpiSCs) also comprise two distinct cell populations that can be distinguished by the expression of a specific Oct4-GFP marker. These two subpopulations, Oct4-GFP positive and negative EpiSCs, are capable of converting into each other in vitro. Oct4-GFP positive and negative EpiSCs are distinct from ESCs with respect to global gene expression pattern, epigenetic profile, and Oct4 enhancer utilization. Oct4-GFP negative cells share features with cells of the late mouse epiblast and cannot form chimeras. However, Oct4-GFP positive EpiSCs, which only represent a minor EpiSC fraction, resemble cells of the early epiblast and can readily contribute to chimeras. Our findings suggest that the rare ability of EpiSCs to contribute to chimeras is due to the presence of the minor EpiSC fraction representing the early epiblast.	[Han, Dong Wook; Tapia, Natalia; Joo, Jin Young; Greber, Boris; Arauzo-Bravo, Marcos J.; Bernemann, Christof; Wu, Guangming; Stehling, Martin; Schoeler, Hans R.] Max Planck Inst Mol Biomed, Dept Cell & Dev Biol, D-48149 Munster, Germany; [Ko, Kinarm] Konkuk Univ, Inst Biomed Sci & Technol, Ctr Stem Cell Res, Seoul 143701, South Korea; [Ko, Kinarm] Konkuk Univ, Sch Med, Dept Neurosci, Seoul 143701, South Korea; [Do, Jeong Tae] CHA Univ, CHA Stem Cell Inst, Lab Stem Cell & Dev Biol, Seoul 135081, South Korea; [Schoeler, Hans R.] Univ Munster, Fac Med, D-48149 Munster, Germany	Max Planck Society; Konkuk University; Konkuk University; Konkuk University Medical Center; Pochon Cha University; University of Munster	Scholer, HR (corresponding author), Max Planck Inst Mol Biomed, Dept Cell & Dev Biol, Rontgenstr 20, D-48149 Munster, Germany.	office@mpi-muenster.mpg.de	Marcos, Arauzo-Bravo/A-1706-2011; , HS/AAB-4434-2019; Han, Dong Wook/D-6041-2011; Tapia, Natalia/H-5500-2012	Marcos, Arauzo-Bravo/0000-0002-3264-464X; , HS/0000-0003-2643-5136; Do, Jeong Tae/0000-0001-6721-1441; Greber, Boris/0000-0002-9404-7293; Tapia, Natalia/0000-0003-0226-1952; Wu, Guangming/0000-0003-1923-7609	Federal Ministry of Education and Research (BMBF) initiative [01GN0539]	Federal Ministry of Education and Research (BMBF) initiative(Federal Ministry of Education & Research (BMBF))	We are indebted to all members of the Scholer laboratory for fruitful discussions on the results. We are especially grateful to Dr. Paul Tesar for providing the T9 EpiSC line. We are also grateful to Goran Key, Inge Sobek-Klocke, Martina Sinn, and David Obridge for technical assistance and Areti Malapetsas for editing the manuscript. This work was supported by the Federal Ministry of Education and Research (BMBF) initiative "Cell-Based Regenerative Medicine" (Grant 01GN0539).	Bao SQ, 2009, NATURE, V461, P1292, DOI 10.1038/nature08534; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Buehr M, 2003, PHILOS T R SOC B, V358, P1397, DOI 10.1098/rstb.2003.1327; Carter MG, 2008, GENE EXPR PATTERNS, V8, P181, DOI 10.1016/j.gep.2007.10.009; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chou YF, 2008, CELL, V135, P449, DOI 10.1016/j.cell.2008.08.035; Furusawa T, 2004, BIOL REPROD, V70, P1452, DOI 10.1095/biolreprod.103.024190; GARDNER RL, 1985, J EMBRYOL EXP MORPH, V88, P349; Greber B, 2010, CELL STEM CELL, V6, P215, DOI 10.1016/j.stem.2010.01.003; Guo G, 2009, DEVELOPMENT, V136, P1063, DOI 10.1242/dev.030957; Han DW, 2008, STEM CELLS, V26, P445, DOI 10.1634/stemcells.2007-0553; Han DW, 2009, STEM CELLS, V27, P1088, DOI 10.1002/stem.43; Hanna J, 2009, CELL STEM CELL, V4, P513, DOI 10.1016/j.stem.2009.04.015; Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Lovell-Badge R, 2007, NAT BIOTECHNOL, V25, P1114, DOI 10.1038/nbt1007-1114; Rivera-Perez JA, 2005, DEV BIOL, V288, P363, DOI 10.1016/j.ydbio.2005.09.012; Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Toyooka Y, 2008, DEVELOPMENT, V135, P909, DOI 10.1242/dev.017400; Western P, 2005, STEM CELLS, V23, P1436, DOI 10.1634/stemcells.2005-0146; Yeom YI, 1996, DEVELOPMENT, V122, P881; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoshimizu T, 1999, DEV GROWTH DIFFER, V41, P675	25	166	172	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					617	627		10.1016/j.cell.2010.10.015	http://dx.doi.org/10.1016/j.cell.2010.10.015			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21056461	Bronze			2022-12-28	WOS:000284149100018
J	Clarkson, AN; Huang, BS; MacIsaac, SE; Mody, I; Carmichael, ST				Clarkson, Andrew N.; Huang, Ben S.; MacIsaac, Sarah E.; Mody, Istvan; Carmichael, S. Thomas			Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke	NATURE			English	Article							RECEPTOR SUBUNITS; ALPHA-5 SUBUNIT; PLASTICITY; BRAIN; MECHANISMS; RATS; MICE; REORGANIZATION; CONDUCTANCES; ACTIVATION	Stroke is a leading cause of disability, but no pharmacological therapy is currently available for promoting recovery. The brain region adjacent to stroke damage-the peri-infarct zone-is critical for rehabilitation, as it shows heightened neuroplasticity, allowing sensorimotor functions to re-map from damaged areas(1-3). Thus, understanding the neuronal properties constraining this plasticity is important for the development of new treatments. Here we show that after a stroke in mice, tonic neuronal inhibition is increased in the peri-infarct zone. This increased tonic inhibition is mediated by extrasynaptic GABA(A) receptors and is caused by an impairment in GABA (gamma-aminobutyric acid) transporter (GAT-3/GAT-4) function. To counteract the heightened inhibition, we administered in vivo a benzodiazepine inverse agonist specific for alpha 5-subunit-containing extrasynaptic GABA(A) receptors at a delay after stroke. This treatment produced an early and sustained recovery of motor function. Genetically lowering the number of alpha 5- or delta-subunit-containing GABA(A) receptors responsible for tonic inhibition also proved beneficial for recovery after stroke, consistent with the therapeutic potential of diminishing extrasynaptic GABA(A) receptor function. Together, our results identify new pharmacological targets and provide the rationale for a novel strategy to promote recovery after stroke and possibly other brain injuries.	[Clarkson, Andrew N.; Huang, Ben S.; MacIsaac, Sarah E.; Mody, Istvan; Carmichael, S. Thomas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Huang, Ben S.; Mody, Istvan] Univ Calif Los Angeles, David Geffen Sch Med, Interdept PhD Program Neurosci, Los Angeles, CA 90095 USA; [Mody, Istvan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Carmichael, ST (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 635 Charles Young Dr S, Los Angeles, CA 90095 USA.	scarmichael@mednet.ucla.edu	Huang, Ben S./AAH-8370-2019	Huang, Ben S./0000-0003-2838-6315; Carmichael, S Thomas/0000-0002-1169-9203; Clarkson, Andrew/0000-0003-3804-3834	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Larry L. Hillblom Foundation; Coelho Endowment; National Institutes of Health/National Institute of Neurological Disorders and Stroke [NS30549]; American Heart Association; New Zealand Neurological Foundation; Health Research Council of New Zealand; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS030549, R01NS030549] Funding Source: NIH RePORTER	Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Larry L. Hillblom Foundation; Coelho Endowment; National Institutes of Health/National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); American Heart Association(American Heart Association); New Zealand Neurological Foundation; Health Research Council of New Zealand(Health Research Council of New Zealand); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	I.M., A.N.C. and S.T.C. were supported by The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. S.T.C. was supported by the Larry L. Hillblom Foundation, I. M. was supported by the Coelho Endowment and National Institutes of Health/National Institute of Neurological Disorders and Stroke grant NS30549. This manuscript was completed partially during tenure of an American Heart Association Postdoctoral Fellowship, a Repatriation Fellowship from the New Zealand Neurological Foundation and the Sir Charles Hercus Fellowship from the Health Research Council of New Zealand (A.N.C.). We thank E. O. Mann, J. Chu, J. J. Overman, J. Zhong and R. M. Lazaro for discussion and assistance.	Alonso-Alonso Miguel, 2007, Cerebrovasc Dis, V24 Suppl 1, P157, DOI 10.1159/000107392; Atack JR, 2006, NEUROPHARMACOLOGY, V51, P1023, DOI 10.1016/j.neuropharm.2006.04.018; BARLOW R, 1990, TRENDS PHARMACOL SCI, V11, P404, DOI 10.1016/0165-6147(90)90146-Y; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brown CE, 2009, J NEUROSCI, V29, P1719, DOI 10.1523/JNEUROSCI.4249-08.2009; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Collinson N, 2002, J NEUROSCI, V22, P5572; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; Cui YJ, 2008, CELL, V135, P549, DOI 10.1016/j.cell.2008.09.060; Di Lazzaro V, 2010, CEREB CORTEX, V20, P1523, DOI 10.1093/cercor/bhp216; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Dobkin BH, 2008, NAT CLIN PRACT NEURO, V4, P76, DOI 10.1038/ncpneuro0709; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P492; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2009, STROKE, V40, pE288, DOI 10.1161/STROKEAHA.109.551820; Foeller E, 2005, J NEUROPHYSIOL, V94, P4387, DOI 10.1152/jn.00553.2005; Frahm C, 2004, J COMP NEUROL, V478, P176, DOI 10.1002/cne.20282; Ginsberg MD, 2008, NEUROPHARMACOLOGY, V55, P363, DOI 10.1016/j.neuropharm.2007.12.007; Glykys J, 2006, J NEUROPHYSIOL, V95, P2796, DOI 10.1152/jn.01122.2005; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; Glykys J, 2007, NEURON, V56, P763, DOI 10.1016/j.neuron.2007.11.002; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hess G, 1996, J NEUROPHYSIOL, V75, P1765, DOI 10.1152/jn.1996.75.5.1765; Keros S, 2005, J NEUROPHYSIOL, V94, P2073, DOI 10.1152/jn.00520.2005; Kharlamov EA, 2008, BRAIN RES, V1210, P29, DOI 10.1016/j.brainres.2008.02.070; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Moore CS, 2008, J NEUROIMMUNOL, V203, P79, DOI 10.1016/j.jneuroim.2008.06.030; Neumann-Haefelin T, 1998, NEUROSCIENCE, V87, P871, DOI 10.1016/S0306-4522(98)00124-9; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Que M, 1999, NEUROSCIENCE, V93, P1233, DOI 10.1016/S0306-4522(99)00197-9; Redecker C, 2000, J NEUROSCI, V20, P5045; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Stell BM, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0003.2002; Tanaka Y, 2008, J NEUROSCI METH, V171, P118, DOI 10.1016/j.jneumeth.2008.02.021; Verheugen JAH, 1999, J NEUROSCI, V19, P2546; Walker Matthew C., 2008, V44, P29, DOI 10.1007/400_2007_030; Yoshiike Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003029	38	574	593	2	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					305	U193		10.1038/nature09511	http://dx.doi.org/10.1038/nature09511			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21048709	Green Accepted, Green Submitted			2022-12-28	WOS:000284051000051
J	Sarewitz, D				Sarewitz, Daniel			Double trouble? To throw cash at science is a mistake	NATURE			English	Editorial Material									Arizona State Univ, Consortium Sci Policy & Outcomes, Washington, DC USA	Arizona State University	Sarewitz, D (corresponding author), Arizona State Univ, Consortium Sci Policy & Outcomes, Washington, DC USA.	dsarewitz@gmail.com							0	3	3	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					135	135		10.1038/468135a	http://dx.doi.org/10.1038/468135a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678DG	21068785	Bronze			2022-12-28	WOS:000284051000004
J	Brawley, SJ; Armitage, S; Beale, J; Leslie, DE; Williams, AI; Laricchia, G				Brawley, S. J.; Armitage, S.; Beale, J.; Leslie, D. E.; Williams, A. I.; Laricchia, G.			Electron-Like Scattering of Positronium	SCIENCE			English	Article									[Brawley, S. J.; Armitage, S.; Beale, J.; Leslie, D. E.; Williams, A. I.; Laricchia, G.] UCL, UCL Dept Phys & Astron, London WC1E 6BT, England	University of London; University College London	Laricchia, G (corresponding author), UCL, UCL Dept Phys & Astron, Gower St, London WC1E 6BT, England.	g.laricchia@ucl.ac.uk		Laricchia, Gaetana/0000-0002-0586-6474	Engineering and Physical Sciences Research Council [EP/E053521/1, GR/S16041/01] Funding Source: researchfish; EPSRC [EP/E053521/1] Funding Source: UKRI	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Basu A, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.052503; Blackwood JE, 1999, PHYS REV A, V60, P4454, DOI 10.1103/PhysRevA.60.4454; Blackwood JE, 2002, J PHYS B-AT MOL OPT, V35, P2661, DOI 10.1088/0953-4075/35/12/303; Boudaiffa B, 2000, SCIENCE, V287, P1658, DOI 10.1126/science.287.5458.1658; Champion C, 2007, PHYS MED BIOL, V52, P6605, DOI 10.1088/0031-9155/52/22/004; Garner AJ, 1996, J PHYS B-AT MOL OPT, V29, P5961, DOI 10.1088/0953-4075/29/23/035; KAUPPILA WE, 1990, ADV ATOM MOL OPT PHY, V26, P1; Kinzer R.L., 1996, A ASS, V120, P317; Sarkadi L, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032706; Starrett C, 2005, PHYS REV A, V72, DOI 10.1103/PhysRevA.72.012508	10	86	86	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					789	789		10.1126/science.1192322	http://dx.doi.org/10.1126/science.1192322			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051631				2022-12-28	WOS:000283855700034
J	Levi, M; Levy, JH; Andersen, HF; Truloff, D				Levi, Marcel; Levy, Jerrold H.; Andersen, Henning Friis; Truloff, David			Safety of Recombinant Activated Factor VII in Randomized Clinical Trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COAGULATION-FACTOR-VII; DOUBLE-BLIND; INTRACEREBRAL HEMORRHAGE; RISK-FACTORS; EFFICACY; CIRRHOSIS; THERAPY; SURGERY; PHARMACOKINETICS; TRANSFUSION	Background: The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat life-threatening bleeding has been associated with a perceived increased risk of thromboembolic complications. However, data from placebo-controlled trials are needed to properly assess the thromboembolic risk. To address this issue, we evaluated the rate of thromboembolic events in all published randomized, placebo-controlled trials of rFVIIa used on an off-label basis. Methods: We analyzed data from 35 randomized clinical trials (26 studies involving patients and 9 studies involving healthy volunteers) to determine the frequency of thromboembolic events. The data were pooled with the use of random-effects models to calculate the odds ratios and 95% confidence intervals. Results: Among 4468 subjects (4119 patients and 349 healthy volunteers), 498 had thromboembolic events (11.1%). Rates of arterial thromboembolic events among all 4468 subjects were higher among those who received rFVIIa than among those who received placebo (5.5% vs. 3.2%, P=0.003). Rates of venous thromboembolic events were similar among subjects who received rFVIIa and those who received placebo (5.3% vs. 5.7%). Among subjects who received rFVIIa, 2.9% had coronary arterial thromboembolic events, as compared with 1.1% of those who received placebo (P=0.002). Rates of arterial thromboembolic events were highest among subjects older than 65 years of age, as compared with those who were 65 years of age or younger (9.0% vs. 3.8%, P=0.003); the rates were especially high among subjects 75 years of age or older, as compared with those who were younger than 75 years of age (10.8% vs. 4.1%, P=0.02). Conclusions: In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.) N Engl J Med 2010;363:1791-800.	[Levi, Marcel] Univ Amsterdam, Acad Med Ctr, Dept Med F4, NL-1105 AZ Amsterdam, Netherlands; [Levy, Jerrold H.] Emory Univ, Sch Med, Atlanta, GA USA; [Andersen, Henning Friis; Truloff, David] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	University of Amsterdam; Academic Medical Center Amsterdam; Emory University; Novo Nordisk	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med F4, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020		Novo Nordisk	Novo Nordisk(Novo Nordisk)	Supported by Novo Nordisk.	Abbott RD, 2003, J CLIN EPIDEMIOL, V56, P479, DOI 10.1016/S0895-4356(02)00611-X; Abshire T, 2008, SEMIN HEMATOL, V45, pS3, DOI 10.1053/j.seminhematol.2008.03.006; Aledort LM, 2004, J THROMB HAEMOST, V2, P1700, DOI 10.1111/j.1538-7836.2004.00944.x; Bijsterveld NR, 2004, BRIT J HAEMATOL, V124, P653, DOI 10.1111/j.1365-2141.2003.04811.x; Bijsterveld NR, 2002, CIRCULATION, V106, P2550, DOI 10.1161/01.CIR.0000038501.87442.02; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bosch J, 2004, GASTROENTEROLOGY, V127, P1123, DOI 10.1053/j.gastro.2004.07.015; Bosch J, 2008, HEPATOLOGY, V47, P1604, DOI 10.1002/hep.22216; CARRENO V, 2001, 18 C INT SOC THROMB, pP2612; Chuansumrit A, 2005, BLOOD COAGUL FIBRIN, V16, P549, DOI 10.1097/01.mbc.0000186837.78432.2f; Diprose P, 2005, BRIT J ANAESTH, V95, P596, DOI 10.1093/bja/aei244; Ekert H, 2006, BLOOD COAGUL FIBRIN, V17, P389, DOI 10.1097/01.mbc.0000233369.03358.c1; Erhardtsen E, 1998, BLOOD COAGUL FIBRIN, V9, P741, DOI 10.1097/00001721-199811000-00003; Fridberg MJ, 2005, BLOOD COAGUL FIBRIN, V16, P259, DOI 10.1097/01.mbc.0000169218.15926.34; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Friederich PW, 2003, LANCET, V361, P1138; Friederich PW, 2001, CIRCULATION, V103, P2555; Gill R, 2009, CIRCULATION, V120, P21, DOI 10.1161/CIRCULATIONAHA.108.834275; Hedner U, 2008, THROMB HAEMOSTASIS, V100, P557, DOI 10.1160/TH08-07-0434; Hedner U, 2006, SEMIN THROMB HEMOST, V32, P77, DOI 10.1055/s-2006-939557; Heit JA, 2005, J THROMB HAEMOST, V3, P1611, DOI 10.1111/j.1538-7836.2005.01415.x; Levi M, 2005, CRIT CARE MED, V33, P883, DOI 10.1097/01.CCM.0000159087.85970.38; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lodge JPA, 2005, LIVER TRANSPLANT, V11, P973, DOI 10.1002/lt.20470; Lodge JPA, 2005, ANESTHESIOLOGY, V102, P269, DOI 10.1097/00000542-200502000-00006; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2005, STROKE, V36, P74, DOI 10.1161/01.STR.0000149628.80251.b8; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mayer SA, 2006, NEUROCRIT CARE, V4, P206, DOI 10.1385/NCC:4:3:206; Murphy GJ, 2007, CIRCULATION, V116, P2544, DOI 10.1161/CIRCULATIONAHA.107.698977; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Pihusch M, 2005, J THROMB HAEMOST, V3, P1935, DOI 10.1111/j.1538-7836.2005.01523.x; Planinsic RM, 2005, LIVER TRANSPLANT, V11, P895, DOI 10.1002/lt.20458; Raobaikady R, 2005, BRIT J ANAESTH, V94, P586, DOI 10.1093/bja/aei102; Rosendaal FR, 1999, THROMB HAEMOSTASIS, V82, P610; Sachs B, 2007, SPINE, V32, P2285, DOI 10.1097/BRS.0b013e3181557d45; Samama MM, 2000, ARCH INTERN MED, V160, P3415, DOI 10.1001/archinte.160.22.3415; Shao YF, 2006, AM J SURG, V191, P245, DOI 10.1016/j.amjsurg.2005.10.019; Villar A, 2004, HAEMOPHILIA, V10, P352, DOI 10.1111/j.1365-2516.2004.00925.x; Wolzt M, 2004, THROMB HAEMOSTASIS, V91, P1090, DOI 10.1160/TH03-09-0605	41	445	466	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1791	1800		10.1056/NEJMoa1006221	http://dx.doi.org/10.1056/NEJMoa1006221			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047223				2022-12-28	WOS:000283787800004
J	Prum, RO				Prum, Richard O.			Moulting tail feathers in a juvenile oviraptorisaur	NATURE			English	Letter									[Prum, Richard O.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; [Prum, Richard O.] Yale Univ, Peabody Nat Hist Museum, New Haven, CT 06520 USA	Yale University; Yale University	Prum, RO (corresponding author), Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA.	richard.prum@Yale.edu		Prum, Richard/0000-0002-4741-7132				Lucas A., 1972, AVIAN ANATOMY INTEGU; Prum RO, 2001, J EXP ZOOL, V291, P30, DOI 10.1002/jez.4; Xu X, 2010, NATURE, V464, P1338, DOI 10.1038/nature08965	3	10	11	0	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					E1	E1		10.1038/nature09480	http://dx.doi.org/10.1038/nature09480			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048715	Bronze			2022-12-28	WOS:000283786900001
J	Schurks, M; Glynn, RJ; Rist, PM; Tzourio, C; Kurth, T				Schuerks, Markus; Glynn, Robert J.; Rist, Pamela M.; Tzourio, Christophe; Kurth, Tobias			Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; SECONDARY PREVENTION; E SUPPLEMENTATION; ANTIOXIDANT VITAMINS; ALPHA-TOCOPHEROL; WOMENS-HEALTH; BETA-CAROTENE; E CONSUMPTION; RISK	Objective To evaluate the effect of vitamin E supplementation on incident total, ischaemic, and haemorrhagic stroke. Design Systematic review and meta-analysis of randomised, placebo controlled trials published until January 2010. Data sources Electronic databases (Medline, Embase, Cochrane Central Register of Controlled Trials) and reference lists of trial reports. Selection criteria Randomised, placebo controlled trials with >= 1 year of follow-up investigating the effect of vitamin E on stroke. Review methods and data extraction Two investigators independently assessed eligibility of identified trials. Disagreements were resolved by consensus. Two different investigators independently extracted data. Risk ratios (and 95% confidence intervals) were calculated for each trial based on the number of cases and non-cases randomised to vitamin E or placebo. Pooled effect estimates were then calculated. Results Nine trials investigating the effect of vitamin E on incident stroke were included, totalling 118 765 participants (59 357 randomised to vitamin E and 59 408 to placebo). Among those, seven trials reported data for total stroke and five trials each for haemorrhagic and ischaemic stroke. Vitamin E had no effect on the risk for total stroke (pooled relative risk 0.98 (95% confidence interval 0.91 to 1.05), P=0.53). In contrast, the risk for haemorrhagic stroke was increased (pooled relative risk 1.22 (1.00 to 1.48), P=0.045), while the risk of ischaemic stroke was reduced (pooled relative risk 0.90 (0.82 to 0.99), P=0.02). There was little evidence for heterogeneity among studies. Meta-regression did not identify blinding strategy, vitamin E dose, or morbidity status of participants as sources of heterogeneity. In terms of absolute risk, this translates into one additional haemorrhagic stroke for every 1250 individuals taking vitamin E, in contrast to one ischaemic stroke prevented per 476 individuals taking vitamin E. Conclusion In this meta-analysis, vitamin E increased the risk for haemorrhagic stroke by 22% and reduced the risk of ischaemic stroke by 10%. This differential risk pattern is obscured when looking at total stroke. Given the relatively small risk reduction of ischaemic stroke and the generally more severe outcome of haemorrhagic stroke, indiscriminate widespread use of vitamin E should be cautioned against.	[Schuerks, Markus; Glynn, Robert J.; Rist, Pamela M.; Kurth, Tobias] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, Boston, MA 02215 USA; [Rist, Pamela M.; Kurth, Tobias] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Glynn, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Tzourio, Christophe; Kurth, Tobias] INSERM, Neuroepidemiol U708, Paris, France; [Tzourio, Christophe; Kurth, Tobias] Univ Paris 06, F-75005 Paris, France; [Schuerks, Markus] Univ Hosp Essen, Dept Neurol, Essen, Germany	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Duisburg Essen	Schurks, M (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med,Dept Med, Boston, MA 02215 USA.	mschuerks@rics.bwh.harvard.edu; tobias.kurth@upmc.fr	Tzourio, christophe/B-4015-2009; Kurth, Tobias/A-9243-2012; Tzourio, christophe/L-6344-2019	Tzourio, christophe/0000-0002-6517-2984; Kurth, Tobias/0000-0001-7169-2620; Tzourio, christophe/0000-0002-6517-2984				Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Brigelius-Flohe R, 2009, FREE RADICAL BIO MED, V46, P543, DOI 10.1016/j.freeradbiomed.2008.12.007; Chiu D, 2010, J STROKE CEREBROVASC, V19, P225, DOI 10.1016/j.jstrokecerebrovasdis.2009.06.002; Chiuve SE, 2008, CIRCULATION, V118, P947, DOI 10.1161/CIRCULATIONAHA.108.781062; Clarke MW, 2008, CRIT REV CL LAB SCI, V45, P417, DOI [10.1080/10408360802118625, 10.1080/10408360802118625 ]; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Cook NR, 2007, ARCH INTERN MED, V167, P1610, DOI 10.1001/archinte.167.15.1610; Deeks J.J., 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Eidelman RS, 2004, ARCH INTERN MED, V164, P1552, DOI 10.1001/archinte.164.14.1552; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; Glynn RJ, 2007, CIRCULATION, V116, P1497, DOI 10.1161/CIRCULATIONAHA.107.716407; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoppe PP, 2000, EUR J NUTR, V39, P183, DOI 10.1007/s003940070010; HOSSMANN KA, 2010, TXB STROKE MED, P1; Johnston SC, 2009, LANCET NEUROL, V8, P345, DOI 10.1016/S1474-4422(09)70023-7; Juni P, 2001, SYSTEMATIC REV HLTH, P87; Kurth T, 2006, ARCH INTERN MED, V166, P1403, DOI 10.1001/archinte.166.13.1403; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; Meagher EA, 2001, JAMA-J AM MED ASSOC, V285, P1178, DOI 10.1001/jama.285.9.1178; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Navab M, 2004, J LIPID RES, V45, P993, DOI 10.1194/jlr.R400001-JLR200; Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1388, DOI 10.1001/jama.288.11.1388; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Tonk M, 2007, J NEUROL SCI, V257, P273, DOI 10.1016/j.jns.2007.01.037; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Violi F, 2010, CIRCULATION, V121, P1033, DOI 10.1161/CIRCULATIONAHA.109.880211; Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zhang HF, 2006, HYPERTENSION, V48, P187, DOI 10.1161/01.HYP.0000231939.40959.60	43	195	204	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	2010	341								c5702	10.1136/bmj.c5702	http://dx.doi.org/10.1136/bmj.c5702			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678DL	21051774	Green Published, hybrid			2022-12-28	WOS:000284051700001
J	Winker, MA				Winker, Margaret A.			Themes of Aging Preserving Function, Improving Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												margaret.winker@jama-archives.org		Winker, Margaret/0000-0002-4708-5641				Boult C, 2010, JAMA-J AM MED ASSOC, V304, P1936, DOI 10.1001/jama.2010.1623; Chattopadhyay A, 2010, JAMA-J AM MED ASSOC, V304, P1948, DOI 10.1001/jama.2010.1634; Dykes PC, 2010, JAMA-J AM MED ASSOC, V304, P1912, DOI 10.1001/jama.2010.1567; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; King AC, 2010, JAMA-J AM MED ASSOC, V304, P1944, DOI 10.1001/jama.2010.1577; Kitzman DW, 2010, JAMA-J AM MED ASSOC, V304, P1950, DOI 10.1001/jama.2010.1592; Mitchell SL, 2010, JAMA-J AM MED ASSOC, V304, P1929, DOI 10.1001/jama.2010.1572; MOORE RA, 1951, JAMA-J AM MED ASSOC, V147, P1327, DOI 10.1001/jama.1951.03670310017005; *POP DIV DESA, UN WORLD POP AG 1950; Quinn JF, 2010, JAMA-J AM MED ASSOC, V304, P1903, DOI 10.1001/jama.2010.1510; Sulmasy DP, 2010, JAMA-J AM MED ASSOC, V304, P1946, DOI 10.1001/jama.2010.1595; WINKER MA, 1997, JAMA-J AM MED ASSOC, V278, P1298; WINKER MA, 2002, JAMA-J AM MED ASSOC, V288, P2223; Winker MA, 2010, JAMA-J AM MED ASSOC, V303, P455, DOI 10.1001/jama.2010.46; XU J, 2009, NATL VITAL STAT  AUG, P19; Yaffe K, 2010, JAMA-J AM MED ASSOC, V304, P1952, DOI 10.1001/jama.2010.1625; 1960, JAMA, V172, P1199	17	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1954	1955		10.1001/jama.2010.1593	http://dx.doi.org/10.1001/jama.2010.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674GT	21045106				2022-12-28	WOS:000283725900030
J	Leslie, WD; Morin, S; Lix, LM				Leslie, William D.; Morin, Suzanne; Lix, Lisa M.			A Before-and-After Study of Fracture Risk Reporting and Osteoporosis Treatment Initiation	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-DENSITY PROGRAM; QUALITY-OF-LIFE; CLINICAL-PRACTICE; POSTMENOPAUSAL WOMEN; ASSESSMENT-TOOL; PHARMACOLOGICAL-TREATMENT; PRACTICE GUIDELINES; OLDER WOMEN; VALIDATION; DENSITOMETRY	Background: Several national organizations recommend that fracture risk assessment and osteoporotic treatment be based on estimated absolute 10-year fracture risk rather than bone mineral density (BMD) alone. Objective: To assess the changes in physician prescribing behavior after introduction of absolute 10-year fracture risk reporting. Design: Before-and-after study. Setting: Manitoba, Canada, which has an integrated BMD program in which tests are linkable to a population-based administrative health database repository. Patients: Women 50 years or older who were not receiving osteoporosis medication (2042 before and 3889 after intervention). Intervention: Introduction of a system reporting absolute 10-year fracture risk along with dual-energy x-ray absorptiometry results. Measurements: The proportion of untreated women who were prescribed osteoporosis medications in the year after baseline BMD measurement. Results: Absolute fracture risk reporting reclassified more women (32.7%) into lower-risk categories than into higher-risk categories (10%). This effect was more prominent in women younger than 65 years. Fewer women per physician were prescribed osteoporosis drugs after introduction of absolute fracture risk reporting. The absolute fracture risk reporting system was associated with an overall reduction in osteoporosis medications dispensed (adjusted absolute reduction, 9.0 percentage points [95% CI, 3.9 to 14.2 percentage points]; relative reduction, 21.3% [CI, 9.2% to 33.5%]; P < 0.001). The reduction was attributed to fewer drugs dispensed to women at low and moderate risk for fracture. No differences in fracture rates were observed. Limitations: This was a nonrandomized study. The risk assessment system studied differs slightly from other 10-year fracture risk assessment models. Conclusion: Change from a T-score-based fracture risk reporting system to a system based on absolute 10-year fracture risk was associated with appropriate, guideline-based changes in prescription of osteoporosis medications.	Univ Saskatchewan, Saskatoon, SK, Canada; McGill Univ, Montreal, PQ, Canada	University of Saskatchewan; McGill University	Leslie, WD (corresponding author), Univ Manitoba, Dept Med C5121, 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	bleslie@sbgh.mb.ca		Morin, Suzanne/0000-0002-4317-492X; Leslie, William/0000-0002-1056-1691				Adachi JD, 2001, OSTEOPOROSIS INT, V12, P903, DOI 10.1007/s001980170017; Balding DJ, 2004, APPL LONGITUDINAL AN; Baltzan MA, 1999, LANCET, V353, P1327, DOI 10.1016/S0140-6736(98)04835-1; Binkley N, 2005, J BONE MINER RES, V20, P195, DOI 10.1359/JBMR.041115; Black DM, 2001, OSTEOPOROSIS INT, V12, P519, DOI 10.1007/s001980170072; Brown JP, 2002, CAN MED ASSOC J, V167, pS1; Browner WS, 1996, ARCH INTERN MED, V156, P1521, DOI 10.1001/archinte.156.14.1521; Cranney A, 2009, OSTEOPOROSIS INT, V20, P1621, DOI 10.1007/s00198-008-0823-8; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; Dawson-Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198-008-0559-5; Donaldson MG, 2009, J BONE MINER RES, V24, P675, DOI [10.1359/jbmr.081203, 10.1359/JBMR.081203]; Fujiwara S, 2008, OSTEOPOROSIS INT, V19, P429, DOI 10.1007/s00198-007-0544-4; Hallberg I, 2004, OSTEOPOROSIS INT, V15, P834, DOI 10.1007/s00198-004-1622-5; Hannan EL, 2001, JAMA-J AM MED ASSOC, V285, P2736, DOI 10.1001/jama.285.21.2736; Hansen KE, 2005, J BONE MINER RES, V20, P501, DOI 10.1359/JBMR.041134; Hu FB, 1998, AM J EPIDEMIOL, V147, P694; Ioannidis G, 2007, CAN FAM PHYSICIAN, V53, P1694; Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Kanis JA, 2007, OSTEOPOROSIS INT, V18, P1033, DOI 10.1007/s00198-007-0343-y; Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; Leslie WD, 2008, OSTEOPOROSIS INT, V19, P459, DOI 10.1007/s00198-008-0565-7; Leslie WD, 2006, BONE, V39, P361, DOI 10.1016/j.bone.2006.02.002; Leslie WD, 2005, J CLIN DENSITOM, V8, P25, DOI 10.1385/JCD:8:1:025; Leslie WD, 2003, OSTEOPOROSIS INT, V14, P334, DOI 10.1007/s00198-003-1375-6; Leslie WD, 2003, J CLIN DENSITOM, V6, P275, DOI 10.1385/JCD:6:3:275; Leslie WD, 2008, BONE, V43, P667, DOI 10.1016/j.bone.2008.06.001; Leslie WD, 2007, ARCH INTERN MED, V167, P1641, DOI 10.1001/archinte.167.15.1641; Leslie WD, 2009, J BONE MINER RES, V24, P353, DOI [10.1359/jbmr.081012, 10.1359/JBMR.081012]; Melton LJ, 2003, ENDOCRIN METAB CLIN, V32, P1, DOI 10.1016/S0889-8529(02)00061-0; Neuner JM, 2006, J AM GERIATR SOC, V54, P485, DOI 10.1111/j.1532-5415.2005.00622.x; Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003-4819-149-6-200809160-00007; Richards JB, 2007, J BONE MINER RES, V22, P228, DOI 10.1359/JBMR.061109; Roos NP, 1999, MED CARE, V37, pJS10, DOI 10.1097/00005650-199906001-00005; Schousboe JT, 2005, ANN INTERN MED, V142, P734, DOI 10.7326/0003-4819-142-9-200505030-00008; Siminoski K, 2005, CAN ASSOC RADIOL J, V56, P178; Stock JL, 1998, ANN INTERN MED, V128, P996, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00006; Straus SE, 2009, CAN MED ASSOC J, V181, P165, DOI 10.1503/cmaj.081229; Watts NB, 2008, J CLIN DENSITOM, V11, P473, DOI 10.1016/j.jocd.2008.04.003; *WHO COLL CTR DRUG, 2005, GUID ATC CLASS DDD A	41	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					580	586		10.7326/0003-4819-153-9-201011020-00007	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	21041577				2022-12-28	WOS:000283667000004
J	Bai, JH; Hu, ZT; Dittman, JS; Pym, ECG; Kaplan, JM				Bai, Jihong; Hu, Zhitao; Dittman, Jeremy S.; Pym, Edward C. G.; Kaplan, Joshua M.			Endophilin Functions as a Membrane-Bending Molecule and Is Delivered to Endocytic Zones by Exocytosis	CELL			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; BAR; PROTEINS; CURVATURE; DOMAIN; TRANSMISSION; SYNAPTOJANIN; DOCKING; DYNAMIN; ACTIN	Two models have been proposed for endophilin function in synaptic vesicle (SV) endocytosis. The scaffolding model proposes that endophilin's SH3 domain recruits essential endocytic proteins, whereas the membrane-bending model proposes that the BAR domain induces positively curved membranes. We show that mutations disrupting the scaffolding function do not impair endocytosis, whereas those disrupting membrane bending cause significant defects. By anchoring endophilin to the plasma membrane, we show that endophilin acts prior to scission to promote endocytosis. Despite acting at the plasma membrane, the majority of endophilin is targeted to the SV pool. Photoactivation studies suggest that the soluble pool of endophilin at synapses is provided by unbinding from the adjacent SV pool and that the unbinding rate is regulated by exocytosis. Thus, endophilin participates in an association-dissociation cycle with SVs that parallels the cycle of exo- and endocytosis. This endophilin cycle may provide a mechanism for functionally coupling endocytosis and exocytosis.	[Bai, Jihong; Hu, Zhitao; Pym, Edward C. G.; Kaplan, Joshua M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; [Bai, Jihong; Hu, Zhitao; Pym, Edward C. G.; Kaplan, Joshua M.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Dittman, Jeremy S.] Weill Cornell Med Coll, Dept Biochem, New York, NY 10065 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Cornell University	Kaplan, JM (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	kaplan@molbio.mgh.harvard.edu	hu, zhitao/H-5626-2011	Hu, Zhitao/0000-0002-2948-3339; Dittman, Jeremy S./0000-0002-3850-9078	Jane Coffin Childs postdoctoral fellowship; NIH [GM54728, K99MH085039]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K99MH085039] Funding Source: NIH RePORTER	Jane Coffin Childs postdoctoral fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We thank the following for strains and reagents: Roger Tsien, Jennifer Lippincott-Schwartz, and the C. elegans Genetics Stock Center. We thank members of the Kaplan lab and Susana Garcia for critical comments. This work was supported by a Jane Coffin Childs postdoctoral fellowship (J.B.) and by NIH grants GM54728 (J.M.K.) and K99MH085039 (J.B.).	Ch'ng Q, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000283; Darcy KJ, 2006, NAT NEUROSCI, V9, P315, DOI 10.1038/nn1640; Dickman DK, 2005, CELL, V123, P521, DOI 10.1016/j.cell.2005.09.026; Dittman J, 2009, ANNU REV CELL DEV BI, V25, P133, DOI 10.1146/annurev.cellbio.042308.113302; Dittman JS, 2006, P NATL ACAD SCI USA, V103, P11399, DOI 10.1073/pnas.0600784103; Fabian-Fine R, 2003, J NEUROSCI, V23, P10732; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ferguson S, 2009, DEV CELL, V17, P811, DOI 10.1016/j.devcel.2009.11.005; Ferguson SM, 2007, SCIENCE, V316, P570, DOI 10.1126/science.1140621; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Jordan R, 2005, BIOPHYS J, V89, P2091, DOI 10.1529/biophysj.105.061663; Kohn RE, 2000, MOL BIOL CELL, V11, P3441, DOI 10.1091/mbc.11.10.3441; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Madison JM, 2005, CURR BIOL, V15, P2236, DOI 10.1016/j.cub.2005.10.049; Mahoney TR, 2006, MOL BIOL CELL, V17, P2617, DOI 10.1091/mbc.E05-12-1170; Mani M, 2007, NEURON, V56, P1004, DOI 10.1016/j.neuron.2007.10.032; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; McEwen JM, 2006, NEURON, V51, P303, DOI 10.1016/j.neuron.2006.06.025; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Schuske KR, 2003, NEURON, V40, P749, DOI 10.1016/S0896-6273(03)00667-6; Shupliakov O, 2009, NEUROSCIENCE, V158, P204, DOI 10.1016/j.neuroscience.2008.03.035; Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Verstreken P, 2002, CELL, V109, P101, DOI 10.1016/S0092-8674(02)00688-8; Verstreken P, 2003, NEURON, V40, P733, DOI 10.1016/S0896-6273(03)00644-5; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118	33	87	95	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					430	441		10.1016/j.cell.2010.09.024	http://dx.doi.org/10.1016/j.cell.2010.09.024			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029864	Green Accepted, Bronze			2022-12-28	WOS:000283603900016
J	Derdowski, A; Sindi, SS; Klaips, CL; DiSalvo, S; Serio, TR				Derdowski, Aaron; Sindi, Suzanne S.; Klaips, Courtney L.; DiSalvo, Susanne; Serio, Tricia R.			A Size Threshold Limits Prion Transmission and Establishes Phenotypic Diversity	SCIENCE			English	Article							PSI+ PRION; NEURODEGENERATIVE DISEASES; SACCHAROMYCES-CEREVISIAE; YEAST; PROTEIN; PROPAGATION; GENERATION; PARTICLES; PROPAGONS; AMYLOIDS	According to the prion hypothesis, atypical phenotypes arise when a prion protein adopts an alternative conformation and persist when that form assembles into self-replicating aggregates. Amyloid formation in vitro provides a model for this protein-misfolding pathway, but the mechanism by which this process interacts with the cellular environment to produce transmissible phenotypes is poorly understood. Using the yeast prion Sup35/[PSI+], we found that protein conformation determined the size distribution of aggregates through its interactions with a molecular chaperone. Shifts in this range created variations in aggregate abundance among cells because of a size threshold for transmission, and this heterogeneity, along with aggregate growth and fragmentation, induced age-dependent fluctuations in phenotype. Thus, prion conformations may specify phenotypes as population averages in a dynamic system.	[Derdowski, Aaron; Sindi, Suzanne S.; Klaips, Courtney L.; DiSalvo, Susanne; Serio, Tricia R.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; [Sindi, Suzanne S.] Brown Univ, Ctr Computat Mol Biol, Providence, RI 02912 USA	Brown University; Brown University	Sindi, SS (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, 185 Meeting St,POB G-L2, Providence, RI 02912 USA.	suzanne_sindi@brown.edu; tricia_serio@brown.edu	Serio, Tricia/GPP-7129-2022; DiSalvo, Susanne/AAR-9746-2020	Klaips, Courtney/0000-0002-4929-1641; Serio, Tricia/0000-0003-2687-7372	NIH [GM069802, GM085976, GM089049, AG034754, AG032818]; NSF [0548311]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007601, F32GM089049, F32GM085976, R01GM069802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [F31AG034754, F31AG032818] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank N. Rhind, M. Duennwald, J. Sherley, and members of their groups for assistance with centrifugal elutriation, and the Center for Computation and Visualization, the Leduc Bioimaging Facility, and the Flow Cytometry and Sorting Facility at Brown University for instrumentation and the assistance of the respective support staffs. We thank J. Bender, J. Laney, M. Tuite, and members of the Serio and Laney labs for helpful discussions and comments on the manuscript. This research was supported by grants from NIH (GM069802 to T.R.S., GM085976 to A.D., GM089049 to S.S.S., AG034754 to C.K., and AG032818 to S.D.) and NSF/ADVANCE (0548311 to T.R.S.).	Allen KD, 2005, GENETICS, V169, P1227, DOI 10.1534/genetics.104.037168; Bagriantsev SN, 2006, METHOD ENZYMOL, V412, P33, DOI 10.1016/S0076-6879(06)12003-0; Benkemoun L, 2006, FUNGAL GENET BIOL, V43, P789, DOI 10.1016/j.fgb.2006.06.006; Brundin P, 2010, NAT REV MOL CELL BIO, V11, P301, DOI 10.1038/nrm2873; Byrne LJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004670; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Cox B, 2003, GENETICS, V165, P23; COX BS, 1965, HEREDITY, V20, P505, DOI 10.1038/hdy.1965.65; Crapeau M, 2009, MOL BIOL CELL, V20, P2286, DOI 10.1091/mbc.E08-11-1097; Derkatch IL, 1996, GENETICS, V144, P1375; Edskes HK, 1999, P NATL ACAD SCI USA, V96, P1498, DOI 10.1073/pnas.96.4.1498; Frost B, 2010, NAT REV NEUROSCI, V11, P155, DOI 10.1038/nrn2786; Halfmann R, 2010, TRENDS CELL BIOL, V20, P125, DOI 10.1016/j.tcb.2009.12.003; Haslberger T, 2010, BIOCHEM CELL BIOL, V88, P63, DOI [10.1139/O09-118, 10.1139/o09-118]; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Kushnirov VV, 2007, PRION, V1, P179, DOI 10.4161/pri.1.3.4840; Lancaster AK, 2010, GENETICS, V184, P393, DOI 10.1534/genetics.109.110213; Ness F, 2002, MOL CELL BIOL, V22, P5593, DOI 10.1128/MCB.22.15.5593-5605.2002; Pezza JA, 2009, MOL BIOL CELL, V20, P1068, DOI 10.1091/mbc.E08-04-0436; Pezza JA, 2007, PRION, V1, P36, DOI 10.4161/pri.1.1.3992; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rikhvanov EG, 2007, PRION, V1, P217, DOI 10.4161/pri.1.4.5058; Salnikova AB, 2005, J BIOL CHEM, V280, P8808, DOI 10.1074/jbc.M410150200; Satpute-Krishnan P, 2007, PLOS BIOL, V5, P251, DOI 10.1371/journal.pbio.0050024; Serio TR, 1999, ANNU REV CELL DEV BI, V15, P661, DOI 10.1146/annurev.cellbio.15.1.661; Silveira JR, 2005, NATURE, V437, P257, DOI 10.1038/nature03989; Sindi SS, 2009, CURR OPIN MICROBIOL, V12, P623, DOI 10.1016/j.mib.2009.09.003; Tanaka M, 2006, NATURE, V442, P585, DOI 10.1038/nature04922; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	30	83	85	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					680	683		10.1126/science.1197785	http://dx.doi.org/10.1126/science.1197785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030659	Green Accepted			2022-12-28	WOS:000283580600051
J	Grill, SW				Grill, Stephan W.			Forced to Be Unequal	SCIENCE			English	Editorial Material							ASYMMETRIC CELL-DIVISION; ELEGANS EMBRYO; CORTICAL FLOWS; C-ELEGANS; POLARITY; SPINDLE; DROSOPHILA; TRANSPORT		[Grill, Stephan W.] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; [Grill, Stephan W.] Max Planck Inst Phys Komplexer Syst, D-01307 Dresden, Germany	Max Planck Society; Max Planck Society	Grill, SW (corresponding author), Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany.	grill@mpi-cbg.de	Grill, Stephan/D-9427-2012					Barros CS, 2003, DEV CELL, V5, P829, DOI 10.1016/S1534-5807(03)00359-9; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Cabernard C, 2010, NATURE, V467, P91, DOI 10.1038/nature09334; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Kozlowski C, 2007, CELL, V129, P499, DOI 10.1016/j.cell.2007.03.027; Larson SM, 2010, MOL BIOL CELL, V21, P3182, DOI 10.1091/mbc.E10-01-0066; Mayer M, 2010, NATURE, V467, P617, DOI 10.1038/nature09376; Monier B, 2010, NAT CELL BIOL, V12, P60, DOI 10.1038/ncb2005; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Ou GS, 2010, SCIENCE, V330, P677, DOI 10.1126/science.1196112; Redemann S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012301; St Johnston D, 2010, CELL, V141, P757, DOI 10.1016/j.cell.2010.05.011	13	4	4	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					597	598		10.1126/science.1198343	http://dx.doi.org/10.1126/science.1198343			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030636				2022-12-28	WOS:000283580600024
J	Vikanes, A; Skjaerven, R; Grjibovski, AM; Gunnes, N; Vangen, S; Magnus, P				Vikanes, Ase; Skjaerven, Rolv; Grjibovski, Andrej M.; Gunnes, Nina; Vangen, Siri; Magnus, Per			Recurrence of hyperemesis gravidarum across generations: population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI INFECTION; NAUSEA; PREGNANCY; RISK; COMPLICATIONS; TERMINATION; PREVALENCE; NORWAY; BIRTH; WOMEN	Objective To estimate the risk of hyperemesis gravidarum ( hyperemesis) according to whether the daughters and sons under study were born after pregnancies complicated by hyperemesis. Design Population based cohort study. Setting Registry data from Norway. Participants Linked generational data from the medical birth registry of Norway (1967-2006): 544 087 units of mother and childbearing daughter and 399 777 units of mother and child producing son. Main outcome measure Hyperemesis in daughters in mother and childbearing daughter units and hyperemesis in female partners of sons in mother and child producing son units. Results Daughters who were born after a pregnancy complicated by hyperemesis had a 3% risk of having hyperemesis in their own pregnancy, while women who were born after an unaffected pregnancy had a risk of 1.1% (unadjusted odds ratio 2.9, 95% confidence interval 2.4 to 3.6). Female partners of sons who were born after pregnancies complicated by hyperemesis had a risk of 1.2% (1.0, 0.7 to 1.6). Daughters born after a pregnancy not complicated by hyperemesis had an increased risk of the condition if the mother had hyperemesis in a previous or subsequent pregnancy (3.2 (1.6 to 6.4) if hyperemesis had occurred in one of the mother's previous pregnancies and 3.7 (1.5 to 9.1) if it had occurred in a later pregnancy). Adjustment for maternal age at childbirth, period of birth, and parity did not change the estimates. Restrictions to firstborns did not influence the results. Conclusions Hyperemesis gravidarum is more strongly influenced by the maternal genotype than the fetal genotype, though environmental influences along the maternal line cannot be excluded as contributing factors.	[Vikanes, Ase; Skjaerven, Rolv; Gunnes, Nina; Vangen, Siri; Magnus, Per] Norwegian Inst Publ Hlth, Div Epidemiol, N-0403 Oslo, Norway; [Skjaerven, Rolv] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, N-5020 Bergen, Norway; [Grjibovski, Andrej M.] Norwegian Inst Publ Hlth, Dept Infect Dis Epidemiol, N-0403 Oslo, Norway; [Grjibovski, Andrej M.] Univ Tromso, Inst Community Med, N-9001 Tromso, Norway; [Grjibovski, Andrej M.] No State Med Univ, Int Sch Publ Hlth, Arkhangelsk, Russia; [Vangen, Siri] Oslo Univ Hosp, Dept Obstet & Gynaecol, Natl Resource Ctr Womens Hlth, Oslo, Norway; [Magnus, Per] Univ Oslo, Inst Gen Practice & Community Med, N-0316 Oslo, Norway	Norwegian Institute of Public Health (NIPH); University of Bergen; Norwegian Institute of Public Health (NIPH); UiT The Arctic University of Tromso; Northern State Medical University; University of Oslo; University of Oslo	Vikanes, A (corresponding author), Norwegian Inst Publ Hlth, Div Epidemiol, POB 4404, N-0403 Oslo, Norway.	ase.vigdis.vikanes@fhi.no	Grjibovski, Andrej/B-9815-2016	Grjibovski, Andrej/0000-0002-5464-0498	Norwegian Research Council [166145/V50]	Norwegian Research Council(Research Council of NorwayEuropean Commission)	The study was funded by the Norwegian Research Council (grant No 166145/V50).	ADAMS MM, 1994, OBSTET GYNECOL, V84, P35; Bailit JL, 2005, AM J OBSTET GYNECOL, V193, P811, DOI 10.1016/j.ajog.2005.02.132; Cedergren M, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.09.029; CHIN RKH, 1989, EUR J OBSTET GYN R B, V33, P215, DOI 10.1016/0028-2243(89)90132-9; COREY LA, 1992, OBSTET GYNECOL, V80, P989; DEPUE RH, 1987, AM J OBSTET GYNECOL, V156, P1137, DOI 10.1016/0002-9378(87)90126-8; Dodds L, 2006, OBSTET GYNECOL, V107, P285, DOI 10.1097/01.AOG.0000195060.22832.cd; Eliakim R, 2000, AM J PERINAT, V17, P207, DOI 10.1055/s-2000-9424; FAIRWEATHER DV, 1968, AM J OBSTET GYNECOL, V102, P135, DOI 10.1016/0002-9378(68)90445-6; Fejzo MS, 2008, EUR J OBSTET GYN R B, V141, P13, DOI 10.1016/j.ejogrb.2008.07.003; Fell DB, 2006, OBSTET GYNECOL, V107, P277, DOI 10.1097/01.AOG.0000195059.82029.74; GADSBY R, 1993, BRIT J GEN PRACT, V43, P245; Gazmararian JA, 2002, OBSTET GYNECOL, V100, P94, DOI 10.1016/S0029-7844(02)02024-0; Golberg D, 2007, OBSTET GYNECOL, V110, P695, DOI 10.1097/01.AOG.0000278571.93861.26; Grjibovski AM, 2008, ACTA OBSTET GYN SCAN, V87, P20, DOI 10.1080/00016340701709273; Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x; Kallen B, 2003, ACTA OBSTET GYN SCAN, V82, P916, DOI 10.1034/j.1600-0412.2003.00307.x; Kim DR, 2009, ARCH WOMEN MENT HLTH, V12, P61, DOI 10.1007/s00737-009-0064-7; Mazzotta P, 2001, J PSYCHOSOM OBST GYN, V22, P7, DOI 10.3109/01674820109049946; Nordtveit TI, 2008, BRIT MED J, V336, P872, DOI 10.1136/bmj.39505.436539.BE; OBRIEN B, 1992, BIRTH-ISS PERINAT C, V19, P138, DOI 10.1111/j.1523-536X.1992.tb00671.x; Poursharif B, 2008, J PERINATOL, V28, P176, DOI 10.1038/sj.jp.7211906; Poursharif B, 2007, CONTRACEPTION, V76, P451, DOI 10.1016/j.contraception.2007.08.009; Sandven I, 2009, ACTA OBSTET GYN SCAN, V88, P1190, DOI 10.3109/00016340903284927; Signorello LB, 1998, EPIDEMIOLOGY, V9, P636, DOI 10.1097/00001648-199811000-00013; Skjaerven R, 2005, BRIT MED J, V331, P877, DOI 10.1136/bmj.38555.462685.8F; Trogstad LIS, 2005, BJOG-INT J OBSTET GY, V112, P1641, DOI 10.1111/j.1471-0528.2005.00765.x; VELLACOTT ID, 1988, INT J GYNECOL OBSTET, V27, P57, DOI 10.1016/0020-7292(88)90088-4; Verberg MFG, 2005, HUM REPROD UPDATE, V11, P527, DOI 10.1093/humupd/dmi021; Vikanes A, 2008, SCAND J PUBLIC HEALT, V36, P135, DOI 10.1177/1403494807085189; World Health Organization (WHO), 2009, INT CLASS DIS	31	36	36	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2010	340								c2050	10.1136/bmj.c2050	http://dx.doi.org/10.1136/bmj.c2050			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	591PO	21030362				2022-12-28	WOS:000277314300003
J	Allotey, P; Reidpath, DD; Yasin, S; Chan, CK; Aikins, AD				Allotey, Pascale; Reidpath, Daniel D.; Yasin, Shajahan; Chan, Carina K.; Aikins, Ama de-Graft			Rethinking health-care systems: a focus on chronicity	LANCET			English	Editorial Material							AFRICA		[Allotey, Pascale; Reidpath, Daniel D.; Yasin, Shajahan; Chan, Carina K.] Monash Univ, Jeffrey Cheah Sch Med & Hlth Sci, Selangor 46150, De, Malaysia; [Aikins, Ama de-Graft] Univ Ghana, Reg Inst Populat Studies, Legon, Ghana; [Aikins, Ama de-Graft] London Sch Econ & Polit Sci, LSE Hlth, London, England	Monash University; Monash University Sunway; University of Ghana; University of London; London School Economics & Political Science	Allotey, P (corresponding author), Monash Univ, Jeffrey Cheah Sch Med & Hlth Sci, Sunway Campus, Selangor 46150, De, Malaysia.	pascale.allotey@monash.edu	Chan, Carina/AAO-6804-2021; Chan, Carina/O-6258-2014	Chan, Carina/0000-0002-1799-7877				Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; MBANYA JC, 2006, DIS MORTALITY SUBSAH, DOI DOI 10.1596/978-0-8213-6397-3; Mbanya JCN, 2010, LANCET, V375, P2254, DOI 10.1016/S0140-6736(10)60550-8; Mbeh George N, 2010, Glob Health Promot, V17, P17, DOI 10.1177/1757975910363925; Nattrass N, 2008, J PUBLIC HEALTH-UK, V30, P398, DOI 10.1093/pubmed/fdn075; Remme JHF, 2010, B WORLD HEALTH ORGAN, V88, P509, DOI 10.2471/BLT.09.069203; RIFKIN SB, 1986, SOC SCI MED, V23, P559, DOI 10.1016/0277-9536(86)90149-8; SAMB B, 2010, LANCET          1111; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; Yeboah-Antwi K, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000340	10	74	74	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 5	2011	377	9764					450	451		10.1016/S0140-6736(10)61856-9	http://dx.doi.org/10.1016/S0140-6736(10)61856-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721TX	21074257				2022-12-28	WOS:000287381800009
J	Park, H; Pontius, W; Guet, CC; Marko, JF; Emonet, T; Cluzel, P				Park, Heungwon; Pontius, William; Guet, Calin C.; Marko, John F.; Emonet, Thierry; Cluzel, Philippe			Interdependence of behavioural variability and response to small stimuli in bacteria	NATURE			English	Article							SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; CHEMOTAXIS; NOISE; SENSITIVITY; ROBUSTNESS; NETWORKS; SYSTEMS; GENE	The chemotaxis signalling network in Escherichia coli that controls the locomotion of bacteria is a classic model system for signal transduction(1,2). This pathway modulates the behaviour of flagellar motors to propel bacteria towards sources of chemical attractants. Although this system relaxes to a steady state in response to environmental changes, the signalling events within the chemotaxis network are noisy and cause large temporal variations of the motor behaviour even in the absence of stimulus(3). That the same signalling network governs both behavioural variability and cellular response raises the question of whether these two traits are independent. Here, we experimentally establish a fluctuation-response relationship in the chemotaxis system of living bacteria. Using this relationship, we demonstrate the possibility of inferring the cellular response from the behavioural variability measured before stimulus. In monitoring the pre- and post-stimulus switching behaviour of individual bacterial motors, we found that variability scales linearly with the response time for different functioning states of the cell. This study highlights that the fundamental relationship between fluctuation and response is not constrained to physical systems at thermodynamic equilibrium(4) but is extensible to living cells(5). Such a relationship not only implies that behavioural variability and cellular response can be coupled traits, but it also provides a general framework within which we can examine how the selection of a network design shapes this interdependence.	[Guet, Calin C.; Cluzel, Philippe] Harvard Univ, FAS Ctr Syst Biol, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Guet, Calin C.; Cluzel, Philippe] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Park, Heungwon] Univ Chicago, James Franck Inst, Inst Biophys Dynam, Chicago, IL 60637 USA; [Park, Heungwon] Univ Chicago, Dept Phys, Chicago, IL 60637 USA; [Pontius, William; Emonet, Thierry] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Pontius, William; Emonet, Thierry] Yale Univ, Dept Phys, New Haven, CT 06520 USA; [Marko, John F.] Northwestern Univ, Dept Mol Biosci, Evanston, IL 60208 USA; [Marko, John F.] Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA	Harvard University; Harvard University; University of Chicago; University of Chicago; Yale University; Yale University; Northwestern University; Northwestern University	Cluzel, P (corresponding author), Harvard Univ, FAS Ctr Syst Biol, Dept Mol & Cellular Biol, 52 Oxford St, Cambridge, MA 02138 USA.	cluzel@mcb.harvard.edu	Emonet, Thierry/AAI-3740-2020; Marko, John F./AAY-7111-2021	Marko, John F./0000-0003-4151-9530	NSF DMR [0213745]; NIH [R01AI059195-03, 1U54CA143869-01]; NSF [CCF0829836, PHY-0852130, DMR-0715099]; Alfred P. Sloan Research Fellowship; National Academies Keck Futures Initiative; Chicago Biomedical Consortium; Chicago Community Trust; NATIONAL CANCER INSTITUTE [U54CA143869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM081892] Funding Source: NIH RePORTER	NSF DMR(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Alfred P. Sloan Research Fellowship(Alfred P. Sloan Foundation); National Academies Keck Futures Initiative; Chicago Biomedical Consortium; Chicago Community Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was funded by an NSF DMR award 0213745 to the Materials Research Science and Engineering Center at the University of Chicago, and NIH award R01AI059195-03 (to P.C.). W.P. and T.E. were supported by NSF CCF0829836, an Alfred P. Sloan Research Fellowship, and a National Academies Keck Futures Initiative award (to T.E.). J.F.M. was supported by NSF awards PHY-0852130 and DMR-0715099 and NIH grant 1U54CA143869-01. This work was also supported by the Chicago Biomedical Consortium with support from The Searle Funds at The Chicago Community Trust. D. Trentham supplied caged L-aspartate. We thank J. S. Parkinson for ADCheB mutant strains RP4972 and RP4992. We thank T. Shimizu for discussions and sharing unpublished work. We thank H. Lee for help with the HPLC measurements. We thank J. Moffitt and K. Wood for comments on the manuscript and all members of the Cluzel laboratory for many discussions. W. Grus provided editorial assistance.	ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Anderson RL, 1942, ANN MATH STAT, V13, P1, DOI 10.1214/aoms/1177731638; Andrews BW, 2006, PLOS COMPUT BIOL, V2, P1407, DOI 10.1371/journal.pcbi.0020154; Bainer R, 2003, J MICROBIOL METH, V55, P315, DOI 10.1016/S0167-7012(03)00112-X; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; Berg HC, 2000, PHYS TODAY, V53, P24, DOI 10.1063/1.882934; Bialek W, 2005, P NATL ACAD SCI USA, V102, P10040, DOI 10.1073/pnas.0504321102; Bourret RB, 2002, J BIOL CHEM, V277, P9625, DOI 10.1074/jbc.R100066200; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Bustamante C, 2000, NAT REV MOL CELL BIO, V1, P130, DOI 10.1038/35040072; Chetrite R, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/08/P08005; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Cugliandolo LF, 1997, PHYS REV LETT, V79, P2168, DOI 10.1103/PhysRevLett.79.2168; Detwiler PB, 2000, BIOPHYS J, V79, P2801, DOI 10.1016/S0006-3495(00)76519-2; Dorignac J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.186105; Emonet T, 2008, P NATL ACAD SCI USA, V105, P3304, DOI 10.1073/pnas.0705463105; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Jasuja R, 1999, P NATL ACAD SCI USA, V96, P11346, DOI 10.1073/pnas.96.20.11346; Korobkova E, 2004, NATURE, V428, P574, DOI 10.1038/nature02404; Korobkova EA, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.058105; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Ratnam R, 2000, J NEUROSCI, V20, P6672, DOI 10.1523/JNEUROSCI.20-17-06672.2000; Shibata T, 2005, P NATL ACAD SCI USA, V102, P331, DOI 10.1073/pnas.0403350102; Shinar G, 2010, SCIENCE, V327, P1389, DOI 10.1126/science.1183372; Sourjik V, 2004, NATURE, V428, P437, DOI 10.1038/nature02406; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998	35	53	53	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	2010	468	7325					819	U114		10.1038/nature09551	http://dx.doi.org/10.1038/nature09551			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691PQ	21076396	Green Accepted			2022-12-28	WOS:000285093700045
J	Andresen, GB; Ashkezari, MD; Baquero-Ruiz, M; Bertsche, W; Bowe, PD; Butler, E; Cesar, CL; Chapman, S; Charlton, M; Deller, A; Eriksson, S; Fajans, J; Friesen, T; Fujiwara, MC; Gill, DR; Gutierrez, A; Hangst, JS; Hardy, WN; Hayden, ME; Humphries, AJ; Hydomako, R; Jenkins, MJ; Jonsell, S; Jorgensen, LV; Kurchaninov, L; Madsen, N; Menary, S; Nolan, P; Olchanski, K; Olin, A; Povilus, A; Pusa, P; Robicheaux, F; Sarid, E; el Nasr, SS; Silveira, DM; So, C; Storey, JW; Thompson, RI; van der Werf, DP; Wurtele, JS; Yamazaki, Y				Andresen, G. B.; Ashkezari, M. D.; Baquero-Ruiz, M.; Bertsche, W.; Bowe, P. D.; Butler, E.; Cesar, C. L.; Chapman, S.; Charlton, M.; Deller, A.; Eriksson, S.; Fajans, J.; Friesen, T.; Fujiwara, M. C.; Gill, D. R.; Gutierrez, A.; Hangst, J. S.; Hardy, W. N.; Hayden, M. E.; Humphries, A. J.; Hydomako, R.; Jenkins, M. J.; Jonsell, S.; Jorgensen, L. V.; Kurchaninov, L.; Madsen, N.; Menary, S.; Nolan, P.; Olchanski, K.; Olin, A.; Povilus, A.; Pusa, P.; Robicheaux, F.; Sarid, E.; el Nasr, S. Seif; Silveira, D. M.; So, C.; Storey, J. W.; Thompson, R. I.; van der Werf, D. P.; Wurtele, J. S.; Yamazaki, Y.			Trapped antihydrogen	NATURE			English	Article							MAGNETIC TRAP; PLASMAS; ANTIPROTONS	Antimatter was first predicted(1) in 1931, by Dirac. Work with high-energy antiparticles is now commonplace, and anti-electrons are used regularly in the medical technique of positron emission tomography scanning. Antihydrogen, the bound state of an antiproton and a positron, has been produced(2,3) at low energies at CERN (the European Organization for Nuclear Research) since 2002. Antihydrogen is of interest for use in a precision test of nature's fundamental symmetries. The charge conjugation/parity/time reversal (CPT) theorem, a crucial part of the foundation of the standard model of elementary particles and interactions, demands that hydrogen and antihydrogen have the same spectrum. Given the current experimental precision of measurements on the hydrogen atom (about two parts in 10(14) for the frequency of the 1s-to-2s transition(4)), subjecting antihydrogen to rigorous spectroscopic examination would constitute a compelling, model-independent test of CPT. Antihydrogen could also be used to study the gravitational behaviour of antimatter(5). However, so far experiments have produced antihydrogen that is not confined, precluding detailed study of its structure. Here we demonstrate trapping of antihydrogen atoms. From the interaction of about 10(7) antiprotons and 7 x 10(8) positrons, we observed 38 annihilation events consistent with the controlled release of trapped antihydrogen from our magnetic trap; the measured background is 1.4 +/- 1.4 events. This result opens the door to precision measurements on anti-atoms, which can soon be subjected to the same techniques as developed for hydrogen.	[Andresen, G. B.; Bowe, P. D.; Hangst, J. S.] Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; [Ashkezari, M. D.; Hayden, M. E.] Simon Fraser Univ, Dept Phys, Burnaby, BC V5A 1S6, Canada; [Baquero-Ruiz, M.; Chapman, S.; Fajans, J.; Povilus, A.; So, C.; Wurtele, J. S.] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; [Bertsche, W.; Butler, E.; Charlton, M.; Deller, A.; Eriksson, S.; Humphries, A. J.; Jenkins, M. J.; Jorgensen, L. V.; Madsen, N.; van der Werf, D. P.] Swansea Univ, Dept Phys, Swansea SA2 8PP, W Glam, Wales; [Cesar, C. L.] Univ Fed Rio de Janeiro, Inst Fis, BR-21941972 Rio De Janeiro, Brazil; [Fajans, J.; Wurtele, J. S.] Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Friesen, T.; Fujiwara, M. C.; Hydomako, R.; Thompson, R. I.] Univ Calgary, Dept Phys & Astron, Calgary, AB T2N 1N4, Canada; [Fujiwara, M. C.; Gill, D. R.; Kurchaninov, L.; Olchanski, K.; Olin, A.; Storey, J. W.] TRIUMF, Vancouver, BC V6T 2A3, Canada; [Gutierrez, A.; Hangst, J. S.; el Nasr, S. Seif] Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; [Jonsell, S.] Stockholm Univ, SE-10691 Stockholm, Sweden; [Menary, S.] York Univ, Dept Phys & Astron, Toronto, ON M3J 1P3, Canada; [Nolan, P.; Pusa, P.] Univ Liverpool, Dept Phys, Liverpool L69 7ZE, Merseyside, England; [Robicheaux, F.] Auburn Univ, Dept Phys, Auburn, AL 36849 USA; [Sarid, E.] Nucl Res Ctr Negev, Dept Phys, IL-84190 Beer Sheva, Israel; [Silveira, D. M.; Yamazaki, Y.] RIKEN, Atom Phys Lab, Wako, Saitama 3510198, Japan; [Yamazaki, Y.] Univ Tokyo, Grad Sch Arts & Sci, Tokyo 1538902, Japan	Aarhus University; Simon Fraser University; University of California System; University of California Berkeley; Swansea University; Universidade Federal do Rio de Janeiro; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of Calgary; University of British Columbia; University of British Columbia; Stockholm University; York University - Canada; University of Liverpool; Auburn University System; Auburn University; RIKEN; University of Tokyo	Hangst, JS (corresponding author), Aarhus Univ, Dept Phys & Astron, DK-8000 Aarhus C, Denmark.	hangst@phys.au.dk	Bertsche, William/A-3678-2012; quantica, Inct Informacao/H-9493-2013; Fajans, Joel/J-6597-2016; Jonsell, Svante/J-2251-2016; Yamazaki, Yasunori/N-8018-2015; Hardy, Walter Newbold/AAN-7827-2020; Madsen, Niels/I-2314-2019; Wurtele, Jonathan S/J-6278-2016; Butler, Eoin/G-6413-2011; Jørgensen, Lars V/B-8991-2012; Madsen, Niels/G-3548-2013; Cesar, Claudio/AAH-4612-2021; Robicheaux, Francis/F-4343-2014; Andresen, Gorm Bruun/M-7610-2018	Bertsche, William/0000-0002-6565-9282; Fajans, Joel/0000-0002-4403-6027; Jonsell, Svante/0000-0003-4969-1714; Yamazaki, Yasunori/0000-0001-5712-0853; Madsen, Niels/0000-0002-7372-0784; Wurtele, Jonathan S/0000-0001-8401-0297; Madsen, Niels/0000-0002-7372-0784; Deller, Adam/0000-0002-3430-1501; Robicheaux, Francis/0000-0002-8054-6040; Andresen, Gorm Bruun/0000-0002-4820-020X; Eriksson, Stefan/0000-0002-5390-1879; Kurchaninov, Leonid/0000-0001-9392-3936; Cesar, Claudio/0000-0003-2638-0032; Friesen, Timothy/0000-0002-7017-9662; Butler, Eoin/0000-0003-0947-7166; van der Werf, Dirk/0000-0001-5436-5214	CNPq (Brazil); FINEP/RENAFAE (Brazil); ISF (Israel); MEXT (Japan); FNU (Denmark); VR (Sweden); NSERC (Canada); NRC/TRIUMF (Canada); AIF (Canada); FQRNT (Canada); DOE (USA); NSF (USA); EPSRC (UK); Royal Society (UK); Leverhulme Trust (UK); Engineering and Physical Sciences Research Council [EP/E048951/1, EP/F019785/1, EP/D038707/1, EP/D040108/1] Funding Source: researchfish; EPSRC [EP/E048951/1, EP/F019785/1, EP/D040108/1, EP/D038707/1] Funding Source: UKRI	CNPq (Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FINEP/RENAFAE (Brazil)(Financiadora de Inovacao e Pesquisa (Finep)); ISF (Israel)(Israel Science Foundation); MEXT (Japan)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); FNU (Denmark)(Danish Natural Science Research Council); VR (Sweden)(Swedish Research Council); NSERC (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); NRC/TRIUMF (Canada); AIF (Canada); FQRNT (Canada)(FQRNT); DOE (USA)(United States Department of Energy (DOE)); NSF (USA)(National Science Foundation (NSF)); EPSRC (UK)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society (UK)(Royal Society of London); Leverhulme Trust (UK)(Leverhulme Trust); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by CNPq, FINEP/RENAFAE (Brazil); ISF (Israel); MEXT (Japan); FNU (Denmark); VR (Sweden); NSERC, NRC/TRIUMF, AIF, FQRNT (Canada); the DOE and the NSF (USA); and EPSRC, the Royal Society and the Leverhulme Trust (UK). We thank them for their generous support. We are grateful to the Antiproton Decelerator team, T. Eriksson, P. Belochitskii, B. Dupuy, L. Bojtar, C. Oliveira, K. Mikluha and G. Tranquille, for the delivery of a high-quality antiproton beam. The contributions of summer students C. C. Bray, C. O. Rasmussen, S. Kemp, K. K. Andersen, D. Wilding, K. Mikkelsen and L. Bryngemark are acknowledged. We would like to thank the following individuals for help: M. Harrison, J. Escallier, A. Marone, M. Anerella, A. Ghosh, B. Parker, G. Ganetis, J. Thornhill, D. Wells, D. Seddon, K. Dahlerup-Pedersen, J. Mourao, T. Fowler, S. Russenschuck, R. De Oliveira, N. Wauquier, J. Hansen, M. Polini, J. M. Geisser, L. Deparis, P. Frichot, J. M. Malzacker, A. Briswalter, P. Moyret, S. Mathot, G. Favre, J. P. Brachet, P. Mesenge, S. Sgobba, A. Cherif, J. Bremer, J. Casas-Cubillos, N. Vauthier, G. Perinic, O. Pirotte, A. Perin, G. Perinic, B. Vullierme, D. Delkaris, N. Veillet, K. Barth, R. Consentino, S. Guido, L. Stewart, M. Malabaila, A. Mongelluzzo, P. Chiggiato, E. Mahner, A. Froton, C. Lasseur, F. Hahn, E. Sondergaard, F. Mikkelsen, W. Carlisle, A. Charman, J. Keller, P. Amaudruz, D. Bishop, R. Bula, K. Langton, P. Vincent, S. Chan, D. Rowbotham, P. Bennet, B. Evans, J.-P. Martin, P. Kowalski, A. Read, T. Willis, J. Kivell, H. Thomas, W. Lai, L. Wasilenko, C. Kolbeck, H. Malik, P. Genoa, L. Posada and R. Funakoshi.	Amoretti M, 2002, NATURE, V419, P456, DOI 10.1038/nature01096; Amoretti M, 2004, PHYS LETT B, V583, P59, DOI 10.1016/j.physletb.2004.01.009; Andresen G, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.023402; Andresen GB, 2011, PHYS LETT B, V695, P95, DOI 10.1016/j.physletb.2010.11.004; Andresen GB, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.013003; Andresen GB, 2010, PHYS LETT B, V685, P141, DOI 10.1016/j.physletb.2010.01.066; Andresen GB, 2009, REV SCI INSTRUM, V80, DOI 10.1063/1.3266967; Andresen GB, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.203401; Barth I, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.155001; Bertsche W, 2006, NUCL INSTRUM METH A, V566, P746, DOI 10.1016/j.nima.2006.07.012; Danielson JR, 2006, PHYS PLASMAS, V13, DOI 10.1063/1.2179410; Dirac PAM, 1931, P R SOC LOND A-CONTA, V133, P60, DOI 10.1098/rspa.1931.0130; DROBYCHEV GY, 2007, SPSCP334 EUR ORG NUC; EGGLESTON DL, 1992, PHYS FLUIDS B-PLASMA, V4, P3432, DOI 10.1063/1.860399; Fajans J, 1999, PHYS REV LETT, V82, P4444, DOI 10.1103/PhysRevLett.82.4444; Fajans J, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.155001; Fujiwara MC, 2008, AIP CONF PROC, V1037, P208, DOI 10.1063/1.2977840; Gabrielse G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.213401; GABRIELSE G, 1988, PHYS LETT A, V129, P38, DOI 10.1016/0375-9601(88)90470-7; GABRIELSE G, 1989, PHYS REV LETT, V63, P1360, DOI 10.1103/PhysRevLett.63.1360; GABRIELSE G, 1986, PHYS REV LETT, V57, P2504, DOI 10.1103/PhysRevLett.57.2504; HESS HF, 1986, PHYS REV B, V34, P3476, DOI 10.1103/PhysRevB.34.3476; Huang XP, 1997, PHYS REV LETT, V78, P875, DOI 10.1103/PhysRevLett.78.875; Jorgensen LV, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.025002; Maury S, 1997, HYPERFINE INTERACT, V109, P43, DOI 10.1023/A:1012632812327; Niering M, 2000, PHYS REV LETT, V84, P5496, DOI 10.1103/PhysRevLett.84.5496; PRITCHARD DE, 1983, PHYS REV LETT, V51, P1336, DOI 10.1103/PhysRevLett.51.1336; Surko CM, 2004, PHYS PLASMAS, V11, P2333, DOI 10.1063/1.1651487	28	243	243	4	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2010	468	7324					673	U1		10.1038/nature09610	http://dx.doi.org/10.1038/nature09610			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	688GB	21085118				2022-12-28	WOS:000284836700036
J	Hallam, MJ; Cubison, T; Dheansa, B; Imray, C				Hallam, Marc-James; Cubison, Tania; Dheansa, Baljit; Imray, Chris			Managing frostbite	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INJURY; HYPOTHERMIA; COLD; EXTREMITIES; MANAGEMENT; AMPUTATION; CHILDHOOD; SKIN		[Imray, Chris] Warwick Med Sch, Warwick, England	University of Warwick		mj_hallam@hotmail.co.uk		Dheansa, Baljit/0000-0003-1418-9986; imray, chris/0000-0001-8451-4102; Christopher, Imray/0000-0001-9889-6308; Hallam, Marc-James/0000-0002-5813-8120				BAKER JR, 1997, ANN PLAST SURG, V38, P275; Biem J, 2003, CAN MED ASSOC J, V168, P305; BIGELOW DR, 1963, J BONE JOINT SURG BR, V45, P122, DOI 10.1302/0301-620X.45B1.122; BRITT LD, 1991, SURG CLIN N AM, V71, P345; Bruen KJ, 2007, ARCH SURG-CHICAGO, V142, P546, DOI 10.1001/archsurg.142.6.546; CARRERA GF, 1981, SKELETAL RADIOL, V6, P33; Cauchy E, 2000, J HAND SURG-AM, V25A, P969, DOI 10.1053/jhsu.2000.16357; Craig R P, 2007, J R Army Med Corps, V153 Suppl 1, P63; DeGroot DW, 2003, AVIAT SPACE ENVIR MD, V74, P564; Ervasti O, 2000, Int J Circumpolar Health, V59, P137; FRANCIS TJR, 1996, TXB VASCULAR MED; Greenwald D, 1998, PLAST RECONSTR SURG, V102, P1069, DOI 10.1097/00006534-199809040-00023; HERVEY GR, 1973, P ROY SOC MED, V66, P1053, DOI 10.1177/003591577306601034; IKAWA G, 1986, ORTHOPEDICS, V9, P1257; Imray C, 2009, POSTGRAD MED J, V85, P481, DOI 10.1136/pgmj.2008.068635; Keatinge W. R., 1994, P307; Lewis T, 1930, HEART-J STUD CIRC, V15, P177; MARZELLA L, 1989, PLAST RECONSTR SURG, V83, P67, DOI 10.1097/00006534-198901000-00012; McCauley R.L., 1995, WILDERNESS MED MANAG, V3rd, P129; MCCAULEY RL, 1983, J TRAUMA, V23, P143, DOI 10.1097/00005373-198302000-00013; Murphy JV, 2000, J TRAUMA, V48, P171, DOI 10.1097/00005373-200001000-00036; QUINTILLANA R, 1947, AM J PHYSIOL, V230, P406; RAINE TJ, 1980, SURG FORUM, V31, P557; Rintamaki H, 2000, Int J Circumpolar Health, V59, P114; ROSSIS CG, 1982, J ROY SOC MED, V75, P715; Sheridan RL, 2009, NEW ENGL J MED, V361, P2654, DOI 10.1056/NEJMcpc0910088; Su CW, 2000, HAND CLIN, V16, P235; SUMNER DS, 1974, MIL MED, V139, P454; Thomas JR., 2002, MED ASPECTS HARSH EN, V1, P467; VALNICEK SM, 1993, PLAST RECONSTR SURG, V92, P633, DOI 10.1097/00006534-199309001-00012; Zook N, 1998, ANN PLAS SURG, V40, P246, DOI 10.1097/00000637-199803000-00009	31	58	60	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 19	2010	341								c5864	10.1136/bmj.c5864	http://dx.doi.org/10.1136/bmj.c5864			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684WU	21097571				2022-12-28	WOS:000284586800004
J	Lerman, J; Palsson, BO				Lerman, Joshua; Palsson, Bernhard O.			Topping Off a Multiscale Balancing Act	SCIENCE			English	Editorial Material							GENOME-SCALE MODELS; ESCHERICHIA-COLI; OPTIMAL-GROWTH; EVOLUTION; CONSEQUENCES; CONSISTENT; CELL		[Lerman, Joshua; Palsson, Bernhard O.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Lerman, J (corresponding author), Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.	palsson@ucsd.edu		Palsson, Bernhard/0000-0003-2357-6785; Lerman, Joshua/0000-0003-0377-2674				Bonneau R, 2007, CELL, V131, P1354, DOI 10.1016/j.cell.2007.10.053; De Smet R, 2010, NAT REV MICROBIOL, V8, P717, DOI 10.1038/nrmicro2419; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Herrgard MJ, 2006, GENOME RES, V16, P627, DOI 10.1101/gr.4083206; Herring CD, 2006, NAT GENET, V38, P1406, DOI 10.1038/ng1906; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Lewis NE, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.47; Ollis D.F., 2006, BIOCH ENG FUNDAMENTA; Palsson B, 2000, NAT BIOTECHNOL, V18, P1147, DOI 10.1038/81125; PIRT SJ, 1965, PROC R SOC SER B-BIO, V163, P224, DOI 10.1098/rspb.1965.0069; Price ND, 2004, NAT REV MICROBIOL, V2, P886, DOI 10.1038/nrmicro1023; Scott M, 2010, SCIENCE, V330, P1099, DOI 10.1126/science.1192588; Teusink B, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000410; Thiele I, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000312	15	1	1	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1058	1059		10.1126/science.1199353	http://dx.doi.org/10.1126/science.1199353			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097927				2022-12-28	WOS:000284374700029
J	Xiong, P; Nocek, JM; Vura-Weis, J; Lockard, JV; Wasielewski, MR; Hoffman, BM				Xiong, Peng; Nocek, Judith M.; Vura-Weis, Josh; Lockard, Jenny V.; Wasielewski, Michael R.; Hoffman, Brian M.			Faster Interprotein Electron Transfer in a [Myoglobin, b(5)] Complex with a Redesigned Interface	SCIENCE			English	Article							CYTOCHROME-OXIDASE; PROTEINS; STATE	Direct measurements of electron transfer (ET) within a protein-protein complex with a redesigned interface formed by physiological partner proteins myoglobin (Mb) and cytochrome b(5) (b(5)) reveal interprotein ET rates comparable to those observed within the photosynthetic reaction center. Brownian dynamics simulations show that Mb in which three surface acid residues are mutated to lysine binds b(5) in an ensemble of configurations distributed around a reactive most-probable structure. Correspondingly, charge-separation ET from a photoexcited singlet zinc porphyrin incorporated within Mb to the heme of b(5) and the follow-up charge-recombination exhibit distributed kinetics, with median rate constants, k(f)(s) = 2.1 x 10(9) second(-1) and k(b)(s) = 4.3 x 10(10) second(-1), respectively. The latter approaches that for the initial step in photosynthetic charge separation, k = 3.3 x 10(11) second(-1).	[Xiong, Peng; Nocek, Judith M.; Vura-Weis, Josh; Lockard, Jenny V.; Wasielewski, Michael R.; Hoffman, Brian M.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Xiong, Peng] Huaiyin Inst Technol, Sch Life Sci & Chem Engn, Huaian 223003, Jiangsu Prov, Peoples R China; [Vura-Weis, Josh; Lockard, Jenny V.; Wasielewski, Michael R.] Northwestern Univ, Argonne NW Solar Energy Res Ctr, Evanston, IL 60208 USA	Northwestern University; Huaiyin Institute of Technology; Northwestern University	Wasielewski, MR (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	bmh@northwestern.edu	Nocek, Judith/D-1254-2010; xiong, peng/AAF-1569-2021; xiong, peng/AAT-6376-2020		National Institute of Health [HL063203]; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-SC0001059]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063203] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding for this work was provided as follows: P. X., J.M.N., and B. M. H., the National Institute of Health (grant HL063203); J.V.-W., J.V.L., and M. R. W., as part of the ANSER Center, an Energy Frontier Research Center funded by U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences (DE-SC0001059).	[Anonymous], 2002, PHOTOSYNTHETICA; Beratan DN, 2009, ACCOUNTS CHEM RES, V42, P1669, DOI 10.1021/ar900123t; Berberan-Santos MN, 2005, CHEM PHYS, V315, P171, DOI 10.1016/j.chemphys.2005.04.006; Davidson VL, 2008, ACCOUNTS CHEM RES, V41, P730, DOI 10.1021/ar700252c; Geren L, 2009, METHOD ENZYMOL, V456, P507, DOI 10.1016/S0076-6879(08)04428-5; Gong XM, 2003, BIOCHEMISTRY-US, V42, P14492, DOI 10.1021/bi035603c; Gray HB, 2005, P NATL ACAD SCI USA, V102, P3534, DOI 10.1073/pnas.0408029102; Ivkovic-Jensen MM, 1999, BIOCHEMISTRY-US, V38, P1589, DOI 10.1021/bi9817156; Lukoyanov D, 2007, P NATL ACAD SCI USA, V104, P1451, DOI 10.1073/pnas.0610975104; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; Nocek JM, 1997, J AM CHEM SOC, V119, P2146, DOI 10.1021/ja9630811; Nocek JM, 2010, J AM CHEM SOC, V132, P6165, DOI 10.1021/ja100499j; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; PAPP S, 1990, BIOPHYS J, V58, P177, DOI 10.1016/S0006-3495(90)82363-8; Prudencio M, 2004, J MOL RECOGNIT, V17, P524, DOI 10.1002/jmr.686; WINKLER JR, 1995, BIOPHYS CHEM, V54, P199, DOI 10.1016/0301-4622(94)00156-E	16	50	50	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1075	1078		10.1126/science.1197054	http://dx.doi.org/10.1126/science.1197054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097931	Green Accepted			2022-12-28	WOS:000284374700035
J	Coker, TR; Chan, LS; Newberry, SJ; Limbos, MA; Suttorp, MJ; Shekelle, PG; Takata, GS				Coker, Tumaini R.; Chan, Linda S.; Newberry, Sydne J.; Limbos, Mary Ann; Suttorp, Marika J.; Shekelle, Paul G.; Takata, Glenn S.			Diagnosis, Microbial Epidemiology, and Antibiotic Treatment of Acute Otitis Media in Children A Systematic Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PNEUMOCOCCAL CONJUGATE VACCINE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; PRESCRIBING STRATEGIES; CLINICAL-EFFICACY; GENERAL-PRACTICE; AMOXICILLIN; MANAGEMENT; CEFACLOR; PLACEBO	Context Acute otitis media (AOM) is the most common condition for which antibiotics are prescribed for US children; however, wide variation exists in diagnosis and treatment. Objectives To perform a systematic review on AOM diagnosis, treatment, and the association of heptavalent pneumococcal conjugate vaccine (PCV7) use with AOM microbiology. Data Sources PubMed, Cochrane Databases, and Web of Science, searched to identify articles published from January 1999 through July 2010. Study Selection Diagnostic studies with a criterion standard, observational studies and randomized controlled trials comparing AOM microbiology with and without PCV7, and randomized controlled trials assessing antibiotic treatment. Data Extraction Independent article review and study quality assessment by 2 investigators with consensus resolution of discrepancies. Results Of 8945 citations screened, 135 were included. Meta-analysis was performed for comparisons with 3 or more trials. Few studies examined diagnosis; otoscopic findings of tympanic membrane bulging (positive likelihood ratio, 51[95% confidence interval {CI}, 36-73]) and redness (positive likelihood ratio, 8.4 [95% CI, 7-11]) were associated with accurate diagnosis. In the few available studies, prevalence of Streptococcus pneumoniae decreased (eg, 33%-48% vs 23%-31% of AOM isolates), while that of Haemophilus influenzae increased (41%-43% vs 56%-57%) pre-vs post-PCV7. Short-term clinical success was higher for immediate use of ampicillin or amoxicillin vs placebo(73% vs 60%; pooled rate difference, 12% [95% CI, 5%-18%]; number needed to treat, 9 [95% CI, 6-20]), while increasing the rate of rash or diarrhea by 3% to 5%. Two of 4 studies showed greater clinical success for immediate vs delayed antibiotics(95% vs 80%; rate difference, 15% [95% CI, 6%-24%] and 86% vs 70%; rate difference, 16% [95% CI, 6%-26%]). Data are absent on long-term effects on antimicrobial resistance. Meta-analyses in general showed no significant differences in antibiotic comparative effectiveness. Conclusions Otoscopic findings are critical to accurate AOM diagnosis. AOM microbiology has changed with use of PCV7. Antibiotics are modestly more effective than no treatment but cause adverse effects in 4% to 10% of children. Most antibiotics have comparable clinical success. JAMA. 2010; 304(19): 2161-2169	[Coker, Tumaini R.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90024 USA; [Coker, Tumaini R.] RAND, Santa Monica, CA USA; [Chan, Linda S.] Los Angeles Cty USC Med Ctr, Div Biostat & Outcomes Assessment, Los Angeles, CA USA; [Chan, Linda S.; Limbos, Mary Ann; Takata, Glenn S.] USC Keck Sch Med, Los Angeles, CA USA; [Newberry, Sydne J.; Suttorp, Marika J.; Shekelle, Paul G.] RAND Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA; [Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA; [Takata, Glenn S.] Childrens Hosp Los Angeles, Div Gen Pediat, Los Angeles, CA 90027 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; RAND Corporation; University of Southern California; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; Children's Hospital Los Angeles	Coker, TR (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, UCLA RAND Ctr Adolescent Hlth Promot, 10960 Wilshire Blvd,Ste 1550, Los Angeles, CA 90024 USA.	tcoker@mednet.ucla.edu			Agency for Healthcare Research and Quality (AHRQ) [290-2007-10056]; EPC	Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); EPC	This article is based on research conducted by the Southern California Evidence-based Practice Center (EPC) under contract with the Agency for Healthcare Research and Quality (AHRQ) (contract 290-2007-10056). This work was commissioned by AHRQ as an update to an earlier report and in support of the update of practice guidelines.; AHRQ had a role, through its sponsorship of the EPC program, in the general methods of EPC systematic reviews and in development of the key questions for each review. However, AHRQ had no role in the specific conduct of the review; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.	Adcock BB, 1996, ARCH FAM MED, V5, P301, DOI 10.1001/archfami.5.5.301; Bartlett JG, 2002, NEW ENGL J MED, V346, P334, DOI 10.1056/NEJMcp011603; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BERMAN S, 1983, PEDIATR INFECT DIS J, V2, P30, DOI 10.1097/00006454-198301000-00008; Block SL, 2004, PEDIATR INFECT DIS J, V23, P829, DOI 10.1097/01.inf.0000136868.91756.80; Brook I, 2009, PEDIATR INFECT DIS J, V28, P640, DOI 10.1097/INF.0b013e3181975221; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Casellas JM, 2005, INT J PEDIATR OTORHI, V69, P1225, DOI 10.1016/j.ijporl.2005.03.016; Casey JR, 2010, PEDIATR INFECT DIS J, V29, P304, DOI 10.1097/INF.0b013e3181c1bc48; Casey JR, 2004, PEDIATR INFECT DIS J, V23, P824, DOI 10.1097/01.inf.0000136871.51792.19; Chan LS, 2001, PEDIATRICS, V108, P248, DOI 10.1542/peds.108.2.248; Coco A, 2010, PEDIATRICS, V125, P214, DOI 10.1542/peds.2009-1115; Cohen J., 1977, STATISTICAL POWER AN, P179, DOI [10.1016/b978-0-12-179060-8.50011-6, DOI 10.1016/B978-0-12-179060-8.50011]; Cohen R, 1998, J PEDIATR-US, V133, P634, DOI 10.1016/S0022-3476(98)70103-9; Dagan R, 2000, PEDIATR INFECT DIS J, V19, P95, DOI 10.1097/00006454-200002000-00002; Daly KA, 1999, PEDIATRICS, V103, P1158, DOI 10.1542/peds.103.6.1158; Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; GEYMAN JP, 1978, J FAM PRACTICE, V7, P493; HALSTED C, 1967, ANN NY ACAD SCI, V145, P372, DOI 10.1111/j.1749-6632.1967.tb50234.x; HEIKKINEN T, 1995, ARCH PEDIAT ADOL MED, V149, P26, DOI 10.1001/archpedi.1995.02170130028006; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; INGVARSSON L, 1982, ACTA PAEDIATR SCAND, V71, P705, DOI 10.1111/j.1651-2227.1982.tb09507.x; JACOBSON JA, 1979, POSTGRAD MED J, V55, P39; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KALEIDA PH, 1991, PEDIATRICS, V87, P466; Kara C.O., 1998, Infez Med, V6, P93; KARMA PH, 1989, INT J PEDIATR OTORHI, V17, P37, DOI 10.1016/0165-5876(89)90292-9; Kontiokari T, 1998, PEDIATR INFECT DIS J, V17, P676, DOI 10.1097/00006454-199808000-00003; Kozyrskyj AL, 1998, JAMA-J AM MED ASSOC, V279, P1736, DOI 10.1001/jama.279.21.1736; Kozyrskyj AL, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001095; Laine MK, 2010, PEDIATRICS, V125, pE1154, DOI 10.1542/peds.2009-2689; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; Le Saux N, 2005, CAN MED ASSOC J, V172, P335, DOI 10.1503/cmaj.1040771; Legros JM, 2007, ARCH PEDIATRIE, V14, P427, DOI 10.1016/j.arcped.2006.12.023; LEIGH AP, 1989, BRIT J CLIN PRACT, V43, P140; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336; Little P, 2006, BRIT J GEN PRACT, V56, P176; MARCY M, 2001, PUBLICATION AGENCY H; McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096; McCormick DP, 2005, PEDIATRICS, V115, P1455, DOI 10.1542/peds.2004-1665; McEllistrem MC, 2005, CLIN INFECT DIS, V40, P1738, DOI 10.1086/429908; MCLINN SE, 1980, AM J DIS CHILD, V134, P560, DOI 10.1001/archpedi.1980.02130180018006; Neumark T, 2007, SCAND J PRIM HEALTH, V25, P166, DOI 10.1080/02813430701267405; NIEMELA M, 1994, PEDIATR INFECT DIS J, V13, P765, DOI 10.1097/00006454-199409000-00002; OWEN MJ, 1993, AM J DIS CHILD, V147, P81, DOI 10.1001/archpedi.1993.02160250083027; Pichichero ME, 2008, PEDIATR INFECT DIS J, V27, P958, DOI 10.1097/INF.0b013e318179a2ac; Rao SDS, 1998, J CHEMOTHERAPY, V10, P460, DOI 10.1179/joc.1998.10.6.460; Rosenfeld RM, 2003, LARYNGOSCOPE, V113, P1645, DOI 10.1097/00005537-200310000-00004; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; Saeed K, 2004, PEDIATR INFECT DIS J, V23, P1030, DOI 10.1097/01.inf.0000143653.69275.4d; Sanders S, 1999, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000219.PUB2; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Simel DL, 2009, RATIONAL CLIN EXAMIN; Simon MW, 1997, ADV THER, V14, P312; *SO CAL EV BAS PRA, 2010, MAN AC OT MED UPD; Spiro DM, 2006, JAMA-J AM MED ASSOC, V296, P1235, DOI 10.1001/jama.296.10.1235; Spurling GKP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004417.pub3; *STATACORP, 2007, VERS 10 COMP PROGR; Takata GS, 2001, PEDIATRICS, V108, P239, DOI 10.1542/peds.108.2.239; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; VANBUCHEM FL, 1981, LANCET, V2, P883; Veenhoven R, 2003, LANCET, V361, P2189, DOI 10.1016/S0140-6736(03)13772-5; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25	70	174	187	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2161	2169		10.1001/jama.2010.1651	http://dx.doi.org/10.1001/jama.2010.1651			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081729	Bronze			2022-12-28	WOS:000284269800027
J	Kamath, A; Jense, RJ				Kamath, Aruna; Jense, Ryan J.			Health Systems Strengthening Mechanism for the Global Health Initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Jense, Ryan J.] VA Puget Sound Med Ctr, Seattle, WA 98108 USA; [Jense, Ryan J.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Jense, Ryan J.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Kamath, Aruna] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University	Jense, RJ (corresponding author), VA Puget Sound Med Ctr, S-112 Anes,1660 S Columbian Way, Seattle, WA 98108 USA.	rjjense@uw.edu						[Anonymous], IMPL GLOB HLTH IN CO; *GLOB HLTH COUNC, POL BRIEF CRIT SHORT; *I MED BOARD GLOB, 2009, US COMM GLOB HLTH RE; Jense Ryan J, 2009, Am J Orthop (Belle Mead NJ), V38, pE18; *KAIS FAM FDN, US GOV GLOB HLTH POL; Kaiser Family Foundation, 2010, US GLOB HLTH IN KEY; *USAID, HLTH SYST REP C SUST; *WHO, 2003, INT MAN EM ESS SURG; World Health Organization (WHO), 2006, WORLD HLTH REP 2006	9	5	5	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2176	2177		10.1001/jama.2010.1675	http://dx.doi.org/10.1001/jama.2010.1675			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081733				2022-12-28	WOS:000284269800031
J	Roxas, R				Roxas, Renato, Jr.			Review: Some drugs are effective for preventing migraine headache; limited evidence exists on the relative effectiveness of drugs	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Wayne State Univ, Sch Med, Detroit, MI 48202 USA	Wayne State University	Roxas, R (corresponding author), Wayne State Univ, Sch Med, Detroit, MI 48202 USA.							FREEMAN MC, 2006, PSYCHIAT TIMES; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; Snow V, 2002, ANN INTERN MED, V137, P840, DOI 10.7326/0003-4819-137-10-200211190-00014	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-4	10.1059/0003-4819-153-10-201011160-02004	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079211				2022-12-28	WOS:000284215800003
J	Shrank, WH; Choudhry, NK; Fischer, MA; Avorn, J; Powell, M; Schneeweiss, S; Liberman, JN; Dollear, T; Brennan, TA; Brookhart, MA				Shrank, William H.; Choudhry, Niteesh K.; Fischer, Michael A.; Avorn, Jerry; Powell, Mark; Schneeweiss, Sebastian; Liberman, Joshua N.; Dollear, Timothy; Brennan, Troyen A.; Brookhart, M. Alan			The Epidemiology of Prescriptions Abandoned at the Pharmacy	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICATION ADHERENCE; NONADHERENCE; PERSISTENCE; MORTALITY; VALIDITY; DRUGS; PROXY	Background: Picking up prescriptions is an essential but previously unstudied component of adherence for patients who use retail pharmacies. Understanding the epidemiology and correlates of prescription abandonment may have an important effect on health care quality. Objective: To evaluate the rates and correlates of prescription abandonment. Design: Cross-sectional cohort study. Setting: One large retail pharmacy chain and one large pharmacy benefits manager (PBM) in the United States. Measurements: Prescriptions bottled at the retail pharmacy chain between 1 July 2008 and 30 September 2008 by patients insured by the PBM were identified. Pharmacy data were used to identify medications that were bottled and either dispensed or returned to stock (RTS) or abandoned. Data from the PBM were used to identify previous or subsequent dispensing at any pharmacy. The first (index) prescription in a class for each patient was assigned to 1 of 3 mutually exclusive outcomes: filled, RTS, or RTS with fill (in the 30 days after abandonment, the patient purchased a prescription for a medication in the same medication class at any pharmacy). Outcome rates were assessed by drug class, and generalized estimating equations were used to assess patient, neighborhood, insurance, and prescription characteristics associated with abandonment. Results: 10 349 139 index prescriptions were filled by 5 249 380 patients. Overall, 3.27% of index prescriptions were abandoned; 1.77% were RTS and 1.50% were RTS with fill. Patients were least likely to abandon opiate prescriptions. Prescriptions with copayments of $40 to $50 and prescriptions costing more than $50 were 3.40 times and 4.68 times more likely, respectively, to be abandoned than prescriptions with no copayment (P < 0.001 for both comparisons). New users of medications had a 2.74 times greater probability of abandonment than prevalent users (P < 0.001), and prescriptions delivered electronically were 1.64 times more likely to be abandoned than those that were not electronic (P < 0.001). Limitation: The study included mainly insured patients and analyzed data collected during the summer months only. Conclusion: Although prescription abandonment represents a small component of medication nonadherence, the correlates to abandonment highlight important opportunities to intervene and thereby improve medication taking.	[Shrank, William H.] Brigham & Womens Hosp, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Ctr Amer Polit Studies, Cambridge, MA 02138 USA; CVS Caremark, Woonsocket, RI USA; CVS Caremark, Hunt Valley, MD USA; Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; University of North Carolina; University of North Carolina Chapel Hill	Shrank, WH (corresponding author), Brigham & Womens Hosp, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	wshrank@partners.org			CVS Caremark; National Heart, Lung, and Blood Institute [HL-090505]; National Institutes of Health [AG-027400]; Pfizer; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL090505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K25AG027400] Funding Source: NIH RePORTER	CVS Caremark; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By a research grant from CVS Caremark. Dr. Shrank is supported by a career development award from the National Heart, Lung, and Blood Institute (HL-090505), and Dr. Brookhart is supported by a career development grant from the National Institutes of Health (AG-027400).; Dr. Shrank: Grants (money to institution): National Institutes of Health (National Heart, Lung, and Blood career development award), CVS Caremark. Drs. Choudhry, Fischer, Avorn, and Brookhart: Grants (money to institution): CVS Caremark. Dr. Schneeweiss: Grants (money to institution): CVS Caremark. Board membership: HealthCore. Consultancy: WHISCON, RTI Health Solutions, The Lewin Group. Grants/grants pending: Pfizer. Drs. Liberman, Dollear, and Brennan: Employment: CVS Caremark. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOf InterestForms.do?msNum = M10-1125.	Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Chernew ME, 2007, HEALTH AFFAIR, V26, pW195, DOI 10.1377/hlthaff.26.2.w195; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; CHOUDHRY NK, 2010, ARCH INTERN IN PRESS, P27953; Fischer MA, 2010, J GEN INTERN MED, V25, P284, DOI 10.1007/s11606-010-1253-9; Gellad WF, 2009, HEALTH SERV RES, V44, P606, DOI 10.1111/j.1475-6773.2008.00917.x; Geronimus AT, 1998, AM J EPIDEMIOL, V148, P475; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; *GRANT THORNT, 2007, COST DISP STUD IND C, P27953; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; *KAIS FAM FDN, US PRESCR DRUGS, P27953; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Lee JY, 1996, AM J HYPERTENS, V9, P719, DOI 10.1016/0895-7061(96)00056-8; Lee TJ, 2004, ALIMENT PHARM THER, V20, P1241, DOI 10.1111/j.1365-2036.2004.02289.x; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Organization WH, 2003, ADHERENCE LONG TERM; Rasmussen JN, 2007, JAMA-J AM MED ASSOC, V297, P177, DOI 10.1001/jama.297.2.177; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Shah NR, 2009, J GEN INTERN MED, V24, P233, DOI 10.1007/s11606-008-0870-z; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2005, AM J MANAG CARE, V11, P16; Shrank WH, 2006, ANN PHARMACOTHER, V40, P1534, DOI 10.1345/aph.1H158; Shrank WH, 2009, MED CARE, V47, P319, DOI 10.1097/MLR.0b013e31818af850; Soobader MJ, 2001, AM J PUBLIC HEALTH, V91, P632, DOI 10.2105/AJPH.91.4.632; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; U. S. Bureau of the Census, 2002, CENS 2000 URB RUR CL	28	79	79	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					633	640		10.7326/0003-4819-153-10-201011160-00005	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680ES	21079218				2022-12-28	WOS:000284215800015
J	Attwell, D; Buchan, AM; Charpak, S; Lauritzen, M; MacVicar, BA; Newman, EA				Attwell, David; Buchan, Alastair M.; Charpak, Serge; Lauritzen, Martin; MacVicar, Brian A.; Newman, Eric A.			Glial and neuronal control of brain blood flow	NATURE			English	Review							CORTICAL SPREADING DEPRESSION; ACTIVITY-DEPENDENT INCREASES; RAT CEREBELLAR CORTEX; TISSUE-PLASMINOGEN ACTIVATOR; EXCITATORY SYNAPTIC ACTIVITY; NITRIC-OXIDE; FUNCTIONAL HYPEREMIA; CEREBRAL-ISCHEMIA; OXYGEN-CONSUMPTION; CEREBROVASCULAR REACTIVITY	Blood flow in the brain is regulated by neurons and astrocytes. Knowledge of how these cells control blood flow is crucial for understanding how neural computation is powered, for interpreting functional imaging scans of brains, and for developing treatments for neurological disorders. It is now recognized that neurotransmitter-mediated signalling has a key role in regulating cerebral blood flow, that much of this control is mediated by astrocytes, that oxygen modulates blood flow regulation, and that blood flow may be controlled by capillaries as well as by arterioles. These conceptual shifts in our understanding of cerebral blood flow control have important implications for the development of new therapeutic approaches.	[Attwell, David] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England; [Buchan, Alastair M.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Acute Stroke Programme, Oxford OX3 9DU, England; [Charpak, Serge] Univ Paris 05, Lab Neurophysiol & New Microscopies, CNRS, INSERM,U603,UMR 8154, F-75006 Paris, France; [Lauritzen, Martin] Univ Copenhagen, Inst Neurosci & Pharmacol, Dept Clin Neurophysiol, DK-2600 Glostrup, Denmark; [Lauritzen, Martin] Glostrup Cty Hosp, DK-2600 Glostrup, Denmark; [MacVicar, Brian A.] Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; [MacVicar, Brian A.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2B5, Canada; [Newman, Eric A.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA	University of London; University College London; University of Oxford; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Copenhagen; University of Copenhagen; University of British Columbia; University of British Columbia; University of Minnesota System; University of Minnesota Twin Cities	Attwell, D (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, Gower St, London WC1E 6BT, England.	d.attwell@ucl.ac.uk	Buchan, Alastair M/B-9095-2009; Attwell, David/ABE-6750-2020; MacVicar, Brian/P-1553-2015; MacVicar, Brian/AAI-7729-2020; Charpak, Serge/M-9412-2017	Buchan, Alastair M/0000-0002-2918-5200; MacVicar, Brian/0000-0003-4596-4623; MacVicar, Brian/0000-0003-4596-4623; Lauritzen, Martin/0000-0002-1517-1131	Fondation Leducq; European Research Council; Wellcome Trust; UK Medical Research Council; Dunhill Medical Trust; Biomedical Research Centres of the UK National Institute for Health Research; European Commission; Human Frontier Science Program; Danish Medical Research Council; Lundbeck Foundation; Nordea Foundation Centre for Healthy Aging; Novo Nordisk Foundation; Canadian Institutes of Health Research; Canada Research Chair in Neuroscience; US National Institutes of Health (National Eye Institute); Medical Research Council [G0500495] Funding Source: researchfish; NATIONAL EYE INSTITUTE [P30EY011374, R01EY004077] Funding Source: NIH RePORTER	Fondation Leducq(Leducq Foundation); European Research Council(European Research Council (ERC)European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dunhill Medical Trust(Dunhill Medical Trust); Biomedical Research Centres of the UK National Institute for Health Research; European Commission(European CommissionEuropean Commission Joint Research Centre); Human Frontier Science Program(Human Frontier Science Program); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); Nordea Foundation Centre for Healthy Aging; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Neuroscience; US National Institutes of Health (National Eye Institute)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We apologize to those whose work we have not cited because of space constraints. We thank the following for useful discussion: K. Caesar, A. Gjedde, C. Hall, A. Mishra, G. Rees and A. Roth. Work in our laboratories is supported by the Fondation Leducq, the European Research Council, the Wellcome Trust, the UK Medical Research Council, the Dunhill Medical Trust, the Biomedical Research Centres of the UK National Institute for Health Research, the European Commission's Sixth Framework Programme, the Human Frontier Science Program, the Danish Medical Research Council, the Lundbeck Foundation, the Nordea Foundation Centre for Healthy Aging, the Novo Nordisk Foundation, the Canadian Institutes of Health Research, the Canada Research Chair in Neuroscience, and the US National Institutes of Health (National Eye Institute).	Akgoren N, 1996, BRAIN RES, V710, P204, DOI 10.1016/0006-8993(95)01354-7; Akgoren N, 1997, AM J PHYSIOL-HEART C, V273, pH1166, DOI 10.1152/ajpheart.1997.273.3.H1166; AKGOREN N, 1994, P NATL ACAD SCI USA, V91, P5903, DOI 10.1073/pnas.91.13.5903; AMES A, 1968, AM J PATHOL, V52, P437; Armstead WM, 2004, J NEUROTRAUM, V21, P1204, DOI 10.1089/0897715041953849; ASTRUP J, 1978, CIBA F S, V56, P313; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; Behm DJ, 2009, J PHARMACOL EXP THER, V328, P231, DOI 10.1124/jpet.108.145102; Blanco VM, 2008, AM J PHYSIOL-HEART C, V294, pH2855, DOI 10.1152/ajpheart.91451.2007; Boas DA, 2008, NEUROIMAGE, V40, P1116, DOI 10.1016/j.neuroimage.2007.12.061; Busija DW, 2007, BRAIN RES REV, V56, P89, DOI 10.1016/j.brainresrev.2007.05.011; Busija DW, 2008, PROG NEUROBIOL, V86, P379, DOI 10.1016/j.pneurobio.2008.09.008; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; Caesar K, 1999, J PHYSIOL-LONDON, V520, P281, DOI 10.1111/j.1469-7793.1999.00281.x; Caesar K, 2008, J PHYSIOL-LONDON, V586, P1337, DOI 10.1113/jphysiol.2007.144154; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Cauli B, 2004, J NEUROSCI, V24, P8940, DOI 10.1523/JNEUROSCI.3065-04.2004; Chaigneau E, 2007, J NEUROSCI, V27, P6452, DOI 10.1523/JNEUROSCI.3141-06.2007; Chow N, 2007, P NATL ACAD SCI USA, V104, P823, DOI 10.1073/pnas.0608251104; Chuquet J, 2007, J NEUROSCI, V27, P4036, DOI 10.1523/JNEUROSCI.0721-07.2007; Cipolla MJ, 2000, STROKE, V31, P940, DOI 10.1161/01.STR.31.4.940; D'Esposito M, 2003, NAT REV NEUROSCI, V4, P863, DOI 10.1038/nrn1246; Davis RJ, 2004, BRIT J PHARMACOL, V141, P580, DOI 10.1038/sj.bjp.0705645; Doengi M, 2009, P NATL ACAD SCI USA, V106, P17570, DOI 10.1073/pnas.0809513106; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Enager P, 2009, J CEREBR BLOOD F MET, V29, P976, DOI 10.1038/jcbfm.2009.23; FABRICIUS M, 1995, AM J PHYSIOL-HEART C, V269, pH23, DOI 10.1152/ajpheart.1995.269.1.H23; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Filosa JA, 2006, NAT NEUROSCI, V9, P1397, DOI 10.1038/nn1779; Fiser J, 2004, NATURE, V431, P573, DOI 10.1038/nature02907; Fleming I, 2004, PHARMACOL RES, V49, P525, DOI 10.1016/j.phrs.2003.11.016; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Fujimoto Y, 2004, PROSTAG LEUKOTR ESS, V71, P335, DOI 10.1016/j.plefa.2004.06.002; Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052; Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005; GOLANOV EV, 1994, J CEREBR BLOOD F MET, V14, P492, DOI 10.1038/jcbfm.1994.61; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Hall CN, 2008, J PHYSIOL-LONDON, V586, P3597, DOI 10.1113/jphysiol.2008.154724; Hall CN, 2009, NITRIC OXIDE-BIOL CH, V21, P92, DOI 10.1016/j.niox.2009.07.002; Hamilton Nicola B, 2010, Front Neuroenergetics, V2, DOI 10.3389/fnene.2010.00005; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Harder DR, 1996, CIRC RES, V79, P54, DOI 10.1161/01.RES.79.1.54; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hauck EF, 2004, J CEREBR BLOOD F MET, V24, P383, DOI 10.1097/00004647-200404000-00003; Hillman EMC, 2007, NEUROIMAGE, V35, P89, DOI 10.1016/j.neuroimage.2006.11.032; Hirst WD, 1999, MOL CELL NEUROSCI, V13, P57, DOI 10.1006/mcne.1998.0731; Hoffmeyer HW, 2007, J CEREBR BLOOD F MET, V27, P575, DOI 10.1038/sj.jcbfm.9600372; IADECOLA C, 1994, AM J PHYSIOL, V266, pR518, DOI 10.1152/ajpregu.1994.266.2.R518; Ido Y, 2001, FASEB J, V15, P1419, DOI 10.1096/fj.00-0652fje; Johnson NA, 2005, RADIOLOGY, V234, P851, DOI 10.1148/radiol.2343040197; Juranek I, 1999, BBA-MOL CELL BIOL L, V1436, P509, DOI 10.1016/S0005-2760(98)00159-3; KAGSTROM E, 1983, ACTA PHYSIOL SCAND, V118, P281, DOI 10.1111/j.1748-1716.1983.tb07272.x; Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8; Kis B, 2003, J CEREBR BLOOD F MET, V23, P1287, DOI 10.1097/01.WCB.0000090681.07515.81; Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318; KO KR, 1990, AM J PHYSIOL, V259, pH1703, DOI 10.1152/ajpheart.1990.259.6.H1703; Kocharyan A, 2008, J CEREBR BLOOD F MET, V28, P221, DOI 10.1038/sj.jcbfm.9600558; Kuchibhotla KV, 2009, SCIENCE, V323, P1211, DOI 10.1126/science.1169096; Lauritzen M, 2005, NAT REV NEUROSCI, V6, P77, DOI 10.1038/nrn1589; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lecoq J, 2009, J NEUROSCI, V29, P1424, DOI 10.1523/JNEUROSCI.4817-08.2009; LEFFLER CW, 1989, AM J PHYSIOL, V257, pH266, DOI 10.1152/ajpheart.1989.257.1.H266; Leithner C, 2010, J CEREBR BLOOD F MET, V30, P311, DOI 10.1038/jcbfm.2009.211; LI J, 1994, NEUROPHARMACOLOGY, V33, P1453, DOI 10.1016/0028-3908(94)90049-3; Lin AL, 2010, P NATL ACAD SCI USA, V107, P8446, DOI 10.1073/pnas.0909711107; Lindauer U, 1999, AM J PHYSIOL-HEART C, V277, pH799, DOI 10.1152/ajpheart.1999.277.2.H799; Lindauer U, 1996, NEUROSCI LETT, V216, P207, DOI 10.1016/S0304-3940(96)13044-5; Lindauer U, 2010, J CEREBR BLOOD F MET, V30, P757, DOI 10.1038/jcbfm.2009.259; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lovick TA, 1999, NEUROSCIENCE, V92, P47, DOI 10.1016/S0306-4522(98)00737-4; Lu K, 2004, AM J PHYSIOL-HEART C, V286, pH584, DOI 10.1152/ajpheart.00594.2003; Ma JY, 1996, AM J PHYSIOL-HEART C, V270, pH1085, DOI 10.1152/ajpheart.1996.270.3.H1085; Madsen PL, 1999, J CEREBR BLOOD F MET, V19, P393, DOI 10.1097/00004647-199904000-00005; Makani S, 2010, J NEUROPHYSIOL, V103, P667, DOI 10.1152/jn.00948.2009; Mangia S, 2009, J CEREBR BLOOD F MET, V29, P441, DOI 10.1038/jcbfm.2008.134; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Mathiesen C, 1998, J PHYSIOL-LONDON, V512, P555, DOI 10.1111/j.1469-7793.1998.555be.x; Metea MR, 2007, J NEUROSCI, V27, P2468, DOI 10.1523/JNEUROSCI.3204-06.2007; Metea MR, 2006, J NEUROSCI, V26, P2862, DOI 10.1523/JNEUROSCI.4048-05.2006; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; Mulligan SJ, 2004, NATURE, V431, P195, DOI 10.1038/nature02827; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356, DOI 10.1152/ajpheart.1992.263.5.H1356; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Nielsen AN, 2001, J PHYSIOL-LONDON, V533, P773, DOI 10.1111/j.1469-7793.2001.00773.x; Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000; Offenhauser N, 2005, J PHYSIOL-LONDON, V565, P279, DOI 10.1113/jphysiol.2005.082776; Ou JW, 2009, GLIA, V57, P1280, DOI 10.1002/glia.20847; Park L, 2004, J CEREBR BLOOD F MET, V24, P334, DOI 10.1097/01.WCB.0000105800.49957.1E; Park L, 2008, P NATL ACAD SCI USA, V105, P1073, DOI 10.1073/pnas.0708823105; PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619; Peng XQ, 2004, J CEREBR BLOOD F MET, V24, P509, DOI 10.1097/00004647-200405000-00004; Peng XQ, 2002, AM J PHYSIOL-HEART C, V283, pH2029, DOI 10.1152/ajpheart.01130.2000; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Petzold GC, 2008, NEURON, V58, P897, DOI 10.1016/j.neuron.2008.04.029; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Porter JT, 1996, J NEUROSCI, V16, P5073; Powers WJ, 1996, AM J PHYSIOL-HEART C, V270, pH554, DOI 10.1152/ajpheart.1996.270.2.H554; Puro DG, 2007, MICROCIRCULATION, V14, P1, DOI 10.1080/10739680601072099; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Ruitenberg A, 2005, ANN NEUROL, V57, P789, DOI 10.1002/ana.20493; Scheckenbach KEL, 2006, EXP NEUROL, V202, P449, DOI 10.1016/j.expneurol.2006.07.007; Scholvinck ML, 2008, NEUROIMAGE, V40, P1460, DOI 10.1016/j.neuroimage.2008.01.032; Schummers J, 2008, SCIENCE, V320, P1638, DOI 10.1126/science.1156120; SEREBRYAKOV V, 1994, PROSTAGLANDINS, V47, P353, DOI 10.1016/0090-6980(94)90053-1; SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472; St Lawrence KS, 2003, MAGNET RESON MED, V50, P99, DOI 10.1002/mrm.10502; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Sun CW, 2000, AM J PHYSIOL-HEART C, V279, pH339; Sun J, 2008, ARCH BIOCHEM BIOPHYS, V471, P126, DOI 10.1016/j.abb.2008.01.003; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Takata F, 2009, NEUROSCI LETT, V449, P71, DOI 10.1016/j.neulet.2008.10.082; THEILEN H, 1994, J CEREBR BLOOD F MET, V14, P1055, DOI 10.1038/jcbfm.1994.138; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; Ugurbil K, 2000, ANNU REV BIOMED ENG, V2, P633, DOI 10.1146/annurev.bioeng.2.1.633; VANHARREVELD A, 1965, J NEUROCHEM, V12, P431; WAGERLE LC, 1988, CIRC RES, V62, P1019, DOI 10.1161/01.RES.62.5.1019; WAHL M, 1994, BRAIN RES, V637, P204, DOI 10.1016/0006-8993(94)91234-3; WAHL M, 1987, BRAIN RES, V411, P72, DOI 10.1016/0006-8993(87)90682-2; Wang XH, 2006, NAT NEUROSCI, V9, P816, DOI 10.1038/nn1703; Winship IR, 2007, J NEUROSCI, V27, P6268, DOI 10.1523/JNEUROSCI.4801-06.2007; Yang G, 2003, AM J PHYSIOL-HEART C, V285, pH298, DOI 10.1152/ajpheart.00043.2003; Yang G, 1999, AM J PHYSIOL-REG I, V277, pR1760, DOI 10.1152/ajpregu.1999.277.6.R1760; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022; Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4	130	1523	1543	9	236	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					232	243		10.1038/nature09613	http://dx.doi.org/10.1038/nature09613			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068832	Green Accepted			2022-12-28	WOS:000284051000040
J	Boztug, K; Schmidt, M; Schwarzer, A; Banerjee, PP; Diez, IA; Dewey, RA; Bohm, M; Nowrouzi, A; Ball, CR; Glimm, H; Naundorf, S; Kuhlcke, K; Blasczyk, R; Kondratenko, I; Marodi, L; Orange, JS; von Kalle, C; Klein, C				Boztug, Kaan; Schmidt, Manfred; Schwarzer, Adrian; Banerjee, Pinaki P.; Diez, Ines Avedillo; Dewey, Ricardo A.; Boehm, Marie; Nowrouzi, Ali; Ball, Claudia R.; Glimm, Hanno; Naundorf, Sonja; Kuehlcke, Klaus; Blasczyk, Rainer; Kondratenko, Irina; Marodi, Laszlo; Orange, Jordan S.; von Kalle, Christof; Klein, Christoph			Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; SYNDROME PROTEIN; SCID-X1; WASP; TRANSPLANTATION; HOMEOSTASIS; DEFICIENCY; ACTIVATION; MUTATIONS	The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We treated two patients who had this disorder with a transfusion of autologous, genetically modified hematopoietic stem cells (HSC). We found sustained expression of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were functionally corrected. After treatment, the patients' clinical condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis.	[Boztug, Kaan; Schwarzer, Adrian; Diez, Ines Avedillo; Dewey, Ricardo A.; Boehm, Marie; Klein, Christoph] Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany; [Blasczyk, Rainer] Hannover Med Sch, Inst Transfus Med, D-30625 Hannover, Germany; [Schmidt, Manfred; Nowrouzi, Ali; Ball, Claudia R.; Glimm, Hanno; von Kalle, Christof] Natl Ctr Tumor Dis, Heidelberg, Germany; [Schmidt, Manfred; Nowrouzi, Ali; Ball, Claudia R.; Glimm, Hanno; von Kalle, Christof] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Naundorf, Sonja; Kuehlcke, Klaus] EUFETS, Idar Oberstein, Germany; [Banerjee, Pinaki P.; Orange, Jordan S.] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA; [Kondratenko, Irina] Russian Clin Childrens Hosp, Dept Clin Immunol, Moscow, Russia; [Marodi, Laszlo] Univ Debrecen, Med & Hlth Sci Ctr, Dept Infect & Pediat Immunol, Debrecen, Hungary	Hannover Medical School; Hannover Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Debrecen	Klein, C (corresponding author), Hannover Med Sch, Dept Pediat Hematol Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	klein.christoph@mh-hannover.de	Marodi, Laszlo/AAU-9915-2020; Schwarzer, Adrian/AAA-2571-2022; Böhm, Michael/C-3638-2011; Boztug, Kaan/AAM-4161-2021	Boztug, Kaan/0000-0001-8387-9185; Blasczyk, Rainer/0000-0003-3875-3190; Ball, Claudia/0000-0002-1749-3791; Schwarzer, Adrian/0000-0001-5684-2280; Dewey, Ricardo/0000-0003-1677-2745; orange, jordan/0000-0001-7117-7725	Deutsche Forschungsgemeinschaft (DFG) [KliFo 110-2, SPP1230]; Bundesministerium fur Bildung und Forschung (BMBF); CONSERT; PERSIST; CLINIGENE; National Institutes of Health [AI-067946]; Else Kroner-Fresenius Stiftung; Care-for-Rare Foundation; TAMOP [4.2.2-08/1-2008-0015]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067946] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); CONSERT; PERSIST; CLINIGENE(European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Else Kroner-Fresenius Stiftung; Care-for-Rare Foundation; TAMOP; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the Deutsche Forschungsgemeinschaft (DFG KliFo 110-2 and SPP1230) and the Bundesministerium fur Bildung und Forschung (BMBF TreatID, BMBF PID-Net, and BMBF iGENE), the Sixth and Seventh Framework European Economic Community Program (CONSERT, PERSIST, and CLINIGENE), a grant (AI-067946) from the National Institutes of Health, TAMOP (4.2.2-08/1-2008-0015), and a fellowship from the Else Kroner-Fresenius Stiftung (to Dr. Boztug).; We thank the patients and their families for their participation in this study and their openness to share the scientific data resulting from this clinical trial; all the physicians and nurses involved in this study; Paul Fisch of the University of Freiburg for help with TCR V beta spectratyping; Roland Jacobs of Hannover Medical School for help with cytotoxicity assays; Anna Paruzynski and Christina Lulay of the National Center for Tumor Diseases (NCT) and the German Cancer Research Center (DKFZ), Heidelberg, for molecular analyses and data mining; Anne Arens of the NCT and DKFZ, Heidelberg, for bioinformatical analyses; Dr. Hans Ochs of the University of Washington, Seattle, for providing rabbit anti-WASP antibody; Ulrike Kohl of the University Hospital Frankfurt am Main for help with CD34+ cell purification; Jana Diestelhorst of Hannover Medical School for expert technical help; the Hannover Clinical Trial Center for monitoring the clinical trial; and the Care-for-Rare Foundation for its support.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182/blood-2008-12-115253; Boztug K, 2006, CURR OPIN MOL THER, V8, P390; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Dewey RA, 2006, EXP HEMATOL, V34, P1162, DOI 10.1016/j.exphem.2006.04.021; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; Humblet-Baron S, 2007, J CLIN INVEST, V117, P407, DOI 10.1172/JCI29539; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182/blood-2003-05-1480; Klein C, 2003, BLOOD, V101, P2159, DOI 10.1182/blood-2002-05-1423; Manfred S, 2007, NAT METHODS, V4, P1051, DOI 10.1038/nmeth1103; Notarangelo LD, 2008, CURR OPIN HEMATOL, V15, P30, DOI 10.1097/MOH.0b013e3282f30448; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073/pnas.162376099; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Ozsahin H, 2008, BLOOD, V111, P439, DOI 10.1182/blood-2007-03-076679; Puck JM, 2006, NEW ENGL J MED, V355, P1759, DOI 10.1056/NEJMp068209; Sabri S, 2006, BLOOD, V108, P134, DOI 10.1182/blood-2005-03-1219; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038/nm.2088; Thrasher AJ, 2010, NAT REV IMMUNOL, V10, P182, DOI 10.1038/nri2724; Westerberg LS, 2008, BLOOD, V112, P4139, DOI 10.1182/blood-2008-02-140715	25	387	411	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1918	1927		10.1056/NEJMoa1003548	http://dx.doi.org/10.1056/NEJMoa1003548			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067383	Green Accepted			2022-12-28	WOS:000284047600007
J	Parnell, J; Boyce, AJ; Mark, D; Bowden, S; Spinks, S				Parnell, John; Boyce, Adrian J.; Mark, Darren; Bowden, Stephen; Spinks, Sam			Early oxygenation of the terrestrial environment during the Mesoproterozoic	NATURE			English	Article							MICROBIAL SULFATE REDUCTION; SULFUR-ISOTOPE; ATMOSPHERIC OXYGEN; NORTHWEST SCOTLAND; PROTEROZOIC OCEAN; EVOLUTION; AGE; FRACTIONATION; COMBUSTION; BIOSPHERE	Geochemical data from ancient sedimentary successions provide evidence for the progressive evolution of Earth's atmosphere and oceans(1-7). Key stages in increasing oxygenation are postulated for the Palaeoproterozoic era (similar to 2.3 billion years ago, Gyr ago) and the late Proterozoic eon (about 0.8 Gyr ago), with the latter implicated in the subsequent metazoan evolutionary expansion(8). In support of this rise in oxygen concentrations, a large database(1-3,9) shows a marked change in the bacterially mediated fractionation of seawater sulphate to sulphide of Delta (34)S, 25 parts per thousand before 1 Gyr to >= 50 parts per thousand after 0.64 Gyr. This change in Delta (34)S has been interpreted to represent the evolution from single-step bacterial sulphate reduction to a combination of bacterial sulphate reduction and sulphide oxidation, largely bacterially mediated(3,7,9). This evolution is seen as marking the rise in atmospheric oxygen concentrations and the evolution of non-photosynthetic sulphide-oxidizing bacteria(3,7,10). Here we report Delta (34)S values exceeding 50 parts per thousand from a terrestrial Mesoproterozoic (1.18 Gyr old) succession in Scotland, a time period that is at present poorly characterized. This level of fractionation implies disproportionation in the sulphur cycle, probably involving sulphide-oxidizing bacteria, that is not evident from Delta (34)S data in the marine record(1-3,9). Disproportionation in both red beds and lacustrine black shales at our study site suggests that the Mesoproterozoic terrestrial environment was sufficiently oxygenated to support a biota that was adapted to an oxygen-rich atmosphere, but had also penetrated into subsurface sediment.	[Parnell, John; Bowden, Stephen; Spinks, Sam] Univ Aberdeen, Sch Geosci, Aberdeen AB24 3UE, Scotland; [Boyce, Adrian J.; Mark, Darren] Scottish Univ Environm Res Ctr, Glasgow G75 0QF, Lanark, Scotland	University of Aberdeen; Scottish Universities Research & Reactor Center	Parnell, J (corresponding author), Univ Aberdeen, Sch Geosci, Aberdeen AB24 3UE, Scotland.	j.parnell@abdn.ac.uk	Boyce, Adrian/AAH-3203-2020; Boyce, Adrian J/D-2263-2010; Mark, Darren/A-5121-2009	Boyce, Adrian/0000-0002-9680-0787; Boyce, Adrian J/0000-0002-9680-0787; 	University of Aberdeen; NERC; Scottish Universities Consortium; NERC [aif10001, icsf010001] Funding Source: UKRI; Natural Environment Research Council [aif10001, icsf010001] Funding Source: researchfish	University of Aberdeen; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Scottish Universities Consortium; NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank D. Fike for criticism of the manuscript; J. Still, J. B. Fulton and C. W. Taylor for technical help. S. S. is funded by the University of Aberdeen. NERC provides funding for the Argon Isotope and Isotope Community Support Facilities, and SUERC is financially supported by the Scottish Universities Consortium.	Amor K, 2008, GEOLOGY, V36, P303, DOI 10.1130/G24454A.1; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 2004, AM J SCI, V304, P839, DOI 10.2475/ajs.304.10.839; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Coleman M.L, 1978, ANAL CHEM, V28, P199; Darabi MH, 2004, GEOL MAG, V141, P15, DOI 10.1017/S0016756803008148; Fike DA, 2006, NATURE, V444, P744, DOI 10.1038/nature05345; Fry B, 1995, ACS SYM SER, V612, P397; Hurtgen MT, 2005, GEOLOGY, V33, P41, DOI 10.1130/G20923.1; Johnston DT, 2009, P NATL ACAD SCI USA, V106, P16925, DOI 10.1073/pnas.0909248106; Johnston DT, 2007, GEOCHIM COSMOCHIM AC, V71, P3929, DOI 10.1016/j.gca.2007.05.008; Johnston DT, 2005, SCIENCE, V310, P1477, DOI 10.1126/science.1117824; Kah LC, 2001, PRECAMBRIAN RES, V111, P203, DOI 10.1016/S0301-9268(01)00161-9; Lowry D, 2005, GEOL SOC SPEC PUBL, V248, P133, DOI 10.1144/GSL.SP.2005.248.01.07; Lyons TW, 2010, ELEMENTS, V6, P93, DOI 10.2113/gselements.6.2.93; LYONS TW, 2004, PRECAMBRIAN EARTH TE, P421; Machel HG, 2001, SEDIMENT GEOL, V140, P143, DOI 10.1016/S0037-0738(00)00176-7; Poulton SW, 2010, NAT GEOSCI, V3, P486, DOI 10.1038/NGEO889; Prave AR, 2002, GEOLOGY, V30, P811, DOI 10.1130/0091-7613(2002)030<0811:LOLITP>2.0.CO;2; ROBINSON BW, 1975, ANAL CHEM, V47, P1179, DOI 10.1021/ac60357a026; Runnegar B, 1991, PALAEOGEOGR PALAEOCL, V97, P97, DOI 10.1016/0031-0182(91)90186-U; Scott C, 2008, NATURE, V452, P456, DOI 10.1038/nature06811; Sillitoe RH, 1996, SCIENCE, V272, P1153, DOI 10.1126/science.272.5265.1153; STEWART AD, 2002, GEOL SOC MEM, V24; STRAUSS H, 1993, PRECAMBRIAN RES, V63, P225, DOI 10.1016/0301-9268(93)90035-Z; Turnbull MJM, 1996, J GEOL SOC LONDON, V153, P955, DOI 10.1144/gsjgs.153.6.0955; Wagner T, 2002, GEOCHIM COSMOCHIM AC, V66, P2855, DOI 10.1016/S0016-7037(02)00891-8; Wortmann UG, 2001, GEOLOGY, V29, P647, DOI 10.1130/0091-7613(2001)029<0647:HDBIES>2.0.CO;2	30	72	78	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					290	293		10.1038/nature09538	http://dx.doi.org/10.1038/nature09538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068840				2022-12-28	WOS:000284051000048
J	Estrin, D; Sim, I				Estrin, Deborah; Sim, Ida			Open mHealth Architecture: An Engine for Health Care Innovation	SCIENCE			English	Editorial Material									[Estrin, Deborah] Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90095 USA; [Sim, Ida] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California Los Angeles; University of California System; University of California San Francisco	Estrin, D (corresponding author), Univ Calif Los Angeles, Dept Comp Sci, Los Angeles, CA 90095 USA.	destrin@cs.ucla.edu						Cipriani A, 2009, LANCET, V373, P746, DOI 10.1016/S0140-6736(09)60046-5; Earth Institute, 2010, BARR GAPS AFF MHEALT; Health Metrics Network & WHO, 2008, FRAM STAND COUNTR HL; Kleinke JD, 2005, HEALTH AFFAIR, V24, P1246, DOI 10.1377/hlthaff.24.5.1246; Lenhart A., 2010, TEENS MOBILE PHONES; Mars M., 2009, HLTH AFF, V29, P237; Olfson M, 2009, ARCH GEN PSYCHIAT, V66, P848, DOI 10.1001/archgenpsychiatry.2009.81; Stone AA, 2007, SCI REAL TIME DATA C; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; *WHO, FACTS REL CHRON DIS; Zarin DA, 2005, NEW ENGL J MED, V353, P2779, DOI 10.1056/NEJMsa053234; [No title captured]	12	195	199	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					759	760		10.1126/science.1196187	http://dx.doi.org/10.1126/science.1196187			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	675SY	21051617				2022-12-28	WOS:000283855700021
J	Hingorani, AD; Shah, T; Kumari, M; Sofat, R; Smeeth, L				Hingorani, Aroon D.; Shah, Tina; Kumari, Meena; Sofat, Reecha; Smeeth, Liam			Science, medicine, and the future Translating genomics into improved healthcare	BMJ-BRITISH MEDICAL JOURNAL			English	Review							C-REACTIVE PROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; WIDE ASSOCIATION; LINKAGE; METAANALYSIS; SEQUENCE; DISEASE; LOCI		[Smeeth, Liam] Univ London London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England; [Hingorani, Aroon D.; Kumari, Meena] UCL, Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, London WC1E 6BT, England; [Hingorani, Aroon D.; Shah, Tina; Sofat, Reecha] UCL, Div Med, Ctr Clin Pharmacol, London WC1E 6BT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of London; University College London	Smeeth, L (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England.	liam.smeeth@lshtm.ac.uk	; Smeeth, Liam/X-5862-2018	Kumari, Meena/0000-0001-9716-1035; Sofat, Reecha/0000-0002-0242-6115; Smeeth, Liam/0000-0002-9168-6022; Hingorani, Aroon/0000-0001-8365-0081; Shah, Tina/0000-0001-7724-7210	Wellcome Trust [082178]; British Heart Foundation [FS05/125]; MRC; Pfizer; British Heart Foundation [RG/07/008/23674] Funding Source: researchfish; Medical Research Council [G8802774, G19/35, G0902037, G0100222] Funding Source: researchfish; MRC [G0902037] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Pfizer(Pfizer); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	LS is supported by a Wellcome Trust Senior Clinical Fellowship (082178). AH is supported by a senior fellowship from the British Heart Foundation (FS05/125) and is the principal investigator on a MRC Biomarker Award with funding from Pfizer. The funders had no role in the manuscript.	Annes JP, 2010, NEW ENGL J MED, V363, P1100, DOI 10.1056/NEJMp1006029; BENLIAN P, 1990, ANN GENET-PARIS, V33, P65; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Casas JP, 2008, J INTERN MED, V264, P295, DOI 10.1111/j.1365-2796.2008.02015.x; Casas JP, 2006, INT J EPIDEMIOL, V35, P922, DOI 10.1093/ije/dyl041; De La Vega FM, 2002, BIOTECHNIQUES, P48; Duggal P, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-516; Edelman E, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4253; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Freeman BD, 2000, SURGERY, V128, P281, DOI 10.1067/msy.2000.107283; Haddad L, 1999, J LIPID RES, V40, P1113; Heath KE, 2001, EUR J HUM GENET, V9, P244, DOI 10.1038/sj.ejhg.5200633; Hingorani A, 2005, LANCET, V366, P1906, DOI 10.1016/S0140-6736(05)67767-7; Holmes MV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007960; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mendel G, 1865, EXPT PLANT HYBRIDIZA; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Sofat R, 2010, CIRCULATION, V121, P52, DOI 10.1161/CIRCULATIONAHA.109.865444; Talmud PJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4838; Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WHITE R, 1989, GENOME, V31, P1066, DOI 10.1139/g89-183; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120	35	13	13	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2010	341								c5945	10.1136/bmj.c5945	http://dx.doi.org/10.1136/bmj.c5945			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678DN	21056961	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000284052400007
J	Krueger, DA; Care, MM; Holland, K; Agricola, K; Tudor, C; Mangeshkar, P; Wilson, KA; Byars, A; Sahmoud, T; Franz, DN				Krueger, Darcy A.; Care, Marguerite M.; Holland, Katherine; Agricola, Karen; Tudor, Cynthia; Mangeshkar, Prajakta; Wilson, Kimberly A.; Byars, Anna; Sahmoud, Tarek; Franz, David Neal			Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RAPAMYCIN; MTOR; COMPLEX; ANGIOMYOLIPOMA; REGRESSION; PATHOGENESIS; SIROLIMUS; TUMORS	Background: Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex. Methods: Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study. The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months. We gave everolimus orally, at a dose of 3.0 mg per square meter of body-surface area, to achieve a trough concentration of 5 to 15 ng per milliliter. Results: We enrolled 28 patients. Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%). Marked reductions were seen within 3 months and were sustained. There were no new lesions, worsening hydrocephalus, evidence of increased intracranial pressure, or necessity for surgical resection or other therapy for subependymal giant-cell astrocytoma. Of the 16 patients for whom 24-hour video electroencephalography data were available, seizure frequency for the 6-month study period (vs. the previous 6-month period) decreased in 9, did not change in 6, and increased in 1 (median change, -1 seizure; P=0.02). The mean (+/-SD) score on the validated Quality-of-Life in Childhood Epilepsy questionnaire (on which scores can range from 0 to 100, with higher scores indicating a better quality of life) was improved at 3 months (63.4+/-12.4) and 6 months (62.1+/-14.2) over the baseline score (57.8+/-14.0). Single cases of grade 3 treatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia were reported. Conclusions: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.) N Engl J Med 2010;363:1801-11.	[Franz, David Neal] Cincinnati Childrens Hosp Med Ctr, Tuberous Sclerosis Clin, Dept Pediat & Neurol, MLC 2015, Cincinnati, OH 45229 USA; [Care, Marguerite M.] Cincinnati Childrens Hosp Med Ctr, Tuberous Sclerosis Clin, Dept Pediat & Radiol, Cincinnati, OH 45229 USA; [Wilson, Kimberly A.] Cincinnati Childrens Hosp Med Ctr, Tuberous Sclerosis Clin, Translat Res Trials Off, Cincinnati, OH 45229 USA; [Sahmoud, Tarek] Novartis Pharmaceut, Florham Pk, NJ USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Novartis	Franz, DN (corresponding author), Cincinnati Childrens Hosp Med Ctr, Tuberous Sclerosis Clin, Dept Pediat & Neurol, MLC 2015, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	tsclinic@cchmc.org		Wilson, Kimberly/0000-0003-2029-2533; Krueger, Darcy/0000-0002-7250-7391	Novartis; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER	Novartis(Novartis); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by Novartis.	Adriaensen MEAPM, 2009, EUR J NEUROL, V16, P691, DOI 10.1111/j.1468-1331.2009.02567.x; Baskin HJ, 2008, PEDIATR RADIOL, V38, P936, DOI 10.1007/s00247-008-0832-y; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bruyn GAW, 2008, ANN RHEUM DIS, V67, P1090, DOI 10.1136/ard.2007.078808; Cancer Therapy Evaluation Program, COMM TERM CRIT ADV E; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236; Clarke Michelle J, 2006, Neurosurg Focus, V20, pE5; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; de Ribaupierre S, 2007, NEUROSURGERY, V60, P83, DOI 10.1227/01.NEU.0000249216.19591.5D; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Figlin Robert A, 2008, J Natl Compr Canc Netw, V6 Suppl 5, pS1; Franz DN, 2009, ARCH DIS CHILD, V94, P75; Franz DN, 2007, EPILEPSIA, V48, P1630, DOI 10.1111/j.1528-1167.2007.01178_2.x; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; Franz DN, 2007, NAT I NEUR DIS STROK; Goh S, 2004, NEUROLOGY, V63, P1457, DOI 10.1212/01.wnl.0000142039.14522.1a; Hoeffer CA, 2010, TRENDS NEUROSCI, V33, P67, DOI 10.1016/j.tins.2009.11.003; Hofbauer GFL, 2008, BRIT J DERMATOL, V159, P473, DOI 10.1111/j.1365-2133.2008.08677.x; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Jaworski J, 2006, MOL NEUROBIOL, V34, P205, DOI 10.1385/MN:34:3:205; Koenig MK, 2008, J CHILD NEUROL, V23, P1238, DOI 10.1177/0883073808321764; Krueger Darcy A, 2008, Paediatr Drugs, V10, P299, DOI 10.2165/00148581-200810050-00004; Lenz G, 2005, J BIOL CHEM, V280, P38121, DOI 10.1074/jbc.C500363200; Levine NB, 2006, MINIM INVAS NEUROSUR, V49, P317, DOI 10.1055/s-2006-950391; Morton JM, 2008, J HEART LUNG TRANSPL, V27, P462, DOI 10.1016/j.healun.2008.01.005; Muncy J, 2009, J CHILD NEUROL, V24, P477, DOI 10.1177/0883073808324535; O'Callaghan FJK, 2008, ARCH DIS CHILD, V93, P751, DOI 10.1136/adc.2007.125880; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Sabaz M, 2003, EPILEPSY BEHAV, V4, P680, DOI 10.1016/j.yebeh.2003.08.012; Sanchez-Fructuoso AI, 2008, EXPERT OPIN DRUG MET, V4, P807, DOI [10.1517/17425255.4.6.807, 10.1517/17425255.4.6.807 ]; Taille C, 2007, ANN INTERN MED, V146, P687, DOI 10.7326/0003-4819-146-9-200705010-00022; Wienecke R, 2006, AM J KIDNEY DIS, V48, pE27, DOI 10.1053/j.ajkd.2006.05.018	32	679	698	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1801	1811		10.1056/NEJMoa1001671	http://dx.doi.org/10.1056/NEJMoa1001671			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047224	Bronze			2022-12-28	WOS:000283787800005
J	Weerapana, E; Wang, C; Simon, GM; Richter, F; Khare, S; Dillon, MBD; Bachovchin, DA; Mowen, K; Baker, D; Cravatt, BF				Weerapana, Eranthie; Wang, Chu; Simon, Gabriel M.; Richter, Florian; Khare, Sagar; Dillon, Myles B. D.; Bachovchin, Daniel A.; Mowen, Kerri; Baker, David; Cravatt, Benjamin F.			Quantitative reactivity profiling predicts functional cysteines in proteomes	NATURE			English	Article							COMPLEX PROTEIN MIXTURES; MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; IDENTIFICATION; THIOL; ELECTROPHILES; PEPTIDES; RESIDUES	Cysteine is the most intrinsically nucleophilic amino acid in proteins, where its reactivity is tuned to perform diverse biochemical functions. The absence of a consensus sequence that defines functional cysteines in proteins has hindered their discovery and characterization. Here we describe a proteomics method to profile quantitatively the intrinsic reactivity of cysteine residues en masse directly in native biological systems. Hyper-reactivity was a rare feature among cysteines and it was found to specify a wide range of activities, including nucleophilic and reductive catalysis and sites of oxidative modification. Hyper-reactive cysteines were identified in several proteins of uncharacterized function, including a residue conserved across eukaryotic phylogeny that we show is required for yeast viability and is involved in iron-sulphur protein biogenesis. We also demonstrate that quantitative reactivity profiling can form the basis for screening and functional assignment of cysteines in computationally designed proteins, where it discriminated catalytically active from inactive cysteine hydrolase designs.	[Weerapana, Eranthie; Wang, Chu; Simon, Gabriel M.; Bachovchin, Daniel A.; Cravatt, Benjamin F.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Weerapana, Eranthie; Wang, Chu; Simon, Gabriel M.; Dillon, Myles B. D.; Bachovchin, Daniel A.; Mowen, Kerri; Cravatt, Benjamin F.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA; [Richter, Florian; Khare, Sagar; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Richter, Florian; Baker, David] Univ Washington, Interdisciplinary Program Biomol Struct & Design, Seattle, WA 98195 USA; [Khare, Sagar; Baker, David] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	Scripps Research Institute; Scripps Research Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.	cravatt@scripps.edu	Baker, David/K-8941-2012; Wang, Chu/AAE-8759-2021; Wang, Chu/C-4442-2015; wang, chu/GYJ-2191-2022	Baker, David/0000-0001-7896-6217; Wang, Chu/0000-0002-6925-1268; Wang, Chu/0000-0002-6925-1268; 	National Institutes of Health [CA087660, MH084512]; Pfizer; Koshland Graduate Fellowship; National Science Foundation; Skaggs Institute for Chemical Biology; NATIONAL CANCER INSTITUTE [R01CA087660, R37CA087660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM090294, R01GM085117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); Koshland Graduate Fellowship; National Science Foundation(National Science Foundation (NSF)); Skaggs Institute for Chemical Biology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	We would like to thank T. Bartfai, I. Wilson and members of the B.F.C. laboratory for comments and critical reading of the manuscript, T. Ji for experimental assistance and J. Gallaher for expression of designed proteins. This work was supported by the National Institutes of Health (CA087660, MH084512), a Pfizer Postdoctoral Fellowship (E.W.), a Koshland Graduate Fellowship in Enzyme Biochemistry (G.M.S.), a National Science Foundation predoctoral fellowship (D.A.B.) and the Skaggs Institute for Chemical Biology.	Baty JW, 2005, BIOCHEM J, V389, P785, DOI 10.1042/BJ20050337; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Chen G, 2003, J AM CHEM SOC, V125, P8130, DOI 10.1021/ja034287m; Codreanu SG, 2009, MOL CELL PROTEOMICS, V8, P670, DOI 10.1074/mcp.M800070-MCP200; Collins SR, 2007, MOL CELL PROTEOMICS, V6, P439, DOI 10.1074/mcp.M600381-MCP200; Dennehy MK, 2006, CHEM RES TOXICOL, V19, P20, DOI 10.1021/tx050312l; Eisenberg D, 2000, NATURE, V405, P823, DOI 10.1038/35015694; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fomenko DE, 2007, SCIENCE, V315, P387, DOI 10.1126/science.1133114; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Giles NM, 2003, BIOCHEM BIOPH RES CO, V300, P1, DOI 10.1016/S0006-291X(02)02770-5; Hao G, 2006, P NATL ACAD SCI USA, V103, P1012, DOI 10.1073/pnas.0508412103; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Isom DG, 2010, P NATL ACAD SCI USA, V107, P4908, DOI 10.1073/pnas.0910421107; Iyer LM, 2004, CELL CYCLE, V3, P1440, DOI 10.4161/cc.3.11.1206; Jiang L, 2008, SCIENCE, V319, P1387, DOI 10.1126/science.1152692; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; Leonard SE, 2009, ACS CHEM BIOL, V4, P783, DOI 10.1021/cb900105q; LEWIS CT, 1989, J BIOL CHEM, V264, P27; Lill R, 2009, NATURE, V460, P831, DOI 10.1038/nature08301; Ma S, 2007, J AM CHEM SOC, V129, P13633, DOI 10.1021/ja074222+; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; Netz DJA, 2007, NAT CHEM BIOL, V3, P278, DOI 10.1038/nchembio872; Okerberg ES, 2005, P NATL ACAD SCI USA, V102, P4996, DOI 10.1073/pnas.0501205102; Park SK, 2008, NAT METHODS, V5, P319, DOI [10.1038/NMETH.1195, 10.1038/nmeth.1195]; Pedrioli PGA, 2004, NAT BIOTECHNOL, V22, P1459, DOI 10.1038/nbt1031; Pierik AJ, 2009, NAT PROTOC, V4, P753, DOI 10.1038/nprot.2009.39; Reddie KG, 2008, CURR OPIN CHEM BIOL, V12, P746, DOI 10.1016/j.cbpa.2008.07.028; Salsbury FR, 2008, PROTEIN SCI, V17, P299, DOI 10.1110/ps.073096508; Sethuraman M, 2004, J PROTEOME RES, V3, P1228, DOI 10.1021/pr049887e; Shiio Y, 2006, NAT PROTOC, V1, P139, DOI 10.1038/nprot.2006.22; Shin NY, 2007, CHEM RES TOXICOL, V20, P859, DOI 10.1021/tx700031r; Silverman JA, 2002, J BIOL CHEM, V277, P30968, DOI 10.1074/jbc.M203172200; Speers AE, 2003, J AM CHEM SOC, V125, P4686, DOI 10.1021/ja034490h; Speers AE, 2005, J AM CHEM SOC, V127, P10018, DOI 10.1021/ja0532842; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; THOMPSON S, 1989, BIOCHEMISTRY-US, V28, P5735, DOI 10.1021/bi00440a006; VALLEE BL, 1955, P NATL ACAD SCI USA, V41, P327, DOI 10.1073/pnas.41.6.327; Voss AA, 2004, J BIOL CHEM, V279, P34514, DOI 10.1074/jbc.M404290200; Weerapana E, 2008, NAT CHEM BIOL, V4, P405, DOI 10.1038/nchembio.91; Weerapana E, 2007, NAT PROTOC, V2, P1414, DOI 10.1038/nprot.2007.194; Zanghellini A, 2006, PROTEIN SCI, V15, P2785, DOI 10.1110/ps.062353106; Zhang X, 2003, STRUCTURE, V11, P509, DOI 10.1016/S0969-2126(03)00071-6; Zhao YM, 2009, PROTEOMICS, V9, P4632, DOI 10.1002/pmic.200900398	50	1033	1059	21	397	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	2010	468	7325					790	U79		10.1038/nature09472	http://dx.doi.org/10.1038/nature09472			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691PQ	21085121	Green Accepted			2022-12-28	WOS:000285093700038
J	Szabo, E; Rampalli, S; Risueno, RM; Schnerch, A; Mitchell, R; Fiebig-Comyn, A; Levadoux-Martin, M; Bhatia, M				Szabo, Eva; Rampalli, Shravanti; Risueno, Ruth M.; Schnerch, Angelique; Mitchell, Ryan; Fiebig-Comyn, Aline; Levadoux-Martin, Marilyne; Bhatia, Mickie			Direct conversion of human fibroblasts to multilineage blood progenitors	NATURE			English	Article							ACUTE MYELOID-LEUKEMIA; STEM-CELLS; MICE LACKING; IPS CELLS; EXPRESSION; TRANSCRIPTION; HEMATOPOIESIS; INDUCTION; TRANSPLANTATION; CIRCUITRY	As is the case for embryo-derived stem cells, application of reprogrammed human induced pluripotent stem cells is limited by our understanding of lineage specification. Here we demonstrate the ability to generate progenitors and mature cells of the haematopoietic fate directly from human dermal fibroblasts without establishing pluripotency. Ectopic expression of OCT4 (also called POU5F1)-activated haematopoietic transcription factors, together with specific cytokine treatment, allowed generation of cells expressing the pan-leukocyte marker CD45. These unique fibroblast-derived cells gave rise to granulocytic, monocytic, megakaryocytic and erythroid lineages, and demonstrated in vivo engraftment capacity. We note that adult haematopoietic programs are activated, consistent with bypassing the pluripotent state to generate blood fate: this is distinct from haematopoiesis involving pluripotent stem cells, where embryonic programs are activated. These findings demonstrate restoration of multipotency from human fibroblasts, and suggest an alternative approach to cellular reprogramming for autologous cell-replacement therapies that avoids complications associated with the use of human pluripotent stem cells.	[Szabo, Eva; Rampalli, Shravanti; Risueno, Ruth M.; Schnerch, Angelique; Mitchell, Ryan; Fiebig-Comyn, Aline; Levadoux-Martin, Marilyne; Bhatia, Mickie] McMaster Univ, Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Schnerch, Angelique; Mitchell, Ryan; Bhatia, Mickie] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Bhatia, M (corresponding author), McMaster Univ, Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada.	mbhatia@mcmaster.ca	Risueño, Ruth Muñoz/G-9969-2015	Risueño, Ruth Muñoz/0000-0003-4048-9536; Rampalli, Shravanti/0000-0002-6391-6409	Canadian Institute of Health Research (CIHR); Canadian Cancer Society Research Institute (CCS-RI); StemCell Network; Ontario Ministry of Research Innovation (MRI); Canadian Chair; Ministry of Research and Innovation (MRI); MITACS; Ontario Graduate Scholarship (OGS)	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute (CCS-RI); StemCell Network; Ontario Ministry of Research Innovation (MRI)(Ministry of Research and Innovation, Ontario); Canadian Chair; Ministry of Research and Innovation (MRI)(Ministry of Research and Innovation, Ontario); MITACS; Ontario Graduate Scholarship (OGS)(Ontario Graduate Scholarship)	This work was supported by grants to M.B. from the Canadian Institute of Health Research (CIHR), the Canadian Cancer Society Research Institute (CCS-RI), the StemCell Network and the Ontario Ministry of Research Innovation (MRI). M.B. is supported by the Canadian Chair Program and holds the Canada Research Chair in human stem cell biology. E.S. is supported by Ministry of Research and Innovation (MRI) and MITACS fellowships, R.M.R is supported by a CCS-RI fellowship and R.M. is supported by an Ontario Graduate Scholarship (OGS). We thank T. Werbowetski-Ogilvie for her help.	Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Chang KH, 2006, BLOOD, V108, P1515, DOI 10.1182/blood-2005-11-011874; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Emslie D, 2008, J EXP MED, V205, P409, DOI 10.1084/jem.20072049; Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105; Feugier P, 2003, TRANSFUSION, V43, P878, DOI 10.1046/j.1537-2995.2003.00446.x; Fried W, 2009, EXP HEMATOL, V37, P1007, DOI 10.1016/j.exphem.2009.05.010; Friedman AD, 2007, ONCOGENE, V26, P6816, DOI 10.1038/sj.onc.1210764; Ghozi MC, 1996, P NATL ACAD SCI USA, V93, P1935, DOI 10.1073/pnas.93.5.1935; Hassan HT, 1996, ACTA HAEMATOL-BASEL, V95, P257; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Ichikawa M, 2004, CELL CYCLE, V3, P722; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Kanawaty A, 2009, BIOESSAYS, V31, P134, DOI 10.1002/bies.200800204; Kang JS, 2009, TRENDS BIOCHEM SCI, V34, P491, DOI 10.1016/j.tibs.2009.06.003; Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436; KISTLER B, 1995, ONCOGENE, V11, P1095; Klimchenko O, 2009, BLOOD, V114, P1506, DOI 10.1182/blood-2008-09-178863; Koschmieder S, 2005, INT J HEMATOL, V81, P368, DOI 10.1532/IJH97.05051; Kwon UK, 2006, BIOCHEM BIOPH RES CO, V344, P146, DOI 10.1016/j.bbrc.2006.03.119; Lebofsky R, 2007, CANCER CELL, V12, P102, DOI 10.1016/j.ccr.2007.07.013; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/NMETH.1393, 10.1038/nmeth.1393]; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Ng ES, 2005, DEVELOPMENT, V132, P873, DOI 10.1242/dev.01657; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Pfisterer P, 1996, MOL CELL BIOL, V16, P6160; Rampalli S, 2007, NAT STRUCT MOL BIOL, V14, P1150, DOI 10.1038/nsmb1316; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Roy NS, 2006, NAT MED, V12, P1259, DOI 10.1038/nm1495; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SILVERSTEIN SC, 1977, ANNU REV BIOCHEM, V46, P669, DOI 10.1146/annurev.bi.46.070177.003321; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Strodtbeck D, 2005, BONE MARROW TRANSPL, V36, P1083, DOI 10.1038/sj.bmt.1705176; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797; Vijayaragavan K, 2009, CELL STEM CELL, V4, P248, DOI 10.1016/j.stem.2008.12.011; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	47	530	616	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2010	468	7323					521	U191		10.1038/nature09591	http://dx.doi.org/10.1038/nature09591			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	684WA	21057492				2022-12-28	WOS:000284584200033
J	Ali, S				Ali, Sabreen			Fast food feud at Golden Gate	LANCET			English	Editorial Material									Univ Sheffield, Sch Med, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Ali, S (corresponding author), Univ Sheffield, Sch Med, Sheffield S10 2RX, S Yorkshire, England.	sabreenmaryam@gmail.com						[Anonymous], 2010, BBC NEWS        1110; NEWSOM G, 2010, SAN FRANCISCO C 1113; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; *RUDD FOOD CTR FOO, 2010, FAST FOOD FACTS EV F	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 20	2010	376	9754					1723	1723		10.1016/S0140-6736(10)62114-9	http://dx.doi.org/10.1016/S0140-6736(10)62114-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690EI	21093638				2022-12-28	WOS:000284984900011
J	Gomory, R				Gomory, Ralph			Benoit Mandelbrot (1924-2010) OBITUARY	NATURE			English	Biographical-Item											Gomory, R (corresponding author), NYU, 550 1st Ave, New York, NY 10012 USA.	gomory@sloan.org						MANDELBROT B, 1967, SCIENCE, V156, P636, DOI 10.1126/science.156.3775.636; MANDELBROT B, 2004, 100 REASONS SCI, P157; Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT, P480	4	9	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2010	468	7322					378	378		10.1038/468378a	http://dx.doi.org/10.1038/468378a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085164	Bronze			2022-12-28	WOS:000284313100024
J	Nicholl, DJ; Hilton-Jones, D; Palace, J; Richmond, S; Finlayson, S; Winer, J; Weir, A; Maddison, P; Fletcher, N; Sussman, J; Silver, N; Nixon, J; Kullmann, D; Embleton, N; Beeson, D; Farrugia, ME; Hill, M; McDermott, C; Llewelyn, G; Leonard, J; Morris, M				Nicholl, David J.; Hilton-Jones, David; Palace, Jacqueline; Richmond, Sam; Finlayson, Sarah; Winer, John; Weir, Andrew; Maddison, Paul; Fletcher, Nick; Sussman, Jon; Silver, Nick; Nixon, John; Kullmann, Dimitri; Embleton, Nick; Beeson, David; Farrugia, Maria Elena; Hill, Marguerite; McDermott, Chris; Llewelyn, Gareth; Leonard, James; Morris, Michael			Orphan Drugs Open letter to prime minister David Cameron and health secretary Andrew Lansley	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Nicholl, David J.] City Hosp, Birmingham, W Midlands, England; [Hilton-Jones, David; Palace, Jacqueline; Finlayson, Sarah] John Radcliffe Infirm, Oxford, England; [Richmond, Sam] Sunderland Royal Hosp, Sunderland, England; [Winer, John] Univ Hosp Birmingham, Birmingham, W Midlands, England; [Weir, Andrew] Royal Berkshire NHS Trust, Reading, Berks, England; [Maddison, Paul] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Fletcher, Nick; Silver, Nick] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England; [Sussman, Jon] Hope Hosp, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England; [Nixon, John] Royal Preston Hosp, Preston, Lancs, England; [Kullmann, Dimitri] Inst Neurol, London, England; [Embleton, Nick] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Beeson, David] Weatherall Inst Mol Med, Oxford, England; [Farrugia, Maria Elena] So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland; [Hill, Marguerite] Abertawe Bro Morgannwg Univ, Local Hlth Board, Swansea, W Glam, Wales; [McDermott, Chris] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; [Llewelyn, Gareth] Royal Gwent Hosp, Newport, Gwent, Wales; [Leonard, James] UCL, Inst Child Hlth, London WC1E 6BT, England; [Morris, Michael] Myasthenia Gravis Assoc, Derby, England	University of Birmingham; Sunderland Royal Hospital; University of Birmingham; Royal Berkshire Hospital; Nottingham University Hospital NHS Trust; Walton Centre; Royal Preston Hospital; University of London; University College London; Newcastle University - UK; University of Oxford; University of Glasgow; University of Sheffield; Royal Gwent Hospital; University of London; University College London	Nicholl, DJ (corresponding author), City Hosp, Birmingham, W Midlands, England.	david.nicholl@nhs.net	McDermott, Christopher/AAU-4988-2020; Embleton, Nicholas/D-4905-2011; McDermott, Chris/GQZ-3919-2022; Kullmann, Dimitri M/A-3162-2009	McDermott, Christopher/0000-0002-1269-9053; Embleton, Nicholas/0000-0003-3750-5566; Kullmann, Dimitri M/0000-0001-6696-3545; Shaw, Pamela/0000-0002-8925-2567	Medical Research Council [G0701521] Funding Source: Medline; MRC [G0701521] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BOSELEY S, 2002, GUARDIAN        0624; Leonard JV, 2009, LANCET, V373, P462, DOI 10.1016/S0140-6736(09)60169-0; MARTIN D, 2010, DAILY MAIL      0927	3	13	13	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2010	341								c6466	10.1136/bmj.c6466	http://dx.doi.org/10.1136/bmj.c6466			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684WJ	21081599				2022-12-28	WOS:000284585600025
J	Rohani, P; Zhong, X; King, AA				Rohani, Pejman; Zhong, Xue; King, Aaron A.			Contact Network Structure Explains the Changing Epidemiology of Pertussis	SCIENCE			English	Article							BORDETELLA-PERTUSSIS; VACCINATION; ADULTS; IMMUNIZATION; RESURGENCE; ADOLESCENTS; INFANTS; MEASLES; SWEDEN; IMPACT	The epidemiology of whooping cough (pertussis) remains enigmatic. A leading cause of infant mortality globally, its resurgence in several developed nations-despite the availability and use of vaccines for many decades-has caused alarm. We combined data from a singular natural experiment and a detailed contact network study to show that age-specific contact patterns alone can explain shifts in prevalence and age-stratified incidence in the vaccine era. The practical implications of our results are notable: Ignoring age-structured contacts is likely to result in misinterpretation of epidemiological data and potentially costly policy missteps.	[Rohani, Pejman; Zhong, Xue; King, Aaron A.] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA; [Rohani, Pejman; Zhong, Xue] Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA; [King, Aaron A.] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA; [Rohani, Pejman; King, Aaron A.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)	Rohani, P (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.	rohani@umich.edu	King, Aaron A/B-8092-2012	King, Aaron A/0000-0001-6159-3207; rohani, pejman/0000-0002-7221-3801	Science and Technology Directorate, Department of Homeland Security; Fogarty International Center, National Institutes of Health; Vaccine Modeling Initiative of the Bill & Melinda Gates Foundation	Science and Technology Directorate, Department of Homeland Security(United States Department of Homeland Security (DHS)); Fogarty International Center, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Vaccine Modeling Initiative of the Bill & Melinda Gates Foundation	We thank three anonymous reviewers for comments. P.R. and A.A.K. are supported by the Research and Policy in Infectious Disease Dynamics program of the Science and Technology Directorate, Department of Homeland Security, and the Fogarty International Center, National Institutes of Health. P.R. was also supported by the Vaccine Modeling Initiative of the Bill & Melinda Gates Foundation.	ANDERSON R M, 1991; ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X; Broutin H, 2004, VACCINE, V22, P594, DOI 10.1016/j.vaccine.2003.07.018; Broutin H, 2010, P ROY SOC B-BIOL SCI, V277, P3239, DOI 10.1098/rspb.2010.0994; Carlsson Rose-Marie, 2009, Vaccine, V27, P5709, DOI 10.1016/j.vaccine.2009.07.092; Celentano LP, 2005, PEDIATR INFECT DIS J, V24, P761, DOI 10.1097/01.inf.0000177282.53500.77; Cherry JD, 2003, PEDIATRICS, V112, P405, DOI 10.1542/peds.112.2.405; CHERRY JD, 1989, WESTERN J MED, V150, P319; Crowcroft NS, 2006, LANCET, V367, P1926, DOI 10.1016/S0140-6736(06)68848-X; Crowcroft NS, 2003, LANCET INFECT DIS, V3, P413, DOI 10.1016/S1473-3099(03)00669-8; DEVILLE JG, 1995, CLIN INFECT DIS, V21, P639, DOI 10.1093/clinids/21.3.639; Edmunds WJ, 2000, EPIDEMIOL INFECT, V125, P635, DOI 10.1017/S0950268800004672; Eidlitz-Markus T, 2007, CLIN PEDIATR, V46, P718, DOI 10.1177/0009922807302093; FINE PEM, 1982, LANCET, V1, P666; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776; Hallander HO, 2005, J CLIN MICROBIOL, V43, P2856, DOI 10.1128/JCM.43.6.2856-2865.2005; Keeling, 2008, MODELLING INFECT DIS; Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1; Mooi FR, 2001, EMERG INFECT DIS, V7, P526, DOI 10.3201/eid0707.017708; Mossong J, 2008, PLOS MED, V5, P381, DOI 10.1371/journal.pmed.0050074; NELSON JD, 1978, AM J DIS CHILD, V132, P371, DOI 10.1001/archpedi.1978.02120290043006; Ntezayabo B, 2003, PEDIATR INFECT DIS J, V22, P22, DOI 10.1097/00006454-200301000-00009; Omer SB, 2006, JAMA-J AM MED ASSOC, V296, P1757, DOI 10.1001/jama.296.14.1757; ROMANUS V, 1987, PEDIATR INFECT DIS J, V6, P364, DOI 10.1097/00006454-198704000-00005; Schellekens Joop, 2005, Pediatr Infect Dis J, V24, pS19, DOI 10.1097/01.inf.0000160909.24879.e6; Schenzle D, 1984, IMA J Math Appl Med Biol, V1, P169; Skowronski DM, 2002, J INFECT DIS, V185, P1448, DOI 10.1086/340280; Tan Tina, 2005, Pediatr Infect Dis J, V24, pS83, DOI 10.1097/01.inf.0000160919.94330.1a; von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8; Walllinga J, 2005, PLOS MED, V2, P1152, DOI 10.1371/journal.pmed.0020316; Wearing HJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000647	32	154	157	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2010	330	6006					982	985		10.1126/science.1194134	http://dx.doi.org/10.1126/science.1194134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071671				2022-12-28	WOS:000284118000048
J	Emery, B				Emery, Ben			Regulation of Oligodendrocyte Differentiation and Myelination	SCIENCE			English	Review							CENTRAL-NERVOUS-SYSTEM; PROTEIN-COUPLED RECEPTOR; CELL-ADHESION MOLECULE; WHITE-MATTER; PROGENITOR DIFFERENTIATION; ELECTRICAL-ACTIVITY; CORPUS-CALLOSUM; CNS MYELINATION; PRECURSOR CELLS; REMYELINATION	Despite the importance of myelin for the rapid conduction of action potentials, the molecular bases of oligodendrocyte differentiation and central nervous system (CNS) myelination are still incompletely understood. Recent results have greatly advanced this understanding, identifying new transcriptional regulators of myelin gene expression, elucidating vital roles for microRNAs in controlling myelination, and clarifying the extracellular signaling mechanisms that orchestrate the development of myelin. Studies have also demonstrated an unexpected level of plasticity of myelin in the adult CNS. These recent advances provide new insight into how remyelination may be stimulated in demyelinating disorders such as multiple sclerosis.	[Emery, Ben] Univ Melbourne, Ctr Neurosci, Carlton, Vic 3053, Australia; [Emery, Ben] Univ Melbourne, Florey Neurosci Inst, Carlton, Vic 3053, Australia	University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Emery, B (corresponding author), Univ Melbourne, Ctr Neurosci, Level 2,Alan Gilbert Bldg,161 Barry St, Carlton, Vic 3053, Australia.	emeryb@unimelb.edu.au	Messier, Claude/A-2322-2008; Emery, Ben/I-6223-2013	Messier, Claude/0000-0002-4791-1763; Emery, Ben/0000-0002-9132-3045	NHMRC; Trish Multiple Sclerosis Research Foundation	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Trish Multiple Sclerosis Research Foundation	I thank B. A. Barres, S. S. Murray, and T.J. Kilpatrick for valuable comments on this article. This work was supported by a NHMRC CJ Martin fellowship and a grant from the Trish Multiple Sclerosis Research Foundation.	BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; BARRES BA, 1990, NEURON, V4, P507, DOI 10.1016/0896-6273(90)90109-S; BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Brinkmann BG, 2008, NEURON, V59, P581, DOI 10.1016/j.neuron.2008.06.028; Budde H, 2010, DEVELOPMENT, V137, P2127, DOI 10.1242/dev.050633; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Chen Y, 2009, NAT NEUROSCI, V12, P1398, DOI 10.1038/nn.2410; Crang AT, 1998, J NEUROCYTOL, V27, P541, DOI 10.1023/A:1006960032023; De Biase LM, 2010, J NEUROSCI, V30, P3600, DOI 10.1523/JNEUROSCI.6000-09.2010; Demerens C, 1996, P NATL ACAD SCI USA, V93, P9887, DOI 10.1073/pnas.93.18.9887; Dugas JC, 2010, NEURON, V65, P597, DOI 10.1016/j.neuron.2010.01.027; Emery B, 2009, CELL, V138, P172, DOI 10.1016/j.cell.2009.04.031; Etxeberria A, 2010, NAT NEUROSCI, V13, P287, DOI 10.1038/nn.2500; Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309; Fields RD, 2005, NEUROSCIENTIST, V11, P528, DOI 10.1177/1073858405282304; Fu H, 2002, DEVELOPMENT, V129, P681; Fu H, 2009, J NEUROSCI, V29, P11399, DOI 10.1523/JNEUROSCI.0160-09.2009; Gallo V, 1996, J NEUROSCI, V16, P2659, DOI 10.1523/jneurosci.16-08-02659.1996; He Y, 2007, NEURON, V55, P217, DOI 10.1016/j.neuron.2007.06.029; Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; ITOH K, 1995, SCIENCE, V270, P1369, DOI 10.1126/science.270.5240.1369; JURASKA JM, 1988, BRAIN RES, V450, P1, DOI 10.1016/0006-8993(88)91538-7; Kao SC, 2009, SCIENCE, V323, P651, DOI 10.1126/science.1166562; Karadottir R, 2008, NAT NEUROSCI, V11, P450, DOI 10.1038/nn2060; Laursen LS, 2009, J NEUROSCI, V29, P9174, DOI 10.1523/JNEUROSCI.5942-08.2009; Li Q, 2010, NEUROSCI LETT, V479, P128, DOI 10.1016/j.neulet.2010.05.043; Lin SC, 2002, J NEUROCYTOL, V31, P537, DOI 10.1023/A:1025799816285; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Miesenbock G, 2009, SCIENCE, V326, P395, DOI 10.1126/science.1174520; Monk KR, 2009, SCIENCE, V325, P1402, DOI 10.1126/science.1173474; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Penfield W, 1924, BRAIN, V47, P430, DOI 10.1093/brain/47.4.430; Richardson WD, 2006, NAT REV NEUROSCI, V7, P11, DOI 10.1038/nrn1826; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Shen SM, 2005, J CELL BIOL, V169, P577, DOI 10.1083/jcb.200412101; Shin D, 2009, ANN NEUROL, V66, P843, DOI 10.1002/ana.21927; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Stidworthy MF, 2004, BRAIN, V127, P1928, DOI 10.1093/brain/awh217; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Tkachev D, 2003, LANCET, V362, P798, DOI 10.1016/S0140-6736(03)14289-4; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Watkins TA, 2008, NEURON, V60, P555, DOI 10.1016/j.neuron.2008.09.011; Wegner M, 2008, J MOL NEUROSCI, V35, P3, DOI 10.1007/s12031-007-9008-8; Ye F, 2009, NAT NEUROSCI, V12, P829, DOI 10.1038/nn.2333; Zhao XH, 2010, NEURON, V65, P612, DOI 10.1016/j.neuron.2010.02.018; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7; Ziskin JL, 2007, NAT NEUROSCI, V10, P321, DOI 10.1038/nn1854	54	446	464	2	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					779	782		10.1126/science.1190927	http://dx.doi.org/10.1126/science.1190927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051629				2022-12-28	WOS:000283855700032
J	Chattopadhyay, A; Bindman, AB				Chattopadhyay, Arpita; Bindman, Andrew B.			Linking a Comprehensive Payment Model to Comprehensive Care of Frail Elderly Patients A Dual Approach	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICARE		[Chattopadhyay, Arpita; Bindman, Andrew B.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Bindman, AB (corresponding author), Univ Calif San Francisco, Box 1364 Parnassus Ave, San Francisco, CA 94143 USA.	abindman@medsfgh.ucsf.edu			NATIONAL INSTITUTE ON AGING [K01AG031304] Funding Source: NIH RePORTER; NIA NIH HHS [K01 AG031304] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHATTERJEE P, 1998, EVALUATION PROGRAM A; Government Accountability Office, 2010, GAO10810; Gross DJ, 1999, HEALTH SERV RES, V34, P241; Institute of Medicine, 2001, CROSSING QUALITY CHA; *KAIS FAM FDN, 2005, DUAL EL PERC TOT MED; Kane RL, 2004, J AM GERIATR SOC, V52, P2039, DOI 10.1111/j.1532-5415.2004.52558.x; *MEDP, 2010, MEDP REP C AL INC ME; Miller EA, 2003, MED CARE RES REV, V60, P123, DOI 10.1177/1077558703060002001; WEISSERT WG, 1988, HEALTH SERV RES, V23, P175	9	6	6	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1948	1949		10.1001/jama.2010.1634	http://dx.doi.org/10.1001/jama.2010.1634			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045103				2022-12-28	WOS:000283725900027
J	Mourre, V; Villa, P; Henshilwood, CS				Mourre, Vincent; Villa, Paola; Henshilwood, Christopher S.			Early Use of Pressure Flaking on Lithic Artifacts at Blombos Cave, South Africa	SCIENCE			English	Article							MIDDLE STONE-AGE; POST-HOWIESONS POORT; TECHNOLOGY; TOOL	Pressure flaking has been considered to be an Upper Paleolithic innovation dating to similar to 20,000 years ago (20 ka). Replication experiments show that pressure flaking best explains the morphology of lithic artifacts recovered from the similar to 75-ka Middle Stone Age levels at Blombos Cave, South Africa. The technique was used during the final shaping of Still Bay bifacial points made on heat-treated silcrete. Application of this innovative technique allowed for a high degree of control during the detachment of individual flakes, resulting in thinner, narrower, and sharper tips on bifacial points. This technology may have been first invented and used sporadically in Africa before its later widespread adoption.	[Villa, Paola] Univ Colorado Museum, Boulder, CO 80309 USA; [Mourre, Vincent] INRAP Mediterranee, F-30900 Nimes, France; [Mourre, Vincent] Univ Toulouse Le Mirail, TRACES UMR 5608, F-31058 Toulouse, France; [Villa, Paola] Univ Bordeaux 1, PACEA, UMR 5199, Inst Prehist & Geol Quaternaire, F-33405 Talence, France; [Villa, Paola] Univ Witwatersrand, Sch Geog & Environm Studies, Johannesburg, South Africa; [Henshilwood, Christopher S.] Univ Bergen, Inst Archaeol Hist Culture & Relig, Bergen, Norway; [Henshilwood, Christopher S.] Univ Witwatersrand, Inst Human Evolut, Johannesburg, South Africa	University of Colorado System; University of Colorado Boulder; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Universite de Toulouse; Universite de Toulouse - Jean Jaures; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite de Bordeaux; University of Witwatersrand; University of Bergen; University of Witwatersrand	Villa, P (corresponding author), Univ Colorado Museum, Boulder, CO 80309 USA.	villap@colorado.edu	Henshilwood, Christopher S/K-3806-2014	Henshilwood, Christopher S/0000-0002-2818-293X; Mourre, Vincent/0000-0002-3089-1866	Wenner-Gren Foundation; European Research Council [249587]; National Research Foundation/Department of Science and Technology; Norwegian Research Council; PROTEA French-South Africa exchange program	Wenner-Gren Foundation; European Research Council(European Research Council (ERC)European Commission); National Research Foundation/Department of Science and Technology(Department of Science & Technology (India)); Norwegian Research Council(Research Council of NorwayEuropean Commission); PROTEA French-South Africa exchange program	This research was funded by the Wenner-Gren Foundation (grant to P. V.). V. M.'s work was facilitated by a research convention between Inrap and the University of the Witwatersrand. Financial support was provided to C. S. H. by a European Research Council Advanced Grant TRACSYMBOLS (FP7 No. 249587); by a National Research Foundation/Department of Science and Technology-funded Chair at the University of the Witwatersrand, South Africa; by a Norwegian Research Council Grant; and by a PROTEA French-South Africa exchange program. We thank K. Brown for sharing information about silcrete heating and helping us in the experiments. V. M. thanks N. Schlanger for assistance. The Iziko Museum in Cape Town provided space and working facilities.	Aubry T., 1998, PALEO, V10, P163, DOI DOI 10.3406/PAL.1998.1135; Bousman CB, 2005, J ANTHROPOL ARCHAEOL, V24, P193, DOI 10.1016/j.jaa.2005.05.001; Bradley BA, 1995, ANTIQUITY, V69, P989, DOI 10.1017/S0003598X00082521; Brown KS, 2009, SCIENCE, V325, P859, DOI 10.1126/science.1175028; Crabtree D.E., 1967, TEBIWA, V10, P8; d'Errico F, 2007, J HUM EVOL, V52, P142, DOI 10.1016/j.jhevol.2006.08.003; Frison G. C., 1991, PREHISTORIC HUNTERS, VSecond; Harrison Rodney, 2004, Archaeology in Oceania, V39, P1; Henshilwood C, 2004, SCIENCE, V304, P404, DOI 10.1126/science.1095905; Henshilwood CS, 2009, J HUM EVOL, V57, P27, DOI 10.1016/j.jhevol.2009.01.005; Inizan M., 1999, PREHISTOIRE PIERRE T; Jacobs Z, 2008, J ARCHAEOL SCI, V35, P1790, DOI 10.1016/j.jas.2007.11.028; Jacobs Z, 2006, J HUM EVOL, V51, P255, DOI 10.1016/j.jhevol.2006.03.007; Liu H, 2006, AM J HUM GENET, V79, P230, DOI 10.1086/505436; Ohnuma K., 1982, B I ARCHAEOL, V19, P161; Pelegrin J., 2000, MEMOIRES PREHISTOIRE, P73; Plisson Hugues., 1989, PAL O, V1, P65; Sellet F, 2004, J ARCHAEOL SCI, V31, P1553, DOI 10.1016/j.jas.2004.03.016; Singer R., 1982, MIDDLE STONE AGE KLA; Soriano S, 2007, J ARCHAEOL SCI, V34, P681, DOI 10.1016/j.jas.2006.06.017; Tiffagom M., 1998, PALEO, V10, P147, DOI DOI 10.3406/PAL.1998.1134; Tixier J., 2001, PALEORIENT, V26, P23; Villa P, 2010, J ARCHAEOL SCI, V37, P630, DOI 10.1016/j.jas.2009.10.028; Villa P., 2006, SOUTH AFR HUMANIT, V18, P89; Villa P, 2009, J ARCHAEOL SCI, V36, P441, DOI 10.1016/j.jas.2008.09.028	25	191	195	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					659	662		10.1126/science.1195550	http://dx.doi.org/10.1126/science.1195550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	672KB	21030655				2022-12-28	WOS:000283580600045
J	Mbanya, JC; Squire, SB; Cazap, E; Puska, P				Mbanya, Jean Claude; Squire, S. B.; Cazap, Eduardo; Puska, Pekka			Mobilising the world for chronic NCDs	LANCET			English	Editorial Material									[Mbanya, Jean Claude] Int Diabet Federat, Brussels, Belgium; [Squire, S. B.] Int Union TB & Lung Dis, Paris, France; [Cazap, Eduardo] Union Int Canc Control, Geneva, Switzerland; [Puska, Pekka] World Heart Federat, Geneva, Switzerland		Mbanya, JC (corresponding author), Int Diabet Federat, Brussels, Belgium.	correspondence@ncdalliance.org	; Mbanya, Jean Claude N/T-5147-2018	Squire, Stephen/0000-0001-7173-9038; Mbanya, Jean Claude N/0000-0001-9651-8653				[Anonymous], LANCET; [Anonymous], 2010, KEEP PROM UN ACH MIL; [Anonymous], PRESS C GEN ASS DES; [Anonymous], 2005, PREV CHRON DIS VIT I; Horton R, 2007, LANCET, V370, P1881, DOI 10.1016/S0140-6736(07)61701-2; World Health Organization, 2008, The global burden of disease: 2004 update	6	16	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	2011	377	9765					536	537		10.1016/S0140-6736(10)61891-0	http://dx.doi.org/10.1016/S0140-6736(10)61891-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	724DQ	21074252				2022-12-28	WOS:000287556700007
J	Kocher, R; Sahni, NR				Kocher, Robert; Sahni, Nikhil R.			Physicians versus Hospitals as Leaders of Accountable Care Organizations.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kocher, Robert] Brookings Inst, McKinsey Ctr US Hlth Syst Reform, Washington, DC 20036 USA; [Kocher, Robert] Brookings Inst, Engleberg Ctr Hlth Care Reform, Washington, DC 20036 USA; [Sahni, Nikhil R.] Harvard Univ, Sch Business, Boston, MA 02163 USA; [Sahni, Nikhil R.] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Brookings Institution; Brookings Institution; Harvard University; Harvard University	Kocher, R (corresponding author), Brookings Inst, McKinsey Ctr US Hlth Syst Reform, Washington, DC 20036 USA.							de Brantes F, 2009, NEW ENGL J MED, V361, P1033, DOI 10.1056/NEJMp0906121; HING E, 2007, DHHS PUBLICATION; Kocher R, 2010, ANN INTERN MED, V153, P536, DOI 10.7326/0003-4819-153-8-201010190-00274; Orszag PR, 2010, NEW ENGL J MED, V363, P601, DOI 10.1056/NEJMp1006571; Schumpeter J, 1944, CAPITALISM SOCIALISM, DOI 10.4324/9780203202050	5	47	48	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2010	363	27					2579	2582		10.1056/NEJMp1011712	http://dx.doi.org/10.1056/NEJMp1011712			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	700SD	21067374				2022-12-28	WOS:000285763700002
J	Grams, M; Coresh, J				Grams, Morgan; Coresh, Josef			Proteinuria and risk of acute kidney injury	LANCET			English	Editorial Material							ACUTE-RENAL-FAILURE; GLOMERULAR-FILTRATION-RATE; MORTALITY; ALBUMINURIA		[Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21287 USA; [Grams, Morgan] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Coresh, J (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21287 USA.	coresh@jhu.edu		Grams, Morgan/0000-0002-4430-6023				Carandang R, 2006, JAMA-J AM MED ASSOC, V296, P2939, DOI 10.1001/jama.296.24.2939; Coca SG, 2009, AM J KIDNEY DIS, V53, P961, DOI 10.1053/j.ajkd.2008.11.034; Grams ME, 2010, J AM SOC NEPHROL, V21, P1757, DOI 10.1681/ASN.2010010128; Hemmelgarn BR, 2010, JAMA-J AM MED ASSOC, V303, P423, DOI 10.1001/jama.2010.39; Hsu CY, 2008, KIDNEY INT, V74, P101, DOI 10.1038/ki.2008.107; James MT, 2010, LANCET, V376, P2096, DOI 10.1016/S0140-6736(10)61271-8; Lafrance JP, 2010, J AM SOC NEPHROL, V21, P345, DOI 10.1681/ASN.2009060636; Lameire N, 2005, LANCET, V365, P417; Liu KD, 2010, NAT REV NEPHROL, V6, P389, DOI 10.1038/nrneph.2010.39; Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; United States Renal Data System, 2009, CONC 2009 ANN DAT RE; Steven DW, 2010, CURR OPIN NEPHROL HY, V19, P539, DOI 10.1097/MNH.0b013e32833d42e3	14	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	2010	376	9758					2046	2048		10.1016/S0140-6736(10)61498-5	http://dx.doi.org/10.1016/S0140-6736(10)61498-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702LA	21094998				2022-12-28	WOS:000285895000006
J	Harbour, JW; Onken, MD; Roberson, EDO; Duan, SH; Cao, L; Worley, LA; Council, ML; Matatall, KA; Helms, C; Bowcock, AM				Harbour, J. William; Onken, Michael D.; Roberson, Elisha D. O.; Duan, Shenghui; Cao, Li; Worley, Lori A.; Council, M. Laurin; Matatall, Katie A.; Helms, Cynthia; Bowcock, Anne M.			Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas	SCIENCE			English	Article							UBIQUITIN HYDROLASE; BRCA1-ASSOCIATED PROTEIN-1; GNAQ; ASSOCIATION	Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-related death, yet the genetics of metastasis are poorly understood. We used exome capture coupled with massively parallel sequencing to search for metastasis-related mutations in highly metastatic uveal melanomas of the eye. Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors, including 15 mutations causing premature protein termination and 5 affecting its ubiquitin carboxyl terminal hydrolase domain. One tumor harbored a frameshift mutation that was germline in origin, thus representing a susceptibility allele. These findings implicate loss of BAP1 in uveal melanoma metastasis and suggest that the BAP1 pathway may be a valuable therapeutic target.	[Harbour, J. William; Onken, Michael D.; Worley, Lori A.; Matatall, Katie A.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; [Roberson, Elisha D. O.; Duan, Shenghui; Cao, Li; Council, M. Laurin; Helms, Cynthia; Bowcock, Anne M.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Harbour, J. William; Bowcock, Anne M.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Harbour, JW (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.	harbour@vision.wustl.edu; bowcock@genetics.wustl.edu	Roberson, Elisha D.O./J-1747-2012; Harbour, J. William/B-1448-2015; Roberson, Elisha/ABC-1810-2020; Onken, Michael D/H-5620-2013; Ferris, Laura/I-7689-2012	Roberson, Elisha D.O./0000-0001-5921-2399; Harbour, J. William/0000-0002-1104-9809; Roberson, Elisha/0000-0001-5921-2399; Onken, Michael D/0000-0003-4082-1105; Bowcock, Anne/0000-0001-8691-9090	National Cancer Institute [R01 CA125970]; Barnes-Jewish Hospital Foundation; Kling Family Foundation; Tumori Foundation; Horncrest Foundation; Research to Prevent Blindness, Inc.; NIH [P30 EY02687c]; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases [AR007279-31A1]; Washington University; NATIONAL CANCER INSTITUTE [R01CA125970] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007279] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Barnes-Jewish Hospital Foundation; Kling Family Foundation; Tumori Foundation; Horncrest Foundation; Research to Prevent Blindness, Inc.(Research to Prevent Blindness (RPB)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Washington University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by grants to J.W.H. from the National Cancer Institute (R01 CA125970), Barnes-Jewish Hospital Foundation, Kling Family Foundation, Tumori Foundation, Horncrest Foundation, and a Research to Prevent Blindness David F. Weeks Professorship, and by awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness, Inc., unrestricted grant, and the NIH Vision Core Grant P30 EY02687c. E.D.O.R. was supported by NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases training grant AR007279-31A1. We thank J. Hoisington-Lopez from the Center for Genome Sciences (Washington University School of Medicine) for running Solexa paired end sequences and M. Lovett for comments on the manuscript. J.W.H. and Washington University may receive income based on a license of related technology by the university to Castle Biosciences, Inc.	Bashiardes S, 2005, NAT METHODS, V2, P63, DOI 10.1038/nmeth0105-63; Bauer J, 2009, BRIT J CANCER, V101, P813, DOI 10.1038/sj.bjc.6605226; Alonso AGD, 2007, GENETICS, V176, P2099, DOI 10.1534/genetics.107.075739; Finger PT, 2009, ARCH PATHOL LAB MED, V133, P1197, DOI 10.1043/1543-2165-133.8.1197; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Landreville S, 2008, FUTURE ONCOL, V4, P629, DOI 10.2217/14796694.4.5.629; Machida YJ, 2009, J BIOL CHEM, V284, P34179, DOI 10.1074/jbc.M109.046755; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Nishikawa H, 2009, CANCER RES, V69, P111, DOI 10.1158/0008-5472.CAN-08-3355; Onken MD, 2004, CANCER RES, V64, P7205, DOI 10.1158/0008-5472.CAN-04-1750; Onken MD, 2006, CANCER RES, V66, P4602, DOI 10.1158/0008-5472.CAN-05-4196; Onken MD, 2010, J MOL DIAGN, V12, P461, DOI 10.2353/jmoldx.2010.090220; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Scheuermann JC, 2010, NATURE, V465, P243, DOI 10.1038/nature08966; Tyagi S, 2007, MOL CELL, V27, P107, DOI 10.1016/j.molcel.2007.05.030; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wang YL, 2007, NUCLEIC ACIDS RES, V35, pD298, DOI 10.1093/nar/gkl952; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Worley LA, 2007, CLIN CANCER RES, V13, P1466, DOI 10.1158/1078-0432.CCR-06-2401	21	935	964	5	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	2010	330	6009					1410	1413		10.1126/science.1194472	http://dx.doi.org/10.1126/science.1194472			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	689BK	21051595	Green Accepted			2022-12-28	WOS:000284902100051
J	Li, AA; Gong, H; Zhang, B; Wang, QD; Yan, C; Wu, JP; Liu, QA; Zeng, SQ; Luo, QM				Li, Anan; Gong, Hui; Zhang, Bin; Wang, Qingdi; Yan, Cheng; Wu, Jingpeng; Liu, Qian; Zeng, Shaoqun; Luo, Qingming			Micro-Optical Sectioning Tomography to Obtain a High-Resolution Atlas of the Mouse Brain	SCIENCE			English	Article							VISUALIZATION	The neuroanatomical architecture is considered to be the basis for understanding brain function and dysfunction. However, existing imaging tools have limitations for brainwide mapping of neural circuits at a mesoscale level. We developed a micro-optical sectioning tomography (MOST) system that can provide micrometer-scale tomography of a centimeter-sized whole mouse brain. Using MOST, we obtained a three-dimensional structural data set of a Golgi-stained whole mouse brain at the neurite level. The morphology and spatial locations of neurons and traces of neurites could be clearly distinguished. We found that neighboring Purkinje cells stick to each other.	[Li, Anan; Gong, Hui; Zhang, Bin; Wang, Qingdi; Yan, Cheng; Wu, Jingpeng; Liu, Qian; Zeng, Shaoqun; Luo, Qingming] Huazhong Univ Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect, Wuhan 430074, Peoples R China	Huazhong University of Science & Technology	Luo, QM (corresponding author), Huazhong Univ Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect, Wuhan 430074, Peoples R China.	qluo@mail.hust.edu.cn	Wu, Jingpeng/H-3955-2019; Liu, Qian/D-8184-2011; liu, qian/HDM-2936-2022; Qian, Liu/GYU-5886-2022; Wu, Jingpeng/B-5489-2019	Liu, Qian/0000-0002-8398-1021; Wu, Jingpeng/0000-0003-1604-8802; Luo, Qingming/0000-0002-6725-9311; Zeng, Shaoqun/0000-0002-1802-337X; LI, Anan/0000-0002-5877-4813	National Natural Science Foundation of China [30727002, 60025514, 30700214, 30925013]; Program for Changjiang Scholars and Innovative Research Team in University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Changjiang Scholars and Innovative Research Team in University(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT))	We thank P. Wu, J. B. Wu, and L. Wu for their early work in MOST; L. Fu, T. H. Xu, and W. Zhou for helpful discussions; Z. Dong and Z. Feng for assistance in experiments; J. Zhou for the nanowire sample; and Diatome AG, Switzerland, for the diamond knife. Supported by the National Natural Science Foundation of China (grants 30727002, 60025514, 30700214, and 30925013) and the Program for Changjiang Scholars and Innovative Research Team in University.	Bohland JW, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000334; Chin MH, 2007, PHYSIOL GENOMICS, V30, P313, DOI 10.1152/physiolgenomics.00287.2006; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Franklin K., 2007, MOUSE BRAIN STEREOTA; Hayworth K. J., 2006, MICROSC MICROANAL, V12, P86; Huisken J, 2004, SCIENCE, V305, P1007, DOI 10.1126/science.1100035; Kandel E R, 2000, PRINCIPLES NEURAL SC, P19; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Mayerich D, 2008, J MICROSC-OXFORD, V231, P134, DOI 10.1111/j.1365-2818.2008.02024.x; Micheva KD, 2007, NEURON, V55, P25, DOI 10.1016/j.neuron.2007.06.014; Pawley J.B., 2006, HDB BIOL CONFOCAL MI, DOI [10.1007/978-0-387-45524-2_23, 10.1007/978-0-387-45524-2, DOI 10.1007/978-0-387-45524-2]; Peng HC, 2010, NAT BIOTECHNOL, V28, P348, DOI 10.1038/nbt.1612; Standring S., 2016, GRAYS ANATOMY ANATOM, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]; Tsai PS, 2003, NEURON, V39, P27, DOI 10.1016/S0896-6273(03)00370-2; Williams RW, 2000, RES PRO CEL, V30, P21; Wilt BA, 2009, ANNU REV NEUROSCI, V32, P435, DOI 10.1146/annurev.neuro.051508.135540	18	311	337	17	292	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2010	330	6009					1404	1408		10.1126/science.1191776	http://dx.doi.org/10.1126/science.1191776			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	689BK	21051596				2022-12-28	WOS:000284902100049
J	Clem, RL; Huganir, RL				Clem, Roger L.; Huganir, Richard L.			Calcium-Permeable AMPA Receptor Dynamics Mediate Fear Memory Erasure	SCIENCE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; CONDITIONED FEAR; SPONTANEOUS-RECOVERY; IN-VIVO; EXTINCTION; AMYGDALA; PHOSPHORYLATION; RECONSOLIDATION; MECHANISMS	Traumatic fear memories can be inhibited by behavioral therapy for humans, or by extinction training in rodent models, but are prone to recur. Under some conditions, however, these treatments generate a permanent effect on behavior, which suggests that emotional memory erasure has occurred. The neural basis for such disparate outcomes is unknown. We found that a central component of extinction-induced erasure is the synaptic removal of calcium-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) in the lateral amygdala. A transient up-regulation of this form of plasticity, which involves phosphorylation of the glutamate receptor 1 subunit of the AMPA receptor, defines a temporal window in which fear memory can be degraded by behavioral experience. These results reveal a molecular mechanism for fear erasure and the relative instability of recent memory.	[Huganir, Richard L.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Huganir, RL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	rhuganir@jhmi.edu			NIH [R01NS036715, F32 MH087037-01]; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH087037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036715] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by grants from NIH (R01NS036715) and the Howard Hughes Medical Institute. R. L. C. was supported by a postdoctoral fellowship from NIH (F32 MH087037-01). We thank G. Thomas, D. Linden, L. Volk, and A. Lade for helpful comments.	Bellone C, 2006, NAT NEUROSCI, V9, P636, DOI 10.1038/nn1682; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; Clem RL, 2006, NEURON, V49, P663, DOI 10.1016/j.neuron.2006.01.019; Conrad KL, 2008, NATURE, V454, P118, DOI 10.1038/nature06995; Gale GD, 2004, J NEUROSCI, V24, P3810, DOI 10.1523/JNEUROSCI.4100-03.2004; Gogolla N, 2009, SCIENCE, V325, P1258, DOI 10.1126/science.1174146; He KW, 2009, P NATL ACAD SCI USA, V106, P20033, DOI 10.1073/pnas.0910338106; Herry C, 2010, EUR J NEUROSCI, V31, P599, DOI 10.1111/j.1460-9568.2010.07101.x; Ho MTW, 2007, J NEUROSCI, V27, P11651, DOI 10.1523/JNEUROSCI.2671-07.2007; Huff NC, 2009, BEHAV NEUROSCI, V123, P834, DOI 10.1037/a0016511; Humeau Y, 2007, J NEUROSCI, V27, P10947, DOI 10.1523/JNEUROSCI.2603-07.2007; Lee HK, 2003, CELL, V112, P631, DOI 10.1016/S0092-8674(03)00122-3; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006; Liu SQJ, 2000, NATURE, V405, P454, DOI 10.1038/35013064; Mao SC, 2006, J NEUROSCI, V26, P8892, DOI 10.1523/JNEUROSCI.0365-06.2006; Maren S, 2006, P NATL ACAD SCI USA, V103, P18020, DOI 10.1073/pnas.0608398103; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; McNally RJ, 2007, CLIN PSYCHOL REV, V27, P750, DOI 10.1016/j.cpr.2007.01.003; Monfils MH, 2009, SCIENCE, V324, P951, DOI 10.1126/science.1167975; Nader K, 2009, NAT REV NEUROSCI, V10, P224, DOI 10.1038/nrn2590; Pape HC, 2010, PHYSIOL REV, V90, P419, DOI 10.1152/physrev.00037.2009; Phelps EA, 2005, NEURON, V48, P175, DOI 10.1016/j.neuron.2005.09.025; Rodrigues SM, 2004, NEURON, V44, P75, DOI 10.1016/j.neuron.2004.09.014; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Rumpel S, 2005, SCIENCE, V308, P83, DOI 10.1126/science.1103944; Sacco T, 2010, SCIENCE, V329, P649, DOI 10.1126/science.1183165; Schiller D, 2010, NATURE, V463, P49, DOI 10.1038/nature08637; Urcelay GP, 2009, LEARN BEHAV, V37, P60, DOI 10.3758/LB.37.1.60; Walker DL, 2002, J NEUROSCI, V22, P2343, DOI 10.1523/JNEUROSCI.22-06-02343.2002	30	360	365	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2010	330	6007					1108	1112		10.1126/science.1195298	http://dx.doi.org/10.1126/science.1195298			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21030604	Green Accepted			2022-12-28	WOS:000284374700045
J	Scott, M; Gunderson, CW; Mateescu, EM; Zhang, ZG; Hwa, T				Scott, Matthew; Gunderson, Carl W.; Mateescu, Eduard M.; Zhang, Zhongge; Hwa, Terence			Interdependence of Cell Growth and Gene Expression: Origins and Consequences	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN; RIBOSOMES; BACTERIA	In bacteria, the rate of cell proliferation and the level of gene expression are intimately intertwined. Elucidating these relations is important both for understanding the physiological functions of endogenous genetic circuits and for designing robust synthetic systems. We describe a phenomenological study that reveals intrinsic constraints governing the allocation of resources toward protein synthesis and other aspects of cell growth. A theory incorporating these constraints can accurately predict how cell proliferation and gene expression affect one another, quantitatively accounting for the effect of translation-inhibiting antibiotics on gene expression and the effect of gratuitous protein expression on cell growth. The use of such empirical relations, analogous to phenomenological laws, may facilitate our understanding and manipulation of complex biological systems before underlying regulatory circuits are elucidated.	[Scott, Matthew; Mateescu, Eduard M.; Hwa, Terence] Univ Calif San Diego, Dept Phys, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA; [Gunderson, Carl W.; Zhang, Zhongge; Hwa, Terence] Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Hwa, T (corresponding author), Univ Calif San Diego, Dept Phys, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA.	hwa@ucsd.edu	Hwa, Terry/GOJ-9904-2022; Hwa, Terence/J-4012-2013	Hwa, Terence/0000-0003-1837-6842	NIH [RO1GM77298]; NSF [MCB0746581, PHY0822283]; Natural Sciences and Engineering Research Council of Canada; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077298] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank H. Bremer, L. Csonka, P. Dennis, M. Ehrenberg, P. Geiduschek, M. Schaechter, A. Tadmor, and members of the Hwa lab for suggestions and discussions; D. Hughes for the Sm mutant strains; and P.-h. Lee and B. Willumsen for the use of unpublished data. Supported by NIH grant RO1GM77298, NSF grant MCB0746581, and the NSF-supported Center for Theoretical Biological Physics (grant PHY0822283). M. S. was supported by a Natural Sciences and Engineering Research Council of Canada fellowship.	Airoldi EM, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000257; Arkin AP, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-8-114; BENTLEY WE, 1990, BIOTECHNOL BIOENG, V35, P668, DOI 10.1002/bit.260350704; Bremer H, 1996, ESCHERICHIA COLI SAL; Chou CP, 2007, APPL MICROBIOL BIOT, V76, P521, DOI 10.1007/s00253-007-1039-0; Dekel E, 2005, NATURE, V436, P588, DOI 10.1038/nature03842; DONG HJ, 1995, J BACTERIOL, V177, P1497, DOI 10.1128/jb.177.6.1497-1504.1995; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; FORCHHAMMER J, 1971, J MOL BIOL, V55, P563, DOI 10.1016/0022-2836(71)90337-8; GLICK BR, 1995, BIOTECHNOL ADV, V13, P247, DOI 10.1016/0734-9750(95)00004-A; Guido NJ, 2006, NATURE, V439, P856, DOI 10.1038/nature04473; Klumpp S, 2009, CELL, V139, P1366, DOI 10.1016/j.cell.2009.12.001; Maaloe O., 1979, BIOL REGUL DEV, V1, P487; MIKKOLA R, 1991, BIOCHIMIE, V73, P1551, DOI 10.1016/0300-9084(91)90190-C; MONOD J, 1949, ANNU REV MICROBIOL, V3, P371, DOI 10.1146/annurev.mi.03.100149.002103; Paul BJ, 2004, ANNU REV GENET, V38, P749, DOI 10.1146/annurev.genet.38.072902.091347; RUUSALA T, 1984, EMBO J, V3, P2575, DOI 10.1002/j.1460-2075.1984.tb02176.x; Stoebel DM, 2008, GENETICS, V178, P1653, DOI 10.1534/genetics.107.085399; Tan C, 2009, NAT CHEM BIOL, V5, P842, DOI 10.1038/nchembio.218; VIND J, 1993, J MOL BIOL, V231, P678, DOI 10.1006/jmbi.1993.1319; Youk H, 2009, NATURE, V462, P875, DOI 10.1038/nature08653; Zaslaver A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000545	22	752	762	8	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1099	1102		10.1126/science.1192588	http://dx.doi.org/10.1126/science.1192588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097934				2022-12-28	WOS:000284374700042
J	Accurso, FJ; Rowe, SM; Clancy, JP; Boyle, MP; Dunitz, JM; Durie, PR; Sagel, SD; Hornick, DB; Konstan, MW; Donaldson, SH; Moss, RB; Pilewski, JM; Rubenstein, RC; Uluer, AZ; Aitken, ML; Freedman, SD; Rose, LM; Mayer-Hamblett, N; Dong, QM; Zha, JH; Stone, AJ; Olson, ER; Ordonez, CL; Campbell, PW; Ashlock, MA; Ramsey, BW				Accurso, Frank J.; Rowe, Steven M.; Clancy, J. P.; Boyle, Michael P.; Dunitz, Jordan M.; Durie, Peter R.; Sagel, Scott D.; Hornick, Douglas B.; Konstan, Michael W.; Donaldson, Scott H.; Moss, Richard B.; Pilewski, Joseph M.; Rubenstein, Ronald C.; Uluer, Ahmet Z.; Aitken, Moira L.; Freedman, Steven D.; Rose, Lynn M.; Mayer-Hamblett, Nicole; Dong, Qunming; Zha, Jiuhong; Stone, Anne J.; Olson, Eric R.; Ordonez, Claudia L.; Campbell, Preston W.; Ashlock, Melissa A.; Ramsey, Bonnie W.			Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CFTR; QUESTIONNAIRE; TRANSPORT; ADULTS	BACKGROUND A new approach in the treatment of cystic fibrosis involves improving the function of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a CFTR potentiator, has been shown to increase the activity of wild-type and defective cell-surface CFTR in vitro. METHODS We randomly assigned 39 adults with cystic fibrosis and at least one G551D-CFTR allele to receive oral VX-770 every 12 hours at a dose of 25, 75, or 150 mg or placebo for 14 days (in part 1 of the study) or VX-770 every 12 hours at a dose of 150 or 250 mg or placebo for 28 days (in part 2 of the study). RESULTS At day 28, in the group of subjects who received 150 mg of VX-770, the median change in the nasal potential difference (in response to the administration of a chloride-free isoproterenol solution) from baseline was -3.5 mV (range, -8.3 to 0.5; P = 0.02 for the within-subject comparison, P = 0.13 vs. placebo), and the median change in the level of sweat chloride was -59.5 mmol per liter (range, -66.0 to -19.0; P = 0.008 within-subject, P = 0.02 vs. placebo). The median change from baseline in the percent of predicted forced expiratory volume in 1 second was 8.7% (range, 2.3 to 31.3; P = 0.008 for the within-subject comparison, P = 0.56 vs. placebo). None of the subjects withdrew from the study. Six severe adverse events occurred in two subjects (diffuse macular rash in one subject and five incidents of elevated blood and urine glucose levels in one subject with diabetes). All severe adverse events resolved without the discontinuation of VX-770. CONCLUSIONS This study to evaluate the safety and adverse-event profile of VX-770 showed that VX-770 was associated with within-subject improvements in CFTR and lung function. These findings provide support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.	[Accurso, Frank J.; Sagel, Scott D.] Univ Colorado Denver, Aurora, CO 80045 USA; [Accurso, Frank J.; Sagel, Scott D.] Childrens Hosp, Aurora, CO USA; [Rowe, Steven M.; Clancy, J. P.] Univ Alabama Birmingham, Birmingham, AL USA; [Boyle, Michael P.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA; [Dunitz, Jordan M.] Univ Minnesota, Minneapolis, MN USA; [Durie, Peter R.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Durie, Peter R.] Univ Toronto, Toronto, ON, Canada; [Hornick, Douglas B.] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Konstan, Michael W.] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Konstan, Michael W.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Donaldson, Scott H.] Univ N Carolina, Chapel Hill, NC USA; [Moss, Richard B.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Pilewski, Joseph M.] Univ Pittsburgh, Pittsburgh, PA USA; [Rubenstein, Ronald C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Rubenstein, Ronald C.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Uluer, Ahmet Z.] Childrens Hosp, Boston, MA 02115 USA; [Freedman, Steven D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Aitken, Moira L.; Rose, Lynn M.; Mayer-Hamblett, Nicole] Univ Washington, Seattle, WA 98195 USA; [Rose, Lynn M.; Mayer-Hamblett, Nicole; Ramsey, Bonnie W.] Seattle Childrens Hosp, Seattle, WA USA; [Dong, Qunming; Zha, Jiuhong; Stone, Anne J.; Olson, Eric R.; Ordonez, Claudia L.] Vertex Pharmaceut, Cambridge, MA USA; [Campbell, Preston W.; Ashlock, Melissa A.] Cyst Fibrosis Fdn Therapeut, Bethesda, MD USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine; University of Minnesota System; University of Minnesota Twin Cities; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Iowa; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Vertex Pharmaceuticals; Cystic Fibrosis Foundation	Accurso, FJ (corresponding author), Univ Colorado Denver, 13123 E 16th Ave,B395, Aurora, CO 80045 USA.	accurso.frank@tchden.org	Pilewski, Joseph/AAF-5149-2021; Moss, Richard B./S-9218-2019; Donaldson, Scott H./ABG-5157-2021	Moss, Richard B./0000-0003-3611-4221; Donaldson, Scott H./0000-0003-4802-0388; Konstan, Michael/0000-0002-0557-7277; Hornick, Douglas/0000-0003-4545-8456; Rubenstein, Ronald/0000-0002-3138-4006; Boyle, Michael/0000-0002-9740-1630	Vertex Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics; Food and Drug Administration Office of Orphan Products Development [FD-R-003432-01]; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) [K23 DK075788]; Cystic Fibrosis Foundation Therapeutics [CLANCY05Y2, DURIE06A0, RAMSEY03Y0]; National Center for Research Resources of the NIH [UL1 RR025005, GCRC M01 RR00070, CTSA 1UL1 RR025744, UL1 RR024989, M01 RR02172, CTSA UL1 RR025014, K23 RR018611-05, CTSA UL1 RR025780, CTSA UL 1RR025747, CTSA UL1 RR024153, CTSA UL1 RR024134]; National Heart, Lung, and Blood Institute of the NIH [U01 HL081335]; Inspire; PTC Therapeutics; Digestive Care; Gilead; Vertex; Altus; KaloBios; Axcan Pharma; Yasoo Health; INO Therapeutics; Mpex; Genentech; Transave; MedImmune; Novartis; Bayer; Roche; Liquidia Technologies; Pfizer; Boehringer Ingelheim; Ovation; CSL Bering; NanoBio; Nektar; Solvay; Aridis; AOP/Lantibio; Johnson Johnson; 23andMe; Uluer; Education Development Center; Pharmaxis; Hood Foundation; Gerber Foundation; Merck; AlgiPharma; Aradigm; CSL Behring; Eurand; GlaxoSmithKline; N30 Pharmaceuticals; Seed-One Ventures; FOOD AND DRUG ADMINISTRATION [R01FD003432] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025005, UL1RR025780, UL1RR025747, UL1RR024989, K23RR018611, UL1RR025744, M01RR000070, UL1RR024134, UL1RR024153, UL1RR025014, M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL081335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651, K23DK075788] Funding Source: NIH RePORTER	Vertex Pharmaceuticals(Vertex Pharmaceuticals); Cystic Fibrosis Foundation Therapeutics(Italian Cystic Fibrosis Research Foundation); Food and Drug Administration Office of Orphan Products Development; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Cystic Fibrosis Foundation Therapeutics(Italian Cystic Fibrosis Research Foundation); National Center for Research Resources of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Heart, Lung, and Blood Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Inspire; PTC Therapeutics; Digestive Care; Gilead(Gilead Sciences); Vertex(Vertex Pharmaceuticals); Altus; KaloBios; Axcan Pharma(Dexcel Pharma); Yasoo Health; INO Therapeutics; Mpex; Genentech(Roche HoldingGenentech); Transave; MedImmune(AstraZenecaMedimmune); Novartis(Novartis); Bayer(Bayer AG); Roche(Roche Holding); Liquidia Technologies; Pfizer(Pfizer); Boehringer Ingelheim(Boehringer Ingelheim); Ovation; CSL Bering; NanoBio; Nektar; Solvay(Solvay SA); Aridis; AOP/Lantibio; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); 23andMe; Uluer; Education Development Center; Pharmaxis; Hood Foundation; Gerber Foundation; Merck(Merck & Company); AlgiPharma; Aradigm; CSL Behring; Eurand; GlaxoSmithKline(GlaxoSmithKline); N30 Pharmaceuticals; Seed-One Ventures; FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by Vertex Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics, and grants from the Food and Drug Administration Office of Orphan Products Development (FD-R-003432-01), the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) (K23 DK075788, to Dr. Rowe), Cystic Fibrosis Foundation Therapeutics (CLANCY05Y2, to Dr. Clancy and the University of Alabama at Birmingham for coordinating the nasal potential difference qualification process; Clinical Facilitation Award DURIE06A0, to Dr. Durie; and RAMSEY03Y0, for the Therapeutics Development Network Coordinating Center, to Dr. Ramsey), the National Center for Research Resources of the NIH (GCRC UL1 RR025005, to Johns Hopkins; GCRC M01 RR00070 and CTSA 1UL1 RR025744, to Stanford University; UL1 RR024989, to Case Western Reserve University; GCRC M01 RR02172, to Children's Hospital Boston; CTSA UL1 RR025014, to the Institute of Translational Health Sciences and the University of Washington; K23 RR018611-05, to Dr. Sagel; CTSA UL1 RR025780, to the University of Colorado Denver; CTSA UL 1RR025747, to the University of North Carolina at Chapel Hill; CTSA UL1 RR024153, to Children's Hospital of Pittsburgh; and CTSA UL1 RR024134, to Children's Hospital of Philadelphia), and the National Heart, Lung, and Blood Institute of the NIH (U01 HL081335, to the University of Colorado Denver).; Dr. Accurso reports receiving consulting fees from Inspire and PTC Therapeutics, grant support from Digestive Care, PTC Therapeutics, Gilead, Vertex, Altus, KaloBios, Axcan Pharma, Yasoo Health, INO Therapeutics, Mpex, and Genentech, and travel support from Vertex Pharmaceuticals, PTC Therapeutics, Inspire Pharmaceuticals, and Gilead Sciences; Dr. Rowe, receiving grant support from Vertex, Novartis, and PTC Therapeutics and consulting fees from PTC Therapeutics and Vertex; Dr. Clancy, receiving consulting fees from Transave and grant support from Vertex, MedImmune, Inspire, Gilead, Transave, and PTC Therapeutics; Dr. Boyle, receiving consulting fees from Novartis, Genentech, Gilead, and Bayer and grant support from Vertex; Dr. Dunitz, receiving grant support from Inspire, Vertex, Altus, Gilead, and Roche (through a clinical trial subcontract with Duke) and travel support from Vertex; Dr. Durie, receiving grant support from Vertex and consulting fees and travel support from Vertex; Dr. Sagel, receiving grant support from Vertex, Yasoo Health, and INO Therapeutics; Dr. Donaldson, receiving consulting fees from Liquidia Technologies, grant support from Inspire, Vertex, and Gilead, and travel support from Gilead and Vertex; Dr. Hornick, receiving consulting fees from Pfizer and Genentech, speaking fees from Pfizer and Boehringer Ingelheim, and travel support from Pfizer, Boehringer Ingelheim, and Genentech; Dr. Konstan, receiving grant support from Vertex, Novartis, Boehringer Ingelheim, Ovation, Axcan Pharma, Genentech, and Altus, consulting fees and travel support from Vertex, Axcan Pharma, Boehringer Ingelheim, CSL Bering, Digestive Care, Genentech, GlaxoSmithKline, Gilead, NanoBio, Nektar, Novartis, PTC Therapeutics, Solvay, and Transave, and speaking fees from Roche and Genentech, and serving on the scientific advisory board for Aradigm; Dr. Moss, receiving consulting fees from Vertex, Novartis, Inspire, Genentech, Mpex, PTC Therapeutics, Aridis, AOP/Lantibio, Johnson & Johnson, and 23andMe, grant support from Vertex, Gilead, PTC Therapeutics, Inspire, and GlaxoSmithKline, speaking fees from Novartis, Genentech, and AstraZeneca and travel support from AstraZeneca, Novartis, Vertex, and Genentech, and owning stock in Gilead and Genentech; Dr. Pilewski, receiving grant support from Novartis and Vertex; Dr. Rubenstein, receiving consulting fees from Transave; Dr. Uluer, receiving grant support from Vertex, Boehringer Ingelheim, Education Development Center, and Bayer, speaking fees from Vertex, and travel support from Vertex and Bayer; Dr. Aitken, receiving grant support from Pharmaxis, Transave, Vertex, and PTC Therapeutics and travel support from Pharmaxis and Vertex; Dr. Freedman, receiving grant support from Vertex, Pfizer, Hood Foundation, Gerber Foundation, and Merck; Drs. Dong, Zha, Olson, Ordonez, and Ms. Stone, being employees of Vertex and holding stock in and receiving travel support from Vertex; and Dr. Ramsey, receiving grants from AlgiPharma, Aradigm, Bayer, CSL Behring, Eurand, GlaxoSmithKline, Inspire, Johnson & Johnson, KaloBios, Mpex, N30 Pharmaceuticals, Novartis, Pharmaxis, PTC Therapeutics, Seed-One Ventures, Transave, and Vertex. No other potential conflict of interest relevant to this article was reported.	Alton EWFW, 1999, LANCET, V353, P947, DOI 10.1016/S0140-6736(98)06532-5; Amaral M, 2007, TRENDS PHARMACOL SCI, V28, P447; Amaral MD, 2007, TRENDS PHARMACOL SCI, V28, P334, DOI 10.1016/j.tips.2007.05.004; ANBAR RD, 1990, PEDIATR PULM, V8, P82, DOI 10.1002/ppul.1950080205; *CYST FIBR FDN, 2008, PAT REG 2007 ANN DAT; Farrell PM, 2008, J PEDIATR-US, V153, pS4, DOI 10.1016/j.jpeds.2008.05.005; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Kerem E, 2008, LANCET, V372, P719, DOI 10.1016/S0140-6736(08)61168-X; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255; Quittner AL, 2005, CHEST, V128, P2347, DOI 10.1378/chest.128.4.2347; Quittner AL, 2009, CHEST, V135, P1610, DOI 10.1378/chest.08-1190; Rowe Steven M, 2007, Proc Am Thorac Soc, V4, P387, DOI 10.1513/pats.200703-043BR; Sawicki GS, 2009, J CYST FIBROS, V8, P91, DOI 10.1016/j.jcf.2008.09.007; Sermet-Gaudelus I, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-5; Van Goor F, 2009, P NATL ACAD SCI USA, V106, P18825, DOI 10.1073/pnas.0904709106; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; YANG YP, 1993, HUM MOL GENET, V2, P1253, DOI 10.1093/hmg/2.8.1253	20	585	596	4	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					1991	2003		10.1056/NEJMoa0909825	http://dx.doi.org/10.1056/NEJMoa0909825			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083385	Green Accepted, Green Submitted			2022-12-28	WOS:000284310000004
J	Muotri, AR; Marchetto, MCN; Coufal, NG; Oefner, R; Yeo, G; Nakashima, K; Gage, FH				Muotri, Alysson R.; Marchetto, Maria C. N.; Coufal, Nicole G.; Oefner, Ruth; Yeo, Gene; Nakashima, Kinichi; Gage, Fred H.			L1 retrotransposition in neurons is modulated by MeCP2	NATURE			English	Article							CPG-BINDING PROTEIN-2; METHYL-CPG; STEM-CELLS; HISTONE DEACETYLASE; ADULT NEUROGENESIS; RETT-SYNDROME; TRANSCRIPTION; HIPPOCAMPUS; SEQUENCES; ELEMENTS	Long interspersed nuclear elements-1 (LINE-1 or L1s) are abundant retrotransposons that comprise approximately 20% of mammalian genomes(1-3). Active L1 retrotransposons can impact the genome in a variety of ways, creating insertions, deletions, new splice sites or gene expression fine-tuning(4-6). We have shown previously that L1 retrotransposons are capable of mobilization in neuronal progenitor cells from rodents and humans and evidence of massive L1 insertions was observed in adult brain tissues but not in other somatic tissues(7,8). In addition, L1 mobility in the adult hippocampus can be influenced by the environment(9). The neuronal specificity of somatic L1 retrotransposition in neural progenitors is partially due to the transition of a Sox2/HDAC1 repressor complex to a Wnt-mediated T-cell factor/lymphoid enhancer factor (TCF/LEF) transcriptional activator(7,10). The transcriptional switch accompanies chromatin remodelling during neuronal differentiation, allowing a transient stimulation of L1 transcription(7). The activity of L1 retrotransposons during brain development can have an impact on gene expression and neuronal function, thereby increasing brain-specific genetic mosaicism(11,12). Further understanding of the molecular mechanisms that regulate L1 expression should provide new insights into the role of L1 retrotransposition during brain development. Here we show that L1 neuronal transcription and retrotransposition in rodents are increased in the absence of methyl-CpG-binding protein 2 (MeCP2), a protein involved in global DNA methylation and human neurodevelopmental diseases. Using neuronal progenitor cells derived from human induced pluripotent stem cells and human tissues, we revealed that patients with Rett syndrome (RTT), carrying MeCP2 mutations, have increased susceptibility for L1 retrotransposition. Our data demonstrate that L1 retrotransposition can be controlled in a tissue-specific manner and that disease-related genetic mutations can influence the frequency of neuronal L1 retrotransposition. Our findings add a new level of complexity to the molecular events that can lead to neurological disorders.	[Muotri, Alysson R.] Univ Calif San Diego, Sch Med, Dept Pediat,Dept Cellular & Mol Med, Rady Childrens Hosp San Diego,Stem Cell Program, La Jolla, CA 92093 USA; [Marchetto, Maria C. N.; Coufal, Nicole G.; Oefner, Ruth; Gage, Fred H.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; [Yeo, Gene] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, Stem Cell Program, La Jolla, CA 92093 USA; [Nakashima, Kinichi] Nara Inst Sci & Technol, Grad Sch Biol Sci, Lab Mol Neurosci, Ikoma 6300101, Japan	Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego; Nara Institute of Science & Technology	Muotri, AR (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat,Dept Cellular & Mol Med, Rady Childrens Hosp San Diego,Stem Cell Program, 9500 Gilman Dr, La Jolla, CA 92093 USA.	muotri@ucsd.edu; gage@salk.edu	Coufal, Nicole/ABA-9471-2021; Yeo, Gene/AAE-7676-2019	Yeo, Gene/0000-0002-0799-6037; Coufal, Nicole/0000-0001-6547-1733	National Institutes of Health [1-DP2-OD006495-01]; Emerald Foundation; Mathers Foundation; Lookout Fund; NIH/NINDS [R01MH088485]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH088485] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD006495] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Emerald Foundation; Mathers Foundation; Lookout Fund; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	A.R.M. is supported by the National Institutes of Health through the NIH Director's New Innovator Award Program, 1-DP2-OD006495-01 and by the Emerald Foundation. F.H.G. is supported by the Mathers Foundation, Lookout Fund, and NIH/NINDS R01MH088485. The authors would like to thank A. Huynh, B. Aimone, K. Stecker, B. Berg and D. Sepp for help during the 3D brain model assembly, J. Moran and J. Garcia-Perez for discussion and critical review of the manuscript, M. Gage for editorial comments, and B. Moddy and G. Peng for experimental assistance.	Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389; Han JS, 2004, NATURE, V429, P268, DOI 10.1038/nature02536; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Klose RJ, 2005, MOL CELL, V19, P667, DOI 10.1016/j.molcel.2005.07.021; Kuwabara T, 2009, NAT NEUROSCI, V12, P1097, DOI 10.1038/nn.2360; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Moran J.V., 2002, MOBILE DNA, P836; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Muotri AR, 2006, NATURE, V441, P1087, DOI 10.1038/nature04959; Muotri AR, 2009, HIPPOCAMPUS, V19, P1002, DOI 10.1002/hipo.20564; Muotri AR, 2005, NATURE, V435, P903, DOI 10.1038/nature03663; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Perepelitsa-Belancio V, 2003, NAT GENET, V35, P363, DOI 10.1038/ng1269; Rowe HM, 2010, NATURE, V463, P237, DOI 10.1038/nature08674; Singer T, 2010, TRENDS NEUROSCI, V33, P345, DOI 10.1016/j.tins.2010.04.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Yu F, 2001, NUCLEIC ACIDS RES, V29, P4493, DOI 10.1093/nar/29.21.4493; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	30	440	484	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2010	468	7322					443	446		10.1038/nature09544	http://dx.doi.org/10.1038/nature09544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085180	Green Submitted, Green Accepted			2022-12-28	WOS:000284313100044
J	Roos, JCP; Hyry, HI; Cox, TM				Roos, Jonathan C. P.; Hyry, Hanna I.; Cox, Timothy M.			Orphan drug pricing may warrant a competition law investigation	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Roos, Jonathan C. P.; Hyry, Hanna I.; Cox, Timothy M.] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England	University of Cambridge	Cox, TM (corresponding author), Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England.	ec432@medschl.cam.ac.uk						Anand G., 2005, WALL STREET J   1115; ANAND G, 2005, WALL STREET J   1116; ANAND GAS, 2005, WALL STREET J   1228; [Anonymous], CONSOLIDATED VERSION; Antman KH, 2001, ONCOLOGIST, V6, P1, DOI 10.1634/theoncologist.6-suppl_2-1; ARIYANCHIRA S, 2010, GENENG NEWS; BARKHODAEE RH, 2007, MOTHERS COURAGE; CHUSTECKA Z, 2004, MEDSCAPE MED NE 1104; Deegan P, 2010, LANCET, V375, P1522, DOI 10.1016/S0140-6736(10)60652-6; Denis Alain, 2010, J Med Econ, V13, P295, DOI 10.3111/13696998.2010.491427; DEVARAX A, STUDY ORPHAN DRUGS P, P26; DOCTEUR E, 2008, OECD HIGH LEV S PHAR, P11; Dolgin E, 2010, NAT MED, V16, P837, DOI 10.1038/nm0810-837a; *EC, COMP ANT OV; *EC COMP DG, 2 EC COMP DG; *EC COMP DG, 2008, PHARM SECT INQ PREL; *EUR, 2008, MUCH IS LIF WORTH SW; *EUR, ORPH DRUGS RIS CHALL; Goozner M, 2004, 800 MILLION (DOLLAR) PILL: THE TRUTH BEHIND THE COST OF NEW DRUGS, P1; GOOZNER M, 2002, AM PROSPECT     1130; GREEN K, 2008, COMPETITION RELEVANT; Hemphill TA, 2010, J BUS ETHICS, V94, P225, DOI 10.1007/s10551-009-0259-x; JACK A, 2010, FINANCIAL TIMES 0629; Kolata Gina, 2008, NY TIMES        0414; McCabe C, 2006, QJM-INT J MED, V99, P341, DOI 10.1093/qjmed/hcl033; MCCABE C, 2010, BMJ-BRIT MED J, V314, pC4777; *OECD, 2009, HLTH POL STUD, P117; Remuzzi G, 2008, LANCET, V371, P1978, DOI 10.1016/S0140-6736(08)60847-8; SUSHIL V, 2004, 03703B CTR MARK; THOMAS H, 2010, FINANCIAL TIMES 1008; *US OTA, 1992, PB93101723; Vedder AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000598; Whish R, 2009, COMPETITION LAW; 2003, ECLR, V70, P82	34	31	31	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2010	341								c6471	10.1136/bmj.c6471	http://dx.doi.org/10.1136/bmj.c6471			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684WJ	21081598				2022-12-28	WOS:000284585600026
J	de Vries, EN; Prins, HA; Crolla, RMPH; den Outer, AJ; van Andel, G; van Helden, SH; Schlack, WS; van Putten, MA; Gouma, DJ; Dijkgraaf, MGW; Smorenburg, SM; Boermeester, MA				de Vries, Eefje N.; Prins, Hubert A.; Crolla, Rogier M. P. H.; den Outer, Adriaan J.; van Andel, George; van Helden, Sven H.; Schlack, Wolfgang S.; van Putten, M. Agnes; Gouma, Dirk J.; Dijkgraaf, Marcel G. W.; Smorenburg, Susanne M.; Boermeester, Marja A.		SURPASS Collaborative Grp	Effect of a Comprehensive Surgical Safety System on Patient Outcomes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-COLLEGE; ADVERSE OUTCOMES; IMPLEMENTATION; MORBIDITY; MORTALITY; SURGEONS; COMPLICATIONS; CHECKLIST; EVENTS; DESIGN	Background: Adverse events in patients who have undergone surgery constitute a large proportion of iatrogenic illnesses. Most surgical safety interventions have focused on the operating room. Since more than half of all surgical errors occur outside the operating room, it is likely that a more substantial improvement in outcomes can be achieved by targeting the entire surgical pathway. Methods: We examined the effects on patient outcomes of a comprehensive, multidisciplinary surgical safety checklist, including items such as medication, marking of the operative side, and use of postoperative instructions. The checklist was implemented in six hospitals with high standards of care. All complications occurring during admission were documented prospectively. We compared the rate of complications during a baseline period of 3 months with the rate during a 3-month period after implementation of the checklist, while accounting for potential confounders. Similar data were collected from a control group of five hospitals. Results: In a comparison of 3760 patients observed before implementation of the checklist with 3820 patients observed after implementation, the total number of complications per 100 patients decreased from 27.3 (95% confidence interval [CI], 25.9 to 28.7) to 16.7 (95% CI, 15.6 to 17.9), for an absolute risk reduction of 10.6 (95% CI, 8.7 to 12.4). The proportion of patients with one or more complications decreased from 15.4% to 10.6% (P<0.001). In-hospital mortality decreased from 1.5% (95% CI, 1.2 to 2.0) to 0.8% (95% CI, 0.6 to 1.1), for an absolute risk reduction of 0.7 percentage points (95% CI, 0.2 to 1.2). Outcomes did not change in the control hospitals. Conclusions: Implementation of this comprehensive checklist was associated with a reduction in surgical complications and mortality in hospitals with a high standard of care. (Netherlands Trial Register number, NTR1943.) N Engl J Med 2010;363:1928-37.	[de Vries, Eefje N.; Gouma, Dirk J.; Boermeester, Marja A.] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands; [de Vries, Eefje N.; van Putten, M. Agnes; Smorenburg, Susanne M.] Univ Amsterdam, Acad Med Ctr, Dept Qual & Proc Innovat, NL-1105 AZ Amsterdam, Netherlands; [Schlack, Wolfgang S.] Univ Amsterdam, Acad Med Ctr, Dept Anesthesiol, NL-1105 AZ Amsterdam, Netherlands; [Dijkgraaf, Marcel G. W.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; [van Andel, George] Onze Lieve Vrouw Hosp, Dept Urol, Amsterdam, Netherlands; [Prins, Hubert A.] Jeroen Bosch Hosp, Dept Surg, Den Bosch, Netherlands; [Crolla, Rogier M. P. H.] Amphia Hosp, Dept Surg, Breda, Netherlands; [den Outer, Adriaan J.] Rijnland Hosp, Dept Surg, Leiderdorp, Netherlands; [van Helden, Sven H.] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Onze Lieve Vrouwe Gasthuis Hospital; Jeroen Bosch Ziekenhuis; Amphia Hospital; Rijnland Hospital; Maastricht University	Boermeester, MA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Surg, Meibergdreef 9,G4-132-1, NL-1105 AZ Amsterdam, Netherlands.	m.a.boermeester@amc.uva.nl	Chang, Shulan/H-2270-2011; Crolla, Rogier/L-9847-2019; Dijkgraaf, Marcel GW/G-6663-2011	Crolla, Rogier/0000-0003-2617-1791; 				Bender R, 2001, CONTROL CLIN TRIALS, V22, P102, DOI 10.1016/S0197-2456(00)00134-3; Bosk CL, 2009, LANCET, V374, P444, DOI 10.1016/S0140-6736(09)61440-9; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P163, DOI 10.1136/qshc.2007.023648; Clarke JR, 2007, ANN SURG, V246, P395, DOI 10.1097/SLA.0b013e3181469987; de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622; de Vries EN, 2009, QUAL SAF HEALTH CARE, V18, P121, DOI 10.1136/qshc.2008.027524; Elhai JD, 2008, PSYCHIAT RES, V160, P129, DOI 10.1016/j.psychres.2007.07.003; Feldman L, 1997, SURGERY, V122, P711, DOI 10.1016/S0039-6060(97)90078-7; Greenberg CC, 2007, J AM COLL SURGEONS, V204, P533, DOI 10.1016/j.jamcollsurg.2007.01.010; Griffen FD, 2007, J AM COLL SURGEONS, V204, P561, DOI 10.1016/j.jamcollsurg.2007.01.013; Gurusamy K, 2008, BRIT J SURG, V95, P1088, DOI 10.1002/bjs.6344; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Hutter MM, 2006, J AM COLL SURGEONS, V203, P618, DOI 10.1016/j.jamcollsurg.2006.07.010; Lingard L, 2008, ARCH SURG-CHICAGO, V143, P12, DOI 10.1001/archsurg.2007.21; Makary MA, 2006, JT COMM J QUAL PATIE, V32, P351, DOI 10.1016/S1553-7250(06)32045-4; van de Mheen PJM, 2008, QUAL SAF HEALTH CARE, V17, P47, DOI 10.1136/qshc.2007.023309; Marang-van de Mheen PJ, 2006, QUAL SAF HEALTH CARE, V15, P320, DOI 10.1136/qshc.2005.016220; Marang-van de Mheen P J, 2003, Ned Tijdschr Geneeskd, V147, P1273; Marang-van de Mheen PJ, 2005, QUAL SAF HEALTH CARE, V14, P378, DOI 10.1136/qshc.2004.013250; McCulloch P, 2009, QUAL SAF HEALTH CARE, V18, P109, DOI 10.1136/qshc.2008.032045; Paige JT, 2008, AM SURGEON, V74, P817; Strasberg SM, 2009, ANN SURG, V250, P177, DOI 10.1097/SLA.0b013e3181afde41; Verdaasdonk EGG, 2009, SURG ENDOSC, V23, P715, DOI 10.1007/s00464-008-0044-4	24	636	646	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1928	1937		10.1056/NEJMsa0911535	http://dx.doi.org/10.1056/NEJMsa0911535			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067384	Bronze			2022-12-28	WOS:000284047600008
J	Knip, M; Virtanen, SM; Seppa, K; Ilonen, J; Savilahti, E; Vaarala, O; Reunanen, A; Teramo, K; Hamalainen, A; Paronen, J; Dosch, H; Hakulinen, T; Akerblom, HK				Knip, Mikael; Virtanen, Suvi M.; Seppa, Karri; Ilonen, Jorma; Savilahti, Erkki; Vaarala, Outi; Reunanen, Antti; Teramo, Kari; Hamalainen, Anu-Maaria; Paronen, Johanna; Dosch, Hans-Michael; Hakulinen, Timo; Akerblom, Hans K.		Finnish TRIGR Study Grp	Dietary Intervention in Infancy and Later Signs of Beta-Cell Autoimmunity.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINNISH CHILDREN; YOUNG-CHILDREN; RISK; AUTOANTIBODIES; PROTEIN; TRENDS; IDDM	Background: Early exposure to complex dietary proteins may increase the risk of beta-cell autoimmunity and type 1 diabetes in children with genetic susceptibility. We tested the hypothesis that supplementing breast milk with highly hydrolyzed milk formula would decrease the cumulative incidence of diabetes-associated autoantibodies in such children. Methods: In this double-blind, randomized trial, we assigned 230 infants with HLA-conferred susceptibility to type 1 diabetes and at least one family member with type 1 diabetes to receive either a casein hydrolysate formula or a conventional, cow's-milk-based formula (control) whenever breast milk was not available during the first 6 to 8 months of life. Autoantibodies to insulin, glutamic acid decarboxylase (GAD), the insulinoma-associated 2 molecule (IA-2), and zinc transporter 8 were analyzed with the use of radiobinding assays, and islet-cell antibodies were analyzed with the use of immunofluorescence, during a median observation period of 10 years (mean, 7.5). The children were monitored for incident type 1 diabetes until they were 10 years of age. Results: The unadjusted hazard ratio for positivity for one or more autoantibodies in the casein hydrolysate group, as compared with the control group, was 0.54 (95% confidence interval [CI], 0.29 to 0.95), and the hazard ratio adjusted for an observed difference in the duration of exposure to the study formula was 0.51 (95% CI, 0.28 to 0.91). The unadjusted hazard ratio for positivity for two or more autoantibodies was 0.52 (95% CI, 0.21 to 1.17), and the adjusted hazard ratio was 0.47 (95% CI, 0.19 to 1.07). The rate of reported adverse events was similar in the two groups. Conclusions: Dietary intervention during infancy appears to have a long-lasting effect on markers of beta-cell autoimmunity -- markers that may reflect an autoimmune process leading to type 1 diabetes. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00570102.) N Engl J Med 2010;363:1900-8.	[Knip, Mikael; Savilahti, Erkki; Paronen, Johanna; Akerblom, Hans K.] Univ Helsinki, Hosp Children & Adolescents, FI-00014 Helsinki, Finland; [Teramo, Kari] Univ Helsinki, Dept Obstet & Gynecol, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FI-00014 Helsinki, Finland; [Virtanen, Suvi M.] Natl Inst Hlth & Welf, Nutr Unit, Helsinki, Finland; [Vaarala, Outi] Natl Inst Hlth & Welf, Immune Response Unit, Helsinki, Finland; [Reunanen, Antti] Natl Inst Hlth & Welf, Dept Hlth & Funct Capac, Helsinki, Finland; [Seppa, Karri; Hakulinen, Timo] Finnish Canc Registry, FIN-00170 Helsinki, Finland; [Knip, Mikael] Tampere Univ Hosp, Dept Pediat, Tampere, Finland; [Virtanen, Suvi M.] Tampere Univ Hosp, Res Unit, Tampere, Finland; [Virtanen, Suvi M.] Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland; [Ilonen, Jorma] Univ Turku, Immunogenet Lab, Turku, Finland; [Ilonen, Jorma] Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; [Hamalainen, Anu-Maaria] Jorvi Hosp, Dept Pediat, SF-02740 Espoo, Finland; [Hamalainen, Anu-Maaria] Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland; [Dosch, Hans-Michael] Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; Finnish Cancer Registry; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Tampere University; University of Turku; University of Eastern Finland; University of Oulu; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Knip, M (corresponding author), Univ Helsinki, Hosp Children & Adolescents, POB 22,Stenbackinkatu 11, FI-00014 Helsinki, Finland.	mikael.knip@helsinki.fi	Knip, Mikael/AAL-3773-2020; Virtanen, Suvi/AAP-1922-2021	Virtanen, Suvi/0000-0001-8928-0878; Hyoty, Heikki/0000-0003-0370-4145; Knip, Mikael/0000-0003-0474-0033	Academy of Finland; European Commission [BMH4-CT96-0233]; Juvenile Diabetes Foundation International [195003]; Helsinki University Central Hospital; University of Helsinki; Finnish Diabetes Research Foundation; Novo Nordisk Foundation; Medical Research Foundation of Tampere University Hospital; Dorothea Olivia, Karl Walter, and Jarl Walter Perklen Foundation; Liv och Halsa Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD040364] Funding Source: NIH RePORTER	Academy of Finland(Academy of Finland); European Commission(European CommissionEuropean Commission Joint Research Centre); Juvenile Diabetes Foundation International; Helsinki University Central Hospital; University of Helsinki; Finnish Diabetes Research Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Medical Research Foundation of Tampere University Hospital; Dorothea Olivia, Karl Walter, and Jarl Walter Perklen Foundation; Liv och Halsa Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by grants from the Academy of Finland; the European Commission (BMH4-CT96-0233); the Juvenile Diabetes Foundation International (File #195003); Helsinki University Central Hospital; University of Helsinki; the Finnish Diabetes Research Foundation; the Novo Nordisk Foundation; the Medical Research Foundation of Tampere University Hospital; the Dorothea Olivia, Karl Walter, and Jarl Walter Perklen Foundation; and the Liv och Halsa Fund.	Akerblom HK, 2005, DIABETOLOGIA, V48, P829, DOI 10.1007/s00125-005-1733-3; Green A, 1998, DIABETOLOGIA, V41, P1151; Harjutsalo V, 2008, LANCET, V371, P1777, DOI 10.1016/S0140-6736(08)60765-5; Holmberg H, 2007, BRIT J NUTR, V97, P111, DOI 10.1017/S0007114507210189; Ilonen J, 1996, DIABETES CARE, V19, P795, DOI 10.2337/diacare.19.8.795; Karges W, 1997, DIABETES, V46, P557, DOI 10.2337/diabetes.46.4.557; Kimpimaki T, 2001, J CLIN ENDOCR METAB, V86, P4782, DOI 10.1210/jc.86.10.4782; Knip M, 2002, HORM RES, V57, P6, DOI 10.1159/000053305; Knip M, 2002, DIABETES CARE, V25, P623, DOI 10.2337/diacare.25.3.623; Knip M, 2008, DIABETES CARE, V31, P622, DOI 10.2337/dc08-0023; Knip M, 2010, AM J CLIN NUTR, V91, p1506S, DOI 10.3945/ajcn.2010.28701C; Krischer J, 2007, PEDIATR DIABETES, V8, P117, DOI 10.1111/j.1399-5448.2007.00239.x; Kukko M, 2005, J CLIN ENDOCR METAB, V90, P2712, DOI 10.1210/jc.2004-1371; Malkani S, 1997, DIABETES, V46, P1133, DOI 10.2337/diabetes.46.7.1133; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Patterson CC, 2009, LANCET, V373, P2027, DOI 10.1016/S0140-6736(09)60568-7; Paxson JA, 1997, DIABETES, V46, P1711, DOI 10.2337/diabetes.46.11.1711; Paxson JA, 1998, DIABETES, V47, P144; R Core Team, 2020, R LANG ENV STAT COMP; Reunanen A, 2000, DIABETES CARE, V23, P1265, DOI 10.2337/diacare.23.9.1265; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Siljander HTA, 2009, DIABETES, V58, P2835, DOI 10.2337/db08-1305; Simonson W, 2002, METABOLISM, V51, P569, DOI 10.1053/meta.2002.31979; SJOROOS M, 1995, BIOTECHNIQUES, V18, P870; TURNBULL BW, 1976, J R STAT SOC B, V38, P290; Virtanen SM, 2006, DIABETOLOGIA, V49, P1512, DOI 10.1007/s00125-006-0236-1; Virtanen SM, 2003, AM J CLIN NUTR, V78, P1053, DOI 10.1093/ajcn/78.6.1053; VIRTANEN SM, 1991, DIABETES CARE, V14, P415, DOI 10.2337/diacare.14.5.415; VISSER JT, 2009, EUR J IMMUNOL S1, V39, pS674; Wenzlau JM, 2007, P NATL ACAD SCI USA, V104, P17040, DOI 10.1073/pnas.0705894104; Ziegler AG, 2003, JAMA-J AM MED ASSOC, V290, P1721, DOI 10.1001/jama.290.13.1721; Ziegler AG, 1999, DIABETES, V48, P460, DOI 10.2337/diabetes.48.3.460	32	201	209	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1900	1908		10.1056/NEJMoa1004809	http://dx.doi.org/10.1056/NEJMoa1004809			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067382	Green Accepted, Bronze			2022-12-28	WOS:000284047600005
J	Sartorius, N				Sartorius, Norman			Short-lived campaigns are not enough	NATURE			English	Editorial Material							PUBLIC-ATTITUDES; MENTAL-ILLNESS		Assoc Improvement Mental Hlth Programmes, CH-1209 Geneva, Switzerland		Sartorius, N (corresponding author), Assoc Improvement Mental Hlth Programmes, 14 Chemin Colladon, CH-1209 Geneva, Switzerland.	sartorius@normansartorius.com						Angermeyer MC, 2009, EUR PSYCHIAT, V24, P225, DOI 10.1016/j.eurpsy.2008.06.010; Baumann AE, 2008, UNDERSTANDING STIGMA, P49; Corrigan PW, 2002, SCHIZOPHRENIA BULL, V28, P293, DOI 10.1093/oxfordjournals.schbul.a006939; Hopper Kim, 2007, RECOVERY SCHIZOPHREN; Mehta N, 2009, BRIT J PSYCHIAT, V194, P278, DOI 10.1192/bjp.bp.108.052654; Sartorius N., 2005, REDUCING STIGMA MENT; Taskin EO, 2003, SOC PSYCH PSYCH EPID, V38, P586, DOI 10.1007/s00127-003-0655-y; Thornicroft G, 2009, LANCET, V373, P408, DOI 10.1016/S0140-6736(08)61817-6; Vaughn G., 2004, MENTAL HLTH PROMOTIO, P62	9	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					163	165		10.1038/468163a	http://dx.doi.org/10.1038/468163a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678DG	21068806				2022-12-28	WOS:000284051000015
J	de Zeeuw, D; Agarwal, R; Amdahl, M; Audhya, P; Coyne, D; Garimella, T; Parving, HH; Pritchett, Y; Remuzzi, G; Ritz, E; Andress, D				de Zeeuw, Dick; Agarwal, Rajiv; Amdahl, Michael; Audhya, Paul; Coyne, Daniel; Garimella, Tushar; Parving, Hans-Henrik; Pritchett, Yili; Remuzzi, Giuseppe; Ritz, Eberhard; Andress, Dennis			Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial	LANCET			English	Article							NEGATIVE ENDOCRINE REGULATOR; CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE; 1,25-DIHYDROXYVITAMIN D-3; COMBINATION THERAPY; ORAL CALCITRIOL; DOUBLE-BLIND; HEMODIALYSIS; NEPHROPATHY; SURVIVAL	Background Despite treatment with renin angiotensin aldosterone system (RAAS) inhibitors, patients with diabetes have increased risk of progressive renal failure that correlates with albuminuria. We aimed to assess whether paricalcitol could be used to reduce albuminuria in patients with diabetic nephropathy. Methods In this multinational, placebo-controlled, double-blind trial, we enrolled patients with type 2 diabetes and albuminuria who were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Patients were assigned (1:1:1) by computer-generated randomisation sequence to receive 24 weeks' treatment with placebo, 1 mu g/day paricalcitol, or 2 mu g/day paricalcitol. The primary endpoint was the percentage change in geometric mean urinary albumin-to-creatinine ratio (UACR) from baseline to last measurement during treatment for the combined paricalcitol groups versus the placebo group. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00421733. Findings Between February, 2007, and October, 2008, 281 patients were enrolled and assigned to receive placebo (n=93), 1 mu g paricalcitol (n=93), or 2 mu g paricalcitol (n=95); 88 patients on placebo, 92 on 1 mu g paricalcitol, and 92 on 2 mu g paricalcitol received at least one dose of study drug, and had UACR data at baseline and at least one timepoint during treatment, and so were included in the primary analysis. Change in UACR was: -3% (from 61 to 60 mg/mmol; 95% Cl -16 to 13) in the placebo group; -16% (from 62 to 51 mg/mmol; -24 to -9) in the combined paricalcitol groups, with a between-group difference versus placebo of -15% (95% CI -28 to 1; p=0.071); -14% (from 63 to 54 mg/mmol; -24 to -1) in the 1 mu g paricalcitol group, with a between-group difference versus placebo of -11% (95% CI -27 to 8; p=0.23); and -20% (from 61 to 49 mg/mmol; -30 to -8) in the 2 mu g paricalcitol group, with a between-group difference versus placebo of -18% (95% CI -32 to 0; p=0.053). Patients on 2 mu g paricalcitol showed an early, sustained reduction in UACR, ranging from -18% to -28% (p=0.014 vs placebo). Incidence of hypercalcaemia, adverse events, and serious adverse events was similar between groups receiving paricalcitol versus placebo. Interpretation Addition of 2 mu g/day paricalcitol to RAAS inhibition safely lowers residual albuminuria in patients with diabetic nephropathy, and could be a novel approach to lower residual renal risk in diabetes.	[de Zeeuw, Dick] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, NL-9700 AD Groningen, Netherlands; [Agarwal, Rajiv] Indiana Univ Sch Med, Indianapolis, IN USA; [Amdahl, Michael; Audhya, Paul; Garimella, Tushar; Pritchett, Yili; Andress, Dennis] Abbott Labs, Chicago, IL USA; [Coyne, Daniel] Washington Univ, Sch Med, St Louis, MO USA; [Parving, Hans-Henrik] Rigshosp, DK-2100 Copenhagen, Denmark; [Parving, Hans-Henrik] Aarhus Univ, Aarhus, Denmark; [Remuzzi, Giuseppe] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy; [Ritz, Eberhard] Heidelberg Univ, Heidelberg, Germany	University of Groningen; Indiana University System; Indiana University Bloomington; Abbott Laboratories; Washington University (WUSTL); Rigshospitalet; University of Copenhagen; Aarhus University; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ruprecht Karls University Heidelberg	de Zeeuw, D (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, POB 196, NL-9700 AD Groningen, Netherlands.	d.de.zeeuw@med.umcg.nl	de Zeeuw, Dick/E-9080-2014; Agarwal, Rajiv/H-3454-2019; Remuzzi, Giuseppe/V-9766-2017	de Zeeuw, Dick/0000-0003-3434-7777; Agarwal, Rajiv/0000-0001-8355-7100; Remuzzi, Giuseppe/0000-0002-6194-3446	Abbott; Watson; Merck; AstraZeneca	Abbott(Abbott Laboratories); Watson; Merck(Merck & Company); AstraZeneca(AstraZeneca)	We thank the investigators, local study coordinators, and patients for their valuable contributions to this study; Jin Tian for contribution to the study design; Shihua Wen, employee of Abbott, for statistical programming support; and Amanda J Fein, employee of Abbott, for medical writing support. Funding for this study, including travel and accommodation expenses for study meetings and honoraria for the steering committee, was provided by Abbott.; DdZ has been a consultant for and his institution has received honoraria from Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Novartis, Noxxon, Johnson & Johnson, Hemocue, and Merck Sharp & Dohme. RA has been a board member for Abbott, has been a consultant for Watson, and has received honoraria from Abbott, Watson, and Merck; RA's institution has received research funding from Abbott, and travel and accommodation expenses from Abbott, Watson, and Merck. DC has been a consultant for and has received travel and accommodation expenses from Abbott, and has received honoraria from Abbott and Merck; DC's institution has received research funding from Abbott. H-HP has been a consultant for and has received honoraria from Abbott, Novartis, and AstraZeneca. GR has been a board member and was a consultant for Abbott, Amgen, and AstraZeneca, with associated honoraria paid to GR's institution; GR's institution has received research funding from AstraZeneca and Abbott. ER has been a consultant and has received honoraria and travel and accommodation expenses from Abbott, Daiichi Sankyo, and Roche. MA, DA, PA, TG, and YP are employed by Abbott, and have stock and stock options in Abbott.	Agarwal R, 2005, KIDNEY INT, V68, P2823, DOI 10.1111/j.1523-1755.2005.00755.x; Alborzi P, 2008, HYPERTENSION, V52, P249, DOI 10.1161/HYPERTENSIONAHA.108.113159; BERTOLI M, 1990, CLIN NEPHROL, V33, P98; Coyne D, 2006, AM J KIDNEY DIS, V47, P263, DOI 10.1053/j.ajkd.2005.10.007; de Zeeuw D., 2009, EUR NEPHROL, V3, P13; Eijkelkamp WBA, 2007, J AM SOC NEPHROL, V18, P1540, DOI 10.1681/ASN.2006050445; Feneis JF, 2010, AM J THER, V17, pE221, DOI 10.1097/MJT.0b013e3181d16999; Fishbane S, 2009, AM J KIDNEY DIS, V54, P647, DOI 10.1053/j.ajkd.2009.04.036; Freundlich M, 2008, KIDNEY INT, V74, P1394, DOI 10.1038/ki.2008.408; Heerspink HL, 2008, NEPHROL DIAL TRANSPL, V23, P1946, DOI 10.1093/ndt/gfm893; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Lambers Heerspink HJ, 2009, AM J NEPHROL, V30, P280, DOI 10.1159/000225903; Levin A, 2007, KIDNEY INT, V71, P31, DOI 10.1038/sj.ki.5002009; Li YC, 2004, J STEROID BIOCHEM, V89-90, P387, DOI 10.1016/j.jsbmb.2004.03.004; Mann JFE, 2008, LANCET, V372, P547, DOI 10.1016/S0140-6736(08)61236-2; Mann JFE, 2010, J AM SOC NEPHROL, V21, P527, DOI 10.1681/ASN.2009060593; Mizobuchi M, 2007, J AM SOC NEPHROL, V18, P1796, DOI 10.1681/ASN.2006091028; Parving HH, 2008, NEW ENGL J MED, V358, P2433, DOI 10.1056/NEJMoa0708379; Perez A, 1996, BRIT J DERMATOL, V134, P1070, DOI 10.1111/j.1365-2133.1996.tb07945.x; Pfeifer M, 2001, J CLIN ENDOCR METAB, V86, P1633, DOI 10.1210/jc.86.4.1633; Rostand SG, 1997, HYPERTENSION, V30, P150, DOI 10.1161/01.HYP.30.2.150; Ruggenenti P, 2003, KIDNEY INT, V63, P2254, DOI 10.1046/j.1523-1755.2003.00033.x; Schwarz U, 1998, KIDNEY INT, V53, P1696, DOI 10.1046/j.1523-1755.1998.00951.x; Shinaberger CS, 2008, CLIN J AM SOC NEPHRO, V3, P1769, DOI 10.2215/CJN.01760408; Szeto CC, 2008, AM J KIDNEY DIS, V51, P724, DOI 10.1053/j.ajkd.2007.12.038; Tan XY, 2008, J AM SOC NEPHROL, V19, P1741, DOI 10.1681/ASN.2007060666; Tan XY, 2006, J AM SOC NEPHROL, V17, P3382, DOI 10.1681/ASN.2006050520; Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536; U.S. Department of Health and Human Services, 2003, 7 US DEP HLTH HUM SE; Vogt L, 2008, J AM SOC NEPHROL, V19, P999, DOI 10.1681/ASN.2007060693; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317; Zhang Z, 2008, KIDNEY INT, V73, P163, DOI 10.1038/sj.ki.5002572; Zhang Z, 2008, P NATL ACAD SCI USA, V105, P15896, DOI 10.1073/pnas.0803751105	34	536	555	0	59	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1543	1551		10.1016/S0140-6736(10)61032-X	http://dx.doi.org/10.1016/S0140-6736(10)61032-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	21055801				2022-12-28	WOS:000284248700031
J	Lind, PA; Berg, OG; Andersson, DI				Lind, Peter A.; Berg, Otto G.; Andersson, Dan I.			Mutational Robustness of Ribosomal Protein Genes	SCIENCE			English	Article							SINGLE-NUCLEOTIDE SUBSTITUTIONS; DNA-SEQUENCE DATA; DELETERIOUS MUTATIONS; BENEFICIAL MUTATIONS; MOLECULAR EVOLUTION; FITNESS; VIRUS; POPULATIONS; LANDSCAPE; SELECTION	The distribution of fitness effects (DFE) of mutations is of fundamental importance for understanding evolutionary dynamics and complex diseases and for conserving threatened species. DFEs estimated from DNA sequences have rarely been subject to direct experimental tests. We used a bacterial system in which the fitness effects of a large number of defined single mutations in two ribosomal proteins were measured with high sensitivity. The obtained DFE appears to be unimodal, where most mutations (120 out of 126) are weakly deleterious and the remaining ones are potentially neutral. The DFEs for synonymous and nonsynonymous substitutions are similar, suggesting that in some genes, strong fitness constraints are present at the level of the messenger RNA.	[Lind, Peter A.; Andersson, Dan I.] Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; [Berg, Otto G.] Uppsala Univ, Dept Mol Evolut, Evolutionary Biol Ctr, SE-75236 Uppsala, Sweden	Uppsala University; Uppsala University	Andersson, DI (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden.	Dan.Andersson@imbim.uu.se		Andersson, Dan/0000-0001-6640-2174; Lind, Peter/0000-0003-1510-8324	Swedish Research Council	Swedish Research Council(Swedish Research CouncilEuropean Commission)	This work was supported by grants from the Swedish Research Council to D. I. A. and O.G.B. We thank D. Hughes and P. B. Rainey for comments on the manuscript.	BUTCHER D, 1995, GENETICS, V141, P431; CABALLERO A, 1994, GENETICS, V138, P883; Carrasco P, 2007, J VIROL, V81, P12979, DOI 10.1128/JVI.00524-07; CHARLESWORTH B, 1993, GENETICS, V134, P1289; Davies EK, 1999, SCIENCE, V285, P1748, DOI 10.1126/science.285.5434.1748; Domingo-Calap P, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000742; EHRENBERG M, 1984, Q REV BIOPHYS, V17, P45, DOI 10.1017/S0033583500005254; Eyre-Walker A, 2007, NAT REV GENET, V8, P610, DOI 10.1038/nrg2146; Eyre-Walker A, 2006, GENETICS, V173, P891, DOI 10.1534/genetics.106.057570; GILLESPIE JH, 1984, EVOLUTION, V38, P1116, DOI 10.1111/j.1558-5646.1984.tb00380.x; Kassen R, 2006, NAT GENET, V38, P484, DOI 10.1038/ng1751; Keightley PD, 2010, PHILOS T R SOC B, V365, P1187, DOI 10.1098/rstb.2009.0266; KIMURA M, 1962, GENETICS, V47, P713; Lind PA, 2010, MOL MICROBIOL, V75, P1078, DOI 10.1111/j.1365-2958.2009.07030.x; MUKAI T, 1964, GENETICS, V50, P1; Nielsen R, 2003, MOL BIOL EVOL, V20, P1231, DOI 10.1093/molbev/msg147; OHTA T, 1992, ANNU REV ECOL SYST, V23, P263, DOI 10.1146/annurev.es.23.110192.001403; Orr HA, 2003, GENETICS, V163, P1519; Perfeito L, 2007, SCIENCE, V317, P813, DOI 10.1126/science.1142284; Piganeau G, 2003, P NATL ACAD SCI USA, V100, P10335, DOI 10.1073/pnas.1833064100; Rokyta DR, 2005, NAT GENET, V37, P441, DOI 10.1038/ng1535; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P8396, DOI 10.1073/pnas.0400146101; Trindade S, 2010, PHILOS T R SOC B, V365, P1177, DOI 10.1098/rstb.2009.0287; Wloch DM, 2001, GENETICS, V159, P441	24	76	76	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					825	827		10.1126/science.1194617	http://dx.doi.org/10.1126/science.1194617			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051637				2022-12-28	WOS:000283855700044
J	Yooseph, S; Nealson, KH; Rusch, DB; McCrow, JP; Dupont, CL; Kim, M; Johnson, J; Montgomery, R; Ferriera, S; Beeson, K; Williamson, SJ; Tovchigrechko, A; Allen, AE; Zeigler, LA; Sutton, G; Eisenstadt, E; Rogers, YH; Friedman, R; Frazier, M; Venter, JC				Yooseph, Shibu; Nealson, Kenneth H.; Rusch, Douglas B.; McCrow, John P.; Dupont, Christopher L.; Kim, Maria; Johnson, Justin; Montgomery, Robert; Ferriera, Steve; Beeson, Karen; Williamson, Shannon J.; Tovchigrechko, Andrey; Allen, Andrew E.; Zeigler, Lisa A.; Sutton, Granger; Eisenstadt, Eric; Rogers, Yu-Hui; Friedman, Robert; Frazier, Marvin; Venter, J. Craig			Genomic and functional adaptation in surface ocean planktonic prokaryotes	NATURE			English	Article							PROTEIN; DIVERSITY; DATABASE; ALIGNMENT; FAMILIES; IRON	The understanding of marine microbial ecology and metabolism has been hampered by the paucity of sequenced reference genomes. To this end, we report the sequencing of 137 diverse marine isolates collected from around the world. We analysed these sequences, along with previously published marine prokaryotic genomes, in the context of marine metagenomic data, to gain insights into the ecology of the surface ocean prokaryotic picoplankton (0.1-3.0 mu m size range). The results suggest that the sequenced genomes define two microbial groups: one composed of only a few taxa that are nearly always abundant in picoplanktonic communities, and the other consisting of many microbial taxa that are rarely abundant. The genomic content of the second group suggests that these microbes are capable of slow growth and survival in energy-limited environments, and rapid growth in energy-rich environments. By contrast, the abundant and cosmopolitan picoplanktonic prokaryotes for which there is genomic representation have smaller genomes, are probably capable of only slow growth and seem to be relatively unable to sense or rapidly acclimate to energy-rich conditions. Their genomic features also lead us to propose that one method used to avoid predation by viruses and/or bacterivores is by means of slow growth and the maintenance of low biomass.	[Yooseph, Shibu; Nealson, Kenneth H.; Rusch, Douglas B.; McCrow, John P.; Dupont, Christopher L.; Kim, Maria; Johnson, Justin; Montgomery, Robert; Ferriera, Steve; Beeson, Karen; Williamson, Shannon J.; Tovchigrechko, Andrey; Allen, Andrew E.; Zeigler, Lisa A.; Sutton, Granger; Eisenstadt, Eric; Rogers, Yu-Hui; Friedman, Robert; Frazier, Marvin; Venter, J. Craig] J Craig Venter Inst, Rockville, MD 20850 USA	J. Craig Venter Institute	Nealson, KH (corresponding author), J Craig Venter Inst, Rockville, MD 20850 USA.	knealson@usc.edu	Allen, Andrew E/C-4896-2012	Allen, Andrew E/0000-0001-5911-6081; Yooseph, Shibu/0000-0001-5581-5002	Gordon and Betty Moore Foundation [521]; Department of Energy, Office of Science, Office of Biological and Environmental Research [DE-FC02-02ER63453]; JCVI; US National Science Foundation [0850256]; Direct For Biological Sciences [0850256] Funding Source: National Science Foundation	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Department of Energy, Office of Science, Office of Biological and Environmental Research(United States Department of Energy (DOE)); JCVI; US National Science Foundation(National Science Foundation (NSF)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We would like to acknowledge the Gordon and Betty Moore Foundation (grant award agreement #521); the Department of Energy, Office of Science, Office of Biological and Environmental Research (DE-FC02-02ER63453); and the JCVI for funding this research. A.T. and S.Y. also acknowledge support from US National Science Foundation grant 0850256. We also thank the JCVI Software Engineering team for their contribution to the analyses, L. Sheehan for help with manuscript editing, and M. Thiagarajan, L. Foster, I. Singh and M. Lewis for help with data management. Finally, we thank the many collaborators who provided strains for sequencing, including R. Amann, F. Azam, D. Bartlett, R. Belas, C. Bolch, E. Bonch-Osmolovskaya, J. Bowman, I. Brettar, T. Brinkhoff, A. Buchan, R. Case, R. Caviccholi, P. Chisholm, R. Edwards, D. Emerson, P. Falkowski, C. Francis, B. Fuchs, S. Giovannoni, J. Gonzalez, D. Green, A. Hagstrom, M. Hart, M. Haygood, R. Hill, M. Hofle, J.-C. Cho, K. Jurgens, S.-J. Kim, G. King, N. King, S. Kjelleberg, M. Klotz, M. Labrenz, E. Lilly, V. T. Marteinsson, M. A. Moran, A. Murray, J. C. Murrell, C. Pedros-Alio, J. Pinhassi, M. Polz, M. Rappe, A.-L. Reysenbach, F. Rodriguez-Valera, E. Rosenberg, N. Ruby, D. Scanlan, H. Schaefer, L. Shimkets, J. Siefert, M. Simon, T. Sokolova, E. Stabb, L. Stal, N. Tandeau de Marsac, B. Tebo, T. Thomas, C. Vetriani, I. Wagner-Dobler, B. Ward, J. Waterbury, B. Wawrik and A. Yayanos.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOND PL, 1995, APPL ENVIRON MICROB, V61, P1910, DOI 10.1128/AEM.61.5.1910-1916.1995; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Dupont CL, 2006, P NATL ACAD SCI USA, V103, P17822, DOI 10.1073/pnas.0605798103; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Fischer D, 1999, BIOINFORMATICS, V15, P759, DOI 10.1093/bioinformatics/15.9.759; Galperin MY, 2005, BMC MICROBIOL, V5, DOI 10.1186/1471-2180-5-35; Giovannoni SJ, 2005, SCIENCE, V309, P1242, DOI 10.1126/science.1114057; Giovannoni SJ., 2000, MICROBIAL ECOLOGY OC, P47; Goldberg SMD, 2006, P NATL ACAD SCI USA, V103, P11240, DOI 10.1073/pnas.0604351103; Grimes DJ, 2000, NONCULTURABLE MICROORGANISMS IN THE ENVIRONMENT, P209; Guell M, 2009, SCIENCE, V326, P1268, DOI 10.1126/science.1176951; Haft DH, 2003, NUCLEIC ACIDS RES, V31, P371, DOI 10.1093/nar/gkg128; Hagstrom A, 2002, APPL ENVIRON MICROB, V68, P3628, DOI 10.1128/AEM.68.7.3628-3633.2002; INGRAHAM JL, 1983, GROWTH BACTERIAL CEL, P435; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Konstantinidis KT, 2009, APPL ENVIRON MICROB, V75, P5345, DOI 10.1128/AEM.00473-09; Kuhner S, 2009, SCIENCE, V326, P1235, DOI 10.1126/science.1176343; Lauro FM, 2009, P NATL ACAD SCI USA, V106, P15527, DOI 10.1073/pnas.0903507106; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Lis H, 2009, AQUAT MICROB ECOL, V56, P241, DOI 10.3354/ame01347; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; McCaig AE, 1999, APPL ENVIRON MICROB, V65, P1721; Morel FMM, 2008, LIMNOL OCEANOGR, V53, P400, DOI 10.4319/lo.2008.53.1.0400; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Nawrocki EP, 2009, BIOINFORMATICS, V25, P1335, DOI 10.1093/bioinformatics/btp157; Nealson KH, 2007, ISME J, V1, P185, DOI 10.1038/ismej.2007.43; NEALSON KH, 1979, MICROBIOL REV, V43, P496, DOI 10.1128/MMBR.43.4.496-518.1979; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Rappe MS, 1997, LIMNOL OCEANOGR, V42, P811, DOI 10.4319/lo.1997.42.5.0811; Rawlings ND, 2006, NUCLEIC ACIDS RES, V34, pD270, DOI 10.1093/nar/gkj089; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Scanlan DJ, 2009, MICROBIOL MOL BIOL R, V73, P249, DOI 10.1128/MMBR.00035-08; Shaw AK, 2008, ENVIRON MICROBIOL, V10, P2200, DOI 10.1111/j.1462-2920.2008.01626.x; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tripp HJ, 2010, NATURE, V464, P90, DOI 10.1038/nature08786; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Yooseph S, 2007, PLOS BIOL, V5, P432, DOI 10.1371/journal.pbio.0050016; Yooseph S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-182; Yus E, 2009, SCIENCE, V326, P1263, DOI 10.1126/science.1177263; Zehr JP, 2008, SCIENCE, V322, P1110, DOI 10.1126/science.1165340	44	200	202	3	110	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					60	+		10.1038/nature09530	http://dx.doi.org/10.1038/nature09530			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048761	hybrid			2022-12-28	WOS:000283786900035
J	Hogg, JR; Goff, SP				Hogg, J. Robert; Goff, Stephen P.			Upf1 Senses 3 ' UTR Length to Potentiate mRNA Decay	CELL			English	Article							EXON JUNCTION COMPLEX; MURINE LEUKEMIA-VIRUS; GAG-POL JUNCTION; TERMINATION CODONS; MEDIATED DECAY; SACCHAROMYCES-CEREVISIAE; TRANSLATION TERMINATION; SURVEILLANCE MACHINERY; MAMMALIAN-CELLS; READ-THROUGH	The selective degradation of mRNAs by the nonsense-mediated decay pathway is a quality control process with important consequences for human disease. From initial studies using RNA hairpin-tagged mRNAs for purification of messenger ribonucleoproteins assembled on transcripts with HIV-1 3' untranslated region (3'UTR) sequences, we uncover a two-step mechanism for Upf1-dependent degradation of mRNAs with long 3'UTRs. We demonstrate that Upf1 associates with mRNAs in a 3'UTR length-dependent manner and is highly enriched on transcripts containing 3'UTRs known to elicit NMD. Surprisingly, Upf1 recruitment and subsequent RNA decay can be antagonized by retroviral RNA elements that promote translational readthrough. By modulating the efficiency of translation termination, recognition of long 3'UTRs by Upf1 is uncoupled from the initiation of decay. We propose a model for 3'UTR length surveillance in which equilibrium binding of Upf1 to mRNAs precedes a kinetically distinct commitment to RNA decay.	[Hogg, J. Robert; Goff, Stephen P.] Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; [Goff, Stephen P.] Columbia Univ, Coll Phys & Surg, Dept Microbiol & Immunol, New York, NY 10032 USA; [Hogg, J. Robert; Goff, Stephen P.] Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute	Hogg, JR (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA.	jh2721@columbia.edu; spg1@columbia.edu	Goff, Stephen P/K-6337-2014; Hogg, J. Robert/O-2327-2018; Hogg, J. Robert/AAE-6539-2021	Goff, Stephen P/0000-0003-0693-5547; Hogg, J. Robert/0000-0001-5729-5135; 	NRSA [1F32GM087737]; NATIONAL CANCER INSTITUTE [R37CA030488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM087737] Funding Source: NIH RePORTER	NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jens Lykke-Andersen and Brian Houck-Loomis for generously providing reagents and Kathleen Collins, Lisa Postow, and Jason Rodriguez for critical reading of the manuscript. Mass spectrometry was performed by Mary Ann Gawinowicz in the Columbia University Medical Center protein core facility. J.R.H. is supported by NRSA postdoctoral fellowship 1F32GM087737. S.P.G. is an investigator of the Howard Hughes Medical Institute.	Allamand V, 2008, J GENE MED, V10, P217, DOI 10.1002/jgm.1140; Amrani N, 2004, NATURE, V432, P112, DOI 10.1038/nature03060; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; Behm-Ansmant I, 2007, EMBO J, V26, P1591, DOI 10.1038/sj.emboj.7601588; Bhattacharya A, 2000, RNA, V6, P1226, DOI 10.1017/S1355838200000546; Bolinger C, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-8; Buhler M, 2006, NAT STRUCT MOL BIOL, V13, P462, DOI 10.1038/nsmb1081; Chamieh H, 2008, NAT STRUCT MOL BIOL, V15, P85, DOI 10.1038/nsmb1330; Chang YF, 2007, ANNU REV BIOCHEM, V76, P51, DOI 10.1146/annurev.biochem.76.050106.093909; Cho H, 2009, MOL CELL, V33, P75, DOI 10.1016/j.molcel.2008.11.022; Eberle AB, 2008, PLOS BIOL, V6, P849, DOI 10.1371/journal.pbio.0060092; FELSENSTEIN KM, 1992, J VIROL, V66, P6601, DOI 10.1128/JVI.66.11.6601-6608.1992; FENG YX, 1990, P NATL ACAD SCI USA, V87, P8860, DOI 10.1073/pnas.87.22.8860; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; Hogg JR, 2007, GENE DEV, V21, P3067, DOI 10.1101/gad.1603907; Hogg JR, 2007, RNA, V13, P868, DOI 10.1261/rna.565207; Hosoda N, 2005, NAT STRUCT MOL BIOL, V12, P893, DOI 10.1038/nsmb995; Hwang J, 2010, MOL CELL, V39, P396, DOI 10.1016/j.molcel.2010.07.004; Isken O, 2008, CELL, V133, P314, DOI 10.1016/j.cell.2008.02.030; Ivanov PV, 2008, EMBO J, V27, P736, DOI 10.1038/emboj.2008.17; Johansson MJO, 2007, P NATL ACAD SCI USA, V104, P20872, DOI 10.1073/pnas.0709257105; Johns L, 2007, MOL CELL BIOL, V27, P5630, DOI 10.1128/MCB.00410-07; JORGENSEN F, 1993, J MOL BIOL, V230, P41, DOI 10.1006/jmbi.1993.1124; Kashima I, 2006, GENE DEV, V20, P355, DOI 10.1101/gad.1389006; Keeling KM, 2004, RNA, V10, P691, DOI 10.1261/rna.5147804; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Kuzmiak HA, 2006, TRENDS MOL MED, V12, P306, DOI 10.1016/j.molmed.2006.05.005; LEHI, 2001, EMBO J, V20, P4987; LEHI, 2000, EMBO J, V19, P6860; Lim F, 2002, NUCLEIC ACIDS RES, V30, P4138, DOI 10.1093/nar/gkf552; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Maderazo AB, 2003, MOL CELL BIOL, V23, P842, DOI 10.1128/MCB.23.3.842-851.2003; Maquat LE, 2010, CELL, V142, P368, DOI 10.1016/j.cell.2010.07.022; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mehta A, 2004, J BIOL CHEM, V279, P37852, DOI 10.1074/jbc.M404639200; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muhlemann O, 2008, BIOCHEM SOC T, V36, P497, DOI 10.1042/BST0360497; Nicholson P, 2010, CELL MOL LIFE SCI, V67, P677, DOI 10.1007/s00018-009-0177-1; Oeffinger M, 2007, NAT METHODS, V4, P951, DOI 10.1038/NMETH1101; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; Rebbapragada I, 2009, CURR OPIN CELL BIOL, V21, P394, DOI 10.1016/j.ceb.2009.02.007; Rehwinkel A, 2005, RNA, V11, P1530, DOI 10.1261/rna.2160905; Salvatori F, 2009, AM J HEMATOL, V84, P720, DOI 10.1002/ajh.21539; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Silva AL, 2008, RNA, V14, P563, DOI 10.1261/rna.815108; Singh G, 2008, PLOS BIOL, V6, P860, DOI 10.1371/journal.pbio.0060111; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Valente ST, 2006, MOL CELL, V23, P597, DOI 10.1016/j.molcel.2006.07.021; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Weischenfeldt J, 2008, GENE DEV, V22, P1381, DOI 10.1101/gad.468808; Weiss SL, 1998, RNA, V4, P816, DOI 10.1017/S1355838298971990; Weng YM, 1998, RNA, V4, P205; Weng YM, 1996, MOL CELL BIOL, V16, P5491, DOI 10.1128/mcb.16.10.5491; Weng YM, 1996, MOL CELL BIOL, V16, P5477; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; WILLS NM, 1994, EMBO J, V13, P4137, DOI 10.1002/j.1460-2075.1994.tb06731.x; Wittmann J, 2006, MOL CELL BIOL, V26, P1272, DOI 10.1128/MCB.26.4.1272-1287.2006; Zhang SA, 1997, RNA, V3, P234	59	234	237	2	39	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 29	2010	143	3					379	389		10.1016/j.cell.2010.10.005	http://dx.doi.org/10.1016/j.cell.2010.10.005			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029861	Green Accepted, Bronze			2022-12-28	WOS:000283603900012
J	Nowacki, A; Wookey, J; Kendall, JM				Nowacki, Andy; Wookey, James; Kendall, J-Michael			Deformation of the lowermost mantle from seismic anisotropy	NATURE			English	Article							POST-PEROVSKITE PHASE; D'' LAYER; AZIMUTHAL ANISOTROPY; LATERAL VARIATIONS; SHEAR DEFORMATION; BENEATH; FLOW; CONSTRAINTS; (MG,FE)O; PACIFIC	The lowermost part of the Earth's mantle-known as D ''-shows significant seismic anisotropy, the variation of seismic wave speed with direction(1-5). This is probably due to deformation-induced alignment of MgSiO3-post-perovskite (ppv), which is believed to be the main mineral phase present in the region. If this is the case, then previous measurements of D '' anisotropy, which are generally made in one direction only, are insufficient to distinguish candidate mechanisms of slip in ppv because the mineral is orthorhombic. Here we measure anisotropy in D '' beneath North and Central America, where material from subducting oceanic slabs impinges(6) on the core-mantle boundary, using shallow as well as deep earthquakes to increase the azimuthal coverage in D ''. We make more than 700 individual measurements of shear wave splitting in D '' in three regions from two different azimuths in each case. We show that the previously assumed(2,3,7) case of vertical transverse isotropy (where wave speed shows no azimuthal variation) is not possible, and that more complicated mechanisms must be involved. We test the fit of different MgSiO3-ppv deformation mechanisms to our results and find that shear on (001) is most consistent with observations and the expected shear above the core-mantle boundary beneath subduction zones. With new models of mantle flow, or improved experimental determination of the dominant ppv slip systems, this method will allow us to map deformation at the core-mantle boundary and link processes in D '', such as plume initiation, to the rest of the mantle.	[Nowacki, Andy; Wookey, James; Kendall, J-Michael] Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	University of Bristol	Nowacki, A (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg,Queens Rd, Bristol BS8 1RJ, Avon, England.	andy.nowacki@bristol.ac.uk	Kendall, Michael/D-5973-2011; Wookey, James/G-6113-2011; Nowacki, Andy/E-1106-2011	Kendall, Michael/0000-0002-1486-3945; Nowacki, Andy/0000-0001-7669-7383; Wookey, James/0000-0002-7403-4380	NERC	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank J. Brodholt and D. Dobson for comments. A.N. was supported by NERC. Seismic data were provided by I. Bastow, D. Thompson, and the IRIS and CNSN data centres.	Blackman DK, 1996, GEOPHYS J INT, V127, P415, DOI 10.1111/j.1365-246X.1996.tb04730.x; Carrez P, 2007, NATURE, V446, P68, DOI 10.1038/nature05593; Evans MS, 2006, GEOPHYS J INT, V165, P931, DOI 10.1111/j.1365-246X.2006.02973.x; Frederiksen AW, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004861; Garnero EJ, 2004, SCIENCE, V306, P259, DOI 10.1126/science.1103411; Iitaka T, 2004, NATURE, V430, P442, DOI 10.1038/nature02702; Karki BB, 1999, SCIENCE, V286, P1705, DOI 10.1126/science.286.5445.1705; Kendall JM, 1996, NATURE, V381, P409, DOI 10.1038/381409a0; Kendall JM, 1998, GEODYNAMICS, V28, P97; Kendall JM, 1996, GEOPHYS RES LETT, V23, P399, DOI 10.1029/95GL02659; Lay T, 1998, GEODYNAMICS, V28, P299; Long MD, 2006, PHYS EARTH PLANET IN, V156, P75, DOI 10.1016/j.pepi.2006.02.006; Long MD, 2009, EARTH PLANET SC LETT, V283, P181, DOI 10.1016/j.epsl.2009.04.019; Maupin V, 2005, J GEOPHYS RES-SOL EA, V110, DOI 10.1029/2004JB003506; McNamara AK, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001970; MEADE C, 1995, GEOPHYS RES LETT, V22, P1293, DOI 10.1029/95GL01091; Merkel S, 2006, SCIENCE, V311, P644, DOI 10.1126/science.1121808; Merkel S, 2007, SCIENCE, V316, P1729, DOI 10.1126/science.1140609; Oganov AR, 2005, NATURE, V438, P1142, DOI 10.1038/nature04439; Okada T, 2010, PHYS EARTH PLANET IN, V180, P195, DOI 10.1016/j.pepi.2009.08.002; Ren Y, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2005JB004154; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; Rokosky JM, 2006, EARTH PLANET SC LETT, V248, P411, DOI 10.1016/j.epsl.2006.06.005; SILVER PG, 1991, J GEOPHYS RES-SOL EA, V96, P16429, DOI 10.1029/91JB00899; Stackhouse S, 2005, EARTH PLANET SC LETT, V230, P1, DOI 10.1016/j.epsl.2004.11.021; Teanby NA, 2004, B SEISMOL SOC AM, V94, P453, DOI 10.1785/0120030123; Tsuchiya T, 2004, EARTH PLANET SC LETT, V224, P241, DOI 10.1016/j.epsl.2004.05.017; Wentzcovitch RM, 2006, P NATL ACAD SCI USA, V103, P543, DOI 10.1073/pnas.0506879103; Wolfe CJ, 1998, J GEOPHYS RES-SOL EA, V103, P749, DOI 10.1029/97JB02023; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230; Wookey J, 2005, NATURE, V438, P1004, DOI 10.1038/nature04345; Wookey J, 2005, GEOPHYS J INT, V161, P829, DOI 10.1111/j.1365-246X.2005.02623.x; Wookey J, 2007, GEOPHYS MONOGR SER, V174, P171, DOI 10.1029/174GM13; Wookey J, 2008, EARTH PLANET SC LETT, V275, P32, DOI 10.1016/j.epsl.2008.07.049; Wustefeld A, 2009, PHYS EARTH PLANET IN, V176, P198, DOI 10.1016/j.pepi.2009.05.006; Yamazaki D, 2002, PHYS EARTH PLANET IN, V131, P251, DOI 10.1016/S0031-9201(02)00037-7; Yamazaki D, 2006, EARTH PLANET SC LETT, V252, P372, DOI 10.1016/j.epsl.2006.10.004	37	65	65	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2010	467	7319					1091	1095		10.1038/nature09507	http://dx.doi.org/10.1038/nature09507			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981097	Green Accepted, Green Published			2022-12-28	WOS:000283548600044
J	Kazatchkine, MD				Kazatchkine, Michel D.			Increased resources for the Global Fund, but pledges fall short of expected demand	LANCET			English	Editorial Material									Global Fund Fight AIDS TB & Malaria, CH-1214 Vernier, Switzerland		Kazatchkine, MD (corresponding author), Global Fund Fight AIDS TB & Malaria, CH-1214 Vernier, Switzerland.	michel.kazatchkine@theglobalfund.org						*GLOB FUND FIGHT A, RES SCEN 2011 2013; *GLOB FUND FIGHT A, 2010, GLOB FUND 3 VOL REPL; International Monetary Fund, 2010, WORLD EC OUTL DAT; MCNEIL DG, 2010, GLOBAL FIGHT AIDS FA	4	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1439	1440		10.1016/S0140-6736(10)61970-8	http://dx.doi.org/10.1016/S0140-6736(10)61970-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	21036260				2022-12-28	WOS:000284248500004
J	Watts, G				Watts, Geoff			David Weatherall: Lasker Award for pioneer in molecular medicine Profile	LANCET			English	Biographical-Item												geoff@scileg.freeserve.co.uk							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1457	1457		10.1016/S0140-6736(10)61981-2	http://dx.doi.org/10.1016/S0140-6736(10)61981-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QC	21036263	Bronze			2022-12-28	WOS:000284248500014
J	Ley, TJ; Ding, L; Walter, MJ; McLellan, MD; Lamprecht, T; Larson, DE; Kandoth, C; Payton, JE; Baty, J; Welch, J; Harris, CC; Lichti, CF; Townsend, RR; Fulton, RS; Dooling, DJ; Koboldt, DC; Schmidt, H; Zhang, QY; Osborne, JR; Lin, L; O'Laughlin, M; McMichael, JF; Delehaunty, KD; McGrath, SD; Fulton, LA; Magrini, VJ; Vickery, TL; Hundal, J; Cook, LL; Conyers, JJ; Swift, GW; Reed, JP; Alldredge, PA; Wylie, T; Walker, J; Kalicki, J; Watson, MA; Heath, S; Shannon, WD; Varghese, N; Nagarajan, R; Westervelt, P; Tomasson, MH; Link, DC; Graubert, TA; DiPersio, JF; Mardis, ER; Wilson, RK				Ley, Timothy J.; Ding, Li; Walter, Matthew J.; McLellan, Michael D.; Lamprecht, Tamara; Larson, David E.; Kandoth, Cyriac; Payton, Jacqueline E.; Baty, Jack; Welch, John; Harris, Christopher C.; Lichti, Cheryl F.; Townsend, R. Reid; Fulton, Robert S.; Dooling, David J.; Koboldt, Daniel C.; Schmidt, Heather; Zhang, Qunyuan; Osborne, John R.; Lin, Ling; O'Laughlin, Michelle; McMichael, Joshua F.; Delehaunty, Kim D.; McGrath, Sean D.; Fulton, Lucinda A.; Magrini, Vincent J.; Vickery, Tammi L.; Hundal, Jasreet; Cook, Lisa L.; Conyers, Joshua J.; Swift, Gary W.; Reed, Jerry P.; Alldredge, Patricia A.; Wylie, Todd; Walker, Jason; Kalicki, Joelle; Watson, Mark A.; Heath, Sharon; Shannon, William D.; Varghese, Nobish; Nagarajan, Rakesh; Westervelt, Peter; Tomasson, Michael H.; Link, Daniel C.; Graubert, Timothy A.; DiPersio, John F.; Mardis, Elaine R.; Wilson, Richard K.			DNMT3A Mutations in Acute Myeloid Leukemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA-METHYLTRANSFERASES; PROGNOSTIC IMPACT; CLINICAL-RESPONSE; ADULT PATIENTS; CANCER; TRANSCRIPTION; RECRUITMENT; SCHEDULE; ICF	Background: The genetic alterations responsible for an adverse outcome in most patients with acute myeloid leukemia (AML) are unknown. Methods: Using massively parallel DNA sequencing, we identified a somatic mutation in DNMT3A, encoding a DNA methyltransferase, in the genome of cells from a patient with AML with a normal karyotype. We sequenced the exons of DNMT3A in 280 additional patients with de novo AML to define recurring mutations. Results: A total of 62 of 281 patients (22.1%) had mutations in DNMT3A that were predicted to affect translation. We identified 18 different missense mutations, the most common of which was predicted to affect amino acid R882 (in 37 patients). We also identified six frameshift, six nonsense, and three splice-site mutations and a 1.5-Mbp deletion encompassing DNMT3A. These mutations were highly enriched in the group of patients with an intermediate-risk cytogenetic profile (56 of 166 patients, or 33.7%) but were absent in all 79 patients with a favorable-risk cytogenetic profile (P<0.001 for both comparisons). The median overall survival among patients with DNMT3A mutations was significantly shorter than that among patients without such mutations (12.3 months vs. 41.1 months, P<0.001). DNMT3A mutations were associated with adverse outcomes among patients with an intermediate-risk cytogenetic profile or FLT3 mutations, regardless of age, and were independently associated with a poor outcome in Cox proportional-hazards analysis. Conclusions: DNMT3A mutations are highly recurrent in patients with de novo AML with an intermediate-risk cytogenetic profile and are independently associated with a poor outcome. (Funded by the National Institutes of Health and others.) N Engl J Med 2010;363:2424-33.	[Ley, Timothy J.; Ding, Li; Zhang, Qunyuan; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Dept Genet, St Louis, MO 63110 USA; [Ley, Timothy J.; Ding, Li; McLellan, Michael D.; Larson, David E.; Kandoth, Cyriac; Harris, Christopher C.; Fulton, Robert S.; Dooling, David J.; Koboldt, Daniel C.; Schmidt, Heather; Zhang, Qunyuan; Osborne, John R.; Lin, Ling; O'Laughlin, Michelle; McMichael, Joshua F.; Delehaunty, Kim D.; McGrath, Sean D.; Fulton, Lucinda A.; Magrini, Vincent J.; Vickery, Tammi L.; Hundal, Jasreet; Cook, Lisa L.; Conyers, Joshua J.; Swift, Gary W.; Reed, Jerry P.; Alldredge, Patricia A.; Wylie, Todd; Walker, Jason; Kalicki, Joelle; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Genome Ctr, St Louis, MO 63110 USA; [Ley, Timothy J.; Walter, Matthew J.; Lamprecht, Tamara; Welch, John; Lichti, Cheryl F.; Townsend, R. Reid; Heath, Sharon; Shannon, William D.; Westervelt, Peter; Tomasson, Michael H.; Link, Daniel C.; Graubert, Timothy A.; DiPersio, John F.] Washington Univ, Dept Med, St Louis, MO 63110 USA; [Ley, Timothy J.; Walter, Matthew J.; Townsend, R. Reid; Watson, Mark A.; Shannon, William D.; Varghese, Nobish; Nagarajan, Rakesh; Westervelt, Peter; Tomasson, Michael H.; Link, Daniel C.; Graubert, Timothy A.; DiPersio, John F.; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA; [Payton, Jacqueline E.; Watson, Mark A.; Varghese, Nobish; Nagarajan, Rakesh] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Baty, Jack] Washington Univ, Div Biostat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ley, TJ (corresponding author), Washington Univ, Dept Genet, 660 S Euclid Ave,Campus Box 8007, St Louis, MO 63110 USA.	timley@wustl.edu	Magrini, Vincent/AAT-5830-2020; Wilson, Richard K./AAF-4139-2019; Walker, Jason/A-9702-2013; Lichti, Cheryl/C-6359-2013; Mardis, Elaine/W-2202-2019; Walter, Matthew J/S-7758-2018; McGrath, Sean David/AAT-3540-2020	Magrini, Vincent/0000-0002-2019-4872; Wilson, Richard K./0000-0002-1992-1358; Walker, Jason/0000-0001-7547-5789; McGrath, Sean David/0000-0001-9064-8449; Westover, Tamara/0000-0002-1000-6698; MCLELLAN, MICHAEL/0000-0002-2703-8784; Larson, David/0000-0001-7934-5906; Kandoth, Cyriac/0000-0002-1345-3573; Graubert, Timothy/0000-0002-7710-1171; Lichti, Cheryl/0000-0003-4099-4954; Tomasson, Michael/0000-0003-4518-7123	National Center for Research Resources [UL1 RR024992]; National Institutes of Health [UL1 RR024992, P41RR000954, PO1 CA101937, U54 HG003079]; Barnes-Jewish Hospital Foundation [00335-0505-02]; Washington University Cancer Genome Initiative; NATIONAL CANCER INSTITUTE [P01CA101937] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992, P41RR000954] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Barnes-Jewish Hospital Foundation; Washington University Cancer Genome Initiative; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported by grants from the National Center for Research Resources (UL1 RR024992), the National Institutes of Health (P41RR000954 and UL1 RR024992, to Dr. Townsend; PO1 CA101937, to Dr. Ley; and U54 HG003079, to Dr. Wilson), and the Barnes-Jewish Hospital Foundation (00335-0505-02, to Dr. Ley).; We thank Nancy Reidelberger for administrative support; Todd Hepler, William Schroeder, Justin Lolofie, Scott Abbott, Shawn Leonard, Ken Swanson, Indraniel Das, and Michael Kiwala for their contributions to the Laboratory Information Management System; Gary Stiehr, Richard Wohlstadter, Matt Weil, and Kelly Fallon for information-technology support; Jin Shao for statistical support; Clara Bloomfield, Michael Caligiuri, and James Vardiman for providing the AML samples from the CALGB Leukemia Bank; the Washington University Cancer Genome Initiative for support; Alvin J. Siteman for supporting the sequencing of the original AML genome that is further described in this study; and our patients.	Blum W, 2010, P NATL ACAD SCI USA, V107, P7473, DOI 10.1073/pnas.1002650107; Boissel N, 2010, J CLIN ONCOL, V28, P3717, DOI 10.1200/JCO.2010.28.2285; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Byrd JC, 2002, BLOOD, V100, P4325, DOI 10.1182/blood-2002-03-0772; Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178; Chou WC, 2010, BLOOD, V115, P2749, DOI 10.1182/blood-2009-11-253070; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Ehrlich M, 2008, AUTOIMMUNITY, V41, P253, DOI 10.1080/08916930802024202; Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI 10.2217/EPI.09.33; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2005, NEW ENGL J MED, V352, P740; Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; Fazi F, 2007, BLOOD, V109, P4432, DOI 10.1182/blood-2006-09-045781; Figueroa ME, 2010, CANCER CELL, V17, P13, DOI 10.1016/j.ccr.2009.11.020; Figueroa ME, 2009, BLOOD, V114, P3448, DOI 10.1182/blood-2009-01-200519; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Gowher H, 2006, J MOL BIOL, V357, P928, DOI 10.1016/j.jmb.2006.01.035; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Jiang YL, 2005, HUM MUTAT, V25, P56, DOI 10.1002/humu.20113; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Payton JE, 2009, J CLIN INVEST, V119, P1714, DOI 10.1172/JCI38248; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Wang YA, 2005, CANCER BIOL THER, V4, P1138, DOI 10.4161/cbt.4.10.2073; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Yamashita Y, 2010, ONCOGENE, V29, P3723, DOI 10.1038/onc.2010.117	37	1390	1434	4	120	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2010	363	25					2424	2433		10.1056/NEJMoa1005143	http://dx.doi.org/10.1056/NEJMoa1005143			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694ZK	21067377	Green Accepted, Green Published			2022-12-28	WOS:000285340200008
J	Van Raamsdonk, CD; Griewank, KG; Crosby, MB; Garrido, MC; Vemula, S; Wiesner, T; Obenauf, AC; Wackernagel, W; Green, G; Bouvier, N; Sozen, MM; Baimukanova, G; Roy, R; Heguy, A; Dolgalev, I; Khanin, R; Busam, K; Speicher, MR; O'Brien, J; Bastian, BC				Van Raamsdonk, Catherine D.; Griewank, Klaus G.; Crosby, Michelle B.; Garrido, Maria C.; Vemula, Swapna; Wiesner, Thomas; Obenauf, Anna C.; Wackernagel, Werner; Green, Gary; Bouvier, Nancy; Sozen, M. Mert; Baimukanova, Gail; Roy, Ritu; Heguy, Adriana; Dolgalev, Igor; Khanin, Raya; Busam, Klaus; Speicher, Michael R.; O'Brien, Joan; Bastian, Boris C.			Mutations in GNA11 in Uveal Melanoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOMATIC MUTATIONS; ALPHA-SUBUNIT; HUMAN CANCER; BRAF; SKIN; MELANOCYTES; ACTIVATION; FREQUENCY; EXPOSURE; TUMORS	Background: Uveal melanoma is the most common intraocular cancer. There are no effective therapies for metastatic disease. Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas. Methods: We sequenced exon 5 of GNAQ and GNA11, a paralogue of GNAQ, in 713 melanocytic neoplasms of different types (186 uveal melanomas, 139 blue nevi, 106 other nevi, and 282 other melanomas). We sequenced exon 4 of GNAQ and GNA11 in 453 of these samples and in all coding exons of GNAQ and GNA11 in 97 uveal melanomas and 45 blue nevi. Results: We found somatic mutations in exon 5 (affecting Q209) and in exon 4 (affecting R183) in both GNA11 and GNAQ, in a mutually exclusive pattern. Mutations affecting Q209 in GNA11 were present in 7% of blue nevi, 32% of primary uveal melanomas, and 57% of uveal melanoma metastases. In contrast, we observed Q209 mutations in GNAQ in 55% of blue nevi, 45% of uveal melanomas, and 22% of uveal melanoma metastases. Mutations affecting R183 in either GNAQ or GNA11 were less prevalent (2% of blue nevi and 6% of uveal melanomas) than the Q209 mutations. Mutations in GNA11 induced spontaneously metastasizing tumors in a mouse model and activated the mitogen-activated protein kinase pathway. Conclusions: Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11. Constitutive activation of the pathway involving these two genes appears to be a major contributor to the development of uveal melanoma. (Funded by the National Institutes of Health and others.) N Engl J Med 2010;363:2191-9.	[Van Raamsdonk, Catherine D.] Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada; [Griewank, Klaus G.; Crosby, Michelle B.; Garrido, Maria C.; Vemula, Swapna; Green, Gary; Bouvier, Nancy; Baimukanova, Gail; Bastian, Boris C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [O'Brien, Joan] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; [Bastian, Boris C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; [Roy, Ritu; O'Brien, Joan; Bastian, Boris C.] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Wiesner, Thomas] Med Univ Graz, Dept Dermatol, Graz, Austria; [Obenauf, Anna C.; Speicher, Michael R.] Med Univ Graz, Inst Human Genet, Graz, Austria; [Wackernagel, Werner] Med Univ Graz, Dept Ophthalmol, Graz, Austria; [Bouvier, Nancy; Sozen, M. Mert; Heguy, Adriana; Dolgalev, Igor; Bastian, Boris C.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Bastian, Boris C.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	University of British Columbia; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Medical University of Graz; Medical University of Graz; Medical University of Graz; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Van Raamsdonk, CD (corresponding author), Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada.	bastianb@mskcc.org	Dolgalev, Igor/AAY-6406-2020; Griewank, Klaus G/A-9097-2017; Sozen, Mert M./E-7278-2011; Speicher, Michael R/B-5362-2013; Wackernagel, Werner/I-8581-2012; Van Raamsdonk, Catherine D./B-6207-2017; Heguy, Adriana/GPP-3907-2022	Dolgalev, Igor/0000-0003-4451-126X; Griewank, Klaus G/0000-0003-3899-9449; Sozen, Mert M./0000-0002-1672-2206; Speicher, Michael R/0000-0003-0105-955X; Wackernagel, Werner/0000-0002-4524-4012; Van Raamsdonk, Catherine D./0000-0002-4309-3513; Wiesner, Thomas/0000-0001-5877-2992; Bastian, Boris/0000-0003-1836-6062; Obenauf, Anna/0000-0002-9556-5914	National Institutes of Health [R01 CA131524]; Melanoma Research Alliance; Canadian Institutes of Health Research [MOP-79511]; Canadian Cancer Society [019055]; European Commission [HEALTH-F2-2008-202230]; Jubilaumsfonds of the Oesterreichische Nationalbank [12480, 13837]; Medical University Graz; Deutsche Forschungsgemeinschaft [GR 3671/1-1]; NATIONAL CANCER INSTITUTE [R01CA142873, R01CA131524] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); European Commission(European CommissionEuropean Commission Joint Research Centre); Jubilaumsfonds of the Oesterreichische Nationalbank; Medical University Graz; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Institutes of Health (R01 CA131524) and the Melanoma Research Alliance (both to Dr. Bastian), the Canadian Institutes of Health Research (MOP-79511) and the Canadian Cancer Society (019055) (both to Dr. Van Raamsdonk), the European Commission (GENINCA, contract no. HEALTH-F2-2008-202230), the Jubilaumsfonds of the Oesterreichische Nationalbank (12480 and 13837), and the Molecular Medicine program of Medical University Graz (to Dr. Obenauf), and Deutsche Forschungsgemeinschaft (research stipend GR 3671/1-1, to Dr. Griewank).	ABRAMSON DH, 2003, CANC MED 6, V2, P1242; Adameyko I, 2009, CELL, V139, P366, DOI 10.1016/j.cell.2009.07.049; Bauer J, 2009, BRIT J CANCER, V101, P813, DOI 10.1038/sj.bjc.6605226; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Fitch KR, 2003, GENE DEV, V17, P214, DOI 10.1101/gad.1023703; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; HORSMAN DE, 1993, CANCER, V71, P811, DOI 10.1002/1097-0142(19930201)71:3<811::AID-CNCR2820710325>3.0.CO;2-F; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KUSTERSVANDEVEL.HV, 2009, ACTA NEUROPATHO 1122; Lamba S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006833; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Li WJ, 2000, CANCER RES, V60, P3757; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Mainster MA, 2010, AM J OPHTHALMOL, V149, P543, DOI 10.1016/j.ajo.2009.11.028; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Mudhar HS, 2004, HISTOPATHOLOGY, V45, P1, DOI 10.1111/j.1365-2559.2004.01874.x; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Orth JHC, 2009, P NATL ACAD SCI USA, V106, P7179, DOI 10.1073/pnas.0900160106; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Saldanha G, 2004, INT J CANCER, V111, P705, DOI 10.1002/ijc.20325; Singh AD, 2004, SURV OPHTHALMOL, V49, P419, DOI 10.1016/j.survophthal.2004.04.009; Singh AD, 1998, OPHTHALMOLOGY, V105, P195, DOI 10.1016/S0161-6420(98)92205-9; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10579; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Van Raamsdonk CD, 2004, NAT GENET, V36, P961, DOI 10.1038/ng1412; White VA, 1998, CANCER, V83, P354, DOI 10.1002/(SICI)1097-0142(19980715)83:2<354::AID-CNCR20>3.3.CO;2-C; Zembowicz A, 2004, HISTOPATHOLOGY, V45, P433, DOI 10.1111/j.1365-2559.2004.01975.x; Zuidervaart W, 2005, BRIT J CANCER, V92, P2032, DOI 10.1038/sj.bjc.6602598	36	964	981	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2010	363	23					2191	2199		10.1056/NEJMoa1000584	http://dx.doi.org/10.1056/NEJMoa1000584			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688EP	21083380	Green Accepted, Bronze			2022-12-28	WOS:000284832900006
J	Kormos, WA; Wu, CC; Branda, JA; Piris, A				Kormos, William A.; Wu, Carol C.; Branda, John A.; Piris, Adriano			A Man with Cough, Hypoxemia, and Rash Coccidioidomycosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRANULOMATOUS DERMATITIS; PULMONARY COCCIDIOIDOMYCOSIS; BLOOD EOSINOPHILIA; PNEUMONIA; DIAGNOSIS		[Kormos, William A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Wu, Carol C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Branda, John A.; Piris, Adriano] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Kormos, William A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Wu, Carol C.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Branda, John A.; Piris, Adriano] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kormos, WA (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.		Branda, John/ABD-5620-2020					Ampel NM, 2009, CLIN CHEST MED, V30, P241, DOI 10.1016/j.ccm.2009.02.004; BATRA P, 1992, J THORAC IMAG, V7, P29, DOI 10.1097/00005382-199209000-00006; Breza TS, 2006, J CUTAN PATHOL, V33, P512, DOI 10.1111/j.1600-0560.2006.00474.x; CORDIER JF, 1993, CHEST, V103, P201, DOI 10.1378/chest.103.1.201; CORDIER JF, 2005, MURRAY NADELS TXB RE, P1679; DiCaudo DJ, 2006, J AM ACAD DERMATOL, V55, P929, DOI 10.1016/j.jaad.2006.04.039; DiCaudo DJ, 2001, J AM ACAD DERMATOL, V45, P840, DOI 10.1067/mjd.2001.117522; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P727; Durkin M, 2008, CLIN INFECT DIS, V47, pE69, DOI 10.1086/592073; ECHOLS RM, 1982, REV INFECT DIS, V4, P656; EDWARDS PQ, 1957, DIS CHEST, V31, P35, DOI 10.1378/chest.31.1.35; Engelthaler D., 2006, Morbidity and Mortality Weekly Report, V55, P627; Gharib AM, 2001, MED CLIN N AM, V85, P1461, DOI 10.1016/S0025-7125(05)70391-6; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Kuberski T, 2007, CLIN INFECT DIS, V44, P50, DOI 10.1086/511684; LOFFLER W, 1956, INT ARCH ALLER A IMM, V8, P54, DOI 10.1159/000228268; Magro CM, 2000, INT J DERMATOL, V39, P126, DOI 10.1046/j.1365-4362.2000.00868.x; Marty FM, 2007, ANN INTERN MED, V147, P70, DOI 10.7326/0003-4819-147-1-200707030-00018; Ong RKC, 1998, CHEST, V113, P1673, DOI 10.1378/chest.113.6.1673; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; Philit F, 2002, AM J RESP CRIT CARE, V166, P1235, DOI 10.1164/rccm.2112056; Renston JP, 2000, MAYO CLIN PROC, V75, P586, DOI 10.4065/75.6.586; Savani DM, 2002, CLIN CHEST MED, V23, P377, DOI 10.1016/S0272-5231(01)00012-0; Segarra-Newnham M, 2007, ANN PHARMACOTHER, V41, P1992, DOI 10.1345/aph.1K302; Tefferi A, 2006, BRIT J HAEMATOL, V133, P468, DOI 10.1111/j.1365-2141.2006.06038.x; Ward CM, 2007, ALLERGY ASTHMA PROC, V28, P382, DOI 10.2500/aap.2007.28.2969; Wheat LJ, 2009, CLIN CHEST MED, V30, P379, DOI 10.1016/j.ccm.2009.02.011; WILLETT FM, 1945, ANN INTERN MED, V23, P349, DOI 10.7326/0003-4819-23-3-349; WU H, 2009, LEVERS HISTOPATHOLOG, P241	29	1	2	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2046	2054		10.1056/NEJMcpc1003888	http://dx.doi.org/10.1056/NEJMcpc1003888			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083390				2022-12-28	WOS:000284310000011
J	Basak, P; Jesmajian, S				Basak, Prasanta; Jesmajian, Stephen			A Smooth Patch on the Tongue.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Basak, Prasanta; Jesmajian, Stephen] Sound Shore Med Ctr, New Rochelle, NY USA		Basak, P (corresponding author), Sound Shore Med Ctr, New Rochelle, NY USA.	pbasak@sshsw.org							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1949	1949		10.1056/NEJMicm1003564	http://dx.doi.org/10.1056/NEJMicm1003564			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067386				2022-12-28	WOS:000284047600010
J	Eroglu, C; Barres, BA				Eroglu, Cagla; Barres, Ben A.			Regulation of synaptic connectivity by glia	NATURE			English	Review							OLIGODENDROCYTE PRECURSOR CELLS; DENDRITIC SPINE MORPHOLOGY; LONG-TERM DEPRESSION; D-SERINE; DROSOPHILA METAMORPHOSIS; NEUROMUSCULAR-JUNCTION; ENGULFMENT RECEPTOR; GLUTAMATE TRANSPORT; CNS SYNAPTOGENESIS; SUPRAOPTIC NUCLEUS	The human brain contains more than 100 trillion (10(14)) synaptic connections, which form all of its neural circuits. Neuroscientists have long been interested in how this complex synaptic web is weaved during development and remodelled during learning and disease. Recent studies have uncovered that glial cells are important regulators of synaptic connectivity. These cells are far more active than was previously thought and are powerful controllers of synapse formation, function, plasticity and elimination, both in health and disease. Understanding how signalling between glia and neurons regulates synaptic development will offer new insight into how the nervous system works and provide new targets for the treatment of neurological diseases.	[Eroglu, Cagla] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Barres, Ben A.] Stanford Univ, Med Ctr, Dept Neurobiol, Stanford, CA 94305 USA	Duke University; Stanford University	Eroglu, C (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709, Durham, NC 27710 USA.	c.eroglu@cellbio.duke.edu	Eroglu, Cagla/P-5315-2014	Eroglu, Cagla/0000-0002-7204-0218	Alfred P. Sloan Foundation; Esther A. & Joseph Klingenstein Fund; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015043] Funding Source: NIH RePORTER	Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); Esther A. & Joseph Klingenstein Fund; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We acknowledge all of our colleagues whose important work was not directly cited here because of space limitations. This work is referenced in the review articles cited here. C. E. is supported by the Alfred P. Sloan Foundation and a Klingenstein Fellowship Award in the Neurosciences, from the Esther A. & Joseph Klingenstein Fund.	Alexander JJ, 2008, J NEUROCHEM, V107, P1169, DOI 10.1111/j.1471-4159.2008.05668.x; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Awasaki T, 2006, NEURON, V50, P855, DOI 10.1016/j.neuron.2006.04.027; Awasaki T, 2004, CURR BIOL, V14, P668, DOI 10.1016/j.cub.2004.04.001; Bacaj T, 2008, SCIENCE, V322, P744, DOI [10.1126/science.1163074, 10.1126/science.1161473]; Barker AJ, 2008, J NEUROSCI, V28, P8150, DOI 10.1523/JNEUROSCI.1744-08.2008; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Bishop DL, 2004, NEURON, V44, P651, DOI 10.1016/j.neuron.2004.10.026; Bolton MM, 2009, CURR OPIN NEUROBIOL, V19, P491, DOI 10.1016/j.conb.2009.09.007; Buckby LE, 2006, MOL CELL NEUROSCI, V31, P805, DOI 10.1016/j.mcn.2006.01.009; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Caceres M, 2007, CEREB CORTEX, V17, P2312, DOI 10.1093/cercor/bhl140; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Cao G, 2007, J NEUROSCI, V27, P6712, DOI 10.1523/JNEUROSCI.1329-07.2007; Carmona MA, 2009, P NATL ACAD SCI USA, V106, P12524, DOI 10.1073/pnas.0903328106; Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chu YX, 2010, P NATL ACAD SCI USA, V107, P7975, DOI 10.1073/pnas.0913449107; Colon-Ramos DA, 2007, SCIENCE, V318, P103, DOI 10.1126/science.1143762; Cullheim S, 2007, BRAIN RES REV, V55, P89, DOI 10.1016/j.brainresrev.2007.03.012; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; De Biase LM, 2010, J NEUROSCI, V30, P3600, DOI 10.1523/JNEUROSCI.6000-09.2010; Doherty J, 2009, J NEUROSCI, V29, P4768, DOI 10.1523/JNEUROSCI.5951-08.2009; Elmariah SH, 2005, NEURON GLIA BIOL, V1, P1; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Eroglu Cagla, 2008, P683, DOI 10.1007/978-0-387-77232-5_23; Feng Z, 2008, J NEUROSCI, V28, P9599, DOI 10.1523/JNEUROSCI.2589-08.2008; Feng ZH, 2007, CURR OPIN PHARMACOL, V7, P316, DOI 10.1016/j.coph.2006.12.003; Fields RD, 2005, NEUROSCIENTIST, V11, P528, DOI 10.1177/1073858405282304; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Fox MA, 2006, J NEUROCHEM, V97, P1215, DOI 10.1111/j.1471-4159.2006.03834.x; Freeman MR, 2006, CURR OPIN NEUROBIOL, V16, P119, DOI 10.1016/j.conb.2005.12.004; Fuentes-Medel Y, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000184; Garrett AM, 2009, J NEUROSCI, V29, P11723, DOI 10.1523/JNEUROSCI.2818-09.2009; Genoud C, 2006, PLOS BIOL, V4, P2057, DOI 10.1371/journal.pbio.0040343; Goritz C, 2005, MOL CELL NEUROSCI, V29, P190, DOI 10.1016/j.mcn.2005.02.006; Grosche J, 1999, NAT NEUROSCI, V2, P139, DOI 10.1038/5692; Haber M, 2006, J NEUROSCI, V26, P8881, DOI 10.1523/JNEUROSCI.1302-06.2006; Halassa MM, 2007, J NEUROSCI, V27, P6473, DOI 10.1523/JNEUROSCI.1419-07.2007; Hama H, 2004, NEURON, V41, P405, DOI 10.1016/S0896-6273(04)00007-8; Hatton GI, 1997, ANNU REV NEUROSCI, V20, P375, DOI 10.1146/annurev.neuro.20.1.375; Hirrlinger J, 2004, EUR J NEUROSCI, V20, P2235, DOI 10.1111/j.1460-9568.2004.03689.x; Hughes EG, 2010, MOL CELL NEUROSCI, V43, P136, DOI 10.1016/j.mcn.2009.10.004; Iijima T, 2010, EUR J NEUROSCI, V31, P1606, DOI 10.1111/j.1460-9568.2010.07202.x; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Koch SM, 2010, J NEUROSCI, V30, P5404, DOI 10.1523/JNEUROSCI.4893-09.2010; Kurant E, 2008, CELL, V133, P498, DOI 10.1016/j.cell.2008.02.052; Kurshan PT, 2009, NAT NEUROSCI, V12, P1415, DOI 10.1038/nn.2417; Li CY, 2004, J NEUROSCI, V24, P8494, DOI 10.1523/JNEUROSCI.2982-04.2004; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lin SC, 2005, NEURON, V46, P773, DOI 10.1016/j.neuron.2005.04.025; Lin SC, 2002, J NEUROCYTOL, V31, P537, DOI 10.1023/A:1025799816285; Lin SC, 2004, NAT NEUROSCI, V7, P24, DOI 10.1038/nn1162; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Matsuda K, 2010, SCIENCE, V328, P363, DOI 10.1126/science.1185152; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Miller RF, 2004, GLIA, V47, P275, DOI 10.1002/glia.20073; MULLER CM, 1989, NATURE, V342, P427, DOI 10.1038/342427a0; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Nishida H, 2007, J NEUROSCI, V27, P331, DOI 10.1523/JNEUROSCI.4466-06.2007; Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009; Oliveira ALR, 2004, P NATL ACAD SCI USA, V101, P17843, DOI 10.1073/pnas.0408154101; Panatier A, 2006, CELL, V125, P775, DOI 10.1016/j.cell.2006.02.051; Pfrieger FW, 1997, SCIENCE, V277, P1684, DOI 10.1126/science.277.5332.1684; Piet R, 2002, J PHYSIOLOGY-PARIS, V96, P231, DOI 10.1016/S0928-4257(02)00010-4; Reichenbach A, 2010, BRAIN RES REV, V63, P11, DOI 10.1016/j.brainresrev.2010.02.003; Rohrbough J, 2000, J NEUROSCI, V20, P6868, DOI 10.1523/JNEUROSCI.20-18-06868.2000; SELIG DK, 1995, NEURON, V15, P417, DOI 10.1016/0896-6273(95)90045-4; Shi Y, 2006, J NEUROSCI, V26, P1813, DOI 10.1523/JNEUROSCI.4091-05.2006; Song JW, 2008, J NEUROSCI, V28, P8993, DOI 10.1523/JNEUROSCI.0720-08.2008; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Taniguchi H, 2007, J NEUROSCI, V27, P2815, DOI 10.1523/JNEUROSCI.0032-07.2007; Taylor CP, 2009, PAIN, V142, P13, DOI 10.1016/j.pain.2008.11.019; Theodosis DT, 2006, MOL CELL NEUROSCI, V31, P785, DOI 10.1016/j.mcn.2006.01.006; Tran MD, 2006, P NATL ACAD SCI USA, V103, P9321, DOI 10.1073/pnas.0603146103; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; Valder CR, 2003, J NEUROCHEM, V87, P560, DOI 10.1046/j.1471-4159.2003.02016.x; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Wang XH, 2006, NAT NEUROSCI, V9, P816, DOI 10.1038/nn1703; Watts RJ, 2004, CURR BIOL, V14, P678, DOI 10.1016/j.cub.2004.03.035; Witcher MR, 2007, GLIA, V55, P13, DOI 10.1002/glia.20415; Wu H, 2007, P NATL ACAD SCI USA, V104, P13821, DOI 10.1073/pnas.0706199104; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Xu JY, 2010, NAT NEUROSCI, V13, P22, DOI 10.1038/nn.2459; Yang YL, 2003, P NATL ACAD SCI USA, V100, P15194, DOI 10.1073/pnas.2431073100; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Ziegenfuss JS, 2008, NATURE, V453, P935, DOI 10.1038/nature06901	97	499	507	2	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					223	231		10.1038/nature09612	http://dx.doi.org/10.1038/nature09612			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068831	Green Accepted			2022-12-28	WOS:000284051000039
J	Ko, H; Takei, K; Kapadia, R; Chuang, S; Fang, H; Leu, PW; Ganapathi, K; Plis, E; Kim, HS; Chen, SY; Madsen, M; Ford, AC; Chueh, YL; Krishna, S; Salahuddin, S; Javey, A				Ko, Hyunhyub; Takei, Kuniharu; Kapadia, Rehan; Chuang, Steven; Fang, Hui; Leu, Paul W.; Ganapathi, Kartik; Plis, Elena; Kim, Ha Sul; Chen, Szu-Ying; Madsen, Morten; Ford, Alexandra C.; Chueh, Yu-Lun; Krishna, Sanjay; Salahuddin, Sayeef; Javey, Ali			Ultrathin compound semiconductor on insulator layers for high-performance nanoscale transistors	NATURE			English	Article							SILICON; DENSITY; DEVICES; INAS	Over the past several years, the inherent scaling limitations of silicon (Si) electron devices have fuelled the exploration of alternative semiconductors, with high carrier mobility, to further enhance device performance(1-8). In particular, compound semiconductors heterogeneously integrated on Si substrates have been actively studied(7,9,10): such devices combine the high mobility of III-V semiconductors and the well established, low-cost processing of Si technology. This integration, however, presents significant challenges. Conventionally, heteroepitaxial growth of complex multilayers on Si has been explored(9,11-13)-but besides complexity, high defect densities and junction leakage currents present limitations in this approach. Motivated by this challenge, here we use an epitaxial transfer method for the integration of ultrathin layers of single-crystal InAs on Si/SiO2 substrates. As a parallel with silicon-on-insulator (SOI) technology(14), we use 'XOI' to represent our compound semiconductoron-insulator platform. Through experiments and simulation, the electrical properties of InAs XOI transistors are explored, elucidating the critical role of quantum confinement in the transport properties of ultrathin XOI layers. Importantly, a high-quality InAs/dielectric interface is obtained by the use of a novel thermally grown interfacial InAsOx layer (similar to 1 nm thick). The fabricated field-effect transistors exhibit a peak transconductance of similar to 1.6 mS mu m(-1) at a drain-source voltage of 0.5 V, with an on/off current ratio of greater than 10,000.	[Ko, Hyunhyub; Takei, Kuniharu; Kapadia, Rehan; Chuang, Steven; Fang, Hui; Leu, Paul W.; Madsen, Morten; Ford, Alexandra C.; Javey, Ali] Univ Calif Berkeley, Berkeley Sensor & Actuator Ctr, Berkeley, CA 94720 USA; [Ko, Hyunhyub; Takei, Kuniharu; Kapadia, Rehan; Chuang, Steven; Fang, Hui; Leu, Paul W.; Madsen, Morten; Ford, Alexandra C.; Javey, Ali] Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA; [Chen, Szu-Ying; Chueh, Yu-Lun] Natl Tsing Hua Univ, Hsinchu 30013, Taiwan; [Plis, Elena; Kim, Ha Sul; Krishna, Sanjay] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87106 USA; [Plis, Elena; Kim, Ha Sul; Krishna, Sanjay] Univ New Mexico, Ctr High Technol Mat, Albuquerque, NM 87106 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; National Tsing Hua University; University of New Mexico; University of New Mexico	Javey, A (corresponding author), Univ Calif Berkeley, Berkeley Sensor & Actuator Ctr, Berkeley, CA 94720 USA.	ajavey@eecs.berkeley.edu	Kapadia, Rehan/B-4100-2013; Fang, Hui/I-8973-2014; Madsen, Morten/K-8597-2012; Javey, Ali/B-4818-2013; Krishna, Sanjay/C-5766-2009; Ganapathi, Kartik/C-7631-2011; Leu, Paul W/B-9989-2008; Ko, Hyunhyub/C-4848-2009; Chueh, Yu-Lun/E-2053-2013	Kapadia, Rehan/0000-0002-7611-0551; Fang, Hui/0000-0002-4651-9786; Madsen, Morten/0000-0001-6503-0479; Javey, Ali/0000-0001-7214-7931; Krishna, Sanjay/0000-0002-3889-4893; Leu, Paul W/0000-0002-1599-7144; Chueh, Yu-Lun/0000-0002-0155-9987	MARCO/MSD Focus Center; Intel Corporation; BSAC; LDRD from Lawrence Berkeley National Laboratory; Sloan research fellowship; NSF; Sunchon National University; Danish Research Council for Technology and Production Sciences; AFOSR [FA9550-10-1-0113]; National Science Council, Taiwan [NSC 98-2112-M-007-025-MY3]	MARCO/MSD Focus Center; Intel Corporation(Intel Corporation); BSAC; LDRD from Lawrence Berkeley National Laboratory; Sloan research fellowship(Alfred P. Sloan Foundation); NSF(National Science Foundation (NSF)); Sunchon National University; Danish Research Council for Technology and Production Sciences; AFOSR(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was funded by the MARCO/MSD Focus Center, Intel Corporation and BSAC. The materials characterization part of this work was partially supported by an LDRD from Lawrence Berkeley National Laboratory. A.J. acknowledges a Sloan research fellowship, an NSF CAREER award, and support from the World Class University programme at Sunchon National University. R.K. and M.M. acknowledge respectively an NSF graduate fellowship and a postdoctoral fellowship from the Danish Research Council for Technology and Production Sciences. S.K. acknowledges support from AFOSR contract FA9550-10-1-0113. Y.-L.C. acknowledges support from the National Science Council, Taiwan, through grant no. NSC 98-2112-M-007-025-MY3.	Balakrishnan G, 2006, ELECTRON LETT, V42, P350, DOI 10.1049/el:20064286; Bryllert T, 2006, IEEE ELECTR DEVICE L, V27, P323, DOI 10.1109/LED.2006.873371; Celler GK, 2003, J APPL PHYS, V93, P4955, DOI 10.1063/1.1558223; Chau R, 2007, NAT MATER, V6, P810, DOI 10.1038/nmat2014; Chueh YL, 2008, NANO LETT, V8, P4528, DOI 10.1021/nl802681x; DESALVO GC, 1994, J ELECTROCHEM SOC, V141, P3526, DOI 10.1149/1.2059366; Heyns M, 2009, MRS BULL, V34, P485, DOI 10.1557/mrs2009.136; Javey A, 2003, NATURE, V424, P654, DOI 10.1038/nature01797; Javorka P, 2002, IEEE ELECTR DEVICE L, V23, P4, DOI 10.1109/55.974794; Kim DH, 2008, SCIENCE, V320, P507, DOI 10.1126/science.1154367; Kim DH, 2009, ADV MATER, V21, P3703, DOI 10.1002/adma.200900405; Kim DH, 2010, IEEE T ELECTRON DEV, V57, P1504, DOI 10.1109/TED.2010.2049075; Liu Y, 2010, FUNDAMENTALS OF III-V SEMICONDUCTOR MOSFETS, P31, DOI 10.1007/978-1-4419-1547-4_3; Lundstrom M, 2003, SCIENCE, V299, P210, DOI 10.1126/science.1079567; Lundstrom M., 2000, FUNDAMENTALS CARRIER, DOI [10.1017/cbo9780511618611.005, DOI 10.1017/CBO9780511618611.005, 10.1017/CBO9780511618611.005]; Martens K, 2008, IEEE T ELECTRON DEV, V55, P547, DOI 10.1109/TED.2007.912365; Meitl MA, 2006, NAT MATER, V5, P33, DOI 10.1038/nmat1532; Melosh NA, 2003, SCIENCE, V300, P112, DOI 10.1126/science.1081940; MIKHAILOVA MP, 1996, HDB SERIES SEMICONDU, V1, P31; Radosavljevic M., 2009, IEDM, P13, DOI [DOI 10.1109/IEDM.2009.5424361, 10.1109/IEDM.2009.5424361]; Theis TN, 2010, SCIENCE, V327, P1600, DOI 10.1126/science.1187597; Wong HSP, 2005, SOLID STATE ELECTRON, V49, P755, DOI 10.1016/j.sse.2004.10.014; Wu Y. Q., 2009, IEDM, P323; YABLONOVITCH E, 1990, APPL PHYS LETT, V56, P2419, DOI 10.1063/1.102896; YOH K, 1992, JPN J APPL PHYS 1, V31, P4515, DOI 10.1143/JJAP.31.4515; Yokoyama M, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3374447; Yonezu H, 2002, SEMICOND SCI TECH, V17, P762, DOI 10.1088/0268-1242/17/8/304; Yoon J, 2010, NATURE, V465, P329, DOI 10.1038/nature09054; Yuan HC, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2397038	29	340	350	1	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					286	289		10.1038/nature09541	http://dx.doi.org/10.1038/nature09541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068839	Green Submitted			2022-12-28	WOS:000284051000047
J	Kuter, DJ; Rummel, M; Boccia, R; Macik, BG; Pabinger, I; Selleslag, D; Rodeghiero, F; Chong, BH; Wang, XN; Berger, DP				Kuter, David J.; Rummel, Mathias; Boccia, Ralph; Macik, B. Gail; Pabinger, Ingrid; Selleslag, Dominik; Rodeghiero, Francesco; Chong, Beng H.; Wang, Xuena; Berger, Dietmar P.			Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED-TRIAL; DOUBLE-BLIND; PURPURA; SPLENECTOMY; TERM; EFFICACY; ITP; COMPLICATIONS; MANAGEMENT; MORTALITY	Background: Romiplostim, a thrombopoietin mimetic, increases platelet counts in patients with immune thrombocytopenia, with few adverse effects. Methods: In this open-label, 52-week study, we randomly assigned 234 adult patients with immune thrombocytopenia, who had not undergone splenectomy, to receive the standard of care (77 patients) or weekly subcutaneous injections of romiplostim (157 patients). Primary end points were incidences of treatment failure and splenectomy. Secondary end points included the rate of a platelet response (a platelet count >50 x 10(sup 9) per liter at any scheduled visit), safety outcomes, and the quality of life. Results: The rate of a platelet response in the romiplostim group was 2.3 times that in the standard-of-care group (95% confidence interval [CI], 2.0 to 2.6; P<0.001). Patients receiving romiplostim had a significantly lower incidence of treatment failure (18 of 157 patients [11%]) than those receiving the standard of care (23 of 77 patients [30%], P<0.001) (odds ratio with romiplostim, 0.31; 95% CI, 0.15 to 0.61). Splenectomy also was performed less frequently in patients receiving romiplostim (14 of 157 patients [9%]) than in those receiving the standard of care (28 of 77 patients [36%], P<0.001) (odds ratio, 0.17; 95% CI, 0.08 to 0.35). The romiplostim group had a lower rate of bleeding events, fewer blood transfusions, and greater improvements in the quality of life than the standard-of-care group. Serious adverse events occurred in 23% of patients (35 of 154) receiving romiplostim and 37% of patients (28 of 75) receiving the standard of care. Conclusions: Patients treated with romiplostim had a higher rate of a platelet response, lower incidence of treatment failure and splenectomy, less bleeding and fewer blood transfusions, and a higher quality of life than patients treated with the standard of care. (Funded by Amgen; ClinicalTrials.gov number, NCT00415532.) N Engl J Med 2010;363:1889-99.	[Kuter, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Rummel, Mathias] Klinikum Justus Liebig Univ, Giessen, Germany; [Pabinger, Ingrid] Med Univ Wien, Vienna, Austria; [Boccia, Ralph] Ctr Canc & Blood Disorders, Bethesda, MD USA; [Macik, B. Gail] Univ Virginia, Charlottesville, VA USA; [Selleslag, Dominik] Algemeen Ziekenhuis St Jan, Brugge, Belgium; [Rodeghiero, Francesco] San Bortolo Hosp, Vicenza, Italy; [Chong, Beng H.] Univ New S Wales, St George Clin Sch, Kogarah, NSW, Australia; [Wang, Xuena; Berger, Dietmar P.] Amgen Inc, Thousand Oaks, CA USA	Harvard University; Massachusetts General Hospital; Justus Liebig University Giessen; Medical University of Vienna; University of Virginia; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of New South Wales Sydney; Amgen	Kuter, DJ (corresponding author), Massachusetts Gen Hosp, Yawkey 7940,55 Fruit St, Boston, MA 02114 USA.	kuter.david@mgh.harvard.edu	Chong, Beng/AAE-2617-2019; Kuter, David/AAS-1123-2020; Chong, Beng/AAM-9010-2021		Amgen; GlaxoSmithKline; Ligand; Pfizer; Eisai; MGI Pharma; Shionogi; Commonwealth Serum Lab	Amgen(Amgen); GlaxoSmithKline(GlaxoSmithKline); Ligand; Pfizer(Pfizer); Eisai(Eisai Co Ltd); MGI Pharma; Shionogi; Commonwealth Serum Lab	Supported by Amgen.; Dr. Kuter reports receiving consulting fees from Amgen, GlaxoSmithKline, Ligand, Pfizer, Eisai, MGI Pharma, Shionogi, and Ono Pharmaceutical and research support from Amgen, GlaxoSmithKline, Eisai, and Shionogi; Dr. Boccia reports receiving speaker's fees, consulting fees, and research support from Amgen; speaker's fees from GlaxoSmithKline; and holding equity in Amgen and Johnson and Johnson; Dr. Pabinger reports receiving consulting fees from Amgen and GlaxoSmithKline and helping to develop speakers' bureau programs for Amgen; Dr. Selleslag reports receiving consulting fees and speaker's fees from Amgen; Dr. Rodeghiero reports receiving research support from and serving on the boards of Amgen, GlaxoSmithKline, and Shionogi, as well as receiving speaker's fees from Amgen and GlaxoSmithKline; Dr. Chong reports serving on the board, receiving honoraria, and receiving research support from Amgen, GlaxoSmithKline, and Commonwealth Serum Lab; and Drs. Wang and Berger report being employees of, and holding equity in, Amgen. No other potential conflict of interest relevant to this article was reported.	Brasseur P, 1996, Rocz Akad Med Bialymst, V41, P117; BUSSEL J, 2009, BLOOD S, V114; Bussel JB, 2009, BLOOD, V113, P4822; Bussel JB, 2009, LANCET, V373, P641, DOI 10.1016/S0140-6736(09)60402-5; Bussel JB, 2009, BLOOD, V113, P2161, DOI 10.1182/blood-2008-04-150078; Cooper N, 2002, BLOOD, V99, P1922, DOI 10.1182/blood.V99.6.1922; Crary SE, 2009, BLOOD, V114, P2861, DOI 10.1182/blood-2009-04-210112; DEODHAR HA, 1993, BRIT MED J, V307, P1408, DOI 10.1136/bmj.307.6916.1408; George JN, 2009, BRIT J HAEMATOL, V144, P409, DOI 10.1111/j.1365-2141.2008.07464.x; George JN, 2000, SEMIN HEMATOL, V37, P290, DOI 10.1053/shem.2000.8955; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; George JN, 2000, SEMIN HEMATOL, V37, P31, DOI 10.1016/S0037-1963(00)90116-1; Gernsheimer TB, 2010, J THROMB HAEMOST, V8, P1372, DOI 10.1111/j.1538-7836.2010.03830.x; Godeau B, 2008, BLOOD, V112, P999, DOI 10.1182/blood-2008-01-131029; HERNANDEZ F, 1995, BRIT J HAEMATOL, V90, P473, DOI 10.1111/j.1365-2141.1995.tb05179.x; Kaznelson P., 1916, WIEN KLIN WOCHENSCHR, V29, P1451; Kojouri K, 2004, BLOOD, V104, P2623, DOI 10.1182/blood-2004-03-1168; Kuter DJ, 2008, LANCET, V371, P395, DOI 10.1016/S0140-6736(08)60203-2; Kuter DJ, 2009, BLOOD, V114, P3748, DOI 10.1182/blood-2009-05-224766; Mathias SD, 2009, CURR MED RES OPIN, V25, P375, DOI 10.1185/03007990802634119 ; Mikhael J, 2009, AM J HEMATOL, V84, P743, DOI 10.1002/ajh.21501; Nugent D, 2009, BRIT J HAEMATOL, V146, P585, DOI 10.1111/j.1365-2141.2009.07717.x; Provan D, 2010, BLOOD, V115, P168, DOI 10.1182/blood-2009-06-225565; Purcell PL, 2009, AM J HEMATOL, V84, P316, DOI 10.1002/ajh.21389; ROBINETTE CD, 1977, LANCET, V2, P127; Saleh MN, 2009, BLOOD, V114, P1326; SCHWARTZ PE, 1982, JAMA-J AM MED ASSOC, V248, P2279, DOI 10.1001/jama.248.18.2279	28	268	278	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1889	1899		10.1056/NEJMoa1002625	http://dx.doi.org/10.1056/NEJMoa1002625			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067381				2022-12-28	WOS:000284047600004
J	Bonnici, K; Stanworth, D; Simmonds, MSJ; Mukherjee, E; Ferner, RE				Bonnici, Kathleen; Stanworth, Denise; Simmonds, Monique S. J.; Mukherjee, Elora; Ferner, Robin E.			Flowers of evil	LANCET			English	Editorial Material									[Ferner, Robin E.] City Hosp, Dept Clin Pharmacol, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England; [Bonnici, Kathleen; Mukherjee, Elora] W Middlesex Univ Hosp NHS Trust, Dept Acute Med, Isleworth, Middx, England; [Stanworth, Denise] Culham Sci Ctr, LGC Forens, Abingdon, Oxon, England; [Simmonds, Monique S. J.] Kew, Royal Bot Gardens, Surrey, England	University of Birmingham; Culham Science Centre; UK Atomic Energy Authority; Royal Botanic Gardens, Kew	Ferner, RE (corresponding author), City Hosp, Dept Clin Pharmacol, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Chan TYK, 2009, CLIN TOXICOL, V47, P279, DOI 10.1080/15563650902904407; CULLIMORE DH, 1884, BRIT MED J, V2, P1275; Fleming A, 1845, INQUIRY PHYSL MED PR, P43; Moritz F, 2005, CLIN TOXICOL, V43, P873, DOI 10.1080/15563650500357594; Ulbricht W, 2005, PHYSIOL REV, V85, P1271, DOI 10.1152/physrev.00024.2004	5	9	9	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1616	1616		10.1016/S0140-6736(10)61059-8	http://dx.doi.org/10.1016/S0140-6736(10)61059-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21056765				2022-12-28	WOS:000284248700038
J	Freiwald, WA; Tsao, DY				Freiwald, Winrich A.; Tsao, Doris Y.			Functional Compartmentalization and Viewpoint Generalization Within the Macaque Face-Processing System	SCIENCE			English	Article							SUPERIOR TEMPORAL SULCUS; INFEROTEMPORAL CORTEX; OBJECT RECOGNITION; SINGLE NEURONS; VISUAL-CORTEX; MONKEY; AREA; REPRESENTATION; PERCEPTION; MEMORY	Primates can recognize faces across a range of viewing conditions. Representations of individual identity should thus exist that are invariant to accidental image transformations like view direction. We targeted the recently discovered face-processing network of the macaque monkey that consists of six interconnected face-selective regions and recorded from the two middle patches (ML, middle lateral, and MF, middle fundus) and two anterior patches (AL, anterior lateral, and AM, anterior medial). We found that the anatomical position of a face patch was associated with a unique functional identity: Face patches differed qualitatively in how they represented identity across head orientations. Neurons in ML and MF were view-specific; neurons in AL were tuned to identity mirror-symetrically across views, thus achieving partial view invariance; and neurons in AM, the most anterior face patch, achieved almost full view invariance.	[Freiwald, Winrich A.] Rockefeller Univ, New York, NY 10065 USA; [Tsao, Doris Y.] CALTECH, Div Biol, Pasadena, CA 91125 USA	Rockefeller University; California Institute of Technology	Freiwald, WA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10065 USA.	wfreiwald@rockefeller.edu; dortsao@caltech.edu			Humboldt Foundation; German Science Foundation [FR 1437/3-1]; German Ministry of Science, Bremen Center for Advanced Imaging [01GO0506]; NIH [1R01EY019702]; Alfred Sloan Foundation; John Merck Foundation; Searle Foundation; Klingenstein Foundation; NSF [BCS-0847798]; Alexander von Humboldt Foundation; Irma T. Hirschl Trust; Monique Weill-Caulier Trust; Klingenstein Fellowship; Sinsheimer Scholar Award; Pew Scholar Award; NATIONAL EYE INSTITUTE [R01EY019702] Funding Source: NIH RePORTER	Humboldt Foundation(Alexander von Humboldt Foundation); German Science Foundation(German Research Foundation (DFG)); German Ministry of Science, Bremen Center for Advanced Imaging; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alfred Sloan Foundation(Alfred P. Sloan Foundation); John Merck Foundation; Searle Foundation; Klingenstein Foundation(Klingenstein Philanthropies); NSF(National Science Foundation (NSF)); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Irma T. Hirschl Trust; Monique Weill-Caulier Trust; Klingenstein Fellowship(Klingenstein Philanthropies); Sinsheimer Scholar Award; Pew Scholar Award; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We are grateful to M. Livingstone, S. Moeller, C. Cadieu, and A. Tsao for discussions; N. Schweers for outstanding technical assistance; S. Chang and the late D. Freeman for stimulus programming; the Humboldt Foundation Sofia Kovalevskaya Award, German Science Foundation grant FR 1437/3-1, the German Ministry of Science (Grant 01GO0506, Bremen Center for Advanced Imaging), and NIH 1R01EY019702 for financial support; and the Otto Loewi Minerva Center for logistic support. D. Y. T. is supported by the Alfred Sloan Foundation, the John Merck Foundation, the Searle Foundation, the Klingenstein Foundation, and NSF CAREER Award BCS-0847798. W. A. F. is supported by a Feodor Lynen Research Fellowship from the Alexander von Humboldt Foundation, an Irma T. Hirschl and Monique Weill-Caulier Trusts Award, a Klingenstein Fellowship Award, a Sinsheimer Scholar Award, and a Pew Scholar Award.	Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Biederman I, 2000, SPATIAL VISION, V13, P241, DOI 10.1163/156856800741063; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Eifuku S, 2004, J NEUROPHYSIOL, V91, P358, DOI 10.1152/jn.00198.2003; HASSELMO ME, 1989, EXP BRAIN RES, V75, P417; Haxby JV, 2000, TRENDS COGN SCI, V4, P223, DOI 10.1016/S1364-6613(00)01482-0; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Leopold DA, 2001, NAT NEUROSCI, V4, P89, DOI 10.1038/82947; Li N, 2008, SCIENCE, V321, P1502, DOI 10.1126/science.1160028; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; McKone E, 2005, J EXP PSYCHOL HUMAN, V31, P1181, DOI 10.1037/0096-1523.31.6.1181; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; Moeller S, 2008, SCIENCE, V320, P1355, DOI 10.1126/science.1157436; PERRETT DI, 1985, PROC R SOC SER B-BIO, V223, P293, DOI 10.1098/rspb.1985.0003; PERRETT DI, 1991, EXP BRAIN RES, V86, P159; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; Pinsk MA, 2005, P NATL ACAD SCI USA, V102, P6996, DOI 10.1073/pnas.0502605102; Riesenhuber M, 1999, NAT NEUROSCI, V2, P1019, DOI 10.1038/14819; Rollenhagen JE, 2000, SCIENCE, V287, P1506, DOI 10.1126/science.287.5457.1506; Rolls ET, 2007, NEUROPSYCHOLOGIA, V45, P124, DOI 10.1016/j.neuropsychologia.2006.04.019; ROLLS ET, 1984, HUM NEUROBIOL, V3, P209; SALEEM KS, 1993, CEREB CORTEX, V3, P454, DOI 10.1093/cercor/3.5.454; Sugase Y, 1999, NATURE, V400, P869, DOI 10.1038/23703; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Tsao DY, 2008, P NATL ACAD SCI USA, V105, P19514, DOI 10.1073/pnas.0809662105; Tsao DY, 2006, SCIENCE, V311, P670, DOI 10.1126/science.1119983; Tsao DY, 2003, NAT NEUROSCI, V6, P989, DOI 10.1038/nn1111; VALENTINE T, 1991, Q J EXP PSYCHOL-A, V43, P161, DOI 10.1080/14640749108400966; VETTER T, 1994, CURR BIOL, V4, P18, DOI 10.1016/S0960-9822(00)00004-X; Wallis G, 2001, P NATL ACAD SCI USA, V98, P4800, DOI 10.1073/pnas.071028598; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	34	408	412	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					845	851		10.1126/science.1194908	http://dx.doi.org/10.1126/science.1194908			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051642	Green Accepted			2022-12-28	WOS:000283855700050
J	Quinn, JF; Raman, R; Thomas, RG; Yurko-Mauro, K; Nelson, EB; Van Dyck, C; Galvin, JE; Emond, J; Jack, CR; Weiner, M; Shinto, L; Aisen, PS				Quinn, Joseph F.; Raman, Rema; Thomas, Ronald G.; Yurko-Mauro, Karin; Nelson, Edward B.; Van Dyck, Christopher; Galvin, James E.; Emond, Jennifer; Jack, Clifford R., Jr.; Weiner, Michael; Shinto, Lynne; Aisen, Paul S.			Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							N-3 FATTY-ACID; LIPID-PEROXIDATION; CLINICAL-TRIALS; RISK; DEMENTIA; FISH; OMEGA-3-FATTY-ACIDS; PHOSPHOLIPIDS; CONSUMPTION; INVENTORY	Context Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology. Objective To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease. Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial of DHA supplementation in individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores, 14-26) was conducted between November 2007 and May 2009 at 51 US clinical research sites of the Alzheimer's Disease Cooperative Study. Intervention Participants were randomly assigned to algal DHA at a dose of 2 g/d or to identical placebo (60% were assigned to DHA and 40% were assigned to placebo). Duration of treatment was 18 months. Main Outcome Measures Change in the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR) sum of boxes. Rate of brain atrophy was also determined by volumetric magnetic resonance imaging in a subsample of participants (n=102). Results A total of 402 individuals were randomized and a total of 295 participants completed the trial while taking study medication (DHA: 171; placebo: 124). Supplementation with DHA had no beneficial effect on rate of change on ADAS-cog score, which increased by a mean of 7.98 points (95% confidence interval [CI], 6.51-9.45 points) for the DHA group during 18 months vs 8.27 points (95% CI, 6.72-9.82 points) for the placebo group (linear mixed-effects model: P=.41). The CDR sum of boxes score increased by 2.87 points (95% CI, 2.44-3.30 points) for the DHA group during 18 months compared with 2.93 points (95% CI, 2.44-3.42 points) for the placebo group (linear mixed-effects model: P=.68). In the subpopulation of participants (DHA: 53; placebo: 49), the rate of brain atrophy was not affected by treatment with DHA. Individuals in the DHA group had a mean decline in total brain volume of 24.7 cm(3) (95% CI, 21.4-28.0 cm(3)) during 18 months and a 1.32% (95% CI, 1.14%-1.50%) volume decline per year compared with 24.0 cm(3) (95% CI, 20-28 cm(3)) for the placebo group during 18 months and a 1.29% (95% CI, 1.07%-1.51%) volume decline per year (P=.79). Conclusion Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease.	[Quinn, Joseph F.; Shinto, Lynne] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA; [Raman, Rema; Thomas, Ronald G.; Emond, Jennifer; Aisen, Paul S.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Yurko-Mauro, Karin; Nelson, Edward B.] Martek Biosci, Columbia, MD USA; [Van Dyck, Christopher] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA; [Galvin, James E.] NYU, Sch Med, Dept Neurol, New York, NY USA; [Jack, Clifford R., Jr.] Mayo Clin, Rochester, MN USA; [Weiner, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA	Oregon Health & Science University; University of California System; University of California San Diego; Yale University; New York University; Mayo Clinic; University of California System; University of California San Francisco	Quinn, JF (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,CR 131, Portland, OR 97239 USA.	quinnj@ohsu.edu	Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X; Quinn, Joseph/0000-0001-7305-2256	National Institute on Aging [UO1-AG10483]; Martek Biosciences; NATIONAL INSTITUTE ON AGING [P30AG008051, U01AG010483, U19AG010483] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Martek Biosciences; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grant UO1-AG10483 from the National Institute on Aging. The placebo and DHA study drugs were provided by Martek Biosciences. Martek also provided plasma and cerebrospinal fluid measurements of fatty acids, as well as partial financial support for the magnetic resonance imaging substudy.	Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Aisen PS, 2003, AM J GERIAT PSYCHIAT, V11, P246, DOI 10.1176/appi.ajgp.11.2.246; Ando K, 1998, LIPIDS, V33, P505, DOI 10.1007/s11745-998-0234-6; Arterburn LM, 2008, J AM DIET ASSOC, V108, P1204, DOI 10.1016/j.jada.2008.04.020; Arterburn LM, 2007, LIPIDS, V42, P1011, DOI 10.1007/s11745-007-3098-5; Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; Barberger-Gateau P, 2002, BRIT MED J, V325, P932, DOI 10.1136/bmj.325.7370.932; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121; ERVIN RW, 2003, ADV DATA VITAL HLTH, V348; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fotuhi M, 2009, NAT CLIN PRACT NEURO, V5, P140, DOI 10.1038/ncpneuro1044; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Heude B, 2003, AM J CLIN NUTR, V77, P803, DOI 10.1093/ajcn/77.4.803; Huang TL, 2005, NEUROLOGY, V65, P1409, DOI 10.1212/01.wnl.0000183148.34197.2e; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450; Kalmijn S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/oxfordjournals.aje.a009029; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lim WS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005379.pub2; Logsdon RG, 2002, PSYCHOSOM MED, V64, P510, DOI 10.1097/00006842-200205000-00016; Mori TA, 2004, REDOX REP, V9, P193, DOI 10.1179/135100004225005200; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Prasad MR, 1998, NEUROCHEM RES, V23, P81, DOI 10.1023/A:1022457605436; *R FDN STAT COMP, 2009, R LANG ENV STAT COMP; Raman R, 2009, ALZ DIS ASSOC DIS, V23, P333, DOI 10.1097/WAD.0b013e3181aba588; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; SODERBERG M, 1991, LIPIDS, V26, P421, DOI 10.1007/BF02536067; Song JH, 2001, ATHEROSCLEROSIS, V155, P9, DOI 10.1016/S0021-9150(00)00523-2; van de Rest O, 2008, NEUROLOGY, V71, P430, DOI 10.1212/01.wnl.0000324268.45138.86; Whalley LJ, 2008, AM J CLIN NUTR, V87, P449, DOI 10.1093/ajcn/87.2.449	40	506	521	2	82	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1903	1911		10.1001/jama.2010.1510	http://dx.doi.org/10.1001/jama.2010.1510			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674GT	21045096	Green Accepted			2022-12-28	WOS:000283725900020
J	Bonasio, R; Tu, SJ; Reinberg, D				Bonasio, Roberto; Tu, Shengjiang; Reinberg, Danny			Molecular Signals of Epigenetic States	SCIENCE			English	Review							H3 LYSINE-9 METHYLATION; NOVO DNA METHYLATION; HISTONE H3; CHROMATIN; POLYCOMB; RNA; TRANSCRIPTION; REQUIRES; MEMORY; CELLS	Epigenetic signals are responsible for the establishment, maintenance, and reversal of metastable transcriptional states that are fundamental for the cell's ability to "remember" past events, such as changes in the external environment or developmental cues. Complex epigenetic states are orchestrated by several converging and reinforcing signals, including transcription factors, noncoding RNAs, DNA methylation, and histone modifications. Although all of these pathways modulate transcription from chromatin in vivo, the mechanisms by which epigenetic information is transmitted through cell division remain unclear. Because epigenetic states are metastable and change in response to the appropriate signals, a deeper understanding of their molecular framework will allow us to tackle the dysregulation of epigenetics in disease.	[Reinberg, Danny] NYU, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA	Howard Hughes Medical Institute; New York University; New York University	Reinberg, D (corresponding author), NYU, Howard Hughes Med Inst, 550 1St Ave, New York, NY 10016 USA.	reinbd01@nyumc.org	Tu, Shengjiang/K-7868-2012; Bonasio, Roberto/P-1356-2014	Tu, Shengjiang/0000-0003-3616-3242; Bonasio, Roberto/0000-0002-0767-0889; Reinberg, Danny/0000-0003-4288-2016	HHMI; NIH [GM064844, GM037120]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064844, R37GM037120, R01GM037120] Funding Source: NIH RePORTER	HHMI(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank L. Vales for critical reading of this manuscript. Work in the Reinberg laboratory is supported by HHMI and NIH grants GM064844 and GM037120. R. B. is a fellow of the Helen Hay Whitney Foundation.	Allis CD, 2007, EPIGENETICS; Alon U, 2006, INTRO SYSTEMS BIOL D; ALVARADO AS, 2006, CELL, V124, P241, DOI DOI 10.1016/J.CELL.2006.01.012; Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003; Arnold SJ, 2009, NAT REV MOL CELL BIO, V10, P91, DOI 10.1038/nrm2618; Bayne EH, 2010, CELL, V140, P666, DOI 10.1016/j.cell.2010.01.038; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Blobel GA, 2009, MOL CELL, V36, P970, DOI 10.1016/j.molcel.2009.12.001; Bonasio R, 2010, SCIENCE, V329, P1068, DOI 10.1126/science.1192428; Bourc'his D, 2010, SCIENCE, V330, P617, DOI 10.1126/science.1194776; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Brennecke J, 2008, SCIENCE, V322, P1387, DOI 10.1126/science.1165171; Brennecke J, 2007, CELL, V128, P1089, DOI 10.1016/j.cell.2007.01.043; Brower-Toland B, 2007, GENE DEV, V21, P2300, DOI 10.1101/gad.1564307; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chen ES, 2008, NATURE, V451, P734, DOI 10.1038/nature06561; Chotalia M, 2009, GENE DEV, V23, P105, DOI 10.1101/gad.495809; Dong KB, 2008, EMBO J, V27, P2691, DOI 10.1038/emboj.2008.193; Epsztejn-Litman S, 2008, NAT STRUCT MOL BIOL, V15, P1176, DOI 10.1038/nsmb.1476; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614; Francis NJ, 2009, CELL, V137, P110, DOI 10.1016/j.cell.2009.02.017; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Gravina S, 2010, PFLUG ARCH EUR J PHY, V459, P247, DOI 10.1007/s00424-009-0730-7; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Halfmann R, 2010, SCIENCE, V330, P629, DOI 10.1126/science.1191081; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787; Hervouet E, 2009, EPIGENETICS-US, V4, P487, DOI 10.4161/epi.4.7.9883; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Kalakonda N, 2008, ONCOGENE, V27, P4293, DOI 10.1038/onc.2008.67; Kanhere A, 2010, MOL CELL, V38, P675, DOI 10.1016/j.molcel.2010.03.019; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Koziol MJ, 2010, CURR OPIN GENET DEV, V20, P142, DOI 10.1016/j.gde.2010.03.003; Kundu S, 2007, GENE DEV, V21, P997, DOI 10.1101/gad.1506607; Lansdorp PM, 2007, CELL, V129, P1244, DOI 10.1016/j.cell.2007.06.017; Lee JT, 2009, GENE DEV, V23, P1831, DOI 10.1101/gad.1811209; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398; Matzke M, 2007, CURR OPIN PLANT BIOL, V10, P512, DOI 10.1016/j.pbi.2007.06.007; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Moazed D, 2009, NATURE, V457, P413, DOI 10.1038/nature07756; Molnar A, 2010, SCIENCE, V328, P872, DOI 10.1126/science.1187959; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; NANNEY DL, 1958, P NATL ACAD SCI USA, V44, P712, DOI 10.1073/pnas.44.7.712; Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Pegoraro G, 2009, AGING-US, V1, P1017, DOI 10.18632/aging.100106; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Rando TA, 2007, CELL, V129, P1239, DOI 10.1016/j.cell.2007.06.019; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; RIGGS AD, 1996, COLD SPRING HARBOR M, V32, P1; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Sarma K, 2008, MOL CELL BIOL, V28, P2718, DOI 10.1128/MCB.02017-07; Saze H, 2008, SEMIN CELL DEV BIOL, V19, P527, DOI 10.1016/j.semcdb.2008.07.017; Schmitt S, 2005, GENE DEV, V19, P697, DOI 10.1101/gad.326205; Si K, 2004, COLD SPRING HARB SYM, V69, P497, DOI 10.1101/sqb.2004.69.497; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; Weinstock GM, 2006, NATURE, V443, P931, DOI 10.1038/nature05260; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; Zacharioudakis L, 2007, CURR BIOL, V17, P2041, DOI 10.1016/j.cub.2007.10.044; Zhu JK, 2009, ANNU REV GENET, V43, P143, DOI 10.1146/annurev-genet-102108-134205	81	605	642	0	209	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					612	616		10.1126/science.1191078	http://dx.doi.org/10.1126/science.1191078			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030644	Green Accepted			2022-12-28	WOS:000283580600032
J	Latko, B; Temporao, JG; Frenk, J; Evans, TG; Chen, LC; Pablos-Mendez, A; Lagomarsino, G; de Ferranti, D				Latko, Brian; Temporao, Jose Gomes; Frenk, Julio; Evans, Timothy G.; Chen, Lincoln C.; Pablos-Mendez, Ariel; Lagomarsino, Gina; de Ferranti, David			The growing movement for universal health coverage	LANCET			English	Editorial Material									[Latko, Brian; Lagomarsino, Gina; de Ferranti, David] Results Dev Inst, Washington, DC 20009 USA; [Temporao, Jose Gomes] Minist Hlth, Brasilia, DF, Brazil; [Frenk, Julio] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; [Evans, Timothy G.] BRAC Univ, Sch Publ Hlth, Dhaka, Bangladesh; [Chen, Lincoln C.] China Med Board, Cambridge, MA USA; [Pablos-Mendez, Ariel] Rockefeller Fdn, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Bangladesh Rural Advancement Committee BRAC; BRAC University	Latko, B (corresponding author), Results Dev Inst, Washington, DC 20009 USA.	blatko@resultsfordevelopment.org						*AFR HLTH EC POL A, 2010, UN HLTH COV AFR; *BUND GES, 2010, INT C HLTH SYST FIN; Carrin G, 2008, B WORLD HEALTH ORGAN, V86, P857, DOI 10.2471/BLT.07.049387; Garrett L, 2009, LANCET, V374, P1294, DOI 10.1016/S0140-6736(09)61503-8; GOTTRET P, 2008, GOOD PRACT HLTH FIN; McIntyre D, 2008, B WORLD HEALTH ORGAN, V86, P871, DOI 10.2471/BLT.08.053413; Twahirwa A, 2008, B WORLD HEALTH ORGAN, V86, P823, DOI 10.2471/BLT.08.021108; WANG S, 2010, WALL STREET J   0924; WHO, 2010, 1 GLOB S HLTH SYST R; WHO, 2008, PHARMAFORUM 0121; *WHO REG OFF S E A, 2010, REG STRAT UN HLTH CO; World Health Assembly, 2005, SUST HLTH FIN UN COV; Yates R, 2009, LANCET, V373, P2078, DOI 10.1016/S0140-6736(09)60258-0; 2010, HINDUSTAN TIMES 1019; 2010, JOINT LEARNING NETWO	15	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN-JUL	2011	377	9784					2161	2163		10.1016/S0140-6736(10)62006-5	http://dx.doi.org/10.1016/S0140-6736(10)62006-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	786XI	21084114				2022-12-28	WOS:000292340800009
J	Chaudhry, SI; Mattera, JA; Curtis, JP; Spertus, JA; Herrin, J; Lin, ZQ; Phillips, CO; Hodshon, BV; Cooper, LS; Krumholz, HM				Chaudhry, Sarwat I.; Mattera, Jennifer A.; Curtis, Jeptha P.; Spertus, John A.; Herrin, Jeph; Lin, Zhenqiu; Phillips, Christopher O.; Hodshon, Beth V.; Cooper, Lawton S.; Krumholz, Harlan M.			Telemonitoring in Patients with Heart Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE-MANAGEMENT; RANDOMIZED-TRIAL; READMISSION; OUTCOMES	BACKGROUND Small studies suggest that telemonitoring may improve heart-failure outcomes, but its effect in a large trial has not been established. METHODS We randomly assigned 1653 patients who had recently been hospitalized for heart failure to undergo either telemonitoring (826 patients) or usual care (827 patients). Telemonitoring was accomplished by means of a telephone-based interactive voice-response system that collected daily information about symptoms and weight that was reviewed by the patients' clinicians. The primary end point was readmission for any reason or death from any cause within 180 days after enrollment. Secondary end points included hospitalization for heart failure, number of days in the hospital, and number of hospitalizations. RESULTS The median age of the patients was 61 years; 42.0% were female, and 39.0% were black. The telemonitoring group and the usual-care group did not differ significantly with respect to the primary end point, which occurred in 52.3% and 51.5% of patients, respectively (difference, 0.8 percentage points; 95% confidence interval [CI], -4.0 to 5.6; P = 0.75 by the chi-square test). Readmission for any reason occurred in 49.3% of patients in the telemonitoring group and 47.4% of patients in the usual-care group (difference, 1.9 percentage points; 95% CI, -3.0 to 6.7; P = 0.45 by the chi-square test). Death occurred in 11.1% of the telemonitoring group and 11.4% of the usual care group (difference, -0.2 percentage points; 95% CI, -3.3 to 2.8; P = 0.88 by the chi-square test). There were no significant differences between the two groups with respect to the secondary end points or the time to the primary end point or its components. No adverse events were reported. CONCLUSIONS Among patients recently hospitalized for heart failure, telemonitoring did not improve outcomes. The results indicate the importance of a thorough, independent evaluation of disease-management strategies before their adoption.	[Curtis, Jeptha P.; Herrin, Jeph; Hodshon, Beth V.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Cardiovasc Med, New Haven, CT 06510 USA; [Chaudhry, Sarwat I.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Gen Med, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Mattera, Jennifer A.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Dept Med, New Haven, CT 06510 USA; [Mattera, Jennifer A.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; [Mattera, Jennifer A.; Curtis, Jeptha P.; Lin, Zhenqiu; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Spertus, John A.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA; [Spertus, John A.] St Lukes Hlth Syst, Mid Amer Heart & Vasc Inst, Kansas City, MO USA; [Phillips, Christopher O.] Morehouse Sch Med, Dept Med, Atlanta, GA 30310 USA; [Cooper, Lawton S.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; University of Missouri System; University of Missouri Kansas City; Saint Luke's Mid America Heart Institute; Morehouse School of Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Sch Publ Hlth, Sect Cardiovasc Med, 1 Church St,Suite 200, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020; Spertus, John/ABD-3075-2021		National Heart, Lung, and Blood Institute [5 R01 HL080228]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG030986] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by a grant (5 R01 HL080228) from the National Heart, Lung, and Blood Institute.	Chaudhry SI, 2007, J CARD FAIL, V13, P709, DOI 10.1016/j.cardfail.2007.06.720; Clark AM, 2009, J AM COLL CARDIOL, V54, P397, DOI 10.1016/j.jacc.2009.04.051; Cox D. R., 1984, ANAL SURVIVAL DATA; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Cutler DM, 2010, NEW ENGL J MED, V362, P1553, DOI 10.1056/NEJMp1002305; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kosiborod M, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.11.019; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Krumholz HM, 2006, CIRCULATION, V114, P1432, DOI 10.1161/CIRCULATIONAHA.106.177322; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006	16	778	791	0	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2010	363	24					2301	2309		10.1056/NEJMoa1010029	http://dx.doi.org/10.1056/NEJMoa1010029			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691PA	21080835	Green Accepted			2022-12-28	WOS:000285092100005
J	Marusic, M				Marusic, Matko			Croatia moves away from fostering research integrity	LANCET			English	Editorial Material							PLAGIARISM; EUROPE		Univ Split, Sch Med, Split 21000, Croatia	University of Split	Marusic, M (corresponding author), Univ Split, Sch Med, Split 21000, Croatia.		Marusic, Matko/E-1834-2017	Marusic, Matko/0000-0001-5562-1777				Bosch X, 2008, NATURE, V454, P574, DOI 10.1038/454574a; *COMM ETH SCI HIGH, RUL 2006 2009; *CROAT NEWS AG, 2007, BEC PLAG KURJ LOS MO; European Science Foundation, 2010, FOST RES INT EUR EX; *FOR ETH DEV SCI H, 2009, STAT PROM AC SCI POS; Kleinert S, 2010, LANCET, V376, P400, DOI 10.1016/S0140-6736(10)61201-9; Kmietowicz Z, 2007, BMJ-BRIT MED J, V335, P1014, DOI 10.1136/bmj.39392.474711.4E; Manusic M, 2008, BMJ-BRIT MED J, V336, P173, DOI 10.1136/bmj.39450.666748.3A; Marcovitch H, 2008, BRIT MED J, V336, P174, DOI 10.1136/bmj.39450.661528.3A; *MIN SCI ED SPORTS, 2010, REP CROAT PUBL DISC; Petrovecki M, 2001, CROAT MED J, V42, P7; Petrovecki M, 2006, CROAT MED J, V47, P809; SARIC M, VECERNJI LIST, P8; Sibbald B, 2009, CAN MED ASSOC J, V181, pE155, DOI 10.1503/cmaj.109-3030; Watts G, 2007, BMJ-BRIT MED J, V334, P1077, DOI 10.1136/bmj.39223.354178.DB; 2008, UNIONS CHANGE MANAGI; 2008, RECTOR BJELIS IT IS; 2009, U PROMOTES DESA MLIK	18	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1627	1628		10.1016/S0140-6736(10)61999-X	http://dx.doi.org/10.1016/S0140-6736(10)61999-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21075244				2022-12-28	WOS:000284451000009
J	Govers, F; Angenent, GC				Govers, Francine; Angenent, Gerco C.			Fertility Goddesses as Trojan Horses	SCIENCE			English	Editorial Material							POLLEN-TUBE RECEPTION; COMPONENTS; RESISTANCE; FUNGI		[Govers, Francine] Wageningen Univ, Phytopathol Lab, NL-16708 PB Wageningen, Netherlands; [Angenent, Gerco C.] Wageningen Univ, Mol Biol Lab, NL-16708 PB Wageningen, Netherlands; [Angenent, Gerco C.] Plant Res Int, Business Unit Biosci, NL-166700 A Wageningen, Netherlands; [Govers, Francine; Angenent, Gerco C.] Ctr BioSyst Genom CBSG, NL-986700 A Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research; Centre for BioSystems Genomics	Govers, F (corresponding author), Wageningen Univ, Phytopathol Lab, NL-16708 PB Wageningen, Netherlands.	francine.govers@wur.nl	Angenent, Gerco C./A-5993-2011; Govers, Francine/A-5616-2009	Govers, Francine/0000-0001-5311-929X				Bhat RA, 2005, P NATL ACAD SCI USA, V102, P3135, DOI 10.1073/pnas.0500012102; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Ellis JG, 2009, CURR OPIN PLANT BIOL, V12, P399, DOI 10.1016/j.pbi.2009.05.004; Hematy K, 2008, CURR OPIN PLANT BIOL, V11, P321, DOI 10.1016/j.pbi.2008.02.008; Huck N, 2003, DEVELOPMENT, V130, P2149, DOI 10.1242/dev.00458; Kessler SA, 2010, SCIENCE, V330, P968, DOI 10.1126/science.1195211; McCormick S, 2007, SCIENCE, V317, P606, DOI 10.1126/science.1146655; Ngugi HK, 2006, ANNU REV PHYTOPATHOL, V44, P261, DOI 10.1146/annurev.phyto.44.070505.143405; Ngugi HK, 2004, PHYSIOL MOL PLANT P, V64, P113, DOI 10.1016/j.pmpp.2004.08.004; Okuda S, 2009, NATURE, V458, P357, DOI 10.1038/nature07882; Panstruga R, 2005, BIOCHEM SOC T, V33, P389, DOI 10.1042/BST0330389; Tudzynski P, 2004, MOL PLANT PATHOL, V5, P377, DOI 10.1111/j.1364-3703.2004.00237.x; Vleeshouwers VGAA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002875	13	4	5	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					922	923		10.1126/science.1198347	http://dx.doi.org/10.1126/science.1198347			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071655				2022-12-28	WOS:000284118000027
J	Choudhry, NK; Shrank, WH				Choudhry, Niteesh K.; Shrank, William H.			Four-Dollar Generics -- Increased Accessibility, Impaired Quality Assurance.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Choudhry, NK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 2008, US TODAY; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; *KAIS FAM FDN HLTH, EMPL HLTH BEN 2009 A; Kohl H, 2007, J AM GERIATR SOC, V55, P1106, DOI 10.1111/j.1532-5415.2007.01286.x; *NAT ASS CHAIN DRU, 2008, RX SAL	5	69	69	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1885	1887		10.1056/NEJMp1006189	http://dx.doi.org/10.1056/NEJMp1006189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678CR	21067379				2022-12-28	WOS:000284047600003
J	McCartney, M				McCartney, Margaret			Medicine and the Media Men and midlife crises	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaretmccartney@doctors.org.uk	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358					0	0	0	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2010	341								c5661	10.1136/bmj.c5661	http://dx.doi.org/10.1136/bmj.c5661			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KO	21068110				2022-12-28	WOS:000284312700010
J	Moore, W				Moore, Wendy			Past Caring Work not welfare	BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com						Dunkley Peter J., 1982, CRISIS OLD POOR LAW; Englander D., 2013, POVERTY POOR LAW REF; SENIOR N, 1905, POOR LAW COMMISSIONE; 2010, BRIT MED J, V341, pC6029, DOI DOI 10.1136/BMJ.C6029; 2010, BRIT MED J, V341, pC6049, DOI DOI 10.1136/BMJ.C6049; 2010, BRIT MED J, V341, pC6022, DOI DOI 10.1136/BMJ.C6022; 2010, BRIT MED J, V341, pC6053, DOI DOI 10.1136/BMJ.C6053	7	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2010	341								c6371	10.1136/bmj.c6371	http://dx.doi.org/10.1136/bmj.c6371			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KO	21068115				2022-12-28	WOS:000284312700019
J	Nutt, DJ; King, LA; Phillips, LD				Nutt, David J.; King, Leslie A.; Phillips, Lawrence D.		Independent Sci Comm Drugs	Drug harms in the UK: a multicriteria decision analysis	LANCET			English	Article							ILLICIT DRUGS; TOXICITY; MISUSE	Background Proper assessment of the harms caused by the misuse of drugs can inform policy makers in health, policing, and social care. We aimed to apply multicriteria decision analysis (MCDA) modelling to a range of drug harms in the UK. Method Members of the Independent Scientific Committee on Drugs, including two invited specialists, met in a 1-day interactive workshop to score 20 drugs on 16 criteria: nine related to the harms that a drug produces in the individual and seven to the harms to others. Drugs were scored out of 100 points, and the criteria were weighted to indicate their relative importance. Findings MCDA modelling showed that heroin, crack cocaine, and metamfetamine were the most harmful drugs to individuals (part scores 34, 37, and 32, respectively), whereas alcohol, heroin, and crack cocaine were the most harmful to others (46, 21, and 17, respectively). Overall, alcohol was the most harmful drug (overall harm score 72), with heroin (55) and crack cocaine (54) in second and third places. Interpretation These findings lend support to previous work assessing drug harms, and show how the improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs. However, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm.	[Nutt, David J.] Univ London Imperial Coll Sci Technol & Med, Neuropsychopharmacol Unit, London W12 0NN, England; [King, Leslie A.] EMCDDA, Lisbon, Portugal; [Phillips, Lawrence D.] Univ London London Sch Econ & Polit Sci, Dept Management, London WC2A 2AE, England	Imperial College London; University of London; London School Economics & Political Science	Nutt, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Neuropsychopharmacol Unit, Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	d.nutt@imperial.ac.uk			Centre for Crime and Justice Studies (UK); Facilitations Limited	Centre for Crime and Justice Studies (UK); Facilitations Limited	This study is funded by the Centre for Crime and Justice Studies (UK). Yuji Wu assisted with some of the data analyses.; DJN and LAK received travel expenses to attend the decision conference meeting. LAK is a consultant to the Department of Health and the EMCDDA. LDP is a director of Facilitations Limited, which paid him a consulting fee because it was the company engaged by the Centre for Crime and Justice Studies to run the study and analyse the data.	Academy of Medical Sciences (AMS), 2004, CALL TIM NAT DRINK M; *ADV COUNC MIS DRU, 2010, CONS US MULT DEC AN; [Anonymous], 2010, DRUGS RES OVERVIEW E; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; *BRIT MED ASS, 1987, LIV RISK; Coomber R, 1999, ADDICT RES, V7, P85, DOI 10.3109/16066359909004376; DODGSON J, 2000, MULTICRITERIA ANAL M; Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x; *HC HLTH COMM, 2010, 1511 HC HLTH COMM; Horn G., 2008, BRAIN SCI ADDICTION; King LA, 2010, HUM PSYCHOPHARM CLIN, V25, P162, DOI 10.1002/hup.1090; Morton A, 2009, RISK ANAL, V29, P764, DOI 10.1111/j.1539-6924.2008.01192.x; Murphy PI, 2007, LANCET, V369, P1856, DOI 10.1016/S0140-6736(07)60841-1; NICE (National Institute of Clinical Excellence), 2010, ALCOHOL USE DISORDER; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Phillips LD, 2007, ADVANCES IN DECISION ANALYSIS: FROM FOUNDATIONS TO APPLICATIONS, P375, DOI 10.1017/CBO9780511611308.020; REGANCIRINCIONE P, 1994, ORG BEHAV HUMAN DECI, V58, P246; United Nations Office on Drugs and Crime, 2010, WORLD DRUG REP 2010; van Amsterdam J, 2010, EUR ADDICT RES, V16, P202, DOI 10.1159/000317249; Werb D., 2010, EFFECT DRUG LAW ENFO	20	870	891	6	247	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1558	1565		10.1016/S0140-6736(10)61462-6	http://dx.doi.org/10.1016/S0140-6736(10)61462-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21036393				2022-12-28	WOS:000284248700033
J	Marciniak, SJ; Lomas, DA				Marciniak, Stefan J.; Lomas, David A.			Alpha(sub 1)-Antitrypsin Deficiency and Autophagy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Marciniak, Stefan J.; Lomas, David A.] Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England	University of Cambridge	Marciniak, SJ (corresponding author), Univ Cambridge, Dept Med, Cambridge Inst Med Res, Cambridge CB2 2QQ, England.		Marciniak, Stefan J/F-1855-2010	Marciniak, Stefan/0000-0001-8472-7183	Medical Research Council [G0601840, G0500306] Funding Source: Medline; MRC [G0500306, G0601840] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Gooptu B, 2009, ANNU REV BIOCHEM, V78, P147, DOI 10.1146/annurev.biochem.78.082107.133320; Hidvegi T, 2010, SCIENCE, V329, P229, DOI 10.1126/science.1190354; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104	4	38	38	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1863	1864		10.1056/NEJMcibr1008007	http://dx.doi.org/10.1056/NEJMcibr1008007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047232				2022-12-28	WOS:000283787800014
J	Sokol, DK				Sokol, Daniel K.			Ethics Man We must do more for doctors trained abroad	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Sokol, DK (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	daniel.sokol@talk21.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 3	2010	341								c4837	10.1136/bmj.c4837	http://dx.doi.org/10.1136/bmj.c4837			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678DE	21047890				2022-12-28	WOS:000284050400016
J	Yamin, CK; Bitton, A; Bates, DW				Yamin, Cyrus K.; Bitton, Asaf; Bates, David W.			E-Cigarettes: A Rapidly Growing Internet Phenomenon	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Electronic cigarettes (e-cigarettes) aerosolize nicotine and produce a vapor that emulates that of cigarettes but purportedly has fewer traditional toxins than secondhand smoke. Although e-cigarettes are widely sold online and by retailers, new research suggests that they may contain unexpected toxins and may provide unreliable nicotine delivery. Many countries have already banned or strictly regulated e-cigarettes. Currently in the United States, e-cigarettes are exempt from regulation as drug-delivery devices. Meanwhile, the presence of e-cigarettes on the Internet, including in Web searches, virtual user communities, and online stores where people sell e-cigarettes on commission, is increasing rapidly. Physicians should be aware of the popularity, questionable efficacy claims, and safety concerns of e-cigarettes so that they may counsel patients against use and advocate for research to inform an evidence-based regulatory approach.	[Bates, David W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02120 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Bates, DW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, 1620 Tremont St, Boston, MA 02120 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					Bullen C, 2010, TOB CONTROL, V19, P98, DOI 10.1136/tc.2009.031567; Connolly GN, 2010, PEDIATRICS, V125, P896, DOI 10.1542/peds.2009-2835; *E CIG FOR, E LIQ REV; Etter JF, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-231; *GOOGL, GOOGL SEARCH E CIG; *GOOGL, 2007, WEB SEARCH INT EL CI; *GREEN SMOK, EL CIG E CIG KITS; *GREEN SMOK, AFF BANN ADS; Henningfield JE, 2010, TOB CONTROL, V19, P89, DOI 10.1136/tc.2009.035279; Jones S., 2009, GENERATIONS ONLINE 2; Laugesen M., 2008, SAFETY REPORT RUYAN; Trtchounian A, 2010, NICOTINE TOB RES, V12, P905, DOI 10.1093/ntr/ntq114; United States Food and Drug Administration, 2009, FDAS MED BRIEF EL CI; Vansickel AR, 2010, CANCER EPIDEM BIOMAR, V19, P1945, DOI 10.1158/1055-9965.EPI-10-0288; Westenberger BJ, 2009, EVALUATION E CIGARET; WHO, 2009, WHO TECH REP SER, V955, P1; SEARCH SAFE CIGARETT	17	149	151	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					607	609		10.7326/0003-4819-153-9-201011020-00011	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	21041581				2022-12-28	WOS:000283667000008
J	Brennan, KA; Genever, RW				Brennan, K. A.; Genever, R. W.			Practice Pointer Managing Parkinson's disease during surgery	BRITISH MEDICAL JOURNAL			English	Editorial Material							PERIOPERATIVE MANAGEMENT; TRANSDERMAL ROTIGOTINE; INDUCED DYSKINESIAS; PROPOFOL; ANESTHESIA		[Genever, R. W.] Chesterfield Royal Hosp NHS Fdn Trust, Calow S44 5BL, Chesterfield, England; [Brennan, K. A.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England	University of Sheffield	Genever, RW (corresponding author), Chesterfield Royal Hosp NHS Fdn Trust, Calow S44 5BL, Chesterfield, England.	Richard.Genever@chesterfieldroyal.nhs.uk			Boehringer Ingelheim; Glaxo Smith Kline; Teva; Lundbeck; Orion	Boehringer Ingelheim(Boehringer Ingelheim); Glaxo Smith Kline(GlaxoSmithKline); Teva(Teva Pharmaceutical Industries); Lundbeck(Lundbeck Corporation); Orion	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that RG has received sponsorship to attend medical conferences from Boehringer Ingelheim, Glaxo Smith Kline, Teva and Lundbeck, and Orion. RG has received honoraria for speaking at meetings from Glaxo Smith Kline and Orion. RG has received honoraria for sitting on advisory boards from Glaxo Smith Kline and Boehringer Ingelheim. KB has no relationships with any companies that might have an interest in the submitted work in the previous 3 years; and RG and KB have no non-financial interests that may be relevant to the submitted work.	ANDERSON BJ, 1994, BRIT J NEUROSURG, V8, P387, DOI 10.3109/02688699409029633; Brady M, 2009, COCHRANE DB SYST REV, V7; Davies RG, 2005, BRIT J ANAESTH, V95, P424, DOI 10.1093/bja/aei579; Furuya R, 1998, ANESTHESIOLOGY, V89, P261, DOI 10.1097/00000542-199807000-00035; Iyer SS, 2005, NEUROLOGY, V65, P1507, DOI 10.1212/01.wnl.0000183286.92632.71; Krauss JK, 1996, ANESTH ANALG, V83, P420, DOI 10.1097/00000539-199608000-00037; LeWitt PA, 2007, CLIN NEUROPHARMACOL, V30, P256, DOI 10.1097/wnf.0b013e318154c7c4; MADOPAR CR, 2009, SUMMARY PRODUCT CHAR; Mehta Samir, 2008, Am J Orthop (Belle Mead NJ), V37, P513; Nicholson G, 2002, BRIT J ANAESTH, V89, P904, DOI 10.4103/0019-5049.82658; *PARK UK, GET IT TIM; Pepper PV, 1999, J AM GERIATR SOC, V47, P967, DOI 10.1111/j.1532-5415.1999.tb01292.x; REED AP, 1992, ANESTH ANALG, V75, P850; Schrag A, 2000, BRIT MED J, V321, P21, DOI 10.1136/bmj.321.7252.21; SINEMET CR, 2009, SUMMARY PRODUCT CHAR; STOLTZ M, 2004, BRIT J ANAESTH, V96, P868; Ueda M, 1999, NEUROLOGY, V52, P777, DOI 10.1212/WNL.52.4.777; Wenzelburger R, 2002, BRAIN, V125, P871, DOI 10.1093/brain/awf084; Wullner U, 2010, J NEURAL TRANSM, V117, P855, DOI 10.1007/s00702-010-0425-4	19	29	31	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 1	2010	341								c5718	10.1136/bmj.c5718	http://dx.doi.org/10.1136/bmj.c5718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CD	21041319				2022-12-28	WOS:000284045500010
J	Chandler, VL				Chandler, Vicki L.			Paramutation's Properties and Puzzles	SCIENCE			English	Editorial Material							MAIZE; TRANS; INHERITANCE; EXPRESSION; LOCUS	Paramutation refers to the process by which homologous DNA sequences communicate in trans to establish meiotically heritable expression states. Although mechanisms are unknown, current data are consistent with the hypothesis that the establishment and heritable transmission of specific chromatin states underlies paramutation. Transcribed, noncoding tandem repeats and proteins implicated in RNA-directed transcriptional silencing in plants and yeast are required for paramutation, yet the specific molecules mediating heritable silencing remain to be determined.	Univ Arizona, Dept Plant Sci, Inst BIO5, Tucson, AZ 85719 USA	University of Arizona	Chandler, VL (corresponding author), Univ Arizona, Dept Plant Sci, Inst BIO5, Tucson, AZ 85719 USA.	chandler@ag.arizona.edu						Arteaga-Vazquez M, 2010, P NATL ACAD SCI USA, V107, P12986, DOI 10.1073/pnas.1007972107; Arteaga-Vazquez MA, 2010, CURR OPIN GENET DEV, V20, P156, DOI 10.1016/j.gde.2010.01.008; Bourc'his D, 2010, SCIENCE, V330, P617, DOI 10.1126/science.1194776; Brzeska K, 2010, P NATL ACAD SCI USA, V107, P5516, DOI 10.1073/pnas.1001576107; Chandler VL, 2007, CELL, V128, P641, DOI 10.1016/j.cell.2007.02.007; COE EH, 1966, GENETICS, V53, P1035; Grewal SIS, 2010, CURR OPIN GENET DEV, V20, P134, DOI 10.1016/j.gde.2010.02.003; Haring M, 2010, PLANT J, V63, P366, DOI 10.1111/j.1365-313X.2010.04245.x; Henderson IR, 2007, NATURE, V447, P418, DOI 10.1038/nature05917; Matzke M, 2009, CURR OPIN CELL BIOL, V21, P367, DOI 10.1016/j.ceb.2009.01.025; Stam M, 2009, MOL PLANT, V2, P578, DOI 10.1093/mp/ssp020; Suter CM, 2010, TRENDS GENET, V26, P9, DOI 10.1016/j.tig.2009.11.003	12	55	55	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					628	629		10.1126/science.1191044	http://dx.doi.org/10.1126/science.1191044			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030647				2022-12-28	WOS:000283580600035
J	Sudmant, PH; Kitzman, JO; Antonacci, F; Alkan, C; Malig, M; Tsalenko, A; Sampas, N; Bruhn, L; Shendure, J; Eichler, EE				Sudmant, Peter H.; Kitzman, Jacob O.; Antonacci, Francesca; Alkan, Can; Malig, Maika; Tsalenko, Anya; Sampas, Nick; Bruhn, Laurakay; Shendure, Jay; Eichler, Evan E.		1000 Genomes Project	Diversity of Human Copy Number Variation and Multicopy Genes	SCIENCE			English	Article							HUMAN GENOME; SEGMENTAL DUPLICATIONS; HUMAN-DISEASE; EVOLUTION; SCHIZOPHRENIA; POLYMORPHISMS; CONVERSION; SELECTION; DELETION; 15Q13.3	Copy number variants affect both disease and normal phenotypic variation, but those lying within heavily duplicated, highly identical sequence have been difficult to assay. By analyzing short-read mapping depth for 159 human genomes, we demonstrated accurate estimation of absolute copy number for duplications as small as 1.9 kilobase pairs, ranging from 0 to 48 copies. We identified 4.1 million "singly unique nucleotide" positions informative in distinguishing specific copies and used them to genotype the copy and content of specific paralogs within highly duplicated gene families. These data identify human-specific expansions in genes associated with brain development, reveal extensive population genetic diversity, and detect signatures consistent with gene conversion in the human species. Our approach makes similar to 1000 genes accessible to genetic studies of disease association.	[Sudmant, Peter H.; Kitzman, Jacob O.; Antonacci, Francesca; Alkan, Can; Malig, Maika; Shendure, Jay; Eichler, Evan E.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA; [Tsalenko, Anya; Sampas, Nick; Bruhn, Laurakay] Agilent Technol, Santa Clara, CA 95051 USA; [Eichler, Evan E.] Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Agilent Technologies; Howard Hughes Medical Institute	Eichler, EE (corresponding author), Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA 98195 USA.	eee@gs.washington.edu	Ye, Kai/B-3640-2012; Antonacci, Francesca/F-5457-2013; Browning, Brian L/A-1178-2010; Shendure, Jay/AAU-3684-2021; Wilson, Richard K./AAF-4139-2019; Sahinalp, Suleyman Cenk/X-7843-2018; Rosenstiel, Philip/A-5137-2009; Khurana, Ekta/C-4933-2013; Altshuler, David M/A-4476-2009; Myers, Simon R/A-6792-2015; Dahl, Andreas/E-3783-2017; Wang, Jun/A-7261-2013; Cooper, David N/H-4384-2011; Alkan, Can/D-2982-2009; Chen, Ken/AAU-1432-2021; Mills, Ryan/F-4225-2010; Li, Yingrui/K-1064-2015; Tumian, Afidalina/J-4404-2014	Antonacci, Francesca/0000-0002-5833-6186; Browning, Brian L/0000-0001-6454-6633; Wilson, Richard K./0000-0002-1992-1358; Sahinalp, Suleyman Cenk/0000-0002-5050-0682; Rosenstiel, Philip/0000-0002-9692-8828; Altshuler, David M/0000-0002-7250-4107; Myers, Simon R/0000-0002-2585-9626; Dahl, Andreas/0000-0002-2668-8371; Cooper, David N/0000-0002-8943-8484; Alkan, Can/0000-0002-5443-0706; Chen, Ken/0000-0003-4013-5279; Mills, Ryan/0000-0003-3425-6998; Keane, Thomas/0000-0001-7532-6898; Hinrichs, Angie/0000-0002-1697-1130; Zalunin, Vadim/0000-0002-7722-1958; Chinwalla, Asif/0000-0001-7831-3996; Leinonen, Rasko/0000-0002-2639-7187; Sudmant, Peter/0000-0002-9573-8248; Shendure, Jay/0000-0002-1516-1865; Balasubramanian, Shankar/0000-0002-0281-5815; Swerdlow, Harold/0000-0002-9510-160X; Radhakrishnan, Rajesh/0000-0001-7170-699X; Kulesha, Eugene/0000-0002-4285-6232; Herrero, Javier/0000-0001-7313-717X; Sebat, Jonathan/0000-0002-9087-526X; Schaffner, Stephen/0000-0001-6699-3568; Eberle, Michael/0000-0001-8965-1253; Keinan, Alon/0000-0002-9760-1122; Aguinaga, Jesus Christ/0000-0003-0664-6219; Abyzov, Alexej/0000-0001-5405-6729; Sherry, Stephen/0000-0002-7982-076X; McLaren, William/0000-0001-6218-1116; Clark, Andrew/0000-0001-7159-8511; MCLELLAN, MICHAEL/0000-0002-2703-8784; Cibulskis, Kristian/0000-0003-1343-1582; Tumian, Afidalina/0000-0003-2763-6677; Haraksingh, Rajini/0000-0002-6644-8874; MacArthur, Daniel/0000-0002-5771-2290; Keenan, Stephen/0000-0002-9141-7690; Kitzman, Jacob/0000-0002-6145-882X; Clarke, Laura/0000-0002-5989-6898; Walter, Klaudia/0000-0003-4448-0301; Stone, Eric/0000-0002-2725-4209	Natural Sciences and Engineering Research Council of Canada; NSF; NIH [HG004120]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003067, P01HG004120, U54HG003273, ZIAHG000024] Funding Source: NIH RePORTER; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute for Health Research(National Institute for Health Research (NIHR))	We thank M. Ventura and M. Ross for sharing unpublished data; C. Lee for technical assistance; C. Campbell, J. Kidd, P. Green, and M. Hoopman for discussion; and T. Brown for manuscript preparation assistance. This work was supported by a Natural Sciences and Engineering Research Council of Canada Fellowship (P. H. S.), an NSF Graduate Research Fellowship (J.O.K.), and NIH grant HG004120 to E. E. E. E. E. E. is an Investigator of the Howard Hughes Medical Institute. E. E. E is on the scientific advisory board for Pacific Biosciences. A. T., N.S., and L. B. are employees of Agilent Technologies. J. S. is a member of the scientific advisory boards of Tandem Technologies, Stratos Genomics, Good Start Genetics, and Adaptive TCR. Sequence and array data are deposited at the NCBI under accessions SRP002878, SRP003500, SRP000031, SRP000032, and GSE24334.	*1000 GEN PROJ, 2010, NATURE          1028, DOI DOI 10.1038/NATURE09534; Alkan C, 2009, NAT GENET, V41, P1061, DOI 10.1038/ng.437; Antonacci F, 2009, HUM MOL GENET, V18, P2555, DOI 10.1093/hmg/ddp187; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Brunetti-Pierri N, 2008, NAT GENET, V40, P1466, DOI 10.1038/ng.279; Chen JM, 2007, NAT REV GENET, V8, P762, DOI 10.1038/nrg2193; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Conrad DF, 2010, NATURE, V464, P704, DOI 10.1038/nature08516; Cooper GM, 2008, NAT GENET, V40, P1199, DOI 10.1038/ng.236; Craddock N, 2010, NATURE, V464, P713, DOI 10.1038/nature08979; Dai L, 2009, AM J MED GENET A, V149A, P302, DOI 10.1002/ajmg.a.32652; Edelmann L, 2007, J MED GENET, V44, P136, DOI 10.1136/jmg.2006.044537; Estivill X, 2002, HUM MOL GENET, V11, P1987, DOI 10.1093/hmg/11.17.1987; Force A, 1999, GENETICS, V151, P1531; Guerrier S, 2009, CELL, V138, P990, DOI 10.1016/j.cell.2009.06.047; Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030; Hirayasu K, 2008, AM J HUM GENET, V82, P1075, DOI 10.1016/j.ajhg.2008.03.012; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Innan H, 2003, P NATL ACAD SCI USA, V100, P8793, DOI 10.1073/pnas.1031592100; Jiang Z, 2007, NAT GENET, V39, P1361, DOI 10.1038/ng.2007.9; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marques-Bonet T, 2009, NATURE, V457, P877, DOI 10.1038/nature07744; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Sharp AJ, 2008, NAT GENET, V40, P322, DOI 10.1038/ng.93; Shinawi M, 2009, NAT GENET, V41, P1269, DOI 10.1038/ng.481; Stefansson H, 2008, NATURE, V455, P232, DOI 10.1038/nature07229; Urban TJ, 2009, NAT MED, V15, P1110, DOI 10.1038/nm1009-1110; Xue YL, 2008, AM J HUM GENET, V83, P337, DOI 10.1016/j.ajhg.2008.08.004	30	458	480	2	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					641	646		10.1126/science.1197005	http://dx.doi.org/10.1126/science.1197005			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030649	Green Submitted, Green Accepted			2022-12-28	WOS:000283580600039
J	Kong, A; Thorleifsson, G; Gudbjartsson, DF; Masson, G; Sigurdsson, A; Jonasdottir, A; Walters, GB; Jonasdottir, A; Gylfason, A; Kristinsson, KT; Gudjonsson, SA; Frigge, ML; Helgason, A; Thorsteinsdottir, U; Stefansson, K				Kong, Augustine; Thorleifsson, Gudmar; Gudbjartsson, Daniel F.; Masson, Gisli; Sigurdsson, Asgeir; Jonasdottir, Aslaug; Walters, G. Bragi; Jonasdottir, Adalbjorg; Gylfason, Arnaldur; Kristinsson, Kari Th.; Gudjonsson, Sigurjon A.; Frigge, Michael L.; Helgason, Agnar; Thorsteinsdottir, Unnur; Stefansson, Kari			Fine-scale recombination rate differences between sexes, populations and individuals	NATURE			English	Article							HUMAN GENOME; MEIOTIC RECOMBINATION; SEQUENCE VARIANTS; SELECTION; HOTSPOTS; HUMANS; PRDM9; MAP; GENE	Meiotic recombinations contribute to genetic diversity by yielding new combinations of alleles. Recently, high-resolution recombination maps were inferred from high-density single-nucleotide polymorphism (SNP) data using linkage disequilibrium (LD) patterns that capture historical recombination events(1,2). The use of these maps has been demonstrated by the identification of recombination hotspots(2) and associated motifs(3), and the discovery that the PRDM(9) gene affects the proportion of recombinations occurring at hotspots(4-6). However, these maps provide no information about individual or sex differences. Moreover, locus-specific demographic factors like natural selection(7) can bias LD-based estimates of recombination rate. Existing genetic maps based on family data avoid these shortcomings(8), but their resolution is limited by relatively few meioses and a low density of markers. Here we used genome-wide SNP data from(15),257 parent-offspring pairs to construct the first recombination maps based on directly observed recombinations with a resolution that is effective down to 10 kilobases (kb). Comparing male and female maps reveals that about 15% of hot-spots in one sex are specific to that sex. Although male recombinations result in more shuffling of exons within genes, female recombinations generate more new combinations of nearby genes. We discover novel associations between recombination characteristics of individuals and variants in the PRDM9 gene and we identify new recombination hotspots. Comparisons of our maps with two LD-based maps inferred from data of HapMap populations of Utah residents with ancestry from northern and western Europe (CEU) and Yoruba in Ibadan, Nigeria (YRI) reveal population differences previously masked by noise and map differences at regions previously described as targets of natural selection.	[Kong, Augustine; Thorleifsson, Gudmar; Gudbjartsson, Daniel F.; Masson, Gisli; Sigurdsson, Asgeir; Jonasdottir, Aslaug; Walters, G. Bragi; Jonasdottir, Adalbjorg; Gylfason, Arnaldur; Kristinsson, Kari Th.; Gudjonsson, Sigurjon A.; Frigge, Michael L.; Helgason, Agnar; Thorsteinsdottir, Unnur; Stefansson, Kari] deCODE Genet, IS-101 Reykjavik, Iceland; [Helgason, Agnar] Univ Iceland, Dept Anthropol, IS-101 Reykjavik, Iceland; [Thorsteinsdottir, Unnur; Stefansson, Kari] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland	University of Iceland; University of Iceland	Kong, A (corresponding author), deCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	kong@decode.is; kari.stefansson@decode.is	Helgason, Agnar/K-1522-2015; Stefansson, Kari/AAE-7187-2019; Walters, G. Bragi/L-4215-2013	Walters, G. Bragi/0000-0002-5415-6487; Gudbjartsson, Daniel/0000-0002-5222-9857; Kong, Augustine/0000-0001-8193-5438; Gudjonsson, Sigurjon A./0000-0001-9314-7412; Helgason, Agnar/0000-0002-8545-3767				Akey JM, 2009, GENOME RES, V19, P711, DOI 10.1101/gr.086652.108; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Baudat F, 2010, SCIENCE, V327, P836, DOI 10.1126/science.1183439; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kong A, 2008, NAT GENET, V40, P1068, DOI 10.1038/ng.216; Kong A, 2008, SCIENCE, V319, P1398, DOI 10.1126/science.1152422; Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625; Lang MR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000744; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Myers S, 2008, NAT GENET, V40, P1124, DOI 10.1038/ng.213; Myers S, 2010, SCIENCE, V327, P876, DOI 10.1126/science.1182363; O'Reilly PF, 2008, GENOME RES, V18, P1304, DOI 10.1101/gr.067181.107; Parvanov ED, 2010, SCIENCE, V327, P835, DOI 10.1126/science.1181495; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508	18	386	391	2	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2010	467	7319					1099	1103		10.1038/nature09525	http://dx.doi.org/10.1038/nature09525			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981099				2022-12-28	WOS:000283548600046
J	Choi, H; Takahashi, D; Kono, K; Kim, E				Choi, H.; Takahashi, D.; Kono, K.; Kim, E.			Evidence of Supersolidity in Rotating Solid Helium	SCIENCE			English	Article								Supersolidity, the appearance of zero-viscosity flow in solids, was first indicated in helium-4 torsional oscillator (TO) experiments. In this apparatus, the irrotationality of the superfluid component causes it to decouple from the underlying normal solid, leading to a reduction in the resonant period of the TO. However, the resonant period may be altered for reasons other than supersolidity, such as the temperature dependence of the elastic modulus of solid helium. Superimposing rotation onto oscillatory measurements may distinguish between supersolidity and classical effects. We performed such simultaneous measurements of the TO and the shear modulus, and observed substantial change in the resonant period with rotational speed where the modulus remained unchanged. This contrasting behavior suggests that the decrease in the TO period is a result of supersolidity.	[Choi, H.; Kim, E.] Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea; [Choi, H.; Kim, E.] Korea Adv Inst Sci & Technol, Ctr Supersolid & Quantum Matter Res, Taejon 305701, South Korea; [Takahashi, D.; Kono, K.] RIKEN, Low Temp Phys Lab, Wako, Saitama 3510198, Japan	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); RIKEN	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea.	eunseong@kaist.edu	Kim, Eunseong/D-4698-2009; Kono, Kimitoshi/H-3329-2012; Choi, Hyoungsoon/G-2724-2011	Kono, Kimitoshi/0000-0002-4446-4419; 	National Research Foundation of Korea through Creative Research Initiatives; Japan Society for the Promotion of Science	National Research Foundation of Korea through Creative Research Initiatives(National Research Foundation of Korea); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Supported by the National Research Foundation of Korea through Creative Research Initiatives and the Japan Society for the Promotion of Science through a Grant-in-Aid for Scientific Research. We thank members of the Center for Supersolid and Quantum Matter Research, in particular D. Y. Kim and S. Kwon, for helpful discussions.	Anderson PW, 2007, NAT PHYS, V3, P160, DOI 10.1038/nphys539; Aoki Y, 2008, LOW TEMP PHYS+, V34, P329, DOI 10.1063/1.2911651; Choi H, 2010, NAT PHYS, V6, P424, DOI 10.1038/NPHYS1630; Day J, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.035301; Day J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.105304; Day J, 2007, NATURE, V450, P853, DOI 10.1038/nature06383; Gumann P, 2009, J PHYS CONF SER, V150, DOI 10.1088/1742-6596/150/3/032026; Iwasa I, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.104527; Kim E, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.115302; Kim E, 2004, SCIENCE, V305, P1941, DOI 10.1126/science.1101501; Kim E, 2004, NATURE, V427, P225, DOI 10.1038/nature02220; Kwon S, 2010, J LOW TEMP PHYS, V158, P590, DOI 10.1007/s10909-009-0044-3; LEGGETT AJ, 1970, PHYS REV LETT, V25, P1543, DOI 10.1103/PhysRevLett.25.1543; Nussinov Z, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.014530; Obata T, 2004, J LOW TEMP PHYS, V134, P559, DOI 10.1023/B:JOLT.0000012609.16930.cb; Prokof'ev N, 2007, ADV PHYS, V56, P381, DOI 10.1080/00018730601183025; Ray MW, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.145301; Ray MW, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.012502; Ray MW, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.224302; Reppy JD, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.255301; Rittner ASC, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.224516; Yoo CD, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.100504	22	54	54	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2010	330	6010					1512	1515		10.1126/science.1196409	http://dx.doi.org/10.1126/science.1196409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	692LE	21097904				2022-12-28	WOS:000285153500057
J	Kaiser, C; Galatius, S; Erne, P; Eberli, F; Alber, H; Rickli, H; Pedrazzini, G; Hornig, B; Bertel, O; Bonetti, P; De Servi, S; Brunner-La Rocca, HP; Ricard, I; Pfisterer, M				Kaiser, Christoph; Galatius, Soeren; Erne, Paul; Eberli, Franz; Alber, Hannes; Rickli, Hans; Pedrazzini, Giovanni; Hornig, Burkhard; Bertel, Osmund; Bonetti, Piero; De Servi, Stefano; Brunner-La Rocca, Hans-Peter; Ricard, Ingrid; Pfisterer, Matthias		BASKET-PROVE Study Grp	Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED-TRIAL; SMALL VESSELS; BALLOON ANGIOPLASTY; FOLLOW-UP; DISEASE; OUTCOMES; BASKET; REVASCULARIZATION; PLACEMENT; DIAMETER	BACKGROUND Recent data have suggested that patients with coronary disease in large arteries are at increased risk for late cardiac events after percutaneous intervention with first-generation drug-eluting stents, as compared with bare-metal stents. We sought to confirm this observation and to assess whether this increase in risk was also seen with second-generation drug-eluting stents. METHODS We randomly assigned 2314 patients needing stents that were 3.0 mm or more in diameter to receive sirolimus-eluting, everolimus-eluting, or bare-metal stents. The primary end point was the composite of death from cardiac causes or nonfatal myocardial infarction at 2 years. Late events (occurring during months 7 to 24) and target-vessel revascularization were the main secondary end points. RESULTS The rates of the primary end point were 2.6% among patients receiving sirolimus-eluting stents, 3.2% among those receiving everolimus-eluting stents, and 4.8% among those receiving bare-metal stents, with no significant differences between patients receiving either drug-eluting stent and those receiving bare-metal stents. There were also no significant between-group differences in the rate of late events or in the rate of death, myocardial infarction, or stent thrombosis. Rates of target-vessel revascularization for reasons unrelated to myocardial infarction were 3.7% among patients receiving sirolimus-eluting stents, 3.1% among those receiving everolimus-eluting stents, and 8.9% among those receiving bare-metal stents. The rate of target-vessel revascularization was significantly reduced among patients receiving either drug-eluting stent, as compared with a bare-metal stent, with no significant difference between the two types of drug-eluting stents. CONCLUSIONS In patients requiring stenting of large coronary arteries, no significant differences were found among sirolimus-eluting, everolimus-eluting, and bare-metal stents with respect to the rate of death or myocardial infarction. With the two drug-eluting stents, similar reductions in rates of target-vessel revascularization were seen.	[Kaiser, Christoph] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland; [Erne, Paul] State Hosp, Luzern, Switzerland; [Eberli, Franz] Triemli Hosp, Zurich, Switzerland; [Rickli, Hans] State Hosp, St Gallen, Switzerland; [Pedrazzini, Giovanni] Cardiocentro, Lugano, Switzerland; [Hornig, Burkhard] Clara Hosp, Basel, Switzerland; [Bertel, Osmund] Cardiovasc Ctr Zurich, Zurich, Switzerland; [Bonetti, Piero] State Hosp, Chur, Switzerland; [Galatius, Soeren] Gentofte Univ Hosp, Hellerup, Denmark; [Alber, Hannes] Univ Innsbruck Hosp, A-6020 Innsbruck, Austria; [De Servi, Stefano] Osped Civile Legnano, Milan, Italy; [Brunner-La Rocca, Hans-Peter] Maastricht Univ, Med Ctr, Maastricht, Netherlands	University of Basel; Triemli Hospital; University of Copenhagen; Herlev & Gentofte Hospital; Medical University of Innsbruck; Maastricht University	Kaiser, C (corresponding author), Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland.	ckaiser@uhbs.ch	De+Servi, Stefano/AAT-2631-2021; Jeger, Raban/ABG-1678-2021; Brunner-La Rocca, Hans-Peter/AAF-7330-2021; Alber, Hannes F/H-6355-2015; Sticherling, Christian/AAY-4435-2021; Kaiser, Christoph/AAA-9284-2022; Hug, Balthasar L./G-1568-2010	Jeger, Raban/0000-0003-1290-5491; Sticherling, Christian/0000-0001-8428-7050; Kurz, David/0000-0002-3921-6939; Brunner-La Rocca, Hans-Peter/0000-0002-4356-8566	Basel Cardiovascular Research Foundation; Swiss National Foundation for Research [32003B-116382]	Basel Cardiovascular Research Foundation; Swiss National Foundation for Research(Swiss National Science Foundation (SNSF))	Supported by the Basel Cardiovascular Research Foundation and a grant from the Swiss National Foundation for Research (32003B-116382).	AGRESTI A, 2002, CATEGORICAL ANAL; Akiyama T, 1998, J AM COLL CARDIOL, V32, P1610, DOI 10.1016/S0735-1097(98)00444-6; Ardissino D, 2004, JAMA-J AM MED ASSOC, V292, P2727, DOI 10.1001/jama.292.22.2727; Bartorelli AL, 2010, CATHETER CARDIO INTE, V76, P60, DOI 10.1002/ccd.22452; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brunner-La Rocca HP, 2007, EUR HEART J, V28, P719, DOI 10.1093/eurheartj/ehl490; Cox DA, 2008, J AM COLL CARDIOL, V51, pB15; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Elezi S, 1998, CIRCULATION, V98, P1875, DOI 10.1161/01.CIR.98.18.1875; Farb A, 2007, NEW ENGL J MED, V356, P984, DOI 10.1056/NEJMp068304; Garg S, 2010, J AM COLL CARDIOL, V56, pS1, DOI 10.1016/j.jacc.2010.06.007; Gordon PC, 2010, CATHETER CARDIO INTE, V75, P179, DOI 10.1002/ccd.22259; Hermiller JB, 2009, AM HEART J, V158, P1005, DOI 10.1016/j.ahj.2009.09.018; James SK, 2009, NEW ENGL J MED, V360, P1933, DOI 10.1056/NEJMoa0809902; Kastrati A, 2000, CIRCULATION, V102, P2593; Kedhi E, 2010, LANCET, V375, P201, DOI 10.1016/S0140-6736(09)62127-9; Kimura T, 2002, CIRCULATION, V105, P2986, DOI 10.1161/01.CIR.0000019743.11941.3B; Leon MB, 2010, J AM COLL CARDIOL, V55, P543, DOI 10.1016/j.jacc.2009.08.067; Moreno R, 2004, J AM COLL CARDIOL, V43, p58A, DOI 10.1016/S0735-1097(04)90244-6; Park SW, 2000, EUR HEART J, V21, P1785, DOI 10.1053/euhj.1999.1947; Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026; Pfisterer M, 2008, AM HEART J, V155, P609, DOI 10.1016/j.ahj.2007.11.011; Pfisterer M, 2009, EUR HEART J, V30, P16, DOI 10.1093/eurheartj/ehn516; Rao SV, 2006, J AM COLL CARDIOL, V47, P809, DOI 10.1016/j.jacc.2005.09.060; Serruys Patrick W, 2007, EuroIntervention, V2, P405; Steinberg DH, 2007, AM J CARDIOL, V99, P599, DOI 10.1016/j.amjcard.2006.09.105; Stone GW, 2008, JAMA-J AM MED ASSOC, V299, P1903, DOI 10.1001/jama.299.16.1903; Stone GW, 2010, NEW ENGL J MED, V362, P1663, DOI 10.1056/NEJMoa0910496; Tu JV, 2007, NEW ENGL J MED, V357, P1393, DOI 10.1056/NEJMoa071076; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; Wykrzykowska JJ, 2009, JACC-CARDIOVASC INTE, V2, P861, DOI 10.1016/j.jcin.2009.05.024; 2000, EUR HEART J, V21, P1502	32	193	205	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2010	363	24					2310	2319		10.1056/NEJMoa1009406	http://dx.doi.org/10.1056/NEJMoa1009406			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691PA	21080780	Bronze			2022-12-28	WOS:000285092100006
J	Tung, CC; Lobo, PA; Kimlicka, L; Van Petegem, F				Tung, Ching-Chieh; Lobo, Paolo A.; Kimlicka, Lynn; Van Petegem, Filip			The amino-terminal disease hotspot of ryanodine receptors forms a cytoplasmic vestibule	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM-RELEASE CHANNEL; MUTATION HOT-SPOT; S-NITROSYLATION; CA2+ RELEASE; MACROMOLECULAR STRUCTURES; CRYSTAL-STRUCTURE; ATOMIC MODELS; MUSCLE; DOMAIN	Many physiological events require transient increases in cytosolic Ca2+ concentrations. Ryanodine receptors (RyRs) are ion channels that govern the release of Ca2+ from the endoplasmic and sarcoplasmic reticulum(1). Mutations in RyRs can lead to severe genetic conditions that affect both cardiac and skeletal muscle, but locating the mutated residues in the full-length channel structure has been difficult(2,3). Here we show the 2.5 angstrom resolution crystal structure of a region spanning three domains of RyR type 1 (RyR1), encompassing amino acid residues 1-559. The domains interact with each other through a predominantly hydrophilic interface. Docking in RyR1 electron microscopy maps(4,5) unambiguously places the domains in the cytoplasmic portion of the channel, forming a 240-kDa cytoplasmic vestibule around the four-fold symmetry axis. We pinpoint the exact locations of more than 50 disease-associated mutations in full-length RyR1 and RyR2. The mutations can be classified into three groups: those that destabilize the interfaces between the three amino-terminal domains, disturb the folding of individual domains or affect one of six interfaces with other parts of the receptor. We propose a model whereby the opening of a RyR coincides with allosterically coupled motions within the N-terminal domains. This process can be affected by mutations that target various interfaces within and across subunits. The crystal structure provides a framework to understand the many disease-associated mutations in RyRs that have been studied using functional methods, and will be useful for developing new strategies to modulate RyR function in disease states.	[Tung, Ching-Chieh; Lobo, Paolo A.; Kimlicka, Lynn; Van Petegem, Filip] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Van Petegem, F (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada.	filip.vanpetegem@gmail.com	Van Petegem, Filip/M-6061-2016	Van Petegem, Filip/0000-0003-2728-8537	Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of Canada	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada)	We thank the staff at beamline 08ID-1 of the Canadian Light source, the Stanford Synchrotron Radiation Lightsource, K. Beam for the rabbit RyR1 clone, K. Lau for assistance with preparing the figures and the movie file, and C. Ahern, E. Moore and R. Pancaroglu for comments on the manuscript. F.V.P. is funded by the Canadian Institutes of Health Research (CIHR) and the Heart and Stroke Foundation of Canada, and is a CIHR new investigator and a Michael Smith Foundation for Health Research Scholar.	Amador FJ, 2009, P NATL ACAD SCI USA, V106, P11040, DOI 10.1073/pnas.0905186106; Aracena-Parks P, 2006, J BIOL CHEM, V281, P40354, DOI 10.1074/jbc.M600876200; Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Bellinger AM, 2009, NAT MED, V15, P325, DOI 10.1038/nm.1916; Betzenhauser MJ, 2010, PFLUG ARCH EUR J PHY, V460, P467, DOI 10.1007/s00424-010-0794-4; Bhuiyan ZA, 2007, CIRCULATION, V116, P1569, DOI 10.1161/CIRCULATIONAHA.107.711606; Bosanac I, 2005, MOL CELL, V17, P193, DOI 10.1016/j.molcel.2004.11.047; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Chan J, 2007, J MOL BIOL, V373, P1269, DOI 10.1016/j.jmb.2007.08.057; Durham WJ, 2008, CELL, V133, P53, DOI 10.1016/j.cell.2008.02.042; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Garzon JI, 2007, BIOINFORMATICS, V23, P427, DOI 10.1093/bioinformatics/btl625; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Langer G, 2008, NAT PROTOC, V3, P1171, DOI 10.1038/nprot.2008.91; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Lobo PA, 2009, STRUCTURE, V17, P1505, DOI 10.1016/j.str.2009.08.016; Ludtke SJ, 2005, STRUCTURE, V13, P1203, DOI 10.1016/j.str.2005.06.005; MacLennan DH, 2009, J PHYSIOL-LONDON, V587, P3113, DOI 10.1113/jphysiol.2009.172155; Marjamaa A, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-12; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Robinson R, 2006, HUM MUTAT, V27, P977, DOI 10.1002/humu.20356; Samso M, 2005, NAT STRUCT MOL BIOL, V12, P539, DOI 10.1038/nsmb938; Samso M, 2009, PLOS BIOL, V7, P980, DOI 10.1371/journal.pbio.1000085; Serysheva I, 2005, J MOL BIOL, V345, P427, DOI 10.1016/j.jmb.2004.10.073; Serysheva II, 2008, P NATL ACAD SCI USA, V105, P9610, DOI 10.1073/pnas.0803189105; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Volkmann N, 2003, METHOD ENZYMOL, V374, P204, DOI 10.1016/S0076-6879(03)74010-5; Volkmann N, 2009, ACTA CRYSTALLOGR D, V65, P679, DOI 10.1107/S0907444909012876; Wang RW, 2007, J BIOL CHEM, V282, P17785, DOI 10.1074/jbc.M700660200; Wriggers W, 2001, STRUCTURE, V9, P779, DOI 10.1016/S0969-2126(01)00648-7; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	37	155	157	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	2010	468	7323					585	U267		10.1038/nature09471	http://dx.doi.org/10.1038/nature09471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	684WA	21048710				2022-12-28	WOS:000284584200047
J	Ruidavets, JB; Ducimetiere, P; Evans, A; Montaye, M; Haas, B; Bingham, A; Yarnell, J; Amouyel, P; Arveiler, D; Kee, F; Bongard, V; Ferrieres, J				Ruidavets, Jean-Bernard; Ducimetiere, Pierre; Evans, Alun; Montaye, Michele; Haas, Bernadette; Bingham, Annie; Yarnell, John; Amouyel, Philippe; Arveiler, Dominique; Kee, Frank; Bongard, Vanina; Ferrieres, Jean			Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALL-CAUSE MORTALITY; NORTHERN-IRELAND; CARDIOVASCULAR-DISEASE; DRINKING PATTERN; ANGINA-PECTORIS; HEAVY DRINKING; AVERAGE VOLUME; CORONARY-EVENT; BINGE DRINKING; RISK-FACTORS	Objective To investigate the effect of alcohol intake patterns on ischaemic heart disease in two countries with contrasting lifestyles, Northern Ireland and France. Design Cohort data from the Prospective Epidemiological Study of Myocardial Infarction (PRIME) were analysed. Weekly alcohol consumption, incidence of binge drinking (alcohol >50 g on at least one day a week), incidence of regular drinking (at least one day a week, and alcohol <50 g if on only one occasion), volume of alcohol intake, frequency of consumption, and types of beverage consumed were assessed once at inclusion. All coronary events that occurred during the 10 year follow-up were prospectively registered. The relation between baseline characteristics and incidence of hard coronary events and angina events was assessed by Cox's proportional hazards regression analysis. Setting One centre in Northern Ireland (Belfast) and three centres in France (Lille, Strasbourg, and Toulouse). Participants 9778 men aged 50-59 free of ischaemic heart disease at baseline, who were recruited between 1991 and 1994. Main outcome measures Incident myocardial infarction and coronary death ("hard" coronary events), and incident angina pectoris. Results A total of 2405 men from Belfast and 7373 men from the French centres were included in the analyses, 1456 (60.5%) and 6679 (90.6%) of whom reported drinking alcohol at least once a week, respectively. Among drinkers, 12% (173/1456) of men in Belfast drank alcohol every day compared with 75% (5008/6679) of men in France. Mean alcohol consumption was 22.1 g/day in Belfast and 32.8 g/day in France. Binge drinkers comprised 9.4% (227/2405) and 0.5% (33/7373) of the Belfast and France samples, respectively. A total of 683 (7.0%) of the 9778 participants experienced ischaemic heart disease events during the 10 year follow-up: 322 (3.3%) hard coronary events and 361 (3.7%) angina events. Annual incidence of hard coronary events per 1000 person years was 5.63 (95% confidence interval 4.69 to 6.69) in Belfast and 2.78 (95% CI 2.41 to 3.20) in France. After multivariate adjustment for classic cardiovascular risk factors and centre, the hazard ratio for hard coronary events compared with regular drinkers was 1.97 (95% CI 1.21 to 3.22) for binge drinkers, 2.03 (95% CI 1.41 to 2.94) for never drinkers, and 1.57 (95% CI 1.11 to 2.21) for former drinkers for the entire cohort. The hazard ratio for hard coronary events in Belfast compared with in France was 1.76 (95% CI 1.37 to 2.67) before adjustment, and 1.09 (95% CI 0.79 to 1.50) after adjustment for alcohol patterns and wine drinking. Only wine drinking was associated with a lower risk of hard coronary events, irrespective of the country. Conclusions Regular and moderate alcohol intake throughout the week, the typical pattern in middle aged men in France, is associated with a low risk of ischaemic heart disease, whereas the binge drinking pattern more prevalent in Belfast confers a higher risk.	[Ruidavets, Jean-Bernard; Bongard, Vanina] Toulouse Univ, Sch Med, INSERM, Dept Epidemiol,U558, Toulouse, France; [Ducimetiere, Pierre] Univ Paris 11, INSERM, Villejuif, France; [Evans, Alun; Yarnell, John; Kee, Frank] Queens Univ Belfast, UK Clin Res Collaborat Ctr Excellence Publ Hlth, Belfast, Antrim, North Ireland; [Montaye, Michele; Amouyel, Philippe] Inst Pasteur, INSERM, Dept Epidemiol & Publ Hlth, U744, F-59019 Lille, France; [Haas, Bernadette; Arveiler, Dominique] Univ Strasbourg, Fac Med, Dept Epidemiol & Publ Hlth, EA 3430, Strasbourg, France; [Bingham, Annie] Hop Paul Brousse, INSERM, U970, Villejuif, France; [Ferrieres, Jean] Toulouse Univ Hosp, INSERM, U558, Dept Cardiol B, Toulouse, France; [Ferrieres, Jean] Toulouse Univ Hosp, INSERM, U558, Dept Epidemiol, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Queens University Belfast; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ruidavets, JB (corresponding author), Toulouse Univ, Sch Med, INSERM, Dept Epidemiol,U558, Toulouse, France.	jean-bernard.ruidavets@cict.fr	; Ferrieres, Jean/S-7993-2016	Bongard, Vanina/0000-0001-5789-0815; Ferrieres, Jean/0000-0001-6144-1297; Amouyel, Philippe/0000-0001-9088-234X	Institut National de la Sante et de la Recherche Medicale (INSERM); Merck, Sharp & Dohme-Chibret Laboratory; British Heart Foundation [PG/09/002/26056] Funding Source: researchfish; Economic and Social Research Council [ES/G007438/1] Funding Source: researchfish; ESRC [ES/G007438/1] Funding Source: UKRI	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Merck, Sharp & Dohme-Chibret Laboratory(Merck & Company); British Heart Foundation(British Heart Foundation); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	PRIME was supported by grants from the Institut National de la Sante et de la Recherche Medicale (INSERM) and the Merck, Sharp & Dohme-Chibret Laboratory.	Anderson P, 2008, BINGE DRINKING EUROP; Britton A, 2000, J EPIDEMIOL COMMUN H, V54, P328, DOI 10.1136/jech.54.5.328; Camargo CA, 1997, ANN INTERN MED, V126, P372, DOI 10.7326/0003-4819-126-5-199703010-00005; Centers for Disease Control and Prevention (CDC), 2009, ALC REL DIS IMP ARDI; CLARK LT, 1992, AM HEART J, V123, P1106, DOI 10.1016/0002-8703(92)91068-C; Di Castelnuovo A, 2002, CIRCULATION, V105, P2836, DOI 10.1161/01.CIR.0000018653.19696.01; Ducimetiere P, 2001, INT J EPIDEMIOL, V30, P1057, DOI 10.1093/ije/30.5.1057; EVANS AE, 1995, QJM-INT J MED, V88, P469; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; Fillmore KM, 2007, ANN EPIDEMIOL, V17, pS16, DOI 10.1016/j.annepidem.2007.01.005; Fuchs FD, 2004, AM J EPIDEMIOL, V160, P466, DOI 10.1093/aje/kwh229; Gronbaek M, 2003, J CARDIOVASC RISK, V10, P5, DOI 10.1097/00043798-200302000-00002; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Karlamangla A, 2006, ADDICTION, V101, P91, DOI 10.1111/j.1360-0443.2005.01299.x; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Kerr WC, 2009, ADDICTION, V104, P27, DOI 10.1111/j.1360-0443.2008.02391.x; Kitamura A, 1998, AM J EPIDEMIOL, V147, P59; Klatsky AL, 2003, AM J EPIDEMIOL, V158, P585, DOI 10.1093/aje/kwg184; Kuntsche E, 2004, SOC SCI MED, V59, P113, DOI 10.1016/j.socscimed.2003.10.009; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; Malyutina S, 2002, LANCET, V360, P1448, DOI 10.1016/S0140-6736(02)11470-X; Marmot MG, 1996, BRIT MED J, V313, P1177, DOI 10.1136/bmj.313.7066.1177; Marques-Vidal P, 2001, HYPERTENSION, V38, P1361, DOI 10.1161/hy1101.095328; Marques-Vidal P, 2000, EUR J CLIN NUTR, V54, P321, DOI 10.1038/sj.ejcn.1600954; McElduff P, 1997, BRIT MED J, V314, P1159, DOI 10.1136/bmj.314.7088.1159; Mukamal KJ, 2005, CIRCULATION, V112, P3839, DOI 10.1161/CIRCULATIONAHA.105.574749; Mukamal KJ, 2005, CIRCULATION, V112, P1406, DOI 10.1161/CIRCULATIONAHA.105.537704; Mukamal KJ, 2003, NEW ENGL J MED, V348, P109, DOI 10.1056/NEJMoa022095; Murray RP, 2002, AM J EPIDEMIOL, V155, P242, DOI 10.1093/aje/155.3.242; Numminen H, 2000, STROKE, V31, P1269, DOI 10.1161/01.STR.31.6.1269; O'Keefe JH, 2007, J AM COLL CARDIOL, V50, P1009, DOI 10.1016/j.jacc.2007.04.089; Poikolainen K, 1999, AM J EPIDEMIOL, V150, P47, DOI 10.1093/oxfordjournals.aje.a009917; Rehm J, 2003, EUR ADDICT RES, V9, P147, DOI 10.1159/000072221; Rehm J, 2001, AM J EPIDEMIOL, V153, P64, DOI 10.1093/aje/153.1.64; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; Rimm EB, 1996, AM J EPIDEMIOL, V143, P1094; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Rose G, 1982, CARDIOVASCULAR SURVE; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Ruidavets JB, 2004, EUR HEART J, V25, P1153, DOI 10.1016/j.ehj.2003.12.022; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; Wannamethee SG, 1999, AM J PUBLIC HEALTH, V89, P685, DOI 10.2105/AJPH.89.5.685; WHO, WHO GLOB INF CARD DI; World Health Organization Department of Mental Health and Substance Abuse, GLOB STAT REP ALC 20; Yarnell JWG, 1998, QJM-INT J MED, V91, P667, DOI 10.1093/qjmed/91.10.667	47	88	91	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 23	2010	341								c6077	10.1136/bmj.c6077	http://dx.doi.org/10.1136/bmj.c6077			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	688DV	21098615	hybrid, Green Published			2022-12-28	WOS:000284830900026
J	Kelleher, RJ; Shen, J				Kelleher, Raymond J., III; Shen, Jie			gamma-Secretase and Human Disease	SCIENCE			English	Editorial Material							ALZHEIMERS-DISEASE; TUMOR-SUPPRESSOR; PRESENILIN-1; HYPOTHESIS; MUTATIONS; RELEASE; MOUSE; SKIN		[Kelleher, Raymond J., III] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Kelleher, Raymond J., III; Shen, Jie] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Shen, Jie] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kelleher, RJ (corresponding author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.	kelleher@helix.mgh.harvard.edu	Shen, Jie/GXH-9449-2022		NIA NIH HHS [RC2 AG036614] Funding Source: Medline; NINDS NIH HHS [R01 NS041783, R01 NS075346, R01 NS042818, RF1 NS041783] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075346, R01NS042818, R01NS041783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [RC2AG036614] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Danby FW, 2010, DERMATOL CLIN, V28, P779, DOI 10.1016/j.det.2010.07.003; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heilig EA, 2010, J BIOL CHEM, V285, P22350, DOI 10.1074/jbc.M110.116962; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Li T, 2007, J BIOL CHEM, V282, P32264, DOI 10.1074/jbc.M703649200; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shen J, 2007, P NATL ACAD SCI USA, V104, P403, DOI 10.1073/pnas.0608332104; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Wang BX, 2010, SCIENCE, V330, P1065, DOI 10.1126/science.1196284; Wolfe MS, 2007, EMBO REP, V8, P136, DOI 10.1038/sj.embor.7400896; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Zhang C, 2009, NATURE, V460, P632, DOI 10.1038/nature08177	13	45	45	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1055	1056		10.1126/science.1198668	http://dx.doi.org/10.1126/science.1198668			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097925	Green Accepted			2022-12-28	WOS:000284374700027
J	Ensrud, KE				Ensrud, Kristine E.			Review: Calcium supplements increase risk for myocardial infarction but not mortality or stroke in adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							VITAMIN-D SUPPLEMENTATION; FRACTURES		Univ Minnesota, Minneapolis VA Med Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Ensrud, KE (corresponding author), Univ Minnesota, Minneapolis VA Med Ctr, Minneapolis, MN 55455 USA.			Ensrud, Kristine/0000-0002-9069-3036				[Anonymous], 2010, CLIN GUID PREV TREAT; Chung M, 2009, VITAMIN D CALCIUM SY; Cranney A., 2007, EFFECTIVENESS SAFETY; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Tang BMP, 2007, LANCET, V370, P657, DOI 10.1016/S0140-6736(07)61342-7	5	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-7	10.1059/0003-4819-153-10-201011160-02007	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079214				2022-12-28	WOS:000284215800006
J	Groves, T				Groves, Trish			Is open peer review the fairest system? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							TRIAL		[Groves, Trish] BMJ, London WC1H 9JR, England		Groves, T (corresponding author), BMJ, London WC1H 9JR, England.	tgroves@bmj.com	Groves, Trish/A-9119-2009	Groves, Trish/0000-0001-7915-6419				*BIOMED CENTR, BMC SER J PEER REV P; BMJ, GUID PEER REV; GODLEE F, 2010, BRIT MED J, V341, pC6481; Smith R, 1999, BRIT MED J, V318, P4; van Rooyen S, 1999, BRIT MED J, V318, P23; van Rooyen S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5729; Walsh E, 2000, BRIT J PSYCHIAT, V176, P47, DOI 10.1192/bjp.176.1.47; NATURES PEER REV DEB	8	32	34	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 16	2010	341								c6424	10.1136/bmj.c6424	http://dx.doi.org/10.1136/bmj.c6424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684WJ	21081602				2022-12-28	WOS:000284585600020
J	Nave, KA				Nave, Klaus-Armin			Myelination and support of axonal integrity by glia	NATURE			English	Review							PELIZAEUS-MERZBACHER-DISEASE; PROTEOLIPID PROTEIN GENE; CENTRAL-NERVOUS-SYSTEM; OLIGODENDROCYTE PRECURSOR CELLS; VANISHING WHITE-MATTER; SCHWANN-CELLS; MULTIPLE-SCLEROSIS; MOUSE MODEL; ACTION-POTENTIALS; TRANSGENIC MICE	The myelination of axons by glial cells was the last major step in the evolution of cells in the vertebrate nervous system, and white-matter tracts are key to the architecture of the mammalian brain. Cell biology and mouse genetics have provided insight into axon-glia signalling and the molecular architecture of the myelin sheath. Glial cells that myelinate axons were found to have a dual role by also supporting the long-term integrity of those axons. This function may be independent of myelin itself. Myelin abnormalities cause a number of neurological diseases, and may also contribute to complex neuropsychiatric disorders.	Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany	Max Planck Society	Nave, KA (corresponding author), Max Planck Inst Expt Med, Dept Neurogenet, Hermann Rein Str 3, D-37075 Gottingen, Germany.	nave@em.mpg.de	Nave, Klaus-Armin/C-8883-2011		German Research Foundation (Center for Molecular Physiology of the Brain in Gottingen) [SFB/TR43]; European Leukodystrophy Association; Myelin Project; German Federal Ministry of Education and Research (Leukonet); European Union	German Research Foundation (Center for Molecular Physiology of the Brain in Gottingen)(German Research Foundation (DFG)); European Leukodystrophy Association; Myelin Project; German Federal Ministry of Education and Research (Leukonet)(Federal Ministry of Education & Research (BMBF)); European Union(European Commission)	I apologize to all colleagues whose important work could not be cited owing to space limitations. I thank S. Goebbels and H. Werner for help with figures, and J. Edgar and D. Dietrich for providing images. I also thank all members of my group as well as D. Attwell, P. Casaccia, J. Edgar, I. Griffiths, O. Peles, J. Salzer, S. Scherer, P. Stys and B. Trapp for discussions. Work in my laboratory is supported by the German Research Foundation (Center for Molecular Physiology of the Brain in Gottingen, SFB/TR43), the European Leukodystrophy Association, the Myelin Project, the German Federal Ministry of Education and Research (Leukonet) and the European Union (Sixth Framework Programme, Neuropromise; Seventh Framework Programme, Ngidd, Leukotreat).	Anderson TJ, 1998, J COMP NEUROL, V394, P506, DOI 10.1002/(SICI)1096-9861(19980518)394:4<506::AID-CNE8>3.0.CO;2-5; Baes M, 2009, NEUROSCIENTIST, V15, P367, DOI 10.1177/1073858409336297; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Bergles DE, 2010, BRAIN RES REV, V63, P130, DOI 10.1016/j.brainresrev.2009.12.003; Brady ST, 1999, J NEUROSCI, V19, P7278, DOI 10.1523/JNEUROSCI.19-17-07278.1999; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Brinkmann BG, 2008, NEURON, V59, P581, DOI 10.1016/j.neuron.2008.06.028; Budel S, 2008, J NEUROSCI, V28, P13161, DOI 10.1523/JNEUROSCI.3828-08.2008; BULLOCK TH, 1984, NEUROSCI LETT, V48, P145, DOI 10.1016/0304-3940(84)90010-7; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Chan JR, 2004, NEURON, V43, P183, DOI 10.1016/j.neuron.2004.06.024; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Chen SZ, 2003, NAT NEUROSCI, V6, P1186, DOI 10.1038/nn1139; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Cotter L, 2010, SCIENCE, V328, P1415, DOI 10.1126/science.1187735; Dan Y, 2004, NEURON, V44, P23, DOI 10.1016/j.neuron.2004.09.007; De Jonghe P, 1999, BRAIN, V122, P281, DOI 10.1093/brain/122.2.281; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; Dietrich J, 2005, NAT MED, V11, P277, DOI 10.1038/nm1195; Edgar JM, 2004, J CELL BIOL, V166, P121, DOI 10.1083/jcb.200312012; Edgar JM, 2010, EMBO MOL MED, V2, P42, DOI 10.1002/emmm.200900057; Edgar JM, 2009, GLIA, V57, P1815, DOI 10.1002/glia.20893; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; Flores AI, 2008, J NEUROSCI, V28, P7174, DOI 10.1523/JNEUROSCI.0150-08.2008; Garbern JY, 2007, CELL MOL LIFE SCI, V64, P50, DOI 10.1007/s00018-006-6182-8; GEREN BB, 1953, P NATL ACAD SCI USA, V39, P880, DOI 10.1073/pnas.39.8.880; Goebbels S, 2010, J NEUROSCI, V30, P8953, DOI 10.1523/JNEUROSCI.0219-10.2010; Gravel M, 2009, J NEUROSCI RES, V87, P1069, DOI 10.1002/jnr.21939; Gregoriou GG, 2009, PROG BRAIN RES, V176, P35, DOI 10.1016/S0079-6123(09)17603-3; Griffin JW, 2008, GLIA, V56, P1518, DOI 10.1002/glia.20778; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Griffiths I, 1998, MICROSC RES TECHNIQ, V41, P344, DOI 10.1002/(SICI)1097-0029(19980601)41:5<344::AID-JEMT2>3.0.CO;2-Q; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hartline DK, 2008, NEURON GLIA BIOL, V4, P153, DOI 10.1017/S1740925X09990263; Henneke M, 2008, NEUROLOGY, V70, P748, DOI 10.1212/01.wnl.0000284828.84464.35; Ip CW, 2006, J NEUROSCI, V26, P8206, DOI 10.1523/JNEUROSCI.1921-06.2006; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; Jahn O, 2009, MOL NEUROBIOL, V40, P55, DOI 10.1007/s12035-009-8071-2; Jessen KR, 2005, NAT REV NEUROSCI, V6, P671, DOI 10.1038/nrn1746; Johnson AB, 2003, J CHILD NEUROL, V18, P625, DOI 10.1177/08830738030180090901; KAGAWA T, 1994, NEURON, V13, P427, DOI 10.1016/0896-6273(94)90358-1; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Karadottir R, 2008, NAT NEUROSCI, V11, P450, DOI 10.1038/nn2060; Kassmann CM, 2007, NAT GENET, V39, P969, DOI 10.1038/ng2070; Keswani SC, 2004, ANN NEUROL, V56, P815, DOI 10.1002/ana.20285; Klugmann M, 1997, NEURON, V18, P59, DOI 10.1016/S0896-6273(01)80046-5; Kroner A, 2010, AM J PATHOL, V176, P549, DOI 10.2353/ajpath.2010.090722; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Kukley M, 2010, J NEUROSCI, V30, P8320, DOI 10.1523/JNEUROSCI.0854-10.2010; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lee J, 2005, J CELL BIOL, V170, P661, DOI 10.1083/jcb.200411047; Li WB, 2007, J NEUROSCI, V27, P2606, DOI 10.1523/JNEUROSCI.4181-06.2007; Maglione M, 2010, GLIA, V58, P1104, DOI 10.1002/glia.20991; Mayatepek E, 2003, J NEUROL, V250, P1259, DOI 10.1007/s00415-003-0189-y; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; Micu I, 2006, NATURE, V439, P988, DOI 10.1038/nature04474; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; Nave KA, 2007, NAT CLIN PRACT NEURO, V3, P453, DOI 10.1038/ncpneuro0583; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Navel KA, 2006, CURR OPIN NEUROBIOL, V16, P492, DOI 10.1016/j.conb.2006.08.008; Nguyen T, 2009, J NEUROSCI, V29, P630, DOI 10.1523/JNEUROSCI.5204-08.2009; Pertusa M, 2007, J BIOL CHEM, V282, P28768, DOI 10.1074/jbc.M701878200; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; READHEAD C, 1994, NEURON, V12, P583, DOI 10.1016/0896-6273(94)90214-3; Richardson WD, 2006, NAT REV NEUROSCI, V7, P11, DOI 10.1038/nrn1826; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Rosenberg SS, 2008, P NATL ACAD SCI USA, V105, P14662, DOI 10.1073/pnas.0805640105; Rosenbluth J, 2006, GLIA, V54, P172, DOI 10.1002/glia.20370; Rudick RA, 2009, NEW ENGL J MED, V361, P1505, DOI 10.1056/NEJMcibr0905482; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Salzer JL, 2008, GLIA, V56, P1532, DOI 10.1002/glia.20750; Sanchez I, 2000, J CELL BIOL, V151, P1013, DOI 10.1083/jcb.151.5.1013; Sanchez I, 1996, J NEUROSCI, V16, P5095; Sherman DL, 2005, NAT REV NEUROSCI, V6, P683, DOI 10.1038/nrn1743; Simon CM, 2010, HUM MOL GENET, V19, P973, DOI 10.1093/hmg/ddp562; Simons M, 2002, J CELL BIOL, V157, P327, DOI 10.1083/jcb.200110138; Simons M, 2007, CURR OPIN NEUROBIOL, V17, P533, DOI 10.1016/j.conb.2007.08.003; Southwood CM, 2007, NEUROCHEM RES, V32, P187, DOI 10.1007/s11064-006-9127-6; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; Suter U, 2003, NAT REV NEUROSCI, V4, P714, DOI 10.1038/nrn1196; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; Taveggia C, 2010, NAT REV NEUROL, V6, P276, DOI 10.1038/nrneurol.2010.37; Toonen RFG, 2006, P NATL ACAD SCI USA, V103, P18332, DOI 10.1073/pnas.0608507103; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Trapp BD, 2009, LANCET NEUROL, V8, P280, DOI 10.1016/S1474-4422(09)70043-2; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Uhlenberg B, 2004, AM J HUM GENET, V75, P251, DOI 10.1086/422763; van der Knaap MS, 2002, ANN NEUROL, V51, P264, DOI 10.1002/ana.10112; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; Werner HB, 2007, J NEUROSCI, V27, P7717, DOI 10.1523/JNEUROSCI.1254-07.2007; Woodward Karen J., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000677; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Zalc B, 2008, CURR BIOL, V18, pR511, DOI 10.1016/j.cub.2008.04.010; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	99	654	668	5	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					244	252		10.1038/nature09614	http://dx.doi.org/10.1038/nature09614			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068833				2022-12-28	WOS:000284051000041
J	Ransohoff, RM; Cardona, AE				Ransohoff, Richard M.; Cardona, Astrid E.			The myeloid cells of the central nervous system parenchyma	NATURE			English	Review							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NASU-HAKOLA-DISEASE; MICROGLIAL CELLS; IN-VIVO; MULTIPLE-SCLEROSIS; CNS INFLAMMATION; SPINAL-CORD; FRACTALKINE RECEPTOR; NEURONAL EXPRESSION; ALZHEIMERS-DISEASE	A microglial cell is both a glial cell of the central nervous system and a mononuclear phagocyte, which belongs to the haematopoietic system and is involved in inflammatory and immune responses. As such, microglia face a challenging task. The neurons of the central nervous system cannot divide and be replenished, and therefore need to be protected against pathogens, which is a key role of the immune system, but without collateral damage. In addition, after physical injury, neural cells need restorative support, which is provided by inflammatory responses. Excessive or chronic inflammatory responses can, however, be harmful. How microglia balance these demands, and how their behaviour can be modified to ameliorate disorders of the central nervous system, is becoming clear.	[Ransohoff, Richard M.] Cleveland Clin, Lerner Res Inst, Dept Neurosci, Neuroinflammat Res Ctr, Cleveland, OH 44195 USA; [Ransohoff, Richard M.] Cleveland Clin, Mellen Ctr MS Treatment & Res, Neurol Inst, Cleveland, OH 44195 USA; [Cardona, Astrid E.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA; [Cardona, Astrid E.] Univ Texas San Antonio, S Texas Ctr Emerging Infect Dis, MBT 1 216, San Antonio, TX 78249 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Texas System; University of Texas at San Antonio (UTSA); University of Texas System; University of Texas at San Antonio (UTSA)	Ransohoff, RM (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Neurosci, Neuroinflammat Res Ctr, Mail Code NC30,9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org	Cardona, Astrid E/K-4749-2013	Cardona, Astrid E/0000-0002-5093-8078	US National Institutes of Health/National Institute of Neurological Diseases and Stroke; US National MS Society; Williams Family Foundation for MS Research	US National Institutes of Health/National Institute of Neurological Diseases and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); US National MS Society(National Multiple Sclerosis Society); Williams Family Foundation for MS Research	Work in our laboratories was supported by research grants from the US National Institutes of Health/National Institute of Neurological Diseases and Stroke (to R.M.R.), by research grants and fellowships from the US National MS Society (to R.M.R. and A.E.C.) and by the Williams Family Foundation for MS Research (to R.M.R.).	Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Aloisi F, 2000, J IMMUNOL, V164, P1705, DOI 10.4049/jimmunol.164.4.1705; ASHWELL K, 1990, DEV BRAIN RES, V55, P219, DOI 10.1016/0165-3806(90)90203-B; ASHWELL K, 1991, DEV BRAIN RES, V58, P1, DOI 10.1016/0165-3806(91)90231-7; Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557; Bailey SL, 2006, CRIT REV IMMUNOL, V26, P149, DOI 10.1615/CritRevImmunol.v26.i2.40; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Becher B, 2006, J MOL MED, V84, P532, DOI 10.1007/s00109-006-0065-1; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Bianchin MM, 2004, CELL MOL NEUROBIOL, V24, P1, DOI 10.1023/B:CEMN.0000012721.08168.ee; Caldero J, 2009, J NEUROSCI RES, V87, P2447, DOI 10.1002/jnr.22084; CARDONA A, 2009, UCSD NATURE MOL PAGE, DOI DOI 10.1038/MP.A000633.01; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chan WY, 2007, BRAIN RES REV, V53, P344, DOI 10.1016/j.brainresrev.2006.11.002; Chang TT, 2003, EUR J IMMUNOL, V33, P2022, DOI 10.1002/eji.200323180; Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055; Chitnis T, 2007, AM J PATHOL, V170, P1695, DOI 10.2353/ajpath.2007.060677; Chouery E, 2008, HUM MUTAT, V29, pE194, DOI 10.1002/humu.20836; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davalos D, 2008, J NEUROSCI METH, V169, P1, DOI 10.1016/j.jneumeth.2007.11.011; DEGROOT CJA, 1992, GLIA, V6, P301, DOI 10.1002/glia.440060408; del Rio Hortega P, 1932, CYTOLOGY CELLULAR PA, P481; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Farber K, 2006, PFLUG ARCH EUR J PHY, V452, P615, DOI 10.1007/s00424-006-0064-7; Farber K, 2005, BRAIN RES REV, V48, P133, DOI 10.1016/j.brainresrev.2004.12.003; Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003; Fedoroff S, 1997, J NEUROSCI RES, V50, P477; Fedoroff S, 1991, Adv Exp Med Biol, V296, P135; Flugel A, 2001, J NEUROSCI RES, V66, P74, DOI 10.1002/jnr.1198; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frohman EM, 2007, ARCH NEUROL-CHICAGO, V64, P903, DOI 10.1001/archneur.64.6.903; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Gahmberg CG, 2008, IMMUNOL LETT, V117, P131, DOI 10.1016/j.imlet.2008.02.004; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Geissmann F, 2010, NAT REV IMMUNOL, V10, P453, DOI 10.1038/nri2784; Gill AS, 2007, NEUROSURGERY, V60, P940, DOI 10.1227/01.NEU.0000255448.97730.34; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; GOLGI C, 1989, J MICROSC-OXFORD, V155, P3, DOI 10.1111/j.1365-2818.1989.tb04294.x; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Huang D, 2006, FASEB J, V20, P896, DOI 10.1096/fj.05-5465com; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Hyman SE, 2010, CELL, V141, P752, DOI 10.1016/j.cell.2010.05.010; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Junker A, 2009, BRAIN, V132, P3342, DOI 10.1093/brain/awp300; Kaufmann MH, 1992, ATLAS MOUSE DEV; Kawakami N, 2004, J EXP MED, V199, P185, DOI 10.1084/jem.20031064; Kim JV, 2010, J IMMUNOL METHODS, V352, P89, DOI 10.1016/j.jim.2009.09.007; Kivisakk P, 2009, ANN NEUROL, V65, P457, DOI 10.1002/ana.21379; Klunemann HH, 2005, NEUROLOGY, V64, P1502, DOI 10.1212/01.WNL.0000160304.00003.CA; Lopez-Munoz F, 2006, BRAIN RES BULL, V70, P391, DOI 10.1016/j.brainresbull.2006.07.010; Man SM, 2007, BRAIN PATHOL, V17, P243, DOI 10.1111/j.1750-3639.2007.00067.x; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mazzarello P, 2006, J HIST NEUROSCI, V15, P318, DOI 10.1080/09647040600653964; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McMahon EJ, 2006, NEUROCHEM INT, V49, P195, DOI 10.1016/j.neuint.2006.04.004; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Mirrione MM, 2010, NEUROBIOL DIS, V39, P85, DOI 10.1016/j.nbd.2010.04.001; Mott RT, 2004, GLIA, V46, P369, DOI 10.1002/glia.20009; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; Nakamura Y, 2002, BIOL PHARM BULL, V25, P945, DOI 10.1248/bpb.25.945; Neumann H, 1998, J NEUROPATH EXP NEUR, V57, P1, DOI 10.1097/00005072-199801000-00001; Neumann H, 2007, J NEUROIMMUNOL, V184, P92, DOI 10.1016/j.jneuroim.2006.11.032; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nissl F., 1899, ARCH PSYCHIAT NERVEN, V32, P1; Orr AG, 2009, NAT NEUROSCI, V12, P872, DOI 10.1038/nn.2341; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Piccio L, 2007, EUR J IMMUNOL, V37, P1290, DOI 10.1002/eji.200636837; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Qian L, 2008, J IMMUNOL, V181, P660, DOI 10.4049/jimmunol.181.1.660; Ransohoff RM, 2007, NAT NEUROSCI, V10, P1507, DOI 10.1038/nn1207-1507; Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Re DB, 2006, NAT NEUROSCI, V9, P859; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Ryu JK, 2009, J THROMB HAEMOST, V7, P151, DOI 10.1111/j.1538-7836.2009.03438.x; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schmid CD, 2009, J NEUROCHEM, V109, P117, DOI 10.1111/j.1471-4159.2009.05984.x; Shpargel Karl B, 2008, Cleve Clin J Med, V75 Suppl 2, pS77; SMINIA T, 1987, IMMUNOBIOLOGY, V174, P43, DOI 10.1016/S0171-2985(87)80083-9; Stefano L, 2009, J NEUROCHEM, V110, P284, DOI 10.1111/j.1471-4159.2009.06130.x; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Streit WJ, 2001, NEUROTOXICOLOGY, V22, P619, DOI 10.1016/S0161-813X(01)00033-X; Takahashi K, 2005, J EXP MED, V201, P647, DOI 10.1084/jem.20041611; Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385; Tanaka J, 2000, NEUROPATHOLOGY, V20, pS25; Vitkovic L, 2001, NEUROIMMUNOMODULAT, V9, P295, DOI 10.1159/000059387; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wakselman S, 2008, J NEUROSCI, V28, P8138, DOI 10.1523/JNEUROSCI.1006-08.2008; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Yong VW, 2009, NEURON, V64, P55, DOI 10.1016/j.neuron.2009.09.035; Zhu B, 2007, J IMMUNOL, V179, P5228, DOI 10.4049/jimmunol.179.8.5228; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	107	570	588	4	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					253	262		10.1038/nature09615	http://dx.doi.org/10.1038/nature09615			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068834				2022-12-28	WOS:000284051000042
J	Hutchon, DJR				Hutchon, David J. R.			Personal View Why do obstetricians and midwives still rush to clamp the cord?	BRITISH MEDICAL JOURNAL			English	Editorial Material												djrhutchon@hotmail.co.uk							0	21	22	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 10	2010	341								c5447	10.1136/bmj.c5447	http://dx.doi.org/10.1136/bmj.c5447			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KO	21068109				2022-12-28	WOS:000284312700017
J	Stang, PE; Ryan, PB; Racoosin, JA; Overhage, JM; Hartzema, AG; Reich, C; Welebob, E; Scarnecchia, T; Woodcock, J				Stang, Paul E.; Ryan, Patrick B.; Racoosin, Judith A.; Overhage, J. Marc; Hartzema, Abraham G.; Reich, Christian; Welebob, Emily; Scarnecchia, Thomas; Woodcock, Janet			Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership	ANNALS OF INTERNAL MEDICINE			English	Article							SAFETY; CARE; ALGORITHMS; EVENTS	The U.S. Food and Drug Administration (FDA) Amendments Act of 2007 mandated that the FDA develop a system for using automated health care data to identify risks of marketed drugs and other medical products. The Observational Medical Outcomes Partnership is a public-private partnership among the FDA, academia, data owners, and the pharmaceutical industry that is responding to the need to advance the science of active medical product safety surveillance by using existing observational databases. The Observational Medical Outcomes Partnership's transparent, open innovation approach is designed to systematically and empirically study critical governance, data resource, and methodological issues and their interrelationships in establishing a viable national program of active drug safety surveillance by using observational data. This article describes the governance structure, data-access model, methods-testing approach, and technology development of this effort, as well as the work that has been initiated.	[Stang, Paul E.] Johnson & Johnson, Pharmaceut Res & Dev, Titusville, NJ 08560 USA; Fdn Natl Inst Hlth, Bethesda, MD USA; GlaxoSmithKline, Res Triangle Pk, NC USA; Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC USA; US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Indianapolis, IN USA; Univ Florida, Coll Pharm, Gainesville, FL USA; Digital Aurora, Manchester, VT USA	Johnson & Johnson; Johnson & Johnson USA; National Institutes of Health (NIH) - USA; GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill; US Food & Drug Administration (FDA); Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; State University System of Florida; University of Florida	Stang, PE (corresponding author), Johnson & Johnson, Pharmaceut Res & Dev, 1125 Trenton Harbourton Rd,POB 200,MS K304, Titusville, NJ 08560 USA.	PStang@its.jnj.com	Ryan, Patrick/HDO-1133-2022	Overhage, Joseph/0000-0003-0223-0195	Foundation for the National Institutes of Health	Foundation for the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The OMOP is funded by the Foundation for the National Institutes of Health, with contributions from a consortium of 17 organizations (Appendix Table, available at www.annals.org). Three members of the research team (Dr. Stang, Mr. Ryan, and Dr. Racoosin) serve in-kind and are not compensated for their participation.	Adamson D, 2008, HLTH RES DATA REAL W; Almenoff JS, 2003, PHARMACOEPIDEM DR S, V12, P517, DOI 10.1002/pds.885; Bennett CL, 2007, ARCH INTERN MED, V167, P1041, DOI 10.1001/archinte.167.10.1041; Berlowitz DR, 2006, PHARMACOEPIDEM DR S, V15, P799, DOI 10.1002/pds.1301; BRESLOW NE, 1993, STAT METHODS CANC RE, V1; Brown JS, 2007, PHARMACOEPIDEM DR S, V16, P1275, DOI 10.1002/pds.1509; Brownstein JS, 2010, DIABETES CARE, V33, P526, DOI 10.2337/dc09-1506; Burnside ES, 2009, RADIOLOGY, V251, P663, DOI 10.1148/radiol.2513081346; Curtis JR, 2008, MED CARE, V46, P969, DOI 10.1097/MLR.0b013e318179253b; Davis J, 2005, 19TH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE (IJCAI-05), P677; Faries D, 2010, ANAL OBSERVATIONAL H; Genkin A, 2007, TECHNOMETRICS, V49, P291, DOI 10.1198/004017007000000245; Gill JM, 2008, INT J PSYCHIAT MED, V38, P203, DOI 10.2190/PM.38.2.g; Gould AL, 2007, BIOMETRICAL J, V49, P151, DOI 10.1002/bimj.200610296; Hauben Manfred, 2005, Expert Opin Drug Saf, V4, P929, DOI 10.1517/14740338.4.5.929; Hochberg AM, 2009, DRUG SAFETY, V32, P509, DOI 10.2165/00002018-200932060-00007; Holbrook Anne, 2005, AMIA Annu Symp Proc, P335; Institute of Medicine, 2006, FUT DRUG SAF PROM PR; Janzen W. P, 2002, HIGH THROUGHPUT SCRE; KULLDORFF M, 2007, MAXIMIZED SEQUENTIAL; Li LL, 2009, STAT MED, V28, P3124, DOI 10.1002/sim.3689; Lieu TA, 2007, MED CARE, V45, pS89, DOI 10.1097/MLR.0b013e3180616c0a; McDonald CJ, 2005, HEALTH AFFAIR, V24, P1214, DOI 10.1377/hlthaff.24.5.1214; *NAT COUNC PUBL PR, PPPS WORK; Noren GN, 2010, DATA MIN KNOWL DISC, V20, P361, DOI 10.1007/s10618-009-0152-3; NOREN GN, 2008, P 14 ACM SIGKDD INT; Palacio A, 2010, AM J MANAG CARE, V16, pS118; Pamer CA, 2010, PHARMACOEPIDEM DR S, V19, P158, DOI 10.1002/pds.1886; Rosenberg L, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P185; Ryan PB, 2009, 25 ANN M INT SOC PHA; RYAN PB, 2008, 13 INT SOC PHARM OUT; Schneeweiss S, 1997, PHARMACOEPIDEM DR S, V6, pS51, DOI 10.1002/(SICI)1099-1557(199710)6:3+<S51::AID-PDS301>3.3.CO;2-J; Shatin D, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P271; Whitaker HJ, 2009, STAT METHODS MED RES, V18, P7, DOI 10.1177/0962280208092342	35	243	248	1	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					600	606		10.7326/0003-4819-153-9-201011020-00010	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	21041580				2022-12-28	WOS:000283667000007
J	Fowler, RA; Jouvet, P				Fowler, Robert A.; Jouvet, Philippe			Paediatric mortality related to H1N1 infection in England	LANCET			English	Editorial Material							CHILDREN		[Fowler, Robert A.] Univ Toronto, Sunnybrook Hosp, Dept Crit Care, Toronto, ON M4N 3M5, Canada; [Fowler, Robert A.] Univ Toronto, Sunnybrook Hosp, Dept Med, Toronto, ON M4N 3M5, Canada; [Jouvet, Philippe] Univ Montreal, Le Ctr Hosp Univ St Justine, Montreal, PQ, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine	Fowler, RA (corresponding author), Univ Toronto, Sunnybrook Hosp, Dept Crit Care, Toronto, ON M4N 3M5, Canada.	rob.fowler@sunnybrook.ca	Jouvet, Philippe A/H-3293-2018	Jouvet, Philippe A/0000-0001-5684-3398				Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; *CAN BROADC CORP, 2009, 13 YEAR OLD TOR BOY; *CDCP, 2010, 2009 2010 INFL SEAS; Centers for Disease Control and Prevention, 2009, MORB MORT WEEKL REP; Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367; Health Protection Agency, 2009, PAND H1N1 2009 ENGL; Khazeni N, 2009, ANN INTERN MED, V151, P829, DOI [10.7326/0000605-200912150-00157, 10.7326/0003-4819-151-12-200912150-00157]; Lister P, 2009, LANCET, V374, P605, DOI [10.1016/S0140-6736(09)61512-9, 10.1016/S0140-6736(09)61513-0]; Sachedina N, 2010, LANCET, V376, P1846, DOI 10.1016/S0140-6736(10)61195-6; SANDER B, 2009, PLOS CURR, V17	10	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV-DEC	2010	376	9755					1808	1810		10.1016/S0140-6736(10)61385-2	http://dx.doi.org/10.1016/S0140-6736(10)61385-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696KG	21030070				2022-12-28	WOS:000285439700009
J	Gilbert, LA; Hemann, MT				Gilbert, Luke A.; Hemann, Michael T.			DNA Damage-Mediated Induction of a Chemoresistant Niche	CELL			English	Article							BONE-MARROW; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; BREAST-CANCER; IN-VIVO; CELLS; SENESCENCE; INTERLEUKIN-6; SURVIVAL; CHEMOTHERAPY	While numerous cell-intrinsic processes are known to play decisive roles in chemotherapeutic response, relatively little is known about the impact of the tumor microenvironment on therapeutic outcome. Here, we use a well-established mouse model of Burkitt's lymphoma to show that paracrine factors in the tumor microenvironment modulate lymphoma cell survival following the administration of genotoxic chemotherapy. Specifically, IL-6 and Timp-1 are released in the thymus in response to DNA damage, creating a "chemo-resistant niche'' that promotes the survival of a minimal residual tumor burden and serves as a reservoir for eventual tumor relapse. Notably, IL-6 is released acutely from thymic endothelial cells in a p38-dependent manner following genotoxic stress, and this acute secretory response precedes the gradual induction of senescence in tumor-associated stromal cells. Thus, conventional chemotherapies can induce tumor regression while simultaneously eliciting stress responses that protect subsets of tumor cells in select anatomical locations from drug action.	[Gilbert, Luke A.; Hemann, Michael T.] MIT, Koch Inst Integrat Canc Res MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Hemann, MT (corresponding author), MIT, Koch Inst Integrat Canc Res MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	hemann@mit.edu	Gilbert, Luke/AAC-5300-2019	Gilbert, Luke/0000-0001-5854-0825	NIH [RO1 CA128803]; Ludwig Center for Molecular Oncology at MIT; MIT; NATIONAL CANCER INSTITUTE [R01CA128803] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Center for Molecular Oncology at MIT; MIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Holly Criscione and Tyler Miller for their experimental assistance. We thank Corbin Meacham for assistance with the cell migration assay. We would also like to acknowledge Eliza Vasile in the Koch Institute Microscopy Core Facility and Glen Paradis in the Koch Institute Flow Cytometry Core Facility for advice and services. Roderick Bronson provided expert pathology analysis, and Justin Pritchard performed bioinformatic analysis of cytokine arrays. We are grateful to Corbin Meacham, David Feldser, and Ross Dickins for critically reading the manuscript and the entire Hemann lab for helpful discussions. M.T.H. is a Rita Allen Fellow and the Latham Family Career Development Assistant Professor of Biology and is supported by NIH RO1 CA128803 and Ludwig Center for Molecular Oncology at MIT. L.A.G. is supported by the MIT Herman Eisen fellowship.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Burgess DJ, 2008, P NATL ACAD SCI USA, V105, P9053, DOI 10.1073/pnas.0803513105; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corradini P, 1999, LEUKEMIA, V13, P1691, DOI 10.1038/sj.leu.2401559; DELREZ M, 1978, EXPERIENTIA, V34, P1221, DOI 10.1007/BF01922970; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eckstein N, 2009, CANCER RES, V69, P2996, DOI 10.1158/0008-5472.CAN-08-3153; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Gu L, 2005, BIOORGAN MED CHEM, V13, P4269, DOI 10.1016/j.bmc.2005.04.022; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Holen KD, 2001, LANCET ONCOL, V2, P290, DOI 10.1016/S1470-2045(00)00324-7; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Igntiadis M, 2008, EUR J CANCER, V44, P2726, DOI 10.1016/j.ejca.2008.09.033; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Morrison AJ, 2005, CELL CYCLE, V4, P568; MULLERHERMELINK HK, 1987, AM J PATHOL, V129, P242; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833; SEYMOUR JF, 1995, J CLIN ONCOL, V13, P575, DOI 10.1200/JCO.1995.13.3.575; Sfikakis PP, 2005, EUR J CLIN INVEST, V35, P380, DOI 10.1111/j.1365-2362.2005.01499.x; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Williams RT, 2007, GENE DEV, V21, P2283, DOI 10.1101/gad.1588607; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Xenidis N, 2009, J CLIN ONCOL, V27, P2177, DOI 10.1200/JCO.2008.18.0497; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	39	318	331	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					355	366		10.1016/j.cell.2010.09.043	http://dx.doi.org/10.1016/j.cell.2010.09.043			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029859	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000283603900010
J	Hemberger, M; Pedersen, R				Hemberger, Myriam; Pedersen, Roger			Epigenome Disruptors	SCIENCE			English	Editorial Material							PLURIPOTENT STEM-CELLS; DNA METHYLATION; PROMOTER; GENOME; LINES		[Hemberger, Myriam] Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB22 3AT, England; [Pedersen, Roger] Univ Cambridge, Anne McLaren Lab Regenerat Med, Cambridge CB2 0SZ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Hemberger, M (corresponding author), Babraham Inst, Lab Dev Genet & Imprinting, Babraham Res Campus, Cambridge CB22 3AT, England.	myriam.hemberger@bbsrc.ac.uk		Hemberger, Myriam/0000-0003-3332-6958	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C230] Funding Source: Medline; Medical Research Council [G0600275] Funding Source: Medline; BBSRC [BBS/E/B/0000C230] Funding Source: UKRI; MRC [G0600275] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; Allegrucci C, 2007, HUM MOL GENET, V16, P1253, DOI 10.1093/hmg/ddm074; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Dean W, 1998, DEVELOPMENT, V125, P2273; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Hemberger M, 2009, NAT REV MOL CELL BIO, V10, P526, DOI 10.1038/nrm2727; Hesson LB, 2010, CURR OPIN GENET DEV, V20, P290, DOI 10.1016/j.gde.2010.02.005; Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Metivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544; Polo JM, 2010, NAT BIOTECHNOL, V28, P848, DOI 10.1038/nbt.1667; Rugg-Gunn PJ, 2005, NAT GENET, V37, P585, DOI 10.1038/ng1556; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Yamanaka S, 2010, CELL STEM CELL, V7, P1, DOI 10.1016/j.stem.2010.06.009; Zvetkova I, 2005, NAT GENET, V37, P1274, DOI 10.1038/ng1663	16	9	10	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					598	599		10.1126/science.1199006	http://dx.doi.org/10.1126/science.1199006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030637				2022-12-28	WOS:000283580600025
J	Baker, M				Baker, Monya			The search for association	NATURE			English	Editorial Material							GENOME-WIDE ASSOCIATION; COMMON; VARIANTS											Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; Burkhardt R, 2008, ARTERIOSCL THROM VAS, V28, P2078, DOI 10.1161/ATVBAHA.108.172288; Craddock N, 2010, NATURE, V464, P713, DOI 10.1038/nature08979; Johansen CT, 2010, NAT GENET, V42, P684, DOI 10.1038/ng.628; Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499; Pang AW, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r52; Park JH, 2010, NAT GENET, V42, P570, DOI 10.1038/ng.610; Pinto D, 2010, NATURE, V466, P368, DOI 10.1038/nature09146; Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661	10	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 28	2010	467	7319					1135	U150		10.1038/4671135a	http://dx.doi.org/10.1038/4671135a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671XW	20981103	Bronze			2022-12-28	WOS:000283548600053
J	Fazel, S; Baillargeon, J				Fazel, Seena; Baillargeon, Jacques			The health of prisoners	LANCET			English	Review							RECENTLY RELEASED PRISONERS; CAUSE-SPECIFIC MORTALITY; C VIRUS-INFECTIONS; HEPATITIS-B-VIRUS; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; FEMALE PRISONERS; STATE PRISON; SUBSTITUTION TREATMENT; CORRECTIONAL INMATES	More than 10 million people are incarcerated worldwide; this number has increased by about a million in the past decade. Mental disorders and infectious diseases are more common in prisoners than in the general population. High rates of suicide within prison and increased mortality from all causes on release have been documented in many countries. The contribution of prisons to illness is unknown, although shortcomings in treatment and aftercare provision contribute to adverse outcomes. Research has highlighted that women, prisoners aged 55 years and older, and juveniles present with higher rates of many disorders than do other prisoners. The contribution of initiatives to improve the health of prisoners by reducing the burden of infectious and chronic diseases, suicide, other causes of premature mortality and violence, and counteracting the cycle of reoffending should be further examined.	[Fazel, Seena] Univ Oxford, Dept Psychiat, Oxford OX3 7JX, England; [Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX USA	University of Oxford; University of Texas System; University of Texas Medical Branch Galveston	Fazel, S (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	seena.fazel@psych.ox.ac.uk	Fazel, Seena/B-5307-2008	Fazel, Seena/0000-0002-5383-5365	HEFCE	HEFCE(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE))	SF is supported by a HEFCE Clinical Senior Lectureship award. We are grateful to Clare Stockdale for preparation of figures on prisoner numbers and rates; to Sophia Anwar, Gwen Baillargeon, and Simon Wilson for helpful comments on previous drafts; and to Leonard Pechacek for editorial assistance.	Abrahao RMCM, 2006, INT J TUBERC LUNG D, V10, P203; Abraldes, 2007, PUBLIC HLTH BARS PRI, V1, P56, DOI DOI 10.1007/978-0-387-71695-4_5; Adjei AA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-33; Adoga MP, 2009, J INFECT DEV COUNTR, V3, P539, DOI 10.3855/jidc.472; Aerts A, 2000, INT J TUBERC LUNG D, V4, P1104; Aerts A, 2006, INT J TUBERC LUNG D, V10, P1215; [Anonymous], 1988, LANCET, V2, P1402; [Anonymous], 2009, LANCET, V373, P603, DOI 10.1016/S0140-6736(09)60374-3; [Anonymous], 1991, Lancet, V337, P647; [Anonymous], 2005, LANCET, V365, P359; [Anonymous], 2009, LANCET, V374, P852, DOI 10.1016/S0140-6736(09)61605-6; [Anonymous], 2001, NAT STRAT SUIC PREV; [Anonymous], 2009, BUREAU JUSTICE STAT; Arndt S, 2002, AM J GERIAT PSYCHIAT, V10, P733, DOI 10.1176/appi.ajgp.10.6.733; Arrigo BA, 2008, INT J OFFENDER THER, V52, P622, DOI 10.1177/0306624X07309720; Assadi SM, 2006, BRIT J PSYCHIAT, V188, P159, DOI 10.1192/bjp.188.2.159; Assefzadeh M, 2009, East Mediterr Health J, V15, P258; Babudieri S, 2005, J MED VIROL, V76, P311, DOI 10.1002/jmv.20375; Baillargen J, 2009, PUBLIC HEALTH REP, V124, P120, DOI 10.1177/003335490912400115; Baillargeon J, 2000, ANN EPIDEMIOL, V10, P74, DOI 10.1016/S1047-2797(99)00033-2; Baillargeon J, 2009, AM J PSYCHIAT, V166, P103, DOI 10.1176/appi.ajp.2008.08030416; Baillargeon J, 2009, J AM ACAD PSYCHIATRY, V37, P188; Baillargeon J, 2009, JAMA-J AM MED ASSOC, V301, P848, DOI 10.1001/jama.2009.202; Banerjee Arnab, 2009, J Indian Med Assoc, V107, P14; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Binswanger IA, 2010, AM J PUBLIC HEALTH, V100, P476, DOI 10.2105/AJPH.2008.149591; Binswanger IA, 2009, JAMA-J AM MED ASSOC, V302, P147, DOI 10.1001/jama.2009.919; Bird SM, 2008, BRIT J PSYCHIAT, V192, P446, DOI 10.1192/bjp.bp.107.038679; Bone A., 2000, TUBERCULOSIS CONTROL; Bridgwood A, 1995, SURVEY PHYS HLTH PRI; Bur S, 2003, INT J TUBERC LUNG D, V7, pS417; Bureau of Justice Statistics, PUBL PROD HIV PRIS J; Butler T, 2006, AUST NZ J PSYCHIAT, V40, P272, DOI 10.1111/j.1440-1614.2006.01785.x; Butler T, 2004, AUST NZ J PUBL HEAL, V28, P344, DOI 10.1111/j.1467-842X.2004.tb00442.x; Butler T, 2007, AUST NZ J PSYCHIAT, V41, P429, DOI 10.1080/00048670701261210; Butler T, 2007, AUST NZ J PUBL HEAL, V31, P44, DOI 10.1111/j.1753-6405.2007.00009.x; Catalan-Soares B C, 2000, Rev Soc Bras Med Trop, V33, P27, DOI 10.1590/S0037-86822000000100004; Christensen PB, 2000, EUR J EPIDEMIOL, V16, P1043, DOI 10.1023/A:1010833917242; CLAVEL F, 1987, LANCET, V2, P1012; Committee of Ministers of the Council of Europe, 1998, R987 COUNC EUR COMM; Coninx R, 2000, BRIT MED J, V320, P440, DOI 10.1136/bmj.320.7232.440; Cornford C, 2007, SURVEY DELIVERY HLTH; Cornford CS, 2008, PRIMARY HLTH CARE RE, V9, P126; Coyle, 2009, HUMAN RIGHTS APPROAC; Crawley E., 2005, J CONTEMP CRIM JUST, V21, P350, DOI DOI 10.1177/1043986205282018; Dara M, 2009, GUIDELINES CONTROL T; Department of Health, 2002, NAT SUIC PREV STRAT; Dolan K, 2007, LANCET INFECT DIS, V7, P32, DOI 10.1016/S1473-3099(06)70685-5; Dressing H, 2009, BEHAV SCI LAW, V27, P801, DOI 10.1002/bsl.893; Driessen M, 2006, J CLIN PSYCHIAT, V67, P1486, DOI 10.4088/JCP.v67n1001; Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x; Fazel S, 2005, LANCET, V366, P1301, DOI 10.1016/S0140-6736(05)67325-4; Fazel S, 2004, AGE AGEING, V33, P396, DOI 10.1093/ageing/afh113; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; Fazel S, 2002, BRIT MED J, V324, P1495, DOI 10.1136/bmj.324.7352.1495; Fazel S, 2001, AGE AGEING, V30, P403, DOI 10.1093/ageing/30.5.403; Fazel S, 2001, BRIT J PSYCHIAT, V179, P535, DOI 10.1192/bjp.179.6.535; Fazel S, 2008, PLOS MED, V5, P1670, DOI 10.1371/journal.pmed.0050225; Fazel S, 2008, J CLIN PSYCHIAT, V69, P1721, DOI 10.4088/JCP.v69n1107; Fazel S, 2008, INT J LAW PSYCHIAT, V31, P369, DOI 10.1016/j.ijlp.2008.06.001; Fazel S, 2006, EUR J PUBLIC HEALTH, V16, P441, DOI 10.1093/eurpub/cki223; Fazel S, 2011, SOC PSYCH PSYCH EPID, V46, P191, DOI 10.1007/s00127-010-0184-4; Fazel S, 2011, SCHIZOPHRENIA BULL, V37, P800, DOI 10.1093/schbul/sbp135; Fazel S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000120; Fazel S, 2008, J AM ACAD CHILD PSY, V47, P1010, DOI [10.1097/CHI.0b013e31817eeef3, 10.1097/CHI.ObO13e31817eecf3]; Fazel S, 2009, BRIT J PSYCHIAT, V194, P183, DOI 10.1192/bjp.bp.107.046490; Feron JM, 2005, J EPIDEMIOL COMMUN H, V59, P651, DOI 10.1136/jech.2004.022269; Fox RK, 2005, CLIN INFECT DIS, V41, P177, DOI 10.1086/430913; Fruhwald S, 2005, LANCET, V366, P1242, DOI 10.1016/S0140-6736(05)67327-8; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; Glueck B, 1918, MENT HYG, V2, P85; Goff Ashley, 2007, Crim Behav Ment Health, V17, P152; Golzari M, 2006, J ADOLESCENT HEALTH, V38, P776, DOI 10.1016/j.jadohealth.2005.06.008; Habeenzu C, 2007, INT J TUBERC LUNG D, V11, P1216; Hammett TM, 2006, AM J PUBLIC HEALTH, V96, P974, DOI 10.2105/AJPH.2005.066993; Hannon F, 2000, GEN HEALTHCARE STUDY; Harzke AJ, 2010, J URBAN HEALTH, V87, P486, DOI 10.1007/s11524-010-9448-2; Harzke AJ, 2009, ANN EPIDEMIOL, V19, P647, DOI 10.1016/j.annepidem.2009.04.001; Heffernan Edward, 2009, Australas Psychiatry, V17 Suppl 1, pS41, DOI 10.1080/10398560902948696; Home Office, 2004, PROB STAT ENGL WAL 2; Horner MJ, 2009, SEER CANC STAT REV 1; Huang GP, 2006, COMPR PSYCHIAT, V47, P20, DOI 10.1016/j.comppsych.2005.04.004; Hunt DR, 2009, AM J GASTROENTEROL, V104, P1024, DOI 10.1038/ajg.2008.143; Jafa K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005416; Jenkins R, 2005, PSYCHOL MED, V35, P257, DOI 10.1017/S0033291704002958; Jittimanee SX, 2007, INT J TUBERC LUNG D, V11, P556; Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009, 2009, AIDS EP UPD DEC 2009; Jurgens R, 2009, LANCET INFECT DIS, V9, P57, DOI 10.1016/S1473-3099(08)70305-0; Kariminia A, 2007, INT J EPIDEMIOL, V36, P310, DOI 10.1093/ije/dyl225; Kariminia A, 2007, EUR J EPIDEMIOL, V22, P417, DOI 10.1007/s10654-007-9134-1; Kinlock TW, 2009, J SUBST ABUSE TREAT, V37, P277, DOI 10.1016/j.jsat.2009.03.002; Knight M, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-111; Knight M, 2005, BJOG-INT J OBSTET GY, V112, P1467, DOI 10.1111/j.1471-0528.2005.00749.x; Kothari G, 2002, BRIT J CRIMINOL, V42, P412, DOI 10.1093/bjc/42.2.412; Langan P, 2002, RECIDIVISM PRISONERS; Larney S, 2010, ADDICTION, V105, P216, DOI 10.1111/j.1360-0443.2009.02826.x; Lobacheva T, 2005, Euro Surveill, V10, P5, DOI 10.2807/esm.10.06.00547-en; Macalino GE, 2004, AM J PUBLIC HEALTH, V94, P1218, DOI 10.2105/AJPH.94.7.1218; MacNeil JR, 2005, AM J PUBLIC HEALTH, V95, P1800, DOI 10.2105/AJPH.2004.055442; Maruschak LM, 2006, MEDICAL PROBLEMS JAI; Mathew P, 2005, CANCER-AM CANCER SOC, V104, P2197, DOI 10.1002/cncr.21468; McLaughlin SI, 2003, INT J TUBERC LUNG D, V7, P665; Michel L, 2008, HARM REDUCT J, V5, DOI 10.1186/1477-7517-5-17; Moser DJ, 2004, COMPR PSYCHIAT, V45, P1, DOI 10.1016/j.comppsych.2003.09.009; Mumola, 2007, MED CAUSES DEATH STA; Mumola C, 2005, SUICIDE HOMICIDE STA; Murray J, 2009, CAMPBELL SYST REV, P4; Office of the United Nations High Commissioner for Human Rights, 2004, 225415RS HOL SEE SEC; Passadouro Rui, 2004, Acta Med Port, V17, P381; Penn JV, 2005, J AM ACAD CHILD PSY, V44, P1085, DOI 10.1097/01.chi.0000175325.14481.21; Perry A, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.C005193.PUB2; Poulin C, 2007, CAN MED ASSOC J, V177, P252, DOI 10.1503/cmaj.060760; Pratt D, 2010, PSYCHOL MED, V40, P827, DOI 10.1017/S0033291709991048; Pratt D, 2006, LANCET, V368, P119, DOI 10.1016/S0140-6736(06)69002-8; Priebe S, 2008, PSYCHIAT SERV, V59, P570, DOI 10.1176/ps.2008.59.5.570; Raimer BG, 2004, JAMA-J AM MED ASSOC, V292, P485, DOI 10.1001/jama.292.4.485; Rao N. A., 2004, JPMA Journal of the Pakistan Medical Association, V54, P413; Reed J, 2003, BRIT J PSYCHIAT, V182, P287, DOI 10.1192/bjp.182.4.287; Rivlin A, 2010, BRIT J PSYCHIAT, V197, P313, DOI 10.1192/bjp.bp.110.077883; Rosen DL, 2008, AM J PUBLIC HEALTH, V98, P2278, DOI 10.2105/AJPH.2007.121855; Rotily M, 1997, INT J STD AIDS, V8, P753, DOI 10.1258/0956462971919228; Sabol WJ, 2009, BUREAU JUSTICE STAT; Scheyett A, 2009, COMMUNITY MENT HLT J, V45, P439, DOI 10.1007/s10597-009-9204-9; Shaw J, 1999, LANCET, V353, P1053, DOI 10.1016/S0140-6736(98)08094-5; Siefert K, 2001, SOC WORK, V46, P125, DOI 10.1093/sw/46.2.125; Singh S, 1999, INT J STD AIDS, V10, P475, DOI 10.1258/0956462991914357; Snell TL., 1994, WOMEN IN PRISON; Sosa LE, 2008, INT J TUBERC LUNG D, V12, P689; Spaulding AC, 2009, PLOS ONE, V4, pA16, DOI 10.1371/journal.pone.0007558; Stallwitz A, 2007, INT J DRUG POLICY, V18, P464, DOI 10.1016/j.drugpo.2006.11.015; Vescio MF, 2008, J EPIDEMIOL COMMUN H, V62, P305, DOI 10.1136/jech.2006.051599; Wallace C, 1998, BRIT J PSYCHIAT, V172, P477, DOI 10.1192/bjp.172.6.477; Walmsley R, 1999, WORLD PRISON POPULAT; Walmsley R, 2000, WORLD PRISON POPULAT; Walmsley R, 2015, WORLD PRISON POPULAT; Weinbaum CA, 2005, AIDS, V19, pS41, DOI 10.1097/01.aids.0000192069.95819.aa; Williams BA, 2006, J AM GERIATR SOC, V54, P702, DOI 10.1111/j.1532-5415.2006.00662.x; Wilper AP, 2009, AM J PUBLIC HEALTH, V99, P666, DOI 10.2105/AJPH.2008.144279; WORMSER GP, 1983, ANN INTERN MED, V98, P297, DOI 10.7326/0003-4819-98-3-297	139	600	617	3	147	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	2011	377	9769					956	965		10.1016/S0140-6736(10)61053-7	http://dx.doi.org/10.1016/S0140-6736(10)61053-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	738GR	21093904				2022-12-28	WOS:000288628800039
J	Qi, XX; Lan, SY; Wang, WJ; Schelde, LM; Dong, HH; Wallat, GD; Ly, H; Liang, YY; Dong, CJ				Qi, Xiaoxuan; Lan, Shuiyun; Wang, Wenjian; Schelde, Lisa McLay; Dong, Haohao; Wallat, Gregor D.; Ly, Hinh; Liang, Yuying; Dong, Changjiang			Cap binding and immune evasion revealed by Lassa nucleoprotein structure	NATURE			English	Article							CRYSTAL-STRUCTURE; VIRUS NUCLEOPROTEIN; L-PROTEIN; DENDRITIC CELLS; RNA; TREX1; TRANSCRIPTION; ENDONUCLEASE; REPLICATION; RECOGNITION	Lassa virus, the causative agent of Lassa fever, causes thousands of deaths annually and is a biological threat agent, for which there is no vaccine and limited therapy. The nucleoprotein (NP) of Lassa virus has essential roles in viral RNA synthesis and immune suppression, the molecular mechanisms of which are poorly understood. Here we report the crystal structure of Lassa virus NP at 1.80 angstrom resolution, which reveals amino (N)- and carboxy (C)-terminal domains with structures unlike any of the reported viral NPs. The N domain folds into a novel structure with a deep cavity for binding the m7GpppN cap structure that is required for viral RNA transcription, whereas the C domain contains 3'-5' exoribonuclease activity involved in suppressing interferon induction. To our knowledge this is the first X-ray crystal structure solved for an arenaviral NP, which reveals its unexpected functions and indicates unique mechanisms in cap binding and immune evasion. These findings provide great potential for vaccine and drug development.	[Qi, Xiaoxuan; Dong, Haohao; Wallat, Gregor D.; Dong, Changjiang] Univ St Andrews, Sch Chem, St Andrews KY16 9ST, Fife, Scotland; [Lan, Shuiyun; Schelde, Lisa McLay; Ly, Hinh; Liang, Yuying] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Wang, Wenjian] Sun Yat Sen Univ, Affiliated Hosp 1, Lab Dept Surg, Guangzhou 510080, Guangdong, Peoples R China	University of St Andrews; Emory University; Sun Yat Sen University	Dong, CJ (corresponding author), Univ St Andrews, Sch Chem, Biomed Sci Res Complex, St Andrews KY16 9ST, Fife, Scotland.	hly@emory.edu; yliang5@emory.edu; cd26@st-andrews.ac.uk		Qi, Xiaoxuan/0000-0001-5191-3713	Southeast Regional Center of Excellence for Emerging Infections and Biodefense [5-U54-AI-057157-06]; Emory University Research Committee (URC); Emory DDRDC [DK64399]; American Cancer Society [RSG-06-162-01-GMC]; NIH [R01AI083409, AI067704];  [5-U19-AI057266-07]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI057266, U54AI057157, R01AI083409, R01AI093580, R01AI067704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399] Funding Source: NIH RePORTER	Southeast Regional Center of Excellence for Emerging Infections and Biodefense(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Emory University Research Committee (URC); Emory DDRDC; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	C.D. wishes to thank J. Naismith for his continuing support, encouragement and advice; R. M. Elliott for providing the human beta-globin containing plasmid phRL-CMV and his critical reading of the manuscript; H. Liu for discussions; and L. Major for the pLou3 plasmid. C.D. is a Wellcome trust career development fellow (083501/Z/07/Z). We thank the staff at IO2 and IO3 beam stations of Diamond light sources for their assistance with data collection. This work was supported in part by funds from the Southeast Regional Center of Excellence for Emerging Infections and Biodefense (5-U54-AI-057157-06), the pilot component of the U19 grant (5-U19-AI057266-07), and the Emory University Research Committee (URC) to Y.L. and H. L.; a seed grant from the Emory DDRDC (DK64399) and a research scholar grant from the American Cancer Society (RSG-06-162-01-GMC) to H.L.; NIH grant R01AI083409 to Y.L.; and NIH grant AI067704 to T. G. Parslow and Y.L. We thank K. Curtis and T. W. Geisbert for providing us with non-infectious genomic RNA samples of LASV, and J. Aronson for the PICV virus.	Albertini AAV, 2006, SCIENCE, V313, P360, DOI 10.1126/science.1125280; Baize S, 2004, J IMMUNOL, V172, P2861, DOI 10.4049/jimmunol.172.5.2861; Baize S, 2009, J VIROL, V83, P5890, DOI 10.1128/JVI.01948-08; Briese T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000455; Buchmeier MJ., 2007, FIELDS VIROLOGY, P1791; Cisneros GA, 2009, J AM CHEM SOC, V131, P1550, DOI 10.1021/ja8082818; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; Crow YJ, 2009, HUM MOL GENET, V18, pR130, DOI 10.1093/hmg/ddp293; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; de Silva U, 2007, J BIOL CHEM, V282, P10537, DOI 10.1074/jbc.M700039200; Delgado S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000047; Dias A, 2009, NATURE, V458, P914, DOI 10.1038/nature07745; EDINGTON GM, 1972, T ROY SOC TROP MED H, V66, P381, DOI 10.1016/0035-9203(72)90268-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fechter P, 2005, J GEN VIROL, V86, P1239, DOI 10.1099/vir.0.80755-0; FISHERHOCH S, 1988, J MED VIROL, V26, P127, DOI 10.1002/jmv.1890260204; Green TJ, 2006, SCIENCE, V313, P357, DOI 10.1126/science.1126953; Guilligay D, 2008, NAT STRUCT MOL BIOL, V15, P500, DOI 10.1038/nsmb.1421; Hall TMT, 2005, CURR OPIN STRUC BIOL, V15, P367, DOI 10.1016/j.sbi.2005.04.004; Hass M, 2004, J VIROL, V78, P13793, DOI 10.1128/JVI.78.24.13793-13803.2004; JIN H, 1993, J VIROL, V67, P1396, DOI 10.1128/JVI.67.3.1396-1404.1993; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Khan SH, 2008, ANTIVIR RES, V78, P103, DOI 10.1016/j.antiviral.2007.11.003; Lan SY, 2008, ARCH VIROL, V153, P1241, DOI 10.1007/s00705-008-0101-2; Lan SY, 2009, J VIROL, V83, P6357, DOI 10.1128/JVI.00019-09; Lee-Kirsch MA, 2007, NAT GENET, V39, P1065, DOI 10.1038/ng2091; Lehtinen DA, 2008, J BIOL CHEM, V283, P31649, DOI 10.1074/jbc.M806155200; Lelke M, 2010, J VIROL, V84, P1934, DOI 10.1128/JVI.01657-09; Lopez N, 2001, J VIROL, V75, P12241, DOI 10.1128/JVI.75.24.12241-12251.2001; Mahanty S, 2003, J IMMUNOL, V170, P2797, DOI 10.4049/jimmunol.170.6.2797; Martinez-Sobrido L, 2007, J VIROL, V81, P12696, DOI 10.1128/JVI.00882-07; Martinez-Sobrido L, 2006, J VIROL, V80, P9192, DOI 10.1128/JVI.00555-06; Martinez-Sobrido L, 2009, J VIROL, V83, P11330, DOI 10.1128/JVI.00763-09; Matthews JM, 2002, IUBMB LIFE, V54, P351, DOI 10.1080/15216540216035; McCartney SA, 2009, IMMUNOL REV, V227, P87, DOI 10.1111/j.1600-065X.2008.00726.x; McCormick JB, 2002, CURR TOP MICROBIOL, V262, P75; MEYER BJ, 1993, J VIROL, V67, P2621, DOI 10.1128/JVI.67.5.2621-2627.1993; Morin B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001038; Muller S, 2007, J GEN VIROL, V88, P1568, DOI 10.1099/vir.0.82529-0; Pinschewer DD, 2003, J VIROL, V77, P3882, DOI 10.1128/JVI.77.6.3882-3887.2003; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; POLYAK SJ, 1995, J VIROL, V69, P3211, DOI 10.1128/JVI.69.5.3211-3215.1995; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Tawar RG, 2009, SCIENCE, V326, P1279, DOI 10.1126/science.1177634; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vagin AA, 2004, ACTA CRYSTALLOGR D, V60, P2184, DOI 10.1107/S0907444904023510; Ye QZ, 2006, NATURE, V444, P1078, DOI 10.1038/nature05379; Yuan PW, 2009, NATURE, V458, P909, DOI 10.1038/nature07720; Zhou SH, 2010, J VIROL, V84, P9452, DOI 10.1128/JVI.00155-10; Zuo YH, 2007, STRUCTURE, V15, P417, DOI 10.1016/j.str.2007.02.004	50	199	208	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	2010	468	7325					779	U65		10.1038/nature09605	http://dx.doi.org/10.1038/nature09605			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691PQ	21085117	Green Accepted			2022-12-28	WOS:000285093700036
J	Oppenheim, J; Wehner, S				Oppenheim, Jonathan; Wehner, Stephanie			The Uncertainty Principle Determines the Nonlocality of Quantum Mechanics	SCIENCE			English	Article							PROBABILITY RELATIONS; SEPARATED SYSTEMS	Two central concepts of quantum mechanics are Heisenberg's uncertainty principle and a subtle form of nonlocality that Einstein famously called "spooky action at a distance." These two fundamental features have thus far been distinct concepts. We show that they are inextricably and quantitatively linked: Quantum mechanics cannot be more nonlocal with measurements that respect the uncertainty principle. In fact, the link between uncertainty and nonlocality holds for all physical theories. More specifically, the degree of nonlocality of any theory is determined by two factors: the strength of the uncertainty principle and the strength of a property called "steering," which determines which states can be prepared at one location given a measurement at another.	[Oppenheim, Jonathan] Univ Cambridge, DAMTP, Cambridge CB3 0WA, England; [Wehner, Stephanie] CALTECH, Inst Quantum Informat, Pasadena, CA 91125 USA; [Wehner, Stephanie] Natl Univ Singapore, Ctr Quantum Technol, Singapore 117543, Singapore	University of Cambridge; California Institute of Technology; National University of Singapore	Oppenheim, J (corresponding author), Univ Cambridge, DAMTP, Cambridge CB3 0WA, England.	jono@damtp.cam.ac.uk; wehner@nus.edu.sg	Oppenheim, Jonathan/E-1518-2017	Oppenheim, Jonathan/0000-0002-8993-412X	Royal Society; NSF [PHY-04056720, PHY-0803371, PHY-0551164]; National Research Foundation of Singapore; Singapore Ministry of Education; Division Of Physics [0803371] Funding Source: National Science Foundation	Royal Society(Royal Society of London); NSF(National Science Foundation (NSF)); National Research Foundation of Singapore(National Research Foundation, Singapore); Singapore Ministry of Education(Ministry of Education, Singapore); Division Of Physics(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	The retrieval game used was discovered in collaboration with A. Doherty. Supported by the Royal Society (J.O.) and by NSF grants PHY-04056720 and PHY-0803371, the National Research Foundation of Singapore, and the Singapore Ministry of Education (S. W.). Part of this work was done while J.O. was visiting California Institute of Technology, and while J.O. and S. W. were visiting the Kavli Institute for Theoretical Physics (Santa Barbara, CA), which is funded by NSF grant PHY-0551164.	Barnum H, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.140401; Bell JS., 1964, PHYS, V1, P195, DOI [10.1103/PhysicsPhysiqueFizika.1.195, 10.1103/Physics-PhysiqueFizika.1.195, DOI 10.1103/PHYSICSPHYSIQUEFIZIKA.1.195]; BIALYNICKIBIRULA I, 1975, COMMUN MATH PHYS, V44, P129, DOI 10.1007/BF01608825; CIRELSON BS, 1980, LETT MATH PHYS, V4, P93, DOI 10.1007/BF00417500; DEUTSCH D, 1983, PHYS REV LETT, V50, P631, DOI 10.1103/PhysRevLett.50.631; Heisenberg W., 1927, Z PHYS J PHYS, V43, P172; Jones SJ, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.052116; Pawlowski M, 2009, NATURE, V461, P1101, DOI 10.1038/nature08400; Peres A., 1995, QUANTUM THEORY CONCE; POPESCU S, 1994, FOUND PHYS, V24, P379, DOI 10.1007/BF02058098; Schrodinger E, 1935, P CAMB PHILOS SOC, V31, P555, DOI 10.1017/S0305004100013554; Schrodinger E, 1936, P CAMB PHILOS SOC, V32, P446, DOI 10.1017/S0305004100019137; Steeg GV, 2009, QUANTUM INF COMPUT, V9, P801; Wehner S, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/2/025009; Wehner S, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.062112; Wiseman HM, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.140402; Wolf MM, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.230402	18	253	254	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1072	1074		10.1126/science.1192065	http://dx.doi.org/10.1126/science.1192065			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097930	Green Submitted			2022-12-28	WOS:000284374700034
J	Bucher, BT; Keller, MS				Bucher, Brian T.; Keller, Martin S.			Meckel's Diverticulum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bucher, Brian T.; Keller, Martin S.] Washington Univ, Sch Med, St Louis, MO 63130 USA	Washington University (WUSTL)	Bucher, BT (corresponding author), Washington Univ, Sch Med, St Louis, MO 63130 USA.	kellerm@wudosis.wustl.edu							0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2045	2045		10.1056/NEJMicm1001158	http://dx.doi.org/10.1056/NEJMicm1001158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083389				2022-12-28	WOS:000284310000009
J	Choi, KS; Goban, A; Papp, SB; van Enk, SJ; Kimble, HJ				Choi, K. S.; Goban, A.; Papp, S. B.; van Enk, S. J.; Kimble, H. J.			Entanglement of spin waves among four quantum memories	NATURE			English	Article							SCHRODINGER CAT STATE; ATOMIC ENSEMBLES; NETWORKS; DIFFERENTIATE; DISTANCE; SYSTEMS	Quantum networks are composed of quantum nodes that interact coherently through quantum channels, and open a broad frontier of scientific opportunities(1). For example, a quantum network can serve as a 'web' for connecting quantum processors for computation(2,3) and communication(4), or as a 'simulator' allowing investigations of quantum critical phenomena arising from interactions among the nodes mediated by the channels(5,6). The physical realization of quantum networks generically requires dynamical systems capable of generating and storing entangled states among multiple quantum memories, and efficiently transferring stored entanglement into quantum channels for distribution across the network. Although such capabilities have been demonstrated for diverse bipartite systems(7-12), entangled states have not been achieved for interconnects capable of 'mapping' multipartite entanglement stored in quantum memories to quantum channels. Here we demonstrate measurement-induced entanglement stored in four atomic memories; user-controlled, coherent transfer of the atomic entanglement to four photonic channels; and characterization of the full quadripartite entanglement using quantum uncertainty relations(13-16). Our work therefore constitutes an advance in the distribution of multipartite entanglement across quantum networks. We also show that our entanglement verification method is suitable for studying the entanglement order of condensed-matter systems in thermal equilibrium(17,18).	[Choi, K. S.; Goban, A.; Papp, S. B.; Kimble, H. J.] CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA; [van Enk, S. J.] Univ Oregon, Dept Phys, Eugene, OR 97403 USA	California Institute of Technology; University of Oregon	Kimble, HJ (corresponding author), CALTECH, Norman Bridge Lab Phys 12 33, Pasadena, CA 91125 USA.	hjkimble@caltech.edu	Goban, Akihisa/N-9445-2018; Choi, Kyung Soo/C-6073-2008	Goban, Akihisa/0000-0002-1766-6779; Choi, Kyung Soo/0000-0003-0757-1183; Goban, Akihisa/0000-0003-0027-1399	National Science Foundation; DOD; Northrop Grumman Corporation; Intelligence Advanced Research Projects Activity; Nakajima Foundation; Center for Physics of Information at Caltech; Direct For Mathematical & Physical Scien [0803371] Funding Source: National Science Foundation	National Science Foundation(National Science Foundation (NSF)); DOD(United States Department of Defense); Northrop Grumman Corporation; Intelligence Advanced Research Projects Activity; Nakajima Foundation; Center for Physics of Information at Caltech; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS))	We acknowledge discussions with K. Hammerer, P. Zoller and J. Ye. This research is supported by the National Science Foundation, the DOD NSSEFF program, the Northrop Grumman Corporation and the Intelligence Advanced Research Projects Activity. A.G. acknowledges support by the Nakajima Foundation. S.B.P. acknowledges support received as a fellow of the Center for Physics of Information at Caltech.	Acin A, 2007, NAT PHYS, V3, P256, DOI 10.1038/nphys549; Amico L, 2008, REV MOD PHYS, V80, P517, DOI 10.1103/RevModPhys.80.517; Aoki T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.080404; Balic V, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.183601; Chefles A, 1998, PHYS LETT A, V239, P339, DOI 10.1016/S0375-9601(98)00064-4; Choi KS, 2008, NATURE, V452, P67, DOI 10.1038/nature06670; Chou CW, 2007, SCIENCE, V316, P1316, DOI 10.1126/science.1140300; Colombe Y, 2007, NATURE, V450, P272, DOI 10.1038/nature06331; DiCarlo L, 2009, NATURE, V460, P240, DOI 10.1038/nature08121; DIEKS D, 1988, PHYS LETT A, V126, P303, DOI 10.1016/0375-9601(88)90840-7; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Eisert J, 2002, J PHYS A-MATH GEN, V35, P3911, DOI 10.1088/0305-4470/35/17/307; Gao WB, 2010, NAT PHYS, V6, P331, DOI 10.1038/NPHYS1603; Guhne O, 2009, PHYS REP, V474, P1, DOI 10.1016/j.physrep.2009.02.004; Haffner H, 2005, NATURE, V438, P643, DOI 10.1038/nature04279; Hammerer K, 2010, REV MOD PHYS, V82, P1041, DOI 10.1103/RevModPhys.82.1041; Heaney L., 2010, EXTREME NONLOCALITY; Hofmann HF, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032103; Horodecki R, 2009, REV MOD PHYS, V81, P865, DOI 10.1103/RevModPhys.81.865; IVANOVIC ID, 1987, PHYS LETT A, V123, P257, DOI 10.1016/0375-9601(87)90222-2; Jost JD, 2009, NATURE, V459, P683, DOI 10.1038/nature08006; Kimble HJ, 2008, NATURE, V453, P1023, DOI 10.1038/nature07127; Laurat J, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/6/207; Leibfried D, 2005, NATURE, V438, P639, DOI 10.1038/nature04251; Lloyd S, 1996, SCIENCE, V273, P1073, DOI 10.1126/science.273.5278.1073; Lougovski P, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/6/063029; Lvovsky AI, 2009, NAT PHOTONICS, V3, P706, DOI 10.1038/nphoton.2009.231; Moehring DL, 2007, NATURE, V449, P68, DOI 10.1038/nature06118; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Papp SB, 2009, SCIENCE, V324, P764, DOI 10.1126/science.1172260; PERES A, 1988, PHYS LETT A, V128, P19, DOI 10.1016/0375-9601(88)91034-1; Preskill J., 1997, PHYS 219 COURS INF; Sangouard N., 2009, QUANTUM REPEATERS BA; Schnorrberger U, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.033003; Simon J, 2007, NAT PHYS, V3, P765, DOI 10.1038/nphys726; Simon J, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.183601; Sorensen AS, 2001, PHYS REV LETT, V86, P4431, DOI 10.1103/PhysRevLett.86.4431; Steffen M, 2006, SCIENCE, V313, P1423, DOI 10.1126/science.1130886; Su XL, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.070502; van Enk SJ, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.052318; Vetsch E, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.203603; Weber B, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.030501; Zhang R, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.233602; Zhao B, 2009, NAT PHYS, V5, P95, DOI 10.1038/NPHYS1153; Zhao R, 2009, NAT PHYS, V5, P100, DOI 10.1038/NPHYS1152	47	98	99	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					412	U235		10.1038/nature09568	http://dx.doi.org/10.1038/nature09568			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085175	Green Submitted, Green Accepted			2022-12-28	WOS:000284313100037
J	Favus, MJ				Favus, Murray J.			Bisphosphonates for Osteoporosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; MEVALONATE PATHWAY; ZOLEDRONIC ACID; FRACTURE RISK; HIP FRACTURE; RENAL SAFETY; ALENDRONATE; OSTEONECROSIS; METAANALYSIS	A 67-year-old woman was referred by her primary care physician for treatment of osteoporosis and progressive bone loss. One year before the visit, the patient had discontinued hormone-replacement therapy. She had subsequently begun to experience midback pain and lost 3.8 cm (1.5 in.) in height. A dual-energy x-ray absorptiometry (DXA) scan showed bone mineral density T scores of -3.1 at the lumbar spine and -2.8 at the femoral neck, which are consistent with a diagnosis of osteoporosis. One year later, a second scan showed a further decrease of 5.4% in bone mineral density at the lumbar spine (Fig. 1), as well as a compression fracture of the 11th thoracic vertebra (Fig. 2). Results of blood and urine tests ruled out the common secondary causes of osteoporosis. To prevent additional vertebral fractures, oral bisphosphonate therapy was recommended.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Favus, MJ (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	mfavus@medicine.bsd.uchicago.edu			CVS Caremark; Amgen	CVS Caremark; Amgen(Amgen)	Dr. Favus reports receiving honoraria and consulting fees from CVS Caremark and Amgen. No other potential conflict of interest relevant to this article was reported.	Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]; ADAMI S, 1987, CALCIFIED TISSUE INT, V41, P326, DOI 10.1007/BF02556671; *ADV GROUP OST, 1994, REP; American College of Obstetricians Gynecologists Women's Health Care Physicians, 2004, OBSTET GYNECOL, V104, p66S; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157; Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312; Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086; Black DM, 2006, JAMA-J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bonnick SL, 2010, MENOPAUSE, V17, P25, DOI [10.1097/gme.0b013e3181c617e6, 10.1097/gme.0b013e3181e617e6]; Boonen S, 2008, KIDNEY INT, V74, P641, DOI 10.1038/ki.2008.193; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Chapurlat RD, 2008, J BONE MINER RES, V23, P1153; Chapurlat RD, 2007, J BONE MINER RES, V22, P1502, DOI 10.1359/JBMR.070609; Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325; COOPER C, 1993, AM J EPIDEMIOL, V137, P1001, DOI 10.1093/oxfordjournals.aje.a116756; Cranney A, 2002, ENDOCR REV, V23, P524, DOI 10.1210/er.2001-4002; Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001-3002; Cranney A, 2002, ENDOCR REV, V23, P540, DOI 10.1210/er.2001-6002; Dawson-Hughes B, 2010, OSTEOPOROSIS INT, V21, P41, DOI 10.1007/s00198-009-1034-7; Department of Health and Human Services, 2004, BON HLTH OST REP SUR; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003-4819-152-6-201003160-00008; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; HODGSON SF, 2004, ENDOCR PRACT, V10, P90; Hodgson Stephen F, 2003, Endocr Pract, V9, P544; HOFBAUER LC, 2010, TRANSLATIONAL ENDOCR, P117; Jamal SA, 2005, OSTEOPOROSIS INT, V16, P534, DOI 10.1007/s00198-004-1718-y; Jorgensen EB, 2008, KAIS, V2021, P1, DOI [DOI 10.1002/14651858.CD001155.PUB2, 10.1002/mp.15257]; KHOSLA S, 2010, TRANSLATIONAL ENDOCR, P55; Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Lewiecki EM, 2007, EXPERT OPIN DRUG SAF, V6, P663, DOI 10.1517/14740338.6.6.663; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Maalouf Naim M, 2006, Endocr Pract, V12, P48; Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756-3282(96)00182-2; McCloskey E, 2004, J BONE MINER RES, V19, P728, DOI 10.1359/JBMR.040116; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; McClung MR, 2003, ENDOCRIN METAB CLIN, V32, P253, DOI 10.1016/S0889-8529(02)00079-8; National Osteoporosis Foundation, 2008, CLIN GUID PREV TREAT; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004-0952; Qaseem A, 2008, ANN INTERN MED, V149, P404, DOI 10.7326/0003-4819-149-6-200809160-00007; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Ribeiro A, 1998, GASTROINTEST ENDOSC, V47, P525, DOI 10.1016/S0016-5107(98)70256-1; Rodan G, 2004, CURR MED RES OPIN, V20, P1291, DOI 10.1185/030079904125004475; Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004; Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198-007-0540-8; SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539; Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077; Shane E, 2010, NEW ENGL J MED, V362, P1825, DOI 10.1056/NEJMe1003064; Stepan JJ, 2007, BONE, V41, P378, DOI 10.1016/j.bone.2007.04.198; Tannenbaum C, 2002, J CLIN ENDOCR METAB, V87, P4431, DOI 10.1210/jc.2002-020275; Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009-1947; Woo SB, 2006, ANN INTERN MED, V145, P235, DOI 10.7326/0003-4819-145-10-200611210-00023; Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003-4819-144-10-200605160-00009	57	121	132	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2027	2035		10.1056/NEJMct1004903	http://dx.doi.org/10.1056/NEJMct1004903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083387				2022-12-28	WOS:000284310000007
J	Gallus, A				Gallus, Alexander			Extended-duration enoxaparin reduced VTE but increased major bleeding in patients with acute medical illness	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Flinders Med Ctr, Dept Haematol, Adelaide, SA, Australia	Flinders Medical Centre	Gallus, A (corresponding author), Flinders Med Ctr, Dept Haematol, Adelaide, SA, Australia.			Gallus, Alexander/0000-0001-7347-9989					0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-8	10.1059/0003-4819-153-10-201011160-02008	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079215				2022-12-28	WOS:000284215800007
J	Marsh, K				Marsh, Kevin			Research priorities for malaria elimination	LANCET			English	Editorial Material									Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Kilifi 80108, Kenya	Kenya Medical Research Institute	Marsh, K (corresponding author), Kenya Govt Med Res Ctr, Wellcome Trust Collaborat Programme, Kilifi 80108, Kenya.							BAIRD JK, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61494.8; Bejon P, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000304; SABOT O, 2010, LANCET, DOI DOI 10.1016/S0140.6236(10)61355.4; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; TATEM AJ, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61301.3	5	21	21	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 13	2010	376	9753					1626	1627		10.1016/S0140-6736(10)61499-7	http://dx.doi.org/10.1016/S0140-6736(10)61499-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21035843				2022-12-28	WOS:000284451000008
J	Li, XY; Gianoulis, TA; Yip, KY; Gerstein, M; Snyder, M				Li, Xiyan; Gianoulis, Tara A.; Yip, Kevin Y.; Gerstein, Mark; Snyder, Michael			Extensive In Vivo Metabolite-Protein Interactions Revealed by Large-Scale Systematic Analyses	CELL			English	Article							GLOBAL ANALYSIS; SACCHAROMYCES-CEREVISIAE; YEAST; KINASE; RECONSTRUCTION; BIOSYNTHESIS; CYTOSCAPE; MUTANTS; PATHWAY	Natural small compounds comprise most cellular molecules and bind proteins as substrates, products, cofactors, and ligands. However, a large-scale investigation of in vivo protein-small metabolite interactions has not been performed. We developed a mass spectrometry assay for the large-scale identification of in vivo protein-hydrophobic small metabolite interactions in yeast and analyzed compounds that bind ergosterol biosynthetic proteins and protein kinases. Many of these proteins bind small metabolites; a few interactions were previously known, but the vast majority are new. Importantly, many key regulatory proteins such as protein kinases bind metabolites. Ergosterol was found to bind many proteins and may function as a general regulator. It is required for the activity of Ypk1, a mammalian AKT/SGK kinase homolog. Our study defines potential key regulatory steps in lipid biosynthetic pathways and suggests that small metabolites may play a more general role as regulators of protein activity and function than previously appreciated.	[Li, Xiyan; Snyder, Michael] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Li, Xiyan; Snyder, Michael] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Gianoulis, Tara A.; Gerstein, Mark] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Yip, Kevin Y.; Gerstein, Mark; Snyder, Michael] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Gerstein, Mark] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA	Stanford University; Yale University; Yale University; Yale University; Yale University	Snyder, M (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	mpsnyder@stanford.edu	Li, Xiyan/B-5495-2011; Yip, Kevin/AAT-4771-2020	Li, Xiyan/0000-0002-1959-2160; Yip, Kevin/0000-0001-5516-9944; Snyder, Michael/0000-0003-0784-7987	NIH; NSF [DBI-1042344]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062480] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank E. Davidov and X. Zhou for technical assistance and Drs. H. Im, M. Bruno, and L. Wu for comments on the manuscript. This work was supported by grants from the NIH (M.S. and M.G.) and in part from an NSF grant DBI-1042344 (X.L. and M.S.). The conceptual design for the project was developed by X.L. and M.S. Laboratory experiments were performed by X.L. Data analyses were performed by X.L., T.G., K.Y.Y., and M.G. The manuscript was prepared by X.L. and M.S.	Alberts B., 2008, MOL BIOL CEL, V5th ed.; Allen J, 2003, NAT BIOTECHNOL, V21, P692, DOI 10.1038/nbt823; Babu P, 2004, J BIOL CHEM, V279, P27138, DOI 10.1074/jbc.M403071200; Beloqui A, 2009, SCIENCE, V326, P252, DOI 10.1126/science.1174094; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Breitkreutz BJ, 2008, NUCLEIC ACIDS RES, V36, pD637, DOI 10.1093/nar/gkm1001; Carrier A, 2000, J CHROMATOGR A, V876, P97, DOI 10.1016/S0021-9673(00)00148-5; Cascante M, 2008, ESSAYS BIOCHEM, V45, P67, DOI 10.1042/BSE0450067; Caydasi AK, 2009, DEV CELL, V16, P146, DOI 10.1016/j.devcel.2008.10.013; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Ejsing CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/pnas.0811700106; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forster J, 2003, GENOME RES, V13, P244, DOI 10.1101/gr.234503; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Herrgard MJ, 2008, NAT BIOTECHNOL, V26, P1155, DOI 10.1038/nbt1492; Hillenmeyer ME, 2008, SCIENCE, V320, P362, DOI 10.1126/science.1150021; Horak Christine E, 2002, Funct Integr Genomics, V2, P171; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Jacquier N, 2010, J CELL SCI, V123, P2218, DOI 10.1242/jcs.063073; KARST F, 1977, MOL GEN GENET, V154, P269, DOI 10.1007/BF00571282; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; Lee YS, 2007, SCIENCE, V316, P109, DOI 10.1126/science.1139080; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Maynard Jennifer A., 2009, Biotechnology Journal, V4, P1542, DOI 10.1002/biot.200900195; Morozov VN, 2003, RAPID COMMUN MASS SP, V17, P2430, DOI 10.1002/rcm.1213; Nicholson JK, 2008, J PROTEOME RES, V7, P3637, DOI 10.1021/pr8005099; PARKS LW, 1995, ANNU REV MICROBIOL, V49, P95, DOI 10.1146/annurev.mi.49.100195.000523; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Ptacek J, 2005, NATURE, V438, P679, DOI 10.1038/nature04187; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Sen Gupta S, 2003, J BIOL CHEM, V278, P28831, DOI 10.1074/jbc.M303300200; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Snyder M, 2009, FEBS LETT, V583, P3895, DOI 10.1016/j.febslet.2009.11.011; Tagore R, 2008, J AM CHEM SOC, V130, P14111, DOI 10.1021/ja806463c; Teichmann SA, 2004, NAT GENET, V36, P492, DOI 10.1038/ng1340; Yano KI, 1997, P NATL ACAD SCI USA, V94, P1721, DOI 10.1073/pnas.94.5.1721; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	39	152	156	3	64	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					639	650		10.1016/j.cell.2010.09.048	http://dx.doi.org/10.1016/j.cell.2010.09.048			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21035178	Green Accepted, Bronze			2022-12-28	WOS:000284149100020
J	Lompe, T; Ottenstein, TB; Serwane, F; Wenz, AN; Zurn, G; Jochim, S				Lompe, Thomas; Ottenstein, Timo B.; Serwane, Friedhelm; Wenz, Andre N.; Zuern, Gerhard; Jochim, Selim			Radio-Frequency Association of Efimov Trimers	SCIENCE			English	Article							BOUND-STATES; ATOMS; UNIVERSALITY; SCATTERING; GAS	The quantum mechanical three-body problem is one of the fundamental challenges of few-body physics. When the two-body interactions become resonant, an infinite series of universal three-body bound states is predicted to occur, whose properties are determined by the strength of the two-body interactions. We used radio-frequency fields to associate Efimov trimers consisting of three distinguishable fermions. The measurements of their binding energy are consistent with theoretical predictions that include nonuniversal corrections.	[Lompe, Thomas; Ottenstein, Timo B.; Serwane, Friedhelm; Wenz, Andre N.; Zuern, Gerhard; Jochim, Selim] Univ Heidelberg, Inst Phys, D-69120 Heidelberg, Germany; [Lompe, Thomas; Ottenstein, Timo B.; Serwane, Friedhelm; Wenz, Andre N.; Zuern, Gerhard; Jochim, Selim] Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; [Lompe, Thomas; Ottenstein, Timo B.; Serwane, Friedhelm; Jochim, Selim] GSI Helmholtzzentrum Schwerionenforsch, ExtreMe Matter Inst EMMI, D-64291 Darmstadt, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Helmholtz Association; GSI Helmholtz-Center for Heavy Ion Research	Lompe, T (corresponding author), Univ Heidelberg, Inst Phys, D-69120 Heidelberg, Germany.	thomas.lompe@mpi-hd.mpg.de	Serwane, Friedhelm/A-6720-2018; Jochim, Selim/G-1287-2011; Serwane, Friedhelm/AAY-6057-2020	Serwane, Friedhelm/0000-0001-6943-8244; Jochim, Selim/0000-0001-6049-2658; Lompe, Thomas/0000-0002-7880-1639	IMPRS-QD; Helmholtz Alliance [HA216/EMMI]; Heidelberg Center for Quantum Dynamics	IMPRS-QD; Helmholtz Alliance; Heidelberg Center for Quantum Dynamics	We thank E. Braaten, J. P. D'Incao, and H. W. Hammer for inspiring discussions; P. Naidon for providing his data on the trimer binding energies; and J. Ullrich and his group for their support. Supported by the IMPRS-QD (G. Z. and A. N. W.), the Helmholtz Alliance HA216/EMMI, and the Heidelberg Center for Quantum Dynamics.	Barontini G, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.043201; Bartenstein M, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.103201; Braaten E, 2006, PHYS REP, V428, P259, DOI 10.1016/j.physrep.2006.03.001; Braaten E, 2010, PHYS REV A, V81, DOI 10.1103/PhysRevA.81.013605; Chin C, 2010, REV MOD PHYS, V82, P1225, DOI 10.1103/RevModPhys.82.1225; EFIMOV VN, 1971, SOV J NUCL PHYS+, V12, P589; Ferlaino F, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.140401; Gross N, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.103203; Gross N, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.163202; Huckans JH, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.165302; Klempt C, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.061602; Knoop S, 2009, NAT PHYS, V5, P227, DOI 10.1038/NPHYS1203; Kraemer T, 2006, NATURE, V440, P315, DOI 10.1038/nature04626; Lompe T, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.103201; Nakajima S, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.023201; Ottenstein TB, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.203202; Pollack SE, 2009, SCIENCE, V326, P1683, DOI 10.1126/science.1182840; Regal CA, 2003, NATURE, V424, P47, DOI 10.1038/nature01738; Shin Y, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.030401; von Stecher J, 2009, NAT PHYS, V5, P417, DOI 10.1038/NPHYS1253; Williams JR, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.130404; Zaccanti M, 2009, NAT PHYS, V5, P586, DOI 10.1038/NPHYS1334	22	136	136	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					940	944		10.1126/science.1193148	http://dx.doi.org/10.1126/science.1193148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071663	Green Submitted			2022-12-28	WOS:000284118000035
J	Vollan, B; Ostrom, E				Vollan, Bjoern; Ostrom, Elinor			Cooperation and the Commons	SCIENCE			English	Editorial Material							CROWDING-OUT; GOVERNANCE; MANAGEMENT		[Vollan, Bjoern] Univ Mannheim, Dept Econ, D-68131 Mannheim, Germany; [Ostrom, Elinor] Arizona State Univ, Tempe, AZ 85287 USA; [Ostrom, Elinor] Indiana Univ, Bloomington, IN 47408 USA	University of Mannheim; Arizona State University; Arizona State University-Tempe; Indiana University System; Indiana University Bloomington	Vollan, B (corresponding author), Univ Mannheim, Dept Econ, L7,3-5, D-68131 Mannheim, Germany.	bjoern.vollan@uni-mannheim.de; ostrom@indiana.edu	Vollan, Björn/AAN-9265-2020; currie, morgan/G-1449-2011	Vollan, Björn/0000-0002-5592-4185; 				Baland J.-M., 2005, HALTING DEGRADATION; Camerer C, 2003, BEHAV GAME THEORY; Cardenas J.C., 2000, ENVIRON DEV SUSTAIN, V2, P305, DOI DOI 10.1023/A:1011422313042; Cardenas JC, 2000, WORLD DEV, V28, P1719, DOI 10.1016/S0305-750X(00)00055-3; Cardenas JC, 2004, FOREST POLICY ECON, V6, P229, DOI 10.1016/j.forpol.2004.03.006; Moreno-Sanchez RD, 2010, ECOL ECON, V69, P2557, DOI 10.1016/j.ecolecon.2010.07.032; Fehr E, 2000, AM ECON REV, V90, P980, DOI 10.1257/aer.90.4.980; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; *NAT RES COUNC, 1986, C COMM PROP RES MAN; Ostrom Elinor, 2002, DRAM COMM; Ostrom, 1990, GOVERNING COMMONS; Ostrom E., 1994, RULES GAMES COMMON P; Ostrom E, 2009, SCIENCE, V325, P419, DOI 10.1126/science.1172133; Poteete AR, 2010, WORKING TOGETHER: COLLECTIVE ACTION, THE COMMONS, AND MULTIPLE METHODS IN PRACTICE, P1; PREDIGER S, 2010, ECOL EC; Rustagi D, 2010, SCIENCE, V330, P961, DOI 10.1126/science.1193649; Velez MA, 2010, ECON INQ, V48, P254, DOI 10.1111/j.1465-7295.2008.00125.x; Vollan B, 2008, ECOL ECON, V67, P560, DOI 10.1016/j.ecolecon.2008.01.015	18	71	74	4	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2010	330	6006					923	924		10.1126/science.1198349	http://dx.doi.org/10.1126/science.1198349			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678XY	21071656				2022-12-28	WOS:000284118000028
J	Connor, CE				Connor, Charles E.			A New Viewpoint on Faces	SCIENCE			English	Editorial Material							MACAQUE TEMPORAL-LOBE; OBJECT RECOGNITION; SINGLE NEURONS; VISUAL-CORTEX; REPRESENTATION; ORGANIZATION; CELLS; AREA		[Connor, Charles E.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21218 USA; [Connor, Charles E.] Johns Hopkins Univ, Sch Arts & Sci, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Connor, CE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21218 USA.	connor@jhu.edu						BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Freiwald WA, 2010, SCIENCE, V330, P845, DOI 10.1126/science.1194908; Freiwald WA, 2009, NAT NEUROSCI, V12, P1187, DOI 10.1038/nn.2363; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Leopold DA, 2006, NATURE, V442, P572, DOI 10.1038/nature04951; Li N, 2008, SCIENCE, V321, P1502, DOI 10.1126/science.1160028; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; Moeller S, 2008, SCIENCE, V320, P1355, DOI 10.1126/science.1157436; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; Sugase Y, 1999, NATURE, V400, P869, DOI 10.1038/23703; Tsao DY, 2006, SCIENCE, V311, P670, DOI 10.1126/science.1119983; VETTER T, 1994, CURR BIOL, V4, P18, DOI 10.1016/S0960-9822(00)00004-X; VETTER T, 1995, CEREB CORTEX, V5, P261, DOI 10.1093/cercor/5.3.261	14	7	7	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					764	765		10.1126/science.1198348	http://dx.doi.org/10.1126/science.1198348			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051621				2022-12-28	WOS:000283855700025
J	Reed, JP; Uchoa, B; Joe, YI; Gan, Y; Casa, D; Fradkin, E; Abbamonte, P				Reed, James P.; Uchoa, Bruno; Joe, Young Il; Gan, Yu; Casa, Diego; Fradkin, Eduardo; Abbamonte, Peter			The Effective Fine-Structure Constant of Freestanding Graphene Measured in Graphite	SCIENCE			English	Article							DYNAMICS	Electrons in graphene behave like Dirac fermions, permitting phenomena from high-energy physics to be studied in a solid-state setting. A key question is whether or not these fermions are critically influenced by Coulomb correlations. We performed inelastic x-ray scattering experiments on crystals of graphite and applied reconstruction algorithms to image the dynamical screening of charge in a freestanding graphene sheet. We found that the polarizability of the Dirac fermions is amplified by excitonic effects, improving screening of interactions between quasiparticles. The strength of interactions is characterized by a scale-dependent, effective fine-structure constant, alpha*(g) (k, omega), the value of which approaches 0.14 +/- 0.092 similar to 1/7 at low energy and large distances. This value is substantially smaller than the nominal alpha(g) = 2.2, suggesting that, on the whole, graphene is more weakly interacting than previously believed.	[Reed, James P.; Uchoa, Bruno; Joe, Young Il; Gan, Yu; Fradkin, Eduardo; Abbamonte, Peter] Univ Illinois, Dept Phys, Urbana, IL 61801 USA; [Reed, James P.; Uchoa, Bruno; Joe, Young Il; Gan, Yu; Fradkin, Eduardo; Abbamonte, Peter] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; [Casa, Diego] Argonne Natl Lab, Adv Photon Source, Argonne, IL 60439 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory	Abbamonte, P (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	abbamonte@mrl.uiuc.edu	Casa, Diego M/F-9060-2016; Fradkin, Eduardo H/B-5612-2013	Fradkin, Eduardo/0000-0001-6837-463X; Uchoa, Bruno/0000-0002-9443-5050	U.S. Department of Energy through the Frederick Seitz Materials Research Laboratory [DE-FG02-07ER46459, DE-FG02-07ER46453, DEAC02-06CH11357]	U.S. Department of Energy through the Frederick Seitz Materials Research Laboratory	We gratefully acknowledge helpful discussions with A. H. MacDonald, D. Maslov, P. Guinea, L. Levitov, and A. J. Millis, and Y. Cai for supplying graphite crystals. This work was supported by the U.S. Department of Energy under grants DE-FG02-07ER46459 and DE-FG02-07ER46453 through the Frederick Seitz Materials Research Laboratory, with use of the Advanced Photon Source supported by DEAC02-06CH11357.	Abbamonte P, 2010, ADV MATER, V22, P1141, DOI 10.1002/adma.200904098; Aryasetiawan F, 1998, REP PROG PHYS, V61, P237, DOI 10.1088/0034-4885/61/3/002; Barlas Y, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.236601; Bolotin KI, 2009, NATURE, V462, P196, DOI 10.1038/nature08582; Bostwick A, 2007, NAT PHYS, V3, P36, DOI 10.1038/nphys477; Castro Neto AH, 2009, REV MOD PHYS, V81, P109, DOI 10.1103/RevModPhys.81.109; Checkelsky JG, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.115434; Drut JE, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.026802; Du X, 2008, NAT NANOTECHNOL, V3, P491, DOI 10.1038/nnano.2008.199; Du X, 2009, NATURE, V462, P192, DOI 10.1038/nature08522; Eberlein T, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.233406; GONZALEZ J, 1994, NUCL PHYS B, V424, P595, DOI 10.1016/0550-3213(94)90410-3; Hiraoka N, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.075103; Hwang EH, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.226801; Jang C, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.146805; Li ZQ, 2008, NAT PHYS, V4, P532, DOI 10.1038/nphys989; Marinopoulos AG, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.245419; Martin J, 2008, NAT PHYS, V4, P144, DOI 10.1038/nphys781; Muller M, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.025301; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Pines D., 1999, THEORY QUANTUM LIQUI; Polini M, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.115426; Ponomarenko LA, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.206603; Schulke W., 2007, ELECT DYNAMICS INELA; Sheehy DE, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.226803; Trevisanutto PE, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.121405; Yang L, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.186802; Zhou SY, 2006, NAT PHYS, V2, P595, DOI 10.1038/nphys393	28	104	105	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					805	808		10.1126/science.1190920	http://dx.doi.org/10.1126/science.1190920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051634	Green Submitted			2022-12-28	WOS:000283855700038
J	Lo, YL; See, S				Lo, Yew Long; See, Siewju			Pseudoathetosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Lo, Yew Long; See, Siewju] Singapore Gen Hosp, Singapore 0316, Singapore	Singapore General Hospital	Lo, YL (corresponding author), Singapore Gen Hosp, Singapore 0316, Singapore.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					E29	E29		10.1056/NEJMicm0907786	http://dx.doi.org/10.1056/NEJMicm0907786			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047218				2022-12-28	WOS:000283787800010
J	Sulmasy, DP; Snyder, L				Sulmasy, Daniel P.; Snyder, Lois			Substituted Interests and Best Judgments An Integrated Model of Surrogate Decision Making	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FAMILY-MEMBER; OTHERS		[Sulmasy, Daniel P.] Univ Chicago, MacLean Ctr Clin Med Eth, Dept Med, Chicago, IL 60637 USA; [Sulmasy, Daniel P.] Univ Chicago, Divin Sch, Chicago, IL 60637 USA; [Snyder, Lois] Amer Coll Physicians, Ctr Eth & Professionalism, Philadelphia, PA USA	University of Chicago; University of Chicago; American College of Physicians	Sulmasy, DP (corresponding author), Univ Chicago, MacLean Ctr Clin Med Eth, Dept Med, MC 6098,5841 S Maryland Ave, Chicago, IL 60637 USA.	dsulmasy@uchicago.edu						Brudney D, 2009, HASTINGS CENT REP, V39, P31; Fagerlin A, 2004, HASTINGS CENT REP, V34, P30, DOI 10.2307/3527683; Fagerlin A, 2001, HEALTH PSYCHOL, V20, P166, DOI 10.1037/0278-6133.20.3.166; Gries CJ, 2008, CHEST, V133, P704, DOI 10.1378/chest.07-1773; Hirschman KB, 2006, AM J GERIAT PSYCHIAT, V14, P659, DOI 10.1097/01.JGP.0000203179.94036.69; Perkins HS, 2007, ANN INTERN MED, V147, P51, DOI 10.7326/0003-4819-147-1-200707030-00008; Shalowitz DI, 2006, ARCH INTERN MED, V166, P493, DOI 10.1001/archinte.166.5.493; Sulmasy DP, 2007, J AM GERIATR SOC, V55, P1981, DOI 10.1111/j.1532-5415.2007.01473.x; Sulmasy DP, 2006, J GEN INTERN MED, V21, P1261, DOI 10.1111/j.1525-1497.2006.00612.x; Vig EK, 2007, J GEN INTERN MED, V22, P1274, DOI 10.1007/s11606-007-0252-y	10	99	101	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1946	1947		10.1001/jama.2010.1595	http://dx.doi.org/10.1001/jama.2010.1595			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045102				2022-12-28	WOS:000283725900026
J	Guclu, M; Lin, L; Erturk, E; Achermann, JC; Cangul, H				Guclu, Metin; Lin, Lin; Erturk, Erdinc; Achermann, John C.; Cangul, Hakan			Puberty, stress, and sudden death	LANCET			English	Editorial Material							ADRENAL INSUFFICIENCY; MUTATION		[Guclu, Metin; Erturk, Erdinc] Uludag Univ, Sch Med, Dept Endocrinol & Metab, TR-16059 Bursa, Turkey; [Cangul, Hakan] Uludag Univ, Sch Med, Dept Med Genet, TR-16059 Bursa, Turkey; [Lin, Lin; Achermann, John C.] UCL, UCL Inst Child Hlth, Clin & Mol Genet Unit, Dev Endocrinol Res Grp, London, England	Uludag University; Uludag University; University of London; University College London	Erturk, E (corresponding author), Uludag Univ, Sch Med, Dept Endocrinol & Metab, TR-16059 Bursa, Turkey.	ererturk@uludag.edu.tr	Erturk, Erdinc/AAJ-6536-2021; Achermann, John/N-2906-2019; Achermann, John/C-5476-2008; Guclu, Metin/ABI-4847-2020	Achermann, John/0000-0001-8787-6272; Achermann, John/0000-0001-8787-6272; 	Wellcome Trust [079666] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arlt W, 2003, LANCET, V361, P1881, DOI 10.1016/S0140-6736(03)13492-7; Arlt W, 2009, J CLIN ENDOCR METAB, V94, P1059, DOI 10.1210/jc.2009-0032; Lin L, 2006, J CLIN ENDOCR METAB, V91, P3048, DOI 10.1210/jc.2006-0603; Ozisik G, 2003, J CLIN ENDOCR METAB, V88, P417, DOI 10.1210/jc.2002-021034; Tabarin A, 2000, J CLIN INVEST, V105, P321, DOI 10.1172/JCI7212	5	14	14	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2010	376	9751					1512	1512		10.1016/S0140-6736(10)61153-1	http://dx.doi.org/10.1016/S0140-6736(10)61153-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	21036276				2022-12-28	WOS:000284248500035
J	James, MT; Hemmelgarn, BR; Wiebe, N; Pannu, N; Manns, BJ; Klarenbach, SW; Tonelli, M				James, Matthew T.; Hemmelgarn, Brenda R.; Wiebe, Natasha; Pannu, Neesh; Manns, Braden J.; Klarenbach, Scott W.; Tonelli, Marcello		Alberta Kidney Dis Network	Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study	LANCET			English	Article							ACUTE-RENAL-FAILURE; PERCUTANEOUS CORONARY INTERVENTION; SERUM CREATININE; DISEASE; RISK; MORTALITY; OUTCOMES; NEPHROPATHY; PREDICTION; INCREASES	Background Low values of estimated glomerular filtration rate (eGFR) predispose to acute kidney injury, and proteinuria is a marker of kidney disease. We aimed to investigate how eGFR and proteinuria jointly modified the risks of acute kidney injury and subsequent adverse clinical outcomes. Methods We did a cohort study of 920 985 adults residing in Alberta, Canada, between 2002 and 2007. Participants not needing chronic dialysis at baseline and with at least one outpatient measurement of both serum creatinine concentration and proteinuria (urine dipstick or albumin-creatinine ratio) were included. We assessed hospital admission with acute kidney injury with validated administrative codes; other outcomes were all-cause mortality and a composite renal outcome of end-stage renal disease or doubling of serum creatinine concentration. Findings During median follow-up of 35 months (range 0-59 months), 6520 (0.7%) participants were admitted with acute kidney injury. In those with eGFR 60 mL/min per 1.73 m(2) or greater, the adjusted risk of admission with this disorder was about 4 times higher in those with heavy proteinuria measured by dipstick (rate ratio 4.4 vs no proteinuria, 95% CI 3.7-5.2). The adjusted rates of admission with acute kidney injury and kidney injury needing dialysis remained high in participants with heavy dipstick proteinuria for all values of eGFR. The adjusted rates of death and the composite renal outcome were also high in participants admitted with acute kidney injury, although the rise associated with this injury was attenuated in those with low baseline eGFR and heavy proteinuria. Interpretation These findings suggest that information on proteinuria and eGFR should be used together when identifying people at risk of acute kidney injury, and that an episode of acute kidney injury provides further long-term prognostic information in addition to eGFR and proteinuria.	[James, Matthew T.; Hemmelgarn, Brenda R.; Manns, Braden J.] Univ Calgary, Dept Med, Calgary, AB, Canada; [James, Matthew T.; Hemmelgarn, Brenda R.; Manns, Braden J.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Wiebe, Natasha; Pannu, Neesh; Klarenbach, Scott W.; Tonelli, Marcello] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Klarenbach, Scott W.; Tonelli, Marcello] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada	University of Calgary; University of Calgary; University of Alberta; University of Alberta	Tonelli, M (corresponding author), 7-129 Clin Sci Bldg,8440 112 St, Edmonton, AB T6B 2G3, Canada.	mtonelli-admin@med.ualberta.ca	Klarenbach, Scott/E-7731-2013; Wiebe, Natasha/V-7803-2019; Hug, Balthasar L./G-1568-2010; Hemmelgarn, Brenda R./I-6894-2012; Manns, Braden J/I-8942-2012; Tonelli, Marcello/B-3028-2009	Klarenbach, Scott/0000-0002-8611-1056; Wiebe, Natasha/0000-0002-5613-1582; Tonelli, Marcello/0000-0002-0846-3187	Alberta Heritage Foundation for Medical Research (AHFMR); Kidney Foundation of Canada/the Canadian Institutes for Health Research (CIHR); CIHR	Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research); Kidney Foundation of Canada/the Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	This study was funded by an interdisciplinary team grant from Alberta Heritage Foundation for Medical Research (AHFMR). MTJ is supported by a KRESCENT award from the Kidney Foundation of Canada/the Canadian Institutes for Health Research (CIHR) and an AHFMR fellowship award. MT is supported by a Health Scholar and SWK and BRH by Population Health Investigator Awards from the AHFMR. MT, BJM, and BRH are supported by New Investigator Awards from the CIHR.	Amdur RL, 2009, KIDNEY INT, V76, P1089, DOI 10.1038/ki.2009.332; Bartholomew BA, 2004, AM J CARDIOL, V93, P1515, DOI 10.1016/j.amjcard.2004.03.008; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; Coca SG, 2007, AM J KIDNEY DIS, V50, P712, DOI 10.1053/j.ajkd.2007.07.018; Coca SG, 2009, AM J KIDNEY DIS, V53, P961, DOI 10.1053/j.ajkd.2008.11.034; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Hallan SI, 2009, J AM SOC NEPHROL, V20, P1069, DOI 10.1681/ASN.2008070730; Hemmelgarn BR, 2009, BMC NEPHROL, V10, DOI 10.1186/1471-2369-10-30; Hemmelgarn BR, 2010, JAMA-J AM MED ASSOC, V303, P423, DOI 10.1001/jama.2010.39; Hillege HL, 2002, CIRCULATION, V106, P1777, DOI 10.1161/01.CIR.0000031732.78052.81; Hsu CY, 2008, KIDNEY INT, V74, P101, DOI 10.1038/ki.2008.107; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Ishani A, 2009, J AM SOC NEPHROL, V20, P8; Khosla N, 2009, CLIN J AM SOC NEPHRO, V4, P1914, DOI 10.2215/CJN.01690309; Lamb EJ, 2009, ANN CLIN BIOCHEM, V46, P205, DOI 10.1258/acb.2009.009007; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levin A, 2007, AM J KIDNEY DIS, V50, P1, DOI 10.1053/j.ajkd.2007.05.008; Lo LJ, 2009, KIDNEY INT, V76, P893, DOI 10.1038/ki.2009.289; Manns BJ, 2001, CLIN INVEST MED, V24, P164; Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068; Newsome BB, 2008, ARCH INTERN MED, V168, P609, DOI 10.1001/archinte.168.6.609; Parikh CR, 2008, ARCH INTERN MED, V168, P987, DOI 10.1001/archinte.168.9.987; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quan HD, 2009, HYPERTENSION, V54, P1423, DOI 10.1161/HYPERTENSIONAHA.109.139279; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Sin DD, 2003, CHEST, V124, P51, DOI 10.1378/chest.124.1.51; Stevens LA, 2008, AM J KIDNEY DIS, V51, P395, DOI 10.1053/j.ajkd.2007.11.018; Tonelli M, 2006, J AM SOC NEPHROL, V17, P2034, DOI 10.1681/ASN.2005101085; Waikar SS, 2008, CLIN J AM SOC NEPHRO, V3, P844, DOI 10.2215/CJN.05191107; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	33	221	236	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	2010	376	9758					2096	2103		10.1016/S0140-6736(10)61271-8	http://dx.doi.org/10.1016/S0140-6736(10)61271-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702LA	21094997				2022-12-28	WOS:000285895000027
J	deFilippi, CR; de Lemos, JA; Christenson, RH; Gottdiener, JS; Kop, WJ; Zhan, M; Seliger, SL				deFilippi, Christopher R.; de Lemos, James A.; Christenson, Robert H.; Gottdiener, John S.; Kop, Willem J.; Zhan, Min; Seliger, Stephen L.			Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREDICTION; DISEASE; RISK; VALIDATION; BIOMARKERS; COMMUNITY; EVENTS; UPDATE; MARKER; HEALTH	Context Older adults comprise the majority of new-onset heart failure (HF) diagnoses, but traditional risk-factor prediction models have limited accuracy in this population to identify those at highest risk for hospitalization or death. Objectives To determine if cardiac troponin T (cTnT) measured by a highly sensitive assay would be detectable in the majority of community-dwelling older adults, and if serial measures were associated with risk of HF hospitalization and cardiovascular death. Design, Setting, and Participants A longitudinal nationwide cohort study (Cardiovascular Health Study) of 4221 community-dwelling adults aged 65 years or older without prior HF who had cTnT measured using a highly sensitive assay at baseline (1989-1990) and repeated after 2 to 3 years (n=2918). Main Outcome Measures New-onset HF and cardiovascular death were examined through June 2008 with respect to cTnT concentrations, accounting for clinical risk predictors. Results Cardiac troponin T was detectable (>= 3.00 pg/mL) in 2794 participants (66.2%). During a median follow-up of 11.8 years, 1279 participants experienced new-onset HF and 1103 cardiovascular deaths occurred, with a greater risk of both end points associated with higher cTnT concentrations. Among those participants with the highest cTnT concentrations (>12.94 pg/mL), there was an incidence rate per 100 person-years of 6.4 (95% confidence interval [CI], 5.8-7.2; adjusted hazard ratio [aHR], 2.48; 95% CI, 2.04-3.00) for HF and an incidence rate of 4.8 (95% CI, 4.3-5.4; aHR, 2.91; 95% CI, 2.37-3.58) for cardiovascular death compared with participants with undetectable cTnT levels (incidence rate, 1.6; 95% CI, 1.4-1.8 and 1.1; 95% CI, 0.9-1.2 for HF and cardiovascular death, respectively). Among individuals with initially detectable cTnT, a subsequent increase of more than 50% (n=393, 22%) was associated with a greater risk for HF (aHR, 1.61; 95% CI, 1.32-1.97) and cardiovascular death (aHR, 1.65; 95% CI, 1.35-2.03) and a decrease of more than 50% (n=247, 14%) was associated with a lower risk for HF (aHR, 0.73; 95% CI, 0.54-0.97) and cardiovascular death (aHR, 0.71; 95% CI, 0.52-0.97) compared with participants with 50% or less change. Addition of baseline cTnT measurements to clinical risk factors was associated with only modest improvement in discrimination, with change in C statistic of 0.015 for HF and 0.013 for cardiovascular death. Conclusion In this cohort of older adults without known HF, baseline cTnT levels and changes in cTnT levels measured with a highly sensitive assay were significantly associated with incident HF and cardiovascular death. JAMA. 2010;304(22):2494-2502 www.jama.com	[deFilippi, Christopher R.; Gottdiener, John S.; Kop, Willem J.; Seliger, Stephen L.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21212 USA; [Christenson, Robert H.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21212 USA; [Zhan, Min] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21212 USA; [de Lemos, James A.] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Southwestern Medical Center Dallas	deFilippi, CR (corresponding author), Univ Maryland, Sch Med, Dept Med, G3K63,22 S Greene St, Baltimore, MD 21212 USA.	cdefilip@medicine.umaryland.edu	de Lemos, James/ABD-6669-2021	Seliger, Stephen/0000-0002-1693-0734	Roche Diagnostics; Siemens Healthcare Diagnostics; Critical Diagnostics; BG Medicine; Biosite; Biosite/Inverness; Siemens; Siemens Medical Diagnostics and Response Biomedical; National Heart, Lung, and Blood Institute (NHLBI) [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085084, N01HC085085, N01HC085083, N01HC055222, N01HC015103, N01HC045133, N01HC075150, N01HC085086, N01HC085079, N01HC085080, N01HC085082, N01HC035129, N01HC085081] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075366, U01HL080295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015928, R01AG020098, P30AG024827, R01AG027058] Funding Source: NIH RePORTER	Roche Diagnostics; Siemens Healthcare Diagnostics; Critical Diagnostics; BG Medicine; Biosite; Biosite/Inverness; Siemens(Siemens AG); Siemens Medical Diagnostics and Response Biomedical; National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr deFilippi reported receiving honorarium, consulting, and grant support from Roche Diagnostics and Siemens Healthcare Diagnostics, and consulting and grant support from Critical Diagnostics and BG Medicine. Dr de Lemos reported receiving research support from Biosite and Roche Diagnostics, and consulting fees, lecture honoraria, or both from Roche Diagnostics, Biosite/Inverness, and Siemens. Dr Christenson reported receiving research funding from Siemens Medical Diagnostics and Response Biomedical. Dr Seliger reported receiving grant and consulting support from Roche Diagnostics. Drs Gottdiener, Kop, and Zahn reported no financial disclosures.; This study was supported by grants N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and U01 HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through R01 AG-15928, R01 AG-20098, and AG-027058 from the National Institute on Aging; R01 HL-075366 from the NHLBI; and the University of Pittsburgh Claude D. Pepper Older Americans Independence Center P30-AG-024827. Additional funding was provided by Roche Diagnostics. Roche Diagnostics provided funding and laboratory reagents for the highly sensitive cardiac troponin T assay.	CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; Daniels LB, 2008, J AM COLL CARDIOL, V52, P450, DOI 10.1016/j.jacc.2008.04.033; deFilippi CR, 2010, J AM COLL CARDIOL, V55, P441, DOI 10.1016/j.jacc.2009.07.069; Di Angelantonio E, 2009, CIRCULATION, V120, P2177, DOI 10.1161/CIRCULATIONAHA.109.884866; Eggers KM, 2008, EUR HEART J, V29, P2252, DOI 10.1093/eurheartj/ehn327; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Giannitsis E, 2010, CLIN CHEM, V56, P254, DOI 10.1373/clinchem.2009.132654; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Hills, 1993, STAT MODELS EPIDEMIO; Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kalogeropoulos A, 2010, CIRC-HEART FAIL, V3, P495, DOI 10.1161/CIRCHEARTFAILURE.109.904300; Latini R, 2007, CIRCULATION, V116, P1242, DOI 10.1161/CIRCULATIONAHA.106.655076; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49, DOI 10.1001/jama.2009.943; Omland T, 2009, NEW ENGL J MED, V361, P2538, DOI 10.1056/NEJMoa0805299; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pencina MJ, 2009, CIRCULATION, V119, P3078, DOI 10.1161/CIRCULATIONAHA.108.816694; Pfisterer M, 2009, JAMA-J AM MED ASSOC, V301, P383, DOI 10.1001/jama.2009.2; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; Rautaharju PM, 1996, HYPERTENSION, V28, P8, DOI 10.1161/01.HYP.28.1.8; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Sabatine MS, 2009, EUR HEART J, V30, P162, DOI 10.1093/eurheartj/ehn504; Schellenbaum GD, 2004, AM J EPIDEMIOL, V160, P628, DOI 10.1093/aje/kwh268; Shlipak MG, 2005, JAMA-J AM MED ASSOC, V293, P1737, DOI 10.1001/jama.293.14.1737; Sundstrom J, 2009, EUR HEART J, V30, P773, DOI 10.1093/eurheartj/ehp047; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; Vasile VC, 2010, CLIN CHEM, V56, P1086, DOI 10.1373/clinchem.2009.140616; Wu AHB, 2009, CLIN CHEM, V55, P52, DOI 10.1373/clinchem.2008.107391; Zethelius B, 2008, NEW ENGL J MED, V358, P2107, DOI 10.1056/NEJMoa0707064	34	538	555	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2010	304	22					2494	2502		10.1001/jama.2010.1708	http://dx.doi.org/10.1001/jama.2010.1708			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691AS	21078811	Bronze, Green Accepted			2022-12-28	WOS:000285053300023
J	Navarro, P; Oldfield, A; Legoupi, J; Festuccia, N; Dubois, A; Attia, M; Schoorlemmer, J; Rougeulle, C; Chambers, I; Avner, P				Navarro, Pablo; Oldfield, Andrew; Legoupi, Julie; Festuccia, Nicola; Dubois, Agnes; Attia, Mikael; Schoorlemmer, Jon; Rougeulle, Claire; Chambers, Ian; Avner, Philip			Molecular coupling of Tsix regulation and pluripotency	NATURE			English	Article							X-CHROMOSOME; TRANSCRIPTIONAL NETWORK; XIST TRANSCRIPTION; INACTIVATION; EXPRESSION; CTCF	The reprogramming of X-chromosome inactivation during the acquisition of pluripotency in vivo and in vitro(1) is accompanied by the repression of Xist(2), the trigger of X-inactivation(3), and the upregulation of its antisense counterpart Tsix(4). We have shown that key factors supporting pluripotency-Nanog, Oct4 and Sox2-bind within Xist intron 1 in undifferentiated embryonic stem cells (ESC) to repress Xist transcription(5). However, the relationship between transcription factors of the pluripotency network and Tsix regulation has remained unclear(5,6). Here we show that Tsix upregulation in embryonic stem cells depends on the recruitment of the pluripotent marker Rex1, and of the reprogramming-associated factors Klf4 and c-Myc, by the DXPas34 minisatellite associated with the Tsix promoter. Upon deletion of DXPas34, binding of the three factors is abrogated and the transcriptional machinery is no longer efficiently recruited to the Tsix promoter. Additional analyses including knockdown experiments further demonstrate that Rex1 is critically important for efficient transcription elongation of Tsix. Hence, distinct embryonic-stem-cell-specific complexes couple X-inactivation reprogramming and pluripotency, with Nanog, Oct4 and Sox2 repressing Xist to facilitate the reactivation of the inactive X, and Klf4, c-Myc and Rex1 activating Tsix to remodel Xist chromatin(7-10) and ensure random X-inactivation upon differentiation(1). The holistic pattern of Xist/Tsix regulation by pluripotent factors that we have identified suggests a general direct governance of complex epigenetic processes by the machinery dedicated to pluripotency.	[Navarro, Pablo; Oldfield, Andrew; Legoupi, Julie; Dubois, Agnes; Attia, Mikael; Rougeulle, Claire; Avner, Philip] Inst Pasteur, URA 2578, Unite Genet Mol Murine, F-75724 Paris 15, France; [Navarro, Pablo; Festuccia, Nicola; Chambers, Ian] Univ Edinburgh, Sch Biol Sci, Inst Stem Cell Res, Ctr Dev Stem Cell Biol,MRC, Edinburgh EH9 3JQ, Midlothian, Scotland; [Oldfield, Andrew; Rougeulle, Claire] Univ Paris Diderot, CNRS, UMR Epigenet & Destin Cellulaire 7216, F-75205 Paris 13, France; [Schoorlemmer, Jon] ARAID Fdn, Zaragoza 50013, Spain; [Schoorlemmer, Jon] Fac Vet, Inst Aragones Ciencias Salud, Dept Anat & Embriol, Zaragoza 50013, Spain	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Edinburgh; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Avner, P (corresponding author), Inst Pasteur, URA 2578, Unite Genet Mol Murine, F-75724 Paris 15, France.	pablo.navarro@ed.ac.uk; pavner@pasteur.fr	Chambers, Ian/H-5416-2011; Oldfield, Andrew J./AAP-4354-2021; Oldfield, Andrew/ABF-1343-2021; Schoorlemmer, Jon/R-6814-2019	Chambers, Ian/0000-0003-2605-1597; Oldfield, Andrew/0000-0002-5401-9909; Schoorlemmer, Jon/0000-0001-6933-0567; Rougeulle, Claire/0000-0003-3861-4940	Institut Pasteur; Royal Society; Centre National de la Recherche Scientifique; Agence Nationale de la Recherche [05-JCJC-0166-01, 07-BLAN-0047-01]; EU Epigenome Network of Excellence; INSERM; European Research Council; Wellcome Trust; EU; Medical Research Council; Medical Research Council [G0700711B] Funding Source: researchfish	Institut Pasteur(European Commission); Royal Society(Royal Society of London); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR)); EU Epigenome Network of Excellence; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); European Research Council(European Research Council (ERC)European Commission); Wellcome Trust(Wellcome Trust); EU(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank P. Clerc for discussions. P.N. was initially supported by recurrent funding from the Institut Pasteur and then by the Royal Society (a Newton International Fellowship). P.A. was supported by recurrent funding from the Centre National de la Recherche Scientifique and the Institut Pasteur, contracts 05-JCJC-0166-01 and 07-BLAN-0047-01 from the Agence Nationale de la Recherche and funding from the EU Epigenome Network of Excellence. C.R. was supported by the INSERM 'Avenir' programme and by the European Research Council 'starting grant' programme. Research in I.C.'s laboratory was supported by the Wellcome Trust, by the EU Framework 7 project "EuroSyStem'' and by a Medical Research Council studentship (to N.F.).	BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Do Kim J, 2007, NUCLEIC ACIDS RES, V35, P3442, DOI 10.1093/nar/gkm235; Donohoe ME, 2009, NATURE, V460, P128, DOI 10.1038/nature08098; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Jonkers I, 2009, CELL, V139, P999, DOI 10.1016/j.cell.2009.10.034; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Mak W, 2004, SCIENCE, V303, P666, DOI 10.1126/science.1092674; Masui S, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-45; Navarro P, 2005, GENE DEV, V19, P1474, DOI 10.1101/gad.341105; Navarro P, 2008, SCIENCE, V321, P1693, DOI 10.1126/science.1160952; Navarro P, 2006, GENE DEV, V20, P2787, DOI 10.1101/gad.389006; Navarro P, 2010, BIOESSAYS, V32, P581, DOI 10.1002/bies.201000019; Navarro P, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-8; Navarro P, 2009, FEBS LETT, V583, P1721, DOI 10.1016/j.febslet.2009.03.043; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Ogawa Y, 2003, MOL CELL, V11, P731, DOI 10.1016/S1097-2765(03)00063-7; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Sado T, 2005, DEV CELL, V9, P159, DOI 10.1016/j.devcel.2005.05.015; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Stavropoulos N, 2005, MOL CELL BIOL, V25, P2757, DOI 10.1128/MCB.25.7.2757-2769.2005; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Vigneau S, 2006, P NATL ACAD SCI USA, V103, P7390, DOI 10.1073/pnas.0602381103	30	144	147	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					457	U287		10.1038/nature09496	http://dx.doi.org/10.1038/nature09496			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085182				2022-12-28	WOS:000284313100047
J	Abou-Alfa, GK; Johnson, P; Knox, JJ; Capanu, M; Davidenko, I; Lacava, J; Leung, T; Gansukh, B; Saltz, LB				Abou-Alfa, Ghassan K.; Johnson, Philip; Knox, Jennifer J.; Capanu, Marinela; Davidenko, Irina; Lacava, Juan; Leung, Thomas; Gansukh, Bolorsukh; Saltz, Leonard B.			Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOLID TUMORS; PHASE-III; RAF/MEK/ERK; BAY-43-9006; COMBINATION; RESISTANCE; SURVIVAL; THERAPY; KINASE	Context In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease. In a phase 1 study, sorafenib combined with doxorubicin, 60 mg/m(2), was well tolerated by patients with refractory solid tumors. The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial. Objective To evaluate the efficacy and safety of doxorubicin plus sorafenib compared with doxorubicin alone in patients with advanced HCC and Child-Pugh A disease. Design, Setting, and Patients In a double-blind phase 2 multinational study, conducted from April 2005 to October 2006, 96 patients (76% male; median age, 65 years [range, 38-82 years]) with advanced HCC, Eastern Cooperative Oncology Group performance status 0 to 2, Child-Pugh A status, and no prior systemic therapy were randomly assigned to receive 60 mg/m2 of doxorubicin intravenously every 21 days plus either 400 mg of sorafenib or placebo orally twice a day. The date of the last patient's follow-up was April 2008. Main Outcome Measure Time to progression as determined by independent review. Results Following complete accrual, an unplanned early analysis for efficacy was performed by the independent data monitoring committee, so the trial was halted. The 2 patients remaining in the placebo group at that time were offered sorafenib. Based on 51 progressions, 63 deaths, and 70 events for progression-free survival, median time to progression was 6.4 months in the sorafenib-doxorubicin group (95% confidence interval [CI], 4.8-9.2), and 2.8 months (95% CI, 1.6-5) in the doxorubicin-placebo monotherapy group (P=.02). Median overall survival was 13.7 months (95% CI, 8.9-not reached) and 6.5 months (95% CI, 4.5-9.9; P=.006), and progression-free survival was 6.0 months (95% CI, 4.6-8.6) and 2.7 months (95% CI, 1.4-2.8) in these groups, respectively (P=.006). Toxicity profiles were similar to those for the single agents. Conclusions Among patients with advanced HCC, treatment with sorafenib plus doxorubicin compared with doxorubicin monotherapy resulted in greater median time to progression, overall survival, and progression-free survival. The degree to which this improvement may represent synergism between sorafenib and doxorubicin remains to be defined. The combination of sorafenib and doxorubicin is not yet indicated for routine clinical use.	[Abou-Alfa, Ghassan K.; Gansukh, Bolorsukh; Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Capanu, Marinela] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Johnson, Philip] Univ Birmingham, Sch Canc Sci, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [Knox, Jennifer J.] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada; [Davidenko, Irina] Krasnodar City Oncol Ctr, Krasnodar, Russia; [Lacava, Juan] Oncol Serv, Unidad Oncol Neuquen, Neuquen, Argentina; [Leung, Thomas] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Hong Kong, Peoples R China	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research UK; University of Birmingham; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Abou-Alfa, GK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	abou-alg@mskcc.org		Saltz, Leonard/0000-0001-8353-4670	Bayer	Bayer(Bayer AG)	This work was supported by a research grant from Bayer.	Abou-Alfa GK, 2006, SEMIN ONCOL, V33, pS79, DOI 10.1053/j.seminoncol.2006.10.015; Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; Alavi AS, 2007, CANCER RES, V67, P2766, DOI 10.1158/0008-5472.CAN-06-3648; Gish RG, 2007, J CLIN ONCOL, V25, P3069, DOI 10.1200/JCO.2006.08.4046; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; IHDE DC, 1977, CANCER TREAT REP, V61, P1385; JOHNSON PJ, 1978, LANCET, V1, P1006; Lacouture ME, 2008, ONCOLOGIST, V13, P1001, DOI 10.1634/theoncologist.2008-0131; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; *NAT CAN I CLIN TR, PHAS 3 RAND STUD SOR; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Richly H, 2006, ANN ONCOL, V17, P866, DOI 10.1093/annonc/mdl017; Satagopan JM, 2004, BRIT J CANCER, V91, P1229, DOI 10.1038/sj.bjc.6602102; SCIARRINO E, 1985, CANCER, V56, P2751, DOI 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Wakabayashi I, 2003, CURR MED CHEM, V10, P427, DOI 10.2174/0929867033368259; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yeo W, 2005, JNCI-J NATL CANCER I, V97, P1532, DOI 10.1093/jnci/dji315; Zhang YL, 2001, J PHARMACOL EXP THER, V299, P426	21	341	353	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2154	2160		10.1001/jama.2010.1672	http://dx.doi.org/10.1001/jama.2010.1672			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081728	Bronze			2022-12-28	WOS:000284269800026
J	Geneau, R; Stuckler, D; Stachenko, S; Mckee, M; Ebrahim, S; Basu, S; Chockalingham, A; Mwatsama, M; Jamal, R; Alwan, A; Beaglehole, R				Geneau, Robert; Stuckler, David; Stachenko, Sylie; McKee, Martin; Ebrahim, Shah; Basu, Sanjay; Chockalingham, Arun; Mwatsama, Modi; Jamal, Rozmin; Alwan, Ala; Beaglehole, Robert			Chronic Diseases: Chronic Diseases and Development 1 Raising the priority of preventing chronic diseases: a political process	LANCET			English	Article							LOW-INCOME; DEVELOPING-COUNTRIES; HEALTH; TOBACCO; POLICY; TUBERCULOSIS; DETERMINANTS; GENERATION; STRATEGIES; MORTALITY	Chronic diseases especially cardiovascular diseases, diabetes cancer and chronic obstructive respiratory diseases, are neglected globally despite growing awareness of the serious burden that they cause Global and national policies have failed to stop, and in many cases have contributed to, the chronic disease pandemic Low cost and highly effective solutions for the prevention of chronic diseases are readily available the failure to respond is now a political rather than a technical issue We seek to understand this failure and to position chronic disease centrally on the global health and development agendas To identify strategies for generation of increased political priority for chronic diseases and to further the involvement of development agencies we use an adapted political process model This model has previously been used to assess the success and failure of social movements On the basis of this analysis we recommend three strategies reframe the debate to emphasise the societal determinants of disease and the inter relation between chronic disease, poverty, and development, mobilise resources through a cooperative and inclusive approach to development and by equitably distributing resources on the basis of avoidable mortality and build on emerging strategic and political opportunities such as the World Health Assembly 2008-13 Action Plan and the high level meeting of the UN General Assembly in 2011 on chronic disease Until the full set of threats which-include chronic disease-that trap poor households in cycles of debt and illness are addressed, progress towards equitable human development will remain inadequate	[Geneau, Robert] Univ Ottawa, Elizabeth Bruyere Res Inst, Ottawa, ON, Canada; [Stuckler, David] Univ Oxford, Dept Sociol, Oxford OX1 2JD, England; [Stachenko, Sylie] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2M7, Canada; [McKee, Martin] London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1, England; [Ebrahim, Shah] S Asia Network Chron Dis, New Delhi, India; [Ebrahim, Shah] Publ Hlth Fdn India, New Delhi, India; [Basu, Sanjay] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Basu, Sanjay] San Francisco Gen Hosp, Div Gen Internal Med, San Francisco, CA USA; [Chockalingham, Arun] NHLBI, Off Global Hlth, Bethesda, MD 20892 USA; [Jamal, Rozmin] Aga Khan Univ, Clin Res Unit, Karachi, Pakistan; [Alwan, Ala] WHO, CH-1211 Geneva, Switzerland; [Beaglehole, Robert] Univ Auckland, Auckland 1, New Zealand	University of Ottawa; University of Oxford; University of Alberta; University of London; London School of Hygiene & Tropical Medicine; Public Health Foundation of India; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Aga Khan University; World Health Organization; University of Auckland	Geneau, R (corresponding author), Univ Ottawa, Elizabeth Bruyere Res Inst, 43 Bruyere, Ottawa, ON, Canada.		Stuckler, David/H-2261-2012; McKee, Marc D/E-2187-2011; McKee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Geneau, Robert/0000-0001-6180-2515; McKee, Martin/0000-0002-0121-9683; Stuckler, David/0000-0002-1288-8401				Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Abegunde DO, 2008, SOC SCI MED, V66, P2296, DOI 10.1016/j.socscimed.2008.01.041; Abubakari AR, 2009, PUBLIC HEALTH, V123, P602, DOI 10.1016/j.puhe.2009.07.009; *AG KHAN DEV NETW, 2009, SUMM MED BRIEF INT C; Alleyne G, 2010, GLOBALIZATION HEALTH, V6, DOI 10.1186/1744-8603-6-15; ALWAN A, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61853.3; Alwan A, 2009, INT HEALTH, V1, P3, DOI 10.1016/j.inhe.2009.02.003; Anderson GF, 2009, HEALTH AFFAIR, V28, P202, DOI 10.1377/hlthaff.28.1.202; [Anonymous], 2003, BRIDGING RES POLICY; [Anonymous], 2008, CLOS GAP GEN HLTH EQ; [Anonymous], 2010, HLTH NUTR POPUL SER; [Anonymous], 2008, WORLD HLTH STAT 2008; [Anonymous], 2005, PREV CHRON DIS VIT I; Asaria P, 2007, LANCET, V370, P2044, DOI 10.1016/S0140-6736(07)61698-5; Balabanova D, 2010, HEALTH RES POLICY SY, V8, DOI 10.1186/1478-4505-8-22; Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; Beran D, 2006, LANCET, V368, P1689, DOI 10.1016/S0140-6736(06)69704-3; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Black N, 2001, BRIT MED J, V323, P275, DOI 10.1136/bmj.323.7307.275; Brownell KD, 2009, MILBANK Q, V87, P259, DOI 10.1111/j.1468-0009.2009.00555.x; Costain AnneN., 1992, INVITING WOMENS REBE; Daar AS, 2007, NATURE, V450, P494, DOI 10.1038/450494a; Diethelm PA, 2005, LANCET, V366, P86, DOI 10.1016/S0140-6736(05)66474-4; Dooley KE, 2009, LANCET INFECT DIS, V9, P737, DOI 10.1016/S1473-3099(09)70282-8; Ebrahim S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000268; Ebrahim Shahul, 2007, Prev Chronic Dis, V4, pA32; ELIADAROUS HE, 2010, EXP CLIN ENDOCRINOL, V118, P220; Emmelin A, 2007, CHEST, V132, P1615, DOI 10.1378/chest.07-1398; Friel S, 2009, LANCET, V374, P2016, DOI 10.1016/S0140-6736(09)61753-0; Fuster V, 2005, LANCET, V366, P1512, DOI 10.1016/S0140-6736(05)67610-6; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; Gajalakshmi V, 2009, INT J EPIDEMIOL, V38, P1018, DOI 10.1093/ije/dyp225; Haines A, 2007, LANCET, V370, P1264, DOI 10.1016/S0140-6736(07)61257-4; Haines A, 2009, LANCET, V374, P2104, DOI 10.1016/S0140-6736(09)61759-1; Harries AD, 2008, PLOS MED, V5, P859, DOI 10.1371/journal.pmed.0050124; Hastings G, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5650; Horton R, 2005, LANCET, V366, P1514, DOI 10.1016/S0140-6736(05)67454-5; Institute of Medicine, 2010, PROM CARD HLTH DEV W; Janssens B, 2007, B WORLD HEALTH ORGAN, V85, P880, DOI 10.2471/BLT.06.036574; Jones H., 2009, EQUITY DEV WHY IT IS; KINGDON JW, 1995, AGENDAS ALTERNATIVE; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; Lomas Jonathan, 2005, Healthc Policy, V1, P55; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lu CL, 2010, LANCET, V375, P1375, DOI 10.1016/S0140-6736(10)60233-4; Marmot M, 2008, LANCET, V372, P1661, DOI 10.1016/S0140-6736(08)61690-6; Marx Karl, 1971, GRUNDRISSE FDN CRITI; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mbatia J, 2009, INT J ENV RES PUB HE, V6, P1991, DOI 10.3390/ijerph6071991; McAdam D., 2010, READINGS SOCIAL MOVE; McAdam D., 1982, POLITICAL PROCESS DE; Mccoy D, 2009, HEALTH POLICY PLANN, V24, P407, DOI 10.1093/heapol/czp026; Mccoy D, 2009, LANCET, V373, P1645, DOI 10.1016/S0140-6736(09)60571-7; McDaniel PA, 2009, WOMEN HEALTH, V49, P441, DOI 10.1080/03630240903238800; McKee M, 2006, BRIT MED J, V333, P871, DOI 10.1136/bmj.39003.629606.BE; McMillen IC, 2008, BASIC CLIN PHARMACOL, V102, P82, DOI 10.1111/j.1742-7843.2007.00188.x; Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106; *NAT HEART LUNG BL, 2009, UN NHLBI CTR EXC; *NCD ALL, NCD ALL PUTT NONC DI; NUGENT R, 2009, CHRONIC DIS POSING G; Nugent R, 2008, ANN NY ACAD SCI, V1136, P70, DOI 10.1196/annals.1425.027; Ong EK, 2001, AM J PUBLIC HEALTH, V91, P1749, DOI 10.2105/AJPH.91.11.1749; *OXF ALL, 2006, CHRON DIS EC PERSP; Pisani E, 2008, WISDOM WHORES; Rabinoff M, 2007, AM J PUBLIC HEALTH, V97, P1981, DOI 10.2105/AJPH.2005.078014; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Ronsmans C, 2009, FOOD NUTR BULL, V30, pS547, DOI 10.1177/15648265090304S409; Sabatier PA, 2007, THEORIES POLICY PROC; SAMB B, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61353.0; Schmidt H, 2008, LANCET, V372, P627, DOI 10.1016/S0140-6736(08)61269-6; Shiffman J, 2007, LANCET, V370, P1370, DOI 10.1016/S0140-6736(07)61579-7; Shiffman J, 2009, B WORLD HEALTH ORGAN, V87, P608, DOI 10.2471/BLT.08.060749; Stanciole A., 2006, ESTIMATION EC IMPACT; Stiglitz J. E., 2010, FREEFALL AM FREE MAR; Stuckler D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000241; *TRUST W, 2010, STAT PLAN 2010 2020; *UN, UN AG LAUDS ASS RES; Walt G, 2008, HEALTH POLICY PLANN, V23, P308, DOI 10.1093/heapol/czn024; Whitehead M, 2001, LANCET, V358, P165, DOI 10.1016/S0140-6736(01)05398-3; *WHO, NCDNET; *WHO, 2009, NONC DIS POV DEV AG; World Economic Forum-Global Risks Report, 2009, GLOB RISKS 2009 GLOB; World Health Organization, 2008, The global burden of disease: 2004 update; World Health Organization, 2008, 2008 2013 ACT PLAN G; World Health Organization, 2004, TOB POV VIC CIRCL; World Health Organization (WHO), STEPWISE APPR SURV S	87	184	185	2	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1689	1698		10.1016/S0140-6736(10)61414-6	http://dx.doi.org/10.1016/S0140-6736(10)61414-6			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	683DD	21074260				2022-12-28	WOS:000284451000034
J	Kessler, SA; Shimosato-Asano, H; Keinath, NF; Wuest, SE; Ingram, G; Panstruga, R; Grossniklaus, U				Kessler, Sharon A.; Shimosato-Asano, Hiroko; Keinath, Nana F.; Wuest, Samuel E.; Ingram, Gwyneth; Panstruga, Ralph; Grossniklaus, Ueli			Conserved Molecular Components for Pollen Tube Reception and Fungal Invasion	SCIENCE			English	Article							MALE-GAMETE DELIVERY; POWDERY MILDEW; ARABIDOPSIS-THALIANA; DOUBLE FERTILIZATION; SYNERGID CELL; RESISTANCE; PROTEINS; GENE; DISRUPTS; FAMILY	During sexual reproduction in flowering plants such as Arabidopsis, a tip-growing pollen tube (PT) is guided to the synergid cells of the female gametophyte, where it bursts and releases the two sperm. Here we show that PT reception and powdery mildew (PM) infection, which involves communication between a tip-growing hypha and a plant epidermal cell, share molecular components. NORTIA (NTA), a member of the MLO family originally discovered in the context of PM resistance, and FERONIA (FER), a receptor-like kinase, both control PT reception in synergids. Homozygous fer mutants also display PM resistance, revealing a new function for FER and suggesting that conserved components, such as FER and distinct MLO proteins, are involved in both PT reception and PM infection.	[Kessler, Sharon A.; Shimosato-Asano, Hiroko; Wuest, Samuel E.; Grossniklaus, Ueli] Univ Zurich, Inst Plant Biol, CH-8008 Zurich, Switzerland; [Keinath, Nana F.; Panstruga, Ralph] Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, D-50829 Cologne, Germany; [Ingram, Gwyneth] Univ Edinburgh, Inst Mol Plant Sci, Edinburgh EH9 3JR, Midlothian, Scotland	University of Zurich; Max Planck Society; University of Edinburgh	Grossniklaus, U (corresponding author), Univ Zurich, Inst Plant Biol, Zollikerstr 107, CH-8008 Zurich, Switzerland.	grossnik@botinst.uzh.ch	Panstruga, Ralph/F-3340-2011; Grossniklaus, Ueli/A-2736-2012; Kessler, Sharon A/T-4784-2017; Grossniklaus, Ueli/E-9995-2016	Panstruga, Ralph/0000-0002-3756-8957; Kessler, Sharon A/0000-0002-7964-0451; Grossniklaus, Ueli/0000-0002-0522-8974; Ingram, Gwyneth/0000-0002-1425-9545; Wuest, Samuel/0000-0003-3982-0770	University of Zurich; Max Planck Society; Human Frontiers in Science Program; Forschungskredit of the University of Zurich; International Max Planck Research School; Royal Society of London; Deutsche Forschungsgemeinschaft [SFB670]; Swiss National Science Foundation	University of Zurich; Max Planck Society(Max Planck SocietyFoundation CELLEX); Human Frontiers in Science Program(Human Frontier Science Program); Forschungskredit of the University of Zurich; International Max Planck Research School; Royal Society of London(Royal Society of London); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank A. Boisson-Dernier for providing pLat52:DsRED and for critical reading of this manuscript; S. Schauer for providing plasmids; A. Reinstadler for technical assistance with pathogen assays; and J. M. Escobar-Restrepo, H. Lindner, M. Bayer, C. Jager-Baroux, S. Pien, V. Gagliardini, and members of the Grossniklaus lab for helpful discussions. This work was supported by the University of Zurich, the Max Planck Society, fellowships of the Human Frontiers in Science Program (to S.A.K.), the Forschungskredit of the University of Zurich (to H.S.-A.), the International Max Planck Research School (to N.F.K.), the Royal Society of London (to G.I.), and grants from the Deutsche Forschungsgemeinschaft (SFB670 to R.P.) and the Swiss National Science Foundation (to U.G.).	Amano K, 1986, HOST RANGE GEOGRAPHI; AMICI JB, 1847, ANN SCI NATURELLES, P193; Amien S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000388; Bari R, 2009, PLANT MOL BIOL, V69, P473, DOI 10.1007/s11103-008-9435-0; Bhat RA, 2005, P NATL ACAD SCI USA, V102, P3135, DOI 10.1073/pnas.0500012102; Boisson-Dernier A, 2008, CURR BIOL, V18, P63, DOI 10.1016/j.cub.2007.11.067; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Capron A, 2008, PLANT CELL, V20, P3038, DOI 10.1105/tpc.108.061713; Chen ZY, 2009, PLANT CELL, V21, P1972, DOI 10.1105/tpc.108.062653; Chen ZY, 2006, PLANT MOL BIOL, V60, P583, DOI 10.1007/s11103-005-5082-x; Consonni C, 2006, NAT GENET, V38, P716, DOI 10.1038/ng1806; Devoto A, 2003, J MOL EVOL, V56, P77, DOI 10.1007/s00239-002-2382-5; Dresselhaus T, 2006, CURR OPIN PLANT BIOL, V9, P41, DOI 10.1016/j.pbi.2005.11.002; Escobar-Restrepo JM, 2007, SCIENCE, V317, P656, DOI 10.1126/science.1143562; Guo HQ, 2009, P NATL ACAD SCI USA, V106, P7648, DOI 10.1073/pnas.0812346106; Higashiyama T, 2002, J PLANT RES, V115, P149, DOI 10.1007/s102650200020; Huck N, 2003, DEVELOPMENT, V130, P2149, DOI 10.1242/dev.00458; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Lehti-Shiu MD, 2009, PLANT PHYSIOL, V150, P12, DOI 10.1104/pp.108.134353; LIVIUS T, AB URBE CONDITA LIBE; Lord EM, 2002, ANNU REV CELL DEV BI, V18, P81, DOI 10.1146/annurev.cellbio.18.012502.083438; O'Connell RJ, 2006, NEW PHYTOL, V171, P699, DOI 10.1111/j.1469-8137.2006.01829.x; Okuda S, 2009, NATURE, V458, P357, DOI 10.1038/nature07882; Panstruga R, 2005, BIOCHEM SOC T, V33, P389, DOI 10.1042/BST0330389; Piffanelli P, 2004, NATURE, V430, P887, DOI 10.1038/nature02781; Piffanelli P, 2002, PLANT PHYSIOL, V129, P1076, DOI 10.1104/pp.010954; Rotman N, 2003, CURR BIOL, V13, P432, DOI 10.1016/S0960-9822(03)00093-9; Sandaklie-Nikolova L, 2007, PLANT PHYSIOL, V144, P1753, DOI 10.1104/pp.107.098236; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; Wuest SE, 2010, CURR BIOL, V20, P506, DOI 10.1016/j.cub.2010.01.051	30	286	312	6	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					968	971		10.1126/science.1195211	http://dx.doi.org/10.1126/science.1195211			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071669				2022-12-28	WOS:000284118000044
J	Kuhnert, F; Mancuso, MR; Shamloo, A; Wang, HT; Choksi, V; Florek, M; Su, H; Fruttiger, M; Young, WL; Heilshorn, SC; Kuo, CJ				Kuhnert, Frank; Mancuso, Michael R.; Shamloo, Amir; Wang, Hsiao-Ting; Choksi, Vir; Florek, Mareike; Su, Hua; Fruttiger, Marcus; Young, William L.; Heilshorn, Sarah C.; Kuo, Calvin J.			Essential Regulation of CNS Angiogenesis by the Orphan G Protein-Coupled Receptor GPR124	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; ALPHA-V INTEGRINS; INACTIVATION; ENDOTHELIUM; LETHALITY; GENE; MICE; NEUROGENESIS; HEMORRHAGE	The orphan G protein-coupled receptor (GPCR) GPR124/tumor endothelial marker 5 is highly expressed in central nervous system (CNS) endothelium. Here, we show that complete null or endothelial-specific GPR124 deletion resulted in embryonic lethality from CNS-specific angiogenesis arrest in forebrain and neural tube. Conversely, GPR124 overexpression throughout all adult vascular beds produced CNS-specific hyperproliferative vascular malformations. In vivo, GPR124 functioned cell-autonomously in endothelium to regulate sprouting, migration, and developmental expression of the blood-brain barrier marker Glut1, whereas in vitro, GPR124 mediated Cdc42-dependent directional migration to forebrain-derived, vascular endothelial growth factor-independent cues. Our results demonstrate CNS-specific angiogenesis regulation by an endothelial receptor and illuminate functions of the poorly understood adhesion GPCR subfamily. Further, the functional tropism of GPR124 marks this receptor as a therapeutic target for CNS-related vascular pathologies.	[Kuhnert, Frank; Mancuso, Michael R.; Wang, Hsiao-Ting; Kuo, Calvin J.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA; [Shamloo, Amir] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Choksi, Vir] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Florek, Mareike] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA; [Fruttiger, Marcus] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England; [Young, William L.] Univ Calif San Francisco, Dept Neurol Surg, Ctr Cerebrovasc Res, Dept Anesthesia & Perioperat Care,Dept Neurol, San Francisco, CA 94110 USA; [Heilshorn, Sarah C.] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; University of London; University College London; University of California System; University of California San Francisco; Stanford University	Kuo, CJ (corresponding author), Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA.	cjkuo@stanford.edu		, amir/0000-0002-0131-0567; Heilshorn, Sarah/0000-0002-9801-6304; Fruttiger, Marcus/0000-0002-6962-5485; Kuo, Calvin/0000-0002-7427-5985	American Heart Association (AHA) [AHA09PRE2110036, 10GRNT3130004]; National Institute of General Medical Science, NIH [GM07365]; NIH [R21 NS070153, R01NS27713, P01NS44155, 1DP2 OD006477, 1R21 NS058600, 1R01NS052830, 1R01NS064517, 1R01HL074267]; U.K. Medical Research Council [G0501711]; National Academies Keck Futures Initiative; Brain Tumor Society; Goldhirsh Foundation; Stanford Center for Children's Brain Tumors; NATIONAL CANCER INSTITUTE [R01CA095654, T32CA009302] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064517, P01NS044155, R01NS027713, R21NS058600, R01NS052830, R21NS070153] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD006477] Funding Source: NIH RePORTER; Medical Research Council [G0501711] Funding Source: researchfish; MRC [G0501711] Funding Source: UKRI	American Heart Association (AHA)(American Heart Association); National Institute of General Medical Science, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Academies Keck Futures Initiative; Brain Tumor Society; Goldhirsh Foundation; Stanford Center for Children's Brain Tumors; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are indebted to R. Daneman, B. Barres, C. Chartier, and the Kuo laboratory for comments; J. Yuan and J. Hampton for animal husbandry and genotyping; and A. Connolly and H. Vogel for neuropathology. F.K. was supported by an American Heart Association (AHA) Postdoctoral Fellowship and M.R.M. by AHA Predoctoral Fellowship AHA09PRE2110036 and the Stanford Medical Scientist Training Program Program (National Institute of General Medical Science, NIH, GM07365). This work was also supported by NIH R21 NS070153 and AHA 10GRNT3130004 (H.S.); NIH R01NS27713 (W.L.Y.); P01NS44155 (W.L.Y. and H.S.); U.K. Medical Research Council G0501711 (M.F.); NIH 1DP2 OD006477, 1R21 NS058600, and National Academies Keck Futures Initiative CS10 grants (S.C.H.); and NIH 1R01NS052830, 1R01NS064517, 1R01HL074267, Brain Tumor Society, Goldhirsh Foundation, and the Stanford Center for Children's Brain Tumors grants (C.J.K.). F.K., H.W., and C.J.K. have a patent pending regarding vascular applications of GPR124.	Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; Ara T, 2005, BLOOD, V105, P3155, DOI 10.1182/blood-2004-07-2563; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Ballabh P, 2010, PEDIATR RES, V67, P1, DOI 10.1203/PDR.0b013e3181c1b176; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Carson-Walter EB, 2001, CANCER RES, V61, P6649; Cattelino A, 2003, J CELL BIOL, V162, P1111, DOI 10.1083/jcb.200212157; Claxton S, 2008, GENESIS, V46, P74, DOI 10.1002/dvg.20367; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Gerhardt H, 2004, DEV DYNAM, V231, P503, DOI 10.1002/dvdy.20148; HERKEN R, 1989, J ANAT, V164, P85; Hogan KA, 2004, DEVELOPMENT, V131, P1503, DOI 10.1242/dev.01039; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mancuso Michael R., 2008, Lymphatic Research and Biology, V6, P173, DOI 10.1089/lrb.2008.1014; McCarty JH, 2005, DEVELOPMENT, V132, P165, DOI 10.1242/dev.01551; Pardridge William M, 2003, Methods Mol Med, V89, P385; Raab S, 2004, THROMB HAEMOSTASIS, V91, P595, DOI 10.1160/TH03-09-0582; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Shamloo A, 2008, LAB CHIP, V8, P1292, DOI 10.1039/b719788h; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Siekmann AF, 2009, GENE DEV, V23, P2272, DOI 10.1101/gad.1813509; St Croix B, 2000, SCIENCE, V289, P1197; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; Vallon M, 2006, J BIOL CHEM, V281, P34179, DOI 10.1074/jbc.M605291200; Vasudevan A, 2008, NAT NEUROSCI, V11, P429, DOI 10.1038/nn2074; Zhu JW, 2002, DEVELOPMENT, V129, P2891	30	204	211	4	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					985	989		10.1126/science.1196554	http://dx.doi.org/10.1126/science.1196554			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071672	Green Accepted			2022-12-28	WOS:000284118000049
J	Prather, MJ; Hsu, J				Prather, Michael J.; Hsu, Juno			Coupling of Nitrous Oxide and Methane by Global Atmospheric Chemistry	SCIENCE			English	Article							OZONE; NOY; N2O	Nitrous oxide (N2O) and methane (CH4) are chemically reactive greenhouse gases with well-documented atmospheric concentration increases that are attributable to anthropogenic activities. We quantified the link between N2O and CH4 emissions through the coupled chemistries of the stratosphere and troposphere. Specifically, we simulated the coupled perturbations of increased N2O abundance, leading to stratospheric ozone (O-3) depletion, altered solar ultraviolet radiation, altered stratosphere-to-troposphere O-3 flux, increased tropospheric hydroxyl radical concentration, and finally lower concentrations of CH4. The ratio of CH4 per N2O change, -36% by mole fraction, offsets a fraction of the greenhouse effect attributable to N2O emissions. These CH4 decreases are tied to the 108-year chemical mode of N2O, which is nine times longer than the residence time of direct CH4 emissions.	[Prather, Michael J.; Hsu, Juno] Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA	University of California System; University of California Irvine	Prather, MJ (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.		Hsu, Juno/O-1869-2019; Hsu, Juno/A-7221-2011		NSF [ATM-0550234]; NASA's Modeling, Analysis, and Prediction/Global Modeling Initiative [NNG06GB84G, NNX09AJ47G]	NSF(National Science Foundation (NSF)); NASA's Modeling, Analysis, and Prediction/Global Modeling Initiative	This research was supported by NSF's Atmospheric Chemistry program (grant ATM-0550234) and NASA's Modeling, Analysis, and Prediction/Global Modeling Initiative program (grants NNG06GB84G and NNX09AJ47G).	ALBRITTON DL, 1995, CLIMATE CHANGE 1994, P204; Denman KL, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P499; Derwent RG, 2001, CLIMATIC CHANGE, V49, P463, DOI 10.1023/A:1010648913655; Ehhalt D, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P239; ENNIS CA, 2006, SCI ASSESSMENT OZONE; Fiore AM, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009162; Forster P, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P129; Hsu J, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006045; Hsu J, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL042243; Hsu J, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD010942; MCELROY MB, 1971, J ATMOS SCI, V28, P1095, DOI 10.1175/1520-0469(1971)028<1095:NOANSO>2.0.CO;2; Prather M, 1995, CLIMATE CHANGE 1994, P73; Prather MJ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036851; PRATHER MJ, 1994, GEOPHYS RES LETT, V21, P801, DOI 10.1029/94GL00840; Prather MJ, 1998, SCIENCE, V279, P1339, DOI 10.1126/science.279.5355.1339; Ravishankara AR, 2009, SCIENCE, V326, P123, DOI 10.1126/science.1176985; Rosenfield JE, 1998, GEOPHYS RES LETT, V25, P4381, DOI 10.1029/1998GL900147; Stevenson DS, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006338; Tang Q, 2010, ATMOS CHEM PHYS, V10, P9681, DOI 10.5194/acp-10-9681-2010; WATSON RT, 1985, 16 WMO; Wild O, 2000, J GEOPHYS RES-ATMOS, V105, P24647, DOI 10.1029/2000JD900399	21	56	58	5	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2010	330	6006					952	954		10.1126/science.1196285	http://dx.doi.org/10.1126/science.1196285			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071666	Green Submitted			2022-12-28	WOS:000284118000039
J	Graeber, MB				Graeber, Manuel B.			Changing Face of Microglia	SCIENCE			English	Editorial Material							MARROW-DERIVED MICROGLIA; PERIVASCULAR CELLS; NEURONAL DEATH; IN-VIVO; ACTIVATION; EXPRESSION; CNS; DAP12; INVOLVEMENT; SYNAPSES	Microglia are resident brain cells that sense pathological tissue alterations. They can develop into brain macrophages and perform immunological functions. However, expression of immune proteins by microglia is not synonymous with inflammation, because these molecules can have central nervous system (CNS)-specific roles. Through their involvement in pain mechanisms, microglia also respond to external threats. Experimental studies support the idea that microglia have a role in the maintenance of synaptic integrity. Analogous to electricians, they are capable of removing defunct axon terminals, thereby helping neuronal connections to stay intact. Microglia in healthy CNS tissue do not qualify as macrophages, and their specific functions are beginning to be explored.	Univ Sydney, Brain & Mind Res Inst, Camperdown, NSW 2050, Australia	University of Sydney	Graeber, MB (corresponding author), Univ Sydney, Brain & Mind Res Inst, Camperdown, NSW 2050, Australia.	manuel@graeber.net	Yan, Shuo/B-8381-2009; Graeber, Manuel/H-3224-2011					Ackman JB, 2006, J NEUROSCI, V26, P11413, DOI 10.1523/JNEUROSCI.3340-06.2006; Bayer TA, 1999, NEUROSCI LETT, V271, P126, DOI 10.1016/S0304-3940(99)00545-5; Beers DR, 2006, P NATL ACAD SCI USA, V103, P16021, DOI 10.1073/pnas.0607423103; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Boulanger LM, 2009, NEURON, V64, P93, DOI 10.1016/j.neuron.2009.09.001; Cagnin A, 2004, ANN NEUROL, V56, P894, DOI 10.1002/ana.20332; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754; Chen SK, 2010, CELL, V141, P775, DOI 10.1016/j.cell.2010.03.055; Chu YX, 2010, BRAIN BEHAV IMMUN, V24, P1176, DOI 10.1016/j.bbi.2010.06.001; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; De Haas AH, 2008, GLIA, V56, P888, DOI 10.1002/glia.20663; Dean B, 2009, AUST NZ J PSYCHIAT, V43, P13, DOI 10.1080/00048670802534416; Dolman CL, 1991, TXB NEUROPATHOLOGY, P141; Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298; Fan WG, 2010, ARCH ORAL BIOL, V55, P706, DOI 10.1016/j.archoralbio.2010.06.007; Flugel A, 2001, J NEUROSCI RES, V66, P74, DOI 10.1002/jnr.1198; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; GRAEBER MB, 1993, ACTA NEUROPATHOL, V86, P179, DOI 10.1007/BF00334886; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; GRAEBER MB, 2004, ENCY NEUROSCIENCE; Hayakawa T, 2005, SCIENCE, V309, P1693, DOI 10.1126/science.1114321; Kaneko M, 2010, NEUROPATHOLOGY, V30, P463, DOI 10.1111/j.1440-1789.2010.01127.x; Kochlamazashvili G, 2010, J NEUROSCI, V30, P4171, DOI 10.1523/JNEUROSCI.5806-09.2010; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4; Liu GJ, 2009, EUR J NEUROSCI, V29, P1108, DOI 10.1111/j.1460-9568.2009.06659.x; Maezawa I, 2010, J NEUROSCI, V30, P5346, DOI 10.1523/JNEUROSCI.5966-09.2010; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Nissl F., 1899, ARCH PSYCHIAT NERVEN, V32, P656; Otero K, 2009, NAT IMMUNOL, V10, P734, DOI 10.1038/ni.1744; R?o-Hortega P., 1919, B SOC ESP BIOL, V9, P68; Rana I, 2010, BRAIN RES, V1326, P96, DOI 10.1016/j.brainres.2010.02.028; Salminen A, 2009, J MOL MED, V87, P697, DOI 10.1007/s00109-009-0472-1; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Siskova Z, 2009, AM J PATHOL, V175, P1610, DOI 10.2353/ajpath.2009.090372; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002; Spielmeyer W, 1922, HISTOPATHOLOGIE NERV; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6; Thrash JC, 2009, NEUROCHEM RES, V34, P38, DOI 10.1007/s11064-008-9657-1; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Tynan RJ, 2010, BRAIN BEHAV IMMUN, V24, P1058, DOI 10.1016/j.bbi.2010.02.001; UNGER ER, 1993, J NEUROPATH EXP NEUR, V52, P460, DOI 10.1097/00005072-199309000-00004; Varki A, 2010, P NATL ACAD SCI USA, V107, P8939, DOI 10.1073/pnas.0914634107; von Eitzen U, 1998, J NEUROPATH EXP NEUR, V57, P246, DOI 10.1097/00005072-199803000-00006; Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009; Wakselman S, 2008, J NEUROSCI, V28, P8138, DOI 10.1523/JNEUROSCI.1006-08.2008; Williams K, 2001, GLIA, V36, P156, DOI 10.1002/glia.1105; Zhou D, 2010, J NEUROSCI, V30, P8042, DOI 10.1523/JNEUROSCI.5377-09.2010	57	438	447	2	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2010	330	6005					783	788		10.1126/science.1190929	http://dx.doi.org/10.1126/science.1190929			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051630				2022-12-28	WOS:000283855700033
J	Hughes, R				Hughes, Richard			Rational Testing Investigation of peripheral neuropathy	BRITISH MEDICAL JOURNAL			English	Editorial Material							SYMMETRIC POLYNEUROPATHY ROLE; PRACTICE PARAMETER EVALUATION; ELECTRODIAGNOSTIC MEDICINE; AMERICAN ASSOCIATION; PHYSICAL MEDICINE; NERVE BIOPSY; REHABILITATION; NEUROLOGY; ACADEMY				Hughes, R (corresponding author), Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	rhughes11@btinternet.com						England JD, 2009, NEUROLOGY, V72, P177, DOI 10.1212/01.wnl.0000336345.70511.0f; England JD, 2009, NEUROLOGY, V72, P185, DOI 10.1212/01.wnl.0000336370.51010.a1; Gabriel CM, 2000, J NEUROL NEUROSUR PS, V69, P442, DOI 10.1136/jnnp.69.4.442; Hughes RAC, 2004, BRAIN, V127, P1723, DOI 10.1093/brain/awh192; Hughes RAC, 2002, BRIT MED J, V324, P466, DOI 10.1136/bmj.324.7335.466; KELLY JJ, 1981, NEUROLOGY, V31, P1480, DOI 10.1212/WNL.31.11.1480; Rosenberg NR, 2001, J NEUROL NEUROSUR PS, V71, P205, DOI 10.1136/jnnp.71.2.205; Saperstein DS, 2003, ARCH NEUROL-CHICAGO, V60, P1296, DOI 10.1001/archneur.60.9.1296	8	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 5	2010	341								c6100	10.1136/bmj.c6100	http://dx.doi.org/10.1136/bmj.c6100			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678DN	21056962				2022-12-28	WOS:000284052400006
J	Indriolo, E; Goring, DR				Indriolo, Emily; Goring, Daphne R.			Pollen Gets More Complex	SCIENCE			English	Editorial Material							SELF-INCOMPATIBILITY		[Indriolo, Emily; Goring, Daphne R.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 3B2, Canada	University of Toronto	Indriolo, E (corresponding author), Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 3B2, Canada.	d.goring@utoronto.ca		Goring, Daphne/0000-0001-5295-4744				Chen G, 2010, J EXP BOT, V61, P2027, DOI 10.1093/jxb/erp381; Franklin-Tong V. E., 2008, P237, DOI 10.1007/978-3-540-68486-2_11; Golz JF, 2001, P NATL ACAD SCI USA, V98, P15372, DOI 10.1073/pnas.261571598; Hua ZH, 2008, MOL PLANT, V1, P575, DOI 10.1093/mp/ssn032; Kubo K, 2010, SCIENCE, V330, P796, DOI 10.1126/science.1195243; McClure B, 2009, J EXP BOT, V60, P1069, DOI 10.1093/jxb/erp024; Minamikawa M, 2010, PLANT MOL BIOL, V74, P143, DOI 10.1007/s11103-010-9662-z; Newbigin E, 2008, PLANT CELL, V20, P2286, DOI 10.1105/tpc.108.060327; Wheeler D, 2007, GENETICS, V177, P2171, DOI 10.1534/genetics.107.076885; Zhou Z, 2003, APPL MATH LETT, V16, P165, DOI 10.1016/S0893-9659(03)80027-7	10	0	0	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2010	330	6005					767	768		10.1126/science.1198346	http://dx.doi.org/10.1126/science.1198346			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051623				2022-12-28	WOS:000283855700027
J	Voorhees, RM; Schmeing, TM; Kelley, AC; Ramakrishnan, V				Voorhees, Rebecca M.; Schmeing, T. Martin; Kelley, Ann C.; Ramakrishnan, V.			The Mechanism for Activation of GTP Hydrolysis on the Ribosome	SCIENCE			English	Article							ELONGATION-FACTOR TU; AMINOACYL-TRANSFER-RNA; TRANSITION-STATE ANALOG; CENTER-DOT-GDP; EF-TU; CRYSTAL-STRUCTURE; BINDING DOMAIN; COMPLEX; PROTEIN; CONFORMATION	Protein synthesis requires several guanosine triphosphatase (GTPase) factors, including elongation factor Tu (EF-Tu), which delivers aminoacyl-transfer RNAs (tRNAs) to the ribosome. To understand how the ribosome triggers GTP hydrolysis in translational GTPases, we have determined the crystal structure of EF-Tu and aminoacyl-tRNA bound to the ribosome with a GTP analog, to 3.2 angstrom resolution. EF-Tu is in its active conformation, the switch I loop is ordered, and the catalytic histidine is coordinating the nucleophilic water in position for inline attack on the gamma-phosphate of GTP. This activated conformation is due to a critical and conserved interaction of the histidine with A2662 of the sarcin-ricin loop of the 23S ribosomal RNA. The structure suggests a universal mechanism for GTPase activation and hydrolysis in translational GTPases on the ribosome.	[Voorhees, Rebecca M.; Schmeing, T. Martin; Kelley, Ann C.; Ramakrishnan, V.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Cambridge CB2 0QH, England.	martin.schmeing@mcgill.ca; ramak@mrc-lmb.cam.ac.uk		Ramakrishnan, V/0000-0002-4699-2194; VOORHEES, REBECCA/0000-0003-1640-2293	Medical Research Council UK; Wellcome Trust; Agouron Institute; Louis-Jeantet Foundation; Gates-Cambridge scholarship; Medical Research Council [MC_U105184332] Funding Source: researchfish; MRC [MC_U105184332] Funding Source: UKRI	Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Agouron Institute(Pfizer); Louis-Jeantet Foundation; Gates-Cambridge scholarship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank R. Green for reagents and D. de Sanctis at the European Synchrotron Radiation Facility for facilitating data collection. This work was supported by the Medical Research Council UK, the Wellcome Trust, the Agouron Institute, and the Louis-Jeantet Foundation. R. M. V. is supported by a Gates-Cambridge scholarship, and T. M. S. by the Human Frontier Science Program and Emmanuel College. V. R. is on the Scientific Advisory Board and holds stock options in Rib-X pharmaceuticals. Transfer of Thermus thermophilis ribosome strain T. th. HB8-MRC-MSAW1 requires a Materials Transfer Agreement with the MRC. Coordinates and structure factors have been deposited at the Protein Data Bank with accession codes 2xqd and 2xqe.	BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BILGIN N, 1994, J MOL BIOL, V235, P813, DOI 10.1006/jmbi.1994.1041; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Diaconu M, 2005, CELL, V121, P991, DOI 10.1016/j.cell.2005.04.015; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; HOLMBERG L, 1994, BIOCHEMISTRY-US, V33, P15159, DOI 10.1021/bi00254a027; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Knudsen C, 2001, J BIOL CHEM, V276, P22183, DOI 10.1074/jbc.M102186200; Margus T, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-15; MESTERS JR, 1994, J MOL BIOL, V242, P644, DOI 10.1006/jmbi.1994.1614; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; RAMBELLI F, 1989, BIOCHEM J, V259, P307, DOI 10.1042/bj2590307; REMACHA M, 1995, MOL CELL BIOL, V15, P4754; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; Schmeing TM, 2009, SCIENCE, V326, P688, DOI 10.1126/science.1179700; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; Sengupta J, 2008, J MOL BIOL, V382, P179, DOI 10.1016/j.jmb.2008.07.004; Taylor DJ, 2007, EMBO J, V26, P2421, DOI 10.1038/sj.emboj.7601677; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Villa E, 2009, P NATL ACAD SCI USA, V106, P1063, DOI 10.1073/pnas.0811370106; Vogeley L, 2001, J BIOL CHEM, V276, P17149, DOI 10.1074/jbc.M100017200; Wieden HJ, 2001, J MOL EVOL, V52, P129, DOI 10.1007/s002390010141	33	268	273	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					835	838		10.1126/science.1194460	http://dx.doi.org/10.1126/science.1194460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051640	Green Accepted			2022-12-28	WOS:000283855700047
J	Lamont, T; Cousins, D; Rosario, C				Lamont, Tara; Cousins, David; Rosario, Catherine			Safety Alerts Safer treatment doses for low molecular weight heparins: summary of a safety report from the National Patient Safety Agency	BRITISH MEDICAL JOURNAL			English	Editorial Material							RISK		[Lamont, Tara; Cousins, David; Rosario, Catherine] Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England		Lamont, T (corresponding author), Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England.	tara.lamont@npsa.nhs.uk						Baglin T, 2006, BRIT J HAEMATOL, V133, P19, DOI 10.1111/j.1365-2141.2005.05953.x; *BMJ GROUP, 2010, BRIT NAT FORM; *DEP HLTH EST FAC, 2010, EFA 2010 001 MED PAT; EDITH AN, 2009, ANN PHARMACOTHER, V43, P1064; Hendershot KM, 2006, J AM COLL SURGEONS, V203, P887, DOI 10.1016/j.jamcollsurg.2006.08.018; Hilmer SN, 2007, INTERN MED J, V37, P647, DOI 10.1111/j.1445-5994.2007.01457.x; LaPointe NMA, 2007, ARCH INTERN MED, V167, P1539, DOI 10.1001/archinte.167.14.1539; Lin BW, 2009, AM J EMERG MED, V27, P1060, DOI 10.1016/j.ajem.2008.08.018; MARCIL A, 2004, CAN J HOSP PHARM, P220; MCARTNEY R, 2009, IJPP S17, V17, pB38; National Institute for Health and Clinical Excellence, 2010, VEN THROMB RED RISK; *NHS PRESCR SERV, PRESCR DAT ENGL 2008	12	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2010	341								c5884	10.1136/bmj.c5884	http://dx.doi.org/10.1136/bmj.c5884			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CU	21045026				2022-12-28	WOS:000284048200022
J	Sauka-Spengler, T; Bronner, M				Sauka-Spengler, Tatjana; Bronner, Marianne			SnapShot: Neural Crest	CELL			English	Editorial Material									[Sauka-Spengler, Tatjana; Bronner, Marianne] CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Sauka-Spengler, T (corresponding author), CALTECH, Pasadena, CA 91125 USA.			Sauka-Spengler, Tatjana/0000-0001-9289-0263; Bronner, Marianne/0000-0003-4274-1862					0	20	20	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 29	2010	143	3					486	486	486.e1	10.1016/j.cell.2010.10.025	http://dx.doi.org/10.1016/j.cell.2010.10.025			1	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029868	Bronze			2022-12-28	WOS:000283603900021
J	Pereyra, FP; Jia, XM; McLaren, PJ; Telenti, A; de Bakker, PIW; Walker, BD; Ripke, S; Brumme, CJ; Pulit, SL; Carrington, M; Kadie, CM; Carlson, JM; Heckerman, D; Graham, RR; Plenge, RM; Deeks, SG; Gianniny, L; Crawford, G; Sullivan, J; Gonzalez, E; Davies, L; Camargo, A; Moore, JM; Beattie, N; Gupta, S; Crenshaw, A; Burtt, NP; Guiducci, C; Gupta, N; Carrington, M; Gao, XJ; Qi, Y; Yuki, Y; Piechocka-Trocha, A; Cutrell, E; Rosenberg, R; Moss, KL; Lemay, P; O'Leary, J; Schaefer, T; Verma, P; Toth, I; Block, B; Baker, B; Rothchild, A; Lian, J; Proudfoot, J; Alvino, DML; Vine, S; Addo, MM; Allen, TM; Altfeld, M; Henn, MR; Le Gall, S; Streeck, H; Haas, DW; Kuritzkes, DR; Robbins, GK; Shafer, RW; Gulick, RM; Shikuma, CM; Haubrich, R; Riddler, S; Sax, PE; Daar, ES; Ribaudo, HJ; Agan, B; Agarwal, S; Ahern, RL; Allen, BL; Altidor, S; Altschuler, EL; Ambardar, S; Anastos, K; Anderson, B; Anderson, V; Andrady, U; Antoniskis, D; Bangsberg, D; Barbaro, D; Barrie, W; Bartczak, J; Barton, S; Basden, P; Basgoz, N; Bazner, S; Bellos, NC; Benson, AM; Berger, J; Bernard, NF; Bernard, AM; Birch, C; Bodner, SJ; Bolan, RK; Boudreaux, ET; Bradley, M; Braun, JF; Brndjar, JE; Brown, SJ; Brown, K; Brown, ST; Burack, J; Bush, LM; Cafaro, V; Campbell, O; Campbell, J; Carlson, RH; Carmichael, JK; Casey, KK; Cavacuiti, C; Celestin, G; Chambers, ST; Chez, N; Chirch, LM; Cimoch, PJ; Cohen, D; Cohn, LE; Conway, B; Cooper, DA; Cornelson, B; Cox, DT; Cristofano, MV; Cuchural, G; Czartoski, JL; Dahman, JM; Daly, JS; Davis, BT; Davis, K; Davod, SM; Deeks, SG; DeJesus, E; Dietz, CA; Dunham, E; Dunn, ME; Ellerin, TB; Eron, JJ; Fangman, JJW; Farel, CE; Ferlazzo, H; Fidler, S; Fleenor-Ford, A; Frankel, R; Freedberg, KA; French, NK; Fuchs, JD; Fuller, JD; Gaberman, J; Gallant, JE; Gandhi, RT; Garcia, E; Garmon, D; Gathe, JC; Gaultier, CR; Gebre, W; Gilman, FD; Gilson, I; Goepfert, PA; Gottlieb, MS; Goulston, C; Groger, RK; Gurley, TD; Haber, S; Hardwicke, R; Hardy, WD; Harrigan, PR; Hawkins, TN; Heath, S; Hecht, FM; Henry, WK; Hladek, M; Hoffman, RP; Horton, JM; Hsu, RK; Huhn, GD; Hunt, P; Hupert, MJ; Illeman, ML; Jaeger, H; Jellinger, RM; John, M; Johnson, JA; Johnson, KL; Johnson, H; Johnson, K; Joly, J; Jordan, WC; Kauffman, CA; Khanlou, H; Killian, RK; Kim, AY; Kim, DD; Kinder, CA; Kirchner, JT; Kogelman, L; Kojic, EM; Korthuis, T; Kurisu, W; Kwon, DS; LaMar, M; Lampiris, H; Lanzafame, M; Lederman, MM; Lee, DM; Lee, JML; Lee, MJ; Lee, ETY; Lemoine, J; Levy, JA; Llibre, JM; Liguori, MA; Little, SJ; Liu, AY; Lopez, AJ; Loutfy, MR; Loy, D; Mohammed, DY; Man, A; Mansour, MK; Marconi, VC; Markowitz, M; Marques, R; Martin, JN; Martin, HL; Mayer, KH; McElrath, MJ; McGhee, TA; McGovern, BH; McGowan, K; McIntyre, D; Mcleod, GX; Menezes, P; Mesa, G; Metroka, CE; Meyer-Olson, D; Miller, AO; Montgomery, K; Mounzer, KC; Nagami, EH; Nagin, I; Nahass, RG; Nelson, MO; Nielsen, C; Norene, DL; O'Connor, DH; Ojikutu, BO; Okulicz, J; Oladehin, OO; Oldfield, EC; Olender, SA; Ostrowski, M; Owen, WF; Pae, E; Parsonnet, J; Pavlatos, AM; Perlmutter, AM; Pierce, MN; Pincus, JM; Pisani, L; Price, LJ; Proia, L; Prokesch, RC; Pujet, HC; Ramgopal, M; Rathod, A; Rausch, M; Ravishankar, J; Rhame, FS; Richards, CS; Richman, DD; Robbins, GK; Rodes, B; Rodriguez, M; Rose, RC; Rosenberg, ES; Rosenthal, D; Ross, PE; Rubin, DS; Rumbaugh, E; Saenz, L; Salvaggio, MR; Sanchez, WC; Sanjana, VM; Santiago, S; Schmidt, W; Schuitemaker, H; Sestak, PM; Shalit, P; Shay, W; Shirvani, VN; Silebi, VI; Sizemore, JM; Skolnik, PR; Sokol-Anderson, M; Sosman, JM; Stabile, P; Stapleton, JT; Starrett, S; Stein, F; Stellbrink, HJ; Sterman, FL; Stone, VE; Stone, DR; Tambussi, G; Taplitz, RA; Tedaldi, EM; Telenti, A; Theisen, W; Torres, R; Tosiello, L; Tremblay, C; Tribble, MA; Trinh, PD; Tsao, A; Ueda, P; Vaccaro, A; Valadas, E; Vanig, TJ; Vecino, I; Vega, VM; Veikley, W; Wade, BH; Walworth, C; Wanidworanun, C; Ward, DJ; Warner, DA; Weber, RD; Webster, D; Weis, S; Wheeler, DA; White, DJ; Wilkins, E; Winston, A; Wlodaver, CG; van't Wout, A; Wright, DP; Yang, OO; Yurdin, DL; Zabukovic, BW; Zachary, KC; Zeeman, B; Zhao, M				Pereyra, Florencia; Jia, Xiaoming; McLaren, Paul J.; Telenti, Amalio; de Bakker, Paul I. W.; Walker, Bruce D.; Ripke, Stephan; Brumme, Chanson J.; Pulit, Sara L.; Carrington, Mary; Kadie, Carl M.; Carlson, Jonathan M.; Heckerman, David; Graham, Robert R.; Plenge, Robert M.; Deeks, Steven G.; Gianniny, Lauren; Crawford, Gabriel; Sullivan, Jordan; Gonzalez, Elena; Davies, Leela; Camargo, Amy; Moore, Jamie M.; Beattie, Nicole; Gupta, Supriya; Crenshaw, Andrew; Burtt, Noel P.; Guiducci, Candace; Gupta, Namrata; Carrington, Mary; Gao, Xiaojiang; Qi, Ying; Yuki, Yuko; Piechocka-Trocha, Alicja; Cutrell, Emily; Rosenberg, Rachel; Moss, Kristin L.; Lemay, Paul; O'Leary, Jessica; Schaefer, Todd; Verma, Pranshu; Toth, Ildiko; Block, Brian; Baker, Brett; Rothchild, Alissa; Lian, Jeffrey; Proudfoot, Jacqueline; Alvino, Donna Marie L.; Vine, Seanna; Addo, Marylyn M.; Allen, Todd M.; Altfeld, Marcus; Henn, Matthew R.; Le Gall, Sylvie; Streeck, Hendrik; Haas, David W.; Kuritzkes, Daniel R.; Robbins, Gregory K.; Shafer, Robert W.; Gulick, Roy M.; Shikuma, Cecilia M.; Haubrich, Richard; Riddler, Sharon; Sax, Paul E.; Daar, Eric S.; Ribaudo, Heather J.; Agan, Brian; Agarwal, Shanu; Ahern, Richard L.; Allen, Brady L.; Altidor, Sherly; Altschuler, Eric L.; Ambardar, Sujata; Anastos, Kathryn; Anderson, Ben; Anderson, Val; Andrady, Ushan; Antoniskis, Diana; Bangsberg, David; Barbaro, Daniel; Barrie, William; Bartczak, J.; Barton, Simon; Basden, Patricia; Basgoz, Nesli; Bazner, Suzane; Bellos, Nicholaos C.; Benson, Anne M.; Berger, Judith; Bernard, Nicole F.; Bernard, Annette M.; Birch, Christopher; Bodner, Stanley J.; Bolan, Robert K.; Boudreaux, Emilie T.; Bradley, Meg; Braun, James F.; Brndjar, Jon E.; Brown, Stephen J.; Brown, Katherine; Brown, Sheldon T.; Burack, Jedidiah; Bush, Larry M.; Cafaro, Virginia; Campbell, Omobolaji; Campbell, John; Carlson, Robert H.; Carmichael, J. Kevin; Casey, Kathleen K.; Cavacuiti, Chris; Celestin, Gregory; Chambers, Steven T.; Chez, Nancy; Chirch, Lisa M.; Cimoch, Paul J.; Cohen, Daniel; Cohn, Lillian E.; Conway, Brian; Cooper, David A.; Cornelson, Brian; Cox, David T.; Cristofano, Michael V.; Cuchural, George, Jr.; Czartoski, Julie L.; Dahman, Joseph M.; Daly, Jennifer S.; Davis, Benjamin T.; Davis, Kristine; Davod, Sheila M.; Deeks, Steven G.; DeJesus, Edwin; Dietz, Craig A.; Dunham, Eleanor; Dunn, Michael E.; Ellerin, Todd B.; Eron, Joseph J.; Fangman, John J. W.; Farel, Claire E.; Ferlazzo, Helen; Fidler, Sarah; Fleenor-Ford, Anita; Frankel, Renee; Freedberg, Kenneth A.; French, Neel K.; Fuchs, Jonathan D.; Fuller, Jon D.; Gaberman, Jonna; Gallant, Joel E.; Gandhi, Rajesh T.; Garcia, Efrain; Garmon, Donald; Gathe, Joseph C., Jr.; Gaultier, Cyril R.; Gebre, Wondwoosen; Gilman, Frank D.; Gilson, Ian; Goepfert, Paul A.; Gottlieb, Michael S.; Goulston, Claudia; Groger, Richard K.; Gurley, T. Douglas; Haber, Stuart; Hardwicke, Robin; Hardy, W. David; Harrigan, P. Richard; Hawkins, Trevor N.; Heath, Sonya; Hecht, Frederick M.; Henry, W. Keith; Hladek, Melissa; Hoffman, Robert P.; Horton, James M.; Hsu, Ricky K.; Huhn, Gregory D.; Hunt, Peter; Hupert, Mark J.; Illeman, Mark L.; Jaeger, Hans; Jellinger, Robert M.; John, Mina; Johnson, Jennifer A.; Johnson, Kristin L.; Johnson, Heather; Johnson, Kay; Joly, Jennifer; Jordan, Wilbert C.; Kauffman, Carol A.; Khanlou, Homayoon; Killian, Robert K.; Kim, Arthur Y.; Kim, David D.; Kinder, Clifford A.; Kirchner, Jeffrey T.; Kogelman, Laura; Kojic, Erna Milunka; Korthuis, Todd; Kurisu, Wayne; Kwon, Douglas S.; LaMar, Melissa; Lampiris, Harry; Lanzafame, Massimiliano; Lederman, Michael M.; Lee, David M.; Lee, Jean M. L.; Lee, Marah J.; Lee, Edward T. Y.; Lemoine, Janice; Levy, Jay A.; Llibre, Josep M.; Liguori, Michael A.; Little, Susan J.; Liu, Anne Y.; Lopez, Alvaro J.; Loutfy, Mono R.; Loy, Dawn; Mohammed, Debbie Y.; Man, Alan; Mansour, Michael K.; Marconi, Vincent C.; Markowitz, Martin; Marques, Rui; Martin, Jeffrey N.; Martin, Harold L., Jr.; Mayer, Kenneth Hugh; McElrath, M. Juliana; McGhee, Theresa A.; McGovern, Barbara H.; McGowan, Katherine; McIntyre, Dawn; Mcleod, Gavin X.; Menezes, Prema; Mesa, Greg; Metroka, Craig E.; Meyer-Olson, Dirk; Miller, Andy O.; Montgomery, Kate; Mounzer, Karam C.; Nagami, Ellen H.; Nagin, Iris; Nahass, Ronald G.; Nelson, Margret O.; Nielsen, Craig; Norene, David L.; O'Connor, David H.; Ojikutu, Bisola O.; Okulicz, Jason; Oladehin, Olakunle O.; Oldfield, Edward C., III; Olender, Susan A.; Ostrowski, Mario; Owen, William F., Jr.; Pae, Eunice; Parsonnet, Jeffrey; Pavlatos, Andrew M.; Perlmutter, Aaron M.; Pierce, Michael N.; Pincus, Jonathan M.; Pisani, Leandro; Price, Lawrence Jay; Proia, Laurie; Prokesch, Richard C.; Pujet, Heather Calderon; Ramgopal, Moti; Rathod, Almas; Rausch, Michael; Ravishankar, J.; Rhame, Frank S.; Richards, Constance Shamuyarira; Richman, Douglas D.; Robbins, Gregory K.; Rodes, Berta; Rodriguez, Milagros; Rose, Richard C., III; Rosenberg, Eric S.; Rosenthal, Daniel; Ross, Polly E.; Rubin, David S.; Rumbaugh, Elease; Saenz, Luis; Salvaggio, Michelle R.; Sanchez, William C.; Sanjana, Veeraf M.; Santiago, Steven; Schmidt, Wolfgang; Schuitemaker, Hanneke; Sestak, Philip M.; Shalit, Peter; Shay, William; Shirvani, Vivian N.; Silebi, Vanessa I.; Sizemore, James M., Jr.; Skolnik, Paul R.; Sokol-Anderson, Marcia; Sosman, James M.; Stabile, Paul; Stapleton, Jack T.; Starrett, Sheree; Stein, Francine; Stellbrink, Hans-Jurgen; Sterman, F. Lisa; Stone, Valerie E.; Stone, David R.; Tambussi, Giuseppe; Taplitz, Randy A.; Tedaldi, Ellen M.; Telenti, Amalio; Theisen, William; Torres, Richard; Tosiello, Lorraine; Tremblay, Cecile; Tribble, Marc A.; Trinh, Phuong D.; Tsao, Alice; Ueda, Peggy; Vaccaro, Anthony; Valadas, Emilia; Vanig, Thanes J.; Vecino, Isabel; Vega, Vilma M.; Veikley, Wenoah; Wade, Barbara H.; Walworth, Charles; Wanidworanun, Chingchai; Ward, Douglas J.; Warner, Daniel A.; Weber, Robert D.; Webster, Duncan; Weis, Steve; Wheeler, David A.; White, David J.; Wilkins, Ed; Winston, Alan; Wlodaver, Clifford G.; van't Wout, Angelique; Wright, David P.; Yang, Otto O.; Yurdin, David L.; Zabukovic, Brandon W.; Zachary, Kimon C.; Zeeman, Beth; Zhao, Meng		Int HIV Controllers Study	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation	SCIENCE			English	Article							DISEASE PROGRESSION; SURFACE EXPRESSION; INFECTION; AIDS; ALLELES; MHC; RESTRICTION; ASSOCIATION; THERAPY; ABSENCE	Infectious and inflammatory diseases have repeatedly shown strong genetic associations within the major histocompatibility complex (MHC); however, the basis for these associations remains elusive. To define host genetic effects on the outcome of a chronic viral infection, we performed genome-wide association analysis in a multiethnic cohort of HIV-1 controllers and progressors, and we analyzed the effects of individual amino acids within the classical human leukocyte antigen (HLA) proteins. We identified >300 genome-wide significant single-nucleotide polymorphisms (SNPs) within the MHC and none elsewhere. Specific amino acids in the HLA-B peptide binding groove, as well as an independent HLA-C effect, explain the SNP associations and reconcile both protective and risk HLA alleles. These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection.	[Pereyra, Florencia; Walker, Bruce D.; Brumme, Chanson J.; Carrington, Mary; Piechocka-Trocha, Alicja; Cutrell, Emily; Rosenberg, Rachel; Moss, Kristin L.; Lemay, Paul; O'Leary, Jessica; Schaefer, Todd; Verma, Pranshu; Toth, Ildiko; Block, Brian; Baker, Brett; Rothchild, Alissa; Lian, Jeffrey; Proudfoot, Jacqueline; Alvino, Donna Marie L.; Vine, Seanna; Addo, Marylyn M.; Allen, Todd M.; Altfeld, Marcus; Le Gall, Sylvie; Streeck, Hendrik; Bazner, Suzane; Birch, Christopher; Bradley, Meg; Kwon, Douglas S.; Nagami, Ellen H.; Pae, Eunice; Rathod, Almas; Tsao, Alice; Ueda, Peggy; Zeeman, Beth] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Regon Inst, Boston, MA USA; [Pereyra, Florencia; Kuritzkes, Daniel R.; Sax, Paul E.; Farel, Claire E.; Johnson, Jennifer A.; Liu, Anne Y.; McGowan, Katherine; Theisen, William] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Infect Dis, Boston, MA 02115 USA; [Jia, Xiaoming] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA; [McLaren, Paul J.; de Bakker, Paul I. W.; Ripke, Stephan; Pulit, Sara L.; Plenge, Robert M.; Gianniny, Lauren; Crawford, Gabriel; Sullivan, Jordan; Gonzalez, Elena; Davies, Leela; Camargo, Amy; Moore, Jamie M.; Beattie, Nicole; Gupta, Supriya; Crenshaw, Andrew; Burtt, Noel P.; Guiducci, Candace; Gupta, Namrata; Henn, Matthew R.] Harvard & MIT, Broad Inst, Cambridge, MA USA; [McLaren, Paul J.; de Bakker, Paul I. W.; Pulit, Sara L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, Boston, MA 02115 USA; [Telenti, Amalio] Univ Lausanne, Inst Microbiol, Lausanne, Switzerland; [de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Med Genet, Div Biomed Genet, Utrecht, Netherlands; [de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Ripke, Stephan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res,Dept Med, Boston, MA USA; [Gao, Xiaojiang; Qi, Ying; Yuki, Yuko] NCI, Canc & Inflammat Program, Expt Immunol Lab, SAIC Frederick, Frederick, MD 21701 USA; [Kadie, Carl M.] Microsoft Res, Redmond, WA USA; [Carlson, Jonathan M.; Heckerman, David] Microsoft Res, Los Angeles, CA USA; [Graham, Robert R.] Genentech Inc, San Francisco, CA 94080 USA; [Plenge, Robert M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Deeks, Steven G.; Hecht, Frederick M.; Hunt, Peter; Lampiris, Harry; Levy, Jay A.; Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Haas, David W.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Shafer, Robert W.] Stanford Univ, Palo Alto, CA 94304 USA; [Gulick, Roy M.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Shikuma, Cecilia M.] Univ Hawaii, John A Burns Sch Med, Hawaii Ctr AIDS, Honolulu, HI 96822 USA; [Haubrich, Richard; Little, Susan J.; Richman, Douglas D.; Taplitz, Randy A.] Univ Calif San Diego, San Diego, CA 92103 USA; [Riddler, Sharon] Univ Pittsburgh, Pittsburgh, PA USA; [Daar, Eric S.; Hardy, W. David; Yang, Otto O.] Univ Calif Los Angeles, Los Angeles, CA USA; [Ribaudo, Heather J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Agan, Brian] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA; [Agarwal, Shanu] Summa Hlth Syst, Akron, OH USA; [Allen, Brady L.; Lee, David M.] Uptown Phys Grp, Dallas, TX USA; [Altidor, Sherly; Metroka, Craig E.] St Lukes Roosevelt Hosp, New York, NY 10025 USA; [Altschuler, Eric L.; Mohammed, Debbie Y.] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp, Newark, NJ 07103 USA; [Anastos, Kathryn] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; [Anderson, Ben] St Leonards Med Ctr, St Leonards, NSW, Australia; [Anderson, Val; Andrady, Ushan] Ysbyty Gwynedd Hosp, Bangor, Gwynedd, Wales; [Antoniskis, Diana; Man, Alan; Rumbaugh, Elease] Kaiser Permanente, Portland, OR USA; [Barbaro, Daniel; Hupert, Mark J.; Johnson, Heather] Tarrant Cty Infect Dis Associates, Ft Worth, TX USA; [Bartczak, J.] Rowan Tree Med, Wilton Manors, FL USA; [Barton, Simon] Chelsea & Westminster Hosp, St Stephens Ctr, London, England; [Bellos, Nicholaos C.] SW Infect Dis Associates, Dallas, TX USA; [Berger, Judith] St Barnabas Hosp, Bronx, NY USA; [Bernard, Nicole F.] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Res Inst, Montreal, PQ H3G 1A4, Canada; [Bernard, Annette M.] Thacker Thompson & Bernard, Atlanta, GA USA; [Bodner, Stanley J.] Vanderbilt Univ, Sch ofMedicine, Hermitage, TN USA; [Bolan, Robert K.] LA Gay & Lesbian Ctr, Los Angeles, CA USA; [Boudreaux, Emilie T.] Louisiana State Univ, Hlth Sci Ctr, Univ Med Ctr E Clin, Lafayatte, LA USA; [Braun, James F.] Callen Lorde Community Hlth Ctr, Phys Res Network, New York, NY USA; [Brndjar, Jon E.] Brndjar Med Associates, Allentown, PA USA; [Brown, Stephen J.] AIDS Res Alliance, Los Angeles, CA USA; [Brown, Katherine] David Powell Community Hlth Ctr, Austin, TX USA; [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA; [Burack, Jedidiah] Sunrise Med Grp, Brooklyn, NY USA; [Bush, Larry M.] Univ Miami, Miller Sch Med, Lake Worth, FL USA; [Cafaro, Virginia] WellSpring Med Grp, San Francisco, CA USA; [Campbell, John] Moses Cone Hlth Syst, Greensboro, NC USA; [Carlson, Robert H.] HealthPartners Infect Dis, St Paul, MN USA; [Carmichael, J. Kevin] El Rio Special Immunol Associates, Tucson, AZ USA; [Casey, Kathleen K.; McIntyre, Dawn] Jersey Shore Univ, Med Ctr, Neptune, NJ USA; [Cavacuiti, Chris; Cornelson, Brian] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Celestin, Gregory] PATH Ctr, Brooklyn Hosp Ctr, Brooklyn, NY USA; [Chambers, Steven T.] Univ Otago, Christchurch, New Zealand; [Chez, Nancy] HELP Project Samaritan, Bronx, NY USA; [Chirch, Lisa M.; Dunham, Eleanor; Joly, Jennifer] David E Rogers Ctr HIV AIDS Care, Southampton, NY USA; [Cimoch, Paul J.; Walworth, Charles] Ctr Special Immunol, Fountain Valley, CA USA; [Cohen, Daniel; Mayer, Kenneth Hugh] Fenway Community Hlth, Boston, MA USA; [Cohn, Lillian E.] 9th St Internal Med Associates, Philadelphia, PA USA; [Conway, Brian] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Cooper, David A.] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; [Cox, David T.] Metro Infect Dis Consultants, Indianapolis, IN USA; [Cristofano, Michael V.] John H Stroger Hosp Cook Cty, Chicago, IL USA; [Cuchural, George, Jr.] New England Qual Care Alliance, Braintree, MA USA; [Czartoski, Julie L.; Lee, Jean M. L.; McElrath, M. Juliana] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Dahman, Joseph M.] Desert AIDS Project, Palm Springs, CA USA; [Daly, Jennifer S.] Univ Massachusetts, Mem Med Ctr, Worcester, MA 01605 USA; [Davis, Kristine] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA; [DeJesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA; [Dietz, Craig A.] Kansas City Free Hlth Clin, Kansas City, MO USA; [Ellerin, Todd B.] S Shore Hosp, Weymouth, MA USA; [Eron, Joseph J.; Menezes, Prema] Univ N Carolina, Chapel Hill, NC USA; [Fangman, John J. W.] AIDS Resource Ctr Wisconsin, Milwaukee, WI USA; [Ferlazzo, Helen; Stein, Francine] Visiting Nurse Assoc Cent New Jersey, Ctr Community Hlth, Asbury Pk, NJ USA; [Fidler, Sarah; Winston, Alan] Univ London Imperial Coll Sci Technol & Med, London, England; [Fleenor-Ford, Anita] Heartland Clin, Paducah, KY USA; [Frankel, Renee] Morristown Mem Hosp, Morristown, NJ USA; [Fuchs, Jonathan D.] San Francisco Dept Publ Hlth, San Francisco, CA USA; [Fuller, Jon D.; Skolnik, Paul R.] Boston Univ, Med Ctr, Boston, MA USA; [Gaberman, Jonna] Baystate Med Ctr, Springfield, MA USA; [Gallant, Joel E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Gaultier, Cyril R.] Tower Infect Dis, Los Angeles, CA USA; [Gebre, Wondwoosen] Nassau Univ Med Ctr, E Meadow, NY USA; [Gilman, Frank D.; Kurisu, Wayne] Sharp Rees Stealy Med Ctr, San Diego, CA USA; [Gilson, Ian] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Goepfert, Paul A.; Heath, Sonya] Univ Alabama, Birmingham, AL USA; [Gottlieb, Michael S.] Synergy Hematol & Oncol, Los Angeles, CA USA; [Goulston, Claudia] Univ Utah, Salt Lake City, UT USA; [Groger, Richard K.] S Dayton Acute Care Consultants, Dayton, OH USA; [Haber, Stuart; Shay, William] St Vincents Hosp, New York, NY USA; [Hardwicke, Robin] Univ Texas Hlth Sci Ctr, Houston, TX USA; [Harrigan, P. Richard] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Hawkins, Trevor N.; Veikley, Wenoah] SW CARE Ctr, Santa Fe, NM USA; [Henry, W. Keith] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; [Hladek, Melissa] Catholic Univ Amer, Sch Nursing, Washington, DC 20064 USA; [Hoffman, Robert P.] St Johns Mercy Med Ctr, Springfield, MA USA; [Horton, James M.] CMC Myers Pk Med Ctr, Charlotte, NC USA; [Hsu, Ricky K.; Liguori, Michael A.] NYU, Med Ctr, New York, NY 10016 USA; [Huhn, Gregory D.] Ruth M Rothshon Care Ctr, Chicago, IL USA; [Illeman, Mark L.] Feldman Med Grp, San Francisco, CA USA; [Jaeger, Hans] HIV Res & Clin Care Ctr, Munich, Germany; [Jellinger, Robert M.] Albany Med Coll, Albany, NY 12208 USA; [John, Mina] Murdoch Univ, Murdoch, WA 6150, Australia; [Johnson, Kay] Univ Cincinnati, Cincinnati, OH USA; [Jordan, Wilbert C.] OASIS Clin, Los Angeles, CA USA; [Kauffman, Carol A.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA; [Khanlou, Homayoon] AIDS Healthcare Fdn, Los Angeles, CA USA; [Killian, Robert K.] Capitol Hill Med, Seattle, WA USA; [Kim, David D.] Astor Med Grp, New York, NY USA; [Kinder, Clifford A.] Kinder Med Grp, Miami, FL USA; [Kirchner, Jeffrey T.] Lancaster Gen Hosp, Lancaster, PA USA; [Kogelman, Laura; McGovern, Barbara H.] Tufts Med Ctr, Boston, MA USA; [Kojic, Erna Milunka] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Korthuis, Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Lanzafame, Massimiliano] GB Rossi Hosp, Verona, Italy; [Lederman, Michael M.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Lee, Marah J.] LifeWay, Ft Lauderdale, FL USA; [Lee, Edward T. Y.] St Claire Med Associate, Toronto, ON, Canada; [Lemoine, Janice] Greater Lawrence Family Hlth Ctr, Lawrence, MA USA; [Llibre, Josep M.] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain; [Lopez, Alvaro J.] Infect Dis Consultants, Tucker, GA USA; [Loutfy, Mono R.; Ostrowski, Mario] Univ Toronto, Toronto, ON, Canada; [Loy, Dawn; Prokesch, Richard C.; Vega, Vilma M.] Infect Dis Associates, Sarasota, FL USA; [Marconi, Vincent C.] Emory Univ, Sch Med, Atlanta, GA USA; [Markowitz, Martin] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA; [Martin, Harold L., Jr.] Pk Nicollet Clin, St Louis, MN USA; [McGhee, Theresa A.] Absolute Care, Atlanta, GA USA; [Mcleod, Gavin X.] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Mesa, Greg] Highland Med Associates, Hendersonville, NC USA; [Meyer-Olson, Dirk] Hannover Med Sch, Abt Klin Immunol, D-30623 Hannover, Germany; [Miller, Andy O.] Hosp Special Surg, New York, NY 10021 USA; [Mounzer, Karam C.] Philadelphia FIGHT, Philadelphia, PA USA; [Nagin, Iris] Lower E Side Serv Ctr, New York, NY USA; [Nielsen, Craig] Univ Colorado, Aurora, CO USA; [Norene, David L.] Sutter Med Grp, Sacramento, CA USA; [O'Connor, David H.; Sosman, James M.] Univ Wisconsin, Madison, WI USA; [Okulicz, Jason] Brooke Army Med Ctr, San Antonio, TX USA; [Oldfield, Edward C., III] Eastern Virginia Med Sch, Norfolk, VA 23501 USA; [Olender, Susan A.] Columbia Univ, Med Ctr, New York, NY USA; [Owen, William F., Jr.] CA Pacific Med Ctr, San Francisco, CA USA; [Parsonnet, Jeffrey] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Pavlatos, Andrew M.] St Joseph Hosp, Chicago, IL USA; [Pincus, Jonathan M.] Codman Sq Hlth Ctr, Dorchester, MA USA; [Pisani, Leandro; Rodriguez, Milagros; Saenz, Luis; Santiago, Steven] CARE Resource, Miami, FL USA; [Price, Lawrence Jay] Castro Mission Hlth Ctr, San Francisco, CA USA; [Proia, Laurie] Rush Med Coll, Chicago, IL 60612 USA; [Pujet, Heather Calderon] Boulder Community Hosp, Boulder, CO USA; [Ramgopal, Moti] Midway Immunol & Res Ctr, Ft Pierce, FL USA; [Rausch, Michael] Aerztezentrum Nollendorfpl, Berlin, Germany; [Ravishankar, J.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA; [Rhame, Frank S.] Clin 42, Minneapolis, MN USA; [Richards, Constance Shamuyarira] King Edward Mem Hosp, Paget, Bermuda; [Rodes, Berta] Hosp Carlos III, Fdn Invest Biomed, Madrid, Spain; [Rose, Richard C., III] Summit Med Grp, Knoxville, TN USA; [Rosenthal, Daniel] Med Consultants S Florida, Coral Springs, FL USA; [Ross, Polly E.] Western N Carolina Community Hlth Serv, Asheville, NC USA; [Rubin, David S.] New York Hosp, Queens Med Ctr, Flushing, NY USA; [Salvaggio, Michelle R.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Sanchez, William C.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA; [Sanjana, Veeraf M.] Village Care Hlth Ctr, New York, NY USA; [Schuitemaker, Hanneke; van't Wout, Angelique] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Sestak, Philip M.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; [Shalit, Peter] Swedish Med Ctr, Seattle, WA USA; [Shirvani, Vivian N.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Silebi, Vanessa I.] Mercy Hosp, Miami, FL USA; [Sizemore, James M., Jr.] Univ Tennessee, Chattanooga, TN USA; [Sokol-Anderson, Marcia] St Louis Univ, St Louis, MO 63103 USA; [Stabile, Paul] William F Ryan Community Hlth Ctr, New York, NY USA; [Stapleton, Jack T.] Univ Iowa, Iowa City, IA USA; [Starrett, Sheree] Rivington House & Village Care, New York, NY USA; [Stellbrink, Hans-Jurgen] Infekt Med Ctr Hamburg, Hamburg, Germany; [Sterman, F. Lisa] Calif Pacific Med Ctr, San Francisco, CA USA; [Stone, David R.] Lemuel Shattuck Hosp, Boston, MA USA; [Tambussi, Giuseppe] Fdn San Raffaele Del Monte Tabor, Milan, Italy; [Tedaldi, Ellen M.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA; [Torres, Richard] Yale Univ, Sch Med, Bridgeport, CT USA; [Tosiello, Lorraine] Jersey City Med Ctr, Jersey City, NJ USA; [Tremblay, Cecile] Univ Montreal, Montreal, PQ, Canada; [Tribble, Marc A.] Baylor Univ, Med Ctr, Dallas, TX USA; [Trinh, Phuong D.] Montgomery Infect Dis Associates, Silver Spring, MD USA; [Vaccaro, Anthony] Northwestern Univ, Chicago, IL 60611 USA; [Valadas, Emilia] Hosp Santa Maria, Fac Med Lisboa, Lisbon, Portugal; [Vanig, Thanes J.] Spectrum Med Grp, Phoenix, AZ USA; [Vecino, Isabel; Weis, Steve] Univ N Texas, Hlth Sci Ctr, Ft Worth, TX USA; [Wade, Barbara H.] Infect Dis Associates NW Florida, Pensacola, FL USA; [Ward, Douglas J.] Dupont Circle Phys Grp, Washington, DC USA; [Weber, Robert D.] Infect Dis Specialists, Colorado Springs, CO USA; [Webster, Duncan] St Johns Hosp, St John, NB, Canada; [Wheeler, David A.] Clin Alliance Res & Educ Infect Dis, Annandale, VA USA; [White, David J.] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; [Wilkins, Ed] N Manchester Grp Hosp, Manchester, Lancs, England; [Wright, David P.] Cent Texas Clin Res, Austin, TX USA; [Yurdin, David L.] Primary Hlth Care, Des Moines, IA USA; [Zabukovic, Brandon W.] Mem Neighborhood Hlth Ctr Cent Clin, South Bend, IN USA; [Zhao, Meng] United Hlth Serv Hosp, Binghamton, NY USA; [Pierce, Michael N.] All Med & Rehabil New York, Bronx, NY USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Lausanne; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Microsoft; Microsoft; Roche Holding; Genentech; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; Vanderbilt University; Stanford University; Cornell University; University of Hawaii System; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; Harvard University; Harvard T.H. Chan School of Public Health; Uniformed Services University of the Health Sciences - USA; Summa Health System; Mount Sinai St. Luke's; Mount Sinai West; Rutgers State University New Brunswick; Rutgers State University Medical Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Kaiser Permanente; Imperial College London; Saint Barnabas Hospital; McGill University; Vanderbilt University; Louisiana State University System; Louisiana State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Jersey Shore University Medical Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Brooklyn Hospital Center; University of Otago; University of British Columbia; University of New South Wales Sydney; Kirby Institute; John H Stroger Junior Hospital Cook County; Fred Hutchinson Cancer Center; University of Massachusetts System; University of Massachusetts Worcester; University of Iowa; Orlando Immunology Center; University of North Carolina; University of North Carolina Chapel Hill; Imperial College London; Atlantic Health System; San Francisco Department of Public Health; Boston University; Baystate Medical Center; Johns Hopkins University; Medical College of Wisconsin; University of Alabama System; University of Alabama Birmingham; Utah System of Higher Education; University of Utah; Saint Vincents Hospital Manhattan; University of Texas System; University of Texas Health Science Center Houston; B.C. Centre for Excellence in HIV/AIDS; Hennepin County Medical Center; Catholic University of America; New York University; Albany Medical College; Murdoch University; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; Tufts Medical Center; Brown University; Oregon Health & Science University; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; Case Western Reserve University; Hospital Germans Trias i Pujol; University of Toronto; Emory University; Rockefeller University; Columbia University; Hannover Medical School; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Wisconsin System; University of Wisconsin Madison; San Antonio Military Medical Center; United States Department of Defense; United States Army; Eastern Virginia Medical School; Columbia University; California Pacific Medical Center; Dartmouth College; Rush University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Hospital Carlos III; NewYork-Presbyterian Hospital; University of Oklahoma System; University of Oklahoma Health Sciences Center; Georgetown University; University of Amsterdam; Academic Medical Center Amsterdam; St. Paul's Hospital; University of Saskatchewan; Swedish Medical Center; Cedars Sinai Medical Center; University of Tennessee System; University of Tennessee at Chattanooga; Saint Louis University; University of Iowa; California Pacific Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yale University; Universite de Montreal; Baylor University; Baylor University Medical Center; Northwestern University; Universidade de Lisboa; Hospital Santa Maria; University of North Texas System; University of North Texas Health Science Center; Heart of England NHS Foundation Trust; University of Birmingham	Walker, BD (corresponding author), Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Regon Inst, Boston, MA USA.	pdebakker@rics.bwh.harvard.edu; bwalker@partners.org	Winston, Alan/AGZ-3015-2022; Lanzafame, Massimiliano/AAU-5736-2021; VALLET, Yannick/F-9979-2011; Addo, Marylyn M./GNP-2548-2022; Robbins, Gregory/F-7988-2011; Marconi, Vincent/AFK-5812-2022; Telenti, Amalio/AAY-1674-2021; Hunt, Peter W./P-2976-2017; Little, Susan/AAA-6116-2019; Rothchild, Alissa/AAM-2635-2020; Ripke, Stephan/AAK-5486-2021; Altfeld, Marcus/AAE-7306-2019; Allen, Todd/F-5473-2011; Bolan, Robert/AAD-4716-2020; Hardy, W. David/AHD-8960-2022; Miller, Andy/AAE-2500-2022; Marconi, Vincent/N-3210-2014; Marconi, Vincent/GRJ-4553-2022; Block, Brian/L-4001-2019; Lewin, Jonathan S/A-4331-2009; de Bakker, Paul IW/B-8730-2009	Winston, Alan/0000-0002-5847-8416; Hunt, Peter W./0000-0002-4571-4870; Rothchild, Alissa/0000-0001-7484-1193; Altfeld, Marcus/0000-0001-5972-2997; Allen, Todd/0000-0002-6609-1318; Miller, Andy/0000-0003-2762-0878; Marconi, Vincent/0000-0001-8409-4689; Marconi, Vincent/0000-0001-8409-4689; Block, Brian/0000-0002-0779-1170; de Bakker, Paul IW/0000-0001-7735-7858; Hladek, Melissa/0000-0002-0625-2474; Gonzalez, Elena/0000-0003-4380-663X; Tambussi, Giuseppe/0000-0002-0604-2960; Birch, Christopher/0000-0001-5824-2676; Ojikutu, Bisola/0000-0001-7957-8881; Campbell, Mobola/0000-0002-5772-2368; Fuller, Jon/0000-0001-9475-1902; Pulit, Sara/0000-0002-2502-3669; van 't Wout, Angelique/0000-0003-3705-2392; Jia, Xiaoming/0000-0002-5104-5431; Addo, Marylyn/0000-0003-2836-9224; Stapleton, Jack/0000-0002-2302-9055; Farel, Claire/0000-0002-4678-7713; McLaren, Paul/0000-0001-6019-7018; Fidler, Sarah/0000-0003-1676-7583; Brumme, Chanson/0000-0003-2722-5288; Valadas, Emilia/0000-0001-5213-1473; Robbins, Gregory/0000-0001-7545-5817; Korthuis, Philip/0000-0001-5556-3597; ripke, stephan/0000-0003-3622-835X; Lian, Jeffrey/0000-0001-9470-7864; Le Gall, Sylvie/0000-0003-0385-926X	Mark and Lisa Schwartz Foundation; Bill and Melinda Gates Foundation; Harvard University Center for AIDS Research [P-30-AI060354]; University of California San Francisco (UCSF) Center for AIDS Research [P-30 AI27763]; UCSF Clinical and Translational Science Institute [UL1 RR024131]; Center for AIDS Research Network of Integrated Clinical Systems [R24 AI067039]; NIH [AI28568, AI030914, AI087145, K24AI069994, AI069513, AI34835, AI069432, AI069423, AI069477, AI069501, AI069474, AI069428, AI69467, AI069415, Al32782, AI27661, AI25859, AI30914, AI069495, AI069471, AI069532, AI069452, AI069450, AI069556, AI069484, AI069472, AI069465, AI069511]; Swiss National Science Foundation (SNF) [33CSC0-108787, 310000-110012]; NIH/National Institute of Mental Health [MH085520]; National Cancer Institute/NIH [HHSN261200800001E]; NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975, TL1RR024978, KL2RR024977, UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI069495, UM1AI069452, R37AI028568, UM1AI069484, UM1AI068636, UM1AI069450, R01AI077505, U01AI027661, U01AI034835, UM1AI069477, U01AI069502, U01AI069415, U01AI069532, UM1AI069513, UM1AI069423, UM1AI069501, UM1AI069556, U01AI069450, UM1AI069472, U01AI069467, R24AI106039, R01AI030914, R24AI067039, P30AI050410, P30AI027763, U01AI034853, T32AI007061, UM1AI069465, U01AI069511, UM1AI069419, U01AI069419, R01AI087145, U01AI069424, U01AI068634, U01AI046370, U01AI069471, UM1AI069424, UM1AI069434, U01AI069465, UM1AI068634, U01AI069477, U01AI069474, U01AI069434, U01AI069452, K24AI051966, U01AI038844, U01AI069501, UM1AI069432, U01AI032782, U01AI069428, UM1AI069467, UM1AI069415, U01AI069495, UM1AI069532, U01AI069423, P30AI060354, U01AI069432, UM1AI069428, U01AI069556, U01AI069513, K24AI069994, UM1AI069502, U01AI069484, R01AI028568, U01AI025859, U01AI069472, K24AI064086, UM1AI069471, U01AI068636, UM1AI069511, UM1AI069474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U01MH085520, R01MH054907, R01MH071205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K23DA019809] Funding Source: NIH RePORTER	Mark and Lisa Schwartz Foundation; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Harvard University Center for AIDS Research; University of California San Francisco (UCSF) Center for AIDS Research; UCSF Clinical and Translational Science Institute; Center for AIDS Research Network of Integrated Clinical Systems; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); NIH/National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Cancer Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was made possible through a generous donation from the Mark and Lisa Schwartz Foundation and a subsequent award from the Collaboration for AIDS Vaccine Discovery of the Bill and Melinda Gates Foundation. This work was also supported in part by the Harvard University Center for AIDS Research (grant P-30-AI060354); University of California San Francisco (UCSF) Center for AIDS Research (grant P-30 AI27763); UCSF Clinical and Translational Science Institute (grant UL1 RR024131); Center for AIDS Research Network of Integrated Clinical Systems (grant R24 AI067039); and NIH grants AI28568 and AI030914 (B. D. W.); AI087145 and K24AI069994 (S. G. D.); AI069513, AI34835, AI069432, AI069423, AI069477, AI069501, AI069474, AI069428, AI69467, AI069415, Al32782, AI27661, AI25859, AI28568, AI30914, AI069495, AI069471, AI069532, AI069452, AI069450, AI069556, AI069484, AI069472, AI34853, AI069465, AI069511, AI38844, AI069424, AI069434, AI46370, AI68634, AI069502, AI069419, AI068636, and RR024975 (AIDS Clinical Trials Group); and AI077505 and MH071205 (D. W. H.). The Swiss HIV Cohort Study is supported by the Swiss National Science Foundation (SNF grants 33CSC0-108787 and 310000-110012). S. Ripke acknowledges support from NIH/National Institute of Mental Health (grant MH085520). This project has been funded in whole or in part with funds from National Cancer Institute/NIH (grant HHSN261200800001E to M. Carrington). The content of this publication does not necessarily reflect the views or policies of the U. S. Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U. S. government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298; Blanco-Gelaz MA, 2006, INT IMMUNOL, V18, P211, DOI 10.1093/intimm/dxh364; Brown WM, 2009, DIABETES OBES METAB, V11, P2, DOI 10.1111/j.1463-1326.2008.00997.x; Carrington M, 2003, ANNU REV MED, V54, P535, DOI 10.1146/annurev.med.54.101601.152346; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; Catano G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003636; Costello C, 1999, AIDS, V13, P1990, DOI 10.1097/00002030-199910010-00031; de Bakker PIW, 2006, NAT GENET, V38, P1166, DOI 10.1038/ng1885; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Fagerberg T, 2006, J MOL BIOL, V356, P521, DOI 10.1016/j.jmb.2005.11.059; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; KLEIN MR, 1994, J INFECT DIS, V169, P1244, DOI 10.1093/infdis/169.6.1244; Leslie A, 2006, J IMMUNOL, V177, P4699, DOI 10.4049/jimmunol.177.7.4699; Leslie S, 2008, AM J HUM GENET, V82, P48, DOI 10.1016/j.ajhg.2007.09.001; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Pelak K, 2010, J INFECT DIS, V201, P1141, DOI 10.1086/651382; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Robinson J, 2009, NUCLEIC ACIDS RES, V37, pD1013, DOI 10.1093/nar/gkn662; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Stewart-Jones GBE, 2005, J IMMUNOL, V175, P2459, DOI 10.4049/jimmunol.175.4.2459; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Thomas R, 2009, NAT GENET, V41, P1290, DOI 10.1038/ng.486; Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898	31	851	864	7	143	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2010	330	6010					1551	1557		10.1126/science.1195271	http://dx.doi.org/10.1126/science.1195271			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	692LE	21051598	Green Accepted, Green Published			2022-12-28	WOS:000285153500069
J	Runguphan, W; Qu, XD; O'Connor, SE				Runguphan, Weerawat; Qu, Xudong; O'Connor, Sarah E.			Integrating carbon-halogen bond formation into medicinal plant metabolism	NATURE			English	Article							INDOLE ALKALOID BIOSYNTHESIS; FLAVIN-DEPENDENT HALOGENASES; CATHARANTHUS-ROSEUS; BENZYLISOQUINOLINE ALKALOIDS; IMMATURE SEEDS; PISUM SATIVUM; REBH; CHLORINATION; PERIWINKLE; STRATEGIES	Halogenation, which was once considered a rare occurrence in nature, has now been observed in many natural product biosynthetic pathways(1). However, only a small fraction of halogenated compounds have been isolated from terrestrial plants(2). Given the impact that halogenation can have on the biological activity of natural products(1), we reasoned that the introduction of halides into medicinal plant metabolism would provide the opportunity to rationally bioengineer a broad variety of novel plant products with altered, and perhaps improved, pharmacological properties. Here we report that chlorination biosynthetic machinery from soil bacteria can be successfully introduced into the medicinal plant Catharanthus roseus (Madagascar periwinkle). These prokaryotic halogenases function within the context of the plant cell to generate chlorinated tryptophan, which is then shuttled into monoterpene indole alkaloid metabolism to yield chlorinated alkaloids. A new functional group-a halide-is thereby introduced into the complex metabolism of C. roseus, and is incorporated in a predictable and regioselective manner onto the plant alkaloid products. Medicinal plants, despite their genetic and developmental complexity, therefore seem to be a viable platform for synthetic biology efforts.	[Runguphan, Weerawat; Qu, Xudong; O'Connor, Sarah E.] MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	O'Connor, SE (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	soc@mit.edu	O'Connor, Sarah Ellen/X-2893-2019; Runguphan, Weerawat/GSM-9179-2022; Qu, Xudong/E-1778-2016; O'Connor, Sarah/O-5850-2016	Qu, Xudong/0000-0002-3301-8536; Runguphan, Weerawat/0000-0001-5707-3516; O'Connor, Sarah/0000-0003-0356-6213	NIH [GM074820]; American Cancer Society [RSG-07-025-01-CDD]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074820] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge support from the NIH (GM074820) and the American Cancer Society (RSG-07-025-01-CDD). We thank H.-Y. Lee and M. Tjandra for assistance with NMR characterizations and L. Li for high-resolution mass spectroscopy analysis.	AMAT M, 1990, J ORG CHEM, V55, P6299, DOI 10.1021/jo00313a017; Bernhardt P, 2007, CHEM BIOL, V14, P888, DOI 10.1016/j.chembiol.2007.07.008; Bitto E, 2008, PROTEINS, V70, P289, DOI 10.1002/prot.21627; Blasiak LC, 2009, ACCOUNTS CHEM RES, V42, P147, DOI 10.1021/ar800088r; DELUCA V, 1987, PLANT PHYSIOL, V85, P1099, DOI 10.1104/pp.85.4.1099; DELUCA V, 1989, P NATL ACAD SCI USA, V86, P2582; Frederich M, 2002, J NAT PROD, V65, P1381, DOI 10.1021/np020070e; GANDAR JC, 1967, CR ACAD SCI D NAT, V265, P1795; Gribble GW, 2003, CHEMOSPHERE, V52, P289, DOI 10.1016/S0045-6535(03)00207-8; Hawkins KM, 2008, NAT CHEM BIOL, V4, P564, DOI 10.1038/nchembio.105; Hughes EH, 2002, BIOTECHNOL PROGR, V18, P1183, DOI 10.1021/bp025603o; Li SW, 2004, CURR MED RES OPIN, V20, P409, DOI 10.1185/030079904125003080; Loris EA, 2007, CHEM BIOL, V14, P979, DOI 10.1016/j.chembiol.2007.08.009; MARUMO S, 1968, NATURE, V219, P959, DOI 10.1038/219959b0; Mccoy E, 2006, J AM CHEM SOC, V128, P14276, DOI 10.1021/ja066787w; Menzies JRW, 1998, EUR J PHARMACOL, V350, P101, DOI 10.1016/S0014-2999(98)00232-5; Minami H, 2008, P NATL ACAD SCI USA, V105, P7393, DOI 10.1073/pnas.0802981105; Neumann CS, 2008, CHEM BIOL, V15, P99, DOI 10.1016/j.chembiol.2008.01.006; O'Connor SE, 2006, NAT PROD REP, V23, P532, DOI 10.1039/b512615k; Roy AD, 2010, J AM CHEM SOC, V132, P12243, DOI 10.1021/ja1060406; Runguphan W, 2009, P NATL ACAD SCI USA, V106, P13673, DOI 10.1073/pnas.0903393106; Runguphan W, 2009, NAT CHEM BIOL, V5, P151, DOI 10.1038/nchembio.141; Sanchez C, 2005, P NATL ACAD SCI USA, V102, P461, DOI 10.1073/pnas.0407809102; Schumacher RW, 1999, TETRAHEDRON, V55, P935, DOI 10.1016/S0040-4020(98)01100-4; Vaillancourt FH, 2006, CHEM REV, V106, P3364, DOI 10.1021/cr050313i; van Pee KH, 2006, APPL MICROBIOL BIOT, V70, P631, DOI 10.1007/s00253-005-0232-2; Yeh E, 2005, P NATL ACAD SCI USA, V102, P3960, DOI 10.1073/pnas.0500755102; Yeh E, 2007, BIOCHEMISTRY-US, V46, P1284, DOI 10.1021/bi0621213; Yeh E, 2006, BIOCHEMISTRY-US, V45, P7904, DOI 10.1021/bi060607d; Zehner S, 2005, CHEM BIOL, V12, P445, DOI 10.1016/j.chembiol.2005.02.005; Zhu WM, 2005, J INTEGR PLANT BIOL, V47, P892, DOI 10.1111/j.1744-7909.2005.00042.x; Zhu XF, 2009, J MOL BIOL, V391, P74, DOI 10.1016/j.jmb.2009.06.008	32	159	163	4	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2010	468	7322					461	U294		10.1038/nature09524	http://dx.doi.org/10.1038/nature09524			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	681KP	21048708	Green Accepted, Green Submitted			2022-12-28	WOS:000284313100048
J	Shopsowitz, KE; Qi, H; Hamad, WY; MacLachlan, MJ				Shopsowitz, Kevin E.; Qi, Hao; Hamad, Wadood Y.; MacLachlan, Mark J.			Free-standing mesoporous silica films with tunable chiral nematic structures	NATURE			English	Article							CHOLESTERIC LIQUID-CRYSTALS; CELLULOSE; ORDER; SUSPENSIONS; GERMANIUM; BAND	Chirality at the molecular level is found in diverse biological structures, such as polysaccharides, proteins and DNA, and is responsible for many of their unique properties(1). Introducing chirality into porous inorganic solids may produce new types of materials that could be useful for chiral separation, stereospecific catalysis, chiral recognition (sensing) and photonic materials(2-5). Template synthesis of inorganic solids using the self-assembly of lyotropic liquid crystals offers access to materials with well-defined porous structures(6-12), but only recently has chirality been introduced into hexagonal mesostructures through the use of a chiral surfactant(13,14). Efforts to impart chirality at a larger length scale using self-assembly are almost unknown. Here we describe the development of a photonic mesoporous inorganic solid that is a cast of a chiral nematic liquid crystal formed from nanocrystalline cellulose. These materials may be obtained as free-standing films with high surface area. The peak reflected wavelength of the films can be varied across the entire visible spectrum and into the near-infrared through simple changes in the synthetic conditions. To the best of our knowledge these are the first materials to combine mesoporosity with long-range chiral ordering that produces photonic properties. Our findings could lead to the development of new materials for applications in, for example, tuneable reflective filters and sensors. In addition, this type of material could be used as a hard template to generate other new materials with chiral nematic structures.	[Shopsowitz, Kevin E.; Qi, Hao; MacLachlan, Mark J.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; [Hamad, Wadood Y.] FPInnovations, Vancouver, BC V6S 2L9, Canada	University of British Columbia	MacLachlan, MJ (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	mmaclach@chem.ubc.ca	Hatzikiriakos, Savvas/AAD-2672-2019; MacLachlan, Mark/Z-2069-2019; MacLachlan, Mark J/I-2961-2013; Shopsowitz, Kevin/A-2915-2013	Hatzikiriakos, Savvas/0000-0002-1456-7927; MacLachlan, Mark/0000-0002-3546-7132; MacLachlan, Mark J/0000-0002-3546-7132; 	Natural Sciences and Engineering Research Council (NSERC) of Canada; FPInnovations; UBC	Natural Sciences and Engineering Research Council (NSERC) of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); FPInnovations(German Research Foundation (DFG)); UBC	This work was supported by the Natural Sciences and Engineering Research Council (NSERC) of Canada and FPInnovations. K.E.S. is grateful to UBC for a graduate fellowship.	Akagi K, 1998, SCIENCE, V282, P1683, DOI 10.1126/science.282.5394.1683; Armatas GS, 2006, SCIENCE, V313, P817, DOI 10.1126/science.1130101; ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0; BROER DJ, 1995, NATURE, V378, P467, DOI 10.1038/378467a0; Che S, 2004, NATURE, V429, P281, DOI 10.1038/nature02529; DEVRIES H, 1951, ACTA CRYSTALLOGR, V4, P219, DOI 10.1107/S0365110X51000751; Dong XM, 1996, LANGMUIR, V12, P2076, DOI 10.1021/la950133b; Dujardin E, 2003, J MATER CHEM, V13, P696, DOI 10.1039/b212689c; Edgar CD, 2001, CELLULOSE, V8, P5, DOI 10.1023/A:1016624330458; Fireman-Shoresh S, 2005, J AM CHEM SOC, V127, P2650, DOI 10.1021/ja0454384; Gabashvili A, 2007, J PHYS CHEM B, V111, P11105, DOI 10.1021/jp072480n; Hodgkinson I, 2001, ADV MATER, V13, P889, DOI 10.1002/1521-4095(200107)13:12/13<889::AID-ADMA889>3.0.CO;2-K; Inagaki S, 2002, NATURE, V416, P304, DOI 10.1038/416304a; Johnson BFG, 1999, CHEM COMMUN, P1167, DOI 10.1039/a902441g; JOHNSON LN, 2005, EUR REV, V13, P77; Kopp VI, 1998, OPT LETT, V23, P1707, DOI 10.1364/OL.23.001707; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; MUKHERJEE SM, 1953, BIOCHIM BIOPHYS ACTA, V10, P499, DOI 10.1016/0006-3002(53)90295-9; Qiu HB, 2009, ANGEW CHEM INT EDIT, V48, P3069, DOI 10.1002/anie.200900303; Revol JF, 1998, J PULP PAP SCI, V24, P146; REVOL JF, 1992, INT J BIOL MACROMOL, V14, P170, DOI 10.1016/S0141-8130(05)80008-X; Robbie K, 1999, NATURE, V399, P764, DOI 10.1038/21612; Sharma V, 2009, SCIENCE, V325, P449, DOI 10.1126/science.1172051; Sun D, 2006, NATURE, V441, P1126, DOI 10.1038/nature04891; Thomas A, 2003, ADV FUNCT MATER, V13, P763, DOI 10.1002/adfm.200304383; YANG DK, 1994, J APPL PHYS, V76, P1331, DOI 10.1063/1.358518; Yang H, 1996, NATURE, V381, P589, DOI 10.1038/381589a0; Yang PD, 1998, NATURE, V396, P152	28	696	719	47	1092	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2010	468	7322					422	U246		10.1038/nature09540	http://dx.doi.org/10.1038/nature09540			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085176				2022-12-28	WOS:000284313100039
J	Idan, A; Griffiths, KA; Harwood, DT; Seibel, MJ; Turner, L; Conway, AJ; Handelsman, DJ				Idan, Amanda; Griffiths, Kaye A.; Harwood, D. Tim; Seibel, Markus J.; Turner, Leo; Conway, Ann J.; Handelsman, David J.			Long-Term Effects of Dihydrotestosterone Treatment on Prostate Growth in Healthy, Middle-Aged Men Without Prostate Disease A Randomized, Placebo-Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							TESTOSTERONE-REPLACEMENT THERAPY; TANDEM MASS-SPECTROMETRY; ANDROGEN RECEPTOR; OLDER MEN; TRANSDERMAL DIHYDROTESTOSTERONE; HYPOGONADAL MEN; BONE-RESORPTION; DOUBLE-BLIND; YOUNG MEN; HYPERPLASIA	Background: Benign prostatic hypertrophy increases with age and can result in substantially decreased quality of life for older men. Surgery is often required to control symptoms. It has been hypothesized that long-term administration of a nonamplifiable pure androgen might decrease prostate growth, thereby decreasing or delaying the need for surgical intervention. Objective: To test the hypothesis that dihydrotestosterone (DHT), a nonamplifiable and nonaromatizable pure androgen, reduces late-life prostate growth in middle-aged men. Design: Randomized, placebo-controlled, parallel-group trial. (Australian New Zealand Clinical Trials Registry number: ACTRN12605000358640) Setting: Ambulatory care research center. Participants: Healthy men (n = 114) older than 50 years without known prostate disease. Intervention: Transdermal DHT (70 mg) or placebo gel daily for 2 years. Measurements: Prostate volume was measured by ultrasonography; bone mineral density (BMD) and body composition were measured by dual-energy x-ray absorptiometry; and blood samples and questionnaires were collected every 6 months, with data analyzed by mixed-model analysis for repeated measures. Results: Over 24 months, there was an increase in total (29% [95% CI, 23% to 34%]) and central (75% [CI, 64% to 86%]; P < 0.01) prostate volume and serum prostate-specific antigen level (15% [CI, 6% to 24%]) with time on study, but DHT had no effect (P > 0.2). Dihydrotestosterone treatment decreased spinal BMD (1.4% [CI, 0.6% to 2.3%]; P < 0.001) at 24 months but not hip BMD (P > 0.2) and increased serum aminoterminal propeptide of type I procollagen in the second year of the study compared with placebo. Dihydrotestosterone increased serum DHT levels and its metabolites (5 alpha-androstane-3 alpha,17 beta-diol and 5 alpha-androstane-3 beta,17 beta-diol) and suppressed serum testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone levels. Dihydrotestosterone increased hemoglobin levels (7% [CI, 5% to 9%]), serum creatinine levels (9% [CI, 5% to 11%]), and lean mass (2.4% [CI, 1.6% to 3.1%) but decreased fat mass (5.2% [CI, 2.6% to 7.7%]) (P < 0.001 for all). Protocol-specific discontinuations due to DHT were asymptomatic increased hematocrit (n = 8), which resolved after stopping treatment, and increased prostate-specific antigen levels (n = 3; none with prostate cancer) in the DHT group. No serious adverse effects due to DHT occurred. Limitation: Negative findings on prostate growth cannot exclude adverse effects on the natural history of prostate cancer. Conclusion: Dihydrotestosterone treatment for 24 months has no beneficial or adverse effect on prostate growth but causes a decrease in spinal but not hip BMD. These findings have important implications for the wider use of nonsteroidal pure androgens in older men.	[Idan, Amanda; Griffiths, Kaye A.; Harwood, D. Tim; Seibel, Markus J.; Turner, Leo; Conway, Ann J.; Handelsman, David J.] Univ Sydney, Concord Hosp, ANZAC Res Inst, Sydney, NSW 2139, Australia	Concord Repatriation General Hospital; University of Sydney; ANZAC Research Institute	Handelsman, DJ (corresponding author), Univ Sydney, Concord Hosp, ANZAC Res Inst, Sydney, NSW 2139, Australia.	djh@anzac.edu.au	Ekanayake, Kanchana/P-8817-2016; Harwood, Tim/H-3636-2012; Handelsman, David/AAR-9580-2021; Research Institute, ANZAC/CAE-9030-2022	Handelsman, David/0000-0002-4200-7476; Seibel, Markus J/0000-0002-2701-378X	BHR Pharma; Bayer Schering; Ascend/Besins	BHR Pharma; Bayer Schering(Bayer AG); Ascend/Besins	Grant Support: By BHR Pharma.; Ms. Idan: Provision of writing assistance, medicines, equipment, or administrative support: BHR Pharma. Employment: BHR Pharma. Ms. Griffiths: Provision of writing assistance, medicines, equipment, or administrative support: BHR Pharma. Mr. Turner: Other relationships: Member of the human research ethics committee, which did not take part in the review of this study. Ms. Conway: Payment for lectures, including service on speakers bureaus: Bayer Schering. Dr. Handelsman: Grants received/pending: Ascend/Besins and BayerSchering. Provision of writing assistance, medicines, equipment, or administrative support: Ascend/Besins. Consultancy: Radius and Clarus Therapeutics. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum = M10-1059.	Attardi BJ, 2008, J STEROID BIOCHEM, V110, P214, DOI 10.1016/j.jsbmb.2007.11.009; Attardi BJ, 2010, J STEROID BIOCHEM, V118, P151, DOI 10.1016/j.jsbmb.2009.11.008; BEHRE HM, 1994, CLIN ENDOCRINOL, V40, P341; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; Bhasin S, 2005, J CLIN ENDOCR METAB, V90, P678, DOI 10.1210/jc.2004-1184; Bhasin S, 2003, J ANDROL, V24, P299; Bhasin S, 2009, CURR OPIN CLIN NUTR, V12, P232, DOI 10.1097/MCO.0b013e32832a3d79; Cockett AT, 1993, 2 INT CONSULTATION B; Coviello AD, 2008, J CLIN ENDOCR METAB, V93, P914, DOI 10.1210/jc.2007-1692; Cummings DE, 1998, J CLIN ENDOCR METAB, V83, P4212, DOI 10.1210/jc.83.12.4212; DESLYPERE JP, 1992, MOL CELL ENDOCRINOL, V88, P15, DOI 10.1016/0303-7207(92)90004-P; Disantostefano RL, 2006, BJU INT, V97, P1007, DOI 10.1111/j.1464-410X.2005.06089.x; Dong ZL, 2009, SYST BIOL REPROD MED, V55, P129, DOI 10.1080/19396360902833235; Emberton M, 2008, BJU INT, V102, P981, DOI 10.1111/j.1464-410X.2008.07717.x; Emmelot-Vonk MH, 2008, JAMA-J AM MED ASSOC, V299, P39, DOI 10.1001/jama.2007.51; Falahati-Nini A, 2000, J CLIN INVEST, V106, P1553, DOI 10.1172/JCI10942; Fitzpatrick JM, 2006, BJU INT, V97, P3, DOI 10.1111/j.1464-410X.2006.06097.x; Gray PB, 2005, J CLIN ENDOCR METAB, V90, P3838, DOI 10.1210/jc.2005-0247; Griffiths KA, 2007, J UROLOGY, V178, P1375, DOI 10.1016/j.juro.2007.05.163; Guo TD, 2008, CLIN BIOCHEM, V41, P736, DOI 10.1016/j.clinbiochem.2008.02.009; Guo TD, 2006, CLIN CHIM ACTA, V372, P76, DOI 10.1016/j.cca.2006.03.034; Handelsman DJ, 2005, TRENDS ENDOCRIN MET, V16, P39, DOI 10.1016/j.tem.2005.01.002; Harwood DT, 2009, CLIN CHIM ACTA, V409, P78, DOI 10.1016/j.cca.2009.09.003; Henry MJ, 2010, OSTEOPOROSIS INT, V21, P909, DOI 10.1007/s00198-009-1042-7; Hsing AW, 2007, CANCER EPIDEM BIOMAR, V16, P1004, DOI 10.1158/1055-9965.EPI-06-0792; Jacobsen SJ, 2001, UROLOGY, V58, P5, DOI 10.1016/S0090-4295(01)01298-5; Jin B, 2001, CLIN ENDOCRINOL, V54, P437, DOI 10.1046/j.1365-2265.2001.01240.x; Kenward MG, 1998, STAT MED, V17, P2723, DOI 10.1002/(SICI)1097-0258(19981215)17:23&lt;2723::AID-SIM38&gt;3.0.CO;2-5; Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1443, DOI 10.1210/jc.87.4.1443; KUMAR N, 1992, ENDOCRINOLOGY, V130, P3677, DOI 10.1210/en.130.6.3677; Kumar N, 1999, J STEROID BIOCHEM, V71, P213, DOI 10.1016/S0960-0760(99)00143-0; Kunelius P, 2002, J CLIN ENDOCR METAB, V87, P1467, DOI 10.1210/jc.87.4.1467; Leder BZ, 2003, J CLIN ENDOCR METAB, V88, P204, DOI 10.1210/jc.2002-021036; Lee KK, 2003, J ANDROL, V24, P688; Little R.J.A., 2002, STAT ANAL MISSING DA; LUKASKI HC, 1987, AM J CLIN NUTR, V46, P537, DOI 10.1093/ajcn/46.4.537; Ly LP, 2001, J CLIN ENDOCR METAB, V86, P4078, DOI 10.1210/jc.86.9.4078; Marks LS, 2006, JAMA-J AM MED ASSOC, V296, P2351, DOI 10.1001/jama.296.19.2351; Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; McPherson SJ, 2007, ENDOCRINOLOGY, V148, P566, DOI 10.1210/en.2006-0906; Meikle AW, 1997, J CLIN ENDOCR METAB, V82, P571, DOI 10.1210/jc.82.2.571; ODRISCOLL SW, 1992, J HAND SURG-AM, V17A, P169, DOI 10.1016/0363-5023(92)90136-D; Oesterling JE, 1996, PROSTATE, P67; Rhoden EL, 2004, NEW ENGL J MED, V350, P482, DOI 10.1056/NEJMra022251; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; Roselli CE, 2001, J STEROID BIOCHEM, V79, P247, DOI 10.1016/S0960-0760(01)00141-8; Sader MA, 2001, J AM COLL CARDIOL, V37, P224, DOI 10.1016/S0735-1097(00)01083-4; Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008-0016; SEIBEL MJ, 1993, J BONE MINER RES, V8, P881; Sikaris K, 2005, J CLIN ENDOCR METAB, V90, P5928, DOI 10.1210/jc.2005-0962; Stanczyk FZ, 2003, STEROIDS, V68, P1173, DOI 10.1016/j.steroids.2003.08.012; Storer TW, 2008, J AM GERIATR SOC, V56, DOI 10.1111/j.1532-5415.2008.01927.x; Swerdloff RS, 1998, BAILLIERE CLIN ENDOC, V12, P501, DOI 10.1016/S0950-351X(98)80267-X; Taieb J, 2003, CLIN CHEM, V49, P1381, DOI 10.1373/49.8.1381; Tong SD, 1998, ULTRASOUND MED BIOL, V24, P673, DOI 10.1016/S0301-5629(98)00039-8; Wang C, 2004, J CLIN ENDOCR METAB, V89, P534, DOI 10.1210/jc.2003-031287; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1167, DOI 10.1016/S0895-4356(98)00108-5; Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zitzmann M, 2003, J CLIN ENDOCR METAB, V88, P2049, DOI 10.1210/jc.2002-021947	62	62	63	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					621	632		10.7326/0003-4819-153-10-201011160-00004	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00004			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079217				2022-12-28	WOS:000284215800014
J	Karlawish, J				Karlawish, Jason			Desktop Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Karlawish, Jason] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Karlawish, Jason] Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Karlawish, J (corresponding author), Univ Penn, Dept Med, 3615 Chestnut St, Philadelphia, PA 19104 USA.	Jason.Karlawish@uphs.upenn.edu						Aronowitz RA, 2009, MILBANK Q, V87, P417, DOI 10.1111/j.1468-0009.2009.00563.x; Greene JWC, 2007, PROCEEDINGS IEEE SOUTHEASTCON 2007, VOLS 1 AND 2, P221; Linnenbringer E, 2010, GENET MED, V12, P219, DOI 10.1097/GIM.0b013e3181cef9e1; National Heart Lung and Blood Institute, RISK ASS TOOL EST 10; Phillips LS, 2008, ANN INTERN MED, V148, P783, DOI 10.7326/0003-4819-148-10-200805200-00011; Vickers AJ, 2008, ANN INTERN MED, V149, P200, DOI 10.7326/0003-4819-149-3-200808050-00010; Vijan S, 2008, ANN INTERN MED, V149, P839, DOI 10.7326/0003-4819-149-11-200812020-00019; Volpp KG, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-272; World Health Organization Collaborating Centre for Metabolic Bone Diseases, WHO FRACT RISK ASS T	9	9	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2061	2062		10.1001/jama.2010.1624	http://dx.doi.org/10.1001/jama.2010.1624			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063017				2022-12-28	WOS:000284000600027
J	Taylor, SM; Molyneux, ME; Simel, DL; Meshnick, SR; Juliano, JJ				Taylor, Steve M.; Molyneux, Malcolm E.; Simel, David L.; Meshnick, Steven R.; Juliano, Jonathan J.			Does This Patient Have Malaria?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMODIUM-FALCIPARUM MALARIA; CLINICAL ALGORITHM; IMPORTED MALARIA; RETURNING TRAVELERS; PREDICTIVE FACTORS; GAMBIAN CHILDREN; UNITED-STATES; DIAGNOSIS; FEVER; AREA	Context Malaria commonly infects residents of and travelers to tropical regions. The clinical features of infection are notoriously nonspecific but have not been comprehensively evaluated. Objective To systematically review and synthesize data related to the predictive value of clinical findings for the diagnosis of malaria in endemic areas and in travelers returning from endemic areas. Data Sources, Study Selection, and Data Extraction The databases of MEDLINE and EMBASE (1950-July 2010) were searched to identify studies published in the English language of endemic and "imported" (acquired during travel) malaria. Additional studies were identified from reference lists. Studies were included that had patients suspected of having acute malaria (usually because of fever) and compared the presence or absence of clinical findings with blood smear confirmation. Two authors independently identified studies, appraised study quality, and extracted data on the patient population, outcome assessment, and clinical findings. Differences between reviewers were resolved by consensus. Data Synthesis Fourteen studies for endemic malaria were identified that met review criteria. Individual symptoms are of limited diagnostic utility but presence of splenomegaly (summary likelihood ratio [LR], 3.3; 95% confidence interval [CI], 2.0-4.7) or hepatomegaly (summary LR, 2.4; 95% CI, 1.6-3.6) make malaria more likely. Combinations of findings can affect the likelihood of malaria, but their performance varies by setting. Seven studies of imported malaria were identified. The presence of fever (LR, 5.1; 95% CI, 4.9-5.3), splenomegaly (summary LR, 6.5; 95% CI, 3.9-11.0), hyperbilirubinemia (LR, 7.3; 95% CI, 5.5-9.6), or thrombocytopenia (summary LR, 5.6; 95% CI, 4.1-7.5) make malaria more likely. Conclusions In endemic areas, the likelihood of malaria is increased by the presence of splenomegaly and hepatomegaly but individual findings are of limited utility and cannot reliably exclude malaria; combinations of findings may be useful to stratify risk in patients. In returning travelers, the clinical assessment can provide substantial diagnostic benefit, although all patients still require laboratory testing because malaria can be rapidly fatal. JAMA. 2010;304(18):2048-2056 www.jama.com	[Taylor, Steve M.; Meshnick, Steven R.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Juliano, Jonathan J.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC 27599 USA; [Taylor, Steve M.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA; [Simel, David L.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Molyneux, Malcolm E.] Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi; [Molyneux, Malcolm E.] Univ Liverpool, Sch Trop Med, Liverpool L69 3BX, Merseyside, England; [Simel, David L.] Durham Dept Vet Affairs Med Ctr, Durham, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University; Duke University; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool	Taylor, SM (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, 135 Dauer Dr,MHRC 3113, Chapel Hill, NC 27599 USA.	taylo115@email.unc.edu			National Center for Research Resources, National Institutes of Health [KL2RR025746]; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025746] Funding Source: NIH RePORTER	National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Dr Juliano is supported by grant KL2RR025746 from the National Center for Research Resources, National Institutes of Health.	Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; [Anonymous], 2008, WORLD MAL REP 2008; Ansart S, 2010, J TRAVEL MED, V17, P124, DOI 10.1111/j.1708-8305.2009.00382.x; Barat LM, 1999, AM J TROP MED HYG, V60, P910, DOI 10.4269/ajtmh.1999.60.910; BASSETT MT, 1991, J TROP MED HYG, V94, P65; Bell D, 2001, B WORLD HEALTH ORGAN, V79, P933; Bojang KA, 2000, TROP MED INT HEALTH, V5, P231, DOI 10.1046/j.1365-3156.2000.00538.x; Bottieau E, 2007, MEDICINE, V86, P18, DOI 10.1097/MD.0b013e3180305c48; Bottieau E, 2006, ARCH INTERN MED, V166, P1642, DOI 10.1001/archinte.166.15.1642; Casalino E, 2002, ARCH INTERN MED, V162, P1625, DOI 10.1001/archinte.162.14.1625; CDC malaria map application, CDC MAL MAP APPL; Centers for Disease Control and Prevention, MAL INF PROPH COUNTR; Chandler CIR, 2008, TROP MED INT HEALTH, V13, P1131, DOI 10.1111/j.1365-3156.2008.02118.x; Chandramohan D, 2001, TROP MED INT HEALTH, V6, P505, DOI 10.1046/j.1365-3156.2001.00739.x; D'Acremont V, 2002, AM J TROP MED HYG, V66, P481, DOI 10.4269/ajtmh.2002.66.481; Daneshvar C, 2009, CLIN INFECT DIS, V49, P852, DOI 10.1086/605439; Griffith KS, 2007, JAMA-J AM MED ASSOC, V297, P2264, DOI 10.1001/jama.297.20.2264; Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616; Koram KA, 2007, AM J TROP MED HYG, V77, P1; Leder K, 2004, CLIN INFECT DIS, V39, P1104, DOI 10.1086/424510; Luxemburger C, 1998, T ROY SOC TROP MED H, V92, P45, DOI 10.1016/S0035-9203(98)90950-6; Mali Sonja, 2010, Morbidity and Mortality Weekly Report, V59, P1; Muhe L, 1999, ARCH DIS CHILD, V81, P216, DOI 10.1136/adc.81.3.216; Ndyomugyenyi R, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-39; Newman RD, 2004, ANN INTERN MED, V141, P547, DOI 10.7326/0003-4819-141-7-200410050-00012; O'Brien D, 2001, CLIN INFECT DIS, V33, P603, DOI 10.1086/322602; Olaleye BO, 1998, T ROY SOC TROP MED H, V92, P300, DOI 10.1016/S0035-9203(98)91021-5; Oster N, 2000, TROP DOCT, V30, P203, DOI 10.1177/004947550003000407; Patel U, 2004, J NATL MED ASSOC, V96, P1212; Price RN, 2009, CURR OPIN INFECT DIS, V22, P430, DOI 10.1097/QCO.0b013e32832f14c1; Redd SC, 1996, LANCET, V347, P223, DOI 10.1016/S0140-6736(96)90404-3; REDD SC, 1992, LANCET, V340, P1140, DOI 10.1016/0140-6736(92)93160-O; Reyburn H, 2005, JAMA-J AM MED ASSOC, V293, P1461, DOI 10.1001/jama.293.12.1461; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; ROOTH I, 1992, T ROY SOC TROP MED H, V86, P479, DOI 10.1016/0035-9203(92)90076-O; Simel DL, 2009, J CLIN EPIDEMIOL, V62, P1292, DOI 10.1016/j.jclinepi.2009.02.007; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Tulloch J, 1999, LANCET, V354, pS16; Vinetz JM, 1998, NEW ENGL J MED, V338, P367, DOI 10.1056/NEJM199802053380605; Warrell DA, 2002, ESSENTIAL MALARIOLOG; Weber MW, 1997, B WORLD HEALTH ORGAN, V75, P25; Yacoub S, 2005, TROP DOCT, V35, P78, DOI 10.1258/0049475054036913; Zamora Javier, 2006, BMC Med Res Methodol, V6, P31, DOI 10.1186/1471-2288-6-31	43	33	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2048	2056		10.1001/jama.2010.1578	http://dx.doi.org/10.1001/jama.2010.1578			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21057136				2022-12-28	WOS:000284000600024
J	van Amsterdam, J; van den Brink, W				van Amsterdam, Jan; van den Brink, Wim			Ranking of drugs: a more balanced risk-assessment	LANCET			English	Editorial Material							ALCOHOL; HARM		[van Amsterdam, Jan] Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, NL-3720 BA Bilthoven, Netherlands; [van den Brink, Wim] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands; [van den Brink, Wim] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Addict Res, NL-1105 AZ Amsterdam, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Amsterdam, J (corresponding author), Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, NL-3720 BA Bilthoven, Netherlands.	Jan.van.Amsterdam@rivm.nl						HEARN WL, 1991, PHARMACOL BIOCHEM BE, V39, P531, DOI 10.1016/0091-3057(91)90222-N; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6; Ramaekers JG, 2000, HUM PSYCHOPHARM CLIN, V15, P551, DOI 10.1002/1099-1077(200010)15:7<551::AID-HUP236>3.0.CO;2-P; van Amsterdam J, 2010, EUR ADDICT RES, V16, P202, DOI 10.1159/000317249; van den Brink W, 2008, CURR OPIN PSYCHIATR, V21, P122, DOI 10.1097/YCO.0b013e3282f57e04	6	10	11	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1524	1525		10.1016/S0140-6736(10)62000-4	http://dx.doi.org/10.1016/S0140-6736(10)62000-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	21036391				2022-12-28	WOS:000284248700008
J	Garneau, JE; Dupuis, ME; Villion, M; Romero, DA; Barrangou, R; Boyaval, P; Fremaux, C; Horvath, P; Magadan, AH; Moineau, S				Garneau, Josiane E.; Dupuis, Marie-Eve; Villion, Manuela; Romero, Dennis A.; Barrangou, Rodolphe; Boyaval, Patrick; Fremaux, Christophe; Horvath, Philippe; Magadan, Alfonso H.; Moineau, Sylvain			The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA	NATURE			English	Article							ESCHERICHIA-COLI; REPEATS; IDENTIFICATION; RNAS; EXPRESSION; RESISTANCE; DEFENSE; GENE; DIVERSITY; SEQUENCES	Bacteria and Archaea have developed several defence strategies against foreign nucleic acids such as viral genomes and plasmids. Among them, clustered regularly interspaced short palindromic repeats (CRISPR) loci together with cas (CRISPR-associated) genes form the CRISPR/Cas immune system, which involves partially palindromic repeats separated by short stretches of DNA called spacers, acquired from extrachromosomal elements. It was recently demonstrated that these variable loci can incorporate spacers from infecting bacteriophages and then provide immunity against subsequent bacteriophage infections in a sequence-specific manner. Here we show that the Streptococcus thermophilus CRISPR1/Cas system can also naturally acquire spacers from a self-replicating plasmid containing an antibiotic-resistance gene, leading to plasmid loss. Acquired spacers that match antibiotic-resistance genes provide a novel means to naturally select bacteria that cannot uptake and disseminate such genes. We also provide in vivo evidence that the CRISPR1/Cas system specifically cleaves plasmid and bacteriophage double-stranded DNA within the proto-spacer, at specific sites. Our data show that the CRISPR/Cas immune system is remarkably adapted to cleave invading DNA rapidly and has the potential for exploitation to generate safer microbial strains.	[Garneau, Josiane E.; Dupuis, Marie-Eve; Villion, Manuela; Magadan, Alfonso H.; Moineau, Sylvain] Univ Laval, Felix dHerelle Reference Ctr Bacterial Viruses, Dept Biochim Microbiol & Bioinformat, Fac Med Dent,Grp Rech Ecol Buccale,Fac Sci & Geni, Quebec City, PQ G1V 0A6, Canada; [Romero, Dennis A.; Barrangou, Rodolphe] Danisco USA Inc, Madison, WI 53716 USA; [Boyaval, Patrick; Fremaux, Christophe; Horvath, Philippe] Danisco France SAS, F-86220 Dange St Romain, France	Laval University	Moineau, S (corresponding author), Univ Laval, Felix dHerelle Reference Ctr Bacterial Viruses, Dept Biochim Microbiol & Bioinformat, Fac Med Dent,Grp Rech Ecol Buccale,Fac Sci & Geni, Quebec City, PQ G1V 0A6, Canada.	Sylvain.Moineau@bcm.ulaval.ca	Moineau, Sylvain/N-3578-2013; Magadán, Alfonso Hernández/K-4455-2012; Barrangou, Rodolphe/I-2878-2014; Moineau, Sylvain/I-7231-2019; HORVATH, Philippe/K-5266-2015; Magadan, Alfonso Hernandez/M-5994-2019	Magadán, Alfonso Hernández/0000-0003-2556-7890; Barrangou, Rodolphe/0000-0002-0648-3504; Moineau, Sylvain/0000-0002-2832-5101; HORVATH, Philippe/0000-0003-2015-8123; Magadan, Alfonso Hernandez/0000-0003-2556-7890	Novalait/FQRNT; Clarin/FICYT; NSERC; CIHR	Novalait/FQRNT(FQRNT); Clarin/FICYT; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR(Canadian Institutes of Health Research (CIHR))	We thank T.R. Klaenhammer for pTRK687, B. Conway for editorial assistance, D. Tremblay, A. Fleury and B. Stahl for technical assistance. M.-E.D. is the recipient of a Novalait/FQRNT graduate scholarship and A.H.M. of a Clarin/FICYT postdoctoral scholarship. S.M. acknowledges funding from NSERC (Discovery program) and CIHR (Team Grant-Emerging: Novel Alternatives to Antibiotics).	Andersson AF, 2008, SCIENCE, V320, P1047, DOI 10.1126/science.1157358; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0; Brouns SJJ, 2008, SCIENCE, V321, P960, DOI 10.1126/science.1159689; Buckley ND, 1999, APPL ENVIRON MICROB, V65, P3800; Carte J, 2008, GENE DEV, V22, P3489, DOI 10.1101/gad.1742908; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Deveau H, 2008, J BACTERIOL, V190, P1390, DOI 10.1128/JB.01412-07; Duplessis M, 2005, VIROLOGY, V340, P192, DOI 10.1016/j.virol.2005.05.033; Fortier LC, 2007, APPL ENVIRON MICROB, V73, P7358, DOI 10.1128/AEM.00582-07; Girard SL, 2007, PLASMID, V58, P174, DOI 10.1016/j.plasmid.2007.03.003; Hale C, 2008, RNA, V14, P2572, DOI 10.1261/rna.1246808; Hale CR, 2009, CELL, V139, P945, DOI 10.1016/j.cell.2009.07.040; Horvath P, 2008, J BACTERIOL, V190, P1401, DOI 10.1128/JB.01415-07; Horvath P, 2010, SCIENCE, V327, P167, DOI 10.1126/science.1179555; ISHINO Y, 1987, J BACTERIOL, V169, P5429, DOI 10.1128/jb.169.12.5429-5433.1987; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; KIEWIET R, 1993, APPL ENVIRON MICROB, V59, P358, DOI 10.1128/AEM.59.2.358-364.1993; Levesque C, 2005, APPL ENVIRON MICROB, V71, P4057, DOI 10.1128/AEM.71.7.4057-4068.2005; Lillestol RK, 2009, MOL MICROBIOL, V72, P259, DOI 10.1111/j.1365-2958.2009.06641.x; Marraffini LA, 2010, NAT REV GENET, V11, P181, DOI 10.1038/nrg2749; Marraffini LA, 2008, SCIENCE, V322, P1843, DOI 10.1126/science.1165771; MOINEAU S, 1992, CAN J MICROBIOL, V38, P875, DOI 10.1139/m92-143; Mojica FJM, 2009, MICROBIOL-SGM, V155, P733, DOI 10.1099/mic.0.023960-0; Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3; Mojica FJM, 2000, MOL MICROBIOL, V36, P244, DOI 10.1046/j.1365-2958.2000.01838.x; Nieto C, 2000, PLASMID, V43, P205, DOI 10.1006/plas.2000.1465; OCHMAN H, 1988, GENETICS, V120, P621; Pourcel C, 2005, MICROBIOL-SGM, V151, P653, DOI 10.1099/mic.0.27437-0; Pul U, 2010, MOL MICROBIOL, V75, P1495, DOI 10.1111/j.1365-2958.2010.07073.x; Sambrook J., 2001, MOL CLONING LAB MANU; SOMKUTI GA, 1986, J IND MICROBIOL, V1, P157, DOI 10.1007/BF01569267; Sturino JM, 2002, APPL ENVIRON MICROB, V68, P588, DOI 10.1128/AEM.68.2.588-596.2002; Tang TH, 2002, P NATL ACAD SCI USA, V99, P7536, DOI 10.1073/pnas.112047299; Turgeon N, 2001, PLASMID, V45, P171, DOI 10.1006/plas.2001.1517; Vaillancourt K, 2008, APPL ENVIRON MICROB, V74, P1264, DOI 10.1128/AEM.01585-07	36	1369	1661	32	791	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					67	71		10.1038/nature09523	http://dx.doi.org/10.1038/nature09523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048762				2022-12-28	WOS:000283786900036
J	Dykes, PC; Carroll, DL; Hurley, A; Lipsitz, S; Benoit, A; Chang, F; Meltzer, S; Tsurikova, R; Zuyov, L; Middleton, B				Dykes, Patricia C.; Carroll, Diane L.; Hurley, Ann; Lipsitz, Stuart; Benoit, Angela; Chang, Frank; Meltzer, Seth; Tsurikova, Ruslana; Zuyov, Lyubov; Middleton, Blackford			Fall Prevention in Acute Care Hospitals A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSEQUENT INJURIES; ELDERLY-PEOPLE; PATIENT FALLS; RISK; PROGRAM; CIRCUMSTANCES; INTERVENTIONS; SETTINGS	Context Falls cause injury and death for persons of all ages, but risk of falls increases markedly with age. Hospitalization further increases risk, yet no evidence exists to support short-stay hospital-based fall prevention strategies to reduce patient falls. Objective To investigate whether a fall prevention tool kit (FPTK) using health information technology (HIT) decreases patient falls in hospitals. Design, Setting, and Patients Cluster randomized study conducted January 1, 2009, through June 30, 2009, comparing patient fall rates in 4 urban US hospitals in units that received usual care (4 units and 5104 patients) or the intervention (4 units and 5160 patients). Intervention The FPTK integrated existing communication and workflow patterns into the HIT application. Based on a valid fall risk assessment scale completed by a nurse, the FPTK software tailored fall prevention interventions to address patients' specific determinants of fall risk. The FPTK produced bed posters composed of brief text with an accompanying icon, patient education handouts, and plans of care, all communicating patient-specific alerts to key stakeholders. Main Outcome Measures The primary outcome was patient falls per 1000 patient-days adjusted for site and patient care unit. A secondary outcome was fall-related injuries. Results During the 6-month intervention period, the number of patients with falls differed between control (n=87) and intervention (n=67) units (P=.02). Site-adjusted fall rates were significantly higher in control units (4.18 [95% confidence interval {CI}, 3.45-5.06] per 1000 patient-days) than in intervention units (3.15 [95% CI, 2.54-3.90] per 1000 patient-days; P=.04). The FPTK was found to be particularly effective with patients aged 65 years or older (adjusted rate difference, 2.08 [95% CI, 0.61-3.56] per 1000 patient-days; P=.003). No significant effect was noted in fall-related injuries. Conclusion The use of a fall prevention tool kit in hospital units compared with usual care significantly reduced rate of falls.	[Dykes, Patricia C.; Benoit, Angela; Chang, Frank; Meltzer, Seth; Middleton, Blackford] Partners HealthCare Syst, Boston, MA USA; [Dykes, Patricia C.; Hurley, Ann; Lipsitz, Stuart; Tsurikova, Ruslana; Middleton, Blackford] Brigham & Womens Hosp, Boston, MA 02115 USA; [Dykes, Patricia C.; Lipsitz, Stuart; Middleton, Blackford] Harvard Univ, Sch Med, Boston, MA USA; [Carroll, Diane L.; Zuyov, Lyubov] Massachusetts Gen Hosp, Boston, MA 02114 USA	Partners Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Dykes, PC (corresponding author), Partners HealthCare Syst, Brigham & Womens Hosp, 93 Worcester St, Wellesley, MA 02481 USA.	pdykes@partners.org	Middleton, Blackford/B-7304-2018	Middleton, Blackford/0000-0002-1819-1234	Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative	Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative	This work was supported by a grant from the Robert Wood Johnson Foundation Interdisciplinary Nursing Quality Research Initiative (Translating Fall Risk Status Into Interventions to Prevent Patient Falls).	BATES DW, 1995, AM J MED, V99, P137, DOI 10.1016/S0002-9343(99)80133-8; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Cameron ID, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005465.pub2; Chen Li Hui, 2009, Vital Health Stat 10, P1; Coussement J, 2008, J AM GERIATR SOC, V56, P29, DOI 10.1111/j.1532-5415.2007.01508.x; Cumming RG, 2008, BMJ-BRIT MED J, V336, P758, DOI 10.1136/bmj.39499.546030.BE; Dykes PC, 2009, J NURS ADMIN, V39, P299, DOI 10.1097/NNA.0b013e3181a7788a; Dykes PC., 2009, AMIA Annu Symp Proc, V2009, P153; Elley CR, 2008, J AM GERIATR SOC, V56, P1383, DOI 10.1111/j.1532-5415.2008.01802.x; Evans D, 2001, Int J Nurs Pract, V7, P38; Gutierrez F, 2008, CRIT CARE NURS Q, V31, P127, DOI 10.1097/01.CNQ.0000314473.72001.b4; Hendriks MRC, 2008, J AM GERIATR SOC, V56, P1390, DOI 10.1111/j.1532-5415.2008.01803.x; Hitcho EB, 2004, J GEN INTERN MED, V19, P732, DOI 10.1111/j.1525-1497.2004.30387.x; Hurley AC, 2009, STUD HEALTH TECHNOL, V146, P455, DOI 10.3233/978-1-60750-024-7-455; Inouye SK, 2009, NEW ENGL J MED, V360, P2390, DOI 10.1056/NEJMp0900963; *JOINT COMM, NAT QUAL FOR NQF END; Kannus P, 2005, LANCET, V366, P1885, DOI 10.1016/S0140-6736(05)67604-0; Klein JP., 2003, SURVIVAL ANAL TECHNI; Koh SLS, 2009, SINGAP MED J, V50, P425; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; Krauss MJ, 2008, INFECT CONT HOSP EP, V29, P539, DOI 10.1086/588222; Krauss MJ, 2007, INFECT CONT HOSP EP, V28, P544, DOI 10.1086/513725; Lakatos BE, 2009, PSYCHOSOMATICS, V50, P218, DOI 10.1176/appi.psy.50.3.218; *MA HOSP ASS PAT C, PAT FALLS PER 1000 P; Massoud MR., 2006, FRAMEWORK SPREAD LOC; MORSE JM, 1989, CAN J AGING, V8, P366, DOI 10.1017/S0714980800008576; Morse JM, 2008, PREVENTING PATIENT F, V2; Oliver D, 2004, AGE AGEING, V33, P122, DOI 10.1093/ageing/afh017; Oliver D, 2000, J AM GERIATR SOC, V48, P1679, DOI 10.1111/j.1532-5415.2000.tb03883.x; Payne PRO, 2005, J AM MED INFORM ASSN, V12, P338, DOI 10.1197/jamia.M1628; Schwendimann R, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-69; Tinetti ME, 2008, J AM GERIATR SOC, V56, P1563, DOI 10.1111/j.1532-5415.2008.01800.x; TINETTI ME, 1990, J GERONTOL, V45, pP239, DOI 10.1093/geronj/45.6.P239; Tzeng HM, 2008, NURS ECON, V26, P179; Tzeng HM, 2010, J NURS CARE QUAL, V25, P22, DOI 10.1097/NCQ.0b013e3181afa321; *US FDA, 2005, GUID IND COLL RAC ET, P18	36	184	189	3	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1912	1918		10.1001/jama.2010.1567	http://dx.doi.org/10.1001/jama.2010.1567			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045097	Green Accepted, Bronze			2022-12-28	WOS:000283725900021
J	King, AC; Guralnik, JM				King, Abby C.; Guralnik, Jack M.			Maximizing the Potential of an Aging Population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DISABILITY		[King, Abby C.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Div Epidemiol, Stanford, CA 94305 USA; [King, Abby C.] Stanford Univ, Sch Med, Dept Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA; [Guralnik, Jack M.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA	Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	King, AC (corresponding author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, Div Epidemiol, 159 Campus Dr,HRP Redwood Bldg,T221, Stanford, CA 94305 USA.	king@stanford.edu	King, Abby/AAD-5257-2021	King, Abby/0000-0002-7949-8811	NATIONAL INSTITUTE ON AGING [U01AG022376] Funding Source: NIH RePORTER; NIA NIH HHS [U01 AG022376, 2U01 AG022376-05A1] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alley DE, 2007, JAMA-J AM MED ASSOC, V298, P2020, DOI 10.1001/jama.298.17.2020; Fried LP, 2004, J URBAN HEALTH, V81, P64, DOI 10.1093/jurban/jth094; Fuller-Thomson E, 2009, J GERONTOL A-BIOL, V64, P1333, DOI 10.1093/gerona/glp130; Kerse N, 2005, J AM GERIATR SOC, V53, P1951, DOI 10.1111/j.1532-5415.2005.00466.x; King AC, 2007, HEALTH PSYCHOL, V26, P718, DOI 10.1037/0278-6133.26.6.718; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Minkler M, 2006, NEW ENGL J MED, V355, P695, DOI 10.1056/NEJMsa044316; Nguyen Huong Q, 2008, Prev Chronic Dis, V5, pA14; Physical Activity Guidelines Advisory Committee, 2008, REP PHYS ACT GUID AD; *US DEP HHS, 2008, ODPHP PUBL U, V42	10	39	40	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1944	1945		10.1001/jama.2010.1577	http://dx.doi.org/10.1001/jama.2010.1577			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045101	Green Accepted			2022-12-28	WOS:000283725900025
J	van Eijk, MMJ; Roes, KCB; Honing, MLH; Kuiper, MA; Karakus, A; van der Jagt, M; Spronk, PE; van Gool, WA; van der Mast, RC; Kesecioglu, J; Slooter, AJC				van Eijk, Maarten M. J.; Roes, Kit C. B.; Honing, Marina L. H.; Kuiper, Michael A.; Karakus, Attila; van der Jagt, Mathieu; Spronk, Peter E.; van Gool, Willem A.; van der Mast, Roos C.; Kesecioglu, Jozef; Slooter, Arjen J. C.			Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial	LANCET			English	Article							MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; UNIT DELIRIUM; EFFICACY; SAFETY; RELIABILITY; PREVENTION; PREDICTOR; SEVERITY; VALIDITY	Background Delirium is frequently diagnosed in critically ill patients and is associated with adverse outcome. Impaired cholinergic neurotransmission seems to have an important role in the development of delirium. We aimed to establish the effect of the cholinesterase inhibitor rivastigmine on the duration of delirium in critically ill patients. Methods Patients (aged 18 years) who were diagnosed with delirium were enrolled from six intensive care units in the Netherlands, and treated between November, 2008, and January, 2010. Patients were randomised (1:1 ratio) to receive an increasing dose of rivastigmine or placebo, starting at 0.75 mL (1.5 mg rivastigmine) twice daily and increasing in increments to 3 mL (6 mg rivastigmine) twice daily from day 10 onwards, as an adjunct to usual care based on haloperidol. The trial pharmacist generated the randomisation sequence by computer, and consecutively numbered bottles of the study drug according to this sequence to conceal allocation. The primary outcome was the duration of delirium during hospital admission. Analysis was by intention to treat. Duration of delirium was censored for patients who died or were discharged from hospital while delirious. Patients, medical staff, and investigators were masked to treatment allocation. Members of the data safety and monitoring board (DSMB) were unmasked and did interim analyses every 3 months. This trial is registered with ClinicalTrials.gov, number NCT00704301. Findings Although a sample size of 440 patients was planned, after inclusion of 104 patients with delirium who were eligible for the intention-to-treat analysis (n=54 on rivastigmine, n=50 on placebo), the DSMB recommended that the trial be halted because mortality in the rivastigmine group (n=12,22%) was higher than in the placebo group (n=4,8%; p=0.07). Median duration of delirium was longer in the rivastigmine group (5.0 days, IQR 2.7-14.2) than in the placebo group (3.0 days, IQR 1.0-9.3; p=0.06). Interpretation Rivastigmine did not decrease duration of delirium and might have increased mortality so we do not recommend use of rivastigmine to treat delirium in critically ill patients.	[van Eijk, Maarten M. J.; Kesecioglu, Jozef; Slooter, Arjen J. C.] Univ Med Ctr, Dept Intens Care Med, NL-3584 CX Utrecht, Netherlands; [Roes, Kit C. B.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3584 CX Utrecht, Netherlands; [Honing, Marina L. H.] Med Ctr Alkmaar, Dept Intens Care, Alkmaar, Netherlands; [Kuiper, Michael A.] Med Ctr Leeuwarden, Dept Intens Care, Leeuwarden, Netherlands; [Karakus, Attila] Diakonessenhuis Utrecht, Dept Intens Care, Utrecht, Netherlands; [van der Jagt, Mathieu] Univ Med Ctr, Erasmus MC, Dept Intens Care, Rotterdam, Netherlands; [Spronk, Peter E.] Gelre Hosp Lukas Site, Dept Intens Care, Apeldoorn, Netherlands; [van Gool, Willem A.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [van der Mast, Roos C.] Leiden Univ, Med Ctr, Dept Psychiat, Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Medical Center Of Alkmaar; Medical Center Leeuwarden; Diakonessenhuis; Erasmus University Rotterdam; Erasmus MC; Gelre Hospitals; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Slooter, AJC (corresponding author), Univ Med Ctr, Dept Intens Care Med, Room F06-149,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	a.slooter-3@umcutrecht.nl	Kuiper, Michael/AAG-9878-2019; Van Gool, Willem A/G-5985-2012; Roes, Kit/AAC-4093-2019; van der Jagt, Mathieu/G-1905-2017	Roes, Kit/0000-0002-6775-1963; Kuiper, Michael/0000-0001-6201-7332; Van Gool, Willem/0000-0003-3174-8233; van der Jagt, Mathieu/0000-0003-2566-8325	Netherlands Society of Psychiatry; Netherlands Society of Intensive Care; Health Care Inspectorate; Academic Medical Centre, University of Amsterdam; ZonMw; Netherlands organisation for health research and development [80-82305-98.08109]; Netherlands Brain Foundation [2008(1).30]; Novartis, Basel, Switzerland	Netherlands Society of Psychiatry; Netherlands Society of Intensive Care; Health Care Inspectorate; Academic Medical Centre, University of Amsterdam; ZonMw(Netherlands Organization for Health Research and Development); Netherlands organisation for health research and development(Netherlands Organization for Health Research and Development); Netherlands Brain Foundation; Novartis, Basel, Switzerland	RCvdM has received payment and travel expenses for presentations and attendance at committee meetings from the following professional organisations: the Netherlands Society of Psychiatry, the Netherlands Society of Intensive Care, the Health Care Inspectorate, and the Academic Medical Centre, University of Amsterdam. All other authors declare that they have no conflicts of interest.; We thank all patients and their legal representatives for participation in this trial; all research nurses in participating centres; medical and nursing staff in participating centres who cared for patients and collected data; data managers who participated in this trial, especially Frank Leus and Joost Schotsman; the pharmacists in all participating centres for their help; Michel Bots and Ardine de Wit for their contribution to the design of the trial; and DSMB members. This study was funded by ZonMw, the Netherlands organisation for health research and development (grant number 80-82305-98.08109), the Netherlands Brain Foundation (grant number 2008(1).30), and Novartis, Basel, Switzerland (unrestricted grant).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 1999, Am J Psychiatry, V156, P1; Bourne RS, 2008, J PSYCHOSOM RES, V65, P273, DOI 10.1016/j.jpsychores.2008.05.025; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Darreh-Shori T, 2010, EXPERT OPIN DRUG SAF, V9, P167, DOI 10.1517/14740330903439717; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; European Medicines Agency, RIV 1A PHARM; Fischer P, 2001, J CLIN PSYCHOPHARM, V21, P118, DOI 10.1097/00004714-200102000-00026; Gamberini M, 2009, CRIT CARE MED, V37, P1762, DOI 10.1097/CCM.0b013e31819da780; Girard TD, 2010, CRIT CARE MED, V38, P428, DOI 10.1097/CCM.0b013e3181c58715; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; Han L, 2001, ARCH INTERN MED, V161, P1099, DOI 10.1001/archinte.161.8.1099; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Jorm AF, 2004, INT PSYCHOGERIATR, V16, P275, DOI 10.1017/S1041610204000390; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; Liptzin B, 2005, AM J GERIAT PSYCHIAT, V13, P1100, DOI 10.1176/appi.ajgp.13.12.1100; Lonergan E, 2009, COCHRANE DB SYST REV, V4; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Oldenbeuving AW, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-34; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Overshott R, 2010, INT PSYCHOGERIATR, V22, P812, DOI 10.1017/S1041610209991359; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; SETTLE EC, 1983, J CLIN PSYCHIAT, V44, P440; Thomason JWW, 2005, CRIT CARE, V9, pR375, DOI 10.1186/cc3729; UK National Health Service National Electronic Library for Medicines, RIV; van Eijk MMJ, 2009, CRIT CARE MED, V37, P1881, DOI 10.1097/CCM.0b013e3181a00118; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016	34	225	248	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2010	376	9755					1829	1837		10.1016/S0140-6736(10)61855-7	http://dx.doi.org/10.1016/S0140-6736(10)61855-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KG	21056464				2022-12-28	WOS:000285439700031
J	Miller, KD				Miller, Kenneth D.			pi = Visual Cortex	SCIENCE			English	Editorial Material							ORIENTATION SELECTIVITY; HORIZONTAL CONNECTIONS; MAPS		Columbia Univ, Coll Phys & Surg, Kavli Inst Brain Sci, Dept Neurosci,Ctr Theoret Neurosci, New York, NY 10032 USA	Columbia University	Miller, KD (corresponding author), Columbia Univ, Coll Phys & Surg, Kavli Inst Brain Sci, Dept Neurosci,Ctr Theoret Neurosci, New York, NY 10032 USA.	ken@neurotheory.columbia.edu			NATIONAL EYE INSTITUTE [R01EY011001] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011001] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Angelucci A, 2006, PROG BRAIN RES, V154, P93, DOI 10.1016/S0079-6123(06)54005-1; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CROSS MC, 1993, REV MOD PHYS, V65, P851, DOI 10.1103/RevModPhys.65.851; HUBEL DH, 2004, BRAIN VISUAL PERCEPT, P25; Huberman AD, 2008, ANNU REV NEUROSCI, V31, P479, DOI 10.1146/annurev.neuro.31.060407.125533; Kaschube M, 2002, J NEUROSCI, V22, P7206; Kaschube M, 2010, SCIENCE, V330, P1113, DOI 10.1126/science.1194869; Kaschube M, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/1/015009; Miller KD, 1999, J NEUROBIOL, V41, P44, DOI 10.1002/(SICI)1097-4695(199910)41:1<44::AID-NEU7>3.0.CO;2-V; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; Van Hooser SD, 2005, J NEUROSCI, V25, P19, DOI 10.1523/JNEUROSCI.4042-04.2005; Van Hooser SD, 2007, NEUROSCIENTIST, V13, P639, DOI 10.1177/1073858407306597; [No title captured]	15	10	10	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1059	1060		10.1126/science.1198857	http://dx.doi.org/10.1126/science.1198857			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097928				2022-12-28	WOS:000284374700030
J	Aoki, SK; Diner, EJ; de Roodenbeke, CT; Burgess, BR; Poole, SJ; Braaten, BA; Jones, AM; Webb, JS; Hayes, CS; Cotter, PA; Low, DA				Aoki, Stephanie K.; Diner, Elie J.; de Roodenbeke, Claire t'Kint; Burgess, Brandt R.; Poole, Stephen J.; Braaten, Bruce A.; Jones, Allison M.; Webb, Julia S.; Hayes, Christopher S.; Cotter, Peggy A.; Low, David A.			A widespread family of polymorphic contact-dependent toxin delivery systems in bacteria	NATURE			English	Article							III SECRETION SYSTEM; ESCHERICHIA-COLI; INHIBITION; GROWTH	Bacteria have developed mechanisms to communicate and compete with one another in diverse environments(1). A new form of intercellular communication, contact-dependent growth inhibition (CDI), was discovered recently in Escherichia coli(2). CDI is mediated by the CdiB/CdiA two-partner secretion (TPS) system. CdiB facilitates secretion of the CdiA 'exoprotein' onto the cell surface. An additional small immunity protein (CdiI) protects CDI+ cells from autoinhibition(2,3). The mechanisms by which CDI blocks cell growth and by which CdiI counteracts this growth arrest are unknown. Moreover, the existence of CDI activity in other bacteria has not been explored. Here we show that the CDI growth inhibitory activity resides within the carboxy-terminal region of CdiA (CdiA-CT), and that CdiI binds and inactivates cognate CdiA-CT, but not heterologous CdiA-CT. Bioinformatic and experimental analyses show that multiple bacterial species encode functional CDI systems with high sequence variability in the CdiA-CT and CdiI coding regions. CdiA-CT heterogeneity implies that a range of toxic activities are used during CDI. Indeed, CdiA-CTs from uropathogenic E. coli and the plant pathogen Dickeya dadantii have different nuclease activities, each providing a distinct mechanism of growth inhibition. Finally, we show that bacteria lacking the CdiA-CT and CdiI coding regions are unable to compete with isogenic wild-type CDI+ cells both in laboratory media and on a eukaryotic host. Taken together, these results suggest that CDI systems constitute an intricate immunity network with an important function in bacterial competition.	[Aoki, Stephanie K.; de Roodenbeke, Claire t'Kint; Burgess, Brandt R.; Poole, Stephen J.; Braaten, Bruce A.; Jones, Allison M.; Webb, Julia S.; Hayes, Christopher S.; Cotter, Peggy A.; Low, David A.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Diner, Elie J.; Hayes, Christopher S.; Cotter, Peggy A.; Low, David A.] Univ Calif Santa Barbara, Biomol Sci & Engn Program, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Low, DA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	low@lifesci.ucsb.edu	Hayes, Christopher/A-5505-2009; Pacific-Southwest, RCE/B-6155-2009		National Science Foundation [0642052]; Tri-Counties Blood Bank; National Institutes of Health [GM078634, AI043986, U54AI065359]; United States Department of Agriculture Cooperative State Research, Education, and Extension Service [2001-52100-11316]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI065359, R01AI043986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078634] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); Tri-Counties Blood Bank; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Department of Agriculture Cooperative State Research, Education, and Extension Service(United States Department of Agriculture (USDA)National Institute of Food and Agriculture); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank A. Charkowski, A. Collmer, J. Roth and H. Schweizer for plasmids, bacterial strains and helpful discussions; W. Lathem for Y. pestis CO92 DNA; and R. Christoffersen for helpful advice on plant experiments. This work was supported by National Science Foundation grant 0642052 (D.A.L.), a Tri-Counties Blood Bank Postdoctoral Fellowship (S.K.A.) and National Institutes of Health grants GM078634 (C.S.H.), AI043986 (P.A.C.) and U54AI065359 (D.A.L., P.A.C. and C.S.H.). The content is the sole responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health. This project made use of preliminary sequences from the Dickeya dadantii 3937 genome project supported by the Initiative for Future Agriculture and Food Systems grant no. 2001-52100-11316 from the United States Department of Agriculture Cooperative State Research, Education, and Extension Service.	Aoki SK, 2009, J BACTERIOL, V191, P1777, DOI 10.1128/JB.01437-08; Aoki SK, 2005, SCIENCE, V309, P1245, DOI 10.1126/science.1115109; Aoki SK, 2008, MOL MICROBIOL, V70, P323, DOI 10.1111/j.1365-2958.2008.06404.x; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; Dobrindt U, 2002, INFECT IMMUN, V70, P6365, DOI 10.1128/IAI.70.11.6365-6372.2002; DUPORT C, 1995, J BIOL CHEM, V270, P8920, DOI 10.1074/jbc.270.15.8920; Edwards RA, 1998, GENE, V207, P149, DOI 10.1016/S0378-1119(97)00619-7; Ham JH, 2004, MOL PLANT MICROBE IN, V17, P184, DOI 10.1094/MPMI.2004.17.2.184; Hibbing ME, 2010, NAT REV MICROBIOL, V8, P15, DOI 10.1038/nrmicro2259; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Luo CW, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-552; Pagni M, 2001, Brief Bioinform, V2, P51, DOI 10.1093/bib/2.1.51; Rojas CM, 2004, MOL PLANT MICROBE IN, V17, P644, DOI 10.1094/MPMI.2004.17.6.644; Yap MN, 2006, J BACTERIOL, V188, P2280, DOI 10.1128/JB.188.6.2280-2284.2006	14	214	227	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					439	442		10.1038/nature09490	http://dx.doi.org/10.1038/nature09490			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085179	Green Accepted			2022-12-28	WOS:000284313100043
J	Clark, WF; Sontrop, JM; Macnab, JJ; Salvadori, M; Moist, L; Suri, R; Garg, AX				Clark, William F.; Sontrop, Jessica M.; Macnab, Jennifer J.; Salvadori, Marina; Moist, Louise; Suri, Rita; Garg, Amit X.			Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOLYTIC-UREMIC SYNDROME; O157-H7 INFECTION; HEALTH SEQUELAE; KIDNEY-FUNCTION; OUTBREAK; CONSUMPTION; PREVALENCE; PREDICTION; CONTINUUM; ILLNESS	Objectives To evaluate the risk for hypertension, renal impairment, and cardiovascular disease within eight years of gastroenteritis from drinking water contaminated with Escherichia coli O157:H7 and Campylobacter. Design A prospective cohort study. Setting Walkerton, Ontario, Canada. Participants 1977 adult participants in the Walkerton Health Study recruited between 2002 and 2005 after an outbreak of gastroenteritis in May 2000, when a municipal water system was contaminated, with no pre-outbreak history of outcome measures. Outcome measures Information was collected annually via survey, physical examination, and laboratory assessment. Primary measures were acute gastroenteritis (diarrhoeal illness lasting >3 days, bloody diarrhoea, or >3 loose stools/day), hypertension (blood pressure >= 140/90 mm Hg), and renal impairment (microalbuminuria or estimated glomerular filtration rate <60 ml/min/1.73 m(2)). Self reported physician diagnosis of cardiovascular disease (myocardial infarction, stroke, or congestive heart failure) was a secondary outcome. Results Acute gastroenteritis at the time of the outbreak was reported by 1067 (54%) of participants. Incident hypertension was detected in 697 (35%) (294 (32%) of group not exposed to acute gastroenteritis v 403 (38%) of exposed group). While 572 (29%) had at least one indicator of renal impairment (266 (29%) of unexposed v 306 (29%) of exposed), only 30 (1.5%) had both (8 (0.9%) of unexposed v 22 (2.1%) of exposed). Cardiovascular disease was reported by 33/1749 (1.9%). The adjusted hazard ratios for hypertension and cardiovascular disease after acute gastroenteritis were 1.33 (95% confidence interval 1.14 to 1.54) and 2.13 (1.03 to 4.43) respectively. The adjusted hazard ratio for the presence of either indicator of renal impairment was 1.15 (0.97 to 1.35) and was 3.41 (1.51 to 7.71) for the presence of both. Conclusion Gastroenteritis from drinking water contaminated with E coli O157:H7 and Campylobacter was associated with an increased risk for hypertension, renal impairment, and self reported cardiovascular disease. Annual monitoring of blood pressure and periodic monitoring of renal function may be warranted for individuals who experience E coli O157:H7 gastroenteritis.	[Clark, William F.; Sontrop, Jessica M.; Moist, Louise; Suri, Rita; Garg, Amit X.] London Hlth Sci Ctr, Dept Med, Div Nephrol, London, ON, Canada; [Clark, William F.; Sontrop, Jessica M.; Moist, Louise; Suri, Rita; Garg, Amit X.] London Hlth Sci Ctr, London Kidney Clin Res Unit, London, ON, Canada; [Sontrop, Jessica M.; Macnab, Jennifer J.; Moist, Louise; Garg, Amit X.] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; [Salvadori, Marina] Childrens Hosp, London Hlth Sci Ctr, Dept Pediat Infect Dis, London, ON, Canada	London Health Sciences Centre; London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Clark, WF (corresponding author), Victoria Hosp, A2-343 Westminster Tower,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	William.Clark@lhsc.on.ca	Moist, Louise/G-3334-2011; Clark, Bill/G-3287-2011; Garg, Amit X/G-3295-2011; Suri, Rita S/G-3348-2011	Suri, Rita S/0000-0002-0519-3927; Sontrop, Jessica M./0000-0001-7784-2028	Ontario Ministry of Health and Long term Care	Ontario Ministry of Health and Long term Care(Ministry of Health and Long-Term Care, Ontario)	This study was funded by the Ontario Ministry of Health and Long term Care, which had no role in design and conduct of the study; collection, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.	Blair A, 2007, AM J IND MED, V50, P199, DOI 10.1002/ajim.20281; Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC; Brenner BM, 1996, KIDNEY INT, V49, P1774, DOI 10.1038/ki.1996.265; Breslow N E, 1980, IARC Sci Publ, P5; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P803; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Dundas S, 2001, CLIN INFECT DIS, V33, P923, DOI 10.1086/322598; Dzau VJ, 2004, CIRCULATION, V109, P1, DOI 10.1161/01.CIR.0000133445.78855.aa; Effler P, 2001, EMERG INFECT DIS, V7, P812; Engstad T, 2000, STROKE, V31, P1602, DOI 10.1161/01.STR.31.7.1602; *EXP COMM DIAGN CL, 2003, DIABETES CARE, V261, P5; *FDA, 2009, BBB CAMP JEJ; Frenzen PD, 2005, J FOOD PROTECT, V68, P2623, DOI 10.4315/0362-028X-68.12.2623; Garg AX, 2006, KIDNEY INT, V70, P807, DOI 10.1038/sj.ki.5001645; Garg AX, 2006, J CLIN EPIDEMIOL, V59, P421, DOI 10.1016/j.jclinepi.2005.08.014; Garg AX, 2005, CAN MED ASSOC J, V173, P261, DOI 10.1503/cmaj.050581; Garg AX, 2005, CAN J PUBLIC HEALTH, V96, P125, DOI 10.1007/BF03403675; Garg AX, 2003, JAMA-J AM MED ASSOC, V290, P1360, DOI 10.1001/jama.290.10.1360; Germani Y, 1997, LANCET, V349, P1670, DOI 10.1016/S0140-6736(05)62636-0; Groenwold RHH, 2010, INT J EPIDEMIOL, V39, P107, DOI 10.1093/ije/dyp332; Halbesma N, 2006, J AM SOC NEPHROL, V17, P2582, DOI 10.1681/ASN.2005121352; Hallan SI, 2009, J AM SOC NEPHROL, V20, P1069, DOI 10.1681/ASN.2008070730; Hamner S, 2007, APPL ENVIRON MICROB, V73, P2369, DOI 10.1128/AEM.00141-07; Hemmelgarn BR, 2010, JAMA-J AM MED ASSOC, V303, P423, DOI 10.1001/jama.2010.39; Hirsch AT, 2004, CIRCULATION, V110, P2774, DOI 10.1161/01.CIR.0000147616.76919.99; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; Karmali MA, 2009, KIDNEY INT, V75, pS4, DOI 10.1038/ki.2008.608; Kehl SC, 2002, J CLIN MICROBIOL, V40, P2711, DOI 10.1128/JCM.40.8.2711-2715.2002; Kleinbaum D.G., 2005, SURVIVAL ANAL SELF L, DOI [10.1007/0-387-29150-4, DOI 10.1007/0-387-29150-4]; Leotta GA, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-46; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Liuzzo G, 2001, Rays, V26, P221; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; Michino H, 1999, AM J EPIDEMIOL, V150, P787, DOI 10.1093/oxfordjournals.aje.a010082; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Ohmi K, 1998, BIOCHEM BIOPH RES CO, V251, P137, DOI 10.1006/bbrc.1998.9417; Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005; Olsen SJ, 2002, EMERG INFECT DIS, V8, P370, DOI 10.3201/eid0804.000218; Petruzziello TN, 2009, KIDNEY INT, V75, pS17, DOI 10.1038/ki.2008.612; Powell M, 2001, INT J FOOD MICROBIOL, V69, P209, DOI 10.1016/S0168-1605(01)00495-0; Rangel JM, 2005, EMERG INFECT DIS, V11, P603, DOI 10.3201/eid1104.040739; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rothman K., 1998, MODERN EPIDEMIOLOGY, P253; Salvadori MI, 2009, KIDNEY INT, V75, pS33, DOI 10.1038/ki.2008.616; Sehgal R, 2008, T ROY SOC TROP MED H, V102, P380, DOI 10.1016/j.trstmh.2008.01.015; SU CY, 1995, ANN INTERN MED, V123, P698, DOI 10.7326/0003-4819-123-9-199511010-00009; Tarr PI, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133817; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; *US FDA, 2009, BBB ESCH COL O157 H7; Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013; Wendel AM, 2009, CLIN INFECT DIS, V48, P1079, DOI 10.1086/597399; Whittaker PJ, 2009, EPIDEMIOL INFECT, V137, P375, DOI 10.1017/S0950268808001702; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363	56	40	44	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2010	341								c6020	10.1136/bmj.c6020	http://dx.doi.org/10.1136/bmj.c6020			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684WO	21084368	Green Published, hybrid			2022-12-28	WOS:000284586200004
J	The, NS; Suchindran, C; North, KE; Popkin, BM; Gordon-Larsen, P				The, Natalie S.; Suchindran, Chirayath; North, Kari E.; Popkin, Barry M.; Gordon-Larsen, Penny			Association of Adolescent Obesity With Risk of Severe Obesity in Adulthood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOR-DISEASE-CONTROL; BODY-MASS INDEX; UNITED-STATES; US ADULTS; MORBID-OBESITY; PREVALENCE; INCREASES; CHILDREN; TRENDS; OVERWEIGHT	Context Although the prevalence of obesity has increased in recent years, individuals who are obese early in life have not been studied over time to determine whether they develop severe obesity in adulthood, thus limiting effective interventions to reduce severe obesity incidence and its potentially life-threatening associated conditions. Objective To determine incidence and risk of severe obesity in adulthood by adolescent weight status. Design, Setting, and Participants A cohort of 8834 individuals aged 12 to 21 years enrolled in 1996 in wave II of the US National Longitudinal Study of Adolescent Health, followed up into adulthood (ages 18-27 years during wave III [2001-2002] and ages 24-33 years during wave IV [2007-2009]). Height and weight were obtained via anthropometry and surveys administered in study participants' homes using standardized procedures. Main Outcome Measures New cases of adult-onset severe obesity were calculated by sex, race/ethnicity, and adolescent weight status. Sex-stratified, discrete time hazard models estimated the net effect of adolescent obesity (aged <20 years; body mass index [BMI] >= 95th percentile of the sex-specific BMI-for-age growth chart or BMI >= 30.0) on risk of severe obesity incidence in adulthood (aged <20 years; BMI >= 40.0), adjusting for race/ethnicity and age and weighted for national representation. Results In 1996, 79 (1.0%; 95% confidence interval [CI], 0.7%-1.4%) adolescents were severely obese; 60 (70.5%; 95% CI, 57.2%-83.9%) remained severely obese in adulthood. By 2009, 703 (7.9%; 95% CI, 7.4%-8.5%) non-severely obese adolescents had become severely obese in adulthood, with the highest rates for non-Hispanic black women. Obese adolescents were significantly more likely to develop severe obesity in young adulthood than normal-weight or overweight adolescents (hazard ratio, 16.0; 95% CI, 12.4-20.5). Conclusion In this cohort, obesity in adolescence was significantly associated with increased risk of incident severe obesity in adulthood, with variations by sex and race/ethnicity. JAMA. 2010;304(18):2042-2047 www.jama.com	[The, Natalie S.; Suchindran, Chirayath; Popkin, Barry M.; Gordon-Larsen, Penny] Univ N Carolina, Gillings Sch Global Publ Hlth, Carolina Populat Ctr, Chapel Hill, NC 27516 USA; [The, Natalie S.; Popkin, Barry M.; Gordon-Larsen, Penny] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27516 USA; [Suchindran, Chirayath] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC 27516 USA; [North, Kari E.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27516 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Gordon-Larsen, P (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Carolina Populat Ctr, 123 W Franklin St, Chapel Hill, NC 27516 USA.	pglarsen@unc.edu	Popkin, Barry/T-6633-2019	popkin, barry/0000-0001-9495-9324	National Institutes of Health [R01-HD057194]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [P01-HD31921]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD057194, P01HD031921, R24HD050924] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by National Institutes of Health grant R01-HD057194.; This research uses data from Add Health, a program project directed by Kathleen Mullan Harris, PhD, and designed by J. Richard Udry, PhD, Peter S. Bearman, PhD, and Kathleen Mullan Harris, PhD at the University of North Carolina, Chapel Hill, and funded by grant P01-HD31921 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. Special acknowledgment is due Ronald R. Rindfuss, PhD, and Barbara Entwisle, PhD, both from the University of North Carolina, Chapel Hill, for assistance in the original design. Information on how to obtain the Add Health data files is available on the Add Health Web site (http://www.cpc.unc.edu/addhealth). No direct support was received from grant P01-HD31921 for this analysis. None of the acknowledged individuals received compensation for their assistance.	Arterburn DE, 2005, INT J OBESITY, V29, P334, DOI 10.1038/sj.ijo.0802896; Bray G A, 2001, Rev Endocr Metab Disord, V2, P403, DOI 10.1023/A:1011808701117; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; Chantala K, NONRESPONSE WAVE 3 A; Colquitt JL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003641.pub3; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; Flegal KM, 2009, AM J CLIN NUTR, V90, P1314, DOI 10.3945/ajcn.2009.28335; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Freedman DS, 2007, J PEDIATR-US, V150, P12, DOI 10.1016/j.jpeds.2006.08.042; Freedman DS, 2002, JAMA-J AM MED ASSOC, V288, P1758, DOI 10.1001/jama.288.14.1758; Freedman DS, 2007, J PEDIAT, V150, pe2; Gordon-Larsen P, 2007, OBESITY, V15, P2790, DOI 10.1038/oby.2007.331; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; McTigue KM, 2002, ANN INTERN MED, V136, P857, DOI 10.7326/0003-4819-136-12-200206180-00006; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Must A, 2006, INT J OBESITY, V30, P590, DOI 10.1038/sj.ijo.0803300; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; National Institutes of Health, 2000, PRACT GUID ID EV TRE; Ogden CL, 2002, PEDIATRICS, V109, P45, DOI 10.1542/peds.109.1.45; Popkin BM, 1998, J NUTR, V128, P701, DOI 10.1093/jn/128.4.701; PRENTICE RL, 1978, BIOMETRICS, V34, P57, DOI 10.2307/2529588; Richardson DB, 2010, OCCUP ENVIRON MED, V67, P67, DOI 10.1136/oem.2008.044834; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Skelton JA, 2009, ACAD PEDIATR, V9, P322, DOI 10.1016/j.acap.2009.04.005; Stevens J, 2003, INT J OBESITY, V27, P287, DOI 10.1038/sj.ijo.0802255; Sturm R, 2007, PUBLIC HEALTH, V121, P492, DOI 10.1016/j.puhe.2007.01.006; Sturm R, 2003, ARCH INTERN MED, V163, P2146, DOI 10.1001/archinte.163.18.2146; Tanner BD, 2009, AM SURGEON, V75, P103; The NS, 2009, OBESITY, V17, P1441, DOI 10.1038/oby.2009.97; Tourangeau R, 1999, NATL LONGITUDINAL ST; Wang YC, 2011, INT J PEDIATR OBES, V6, P12, DOI 10.3109/17477161003587774; Zheng H, 2009, INT J OBESITY, V33, pS8, DOI 10.1038/ijo.2009.65	33	288	291	2	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2042	2047		10.1001/jama.2010.1635	http://dx.doi.org/10.1001/jama.2010.1635			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063014	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000284000600023
J	Kraman, M; Bambrough, PJ; Arnold, JN; Roberts, EW; Magiera, L; Jones, JO; Gopinathan, A; Tuveson, DA; Fearon, DT				Kraman, Matthew; Bambrough, Paul J.; Arnold, James N.; Roberts, Edward W.; Magiera, Lukasz; Jones, James O.; Gopinathan, Aarthi; Tuveson, David A.; Fearon, Douglas T.			Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-alpha	SCIENCE			English	Article							IFN-GAMMA; T-CELLS; TUMOR PROGRESSION; HUMAN-MELANOMA; BONE-MARROW; CANCER; INHIBITION; GROWTH; DIFFERENTIATION; IMMUNOGENICITY	The stromal microenvironment of tumors, which is a mixture of hematopoietic and mesenchymal cells, suppresses immune control of tumor growth. A stromal cell type that was first identified in human cancers expresses fibroblast activation protein-alpha (FAP). We created a transgenic mouse in which FAP-expressing cells can be ablated. Depletion of FAP-expressing cells, which made up only 2% of all tumor cells in established Lewis lung carcinomas, caused rapid hypoxic necrosis of both cancer and stromal cells in immunogenic tumors by a process involving interferon-gamma and tumor necrosis factor-alpha. Depleting FAP-expressing cells in a subcutaneous model of pancreatic ductal adenocarcinoma also permitted immunological control of growth. Therefore, FAP-expressing cells are a nonredundant, immune-suppressive component of the tumor microenvironment.	[Kraman, Matthew; Bambrough, Paul J.; Arnold, James N.; Roberts, Edward W.; Magiera, Lukasz; Jones, James O.; Fearon, Douglas T.] Univ Cambridge, MRC Ctr, Dept Med, Wellcome Trust Immunol Unit, Cambridge CB2 2QH, England; [Gopinathan, Aarthi; Tuveson, David A.] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England; [Gopinathan, Aarthi] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	MRC Laboratory Molecular Biology; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Pennsylvania; Pennsylvania Medicine	Fearon, DT (corresponding author), Univ Cambridge, MRC Ctr, Dept Med, Wellcome Trust Immunol Unit, Hills Rd, Cambridge CB2 2QH, England.	dtf1000@cam.ac.uk	Arnold, James/ABE-3900-2021	Arnold, James/0000-0002-6949-0613; Kraman, Matthew/0000-0002-5040-0067; Magiera, Lukasz/0000-0002-8234-5066; Roberts, Edward/0000-0002-8229-1715	Wellcome Trust; National Institutes for Health Research Cambridge Biomedical Research Centre; Cancer Research UK; Hutchison Whampoa; University of Cambridge	Wellcome Trust(Wellcome Trust); National Institutes for Health Research Cambridge Biomedical Research Centre; Cancer Research UK(Cancer Research UK); Hutchison Whampoa; University of Cambridge(University of Cambridge)	We thank A. Betz, F. Randow, and C. Feig for their discussions. This research was supported by the Wellcome Trust and the National Institutes for Health Research Cambridge Biomedical Research Centre. D. A. T. was supported by Cancer Research UK, Hutchison Whampoa, and the University of Cambridge.	Bae S, 2008, BRIT J HAEMATOL, V142, P827, DOI 10.1111/j.1365-2141.2008.07241.x; Bauer S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2080; BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69; Zhang B, 2008, J CLIN INVEST, V118, P1398, DOI 10.1172/JCI33522; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Dolznig Helmut, 2005, Cancer Immun, V5, P10; DOUKAS J, 1990, J IMMUNOL, V145, P1727; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; KLEIN G, 1960, CANCER RES, V20, P1561; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Nelson DJ, 2001, J IMMUNOL, V166, P5557, DOI 10.4049/jimmunol.166.9.5557; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Peggs KS, 2008, IMMUNOL REV, V224, P141, DOI 10.1111/j.1600-065X.2008.00649.x; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; PEKAREK LA, 1995, J EXP MED, V181, P435, DOI 10.1084/jem.181.1.435; Rosenberg SA, 2005, J IMMUNOL, V175, P6169, DOI 10.4049/jimmunol.175.9.6169; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Schuler T, 2003, J IMMUNOL, V170, P4427, DOI 10.4049/jimmunol.170.9.4427; Speiser DE, 2006, J IMMUNOL, V177, P1338, DOI 10.4049/jimmunol.177.2.1338; Terabe M, 2005, J EXP MED, V202, P1627, DOI 10.1084/jem.20051381; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; Valmori D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI 10.1073/pnas.0703395104; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Willimsky G, 2008, J EXP MED, V205, P1687, DOI 10.1084/jem.20072016; Yu P, 2005, J EXP MED, V201, P779, DOI 10.1084/jem.20041684	30	769	805	6	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					827	830		10.1126/science.1195300	http://dx.doi.org/10.1126/science.1195300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051638				2022-12-28	WOS:000283855700045
J	Patel, AG; Kaufmann, SH				Patel, Anand G.; Kaufmann, Scott H.			Targeting Bacteria to Improve Cancer Therapy	SCIENCE			English	Editorial Material							IRINOTECAN; DIARRHEA; CPT-11		[Patel, Anand G.; Kaufmann, Scott H.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Kaufmann, Scott H.] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Patel, AG (corresponding author), Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA.	kaufmann.scott@mayo.edu	Patel, Anand/G-9877-2018	Patel, Anand/0000-0002-1438-8275; Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [R01 CA073709] Funding Source: Medline; NIGMS NIH HHS [T32 GM072474] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Flieger D, 2007, ONCOLOGY-BASEL, V72, P10, DOI 10.1159/000111083; HUSAIN I, 1994, CANCER RES, V54, P539; Kehrer DFS, 2001, CLIN CANCER RES, V7, P1136; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; Nagar S, 2006, DRUG METAB REV, V38, P393, DOI 10.1080/03602530600739835; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; SPARREBOOM A, 2005, CANC CHEMOTHERAPY BI, P371; Takasuna K, 1996, CANCER RES, V56, P3752; Wallace BD, 2010, SCIENCE, V330, P831, DOI 10.1126/science.1191175	9	6	6	3	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					766	767		10.1126/science.1198310	http://dx.doi.org/10.1126/science.1198310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051622				2022-12-28	WOS:000283855700026
J	Wallace, BD; Wang, HW; Lane, KT; Scott, JE; Orans, J; Koo, JS; Venkatesh, M; Jobin, C; Yeh, LA; Mani, S; Redinbo, MR				Wallace, Bret D.; Wang, Hongwei; Lane, Kimberly T.; Scott, John E.; Orans, Jillian; Koo, Ja Seol; Venkatesh, Madhukumar; Jobin, Christian; Yeh, Li-An; Mani, Sridhar; Redinbo, Matthew R.			Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme	SCIENCE			English	Article							BETA-GLUCURONIDASE; METABOLISM; PHARMACOGENETICS; DIARRHEA; COLITIS; COLON	The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial beta-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial beta-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial beta-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.	[Wallace, Bret D.; Lane, Kimberly T.; Orans, Jillian; Redinbo, Matthew R.] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; [Wang, Hongwei; Venkatesh, Madhukumar; Mani, Sridhar] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Wang, Hongwei; Venkatesh, Madhukumar; Mani, Sridhar] Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA; [Wang, Hongwei; Venkatesh, Madhukumar; Mani, Sridhar] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Scott, John E.; Yeh, Li-An] N Carolina Cent Univ, BRITE, Durham, NC 27707 USA; [Koo, Ja Seol; Jobin, Christian] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; [Redinbo, Matthew R.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Redinbo, Matthew R.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of North Carolina; North Carolina Central University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Redinbo, MR (corresponding author), Univ N Carolina, Dept Chem, CB 3290, Chapel Hill, NC 27599 USA.	redinbo@unc.edu		Koo, Ja Seol/0000-0002-1202-075X; Wallace, Bret/0000-0002-9107-5045	NIH [CA98468, CA127231]; UNC Chapel Hill; Damon Runyon Cancer Research Foundation [CI15-02]; Golden Leaf Foundation; State of North Carolina; NATIONAL CANCER INSTITUTE [R01CA098468, R01CA127231, R01CA161879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073338] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC Chapel Hill; Damon Runyon Cancer Research Foundation; Golden Leaf Foundation; State of North Carolina; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of the Redinbo Laboratory at UNC Chapel Hill, the Mani lab and Einstein College of Medicine, and the BRITE Institute for experimental assistance and helpful discussions; B. Allard at UNC Chapel Hill for her expert help with the cytotoxicity assay; B. Sartor at UNC for providing bacterial cell lines; and E. Burgos in the Schramm lab at Einstein for use of the HPLC. Supported by NIH grant CA98468 ( M. R. R.), the SPIRE Postdoctoral Fellowship Program at UNC Chapel Hill (K. T. L.), Damon Runyon Cancer Research Foundation grant CI15-02 and NIH grant CA127231 ( S. M.), and a grant from the Golden Leaf Foundation and the State of North Carolina (L.-A.Y.). Atomic coordinates and structure factors have been deposited with the PDB ( accession codes: 3K4A, 3K46, 3K4D, 3LPF, and 3LPG). The authors remember Lisa Benkowski and Stacey Micoli, for whom CPT-11's efficacy was limited by its toxicity.	Basinska Agnieszka, 2003, Ann Univ Mariae Curie Sklodowska Med, V58, P386; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Cummings JH, 1997, JPEN-PARENTER ENTER, V21, P357, DOI 10.1177/0148607197021006357; Farnleitner AH, 2002, WATER RES, V36, P975, DOI 10.1016/S0043-1354(01)00288-3; Fittkau M, 2004, J CANCER RES CLIN, V130, P388, DOI 10.1007/s00432-004-0557-8; Flieger D, 2007, ONCOLOGY-BASEL, V72, P10, DOI 10.1159/000111083; GRILL JP, 1995, CURR MICROBIOL, V31, P23, DOI 10.1007/BF00294629; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Hu ZP, 2006, TOXICOL APPL PHARM, V216, P225, DOI 10.1016/j.taap.2006.05.020; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; Kurita A, 2011, CANCER CHEMOTH PHARM, V67, P201, DOI 10.1007/s00280-010-1310-4; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Yang LY, 2006, WORLD J GASTROENTERO, V12, P6741, DOI 10.3748/wjg.v12.i42.6741; Ma MK, 2003, CURR MED CHEM, V10, P41, DOI 10.2174/0929867033368619; Marchler-Bauer A, 2009, NUCLEIC ACIDS RES, V37, pD205, DOI 10.1093/nar/gkn845; Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182; Nagar S, 2006, DRUG METAB REV, V38, P393, DOI 10.1080/03602530600739835; NIWA T, 1972, J BIOCHEM-TOKYO, V72, P207, DOI 10.1093/oxfordjournals.jbchem.a129889; NORD CE, 1984, AM J MED, V76, P99, DOI 10.1016/0002-9343(84)90250-X; Pizzolato JF, 2003, LANCET, V361, P2235, DOI 10.1016/S0140-6736(03)13780-4; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Ray J, 1999, J HERED, V90, P119, DOI 10.1093/jhered/90.1.119; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Russell WM, 2001, APPL ENVIRON MICROB, V67, P1253, DOI 10.1128/AEM.67.3.1253-1261.2001; Sears CL, 2005, ANAEROBE, V11, P247, DOI 10.1016/j.anaerobe.2005.05.001; Sears S, 1999, GASTROINTEST ENDOSC, V50, P841, DOI 10.1016/S0016-5107(99)70171-9; Siegmund B, 2001, J PHARMACOL EXP THER, V296, P99; Smith NF, 2006, TOXICOL IN VITRO, V20, P163, DOI 10.1016/j.tiv.2005.06.045; Stamp D, 2004, MED HYPOTHESES, V63, P555, DOI 10.1016/j.mehy.2004.05.005; Stein Alexander, 2010, Ther Adv Med Oncol, V2, P51, DOI 10.1177/1758834009355164; Tobin PJ, 2003, ONCOL REP, V10, P1977; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	36	576	607	10	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2010	330	6005					831	835		10.1126/science.1191175	http://dx.doi.org/10.1126/science.1191175			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051639	Green Accepted, Green Published			2022-12-28	WOS:000283855700046
J	Walters, HRJ				Walters, H. R. J.			Antimatter Atomic Physics	SCIENCE			English	Editorial Material							ANTIHYDROGEN; ANNIHILATION; POSITRONIUM; MOLECULES		Queens Univ Belfast, Sch Math & Phys, Ctr Theoret Atom Mol & Opt Phys, Belfast BT7 1NN, Antrim, North Ireland	Queens University Belfast	Walters, HRJ (corresponding author), Queens Univ Belfast, Sch Math & Phys, Ctr Theoret Atom Mol & Opt Phys, Belfast BT7 1NN, Antrim, North Ireland.	h.walters@qub.ac.uk						Armour EAG, 2008, NUCL INSTRUM METH B, V266, P363, DOI 10.1016/j.nimb.2007.12.012; Armour EAG, 2006, NUCL INSTRUM METH B, V247, P123, DOI 10.1016/j.nimb.2006.01.048; Brawley SJ, 2010, SCIENCE, V330, P789, DOI 10.1126/science.1192322; Cassidy DB, 2007, NATURE, V449, P195, DOI 10.1038/nature06094; Cassidy DB, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.173401; CHARLTON M, 1994, PHYS REP, V241, P65, DOI 10.1016/0370-1573(94)90081-7; Gabrielse G, 2010, PHYS TODAY, V63, P68, DOI 10.1063/1.3366248; Gribakin GF, 2010, REV MOD PHYS, V82, P2557, DOI 10.1103/RevModPhys.82.2557; Kellerbauer A, 2008, NUCL INSTRUM METH B, V266, P351, DOI 10.1016/j.nimb.2007.12.010; Mills AP, 2002, NUCL INSTRUM METH B, V192, P107, DOI 10.1016/S0168-583X(02)00790-5; Ryzhikh GG, 1997, PHYS REV LETT, V79, P4124, DOI 10.1103/PhysRevLett.79.4124; Walters HRJ, 2005, NUCL INSTRUM METH B, V233, P78, DOI 10.1016/j.nimb.2005.03.089	12	7	7	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					762	763		10.1126/science.1197822	http://dx.doi.org/10.1126/science.1197822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051619				2022-12-28	WOS:000283855700023
J	Lewis, SL				Lewis, Simon L.			How to beat the media in the climate street fight	NATURE			English	Editorial Material									[Lewis, Simon L.] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England	University of Leeds		s.l.lewis@leeds.ac.uk		Lewis, Simon/0000-0002-8066-6851					0	1	1	1	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					7	7		10.1038/468007a	http://dx.doi.org/10.1038/468007a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	674YF	21048720	Bronze			2022-12-28	WOS:000283786900006
J	Skrobik, Y				Skrobik, Yoanna			Delirium treatment: an unmet challenge	LANCET			English	Editorial Material							SEPTIC SHOCK		Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada	Universite de Montreal	Skrobik, Y (corresponding author), Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada.	skrobik@sympatico.ca	Skrobik, Yoanna/K-8165-2014; Skrobik, Yoanna/J-6393-2013	Skrobik, Yoanna/0000-0002-5315-6020; 				Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Marquis F, 2007, CRIT CARE MED, V35, P2533, DOI 10.1097/01.CCM.0000284506.43390.F3; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Oldenbeuving AW, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-34; Ouimet S, 2007, INTENS CARE MED, V33, P1007, DOI 10.1007/s00134-007-0618-y; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Plum F, 1972, Contemp Neurol Ser, V10, P1; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Skrobik V, 2010, INTENS CARE MED, DOI [10.1007/s00134-010-1375-5, DOI 10.1007/S00134-010-1375-5]; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; van Eijk MMJ, 2010, LANCET, V376, P1829, DOI 10.1016/S0140-6736(10)61855-7; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892	14	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV-DEC	2010	376	9755					1805	1807		10.1016/S0140-6736(10)61998-8	http://dx.doi.org/10.1016/S0140-6736(10)61998-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KG	21056463				2022-12-28	WOS:000285439700007
J	Logan, GD; Crump, MJC				Logan, Gordon D.; Crump, Matthew J. C.			Cognitive Illusions of Authorship Reveal Hierarchical Error Detection in Skilled Typists	SCIENCE			English	Article							NEURAL SYSTEM; HANDS	The ability to detect errors is an essential component of cognitive control. Studies of error detection in humans typically use simple tasks and propose single-process theories of detection. We examined error detection by skilled typists and found illusions of authorship that provide evidence for two error-detection processes. We corrected errors that typists made and inserted errors in correct responses. When asked to report errors, typists took credit for corrected errors and accepted blame for inserted errors, claiming authorship for the appearance of the screen. However, their typing rate showed no evidence of these illusions, slowing down after corrected errors but not after inserted errors. This dissociation suggests two error-detection processes: one sensitive to the appearance of the screen and the other sensitive to keystrokes.	[Logan, Gordon D.; Crump, Matthew J. C.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37203 USA	Vanderbilt University	Logan, GD (corresponding author), Vanderbilt Univ, Dept Psychol, Nashville, TN 37203 USA.	gordon.logan@vanderbilt.edu	Crump, Matthew/A-9103-2011	Crump, Matthew/0000-0002-5612-0090; Logan, Gordon/0000-0002-8301-7726	NSF [BCS 0646588, BCS 0957074]	NSF(National Science Foundation (NSF))	We thank J. D. Schall for comments on the manuscript. This research was supported by grants BCS 0646588 and BCS 0957074 from the NSF.	Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; Botvinick MM, 2008, TRENDS COGN SCI, V12, P201, DOI 10.1016/j.tics.2008.02.009; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Cooper R, 2000, COGN NEUROPSYCHOL, V17, P297, DOI 10.1080/026432900380427; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gordon AM, 1995, EXP BRAIN RES, V107, P281; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Knoblich G, 2004, J EXP PSYCHOL HUMAN, V30, P657, DOI 10.1037/0096-1523.30.4.657; Lashley K., 1951, CEREBRAL MECH BEHAV, P112, DOI DOI 10.1093/RFS/HHQ153; Liu X, 2010, MEM COGNITION, V38, P474, DOI 10.3758/MC.38.4.474; Logan GD, 2009, PSYCHOL SCI, V20, P1296, DOI 10.1111/j.1467-9280.2009.02442.x; LONG J, 1976, ERGONOMICS, V19, P93, DOI 10.1080/00140137608931517; NIELSEN TI, 1963, SCAND J PSYCHOL, V4, P225, DOI 10.1111/j.1467-9450.1963.tb01326.x; NORMAN DA, 1981, PSYCHOL REV, V88, P1, DOI 10.1037/0033-295X.88.1.1; RABBITT P, 1978, ERGONOMICS, V21, P945, DOI 10.1080/00140137808931800; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RUMELHART DE, 1982, COGNITIVE SCI, V6, P1; SALTHOUSE TA, 1986, PSYCHOL BULL, V99, P303, DOI 10.1037/0033-2909.99.3.303; SHAFFER LH, 1976, PSYCHOL REV, V83, P375, DOI 10.1037/0033-295X.83.5.375; Wegner DM, 2002, BRADFORD BOOKS, P1; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	22	95	95	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					683	686		10.1126/science.1190483	http://dx.doi.org/10.1126/science.1190483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	672KB	21030660				2022-12-28	WOS:000283580600052
J	Jaeger, JJ; Beard, KC; Chaimanee, Y; Salem, M; Benammi, M; Hlal, O; Coster, P; Bilal, AA; Duringer, P; Schuster, M; Valentin, X; Marandat, B; Marivaux, L; Metais, E; Hammuda, O; Brunet, M				Jaeger, Jean-Jacques; Beard, K. Christopher; Chaimanee, Yaowalak; Salem, Mustafa; Benammi, Mouloud; Hlal, Osama; Coster, Pauline; Bilal, Awad A.; Duringer, Philippe; Schuster, Mathieu; Valentin, Xavier; Marandat, Bernard; Marivaux, Laurent; Metais, Eddy; Hammuda, Omar; Brunet, Michel			Late middle Eocene epoch of Libya yields earliest known radiation of African anthropoids	NATURE			English	Article							PRIMATE; MAMMALIA; MYANMAR; ORIGINS; CHINA; TARSIIDAE; ALGERIA; SHANXI	Reconstructing the early evolutionary history of anthropoid primates is hindered by a lack of consensus on both the timing and biogeography of anthropoid origins(1-3). Some prefer an ancient (Cretaceous) origin for anthropoids in Africa or some other Gondwanan landmass(4), whereas others advocate a more recent (early Cenozoic) origin for anthropoids in Asia(1,2,5), with subsequent dispersal of one or more early anthropoid taxa to Africa. The oldest undoubted African anthropoid primates described so far are three species of the parapithecid Biretia from the late middle Eocene Bir El Ater locality of Algeria(6) and the late Eocene BQ-2 site in the Fayum region of northern Egypt(7). Here we report the discovery of the oldest known diverse assemblage of African anthropoids from the late middle Eocene Dur At-Talah escarpment in central Libya. The primate assemblage from Dur At-Talah includes diminutive species pertaining to three higher-level anthropoid clades (Afrotarsiidae, Parapithecidae and Oligopithecidae) as well as a small species of the early strepsirhine primate Karanisia. The high taxonomic diversity of anthropoids at Dur At-Talah indicates either a much longer interval of anthropoid evolution in Africa than is currently documented in the fossil record or the nearly synchronous colonization of Africa by multiple anthropoid clades at some time during the middle Eocene epoch.	[Jaeger, Jean-Jacques; Benammi, Mouloud; Coster, Pauline; Schuster, Mathieu; Valentin, Xavier; Brunet, Michel] Univ Poitiers, Inst Int Paleoprimatol & Paleontol Humaine, CNRS, UMR 6046, F-86022 Poitiers, France; [Beard, K. Christopher] Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA; [Chaimanee, Yaowalak] Dept Mineral Resources, Paleontol Sect, Bangkok 10400, Thailand; [Salem, Mustafa; Hlal, Osama; Hammuda, Omar] Al Fateh Univ, Dept Geol, Tripoli, Libya; [Bilal, Awad A.] Garyounis Univ, Dept Geol, Benghazi, Libya; [Duringer, Philippe] Univ Strasbourg, Inst Phys Globe Strasbourg, Inst Geol, CNRS,UMR 7516, F-67084 Strasbourg, France; [Marandat, Bernard; Marivaux, Laurent] Univ Montpellier 2, Inst Sci Evolut, UMR 5554, CNRS, F-34095 Montpellier, France; [Metais, Eddy] Grp TOTAL, F-92400 Courbevoie, France; [Brunet, Michel] Coll France, Chaire Paleontol Humaine, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Department of Mineral Resources - Thailand; Al Fateh University; University of Benghazi; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; College de France	Jaeger, JJ (corresponding author), Univ Poitiers, Inst Int Paleoprimatol & Paleontol Humaine, CNRS, UMR 6046, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	jean-jacques.jaeger@univ-poitiers.fr	Beard, K. Christopher/AAQ-4438-2021; Bilal, Awad/AAP-9486-2020; Lund, Laura/H-7335-2012	Beard, K. Christopher/0000-0002-6279-9837; Bilal, Awad/0000-0002-4903-2682; chaimanee, yaowalak/0000-0002-8432-3880; Coster, Pauline/0000-0003-4015-252X; Schuster, Mathieu/0000-0002-4412-8685; Benammi, Mouloud/0000-0003-4707-7518	University of Poitiers; CNRS [ANR-05-BLAN-0235, ANR-09-BLAN-0238-02-EVAH]; Groupe 'TOTAL'; National Science Foundation	University of Poitiers; CNRS(Centre National de la Recherche Scientifique (CNRS)); Groupe 'TOTAL'; National Science Foundation(National Science Foundation (NSF))	This work has been completed under the framework of a cooperative programme between the University of Poitiers and Al Fateh University. Logistic and travel arrangements were provided by Al Fateh University. Financial support came from the University of Poitiers, from the CNRS 'Eclipse2' program and the ANR-05-BLAN-0235 and ANR-09-BLAN-0238-02-EVAH programs, from the Groupe 'TOTAL' and from a National Science Foundation grant to K. C. B. Scanning electron microscope images were produced by M. Bordes. Figures were designed by S. Riffaut and M. Klingler.	Beard K.C., 2004, HUNT DAWN MONKEY UNE; Beard KC, 2009, P ROY SOC B-BIOL SCI, V276, P3285, DOI 10.1098/rspb.2009.0836; Beard KC, 2006, DEV PRIMATOL, P439, DOI 10.1007/0-387-31710-4_15; Beard K. Christopher, 1998, Bulletin of Carnegie Museum of Natural History, V34, P260; Beard KC, 2004, J HUM EVOL, V46, P401, DOI 10.1016/j.jhevol.2004.01.002; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; Bininda-Emonds ORP, 2007, NATURE, V446, P507, DOI 10.1038/nature05634; Ciochon RL, 2002, YEARB PHYS ANTHROPOL, V45, P2, DOI 10.1002/ajpa.10175; CONROY GC, 1987, INT J PRIMATOL, V8, P115, DOI 10.1007/BF02735160; DEBONIS L, 1988, CR ACAD SCI II, V306, P929; FLEAGLE JG, 1987, J HUM EVOL, V16, P483, DOI 10.1016/0047-2484(87)90036-4; Gebo DL, 2000, J HUM EVOL, V38, P585, DOI 10.1006/jhev.2000.0395; GINSBURG L, 1987, CR ACAD SCI II, V304, P1213; Gradstein F.M., 2004, A; Jaeger JJ, 2010, ZOOL J LINN SOC-LOND, V160, P195, DOI 10.1111/j.1096-3642.2009.00600.x; Jaeger JJ, 1999, SCIENCE, V286, P528, DOI 10.1126/science.286.5439.528; Kay Richard F., 2004, P91; Miller ER, 2005, YEARB PHYS ANTHROPOL, V48, P60, DOI 10.1002/ajpa.20352; Seiffert ER, 2005, SCIENCE, V310, P300, DOI 10.1126/science.1116569; Seiffert ER, 2003, NATURE, V422, P421, DOI 10.1038/nature01489; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1992, P NATL ACAD SCI USA, V89, P10743, DOI 10.1073/pnas.89.22.10743; Tabuce R, 2000, CR ACAD SCI II A, V331, P61, DOI 10.1016/S1251-8050(00)01381-1; Tabuce R, 2001, J VERTEBR PALEONTOL, V21, P535, DOI 10.1671/0272-4634(2001)021[0535:ANGOMM]2.0.CO;2; Tabuce R, 2009, P ROY SOC B-BIOL SCI, V276, P4087, DOI 10.1098/rspb.2009.1339; Wight A.W.R., 1980, GEOLOGY LIBYA, P309; Williams BA, 2010, P NATL ACAD SCI USA, V107, P4797, DOI 10.1073/pnas.0908320107	29	60	62	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 28	2010	467	7319					1096	U103		10.1038/nature09425	http://dx.doi.org/10.1038/nature09425			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	671XW	20981098				2022-12-28	WOS:000283548600045
J	Tsuchida, T; Koga, R; Horikawa, M; Tsunoda, T; Maoka, T; Matsumoto, S; Simon, JC; Fukatsu, T				Tsuchida, Tsutomu; Koga, Ryuichi; Horikawa, Mitsuyo; Tsunoda, Tetsuto; Maoka, Takashi; Matsumoto, Shogo; Simon, Jean-Christophe; Fukatsu, Takema			Symbiotic Bacterium Modifies Aphid Body Color	SCIENCE			English	Article							ACYRTHOSIPHON-PISUM; ENDOSYMBIONT; RESISTANCE; PARASITISM; INSECTS	Color variation within populations of the pea aphid influences relative susceptibility to predators and parasites. We have discovered that infection with a facultative endosymbiont of the genus Rickettsiella changes the insects' body color from red to green in natural populations. Approximately 8% of pea aphids collected in Western Europe carried the Rickettsiella infection. The infection increased amounts of blue-green polycyclic quinones, whereas it had less of an effect on yellow-red carotenoid pigments. The effect of the endosymbiont on body color is expected to influence prey-predator interactions, as well as interactions with other endosymbionts.	[Tsuchida, Tsutomu; Matsumoto, Shogo] RIKEN, Adv Sci Inst, Mol Entomol Lab, Wako, Saitama 3510198, Japan; [Koga, Ryuichi; Fukatsu, Takema] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan; [Horikawa, Mitsuyo; Tsunoda, Tetsuto] Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan; [Maoka, Takashi] Res Inst Prod Dev, Kyoto 6060805, Japan; [Simon, Jean-Christophe] Univ Rennes 1, INRA, UMR 1099, BiO3P, F-35653 Le Rheu, France	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST); Tokushima Bunri University; INRAE; Universite de Rennes	Tsuchida, T (corresponding author), RIKEN, Adv Sci Inst, Mol Entomol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	t-tsuchida@riken.jp; t-fukatsu@aist.go.jp	Simon, Jean-Christophe/I-2700-2014		Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology, Japan [22128007]; INRA AIP Bioresources; RIKEN; Grants-in-Aid for Scientific Research [22590032] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); INRA AIP Bioresources; RIKEN; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank J. Peccoud, Y. Outreman, S. Stoeckel, L. Mieuzet, J. Jaquiery, and W. Weisser for aphid sampling; J. Bonhomme, L. Mieuzet, and J. Makino for aphid rearing and genotyping; and X.-Y. Meng and S. Hanada for help with electron microscopy. This work was supported by the Japan-France Integrated Action Program SAKURA of the Japan Society for the Promotion of Science (to T. F. and J.-C.S.); the Grant-in-Aid for Scientific Research on Innovative Areas (22128007) of the Ministry of Education, Culture, Sports, Science and Technology, Japan (to T. F.); and funds from INRA AIP Bioresources (to J.-C.S.). T. T. was supported by a RIKEN special postdoctoral research fellowship.	BOWIE JH, 1966, NATURE, V210, P395, DOI 10.1038/210395a0; BROWN KS, 1975, CHEM SOC REV, V4, P263, DOI 10.1039/cs9750400263; Cordaux R, 2007, APPL ENVIRON MICROB, V73, P5045, DOI 10.1128/AEM.00378-07; Koga R, 2003, P ROY SOC B-BIOL SCI, V270, P2543, DOI 10.1098/rspb.2003.2537; Leonard J, 2010, EVOLUTION PRIMARY SE; Libbrecht R, 2007, J INSECT BEHAV, V20, P25, DOI 10.1007/s10905-006-9055-y; Losey JE, 1997, NATURE, V388, P269, DOI 10.1038/40849; Montllor CB, 2002, ECOL ENTOMOL, V27, P189, DOI 10.1046/j.1365-2311.2002.00393.x; Moran NA, 2005, APPL ENVIRON MICROB, V71, P3302, DOI 10.1128/AEM.71.6.3302-3310.2005; Moran NA, 2010, SCIENCE, V328, P624, DOI 10.1126/science.1187113; MULLER F. P., 1962, Z. PflKrarikh., V69, P129; Oliver KM, 2010, ANNU REV ENTOMOL, V55, P247, DOI 10.1146/annurev-ento-112408-085305; Oliver KM, 2005, P NATL ACAD SCI USA, V102, P12795, DOI 10.1073/pnas.0506131102; Oliver KM, 2003, P NATL ACAD SCI USA, V100, P1803, DOI 10.1073/pnas.0335320100; Russell JA, 2006, P ROY SOC B-BIOL SCI, V273, P603, DOI 10.1098/rspb.2005.3348; RUXTON GD, 2005, AVOIDING ATTAK EVOLU; Scarborough CL, 2005, SCIENCE, V310, P1781, DOI 10.1126/science.1120180; Tsuchida T, 2004, SCIENCE, V303, P1989, DOI 10.1126/science.1094611	18	287	316	5	197	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1102	1104		10.1126/science.1195463	http://dx.doi.org/10.1126/science.1195463			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097935				2022-12-28	WOS:000284374700043
J	Bendavid, E; Leroux, E; Bhattacharya, J; Smith, N; Miller, G				Bendavid, Eran; Leroux, Eric; Bhattacharya, Jay; Smith, Nicole; Miller, Grant			The relation of price of antiretroviral drugs and foreign assistance with coverage of HIV treatment in Africa: retrospective study	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; AIDS; SETTINGS; THERAPY; WILL	Objective To determine the association of reductions in price of antiretroviral drugs and foreign assistance for HIV with coverage of antiretroviral treatment. Design Retrospective study. Setting Africa. Participants 13 African countries, 2003-8. Main outcome measures A price index of first line antiretroviral therapy with data on foreign assistance for HIV was used to estimate the associations of prices and foreign assistance with antiretroviral coverage (percentage of people with advanced HIV infection receiving antiretroviral therapy), controlling for national public health spending, HIV prevalence, governance, and fixed effects for countries and years. Results Between 2003 and 2008 the annual price of first line antiretroviral therapy decreased from $1177 (733; pound (sic)844) to $96 and foreign assistance for HIV per capita increased from $0.4 to $13.8. At an annual price of $100, a $10 decrease was associated with a 0.16% adjusted increase in coverage (95% confidence interval 0.11% to 0.20%; 0.19% unadjusted, 0.14% to 0.24%). Each additional $1 per capita in foreign assistance for HIV was associated with a 1.0% adjusted increase in coverage (0.7% to 1.2%; 1.4% unadjusted, 1.1% to 1.6%). If the annual price of antiretroviral therapy stayed at $100, foreign assistance would need to quadruple to $64 per capita to be associated with universal coverage. Government effectiveness and national public health expenditures were also positively associated with increasing coverage. Conclusions Reductions in price of antiretroviral drugs were important in broadening coverage of HIV treatment in Africa from 2003 to 2008, but their future role may be limited. Foreign assistance and national public health expenditures for HIV seem more important in expanding future coverage.	[Bendavid, Eran] Stanford Univ, Div Gen Internal Med, Stanford, CA 94305 USA; [Bendavid, Eran; Bhattacharya, Jay; Smith, Nicole; Miller, Grant] Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA; [Bendavid, Eran; Bhattacharya, Jay; Smith, Nicole; Miller, Grant] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; [Leroux, Eric] Stanford Med Sch, Stanford, CA USA; [Bhattacharya, Jay; Miller, Grant] Natl Bur Econ Res, Stanford, CA USA	Stanford University; Stanford University; Stanford University; Stanford University; National Bureau of Economic Research	Bendavid, E (corresponding author), Stanford Univ, Div Gen Internal Med, Stanford, CA 94305 USA.	ebd@stanford.edu		Miller, Grant/0000-0003-3191-2558	National Institute of Allergy and Infectious Diseases [K01-AI084582]; National Institute of Child Health and Development; National Institute of Aging; Center on the Demography and Economics of Health and Aging [P30-AG17253]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K01AI084582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG017253] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Child Health and Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Center on the Demography and Economics of Health and Aging; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	EB is supported by the National Institute of Allergy and Infectious Diseases (K01-AI084582). GM and JB receive support from the National Institute of Child Health and Development. All three receive support from the National Institute of Aging and the Center on the Demography and Economics of Health and Aging (P30-AG17253).	*AVERT, 2009, PEPFAR FUND IS MON S; *AVERT, 2009, DOES AIDS FUND COME; Baleta A, 2000, LANCET, V355, P1799, DOI 10.1016/S0140-6736(05)73071-3; Bender MA, 2010, CLIN INFECT DIS, V50, P416, DOI 10.1086/649884; *BUR EC AN, 2008, IMPL PRIC DEFL GROSS; El-Sadr WM, 2008, NEW ENGL J MED, V359, P553, DOI 10.1056/NEJMp0803762; Ghys PD, 2008, SEX TRANSM INFECT, V84, pI1, DOI 10.1136/sti.2008.032573; GLOBAL FUND, 2010, PLEDG CONTR; Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Kumarasamy N, 2004, LANCET, V364, P3, DOI 10.1016/S0140-6736(04)16605-1; LUCCHINI S, 2003, EC AIDS ACCESS HIV C; MCNEIL DG, 2010, NY TIMES        0509; Medecins Sans Frontieres, 2010, UNT WEB ANT PRIC RED; *OECD, 2010, STAT DAT CRED REP SY; *PEPFAR, 2009, FISC YEAR 2009 PEPFA; Stock J.H., 2015, INTRO ECONOMETRICS, V3rd ed.; Stover J, 2006, SEX TRANSM INFECT, V82, pIII45, DOI 10.1136/sti.2006.020172; *UNAIDS, 2007, UN ACC SCAL PRIOR HI; UNAIDS, 2008, REP GLOB AIDS EP; UNAIDS, 2007, FIN RES REQ ACH UN A; *UNAIDS, 2009, REP GLOB AIDS EP EP; *UNAIDS KAIS FAM F, 2009, FIN RESP AIDS LOW MI; *UNAIDS WHO, 2008, UN ACC SCAL PRIOR HI; *UNAIDS WHO, 2009, UN ACC SCAL PRIOR HI; Walensky RP, 2009, ANN INTERN MED, V151, P157, DOI 10.7326/0003-4819-151-3-200908040-00138; Walker N, 2004, LANCET, V363, P2180, DOI 10.1016/S0140-6736(04)16511-2; *WHO, 2009, 3 BY 5 IN; *WORLD BANK, 2010, APPR HIV AIDS PROJ F; *WORLD BANK, 2010, GOV MATT WORLDW GOV; World Health Organization, 2009, GLOB PRIC REP MECH; World Health Organization, 2003, SCAL ANT THER RES LT; World Health Organization, 2009, RAP ADV ANT THER HIV; World Health Organization, 2006, ANT THER HIV INF AD; World Health Organization (WHO), 2010, MOR 5 MILL PEOPL REC; 2009, EPIDEMIOLOGICAL FACT	36	8	8	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 18	2010	341								c6218	10.1136/bmj.c6218	http://dx.doi.org/10.1136/bmj.c6218			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684WS	21088074	Green Published, hybrid			2022-12-28	WOS:000284586600002
J	Gaster, B; Edwards, K; Trinidad, SB; Gallagher, TH; Braddock, CH				Gaster, Barak; Edwards, Kelly; Trinidad, Susan Brown; Gallagher, Thomas H.; Braddock, Clarence H., III			Patient-Centered Discussions About Prostate Cancer Screening: A Real-World Approach	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							INFORMED DECISION-MAKING; AFRICAN-AMERICAN; PRIMARY-CARE; HEALTH-CARE; MEDICAL-DECISIONS; BREAST-CANCER; TIME; MEN; INTERVENTION; PREFERENCES	National guidelines recommend that primary care providers discuss the risks and benefits of prostate cancer screening with their patients but give little guidance on how to fit such a complex discussion into a busy clinic encounter. The authors propose a process-oriented approach (Ask-Tell-Ask) that promotes tailored conversations and value-based recommendations. The Ask-Tell-Ask approach includes diagnosing a patient's informational needs, providing targeted education based on those needs, and making a shared decision about testing. This time-efficient model emphasizes the provider's role as an interactive guide rather than a one-way supplier of information. Although there is no way to make these discussions simple, this streamlined strategy can help patients and providers efficiently negotiate the complex and important decision of screening for prostate cancer.	[Gaster, Barak] Univ Washington, Sch Med, Seattle, WA 98105 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	University of Washington; University of Washington Seattle; Stanford University	Gaster, B (corresponding author), Univ Washington, Sch Med, 4245 Roosevelt Way NE, Seattle, WA 98105 USA.	barakg@uw.edu		Trinidad, Susan Brown/0000-0002-5956-6557	CDC; National Cancer Institute through the Cancer Prevention and Control Research Network [1-U48-DP-000050]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U48DP000050] Funding Source: NIH RePORTER	CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Cancer Institute through the Cancer Prevention and Control Research Network; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	In part by the CDC and the National Cancer Institute through the Cancer Prevention and Control Research Network, a network within the CDC's Prevention Research Centers Program (grant 1-U48-DP-000050).	Allen JD, 2009, AM J MENS HEALTH, V3, P340, DOI 10.1177/1557988308325460; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Arora NK, 2000, MED CARE, V38, P335, DOI 10.1097/00005650-200003000-00010; Back AL, 2005, CA-CANCER J CLIN, V55, P164, DOI 10.3322/canjclin.55.3.164; Bao YH, 2007, HEALTH SERV RES, V42, P950, DOI 10.1111/j.1475-6773.2006.00638.x; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Braddock C, 2008, J BONE JOINT SURG AM, V90A, P1830, DOI 10.2106/JBJS.G.00840; Briss P, 2004, AM J PREV MED, V26, P67, DOI 10.1016/j.amepre.2003.09.012; BRODY H, 1989, HASTINGS CENT REP, V19, P5, DOI 10.2307/3562634; Chan ECY, 2003, J COMMUN HEALTH, V28, P393, DOI 10.1023/A:1026072022853; Chan ECY, 2003, J GEN INTERN MED, V18, P350, DOI 10.1046/j.1525-1497.2003.20626.x; Cole SA, 1997, AM J MANAG C, V3, P649; Davison BJ, 2004, BJU INT, V93, P47, DOI 10.1111/j.1464-410X.2004.04553.x; Drake BF, 2010, J NATL MED ASSOC, V102, P164, DOI 10.1016/S0027-9684(15)30521-6; Dunn AS, 2001, AM J PREV MED, V20, P130, DOI 10.1016/S0749-3797(00)00288-9; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; Epstein RM, 2009, JAMA-J AM MED ASSOC, V302, P195, DOI 10.1001/jama.2009.984; Frosch DL, 2008, ARCH INTERN MED, V168, P363, DOI 10.1001/archinternmed.2007.111; Greene GW, 1999, J AM DIET ASSOC, V99, P673, DOI 10.1016/S0002-8223(99)00164-9; Guerra CE, 2007, J GEN INTERN MED, V22, P901, DOI 10.1007/s11606-007-0142-3; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hoffman RM, 2007, J GEN INTERN MED, V22, P1056, DOI 10.1007/s11606-007-0167-7; Hoffman RM, 2009, ARCH INTERN MED, V169, P1611, DOI 10.1001/archinternmed.2009.262; JAEN CR, 1994, J FAM PRACTICE, V38, P166; Kemp EC, 2008, J AM BOARD FAM MED, V21, P24, DOI 10.3122/jabfm.2008.01.070093; Kilbridge KL, 2009, J CLIN ONCOL, V27, P2015, DOI 10.1200/JCO.2008.17.3468; Kripalani S, 2007, AM J PREV MED, V33, P83, DOI 10.1016/j.amepre.2007.03.018; Krist AH, 2007, ANN FAM MED, V5, P112, DOI 10.1370/afm.623; Lim LS, 2008, AM J PREV MED, V34, P164, DOI 10.1016/j.amepre.2007.10.003; Linder SK, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-19; Linzer M, 2000, J GEN INTERN MED, V15, P441, DOI 10.1046/j.1525-1497.2000.05239.x; LUQUE JS, 2010, AM J MENS HLTH, P27953; Lyman GH, 2010, CANCER INVEST, V28, P1, DOI 10.3109/07357900903517001; McFall SL, 2009, HEALTH EDUC RES, V24, P280, DOI 10.1093/her/cyn018; Murphy AM, 2010, JAMA-J AM MED ASSOC, V303, P166, DOI 10.1001/jama.2009.1991; Myers R E, 2000, Semin Urol Oncol, V18, P172; Myers RE, 2005, J NATL MED ASSOC, V97, P1143; NEASE RF, 1995, J GEN INTERN MED, V10, P593, DOI 10.1007/BF02602742; Roobol MJ, 2009, EUR UROL, V56, P584, DOI 10.1016/j.eururo.2009.07.018; Ross L, 2010, J NATL MED ASSOC, V102, P228, DOI 10.1016/S0027-9684(15)30529-0; Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084; Sheridan SL, 2004, AM J PREV MED, V26, P56, DOI 10.1016/j.amepre.2003.09.011; Steginga SK, 2005, BJU INT, V96, P1209, DOI 10.1111/j.1464-410X.2005.05782.x; Talcott JA, 2003, UROLOGY, V61, P7, DOI 10.1016/S0090-4295(02)02148-9; US Preventive Serv Task Force, 2008, ANN INTERN MED, V149, P185, DOI 10.7326/0003-4819-149-3-200808050-00008; Vig EK, 2007, J GEN INTERN MED, V22, P1274, DOI 10.1007/s11606-007-0252-y; Volk RJ, 2007, AM J PREV MED, V33, P428, DOI 10.1016/j.amepre.2007.07.030; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066; Woolf SH, 2005, ANN INTERN MED, V143, P293, DOI 10.7326/0003-4819-143-4-200508160-00010; Woolf SH, 2005, AM FAM PHYSICIAN, V71, P1871; Woolf SH, 2005, PATIENT EDUC COUNS, V56, P116, DOI 10.1016/j.pec.2003.12.002; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	52	13	13	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					661	665		10.7326/0003-4819-153-10-201011160-00010	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680ES	21079223	Green Accepted			2022-12-28	WOS:000284215800020
J	Khan, K				Khan, Karim			Is open peer review the fairest system? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Khan, Karim] British J Sports Med, London, England		Khan, K (corresponding author), British J Sports Med, London, England.	karim.khan@familymed.ubc.ca						Benos DJ, 2007, ADV PHYSIOL EDUC, V31, P145, DOI 10.1152/advan.00104.2006; Ceci S J, 1982, Change, V14, P44; Cialdini RB, 2001, HARVARD BUS REV, V79, P72; van Rooyen S, 1999, BRIT MED J, V318, P23	4	31	34	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2010	341								c6425	10.1136/bmj.c6425	http://dx.doi.org/10.1136/bmj.c6425			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684WJ	21081603				2022-12-28	WOS:000284585600021
J	Cyster, JG				Cyster, Jason G.			Shining a Light on Germinal Center B Cells	CELL			English	Editorial Material							REVEALS		[Cyster, Jason G.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; [Cyster, Jason G.] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Cyster, JG (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	jason.cyster@ucsf.edu						Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736; Basso K, 2004, BLOOD, V104, P4088, DOI 10.1182/blood-2003-12-4291; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Depoil D, 2005, IMMUNITY, V22, P185, DOI 10.1016/j.immuni.2004.12.010; Hauser AE, 2007, IMMUNITY, V26, P655, DOI 10.1016/j.immuni.2007.04.008; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032	9	11	11	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 12	2010	143	4					503	505		10.1016/j.cell.2010.10.036	http://dx.doi.org/10.1016/j.cell.2010.10.036			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074042	Bronze			2022-12-28	WOS:000284149100008
J	Harel-Sharvit, L; Eldad, N; Haimovich, G; Barkai, O; Duek, L; Choder, M				Harel-Sharvit, Liat; Eldad, Naama; Haimovich, Gal; Barkai, Oren; Duek, Lea; Choder, Mordechai			RNA Polymerase II Subunits Link Transcription and mRNA Decay to Translation	CELL			English	Article							P-BODIES; SACCHAROMYCES-CEREVISIAE; DEPENDENT TRANSLATION; INITIATION-FACTORS; YEAST; PROTEIN; RPB4; COMPLEX; MUTATIONS; BINDING	Little is known about crosstalk between the eukaryotic transcription and translation machineries that operate in different cell compartments. The yeast proteins Rpb4p and Rpb7p represent one such link as they form a heterodimer that shuttles between the nucleus, where it functions in transcription, and the cytoplasm, where it functions in the major mRNA decay pathways. Here we show that the Rpb4/7 heterodimer interacts physically and functionally with components of the translation initiation factor 3 (eIF3), and is required for efficient translation initiation. Efficient translation in the cytoplasm depends on association of Rpb4/7 with RNA polymerase II (Pol II) in the nucleus, leading to a model in which Pol II remotely controls translation. Hence, like in prokaryotes, the eukaryotic translation is coupled to transcription. We propose that Rpb4/7, through its interactions at each step in the mRNA life-cycle, represents a class of factors, "mRNA coordinators," which integrate the various stages of gene expression into a system.	[Harel-Sharvit, Liat; Eldad, Naama; Haimovich, Gal; Barkai, Oren; Duek, Lea; Choder, Mordechai] Technion Israel Inst Technol, Rappaport Fac Med, Dept Mol Microbiol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Choder, M (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Dept Mol Microbiol, IL-31096 Haifa, Israel.	choder@technion.ac.il	Haimovich, Gal/H-3316-2019	Haimovich, Gal/0000-0002-3360-5108	Israel Science Foundation; Rappaport Foundation; Paamei Tikva	Israel Science Foundation(Israel Science Foundation); Rappaport Foundation; Paamei Tikva	We thank Nancy Woychik for the rpb6<SUP>Q100R</SUP> strain, David Jansma for the rpb1<SUP>C67S;</SUP> <SUP>C70S</SUP> strain, Allan Hinnebusch for anti-Nip1p and for GST fusion constructs, Tien-Hsien Chang for the DHH1-GFP plasmid and Parag Sadhale for anti-Rpb7p Abs. The help of Almog Bregman is highly appreciated. We thank Elite Levin for statistical analyses. We thank Allan Hinnebusch and Leos Valasec for critically reading the manuscript and for their advice. This work was supported by the Israel Science Foundation, by Rappaport Foundation and by Paamei Tikva.	Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Balagopal V, 2009, CURR OPIN CELL BIOL, V21, P403, DOI 10.1016/j.ceb.2009.03.005; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Brengues M, 2007, MOL BIOL CELL, V18, P2592, DOI 10.1091/mbc.E06-12-1149; Brodsky AS, 2000, RNA, V6, P1737, DOI 10.1017/S1355838200001059; Buchan JR, 2008, J CELL BIOL, V183, P441, DOI 10.1083/jcb.200807043; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; CHODER M, 1993, J BACTERIOL, V175, P6358, DOI 10.1128/JB.175.19.6358-6363.1993; Choder M, 2004, TRENDS BIOCHEM SCI, V29, P674, DOI 10.1016/j.tibs.2004.10.007; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Chowdhury A, 2007, RNA, V13, P998, DOI 10.1261/rna.502507; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Daulny A, 2008, P NATL ACAD SCI USA, V105, P19649, DOI 10.1073/pnas.0809372105; Decker CJ, 2007, J CELL BIOL, V179, P437, DOI 10.1083/jcb.200704147; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; Donaldson IM, 2000, J BIOL CHEM, V275, P13780, DOI 10.1074/jbc.275.18.13780; Eldad N, 2008, NUCLEIC ACIDS RES, V36, P6728, DOI 10.1093/nar/gkn754; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Farago M, 2003, MOL BIOL CELL, V14, P2744, DOI 10.1091/mbc.E02-11-0740; FUGE EK, 1994, J BACTERIOL, V176, P5802, DOI 10.1128/JB.176.18.5802-5813.1994; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goler-Baron V, 2008, GENE DEV, V22, P2022, DOI 10.1101/gad.473608; Gross T, 2007, SCIENCE, V315, P646, DOI 10.1126/science.1134641; Hinnebusch AG, 2006, TRENDS BIOCHEM SCI, V31, P553, DOI 10.1016/j.tibs.2006.08.005; Hu WQ, 2009, NATURE, V461, P225, DOI 10.1038/nature08265; Kamenski T, 2004, MOL CELL, V15, P399, DOI 10.1016/j.molcel.2004.06.035; LaGrandeur T, 1999, RNA, V5, P420, DOI 10.1017/S1355838299981748; Lotan R, 2005, GENE DEV, V19, P3004, DOI 10.1101/gad.353205; Lotan R, 2007, J CELL BIOL, V178, P1133, DOI 10.1083/jcb.200701165; Malagon F, 2006, GENETICS, V172, P2201, DOI 10.1534/genetics.105.052415; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; Muhlrad D, 1999, MOL BIOL CELL, V10, P3971, DOI 10.1091/mbc.10.11.3971; Parker R, 2007, MOL CELL, V25, P635, DOI 10.1016/j.molcel.2007.02.011; Paz I, 2001, J BACTERIOL, V183, P4477, DOI 10.1128/JB.183.15.4477-4483.2001; Pestova TV, 2007, TRANSLATIONAL CONTRO, V4, P87; Pillai B, 2003, J BIOL CHEM, V278, P3339, DOI 10.1074/jbc.M112180200; Ptushkina M, 1998, EMBO J, V17, P4798, DOI 10.1093/emboj/17.16.4798; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Rosenheck S, 1998, J BACTERIOL, V180, P6187; Ruiz-Echevarria MJ, 1998, P NATL ACAD SCI USA, V95, P8721, DOI 10.1073/pnas.95.15.8721; Runner VM, 2008, MOL CELL BIOL, V28, P1883, DOI 10.1128/MCB.01714-07; Schwartz DC, 2000, MOL CELL BIOL, V20, P7933, DOI 10.1128/MCB.20.21.7933-7942.2000; Schwartz DC, 1999, MOL CELL BIOL, V19, P5247; Selitrennik M, 2006, EUKARYOT CELL, V5, P2092, DOI 10.1128/EC.00288-06; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Singh SR, 2007, BIOCHEM BIOPH RES CO, V356, P266, DOI 10.1016/j.bbrc.2007.02.120; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Tan Q, 2003, MOL CELL BIOL, V23, P3329, DOI 10.1128/MCB.23.9.3329-3338.2003; Teixeira D, 2005, RNA, V11, P371, DOI 10.1261/rna.7258505; Ujvari A, 2006, NAT STRUCT MOL BIOL, V13, P49, DOI 10.1038/nsmb1026; Valasek L, 2007, METHOD ENZYMOL, V429, P163, DOI 10.1016/S0076-6879(07)29008-1; Verma-Gaur J, 2008, EUKARYOT CELL, V7, P1009, DOI 10.1128/EC.00057-08; Wyers F, 2000, MOL CELL BIOL, V20, P3538, DOI 10.1128/MCB.20.10.3538-3549.2000	59	140	142	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					552	563		10.1016/j.cell.2010.10.033	http://dx.doi.org/10.1016/j.cell.2010.10.033			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074047	Bronze			2022-12-28	WOS:000284149100013
J	Marchetto, MCN; Carromeu, C; Acab, A; Yu, D; Yeo, GW; Mu, YL; Chen, G; Gage, FH; Muotri, AR				Marchetto, Maria C. N.; Carromeu, Cassiano; Acab, Allan; Yu, Diana; Yeo, Gene W.; Mu, Yangling; Chen, Gong; Gage, Fred H.; Muotri, Alysson R.			A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells	CELL			English	Article							AUTISM-SPECTRUM; MOUSE MODEL; MECP2; BRAIN; DISEASE; MUTATIONS; PHENOTYPE; SYMPTOMS; GENE; PHOSPHORYLATION	Autism spectrum disorders (ASD) are complex neurodevelopmental diseases in which different combinations of genetic mutations may contribute to the phenotype. Using Rett syndrome (RTT) as an ASD genetic model, we developed a culture system using induced pluripotent stem cells (iPSCs) from RTT patients' fibroblasts. RTT patients' iPSCs are able to undergo X-inactivation and generate functional neurons. Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls. Our data uncovered early alterations in developing human RTT neurons. Finally, we used RTT neurons to test the effects of drugs in rescuing synaptic defects. Our data provide evidence of an unexplored developmental window, before disease onset, in RTT syndrome where potential therapies could be successfully employed. Our model recapitulates early stages of a human neurodevelopmental disease and represents a promising cellular tool for drug screening, diagnosis and personalized treatment.	[Carromeu, Cassiano; Acab, Allan; Muotri, Alysson R.] Univ Calif San Diego, Sch Med, Rady Childrens Hosp San Diego,Stem Cell Program, Dept Pediat,Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Marchetto, Maria C. N.; Yu, Diana; Mu, Yangling; Gage, Fred H.] Salk Inst Biol Studies, La Jolla, CA 92037 USA; [Yeo, Gene W.] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, Stem Cell Program, La Jolla, CA 92093 USA; [Chen, Gong] Penn State Univ, Dept Biol, University Pk, PA 16802 USA	Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Salk Institute; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Muotri, AR (corresponding author), Univ Calif San Diego, Sch Med, Rady Childrens Hosp San Diego,Stem Cell Program, Dept Pediat,Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	muotri@ucsd.edu	Carromeu, Cassiano/B-1487-2014; Yeo, Gene/AAE-7676-2019	Yeo, Gene/0000-0002-0799-6037; Carromeu, Cassiano/0000-0002-7570-2213; Chen JNU, Gong/0000-0002-1857-3670	Emerald Foundation; National Institutes of Health [1-DP2-OD006495-01]; California Institute for Regenerative Medicine [RL1-00649-1, RC1-00115-1]; Lookout Fund; Mathers Foundation; Glenn Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008666] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD006495] Funding Source: NIH RePORTER	Emerald Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Lookout Fund; Mathers Foundation; Glenn Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The work was supported by the Emerald Foundation and by the National Institutes of Health through the NIH Director's New Innovator Award Program, 1-DP2-OD006495-01. F.H.G. is supported by California Institute for Regenerative Medicine RL1-00649-1 and RC1-00115-1, The Lookout Fund and the Mathers Foundation. C.C. is a fellow from the International Rett Syndrome Foundation. M.C.N.M. is a Christopher and Danna Reeve Foundation fellow. G.C. was supported by the Glenn Foundation. We would like to thank Monica Coenraads for critical discussion; the Greenwood Genetic Center clinical diagnostic laboratory for X-inactivation analysis; Dr. Jeannie T. Lee for the Xist probe; and M.L. Gage for editorial comments.	ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ballas N, 2009, NAT NEUROSCI, V12, P311, DOI 10.1038/nn.2275; Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Chapleau CA, 2009, NEUROBIOL DIS, V35, P219, DOI 10.1016/j.nbd.2009.05.001; Charman T, 2002, BRAIN DEV-JPN, V24, P281, DOI 10.1016/S0387-7604(02)00058-X; Collins AL, 2004, HUM MOL GENET, V13, P2679, DOI 10.1093/hmg/ddh282; Courchesne E, 2003, JAMA-J AM MED ASSOC, V290, P337, DOI 10.1001/jama.290.3.337; De Filippis B, 2010, GENES BRAIN BEHAV, V9, P213, DOI 10.1111/j.1601-183X.2009.00551.x; Dhara SK, 2004, NUCLEIC ACIDS RES, V32, P3995, DOI 10.1093/nar/gkh746; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677; Giacometti E, 2007, P NATL ACAD SCI USA, V104, P1931, DOI 10.1073/pnas.0610593104; Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389; Hagberg G, 2001, BRAIN DEV-JPN, V23, pS227, DOI 10.1016/S0387-7604(01)00375-8; Hammer S, 2002, MENT RETARD DEV D R, V8, P94, DOI 10.1002/mrdd.10023; Hotta A, 2009, NAT METHODS, V6, P370, DOI [10.1038/NMETH.1325, 10.1038/nmeth.1325]; Kellermayer R, 2006, EUR J MED GENET, V49, P445, DOI 10.1016/j.ejmg.2006.04.003; KERR AM, 1987, BRAIN DEV-JPN, V9, P487, DOI 10.1016/S0387-7604(87)80070-0; Kishi N, 2010, EXP NEUROL, V222, P51, DOI 10.1016/j.expneurol.2009.12.007; Laccone F, 2001, HUM MUTAT, V17, P183, DOI 10.1002/humu.3; Lee G, 2009, NATURE, V461, P402, DOI 10.1038/nature08320; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Maezawa I, 2009, J NEUROSCI, V29, P5051, DOI 10.1523/JNEUROSCI.0324-09.2009; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Marchetto MCN, 2010, HUM MOL GENET, V19, pR71, DOI 10.1093/hmg/ddq159; Mironov SL, 2009, J PHYSIOL-LONDON, V587, P2473, DOI 10.1113/jphysiol.2009.169805; Muotri AR, 2009, EPILEPSY BEHAV, V14, P81, DOI 10.1016/j.yebeh.2008.09.021; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nudelman I, 2009, J MED CHEM, V52, P2836, DOI 10.1021/jm801640k; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Picker JD, 2006, NEUROREPORT, V17, P541, DOI 10.1097/01.wnr.0000208995.38695.2f; Piven J, 1997, AM J PSYCHIAT, V154, P185; Ramocki MB, 2009, ANN NEUROL, V66, P771, DOI 10.1002/ana.21715; Rice Catherine, 2007, Morbidity and Mortality Weekly Report, V56, P1; Ronald A, 2006, J AM ACAD CHILD PSY, V45, P691, DOI 10.1097/01.chi.0000215325.13058.9d; Samaco RC, 2004, HUM MOL GENET, V13, P629, DOI 10.1093/hmg/ddh063; Santos M, 2007, GENES BRAIN BEHAV, V6, P277, DOI 10.1111/j.1601-183X.2006.00258.x; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Spitzer NC, 2004, TRENDS NEUROSCI, V27, P415, DOI 10.1016/j.tins.2004.05.003; Splawski I, 2006, J BIOL CHEM, V281, P22085, DOI 10.1074/jbc.M603316200; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Tao JF, 2009, P NATL ACAD SCI USA, V106, P4882, DOI 10.1073/pnas.0811648106; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Traynor Jeff, 2002, BMC Med Genet, V3, P12, DOI 10.1186/1471-2350-3-12; Tropea D, 2009, P NATL ACAD SCI USA, V106, P2029, DOI 10.1073/pnas.0812394106; Van Esch H, 2005, AM J HUM GENET, V77, P442, DOI 10.1086/444549; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zappella M, 2003, AM J MED GENET B, V119B, P102, DOI 10.1002/ajmg.b.10070; Zhou ZL, 2006, NEURON, V52, P255, DOI 10.1016/j.neuron.2006.09.037; Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071	57	938	975	3	180	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					527	539		10.1016/j.cell.2010.10.016	http://dx.doi.org/10.1016/j.cell.2010.10.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074045	Green Accepted, Bronze			2022-12-28	WOS:000284149100011
J	Murphy, R; Vyshedskiy, A				Murphy, Raymond; Vyshedskiy, Andrey			Acoustic Findings in a Patient with Radiation Pneumonitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Murphy, Raymond; Vyshedskiy, Andrey] Faulkner Hosp, Boston, MA USA		Murphy, R (corresponding author), Faulkner Hosp, Boston, MA USA.	rlmurphy@partners.org		Vyshedskiy, Andrey/0000-0002-1610-8716					0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					E31	E31		10.1056/NEJMicm0803655	http://dx.doi.org/10.1056/NEJMicm0803655			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067378				2022-12-28	WOS:000284047600011
J	Sundstrom, A; Alfredsson, L; Sjolin-Forsberg, G; Gerden, B; Bergman, U; Jokinen, J				Sundstrom, Anders; Alfredsson, Lars; Sjolin-Forsberg, Gunilla; Gerden, Barbro; Bergman, Ulf; Jokinen, Jussi			Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							13-CIS-RETINOIC ACID ALTERS; PSYCHOLOGICAL MORBIDITY; VULGARIS PATIENTS; DEPRESSION; ANXIETY; THERAPY; RISK; MICE; ADOLESCENTS; MORPHOLOGY	Objective To assess the risk of attempted suicide before, during, and after treatment with isotretinoin for severe acne. Design Retrospective cohort study linking a named patient register of isotretinoin users (1980-9) to hospital discharge and cause of death registers (1980-2001). Setting Sweden, 1980-2001. Population 5756 patients aged 15 to 49 years prescribed isotretinoin for severe acne observed for 17 197 person years before, 2905 person years during, and 87 120 person years after treatment. Main outcome measures Standardised incidence ratio (observed number divided by expected number of suicide attempts standardised by sex, age, and calendar year), calculated up to three years before, during, and up to 15 years after end of treatment. Results 128 patients were admitted to hospital for attempted suicide. During the year before treatment, the standardised incidence ratio for attempted suicide was raised: 1.57 (95% confidence interval 0.86 to 2.63) for all (including repeat) attempts and 1.36 (0.65 to 2.50) counting only first attempts. The standardised incidence ratio during and up to six months after treatment was 1.78 (1.04 to 2.85) for all attempts and 1.93 (1.08 to 3.18) for first attempts. Three years after treatment stopped, the observed number of attempts was close to the expected number and remained so during the 15 years of follow-up: standardised incidence ratio 1.04 (0.74 to 1.43) for all attempts and 0.97 (0.64 to 1.40) for first attempts. Twelve (38%) of 32 patients who made their first suicide attempt before treatment made a new attempt or committed suicide thereafter. In contrast, 10 (71%) of the 14 who made their first suicide attempt within six months after treatment stopped made a new attempt or committed suicide during follow-up (two sample test of proportions, P=0.034). The number needed to harm was 2300 new six month treatments per year for one additional first suicide attempt to occur and 5000 per year for one additional repeat attempt. Conclusions An increased risk of attempted suicide was apparent up to six months after the end of treatment with isotretinoin, which motivates a close monitoring of patients for suicidal behaviour for up to a year after treatment has ended. However, the risk of attempted suicide was already rising before treatment, so an additional risk due to the isotretinoin treatment cannot be established. As patients with a history of suicide attempts before treatment made new attempts to a lesser extent than did patients who started such behaviour in connection with treatment, patients with severe acne should not automatically have isotretinoin treatment withheld because of a history of attempted suicide.	[Sundstrom, Anders] Karolinska Inst, Karolinska Univ Hosp, Ctr Pharmacoepidemiol, S-17176 Stockholm, Sweden; [Sundstrom, Anders; Sjolin-Forsberg, Gunilla; Gerden, Barbro] Med Prod Agcy, S-75103 Uppsala, Sweden; [Sundstrom, Anders; Bergman, Ulf] Karolinska Inst, Div Clin Pharmacol, S-17176 Stockholm, Sweden; [Alfredsson, Lars] Karolinska Inst, Inst Environm Med, S-17176 Stockholm, Sweden; [Jokinen, Jussi] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Medical Products Agency; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Sundstrom, A (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Ctr Pharmacoepidemiol, S-17176 Stockholm, Sweden.	Anders.Sundstrom@Ki.se	Alfredsson, Lars/AAC-9007-2019	Alfredsson, Lars/0000-0003-1688-6697; Bergman, Ulf/0000-0003-4654-2211	Swedish Research Council [K2009-61P-21304-04-4]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	JJ received funding for this study from the Swedish Research Council (project number K2009-61P-21304-04-4).	Aktan S, 2000, INT J DERMATOL, V39, P354, DOI 10.1046/j.1365-4362.2000.00907.x; Azoulay L, 2008, J CLIN PSYCHIAT, V69, P526, DOI 10.4088/JCP.v69n0403; Bremmer JD, 2008, PROG NEURO-PSYCHOPH, V32, P315, DOI 10.1016/j.pnpbp.2007.07.001; Bremner JD, 2005, AM J PSYCHIAT, V162, P983, DOI 10.1176/appi.ajp.162.5.983; Chia CY, 2005, ARCH DERMATOL, V141, P557, DOI 10.1001/archderm.141.5.557; Citrome L, 1998, POSTGRAD MED, V104, P38, DOI 10.3810/pgm.1998.10.1768; Crandall J, 2004, P NATL ACAD SCI USA, V101, P5111, DOI 10.1073/pnas.0306336101; Ferguson SA, 2007, NEUROTOXICOL TERATOL, V29, P642, DOI 10.1016/j.ntt.2007.09.003; Friedman T, 2006, EUR NEUROPSYCHOPHARM, V16, P413, DOI 10.1016/j.euroneuro.2005.11.006; Gupta MA, 2003, AM J CLIN DERMATOL, V4, P833, DOI 10.2165/00128071-200304120-00003; Hahm BJ, 2009, J DERMATOL, V36, P255, DOI 10.1111/j.1346-8138.2009.00635.x; HAZEN PG, 1983, J AM ACAD DERMATOL, V9, P278; Ishikawa J, 2008, EUR J NEUROSCI, V27, P2363, DOI 10.1111/j.1460-9568.2008.06191.x; Jick SS, 2000, ARCH DERMATOL, V136, P1231, DOI 10.1001/archderm.136.10.1231; Kaymak Y, 2006, PSYCHOL REP, V99, P897, DOI 10.2466/PR0.99.3.897-906; Kaymak Y, 2009, INT J DERMATOL, V48, P41, DOI 10.1111/j.1365-4632.2009.03806.x; Kellett SC, 2005, EUR J DERMATOL, V15, P484; Kolves K, 2010, J AFFECT DISORDERS, V120, P48, DOI 10.1016/j.jad.2009.04.019; Kontaxakis Vassilis P, 2009, Ann Gen Psychiatry, V8, P2, DOI 10.1186/1744-859X-8-2; Liu Y, 2008, J NEUROCHEM, V106, P1104, DOI 10.1111/j.1471-4159.2008.05445.x; Magin PJ, 2008, J EUR ACAD DERMATOL, V22, P1435, DOI 10.1111/j.1468-3083.2008.02890.x; Marcil I, 2001, LANCET, V358, P1042, DOI 10.1016/S0140-6736(01)06179-7; O'Reilly K, 2008, EXP BIOL MED, V233, P251, DOI 10.3181/0706-MR-158; O'Reilly KC, 2007, EXP BIOL MED, V232, P1195, DOI 10.3181/0703-RM-83; O'Reilly KC, 2006, NEUROPSYCHOPHARMACOL, V31, P1919, DOI 10.1038/sj.npp.1300998; O'Reilly KC, 2009, EUR J PHARMACOL, V605, P68, DOI 10.1016/j.ejphar.2008.12.037; Purvis D, 2006, J PAEDIATR CHILD H, V42, P793, DOI 10.1111/j.1440-1754.2006.00979.x; Smithard A, 2001, BRIT J DERMATOL, V145, P274, DOI 10.1046/j.1365-2133.2001.04346.x; Stuckler D, 2010, LANCET, V375, P372, DOI 10.1016/S0140-6736(10)60160-2; Wyder M, 2009, J AFFECT DISORDERS, V116, P208, DOI 10.1016/j.jad.2008.11.007; Wysowski DK, 2005, ARCH DERMATOL, V141, P640, DOI 10.1001/archderm.141.5.640; Yazici K, 2004, J EUR ACAD DERMATOL, V18, P435, DOI 10.1111/j.1468-3083.2004.00946.x	32	93	96	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2010	341								c5812	10.1136/bmj.c5812	http://dx.doi.org/10.1136/bmj.c5812			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KQ	21071484	Green Published, hybrid			2022-12-28	WOS:000284313200001
J	Moonen, B; Cohen, JM; Snow, RW; Slutsker, L; Drakeley, C; Smith, DL; Abeyasinghe, RR; Rodriguez, MH; Maharaj, R; Tanner, M; Targett, G				Moonen, Bruno; Cohen, Justin M.; Snow, Robert W.; Slutsker, Laurence; Drakeley, Chris; Smith, David L.; Abeyasinghe, Rabindra R.; Henry Rodriguez, Mario; Maharaj, Rajendra; Tanner, Marcel; Targett, Geoffrey			Malaria Elimination 3 Operational strategies to achieve and maintain malaria elimination	LANCET			English	Article							PLASMODIUM-VIVAX-MALARIA; FALCIPARUM-MALARIA; PRIMAQUINE THERAPY; TREATMENT-SEEKING; GAMETOCYTE CARRIAGE; ANTIMALARIAL-DRUGS; RISK-FACTORS; TRANSMISSION; SURVEILLANCE; INFECTION	Present elimination strategies are based on recommendations derived during the Global Malaria Eradication Program of the 1960s. However, many countries considering elimination nowadays have high intrinsic transmission potential and, without the support of a regional campaign, have to deal with the constant threat of imported cases of the disease, emphasising the need to revisit the strategies on which contemporary elimination programmes are based. To eliminate malaria, programmes need to concentrate on identification and elimination of foci of infections through both passive and active methods of case detection. This approach needs appropriate treatment of both clinical cases and asymptomatic infections, combined with targeted vector control. Draining of infectious pools entirely will not be sufficient since they could be replenished by imported malaria. Elimination will thus additionally need identification and treatment of incoming infections before they lead to transmission, or, more realistically, embarking on regional initiatives to dry up importation at its source.	[Moonen, Bruno] Clinton Hlth Access Initiat, Nairobi, Kenya; [Moonen, Bruno] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA; [Cohen, Justin M.] Clinton Hlth Access Initiat, Boston, MA USA; [Snow, Robert W.] Kenya Govt Med Res Ctr, Ctr Geog Med, Malaria Publ Hlth & Epidemiol Grp, Nairobi, Kenya; [Snow, Robert W.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; [Slutsker, Laurence] Ctr Dis Control & Prevent, Atlanta, GA USA; [Drakeley, Chris; Targett, Geoffrey] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England; [Smith, David L.] Univ Florida, Dept Biol, Gainesville, FL USA; [Smith, David L.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA; [Abeyasinghe, Rabindra R.] Minist Hlth, Colombo, Sri Lanka; [Henry Rodriguez, Mario] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Maharaj, Rajendra] MRC, Durban, Kwazulu Natal, South Africa; [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Tanner, Marcel] Univ Basel, Basel, Switzerland	University of California System; University of California San Francisco; Kenya Medical Research Institute; University of Oxford; Centers for Disease Control & Prevention - USA; University of London; London School of Hygiene & Tropical Medicine; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Instituto Nacional de Salud Publica; University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Moonen, B (corresponding author), Clinton Hlth Access Initiat, Timau Plaza,3rd Floor,Argwings Kodhek Rd,POB 2011, Nairobi, Kenya.	bmoonen@clintonhealthaccess.org	Smith, David L/L-8850-2013; Snow, Robert William/AFR-1436-2022	Smith, David L/0000-0003-4367-3849; Snow, Robert William/0000-0003-3725-6088; Cohen, Justin/0000-0003-4481-6784	Novartis; Pfizer; Bill & Melinda Gates Foundation; ExxonMobil; Science and Technology Directorate, Department of Homeland Security; Fogarty International Center, National Institutes of Health; Wellcome Trust [079080, 078925]	Novartis(Novartis); Pfizer(Pfizer); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); ExxonMobil(Exxon Mobil Corporation); Science and Technology Directorate, Department of Homeland Security(United States Department of Homeland Security (DHS)); Fogarty International Center, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission)	BM and (MC work within the malaria programme at the Clinton Health Access Initiative, which is supporting malaria elimination in southern Africa in collaboration with Global Health Group of the University of California, San Francisco, CA, USA. RA, MHR, and RM play leading roles in the elimination programmes of Sri Lanka, Mexico, and South Africa, respectively. MT. LS, and MHR are members of the Malaria Eradication Research Agenda project (MalERA) steering committee, of the Bill & Melinda Gates Foundation. MT is a scientific advisor to the Novartis Institute for Tropical Diseases board and is a board member of the UBS Optimus Foundation. BM, RWS, LS, DLS, ERA, MHR, RA, RM, MT, and GT serve as members of the Malaria Elimination Group. RWS has received funding from Novartis for chairing meetings of national control programmes in Africa and has received a research grant from Pfizer. CD declares that he has no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of their employing organisations nor of the sources of funding.; BM and (MC acknowledge support from the Global Health Group of the University of California, San Francisco, CA, USA, which is funded by the Bill & Melinda Gates Foundation and ExxonMobil. DLS, BM, I MC, and GT acknowledge support from the Bill & Melinda Gates Foundation. DLS also acknowledges funding from the RAPIDD program of the Science and Technology Directorate, Department of Homeland Security, and the Fogarty International Center, National Institutes of Health. RWS is a Wellcome Trust Principal Research Fellow (#079080) and acknowledges the support of the Kenyan Medical Research Institute (KEMRI). CD is supported by the Wellcome Trust (#078925). We thank Majed Al-Zjedali, Kee Tai Goh, Allison Tatarsky, and Peter Chiodini for providing updated information used in the table; Chris Cotter and Allison Phillips who assisted in the literature review; Bernard Nahlen, G Dennis Shanks, and the Malaria Elimination Group for extensive comments on the report; and Kevin Baird for insights into P vivax treatment and John Silver for insights into vector behaviour.	Abdalla H, 2008, T ROY SOC TROP MED H, V102, P263, DOI 10.1016/j.trstmh.2007.10.008; Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; AITKEN T, 1961, REPLACEMENT PHENOMEN; Alves FP, 2005, J MED ENTOMOL, V42, P777, DOI 10.1603/0022-2585(2005)042[0777:ACOPSA]2.0.CO;2; [Anonymous], 2010, SCIENCE, V328, P843, DOI 10.1126/science.328.5980.843; [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000363.PUB2; [Anonymous], 2009, WORLD MAL REP 2009; [Anonymous], 1969, TXB MALARIA ERADICAT; [Anonymous], GLOB MAL ACT PLAN; Baird JK, 2009, CLIN MICROBIOL REV, V22, P508, DOI 10.1128/CMR.00008-09; Baird JK, 2003, TRENDS PARASITOL, V19, P115, DOI 10.1016/S1471-4922(03)00005-9; Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; Beier JC, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S4; Beutler E, 2007, AM J TROP MED HYG, V77, P779, DOI 10.4269/ajtmh.2007.77.779; Bousema T, 2010, EMERG INFECT DIS, V16, P392, DOI 10.3201/eid1603.090732; Branch O, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-27; Breman JG, 2007, AM J TROP MED HYG, V77, P36; Brooker S, 2004, TROP MED INT HEALTH, V9, P757, DOI 10.1111/j.1365-3156.2004.01272.x; BRUCECHWATT LJ, 1975, J TROP MED HYG, V78, P194; BRUCECHWATT LJ, 1973, LANCET, V2, P547; BUNNAG D, 1994, T ROY SOC TROP MED H, V88, P218, DOI 10.1016/0035-9203(94)90305-0; CHOMCHARN Y, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P408; Cohen JM, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-213; Coleman RE, 2002, AM J TROP MED HYG, V66, P379, DOI 10.4269/ajtmh.2002.66.379; Coleman RE, 2002, AM J TROP MED HYG, V67, P141, DOI 10.4269/ajtmh.2002.67.141; Collins WE, 1999, AM J TROP MED HYG, V61, P44, DOI 10.4269/tropmed.1999.61-044; Cook J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-169; Corran P, 2007, TRENDS PARASITOL, V23, P575, DOI 10.1016/j.pt.2007.08.023; Cropley L, 2004, HEALTH PROMOT INT, V19, P445, DOI 10.1093/heapro/dah406; DeSavigny D, 2009, SYSTEMS THINKING FOR HEALTH SYSTEMS STRENGTHENING, P1; ELHASSAN IM, 1995, AM J TROP MED HYG, V53, P78, DOI 10.4269/ajtmh.1995.53.78; ELKHYARI T, 1999, MALARIA ELIMINATION; ELLIOTT R, 1972, MED HYG, V21, P755; Elmes NJ, 2008, T ROY SOC TROP MED H, V102, P1095, DOI 10.1016/j.trstmh.2008.04.024; FAIRD MA, 1998, WORLD HEALTH FORUM, V19, P417; Faraj C, 2009, ACTA TROP, V109, P70, DOI 10.1016/j.actatropica.2008.09.021; Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6; Galappaththy GNL, 2007, COCHRANE DB SYST REV, V7.; GARFIELD RM, 1983, LANCET, V2, P500; Gaudart J, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-286; GILLIES M. T., 1960, BULL ENT RES, V51, P243, DOI 10.1017/S0007485300057953; GOVELLA NJ, 2010, MED HYG, V82, P415; Hernandez-Avila JE, 2006, SALUD PUBLICA MEXICO, V48, P405, DOI 10.1590/S0036-36342006000500007; HSIANG M, J CLIN MICR IN PRESS; Hui FM, 2009, AM J TROP MED HYG, V81, P503; JEFFERY GM, 1976, AM J TROP MED HYG, V25, P361, DOI 10.4269/ajtmh.1976.25.361; Johansson EW, 2010, MALARIA FUNDING RESO; KAISER RL, 1966, HEALTH, V56, P90; Kaneko A, 2000, LANCET, V356, P1560, DOI 10.1016/S0140-6736(00)03127-5; Kaneko A, 2010, ACTA TROP, V114, P177, DOI 10.1016/j.actatropica.2010.01.012; Kelly-Hope L, 2008, LANCET INFECT DIS, V8, P387, DOI 10.1016/S1473-3099(08)70045-8; Krudsood S, 2008, AM J TROP MED HYG, V78, P736, DOI 10.4269/ajtmh.2008.78.736; Kuwahata M, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-223; Lawpoolsri S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-159; Lee Y, 2009, ANN ACAD MED SINGAP, V38, P840; Li Zizhao, 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P240; Litsios S., 2000, Parassitologia (Rome), V42, P167; Macauley C, 2005, SOC SCI MED, V60, P563, DOI 10.1016/j.socscimed.2004.05.025; Maharaj R, 2005, SAMJ S AFR MED J, V95, P871; Mali Sonja, 2010, Morbidity and Mortality Weekly Report, V59, P1; McCombie SC, 1996, SOC SCI MED, V43, P933, DOI 10.1016/0277-9536(95)00446-7; Moonen B., 2009, SHRINKING MALARIA MA; Ndao M, 2004, J CLIN MICROBIOL, V42, P2694, DOI 10.1128/JCM.42.6.2694-2700.2004; Osorio L, 2007, TROP MED INT HEALTH, V12, P331, DOI 10.1111/j.1365-3156.2006.01791.x; Paris DH, 2007, AM J TROP MED HYG, V77, P972, DOI 10.4269/ajtmh.2007.77.972; Phillips EJ, 1996, CLIN INFECT DIS, V23, P1171, DOI 10.1093/clinids/23.5.1171; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; PUKRITTAYAKAMEE S, 1994, J INFECT DIS, V169, P932, DOI 10.1093/infdis/169.4.932; Pukrittayakamee S, 2008, AM J TROP MED HYG, V79, P378, DOI 10.4269/ajtmh.2008.79.378; Pukrittayakamee S, 2010, AM J TROP MED HYG, V82, P542, DOI 10.4269/ajtmh.2010.09-0428; PULL JH, 1972, MED HYG, V21, P651; Shanks GD, 2001, CLIN INFECT DIS, V33, P1968, DOI 10.1086/324081; SHEKALAGHE S, 2007, PLOS CLIN TRIALS, V2, pNIL1, DOI DOI 10.1371/journal.pone.0001023; Shekalaghe SA, 2010, ANTIMICROB AGENTS CH, V54, P1762, DOI 10.1128/AAC.01135-09; Smith DL, 2009, TRENDS PARASITOL, V25, P511, DOI 10.1016/j.pt.2009.08.002; Smith DL, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-87; Smith DL, 2005, NATURE, V438, P492, DOI 10.1038/nature04024; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Song JP, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-57; Stewart L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006083; Sutherland CJ, 2005, PLOS MED, V2, P338, DOI 10.1371/journal.pmed.0020092; Tanner M, 1998, SOC SCI MED, V46, P523, DOI 10.1016/S0277-9536(97)00195-0; Tatem AJ, 2010, LANCET, V376, P1579, DOI 10.1016/S0140-6736(10)61301-3; Tatem AJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-287; Taylor SM, 2010, J CLIN MICROBIOL, V48, P512, DOI 10.1128/JCM.01800-09; Teutsch S.M., 2000, PRINCIPLES PRACTICE; Vale N, 2009, EUR J MED CHEM, V44, P937, DOI 10.1016/j.ejmech.2008.08.011; von Seidlein L, 2003, TRENDS PARASITOL, V19, P452, DOI 10.1016/j.pt.2003.08.003; von Seidlein L, 2001, AM J TROP MED HYG, V65, P523, DOI 10.4269/ajtmh.2001.65.523; Wells TNC, 2010, TRENDS PARASITOL, V26, P145, DOI 10.1016/j.pt.2009.12.005; White NJ, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-9; *WHO, 1964, 10 WHO EXP COMM MAL; WHO, 1956, WHO MAL ER; *WHO, 1962, 9 WHO EXP COMM MAL; *WHO, 1954, 5 WHO EXP COMM MAL; *WHO, 1974, WHO INT C GEN WHO; WHO, 2010, GUID TREATM MAL, V2nd; *WHO, 1957, 6 WHO EXP COMM MAL; *WHO, 1961, 8 WHO EXP COMM MAL; *WHO, 1959, 7 WHO EXP COMM MAL; WHO/EMRO, 2007, GUID PREV REINTR MAL; WHO/WPRO, 2004, INT WORKSH CONTR VIV; World Health Organization, 2007, MAL EL FIELD MAN LOW; YEKUTIEL P, 1960, Bull World Health Organ, V22, P669; YEKUTIEL P, 1965, MILBANK FUND Q, V43, P375, DOI 10.2307/3348907; Yeshiwondim AK, 2010, ACTA TROP, V113, P105, DOI 10.1016/j.actatropica.2009.10.001; Yip K., 2000, Parassitologia (Rome), V42, P117; *ZANZ MAL CONTR PR, 2009, ZANZ MAL EARL EP DET; Zanzibar Malaria Control Program, 2009, MAL EL ZANZ FEAS ASS	109	264	268	0	49	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1592	1603		10.1016/S0140-6736(10)61269-X	http://dx.doi.org/10.1016/S0140-6736(10)61269-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21035841	Green Published, Green Accepted			2022-12-28	WOS:000284248700036
J	Grad, YH; Seifter, JL; Levy, BD; Loscalzo, J				Grad, Yonatan H.; Seifter, Julian L.; Levy, Bruce D.; Loscalzo, Joseph			Bitter Pills	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE INTERSTITIAL NEPHRITIS; EOSINOPHILURIA	A 60-year-old man presented to an urgent care clinic with fatigue of 1 month's duration and increasing frequency of urination, nighttime urination, and increasing thirst over the previous week. He had earlier been told that he had prediabetes and was now concerned that his symptoms reflected progression to diabetes mellitus. He was otherwise in his usual state of health. He reported no dysuria, urgency, incomplete bladder emptying, straining to initiate urination, fevers, chills, arthralgias, or rash.	[Levy, Bruce D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Levy, BD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	blevy@partners.org	Loscalzo, Joseph/ABD-8980-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007061] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baker RJ, 2004, NEPHROL DIAL TRANSPL, V19, P8, DOI 10.1093/ndt/gfg464; Brewster UC, 2007, CLIN NEPHROL, V68, P65; Clarkson MR, 2004, NEPHROL DIAL TRANSPL, V19, P2778, DOI 10.1093/ndt/gfh485; Fisher AA, 2001, DRUG SAFETY, V24, P39, DOI 10.2165/00002018-200124010-00004; Fletcher A, 2008, NEW ENGL J MED, V358, P1760, DOI 10.1056/NEJMc0708475; Gonzalez E, 2008, KIDNEY INT, V73, P940, DOI 10.1038/sj.ki.5002776; Michel DM, 1998, J AM SOC NEPHROL, V9, P506; Nielsen GL, 2001, AM J MED, V111, P541, DOI 10.1016/S0002-9343(01)00941-X; NOLAN CR, 1986, NEW ENGL J MED, V315, P1516, DOI 10.1056/NEJM198612113152404	9	0	0	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1847	1851		10.1056/NEJMcps0904937	http://dx.doi.org/10.1056/NEJMcps0904937			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047229	Green Accepted			2022-12-28	WOS:000283787800011
J	Santangeli, P; Di Biase, L; Dello Russo, A; Casella, M; Bartoletti, S; Santarelli, P; Pelargonio, G; Natale, A				Santangeli, Pasquale; Di Biase, Luigi; Dello Russo, Antonio; Casella, Michela; Bartoletti, Stefano; Santarelli, Pietro; Pelargonio, Gemma; Natale, Andrea			Meta-analysis: Age and Effectiveness of Prophylactic Implantable Cardioverter-Defibrillators	ANNALS OF INTERNAL MEDICINE			English	Review							CARDIAC-RESYNCHRONIZATION THERAPY; ELDERLY-PATIENTS; MYOCARDIAL-INFARCTION; IMPROVED SURVIVAL; SUDDEN-DEATH; HIGH-RISK; PREVENTION; CARDIOMYOPATHY; AMIODARONE; MORTALITY	Background: Implantable cardioverter-defibrillators (ICDs) for the primary prevention of sudden cardiac death have been proven effective in several clinical trials. Purpose: To summarize evidence about the effectiveness of ICDs versus standard medical therapy for the primary prevention of sudden cardiac death in different age groups of patients with severe left ventricular dysfunction. Data Sources: MEDLINE, Embase, CENTRAL, BioMed Central, Cardiosource, ClinicalTrials.gov, and ISI Web of Science (January 1970 to April 2010) were searched with no language restrictions. Study Selection: Two independent reviewers screened titles and abstracts to identify randomized, controlled trials of prophylactic ICD versus medical therapy in patients with severe left ventricular dysfunction that provided data about mortality outcomes for different age groups. Data Extraction: Two independent reviewers assessed risk for bias of trials and extracted patient and study characteristics and hazard ratios (HRs) relevant to all-cause mortality. Data Synthesis: Five trials (MADIT-II, DEFINITE, DINAMIT, SCD-HeFT, and IRIS) that enrolled 5783 patients (44% were elderly) were included. The primary analysis, which excluded the 2 trials enrolling patients early after acute myocardial infarction (DINAMIT and IRIS), found that prophylactic ICD therapy reduced mortality in younger patients (HR, 0.65 [95% CI, 0.50 to 0.83]; P < 0.001). A smaller and statistically nonsignificant survival benefit was found in elderly patients (HR, 0.81 [CI, 0.62 to 1.05]; P = 0.11). The inclusion of data from DINAMIT and IRIS did not change these results. Limitations: Four potentially eligible trials were not included in the meta-analysis because mortality data by age group were not available. Adjustment for differences in comorbid conditions and medical therapies among patients enrolled in the trials was not possible. Conclusion: Available data do not conclusively show that prophylactic ICD therapy improves survival in elderly patients with severe left ventricular dysfunction.	[Santangeli, Pasquale] Univ Cattolica Sacro Cuore, Dept Cardiol, I-00168 Rome, Italy; Univ Texas Austin, Austin, TX 78712 USA; St Davids Med Ctr, Austin, TX USA; Univ Foggia, Foggia, Italy; Univ Milan, Milan, Italy; Ist Ricovero & Cura Carattere Sci, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Texas System; University of Texas Austin; Saint David's Medical Center; University of Foggia; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Santangeli, P (corresponding author), Univ Cattolica Sacro Cuore, Dept Cardiol, Largo A Gemelli 8, I-00168 Rome, Italy.	pasquale.santangeli@libero.it	Dello Russo, Antonio/AAB-5030-2022; Casella, Michela/HDN-5651-2022; Casella, Michela/F-6737-2018; Casella, Michela/Y-9354-2019	Dello Russo, Antonio/0000-0001-7737-421X; Casella, Michela/0000-0002-5322-1742; Casella, Michela/0000-0002-5322-1742; Di Biase, Luigi/0000-0001-6508-4047				Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; BA N, 2002, CIRCULATION PMID, V105, P1453; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Daubert JP, 2008, J AM COLL CARDIOL, V51, P1357, DOI 10.1016/j.jacc.2007.09.073; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Desai AS, 2004, JAMA-J AM MED ASSOC, V292, P2874, DOI 10.1001/jama.292.23.2874; Duray G, 2005, J INTERV CARD ELECTR, V14, P169, DOI 10.1007/s10840-006-5200-y; Epstein AE, 2008, CIRCULATION, V117, P2820, DOI 10.1161/CIRCUALTIONAHA.108.189741; Epstein AE, 2009, HEART RHYTHM, V6, P1136, DOI 10.1016/j.hrthm.2009.04.010; Germano JJ, 2006, AM J CARDIOL, V97, P1255, DOI 10.1016/j.amjcard.2005.11.048; Healey JS, 2007, EUR HEART J, V28, P1746, DOI 10.1093/eurheartj/ehl438; Higgins JPT., 2008, COCHRANE HDB SYSTEMA, V1 edn; Hohnloser SH, 2004, NEW ENGL J MED, V351, P2481, DOI 10.1056/NEJMoa041489; Huang DT, 2007, J CARDIOVASC ELECTR, V18, P833, DOI 10.1111/j.1540-8167.2007.00857.x; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; Krahn AD, 2004, AM HEART J, V147, P837, DOI 10.1016/j.ahj.2003.12.017; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; *NAT CTR HLTH STAT, 2001, FED INT FOR AG REL S, P22; Panotopoulos PT, 1997, J AM COLL CARDIOL, V29, P556, DOI 10.1016/S0735-1097(96)00527-X; PETERSON MA, 2003, PACING CLIN ELECTROP, V26, P973; Santangeli P, 2010, HEART RHYTHM, V7, P876, DOI 10.1016/j.hrthm.2010.03.042; Steinbeck G, 2009, NEW ENGL J MED, V361, P1427, DOI 10.1056/NEJMoa0901889; Strickberger SA, 2003, J AM COLL CARDIOL, V41, P1707, DOI 10.1016/S0735-1097(03)00297-3; Swindle JP, 2010, ARCH INTERN MED, V170, P631, DOI 10.1001/archinternmed.2010.30; Tung R, 2008, J AM COLL CARDIOL, V52, P1111, DOI 10.1016/j.jacc.2008.05.058	31	117	120	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					592	599		10.7326/0003-4819-153-9-201011020-00009	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	21041579				2022-12-28	WOS:000283667000006
J	Wilkinson, RG; Pickett, KE; De Vogli, R				Wilkinson, Richard G.; Pickett, Kate E.; De Vogli, Roberto			Essay Equality, sustainability, and quality of life	BRITISH MEDICAL JOURNAL			English	Editorial Material							ORIENTATION; VALIDATION; MORTALITY		[Wilkinson, Richard G.] Univ Nottingham, Nottingham NG7 2RD, England; [Pickett, Kate E.] Univ York, York YO10 5DD, N Yorkshire, England; [De Vogli, Roberto] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of Nottingham; University of York - UK; University of London; University College London	Wilkinson, RG (corresponding author), Univ Nottingham, Nottingham NG7 2RD, England.	Richard@RichardWilkinson.net			ESRC [ES/H033084/1] Funding Source: UKRI; Department of Health [CSA/03/07/014] Funding Source: Medline; Economic and Social Research Council [ES/H033084/1] Funding Source: researchfish; National Institute for Health Research [CSA/03/07/014] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health; Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research(National Institute for Health Research (NIHR))		Blanden J., 2009, CTR EC ED CEE DISCUS, V139, P673; DORLING D, 2010, COMMUNICATION   0517; Hare B., 2006, AVOIDING DANGEROUS C, P191; *INT PAN CLIM CHAN, 2007, 4 IPPC INT PAN CLIM; JOWIT J, 2008, GUARDIAN        0628; Layard R., 2005, PROSPECT, V108; LOMBORG B, 2010, SMARTSOLUTIONS CLIMA; Moore PJ, 1996, ADDICT BEHAV, V21, P645, DOI 10.1016/0306-4603(95)00100-X; Nichols A, 2009, ENVIRON HEALTH INSIG, V3, P63; Preston SH, 2007, INT J EPIDEMIOL, V36, P484, DOI 10.1093/ije/dym075; RICHINS ML, 1992, J CONSUM RES, V19, P303, DOI 10.1086/209304; Roberts J. T., 2006, CLIMATE INJUSTICE GL; Ross NA, 2005, J URBAN HEALTH, V82, P101, DOI 10.1093/jurban/jti012; Saunders S, 2000, SOC BEHAV PERSONAL, V28, P219, DOI 10.2224/sbp.2000.28.3.219; Sheldon KM, 2000, J PERS, V68, P383, DOI 10.1111/1467-6494.00101; Wilkinson R., 2010, IMPACT INCOME INEQUA; Wilkinson R., 2010, SPIRIT LEVEL WHY EQU; Wilkinson RG, 2007, SOC SCI MED, V65, P1965, DOI 10.1016/j.socscimed.2007.05.041; World Economic Forum, 2002, GLOB COMP REP 2001 2	19	25	25	1	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2010	341								c5816	10.1136/bmj.c5816	http://dx.doi.org/10.1136/bmj.c5816			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678CU	21045025				2022-12-28	WOS:000284048200003
J	Chung, K; Lee, CH; Yi, GC				Chung, Kunook; Lee, Chul-Ho; Yi, Gyu-Chul			Transferable GaN Layers Grown on ZnO-Coated Graphene Layers for Optoelectronic Devices	SCIENCE			English	Article							LIGHT-EMITTING-DIODES; STIMULATED-EMISSION; THIN-FILMS; BLUE	We fabricated transferable gallium nitride (GaN) thin films and light-emitting diodes (LEDs) using graphene-layered sheets. Heteroepitaxial nitride thin films were grown on graphene layers by using high-density, vertically aligned zinc oxide nanowalls as an intermediate layer. The nitride thin films on graphene layers show excellent optical characteristics at room temperature, such as stimulated emission. As one of the examples for device applications, LEDs that emit strong electroluminescence emission under room illumination were fabricated. Furthermore, the layered structure of a graphene substrate made it possible to easily transfer GaN thin films and GaN-based LEDs onto foreign substrates such as glass, metal, or plastic.	[Chung, Kunook; Lee, Chul-Ho; Yi, Gyu-Chul] Seoul Natl Univ, Natl Creat Res Initiat Ctr Semicond Nanorods, Seoul 151747, South Korea; [Chung, Kunook; Lee, Chul-Ho; Yi, Gyu-Chul] Seoul Natl Univ, Dept Phys & Astron, Seoul 151747, South Korea; [Lee, Chul-Ho] Pohang Univ Sci & Technol, Dept Mat Sci & Engn, Pohang 790784, Gyeongbuk, South Korea	Seoul National University (SNU); Seoul National University (SNU); Pohang University of Science & Technology (POSTECH)	Yi, GC (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Semicond Nanorods, Seoul 151747, South Korea.	gcyi@snu.ac.kr	Lee, Chul-Ho/AAI-6876-2020; Yi, Gyu-Chul/F-1326-2011; Lee, Chul-Ho/D-2545-2009	Lee, Chul-Ho/0000-0003-1570-8688; Yi, Gyu-Chul/0000-0002-7703-3455; 	Korea Science and Engineering Foundations (KOSEF) [R16-2004-004-01001-0]	Korea Science and Engineering Foundations (KOSEF)(Korea Science and Engineering Foundation)	This work was financially supported by the National Creative Research Initiative Project (grant R16-2004-004-01001-0) of the Korea Science and Engineering Foundations (KOSEF). G.-C.Y. planned the project; K. C. designed and progressed the experiments; C.-H. L. provided technical support for LED device fabrication and characterization; G.-C.Y. advised on the project; and all authors analyzed the data, interpreted the results, and wrote the manuscript. The authors declare that they have no competing financial interests.	Bidnyk S, 1999, J APPL PHYS, V85, P1792, DOI 10.1063/1.369325; Bour DP, 2000, APPL PHYS LETT, V76, P2182, DOI 10.1063/1.126291; Cho HK, 2008, IEEE PHOTONIC TECH L, V20, P2096, DOI 10.1109/LPT.2008.2006506; David A, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2189159; KHAN MA, 1991, APPL PHYS LETT, V58, P1515, DOI 10.1063/1.105163; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Kim YJ, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3266836; Kuokstis E, 2002, APPL PHYS LETT, V80, P977, DOI 10.1063/1.1433164; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Lu XK, 1999, APPL PHYS LETT, V75, P193, DOI 10.1063/1.124316; NAKAMURA S, 1994, APPL PHYS LETT, V64, P1687, DOI 10.1063/1.111832; Nakamura S., 2000, BLUE LASER DIODE COM; Ponce FA, 1997, NATURE, V386, P351, DOI 10.1038/386351a0; Wong WS, 1999, APPL PHYS LETT, V75, P1360, DOI 10.1063/1.124693; Wong WS, 1998, APPL PHYS LETT, V72, P599, DOI 10.1063/1.120816; Yablonskii GP, 2002, PHYS STATUS SOLIDI A, V192, P54, DOI 10.1002/1521-396X(200207)192:1<54::AID-PSSA54>3.0.CO;2-2	16	510	546	22	705	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					655	657		10.1126/science.1195403	http://dx.doi.org/10.1126/science.1195403			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030653				2022-12-28	WOS:000283580600043
J	Howard, AW; Marcy, GW; Johnson, JA; Fischer, DA; Wright, JT; Isaacson, H; Valenti, JA; Anderson, J; Lin, DNC; Ida, S				Howard, Andrew W.; Marcy, Geoffrey W.; Johnson, John Asher; Fischer, Debra A.; Wright, Jason T.; Isaacson, Howard; Valenti, Jeff A.; Anderson, Jay; Lin, Doug N. C.; Ida, Shigeru			The Occurrence and Mass Distribution of Close-in Super-Earths, Neptunes, and Jupiters	SCIENCE			English	Article							DETERMINISTIC MODEL; PLANETARY FORMATION; EXTRASOLAR PLANETS; EXOPLANETS; SYSTEMS; SEARCH; STAR; TELESCOPE; COMPANION; VIRGINIS	The questions of how planets form and how common Earth-like planets are can be addressed by measuring the distribution of exoplanet masses and orbital periods. We report the occurrence rate of close-in planets (with orbital periods less than 50 days), based on precise Doppler measurements of 166 Sun-like stars. We measured increasing planet occurrence with decreasing planet mass (M). Extrapolation of a power-law mass distribution fitted to our measurements, df/dlogM = 0.39 M-0.48, predicts that 23% of stars harbor a close-in Earth-mass planet (ranging from 0.5 to 2.0 Earth masses). Theoretical models of planet formation predict a deficit of planets in the domain from 5 to 30 Earth masses and with orbital periods less than 50 days. This region of parameter space is in fact well populated, implying that such models need substantial revision.	[Howard, Andrew W.; Marcy, Geoffrey W.; Isaacson, Howard] Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; [Howard, Andrew W.] Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; [Johnson, John Asher] CALTECH, Dept Astrophys, Pasadena, CA 91125 USA; [Fischer, Debra A.] Yale Univ, Dept Astron, New Haven, CT 06511 USA; [Wright, Jason T.] Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; [Valenti, Jeff A.; Anderson, Jay] Space Telescope Sci Inst, Baltimore, MD 21218 USA; [Lin, Doug N. C.] Univ Calif Santa Cruz, Lick Observ, Univ Calif Observ, Santa Cruz, CA 95064 USA; [Lin, Doug N. C.] Peking Univ, Kavli Inst Astron & Astrophys, Beijing 100871, Peoples R China; [Ida, Shigeru] Tokyo Inst Technol, Meguro Ku, Tokyo 1528551, Japan	University of California System; University of California Berkeley; University of California System; University of California Berkeley; California Institute of Technology; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Space Telescope Science Institute; University of California System; University of California Santa Cruz; Peking University; Tokyo Institute of Technology	Howard, AW (corresponding author), Univ Calif Berkeley, Dept Astron, 601 Campbell Hall, Berkeley, CA 94720 USA.	howard@astro.berkeley.edu	Ida, Shigeru/A-7840-2014; Fischer, Debra A/C-1639-2014; Marcy, Geoff/AAC-6050-2019	Ida, Shigeru/0000-0002-9676-3891; Fischer, Debra A/0000-0003-2221-0861; Wright, Jason/0000-0001-6160-5888; Valenti, Jeff/0000-0003-3305-6281	UC Berkeley Space Sciences Laboratory; NASA [NNX06AH52G]	UC Berkeley Space Sciences Laboratory; NASA(National Aeronautics & Space Administration (NASA))	This work was based on observations at the W. M. Keck Observatory granted by NASA and the University of California (UC). We thank the many observers who contributed to the measurements reported here and acknowledge the efforts and dedication of the Keck Observatory staff, especially S. Dahm, H. Tran, and G. Hill for support of HIRES and G. Wirth for support of remote observing. We acknowledge R. P. Butler and S. Vogt for many years of contributing to the data presented here. A. H. acknowledges support from a Townes Postdoctoral Fellowship at the UC Berkeley Space Sciences Laboratory. G. M. acknowledges NASA grant NNX06AH52G. Finally, we extend special thanks to those of Hawai'ian ancestry on whose sacred mountain of Mauna Kea we are privileged to be guests.	Batalha NM, 2010, ASTROPHYS J LETT, V713, pL109, DOI 10.1088/2041-8205/713/2/L109; Borucki WJ, 2010, SCIENCE, V327, P977, DOI 10.1126/science.1185402; BORUCKI WJ, 2010, ASTROPHYS J; Butler RP, 2006, ASTROPHYS J, V646, P505, DOI 10.1086/504701; Cumming A, 2008, PUBL ASTRON SOC PAC, V120, P531, DOI 10.1086/588487; Fischer DA, 2002, ASTROPHYS J, V564, P1028, DOI 10.1086/324336; Fischer D, 2009, ASTROPHYS J, V703, P1545, DOI 10.1088/0004-637X/703/2/1545; Howard AW, 2009, ASTROPHYS J, V696, P75, DOI 10.1088/0004-637X/696/1/75; HOWARD AW, 2010, ASTROPHYS J; Ida S, 2008, ASTROPHYS J, V685, P584, DOI 10.1086/590401; Ida S, 2005, ASTROPHYS J, V626, P1045, DOI 10.1086/429953; Ida S, 2004, ASTROPHYS J, V604, P388, DOI 10.1086/381724; Johnson JA, 2010, PUBL ASTRON SOC PAC, V122, P149; Marcy G, 2005, PROG THEOR PHYS SUPP, P24, DOI 10.1143/PTPS.158.24; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; Mayor M, 2009, ASTRON ASTROPHYS, V493, P639, DOI 10.1051/0004-6361:200810451; MAYOR M, 2010, KITP C EX RIS ASTR P; Mordasini C, 2009, ASTRON ASTROPHYS, V501, P1139, DOI 10.1051/0004-6361/200810301; Mordasini C, 2009, ASTRON ASTROPHYS, V501, P1161, DOI 10.1051/0004-6361/200810697; MORDASINI C, ASTRON ASTROPHYS; O'Toole SJ, 2009, ASTROPHYS J, V701, P1732, DOI 10.1088/0004-637X/701/2/1732; Sumi T, 2010, ASTROPHYS J, V710, P1641, DOI 10.1088/0004-637X/710/2/1641; VOGT S, 1994, P SOC PHOTO-OPT INS, V2198, P362, DOI 10.1117/12.176725; Vogt SS, 2005, ASTROPHYS J, V632, P638, DOI 10.1086/432901; Vogt SS, 2010, ASTROPHYS J, V708, P1366, DOI 10.1088/0004-637X/708/2/1366; Wittenmyer RA, 2009, ASTROPHYS J SUPPL S, V182, P97, DOI 10.1088/0067-0049/182/1/97; Wright JT, 2009, ASTROPHYS J, V693, P1084, DOI 10.1088/0004-637X/693/2/1084	32	427	428	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					653	655		10.1126/science.1194854	http://dx.doi.org/10.1126/science.1194854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030652	Green Submitted, Green Accepted			2022-12-28	WOS:000283580600042
J	Chertow, GM; Levin, NW; Beck, GJ; Depner, TA; Eggers, PW; Gassman, JJ; Gorodetskaya, I; Greene, T; James, S; Larive, B; Lindsay, RM; Mehta, RL; Miller, B; Ornt, DB; Rajagopalan, S; Rastogi, A; Rocco, MV; Schiller, B; Sergeyeva, O; Schulman, G; Ting, GO; Unruh, ML; Star, RA; Kliger, AS				Chertow, Glenn M.; Levin, Nathan W.; Beck, Gerald J.; Depner, Thomas A.; Eggers, Paul W.; Gassman, Jennifer J.; Gorodetskaya, Irina; Greene, Tom; James, Sam; Larive, Brett; Lindsay, Robert M.; Mehta, Ravindra L.; Miller, Brent; Ornt, Daniel B.; Rajagopalan, Sanjay; Rastogi, Anjay; Rocco, Michael V.; Schiller, Brigitte; Sergeyeva, Olga; Schulman, Gerald; Ting, George O.; Unruh, Mark L.; Star, Robert A.; Kliger, Alan S.		FHN Trial Grp	In-Center Hemodialysis Six Times per Week versus Three Times per Week	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; QUALITY-OF-LIFE; STAGE RENAL-DISEASE; CONVENTIONAL HEMODIALYSIS; NOCTURNAL HEMODIALYSIS; BLOOD-PRESSURE; LONG-TERM; FOLLOW-UP; MORTALITY; UREA	BACKGROUND In this randomized clinical trial, we aimed to determine whether increasing the frequency of in-center hemodialysis would result in beneficial changes in left ventricular mass, self-reported physical health, and other intermediate outcomes among patients undergoing maintenance hemodialysis. METHODS Patients were randomly assigned to undergo hemodialysis six times per week (frequent hemodialysis, 125 patients) or three times per week (conventional hemodialysis, 120 patients) for 12 months. The two coprimary composite outcomes were death or change (from baseline to 12 months) in left ventricular mass, as assessed by cardiac magnetic resonance imaging, and death or change in the physical-health composite score of the RAND 36-item health survey. Secondary outcomes included cognitive performance; self-reported depression; laboratory markers of nutrition, mineral metabolism, and anemia; blood pressure; and rates of hospitalization and of interventions related to vascular access. RESULTS Patients in the frequent-hemodialysis group averaged 5.2 sessions per week; the weekly standard Kt/V-urea (the product of the urea clearance and the duration of the dialysis session normalized to the volume of distribution of urea) was significantly higher in the frequent-hemodialysis group than in the conventional-hemodialysis group (3.54 +/- 0.56 vs. 2.49 +/- 0.27). Frequent hemodialysis was associated with significant benefits with respect to both coprimary composite outcomes (hazard ratio for death or increase in left ventricular mass, 0.61; 95% confidence interval [CI], 0.46 to 0.82; hazard ratio for death or a decrease in the physical-health composite score, 0.70; 95% CI, 0.53 to 0.92). Patients randomly assigned to frequent hemodialysis were more likely to undergo interventions related to vascular access than were patients assigned to conventional hemodialysis (hazard ratio, 1.71; 95% CI, 1.08 to 2.73). Frequent hemodialysis was associated with improved control of hypertension and hyperphosphatemia. There were no significant effects of frequent hemodialysis on cognitive performance, self-reported depression, serum albumin concentration, or use of erythropoiesis-stimulating agents. CONCLUSIONS Frequent hemodialysis, as compared with conventional hemodialysis, was associated with favorable results with respect to the composite outcomes of death or change in left ventricular mass and death or change in a physical-health composite score but prompted more frequent interventions related to vascular access.	[Chertow, Glenn M.; Gorodetskaya, Irina; Schiller, Brigitte; Ting, George O.] Stanford Univ, Palo Alto, CA 94304 USA; [Chertow, Glenn M.; Gorodetskaya, Irina; James, Sam] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Levin, Nathan W.; Sergeyeva, Olga] Renal Res Inst, New York, NY USA; [Beck, Gerald J.; Gassman, Jennifer J.; Greene, Tom; Larive, Brett] Cleveland Clin Fdn, Cleveland, OH USA; [Depner, Thomas A.] Univ Calif Davis, Davis, CA 95616 USA; [Eggers, Paul W.; Star, Robert A.] NIDDK, Bethesda, MD USA; [Greene, Tom] Univ Utah, Salt Lake City, UT USA; [Lindsay, Robert M.] Univ Western Ontario, London, ON, Canada; [Mehta, Ravindra L.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Miller, Brent] Washington Univ, St Louis, MO 63130 USA; [Ornt, Daniel B.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Rajagopalan, Sanjay] Ohio State Univ, Columbus, OH 43210 USA; [Rastogi, Anjay] Univ Calif Los Angeles, Los Angeles, CA USA; [Rocco, Michael V.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Schiller, Brigitte] Satellite Healthcare, San Jose, CA USA; [Schulman, Gerald] Vanderbilt Univ, Nashville, TN USA; [Ting, George O.] El Camino Hosp, Mountain View, CA USA; [Unruh, Mark L.] Univ Pittsburgh, Pittsburgh, PA USA; [Kliger, Alan S.] Hosp St Raphael, New Haven, CT 06511 USA; [Kliger, Alan S.] Yale Univ, New Haven, CT USA	Stanford University; University of California System; University of California San Francisco; Renal Research Institute; Cleveland Clinic Foundation; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Utah System of Higher Education; University of Utah; Western University (University of Western Ontario); University of California System; University of California San Diego; Washington University (WUSTL); Case Western Reserve University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; Wake Forest University; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hospital Saint Raphael; Yale University	Chertow, GM (corresponding author), Stanford Univ, Palo Alto, CA 94304 USA.		Schiller, Brigitte/AAW-3230-2021; Kliger, Alan/AAN-6653-2021; Mehta, Ravindra/ACD-4769-2022; Lindsay, Bob/G-3321-2011	Mehta, Ravindra/0000-0002-0908-2968; Chertow, Glenn/0000-0002-7599-0534	National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases; Center for Medicare and Medical Services; NIH Research Foundation; Amgen; Baxter; Dialysis Clinics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK085446, U01DK066481] Funding Source: NIH RePORTER	National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Center for Medicare and Medical Services; NIH Research Foundation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen(Amgen); Baxter; Dialysis Clinics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases, the Center for Medicare and Medical Services, and the NIH Research Foundation. Contributors to the NIH Foundation in support of the FHN trials included Amgen, Baxter, and Dialysis Clinics. Additional support was provided by DaVita, Dialysis Clinics, Fresenius Medical Care, Renal Advantage, Renal Research Institute, and Satellite Healthcare.	Ayus JC, 2005, J AM SOC NEPHROL, V16, P2778, DOI 10.1681/ASN.2005040392; Bock HA, 2008, NEPHROL DIAL TRANSPL, V23, P301, DOI 10.1093/ndt/gfm579; Buoncristiani U, 1988, Kidney Int Suppl, V24, pS137; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Daugirdas JT, 2010, KIDNEY INT, V77, P637, DOI 10.1038/ki.2009.525; DAUGIRDAS SURI, 2004, HEMO STUDY J AM SOC, V15, P194; DePalma John R, 2004, Hemodial Int, V8, P19, DOI 10.1111/j.1492-7535.2004.00082.x; Depner T, 2004, KIDNEY INT, V65, P1386, DOI 10.1111/j.1523-1755.2004.00519.x; Depner TA, 2001, ADV RENAL REPLACE TH, V8, P227, DOI 10.1053/jarr.2001.27594; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Foley RN, 2002, KIDNEY INT, V62, P1784, DOI 10.1046/j.1523-1755.2002.00636.x; Gorodetskaya I, 2005, KIDNEY INT, V68, P2801, DOI 10.1111/j.1523-1755.2005.00752.x; Gotch FA, 1998, NEPHROL DIAL TRANSPL, V13, P10, DOI 10.1093/ndt/13.suppl_6.10; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; HELD PJ, 1983, J HEALTH ECON, V2, P95, DOI 10.1016/0167-6296(83)90001-2; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Hemmelgarn BR, 2003, AM J KIDNEY DIS, V42, P125, DOI 10.1016/S0272-6386(03)00415-3; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Lacson E, 2010, CLIN J AM SOC NEPHRO, V5, P252, DOI 10.2215/CJN.07231009; Lockridge Robert S Jr, 2004, Hemodial Int, V8, P61, DOI 10.1111/j.1492-7535.2004.00076.x; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; Mapes DL, 2003, KIDNEY INT, V64, P339, DOI 10.1046/j.1523-1755.2003.00072.x; McClellan WM, 1998, J AM SOC NEPHROL, V9, P1940; Miskulin DC, 2001, KIDNEY INT, V60, P1498, DOI 10.1046/j.1523-1755.2001.00954.x; Neves PL, 1997, AM J KIDNEY DIS, V30, P224, DOI 10.1016/S0272-6386(97)90056-1; Okin PM, 2004, JAMA-J AM MED ASSOC, V292, P2343, DOI 10.1001/jama.292.19.2343; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; *REN DAT SYST, 2009, USRDS 2009 ANN DAT R; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P114; Suri RS, 2007, KIDNEY INT, V71, P349, DOI 10.1038/sj.ki.5002032; Suri RS, 2006, CLIN J AM SOC NEPHRO, V1, P33, DOI 10.2215/CJN.00340705; Szczech LA, 2003, NEPHROL DIAL TRANSPL, V18, P1585, DOI 10.1093/ndt/gfg225; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; TESCHAN PE, 1975, T AM SOC ART INT ORG, V21, P488; Ting GO, 2003, AM J KIDNEY DIS, V42, P1020, DOI 10.1016/j.ajkd.2003.07.020; Walsh M, 2005, KIDNEY INT, V67, P1500, DOI 10.1111/j.1523-1755.2005.00228.x; Zoccali C, 2004, KIDNEY INT, V65, P1492, DOI 10.1111/j.1523-1755.2004.00530.x	39	725	765	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2010	363	24					2287	2300		10.1056/NEJMoa1001593	http://dx.doi.org/10.1056/NEJMoa1001593			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691PA	21091062	Green Accepted, Green Published			2022-12-28	WOS:000285092100004
J	Meltzer, DO; Detsky, AS				Meltzer, David O.; Detsky, Allan S.			The Real Meaning of Rationing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE; INSURANCE		[Detsky, Allan S.] Univ Toronto, Dept Med, Mt Sinai Hosp, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Toronto, Dept Med, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada; [Meltzer, David O.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Meltzer, David O.] Univ Chicago, Dept Econ, Chicago, IL 60637 USA; [Meltzer, David O.] Univ Chicago, Harris Sch Publ Policy Studies, Chicago, IL 60637 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Chicago; University of Chicago; University of Chicago	Detsky, AS (corresponding author), Univ Toronto, Dept Med, Mt Sinai Hosp, Dept Hlth Policy Management & Evaluat, 600 Univ Ave,Ste 429, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca	Meltzer, David/C-2926-2009	Meltzer, David/0000-0003-2790-7393	AHRQ HHS [U18 HS016967-01] Funding Source: Medline; NIA NIH HHS [1 K24 AG031326-0] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG031326] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DETSKY AS, 1983, NEW ENGL J MED, V309, P151, DOI 10.1056/NEJM198307213090306; FELDSTEIN MS, 1973, J POLIT ECON, V81, P251, DOI 10.1086/260027; Fendrick AM, 2007, J GEN INTERN MED, V22, P890, DOI 10.1007/s11606-007-0188-2; Newhouse JP, 1993, FREE ALL LESSONS RAN; Sessions SY, 2010, JAMA-J AM MED ASSOC, V303, P2078, DOI 10.1001/jama.2010.654; Wells DA, 2007, JAMA-J AM MED ASSOC, V298, P2785, DOI 10.1001/jama.298.23.2785; Woolhandler S, 2007, J GEN INTERN MED, V22, P879, DOI 10.1007/s11606-007-0187-3	7	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2010	304	20					2292	2293		10.1001/jama.2010.1671	http://dx.doi.org/10.1001/jama.2010.1671			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KI	21041419				2022-12-28	WOS:000284548400030
J	Bronson, DL				Bronson, David L.			Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Cleveland Clin, Cleveland, OH 44106 USA	Cleveland Clinic Foundation	Bronson, DL (corresponding author), Cleveland Clin, Cleveland, OH 44106 USA.							Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS11, DOI 10.2337/dc10-S011; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Ismail-Beigi F, 2010, LANCET, V376, P419, DOI 10.1016/S0140-6736(10)60576-4	3	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-10	10.1059/0003-4819-153-10-201011160-02010	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079205				2022-12-28	WOS:000284215800009
J	Hughes, J				Hughes, James			Review: Aspirin reduces acute migraine pain in adults	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Tamworth Rural Referral Hosp, Tamworth, NSW, Australia		Hughes, J (corresponding author), Tamworth Rural Referral Hosp, Tamworth, NSW, Australia.							Brandes JL, 2007, JAMA-J AM MED ASSOC, V297, P1443, DOI 10.1001/jama.297.13.1443	1	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-5	10.1059/0003-4819-153-10-201011160-02005	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079212				2022-12-28	WOS:000284215800004
J	Ciocchi, S; Herry, C; Grenier, F; Wolff, SBE; Letzkus, JJ; Vlachos, I; Ehrlich, I; Sprengel, R; Deisseroth, K; Stadler, MB; Muller, C; Luthi, A				Ciocchi, Stephane; Herry, Cyril; Grenier, Francois; Wolff, Steffen B. E.; Letzkus, Johannes J.; Vlachos, Ioannis; Ehrlich, Ingrid; Sprengel, Rolf; Deisseroth, Karl; Stadler, Michael B.; Mueller, Christian; Luethi, Andreas			Encoding of conditioned fear in central amygdala inhibitory circuits	NATURE			English	Article							LONG-TERM POTENTIATION; CENTRAL NUCLEUS; SYNAPTIC PLASTICITY; PROJECTION NEURONS; RAT; COMPLEX; ORGANIZATION; FOREBRAIN; TRANSMISSION; MECHANISMS	The central amygdala (CEA), a nucleus predominantly composed of GABAergic inhibitory neurons, is essential for fear conditioning. How the acquisition and expression of conditioned fear are encoded within CEA inhibitory circuits is not understood. Using in vivo electrophysiological, optogenetic and pharmacological approaches in mice, we show that neuronal activity in the lateral subdivision of the central amygdala (CEl) is required for fear acquisition, whereas conditioned fear responses are driven by output neurons in the medial subdivision (CEm). Functional circuit analysis revealed that inhibitory CEA microcircuits are highly organized and that cell-type-specific plasticity of phasic and tonic activity in the CEl to CEm pathway may gate fear expression and regulate fear generalization. Our results define the functional architecture of CEA microcircuits and their role in the acquisition and regulation of conditioned fear behaviour.	[Ciocchi, Stephane; Herry, Cyril; Grenier, Francois; Wolff, Steffen B. E.; Letzkus, Johannes J.; Ehrlich, Ingrid; Stadler, Michael B.; Mueller, Christian; Luethi, Andreas] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Vlachos, Ioannis] Bernstein Ctr Computat Neurosci, D-79104 Freiburg, Germany; [Sprengel, Rolf] Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany; [Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA	Friedrich Miescher Institute for Biomedical Research; Max Planck Society; Stanford University	Luthi, A (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	andreas.luthi@fmi.ch	Yan, Shuo/B-8381-2009; Ehrlich, Ingrid/G-8551-2015; Herry, Cyril/AAP-9902-2020	Ehrlich, Ingrid/0000-0001-9078-2429; Herry, Cyril/0000-0003-2973-0843; Ciocchi, Stephane/0000-0002-5701-9250; Letzkus, Johannes/0000-0001-5678-3030	Austrian Science Fund (FWF); Swiss National Science Foundation; Schering Foundation; European Commission [HEALTH-F2-2009-241498]; Indo Swiss Joint Research Programme; BMBF [01GQ0420]; Neurex Interreg-IV; Volkswagen Stiftung; Novartis Institutes for Biomedical Research; Novartis Research Foundation	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Schering Foundation; European Commission(European CommissionEuropean Commission Joint Research Centre); Indo Swiss Joint Research Programme; BMBF(Federal Ministry of Education & Research (BMBF)); Neurex Interreg-IV; Volkswagen Stiftung(Volkswagen); Novartis Institutes for Biomedical Research; Novartis Research Foundation	We thank all members of the Luthi laboratory for discussions and critical comments on the manuscript. This work was supported by grants from the Austrian Science Fund (FWF), the Swiss National Science Foundation, the Schering Foundation, the European Commission (Eurospin Project, Contract HEALTH-F2-2009-241498), the Indo Swiss Joint Research Programme, the BMBF (grant 01GQ0420 to BCCN Freiburg), Neurex Interreg-IV, the Volkswagen Stiftung, the Novartis Institutes for Biomedical Research, and the Novartis Research Foundation.	Balleine BW, 2006, TRENDS NEUROSCI, V29, P272, DOI 10.1016/j.tins.2006.03.002; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Cassell MD, 1999, ANN NY ACAD SCI, V877, P217, DOI 10.1111/j.1749-6632.1999.tb09270.x; Davis M., 2000, AMYGDALA, P213; Delaney AJ, 2007, NEURON, V56, P880, DOI 10.1016/j.neuron.2007.10.022; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; Fu Y, 2005, J NEUROPHYSIOL, V93, P3012, DOI 10.1152/jn.00871.2004; Fujisawa S, 2008, NAT NEUROSCI, V11, P823, DOI 10.1038/nn.2134; Goosens KA, 2003, BEHAV NEUROSCI, V117, P738, DOI 10.1037/0735-7044.117.4.738; Gozzi A, 2010, NEURON, V67, P656, DOI 10.1016/j.neuron.2010.07.008; Gradinaru V, 2007, J NEUROSCI, V27, P14231, DOI 10.1523/JNEUROSCI.3578-07.2007; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Herry C, 2007, J NEUROSCI, V27, P5958, DOI 10.1523/JNEUROSCI.5218-06.2007; Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636; JARRELL TW, 1987, BRAIN RES, V412, P285, DOI 10.1016/0006-8993(87)91135-8; Jolkkonen E, 2002, NEUROSCIENCE, V111, P133, DOI 10.1016/S0306-4522(01)00578-4; KRETTEK JE, 1978, J COMP NEUROL, V178, P255, DOI 10.1002/cne.901780205; Lang EJ, 1997, J NEUROPHYSIOL, V77, P353, DOI 10.1152/jn.1997.77.1.353; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LEDOUX JE, 1988, J NEUROSCI, V8, P2517; Lima SQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006099; Linke R, 2000, EXP BRAIN RES, V134, P520, DOI 10.1007/s002210000475; Lopez de Armentia M, 2007, J PHYSIOL-LONDON, V581, P961, DOI 10.1113/jphysiol.2007.101822; Maren S, 2004, NAT REV NEUROSCI, V5, P844, DOI 10.1038/nrn1535; MILLHOUSE OE, 1986, J COMP NEUROL, V247, P246, DOI 10.1002/cne.902470209; Neugebauer V, 2009, BRAIN RES REV, V60, P226, DOI 10.1016/j.brainresrev.2008.12.014; Nicolelis MAL, 2003, P NATL ACAD SCI USA, V100, P11041, DOI 10.1073/pnas.1934665100; PARE D, 1993, NEUROSCIENCE, V57, P1077, DOI 10.1016/0306-4522(93)90050-P; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004; PASCOE JP, 1985, BEHAV BRAIN RES, V16, P117, DOI 10.1016/0166-4328(85)90087-7; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Roberto M, 2003, P NATL ACAD SCI USA, V100, P2053, DOI 10.1073/pnas.0437926100; Sah P, 2008, ANN NY ACAD SCI, V1129, P88, DOI 10.1196/annals.1417.020; Samson RD, 2005, REV NEUROSCIENCE, V16, P287; Samson RD, 2005, J NEUROSCI, V25, P1847, DOI 10.1523/JNEUROSCI.3713-04.2005; Shaban H, 2006, NAT NEUROSCI, V9, P1028, DOI 10.1038/nn1732; Sigurdsson T, 2007, NEUROPHARMACOLOGY, V52, P215, DOI 10.1016/j.neuropharm.2006.06.022; SUN N, 1994, J COMP NEUROL, V340, P43, DOI 10.1002/cne.903400105; Tang W, 2009, J NEUROSCI, V29, P8621, DOI 10.1523/JNEUROSCI.0359-09.2009; THOMPSON RF, 1962, J COMP PHYSIOL PSYCH, V55, P279, DOI 10.1037/h0047856; TURNER BH, 1991, J COMP NEUROL, V313, P295, DOI 10.1002/cne.903130208; VEENING JG, 1984, BRAIN RES, V303, P337, DOI 10.1016/0006-8993(84)91220-4; Veinante P, 2003, ANN NY ACAD SCI, V985, P552; Wickens JR, 2007, PROG BRAIN RES, V160, P313, DOI 10.1016/S0079-6123(06)60018-6; Wilensky AE, 2006, J NEUROSCI, V26, P12387, DOI 10.1523/JNEUROSCI.4316-06.2006	46	616	630	2	117	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					277	U239		10.1038/nature09559	http://dx.doi.org/10.1038/nature09559			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068837				2022-12-28	WOS:000284051000045
J	Ring, DC; Herndon, JH; Meyer, GS				Ring, David C.; Herndon, James H.; Meyer, Gregg S.			Case 34-2010: A 65-Year-Old Woman with an Incorrect Operation on the Left Hand.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL ERRORS; SITE; ORTHOPEDICS; DISCLOSURE; SURGERY		[Ring, David C.; Herndon, James H.] Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA; [Meyer, Gregg S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Meyer, Gregg S.] Massachusetts Gen Hosp, Massachusetts Gen Phys Org, Boston, MA 02114 USA; [Ring, David C.; Herndon, James H.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Boston, MA USA; [Meyer, Gregg S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ring, DC (corresponding author), Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA.		Ring, David/AAV-9035-2021; Greiver, Michelle/N-8764-2015	Ring, David/0000-0002-6506-4879; Greiver, Michelle/0000-0001-8957-0285	Wright Medical; Biomet; Skeletal Dynamics; Acumed; Tornier; Joint Active Systems; Stryker; AO North America; AO International; board of trustees of the Journal of Bone and Joint Surgery; Boston Consulting Group; CRICO Risk Management Foundation	Wright Medical; Biomet; Skeletal Dynamics; Acumed; Tornier; Joint Active Systems; Stryker; AO North America; AO International; board of trustees of the Journal of Bone and Joint Surgery; Boston Consulting Group; CRICO Risk Management Foundation	Dr. Ring reports receiving consulting fees from Wright Medical, Biomet, Skeletal Dynamics, Acumed, and Tornier; payment for expert testimony from motor vehicle insurance companies, corporations, and legal firms regarding personal injury and malpractice lawsuits; grant support from Joint Active Systems, Stryker, and Biomet; lecture fees from AO North America and AO International; and royalties from Hand Innovations, Wright Medical, Skeletal Dynamics, and Biomet; and owning stock in Illuminos and Mimedex. Dr. Herndon reports receiving payment for serving on the board of trustees of the Journal of Bone and Joint Surgery. Dr. Meyer reports receiving consulting fees from Boston Consulting Group, honoraria from the Agency for Healthcare Research and Quality, and grant support to his institution from CRICO Risk Management Foundation. No other potential conflict of interest relevant to this article was reported.	Alt KW, 1997, NATURE, V387, P360, DOI 10.1038/387360a0; *AM MED ASS, 1957, PRINC MED ETH; Cowell HR, 1998, J BONE JOINT SURG AM, V80A, P463, DOI 10.2106/00004623-199804000-00001; Cronen G, 2005, J BONE JOINT SURG AM, V87A, P2193, DOI 10.2106/JBJS.E.00293; DiGiovanni CW, 2003, J BONE JOINT SURG AM, V85A, P815, DOI 10.2106/00004623-200305000-00007; Edmondson AC, 2004, QUAL SAF HEALTH CARE, V13, P3, DOI 10.1136/qshc.2003.009597; Frankel AS, 2006, HEALTH SERV RES, V41, P1690, DOI 10.1111/j.1475-6773.2006.00572.x; FREYER FJ, 2007, PROVIDENCE J    1126; Furey A, 2002, J BONE JOINT SURG AM, V84A, P1066, DOI 10.2106/00004623-200206000-00025; Kachalia A, 2010, ANN INTERN MED, V153, P213, DOI 10.7326/0003-4819-153-4-201008170-00002; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Kwaan MR, 2006, ARCH SURG-CHICAGO, V141, P353, DOI 10.1001/archsurg.141.4.353; *MA COAL PREV MED, 2006, THINGS GO WRONG RESP; Marx D, 2001, PATIENT SAFETY JUST; Meinberg EG, 2003, J BONE JOINT SURG AM, V85A, P193, DOI 10.2106/00004623-200302000-00002; Neily Julia, 2003, Jt Comm J Qual Saf, V29, P434; RASMUSSEN J, 1990, ERGONOMICS, V33, P1185, DOI 10.1080/00140139008925325; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1990, HUMAN ERROR; The Joint Commission, UN PROT PREV WRONG S; Wong D, 2002, J BONE JOINT SURG AM, V84A, P2097, DOI 10.2106/00004623-200211000-00027; Wong DA, 2009, J BONE JOINT SURG AM, V91A, P1534, DOI 10.2106/JBJS.H.01462; Wong DA, 2009, J BONE JOINT SURG AM, V91A, P547, DOI 10.2106/JBJS.G.01439; Wu AW, 1999, ANN INTERN MED, V131, P970, DOI 10.7326/0003-4819-131-12-199912210-00012; ZAPT D, 1994, APPL PSYCHOL, V43, P427; 1852, NY TIMES        1123	26	23	23	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1951	1958		10.1056/NEJMcpc1007085	http://dx.doi.org/10.1056/NEJMcpc1007085			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067387	Bronze			2022-12-28	WOS:000284047600012
J	Boult, C; Wieland, GD				Boult, Chad; Wieland, G. Darryl			Comprehensive Primary Care for Older Patients With Multiple Chronic Conditions "Nobody Rushes You Through"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; ALL-INCLUSIVE CARE; LOW-INCOME SENIORS; GUIDED CARE; HEALTH-CARE; GERIATRIC RESOURCES; FAMILY CAREGIVERS; CHRONIC ILLNESS; MANAGEMENT	Older patients with multiple chronic health conditions and complex health care needs often receive care that is fragmented, incomplete, inefficient, and ineffective. This article describes the case of an older woman whose case cannot be managed effectively through the customary approach of simply diagnosing and treating her individual diseases. Based on expert consensus about the available evidence, this article identifies 4 proactive, continuous processes that can substantially improve the primary care of community-dwelling older patients who have multiple chronic conditions: comprehensive assessment, evidence-based care planning and monitoring, promotion of patients' and (family caregivers') active engagement in care, and coordination of professionals in care of the patient-all tailored to the patient's goals and preferences. Three models of chronic care that include these processes and that appear to improve some aspects of the effectiveness and the efficiency of complex primary care-the Geriatric Resources for Assessment and Care of Elders (GRACE) model, Guided Care, and the Program of All-inclusive Care for the Elderly (PACE)-are described briefly, and steps toward their implementation are discussed. JAMA. 2010; 304(17): 1936-1943	[Boult, Chad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Wieland, G. Darryl] Palmetto Hlth Richland Hosp, Columbia, SC USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Boult, C (corresponding author), 624 N Broadway,Room 693, Baltimore, MD 21205 USA.	cboult@jhsph.edu	Martin, Carmel Mary/B-6358-2011	Martin, Carmel Mary/0000-0001-8174-7859	Agency for Healthcare Research Quality; National Institute on Aging; John A. Hartford Foundation; Jacob and Valeria Langeloth Foundation; National PACE Association; SCAN Foundation	Agency for Healthcare Research Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); John A. Hartford Foundation; Jacob and Valeria Langeloth Foundation; National PACE Association; SCAN Foundation	Dr Boult reports possible future royalties from sales of a book (Guided Care: A Nurse-Physician Partnership in Chronic Care, Springer Publishing Co, 2009); and previous grant support for a study of Guided Care from the Agency for Healthcare Research & Quality, the National Institute on Aging, the John A. Hartford Foundation, and the Jacob and Valeria Langeloth Foundation. Dr Wieland reports that he is employed by a health care system that operates a PACE site; and that he has formerly received grant funding from and served on committees and task forces of the National PACE Association.; The Care of the Aging Patient series is made possible by funding from The SCAN Foundation.	[Anonymous], 2001, ANN INTERN MED, V135, P653, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00004; Beauchamp J., 2008, EFFECT PROGRAM ALL I; Beeber AS, 2008, PROF CASE MANAG, V13, P277, DOI 10.1097/01.PCAMA.0000336691.00694.65; Beland F, 2006, J GERONTOL A-BIOL, V61, P367, DOI 10.1093/gerona/61.4.367; Bennett JA, 2005, RES NURS HEALTH, V28, P187, DOI 10.1002/nur.20077; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BOULT C, 1993, J AM GERIATR SOC, V41, P811, DOI 10.1111/j.1532-5415.1993.tb06175.x; Boult C, 2010, HEALTH AFFAIR, V29, P811, DOI 10.1377/hlthaff.2010.0095; Boyd CM, 2007, GERONTOLOGIST, V47, P697, DOI 10.1093/geront/47.5.697; Boyd CM, 2010, J GEN INTERN MED, V25, P235, DOI 10.1007/s11606-009-1192-5; Brodaty H, 2003, J AM GERIATR SOC, V51, P657, DOI 10.1034/j.1600-0579.2003.00210.x; Centers for Disease Control and Prevention, 2004, 2004 NAT NURS HOM SU; Centers for Medicare & Medicaid Services, PROGR ALL INCL CAR E; Chen A., 2000, BEST PRACTICES COORD; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Counsell SR, 2007, JAMA-J AM MED ASSOC, V298, P2623, DOI 10.1001/jama.298.22.2623; Counsell SR, 2006, J AM GERIATR SOC, V54, P1136, DOI 10.1111/j.1532-5415.2006.00791.x; Counsell SR, 2009, J AM GERIATR SOC, V57, P1420, DOI 10.1111/j.1532-5415.2009.02383.x; Darer JD, 2004, ACAD MED, V79, P541, DOI 10.1097/00001888-200406000-00009; DiMatteo MR, 2004, HEALTH PSYCHOL, V23, P207, DOI 10.1037/0278-6133.23.2.207; Dorr DA, 2008, J AM GERIATR SOC, V56, P2195, DOI 10.1111/j.1532-5415.2008.02005.x; Gravelle H, 2007, BMJ-BRIT MED J, V334, P31, DOI 10.1136/bmj.39020.413310.55; Gross DL, 2004, MILBANK Q, V82, P257, DOI 10.1111/j.0887-378X.2004.00310.x; Harrington C., 2009, HOME COMMUNITY BASED; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Institute of Medicine, 2001, CROSSING QUALITY CHA; Institute of Medicine (US) Committee on the Future Health Care Workforce for Older Americans, 2008, RET AG AM BUILD HLTH, DOI DOI 10.17226/12089; Irvin CV, 1997, HEALTH CARE FINANC R, V19, P135; *J HOPK U, CAR WHOL PERS THOS W; *J HOPK U, MEDHOMEINFO YOUR RES; Kane RL, 2006, J GERONTOL A-BIOL, V61, P689, DOI 10.1093/gerona/61.7.689; Leff B, 2009, AM J MANAG CARE, V15, P555; Leutz Walter, 2005, Int J Integr Care, V5, pe25; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Marsteller JA, 2010, ANN FAM MED, V8, P308, DOI 10.1370/afm.1134; *MATH POL RES, EFF PROGR ALL INCL C; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Melis RJF, 2008, J GERONTOL A-BIOL, V63, P283, DOI 10.1093/gerona/63.3.283; Nadash P, 2004, GERONTOLOGIST, V44, P644, DOI 10.1093/geront/44.5.644; *NAT PACE ASS, PACE SERV AR; *NAT PACE ASS, PACE VIT STAT; National PACE Association, 2011, WHAT IS PACE; *PAT CTR PRIM CAR, 2010, PIL DEM; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Pinquart M, 2006, INT PSYCHOGERIATR, V18, P577, DOI 10.1017/S1041610206003462; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Rabow MW, 2004, JAMA-J AM MED ASSOC, V291, P483, DOI 10.1001/jama.291.4.483; Schraeder C, 2001, J GERONTOL A-BIOL, V56, pM106, DOI 10.1093/gerona/56.2.M106; SHEA K, 2008, HLTH CARE OPINION LE; Stock R, 2008, J AM GERIATR SOC, V56, P1342, DOI 10.1111/j.1532-5415.2008.01763.x; Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x; Weaver FM, 2008, J AM GERIATR SOC, V56, P345, DOI 10.1111/j.1532-5415.2007.01538.x; Wieland D, 2003, CRIT REV ONCOL HEMAT, V48, P227, DOI 10.1016/j.critrevonc.2003.06.005; Wieland D., 2006, ENCY AGING, P973; Wieland D, 2010, J GERONTOL A-BIOL, V65, P721, DOI 10.1093/gerona/glq040; Wolff JL, 2010, GERONTOLOGIST, V50, P459, DOI 10.1093/geront/gnp124; Wolff JL, 2009, J GERONTOL A-BIOL, V64, P785, DOI 10.1093/gerona/glp030; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269	60	121	125	3	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1936	1943		10.1001/jama.2010.1623	http://dx.doi.org/10.1001/jama.2010.1623			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045100				2022-12-28	WOS:000283725900024
J	Mitchell, SL; Miller, SC; Teno, JM; Kiely, DK; Davis, RB; Shaffer, ML				Mitchell, Susan L.; Miller, Susan C.; Teno, Joan M.; Kiely, Dan K.; Davis, Roger B.; Shaffer, Michele L.			Prediction of 6-Month Survival of Nursing Home Residents With Advanced Dementia Using ADEPT vs Hospice Eligibility Guidelines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; END; LIFE; ENROLLMENT; AGREEMENT; DISEASE; RISK; LONG; MDS	Context Estimating life expectancy is challenging in advanced dementia, potentially limiting the use of hospice care in these patients. Objective To prospectively validate and compare the performance of the Advanced Dementia Prognostic Tool (ADEPT) and hospice eligibility guidelines to estimate 6-month survival in nursing home residents with advanced dementia. Design, Setting, and Participants A prospective cohort study conducted in 21 nursing homes in Boston, Massachusetts, of 606 residents with advanced dementia who were recruited between November 1, 2007, and July 30, 2009. Data were ascertained at baseline to determine the residents' ADEPT score (range, 1.0-32.5; higher scores indicate worse prognosis) and whether they met Medicare hospice eligibility guidelines. Survival was followed up to 6 months. Main Outcome Measures Assessment and comparison of the performance of the ADEPT score and hospice guidelines to predict 6-month survival using sensitivity, specificity, and the area under the receiver operating characteristic (AUROC) curve. Results At baseline, the residents' mean (SD) ADEPT score was 10.1 (3.1) points and 65 residents (10.7%) met hospice eligibility guidelines. Over 6 months, 111 residents (18.3%) died. The AUROC for the ADEPT score's prediction of 6-month mortality as a continuous variable was 0.67 (95% confidence interval [CI], 0.62-0.72). The AUROC for Medicare hospice eligibility guidelines was 0.55 (95% CI, 0.51-0.59), the specificity was 0.89 (95% CI, 0.86-0.92), and the sensitivity was 0.20 (95% CI, 0.13-0.28). Using a cutoff of 13.5 on the ADEPT score, which also had specificity of 0.89, the AUROC was 0.58 (95% CI, 0.54-0.63) and the sensitivity was 0.27 (95% CI, 0.19-0.36). Conclusions When prospectively validated at the bedside and used as a continuous measure, the ability of the ADEPT score to identify nursing home residents with advanced dementia at high risk of death within 6 months was modest, albeit better than hospice eligibility guidelines. Care provided to these residents should be guided by their goals of care rather than estimated life expectancy. JAMA. 2010; 304(17): 1929-1935	[Mitchell, Susan L.; Kiely, Dan K.] Inst Aging Res, Boston, MA 02131 USA; [Mitchell, Susan L.; Davis, Roger B.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Miller, Susan C.; Teno, Joan M.] Brown Univ, Sch Med, Dept Community Hlth, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; [Shaffer, Michele L.] Penn State Coll Med, Hershey, PA USA	Harvard University; Beth Israel Deaconess Medical Center; Brown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mitchell, SL (corresponding author), Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.	smitchell@hsl.harvard.edu	Miller, Susan/J-5450-2014	Miller, Susan/0000-0003-2008-6385	National Institutes of Health-National Institute on Aging (NIH-NIA) [R01 AG028423, K24AG033640]; NATIONAL INSTITUTE ON AGING [R01AG028423, K24AG033640] Funding Source: NIH RePORTER	National Institutes of Health-National Institute on Aging (NIH-NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by the National Institutes of Health-National Institute on Aging (NIH-NIA) grant R01 AG028423. Dr Mitchell is supported by the NIH-NIA grant K24AG033640.	[Anonymous], HOSPICE J; BEAM CA, 1991, BIOMETRICS, V47, P907, DOI 10.2307/2532648; BLOCH DA, 1989, BIOMETRICS, V45, P269, DOI 10.2307/2532052; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Efron B., 1982, SOC IND APPL MATH CB, V38; Ely D.M., 2021, NATL VITAL STAT REPO, V70; HANRAHAN P, 1995, J AM GERIATR SOC, V43, P56, DOI 10.1111/j.1532-5415.1995.tb06243.x; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; LIU KB, 1994, MED CARE, V32, P315, DOI 10.1097/00005650-199404000-00001; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; Marsh GW, 2000, APPL NURS RES, V13, P187, DOI 10.1053/apnr.2000.7654; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; Miller SC, 2004, J AM GERIATR SOC, V52, P1284, DOI 10.1111/j.1532-5415.2004.52357.x; Miller SC, 2001, AM J MED, V111, P38, DOI 10.1016/S0002-9343(01)00747-1; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Mitchell SL, 2005, J AM GERIATR SOC, V53, P299, DOI 10.1111/j.1532-5415.2005.53118.x; Mitchell SL, 2004, JAMA-J AM MED ASSOC, V291, P2734, DOI 10.1001/jama.291.22.2734; Mitchell SL, 2007, J PAIN SYMPTOM MANAG, V34, P7, DOI 10.1016/j.jpainsymman.2007.01.003; Mitchell SL, 2010, J PAIN SYMPTOM MANAG, V40, P639, DOI 10.1016/j.jpainsymman.2010.02.014; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; National Hospice and Palliative Care Organization, FACTS HOSP PALL CAR; REISBERG B, 1988, PSYCHOPHARMACOL BULL, V24, P653; Schonwetter Ronald S, 2003, Am J Hosp Palliat Care, V20, P105, DOI 10.1177/104990910302000208; Shega JW, 2008, J PAIN SYMPTOM MANAG, V35, P499, DOI 10.1016/j.jpainsymman.2007.06.011; van der Steen JT, 2007, J AM MED DIR ASSOC, V8, P464, DOI 10.1016/j.jamda.2007.05.004; van der Steen JT, 2006, J CLIN EPIDEMIOL, V59, P970, DOI 10.1016/j.jclinepi.2005.12.005; van der Steen JT, 2002, ARCH INTERN MED, V162, P1753, DOI 10.1001/archinte.162.15.1753; VOLICER BJ, 1993, J AM GERIATR SOC, V41, P535, DOI 10.1111/j.1532-5415.1993.tb01891.x; Volicer L, 1997, J AM GERIATR SOC, V45, P1147, DOI 10.1111/j.1532-5415.1997.tb05982.x; World Health Organization(WHO), BMI CLASS	37	151	152	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1929	1935		10.1001/jama.2010.1572	http://dx.doi.org/10.1001/jama.2010.1572			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045099	Green Accepted			2022-12-28	WOS:000283725900023
J	Allen, KD; Oddone, EZ; Coffman, CJ; Datta, SK; Juntilla, KA; Lindquist, JH; Walker, TA; Weinberger, M; Bosworth, HB				Allen, Kelli D.; Oddone, Eugene Z.; Coffman, Cynthia J.; Datta, Santanu K.; Juntilla, Karen A.; Lindquist, Jennifer H.; Walker, Tessa A.; Weinberger, Morris; Bosworth, Hayden B.			Telephone-Based Self-management of Osteoarthritis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-STATUS; EDUCATION-PROGRAMS; CLINICAL-TRIALS; CHRONIC DISEASE; ARTHRITIS; VETERANS; OUTCOMES; KNEE; INTERVENTIONS; METAANALYSIS	Background: Osteoarthritis is a leading cause of pain and disability, and self-management behaviors for osteoarthritis are underutilized. Objective: To examine the effectiveness of a telephone-based self-management intervention for hip or knee osteoarthritis in a primary care setting. Design: Randomized clinical trial with equal assignment to osteoarthritis self-management, health education (attention control), and usual care control groups. (ClinicalTrials.gov registration number: NCT00288912) Setting: Primary care clinics in a Veterans Affairs Medical Center. Patients: 515 patients with symptomatic hip or knee osteoarthritis. Intervention: The osteoarthritis self-management intervention involved educational materials and 12 monthly telephone calls to support individualized goals and action plans. The health education intervention involved nonosteoarthritis educational materials and 12 monthly telephone calls related to general health screening topics. Measurements: The primary outcome was score on the Arthritis Impact Measurement Scales-2 pain subscale (range, 0 to 10). Pain was also assessed with a 10-cm visual analog scale. Measurements were collected at baseline and 12 months. Results: 461 participants (90%) completed the 12-month assessment. The mean Arthritis Impact Measurement Scales-2 pain score in the osteoarthritis self-management group was 0.4 point lower (95% CI, -0.8 to 0.1 point; P = 0.105) than in the usual care group and 0.6 point lower (CI, -1.0 to -0.2 point; P = 0.007) than in the health education group at 12 months. The mean visual analog scale pain score in the osteoarthritis self-management group was 1.1 points lower (CI, -1.6 to -0.6 point; P < 0.001) than in the usual care group and 1.0 point lower (CI, -1.5 to -0.5 point; P < 0.001) than in the health education group. Health care use did not differ across the groups. Limitation: The study was conducted at 1 Veterans Affairs Medical Center, and the sample consisted primarily of men. Conclusion: A telephone-based osteoarthritis self-management program produced moderate improvements in pain, particularly compared with a health education control group.	Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Durham, NC 27706 USA; Univ N Carolina, Chapel Hill, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Allen, KD (corresponding author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv 152, Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.	kelli.allen@duke.edu			U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 04-016, 08-027, 91-408]	U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service(US Department of Veterans Affairs)	By the U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 04-016 and Career Scientist Awards 08-027 [Dr. Bosworth] and 91-408 [Dr. Weinberger]).	Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; Allen KD, 2010, OSTEOARTHR CARTILAGE, V18, P160, DOI 10.1016/j.joca.2009.09.010; Allen KD, 2009, OSTEOARTHR CARTILAGE, V17, P1132, DOI 10.1016/j.joca.2009.03.003; Allen KD, 2008, CONTEMP CLIN TRIALS, V29, P596, DOI 10.1016/j.cct.2007.11.004; [Anonymous], 1999, STAT MED, V18, P1905; Balding DJ, 2004, APPL LONGITUDINAL AN; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; BELLAMY N, 1992, J RHEUMATOL, V19, P451; Brady TJ, 2003, HEALTH EDUC BEHAV, V30, P44, DOI 10.1177/1090198102239258; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P484; Centers for Disease Control and Prevention (CDC), 2002, MMWR MORB MORTAL WKL, V51, P948; Cherry Donald K, 2007, Adv Data, P1; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Devos-Comby L, 2006, J RHEUMATOL, V33, P744; Dominick Kelli L, 2005, Ethn Dis, V15, P116; Dominick KL, 2006, J RHEUMATOL, V33, P348; Eberle E, 1999, OSTEOARTHR CARTILAGE, V7, P502, DOI 10.1053/joca.1999.0246; Fontaine KR, 2004, ARTHRITIS RHEUM-US, V50, P624, DOI 10.1002/art.20057; Hootman JM, 2003, ARTHRIT RHEUM-ARTHR, V49, P129, DOI 10.1002/art.10911; Johnson SS, 2008, PREV MED, V46, P238, DOI 10.1016/j.ypmed.2007.09.010; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Little R.J.A., 2002, STAT ANAL MISSING DA; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; Lorig KR, 2004, MED CARE, V42, P346, DOI 10.1097/01.mlr.0000118709.74348.65; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Maisiak R, 1996, ARTHRITIS RHEUM-US, V39, P1391, DOI 10.1002/art.1780390818; Marcus BH, 1998, ANN BEHAV MED, V20, P174, DOI 10.1007/BF02884958; Mazzuca SA, 1997, ARTHRIT CARE RES, V10, P289, DOI 10.1002/art.1790100503; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; MEENAN RF, 1984, ARTHRITIS RHEUM, V27, P1344, DOI 10.1002/art.1780271204; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; Phibbs CS, 2003, MED CARE RES REV, V60, p54S, DOI 10.1177/1077558703256725; ROGERS WH, 2004, PMID, V27, P249; STASON WB, 1994, MED CARE, V32, P1197, DOI 10.1097/00005650-199412000-00004; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Verbeke G, 2000, LINEAR MIXED MODELS; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; Warsi A, 2003, ARTHRITIS RHEUM-US, V48, P2207, DOI 10.1002/art.11210; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhao GX, 2009, PREV MED, V48, P117, DOI 10.1016/j.ypmed.2008.11.002	42	76	80	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					570	579		10.7326/0003-4819-153-9-201011020-00006	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	673MH	21041576				2022-12-28	WOS:000283667000003
J	Olsen, A; Ninnemann, U				Olsen, Are; Ninnemann, Ulysses			Large delta C-13 Gradients in the Preindustrial North Atlantic Revealed	SCIENCE			English	Article							CIRCULATION; C-13	The carbon isotopic composition (C-13/C-12, expressed as delta C-13) of fossil foraminifera is the primary tracer used to infer changes in past ocean ventilation, and its variations are interpreted by using the modern oceanic delta C-13 distribution as a framework. However, the present ocean delta C-13 distribution is strongly overprinted by isotopically light anthropogenic carbon dioxide. A correction for this oceanic C-13 Suess effect in the North Atlantic (NA) shows that the pristine NA delta C-13 distribution has a richer and more detailed structure that is more clearly related to water mass distributions. Our results revise some fundamental perceptions regarding glacial-interglacial ocean delta C-13 differences and allow paleo-delta C-13 variations to be understood within the context of modern climate variability.	[Olsen, Are] Uni Bjerknes Ctr, N-5007 Bergen, Norway; [Olsen, Are; Ninnemann, Ulysses] Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; [Ninnemann, Ulysses] Univ Bergen, Dept Earth Sci, N-5007 Bergen, Norway	Bjerknes Centre for Climate Research; Bjerknes Centre for Climate Research; University of Bergen	Olsen, A (corresponding author), Uni Bjerknes Ctr, Allegaten 55, N-5007 Bergen, Norway.	are.olsen@uni.no	Olsen, Are/A-1511-2011	Olsen, Are/0000-0003-1696-9142	Norwegian Research Council	Norwegian Research Council(Research Council of NorwayEuropean Commission)	This work was supported by funding from the Norwegian Research Council (A-CARB) and contributes to EU-FP7 IP Past4Future. It is publication no. A305 from the Bjerknes Centre for Climate Research.	Broecker WS, 1992, GLOBAL BIOGEOCHEM CY, V6, P315, DOI 10.1029/92GB01672; Curry WB, 2005, PALEOCEANOGRAPHY, V20, DOI 10.1029/2004PA001021; Keir R, 1998, GLOBAL BIOGEOCHEM CY, V12, P467, DOI 10.1029/98GB02054; KROOPNICK PM, 1985, DEEP-SEA RES, V32, P57, DOI 10.1016/0198-0149(85)90017-2; Lyell C., 1833, PRINCIPLES GEOLOGY; Marchal O, 2008, J PHYS OCEANOGR, V38, P2014, DOI 10.1175/2008JPO3895.1; Oppo DW, 2003, NATURE, V422, P277, DOI 10.1038/422277b; OPPO DW, 1993, SCIENCE, V259, P1148, DOI 10.1126/science.259.5098.1148; QUAY PD, 1992, SCIENCE, V256, P74, DOI 10.1126/science.256.5053.74; Yashayaev I, 2008, OCEANOGRAPHY, V21, P30, DOI 10.5670/oceanog.2008.65	10	45	45	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					658	659		10.1126/science.1193769	http://dx.doi.org/10.1126/science.1193769			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030654				2022-12-28	WOS:000283580600044
J	Vaidhyanathan, R; Iremonger, SS; Shimizu, GKH; Boyd, PG; Alavi, S; Woo, TK				Vaidhyanathan, Ramanathan; Iremonger, Simon S.; Shimizu, George K. H.; Boyd, Peter G.; Alavi, Saman; Woo, Tom K.			Direct Observation and Quantification of CO2 Binding Within an Amine-Functionalized Nanoporous Solid	SCIENCE			English	Article							METAL-ORGANIC FRAMEWORKS; CARBON-DIOXIDE; MESOPOROUS SILICA; AQUEOUS-SOLUTIONS; ADSORPTION SITES; CRYSTAL; DIFFRACTION	Understanding the molecular details of CO2-sorbent interactions is critical for the design of better carbon-capture systems. Here we report crystallographic resolution of CO2 molecules and their binding domains in a metal-organic framework functionalized with amine groups. Accompanying computational studies that modeled the gas sorption isotherms, high heat of adsorption, and CO2 lattice positions showed high agreement on all three fronts. The modeling apportioned specific binding interactions for each CO2 molecule, including substantial cooperative binding effects among the guest molecules. The validation of the capacity of such simulations to accurately model molecular-scale binding bodes well for the theory-aided development of amine-based CO2 sorbents. The analysis shows that the combination of appropriate pore size, strongly interacting amine functional groups, and the cooperative binding of CO2 guest molecules is responsible for the low-pressure binding and large uptake of CO2 in this sorbent material.	[Vaidhyanathan, Ramanathan; Iremonger, Simon S.; Shimizu, George K. H.] Univ Calgary, Dept Chem, Calgary, AB T2N 1N4, Canada; [Boyd, Peter G.; Alavi, Saman; Woo, Tom K.] Univ Ottawa, Ctr Catalysis Res & Innovat, Dept Chem, Ottawa, ON K1N 6N5, Canada	University of Calgary; University of Ottawa	Vaidhyanathan, R (corresponding author), Univ Calgary, Dept Chem, Calgary, AB T2N 1N4, Canada.	vvramana@ucalgary.ca; gshimizu@ucalgary.ca; twoo@uottawa.ca	Alavi, Saman/A-1373-2012; Vaidhyanathan, Ramanathan/X-9314-2019; Woo, Tom/D-7701-2011	Alavi, Saman/0000-0001-9463-8766; 	Institute for Sustainable Energy, Environment and Economy at the University of Calgary; Alberta Energy Research Institute; Canada Research Chairs Program; High Performance Computing Virtual Laboratory	Institute for Sustainable Energy, Environment and Economy at the University of Calgary; Alberta Energy Research Institute; Canada Research Chairs Program(Canada Research Chairs); High Performance Computing Virtual Laboratory	T.K.W. and G. K. H. S. thank the Natural Sciences and Engineering Research Council of Canada. G. K. H. S. thanks the Institute for Sustainable Energy, Environment and Economy at the University of Calgary and the Alberta Energy Research Institute for partial financial support of this work. T. K. W. and P. G. B. thank the Canada Research Chairs Program and the High Performance Computing Virtual Laboratory for financial support. Crystallographic data for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre (CCDC) under reference numbers CCDC 782638 to 782642. These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK).	An J, 2010, J AM CHEM SOC, V132, P38, DOI 10.1021/ja909169x; Arstad B, 2008, ADSORPTION, V14, P755, DOI 10.1007/s10450-008-9137-6; Arstad B, 2007, J PHYS CHEM A, V111, P1222, DOI 10.1021/jp065301v; Belmabkhout Y, 2009, ADSORPTION, V15, P318, DOI 10.1007/s10450-009-9185-6; Campana C, 2009, J CHEM THEORY COMPUT, V5, P2866, DOI 10.1021/ct9003405; Caskey SR, 2008, J AM CHEM SOC, V130, P10870, DOI 10.1021/ja8036096; Deguchi H, 2010, IND ENG CHEM RES, V49, P6, DOI 10.1021/ie9009556; Demessence A, 2009, J AM CHEM SOC, V131, P8784, DOI 10.1021/ja903411w; Dietzel PDC, 2008, CHEM COMMUN, P5125, DOI 10.1039/b810574j; Duren T, 2009, CHEM SOC REV, V38, P1237, DOI 10.1039/b803498m; Grimme S, 2006, J COMPUT CHEM, V27, P1787, DOI 10.1002/jcc.20495; Kim BJ, 2010, J COLLOID INTERF SCI, V342, P575, DOI 10.1016/j.jcis.2009.10.045; Kim S, 2005, J PHYS CHEM B, V109, P6287, DOI 10.1021/jp045634x; Kim SN, 2008, MICROPOR MESOPOR MAT, V115, P497, DOI 10.1016/j.micromeso.2008.02.025; Kitaura R, 2002, SCIENCE, V298, P2358, DOI 10.1126/science.1078481; Matsuda R, 2005, NATURE, V436, P238, DOI 10.1038/nature03852; Millward AR, 2005, J AM CHEM SOC, V127, P17998, DOI 10.1021/ja0570032; Peterson VK, 2006, J AM CHEM SOC, V128, P15578, DOI 10.1021/ja0660857; Phan A, 2010, ACCOUNTS CHEM RES, V43, P58, DOI 10.1021/ar900116g; Ramsahye NA, 2008, J PHYS CHEM C, V112, P514, DOI 10.1021/jp075782y; Rochelle GT, 2009, SCIENCE, V325, P1652, DOI 10.1126/science.1176731; SIMON A, 1980, ACTA CRYSTALLOGR B, V36, P2750, DOI 10.1107/S0567740880009879; Siriwardane RV, 2005, ENERG FUEL, V19, P1153, DOI 10.1021/ef040059h; Tafipolsky M, 2010, MICROPOR MESOPOR MAT, V129, P304, DOI 10.1016/j.micromeso.2009.07.006; Takamizawa S, 2010, J AM CHEM SOC, V132, P3783, DOI 10.1021/ja9091598; Thallapally PK, 2008, J AM CHEM SOC, V130, P16842, DOI 10.1021/ja806391k; Vaidhyanathan R, 2009, CHEM COMMUN, P5230, DOI 10.1039/b911481e; Villiers C, 2010, ANGEW CHEM INT EDIT, V49, P3465, DOI 10.1002/anie.201001035; Walton KS, 2008, J AM CHEM SOC, V130, P406, DOI 10.1021/ja076595g; Wang B, 2008, NATURE, V453, P207, DOI 10.1038/nature06900; Wei JW, 2008, MICROPOR MESOPOR MAT, V116, P394, DOI 10.1016/j.micromeso.2008.04.028; Wu H, 2010, J PHYS CHEM LETT, V1, P1946, DOI 10.1021/jz100558r; Zhang JP, 2009, J AM CHEM SOC, V131, P5516, DOI 10.1021/ja8089872; Zukal A, 2009, LANGMUIR, V25, P10314, DOI 10.1021/la901156z	34	770	784	15	565	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					650	653		10.1126/science.1194237	http://dx.doi.org/10.1126/science.1194237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030651				2022-12-28	WOS:000283580600041
J	Robinson, A				Robinson, Andrew			The art of medicine: Perspiration, inspiration, and the 10-year rule	LANCET			English	Editorial Material									Univ Cambridge Wolfson Coll, Cambridge CB3 9BB, England	University of Cambridge	Robinson, A (corresponding author), Univ Cambridge Wolfson Coll, Cambridge CB3 9BB, England.	andrew.robinson33@virgin.net							0	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2010	376	9751					1458	1459		10.1016/S0140-6736(10)61982-4	http://dx.doi.org/10.1016/S0140-6736(10)61982-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	21046705	Bronze			2022-12-28	WOS:000284248500015
J	Esler, MD; Krum, H; Sobotka, PA; Schlaich, MP; Schmieder, RE; Boehm, M; Mahfoud, F; Sievert, H; Wunderlich, N; Rump, LC; Vonend, O; Uder, M; Lobo, M; Caulfield, M; Erglis, A; Azizi, M; Sapoval, M; Thambar, S; Persu, A; Renkin, J; Schunkert, H; Weil, J; Hoppe, UC; Walton, T; Scheinert, D; Binder, T; Januszewicz, A; Witkowski, A; Ruilope, LM; Whitbourn, R; Bruck, H; Downes, M; Luscher, TF; Jardine, AG; Webster, MW; Zeller, T; Sadowski, J; Bartus, K; Straley, CA; Barman, NC; Lee, DP; Witteles, RM; Bhalla, V; Massaro, JM				Esler, Murray D.; Krum, Henry; Sobotka, Paul A.; Schlaich, Markus P.; Schmieder, Roland E.; Boehm, Michael; Mahfoud, Felix; Sievert, Horst; Wunderlich, Nina; Rump, Lars Christian; Vonend, Oliver; Uder, Michael; Lobo, Mel; Caulfield, Mark; Erglis, Andrejs; Azizi, Michel; Sapoval, Marc; Thambar, Suku; Persu, Alexandre; Renkin, Jean; Schunkert, Heribert; Weil, Joachim; Hoppe, Uta C.; Walton, Tony; Scheinert, Dierk; Binder, Thomas; Januszewicz, Andrzej; Witkowski, Adam; Ruilope, Luis M.; Whitbourn, Robert; Bruck, Heike; Downes, Mark; Luescher, Thomas F.; Jardine, Alan G.; Webster, Mark W.; Zeller, Thomas; Sadowski, Jerzy; Bartus, Krzysztof; Straley, Craig A.; Barman, Neil C.; Lee, David P.; Witteles, Ronald M.; Bhalla, Vivek; Massaro, Joseph M.		Symplicity HTN-2 Investigators	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial	LANCET			English	Article							NERVOUS-SYSTEM; BLOOD-PRESSURE; ACTIVATION; MECHANISMS; SPILLOVER; NERVES	Background Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. We aimed to assess effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Methods In this multicentre, prospective, randomised trial, patients who had a baseline systolic blood pressure of 160 mm Hg or more (>= 150 mm Hg for patients with type 2 diabetes), despite taking three or more antihypertensive drugs, were randomly allocated in a one-to-one ratio to undergo renal denervation with previous treatment or to maintain previous treatment alone (control group) at 24 participating centres. Randomisation was done with sealed envelopes. Data analysers were not masked to treatment assignment. The primary effectiveness endpoint was change in seated office-based measurement of systolic blood pressure at 6 months. Primary analysis included all patients remaining in follow-up at 6 months. This trial is registered with ClinicalTrials.gov, number NCT00888433. Findings 106 (56%) of 190 patients screened for eligibility were randomly allocated to renal denervation (n=52) or control (n=54) groups between June 9, 2009, and Jan 15, 2010. 49 (94%) of 52 patients who underwent renal denervation and 51 (94%) of 54 controls were assessed for the primary endpoint at 6 months. Office-based blood pressure measurements in the renal denervation group reduced by 32/12 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p<0.0001), whereas they did not differ from baseline in the control group (change of 1/0 mm Hg [21/10], baseline of 178/97 mm Hg, p=0.77 systolic and p=0.83 diastolic). Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p<0.0001). At 6 months, 41 (84%) of 49 patients who underwent renal denervation had a reduction in systolic blood pressure of 10 mm Hg or more, compared with 18 (35%) of 51 controls (p<0.0001). We noted no serious procedure-related or device-related complications and occurrence of adverse events did not differ between groups; one patient who had renal denervation had possible progression of an underlying atherosclerotic lesion, but required no treatment. Interpretation Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients.	[Krum, Henry; Walton, Tony] Alfred Hosp, Melbourne, Vic, Australia; [Sobotka, Paul A.; Straley, Craig A.; Barman, Neil C.] Ardian, Mountain View, CA USA; [Schmieder, Roland E.; Uder, Michael] Univ Erlangen Nurnberg, Erlangen, Germany; [Boehm, Michael; Mahfoud, Felix] Univ Klinikum Saarlandes, Homburg, Germany; [Sievert, Horst; Wunderlich, Nina] CardioVasc Ctr Frankfurt, Frankfurt, Germany; [Rump, Lars Christian; Vonend, Oliver] Univ Klinikum Dusseldorf, Dusseldorf, Germany; [Lobo, Mel; Caulfield, Mark] Queen Mary Univ London, Barts & London NIHR Cardiovasc Biomed Res Unit, William Harvey Res Inst, London, England; [Erglis, Andrejs] Paula Stradins Clin Univ Hosp, Riga, Latvia; [Azizi, Michel; Sapoval, Marc] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Thambar, Suku] John Hunter Hosp, Newcastle, NSW, Australia; [Persu, Alexandre; Renkin, Jean] Clin Univ St Luc, B-1200 Brussels, Belgium; [Schunkert, Heribert; Weil, Joachim] Univ Klinikum Schleswig Holstein, D-23538 Lubeck, Germany; [Hoppe, Uta C.] Univ Cologne, Cologne, Germany; [Scheinert, Dierk] Univ Leipzig, Herzzentrum, Leipzig, Germany; [Binder, Thomas] Allgemeines Krankenhaus Stadt Wien, Vienna, Austria; [Januszewicz, Andrzej; Witkowski, Adam] Samodzielna Pracownia Hemodynamiczna, Warsaw, Poland; [Ruilope, Luis M.] Hosp 12 Octubre, E-28041 Madrid, Spain; [Whitbourn, Robert] St Vincents Hosp, Melbourne, Vic, Australia; [Bruck, Heike] Univ Klinikum Essen, Essen, Germany; [Downes, Mark] Kent & Canterbury Hosp, Canterbury, Kent, England; [Luescher, Thomas F.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Jardine, Alan G.] Univ Glasgow, Glasgow, Lanark, Scotland; [Webster, Mark W.] Auckland City Hosp, Auckland, New Zealand; [Zeller, Thomas] Herz Zentrum Bad Krozingen, Bad Krozingen, Germany; [Sadowski, Jerzy; Bartus, Krzysztof] Jagiellonian Univ, John Paul II Hosp, Krakow, Poland; [Lee, David P.; Witteles, Ronald M.; Bhalla, Vivek] Stanford Univ, Stanford, CA 94305 USA; [Massaro, Joseph M.] Harvard Clin Res Inst, Boston, MA USA; [Esler, Murray D.; Schlaich, Markus P.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; University of Erlangen Nuremberg; Universitatsklinikum des Saarlandes; Cardiovascular Center (CVC) Frankfurt; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of London; Queen Mary University London; Pauls Stradins Clinical University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; John Hunter Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Kiel; Schleswig Holstein University Hospital; University of Cologne; Heart Center Leipzig GMBH; Leipzig University; Hospital Universitario 12 de Octubre; St Vincent's Hospital Melbourne; University of Duisburg Essen; University of Kent; University of Zurich; University Zurich Hospital; University of Glasgow; Auckland City Hospital; Jagiellonian University; Stanford University; Harvard University; Harvard Medical School; Baker Heart and Diabetes Institute	Esler, MD (corresponding author), Baker IDI Heart & Diabet Inst, POB 6492,St Kilda Rd, Cent Melbourne, Vic 8008, Australia.	murray.esler@bakeridi.edu.au	Azizi, Michel/L-3418-2013; Azizi, Michel/Y-9580-2019; Mahfoud, Felix/D-7707-2011; Jardine, Alan/L-5770-2019; Bartus, Krzysztof/AAR-3822-2021; Böhm, Michael/C-3638-2011	Bartus, Krzysztof/0000-0002-3457-6978; Thambar, Suku/0000-0002-0801-7021; Jardine, Alan/0000-0001-5815-9370; Caulfield, Mark/0000-0001-9295-3594; Barman, Neil/0000-0001-5713-6716; Bhalla, Vivek/0000-0002-5420-9657; Sapoval, marc/0000-0003-4226-6192; Persu, Alexandre/0000-0002-4007-9695; Erglis, Andrejs/0000-0002-3999-0182; Schlaich, Markus/0000-0002-1765-0195; Ruilope, Luis M/0000-0001-6278-7951	Ardian; Australian National Health and Medical Research Council; Abbott; Servier; Boehringer Ingelheim; Novartis; AstraZeneca	Ardian; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Abbott(Abbott Laboratories); Servier(Servier); Boehringer Ingelheim(Boehringer Ingelheim); Novartis(Novartis); AstraZeneca(AstraZeneca)	MDE has received consulting fees and travel expenses from Ardian; M DE's institution (Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia) has received a research grant from Ardian. HK has received travel expenses from Ardian. PAS is an employee of Ardian and has stock options. MPS has received grant support from Ardian and the Australian National Health and Medical Research Council, is a board member of Abbott Hypertension Steering Committee, has received payment for lectures from Abbott, Servier, Boehringer Ingelheim, Novartis, and AstraZeneca, and has received travel expenses from Novartis and AstraZeneca. RES has recieved grant support from Ardian. MB has received grant support from Ardian, and is a consultant for Seriver, Boehringer Ingelheim, and is on the speakers' bureau for Servier, Pfizer, Boehringer Ingelheim, AstraZeneca, and Sanofi.	Bakris GL, 2000, AM J KIDNEY DIS, V36, P646, DOI 10.1053/ajkd.2000.16225; CAMPESE VM, 1995, HYPERTENSION, V25, P878, DOI 10.1161/01.HYP.25.4.878; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; DiBona GF, 2010, AM J PHYSIOL-REG I, V298, pR245, DOI 10.1152/ajpregu.00647.2009; DiBona GF, 1997, PHYSIOL REV, V77, P75, DOI 10.1152/physrev.1997.77.1.75; ESLER M, 1988, HYPERTENSION, V11, P3, DOI 10.1161/01.HYP.11.1.3; Esler M, 2004, HBK HYPERT, V22, P81; Esler M, 2009, J HYPERTENS, V27, pS167; ESLER M, 1985, J HYPERTENS, V3, pS549; ESLER M, 1992, ANN INTERN MED, V116, P446, DOI 10.7326/0003-4819-116-6-446; Esler M, 2010, J APPL PHYSIOL, V108, P227, DOI 10.1152/japplphysiol.00832.2009; HANSEN JM, 1994, CLIN SCI, V87, P13, DOI 10.1042/cs0870013; HASKING GJ, 1986, CIRCULATION, V73, P615, DOI 10.1161/01.CIR.73.4.615; Hausberg M, 2002, CIRCULATION, V106, P1974, DOI 10.1161/01.CIR.0000034043.16664.96; HOOBLER SW, 1951, CIRCULATION, V4, P173, DOI 10.1161/01.CIR.4.2.173; KATHOLI RE, 1983, AM J PHYSIOL, V245, pF1, DOI 10.1152/ajprenal.1983.245.1.F1; KATHOLI RE, 1985, FED PROC, V44, P2846; KAYE DM, 1993, CIRCULATION, V88, P1110, DOI 10.1161/01.CIR.88.3.1110; Kopp UC, 2007, AM J PHYSIOL-REG I, V293, pR1561, DOI 10.1152/ajpregu.00485.2007; Krum H, 2009, LANCET, V373, P1275, DOI 10.1016/S0140-6736(09)60566-3; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; Rumantir MS, 1999, J HYPERTENS, V17, P1125, DOI 10.1097/00004872-199917080-00012; Schlaich M, 2010, J HYPERTENS, V28, pE446, DOI 10.1097/01.hjh.0000379536.30499.40; Schlaich M, 2009, J HYPERTENS, V27, pS27; Schlaich MP, 2009, NEW ENGL J MED, V361, P932, DOI 10.1056/NEJMc0904179; SMITHWICK RH, 1953, JAMA-J AM MED ASSOC, V152, P1501, DOI 10.1001/jama.1953.03690160001001; STELLA A, 1991, PHYSIOL REV, V71, P659, DOI 10.1152/physrev.1991.71.3.659; Wolf-Maier K, 2004, HYPERTENSION, V43, P10, DOI 10.1161/01.HYP.0000103630.72812.10	31	1610	1878	7	151	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	2010	376	9756					1903	1909		10.1016/S0140-6736(10)62039-9	http://dx.doi.org/10.1016/S0140-6736(10)62039-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KH	21093036				2022-12-28	WOS:000285439800031
J	Lubitz, SA; Yin, XY; Fontes, JD; Magnani, JW; Rienstra, M; Pai, M; Villalon, ML; Vasan, RS; Pencina, MJ; Levy, D; Larson, MG; Ellinor, PT; Benjamin, EJ				Lubitz, Steven A.; Yin, Xiaoyan; Fontes, Joao D.; Magnani, Jared W.; Rienstra, Michiel; Pai, Manju; Villalon, Mark L.; Vasan, Ramachandran S.; Pencina, Michael J.; Levy, Daniel; Larson, Martin G.; Ellinor, Patrick T.; Benjamin, Emelia J.			Association Between Familial Atrial Fibrillation and Risk of New-Onset Atrial Fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DISEASE; COMMON VARIANTS; AGGREGATION; HISTORY; REGRESSION; INTERVAL; ZFHX3; SCORE	Context Although the heritability of atrial fibrillation (AF) is established, the contribution of familial AF to predicting new-onset AF remains unknown. Objective To determine whether familial occurrence of AF is associated with new-onset AF beyond established risk factors. Design, Setting, and Participants The Framingham Heart Study, a prospective community-based cohort study started in 1948. Original and Offspring Cohort participants were aged at least 30 years, were free of AF at the baseline examination, and had at least 1 parent or sibling enrolled in the study. The 4421 participants in this analysis (mean age, 54 [SD, 13] years; 54% women) were followed up through December 31, 2007. Main Outcome Measures Incremental predictive value of incorporating different features of familial AF (any familial AF, premature familial AF [onset <65 years old], number of affected relatives, and youngest age of onset in a relative) into a risk model for new-onset AF. Results Across 11 971 examinations during the period 1968-2007, 440 participants developed AF. Familial AF occurred among 1185 participants (26.8%) and premature familial AF occurred among 351 participants (7.9%). Atrial fibrillation occurred more frequently among participants with familial AF than without familial AF (unadjusted absolute event rates of 5.8% and 3.1%, respectively). The association was not attenuated by adjustment for AF risk factors (multivariable-adjusted hazard ratio, 1.40; 95% confidence interval [CI], 1.13-1.74) or reported AF-related genetic variants. Among the different features of familial AF examined, premature familial AF was associated with improved discrimination beyond traditional risk factors to the greatest extent (traditional risk factors, C statistic, 0.842 [95% CI, 0.826-0.858]; premature familial AF, C statistic, 0.846 [95% CI, 0.831-0.862]; P=.004). Modest changes in integrated discrimination improvement were observed with premature familial AF (2.1%). Net reclassification improvement (assessed using 8-year risk thresholds of <5%, 5%-10%, and >10%) did not change significantly with premature familial AF (index statistic, 0.011; 95% CI, -0.021 to 0.042; P=.51), although categoryless net reclassification was improved (index statistic, 0.127; 95% CI, 0.064-0.189; P=.009). Conclusions In this cohort, familial AF was associated with an increased risk of AF that was not attenuated by adjustment for AF risk factors including genetic variants. Assessment of premature familial AF was associated with a very slight increase in predictive accuracy compared with traditional risk factors. JAMA. 2010;304(20):2263-2269 www.jama.com	[Yin, Xiaoyan; Fontes, Joao D.; Magnani, Jared W.; Vasan, Ramachandran S.; Pencina, Michael J.; Levy, Daniel; Larson, Martin G.; Benjamin, Emelia J.] Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA; [Lubitz, Steven A.; Rienstra, Michiel; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA; [Lubitz, Steven A.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; [Fontes, Joao D.; Magnani, Jared W.; Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA; [Vasan, Ramachandran S.; Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med Sect, Boston, MA 02118 USA; [Pai, Manju; Villalon, Mark L.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Pencina, Michael J.; Larson, Martin G.] Boston Univ, Dept Biostat, Boston, MA 02215 USA; [Benjamin, Emelia J.] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA; [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; [Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA; [Rienstra, Michiel] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA	Framingham Heart Study; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Harvard University; Massachusetts General Hospital; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Benjamin, EJ (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave,Ste 2, Framingham, MA 01702 USA.	emelia@bu.edu	Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Ramachandran, Vasan/Y-2527-2019; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Larson, Martin/0000-0002-9631-1254; Ellinor, Patrick/0000-0002-2067-0533; Pencina, Michael/0000-0001-5798-8855; Rienstra, Michiel/0000-0002-2581-070X; Fontes, Joao Daniel/0000-0001-5011-0855; Benjamin, Emelia/0000-0003-4076-2336	National Institutes of Health (NIH) [T32HL007575, 6R01-NS17950, HL092577, R01AG028321, RC1-HL01056, 1R01HL102214, DA027021, HL104156]; American Heart Association [09FTF2190028]; Netherlands Organization for Scientific Research [825.09.020]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006001] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Lubitz was supported by a National Institutes of Health (NIH) training grant in the Epidemiology of Cardiovascular Disease (grant T32HL007575). Dr Magnani is supported by American Heart Association grant 09FTF2190028. Dr Rienstra is supported by a Rubicon grant from the Netherlands Organization for Scientific Research (grant 825.09.020). Dr Benjamin is supported by NIH grant 6R01-NS17950. This work was supported by grants from the NIH to Drs Benjamin and Ellinor (grant HL092577), Dr Benjamin (grants R01AG028321, RC1-HL01056, and 1R01HL102214), and Dr Ellinor (grants DA027021 and HL104156).	[Anonymous], 2008, SAS 9 2 US GUID, P4517; Arnar DO, 2006, EUR HEART J, V27, P708, DOI 10.1093/eurheartj/ehi727; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; Benjamin EJ, 2009, NAT GENET, V41, P879, DOI 10.1038/ng.416; Christophersen IE, 2009, CIRC-ARRHYTHMIA ELEC, V2, P378, DOI 10.1161/CIRCEP.108.786665; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Darbar D, 2003, J AM COLL CARDIOL, V41, P2185, DOI 10.1016/S0735-1097(03)00465-0; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dublin S, 2010, J GEN INTERN MED, V25, P853, DOI 10.1007/s11606-010-1340-y; Dupuis J, 2010, NAT GENET, V42, P105, DOI 10.1038/ng.520; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Ellinor PT, 2010, NAT GENET, V42, P240, DOI 10.1038/ng.537; Ellinor PT, 2005, HUM GENET, V118, P179, DOI 10.1007/s00439-005-0034-8; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P2851, DOI 10.1001/jama.291.23.2851; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Gudbjartsson DF, 2007, NATURE, V448, P353, DOI 10.1038/nature06007; Gudbjartsson DF, 2009, NAT GENET, V41, P876, DOI 10.1038/ng.417; Holm H, 2010, NAT GENET, V42, P117, DOI 10.1038/ng.511; Lloyd-Jones DM, 2004, JAMA-J AM MED ASSOC, V291, P2204, DOI 10.1001/jama.291.18.2204; Marcus GM, 2008, HEART RHYTHM, V5, P826, DOI 10.1016/j.hrthm.2008.02.016; Murabito JM, 2005, JAMA-J AM MED ASSOC, V294, P3117, DOI 10.1001/jama.294.24.3117; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pencina MJ, 2011, STAT MED, V30, P11, DOI 10.1002/sim.4085; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; Pfeufer A, 2010, NAT GENET, V42, P153, DOI 10.1038/ng.517; Ridker PM, 2008, CIRCULATION, V118, P2243, DOI 10.1161/CIRCULATIONAHA.108.814251; Schnabel RB, 2009, LANCET, V373, P739, DOI 10.1016/S0140-6736(09)60443-8; Sesso HD, 2001, CIRCULATION, V104, P393, DOI 10.1161/hc2901.093115; GAINING MORE FLEXIBI	33	207	210	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2010	304	20					2263	2269		10.1001/jama.2010.1690	http://dx.doi.org/10.1001/jama.2010.1690			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KI	21076174	Green Accepted, Bronze			2022-12-28	WOS:000284548400025
J	Jaramillo, C; Ochoa, D; Contreras, L; Pagani, M; Carvajal-Ortiz, H; Pratt, LM; Krishnan, S; Cardona, A; Romero, M; Quiroz, L; Rodriguez, G; Rueda, MJ; de la Parra, F; Moron, S; Green, W; Bayona, G; Montes, C; Quintero, O; Ramirez, R; Mora, G; Schouten, S; Bermudez, H; Navarrete, R; Parra, F; Alvaran, M; Osorno, J; Crowley, JL; Valencia, V; Vervoort, J				Jaramillo, Carlos; Ochoa, Diana; Contreras, Lineth; Pagani, Mark; Carvajal-Ortiz, Humberto; Pratt, Lisa M.; Krishnan, Srinath; Cardona, Agustin; Romero, Millerlandy; Quiroz, Luis; Rodriguez, Guillermo; Rueda, Milton J.; de la Parra, Felipe; Moron, Sara; Green, Walton; Bayona, German; Montes, Camilo; Quintero, Oscar; Ramirez, Rafael; Mora, German; Schouten, Stefan; Bermudez, Hermann; Navarrete, Rosa; Parra, Francisco; Alvaran, Mauricio; Osorno, Jose; Crowley, James L.; Valencia, Victor; Vervoort, Jeff			Effects of Rapid Global Warming at the Paleocene-Eocene Boundary on Neotropical Vegetation	SCIENCE			English	Article							THERMAL MAXIMUM; CERREJON FORMATION; CLIMATE; TEMPERATURE; DISCRIMINATION; COLOMBIA; CANOPY; FOREST; TREE; CO2	Temperatures in tropical regions are estimated to have increased by 3 degrees to 5 degrees C, compared with Late Paleocene values, during the Paleocene-Eocene Thermal Maximum (PETM, 56.3 million years ago) event. We investigated the tropical forest response to this rapid warming by evaluating the palynological record of three stratigraphic sections in eastern Colombia and western Venezuela. We observed a rapid and distinct increase in plant diversity and origination rates, with a set of new taxa, mostly angiosperms, added to the existing stock of low-diversity Paleocene flora. There is no evidence for enhanced aridity in the northern Neotropics. The tropical rainforest was able to persist under elevated temperatures and high levels of atmospheric carbon dioxide, in contrast to speculations that tropical ecosystems were severely compromised by heat stress.	[Jaramillo, Carlos; Ochoa, Diana; Contreras, Lineth; Carvajal-Ortiz, Humberto; Cardona, Agustin; Romero, Millerlandy; Quiroz, Luis; Moron, Sara; Green, Walton; Bayona, German; Montes, Camilo] Smithsonian Trop Res Inst, Balboa, Panama; [Ochoa, Diana] E Tennessee State Univ, Dept Biol Sci, Johnson City, TN 37614 USA; [Contreras, Lineth; Rodriguez, Guillermo; Rueda, Milton J.; de la Parra, Felipe] Colombian Petr Inst, Bucaramanga, Colombia; [Contreras, Lineth] Goethe Univ Frankfurt, Inst Geosci, D-60438 Frankfurt, Germany; [Pagani, Mark; Krishnan, Srinath] Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; [Carvajal-Ortiz, Humberto; Pratt, Lisa M.] Indiana Univ, Dept Geol Sci, Bloomington, IN 47405 USA; [Quiroz, Luis] Univ Saskatchewan, Dept Geol, Saskatoon, SK, Canada; [Rodriguez, Guillermo] Missouri Univ Sci & Technol, Dept Geol Sci & Engn, Rolla, MO 65409 USA; [Rueda, Milton J.] Paleoflora Ltd, Zapatoca, Colombia; [Moron, Sara] Univ Minnesota, Dept Geol, Minneapolis, MN 55455 USA; [Bayona, German; Montes, Camilo] Corp Geol Ares, Bogota, Colombia; [Quintero, Oscar] Petroleos Venezuela SA PDVSA Explorac, Nucleoteca Concepc, Maracaibo, Venezuela; [Mora, German] Goucher Coll, Baltimore, MD 21204 USA; [Schouten, Stefan] Royal Netherlands Inst Sea Res NIOZ, Dept Marine Organ Biogeochem, NL-1790 AB Den Burg, Texel, Netherlands; [Bermudez, Hermann; Alvaran, Mauricio] Univ Caldas, Dept Geol Sci, Manizales, Colombia; [Parra, Francisco] Univ Toulouse 3, CU Ponsan Bellevue, F-31078 Tolulouse 04, France; [Osorno, Jose] Agencia Nacl Hidrocarburos, Bogota, Colombia; [Crowley, James L.] Boise State Univ, Dept Geosci, Boise, ID 83725 USA; [Valencia, Victor] Valencia Geoserv, Tucson, AZ 85712 USA; [Vervoort, Jeff] Washington State Univ, Sch Earth & Environm Sci, Pullman, WA 99164 USA	Smithsonian Institution; Smithsonian Tropical Research Institute; East Tennessee State University; Goethe University Frankfurt; Yale University; Indiana University System; Indiana University Bloomington; University of Saskatchewan; University of Missouri System; Missouri University of Science & Technology; University of Minnesota System; University of Minnesota Twin Cities; PDVSA; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); Universidad de Caldas; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Idaho; Boise State University; Washington State University	Jaramillo, C (corresponding author), Smithsonian Trop Res Inst, Box 0843-03092, Balboa, Panama.	jaramilloc@si.edu	Vervoort, Jeff/AAJ-6234-2020; Ochoa, Diana/AAV-1916-2020; Morón, Sara/AAK-5199-2021; Pagani, Mark/B-3233-2008	Ochoa, Diana/0000-0001-6242-4202; Montes, Camilo/0000-0002-3553-0787; Bermudez, Hermann/0000-0003-0656-2007; Crowley, James/0000-0001-5069-0773; Polanco, Sara/0000-0002-1270-4377; Parra Navarrete, Francisco Javier/0000-0003-0801-9446; jaramillo, carlos/0000-0002-2616-5079; Vervoort, Jeff/0000-0002-1138-4527	Banco de la Republica; National Geographic; Smithsonian Women's Club; Instituto de Colombiano de Petroleo (ICP)-Ecopetrol SA; NSF [EAR-0628358, ATM-0902882]; Netherlands Organisation for Scientific Research; Smithsonian	Banco de la Republica; National Geographic(National Geographic Society); Smithsonian Women's Club; Instituto de Colombiano de Petroleo (ICP)-Ecopetrol SA; NSF(National Science Foundation (NSF)); Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Smithsonian(Smithsonian Institution)	Supported by Banco de la Republica, National Geographic, Smithsonian Women's Club, Instituto de Colombiano de Petroleo (ICP)-Ecopetrol SA, and Smithsonian, M.P. was supported by NSF EAR-0628358 and ATM-0902882. S.S. was supported by a VISI grant from Netherlands Organisation for Scientific Research. Thanks to PDVSA for access to Mar 2X and the Instituto de Patrimonio Cultural of Venezuela for allowing us to sample in Riecito Mache. Thanks to Agencia Nacional de Hidrocarburos, A. Pardo, J. Sanchez, C. Guerrero, M. Carvalho, and the Colombian Armed Forces for logistic support. Thanks to the biostratigraphic team at ICP. Patrice Brenac did preliminary palynological analysis of Gonzales. N. Atkins provided editing support. A. Mets (NIOZ) is thanked for analytical assistance. K. Winter, H. Muller-Landau, J. Wright, and S. Punyasena and three anonymous reviewers provided comments on the manuscript. Special thanks to M. I. Barreto for continuous support and sources of ideas.	BASSOW SL, 1994, ECOL APPL, V4, P593, DOI 10.2307/1941960; Clyde WC, 1998, GEOLOGY, V26, P1011, DOI 10.1130/0091-7613(1998)026<1011:MCRTTL>2.3.CO;2; Diefendorf AF, 2010, P NATL ACAD SCI USA, V107, P5738, DOI 10.1073/pnas.0910513107; FARQUHAR GD, 1989, ANNU REV PLANT PHYS, V40, P503, DOI 10.1146/annurev.pp.40.060189.002443; Krause GH, 2010, FUNCT PLANT BIOL, V37, P890, DOI 10.1071/FP10034; Huber M, 2008, SCIENCE, V321, P353, DOI 10.1126/science.1161170; Huber M, 2009, NATURE, V457, P669, DOI 10.1038/457669a; Jaramillo C, 2006, SCIENCE, V311, P1893, DOI 10.1126/science.1121380; Jaramillo CA, 2007, PALYNOLOGY, V31, P153, DOI 10.2113/gspalynol.31.1.153; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Lewis SL, 2004, PHILOS T R SOC B, V359, P437, DOI 10.1098/rstb.2003.1432; Lloyd J, 2008, PHILOS T R SOC B, V363, P1811, DOI 10.1098/rstb.2007.0032; MULLER J, 1981, BOT REV, V47, P1, DOI 10.1007/BF02860537; Pagani M, 2006, SCIENCE, V314, P1556, DOI 10.1126/science.1136110; Punyasena SW, 2008, J BIOGEOGR, V35, P117, DOI 10.1111/j.1365-2699.2007.01773.x; Ramirez SR, 2007, NATURE, V448, P1042, DOI 10.1038/nature06039; Royer DL, 2010, P NATL ACAD SCI USA, V107, P517, DOI 10.1073/pnas.0913188107; Schuettpelz E, 2009, P NATL ACAD SCI USA, V106, P11200, DOI 10.1073/pnas.0811136106; Scotese CR., 2001, ATLAS EARTH HIST PRO; STOSKOPF NC, 1981, UNDERSTANDING CROP P; Tewksbury JJ, 2008, SCIENCE, V320, P1296, DOI 10.1126/science.1159328; VANDERMERWE NJ, 1991, J ARCHAEOL SCI, V18, P249, DOI 10.1016/0305-4403(91)90064-V; Westerhold T, 2009, EARTH PLANET SC LETT, V287, P412, DOI 10.1016/j.epsl.2009.08.027; Wing SL, 2009, P NATL ACAD SCI USA, V106, P18627, DOI 10.1073/pnas.0905130106; Wing SL, 2005, SCIENCE, V310, P993, DOI 10.1126/science.1116913; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110; Zeebe RE, 2009, NAT GEOSCI, V2, P576, DOI 10.1038/NGEO578	27	198	203	3	147	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					957	961		10.1126/science.1193833	http://dx.doi.org/10.1126/science.1193833			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071667				2022-12-28	WOS:000284118000041
J	Killingsworth, MA; Gilbert, DT				Killingsworth, Matthew A.; Gilbert, Daniel T.			A Wandering Mind Is an Unhappy Mind	SCIENCE			English	Article							DEFAULT NETWORK; DAILY-LIFE; EXPERIENCE; BRAIN; THOUGHT		[Killingsworth, Matthew A.; Gilbert, Daniel T.] Harvard Univ, Cambridge, MA 02138 USA	Harvard University	Killingsworth, MA (corresponding author), Harvard Univ, Cambridge, MA 02138 USA.	mkilling@fas.harvard.edu	Killingsworth, Murray/O-3736-2019	Killingsworth, Murray/0000-0002-6125-1183				Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Kahneman D, 2004, SCIENCE, V306, P1776, DOI 10.1126/science.1103572; Kane MJ, 2007, PSYCHOL SCI, V18, P614, DOI 10.1111/j.1467-9280.2007.01948.x; Krueger AB, 2008, J PUBLIC ECON, V92, P1833, DOI 10.1016/j.jpubeco.2007.12.015; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; McVay JC, 2009, PSYCHON B REV, V16, P857, DOI 10.3758/PBR.16.5.857; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20037; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smallwood J, 2009, EMOTION, V9, P271, DOI 10.1037/a0014855	12	1287	1314	41	554	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					932	932		10.1126/science.1192439	http://dx.doi.org/10.1126/science.1192439			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678XY	21071660	Green Submitted			2022-12-28	WOS:000284118000032
J	Pan, BC; Xiong, Y; Steitz, TA				Pan, Baocheng; Xiong, Yong; Steitz, Thomas A.			How the CCA-Adding Enzyme Selects Adenine over Cytosine at Position 76 of tRNA	SCIENCE			English	Article							STRUCTURAL BASIS; CRYSTAL-STRUCTURE; POLYMERIZATION; TRANSLOCATION; POLYMERASE; MECHANISM; SUBSTRATE; TEMPLATE; NUCLEOTIDYLTRANSFERASE; MATURATION	CCA-adding enzymes [ATP(CTP):tRNA nucleotidyltransferases] add CCA onto the 3' end of transfer RNA (tRNA) precursors without using a nucleic acid template. Although the mechanism by which cytosine (C) is selected at position 75 of tRNA has been established, the mechanism by which adenine (A) is selected at position 76 remains elusive. Here, we report five cocrystal structures of the enzyme complexed with both a tRNA mimic and nucleoside triphosphates under catalytically active conditions. These structures suggest that adenosine 5'-monophosphate is incorporated onto the A76 position of the tRNA via a carboxylate-assisted, one-metal-ion mechanism with aspartate 110 functioning as a general base. The discrimination against incorporation of cytidine 5'-triphosphate (CTP) at position 76 arises from improper placement of the alpha phosphate of the incoming CTP, which results from the interaction of C with arginine 224 and prevents the nucleophilic attack by the 3' hydroxyl group of cytidine75.	[Pan, Baocheng; Xiong, Yong; Steitz, Thomas A.] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Steitz, Thomas A.] Yale Univ, Dept Chem, New Haven, CT 06520 USA; [Steitz, Thomas A.] Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	thomas.steitz@yale.edu	Steitz, Thomas A./C-6559-2009		NIH [GM57510]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057510] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the staff at the Advanced Photon Source beamline ID19 and at the National Synchrotron Light Source beamline X25. We also thank the staff of the Center for Structural Biology core facility at Yale University. This work was supported by NIH grant GM57510 (to T.A.S.). The coordinates and structure factors for the five structures have been deposited in the Research Collaboratory for Structural Bioinformatics Protein Data Bank with accession numbers 3OVA, 3OV7, 3OVB, 3OUY, and 3OVS for preinsertion, initial, intermediate, product, and CTP complexes, respectively.	Augustin MA, 2003, J MOL BIOL, V328, P985, DOI 10.1016/S0022-2836(03)00381-4; Balbo PB, 2007, STRUCTURE, V15, P1117, DOI 10.1016/j.str.2007.07.010; Berman AJ, 2007, EMBO J, V26, P3494, DOI 10.1038/sj.emboj.7601780; Cho HD, 2005, J BIOL CHEM, V280, P9555, DOI 10.1074/jbc.M412594200; Cho HDD, 2006, J BIOL CHEM, V281, P9801, DOI 10.1074/jbc.M512603200; DEUTSCHER MP, 1982, ENZYMES, V15, P183, DOI DOI 10.1016/S1874-6047(08)60279-6; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Okabe M, 2003, EMBO J, V22, P5918, DOI 10.1093/emboj/cdg563; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Steitz TA, 2007, STRUCTURE, V15, P1523, DOI 10.1016/j.str.2007.11.005; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Toh Y, 2008, EMBO J, V27, P1944, DOI 10.1038/emboj.2008.124; Tomita K, 2004, NATURE, V430, P700, DOI 10.1038/nature02712; Tomita K, 2006, NATURE, V443, P956, DOI 10.1038/nature05204; Vassylyev DG, 2007, NATURE, V448, P163, DOI 10.1038/nature05931; Xiong Y, 2006, CURR OPIN STRUC BIOL, V16, P12, DOI 10.1016/j.sbi.2005.12.001; Xiong Y, 2004, NATURE, V430, P640, DOI 10.1038/nature02711; Xiong Y, 2003, MOL CELL, V12, P1165, DOI 10.1016/S1097-2765(03)00440-4; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yue DX, 1996, RNA, V2, P895	24	24	25	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					937	940		10.1126/science.1194985	http://dx.doi.org/10.1126/science.1194985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678XY	21071662	Green Accepted			2022-12-28	WOS:000284118000034
J	Victora, GD; Schwickert, TA; Fooksman, DR; Kamphorst, AO; Meyer-Hermann, M; Dustin, ML; Nussenzweig, MC				Victora, Gabriel D.; Schwickert, Tanja A.; Fooksman, David R.; Kamphorst, Alice O.; Meyer-Hermann, Michael; Dustin, Michael L.; Nussenzweig, Michel C.			Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter	CELL			English	Article							ANTI-HAPTEN ANTIBODY; HELPER T-CELLS; CENTER B-CELLS; IN-VIVO; DENDRITIC CELLS; AFFINITY MATURATION; IMMUNE-RESPONSE; SELF-TOLERANCE; PLASMA-CELL; SELECTION	The germinal center (GC) reaction produces high-affinity antibodies by random mutation and selective clonal expansion of B cells with high-affinity receptors. The mechanism by which B cells are selected remains unclear, as does the role of the two anatomically defined areas of the GC, light zone (LZ) and dark zone (DZ). We combined a transgenic photoactivatable fluorescent protein tracer with multiphoton laser-scanning microscopy and flow cytometry to examine anatomically defined LZ and DZ B cells and GC selection. We find that B cell division is restricted to the DZ, with a net vector of B cell movement from the DZ to the LZ. The decision to return to the DZ and undergo clonal expansion is controlled by T helper cells in the GC LZ, which discern between LZ B cells based on the amount of antigen captured and presented. Thus, T cell help, and not direct competition for antigen, is the limiting factor in GC selection.	[Victora, Gabriel D.; Schwickert, Tanja A.; Kamphorst, Alice O.; Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA; [Victora, Gabriel D.; Fooksman, David R.; Dustin, Michael L.] NYU, Sch Med, Skirball Inst Biomol Med, Martin & Helen Kimmel Ctr Biol & Med, New York, NY 10016 USA; [Meyer-Hermann, Michael] Helmholtz Ctr Infect Res, Dept Syst Immunol, D-38124 Braunschweig, Germany	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; New York University; Helmholtz Association; Helmholtz-Center for Infection Research	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.	nussen@rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019; Victora, Gabriel/C-5946-2011; Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389; Schwickert, Tanja/0000-0002-3371-2376; Kamphorst, Alice/0000-0002-9230-9501; Victora, Gabriel/0000-0001-8807-348X	NIH [R01 AI072529, P01 AI071195, CA009161-34]; NYSDOH [C023046]; EU-NEST; NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072529, P01AI071195] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NYSDOH; EU-NEST(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We would like to thank J. Lippincott-Schwartz (NIH), R. Tsien (UCSD), and B. Schaefer (USU) for the PA-GFP, tdTomato, and UbC constructs, respectively; the MSKCC Genomics Facility for performing the microarray experiments; J. Zavadil (NYU) for guidance in microarray analysis; A. North and S. Bhuvanendran (Rockefeller University Bio-Imaging Resource Center) for help with multiphoton imaging; R. Scheuerman (University of Texas Southwestern Medical Center) for ACS gene lists for GSEA analysis; and T. Cameron for helpful discussion. This work was supported in part by NIH grants R01 AI072529 (M.C.N. and M.L.D.) and P01 AI071195 (M.L.D.). Support for the Rockefeller University multiphoton microscope and cell sorter was granted by the Empire State Stem Cell Fund through NYSDOH Contract #C023046. D.R.F. was supported by NIH training grant CA009161-34. M.M.-H. was supported by the EU-NEST project MAMOCELL in FP6. M.C.N. is an HHMI Investigator.	Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Allen CDC, 2007, IMMUNITY, V27, P190, DOI 10.1016/j.immuni.2007.07.009; Allen CDC, 2007, SCIENCE, V315, P528, DOI 10.1126/science.1136736; ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; Basso K, 2004, BLOOD, V104, P4088, DOI 10.1182/blood-2003-12-4291; Batista FD, 2001, NATURE, V411, P489, DOI 10.1038/35078099; Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639; Brink R, 2008, IMMUNOL CELL BIOL, V86, P31, DOI 10.1038/sj.icb.7100143; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Delbos F, 2005, J EXP MED, V201, P1191, DOI 10.1084/jem.20050292; Depoil D, 2005, IMMUNITY, V22, P185, DOI 10.1016/j.immuni.2004.12.010; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; Figge MT, 2008, J EXP MED, V205, P3019, DOI 10.1084/jem.20081160; Fooksman DR, 2010, IMMUNITY, V33, P118, DOI 10.1016/j.immuni.2010.06.015; GOIDL EA, 1968, J IMMUNOL, V100, P371; Guo M, 2000, HUM IMMUNOL, V61, P729, DOI 10.1016/S0198-8859(00)00144-0; HAN SH, 1995, J EXP MED, V182, P1635, DOI 10.1084/jem.182.6.1635; HAN SH, 1995, J IMMUNOL, V155, P556; Hauser AE, 2007, NAT REV IMMUNOL, V7, P499, DOI 10.1038/nri2120; Hauser AE, 2007, IMMUNITY, V26, P655, DOI 10.1016/j.immuni.2007.04.008; Hogerkorp CM, 2006, J IMMUNOL, V177, P4341, DOI 10.4049/jimmunol.177.7.4341; Huntington ND, 2006, NAT IMMUNOL, V7, P190, DOI 10.1038/ni1292; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kamphorst AO, 2010, J IMMUNOL, V185, P3426, DOI 10.4049/jimmunol.1001205; KATZ DH, 1970, J EXP MED, V132, P261, DOI 10.1084/jem.132.2.261; Kim HJ, 2010, NATURE, V467, P328, DOI 10.1038/nature09370; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Manser T, 2004, J IMMUNOL, V172, P3369, DOI 10.4049/jimmunol.172.6.3369; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; Meyer-Hermann M, 2001, J THEOR BIOL, V210, P265, DOI 10.1006/jtbi.2001.2297; Meyer-Hermann M, 2009, TRENDS IMMUNOL, V30, P157, DOI 10.1016/j.it.2009.01.005; Meyer-Hermann ME, 2006, MATH MED BIOL, V23, P255, DOI 10.1093/imammb/dql012; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nagaoka H, 2000, J EXP MED, V191, P2113, DOI 10.1084/jem.191.12.2113; Nie YC, 2004, J EXP MED, V200, P1145, DOI 10.1084/jem.20041185; NIEUWENHUIS P, 1984, AM J ANAT, V170, P421, DOI 10.1002/aja.1001700315; Nowotschin S, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-49; NUSSENZWEIG V, 1967, J EXP MED, V126, P727, DOI 10.1084/jem.126.4.727; Oprea M, 1997, J IMMUNOL, V158, P5155; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Phan TG, 2006, J EXP MED, V203, P2419, DOI 10.1084/jem.20061254; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAJEWSKY K, 1969, J EXP MED, V129, P1131, DOI 10.1084/jem.129.6.1131; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; Schaefer BC, 2001, CELL IMMUNOL, V214, P110, DOI 10.1006/cimm.2001.1895; Schneider M, 2005, BIOPHYS J, V89, P1346, DOI 10.1529/biophysj.104.054502; Schwickert TA, 2007, NATURE, V446, P83, DOI 10.1038/nature05573; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shih TAY, 2002, NAT IMMUNOL, V3, P399, DOI 10.1038/ni776; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki K, 2009, J EXP MED, V206, P1485, DOI 10.1084/jem.20090209; Tarlinton DM, 2008, IMMUNOL CELL BIOL, V86, P133, DOI 10.1038/sj.icb.7100148; Tarlinton DM, 2000, IMMUNOL TODAY, V21, P436, DOI 10.1016/S0167-5699(00)01687-X; Tomura M, 2008, P NATL ACAD SCI USA, V105, P10871, DOI 10.1073/pnas.0802278105; Vinuesa CG, 2005, NAT REV IMMUNOL, V5, P853, DOI 10.1038/nri1714; Vinuesa CG, 2005, NATURE, V435, P452, DOI 10.1038/nature03555; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zhu XC, 2004, J IMMUNOL, V173, P7141, DOI 10.4049/jimmunol.173.12.7141	66	767	777	1	64	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 12	2010	143	4					592	605		10.1016/j.cell.2010.10.032	http://dx.doi.org/10.1016/j.cell.2010.10.032			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074050	Bronze, Green Accepted			2022-12-28	WOS:000284149100016
J	Chouard, T; Gray, N				Chouard, Tanguy; Gray, Noah			GLIA	NATURE			English	Editorial Material														Gray, Noah/0000-0002-4672-7403					0	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					213	213		10.1038/468213a	http://dx.doi.org/10.1038/468213a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678DG	21068829	Bronze			2022-12-28	WOS:000284051000037
J	Tatem, AJ; Smith, DL; Gething, PW; Kabaria, CW; Snow, RW; Hay, SI				Tatem, Andrew J.; Smith, David L.; Gething, Peter W.; Kabaria, Caroline W.; Snow, Robert W.; Hay, Simon I.			Malaria Elimination 2 Ranking of elimination feasibility between malaria-endemic countries	LANCET			English	Article							PLASMODIUM-VIVAX TRANSMISSION; VACCINATION COVERAGE; POPULATION-MOVEMENTS; INFECTION; HEALTH; RISK; ERADICATION; LIMITS; GAPS	Experience gained from the Global Malaria Eradication Program (1955-72) identified a set of shared technical and operational factors that enabled some countries to successfully eliminate malaria. Spatial data for these factors were assembled for all malaria-endemic countries and combined to provide an objective, relative ranking of countries by technical, operational, and combined elimination feasibility. The analysis was done separately for Plasmodium falciparum and Plasmodium vivax, and the limitations of the approach were discussed. The relative rankings suggested that malaria elimination would be most feasible in countries in the Americas and Asia, and least feasible in countries in central and west Africa. The results differed when feasibility was measured by technical or operational factors, highlighting the different types of challenge faced by each country. The results are not intended to be prescriptive, predictive, or to provide absolute assessments of feasibility, but they do show that spatial information is available to facilitate evidence-based assessments of the relative feasibility of malaria elimination by country that can be rapidly updated.	[Tatem, Andrew J.; Smith, David L.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL 32610 USA; [Tatem, Andrew J.] Univ Florida, Dept Geog, Gainesville, FL 32610 USA; [Smith, David L.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA; [Snow, Robert W.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Ctr Vaccinol & Trop Med CCVTM, Oxford, England; [Kabaria, Caroline W.; Snow, Robert W.] Kenya Govt Med Res Ctr, Malaria Publ Hlth & Epidemiol Grp, Ctr Geog Med, Nairobi, Kenya; [Gething, Peter W.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Oxford; Kenya Medical Research Institute; University of Oxford	Tatem, AJ (corresponding author), Univ Florida, Emerging Pathogens Inst, POB 100009,2055 Mowry Rd, Gainesville, FL 32610 USA.	atatem@ufl.edu	Smith, David L/L-8850-2013; Gething, Peter/GQR-1884-2022; Hay, Simon Iain/F-8967-2015; Gething, Peter/ABD-2110-2020; Snow, Robert William/AFR-1436-2022	Smith, David L/0000-0003-4367-3849; Gething, Peter/0000-0001-6759-5449; Hay, Simon Iain/0000-0002-0611-7272; Snow, Robert William/0000-0003-3725-6088; Tatem, Andrew/0000-0002-7270-941X; Kabaria, Caroline/0000-0002-5641-5243	Novartis; Pfizer; Kenyan Medical Research Institute (KEMRI); Bill & Melinda Gates Foundation [49446]; Science and Technology Directorate, Department of Homeland Security; Fogarty International Center, US National Institutes of Health; Wellcome Trust [076951, 079080]; Wellcome Trust, UK	Novartis(Novartis); Pfizer(Pfizer); Kenyan Medical Research Institute (KEMRI); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Science and Technology Directorate, Department of Homeland Security(United States Department of Homeland Security (DHS)); Fogarty International Center, US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission); Wellcome Trust, UK(Wellcome Trust)	AJT, DLS, RWS, and SIH serve as members of the Malaria Elimination Group. RWS has received funding from Novartis for chairing meetings of national control programmes in Africa and has received a research grant from Pfizer. PWG and CWK declare that they have no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of their employing organisations nor of the sources of funding.; We thank Carlos Guerra, Anand Patil, Will Temperley, and Rosalind Howes for supplying P vivax-related datasets, and Nicholas Campiz for help with data processing. We also thank Kevin Baird, Marcel Tanner, Dean Jamison, Anja Bibby, and the Malaria Elimination Group for extensive comments on the manuscript. We also acknowledge the support of the Kenyan Medical Research Institute (KEMRI). This report is published with the permission of the director of KEMRI. AJT and DLS are supported by a grant from the Bill & Melinda Gates Foundation (#49446) and acknowledge (with S I H) funding support from the RAPIDD programme of the Science and Technology Directorate, Department of Homeland Security, and the Fogarty International Center, US National Institutes of Health. SIH is a Wellcome Trust Senior Research Fellow (#076951) and the grant supports PWG and CWK. RWS is a Wellcome Trust Principal Research Fellow (#079080) and acknowledges the support of the Kenyan Medical Research Institute (KEMRI). This work forms part of the output of the Malaria Atlas Project, principally funded by the Wellcome Trust, UK.	Akhtar R, 2010, ADV ASIAN HUM-ENV RE, V1, P141, DOI 10.1007/978-90-481-3358-1_8; Anand S, 2007, LANCET, V369, P1277, DOI 10.1016/S0140-6736(07)60599-6; [Anonymous], 2008, GLOB MAL ACT PLAN; [Anonymous], 1969, TXB MALARIA ERADICAT; Backman G, 2008, LANCET, V372, P2047, DOI 10.1016/S0140-6736(08)61781-X; Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011; Bos E, 2000, USING IMMUNIZATION C; Cosner C, 2009, J THEOR BIOL, V258, P550, DOI 10.1016/j.jtbi.2009.02.016; de Castro MC, 2006, P NATL ACAD SCI USA, V103, P2452, DOI 10.1073/pnas.0510576103; DeSavigny D, 2009, SYSTEMS THINKING FOR HEALTH SYSTEMS STRENGTHENING, P1; Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103; Eastman RT, 2009, NAT REV MICROBIOL, V7, P864, DOI 10.1038/nrmicro2239; Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0; Feachem RGA, 2009, SHRINKING MALARIA MA; Feachem R, 2008, LANCET, V371, P1633, DOI 10.1016/S0140-6736(08)60424-9; Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6; Garnham P. C. C., 1988, Malaria: principles and practice of malariology. Volume 1., P61; Gething PW, 2010, NATURE, V465, P342, DOI 10.1038/nature09098; Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038; Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774; Hammadi D, 2009, Bull Soc Pathol Exot, V102, P185; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0; Hay SI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000209; Hay SI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000048; JULVEZ J, 1990, ANN SOC BELG MED TR, V70, P249; Kaufmann D., 2008, GOVERNANCE MATTERS 7; Killeen GF, 2007, T ROY SOC TROP MED H, V101, P867, DOI 10.1016/j.trstmh.2007.04.022; KOELLA JC, 1991, ACTA TROP, V49, P1, DOI 10.1016/0001-706X(91)90026-G; Lawpoolsri S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-159; Le Menach A, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-10; Alvarez JL, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-462; MacDONALD G., 1956, BULL WORLD HEALTH ORGAN, V15, P613; Matthys B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-217; Meleigy May, 2007, BMJ, V334, P117, DOI 10.1136/bmj.39097.499641.4E; *MIN HLTH SOC SERV, 2009, 8 COUNTR LAUNCH CROS; Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X; Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X; NARDO M, 2005, HDB CONTRUCTING COMP; Noor AM, 2009, LANCET, V373, P58, DOI 10.1016/S0140-6736(08)61596-2; Okell LC, 2008, PLOS MED, V5, P1617, DOI 10.1371/journal.pmed.0050226; PARSONS CR, 2007, 4165 WORLD BANK; Patil GP, 2004, ENVIRON ECOL STAT, V11, P199, DOI 10.1023/B:EEST.0000027209.93218.d9; PROTHERO RM, 1961, B WORLD HEALTH ORGAN, V24, P405; Rajakaruna RS, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-25; ROJAS W, 1992, PARASITOL TODAY, V8, P141, DOI 10.1016/0169-4758(92)90287-C; Rudan I, 2005, LANCET, V365, P2031, DOI 10.1016/S0140-6736(05)66697-4; Sabot O, 2010, LANCET, V376, P1604, DOI 10.1016/S0140-6736(10)61355-4; Sattabongkot J, 2004, TRENDS PARASITOL, V20, P192, DOI 10.1016/j.pt.2004.02.001; SCHAPIRA A, 2007, PROSPECTS ERADICATIO; Schroder B.S.W., 2003, ORDERED SETS INTRO; SIVAGNANASUNDRAM C, 1973, J TROP MED HYG, V76, P83; Smith DL, 2009, TRENDS PARASITOL, V25, P511, DOI 10.1016/j.pt.2009.08.002; Smith DL, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-87; Smith DL, 2007, PLOS BIOL, V5, P531, DOI 10.1371/journal.pbio.0050042; Smith DL, 2005, NATURE, V438, P492, DOI 10.1038/nature04024; Smith DL, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-13; Smith DL, 2009, SHRINKING MALARIA MA; Stoddard ST, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000481; Tatem AJ, 2010, P NATL ACAD SCI USA, V107, P12222, DOI 10.1073/pnas.1002971107; Tatem AJ, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-287; *U CA SAN FRANC, 2009, AS PAC MAL EL NETW A; UCHIDA H, 2008, ACCESSIBILITY MODEL; *UNICEF, 2009, IMM SUMM; WHO, 2008, GLOB MAL CONTR EL RE; World Bank, 2009, WORLDW GOV IND; World Health Organization, 2008, WORLD MAL REP; World Health Organization (WHO), 2009, WORLD HLTH STAT; YEKUTIEL P, 1960, Bull World Health Organ, V22, P669; YEKUTIEL P, 1980, CONTRIBUTIONS EPIDEM	70	108	108	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1579	1591		10.1016/S0140-6736(10)61301-3	http://dx.doi.org/10.1016/S0140-6736(10)61301-3			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	21035838	Green Published			2022-12-28	WOS:000284248700035
J	Schreiber, H; Rowley, DA				Schreiber, Hans; Rowley, Donald A.			Awakening Immunity	SCIENCE			English	Editorial Material							FIBROBLAST ACTIVATION PROTEIN; TUMOR-GROWTH; CANCER MODEL; T-CELLS; ELIMINATION; METASTASIS; INHIBITION		[Schreiber, Hans; Rowley, Donald A.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago	Schreiber, H (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	hszz@midway.uchicago.edu						Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kryczek I, 2007, AM J PHYSIOL-CELL PH, V292, pC987, DOI 10.1152/ajpcell.00406.2006; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Niedermeyer J, 2000, MOL CELL BIOL, V20, P1089, DOI 10.1128/MCB.20.3.1089-1094.2000; PEKAREK LA, 1995, J EXP MED, V181, P435, DOI 10.1084/jem.181.1.435; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Poznansky MC, 2000, NAT MED, V6, P543, DOI 10.1038/75022; SEUNG LP, 1995, P NATL ACAD SCI USA, V92, P6254, DOI 10.1073/pnas.92.14.6254; Spiotto MT, 2004, NAT MED, V10, P294, DOI 10.1038/nm999; Wen YA, 2010, CANCER SCI, V101, P2325, DOI 10.1111/j.1349-7006.2010.01695.x; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056	14	24	27	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					761	762		10.1126/science.1198345	http://dx.doi.org/10.1126/science.1198345			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051618				2022-12-28	WOS:000283855700022
J	Roberts, I; Stott, R				Roberts, Ian; Stott, Robin			Doctors and climate change	LANCET			English	Editorial Material							HEALTH		[Roberts, Ian] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Roberts, I (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	ian.roberts@lshtm.ac.uk						Friel S, 2009, LANCET, V374, P2016, DOI 10.1016/S0140-6736(09)61753-0; GOLDSMITH B, 2010, TORONTO SUN; Haines A, 2009, LANCET, V374, P2035, DOI 10.1016/S0140-6736(09)61667-6; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; Roberts I, 2010, ENERGY GLUT POLITICS; Roberts I, 2008, BMJ-BRIT MED J, V336, P165, DOI 10.1136/bmj.39468.596262.80; Ruiz- Arregui L, 2007, SALUD PUBLICA MEX; TFWG, 2010, UN CLIM CHANG C CANC; Woodcock J, 2009, LANCET, V374, P1930, DOI 10.1016/S0140-6736(09)61714-1	9	6	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV-DEC	2010	376	9755					1801	1802		10.1016/S0140-6736(10)62106-X	http://dx.doi.org/10.1016/S0140-6736(10)62106-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696KG	21093038	Green Accepted			2022-12-28	WOS:000285439700004
J	Cheong, C; Matos, I; Choi, JH; Dandamudi, DB; Shrestha, E; Longhi, MP; Jeffrey, KL; Anthony, RM; Kluger, C; Nchinda, G; Koh, H; Rodriguez, A; Idoyaga, J; Pack, M; Velinzon, K; Park, CG; Steinman, RM				Cheong, Cheolho; Matos, Ines; Choi, Jae-Hoon; Dandamudi, Durga Bhavani; Shrestha, Elina; Longhi, M. Paula; Jeffrey, Kate L.; Anthony, Robert M.; Kluger, Courtney; Nchinda, Godwin; Koh, Hyein; Rodriguez, Anthony; Idoyaga, Juliana; Pack, Maggi; Velinzon, Klara; Park, Chae Gyu; Steinman, Ralph M.			Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209(+) Dendritic Cells for Immune T Cell Areas	CELL			English	Article							DC-SIGN; LYMPH-NODES; CROSS-PRESENTATION; MELANOMA PATIENTS; IN-VIVO; RECEPTOR; ANTIGEN; IDENTIFICATION; TOLERANCE; RESPONSES	Dendritic cells (DCs), critical antigen-presenting cells for immune control, normally derive from bone marrow precursors distinct from monocytes. It is not yet established if the large reservoir of monocytes can develop into cells with critical features of DCs in vivo. We now show that fully differentiated monocyte-derived DCs (Mo-DCs) develop in mice and DC-SIGN/CD209a marks the cells. Mo-DCs are recruited from blood monocytes into lymph nodes by lipopolysaccharide and live or dead gram-negative bacteria. Mobilization requires TLR4 and its CD14 coreceptor and Trif. When tested for antigen-presenting function, Mo-DCs are as active as classical DCs, including cross-presentation of proteins and live gram-negative bacteria on MHC I in vivo. Fully differentiated Mo-DCs acquire DC morphology and localize to T cell areas via L-selectin and CCR7. Thus the blood monocyte reservoir becomes the dominant presenting cell in response to select microbes, yielding DC-SIGN(+) cells with critical functions of DCs.	[Cheong, Cheolho; Matos, Ines; Choi, Jae-Hoon; Dandamudi, Durga Bhavani; Shrestha, Elina; Longhi, M. Paula; Kluger, Courtney; Nchinda, Godwin; Koh, Hyein; Rodriguez, Anthony; Idoyaga, Juliana; Pack, Maggi; Park, Chae Gyu; Steinman, Ralph M.] Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10065 USA; [Cheong, Cheolho; Matos, Ines; Choi, Jae-Hoon; Dandamudi, Durga Bhavani; Shrestha, Elina; Longhi, M. Paula; Kluger, Courtney; Nchinda, Godwin; Koh, Hyein; Rodriguez, Anthony; Idoyaga, Juliana; Pack, Maggi; Park, Chae Gyu; Steinman, Ralph M.] Rockefeller Univ, Chris Browne Ctr Immunol & Immune Dis, New York, NY 10065 USA; [Jeffrey, Kate L.] Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10065 USA; [Anthony, Robert M.] Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10065 USA; [Velinzon, Klara] Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10065 USA	Rockefeller University; Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Cheong, C (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10065 USA.	ccheong@rockefeller.edu; parkc@rockefeller.edu; steinma@rockefeller.edu	Markofski, Melissa M/Q-6372-2016; Steinman, Ralph/F-7729-2012	Markofski, Melissa M/0000-0003-0214-4246; Longhi, Paula/0000-0003-1854-4594; Park, Chae Gyu/0000-0003-1906-1308; Jeffrey, Kate/0000-0001-5746-0153	NIGMS [GM62116]; NIH [AI40045, AI40874]; Bill and Melinda Gates Foundation; New York Community Trust; Fundacao para a Ciencia e Tecnologia [SFRH/BD/41073/2007]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040045, R56AI040045, R01AI040874, R37AI040045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); New York Community Trust; Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Steinman lab for valuable discussion, J. Adams for graphics, A.J. North and S.A. Galdeen for DIC imaging at the bioimaging resource center, S. Mazel and C. Bare for flow cytometry at the resource center of Rockefeller University, Y. Oh and I. Jang for CSP preparation, J.D. Schauer for mAb purification, J. Gonzalez for ELISA assays (Rockefeller University Center for Clinical and Translational Science, UL1RR024143 from National Center for Research Resource). We thank the Consortium for Functional Glycomics supported by NIGMS (GM62116) for DC-SIGN/CD209a<SUP>-/-</SUP> mice. We were supported by grants from the NIH (AI40045 and AI40874), the Bill and Melinda Gates Foundation (R.M.S.), New York Community Trust's Francis Florio funds for blood diseases (C.C.), and a Fundacao para a Ciencia e Tecnologia PhD scholarship (I.M. SFRH/BD/41073/2007).	Agger R, 2000, SCAND J IMMUNOL, V52, P138; Cheong C, 2010, J IMMUNOL METHODS, V360, P66, DOI 10.1016/j.jim.2010.06.006; Choi JH, 2009, J EXP MED, V206, P497, DOI 10.1084/jem.20082129; D'Amico A, 2003, J EXP MED, V198, P293, DOI 10.1084/jem.20030107; de Vries IJM, 2003, CANCER RES, V63, P12; den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Ginhoux F, 2006, NAT IMMUNOL, V7, P265, DOI 10.1038/ni1307; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Goren I, 2009, AM J PATHOL, V175, P132, DOI 10.2353/ajpath.2009.081002; Granelli-Piperno A, 2005, J IMMUNOL, V175, P4265, DOI 10.4049/jimmunol.175.7.4265; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; Heath WR, 2009, NAT IMMUNOL, V10, P1237, DOI 10.1038/ni.1822; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hohl TM, 2009, CELL HOST MICROBE, V6, P470, DOI 10.1016/j.chom.2009.10.007; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; JOHNSON WD, 1977, J EXP MED, V146, P1613, DOI 10.1084/jem.146.6.1613; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Liu K, 2009, SCIENCE, V324, P392, DOI 10.1126/science.1170540; Luckashenak N, 2008, IMMUNITY, V28, P521, DOI 10.1016/j.immuni.2008.02.018; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236; Moron VG, 2003, J IMMUNOL, V171, P2242, DOI 10.4049/jimmunol.171.5.2242; Naik SH, 2005, J IMMUNOL, V174, P6592, DOI 10.4049/jimmunol.174.11.6592; Naik SH, 2006, NAT IMMUNOL, V7, P663, DOI 10.1038/ni1340; Naik SH, 2007, NAT IMMUNOL, V8, P1217, DOI 10.1038/ni1522; Nakano H, 2009, NAT IMMUNOL, V10, P394, DOI 10.1038/ni.1707; ONAI N, 2007, J EXP MED, V193, P233; Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Schnorrer P, 2006, P NATL ACAD SCI USA, V103, P10729, DOI 10.1073/pnas.0601956103; Schreurs MWJ, 1999, EUR J IMMUNOL, V29, P2835, DOI 10.1002/(SICI)1521-4141(199909)29:09<2835::AID-IMMU2835>3.0.CO;2-Q; Schuler-Thurner B, 2000, J IMMUNOL, V165, P3492, DOI 10.4049/jimmunol.165.6.3492; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; Shakhar G, 2005, NAT IMMUNOL, V6, P707, DOI 10.1038/ni1210; Siddiqui KRR, 2010, IMMUNITY, V32, P557, DOI 10.1016/j.immuni.2010.03.017; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Swirski FK, 2009, SCIENCE, V325, P612, DOI 10.1126/science.1175202; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Vremec D, 1997, J IMMUNOL, V159, P565; Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615; Xu YK, 2007, J IMMUNOL, V179, P7577, DOI 10.4049/jimmunol.179.11.7577	63	436	441	3	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2010	143	3					416	429		10.1016/j.cell.2010.09.039	http://dx.doi.org/10.1016/j.cell.2010.09.039			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	672RF	21029863	Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000283603900015
J	Staples, J; Ponsonby, AL; Lim, L				Staples, Judith; Ponsonby, Anne-Louise; Lim, Lynette			Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VITAMIN-D DEFICIENCY; BRAIN-DEVELOPMENT; DISEASE PROGRESSION; D SUPPLEMENTATION; RAT-BRAIN; EPIDEMIOLOGY; CHILDHOOD; AUSTRALIA; SEASON; MS	Objectives To investigate the distribution of month of birth in people with multiple sclerosis in Australia. To use the large regional and seasonal variation in ambient ultraviolet radiation in Australia to explore the association between exposure to ultraviolet radiation during pregnancy and subsequent risk of multiple sclerosis in offspring. Design Data were gathered on birth month and year (1920-1950), sex, and state of birth for all patients surveyed in 1981 in Queensland, Western Australia, New South Wales (including Australian Capital Territory), South Australia, and Hobart (Tasmania). Population denominators were derived from the 1981 census and supplementary birth registration data. A variable for exposure to ambient ultraviolet radiation "at birth" was generated from monthly averages of daily total ambient ultraviolet radiation for each region. Negative binomial regression models were used to investigate exposure to ambient ultraviolet radiation at birth and at various intervals before birth. Setting Patient data from multiple sclerosis prevalence surveys carried out in 1981; 1981 Australian census (giving the total number of people born in Australia and still alive and living in Australia in 1981 by year of birth 1920-50); supplementary Australian birth registration data covering the same birth years by month and state. Participants 1524 patients with multiple sclerosis born in Australia 1920-50 from total population of 2 468 779. Main outcome measure Cumulative incidence rate of multiple sclerosis. Results There was a pattern of risk of multiple sclerosis with month of birth (adjusted incidence rate ratio 1.32, 95% confidence interval 1.10 to 1.58, P<0.01, for those born in November-December compared with those born in May-June). This pattern mirrored that previously reported in the northern hemisphere. Region of birth was related to risk. After adjustment for region of birth and other factors, there was an inverse association between ambient ultraviolet radiation in the first trimester and risk of multiple sclerosis (with >= 25 erythemal (skin reddening) dose units as reference (that is, adjusted incidence rate ratio=1.00), the rates were 1.54 (1.10 to 2.16) for 20-<25 units; 1.58 (1.12 to 2.22) for 15-<20 units; 1.65 (1.17 to 2.33) for 10-<15 units; 1.65 (1.18 to 2.29) for 5-<10 units; and 1.67 (1.18 to 2.37) for <5 units). After adjustment for this exposure during early pregnancy, there was no residual association between month of birth and multiple sclerosis. Conclusion Region of birth and low maternal exposure to ultraviolet radiation in the first trimester are independently associated with subsequent risk of multiple sclerosis in offspring in Australia.	[Ponsonby, Anne-Louise] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Staples, Judith; Lim, Lynette] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Australian National University	Ponsonby, AL (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.	anne-louise.ponsonby@mcri.edu.au	Ponsonby, Anne-Louise/AAE-4351-2019	Ponsonby, Anne-Louise/0000-0002-6581-3657	Australian National University (ANU); National Centre for Epidemiology and Population Health, ANU	Australian National University (ANU)(Australian National University); National Centre for Epidemiology and Population Health, ANU(Australian National University)	The research was supported by an Australian National University (ANU) Graduate School scholarship and a supplementary scholarship from the National Centre for Epidemiology and Population Health, ANU, awarded to JS.	Abe S, 2004, PRENATAL DIAG, V24, P352, DOI 10.1002/pd.873; ALTER M, 1968, EPIDEMIOLOGY MULTIPL, P83; Ascherio A, 2008, SEMIN NEUROL, V28, P17, DOI 10.1055/s-2007-1019126; Chaudhuri A, 2005, MED HYPOTHESES, V64, P608, DOI 10.1016/j.mehy.2004.06.022; Correale J, 2009, BRAIN, V132, P1146, DOI 10.1093/brain/awp033; Cui XY, 2007, INT J DEV NEUROSCI, V25, P227, DOI 10.1016/j.ijdevneu.2007.03.006; Datt S, 2002, BJOG-INT J OBSTET GY, V109, P905, DOI 10.1016/S1470-0328(02)01171-0; DEAN G, 1967, BRIT MED J, V2, P724, DOI 10.1136/bmj.2.5554.724; DELVIN EE, 1982, ARCH DIS CHILD, V57, P754, DOI 10.1136/adc.57.10.754; Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6; Eyles D, 2007, J STEROID BIOCHEM, V103, P538, DOI 10.1016/j.jsbmb.2006.12.096; Eyles D, 2003, NEUROSCIENCE, V118, P641, DOI 10.1016/S0306-4522(03)00040-X; Eyles DW, 2005, J CHEM NEUROANAT, V29, P21, DOI 10.1016/j.jchemneu.2004.08.006; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; GIES HP, 1994, P SOC PHOTO-OPT INS, V2282, P274, DOI 10.1117/12.186621; Gogal RA, 2008, J IMMUNOTOXICOL, V5, P413, DOI 10.1080/10408360802483201; Goodin DS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004565; HAMMOND SR, 1987, J NEUROL SCI, V80, P185, DOI 10.1016/0022-510X(87)90154-7; HAMMOND SR, 1988, BRAIN, V111, P1, DOI 10.1093/brain/111.1.1; Hammond SR, 2000, BRAIN, V123, P968, DOI 10.1093/brain/123.5.968; Herrera BM, 2008, NEUROLOGY, V71, P799, DOI 10.1212/01.wnl.0000312377.50395.00; Islam T, 2007, NEUROLOGY, V69, P381, DOI 10.1212/01.wnl.0000268266.50850.48; Jakovcevski I, 2007, NEUROSCIENCE, V149, P328, DOI 10.1016/j.neuroscience.2007.07.044; Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1; Kampman MT, 2007, J NEUROL, V254, P471, DOI 10.1007/s00415-006-0395-5; Koch M, 2008, MULT SCLER J, V14, P793, DOI 10.1177/1352458508090662; KURTZKE JF, 1985, NEUROLOGY, V35, P672, DOI 10.1212/WNL.35.5.672; Lucas RM, 2008, NUTR REV, V66, P710, DOI 10.1111/j.1753-4887.2008.00126.x; Maghbooli Zhila, 2007, BMC Pregnancy Childbirth, V7, P1, DOI 10.1186/1471-2393-7-1; McGrath JJ, 2004, J STEROID BIOCHEM, V89-90, P557, DOI 10.1016/j.jsbmb.2004.03.070; MCLEOD JG, 1994, MED J AUSTRALIA, V160, P117, DOI 10.5694/j.1326-5377.1994.tb126553.x; Meyer U, 2007, NEUROSCIENTIST, V13, P241, DOI 10.1177/1073858406296401; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Munns C, 2006, MED J AUSTRALIA, V185, P268, DOI 10.5694/j.1326-5377.2006.tb00558.x; Ramagopalan SV, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000369; ROSE AS, 1976, NEUROLOGY, V26, P20, DOI 10.1212/WNL.26.6_Part_2.20; Sadovnick AD, 2007, NEUROLOGY, V69, P60, DOI 10.1212/01.wnl.0000265053.22905.64; SADOVNICK AD, 1994, ACTA NEUROL SCAND, V89, P190; Salemi G, 2000, ACTA NEUROL SCAND, V101, P381, DOI 10.1034/j.1600-0404.2000.90336.x; Sayers A, 2009, INT J EPIDEMIOL, V38, P1681, DOI 10.1093/ije/dyp237; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; TEMPLER DI, 1992, ACTA NEUROL SCAND, V85, P107, DOI 10.1111/j.1600-0404.1992.tb04007.x; Torrey EF, 2000, NEUROEPIDEMIOLOGY, V19, P177, DOI 10.1159/000026253; Tremlett H, 2008, NEUROEPIDEMIOLOGY, V31, P271, DOI 10.1159/000166602; Tremlett HL, 2006, NEUROEPIDEMIOLOGY, V26, P195, DOI 10.1159/000092406; Tustin K, 2004, DEV PSYCHOBIOL, V45, P221, DOI 10.1002/dev.20030; van der Mei IAF, 2003, BRIT MED J, V327, P316, DOI 10.1136/bmj.327.7410.316; Vieth R, 1999, AM J CLIN NUTR, V69, P842; Wiberg MA, 1994, J ORTHOMOL MED, V9, P71; Willer CJ, 2005, BMJ-BRIT MED J, V330, P120, DOI 10.1136/bmj.38301.686030.63; WION D, 1991, J NEUROSCI RES, V28, P110, DOI 10.1002/jnr.490280111; 2007, PAEDIAT CHILD HLTH, V12, P583	53	121	121	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2010	340								c1640	10.1136/bmj.c1640	http://dx.doi.org/10.1136/bmj.c1640			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	591PO	21030361				2022-12-28	WOS:000277314300002
J	Cannon, CP; Shah, S; Dansky, HM; Davidson, M; Brinton, EA; Gotto, AM; Stepanavage, M; Liu, SX; Gibbons, P; Ashraf, TB; Zafarino, J; Mitchel, Y; Barter, P				Cannon, Christopher P.; Shah, Sukrut; Dansky, Hayes M.; Davidson, Michael; Brinton, Eliot A.; Gotto, Antonio M., Jr.; Stepanavage, Michael; Liu, Sherry Xueyu; Gibbons, Patrice; Ashraf, Tanya B.; Zafarino, Jennifer; Mitchel, Yale; Barter, Philip		DEFINE Investigators	Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTER TRANSFER PROTEIN; CHOLESTEROL EFFLUX; BLOOD-PRESSURE; TORCETRAPIB; ATORVASTATIN; LIPOPROTEIN; INHIBITION; TRIALS	Background: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. Methods: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. Results: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001) -- a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001) -- a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P=0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. Conclusions: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.) N Engl J Med 2010;363:2406-15.	[Cannon, Christopher P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA; [Shah, Sukrut; Dansky, Hayes M.; Stepanavage, Michael; Liu, Sherry Xueyu; Gibbons, Patrice; Ashraf, Tanya B.; Zafarino, Jennifer; Mitchel, Yale] Merck Res Labs, Rahway, NJ USA; [Davidson, Michael] Radiant Res, Chicago, IL USA; [Brinton, Eliot A.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Gotto, Antonio M., Jr.] Weill Cornell Med Coll, New York, NY USA; [Barter, Philip] Heart Res Inst, Sydney, NSW, Australia	Harvard University; Brigham & Women's Hospital; Merck & Company; Utah System of Higher Education; University of Utah; Cornell University; University of Sydney; Heart Research Institute	Cannon, CP (corresponding author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Fl, Boston, MA 02115 USA.	cpcannon@partners.org	Cannon, Christopher P/AAY-7644-2020; Taskinen, Marja-Riitta/AAN-5432-2020	Cannon, Christopher P/0000-0003-4596-2791; Taskinen, Marja-Riitta/0000-0002-6229-3588; Howes, Laurence/0000-0002-1507-8260	Merck Research Laboratories	Merck Research Laboratories(Merck & Company)	Supported by Merck Research Laboratories.	Baigent C, 2008, LANCET, V371, P2084; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; BLOOMFIELD D, 1957, AM HEART J, V352; Brousseau ME, 2004, NEW ENGL J MED, V350, P1505, DOI 10.1056/NEJMoa031766; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Cannon CP, 2006, NEW ENGL J MED, V354, P778; CANNON CP, 1958, AM HEART J, V158; Forrest MJ, 2008, BRIT J PHARMACOL, V154, P1465, DOI 10.1038/bjp.2008.229; GOULD AL, 1988, BIOPHARMACEUTICAL ST, P509; Grundy SM, 2004, CIRCULATION, V110, pE35; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Krishna R, 2007, LANCET, V370, P1907, DOI 10.1016/S0140-6736(07)61813-3; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; Pedersen TR, 2005, JAMA-J AM MED ASSOC, V294, P2437, DOI 10.1001/jama.294.19.2437; PEDERSEN TR, 2005, JAMA-J AM MED ASSOC, V294, P3092; Stein EA, 2010, EUR HEART J, V31, P480, DOI 10.1093/eurheartj/ehp601; Stroes ES, 2008, ARTERIOSCL THROM VAS, V28, P2303, DOI 10.1161/ATVBAHA.108.175620; Thompson A, 2008, JAMA-J AM MED ASSOC, V299, P2777, DOI 10.1001/jama.299.23.2777; Vasan RS, 2009, CIRCULATION, V120, P2414, DOI 10.1161/CIRCULATIONAHA.109.872705; Yvan-Charvet L, 2007, ARTERIOSCL THROM VAS, V27, P1132, DOI 10.1161/ATVBAHA.106.138347; Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P1430, DOI 10.1161/ATVBAHA.110.207142	22	602	620	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 16	2010	363	25					2406	2415		10.1056/NEJMoa1009744	http://dx.doi.org/10.1056/NEJMoa1009744			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694ZK	21082868				2022-12-28	WOS:000285340200006
J	Kaelberer, T; Fedotov, VA; Papasimakis, N; Tsai, DP; Zheludev, NI				Kaelberer, T.; Fedotov, V. A.; Papasimakis, N.; Tsai, D. P.; Zheludev, N. I.			Toroidal Dipolar Response in a Metamaterial	SCIENCE			English	Article								Toroidal multipoles are fundamental electromagnetic excitations different from those associated with the familiar charge and magnetic multipoles. They have been held responsible for parity violation in nuclear and particle physics, but direct evidence of their existence in classical electrodynamics has remained elusive. We report on the observation of a resonant electromagnetic response in an artificially engineered medium, or metamaterial, that cannot be attributed to magnetic or charge multipoles and can only be explained by the existence of a toroidal dipole. Our direct experimental evidence of the toroidal response brings attention to the often ignored electromagnetic interactions involving toroidal multipoles, which could be present in naturally occurring systems, especially at the macromolecule level, where toroidal symmetry is ubiquitous.	[Kaelberer, T.; Fedotov, V. A.; Papasimakis, N.; Zheludev, N. I.] Univ Southampton, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England; [Kaelberer, T.; Fedotov, V. A.; Papasimakis, N.; Zheludev, N. I.] Univ Southampton, Ctr Photon Metamat, Southampton SO17 1BJ, Hants, England; [Tsai, D. P.] Natl Taiwan Univ, Dept Phys, Taipei 10617, Taiwan; [Tsai, D. P.] Natl Appl Res Labs, Instrument Technol Res Ctr, Hsinchu 300, Taiwan	University of Southampton; University of Southampton; National Taiwan University; National Applied Research Laboratories - Taiwan	Fedotov, VA (corresponding author), Univ Southampton, Optoelect Res Ctr, Southampton SO17 1BJ, Hants, England.	vaf@orc.soton.ac.uk; niz@orc.soton.ac.uk	Tsai, Din Ping/F-1734-2011; Zheludev, Nikolay I/C-2284-2014; Papasimakis, Nikitas/G-1453-2015; ZHELUDEV, Nikolay I./Z-1553-2019; Metamaterials, Nanophotonics and/AAF-3156-2019; Papasimakis, Nikitas/M-1754-2019	Tsai, Din Ping/0000-0002-0883-9906; Zheludev, Nikolay I/0000-0002-1013-6636; Papasimakis, Nikitas/0000-0002-6347-6466; ZHELUDEV, Nikolay I./0000-0002-1013-6636; 	UK Engineering and Physical Sciences Research Council; Royal Society; Leverhulme Trust; Engineering and Physical Sciences Research Council [EP/G060363/1] Funding Source: researchfish; EPSRC [EP/G060363/1] Funding Source: UKRI	UK Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Royal Society(Royal Society of London); Leverhulme Trust(Leverhulme Trust); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	Supported by the UK Engineering and Physical Sciences Research Council, the Royal Society, and the Leverhulme Trust.	Afanasiev GN, 1998, PHYS PART NUCLEI, V29, P366, DOI 10.1134/1.953084; AFANASIEV GN, 1992, J PHYS A-MATH GEN, V25, P4869, DOI 10.1088/0305-4470/25/18/020; Afanasiev GN, 2001, J PHYS D APPL PHYS, V34, P539, DOI 10.1088/0022-3727/34/4/316; Alborghetti S, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/6/063019; Boardman AD, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.036603; Ceulemans A, 1998, PHYS REV LETT, V80, P1861, DOI 10.1103/PhysRevLett.80.1861; Dubovik V. M., 1986, Soviet Physics - JETP, V63, P344; Dubovik V. M., 1975, SOV J PART NUCL, V5, P318; Dubovik VM, 2000, PHYS REV E, V61, P7087, DOI 10.1103/PhysRevE.61.7087; DUBOVIK VM, 1990, PHYS REP, V187, P145, DOI 10.1016/0370-1573(90)90042-Z; Fedotov VA, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/4/095; Gongora A., 2006, REV MEX FIS E, V52, P188; Haxton WC, 1997, SCIENCE, V275, P1753, DOI 10.1126/science.275.5307.1753; JACKSON JD, 1999, CLASSICAL ELECTRODYN, pCH16; LANDAU LD, 1993, COURSE THEORETICAL P, V2; Marinov K, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/9/324; Naumov II, 2004, NATURE, V432, P737, DOI 10.1038/nature03107; Papasimakis N, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.093901; Radescu EE, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.046609; Sawada K, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.237402; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Tkalya EV, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.022504; Withers RL, 2001, FERROELECTRICS, V250, P47, DOI 10.1080/00150190108225030; ZELDOVICH IB, 1958, SOV PHYS JETP-USSR, V6, P1184	24	513	516	29	299	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2010	330	6010					1510	1512		10.1126/science.1197172	http://dx.doi.org/10.1126/science.1197172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	692LE	21051597	Green Submitted			2022-12-28	WOS:000285153500056
J	Oberlander, J				Oberlander, Jonathan			Beyond Repeal - The Future of Health Care Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Oberlander, J (corresponding author), Univ N Carolina, Chapel Hill, NC 27515 USA.							Balkin JM, 2010, NEW ENGL J MED, V362, P482, DOI 10.1056/NEJMp1000087; Kaiser Family Foundation, 2010, KAIS HLTH TRACK POLL; Sack Kevin, 2010, NY TIMES        1027, pA16; Sage WM, 2010, HEALTH AFFAIR, V29, P1496, DOI 10.1377/hlthaff.2010.0465	4	8	8	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2010	363	24					2277	2279		10.1056/NEJMp1012779	http://dx.doi.org/10.1056/NEJMp1012779			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	691PA	21083378				2022-12-28	WOS:000285092100001
J	Robertson, JL; Kolmakova-Partensky, L; Miller, C				Robertson, Janice L.; Kolmakova-Partensky, Ludmila; Miller, Christopher			Design, function and structure of a monomeric ClC transporter	NATURE			English	Article							EXCHANGE TRANSPORTER; AMMONIA TRANSPORT; CHLORIDE CHANNEL; MECHANISM; ENERGETICS; REVEALS; AMTB	Channels and transporters of the ClC family cause the transmembrane movement of inorganic anions in service of a variety of biological tasks, from the unusual-the generation of the kilowatt pulses with which electric fish stun their prey-to the quotidian-the acidification of endosomes, vacuoles and lysosomes(1). The homodimeric architecture of ClC proteins, initially inferred from single-molecule studies of an elasmobranch Cl- channel(2) and later confirmed by crystal structures of bacterial Cl-/H+ antiporters(3,4), is apparently universal. Moreover, the basic machinery that enables ion movement through these proteins-the aqueous pores for anion diffusion in the channels and the ion-coupling chambers that coordinate Cl- and H+ antiport in the transporters-are contained wholly within each subunit of the homodimer. The near-normal function of a bacterial ClC transporter straitjacketed by covalent cross-links across the dimer interface and the behaviour of a concatemeric human homologue argue that the transport cycle resides within each subunit and does not require rigid-body rearrangements between subunits(5,6). However, this evidence is only inferential, and because examples are known in which quaternary rearrangements of extramembrane ClC domains that contribute to dimerization modulate transport activity(7), we cannot declare as definitive a 'parallel-pathways' picture in which the homodimer consists of two singlesubunit transporters operating independently. A strong prediction of such a view is that it should in principle be possible to obtain a monomeric ClC. Here we exploit the known structure of a ClC Cl-/H+ exchanger, ClC-ec1 from Escherichia coli, to design mutants that destabilize the dimer interface while preserving both the structure and the transport function of individual subunits. The results demonstrate that the ClC subunit alone is the basic functional unit for transport and that cross-subunit interaction is not required for Cl-/H+ exchange in ClC transporters.	[Robertson, Janice L.; Kolmakova-Partensky, Ludmila; Miller, Christopher] Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute	Miller, C (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.	cmiller@brandeis.edu		Robertson, Janice/0000-0002-5499-9943	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031768, R01GM031768] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [R01 GM031768, R37 GM031768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Accardi A, 2006, J MOL BIOL, V362, P691, DOI 10.1016/j.jmb.2006.07.081; Bykova EA, 2006, NAT STRUCT MOL BIOL, V13, P1115, DOI 10.1038/nsmb1176; Chen LR, 2009, BIOPHYS J, V96, P4622, DOI 10.1016/j.bpj.2009.03.004; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Dutzler R, 2003, SCIENCE, V300, P108, DOI 10.1126/science.1082708; Elvington SM, 2009, EMBO J, V28, P3090, DOI 10.1038/emboj.2009.259; Fang YL, 2007, J BIOL CHEM, V282, P176, DOI 10.1074/jbc.M610075200; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Jentsch TJ, 2005, ANNU REV PHYSIOL, V67, P779, DOI 10.1146/annurev.physiol.67.032003.153245; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Levin EJ, 2009, NATURE, V462, P757, DOI 10.1038/nature08558; MacKenzie KR, 2008, CURR OPIN STRUC BIOL, V18, P412, DOI 10.1016/j.sbi.2008.04.007; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; Metcalf DG, 2009, J MOL BIOL, V392, P1087, DOI 10.1016/j.jmb.2009.06.032; Middleton Richard E., 1994, Methods (Orlando), V6, P28, DOI 10.1006/meth.1994.1005; Miller C, 2009, PHILOS T R SOC B, V364, P175, DOI 10.1098/rstb.2008.0138; Nguitragool W, 2007, P NATL ACAD SCI USA, V104, P20659, DOI 10.1073/pnas.0708639104; Nguitragool W, 2006, J MOL BIOL, V362, P682, DOI 10.1016/j.jmb.2006.07.006; Reyes N, 2009, NATURE, V462, P880, DOI 10.1038/nature08616; Shaffer PL, 2009, SCIENCE, V325, P1010, DOI 10.1126/science.1176088; Theobald DL, 2010, NAT STRUCT MOL BIOL, V17, P2, DOI 10.1038/nsmb0110-2; Waight AB, 2010, NAT STRUCT MOL BIOL, V17, P31, DOI 10.1038/nsmb.1740; Walden M, 2007, J GEN PHYSIOL, V129, P317, DOI 10.1085/jgp.200709756; Wang Y, 2009, NATURE, V462, P467, DOI 10.1038/nature08610; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Zdebik AA, 2008, J BIOL CHEM, V283, P4219, DOI 10.1074/jbc.M708368200; Zheng L, 2004, P NATL ACAD SCI USA, V101, P17090, DOI 10.1073/pnas.0406475101	30	82	84	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	2010	468	7325					844	847		10.1038/nature09556	http://dx.doi.org/10.1038/nature09556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691PQ	21048711	Green Accepted			2022-12-28	WOS:000285093700050
J	Kaschube, M; Schnabel, M; Lowel, S; Coppola, DM; White, LE; Wolf, F				Kaschube, Matthias; Schnabel, Michael; Loewel, Siegrid; Coppola, David M.; White, Leonard E.; Wolf, Fred			Universality in the Evolution of Orientation Columns in the Visual Cortex	SCIENCE			English	Article							SELECTIVITY; ARRANGEMENT; EXPERIENCE; SYMMETRY	The brain's visual cortex processes information concerning form, pattern, and motion within functional maps that reflect the layout of neuronal circuits. We analyzed functional maps of orientation preference in the ferret, tree shrew, and galago-three species separated since the basal radiation of placental mammals more than 65 million years ago-and found a common organizing principle. A symmetry-based class of models for the self-organization of cortical networks predicts all essential features of the layout of these neuronal circuits, but only if suppressive long-range interactions dominate development. We show mathematically that orientation-selective long-range connectivity can mediate the required interactions. Our results suggest that self-organization has canalized the evolution of the neuronal circuitry underlying orientation preference maps into a single common design.	[Kaschube, Matthias; Schnabel, Michael; Wolf, Fred] Univ Gottingen, Fac Phys, Bernstein Ctr Computat Neurosci, Max Planck Inst Dynam & Self Org, D-37073 Gottingen, Germany; [Kaschube, Matthias; Schnabel, Michael; Wolf, Fred] Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA; [Kaschube, Matthias] Princeton Univ, Dept Phys, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA; [Schnabel, Michael] Northwestern Univ, Phys Sci Oncol Ctr, NW Inst Complex Syst, Dept Appl Math, Evanston, IL 60208 USA; [Schnabel, Michael] Northwestern Univ, Phys Sci Oncol Ctr, NW Inst Complex Syst, Dept Phys, Evanston, IL 60208 USA; [Loewel, Siegrid] Univ Jena, Inst Gen Zool & Anim Physiol, D-07743 Jena, Germany; [Loewel, Siegrid] Univ Gottingen, Sch Biol, D-37073 Gottingen, Germany; [Coppola, David M.] Randolph Macon Coll, Dept Biol, Ashland, VA 23005 USA; [White, Leonard E.] Duke Univ, Duke Inst Brain Sci, Dept Community & Family Med, Durham, NC 27710 USA	Max Planck Society; University of Gottingen; Princeton University; Northwestern University; Northwestern University; Friedrich Schiller University of Jena; University of Gottingen; Duke University	Kaschube, M (corresponding author), Univ Gottingen, Fac Phys, Bernstein Ctr Computat Neurosci, Max Planck Inst Dynam & Self Org, D-37073 Gottingen, Germany.	kaschube@princeton.edu; fred-wl@nld.ds.mpg.de	Wolf, Fred/D-5771-2011	Wolf, Fred/0000-0002-7068-3762	Human Frontier Science Program; Bundesministerium fur Bildung, Wissenschaft, Forschung und Technologie [01GQ0430, 01GQ0922]; NSF [0641433]; NIH/National Institute of General Medical Sciences [P50 GM071508]; Whitehall Foundation; National Science Foundation (NSF) [PHY05-51164]; NATIONAL EYE INSTITUTE [R01EY006821, R01EY011488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER	Human Frontier Science Program(Human Frontier Science Program); Bundesministerium fur Bildung, Wissenschaft, Forschung und Technologie(Federal Ministry of Education & Research (BMBF)); NSF(National Science Foundation (NSF)); NIH/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Whitehall Foundation; National Science Foundation (NSF)(National Science Foundation (NSF)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Crowley, J. Fischer, T. Geisel, H. Greenside, A. Grinvald, M. Gutnick, J. Kaas, T. Kottos, T. Moser, and J. Schmitz for discussions; B. Bosking for acquiring and processing imaging data; W. Keil and L. Reichl for calculations; B. Goetze for graphics; D. Fitzpatrick for support of imaging experiments (NIH/National Eye Institute (NEI) EY06821 and EY11488); and the Kavli Institute for Theoretical Physics for its hospitality. This work was funded by grants from the Human Frontier Science Program and Bundesministerium fur Bildung, Wissenschaft, Forschung und Technologie to S. L. and F. W. (01GQ0430 and 01GQ0922); NSF to D. M. C. (0641433); NIH/National Institute of General Medical Sciences to M. K. (P50 GM071508); and the Whitehall Foundation to L. E. W. and was supported in part by the National Science Foundation (NSF PHY05-51164).	Akerman CJ, 2002, NEURON, V36, P869, DOI 10.1016/S0896-6273(02)01010-3; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 1997, J NEUROSCI, V17, P2112; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; Flatt T, 2005, Q REV BIOL, V80, P287, DOI 10.1086/432265; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; Kaas JH, 2008, BRAIN RES BULL, V75, P384, DOI 10.1016/j.brainresbull.2007.10.009; Kaschube M, 2002, J NEUROSCI, V22, P7206; Kaschube M, 2009, P NATL ACAD SCI USA, V106, P17205, DOI 10.1073/pnas.0901615106; Kaschube M, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/1/015009; Kriegs JO, 2007, TRENDS GENET, V23, P158, DOI 10.1016/j.tig.2007.02.002; Kriegs JO, 2006, PLOS BIOL, V4, P537, DOI 10.1371/journal.pbio.0040091; Lee HY, 2003, P NATL ACAD SCI USA, V100, P16036, DOI 10.1073/pnas.2531343100; Li Y, 2006, NAT NEUROSCI, V9, P676, DOI 10.1038/nn1684; Mayer N, 2002, NEUROCOMPUTING, V44, P533, DOI 10.1016/S0925-2312(02)00417-4; Maynard Smith J., 1985, Q REV BIOL, V60, P265, DOI DOI 10.1086/414425); Niven JE, 2004, PLOS BIOL, V2, P22, DOI 10.1371/journal.pbio.0020019; Obermayer K, 1997, NEURAL COMPUT, V9, P555, DOI 10.1162/neco.1997.9.3.555; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Ohki K, 2006, NATURE, V442, P925, DOI 10.1038/nature05019; Reichl L, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.208101; Van Hooser SD, 2007, NEUROSCIENTIST, V13, P639, DOI 10.1177/1073858407306597; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; White LE, 2001, NATURE, V411, P1049, DOI 10.1038/35082568; White LE, 2007, NEURON, V56, P327, DOI 10.1016/j.neuron.2007.10.011; Wolf F, 1998, NATURE, V395, P73, DOI 10.1038/25736; Wolf F, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.208701	28	114	115	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2010	330	6007					1113	1116		10.1126/science.1194869	http://dx.doi.org/10.1126/science.1194869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21051599	Green Accepted			2022-12-28	WOS:000284374700046
J	Mangalmurti, SS; Murtagh, L; Mello, MM				Mangalmurti, Sandeep S.; Murtagh, Lindsey; Mello, Michelle M.			Medical Malpractice Liability in the Age of Electronic Health Records	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN ORDER ENTRY; INFORMATION-TECHNOLOGY; DIAGNOSTIC ERRORS; LEGAL ISSUES; PRIMARY-CARE; SYSTEM; CLAIMS; IMPLEMENTATION; DOCUMENTATION; COMMUNICATION		[Murtagh, Lindsey; Mello, Michelle M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Mangalmurti, Sandeep S.] NYU, Med Ctr, Dept Med, New York, NY 10016 USA	Harvard University; Harvard T.H. Chan School of Public Health; New York University	Mello, MM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	mmello@hsph.harvard.edu	Tao, Youyou/D-2367-2014					Adler-Milstein J, 2009, HEALTH AFFAIR, V28, P483, DOI 10.1377/hlthaff.28.2.483; *AM MED ASS, 2002, GUID PHYS PAT EL COM; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Blumenthal D, 2007, NEW ENGL J MED, V356, P2527, DOI 10.1056/NEJMhpr066212; Blumenthal D, 2010, NEW ENGL J MED, V362, P382, DOI 10.1056/NEJMp0912825; Casalino, 2009, ARCH INTERN MED, V169, P1626; Casalino LP, 2009, ARCH INTERN MED, V169, P1123, DOI 10.1001/archinternmed.2009.130; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Comm. Maint. Priv. Secur. Health Care Appl. Natl. Inf. Infrastruct. Comm. Phys. Sci. Math. Appl.. Natl. Res. Counc, 1997, REC PROT EL HLTH INF; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; DesRoches CM, 2010, HEALTH AFFAIR, V29, P639, DOI 10.1377/hlthaff.2009.1086; Fernandopulle R, 2010, HEALTH AFFAIR, V29, P622, DOI 10.1377/hlthaff.2010.0065; Ferris N, 2010, HEALTH AFFAIR, V29, P583, DOI 10.1377/hlthaff.2010.0217; Hall MA, 2010, IOWA LAW REV, V95, P631; Hammond Kenric W, 2003, AMIA Annu Symp Proc, P269; Han, 2006, PEDIATRICS, V117, P594, DOI 10.1542/peds.2005-2970; Han YY, 2005, PEDIATRICS, V116, P1506, DOI 10.1542/peds.2005-1287; Hartzband P, 2008, NEW ENGL J MED, V358, P1656, DOI 10.1056/NEJMp0802221; HICKSON GB, 1992, JAMA-J AM MED ASSOC, V267, P1359, DOI 10.1001/jama.267.10.1359; Hickson GB, 2002, JAMA-J AM MED ASSOC, V287, P2951, DOI 10.1001/jama.287.22.2951; Hodge JG, 1999, JAMA-J AM MED ASSOC, V282, P1466, DOI 10.1001/jama.282.15.1466; Hoffman Sharona, 2009, BERKELEY TECHNOL LAW, V24, P1523; HSIAO CJ, 2009, ELECT MED RECORD ELE; Jha AK, 2009, NEW ENGL J MED, V360, P1628, DOI 10.1056/NEJMsa0900592; Jones SC, 2008, FOOD DRUG LAW J, V63, P75; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; Kaushal R, 2003, ARCH INTERN MED, V163, P1409, DOI 10.1001/archinte.163.12.1409; Kaushal R, 2006, J AM MED INFORM ASSN, V13, P261, DOI 10.1197/jamia.M1984; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; *LEAPFR GROUP, 2008, COMP PHYS ORD ENTR F; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lorenzi NM, 2008, J AM MED INFORM ASSN, V15, P290, DOI 10.1197/jamia.M2583; McLean TR, 2008, J AM COLL SURGEONS, V206, P405, DOI 10.1016/j.jamcollsurg.2007.09.018; Mello MM, 2003, HEALTH AFFAIR, V22, P46, DOI 10.1377/hlthaff.22.2.46; Mello MM, 2001, U PENN LAW REV, V149, P645, DOI 10.2307/3312867; MILLER AR, 2009, ELECT DISCOVERY ELEC; Ralston JD, 2010, HEALTH AFFAIR, V29, P607, DOI 10.1377/hlthaff.2010.0113; Rosenbaum S, 2005, PUBLIC HEALTH REP, V120, P350, DOI 10.1177/003335490512000321; ROSENBAUM S, 2010, MED PROFESSIONALISM, P66; Schiff GD, 2010, NEW ENGL J MED, V362, P1066, DOI 10.1056/NEJMp0911734; Singh H, 2008, J GEN INTERN MED, V23, P489, DOI 10.1007/s11606-007-0393-z; TERRY NP, 2005, WIDENER LAW REV, V12, P133; Thielke Stephen, 2007, Int J Med Inform, V76 Suppl 1, pS122, DOI 10.1016/j.ijmedinf.2006.06.004; Vigoda MM, 2006, ANESTH ANALG, V102, P1798, DOI 10.1213/01.ane.0000217235.25350.5e; Vigoda MM, 2006, ANESTH ANALG, V103, P131, DOI 10.1213/01.ane.0000221602.90315.49; Virapongse A, 2008, ARCH INTERN MED, V168, P2362, DOI 10.1001/archinte.168.21.2362; Walsh Diana, 2008, Int J Electron Healthc, V4, P311, DOI 10.1504/IJEH.2008.022668; Walsh KE, 2006, PEDIATRICS, V118, P1872, DOI 10.1542/peds.2006-0810; Weingart SN, 2003, ARCH INTERN MED, V163, P2625, DOI 10.1001/archinte.163.21.2625; WOODWARD B, 1995, NEW ENGL J MED, V333, P1419, DOI 10.1056/NEJM199511233332112	50	54	54	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2060	2067		10.1056/NEJMhle1005210	http://dx.doi.org/10.1056/NEJMhle1005210			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KC	21083393				2022-12-28	WOS:000284310000014
J	Shaner, DM				Shaner, D. Malcolm			Up in the Air - Suspending Ethical Medical Practice	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Shaner, D. Malcolm] W Los Angeles Med Ctr, Kaiser Permanente Med Care Program, Dept Neurol, Los Angeles, CA USA; [Shaner, D. Malcolm] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Kaiser Permanente; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Shaner, DM (corresponding author), W Los Angeles Med Ctr, Kaiser Permanente Med Care Program, Dept Neurol, Los Angeles, CA USA.								0	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					1988	1989		10.1056/NEJMp1006331	http://dx.doi.org/10.1056/NEJMp1006331			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KC	21083383				2022-12-28	WOS:000284310000003
J	Einstein, AJ; Weiner, SD; Bernheim, A; Kulon, M; Bokhari, S; Johnson, LL; Moses, JW; Balter, S				Einstein, Andrew J.; Weiner, Shepard D.; Bernheim, Adam; Kulon, Michal; Bokhari, Sabahat; Johnson, Lynne L.; Moses, Jeffrey W.; Balter, Stephen			Multiple Testing, Cumulative Radiation Dose, and Clinical Indications in Patients Undergoing Myocardial Perfusion Imaging	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMERICAN-HEART-ASSOCIATION; NUCLEAR-MEDICINE; COMPUTED-TOMOGRAPHY; IONIZING-RADIATION; EXPOSURE; CANCER; RADIOLOGY; RISK; REVASCULARIZATION; ECHOCARDIOGRAPHY	Context Myocardial perfusion imaging (MPI) is the single medical test with the highest radiation burden to the US population. Although many patients undergoing MPI receive repeat MPI testing, or additional procedures involving ionizing radiation, no data are available characterizing their total longitudinal radiation burden and relating radiation burden with reasons for testing. Objectives To characterize procedure counts, cumulative estimated effective doses of radiation, and clinical indications for patients undergoing MPI. Design, Setting, and Patients A retrospective cohort study of 1097 consecutive patients undergoing index MPI during the first 100 days of 2006 (January 1-April 10) at Columbia University Medical Center, New York, New York, that evaluated all preceding medical imaging procedures involving ionizing radiation undergone beginning October 1988, and all subsequent procedures through June 2008, at the center. Main Outcome Measures Cumulative estimated effective dose of radiation, number of procedures involving radiation, and indications for testing. Results Patients underwent a median of 15 (interquartile range [IQR], 6-32; mean, 23.9) procedures involving radiation exposure; of which 4 (IQR, 2-8; mean, 6.5) were high-dose procedures (>= 3 mSv; ie, 1 year's background radiation), including 1 (IQR, 1-2; mean, 1.8) MPI study per patient. A total of 344 patients (31.4%) received cumulative estimated effective dose from all medical sources of more than 100 mSv. Multiple MPIs were performed in 424 patients (38.6%), for whom cumulative estimated effective dose was 121 mSv (IQR, 81-189; mean, 149 mSv). Men and white patients had higher cumulative estimated effective doses. More than 80% of initial and 90% of repeat MPI examinations were performed in patients with known cardiac disease or symptoms consistent with it. Conclusion In this institution, multiple testing with MPI was common and in many patients associated with high cumulative estimated doses of radiation. JAMA. 2010;304(19):2137-2144 www.jama.com	[Einstein, Andrew J.; Weiner, Shepard D.; Bernheim, Adam; Bokhari, Sabahat; Johnson, Lynne L.; Moses, Jeffrey W.; Balter, Stephen] Columbia Univ, Med Ctr, Div Cardiol, Dept Med, New York, NY 10032 USA; [Einstein, Andrew J.; Kulon, Michal; Balter, Stephen] Columbia Univ, Med Ctr, Dept Radiol, New York, NY 10032 USA; [Bernheim, Adam] New York Presbyterian Hosp, New York, NY USA; [Bernheim, Adam] Staten Isl Univ Hosp, Dept Radiol, New York, NY USA	Columbia University; Columbia University; NewYork-Presbyterian Hospital; Northwell Health	Einstein, AJ (corresponding author), Columbia Univ, Med Ctr, Div Cardiol, Dept Med, 622 W 168th St,PH 10-203A, New York, NY 10032 USA.	andrew.einstein@columbia.edu	Balter, S/P-6211-2019; Bokhari, Sabahat/GZM-2572-2022; Bokhari, Sabahat/GSI-6376-2022		Covidien; GE Healthcare; INVIA; Philips Medical Systems; Toshiba America Medical Systems; National Institutes of Health [KL2 RR024157]; Louis V. Gerstner, Jr. Scholars Program; Lewis Katz Cardiovascular Research Prize; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024157] Funding Source: NIH RePORTER	Covidien; GE Healthcare(General ElectricGE Healthcare); INVIA; Philips Medical Systems; Toshiba America Medical Systems; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louis V. Gerstner, Jr. Scholars Program; Lewis Katz Cardiovascular Research Prize; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Dr Einstein reported having served as a consultant for the International Atomic Energy Agency and for GE Healthcare, having received support for other research from Spectrum Dynamics and a Nuclear Cardiology Foundation grant funded by Covidien, and having received travel funding from GE Healthcare, INVIA, Philips Medical Systems, and Toshiba America Medical Systems. Dr Moses reported having served as a consultant for GE Healthcare. Dr Balter reported having served as a consultant for the International Atomic Energy Agency and Siemens. All other authors reported no disclosures.; Dr Einstein was supported by a National Institutes of Health K12 institutional career development award (KL2 RR024157), by the Louis V. Gerstner, Jr. Scholars Program, and by the Lewis Katz Cardiovascular Research Prize for a Young Investigator.	[Anonymous], 1991, Ann ICRP, V21, P1; [Anonymous], 1998, Ann ICRP, V28, P1; [Anonymous], 2008, ANN ICRP, V38, P1; Bedetti G, 2008, BRIT J RADIOL, V81, P699, DOI 10.1259/bjr/29507259; Berman DS, 2009, JACC-CARDIOVASC IMAG, V2, P273, DOI 10.1016/j.jcmg.2008.12.012; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Chang SM, 2010, J AM COLL CARDIOL, V55, P221, DOI 10.1016/j.jacc.2009.09.022; Charles MW, 2006, J RADIOL PROT, V26, P325, DOI 10.1088/0952-4746/26/3/N02; Chen J, 2010, J AM COLL CARDIOL, V56, P702, DOI 10.1016/j.jacc.2010.05.014; DePuey G, 2009, CIRCULATION, V120, pS334; Einstein AJ, 2007, CIRCULATION, V116, P1290, DOI 10.1161/CIRCULATIONAHA.107.688101; Einstein AJ, 2007, JAMA-J AM MED ASSOC, V298, P317, DOI 10.1001/jama.298.3.317; Einstein AJ, 2009, JACC-CARDIOVASC IMAG, V2, P369, DOI 10.1016/j.jcmg.2008.10.008; *EUR COMM, 2008, RAD PROT 154 EUR GUI; Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; Fiscella K, 2001, MED CARE, V39, P8, DOI 10.1097/00005650-200101000-00003; Gerber TC, 2009, CIRCULATION, V119, P1056, DOI 10.1161/CIRCULATIONAHA.108.191650; Griffey RT, 2009, AM J ROENTGENOL, V192, P887, DOI 10.2214/AJR.08.1351; Hachamovitch R, 2003, J AM COLL CARDIOL, V41, P1329, DOI 10.1016/S0735-1097(03)00125-6; Hendel RC, 2009, J AM COLL CARDIOL, V53, P2201, DOI 10.1016/j.jacc.2009.02.013; Hunter C, 2010, J NUCL MED, V51; Iglehart JK, 2006, NEW ENGL J MED, V354, P2822, DOI 10.1056/NEJMhpr061219; *IMV MED INF DIV, 2003, 2003 NUCL MED CENS M; Krieger N, 2003, AM J PUBLIC HEALTH, V93, P1655, DOI 10.2105/AJPH.93.10.1655; Lucas FL, 2006, CIRCULATION, V113, P374, DOI 10.1161/CIRCULATIONAHA.105.560433; Lucas FL, 2007, AM HEART J, V154, P502, DOI 10.1016/j.ahj.2007.04.044; Mettler FA, 2008, RADIOLOGY, V248, P254, DOI 10.1148/radiol.2481071451; Metz LD, 2007, J AM COLL CARDIOL, V49, P227, DOI 10.1016/j.jacc.2006.08.048; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; National Council on Radiation Protection and Measurements, 2009, 160 NCRP; National Research Council of the National Academies NRC, 2006, HLTH RISKS EXP LOW L; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; Schinkel AFL, 2006, AM J CARDIOL, V97, P1, DOI 10.1016/j.amjcard.2005.07.102; Senthamizhchelvan S, 2010, J NUCL MED, V51, P1592, DOI 10.2967/jnumed.110.077669; Shaw LJ, 2008, CIRCULATION, V117, P1283, DOI 10.1161/CIRCULATIONAHA.107.743963; Sodickson A, 2009, RADIOLOGY, V251, P175, DOI 10.1148/radiol.2511081296; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Stabin MG, 2001, J NUCL MED, V42, p243P; Stabin M, 2008, J NUCL MED, V49, p20N	40	129	129	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2137	2144		10.1001/jama.2010.1664	http://dx.doi.org/10.1001/jama.2010.1664			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21078807	Bronze, Green Accepted			2022-12-28	WOS:000284269800024
J	Spence, D				Spence, Des			From the Frontline Bad medicine: paediatric ear, nose, and throat surgery	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	4	4	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 17	2010	341								c6560	10.1136/bmj.c6560	http://dx.doi.org/10.1136/bmj.c6560			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684WO	21084364				2022-12-28	WOS:000284586200003
J	Hegmann, KT				Hegmann, Kurt T.			Adding steroid injection to exercise and manual mobilization did not reduce shoulder pain and disability over the long term	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Utah, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Hegmann, KT (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.							Burbank KM, 2008, AM FAM PHYSICIAN, V77, P493; HEGMANN KT, 2010, OCCUPATIONAL MED PRA; PETRI M, 1987, ARTHRITIS RHEUM-US, V30, P1040, DOI 10.1002/art.1780300911	3	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-6	10.1059/0003-4819-153-10-201011160-02006	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079213				2022-12-28	WOS:000284215800005
J	Ding, BS; Nolan, DJ; Butler, JM; James, D; Babazadeh, AO; Rosenwaks, Z; Mittal, V; Kobayashi, H; Shido, K; Lyden, D; Sato, TN; Rabbany, SY; Rafii, S				Ding, Bi-Sen; Nolan, Daniel J.; Butler, Jason M.; James, Daylon; Babazadeh, Alexander O.; Rosenwaks, Zev; Mittal, Vivek; Kobayashi, Hideki; Shido, Koji; Lyden, David; Sato, Thomas N.; Rabbany, Sina Y.; Rafii, Shahin			Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration	NATURE			English	Article							CELLS; ANGIOGENESIS; GROWTH; VEGF; DIFFERENTIATION; EXPRESSION; ID1	During embryogenesis, endothelial cells induce organogenesis before the development of circulation(1-4). These findings suggest that endothelial cells not only form passive conduits to deliver nutrients and oxygen, but also establish an instructive vascular niche, which through elaboration of paracrine trophogens stimulates organ regeneration, in a manner similar to endothelial-cell-derived angiocrine factors that support haematopoiesis(5-7). However, the precise mechanism by which tissue-specific subsets of endothelial cells promote organogenesis in adults is unknown. Here we demonstrate that liver sinusoidal endothelial cells (LSECs) constitute a unique population of phenotypically and functionally defined VEGFR3(+)CD34(-)VEGFR2(+)VE-cadherin(+)FactorVIII(+)CD452(-) endothelial cells, which through the release of angiocrine trophogens initiate and sustain liver regeneration induced by 70% partial hepatectomy. After partial hepatectomy, residual liver vasculature remains intact without experiencing hypoxia or structural damage, which allows study of physiological liver regeneration. Using this model, we show that inducible genetic ablation of vascular endothelial growth factor (VEGF)-A receptor-2 (VEGFR2) in the LSECs impairs the initial burst of hepatocyte proliferation (days 1-3 after partial hepatectomy) and subsequent reconstitution of the hepatovascular mass (days 4-8 after partial hepatectomy) by inhibiting upregulation of the endothelial-cell-specific transcription factor Id1. Accordingly, Id1-deficient mice also manifest defects throughout liver regeneration, owing to diminished expression of LSEC-derived angiocrine factors, including hepatocyte growth factor (HGF) and Wnt2. Notably, in in vitro co-cultures, VEGFR2-Id1 activation in LSECs stimulates hepatocyte proliferation. Indeed, intrasplenic transplantation of Id1(+/+) or Id1(-/-) LSECs transduced with Wnt2 and HGF (Id1(-/-)Wnt2(+)HGF(+) LSECs) re-establishes an inductive vascular niche in the liver sinusoids of the Id1(-/-) mice, initiating and restoring hepatovascular regeneration. Therefore, in the early phases of physiological liver regeneration, VEGFR2-Id1-mediated inductive angiogenesis in LSECs through release of angiocrine factors Wnt2 and HGF provokes hepatic proliferation. Subsequently, VEGFR2-Id1-dependent proliferative angiogenesis reconstitutes liver mass. Therapeutic co-transplantation of inductive VEGFR2(+)Id1(+)Wnt2(+)HGF(+) LSECs with hepatocytes provides an effective strategy to achieve durable liver regeneration.	[Ding, Bi-Sen; Nolan, Daniel J.; Butler, Jason M.; James, Daylon; Babazadeh, Alexander O.; Kobayashi, Hideki; Shido, Koji; Rabbany, Sina Y.; Rafii, Shahin] Weill Cornell Med Coll, Ansary Stem Cell Inst, Howard Hughes Med Inst, New York, NY 10065 USA; [Ding, Bi-Sen; Nolan, Daniel J.; Butler, Jason M.; James, Daylon; Babazadeh, Alexander O.; Kobayashi, Hideki; Shido, Koji; Rabbany, Sina Y.; Rafii, Shahin] Weill Cornell Med Coll, Dept Med Genet, New York, NY 10065 USA; [Rosenwaks, Zev] Ronald O Perelman & Claudia Cohen Ctr Reprod Med, New York, NY 10065 USA; [Mittal, Vivek] Weill Cornell Med Coll, Dept Surg, New York, NY 10065 USA; [Lyden, David] Weill Cornell Med Coll, Dept Pediat, New York, NY 10065 USA; [Sato, Thomas N.] Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara, Japan; [Rabbany, Sina Y.] Hofstra Univ, Bioengn Program, Hempstead, NY 11549 USA	Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University; Cornell University; Nara Institute of Science & Technology; Hofstra University	Rafii, S (corresponding author), Weill Cornell Med Coll, Ansary Stem Cell Inst, Howard Hughes Med Inst, New York, NY 10065 USA.	srafii@med.cornell.edu			Howard Hughes Medical Institute; Ansary Stem Cell Institute; National Institutes of Health [HL097797, U01 HL-66592-03, RC1 AI080309]; Qatar National Priorities Research Program; Anbinder and Newmans Own Foundations; Empire State Stem Cell Board; New York State Department of Health [NYS C024180]; MEXT; Takeda Science Foundation; Uehara Memorial Life Science Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL097797, P01HL059312, P50HL084936, P01HL067839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [RC1AI080309] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Ansary Stem Cell Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Qatar National Priorities Research Program(Qatar National Research Fund (QNRF)); Anbinder and Newmans Own Foundations; Empire State Stem Cell Board; New York State Department of Health; MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Uehara Memorial Life Science Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S.R. is supported by the Howard Hughes Medical Institute, the Ansary Stem Cell Institute, National Institutes of Health grants HL097797, U01 HL-66592-03 and RC1 AI080309, the Qatar National Priorities Research Program, the Anbinder and Newmans Own Foundations, the Empire State Stem Cell Board and a New York State Department of Health grant, NYS C024180. T.N.S is supported by MEXT (Kiban-S), the Takeda Science Foundation and the Uehara Memorial Life Science Foundation. We are grateful to N. K. Hong for advice on mouse surgical procedure and F. Roth for editing the manuscript.	Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Butler JM, 2010, CELL STEM CELL, V6, P251, DOI 10.1016/j.stem.2010.02.001; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Ema M, 2006, BLOOD, V107, P111, DOI 10.1182/blood-2005-05-1970; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Follenzi A, 2008, J CLIN INVEST, V118, P935, DOI 10.1172/JCI32748; Friedman SL, 2008, PHYSIOL REV, V88, P125, DOI 10.1152/physrev.00013.2007; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Greene AK, 2003, ANN SURG, V237, P530, DOI 10.1097/00000658-200304000-00015; Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Klein D, 2008, HEPATOLOGY, V47, P1018, DOI 10.1002/hep.22084; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Kumar V, 2006, J CLIN INVEST, V116, P512, DOI 10.1172/JCI25536; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Lee JS, 2007, HEPATOLOGY, V45, P817, DOI 10.1002/hep.21564; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Makita T, 2008, NATURE, V452, P759, DOI 10.1038/nature06859; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; McDonald B, 2008, J EXP MED, V205, P915, DOI 10.1084/jem.20071765; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nam HS, 2009, CELL STEM CELL, V5, P515, DOI 10.1016/j.stem.2009.08.017; Ober EA, 2006, NATURE, V442, P688, DOI 10.1038/nature04888; Passino MA, 2007, SCIENCE, V315, P1853, DOI 10.1126/science.1137603; Rafii S, 2008, SCIENCE, V319, P163, DOI 10.1126/science.1153615; Sakaguchi TF, 2008, CURR BIOL, V18, P1565, DOI 10.1016/j.cub.2008.08.065; Tam BYY, 2006, NAT MED, V12, P793, DOI 10.1038/nm1428; Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651; van Buren G, 2008, J CLIN ONCOL, V26, P1836, DOI 10.1200/JCO.2007.11.6566; Winau F, 2007, IMMUNITY, V26, P117, DOI 10.1016/j.immuni.2006.11.011; Zaret KS, 2008, SCIENCE, V322, P1490, DOI 10.1126/science.1161431	36	531	557	2	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					310	U240		10.1038/nature09493	http://dx.doi.org/10.1038/nature09493			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068842	Green Accepted			2022-12-28	WOS:000284051000052
J	Lin, MY; Hota, B; Khan, YM; Woeltje, KF; Borlawsky, TB; Doherty, JA; Stevenson, KB; Weinstein, RA; Trick, WE				Lin, Michael Y.; Hota, Bala; Khan, Yosef M.; Woeltje, Keith F.; Borlawsky, Tara B.; Doherty, Joshua A.; Stevenson, Kurt B.; Weinstein, Robert A.; Trick, William E.		CDC Prevention Epictr Program	Quality of Traditional Surveillance for Public Reporting of Nosocomial Bloodstream Infection Rates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE-ASSOCIATED INFECTIONS; UNIT PATIENTS; CENTRAL-LINE	Context Central line-associated bloodstream infection (BSI) rates, determined by infection preventionists using the Centers for Disease Control and Prevention (CDC) surveillance definitions, are increasingly published to compare the quality of patient care delivered by hospitals. However, such comparisons are valid only if surveillance is performed consistently across institutions. Objective To assess institutional variation in performance of traditional centralline-associated BSI surveillance. Design, Setting, and Participants We performed a retrospective cohort study of 20 intensive care units among 4 medical centers (2004-2007). Unit-specific central line-associated BSI rates were calculated for 12-month periods. Infection preventionists, blinded to study participation, performed routine prospective surveillance using CDC definitions. A computer algorithm reference standard was applied retrospectively using criteria that adapted the same CDC surveillance definitions. Main Outcome Measures Correlation of central line-associated BSI rates as determined by infection preventionist vs the computer algorithm reference standard. Variation in performance was assessed by testing for institution-dependent heterogeneity in a linear regression model. Results Forty-one unit-periods among 20 intensive care units were analyzed, representing 241 518 patient-days and 165 963 central line-days. The median infection preventionist and computer algorithm central line-associated BSI rates were 3.3 (interquartile range [IQR], 2.0-4.5) and 9.0 (IQR, 6.3-11.3) infections per 1000 central line-days, respectively. Overall correlation between computer algorithm and infection preventionist rates was weak (p = 0.34), and when stratified by medical center, point estimates for institution-specific correlations ranged widely: medical center A: 0.83; 95% confidence interval (CI), 0.05 to 0.98; P = .04; medical center B: 0.76; 95% CI, 0.32 to 0.93; P = .003; medical center C: 0.50, 95% CI, -0.11 to 0.83; P = .10; and medical center D: 0.10; 95% CI -0.53 to 0.66; P = .77. Regression modeling demonstrated significant heterogeneity among medical centers in the relationship between computer algorithm and expected infection preventionist rates (P < .001). The medical center that had the lowest rate by traditional surveillance (2.4 infections per 1000 central line-days) had the highest rate by computer algorithm (12.6 infections per 1000 central line-days). Conclusions Institutional variability of infection preventionist rates relative to a computer algorithm reference standard suggests that there is significant variation in the application of standard central line-associated BSI surveillance definitions across medical centers. Variation in central line-associated BSI surveillance practice may complicate interinstitutional comparisons of publicly reported central line-associated BSI rates. JAMA. 2010;304(18):2035-2041 www.jama.com	[Lin, Michael Y.; Hota, Bala; Weinstein, Robert A.] Rush Univ, Med Ctr, Infect Dis Sect, Chicago, IL 60612 USA; [Lin, Michael Y.; Hota, Bala; Weinstein, Robert A.; Trick, William E.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA; [Hota, Bala; Weinstein, Robert A.] John H Stroger Jr Hosp Cook Cty, Div Infect Dis, Chicago, IL USA; [Hota, Bala; Weinstein, Robert A.; Trick, William E.] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL USA; [Woeltje, Keith F.] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63130 USA; [Doherty, Joshua A.] BJC Healthcare, Dept Med Informat, St Louis, MO USA; [Borlawsky, Tara B.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Khan, Yosef M.; Stevenson, Kurt B.] Ohio State Univ, Coll Med, Div Infect Dis, Columbus, OH 43210 USA	Rush University; Rush University; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Washington University (WUSTL); University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lin, MY (corresponding author), Rush Univ, Med Ctr, Infect Dis Sect, 600 S Paulina St,Ste 143, Chicago, IL 60612 USA.	Michael_Lin@rush.edu		Woeltje, Keith/0000-0002-6385-3970; Trick, William/0000-0002-3243-5098	CDC [U01-CI000327, U01-CI000328, U01-CI000333]; NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID) [U01CI000328, U01CI000333, U01CI000327] Funding Source: NIH RePORTER	CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was funded by CDC Cooperative Agreements U01-CI000327, U01-CI000328, and U01-CI000333 from the CDC Prevention Epicenter Grants.	Bleasdale SC, 2007, ARCH INTERN MED, V167, P2073, DOI 10.1001/archinte.167.19.2073; *CTR MED MED SERV, 2010, MED FACT SHEET NEW P; Division of Healthcare Quality Promotion Centers for Disease Control and Prevention, NAT HEALTHC SAF NETW; Edmond MB, 2009, INFECT CONT HOSP EP, V30, P74, DOI 10.1086/592411; Emori TG, 1998, INFECT CONT HOSP EP, V19, P308; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hota B, 2010, J AM MED INFORM ASSN, V17, P42, DOI 10.1197/jamia.M3196; Hulley SB, 2013, DESIGNING CLIN RES; Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205; McBryde ES, 2009, INFECT CONT HOSP EP, V30, P1045, DOI 10.1086/606168; McKibben L, 2005, INFECT CONT HOSP EP, V26, P580, DOI 10.1086/502585; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; Perencevich EN, 2007, INFECT CONT HOSP EP, V28, P1121, DOI 10.1086/521852; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2007, JAMA-J AM MED ASSOC, V298, P1800, DOI 10.1001/jama.298.15.1800; Rubin Michael A, 2008, AMIA Annu Symp Proc, P631; Tokars JI, 2004, CLIN INFECT DIS, V39, P1347, DOI 10.1086/425000; Trick WE, 2004, EMERG INFECT DIS, V10, P1612, DOI 10.3201/eid1009.030978; Weinstein RA, 2005, NEW ENGL J MED, V353, P225, DOI 10.1056/NEJMp058073; Werner RM, 2005, JAMA-J AM MED ASSOC, V293, P1239, DOI 10.1001/jama.293.10.1239; Woeltje KF, 2008, INFECT CONT HOSP EP, V29, P842, DOI 10.1086/590261; Worth LJ, 2009, AM J INFECT CONTROL, V37, P643, DOI 10.1016/j.ajic.2009.02.013; Yokoe DS, 1998, INFECT CONT HOSP EP, V19, P657; 2008, INFECT CONTROL  0711; 2010, DATA PATIENTS FARE B	28	128	127	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2035	2041		10.1001/jama.2010.1637	http://dx.doi.org/10.1001/jama.2010.1637			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063013	Green Accepted, Bronze			2022-12-28	WOS:000284000600022
J	Fields, RD				Fields, R. Douglas			Change in the Brain's White Matter	SCIENCE			English	Editorial Material							MYELINATION; RELEASE; OLIGODENDROCYTES; ARCHITECTURE; MECHANISM; IMPULSES; NEURONS; CELLS		NICHHD, Nervous Syst Dev & Plast Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Fields, RD (corresponding author), NICHHD, Nervous Syst Dev & Plast Sect, NIH, Bethesda, MD 20892 USA.	fieldsd@mail.nih.gov	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000713] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA HD000713-23, Z99 HD999999] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartzokis G, 2010, NEUROBIOL AGING, V31, P1554, DOI 10.1016/j.neurobiolaging.2008.08.015; Carreiras M, 2009, NATURE, V461, P983, DOI 10.1038/nature08461; Cirelli C, 2004, NEURON, V41, P35, DOI 10.1016/S0896-6273(03)00814-6; Fields RD, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001128; Ishibashi T, 2006, NEURON, V49, P823, DOI 10.1016/j.neuron.2006.02.006; Kukley M, 2010, J NEUROSCI, V30, P8320, DOI 10.1523/JNEUROSCI.0854-10.2010; Lawrence JJ, 2008, TRENDS NEUROSCI, V31, P317, DOI 10.1016/j.tins.2008.03.008; Markham JA, 2004, NEURON GLIA BIOL, V1, P351, DOI 10.1017/S1740925X05000219; Markham JA, 2009, BRAIN RES, V1288, P9, DOI 10.1016/j.brainres.2009.06.087; Psachoulia K, 2009, NEURON GLIA BIOL, V5, P57, DOI 10.1017/S1740925X09990354; Quallo MM, 2009, P NATL ACAD SCI USA, V106, P18379, DOI 10.1073/pnas.0909751106; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Roy K, 2007, P NATL ACAD SCI USA, V104, P8131, DOI 10.1073/pnas.0702157104; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Stevens B, 1998, J NEUROSCI, V18, P9303; Ullen F, 2009, NEURON GLIA BIOL, V5, P28, DOI 10.1017/S1740925X09990330	18	141	146	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					768	769		10.1126/science.1199139	http://dx.doi.org/10.1126/science.1199139			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051624	Green Accepted			2022-12-28	WOS:000283855700028
J	Kubo, K; Entani, T; Takara, A; Wang, N; Fields, AM; Hua, ZH; Toyoda, M; Kawashima, S; Ando, T; Isogai, A; Kao, T; Takayama, S				Kubo, Ken-ichi; Entani, Tetsuyuki; Takara, Akie; Wang, Ning; Fields, Allison M.; Hua, Zhihua; Toyoda, Mamiko; Kawashima, Shin-ichi; Ando, Toshio; Isogai, Akira; Kao, Teh-hui; Takayama, Seiji			Collaborative Non-Self Recognition System in S-RNase-Based Self-Incompatibility	SCIENCE			English	Article							F-BOX GENE; POLLEN; LOCUS; IDENTIFICATION; DETERMINANT; REGION; SLF	Self-incompatibility in flowering plants prevents inbreeding and promotes outcrossing to generate genetic diversity. In Solanaceae, a multiallelic gene, S-locus F-box (SLF), was previously shown to encode the pollen determinant in self-incompatibility. It was postulated that an SLF allelic product specifically detoxifies its non-self S-ribonucleases (S-RNases), allelic products of the pistil determinant, inside pollen tubes via the ubiquitin-26S-proteasome system, thereby allowing compatible pollinations. However, it remained puzzling how SLF, with much lower allelic sequence diversity than S-RNase, might have the capacity to recognize a large repertoire of non-self S-RNases. We used in vivo functional assays and protein interaction assays to show that in Petunia, at least three types of divergent SLF proteins function as the pollen determinant, each recognizing a subset of non-self S-RNases. Our findings reveal a collaborative non-self recognition system in plants.	[Wang, Ning; Hua, Zhihua; Kao, Teh-hui] Penn State Univ, Intercoll Grad Degree Program Plant Biol, University Pk, PA 16802 USA; [Kubo, Ken-ichi; Entani, Tetsuyuki; Takara, Akie; Toyoda, Mamiko; Kawashima, Shin-ichi; Isogai, Akira; Takayama, Seiji] Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300192, Japan; [Fields, Allison M.; Kao, Teh-hui] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; [Ando, Toshio] Chiba Univ, Grad Sch Hort, Chiba 2718510, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Nara Institute of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Chiba University	Kao, T (corresponding author), Penn State Univ, Intercoll Grad Degree Program Plant Biol, University Pk, PA 16802 USA.	txk3@psu.edu; takayama@bs.naist.jp	ANDO, Toshio/E-7054-2015; Messier, Claude/A-2322-2008; Isogai, Akira/O-8897-2017; Hua, Zhihua/B-8835-2012; Hua, Zhihua/AAD-1146-2021	ANDO, Toshio/0000-0001-8819-154X; Messier, Claude/0000-0002-4791-1763; Isogai, Akira/0000-0001-8095-0441; 	Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology of Japan; NSF [IOB-0543201, IOS-0843195]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NSF(National Science Foundation (NSF))	We thank A. Miyawaki for Venus vectors; M. Iwano, H. Shiba, Y. Wada, P. Nakayama, M. Kakita, X. Meng, T. Tsuchimatsu, and K. K. Shimizu for discussion; and N. Katsui, M. Matsumura-Kawashima, M. Okamura, Y. Egusa, K. Kajihara, M. Bothe, and M. Goralczyk for technical assistance. Supported by Grant-in-Aid for Creative Scientific Research (A.I.) and Grant-in-Aid for Scientific Research (A) from the Japan Society for the Promotion of Science (S.T.), Grant-in-Aid for the Global Center of Excellence Program from the Ministry of Education, Culture, Sports, Science and Technology of Japan to the Nara Institute of Science and Technology, and NSF grants IOB-0543201 and IOS-0843195 (T.-h. K.). Sequence data have been deposited in GenBank under accession numbers AB568388 to AB568423.	Boehm T, 2006, CELL, V125, P845, DOI 10.1016/j.cell.2006.05.017; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; Entani T, 2003, GENES CELLS, V8, P203, DOI 10.1046/j.1365-2443.2003.00626.x; Entani T, 1999, BIOSCI BIOTECH BIOCH, V63, P1882, DOI 10.1271/bbb.63.1882; Franklin-Tong V. E., 2008, P237, DOI 10.1007/978-3-540-68486-2_11; Hua ZH, 2008, MOL PLANT, V1, P575, DOI 10.1093/mp/ssn032; Hua ZH, 2007, PLANT CELL, V19, P3593, DOI 10.1105/tpc.107.055426; Hua ZH, 2006, PLANT CELL, V18, P2531, DOI 10.1105/tpc.106.041061; Lai Z, 2002, PLANT MOL BIOL, V50, P29, DOI 10.1023/A:1016050018779; McClure B, 2009, J EXP BOT, V60, P1069, DOI 10.1093/jxb/erp024; Minamikawa M, 2010, PLANT MOL BIOL, V74, P143, DOI 10.1007/s11103-010-9662-z; Newbigin E, 2008, PLANT CELL, V20, P2286, DOI 10.1105/tpc.108.060327; Okada K, 2004, J JPN SOC HORTIC SCI, V73, P524, DOI 10.2503/jjshs.73.524; Okada K, 2008, PLANT MOL BIOL, V66, P389, DOI 10.1007/s11103-007-9277-1; Qiao H, 2004, PLANT CELL, V16, P582, DOI 10.1105/tpc.017673; Sassa H, 2007, GENETICS, V175, P1869, DOI 10.1534/genetics.106.068858; Sijacic P, 2004, NATURE, V429, P302, DOI 10.1038/nature02523; Takayama S, 2005, ANNU REV PLANT BIOL, V56, P467, DOI 10.1146/annurev.arplant.56.032604.144249; Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104; Tsukamoto T, 2005, PLANT MOL BIOL, V57, P141, DOI 10.1007/s11103-004-6852-6; Wheeler D, 2007, GENETICS, V177, P2171, DOI 10.1534/genetics.107.076885; Wheeler MJ, 2009, NATURE, V459, P992, DOI 10.1038/nature08027; Zhou Z, 2003, APPL MATH LETT, V16, P165, DOI 10.1016/S0893-9659(03)80027-7	23	204	221	6	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2010	330	6005					796	799		10.1126/science.1195243	http://dx.doi.org/10.1126/science.1195243			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051632				2022-12-28	WOS:000283855700036
J	Bassani, DG; Kumar, R; Awasthi, S; Morris, SK; Paul, VK; Shet, A; Ram, U; Gaffey, MF; Black, RE; Jha, P; Mishra, B; Ramji, S; Subramaniyam, M				Bassani, Diego G.; Kumar, Rajesh; Awasthi, Shally; Morris, Shaun K.; Paul, Vinod K.; Shet, Anita; Ram, Usha; Gaffey, Michelle F.; Black, Robert E.; Jha, Prabhat; Mishra, Bhaskar; Ramji, Siddarth; Subramaniyam, Mani		Million Death Study Collaborators	Causes of neonatal and child mortality in India: a nationally representative mortality survey	LANCET			English	Article							DEATHS; MANAGEMENT; BANGLADESH; RATES	Background More than 2.3 million children died in India in 2005; however, the major causes of death have not been measured in the country. We investigated the causes of neonatal and child mortality in India and their differences by sex and region. Methods The Registrar General of India surveyed all deaths occurring in 2001-03 in 1.1 million nationally representative homes. Field staff interviewed household members and completed standard questions about events that preceded the death. Two of 130 physicians then independently assigned a cause to each death. Cause-specific mortality rates for 2005 were calculated nationally and for the six regions by combining the recorded proportions for each cause in the neonatal deaths and deaths at ages 1-59 months in the study with population and death totals from the United Nations. Findings There were 10 892 deaths in neonates and 12 260 in children aged 1-59 months in the study. When these details were projected nationally, three causes accounted for 78% (0.79 million of 1.01 million) of all neonatal deaths: prematurity and low birthweight (0.33 million, 99% CI 0.31 million to 0.35 million), neonatal infections (0.27 million, 0.25 million to 0.29 million), and birth asphyxia and birth trauma (0.19 million, 0.18 million to 0.21 million). Two causes accounted for 50% (0.67 million of 1.34 million) of all deaths at 1-59 months: pneumonia (0.37 million, 0.35 million to 0.39 million) and diarrhoeal diseases (0.30 million, 0.28 million to 0.32 million). In children aged 1-59 months, girls in central India had a five-times higher mortality rate (per 1000 livebirths) from pneumonia (20.9, 19.4-22.6) than did boys in south India (4.1, 3.0-5.6) and four-times higher mortality rate from diarrhoeal disease (17.7, 16.2-19.3) than did boys in west India (4.1, 3.0-5.5). Interpretation Five avoidable causes accounted for nearly 1.5 million child deaths in India in 2005, with substantial differences between regions and sexes. Expanded neonatal and intrapartum care, case management of diarrhoea and pneumonia, and addition of new vaccines to immunisation programmes could substantially reduce child deaths in India.	[Jha, Prabhat] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Global Hlth Res, Toronto, ON M5B 1W8, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Jha, P (corresponding author), Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Global Hlth Res, Toronto, ON M5B 1W8, Canada.	prabhat.jha@utoronto.ca	Ram, Usha/AAS-4140-2020; Bassani, Diego/G-2827-2015	Ram, Usha/0000-0001-6722-7347; Bassani, Diego/0000-0001-6704-3820; Shet, Anita/0000-0002-7204-8164; Jha, Prabhat/0000-0001-7067-8341	Fogarty International Centre of the US National Institutes of Health [R01 TW05991-01]; Canadian Institute of Health Research (CIHR) [IEG-53506]; International Development Research Centre [102172]; Li Ka Shing Knowledge Institute and Keenan Research Centre at St Michael's Hospital, University of Toronto; US Fund for UNICEF via Bill & Melinda Gates Foundation for CHERG [50140]; Canada Research Chair programme; FOGARTY INTERNATIONAL CENTER [R01TW005991] Funding Source: NIH RePORTER	Fogarty International Centre of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); International Development Research Centre; Li Ka Shing Knowledge Institute and Keenan Research Centre at St Michael's Hospital, University of Toronto; US Fund for UNICEF via Bill & Melinda Gates Foundation for CHERG; Canada Research Chair programme(Canada Research Chairs); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The Registrar General of India established the SRS in 1971, has continued it ever since, and is collaborating with several of the authors on the ongoing Million Death Study. External funding is from the Fogarty International Centre of the US National Institutes of Health (grant R01 TW05991-01), Canadian Institute of Health Research (CIHR; IEG-53506), International Development Research Centre (Grant 102172), Li Ka Shing Knowledge Institute and Keenan Research Centre at St Michael's Hospital, University of Toronto, and the US Fund for UNICEF (via a grant from the Bill & Melinda Gates Foundation for CHERG; subgrant 50140). PJ is supported by the Canada Research Chair programme. SKM is a Fellow of the Pediatric Scientist Development Program. The opinions expressed in this paper are those of the authors and do not necessarily represent those of the Government of India. We thank Joy Lawn, Colin Mathers, Mikkel Oestergaard, Prem Mony, and Alvin Zipursky for comments; and Maya Kesler, Brendon Pezzack, Chinthanie Ramasundarahettige, Peter Rodriguez, and Wilson Suraweera for data support.	Ali M, 2005, B WORLD HEALTH ORGAN, V83, P27; ANKER M, 1999, STANDARD VERBAL AUTO; [Anonymous], WORLD POP PROSP 2008; [Anonymous], 2005, SPEC FERT MORT SURV; Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X; Baqui AH, 2006, B WORLD HEALTH ORGAN, V84, P706, DOI 10.2471/BLT.05.026443; Bassani DG, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-491; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Bhat PNM, 2002, POP STUD-J DEMOG, V56, P119, DOI 10.1080/00324720215930; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Corsi DJ, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-S1-S3; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dhingra N, 2010, LANCET, V376, P1768, DOI 10.1016/S0140-6736(10)60831-8; *IIPS MACR, 2008, NAT FAM HLTH SURV NF; International Institute for Population Sciences (IIPS), 2010, DISTR LEV HOUS FAC S; Jha P, 2006, PLOS MED, V3, P191, DOI 10.1371/journal.pmed.0030018; Jha P, 2006, LANCET, V367, P211, DOI 10.1016/S0140-6736(06)67930-0; Jha P, 2002, NATL MED J INDIA, V15, P32; Jha P, 2009, CHOOS HLTH ENT ALL I; Jha P, 2008, NEW ENGL J MED, V358, P1137, DOI 10.1056/NEJMsa0707719; Jha P, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c621; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Maude GH, 1997, INT J EPIDEMIOL, V26, P1097, DOI 10.1093/ije/26.5.1097; Morris SK, 2010, PLOS ONE, V5, pA170, DOI 10.1371/journal.pone.0009583; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; *REG GEN IND, 2005, MED CERT CAUS DEATH; *REG GEN IND, 2001, CENS IND 2001; [Registrar General of India Centre for Global Health Research Ministry of Home Affairs], 2009, CAUS DEATH IND 2001; Ronsmans C, 2008, PAEDIATR PERINAT EP, V22, P269, DOI 10.1111/j.1365-3016.2008.00939.x; Wolter KM, 2007, STAT SOC BEHAV SC, P1, DOI 10.1007/978-0-387-35099-8; World Health Organization, 1994, INT STAT CLASS DIS R; Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6; [No title captured]; [No title captured]	35	304	308	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2010	376	9755					1853	1860		10.1016/S0140-6736(10)61461-4	http://dx.doi.org/10.1016/S0140-6736(10)61461-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KG	21075444	Green Accepted			2022-12-28	WOS:000285439700034
J	Lester, RT; Ritvo, P; Mills, EJ; Kariri, A; Karanja, S; Chung, MH; Jack, W; Habyarimana, J; Sadatsafavi, M; Najafzadeh, M; Marra, CA; Estambale, B; Ngugi, E; Ball, TB; Thabane, L; Gelmon, LJ; Kimani, J; Ackers, M; Plummer, FA				Lester, Richard T.; Ritvo, Paul; Mills, Edward J.; Kariri, Antony; Karanja, Sarah; Chung, Michael H.; Jack, William; Habyarimana, James; Sadatsafavi, Mohsen; Najafzadeh, Mehdi; Marra, Carlo A.; Estambale, Benson; Ngugi, Elizabeth; Ball, T. Blake; Thabane, Lehana; Gelmon, Lawrence J.; Kimani, Joshua; Ackers, Marta; Plummer, Francis A.			Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial	LANCET			English	Article							SUB-SAHARAN AFRICA; MEDICATION ADHERENCE; THERAPY ADHERENCE; CELL PHONES; HEALTH; PREVENTION; HIV/AIDS; OUTCOMES; SUPPORT; IMPACT	Background Mobile (cell) phone communication has been suggested as a method to improve delivery of health services. However, data on the effects of mobile health technology on patient outcomes in resource-limited settings are limited. We aimed to assess whether mobile phone communication between health-care workers and patients starting antiretroviral therapy in Kenya improved drug adherence and suppression of plasma HIV-1 RNA load. Methods WelTel Kenya1 was a multisite randomised clinical trial of HIV-infected adults initiating antiretroviral therapy (ART) in three clinics in Kenya. Patients were randomised (1:1) by simple randomisation with a random number generating program to a mobile phone short message service (SMS) intervention or standard care. Patients in the intervention group received weekly SMS messages from a clinic nurse and were required to respond within 48 h. Randomisation, laboratory assays, and analyses were done by investigators masked to treatment allocation; however, study participants and clinic staff were not masked to treatment. Primary outcomes were self-reported ART adherence (>95% of prescribed doses in the past 30 days at both 6 and 12 month follow-up visits) and plasma HIV-1 viral RNA load suppression (<400 copies per mL) at 12 months. The primary analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT00830622. Findings Between May, 2007, and October, 2008, we randomly assigned 538 participants to the SMS intervention (n=273) or to standard care (n=265). Adherence to ART was reported in 168 of 273 patients receiving the SMS intervention compared with 132 of 265 in the control group (relative risk [RR] for non-adherence 0.81, 95% CI 0.69-0-94; p=0.006). Suppressed viral loads were reported in 156 of 273 patients in the SMS group and 128 of 265 in the control group, (RR for virologic failure 0.84, 95% CI 0.71-0.99; p=0.04). The number needed to treat (NNT) to achieve greater than 95% adherence was nine (95% CI 5.0-29.5) and the NNT to achieve viral load suppression was 11 (5.8-227.3). Interpretation Patients who received SMS support had significantly improved ART adherence and rates of viral suppression compared with the control individuals. Mobile phones might be effective tools to improve patient outcome in resource-limited settings.	[Lester, Richard T.; Kariri, Antony; Karanja, Sarah; Ngugi, Elizabeth; Gelmon, Lawrence J.; Kimani, Joshua] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; [Lester, Richard T.; Ball, T. Blake; Gelmon, Lawrence J.; Kimani, Joshua; Plummer, Francis A.] Univ Manitoba, Hlth Sci Ctr, Dept Med Microbiol, Winnipeg, MB, Canada; [Lester, Richard T.] Univ British Columbia, Dept Med, Div Infect Dis, Vancouver, BC, Canada; [Ritvo, Paul] York Univ, Dept Psychol, Sch Kinesiol & Hlth Sci, York, ON, Canada; [Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada; [Chung, Michael H.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Jack, William] Georgetown Univ, Dept Econ, Washington, DC USA; [Habyarimana, James] Georgetown Univ, Georgetown Publ Policy Inst, Washington, DC USA; [Sadatsafavi, Mohsen; Najafzadeh, Mehdi; Marra, Carlo A.] Univ British Columbia, Fac Pharmaceut Sci, Collaborat Outcome Res & Evaluat, Vancouver, BC, Canada; [Estambale, Benson] Univ Nairobi, Inst Trop & Infect Dis, Nairobi, Kenya; [Thabane, Lehana] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Ackers, Marta] US Ctr Dis Control & Prevent, Global AIDS Program, Nairobi, Kenya; [Plummer, Francis A.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada	University of Nairobi; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of British Columbia; York University - Canada; University of Ottawa; University of Washington; University of Washington Seattle; Georgetown University; Georgetown University; University of British Columbia; University of Nairobi; McMaster University; Public Health Agency of Canada	Lester, RT (corresponding author), British Columbia Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada.	rlester.id@gmail.com	Sadatsafayi, Mohsen/AAZ-1593-2020; Harding, Richard/G-9729-2012; Marra, Carlo/AAE-4904-2021	Sadatsafayi, Mohsen/0000-0002-0419-7862; Marra, Carlo/0000-0002-2625-2121	US President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC [5U62PS024510, PHE:KE070045, U62/CCU024512.04]; Government of Kenya Ministry of Health; APHIA II programme; Association of Medical Microbiology and Infectious Diseases; Bristol-Myers-Squibb (Canada); Canadian Institute for Health Research (CIHR); University of Manitoba hosted CIHR/ICID (International Center for Infectious Diseases); National Institutes of Health [5K23A1065222-04]; National Training Program in Infectious Diseases; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION [U62PS024510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI065222, P30AI027757] Funding Source: NIH RePORTER	US President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC; Government of Kenya Ministry of Health; APHIA II programme; Association of Medical Microbiology and Infectious Diseases; Bristol-Myers-Squibb (Canada)(Bristol-Myers Squibb); Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); University of Manitoba hosted CIHR/ICID (International Center for Infectious Diseases)(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Training Program in Infectious Diseases; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The trial was funded by the US President's Emergency Plan for AIDS Relief (PEPFAR) through the CDC cooperative agreement 5U62PS024510 as a public-health evaluation (PHE:KE070045). The Coptic Hope Center for Infectious Diseases is supported by PEPFAR through the CDC cooperative agreement (U62/CCU024512.04). Kajiado District Hospital Comprehensive Care Clinic is supported by the Government of Kenya Ministry of Health and APHIA II programme. RTL was supported by an unrestricted research award through Association of Medical Microbiology and Infectious Diseases-Bristol-Myers-Squibb (Canada) and a Canadian Institute for Health Research (CIHR) training award, and from the University of Manitoba hosted CIHR/ICID (International Center for Infectious Diseases) National Training Program in Infectious Diseases. EJM is a tier 2 Canada Research Chair in global health. MHC was supported by a K23 grant from the National Institutes of Health (5K23A1065222-04). FAP is a tier 1 Canada Research Chair in resistance and susceptibility to infections. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the funding agencies. We thank the health-care staff and patients who participated in the study. We dedicate our greatest thanks to our Kenyan statistician, Rosemary Ngugi, who died of cancer during preparation of this manuscript.	Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Bahadur KCM, 2010, STUD HEALTH TECHNOL, V160, P530, DOI 10.3233/978-1-60750-588-4-530; Barth RE, 2008, EUR J CLIN MICROBIOL, V27, P977, DOI 10.1007/s10096-008-0534-2; Behforouz HL, 2004, CLIN INFECT DIS, V38, pS429, DOI 10.1086/421408; Bennett DE, 2008, ANTIVIR THER, V13, P1; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Cellular-news, CELLULAR NEWS; Chang LW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010923; Chung MH, 2009, CURR HIV RES, V7, P441, DOI 10.2174/157016209788680552; Cohen MS, 2008, J CLIN INVEST, V118, P1244, DOI 10.1172/JCI34706; Collier AC, 2005, J INFECT DIS, V192, P1398, DOI 10.1086/466526; Curioso WH, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-24; De Cock KM, 2009, LANCET, V373, P7, DOI 10.1016/S0140-6736(08)61732-8; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Haberer JE, 2010, AIDS BEHAV, V14, P1294, DOI 10.1007/s10461-010-9720-1; Hoffman JA, 2010, AM J PREV MED, V39, P78, DOI 10.1016/j.amepre.2010.02.018; Kaplan WA, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-9; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; Krishna S, 2009, TELEMED J E-HEALTH, V15, P231, DOI 10.1089/tmj.2008.0099; Kunutsor S, 2010, JAIDS-J ACQ IMM DEF, V55, P221, DOI 10.1097/QAI.0b013e3181e255ec; Lester R. T., 2009, WHO ESSENTIAL MED MO, V2, P1; Lester R, 2008, LANCET INFECT DIS, V8, P738, DOI 10.1016/S1473-3099(08)70265-2; Lester RT, 2006, AIDS, V20, P2242, DOI 10.1097/QAD.0b013e3280108508; Lester RT, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-87; Losina E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000173; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; National AIDS and STI Control Programme (NASCOP) MoH, 2005, GUID ANT DRUG THER K; National AIDS and STI Programme Ministry of Health Kenya, 2008, KEN AIDS IND SURV 20; Oyugi JH, 2004, JAIDS-J ACQ IMM DEF, V36, P1100, DOI 10.1097/00126334-200408150-00014; Padma TV, 2010, NATURE, V466, pS16, DOI 10.1038/nature09242; Perneger TV, 1999, BRIT MED J, V318, P1288; Rabkin M, 2009, JAIDS-J ACQ IMM DEF, V52, pS6, DOI 10.1097/QAI.0b013e3181bbcd69; Remien RH, 2008, AIDS, V22, pS57, DOI 10.1097/01.aids.0000327437.13291.86; Reynolds NR, 2008, JAIDS-J ACQ IMM DEF, V47, P62, DOI 10.1097/QAI.0b013e3181582d54; Rice X, 2007, GUARDIAN        0320; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Rueda S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001442.pub2; Schulz KF, 2002, LANCET, V359, P966, DOI 10.1016/S0140-6736(02)08029-7; Simoni JM, 2006, AIDS BEHAV, V10, P227, DOI 10.1007/s10461-006-9078-6; Strandbygaard U, 2010, RESP MED, V104, P166, DOI 10.1016/j.rmed.2009.10.003; UNAIDS, 2009, TEL TOOLS CONN WORLD; Vitoria M, 2009, AM J CLIN PATHOL, V131, P844, DOI 10.1309/AJCP5XHDB1PNAEYT; Vreeman Rachel C, 2009, Confl Health, V3, P5, DOI 10.1186/1752-1505-3-5; Ware NC, 2009, PLOS MED, V6, P39, DOI 10.1371/journal.pmed.1000011; Williams AB, 2006, JAIDS-J ACQ IMM DEF, V42, P314, DOI 10.1097/01.qai.0000221681.60187.88; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; Ybarra Michele L, 2007, Curr HIV/AIDS Rep, V4, P201, DOI 10.1007/s11904-007-0029-2	50	860	875	10	145	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2010	376	9755					1838	1845		10.1016/S0140-6736(10)61997-6	http://dx.doi.org/10.1016/S0140-6736(10)61997-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KG	21071074				2022-12-28	WOS:000285439700032
J	Del Bene, F; Wyart, C; Robles, E; Tran, A; Looger, L; Scott, EK; Isacoff, EY; Baier, H				Del Bene, Filippo; Wyart, Claire; Robles, Estuardo; Tran, Amanda; Looger, Loren; Scott, Ethan K.; Isacoff, Ehud Y.; Baier, Herwig			Filtering of Visual Information in the Tectum by an Identified Neural Circuit	SCIENCE			English	Article							ZEBRAFISH OPTIC TECTUM; SUPERIOR COLLICULUS; LARVAL ZEBRAFISH; IN-VIVO; ENHANCER; CELLS	The optic tectum of zebrafish is involved in behavioral responses that require the detection of small objects. The superficial layers of the tectal neuropil receive input from retinal axons, while its deeper layers convey the processed information to premotor areas. Imaging with a genetically encoded calcium indicator revealed that the deep layers, as well as the dendrites of single tectal neurons, are preferentially activated by small visual stimuli. This spatial filtering relies on GABAergic interneurons (using the neurotransmitter gamma-aminobutyric acid) that are located in the superficial input layer and respond only to large visual stimuli. Photo-ablation of these cells with KillerRed, or silencing of their synaptic transmission, eliminates the size tuning of deeper layers and impairs the capture of prey.	[Wyart, Claire; Isacoff, Ehud Y.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Wyart, Claire; Isacoff, Ehud Y.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Del Bene, Filippo; Robles, Estuardo; Tran, Amanda; Scott, Ethan K.; Baier, Herwig] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; [Looger, Loren] Howard Hughes Med Inst, Ashburn, VA 20147 USA; [Isacoff, Ehud Y.] Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA; [Isacoff, Ehud Y.] Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Isacoff, EY (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	ehud@calmail.berkeley.edu; herwig.baier@ucsf.edu	isacoff, ehud/AAP-1459-2020; Wyart, Claire/H-3783-2016; del bene, filippo/D-1245-2010; Wyart, Claire/AAB-4603-2020	Wyart, Claire/0000-0002-1668-4975; del bene, filippo/0000-0001-8551-2846; Wyart, Claire/0000-0002-1668-4975; Tran, Amanda/0000-0002-8393-6124; Isacoff, Ehud Y./0000-0003-4775-9359; Robles, Estuardo/0000-0002-1202-2050; Scott, Ethan/0000-0003-3150-9216	Human Frontier Science Program long-term postdoctoral fellowship; Marie Curie Outgoing International Fellowship [UMR5020]; CNRS [UMR5020]; NSF; NIH Nanomedicine Development Center for the Optical Control of Biological Function [PN2 EY018241]; NSF/FIBR [0623527]; Sandler Opportunity Award; Byers Basic Science Award; NIHR [R01 EY012406, R01 NS053358]; NATIONAL EYE INSTITUTE [R01EY012406, PN2EY018241] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050833, R01NS053358] Funding Source: NIH RePORTER	Human Frontier Science Program long-term postdoctoral fellowship(Human Frontier Science Program); Marie Curie Outgoing International Fellowship(European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); NSF(National Science Foundation (NSF)); NIH Nanomedicine Development Center for the Optical Control of Biological Function(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF/FIBR(National Science Foundation (NSF)); Sandler Opportunity Award; Byers Basic Science Award; NIHR(National Institute for Health Research (NIHR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank W. Staub for care of animals, T. Muller for the gad67 probe, K. Kawakami for Tol2 and TeTxLC-CFP reagents, L. Garner for advice on the visual setup, and J. Nakai for the GCaMP1.6 vector. F. D. B. and C. W. were supported, respectively, by a Human Frontier Science Program long-term postdoctoral fellowship and a Marie Curie Outgoing International Fellowship (with CNRS UMR5020 "Neurosciences Sensorielles, Comportement Cognition," Lyon, France). E. R. was supported by an NSF postdoctoral fellowship. This work was funded by the NIH Nanomedicine Development Center for the Optical Control of Biological Function (PN2 EY018241, E.Y.I. and H. B.), NSF/FIBR 0623527 (E.Y.I.), a Sandler Opportunity Award (H. B.), the Byers Basic Science Award (H. B.), and NIH grants R01 EY012406 and R01 NS053358 (H.B.).	Asakawa K, 2008, P NATL ACAD SCI USA, V105, P1255, DOI 10.1073/pnas.0704963105; Baier H, 2009, CURR OPIN NEUROBIOL, V19, P553, DOI 10.1016/j.conb.2009.08.001; Bollmann JH, 2009, NEURON, V61, P895, DOI 10.1016/j.neuron.2009.01.018; Bulina ME, 2006, NAT BIOTECHNOL, V24, P95, DOI 10.1038/nbt1175; DRAGER UC, 1975, NATURE, V253, P203, DOI 10.1038/253203a0; Gahtan E, 2005, J NEUROSCI, V25, P9294, DOI 10.1523/JNEUROSCI.2678-05.2005; Isa T, 2002, CURR OPIN NEUROBIOL, V12, P668, DOI 10.1016/S0959-4388(02)00387-2; MEEK J, 1978, J COMP NEUROL, V182, P89, DOI 10.1002/cne.901820107; Meyer MP, 2006, J NEUROSCI, V26, P3604, DOI 10.1523/JNEUROSCI.0223-06.2006; Nevin LM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-126; Nevin LM, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-36; Niell CM, 2005, NEURON, V45, P941, DOI 10.1016/j.neuron.2005.01.047; Ohkura M, 2005, ANAL CHEM, V77, P5861, DOI 10.1021/ac0506837; Portugues R, 2009, CURR OPIN NEUROBIOL, V19, P644, DOI 10.1016/j.conb.2009.10.007; Ramdya P, 2008, NAT NEUROSCI, V11, P1083, DOI 10.1038/nn.2166; Ramdya P, 2006, J NEUROSCI METH, V157, P230, DOI 10.1016/j.jneumeth.2006.04.021; Roeser T, 2003, J NEUROSCI, V23, P3726; SAJOVIC P, 1982, NEUROSCIENCE, V7, P2407, DOI 10.1016/0306-4522(82)90204-4; Sato T, 2007, J NEUROSCI, V27, P5271, DOI 10.1523/JNEUROSCI.0883-07.2007; Scott EK, 2007, NAT METHODS, V4, P323, DOI 10.1038/NMETH1033; Scott Jared M., 2009, Journal of the Botanical Research Institute of Texas, V3, P13; Smear MC, 2007, NEURON, V53, P65, DOI 10.1016/j.neuron.2006.12.013; Sumbre G, 2008, NATURE, V456, P102, DOI 10.1038/nature07351; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; VANEGAS H, 1974, J COMP NEUROL, V154, P43, DOI 10.1002/cne.901540104; Vanegas H, 1984, COMP NEUROLOGY OPTIC; Xiao T, 2005, DEVELOPMENT, V132, P2955, DOI 10.1242/dev.01861; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000	28	172	174	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					669	673		10.1126/science.1192949	http://dx.doi.org/10.1126/science.1192949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030657	Green Accepted			2022-12-28	WOS:000283580600048
J	Mackenbach, JP				Mackenbach, Johan P.			The English strategy to reduce health inequalities	LANCET			English	Editorial Material							ENGLAND; POLICY		Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Mackenbach, JP (corresponding author), Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands.	j.mackenbach@erasmusmc.nl						Acheson D., 1998, INDEPENDENT INQUIRY; Bauld L, 2007, TOB CONTROL, V16, P400, DOI 10.1136/tc.2007.021626; *COMPTR AUD GEN NA, 2010, TACKL IN LIF EXP AR; *DEP HLTH, 2007, TACKL HLTH IN 2007 S; Department of Health, 2009, TACKL HLTH IN 10 YEA; Department of Health, 2003, TACKL HLTH IN PROGR; Department of Health, 1999, RED HLTH IN ACT REP; *GLOB HLTH EQ GROU, 2010, FAIR SOC HLTH LIV MA; House of Commons Health Committee, 2009, 3 HOUS COMM HLTH COM; Judge K, 2006, EUR J PUBLIC HEALTH, V16, P341, DOI 10.1093/eurpub/ckl068; Macintyre S, 2001, BRIT MED J, V322, P222, DOI 10.1136/bmj.322.7280.222; McKee M, 2005, LANCET, V365, P369; Melhuish E, 2008, LANCET, V372, P1641, DOI 10.1016/S0140-6736(08)61687-6; Shaw M, 2005, BMJ-BRIT MED J, V330, P1016, DOI 10.1136/bmj.330.7498.1016	14	14	14	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 11	2011	377	9782					1986	1988		10.1016/S0140-6736(10)62055-7	http://dx.doi.org/10.1016/S0140-6736(10)62055-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	782LR	21074842				2022-12-28	WOS:000292011700008
J	Grant, RM; Lama, JR; Anderson, PL; McMahan, V; Liu, AY; Vargas, L; Goicochea, P; Casapia, M; Guanira-Carranza, JV; Ramirez-Cardich, ME; Montoya-Herrera, O; Fernandez, T; Veloso, VG; Buchbinder, SP; Chariyalertsak, S; Schechter, M; Bekker, LG; Mayer, KH; Kallas, EG; Amico, KR; Mulligan, K; Bushman, LR; Hance, RJ; Ganoza, C; Defechereux, P; Postle, B; Wang, FR; McConnell, JJ; Zheng, JH; Lee, J; Rooney, JF; Jaffe, HS; Martinez, AI; Burns, DN; Glidden, DV				Grant, Robert M.; Lama, Javier R.; Anderson, Peter L.; McMahan, Vanessa; Liu, Albert Y.; Vargas, Lorena; Goicochea, Pedro; Casapia, Martin; Guanira-Carranza, Juan Vicente; Ramirez-Cardich, Maria E.; Montoya-Herrera, Orlando; Fernandez, Telmo; Veloso, Valdilea G.; Buchbinder, Susan P.; Chariyalertsak, Suwat; Schechter, Mauro; Bekker, Linda-Gail; Mayer, Kenneth H.; Kallas, Esper Georges; Amico, K. Rivet; Mulligan, Kathleen; Bushman, Lane R.; Hance, Robert J.; Ganoza, Carmela; Defechereux, Patricia; Postle, Brian; Wang, Furong; McConnell, J. Jeff; Zheng, Jia-Hua; Lee, Jeanny; Rooney, James F.; Jaffe, Howard S.; Martinez, Ana I.; Burns, David N.; Glidden, David V.		iPrEx Study Team	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS; MALE CIRCUMCISION; LIMITED KNOWLEDGE; HOMOSEXUAL-MEN; INFECTION; TRANSMISSION; RISK; TENOFOVIR; MACAQUES; TRIAL	Background: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. Methods: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. Results: The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57). Conclusions: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.) N Engl J Med 2010;363:2587-99.	[Liu, Albert Y.; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, HIV Res Sect, San Francisco, CA USA; [Lama, Javier R.; Vargas, Lorena] Invest Med Salud, Lima, Peru; [Lama, Javier R.; Guanira-Carranza, Juan Vicente; Ramirez-Cardich, Maria E.; Ganoza, Carmela] Asociac Civil Impacta Salud & Educ, Lima, Peru; [Casapia, Martin] Asociac Civil Selva Amazon, Iquitos, Peru; [Anderson, Peter L.; Bushman, Lane R.; Zheng, Jia-Hua] Univ Colorado, Denver, CO 80202 USA; [Montoya-Herrera, Orlando; Fernandez, Telmo] Fdn Ecuatoriana Equidad, Guayaquil, Ecuador; [Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil; [Schechter, Mauro] Univ Fed Rio de Janeiro, Hosp Escola Sao Francisco de Assis, Projeto Praca Onze, Rio De Janeiro, Brazil; [Mayer, Kenneth H.] Brown Univ, Providence, RI 02912 USA; [Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA; [Kallas, Esper Georges] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, Brazil; [Kallas, Esper Georges] Inst Invest Imunol, Sao Paulo, Brazil; [Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand; [Bekker, Linda-Gail] Univ Cape Town, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa; [Bekker, Linda-Gail] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Martinez, Ana I.; Burns, David N.] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA; [Rooney, James F.; Jaffe, Howard S.] Gilead Sci Inc, Foster City, CA 94404 USA; [Postle, Brian] DF Net Res, Seattle, WA USA; [Amico, K. Rivet] Appl Hlth Res, Brighton, MI USA; [Amico, K. Rivet] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA; [Grant, Robert M.; McMahan, Vanessa; Goicochea, Pedro; Hance, Robert J.; Defechereux, Patricia; McConnell, J. Jeff; Lee, Jeanny] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA	San Francisco Department of Public Health; University of Colorado System; University of Colorado Denver; Fundacao Oswaldo Cruz; Universidade Federal do Rio de Janeiro; Brown University; Fenway Health; Universidade de Sao Paulo; Chiang Mai University; University of Cape Town; University of Cape Town; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Gilead Sciences; University of Connecticut; University of California System; University of California San Francisco; The J David Gladstone Institutes	Grant, RM (corresponding author), Univ Calif San Francisco, J David Gladstone Inst, 1650 Owens St, San Francisco, CA 94158 USA.	robert.grant@ucsf.edu	Schechter, Mauro/AAG-7445-2020; Veloso, Valdilea Gonçalves/J-6189-2012; Trajman, Anete/C-7679-2016; Kallas, Esper G/C-9539-2012; Cardoso, Sandra W/D-7965-2015; Bekker, Linda-Gail/AAZ-8929-2020; Mathias, Augusto/C-3247-2017; Glidden, David/AAD-4730-2020; /AAE-4700-2020; KALIL, JORGE/C-8029-2012; Defechereux, Patricia/AHD-3713-2022	Trajman, Anete/0000-0002-4000-4984; Cardoso, Sandra W/0000-0001-5230-0003; KALIL, JORGE/0000-0001-8415-4274; Glidden, David/0000-0001-5888-1419; Guanira, Juan/0000-0002-2746-3086; Scheibe, Andrew/0000-0002-3238-0699; Amico, K Rivet/0000-0002-4458-6934; Popuche, Dina/0000-0002-4729-7599; Casapia Morales, Wilfredo Martin/0000-0002-5972-0948; Kallas, Esper/0000-0003-2026-6925; Grant, Robert/0000-0002-0851-7085; BEKKER, LINDA-GAIL/0000-0002-0755-4386	Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health [UO1 AI64002]; Bill and Melinda Gates Foundation; DAIDS [UO1 AI84735, AI062333]; National Institutes of Health [UL1 RR024131]; Gilead; Merck; Bristol-Myers Squibb; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI084735, R01AI062333, U01AI064002] Funding Source: NIH RePORTER	Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); DAIDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gilead(Gilead Sciences); Merck(Merck & Company); Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Acquired Immunodeficiency Syndrome (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health, as a cooperative agreement (UO1 AI64002, to Dr. Grant) and by the Bill and Melinda Gates Foundation. Study drugs were donated by Gilead Sciences. The pharmacological studies were sponsored by a cooperative agreement with DAIDS (UO1 AI84735, to Dr. Anderson). Support for some specimen handling came from a grant from DAIDS (RO1 AI062333, to Dr. Grant) and by the J. David Gladstone Institutes. Some infrastructure support at the University of California at San Francisco was provided by a grant from the National Institutes of Health (UL1 RR024131).; Dr. Grant reports receiving support as an advisor to Siemens (the manufacturer of TruGene HIV-1 Genotyping Kit); Dr. Mayer reports receiving grant support from Gilead, Merck, and Bristol-Myers Squibb; Dr. Kallas reports serving on a data and safety monitoring board for Merck; Dr. Schechter reports receiving consulting fees and grants from Gilead; Drs. Liu and Anderson report receiving donations of study drug from Gilead for various PrEP projects; and Drs. Jaffe and Rooney report being employees of Gilead Sciences and owning stock in the company. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Auvert B, 2006, PLOS MED, V3, P705, DOI 10.1371/journal.pmed.0030226; Baggaley RF, 2010, INT J EPIDEMIOL, V39, P1048, DOI 10.1093/ije/dyq057; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Beyrer C, 2010, EPIDEMIOL REV, V32, P137, DOI 10.1093/epirev/mxq011; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Gallant JE, 2008, AIDS, V22, P2155, DOI 10.1097/QAD.0b013e3283112b8e; Garcia-Lerma JG, 2008, PLOS MED, V5, P291, DOI 10.1371/journal.pmed.0050028; Garcia-Lerma JG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000391; Grant RM, 2005, SCIENCE, V309, P2170, DOI 10.1126/science.1116204; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Hofer CB, 2000, J ACQ IMMUN DEF SYND, V25, P188, DOI 10.1097/00126334-200010010-00014; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Koblin B, 2004, LANCET, V364, P41, DOI 10.1016/S0140-6736(04)16588-4; LIU A, 2010, 17 C RETR OPP INF SA; Liu AY, 2008, JAIDS-J ACQ IMM DEF, V47, P241, DOI 10.1097/QAI.0b013e31815e4041; Martin JN, 2004, AIDS, V18, P787, DOI 10.1097/00002030-200403260-00010; Mayer KH, 2008, JAIDS-J ACQ IMM DEF, V47, P494, DOI 10.1097/QAI.0b013e318162afcb; Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27; Noorani S, 2007, GOOD PART PRACT GUID; Peterson Leigh, 2007, PLoS Clin Trials, V2, pe27, DOI 10.1371/journal.pctr.0020027; Roland ME, 2005, CLIN INFECT DIS, V41, P1507, DOI 10.1086/497268; Schacker TW, 1998, ANN INTERN MED, V128, P613, DOI 10.7326/0003-4819-128-8-199804150-00001; Schechter M, 2004, JAIDS-J ACQ IMM DEF, V35, P519, DOI 10.1097/00126334-200404150-00010; Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1; Templeton DJ, 2010, CURR OPIN INFECT DIS, V23, P45, DOI 10.1097/QCO.0b013e328334e54d; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; van Griensven F, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-13; van Griensven F, 2009, CURR OPIN HIV AIDS, V4, P300, DOI 10.1097/COH.0b013e32832c3bb3; Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781	33	3442	3509	6	334	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2010	363	27					2587	2599		10.1056/NEJMoa1011205	http://dx.doi.org/10.1056/NEJMoa1011205			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	700SD	21091279	Green Accepted, Green Published			2022-12-28	WOS:000285763700004
J	Doumas, M; Douma, S				Doumas, Michael; Douma, Stella			Renal sympathetic denervation: the jury is still out	LANCET			English	Editorial Material							RESISTANT HYPERTENSION		[Doumas, Michael] George Washington Univ, Vet Affairs Med Ctr, Washington, DC 20422 USA; [Douma, Stella] Aristotle Univ Thessaloniki, Propedeut Dept Internal Med 2, GR-54006 Thessaloniki, Greece	George Washington University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Aristotle University of Thessaloniki	Doumas, M (corresponding author), George Washington Univ, Vet Affairs Med Ctr, Washington, DC 20422 USA.	michalisdoumas@yahoo.co.uk		Doumas, Michael/0000-0002-7269-8044				Bakris GL, 2010, HYPERTENSION, V56, P824, DOI 10.1161/HYPERTENSIONAHA.110.156976; Calhoun DA, 2008, CIRCULATION, V117, pE510, DOI 10.1161/CIRCULATIONAHA.108.189141; Douma S, 2008, LANCET, V371, P1921, DOI 10.1016/S0140-6736(08)60834-X; Doumas M, 2010, AM J CARDIOL, V105, P570, DOI 10.1016/j.amjcard.2009.10.027; Doumas M, 2009, LANCET, V373, P1228, DOI 10.1016/S0140-6736(09)60624-3; Esler MD, 2010, LANCET, V376, P1903, DOI 10.1016/S0140-6736(10)62039-9; Krum H, 2009, LANCET, V373, P1275, DOI 10.1016/S0140-6736(09)60566-3; PEET MM, 1948, AM J SURG, V75, P48, DOI 10.1016/0002-9610(48)90284-0; Sarafidis PA, 2008, J AM COLL CARDIOL, V52, P1749, DOI 10.1016/j.jacc.2008.08.036; Scheffers IJM, 2010, J AM COLL CARDIOL, V56, P1254, DOI 10.1016/j.jacc.2010.03.089; Weber MA, 2009, LANCET, V374, P1423, DOI 10.1016/S0140-6736(09)61500-2; Williams B, 2009, LANCET, V374, P1396, DOI 10.1016/S0140-6736(09)61600-7	12	36	44	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	2010	376	9756					1878	1880		10.1016/S0140-6736(10)62111-3	http://dx.doi.org/10.1016/S0140-6736(10)62111-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696KH	21093037				2022-12-28	WOS:000285439800006
J	Reis, PM; Jung, SH; Aristoff, JM; Stocker, R				Reis, Pedro M.; Jung, Sunghwan; Aristoff, Jeffrey M.; Stocker, Roman			How Cats Lap: Water Uptake by Felis catus	SCIENCE			English	Article							MECHANICAL DETERMINANTS; LICKING BEHAVIOR; DRINKING; TONGUE; MORPHOLOGY; SIZE; ENERGETICS; FREQUENCY; TRANSPORT; SURFACE	Animals have developed a range of drinking strategies depending on physiological and environmental constraints. Vertebrates with incomplete cheeks use their tongue to drink; the most common example is the lapping of cats and dogs. We show that the domestic cat (Felis catus) laps by a subtle mechanism based on water adhesion to the dorsal side of the tongue. A combined experimental and theoretical analysis reveals that Felis catus exploits fluid inertia to defeat gravity and pull liquid into the mouth. This competition between inertia and gravity sets the lapping frequency and yields a prediction for the dependence of frequency on animal mass. Measurements of lapping frequency across the family Felidae support this prediction, which suggests that the lapping mechanism is conserved among felines.	[Reis, Pedro M.; Stocker, Roman] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; [Reis, Pedro M.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Jung, Sunghwan] Virginia Polytech Inst & State Univ, Dept Engn Sci & Mech, Blacksburg, VA 24061 USA; [Aristoff, Jeffrey M.] Princeton Univ, Dept Mech & Aerosp Engn, Princeton, NJ 08544 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Virginia Polytechnic Institute & State University; Princeton University	Stocker, R (corresponding author), MIT, Dept Civil & Environm Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	romans@mit.edu	Stocker, Roman/N-8987-2019; Jung, Sunghwan/E-8752-2010; Reis, Pedro/F-1176-2010; Stocker, Roman/T-9456-2017	Reis, Pedro/0000-0003-3984-828X; Stocker, Roman/0000-0002-3199-0508				AHL AS, 1986, VET RES COMMUN, V10, P245, DOI 10.1007/BF02213989; [Anonymous], 1940, QUICK N WINK; Attenborough David, 2011, LECT ROYAL SOC ENCOU; BENTLEY PJ, 1979, J EXP BIOL, V79, P41; CHIEL HJ, 1992, BIOL CYBERN, V67, P403, DOI 10.1007/BF00200984; Christiansen P, 2005, J ZOOL, V266, P133, DOI 10.1017/S0952836905006643; Cundall D, 2000, J EXP BIOL, V203, P2171; DANIEL TL, 1989, OECOLOGIA, V79, P66, DOI 10.1007/BF00378241; Day LM, 2007, J EXP BIOL, V210, P642, DOI 10.1242/jeb.02703; Dilger W. C., 1962, ROOTS BEHAVIOR, P35; Doube M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004742; Glasheen JW, 1996, J EXP BIOL, V199, P2611; Gussekloo SWS, 2005, J EXP BIOL, V208, P3395, DOI 10.1242/jeb.01769; HEGLUND NC, 1974, SCIENCE, V186, P1112, DOI 10.1126/science.186.4169.1112; HEIDWEILLER J, 1990, CONDOR, V92, P1, DOI 10.2307/1368379; HEIDWEILLER J, 1992, ZOOMORPHOLOGY, V111, P141, DOI 10.1007/BF01632904; Hiiemae K.M., 1985, P262; KINGSOLVER JG, 1983, OECOLOGIA, V60, P214, DOI 10.1007/BF00379523; KOOLOOS JGM, 1989, J MORPHOL, V199, P327, DOI 10.1002/jmor.1051990308; Meachen-Samuels J, 2009, J MORPHOL, V270, P729, DOI 10.1002/jmor.10712; Ojima K, 2000, ANN ANAT, V182, P47, DOI 10.1016/S0940-9602(00)80120-X; Prakash M, 2008, SCIENCE, V320, P931, DOI 10.1126/science.1156023; PRANGE HD, 1970, J EXP BIOL, V53, P763; RUSSELL AP, 1995, J ZOOL, V236, P161, DOI 10.1111/j.1469-7998.1995.tb01791.x; Smith K.K., 1989, American Scientist, V77, P28; THEXTON AJ, 1988, ARCH ORAL BIOL, V33, P331, DOI 10.1016/0003-9969(88)90066-0; Thexton AJ, 1998, J EXP ZOOL, V280, P327, DOI 10.1002/(SICI)1097-010X(19980401)280:5&lt;327::AID-JEZ2&gt;3.0.CO;2-Q; Trivedi Deepak, 2008, Applied Bionics and Biomechanics, V5, P99, DOI 10.1080/11762320802557865; Weijnen JAWM, 1998, NEUROSCI BIOBEHAV R, V22, P751, DOI 10.1016/S0149-7634(98)00003-7	29	87	89	10	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2010	330	6008					1231	1234		10.1126/science.1195421	http://dx.doi.org/10.1126/science.1195421			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	685FE	21071630				2022-12-28	WOS:000284613700038
J	Gagliardi, G; Salza, M; Avino, S; Ferraro, P; De Natale, P				Gagliardi, G.; Salza, M.; Avino, S.; Ferraro, P.; De Natale, P.			Probing the Ultimate Limit of Fiber-Optic Strain Sensing	SCIENCE			English	Article							FREQUENCY-COMB GENERATOR; BRAGG-GRATING RESONATORS; DISPLACEMENT METROLOGY; THERMAL NOISE; SENSOR; INTERROGATION; FLUCTUATIONS; RESOLUTION; LASERS	The measurement of relative displacements and deformations is important in many fields such as structural engineering, aerospace, geophysics, and nanotechnology. Optical-fiber sensors have become key tools for strain measurements, with sensitivity limits ranging between 10(-9) and 10(-6)epsilon hertz (Hz)(-1/2) (where epsilon is the fractional length change). We report on strain measurements at the 10(-13)epsilon-Hz(-1/2) level using a fiber Bragg-grating resonator with a diode-laser source that is stabilized against a quartz-disciplined optical frequency comb, thus approaching detection limits set by thermodynamic phase fluctuations in the fiber. This scheme may provide a route to a new generation of strain sensors that is entirely based on fiber-optic systems, which are aimed at measuring fundamental physical quantities; for example, in gyroscopes, accelerometers, and gravity experiments.	[Gagliardi, G.; Salza, M.; Avino, S.; Ferraro, P.] CNR, INO, I-80078 Naples, Italy; [Gagliardi, G.; Salza, M.; Avino, S.; Ferraro, P.] European Lab Nonlinear Spect LENS, I-80078 Naples, Italy; [De Natale, P.] CNR, INO, I-50125 Florence, Italy; [De Natale, P.] LENS, I-50125 Florence, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale di Ottica (INO-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale di Ottica (INO-CNR)	Gagliardi, G (corresponding author), CNR, INO, Via Campi Flegrei 34, I-80078 Naples, Italy.	gianluca.gagliardi@ino.it	De Natale, Paolo/B-7505-2019; calloni, enrico/K-5852-2019; Gagliardi, Gianluca/A-4079-2010; Ferraro, Pietro/A-5288-2009; Ferraro, Pietro/ABA-2985-2020	De Natale, Paolo/0000-0002-3308-8569; Gagliardi, Gianluca/0000-0003-0638-428X; Ferraro, Pietro/0000-0002-0158-3856; Ferraro, Pietro/0000-0002-0158-3856; Avino, Saverio/0000-0001-6623-9784	Ente Cassa di Risparmio di Firenze	Ente Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze)	We thank M. Prevedelli, A. Arie, M. De Rosa, and J. H. Chow for helpful discussions. Technical assistance on the electronic setup was provided by R. Abbate, who passed away in September 2008. We thank Avanex Corp. (San Donato, Milan, Italy) for kindly providing part of the equipment. This experiment was partly funded by Ente Cassa di Risparmio di Firenze.	AGNEW DC, 1986, REV GEOPHYS, V24, P579, DOI 10.1029/RG024i003p00579; Arie A, 1999, J LIGHTWAVE TECHNOL, V17, P1849, DOI 10.1109/50.793765; Balling P, 2009, OPT EXPRESS, V17, P9300, DOI 10.1364/OE.17.009300; Bitou Y, 2009, OPT LETT, V34, P1540, DOI 10.1364/OL.34.001540; Bitou Y, 2009, PRECIS ENG, V33, P187, DOI 10.1016/j.precisioneng.2008.05.004; Chang S, 2000, CHINESE J PHYS, V38, P437; Chow JH, 2005, OPT LETT, V30, P1923, DOI 10.1364/OL.30.001923; Chow JH, 2005, J LIGHTWAVE TECHNOL, V23, P1881, DOI 10.1109/JLT.2005.846895; Cranch GA, 2003, IEEE PHOTONIC TECH L, V15, P1579, DOI 10.1109/LPT.2003.818686; Foster S, 2007, IEEE J QUANTUM ELECT, V43, P378, DOI 10.1109/JQE.2007.894744; Gagliardi G, 2007, OPT EXPRESS, V15, P3715, DOI 10.1364/OE.15.003715; GLENN WH, 1989, IEEE J QUANTUM ELECT, V25, P1218, DOI 10.1109/3.29251; Jones M, 2008, NAT PHOTONICS, V2, P153, DOI 10.1038/nphoton.2008.20; KNUDSEN S, 1995, IEEE PHOTONIC TECH L, V7, P90, DOI 10.1109/68.363366; Lam TTY, 2010, MEAS SCI TECHNOL, V21, DOI 10.1088/0957-0233/21/9/094010; Lam TTY, 2009, IEEE SENS J, V9, P983, DOI 10.1109/JSEN.2009.2024040; MacMynowski DG, 2009, APPL OPTICS, V48, P2105, DOI 10.1364/AO.48.002105; Maddaloni P, 2009, MEAS SCI TECHNOL, V20, DOI 10.1088/0957-0233/20/5/052001; Moeller RP, 1996, OPT LETT, V21, P171, DOI 10.1364/OL.21.000171; Nikles M., 2010, NAT PHOTONICS, V4, P431, DOI [10.1038/nphoton.2010.149, DOI 10.1038/NPHOTON.2010.149]; Rao YJ, 1997, MEAS SCI TECHNOL, V8, P355, DOI 10.1088/0957-0233/8/4/002; Reitze D, 2008, NAT PHOTONICS, V2, P582, DOI 10.1038/nphoton.2008.186; Su L, 2010, OPT LETT, V35, P1212, DOI 10.1364/OL.35.001212; Vollmer F, 2008, NAT METHODS, V5, P591, DOI 10.1038/nmeth.1221; Wanser K. H., 1993, OPT PHOTONICS NEWS, V4, P37; WANSER KH, 1992, ELECTRON LETT, V28, P53, DOI 10.1049/el:19920033	26	172	179	14	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1081	1084		10.1126/science.1195818	http://dx.doi.org/10.1126/science.1195818			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21030606				2022-12-28	WOS:000284374700037
J	Victor, P				Victor, Peter			Questioning economic growth	NATURE			English	Editorial Material									York Univ, Toronto, ON M3J 2R7, Canada	York University - Canada	Victor, P (corresponding author), York Univ, Toronto, ON M3J 2R7, Canada.	pvictor@yorku.ca						Arndt H. W., 1978, RISE FALL EC GROWTH; Crafts N, 2004, ECON J, V114, P338, DOI 10.1111/j.1468-0297.2003.00200.x; *FRIENDS EARTH, IND SUST EC WELF; Krausmann F, 2009, ECOL ECON, V68, P2696, DOI 10.1016/j.ecolecon.2009.05.007; Kuznets S., 1934, 124 US C; Rockstrom J, 2009, NATURE, V461, P472, DOI 10.1038/461472a; Smil V., 1994, ENERGY WORLD HIST, V36, P690; Stiglitz J. E., 2010, FREEFALL AM FREE MAR; Stoll S., 2008, HARPERS MAGAZINE MAR; Victor P., 2008, MANAGING GROWTH SLOW	10	98	102	3	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2010	468	7322					370	371		10.1038/468370a	http://dx.doi.org/10.1038/468370a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	681KP	21085153	Bronze			2022-12-28	WOS:000284313100016
J	Aaron, SD; Vandemheen, KL; Ramotar, K; Giesbrecht-Lewis, T; Tullis, E; Freitag, A; Paterson, N; Jackson, M; Lougheed, MD; Dowson, C; Kumar, V; Ferris, W; Chan, F; Doucette, S; Fergusson, D				Aaron, Shawn D.; Vandemheen, Katherine L.; Ramotar, Karam; Giesbrecht-Lewis, Tracy; Tullis, Elizabeth; Freitag, Andreas; Paterson, Nigel; Jackson, Mary; Lougheed, M. Diane; Dowson, Christopher; Kumar, Vijay; Ferris, Wendy; Chan, Francis; Doucette, Steve; Fergusson, Dean			Infection With Transmissible Strains of Pseudomonas aeruginosa and Clinical Outcomes in Adults With Cystic Fibrosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONIZATION; EPIDEMIOLOGY; CEPACIA; SPREAD; CF; IDENTIFICATION; MORBIDITY; MORTALITY; PATIENT; CANADA	Context Studies from Australia and the United Kingdom have shown that some patients with cystic fibrosis are infected with common transmissible strains of Pseudomonas aeruginosa. Objectives To determine the prevalence and incidence of infection with transmissible strains of P aeruginosa and whether presence of the organism was associated with adverse clinical outcomes in Canada. Design, Setting, and Participants Prospective observational cohort study of adult patients cared for at cystic fibrosis clinics in Ontario, Canada, with enrollment from September 2005 to September 2008. Sputum was collected at baseline, 3 months, and yearly thereafter for 3 years; and retrieved P aeruginosa isolates were genotyped. Vital status (death or lung transplant) was assessed for all enrolled patients until December 31, 2009. Main Outcome Measures Incidence and prevalence of P aeruginosa isolation, rates of decline in lung function, and time to death or lung transplantation. Results Of the 446 patients with cystic fibrosis studied, 102 were discovered to be infected with 1 of 2 common transmissible strains of P aeruginosa at study entry. Sixty-seven patients were infected with strain A (15%), 32 were infected with strain B (7%), and 3 were simultaneously infected with both strains (0.6%). Strain A was found to be genetically identical to the Liverpool epidemic strain but strain B has not been previously described as an epidemic strain. The incidence rate of new infections with these 2 transmissible strains was relatively low (7.0 per 1000 person-years; 95% confidence interval [CI], 1.8-12.2 per 1000 person-years). Compared with patients infected with unique strains of P aeruginosa, patients infected with the Liverpool epidemic strain (strain A) and strain B had similar declines in lung function (difference in decline in percent predicted forced expiratory volume in the first second of expiration of 0.64% per year [95% CI, -1.52% to 2.80% per year] and 1.66% per year [95% CI, -1.00% to 4.30%], respectively). However, the 3-year rate of death or lung transplantation was greater in those infected with the Liverpool epidemic strain (18.6%) compared with those infected with unique strains (8.7%) (adjusted hazard ratio, 3.26 [95% CI, 1.41 to 7.54]; P = .01). Conclusions A common strain of P aeruginosa (Liverpool epidemic strain/strain A) infects patients with cystic fibrosis in Canada and the United Kingdom. Infection with this strain in adult Canadian patients with cystic fibrosis was associated with a greater risk of death or lung transplantation. JAMA, 2010;304(19):2145-2153 www.jama.com	[Aaron, Shawn D.; Vandemheen, Katherine L.; Ramotar, Karam; Giesbrecht-Lewis, Tracy; Doucette, Steve; Fergusson, Dean] Univ Ottawa, Ottawa Hosp, Res Inst, Ottawa, ON K1H 8L6, Canada; [Tullis, Elizabeth] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Freitag, Andreas] McMaster Univ, Hamilton, ON, Canada; [Paterson, Nigel] Univ Western Ontario, London, ON, Canada; [Jackson, Mary] Grand River Hosp, Kitchener, ON, Canada; [Lougheed, M. Diane] Queens Univ, Kingston, ON, Canada; [Dowson, Christopher] Univ Warwick, Coventry CV4 7AL, W Midlands, England; [Kumar, Vijay] Sudbury Reg Hosp, Sudbury, ON, Canada; [Ferris, Wendy; Chan, Francis] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; Western University (University of Western Ontario); Queens University - Canada; University of Warwick; Health Sciences North; University of Ottawa; Children's Hospital of Eastern Ontario	Aaron, SD (corresponding author), Univ Ottawa, Ottawa Hosp, Res Inst, Gen Campus,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	saaron@ohri.ca	Dowson, Christopher/ABG-5083-2021; Dowson, Chris/N-6195-2014	Dowson, Christopher/0000-0002-8294-8836; Dowson, Chris/0000-0002-8294-8836; Aaron, Shawn/0000-0002-4762-3542; Fergusson, Dean/0000-0002-3389-2485	Canadian Institutes of Health Research; Canadian Cystic Fibrosis Foundation; Ontario Thoracic Society	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cystic Fibrosis Foundation; Ontario Thoracic Society	Funded by the Canadian Institutes of Health Research, the Canadian Cystic Fibrosis Foundation, and the Ontario Thoracic Society.	Aaron SD, 2004, AM J RESP CRIT CARE, V169, P811, DOI 10.1164/rccm.200309-1306OC; Al-Aloul M, 2004, THORAX, V59, P334, DOI 10.1136/thx.2003.014258; Armstrong DS, 2002, AM J RESP CRIT CARE, V166, P983, DOI 10.1164/rccm.200204-269OC; Burns JL, 1998, CLIN INFECT DIS, V27, P158, DOI 10.1086/514631; Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0; Corey M, 1996, AM J EPIDEMIOL, V143, P1007, DOI 10.1093/oxfordjournals.aje.a008664; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Doring G, 2000, EUR RESPIR J, V16, P749, DOI 10.1034/j.1399-3003.2000.16d30.x; Emerson J, 2002, PEDIATR PULM, V34, P91, DOI 10.1002/ppul.10127; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; Griffiths AL, 2005, AM J RESP CRIT CARE, V171, P1020, DOI 10.1164/rccm.200409-1194OC; GROTHUES D, 1988, J CLIN MICROBIOL, V26, P1973, DOI 10.1128/JCM.26.10.1973-1977.1988; JOHN M, 1994, PEDIATR PULM, V18, P108, DOI 10.1002/ppul.1950180210; Jones AM, 2003, THORAX, V58, P525, DOI 10.1136/thorax.58.6.525; Jones AM, 2001, LANCET, V358, P557, DOI 10.1016/S0140-6736(01)05714-2; Jones AM, 2010, CHEST, V137, P1405, DOI 10.1378/chest.09-2406; LAING FPY, 1995, J CLIN MICROBIOL, V33, P513, DOI 10.1128/JCM.33.3.513-518.1995; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; McCallum SJ, 2002, THORAX, V57, P559, DOI 10.1136/thorax.57.6.559; Mohan K, 2008, THORAX, V63, P839, DOI 10.1136/thx.2007.092486; Ramsey BW, 2002, AM J RESP CRIT CARE, V166, P906, DOI 10.1164/rccm.2207005; Scott FW, 2004, J MED MICROBIOL, V53, P609, DOI 10.1099/jmm.0.45620-0; Speert DP, 2002, AM J RESP CRIT CARE, V166, P988, DOI 10.1164/rccm.2203011; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Waine DJ, 2009, J CLIN MICROBIOL, V47, P3444, DOI 10.1128/JCM.00459-09; Wainwright CE, 2009, THORAX, V64, P926, DOI 10.1136/thx.2008.112466; Winstanley C, 2009, GENOME RES, V19, P12, DOI 10.1101/gr.086082.108	28	132	133	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2145	2153		10.1001/jama.2010.1665	http://dx.doi.org/10.1001/jama.2010.1665			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081727	Bronze			2022-12-28	WOS:000284269800025
J	Aron, DC; Pogach, LM				Aron, David C.; Pogach, Leonard M.			Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Aron, David C.] Cleveland VA Med Ctr, Cleveland, OH USA; [Pogach, Leonard M.] New Jersey VA Healthcare Syst, E Orange, NJ USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; New Jersey Department of Health & Senior Services	Aron, DC (corresponding author), Cleveland VA Med Ctr, Cleveland, OH USA.							Aron DC, 2007, JT COMM J QUAL PATIE, V33, P636, DOI 10.1016/S1553-7250(07)33073-0; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Pogach L, 2010, JAMA-J AM MED ASSOC, V303, P2076, DOI 10.1001/jama.2010.655	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-9	10.1059/0003-4819-153-10-201011160-02009	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02009			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079216				2022-12-28	WOS:000284215800008
J	Kirshner, HS				Kirshner, Howard S.			Stenting and endarterectomy for carotid artery stenosis did not differ for a composite of stroke, MI, or death	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TRIAL		Vanderbilt Univ, Med Ctr, Nashville, TN 37203 USA	Vanderbilt University	Kirshner, HS (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37203 USA.							Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Naylor AR, 1998, J VASC SURG, V28, P326, DOI 10.1016/S0741-5214(98)70182-X; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10							JC5-12	10.1059/0003-4819-153-10-201011160-02012	http://dx.doi.org/10.1059/0003-4819-153-10-201011160-02012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079207				2022-12-28	WOS:000284215800011
J	van Rooyen, S; Delamothe, T; Evans, SJW				van Rooyen, Susan; Delamothe, Tony; Evans, Stephen J. W.			Effect on peer review of telling reviewers that their signed reviews might be posted on the web: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY; ANONYMITY; UNMASKING; AUTHORS	Objectives To see whether telling peer reviewers that their signed reviews of original research papers might be posted on the BMJ's website would affect the quality of their reviews. Design Randomised controlled trial. Setting A large international general medical journal based in the United Kingdom. Participants 541 authors, 471 peer reviewers, 12 editors. Intervention Consecutive eligible papers were randomised either to have the reviewer's signed report made available on the BMJ's website alongside the published paper (intervention group) or to have the report made available only to the author-the BMJ's normal procedure (control group). The intervention was the act of revealing to reviewers-after they had agreed to review but before they undertook their review-that their signed report might appear on the website. Main outcome measures The main outcome measure was the quality of the reviews, as independently rated on a scale of 1 to 5 using a validated instrument by two editors and the corresponding author. Authors and editors were blind to the intervention group. Authors rated review quality before the fate of their paper had been decided. Additional outcomes were the time taken to complete the review and the reviewer's recommendation regarding publication. Results 558 manuscripts were randomised, and 471 manuscripts remained after exclusions. Of the 1039 reviewers approached to take part in the study, 568 (55%) declined. Two editors' evaluations of the quality of the peer review were obtained for all 471 manuscripts, with the corresponding author's evaluation obtained for 453. There was no significant difference in review quality between the intervention and control groups (mean difference for editors 0.04, 95% CI -0.09 to 0.17; for authors 0.06, 95% CI -0.09 to 0.20). Any possible difference in favour of the control group was well below the level regarded as editorially significant. Reviewers in the intervention group took significantly longer to review (mean difference 25 minutes, 95% CI 3.0 to 47.0 minutes). Conclusion Telling peer reviewers that their signed reviews might be available in the public domain on the BMJ's website had no important effect on review quality. Although the possibility of posting reviews online was associated with a high refusal rate among potential peer reviewers and an increase in the amount of time taken to write a review, we believe that the ethical arguments in favour of open peer review more than outweigh these disadvantages.	[van Rooyen, Susan; Delamothe, Tony] BMJ, London, England; [Evans, Stephen J. W.] London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Delamothe, T (corresponding author), BMJ, BMA House, London, England.	tdelamothe@bmj.com		Evans, Stephen/0000-0002-1474-2596				Callaham M.L., 2003, PEER REV HLTH SCI, V2nd ed., P164; FABIATO A, 1994, CARDIOVASC RES, V28, P1134, DOI 10.1093/cvr/28.8.1134; FLETCHER RH, 1994, CARDIOVASC RES, V28, P1140, DOI 10.1093/cvr/28.8.1140; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1376, DOI 10.1001/jama.263.10.1376; HABIBZADEH F, 2009, P 6 INT C PEER REV B, P48; HEARSE DJ, 1994, CARDIOVASC RES, V28, P1133, DOI 10.1093/cvr/28.8.1133; Justice AC, 1998, JAMA-J AM MED ASSOC, V280, P240, DOI 10.1001/jama.280.3.240; Lock S., 1985, DIFFICULT BALANCE ED; MCNUTT RA, 1990, JAMA-J AM MED ASSOC, V263, P1371, DOI 10.1001/jama.263.10.1371; Regehr G, 2006, MED EDUC, V40, P832, DOI 10.1111/j.1365-2929.2006.02539.x; Rennie D, 1998, JAMA-J AM MED ASSOC, V280, P300, DOI 10.1001/jama.280.3.300; van Rooyen S, 1999, J GEN INTERN MED, V14, P622, DOI 10.1046/j.1525-1497.1999.09058.x; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; van Rooyen S, 1999, J CLIN EPIDEMIOL, V52, P625, DOI 10.1016/S0895-4356(99)00047-5; van Rooyen S, 1999, BRIT MED J, V318, P23; Walsh E, 2000, BRIT J PSYCHIAT, V176, P47, DOI 10.1192/bjp.176.1.47; 2007, PLOS MED, V4, pE58	17	93	93	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2010	341								c5729	10.1136/bmj.c5729	http://dx.doi.org/10.1136/bmj.c5729			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684WJ	21081600	hybrid, Green Published			2022-12-28	WOS:000284585600009
J	Collier, P; Alles, CM				Collier, Paul; Alles, Carina Maria			Materials Ecology: An Industrial Perspective	SCIENCE			English	Editorial Material									[Collier, Paul] Johnson Matthey Technol Ctr, Reading RG4 9NH, Berks, England; [Alles, Carina Maria] DuPont Engn Res & Technol, Wilmington, DE 19898 USA	DuPont	Collier, P (corresponding author), Johnson Matthey Technol Ctr, Blounts Court Rd, Reading RG4 9NH, Berks, England.	col-lipj@matthey.com; carina.alles@usa.dupont.com						Ayres Robert U., 2002, HDB IND ECOLOGY; DESROCHERS P, 2007, ELECT J SUSTAINABLE, V1, P1; Ellis, 2010, NEW PIONEERS SUSTAIN; Graedel T., 2002, IND ECOLOGY; Hill M.K., 2010, UNDERSTANDING ENV PO, Vthird; McDonough W., 2002, CRADLE CRADLE REMAKI; *NAT AC ENG ROYAL, 2010, FRONT ENG EU US S CA; Reuter MA, 2005, DEV MINERAL PROCESSI, V16	8	16	16	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2010	330	6006					919	920		10.1126/science.1197478	http://dx.doi.org/10.1126/science.1197478			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	678XY	21071653				2022-12-28	WOS:000284118000025
J	Gilchrist, DA; Dos Santos, G; Fargo, DC; Xie, B; Gao, YA; Li, LP; Adelman, K				Gilchrist, Daniel A.; Dos Santos, Gilberto; Fargo, David C.; Xie, Bin; Gao, Yuan; Li, Leping; Adelman, Karen			Pausing of RNA Polymerase II Disrupts DNA-Specified Nucleosome Organization to Enable Precise Gene Regulation	CELL			English	Article							DROSOPHILA-MELANOGASTER; PROMOTER ARCHITECTURE; GAGA FACTOR; POL-II; P-TEFB; TRANSCRIPTION; ELONGATION; CHROMATIN; BINDING; NELF	Metazoan transcription is controlled through either coordinated recruitment of transcription machinery to the gene promoter or regulated pausing of RNA polymerase II (Pol II) in early elongation. We report that a striking difference between genes that use these distinct regulatory strategies lies in the "default" chromatin architecture specified by their DNA sequences. Pol II pausing is prominent at highly regulated genes whose sequences inherently disfavor nucleosome formation within the gene but favor occlusion of the promoter by nucleosomes. In contrast, housekeeping genes that lack pronounced Pol II pausing show higher nucleosome occupancy downstream, but their promoters are deprived of nucleosomes regardless of polymerase binding. Our results indicate that a key role of paused Pol II is to compete with nucleosomes for occupancy of highly regulated promoters, thereby preventing the formation of repressive chromatin architecture	[Gilchrist, Daniel A.; Dos Santos, Gilberto; Adelman, Karen] NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; [Fargo, David C.] NIEHS, Lib Informat Serv, NIH, Res Triangle Pk, NC 27709 USA; [Li, Leping] NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA; [Gao, Yuan] Johns Hopkins Univ, Inst Cell Engn, Neurogenerat & Stem Cell Biol Program, Baltimore, MD 21205 USA; [Xie, Bin; Gao, Yuan] Johns Hopkins Univ, Lieber Inst Brain Dev, Div Genom Epigenom & Bioinformat, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins University	Adelman, K (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	adelmank@niehs.nih.gov	Gao, Yuan/E-1706-2011; Li, Leping/F-6497-2019	Li, Leping/0000-0003-4208-0259; Gilchrist, Daniel/0000-0003-1668-2790; Adelman, Karen/0000-0001-5364-334X	NIH, National Institute of Environmental Health Sciences [Z01 ES101987, ES101765]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES101765, ZIAES101987, Z01ES101987, ZICES102445, Z01ES101765] Funding Source: NIH RePORTER	NIH, National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank S. Nechaev, T. Kunkel, and G. Hu for critical reading of the manuscript. We acknowledge L. Pederson for production of the NELF-B protein, J. Tucker and the NIEHS microarray core for help with arrays, and S. Dai and J. Grovenstein for computational support. This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (grant Z01 ES101987 to K.A. and grant ES101765 to L.L.). D.A.G. and K.A. designed experiments, D.A.G., G.D.S., B.X., and Y.G. performed experiments, D.A.G., D.C.F., L.L., and K.A. performed data analysis, and D.A.G. and K.A. prepared the manuscript.	Albert I, 2007, NATURE, V446, P572, DOI 10.1038/nature05632; Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Boettiger AN, 2009, SCIENCE, V325, P471, DOI 10.1126/science.1173976; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; Cheng B, 2007, J BIOL CHEM, V282, P21901, DOI 10.1074/jbc.M702936200; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208; Gilchrist DA, 2009, METHODS, V48, P398, DOI 10.1016/j.ymeth.2009.02.024; Hendrix DA, 2008, P NATL ACAD SCI USA, V105, P7762, DOI 10.1073/pnas.0802406105; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Juven-Gershon T, 2008, CURR OPIN CELL BIOL, V20, P253, DOI 10.1016/j.ceb.2008.03.003; Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Lee CY, 2008, MOL CELL BIOL, V28, P3290, DOI 10.1128/MCB.02224-07; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Mavrich TN, 2008, NATURE, V453, P358, DOI 10.1038/nature06929; Mito Y, 2005, NAT GENET, V37, P1090, DOI 10.1038/ng1637; Muse GW, 2007, NAT GENET, V39, P1507, DOI 10.1038/ng.2007.21; Nechaev S, 2010, SCIENCE, V327, P335, DOI 10.1126/science.1181421; Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Roeder RG, 2005, FEBS LETT, V579, P909, DOI 10.1016/j.febslet.2004.12.007; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022; Schwartz S, 2009, NAT STRUCT MOL BIOL, V16, P990, DOI 10.1038/nsmb.1659; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; Tillo D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009129; Tirosh I, 2008, GENOME RES, V18, P1084, DOI 10.1101/gr.076059.108; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Weiner A, 2010, GENOME RES, V20, P90, DOI 10.1101/gr.098509.109; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Yamaguchi Y, 2002, MOL CELL BIOL, V22, P2918, DOI 10.1128/MCB.22.9.2918-2927.2002; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26; Zhang Y, 2009, NAT STRUCT MOL BIOL, V16, P847, DOI 10.1038/nsmb.1636	42	290	292	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					540	551		10.1016/j.cell.2010.10.004	http://dx.doi.org/10.1016/j.cell.2010.10.004			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074046	Green Accepted, Bronze			2022-12-28	WOS:000284149100012
J	Walsh, RM; Hochedlinger, K				Walsh, Ryan M.; Hochedlinger, Konrad			Modeling Rett Syndrome with Stem Cells	CELL			English	Editorial Material							CPG-BINDING PROTEIN-2; MECP2; SYMPTOMS; REVERSAL; MICE		[Walsh, Ryan M.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Regenerat Med, Boston, MA 02114 USA; [Walsh, Ryan M.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Canc, Boston, MA 02114 USA; [Walsh, Ryan M.; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Walsh, Ryan M.; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Walsh, Ryan M.; Hochedlinger, Konrad] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard University; Harvard University	Hochedlinger, K (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Ctr Regenerat Med, Boston, MA 02114 USA.	khochedlinger@helix.mgh.harvard.edu			NICHD NIH HHS [R01 HD058013] Funding Source: Medline; NIH HHS [DP2 OD003266] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD058013] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD003266] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Chao HT, 2007, NEURON, V56, P58, DOI 10.1016/j.neuron.2007.08.018; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Guy J, 2007, SCIENCE, V315, P1143, DOI 10.1126/science.1138389; Marchetto MCN, 2010, CELL, V143, P527, DOI 10.1016/j.cell.2010.10.016; Percy AK, 2005, J CHILD NEUROL, V20, P718, DOI 10.1177/08830738050200090301; Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910; Tchieu J, 2010, CELL STEM CELL, V7, P329, DOI 10.1016/j.stem.2010.06.024; Tropea D, 2009, P NATL ACAD SCI USA, V106, P2029, DOI 10.1073/pnas.0812394106	10	16	17	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2010	143	4					499	500		10.1016/j.cell.2010.10.037	http://dx.doi.org/10.1016/j.cell.2010.10.037			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074040	Bronze, Green Accepted			2022-12-28	WOS:000284149100006
J	Ranero, CR; Perez-Gussinye, M				Ranero, Cesar R.; Perez-Gussinye, Marta			Sequential faulting explains the asymmetry and extension discrepancy of conjugate margins	NATURE			English	Article							NONVOLCANIC RIFTED MARGINS; CONTINENTAL EXTENSION; FLEMISH CAP; EVOLUTION; IBERIA; SEA; MODELS; BASIN; WEST; NEWFOUNDLAND	During early extension, cold continental lithosphere thins and subsides, creating rift basins. If extension continues to final break-up, the split and greatly thinned plates subside deep below sea level to form a conjugate pair of rifted margins. Although basins and margins are ubiquitous structures, the deformation processes leading from moderately extended basins to highly stretched margins are unclear, as studies consistently report that crustal thinning is greater than extension caused by brittle faulting(1-4). This extension discrepancy might arise from differential stretching of brittle and ductile crustal layers(2), but that does not readily explain the typical asymmetric structure of conjugate margins(5,6)-in cross-section, one margin displays gradual thinning accompanied by large faults, and the conjugate margin displays abrupt thinning but smaller-scale faulting(5). Whole-crust detachments, active from early in the rifting, could in theory create both thinning and asymmetry(1), but are mechanically problematical. Furthermore, the extension discrepancy occurs at both conjugate margins, leading to the apparent contradiction that both seem to be upper plates to a detachment fault(7,8). Alternative models propose that much brittle extension is undetected because of seismic imaging limitations caused either by subseismic-resolution faulting(9), invisible deformation along top-basement 100-km-scale detachments(8) or the structural complexity of cross-cutting arrays of faults(3). Here we use depth-migrated seismic images to accurately measure fault extension and compare it with crustal thinning. The observations are used to create a balanced kinematic model of rifting that resolves the extension discrepancy by producing both fault-controlled crustal thinning which progresses from a rift basin to the asymmetric structure, and extreme thinning of conjugate rifted margins. Contrary to current wisdom, the observations support the idea that thinning is to a first degree explained by simple Andersonian faulting that is unambiguously visible in seismic data.	[Ranero, Cesar R.] CSIC, Inst Ciencias Mar, Barcelona Ctr Subsurface Imaging, ICREA, E-08003 Barcelona, Spain; [Perez-Gussinye, Marta] Univ London, Dept Earth Sci, Egham TW20 0BD, Surrey, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Mediterraneo de Investigaciones Marinas y Ambientales (CMIMA); CSIC - Instituto de Ciencias del Mar (ICM); ICREA; University of London; Royal Holloway University London	Ranero, CR (corresponding author), CSIC, Inst Ciencias Mar, Barcelona Ctr Subsurface Imaging, ICREA, Passeig Maritim Barcelona 37-49, E-08003 Barcelona, Spain.	cranero@icm.csic.es; m.perez@es.rhul.ac.uk	Perez-Gussinye, Marta/R-1704-2016; Ranero, César R/B-9165-2009	Perez-Gussinye, Marta/0000-0003-4109-1810; Ranero, César R/0000-0002-5204-545X	Repsol; Ministry of Science and Innovation; ICREA Funding Source: Custom	Repsol; Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); ICREA(ICREA)	The ideas presented in this work have benefited from discussions with J. Adam, A. Amilibia, E. Casciello, T. Cunha, M. R. Fowler, S. Hardy, J. Garcia-Pintado, G. Manatschal, K. McClay, M. Menzies, E. Saura and F. Storti, and from numerous discussions and previous collaborations with T. J. Reston. The early work that led to the ideas presented here was carried out when C.R.R. worked at IFM-GEOMAR and M.P.-G. at IFM-GEOMAR and later at ICTJA-CSIC. We are grateful to J. Collier and C. Beaumont for their reviews, which helped improved this article. This is a publication of the Department of Earth Sciences of the Royal Holloway, University of London. C.R.R. has been supported by the Kaleidoscope project, funded by Repsol, and by the Spanish National Project Medoc of the Ministry of Science and Innovation.	Ackermann RV, 2001, J STRUCT GEOL, V23, P1803, DOI 10.1016/S0191-8141(01)00028-1; Anderson E.M., 1905, T EDINBURGH GEOLOGIC, V8, P387, DOI DOI 10.1144/TRANSED.8.3.387; BOILLOT G, 1988, P ODP SCI RESULTS, V103, P809; BUCK WR, 1988, TECTONICS, V7, P959, DOI 10.1029/TC007i005p00959; Celerier B, 2008, REV GEOPHYS, V46, DOI 10.1029/2007RG000240; CHIAN DP, 1995, GEOLOGY, V23, P589, DOI 10.1130/0091-7613(1995)023<0589:EONRMN>2.3.CO;2; Cowie PA, 2005, EARTH PLANET SC LETT, V234, P401, DOI 10.1016/j.epsl.2005.01.039; Davis M, 2004, MARG THEOR EXP EARTH, P92; Driscoll NW, 1998, J GEOPHYS RES-SOL EA, V103, P4975, DOI 10.1029/97JB03295; ERCILLA G, MAR GEOPHYS IN PRESS; Fournier M, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2006GC001526; Gardien V, 2001, GEOL SOC SPEC PUBL, V187, P191, DOI 10.1144/GSL.SP.2001.187.01.10; Gawthorpe RL, 2003, J STRUCT GEOL, V25, P1347, DOI 10.1016/S0191-8141(03)00059-2; Hopper JR, 2004, GEOLOGY, V32, P93, DOI 10.1130/G19694.1; Hopper JR, 1998, GEOLOGY, V26, P699, DOI 10.1130/0091-7613(1998)026<0699:SOED>2.3.CO;2; Huismans RS, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002026; JACKSON JA, 1987, SPEC PUBL GEOL SOC L, V28, P3; KEEN C, 1989, GEOLOGY, V17, P173, DOI 10.1130/0091-7613(1989)017<0173:CMOCAE>2.3.CO;2; Kington JD, 2008, TECTONOPHYSICS, V458, P82, DOI 10.1016/j.tecto.2007.11.027; Kusznir NJ., 1991, GEOMETRY NORMAL FAUL, P41; Lavier LL, 2006, NATURE, V440, P324, DOI 10.1038/nature04608; LISTER GS, 1991, TECTONICS, V10, P1038, DOI 10.1029/90TC01007; Louden KE, 1999, PHILOS T R SOC A, V357, P767, DOI 10.1098/rsta.1999.0352; Maillard A, 2006, EARTH PLANET SC LETT, V241, P686, DOI 10.1016/j.epsl.2005.11.013; Manatschal G, 2004, INT J EARTH SCI, V93, P432, DOI 10.1007/s00531-004-0394-7; MARRETT R, 1992, GEOLOGY, V20, P47, DOI 10.1130/0091-7613(1992)020<0047:AOEOSF>2.3.CO;2; Mattei M, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002506; Muntener O, 2000, J PETROL, V41, P175, DOI 10.1093/petrology/41.2.175; Perez-Gussinye M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000901; Perez-Gussinye M, 2001, J GEOPHYS RES-SOL EA, V106, P3961, DOI 10.1029/2000JB900325; Peron-Pinvidic G, 2007, TECTONICS, V26, DOI 10.1029/2006TC001970; Reston TJ, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2006GC001437; Reston T, 2007, GEOLOGY, V35, P367, DOI 10.1130/G23213A.1; Reston TJ, 2004, J GEOL SOC LONDON, V161, P783, DOI 10.1144/0016-764903-036; Sibson RH, 2000, J GEODYN, V29, P469, DOI 10.1016/S0264-3707(99)00042-3; SIBUET JC, 1992, J GEOL SOC LONDON, V149, P829, DOI 10.1144/gsjgs.149.5.0829; Soliva R, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2004JB003507; Srivastava SP, 2000, EARTH PLANET SC LETT, V182, P61, DOI 10.1016/S0012-821X(00)00231-4; THATCHER W, 1995, J GEOPHYS RES-SOL EA, V100, P561, DOI 10.1029/94JB02593; Walsh JJ, 2003, J STRUCT GEOL, V25, P307, DOI 10.1016/S0191-8141(02)00028-7; WESTAWAY R, 1993, J STRUCT GEOL, V15, P753, DOI 10.1016/0191-8141(93)90060-N; Whitmarsh RB, 1996, J GEOPHYS RES-SOL EA, V101, P28291, DOI 10.1029/96JB02579; Whitmarsh RB, 2001, NATURE, V413, P150, DOI 10.1038/35093085; Wilson RCL, 2001, GEOL SOC SPEC PUBL, V187, P429, DOI 10.1144/GSL.SP.2001.187.01.21	44	158	166	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					294	U180		10.1038/nature09520	http://dx.doi.org/10.1038/nature09520			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21048712				2022-12-28	WOS:000284051000049
J	Rowitch, DH; Kriegstein, AR				Rowitch, David H.; Kriegstein, Arnold R.			Developmental genetics of vertebrate glial-cell specification	NATURE			English	Review							NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; DEVELOPING SPINAL-CORD; OLIGODENDROCYTE PRECURSOR CELLS; INHIBITORY FACTOR-RECEPTOR; ADULT CEREBRAL-CORTEX; PROGENITOR CELLS; SUBVENTRICULAR ZONE; CORTICAL-NEURONS; RADIAL GLIA	Oligodendrocytes and astrocytes are macroglial cells of the vertebrate central nervous system. These cells have diverse roles in the maintenance of neurological function. In the embryo, the genetic mechanisms that underlie the specification of macroglial precursors in vivo appear strikingly similar to those that regulate the development of the diverse neuron types. The switch from producing neuronal to glial subtype-specific precursors can be modelled as an interplay between region-restricted components and temporal regulators that determine neurogenic or gliogenic phases of development, contributing to glial diversity. Gaining insight into the developmental genetics of macroglia has great potential to improve our understanding of a variety of neurological disorders in humans.	[Rowitch, David H.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; [Rowitch, David H.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Rowitch, David H.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Kriegstein, Arnold R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Rowitch, DH (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.	rowitchd@peds.ucsf.edu; kriegsteina@stemcell.ucsf.edu		Rowitch, David/0000-0002-0079-0060	National Institutes of Health; California Institute for Regenerative Medicine	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	We apologize to those whose work we could not cite owing to space limitations. We thank A. Molofsky for comments and M. Jenner for formatting the manuscript. Work in our laboratories is supported by grants from the National Institutes of Health (A. R. K. and D. H. R.) and the California Institute for Regenerative Medicine (A. R. K.). D. H. R. is a Howard Hughes Medical Institute investigator.	Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Anthony TE, 2007, J COMP NEUROL, V500, P368, DOI 10.1002/cne.21179; Barnabe-Heider F, 2005, NEURON, V48, P253, DOI 10.1016/j.neuron.2005.08.037; Battiste J, 2007, DEVELOPMENT, V134, P285, DOI 10.1242/dev.02727; Billiards SS, 2008, BRAIN PATHOL, V18, P153, DOI 10.1111/j.1750-3639.2007.00107.x; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Briscoe J, 2008, PHILOS T R SOC B, V363, P57, DOI 10.1098/rstb.2006.2012; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bylund M, 2003, NAT NEUROSCI, V6, P1162, DOI 10.1038/nn1131; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Campos LS, 2001, J NEUROSCI RES, V64, P590, DOI 10.1002/jnr.1111.abs; Cebolla B, 2006, J NEUROCHEM, V97, P1057, DOI 10.1111/j.1471-4159.2006.03804.x; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Costa MR, 2009, CEREB CORTEX, V19, pI135, DOI 10.1093/cercor/bhp046; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; Deneen B, 2006, NEURON, V52, P953, DOI 10.1016/j.neuron.2006.11.019; Desai AR, 2000, DEVELOPMENT, V127, P2863; Dessaud E, 2007, NATURE, V450, P717, DOI 10.1038/nature06347; Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002; Esain V, 2010, DEVELOPMENT, V137, P33, DOI 10.1242/dev.038026; Fogarty M, 2005, DEVELOPMENT, V132, P1951, DOI 10.1242/dev.01777; Fox IJ, 2005, J NEUROSCI RES, V79, P584, DOI 10.1002/jnr.20381; FREEMAN M, SCIENCE IN PRESS; Fu H, 2009, J NEUROSCI, V29, P11399, DOI 10.1523/JNEUROSCI.0160-09.2009; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gaspard N, 2008, NATURE, V455, P351, DOI 10.1038/nature07287; Genethliou N, 2009, BIOCHEM BIOPH RES CO, V382, P69, DOI 10.1016/j.bbrc.2009.02.134; Ghashghaei HT, 2007, GENE DEV, V21, P3258, DOI 10.1101/gad.1580407; Goldman SA, 2008, HUM MOL GENET, V17, pR76, DOI 10.1093/hmg/ddn052; GRAY GE, 1991, NEURON, V6, P211, DOI 10.1016/0896-6273(91)90357-6; HATTON JD, 1993, GLIA, V9, P113, DOI 10.1002/glia.440090204; Haubensak W, 2004, P NATL ACAD SCI USA, V101, P3196, DOI 10.1073/pnas.0308600100; Hermanson O, 2002, NATURE, V419, P934, DOI 10.1038/nature01156; Herrera J, 2001, EXP NEUROL, V171, P11, DOI 10.1006/exnr.2001.7729; Hirabayashi Y, 2009, NEURON, V63, P600, DOI 10.1016/j.neuron.2009.08.021; Hoch RV, 2009, SEMIN CELL DEV BIOL, V20, P378, DOI 10.1016/j.semcdb.2009.02.005; Hochstim C, 2008, CELL, V133, P510, DOI 10.1016/j.cell.2008.02.046; Itoh M, 2003, DEV CELL, V4, P67, DOI 10.1016/S1534-5807(02)00409-4; Jablonska B, 2010, NAT NEUROSCI, V13, P541, DOI 10.1038/nn.2536; Jacobsen CT, 2003, DEV NEUROSCI-BASEL, V25, P207, DOI 10.1159/000072269; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Karcavich R, 2005, J COMP NEUROL, V481, P240, DOI 10.1002/cne.20371; Kessaris N, 2006, NAT NEUROSCI, V9, P173, DOI 10.1038/nn1620; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; Lee SK, 2005, GENE DEV, V19, P282, DOI 10.1101/gad.1257105; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Lin SC, 2004, NAT NEUROSCI, V7, P24, DOI 10.1038/nn1162; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Mabie PC, 1999, J NEUROSCI, V19, P7077, DOI 10.1523/JNEUROSCI.19-16-07077.1999; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Masahira N, 2006, DEV BIOL, V293, P358, DOI 10.1016/j.ydbio.2006.02.029; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Miyata T, 2004, DEVELOPMENT, V131, P3133, DOI 10.1242/dev.01173; Miyata T, 2001, NEURON, V31, P727, DOI 10.1016/S0896-6273(01)00420-2; Molne M, 2000, J NEUROSCI RES, V59, P301, DOI 10.1002/(SICI)1097-4547(20000201)59:3<301::AID-JNR3>3.0.CO;2-H; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Namihira M, 2009, DEV CELL, V16, P245, DOI 10.1016/j.devcel.2008.12.014; Nery S, 2001, DEVELOPMENT, V128, P527; Nicoll JAR, 2003, TRENDS MOL MED, V9, P281, DOI 10.1016/S1471-4914(03)00109-6; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Noctor SC, 2004, NAT NEUROSCI, V7, P136, DOI 10.1038/nn1172; Noctor SC, 2008, J COMP NEUROL, V508, P28, DOI 10.1002/cne.21669; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Ochiai W, 2001, CYTOKINE, V14, P264, DOI 10.1006/cyto.2001.0883; Orentas DM, 1999, DEVELOPMENT, V126, P2419; Owada Y, 1996, J CHEM NEUROANAT, V12, P113, DOI 10.1016/S0891-0618(96)00192-5; Park HC, 2003, DEVELOPMENT, V130, P3747, DOI 10.1242/dev.00576; Parnavelas JG, 1999, EXP NEUROL, V156, P418, DOI 10.1006/exnr.1999.7044; Parras CM, 2007, J NEUROSCI, V27, P4233, DOI 10.1523/JNEUROSCI.0126-07.2007; Parras CM, 2004, EMBO J, V23, P4495, DOI 10.1038/sj.emboj.7600447; Petryniak MA, 2007, NEURON, V55, P417, DOI 10.1016/j.neuron.2007.06.036; Pringle NP, 2003, DEVELOPMENT, V130, P93, DOI 10.1242/dev.00184; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Raymond CS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000162; Richardson WD, 2006, NAT REV NEUROSCI, V7, P11, DOI 10.1038/nrn1826; Roots BI, 2008, NEURON GLIA BIOL, V4, P101, DOI 10.1017/S1740925X0900012X; Saijo K, 2009, CELL, V137, P47, DOI 10.1016/j.cell.2009.01.038; Sandberg M, 2005, NAT NEUROSCI, V8, P995, DOI 10.1038/nn1493; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Shen Q, 2006, NAT NEUROSCI, V9, P743, DOI 10.1038/nn1694; Shibata T, 1997, J NEUROSCI, V17, P9212; Steele-Perkins G, 2005, MOL CELL BIOL, V25, P685, DOI 10.1128/MCB.25.2.685-698.2005; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Tatsumi K, 2008, J NEUROSCI RES, V86, P3494, DOI 10.1002/jnr.21862; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Ulloa F, 2010, DEV DYNAM, V239, P69, DOI 10.1002/dvdy.22058; Vallstedt A, 2005, NEURON, V45, P55, DOI 10.1016/j.neuron.2004.12.026; WARE CB, 1995, DEVELOPMENT, V121, P1283; Wilczynska KM, 2009, STEM CELLS, V27, P1173, DOI 10.1002/stem.35; Wu S, 2006, DEVELOPMENT, V133, P581, DOI 10.1242/dev.02236; Yang XD, 2006, DEV NEUROSCI-BASEL, V28, P102, DOI 10.1159/000090757; Yoon KJ, 2008, NEURON, V58, P519, DOI 10.1016/j.neuron.2008.03.018; Zalc B, 2000, SCIENCE, V288, P271; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; ZHOU HF, 1992, J COMP NEUROL, V317, P145, DOI 10.1002/cne.903170204; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3; Zong H, 2005, CELL, V121, P479, DOI 10.1016/j.cell.2005.02.012	105	422	427	2	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2010	468	7321					214	222		10.1038/nature09611	http://dx.doi.org/10.1038/nature09611			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068830				2022-12-28	WOS:000284051000038
J	Pulverer, B				Pulverer, Bernd			Transparency showcases strength of peer review	NATURE			English	Editorial Material									[Pulverer, Bernd] European Mol Biol Org, D-69117 Heidelberg, Germany; [Pulverer, Bernd] EMBO Journal, D-69117 Heidelberg, Germany		Pulverer, B (corresponding author), European Mol Biol Org, Meyerhofstr 1, D-69117 Heidelberg, Germany.	bernd.pulverer@embo.org						[Anonymous], 2006, NATURE, V444, P971; PULVERER B, EMBO J IN PRESS, V29; Rorth P, 2009, EMBO J, V28, P1, DOI 10.1038/emboj.2008.250; Smith R, 1999, BRIT MED J, V318, P4; 2007, NATURE CELL BIOL, V9, P1	5	29	29	0	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					29	31		10.1038/468029a	http://dx.doi.org/10.1038/468029a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	674YF	21048742	Bronze			2022-12-28	WOS:000283786900017
J	Kitzman, DW; Rich, MW				Kitzman, Dalane W.; Rich, Michael W.			Age Disparities in Heart Failure Research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRESERVED EJECTION FRACTION; RANDOMIZED CONTROLLED-TRIAL; ASSOCIATION; UPDATE		[Kitzman, Dalane W.] Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; [Rich, Michael W.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA	Wake Forest University; Washington University (WUSTL)	Kitzman, DW (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dkitzman@wfubmc.edu	Rich, Michael/AAD-6167-2022	Rich, Michael/0000-0002-4243-9391	NATIONAL INSTITUTE ON AGING [R01AG018915, R37AG018915, P30AG021332] Funding Source: NIH RePORTER; NIA NIH HHS [R37AG18915, P30 AG021332, P30AG21332, R37 AG018915, R01 AG018915] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Braunstein JB, 2003, J AM COLL CARDIOL, V42, P1226, DOI 10.1016/S0735-1097(03)00947-1; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Heiat A, 2002, ARCH INTERN MED, V162, P1682, DOI 10.1001/archinte.162.15.1682; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Massie BM, 2008, NEW ENGL J MED, V359, P2456, DOI 10.1056/NEJMoa0805450; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282	10	52	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1950	1951		10.1001/jama.2010.1592	http://dx.doi.org/10.1001/jama.2010.1592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674GT	21045104	Green Accepted			2022-12-28	WOS:000283725900028
J	Veldhoen, M; Withers, DR				Veldhoen, Marc; Withers, David R.			Innate Lymphoid Cell Relations	SCIENCE			English	Editorial Material									[Veldhoen, Marc] Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge CB22 3AT, England; [Withers, David R.] Univ Birmingham, Sch Med, Inst Biomed Res, MRC Ctr Immune Regulat, Birmingham B15 2TT, W Midlands, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Birmingham	Veldhoen, M (corresponding author), Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge CB22 3AT, England.	marc.veldhoen@bbsrc.ac.uk	Veldhoen, Marc/AAM-5357-2021; Withers, David/C-7055-2015; Veldhoen, Marc/AAJ-2759-2020	Withers, David/0000-0003-3757-7594; Veldhoen, Marc/0000-0002-1478-9562				Aliahmad P, 2010, NAT IMMUNOL, V11, P945, DOI 10.1038/ni.1930; Bouskra D, 2008, NATURE, V456, P507, DOI 10.1038/nature07450; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Luci C, 2009, NAT IMMUNOL, V10, P75, DOI 10.1038/ni.1681; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Sawa S, 2010, SCIENCE, V330, P665, DOI 10.1126/science.1194597; Tsuji M, 2008, IMMUNITY, V29, P261, DOI 10.1016/j.immuni.2008.05.014	12	11	12	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	2010	330	6004					594	595		10.1126/science.1198298	http://dx.doi.org/10.1126/science.1198298			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030634				2022-12-28	WOS:000283580600022
J	Westerlund, H; Vahtera, J; Ferrie, JE; Singh-Manoux, A; Pentti, J; Melchior, M; Leineweber, C; Jokela, M; Siegrist, J; Goldberg, M; Zins, M; Kivimaki, M				Westerlund, Hugo; Vahtera, Jussi; Ferrie, Jane E.; Singh-Manoux, Archana; Pentti, Jaana; Melchior, Maria; Leineweber, Constanze; Jokela, Markus; Siegrist, Johannes; Goldberg, Marcel; Zins, Marie; Kivimaeki, Mika			Effect of retirement on major chronic conditions and fatigue: French GAZEL occupational cohort study	BRITISH MEDICAL JOURNAL			English	Article							PSYCHOSOCIAL WORK CHARACTERISTICS; MENTAL-HEALTH; DEPRESSIVE SYMPTOMS; SLEEP DISTURBANCES; PHYSICAL HEALTH; NATIONAL-SURVEY; MORTALITY; RISK; POPULATION; TIREDNESS	Objectives To determine, using longitudinal analyses, if retirement is followed by a change in the risk of incident chronic diseases, depressive symptoms, and fatigue. Design Prospective study with repeat measures from 7 years before to 7 years after retirement. Setting Large French occupational cohort (the GAZEL study), 1989-2007. Participants 11 246 men and 2858 women. Main outcome measures Respiratory disease, diabetes, coronary heart disease and stroke, mental fatigue, and physical fatigue, measured annually by self report over the 15 year observation period; depressive symptoms measured at four time points. Results The average number of repeat measurements per participant was 12.1. Repeated measures logistic regression with generalised estimating equations showed that the cumulative prevalence of self reported respiratory disease, diabetes, and coronary heart disease and stroke increased with age, with no break in the trend around retirement. In contrast, retirement was associated with a substantial decrease in the prevalence of both mental fatigue (odds ratio for fatigue one year after versus one year before retirement 0.19, 95% confidence interval 0.18 to 0.21) and physical fatigue (0.27, 0.26 to 0.30). A major decrease was also observed in depressive symptoms (0.60, 0.53 to 0.67). The decrease in fatigue around retirement was more pronounced among people with a chronic disease before retirement. Conclusions Longitudinal modelling of repeat data showed that retirement did not change the risk of major chronic diseases but was associated with a substantial reduction in mental and physical fatigue and depressive symptoms, particularly among people with chronic diseases.	[Westerlund, Hugo; Leineweber, Constanze] Stockholm Univ, Stress Res Inst, SE-10691 Stockholm, Sweden; [Westerlund, Hugo; Ferrie, Jane E.; Singh-Manoux, Archana; Jokela, Markus; Kivimaeki, Mika] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Vahtera, Jussi; Pentti, Jaana; Kivimaeki, Mika] Finnish Inst Occupat Hlth, FI-00250 Helsinki, Finland; [Vahtera, Jussi] Univ Turku, Dept Publ Hlth, FI-20520 Turku, Finland; [Vahtera, Jussi] Turku Univ Hosp, FI-20520 Turku, Finland; [Singh-Manoux, Archana; Melchior, Maria; Goldberg, Marcel; Zins, Marie] INSERM, U1018, F-94807 Villejuif, France; [Singh-Manoux, Archana; Melchior, Maria; Goldberg, Marcel; Zins, Marie] Univ Versailles, St Quentin En Yvelines, France; [Siegrist, Johannes] Univ Dusseldorf, Inst Med Soziol, D-40001 Dusseldorf, Germany	Stockholm University; University of London; University College London; Finnish Institute of Occupational Health; University of Turku; University of Turku; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Heinrich Heine University Dusseldorf	Westerlund, H (corresponding author), Stockholm Univ, Stress Res Inst, SE-10691 Stockholm, Sweden.	hugo.westerlund@stress.su.se	Singh-Manoux, Archana/F-6804-2013; Ferrie, Jane/AAZ-2009-2020; Goldberg, Marcel/I-7834-2012; Vahtera, Jussi/J-3271-2013; Zins, Marie/AAX-6551-2021; Leineweber, Constanze/G-7052-2012; Siegrist, Johannes/AAL-6814-2021; Melchior, Maria/E-3992-2017; Jokela, Markus/A-4669-2009; Kivimaki, Mika/B-3607-2012; Westerlund, Hugo/A-3049-2012; Leineweber, Constanze/Z-1330-2019	Singh-Manoux, Archana/0000-0002-1244-5037; Goldberg, Marcel/0000-0002-6161-5880; Leineweber, Constanze/0000-0001-8433-2405; Siegrist, Johannes/0000-0002-7530-4178; Jokela, Markus/0000-0003-0117-0012; Kivimaki, Mika/0000-0002-4699-5627; Westerlund, Hugo/0000-0002-8806-5698; 	Swedish Council for Working Life and Social Research [2004-2021, 2007-1143, 2009-1758]; Academy of Finland [124271, 124322, 129262, 132944]; BUPA Foundation UK; National Institutes of Health/National Heart, Lung, and Blood Institute (NIH) [R01HL036310-20A2]; National Institute on Aging, NIH [R01AG013196, R01AG034454]; European Science Foundation; ESRC [RES-451-26-0491]; Agence nationale de la recherche (ANR); Agence francaise de securite sanitaire de l'environnement et du travail (AFSSET); Academy of Finland; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196, R01AG034454] Funding Source: NIH RePORTER; Economic and Social Research Council [RES-451-26-0491] Funding Source: researchfish	Swedish Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Academy of Finland(Academy of Finland); BUPA Foundation UK; National Institutes of Health/National Heart, Lung, and Blood Institute (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); European Science Foundation(European Science Foundation (ESF)European Commission); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Agence nationale de la recherche (ANR)(French National Research Agency (ANR)); Agence francaise de securite sanitaire de l'environnement et du travail (AFSSET); Academy of Finland(Academy of Finland); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	HW and CL are supported by the Swedish Council for Working Life and Social Research (FAS, grants #2004-2021, #2007-1143, and #2009-1758), JV and MK are supported by the Academy of Finland (grants #124271, #124322, #129262, and #132944), MK is additionally supported by a BUPA Foundation UK specialist research grant and the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH) (R01HL036310-20A2). MK and AS-M are supported by the National Institute on Aging, NIH (R01AG013196; R01AG034454); AS-M is also supported by a EUYRI award from the European Science Foundation. This work was additionally supported by a grant from the ESRC Research Seminar Series Competition 2007/8 (RES-451-26-0491). The GAZEL Cohort Study was funded by EDF-GDF and INSERM and received grants from the "Cohortes Sante TGIR Program," Agence nationale de la recherche (ANR), and Agence francaise de securite sanitaire de l'environnement et du travail (AFSSET). The study sponsors did not contribute to the study design and had no role in the conduct of the study, data collection, data management, data analysis, or interpretation of the data, nor in the preparation, review, or approval of the manuscript.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) regarding the submitted work HW and CL have support from the Swedish Council for Working Life and Social Research (FAS); JV and MK have support from the Academy of Finland; MK has additional support from the BU PA Foundation, UK; MK and AS-M also have support from the National Institutes of Health (NIH), USA; AS-M has additional support from the European Science Foundation (ESF); JF and all other authors except JS have additional support from ESRC, UK; MG and MZ have additional support from the Institut de recherche en sante publique (INSERM) and Caisse centrale d'action sociale, France; and JS had support from Agence nationale de la recherche (ANR), France; (2) none of the authors have any relationships with any company or organisation that might have an interest in the submitted work in the previous 3 years; (3) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (4) the authors have no non-financial interests that may be relevant to the submitted work."	Alavinia SM, 2008, INT ARCH OCC ENV HEA, V82, P39, DOI 10.1007/s00420-008-0304-6; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Avlund K, 1998, J CLIN EPIDEMIOL, V51, P323, DOI 10.1016/S0895-4356(97)00296-5; BOSSE R, 1987, PSYCHOL AGING, V2, P383, DOI 10.1037/0882-7974.2.4.383; Bultmann U, 2002, INT ARCH OCC ENV HEA, V75, P259, DOI 10.1007/s00420-001-0294-0; Butterworth P, 2006, SOC SCI MED, V62, P1179, DOI 10.1016/j.socscimed.2005.07.013; Buxton JW, 2005, SOC PSYCH PSYCH EPID, V40, P99, DOI 10.1007/s00127-005-0866-5; De Lange AH, 2009, J SLEEP RES, V18, P374, DOI 10.1111/j.1365-2869.2009.00735.x; De Raeve L, 2007, J OCCUP ENVIRON MED, V49, P890, DOI 10.1097/JOM.0b013e31811eadd3; Doyle Y, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3926; Drentea P, 2002, J AGING HEALTH, V14, P167, DOI 10.1177/089826430201400201; EKERDT DJ, 1983, AM J PUBLIC HEALTH, V73, P779, DOI 10.2105/AJPH.73.7.779; Evenson KR, 2002, AM J EPIDEMIOL, V155, P692, DOI 10.1093/aje/155.8.692; Fahlen G, 2006, INT ARCH OCC ENV HEA, V79, P371, DOI 10.1007/s00420-005-0063-6; FUHRER R, 1989, Psychiatrie and Psychobiologie, V4, P163; Gall TL, 1997, J GERONTOL B-PSYCHOL, V52, pP110, DOI 10.1093/geronb/52B.3.P110; Goldberg M, 2001, AM J EPIDEMIOL, V154, P373, DOI 10.1093/aje/154.4.373; Goldberg M, 2007, INT J EPIDEMIOL, V36, P32, DOI 10.1093/ije/dyl247; Goldberg M, 2006, J CLIN EPIDEMIOL, V59, P1213, DOI 10.1016/j.jclinepi.2006.02.020; Goldberg P, 2001, J EPIDEMIOL COMMUN H, V55, P233, DOI 10.1136/jech.55.4.233; Gump BB, 2005, STROKE, V36, P98, DOI 10.1161/01.STR.0000149626.50127.d0; Hanson LLM, 2009, INT ARCH OCC ENV HEA, V82, P951, DOI 10.1007/s00420-009-0406-9; Hardy SE, 2008, J AM GERIATR SOC, V56, P1910, DOI 10.1111/j.1532-5415.2008.01957.x; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; Jokela M, 2010, EPIDEMIOLOGY, V21, P284, DOI 10.1097/EDE.0b013e3181d61f53; Mein G, 2003, J EPIDEMIOL COMMUN H, V57, P46, DOI 10.1136/jech.57.1.46; Melamed S, 2006, PSYCHOL BULL, V132, P327, DOI 10.1037/0033-2909.132.3.327; Melchior M, 2009, AM J PUBLIC HEALTH, V99, P1417, DOI 10.2105/AJPH.2008.142273; Metzger MH, 2002, J CLIN EPIDEMIOL, V55, P48, DOI 10.1016/S0895-4356(01)00409-7; Mojon-Azzi S, 2007, SWISS MED WKLY, V137, P581; Moncrieff G, 2007, BRIT MED J, V334, P1221, DOI 10.1136/bmj.39182.615405.94; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rothman KJ, 2002, EPIDEMIOLOGY INTRO; Vahtera J, 2009, SLEEP, V32, P1459, DOI 10.1093/sleep/32.11.1459; van Solinge H, 2007, RES AGING, V29, P225, DOI 10.1177/0164027506298223; Villamil E, 2006, PSYCHOL MED, V36, P999, DOI 10.1017/S0033291706007719; VOGEL J, 2006, HEALTHIER SOC ANAL A, P267; Westerlund H, 2009, LANCET, V374, P1889, DOI 10.1016/S0140-6736(09)61570-1	38	149	150	0	31	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	NOV 23	2010	341								c6149	10.1136/bmj.c6149	http://dx.doi.org/10.1136/bmj.c6149			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	688DV	21098617	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000284830900010
J	Okie, S				Okie, Susan			A Flood of Opioids, a Rising Tide of Deaths	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; OVERDOSE		Georgetown Univ, Sch Med, Washington, DC 20057 USA	Georgetown University	Okie, S (corresponding author), Georgetown Univ, Sch Med, Washington, DC 20057 USA.							[Anonymous], 2010, MMWR MORB MORTAL WKL, V59, P705; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; *SUBST AB MENT HLT, SUBST AB TREATM ADM	5	635	645	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					1981	1985		10.1056/NEJMp1011512	http://dx.doi.org/10.1056/NEJMp1011512			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KC	21083382				2022-12-28	WOS:000284310000001
J	Bertero, MG; Verschueren, E; Paetzold, B; Serrrano, L				Bertero, Michela G.; Verschueren, Erik; Paetzold, Bernhard; Serrrano, Luis			ENHANCED SnapShot: Macromolecular Machines	CELL			English	Editorial Material									[Bertero, Michela G.; Verschueren, Erik; Paetzold, Bernhard; Serrrano, Luis] Univ Pompeu Fabra, Ctr Genom Regulat, Barcelona 08003, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG)	Bertero, MG (corresponding author), Univ Pompeu Fabra, Ctr Genom Regulat, Barcelona 08003, Spain.		verschueren, erik/D-4436-2015	verschueren, erik/0000-0001-5842-6344; Bertero, Michela/0000-0002-2012-6706; Paetzold, Bernhard/0000-0003-3882-9036				Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750	3	0	0	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 12	2010	143	4							652.e1	10.1016/j.cell.2010.10.035	http://dx.doi.org/10.1016/j.cell.2010.10.035			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	679GF	21074054	Bronze			2022-12-28	WOS:000284149100022
J	van Gent, WB; Wilschut, ED; Wittens, C				van Gent, Wijnand Bert; Wilschut, Esther Dorine; Wittens, Cees			Management of venous ulcer disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INCOMPETENT PERFORATING VEINS; LEG ULCERS; SURGERY; RECURRENCE; ABLATION		[van Gent, Wijnand Bert; Wilschut, Esther Dorine] Groene Hart Hosp, Dept Vasc Surg, NL-2800 BB Gouda, Netherlands; [Wittens, Cees] Eur Vasc Ctr Aachen-Maastricht, Maastricht, Germany	Maastricht University; Maastricht University Medical Centre (MUMC)	van Gent, WB (corresponding author), Groene Hart Hosp, Dept Vasc Surg, NL-2800 BB Gouda, Netherlands.	wbvangent@yahoo.com						Amsler F, 2010, J VASC SURG, V51, P289; BERGAN JJ, 2006, SCIENCE, V355, P488; Bianchi C, 2003, J VASC SURG, V38, P67, DOI 10.1016/S0741-5214(03)00472-5; BURNAND KG, 1982, BMJ-BRIT MED J, V285, P1071, DOI 10.1136/bmj.285.6348.1071; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; Coleridge-Smith P, 2006, EUR J VASC ENDOVASC, V31, P83, DOI 10.1016/j.ejvs.2005.07.019; Etufugh CN, 2007, CLIN DERMATOL, V25, P121, DOI 10.1016/j.clindermatol.2006.09.004; Ghauri ASK, 2000, BRIT J SURG, V87, P1048, DOI 10.1046/j.1365-2168.2000.01491.x; GOHEL MS, 2007, BMJ-BRIT MED J, V335, P55; HOMANS J, 1917, SURG GYNECOL OBSTET, V24, P300; MAYBERRY JC, 1991, SURGERY, V109, P575; Nelson EA, 2000, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD002303; Nelzen O, 2007, EUR J VASC ENDOVASC, V34, P605, DOI 10.1016/j.ejvs.2007.07.007; Nelzen O, 2000, PHLEBOLOGY, V15, P110, DOI 10.1007/s005230070005; O'Meara S, 2009, COCHRANE DB SYST REV, V1, P1; O'Meara S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003557.pub3; O'Meara S, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1344; Palfreyman SJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001103.pub2; Pappas PJ, 2009, EUR J VASC ENDOVASC, V38, P518, DOI 10.1016/j.ejvs.2009.05.012; PHILLIPS T, 1994, J AM ACAD DERMATOL, V31, P49, DOI 10.1016/S0190-9622(94)70134-2; Pierik EGJM, 1997, J VASC SURG, V26, P49, DOI 10.1016/S0741-5214(97)70146-0; Purwins S, 2010, INT WOUND J, V7, P97, DOI 10.1111/j.1742-481X.2010.00660.x; Reichenberg J, 2005, SEMIN CUTAN MED SURG, V24, P216, DOI 10.1016/j.sder.2005.10.002; Roka F, 2006, J VASC SURG, V44, P359, DOI 10.1016/j.jvs.2006.04.028; TenBrook JA, 2004, J VASC SURG, V39, P583, DOI 10.1016/j.jvs.2003.09.017; Ting ACW, 2006, J VASC SURG, V43, P546, DOI 10.1016/j.jvs.2005.11.020; van Gent WB, 2006, J VASC SURG, V44, P563, DOI 10.1016/j.jvs.2006.04.053; WILKINSON EA, 2000, COCHRANE DB SYST REV, V2	28	41	43	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2010	341								c6045	10.1136/bmj.c6045	http://dx.doi.org/10.1136/bmj.c6045			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KU	21075818				2022-12-28	WOS:000284313900007
J	Capewell, S; Lloyd-Jones, DM				Capewell, Simon; Lloyd-Jones, Donald M.			Optimal Cardiovascular Prevention Strategies for the 21st Century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEART-DISEASE MORTALITY		[Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Lloyd-Jones, Donald M.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Cardiol, Chicago, IL 60611 USA; [Capewell, Simon] Univ Liverpool, Div Publ Hlth, Liverpool L69 3BX, Merseyside, England	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Liverpool	Lloyd-Jones, DM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Ste 1400, Chicago, IL 60611 USA.	dlj@northwestern.edu	Lloyd-Jones, Donald M/C-5899-2009	Lloyd-Jones, Donald/0000-0003-0847-6110	Medical Research Council [G0500920] Funding Source: Medline; MRC [G0500920] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bibbins-Domingo K, 2010, NEW ENGL J MED, V362, P590, DOI 10.1056/NEJMoa0907355; Capewell S, 2010, B WORLD HEALTH ORGAN, V88, P120, DOI 10.2471/BLT.08.057885; Ford ES, 2007, J AM COLL CARDIOL, V50, P2128, DOI 10.1016/j.jacc.2007.05.056; Lloyd-Jones DM, 2006, CIRCULATION, V113, P791, DOI 10.1161/CIRCULATIONAHA.105.548206; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703; National Institute for Health and Clinical Excellence, 2010, NICE PUBL HLTH GUID; Puska P, 1998, B WORLD HEALTH ORGAN, V76, P419; Rose G., 1992, STRATEGY PREVENTIVE; Zatonski W, 2008, EUR J EPIDEMIOL, V23, P3, DOI 10.1007/s10654-007-9195-1	10	30	32	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2010	304	18					2057	2058		10.1001/jama.2010.1641	http://dx.doi.org/10.1001/jama.2010.1641			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	677OB	21063015				2022-12-28	WOS:000284000600025
J	Freeman, MR				Freeman, Marc R.			Specification and Morphogenesis of Astrocytes	SCIENCE			English	Review							NEURAL PRECURSOR CELLS; DENDRITIC SPINE MORPHOLOGY; NEURONAL DIFFERENTIATION; PROTOPLASMIC ASTROCYTES; GLUTAMATE TRANSPORT; SUPERIOR COLLICULUS; STEM-CELLS; GLIA; BRAIN; DOMAINS	Astrocytes are the most abundant cell type in the mammalian brain. Interest in astrocyte function has increased dramatically in recent years because of their newly discovered roles in synapse formation, maturation, efficacy, and plasticity. However, our understanding of astrocyte development has lagged behind that of other brain cell types. We do not know the molecular mechanism by which astrocytes are specified, how they grow to assume their complex morphologies, and how they interact with and sculpt developing neuronal circuits. Recent work has provided a basic understanding of how intrinsic and extrinsic mechanisms govern the production of astrocytes from precursor cells and the generation of astrocyte diversity. Moreover, new studies of astrocyte morphology have revealed that mature astrocytes are extraordinarily complex, interact with many thousands of synapses, and tile with other astrocytes to occupy unique spatial domains in the brain. A major challenge for the field is to understand how astrocytes talk to each other, and to neurons, during development to establish appropriate astrocytic and neuronal network architectures.	Univ Massachusetts, Sch Med, Dept Neurobiol, Howard Hughes Med Inst, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Freeman, MR (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Howard Hughes Med Inst, Worcester, MA 01605 USA.	marc.freeman@umassmed.edu		Freeman, Marc/0000-0003-3481-3715	NIH [NS053538]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053538, R37NS053538] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	M. R. F. is supported by NIH grant NS053538 and is a Howard Hughes Medical Institute Early Career Scientist.	Barnabe-Heider F, 2005, NEURON, V48, P253, DOI 10.1016/j.neuron.2005.08.037; Benediktsson AM, 2005, J NEUROSCI METH, V141, P41, DOI 10.1016/j.jneumeth.2004.05.013; Bushong EA, 2004, INT J DEV NEUROSCI, V22, P73, DOI 10.1016/j.ijdevneu.2003.12.008; Bushong EA, 2002, J NEUROSCI, V22, P183, DOI 10.1523/JNEUROSCI.22-01-00183.2002; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Carmona MA, 2009, P NATL ACAD SCI USA, V106, P12524, DOI 10.1073/pnas.0903328106; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Deneen B, 2006, NEURON, V52, P953, DOI 10.1016/j.neuron.2006.11.019; Doherty J, 2009, J NEUROSCI, V29, P4768, DOI 10.1523/JNEUROSCI.5951-08.2009; Doyle JP, 2008, CELL, V135, P749, DOI 10.1016/j.cell.2008.10.029; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Fu H, 2009, J NEUROSCI, V29, P11399, DOI 10.1523/JNEUROSCI.0160-09.2009; Genoud C, 2006, PLOS BIOL, V4, P2057, DOI 10.1371/journal.pbio.0040343; Halassa MM, 2007, J NEUROSCI, V27, P6473, DOI 10.1523/JNEUROSCI.1419-07.2007; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; Hirabayashi Y, 2009, NEURON, V63, P600, DOI 10.1016/j.neuron.2009.08.021; Hirrlinger J, 2004, EUR J NEUROSCI, V20, P2235, DOI 10.1111/j.1460-9568.2004.03689.x; Hochstim C, 2008, CELL, V133, P510, DOI 10.1016/j.cell.2008.02.046; Israsena N, 2004, DEV BIOL, V268, P220, DOI 10.1016/j.ydbio.2003.12.024; Kawai H, 2001, GLIA, V36, P406, DOI 10.1002/glia.1126; Lovatt D, 2007, J NEUROSCI, V27, P12255, DOI 10.1523/JNEUROSCI.3404-07.2007; LUND RD, 1972, BRAIN RES, V42, P1, DOI 10.1016/0006-8993(72)90038-8; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Lushnikova I, 2009, HIPPOCAMPUS, V19, P753, DOI 10.1002/hipo.20551; Miller FD, 2007, NEURON, V54, P357, DOI 10.1016/j.neuron.2007.04.019; Morrow T, 2001, DEVELOPMENT, V128, P3585; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; Naka H, 2008, NAT NEUROSCI, V11, P1014, DOI 10.1038/nn.2168; Namihira M, 2009, DEV CELL, V16, P245, DOI 10.1016/j.devcel.2008.12.014; Nestor MW, 2007, J NEUROSCI, V27, P12817, DOI 10.1523/JNEUROSCI.2442-07.2007; Nimmerjahn A, 2009, NEURON, V62, P400, DOI 10.1016/j.neuron.2009.03.019; Nimmerjahn A, 2009, J PHYSIOL-LONDON, V587, P1639, DOI 10.1113/jphysiol.2008.167171; Nishida H, 2007, J NEUROSCI, V27, P331, DOI 10.1523/JNEUROSCI.4466-06.2007; Oberheim NA, 2008, J NEUROSCI, V28, P3264, DOI 10.1523/JNEUROSCI.4980-07.2008; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Ogata K, 2002, NEUROSCIENCE, V113, P221, DOI 10.1016/S0306-4522(02)00041-6; Petzold GC, 2008, NEURON, V58, P897, DOI 10.1016/j.neuron.2008.04.029; Regan MR, 2007, J NEUROSCI, V27, P6607, DOI 10.1523/JNEUROSCI.0790-07.2007; Schools GP, 1999, J NEUROSCI RES, V58, P533, DOI 10.1002/(SICI)1097-4547(19991115)58:4<533::AID-JNR6>3.0.CO;2-G; Shaham S, 2006, CURR OPIN NEUROBIOL, V16, P522, DOI 10.1016/j.conb.2006.08.001; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Takahashi M, 2002, DEVELOPMENT, V129, P1327; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Theodosis DT, 2008, PHYSIOL REV, V88, P983, DOI 10.1152/physrev.00036.2007; Ullian EM, 2004, GLIA, V47, P209, DOI 10.1002/glia.20082; Verkhratsky A, 2000, BRAIN RES REV, V32, P380, DOI 10.1016/S0165-0173(99)00093-4; Wang XH, 2006, NAT NEUROSCI, V9, P816, DOI 10.1038/nn1703; WARTON SS, 1989, SYNAPSE, V3, P136, DOI 10.1002/syn.890030205; WENZEL J, 1991, BRAIN RES, V560, P122, DOI 10.1016/0006-8993(91)91222-M; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Yang Yongjie, 2009, P69, DOI 10.1007/978-0-387-79492-1_4; Zhou CJ, 2006, NEUROSCIENCE, V142, P1119, DOI 10.1016/j.neuroscience.2006.07.007	53	252	262	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					774	778		10.1126/science.1190928	http://dx.doi.org/10.1126/science.1190928			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051628	Green Accepted			2022-12-28	WOS:000283855700031
J	Hosono, N; Kajitani, T; Fukushima, T; Ito, K; Sasaki, S; Takata, M; Aida, T				Hosono, Nobuhiko; Kajitani, Takashi; Fukushima, Takanori; Ito, Kazuki; Sasaki, Sono; Takata, Masaki; Aida, Takuzo			Large-Area Three-Dimensional Molecular Ordering of a Polymer Brush by One-Step Processing	SCIENCE			English	Article							LIQUID-CRYSTALS; PHOTOIRRADIATION; FILMS; ALIGNMENT; GROWTH; LIGHT	Rational molecular design and processing, enabling large-area molecular ordering, are important for creating high-performance organic materials and devices. We show that, upon one-step hot-pressing with uniaxially stretched Teflon sheets, a polymer brush carrying azobenzene-containing mesogenic side chains self-assembles into a freestanding film, where the polymer backbone aligns homeotropically to the film plane and the side chains align horizontally. Such an ordered structure forms through translation of a one-dimensional molecular order of the Teflon sheet and propagates from the interface macroscopically on both sides of the film. The resultant wide-area bimorph configuration allows the polymer film to bend rapidly and reversibly when the azobenzene units are photoisomerized. The combination of polymer brushes with hot-pressing and Teflon sheets provides many possibilities in designing functional soft materials.	[Hosono, Nobuhiko; Kajitani, Takashi; Fukushima, Takanori; Aida, Takuzo] RIKEN Adv Sci Inst, Wako, Saitama 3510198, Japan; [Hosono, Nobuhiko; Aida, Takuzo] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Ito, Kazuki; Takata, Masaki] RIKEN SPring 8 Ctr, Sayo, Hyogo 6795198, Japan; [Sasaki, Sono; Takata, Masaki] Japan Synchrotron Radiat Res Inst JASRI, Sayo, Hyogo 6795198, Japan	RIKEN; University of Tokyo; RIKEN; Japan Synchrotron Radiation Research Institute	Fukushima, T (corresponding author), RIKEN Adv Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	fukushima@riken.jp; aida@macro.t.u-tokyo.ac.jp	Hosono, Nobuhiko/L-7635-2017; Aida, Takuzo/I-9117-2012; Ito, Kazuki/A-8776-2015; Kajitani, Takashi/C-9775-2015; Takata, Masaki/M-1525-2014; Fukushima, Takanori/D-2474-2015	Hosono, Nobuhiko/0000-0002-4145-0046; Ito, Kazuki/0000-0002-8550-6937; Kajitani, Takashi/0000-0001-9814-654X; Fukushima, Takanori/0000-0001-5586-9238	Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science, and Technology, Japan [21350108]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank D. Hashizume (RIKEN) for his helpful discussion on x-ray analysis. N.H. thanks the RIKEN Junior Research Associate Fellowship and the Japan Society for the Promotion of Science Young Scientist Fellowship. T. F. is thankful to the Ministry of Education, Culture, Sports, Science, and Technology, Japan, for financial support (21350108). The synchrotron x-ray diffraction experiments were performed at the BL45XU in the SPring-8 with the approval of the RIKEN SPring-8 Center (proposal 20090053).	Camacho-Lopez M, 2004, NAT MATER, V3, P307, DOI 10.1038/nmat1118; Dziezok P, 1997, ANGEW CHEM INT EDIT, V36, P2812, DOI 10.1002/anie.199728121; Finkelmann H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.015501; Gearba RI, 2007, ADV MATER, V19, P815, DOI 10.1002/adma.200602460; Gupta VK, 1997, SCIENCE, V276, P1533, DOI 10.1126/science.276.5318.1533; Hugel T, 2002, SCIENCE, V296, P1103, DOI 10.1126/science.1069856; IKEDA T, 1995, SCIENCE, V268, P1873, DOI 10.1126/science.268.5219.1873; Ikeda T, 2007, ANGEW CHEM INT EDIT, V46, P506, DOI 10.1002/anie.200602372; Irie M, 2001, SCIENCE, V291, P1769, DOI 10.1126/science.291.5509.1769; JEROME B, 1998, HDB LIQUID CRYSTALS, V1, pCH10; Kobatake S, 2007, NATURE, V446, P778, DOI 10.1038/nature05669; Koshima H, 2009, J AM CHEM SOC, V131, P6890, DOI 10.1021/ja8098596; KUMAR GS, 1989, CHEM REV, V89, P1915, DOI 10.1021/cr00098a012; SCHNEIDER F, 1998, HDB LIQUID CRYSTALS, V1, pCH8; Sheiko SS, 2008, PROG POLYM SCI, V33, P759, DOI 10.1016/j.progpolymsci.2008.05.001; van de Craats AM, 2003, ADV MATER, V15, P495, DOI 10.1002/adma.200390114; van Hameren R, 2006, SCIENCE, V314, P1433, DOI 10.1126/science.1133004; van Oosten CL, 2009, NAT MATER, V8, P677, DOI [10.1038/NMAT2487, 10.1038/nmat2487]; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; WITTMANN JC, 1991, NATURE, V352, P414, DOI 10.1038/352414a0; Yu YL, 2003, NATURE, V425, P145, DOI 10.1038/425145a; Zhang MF, 2005, J POLYM SCI POL CHEM, V43, P3461, DOI 10.1002/pola.20900; Zhang SM, 2010, NAT MATER, V9, P594, DOI [10.1038/NMAT2778, 10.1038/nmat2778]; [No title captured]	24	140	144	1	214	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2010	330	6005					808	811		10.1126/science.1195302	http://dx.doi.org/10.1126/science.1195302			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	675SY	21051635				2022-12-28	WOS:000283855700039
J	Schwab, SA; Janka, R				Schwab, Siegfried A.; Janka, Rolf			Calcified Object in the Mid-Maxilla.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Schwab, Siegfried A.; Janka, Rolf] Univ Erlangen Nurnberg, Erlangen, Germany	University of Erlangen Nuremberg	Schwab, SA (corresponding author), Univ Erlangen Nurnberg, Erlangen, Germany.	siegfried.schwab@uk-erlangen.de		Janka, Rolf/0000-0003-1698-9741					0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1846	1846		10.1056/NEJMicm0801240	http://dx.doi.org/10.1056/NEJMicm0801240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047228				2022-12-28	WOS:000283787800009
J	Evers, ACC; Brouwers, HAA; Hukkelhoven, CWPM; Nikkels, PGJ; Boon, J; van Egmond-Linden, A; Hillegersberg, J; Snuif, YS; Sterken-Hooisma, S; Bruinse, HW; Kwee, A				Evers, Annemieke C. C.; Brouwers, Hens A. A.; Hukkelhoven, Chantal W. P. M.; Nikkels, Peter G. J.; Boon, Janine; van Egmond-Linden, Anneke; Hillegersberg, Jacqueline; Snuif, Yvette S.; Sterken-Hooisma, Sietske; Bruinse, Hein W.; Kwee, Anneke			Perinatal mortality and severe morbidity in low and high risk term pregnancies in the Netherlands: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							CARE; HEALTH; EUROPE; INDICATORS; BIRTHS; FETAL	Objective To compare incidences of perinatal mortality and severe perinatal morbidity between low risk term pregnancies supervised in primary care by a midwife and high risk pregnancies supervised in secondary care by an obstetrician. Design Prospective cohort study using aggregated data from a national perinatal register. Setting Catchment area of the neonatal intensive care unit (NICU) of the University Medical Center in Utrecht, a region in the centre of the Netherlands covering 13% of the Dutch population. Participants Pregnant women at 37 weeks' gestation or later with a singleton or twin pregnancy without congenital malformations. Main outcome measures Perinatal death (antepartum, intrapartum, and neonatal) or admission to a level 3 NICU. Results During the study period 37 735 normally formed infants were delivered at 37 weeks' gestation or later. Sixty antepartum stillbirths (1.59 (95% confidence interval 1.19 to 1.99) per 1000 babies delivered), 22 intrapartum stillbirths (0.58 (0.34 to 0.83) per 1000 babies delivered), and 210 NICU admissions (5.58 (4.83 to 6.33) per 1000 live births) occurred, of which 17 neonates died (0.45 (0.24 to 0.67) per 1000 live births). The overall perinatal death rate was 2.62 (2.11 to 3.14) per 1000 babies delivered and was significantly higher for nulliparous women compared with multiparous women (relative risk 1.65, 95% confidence interval 1.11 to 2.45). Infants of pregnant women at low risk whose labour started in primary care under the supervision of a midwife had a significant higher risk of delivery related perinatal death than did infants of pregnant women at high risk whose labour started in secondary care under the supervision of an obstetrician (relative risk 2.33, 1.12 to 4.83). NICU admission rates did not differ between pregnancies supervised by a midwife and those supervised by an obstetrician. Infants of women who were referred by a midwife to an obstetrician during labour had a 3.66 times higher risk of delivery related perinatal death than did infants of women who started labour supervised by an obstetrician (relative risk 3.66, 1.58 to 8.46) and a 2.5-fold higher risk of NICU admission (2.51, 1.87 to 3.37). Conclusions Infants of pregnant women at low risk whose labour started in primary care under the supervision of a midwife in the Netherlands had a higher risk of delivery related perinatal death and the same risk of admission to the NICU compared with infants of pregnant women at high risk whose labour started in secondary care under the supervision of an obstetrician. An important limitation of the study is that aggregated data of a large birth registry database were used and adjustment for confounders and clustering was not possible. However, the findings are unexpected and the obstetric care system of the Netherlands needs further evaluation.	[Evers, Annemieke C. C.; Bruinse, Hein W.; Kwee, Anneke] Univ Med Ctr Utrecht, Dept Obstet, NL-3584 EA Utrecht, Netherlands; [Brouwers, Hens A. A.] Univ Med Ctr Utrecht, Dept Neonatol, NL-3584 EA Utrecht, Netherlands; [Hukkelhoven, Chantal W. P. M.] Netherlands Perinatal Registry, Utrecht, Netherlands; [Nikkels, Peter G. J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3584 EA Utrecht, Netherlands; [Boon, Janine] Diakonessenhosp, Dept Obstet & Gynaecol, Utrecht, Netherlands; [van Egmond-Linden, Anneke] Zuwe Hofpoort Hosp, Dept Obstet & Gynaecol, Woerden, Netherlands; [Hillegersberg, Jacqueline] St Antonius Hosp, Dept Pediat, Nieuwegein, Netherlands; [Snuif, Yvette S.] Admiraal de Ruyter Hosp, Dept Obstet & Gynaecol, Goes, Netherlands; [Sterken-Hooisma, Sietske] Meander Med Ctr, Dept Obstet & Gynaecol, Amersfoort, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Diakonessenhuis; St. Antonius Hospital Utrecht; Meander Medisch Centrum	Evers, ACC (corresponding author), Univ Med Ctr Utrecht, Dept Obstet, NL-3584 EA Utrecht, Netherlands.	a.evers@umcutrecht.nl		Hukkelhoven, Chantal/0000-0002-0015-1883				Achterberg P. W., 2005, MEASURING BEST INT D; Amelink-Verburg MP, 2008, BJOG-INT J OBSTET GY, V115, P570, DOI 10.1111/j.1471-0528.2007.01580.x; Anthony S, 2009, PAEDIATR PERINAT EP, V23, P292, DOI 10.1111/j.1365-3016.2009.01044.x; Buitendijk S, 2003, EUR J OBSTET GYN R B, V111, pS66, DOI 10.1016/j.ejogrb.2003.09.007; Buitendijk S E, 2004, Ned Tijdschr Geneeskd, V148, P1855; College voor Zorgverzekeringen, 2003, VERL VAD 2003; de Jonge A, 2009, BJOG-INT J OBSTET GY, V116, P1177, DOI 10.1111/j.1471-0528.2009.02175.x; Merkus J M W M, 2008, Ned Tijdschr Geneeskd, V152, P2707; Mohangoo A D, 2008, Ned Tijdschr Geneeskd, V152, P2718; Ravelli A C J, 2008, Ned Tijdschr Geneeskd, V152, P2728; Richardus JH, 2003, BJOG-INT J OBSTET GY, V110, P97; Wildman K, 2003, EUR J OBSTET GYN R B, V111, pS53, DOI 10.1016/j.ejogrb.2003.09.006; Zeitlin J, 2009, J EPIDEMIOL COMMUN H, V63, P681, DOI 10.1136/jech.2009.087296	13	100	101	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 2	2010	341								c5639	10.1136/bmj.c5639	http://dx.doi.org/10.1136/bmj.c5639			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CU	21045050	hybrid			2022-12-28	WOS:000284048200001
J	McCulloch, P; Kreckler, S; New, S; Sheena, Y; Handa, A; Catchpole, K				McCulloch, Peter; Kreckler, Simon; New, Steve; Sheena, Yezen; Handa, Ashok; Catchpole, Ken			Quality Improvement Report Effect of a "Lean" intervention to improve safety processes and outcomes on a surgical emergency unit	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TOYOTA PRODUCTION SYSTEM; ADVERSE EVENTS; HOSPITALIZED-PATIENTS; PATIENT SAFETY; CARE; MISSES		[McCulloch, Peter; Catchpole, Ken] Univ Oxford, Nuffield Dept Surg, QRSTU, Oxford OX3 9DU, England; [Kreckler, Simon; New, Steve] Univ Oxford, Said Business Sch, Oxford OX3 9DU, England	University of Oxford; University of Oxford	McCulloch, P (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Surg, QRSTU, Oxford OX3 9DU, England.	peter.mcculloch@nds.ox.ac.uk	Catchpole, Ken/A-6149-2008	Catchpole, Ken/0000-0003-4073-3025; McCulloch, Peter/0000-0002-3210-8273; New, Steve/0000-0002-0350-7902				Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; Balas MC, 2004, APPL NURS RES, V17, P224, DOI 10.1016/j.apnr.2004.09.002; Berwick Donald, 2005, Mod Healthc, V35, P18; BICHENO J., 2008, LEAN TOOLBOX ESSENTI; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Burkitt KH, 2009, AM J MANAG CARE, V15, P633; Catchpole KR, 2007, SURGERY, V142, P102, DOI 10.1016/j.surg.2007.01.033; Chalice R, 2007, IMPROVING HEALTHCARE; Collins K.F., 2007, QUALITY MANAGEMENT J, V14, P41, DOI 10.1080/10686967.2007.11918045; Condel JL, 2004, CLIN LAB MED, V24, P865, DOI 10.1016/j.cll.2004.07.001; Davis P., 2002, NZ MED J, V115, pU271; de Leval MR, 2000, J THORAC CARDIOV SUR, V119, P661, DOI 10.1016/S0022-5223(00)70006-7; Deming EW., 1986, OUT CRISIS; Dickson EW, 2009, ANN EMERG MED, V54, P504, DOI 10.1016/j.annemergmed.2009.03.024; Dickson EW, 2009, J EMERG MED, V37, P177, DOI 10.1016/j.jemermed.2007.11.108; Fillingham D, 2007, LEADERSH HEALTH SERV, V20, P231, DOI 10.1108/17511870710829346; Furman C, 2007, JT COMM J QUAL PATIE, V33, P376, DOI 10.1016/S1553-7250(07)33043-2; Gawande AA, 1999, SURGERY, V126, P66, DOI 10.1067/msy.1999.98664; Jeffs L, 2009, J NURS CARE QUAL, V24, P166, DOI 10.1097/01.NCQ.0000347455.21171.49; Jeffs L, 2008, INT J NURS PRACT, V14, P486, DOI 10.1111/j.1440-172X.2008.00724.x; Jones Daniel., 2006, LEAN THINKING NHS RE; KAUL A, 2007, J PATIENT SAF, V3, P22; King Diane L, 2006, Emerg Med Australas, V18, P391, DOI 10.1111/j.1742-6723.2006.00872.x; Kohn KT, 2000, ERR IS HUMAN BUILDIN; Kreckler S, 2009, ANN SURG, V250, P1035, DOI 10.1097/SLA.0b013e3181bd54c2; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Liker J.K., 2004, TOYOTA WAY; National Patient Safety Agency, 2004, 7 STEPS PAT SAF FULL; Newman K, 1997, TOTAL QUAL MANAGE, V8, P255, DOI 10.1080/0954412979505; PLENERT G, 2007, REINVENTING LEAN; Printezis Antonios, 2007, Qual Manag Health Care, V16, P226; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Raab SS, 2006, AM J CLIN PATHOL, V126, P585, DOI 10.1309/NJQ1L7KA10UKV93Q; Reason J., 1990, HUMAN ERROR; Robb E, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1234; Rother Mike, 1999, LEARNING SEE VALUE S, DOI [10.1109/6.490058, DOI 10.1109/6.490058]; Sari ABA, 2007, QUAL SAF HEALTH CARE, V16, P434, DOI 10.1136/qshc.2006.021154; Sarkar D., 2006, 5S SERVICE ORG OFFIC; Simmons Janice C, 2002, Qual Lett Healthc Lead, V14, P2; Spear SJ, 2005, HARVARD BUS REV, V83, P78; SUGIMORI Y, 1977, INT J PROD RES, V15, P553, DOI 10.1080/00207547708943149; Tamuz M, 2004, QUAL SAF HEALTH CARE, V13, P13, DOI 10.1136/qshc.2002.003376; Thompson DN, 2003, J NURS ADMIN, V33, P585, DOI 10.1097/00005110-200311000-00008; Tworek JA., 2008, DIAGN HISTOPATHOL, V14, P292; van den Heuvel J, 2006, JT COMM J QUAL PATIE, V32, P393, DOI 10.1016/S1553-7250(06)32051-X; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Vincent CA, 2004, QUAL SAF HEALTH CARE, V13, P242, DOI 10.1136/qshc.2004.010454; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Womack J.P., 2003, LEAN THINKING BANISH; WOMAK JP, 1990, MACHINE CHANGED WORL; Zhao B, 2006, ACAD MANAGE REV, V31, P1012, DOI 10.5465/AMR.2006.22528167	51	29	29	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 2	2010	341								c5469	10.1136/bmj.c5469	http://dx.doi.org/10.1136/bmj.c5469			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678CU	21045024				2022-12-28	WOS:000284048200002
J	Smith, AK; Cenzer, IS; Knight, SJ; Puntillo, KA; Widera, E; Williams, BA; Boscardin, WJ; Covinsky, KE				Smith, Alexander K.; Cenzer, Irena Stijacic; Knight, Sara J.; Puntillo, Kathleen A.; Widera, Eric; Williams, Brie A.; Boscardin, W. John; Covinsky, Kenneth E.			The Epidemiology of Pain During the Last 2 Years of Life	ANNALS OF INTERNAL MEDICINE			English	Article							FAMILY-MEMBERS; OF-LIFE; CANCER; OLDER; AGE; PREVALENCE; MANAGEMENT; CARE; END; INTERFERENCE	Background: The epidemiology of pain during the last years of life has not been well described. Objective: To describe the prevalence and correlates of pain during the last 2 years of life. Design: Observational study. Data from participants who died while enrolled in the Health and Retirement Study were analyzed. The survey interview closest to death was used. Each participant or proxy was interviewed once in the last 24 months of life and was classified into 1 of 24 cohorts on the basis of the number of months between the interview and death. The relationship between time before death and pain was modeled and was adjusted for age, sex, race or ethnicity, education level, net worth, income, terminal diagnosis category, presence of arthritis, and proxy status. Setting: The Health and Retirement Study, a nationally representative survey of community-living older adults (1994 to 2006). Participants: Older adult decedents. Measurements: Clinically significant pain, as indicated by a report that the participant was "often troubled" by pain of at least moderate severity. Results: The sample included 4703 decedents. Mean age (SD) of participants was 75.7 years (SD, 10.8); 83.1% were white, 10.7% were black, 4.7% were Hispanic; and 52.3% were men. The adjusted prevalence of pain 24 months before death was 26% (95% CI, 23% to 30%). The prevalence remained flat until 4 months before death (28% [CI, 25% to 32%]), then it increased, reaching 46% (CI, 38% to 55%) in the last month of life. The prevalence of pain in the last month of life was 60% among patients with arthritis versus 26% among patients without arthritis (P < 0.001) and did not differ by terminal diagnosis category (cancer [45%], heart disease [48%], frailty [50%], sudden death [42%], or other causes [47%]; P = 0.195). Limitation: Data are cross-sectional; 19% of responses were from proxies; and information about cause, location, and treatment of pain was not available. Conclusion: Although the prevalence of pain increases in the last 4 months of life, pain is present in more than one quarter of elderly persons during the last 2 years of life. Arthritis is strongly associated with pain at the end of life.	[Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94121 USA; [Smith, Alexander K.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Smith, AK (corresponding author), Univ Calif San Francisco, Div Geriatr, Dept Med, 4150 Clement St 181G, San Francisco, CA 94121 USA.	aksmith@ucsf.edu	Knight, Sara/AAJ-3818-2020		National Institute on Aging [R01AG028481, K24AG029812]; National Center for Research Resources UCSF-CTSI [UL1 RR024131]; National Palliative Care Research Center; National Institute on Musculoskeletal and Skin Diseases [P60 AR053308]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR053308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG029812, K23AG033102, R01AG028481] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Research Resources UCSF-CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Palliative Care Research Center; National Institute on Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr. Smith is supported by a Research Supplement to Promote Diversity in Health Related Research from the National Institute on Aging (R01AG028481), the National Center for Research Resources UCSF-CTSI (UL1 RR024131), and the National Palliative Care Research Center. Dr. Covinsky is supported by a K-24 grant from the National Institute on Aging (K24AG029812) and a grant from the National Institute on Musculoskeletal and Skin Diseases (P60 AR053308).	ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; *AM GER SOC, AGS CLIN PRACT GUID; Archer KJ, 2006, STATA J, V6, P97, DOI 10.1177/1536867X0600600106; BELLVILL.JW, 1971, J AMER MED ASSOC, V217, P1835, DOI 10.1001/jama.217.13.1835; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Christakis NA., 2001, DEATH FORETOLD PROPH; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Conill C, 1997, J PAIN SYMPTOM MANAG, V14, P328, DOI 10.1016/S0885-3924(97)00263-7; Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005; Desbiens NA, 1997, J AM GERIATR SOC, V45, P1167, DOI 10.1111/j.1532-5415.1997.tb03765.x; DOBRATZ MC, 1991, CANCER NURS, V14, P20; Dominick Kelli L, 2004, Health Qual Life Outcomes, V2, P5; Du Pen SL, 1999, J CLIN ONCOL, V17, P361, DOI 10.1200/JCO.1999.17.1.361; Dunlop DD, 2001, ARTHRITIS RHEUM-US, V44, P212, DOI 10.1002/1529-0131(200101)44:1<212::AID-ANR28>3.0.CO;2-Q; Edwards RR, 2001, PSYCHOSOM MED, V63, P316, DOI 10.1097/00006842-200103000-00018; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; HARKINS SW, 1976, PAIN, V2, P253, DOI 10.1016/0304-3959(76)90004-X; HARKINS SW, 1986, J GERONTOL, V41, P58, DOI 10.1093/geronj/41.1.58; Helme RD, 2001, CLIN GERIATR MED, V17, P417, DOI 10.1016/S0749-0690(05)70078-1; HIGGINSON I, 1994, SOC SCI MED, V38, P553, DOI 10.1016/0277-9536(94)90251-8; *HLTH RET STUD, SURV DES; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003; Lloyd-Williams M, 2004, PALLIATIVE MED, V18, P558, DOI 10.1191/0269216304pm923oa; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; McPherson CJ, 2003, SOC SCI MED, V56, P95, DOI 10.1016/S0277-9536(02)00011-4; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P104, DOI 10.1016/S0885-3924(00)00160-3; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; National Comprehensive Cancer Network, NCCN CLIN PRACT GUID; Owens M R, 2001, Am J Hosp Palliat Care, V18, P124, DOI 10.1177/104990910101800211; PAPPAGALLO M, 2004, NEUROLOGIC BASIS PAI; Peat G, 2004, PAIN, V112, P397, DOI 10.1016/j.pain.2004.09.029; Reynolds KS, 2008, J PAIN SYMPTOM MANAG, V35, P388, DOI 10.1016/j.jpainsymman.2008.01.001; Scheetz J, 1988, Dimens Oncol Nurs, V2, P9; SCHLUDERMANN E, 1962, PERCEPT MOTOR SKILL, V14, P295; Silveira Maria J, 2005, J Palliat Med, V8, P827, DOI 10.1089/jpm.2005.8.827; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stewart AL, 1999, J PAIN SYMPTOM MANAG, V17, P93, DOI 10.1016/S0885-3924(98)00131-6; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Thomas E, 2004, PAIN, V110, P361, DOI 10.1016/j.pain.2004.04.017; TURK DC, 1995, PAIN, V61, P93, DOI 10.1016/0304-3959(94)00167-D; Ventafridda V, 1990, J Palliat Care, V6, P7; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3; WOODROW KM, 1972, PSYCHOSOM MED, V34, P548, DOI 10.1097/00006842-197211000-00007	50	100	101	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					563	569		10.7326/0003-4819-153-9-201011020-00005	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	673MH	21041575	Green Accepted			2022-12-28	WOS:000283667000002
J	Feng, SH; Jacobsen, SE; Reik, W				Feng, Suhua; Jacobsen, Steven E.; Reik, Wolf			Epigenetic Reprogramming in Plant and Animal Development	SCIENCE			English	Review							PRIMORDIAL GERM-CELLS; ZYGOTIC PATERNAL GENOME; DNA METHYLATION; STEM-CELLS; MOUSE OOCYTES; HISTONE H3; DEMETHYLATION; ARABIDOPSIS; GENE; CHROMATIN	Epigenetic modifications of the genome are generally stable in somatic cells of multicellular organisms. In germ cells and early embryos, however, epigenetic reprogramming occurs on a genome-wide scale, which includes demethylation of DNA and remodeling of histones and their modifications. The mechanisms of genome-wide erasure of DNA methylation, which involve modifications to 5-methylcytosine and DNA repair, are being unraveled. Epigenetic reprogramming has important roles in imprinting, the natural as well as experimental acquisition of totipotency and pluripotency, control of transposons, and epigenetic inheritance across generations. Small RNAs and the inheritance of histone marks may also contribute to epigenetic inheritance and reprogramming. Reprogramming occurs in flowering plants and in mammals, and the similarities and differences illuminate developmental and reproductive strategies.	[Feng, Suhua; Jacobsen, Steven E.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; [Feng, Suhua; Jacobsen, Steven E.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; [Reik, Wolf] Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB22 3AT, England; [Reik, Wolf] Univ Cambridge, Ctr Trophoblast Res, Cambridge CB2 3EG, England	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Jacobsen, SE (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	jacobsen@ucla.edu; wolf.reik@bbsrc.ac.uk	Reik, Wolf/I-6794-2012	Reik, Wolf/0000-0003-0216-9881	NIH [GM60398]; UK Biotechnology and Biological Sciences Research Council; UK Medical Research Council; European Union; BBSRC [BBS/E/B/0000M220] Funding Source: UKRI; MRC [G0700098] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/B/0000M220] Funding Source: researchfish; Medical Research Council [G0700098] Funding Source: researchfish; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM060398, R01GM060398] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. A. Law for reading and commenting on the manuscript, and F. Santos for help with figures. S. F. is a Special Fellow of the Leukemia & Lymphoma Society. Supported by NIH grant GM60398 (S. E. J.) and by grants from the UK Biotechnology and Biological Sciences Research Council, UK Medical Research Council, and European Union (W. R.). S. E. J. is an investigator of the Howard Hughes Medical Institute.	Aravin AA, 2008, COLD SH Q B, V73, P283, DOI 10.1101/sqb.2008.73.058; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078; Brykczynska U, 2010, NAT STRUCT MOL BIOL, V17, P679, DOI 10.1038/nsmb.1821; Chen TP, 2003, MOL CELL BIOL, V23, P5594, DOI 10.1128/MCB.23.16.5594-5605.2003; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Chotalia M, 2009, GENE DEV, V23, P105, DOI 10.1101/gad.495809; Ciccone DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315; Farthing CR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000116; Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107; Gehring M, 2009, SCIENCE, V324, P1447, DOI 10.1126/science.1171609; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Hemberger M, 2009, NAT REV MOL CELL BIO, V10, P526, DOI 10.1038/nrm2727; Hsieh TF, 2009, SCIENCE, V324, P1451, DOI [10.1126/science.1172417, 10.1126/science.112417]; Huh JH, 2008, CELL, V132, P735, DOI 10.1016/j.cell.2008.02.018; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jacob Y, 2010, NATURE, V466, P987, DOI 10.1038/nature09290; Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146; Katz DJ, 2009, CELL, V137, P308, DOI 10.1016/j.cell.2009.02.015; Kim DH, 2009, ANNU REV CELL DEV BI, V25, P277, DOI 10.1146/annurev.cellbio.042308.113411; Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342; Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719; Lee J, 2002, DEVELOPMENT, V129, P1807; Li XJ, 2008, DEV CELL, V15, P547, DOI 10.1016/j.devcel.2008.08.014; Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Maatouk DM, 2006, DEVELOPMENT, V133, P3411, DOI 10.1242/dev.02500; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; Mosher RA, 2009, NATURE, V460, P283, DOI 10.1038/nature08084; Nakamura T, 2007, NAT CELL BIOL, V9, P64, DOI 10.1038/ncb1519; Okada Y, 2010, NATURE, V463, P554, DOI 10.1038/nature08732; Ollinger R, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000199; Olmedo-Monfil V, 2010, NATURE, V464, P628, DOI 10.1038/nature08828; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Penterman J, 2007, P NATL ACAD SCI USA, V104, P6752, DOI 10.1073/pnas.0701861104; Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829; Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295; Seki Y, 2007, DEVELOPMENT, V134, P2627, DOI 10.1242/dev.005611; Slotkin RK, 2009, CELL, V136, P461, DOI 10.1016/j.cell.2008.12.038; Stancheva I, 2002, DEV BIOL, V243, P155, DOI 10.1006/dbio.2001.0560; Tam OH, 2008, NATURE, V453, P534, DOI 10.1038/nature06904; Teixeira FK, 2009, SCIENCE, V323, P1600, DOI 10.1126/science.1165313; Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924; Watanabe T, 2008, NATURE, V453, P539, DOI 10.1038/nature06908; Wossidlo M, 2010, EMBO J, V29, P1877, DOI 10.1038/emboj.2010.80; Yamanaka S, 2010, NATURE, V465, P704, DOI 10.1038/nature09229; Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366; Zhu JK, 2009, ANNU REV GENET, V43, P143, DOI 10.1146/annurev-genet-102108-134205	54	812	864	11	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	2010	330	6004					622	627		10.1126/science.1190614	http://dx.doi.org/10.1126/science.1190614			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	672KB	21030646	Green Accepted			2022-12-28	WOS:000283580600034
J	Bate, R; Attaran, A				Bate, Roger; Attaran, Amir			A counterfeit drug treaty: great idea, wrong implementation	LANCET			English	Editorial Material									[Attaran, Amir] Univ Ottawa, Fac Law, Ottawa, ON K1N 6N5, Canada; [Attaran, Amir] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; [Bate, Roger] Amer Enterprise Inst Publ Policy Res, Washington, DC USA	University of Ottawa; University of Ottawa; American Enterprise Institute for Public Policy Research	Attaran, A (corresponding author), Univ Ottawa, Fac Law, Ottawa, ON K1N 6N5, Canada.	aattaran@uottawa.ca						ATTARAN A, WHY MAKE INT CRIME M; Cockburn R, 2005, PLOS MED, V2, P302, DOI 10.1371/journal.pmed.0020100; *COUNC EUR, 2010, MEDICRIME DRAFT COUN; Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x; *ECCP COUNC EUR, 2008, 3 M APR 15; *EUR COMM CRIM PRO, 2009, DRAFT COUNC EUR CONV; Ludwig SP, 2005, DRUG DEV IND PHARM, V31, P215, DOI 10.1081/DDC-200047811; LYNN J, 2010, REUTERS         0512; Mullard A, 2010, LANCET, V375, P1335, DOI 10.1016/S0140-6736(10)60560-0; *US FDA, 2008, UPD QUEST ANSW HEP S; 1929, INT CONV SUPPR COUNT	11	13	13	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2010	376	9751					1446	1448		10.1016/S0140-6736(10)61416-X	http://dx.doi.org/10.1016/S0140-6736(10)61416-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	21036261				2022-12-28	WOS:000284248500008
J	Shah, ND; Montori, VM; Krumholz, HM; Tu, K; Alexander, GC; Jackevicius, CA				Shah, Nilay D.; Montori, Victor M.; Krumholz, Harlan M.; Tu, Karen; Alexander, G. Caleb; Jackevicius, Cynthia A.			Responding to an FDA Warning - Geographic Variation in the Use of Rosiglitazone.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Shah, Nilay D.; Montori, Victor M.] Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA; [Tu, Karen; Jackevicius, Cynthia A.] Univ Toronto, Toronto, ON, Canada; [Tu, Karen] Toronto Western Hosp, Family Hlth Team, Toronto, ON M5T 2S8, Canada; [Tu, Karen; Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Alexander, G. Caleb] Univ Chicago, Chicago, IL 60637 USA; [Alexander, G. Caleb] Univ Illinois, Chicago Sch Pharm, Chicago, IL USA; [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Los Angeles, CA USA; [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA	Mayo Clinic; Yale University; Yale University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Western University of Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shah, ND (corresponding author), Mayo Clin, Knowledge & Encounter Res Unit, Rochester, MN 55905 USA.		, Harlan/AAI-2875-2020					Congress of The United States Congressional Budget Office, 2008, GEOGR VAR HLTH CAR S; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; Nissen SE, 2007, NEW ENGL J MED, V357, P100; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Wagner AK, 2006, PHARMACOEPIDEM DR S, V15, P369, DOI 10.1002/pds.1193; Wang AT, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1344	6	53	53	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2010	363	22					2081	2084		10.1056/NEJMp1011042	http://dx.doi.org/10.1056/NEJMp1011042			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	684XE	21083379	Bronze			2022-12-28	WOS:000284587800001
J	Utz, M; Landers, J				Utz, Marcel; Landers, James			Magnetic Resonance and Microfluidics	SCIENCE			English	Editorial Material							NMR		[Utz, Marcel; Landers, James] Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; [Utz, Marcel; Landers, James] Univ Virginia, Dept Mech & Aerosp Engn, Charlottesville, VA 22904 USA	University of Virginia; University of Virginia	Utz, M (corresponding author), Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA.	mu3q@virginia.edu; jpl5e@virginia.edu						Albert K., 2002, ON LINE LC NMR RELAT, V1st ed.; Bajaj VS, 2010, SCIENCE, V330, P1078, DOI 10.1126/science.1192313; Bart J, 2009, J MAGN RESON, V201, P175, DOI 10.1016/j.jmr.2009.09.007; Blazej RG, 2006, P NATL ACAD SCI USA, V103, P7240, DOI 10.1073/pnas.0602476103; Easley CJ, 2006, P NATL ACAD SCI USA, V103, P19272, DOI 10.1073/pnas.0604663103; GRANWEHR J, 2004, PHSY REV LETT, V95; Hilty C, 2005, P NATL ACAD SCI USA, V102, P14960, DOI 10.1073/pnas.0507566102; Krojanski HG, 2008, ANAL CHEM, V80, P8668, DOI 10.1021/ac801636a; Leslie DC, 2010, LAB CHIP, V10, P1960, DOI 10.1039/c003244a; Massin C, 2003, J MAGN RESON, V164, P242, DOI 10.1016/S1090-7807(03)00151-4; OLSON DL, 1995, SCIENCE, V270, P1967, DOI 10.1126/science.270.5244.1967; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996; UTZ M, 2009, P 13 INT C MIN SYST, P1656; Utz M, 2009, J MAGN RESON, V198, P132, DOI 10.1016/j.jmr.2009.01.028	14	12	12	7	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2010	330	6007					1056	1058		10.1126/science.1198402	http://dx.doi.org/10.1126/science.1198402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	682BU	21097926				2022-12-28	WOS:000284374700028
J	Albrecht, E; Schoettker, P				Albrecht, Eric; Schoettker, Patrick			The Jaw-Thrust Maneuver	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Albrecht, Eric; Schoettker, Patrick] CHU Vaudois, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Albrecht, E (corresponding author), CHU Vaudois, CH-1011 Lausanne, Switzerland.		Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; Albrecht, Prof. Dr. Eric/0000-0001-6432-1311					0	7	7	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					E32	E32		10.1056/NEJMicm0910490	http://dx.doi.org/10.1056/NEJMicm0910490			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083381	Green Published			2022-12-28	WOS:000284310000010
J	Bertone, G				Bertone, Gianfranco			The moment of truth for WIMP dark matter	NATURE			English	Review							GALAXIES; PHOTINO; PROOF; MASS	We know that dark matter constitutes 85 per cent of all the matter in the Universe, but we do not know of what it is made. Amongst the many dark matter candidates proposed, WIMPs (weakly interacting massive particles) occupy a special place, because they arise naturally from new theories that seek to extend the standard model of particle physics. With the advent of the Large Hadron Collider at CERN, and anew generation of astroparticle experiments, the moment of truth has come for WIMPs: either we will discover them in the next five to ten years, or we will witness their inevitable decline.	[Bertone, Gianfranco] Univ Paris 06, Inst Astrophys Paris, CNRS, UMR 7095, F-75014 Paris, France; [Bertone, Gianfranco] Univ Zurich, Inst Theoret Phys, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; University of Zurich	Bertone, G (corresponding author), Univ Paris 06, Inst Astrophys Paris, CNRS, UMR 7095, 98 Bis Blvd Arago, F-75014 Paris, France.	bertone@iap.fr						Aalseth C. E., 2010, RESULTS SEARCH LIGHT; Abdo AA, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.091302; Adriani O, 2009, NATURE, V458, P607, DOI 10.1038/nature07942; Ahmed Z., 2009, RESULTS FINAL EXPOSU; Ando S, 2006, PHYS REV D, V73, DOI 10.1103/PhysRevD.73.023521; Angus GW, 2007, ASTROPHYS J, V654, pL13, DOI 10.1086/510738; Aprile E., 2010, 1 DARK MATTER RESULT; Babcock H.W., 1939, LICOB, V19, P41, DOI DOI 10.5479/ADS/BIB/1939LICOB.19.41B; Baltz EA, 2004, J HIGH ENERGY PHYS; Baltz EA, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.103521; Battaglia M, 2004, EUR PHYS J C, V33, P273, DOI 10.1140/epjc/s2003-01575-7; Bergstrom L, 2000, REP PROG PHYS, V63, P793, DOI 10.1088/0034-4885/63/5/2r3; Bernabei R, 2008, EUR PHYS J C, V56, P333, DOI 10.1140/epjc/s10052-008-0662-y; Bertone G, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.151301; Bertone G, 2005, PHYS REP, V405, P279, DOI 10.1016/j.physrep.2004.08.031; Bertone G., 2010, PARTICLE DARK MATTER; Bertone G., 2010, PHYS REV D IN PRESS; BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; Bosma A., 1978, THESIS GRONINGEN U; Boyarsky A, 2009, ANNU REV NUCL PART S, V59, P191, DOI 10.1146/annurev.nucl.010909.083654; Catena R, 2010, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2010/08/004; Clowe D, 2006, ASTROPHYS J, V648, pL109, DOI 10.1086/508162; Diemand J., 2010, PARTICLE DARK MATTER, P14; Drees M, 2008, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2008/06/012; EINASTO J, 1982, MON NOT R ASTRON SOC, V199, P67, DOI 10.1093/mnras/199.1.67; Einasto J., 2009, UNESCO EOLSS ENCY; ELLIS J, 1984, NUCL PHYS B, V238, P453, DOI 10.1016/0550-3213(84)90461-9; Ellis J., 2010, PARTICLE DARK MATTER, P142; Fornengo N., 2010, PARTICLE DARK MATTER, P383; Galli S, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.023505; Goldberg H, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.099905; Gondolo P, 2004, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2004/07/008; GOODMAN MW, 1985, PHYS REV D, V31, P3059, DOI 10.1103/PhysRevD.31.3059; Green AM, 2008, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2008/07/005; Halzen F, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/10/105019; Jungman G, 1996, PHYS REP, V267, P195, DOI 10.1016/0370-1573(95)00058-5; KAHN FD, 1959, ASTROPHYS J, V130, P705, DOI 10.1086/146762; Komatsu E., 2010, 7 YEAR WILKINSON MIC; Mellier Y., 2010, PARTICLE DARK MATTER, P56; MILGROM M, 1987, IAU S, V117, P319; Nath P, 2010, NUCL PHYS B-PROC SUP, V200-02, P185, DOI 10.1016/j.nuclphysbps.2010.03.001; Pato M, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.023531; Profumo S., 2010, PARTICLE DARK MATTER, P547; RUBIN VC, 1980, ASTROPHYS J, V238, P471, DOI 10.1086/158003; Savage C., 2010, XENON10 100 DARK MAT; Shaposhnikov M., 2010, PARTICLE DARK MATTER, P228; Sikivie P., 2010, PARTICLE DARK MATTER, P204; SILK J, 1984, PHYS REV LETT, V53, P624, DOI 10.1103/PhysRevLett.53.624; SILK J, 1985, PHYS REV LETT, V55, P257, DOI 10.1103/PhysRevLett.55.257; Slatyer TR, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.043526; Strigari LE, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/10/105011; Taoso M, 2008, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2008/03/022; Trotta R, 2008, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/2008/12/024; Visinelli L, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.035024; Zwicky F., 1933, HELV PHYS ACTA, V6, P110, DOI [DOI 10.1007/S10714-008-0707-4, 10.1007/s10714-008-0707-4]	58	102	105	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					389	393		10.1038/nature09509	http://dx.doi.org/10.1038/nature09509			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085174	Green Accepted, Green Submitted			2022-12-28	WOS:000284313100033
J	Branch, TA; Watson, R; Fulton, EA; Jennings, S; McGilliard, CR; Pablico, GT; Ricard, D; Tracey, SR				Branch, Trevor A.; Watson, Reg; Fulton, Elizabeth A.; Jennings, Simon; McGilliard, Carey R.; Pablico, Grace T.; Ricard, Daniel; Tracey, Sean R.			The trophic fingerprint of marine fisheries	NATURE			English	Article							FOOD WEBS; ECOLOGICAL INDICATORS; GLOBAL FISHERIES; WORLD FISHERIES; GULF; BIODIVERSITY; PERSPECTIVE; AQUACULTURE; ECOSYSTEMS; IMPACTS	Biodiversity indicators provide a vital window on the state of the planet, guiding policy development and management(1,2). The most widely adopted marine indicator is mean trophic level (MTL) from catches, intended to detect shifts from high-trophic-level predators to low-trophic-level invertebrates and plankton-feeders(3-5). This indicator underpins reported trends in human impacts, declining when predators collapse ("fishing down marine food webs'')(3) and when low-trophic-level fisheries expand ("fishing through marine food webs'')(6). The assumption is that catch MTL measures changes in ecosystem MTL and biodiversity(2,5). Here we combine model predictions with global assessments of MTL from catches, trawl surveys and fisheries stock assessments(7) and find that catch MTL does not reliably predict changes in marine ecosystems. Instead, catch MTL trends often diverge from ecosystem MTL trends obtained from surveys and assessments. In contrast to previous findings of rapid declines in catch MTL3, we observe recent increases in catch, survey and assessment MTL. However, catches from most trophic levels are rising, which can intensify fishery collapses even when MTL trends are stable or increasing. To detect fishing impacts on marine biodiversity, we recommend greater efforts to measure true abundance trends for marine species, especially those most vulnerable to fishing.	[Branch, Trevor A.; McGilliard, Carey R.] Univ Washington, Sch Aquat & Fishery Sci, Seattle, WA 98195 USA; [Watson, Reg; Pablico, Grace T.] Univ British Columbia, Fisheries Ctr, Sea Around Us Project, Vancouver, BC V6T 1Z4, Canada; [Fulton, Elizabeth A.] CSIRO Wealth Oceans, Hobart, Tas 7001, Australia; [Jennings, Simon] Ctr Environm Fisheries & Aquaculture Sci, Lowestoft NR33 0HT, Suffolk, England; [Jennings, Simon] Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; [Ricard, Daniel] Dalhousie Univ, Dept Biol, Halifax, NS B3H 4J1, Canada; [Tracey, Sean R.] Univ Tasmania, Tasmanian Aquaculture & Fisheries Inst, Marine Res Labs, Hobart, Tas 7001, Australia	University of Washington; University of Washington Seattle; University of British Columbia; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Centre for Environment Fisheries & Aquaculture Science; University of East Anglia; Dalhousie University; University of Tasmania	Branch, TA (corresponding author), Univ Washington, Sch Aquat & Fishery Sci, Box 355020, Seattle, WA 98195 USA.	tbranch@uw.edu	Fulton, Beth/AAJ-1398-2021; Fulton, Beth/A-2871-2008; Jennings, Simon/F-5085-2012; Watson, Reg A/F-4850-2012; Ricard, Daniel/G-1814-2014; Branch, Trevor/A-5691-2009	Fulton, Beth/0000-0002-5904-7917; Fulton, Beth/0000-0002-5904-7917; Jennings, Simon/0000-0002-2390-7225; Watson, Reg A/0000-0001-7201-8865; McGilliard, Carey/0000-0001-5708-8283	University of California Santa Barbara; US National Science Foundation (NSF); Moore Foundation; School of Aquatic and Fishery Sciences, University of Washington; Canadian Natural Sciences and Engineering Research Council; Canadian Foundation for Innovation; Pew Charitable Trusts	University of California Santa Barbara(University of California System); US National Science Foundation (NSF)(National Science Foundation (NSF)); Moore Foundation(Gordon and Betty Moore Foundation); School of Aquatic and Fishery Sciences, University of Washington(University of Washington); Canadian Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Pew Charitable Trusts	This work arose out of a working group at the National Center for Ecological Analysis and Synthesis (NCEAS), funded by the University of California Santa Barbara, the US National Science Foundation (NSF), and the Moore Foundation. T.A.B. was additionally funded by the School of Aquatic and Fishery Sciences, University of Washington. The RAM Legacy stock assessment database was funded by the Canadian Natural Sciences and Engineering Research Council and the Canadian Foundation for Innovation; the Sea Around Us Project was funded by Pew Charitable Trusts. Additional collaborators and data contributors are acknowledged in the Supplementary Information.	Anderson PJ, 1999, MAR ECOL PROG SER, V189, P117, DOI 10.3354/meps189117; Butchart SHM, 2010, SCIENCE, V328, P1164, DOI 10.1126/science.1187512; Caddy J.F., 1998, SCIENCE, V282, p1383a, DOI 10.1126/science.282.5393.1383a; Caddy JF, 2000, OCEAN COAST MANAGE, V43, P615, DOI 10.1016/S0964-5691(00)00052-1; Chavez FP, 2003, SCIENCE, V299, P217, DOI 10.1126/science.1075880; Christensen V, 2004, ECOL MODEL, V172, P109, DOI 10.1016/j.ecolmodel.2003.09.003; Christensen V, 1998, J FISH BIOL, V53, P128, DOI 10.1006/jfbi.1998.0809; de Mutsert K, 2008, P NATL ACAD SCI USA, V105, P2740, DOI 10.1073/pnas.0704354105; Essington TE, 2006, P NATL ACAD SCI USA, V103, P3171, DOI 10.1073/pnas.0510964103; Fulton EA, 2005, ICES J MAR SCI, V62, P540, DOI 10.1016/j.icesjms.2004.12.012; JIMING Y, 1982, MAR ECOL PROG SER, V7, P247, DOI 10.3354/meps007247; Litzow MA, 2009, CAN J FISH AQUAT SCI, V66, P201, DOI 10.1139/F08-207; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; Pauly D, 2005, B MAR SCI, V76, P197; Pauly D, 2005, PHILOS T ROY SOC B, V360, P415, DOI 10.1098/rstb.2004.1597; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; Pauly D, 2005, PHILOS T R SOC B, V360, P5, DOI 10.1098/rstb.2004.1574; Pikitch EK, 2004, SCIENCE, V305, P346, DOI 10.1126/science.1098222; Powers JE, 2010, MAR POLICY, V34, P723, DOI 10.1016/j.marpol.2009.11.009; Rochet MJ, 2003, CAN J FISH AQUAT SCI, V60, P86, DOI 10.1139/F02-164; Secretariat of the Convention on Biological Diversity, 2006, GLOB BIOD OUTL 2; Sethi SA, 2010, P NATL ACAD SCI USA, V107, P12163, DOI 10.1073/pnas.1003236107; Shannon LJ, 2009, ECOL INDIC, V9, P1078, DOI 10.1016/j.ecolind.2008.12.007; Shin YJ, 2010, ICES J MAR SCI, V67, P692, DOI 10.1093/icesjms/fsp294; Tacon AGJ, 2010, REV FISH SCI, V18, P94, DOI 10.1080/10641260903325680; Tacon AGJ, 2009, REV FISH SCI, V17, P305, DOI 10.1080/10641260802677074; Watson R, 2001, NATURE, V414, P534, DOI 10.1038/35107050; Worm B, 2009, SCIENCE, V325, P578, DOI 10.1126/science.1173146; Zeller D, 2005, FISH FISH, V6, P156, DOI 10.1111/j.1467-2979.2005.00177.x	29	263	274	1	312	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2010	468	7322					431	435		10.1038/nature09528	http://dx.doi.org/10.1038/nature09528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	681KP	21085178				2022-12-28	WOS:000284313100041
J	Stock, PG; Barin, B; Murphy, B; Hanto, D; Diego, JM; Light, J; Davis, C; Blumberg, E; Simon, D; Subramanian, A; Millis, JM; Lyon, GM; Brayman, K; Slakey, D; Shapiro, R; Melancon, J; Jacobson, JM; Stosor, V; Olson, JL; Stablein, DM; Roland, ME				Stock, Peter G.; Barin, Burc; Murphy, Barbara; Hanto, Douglas; Diego, Jorge M.; Light, Jimmy; Davis, Charles; Blumberg, Emily; Simon, David; Subramanian, Aruna; Millis, J. Michael; Lyon, G. Marshall; Brayman, Kenneth; Slakey, Doug; Shapiro, Ron; Melancon, Joseph; Jacobson, Jeffrey M.; Stosor, Valentina; Olson, Jean L.; Stablein, Donald M.; Roland, Michelle E.			Outcomes of Kidney Transplantation in HIV-Infected Recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	9th American Transplant Congress	MAY 30-JUN 03, 2009	Boston, MA				ACQUIRED IMMUNODEFICIENCY SYNDROME; HETEROLOGOUS IMMUNITY; DOSING MODIFICATIONS; T-CELLS; VIRUS; TOLERANCE; NEPHROPATHY; LIVER; PHARMACOKINETICS; PREVALENCE	BACKGROUND The outcomes of kidney transplantation and immunosuppression in people infected with human immunodeficiency virus (HIV) are incompletely understood. METHODS We undertook a prospective, nonrandomized trial of kidney transplantation in HIV-infected candidates who had CD4+ T-cell counts of at least 200 per cubic millimeter and undetectable plasma HIV type 1 (HIV-1) RNA levels while being treated with a stable antiretroviral regimen. Post-transplantation management was provided in accordance with study protocols that defined prophylaxis against opportunistic infection, indications for biopsy, and acceptable approaches to immunosuppression, management of rejection, and antiretroviral therapy. RESULTS Between November 2003 and June 2009, a total of 150 patients underwent kidney transplantation; survivors were followed for a median period of 1.7 years. Patient survival rates (+/- SD) at 1 year and 3 years were 94.6 +/- 2.0% and 88.2 +/- 3.8%, respectively, and the corresponding mean graft-survival rates were 90.4% and 73.7%. In general, these rates fall somewhere between those reported in the national database for older kidney-transplant recipients (>= 65 years) and those reported for all kidney-transplant recipients. A multivariate proportional-hazards analysis showed that the risk of graft loss was increased among patients treated for rejection (hazard ratio, 2.8; 95% confidence interval [CI], 1.2 to 6.6; P = 0.02) and those receiving antithymocyte globulin induction therapy (hazard ratio, 2.5; 95% CI, 1.1 to 5.6; P = 0.03); living-donor transplants were protective (hazard ratio, 0.2; 95% CI, 0.04 to 0.8; P = 0.02). A higher-than-expected rejection rate was observed, with 1-year and 3-year estimates of 31% (95% CI, 24 to 40) and 41% (95% CI, 32 to 52), respectively. HIV infection remained well controlled, with stable CD4+ T-cell counts and few HIV-associated complications. CONCLUSIONS In this cohort of carefully selected HIV-infected patients, both patient-and graft-survival rates were high at 1 and 3 years, with no increases in complications associated with HIV infection. The unexpectedly high rejection rates are of serious concern and indicate the need for better immunotherapy.	[Stock, Peter G.; Olson, Jean L.; Roland, Michelle E.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Barin, Burc; Stablein, Donald M.] EMMES Corp, Rockville, MD USA; [Murphy, Barbara] Mt Sinai Sch Med, New York, NY USA; [Hanto, Douglas] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Diego, Jorge M.] Univ Miami, Sch Med, Miami, FL USA; [Light, Jimmy] Washington Hosp Ctr, Washington, DC 20010 USA; [Melancon, Joseph] Georgetown Univ, Washington, DC USA; [Davis, Charles] Univ Maryland, Baltimore, MD 21201 USA; [Subramanian, Aruna] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Blumberg, Emily] Univ Penn, Philadelphia, PA 19104 USA; [Jacobson, Jeffrey M.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; [Slakey, Doug] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [Millis, J. Michael] Univ Chicago, Chicago, IL 60637 USA; [Stosor, Valentina] Northwestern Univ, Chicago, IL 60611 USA; [Lyon, G. Marshall] Emory Univ, Atlanta, GA 30322 USA; [Brayman, Kenneth] Univ Virginia, Charlottesville, VA USA; [Slakey, Doug] Tulane Univ Med Ctr Hosp & Clin, New Orleans, LA USA; [Shapiro, Ron] Univ Pittsburgh, Pittsburgh, PA USA	University of California System; University of California San Francisco; Emmes Corporation; Icahn School of Medicine at Mount Sinai; Harvard University; Beth Israel Deaconess Medical Center; University of Miami; MedStar Washington Hospital Center; Georgetown University; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; University of Pennsylvania; Drexel University; Rush University; University of Chicago; Northwestern University; Emory University; University of Virginia; Tulane University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stock, PG (corresponding author), Univ Calif San Francisco, 505 Parnassus Ave,M-884,Box 0116, San Francisco, CA 94143 USA.	peter.stock@ucsfmedctr.org	Millis, Michael/K-5346-2019; Hanto, Douglas/AAZ-5390-2021; Slakey, Douglas/AAG-8505-2019	Hanto, Douglas/0000-0003-4088-3568; Slakey, Douglas/0000-0001-8314-2730; Subramanian, Aruna/0000-0002-1373-6768	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI052748] Funding Source: NIH RePORTER; NIAID NIH HHS [AI052748, U01 AI052748-08, U01 AI052748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott Kevin C, 2003, BMC Nephrol, V4, P5, DOI 10.1186/1471-2369-4-5; Adams AB, 2003, J CLIN INVEST, V111, P1887, DOI 10.1172/JCI200317477; Ahuja TS, 1999, AM J NEPHROL, V19, P655, DOI 10.1159/000013537; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Bosmans JL, 2007, KIDNEY INT, V71, P1197, DOI 10.1038/sj.ki.5002306; Brehm MA, 2003, J IMMUNOL, V170, P4077, DOI 10.4049/jimmunol.170.8.4077; CHAN WL, 1992, J EXP MED, V176, P1203, DOI 10.1084/jem.176.4.1203; Choi AI, 2007, CLIN INFECT DIS, V45, P1633, DOI 10.1086/523729; Fine DM, 2008, DRUGS, V68, P963, DOI 10.2165/00003495-200868070-00006; Firpi RJ, 2006, LIVER TRANSPLANT, V12, P51, DOI 10.1002/lt.20532; Frassetto L, 2005, TRANSPLANTATION, V80, P13, DOI 10.1097/01.TP.0000165111.09687.4E; Frassetto LA, 2007, AM J TRANSPLANT, V7, P2816, DOI 10.1111/j.1600-6143.2007.02007.x; Frassetto Lynda, 2003, Drug Metab Pharmacokinet, V18, P114, DOI 10.2133/dmpk.18.114; LANGLOIS AJ, 1992, AIDS RES HUM RETROV, V8, P1641, DOI 10.1089/aid.1992.8.1641; Monahan M, 2001, SEMIN NEPHROL, V21, P394, DOI 10.1053/snep.2001.23771; PARDO V, 1984, ANN INTERN MED, V101, P429, DOI 10.7326/0003-4819-101-4-429; RAO TKS, 1984, NEW ENGL J MED, V310, P669, DOI 10.1056/NEJM198403153101101; ROLAND MBB, 2006, P 16 INT AIDS C TOR; Ross MJ, 2002, J AM SOC NEPHROL, V13, P2997, DOI 10.1097/01.ASN.0000040750.40907.99; Selin LK, 2006, IMMUNOL REV, V211, P164, DOI 10.1111/j.0105-2896.2006.00394.x; Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Tricot L, 2009, AM J TRANSPLANT, V9, P1946, DOI 10.1111/j.1600-6143.2009.02684.x; Trullas JC, 2008, AIDS RES HUM RETROV, V24, P1229, DOI 10.1089/aid.2008.0158; USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999, MMWR RECOMM REP, V48, P61; Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449; Welsh RM, 2000, J VIROL, V74, P2210, DOI 10.1128/JVI.74.5.2210-2218.2000; Williams MA, 2002, J IMMUNOL, V169, P5387, DOI 10.4049/jimmunol.169.10.5387; Williams MA, 2001, J IMMUNOL, V167, P4987, DOI 10.4049/jimmunol.167.9.4987; Wu ZH, 2004, NAT MED, V10, P87, DOI 10.1038/nm965; YANG H, 1986, J IMMUNOL, V136, P1186; YANG HY, 1989, J IMMUNOL, V142, P1710	32	343	361	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					2004	2014		10.1056/NEJMoa1001197	http://dx.doi.org/10.1056/NEJMoa1001197			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	681KC	21083386	Green Accepted			2022-12-28	WOS:000284310000005
J	Friedman, AL				Friedman, Amy L.			Secret Shopper	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												friedmaa@upstate.edu							0	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2103	2104		10.1001/jama.2010.1666	http://dx.doi.org/10.1001/jama.2010.1666			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081716				2022-12-28	WOS:000284269800001
J	Reyes, H				Reyes, Humberto			Students' Response to Disaster: A Lesson for Health Care Professional Schools	ANNALS OF INTERNAL MEDICINE			English	Article							HAITIAN EARTHQUAKE; MEDICAL-EDUCATION	The response of medical students, young physicians, and other health professionals to the February 2010 earthquake and tsunami in Chile provides important lessons about health care delivery during disasters and about the development of professionalism. Tertiary and secondary care of victims of these disasters was possible because local and national resources were available and field hospitals provided by Chile's armed forces and foreign countries replaced damaged hospitals. However, primary care of persons living on the outskirts of towns and in small villages and coves that were destroyed and isolated by the disaster required the involvement of volunteer groups that were largely composed of students and other young members of the health professions, all of whom were motivated by solidarity, compassion, and social commitment. This experience, similar to previous catastrophes in Chile and elsewhere, reinforces that medical and other health professional schools must instill in graduates an understanding that the privileges of being a health professional come with responsibilities to society. Beyond providing high-quality scientific and technological education, curricula in these schools should include training that enables graduates to meaningfully contribute in the setting of unexpected disasters and that nurtures a sense of responsibility to do so.	[Reyes, Humberto] Univ Chile, Sch Med, Santiago, Chile	Universidad de Chile	Reyes, H (corresponding author), Revista Med Chile, Bernarda Morin 488, Santiago 7500781, Chile.	revmedchile@smschile.cl						Amundson D, 2010, ANN INTERN MED, V152, P733, DOI 10.7326/0003-4819-152-11-201006010-00215; BAYARD D, 2010, PMID, V362, P1858; Figueroa RA, 2010, REV MED CHILE, V138, P143, DOI /S0034-98872010000200001; Iezzoni LI, 2010, ANN INTERN MED, V152, P812, DOI 10.7326/0003-4819-152-12-201006150-00234; Kreiss Y, 2010, ANN INTERN MED, V153, P45, DOI 10.7326/0003-4819-153-1-201007060-00253; Mullan F, 2010, ANN INTERN MED, V152, P804, DOI 10.7326/0003-4819-152-12-201006150-00009; O'Ryan M, 2010, REV MED CHILE, V138, P270, DOI /S0034-98872010000300002; Reyes H, 2010, REV MED CHILE, V138, P267, DOI /S0034-98872010000300001; Schwarz MR, 2002, MED TEACH, V24, P125, DOI 10.1080/01421590220120740; Smith LG, 2010, ANN INTERN MED, V152, P818, DOI 10.7326/0003-4819-152-12-201006150-00012	10	10	10	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					658	660		10.7326/0003-4819-153-10-201011160-00009	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680ES	21079222				2022-12-28	WOS:000284215800019
J	Cheung, BMY; Lam, KSL				Cheung, Bernard M. Y.; Lam, Karen S. L.			Is intensive LDL-cholesterol lowering beneficial and safe?	LANCET			English	Editorial Material							STATINS; DISEASE		[Cheung, Bernard M. Y.] Univ Hong Kong, Dept Med, Div Clin Pharmacol & Therapeut, Pokfulam, Hong Kong, Peoples R China; [Lam, Karen S. L.] Univ Hong Kong, Div Endocrinol & Metab, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Cheung, BMY (corresponding author), Univ Hong Kong, Dept Med, Div Clin Pharmacol & Therapeut, Pokfulam, Hong Kong, Peoples R China.		/E-9829-2010	/0000-0001-9106-7363				Amarenco P, 2006, NEW ENGL J MED, V355, P549; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; *CTT COLL, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)61350.5; Kelly TN, 2008, CIRCULATION, V118, P1558, DOI 10.1161/CIRCULATIONAHA.107.723593; Kumana CR, 1999, JAMA-J AM MED ASSOC, V282, P1899, DOI 10.1001/jama.282.20.1899; Li MF, 2010, ATHEROSCLEROSIS, V208, P456, DOI 10.1016/j.atherosclerosis.2009.08.001; Noda H, 2009, CIRCULATION, V119, P2136, DOI 10.1161/CIRCULATIONAHA.108.795666; PEDERSEN TR, 1994, LANCET, V344, P1383; Rosamond W, 2007, CIRCULATION, V115, pE69, DOI 10.1161/CIRCULATIONAHA.106.179918; *SEARCH COLL GROUP, 2010, LANCET, DOI DOI 10.1016/S0140.6736(10)60310.8	10	9	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2010	376	9753					1622	1624		10.1016/S0140-6736(10)61545-0	http://dx.doi.org/10.1016/S0140-6736(10)61545-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	683DD	21067806				2022-12-28	WOS:000284451000006
J	Foulkes, WD; Smith, IE; Reis, JS				Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.			Triple-Negative Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR; PROGNOSTIC-SIGNIFICANCE; SPORADIC BREAST; STEM-CELLS; BASAL; BRCA1; EXPRESSION; PHENOTYPE; MUTATION		[Foulkes, William D.] McGill Univ, Ctr Hlth, Res Inst, Program Canc Genet, Montreal, PQ H2W 1S6, Canada; [Foulkes, William D.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H2W 1S6, Canada; [Smith, Ian E.] Royal Marsden Hosp, Breast Unit, London, England; [Reis-Filho, Jorge S.] Breakthrough Breast Canc Res Ctr, Inst Canc Res, London, England	McGill University; Lady Davis Institute; McGill University; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Foulkes, WD (corresponding author), McGill Univ, Gerald Bronfman Ctr Clin Res Oncol, Dept Oncol, Program Canc Genet, 546 Pine Ave W, Montreal, PQ H2W 1S6, Canada.	william.foulkes@mcgill.ca	Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651	Susan G. Komen for the Cure; Breakthrough Breast Cancer	Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Breakthrough Breast Cancer	Supported by grants from Susan G. Komen for the Cure (to Dr. Foulkes) and Breakthrough Breast Cancer (to Dr. Reis-Filho).	Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Baselga J, 2009, J CLIN ONCOL, V27, P526, DOI 10.1200/JCO.2007.14.2646; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9; Carey LA, 2008, J CLIN ONCOL, V26, p15s; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Colleoni M, 2010, J CLIN ONCOL, V28, P2966, DOI 10.1200/JCO.2009.25.9549; Collett K, 2005, CANCER EPIDEM BIOMAR, V14, P1108, DOI 10.1158/1055-9965.EPI-04-0394; Collins LC, 2009, AM J SURG PATHOL, V33, P1093, DOI 10.1097/PAS.0b013e31819c1c93; DAIRKEE SH, 1987, LANCET, V1, P514; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; DILEO A, 2008, BREAST CANC RES TREA, V107, pS24; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Ellis P, 2009, LANCET, V373, P1681, DOI 10.1016/S0140-6736(09)60740-6; Esserman LJ, 2009, J CLIN ONCOL, V27; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Foulkes WD, 2009, BREAST CANCER RES TR, V117, P199, DOI 10.1007/s10549-008-0102-6; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Hayes DF, 2007, NEW ENGL J MED, V357, P1496, DOI 10.1056/NEJMoa071167; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Manie E, 2009, CANCER RES, V69, P663, DOI 10.1158/0008-5472.CAN-08-1560; Marty B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2204; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morrison BJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2111; O'Shaughnessy J, 2009, J CLIN ONCOL, V27; O'Shaughnessy J, 2009, CANCER RES, V69, p686S; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Rodriguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Tan DSP, 2008, BREAST CANCER RES TR, V111, P27, DOI 10.1007/s10549-007-9756-8; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Tung N, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2478; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Uematsu T, 2009, RADIOLOGY, V250, P638, DOI 10.1148/radiol.2503081054; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; Weigelt B, 2009, NAT REV CLIN ONCOL, V6, P718, DOI 10.1038/nrclinonc.2009.166; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yang XR, 2007, CANCER EPIDEM BIOMAR, V16, P439, DOI 10.1158/1055-9965.EPI-06-0806	64	2514	2628	27	666	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1938	1948		10.1056/NEJMra1001389	http://dx.doi.org/10.1056/NEJMra1001389			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678CR	21067385				2022-12-28	WOS:000284047600009
J	Haubensak, W; Kunwar, PS; Cai, HJ; Ciocchi, S; Wall, NR; Ponnusamy, R; Biag, J; Dong, HW; Deisseroth, K; Callaway, EM; Fanselow, MS; Luthi, A; Anderson, DJ				Haubensak, Wulf; Kunwar, Prabhat S.; Cai, Haijiang; Ciocchi, Stephane; Wall, Nicholas R.; Ponnusamy, Ravikumar; Biag, Jonathan; Dong, Hong-Wei; Deisseroth, Karl; Callaway, Edward M.; Fanselow, Michael S.; Luethi, Andreas; Anderson, David J.			Genetic dissection of an amygdala microcircuit that gates conditioned fear	NATURE			English	Article							CENTRAL EXTENDED AMYGDALA; RAT CENTRAL NUCLEUS; BACTERIAL ARTIFICIAL CHROMOSOMES; NEURONS IN-VITRO; PERIAQUEDUCTAL GRAY; NEURAL CIRCUITS; BASAL GANGLIA; RABIES VIRUS; EXPRESSION; VIVO	The role of different amygdala nuclei (neuroanatomical subdivisions) in processing Pavlovian conditioned fear has been studied extensively, but the function of the heterogeneous neuronal subtypes within these nuclei remains poorly understood. Here we use molecular genetic approaches to map the functional connectivity of a subpopulation of GABA-containing neurons, located in the lateral subdivision of the central amygdala (CEl), which express protein kinase C-delta (PKC-delta). Channelrhodopsin-2-assisted circuit mapping in amygdala slices and cell-specific viral tracing indicate that PKC-delta(+) neurons inhibit output neurons in the medial central amygdala (CEm), and also make reciprocal inhibitory synapses with PKC-delta(-) neurons in CEl. Electrical silencing of PKC-delta(+) neurons in vivo suggests that they correspond to physiologically identified units that are inhibited by the conditioned stimulus, called CEl(off) units. This correspondence, together with behavioural data, defines an inhibitory microcircuit in CEl that gates CEm output to control the level of conditioned freezing.	[Haubensak, Wulf; Kunwar, Prabhat S.; Cai, Haijiang; Anderson, David J.] CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; [Anderson, David J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Ciocchi, Stephane; Luethi, Andreas] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; [Wall, Nicholas R.; Callaway, Edward M.] Salk Inst Biol Studies, Syst Neurobiol Lab, La Jolla, CA 92037 USA; [Ponnusamy, Ravikumar; Fanselow, Michael S.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Ponnusamy, Ravikumar; Fanselow, Michael S.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; [Biag, Jonathan; Dong, Hong-Wei] Univ Calif Los Angeles, Lab Neuroimaging, Los Angeles, CA 90095 USA; [Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Friedrich Miescher Institute for Biomedical Research; Salk Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Stanford University	Anderson, DJ (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.	wuwei@caltech.edu	Callaway, Edward/D-4336-2011	Callaway, Edward/0000-0002-6366-5267; Haubensak, Wulf/0000-0002-2034-9184; Wall, Nicholas/0000-0003-2039-8258; Biag, Jonathan/0000-0003-0891-9567; Cai, Haijiang/0000-0003-3775-903X; Ciocchi, Stephane/0000-0002-5701-9250	NIH [1 R01 MH085082-01A1]; Caltech; Human Frontier Science Program; Jane Coffin Childs Memorial Fund for Medical Research; Novartis Research Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063912, R01MH085082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [RC2NS069464] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Caltech; Human Frontier Science Program(Human Frontier Science Program); Jane Coffin Childs Memorial Fund for Medical Research; Novartis Research Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank N. Heinz and X. Gong for generating BAC transgenic mice; C. Saper for providing the Cre-dependent hrGFP AAV construct; C. Xiao for training in slice electrophysiology and preliminary experiments; H. Lester for advice on the GluCl system; L. van Tright for performing in situ hybridizations; W. Lerchner for providing a CAG-driven GluCl beta construct; A. Chang for help with behavioural scoring; M. Martinez for tail genotyping; G. Mosconi for laboratory management; and J. Alex, R. Bayon and R. Sauza for animal care. This work was supported by NIH grant 1 R01 MH085082-01A1 and by funds from the Caltech 'Conscious Mouse' project. W.H. was supported by a fellowship of the Human Frontier Science Program and P.S.K. by the Jane Coffin Childs Memorial Fund for Medical Research. S.C. and A.L. were supported by the Novartis Research Foundation. D.J.A. is an Investigator of the Howard Hughes Medical Institute.	Atasoy D, 2008, J NEUROSCI, V28, P7025, DOI 10.1523/JNEUROSCI.1954-08.2008; Callaway EM, 2005, TRENDS NEUROSCI, V28, P196, DOI 10.1016/j.tins.2005.01.007; Cardin JA, 2010, NAT PROTOC, V5, P247, DOI 10.1038/nprot.2009.228; CASSELL MD, 1986, J COMP NEUROL, V246, P478, DOI 10.1002/cne.902460406; Cassell MD, 1999, ANN NY ACAD SCI, V877, P217, DOI 10.1111/j.1749-6632.1999.tb09270.x; Chieng BCH, 2006, J COMP NEUROL, V497, P910, DOI 10.1002/cne.21025; Davis M, 2003, ANN NY ACAD SCI, V985, P218; Day HEW, 1999, J COMP NEUROL, V413, P113; Day HEW, 2005, EUR J NEUROSCI, V21, P441, DOI 10.1111/j.1460-9568.2005.03865.x; De Armentia ML, 2004, J NEUROPHYSIOL, V92, P1285, DOI 10.1152/jn.00211.2004; De Oca BM, 1998, J NEUROSCI, V18, P3426; EDWARDS AL, 1972, EXPT DESIGN PSYCHOL, P249; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; Etessami R, 2000, J GEN VIROL, V81, P2147, DOI 10.1099/0022-1317-81-9-2147; Furler S, 2001, GENE THER, V8, P864, DOI 10.1038/sj.gt.3301469; Gautron L, 2010, J COMP NEUROL, V518, P2090, DOI 10.1002/cne.22323; Gong SC, 2003, NATURE, V425, P917, DOI 10.1038/nature02033; Gong SC, 2002, GENOME RES, V12, P1992, DOI 10.1101/gr.476202; Gozzi A, 2010, NEURON, V67, P656, DOI 10.1016/j.neuron.2010.07.008; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Huber D, 2005, SCIENCE, V308, P245, DOI 10.1126/science.1105636; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; Kravitz AV, 2010, NATURE, V466, P622, DOI 10.1038/nature09159; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; LEDOUX JE, 1988, J NEUROSCI, V8, P2517; Lerchner W, 2007, NEURON, V54, P35, DOI 10.1016/j.neuron.2007.02.030; Li P, 2002, FEBS LETT, V528, P77, DOI 10.1016/S0014-5793(02)03245-3; Luo L, 2008, NEURON, V57, P634, DOI 10.1016/j.neuron.2008.01.002; Marchant NJ, 2007, J COMP NEUROL, V504, P702, DOI 10.1002/cne.21464; Maren S, 2004, NAT REV NEUROSCI, V5, P844, DOI 10.1038/nrn1535; Medina JF, 2002, NAT REV NEUROSCI, V3, P122, DOI 10.1038/nrn728; Nicolelis MAL, 2003, P NATL ACAD SCI USA, V100, P11041, DOI 10.1073/pnas.1934665100; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004; Petreanu L, 2007, NAT NEUROSCI, V10, P663, DOI 10.1038/nn1891; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Ressler KJ, 2007, NAT NEUROSCI, V10, P1116, DOI 10.1038/nn1944; Schiess MC, 1999, J NEUROSCI RES, V58, P663, DOI 10.1002/(SICI)1097-4547(19991201)58:5<663::AID-JNR7>3.3.CO;2-1; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Slimko EM, 2003, J NEUROSCI METH, V124, P75, DOI 10.1016/S0165-0270(02)00362-X; Slimko EM, 2002, J NEUROSCI, V22, P7373; SUN N, 1994, J COMP NEUROL, V340, P43, DOI 10.1002/cne.903400105; Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957; Tsetsenis T, 2007, NAT NEUROSCI, V10, P896, DOI 10.1038/nn1919; Veinante P, 2003, ANN NY ACAD SCI, V985, P552; Wagstaff MJD, 1998, GENE THER, V5, P1566, DOI 10.1038/sj.gt.3300754; Wickens JR, 2007, PROG BRAIN RES, V160, P313, DOI 10.1016/S0079-6123(06)60018-6; Wickersham IR, 2007, NEURON, V53, P639, DOI 10.1016/j.neuron.2007.01.033; Wickersham IR, 2007, NAT METHODS, V4, P47, DOI 10.1038/NMETH999; Wilensky AE, 2006, J NEUROSCI, V26, P12387, DOI 10.1523/JNEUROSCI.4316-06.2006; Zhang F, 2007, NAT REV NEUROSCI, V8, P577, DOI 10.1038/nrn2192; Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744; Zirlinger M, 2003, GENES BRAIN BEHAV, V2, P282, DOI 10.1034/j.1601-183X.2003.00039.x; Zirlinger M, 2001, P NATL ACAD SCI USA, V98, P5270, DOI 10.1073/pnas.091094698	53	553	565	2	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2010	468	7321					270	U230		10.1038/nature09553	http://dx.doi.org/10.1038/nature09553			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678DG	21068836	Green Accepted, Green Submitted			2022-12-28	WOS:000284051000044
J	Blanche, PA; Bablumian, A; Voorakaranam, R; Christenson, C; Lin, W; Gu, T; Flores, D; Wang, P; Hsieh, WY; Kathaperumal, M; Rachwal, B; Siddiqui, O; Thomas, J; Norwood, RA; Yamamoto, M; Peyghambarian, N				Blanche, P-A; Bablumian, A.; Voorakaranam, R.; Christenson, C.; Lin, W.; Gu, T.; Flores, D.; Wang, P.; Hsieh, W-Y; Kathaperumal, M.; Rachwal, B.; Siddiqui, O.; Thomas, J.; Norwood, R. A.; Yamamoto, M.; Peyghambarian, N.			Holographic three-dimensional telepresence using large-area photorefractive polymer	NATURE			English	Article							COMPUTER-GENERATED HOLOGRAPHY; DISPLAY	Holography is a technique that is used to display objects or scenes in three dimensions. Such three-dimensional (3D) images, or holograms, can be seen with the unassisted eye and are very similar to how humans see the actual environment surrounding them. The concept of 3D telepresence, a real-time dynamic hologram depicting a scene occurring in a different location, has attracted considerable public interest since it was depicted in the original Star Wars film in 1977. However, the lack of sufficient computational power to produce realistic computer-generated holograms(1) and the absence of large-area and dynamically updatable holographic recording media(2) have prevented realization of the concept. Here we use a holographic stereographic technique(3) and a photorefractive polymer material as the recording medium(4) to demonstrate a holographic display that can refresh images every two seconds. A 50 Hz nanosecond pulsed laser is used to write the holographic pixels(5). Multicoloured holographic 3D images are produced by using angular multiplexing, and the full parallax display employs spatial multiplexing. 3D telepresence is demonstrated by taking multiple images from one location and transmitting the information via Ethernet to another location where the hologram is printed with the quasi-real-time dynamic 3D display. Further improvements could bring applications in telemedicine, prototyping, advertising, updatable 3D maps and entertainment.	[Blanche, P-A; Bablumian, A.; Voorakaranam, R.; Christenson, C.; Thomas, J.; Norwood, R. A.; Peyghambarian, N.] Univ Arizona, Coll Opt Sci, Tucson, AZ 85721 USA; [Lin, W.; Gu, T.; Flores, D.; Wang, P.; Hsieh, W-Y; Kathaperumal, M.; Rachwal, B.; Siddiqui, O.; Yamamoto, M.] Nitto Denko Tech Corp, Oceanside, CA 92054 USA	University of Arizona; Nitto Denko Corporation	Peyghambarian, N (corresponding author), Univ Arizona, Coll Opt Sci, Tucson, AZ 85721 USA.	nnp@u.arizona.edu	Blanche, Pierre-Alexandre/A-7025-2018	Blanche, Pierre-Alexandre/0000-0002-9592-2010	AFOSR; DARPA; NSF ERC Center on Integrated Access Networks (CIAN)	AFOSR(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); DARPA(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NSF ERC Center on Integrated Access Networks (CIAN)	We acknowledge support from AFOSR, DARPA and the NSF ERC Center on Integrated Access Networks (CIAN).	Ackermann G, 2007, HOLOGRAPHY PRACTICAL; Balogh T, 2008, P TMCE, P1; Benton Stephen A., 2008, HOLOGRAPHIC IMAGING; Blanche PA, 2008, J DISP TECHNOL, V4, P424, DOI 10.1109/JDT.2008.2001574; Chen ST, 1998, APPL OPTICS, V37, P7504, DOI 10.1364/AO.37.007504; DEBITETTO DJ, 1969, APPL OPTICS, V8, P1740, DOI 10.1364/AO.8.001740; DEBITETTO DJ, 1970, APPL OPTICS, V9, P498, DOI 10.1364/AO.9.000498; Eralp M, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2354037; Haussler R., 2008, P SPIE, V6803; Ketchel BP, 1999, APPL OPTICS, V38, P6159, DOI 10.1364/AO.38.006159; Liu YZ, 2010, OPT EXPRESS, V18, P3345, DOI 10.1364/OE.18.003345; Lucente M., 1994, THESIS MIT; Paturzo M, 2010, OPT EXPRESS, V18, P8806, DOI 10.1364/OE.18.008806; Peyghambarian N, 2008, OPT PHOTONICS NEWS, V19, P22, DOI 10.1364/OPN.19.7.000022; Sang XZ, 2009, OPT LETT, V34, P3803, DOI 10.1364/OL.34.003803; Shin SH, 2002, APPL OPTICS, V41, P2644, DOI 10.1364/AO.41.002644; Slinger C, 2005, COMPUTER, V38, P46, DOI 10.1109/MC.2005.260; Slinger C, 2004, P SOC PHOTO-OPT INS, V5290, P27, DOI 10.1117/12.526690; STHILAIRE P, 1992, J OPT SOC AM A, V9, P1969, DOI 10.1364/JOSAA.9.001969; Tay S, 2008, NATURE, V451, P694, DOI 10.1038/nature06596; Thomas J, 2004, ADV MATER, V16, P2032, DOI 10.1002/adma.200400102; Thomas J, 2009, J MATER CHEM, V19, P7476, DOI 10.1039/b908130e; WATERS JP, 1966, APPL PHYS LETT, V9, P405, DOI 10.1063/1.1754630	23	390	433	8	521	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	2010	468	7320					80	83		10.1038/nature09521	http://dx.doi.org/10.1038/nature09521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	674YF	21048763				2022-12-28	WOS:000283786900039
J	Kesselheim, AS				Kesselheim, Aaron S.			Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BAYH-DOLE ACT; USER FEE ACT; DRUG DEVELOPMENT; CLINICAL-TRIALS; NEGLECTED DISEASES; HEALTH-POLICY; PATENTS; SAFETY; INDUSTRY; SCIENCE		[Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; [Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666				Arias CA, 2009, NEW ENGL J MED, V360, P439, DOI 10.1056/NEJMp0804651; ARNO PS, 1995, MILBANK Q, V73, P231, DOI 10.2307/3350258; Arnon SS, 2007, PEDIATRICS, V119, P785, DOI 10.1542/peds.2006-0646; Baker-Smith CM, 2008, AM HEART J, V156, P682, DOI 10.1016/j.ahj.2008.05.001; Benjamin DK, 2008, HYPERTENSION, V51, P834, DOI 10.1161/HYPERTENSIONAHA.107.108886; Benjamin DK, 2006, JAMA-J AM MED ASSOC, V296, P1266, DOI 10.1001/jama.296.10.1266; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Boots I, 2007, EUR J PEDIATR, V166, P849, DOI 10.1007/s00431-006-0381-z; Bulut H, 2009, ECON INNOV NEW TECH, V18, P123, DOI 10.1080/10438590701709025; Campbell EG, 2002, JAMA-J AM MED ASSOC, V287, P473, DOI 10.1001/jama.287.4.473; Carpenter D, 2008, NEW ENGL J MED, V358, P1354, DOI 10.1056/NEJMsa0706341; Congressional Budget Office, 1998, INCR COMP GEN DRUGS; *DEP HLTH HUM SERV, 1989, REP NAT COMM ORPH DI; DeVeaugh-Geiss J, 2006, J AM ACAD CHILD PSY, V45, P261, DOI 10.1097/01.chi.0000194568.70912.ee; Eisenberg RS, 1996, VA LAW REV, V82, P1663, DOI 10.2307/1073686; Engelberg A., 1999, IDEA, V39, P389; Frantz S, 2006, NAT REV DRUG DISCOV, V5, P443, DOI 10.1038/nrd2071; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; *GEN ACC OFF, 2002, PUBL GEN ACC OFF; *GEN ACC OFF, 1987, GAO PUBL; Goldman D P, 1992, Int J Technol Assess Health Care, V8, P583; *GOV ACC OFF, 2006, PUBL GOV ACC OFF; *GOV ACC OFF, 1998, PUBL GOV ACC OFF; Grabowski H, 1996, PHARMACOECONOMICS, V10, P110, DOI 10.2165/00019053-199600102-00017; Grabowski H, 2008, J LAW ECON, V51, P377, DOI 10.1086/589934; Grabowski HG, 2000, INT J TECHNOL MANAGE, V19, P98, DOI 10.1504/IJTM.2000.002803; Griggs RC, 2009, MOL GENET METAB, V96, P20, DOI 10.1016/j.ymgme.2008.10.003; Haffner ME, 2006, NEW ENGL J MED, V354, P445, DOI 10.1056/NEJMp058317; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Hemphill CS, 2006, NEW YORK U LAW REV, V81, P1553; Henderson R, 1998, REV ECON STAT, V80, P119, DOI 10.1162/003465398557221; Hennessy S, 2007, NEW ENGL J MED, V356, P1703, DOI 10.1056/NEJMp078048; Higgins MJ, 2009, SCIENCE, V326, P370, DOI 10.1126/science.1176116; Hollis Aidan, 2008, HLTH IMPACT FUND MAK, P53; Horton R, 2001, LANCET, V357, P1544, DOI 10.1016/S0140-6736(00)04776-0; Jaffe AB, 1998, INVESTING IN INNOVATION, P64; Jensen R, 2001, AM ECON REV, V91, P240, DOI 10.1257/aer.91.1.240; Kaitin K I, 1997, Am J Ther, V4, P167, DOI 10.1097/00045391-199705000-00002; Kesselheim AS, 2008, NEW ENGL J MED, V359, P1981, DOI 10.1056/NEJMp0806684; Kesselheim AS, 2005, JAMA-J AM MED ASSOC, V293, P850, DOI 10.1001/jama.293.7.850; Korn DE, 2009, FOOD DRUG LAW J, V64, P335; Li JS, 2007, JAMA-J AM MED ASSOC, V297, P480, DOI 10.1001/jama.297.5.480; Mowery DC, 2001, RES POLICY, V30, P99, DOI 10.1016/S0048-7333(99)00100-6; Mowery DC., 2004, IVORY TOWER IND INNO; Nardinelli C, 2008, NEW ENGL J MED, V359, P95, DOI 10.1056/NEJMc086158; National Institutes of Health, 2001, PLAN ENS TAXP INT AR; Okie S, 2005, NEW ENGL J MED, V352, P1063, DOI 10.1056/NEJMp058003; Okie S, 2005, NEW ENGL J MED, V352, P2563; Olsen M., 2008, J HLTH EC, V27, P175; Pasquali SK, 2002, AM HEART J, V144, P608, DOI 10.1067/mhj.2002.125323; PEABODY JW, 1995, PHARMACOECONOMICS, V8, P374, DOI 10.2165/00019053-199508050-00002; PhRMA, 2009, PHARM IND PROF; Pressman L, 2006, NAT BIOTECHNOL, V24, P31, DOI 10.1038/nbt0106-31; *PUBL CIT, PROBL NEW DRUG APPR; RABIN RC, 2010, NY TIMES        0427; Rai Arti K, 2008, Yale J Health Policy Law Ethics, V8, P1; Ridley DB, 2006, HEALTH AFFAIR, V25, P313, DOI 10.1377/hlthaff.25.2.313; Rodriguez W, 2008, PEDIATRICS, V121, P530, DOI 10.1542/peds.2007-1529; Roin BN, 2009, TEX LAW REV, V87, P503; Sampat BN, 2003, INT J IND ORGAN, V21, P1371, DOI 10.1016/S0167-7187(03)00087-0; SEOANEVAZQUEZ E, 2008, J PHARM FINANCE EC P, V16, P67; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; Shulman SR, 1996, PHARMACOECONOMICS, V9, P121, DOI 10.2165/00019053-199609020-00004; SINGER N, 2010, NY TIMES        0321, pB3; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; So AD, 2008, PLOS BIOL, V6, P2078, DOI 10.1371/journal.pbio.0060262; Sobolski GK, 2005, JAMA-J AM MED ASSOC, V294, P3137, DOI 10.1001/jama.294.24.3137; Szefler SJ, 2003, CURR ALLERGY ASTHM R, V3, P478, DOI 10.1007/s11882-003-0058-x; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; VERNON JA, 2006, 0621 AEI BROOK JOINT; Walsh B, 2009, TIER 4 PHENOMENON SH; Walsh JP, 2005, SCIENCE, V309, P2002, DOI 10.1126/science.1115813; Walsh JP, 2003, SCIENCE, V299, P1021, DOI 10.1126/science.299.5609.1021; Walton SN, 2008, PHARMACOTHERAPY, V28, P1443, DOI 10.1592/phco.28.12.1443; Weiswasser ES, 2003, ANTITRUST LAW J, V71, P585; Wheadon DE, 2010, NEW ENGL J MED, V362, P661, DOI 10.1056/NEJMc0912463; Yin W, 2009, J HEALTH ECON, V28, P950, DOI 10.1016/j.jhealeco.2009.06.011; Zelenay JL, 2005, FOOD DRUG LAW J, V60, P261; Ziedonis A., 2000, INNOVATION POLICY EC, V1, P187	81	48	50	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1855	1862		10.1056/NEJMhle1002961	http://dx.doi.org/10.1056/NEJMhle1002961			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674YK	21047231				2022-12-28	WOS:000283787800013
J	Bouhanick, B; Fauvel, J; Pont, F				Bouhanick, Beatrice; Fauvel, Josette; Pont, Frederic			Biochemical Misdiagnosis of Pheochromocytoma in Patients Treated With Sulfasalazine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADRENAL INCIDENTALOMA		[Bouhanick, Beatrice] Univ Hosp Rangueil, Dept Internal Med & Hypertens, Toulouse, France; [Fauvel, Josette] Univ Hosp Purpan, Dept Biochem, Inst Federatif Biol, Toulouse, France; [Pont, Frederic] Inst Federatif Rech Biomed Toulouse IFR150, INSERM, Toulouse, France	CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bouhanick, B (corresponding author), Univ Hosp Rangueil, Dept Internal Med & Hypertens, Toulouse, France.	duly-bouhanick.b@chu-toulouse.fr	PONT, Frédéric/G-6289-2011	PONT, Frédéric/0000-0002-5493-527X				Ito T, 2006, SURG TODAY, V36, P961, DOI 10.1007/s00595-006-3291-9; Lenders JWM, 2002, JAMA-J AM MED ASSOC, V287, P1427, DOI 10.1001/jama.287.11.1427; Pacak K, 2007, NAT CLIN PRACT ENDOC, V3, P92, DOI 10.1038/ncpendmet0396; Peaston RT, 2010, CLIN CHIM ACTA, V411, P546, DOI 10.1016/j.cca.2010.01.012; Terzolo M, 2009, BEST PRACT RES CL EN, V23, P233, DOI 10.1016/j.beem.2009.04.001; Walsh N, 2006, RHEUMATOLOGY NEWS, V5, P11	6	16	16	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1898	1901		10.1001/jama.2010.1563	http://dx.doi.org/10.1001/jama.2010.1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674GT	21045095	Bronze			2022-12-28	WOS:000283725900017
